<ALL>	O
Hepatocyte	B-Gene
nuclear	I-Gene
factor	I-Gene
-	I-Gene
6	I-Gene
:	O
associations	O
between	O
genetic	O
variability	O
and	O
type	B-Disease
II	I-Disease
diabetes	I-Disease
and	O
between	O
genetic	O
variability	O
and	O
estimates	O
of	O
insulin	B-Gene
secretion	O
.	O
</ALL>	O

<ALL>	O
The	O
transcription	O
factor	O
hepatocyte	B-Gene
nuclear	I-Gene
factor	I-Gene
(	I-Gene
HNF	I-Gene
)	I-Gene
-	I-Gene
6	I-Gene
is	O
an	O
upstream	O
regulator	O
of	O
several	O
genes	O
involved	O
in	O
the	O
pathogenesis	O
of	O
maturity	B-Disease
-	I-Disease
onset	I-Disease
diabetes	I-Disease
of	O
the	O
young	O
.	O
</ALL>	O

<ALL>	O
We	O
therefore	O
tested	O
the	O
hypothesis	O
that	O
variability	O
in	O
the	O
HNF	B-Gene
-	I-Gene
6	I-Gene
gene	O
is	O
associated	O
with	O
subsets	O
of	O
Type	B-Disease
II	I-Disease
(	I-Disease
non	I-Disease
-	I-Disease
insulin	I-Disease
-	I-Disease
dependent	I-Disease
)	I-Disease
diabetes	I-Disease
mellitus	I-Disease
and	O
estimates	O
of	O
insulin	B-Gene
secretion	O
in	O
glucose	B-Chemical
tolerant	O
subjects	O
.	O
</ALL>	O

<ALL>	O
We	O
cloned	O
the	O
coding	O
region	O
as	O
well	O
as	O
the	O
intron	O
-	O
exon	O
boundaries	O
of	O
the	O
HNF	B-Gene
-	I-Gene
6	I-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
We	O
then	O
examined	O
them	O
on	O
genomic	O
DNA	O
in	O
six	O
MODY	B-Gene
probands	O
without	O
mutations	O
in	O
the	O
MODY1	B-Gene
,	O
MODY3	B-Gene
and	O
MODY4	B-Gene
genes	O
and	O
in	O
54	O
patients	B-Species
with	O
late	O
-	O
onset	O
Type	B-Disease
II	I-Disease
diabetes	I-Disease
by	O
combined	O
single	O
strand	O
conformational	O
polymorphism	O
-	O
heteroduplex	O
analysis	O
followed	O
by	O
direct	O
sequencing	O
of	O
identified	O
variants	O
.	O
</ALL>	O

<ALL>	O
An	O
identified	O
missense	O
variant	O
was	O
examined	O
in	O
association	O
studies	O
and	O
genotype	O
-	O
phenotype	O
studies	O
.	O
</ALL>	O

<ALL>	O
We	O
identified	O
two	O
silent	O
and	O
one	O
missense	O
(	O
Pro75	B-Variant
Ala	I-Variant
)	O
variant	O
.	O
</ALL>	O

<ALL>	O
In	O
an	O
association	O
study	O
the	O
allelic	O
frequency	O
of	O
the	O
Pro75Ala	B-Variant
polymorphism	O
was	O
3.2	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
1.9	O
-	O
4.5	O
)	O
in	O
330	O
patients	B-Species
with	O
Type	B-Disease
II	I-Disease
diabetes	I-Disease
mellitus	I-Disease
compared	O
with	O
4.2	O
%	O
(	O
2.4	O
-	O
6.0	O
)	O
in	O
238	O
age	O
-	O
matched	O
glucose	B-Chemical
tolerant	O
control	O
subjects	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
in	O
studies	O
of	O
238	O
middle	O
-	O
aged	O
glucose	B-Chemical
tolerant	O
subjects	O
,	O
of	O
226	O
glucose	B-Chemical
tolerant	O
offspring	O
of	O
Type	B-Disease
II	I-Disease
diabetic	I-Disease
patients	B-Species
and	O
of	O
367	O
young	O
healthy	O
subjects	O
,	O
the	O
carriers	O
of	O
the	O
polymorphism	O
did	O
not	O
differ	O
from	O
non	O
-	O
carriers	O
in	O
glucose	B-Chemical
induced	O
serum	O
insulin	B-Gene
or	O
C	B-Gene
-	I-Gene
peptide	I-Gene
responses	O
.	O
</ALL>	O

<ALL>	O
Mutations	O
in	O
the	O
coding	O
region	O
of	O
the	O
HNF	B-Gene
-	I-Gene
6	I-Gene
gene	O
are	O
not	O
associated	O
with	O
Type	B-Disease
II	I-Disease
diabetes	I-Disease
or	O
with	O
changes	O
in	O
insulin	B-Gene
responses	O
to	O
glucose	B-Chemical
among	O
the	O
Caucasians	O
examined	O
.	O
</ALL>	O

<ALL>	O
Langerin	B-Gene
,	O
a	O
novel	O
C	B-Gene
-	I-Gene
type	I-Gene
lectin	I-Gene
specific	O
to	O
Langerhans	O
cells	O
,	O
is	O
an	O
endocytic	O
receptor	O
that	O
induces	O
the	O
formation	O
of	O
Birbeck	O
granules	O
.	O
</ALL>	O

<ALL>	O
We	O
have	O
identified	O
a	O
type	B-Gene
II	I-Gene
Ca2	I-Gene
+	I-Gene
-	I-Gene
dependent	I-Gene
lectin	I-Gene
displaying	O
mannose	B-Chemical
-	O
binding	O
specificity	O
,	O
exclusively	O
expressed	O
by	O
Langerhans	O
cells	O
(	O
LC	O
)	O
,	O
and	O
named	O
Langerin	B-Gene
.	O
</ALL>	O

<ALL>	O
LC	O
are	O
uniquely	O
characterized	O
by	O
Birbeck	O
granules	O
(	O
BG	O
)	O
,	O
which	O
are	O
organelles	O
consisting	O
of	O
superimposed	O
and	O
zippered	O
membranes	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
have	O
shown	O
that	O
Langerin	B-Gene
is	O
constitutively	O
associated	O
with	O
BG	O
and	O
that	O
antibody	O
to	O
Langerin	B-Gene
is	O
internalized	O
into	O
these	O
structures	O
.	O
</ALL>	O

<ALL>	O
Remarkably	O
,	O
transfection	O
of	O
Langerin	B-Gene
cDNA	O
into	O
fibroblasts	O
created	O
a	O
compact	O
network	O
of	O
membrane	O
structures	O
with	O
typical	O
features	O
of	O
BG	O
.	O
</ALL>	O

<ALL>	O
Langerin	B-Gene
is	O
thus	O
a	O
potent	O
inducer	O
of	O
membrane	O
superimposition	O
and	O
zippering	O
leading	O
to	O
BG	O
formation	O
.	O
</ALL>	O

<ALL>	O
Our	O
data	O
suggest	O
that	O
induction	O
of	O
BG	O
is	O
a	O
consequence	O
of	O
the	O
antigen	O
-	O
capture	O
function	O
of	O
Langerin	B-Gene
,	O
allowing	O
routing	O
into	O
these	O
organelles	O
and	O
providing	O
access	O
to	O
a	O
nonclassical	O
antigen	O
-	O
processing	O
pathway	O
.	O
</ALL>	O

<ALL>	O
Founder	O
mutations	O
in	O
the	O
BRCA1	B-Gene
gene	O
in	O
Polish	O
families	O
with	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
We	O
have	O
undertaken	O
a	O
hospital	O
-	O
based	O
study	O
,	O
to	O
identify	O
possible	O
BRCA1	B-Gene
and	O
BRCA2	B-Gene
founder	O
mutations	O
in	O
the	O
Polish	O
population	O
.	O
</ALL>	O

<ALL>	O
The	O
study	O
group	O
consisted	O
of	O
66	O
Polish	O
families	O
with	O
cancer	B-Disease
who	O
have	O
at	O
least	O
three	O
related	O
females	O
affected	O
with	O
breast	B-Disease
or	I-Disease
ovarian	I-Disease
cancer	I-Disease
and	O
who	O
had	O
cancer	B-Disease
diagnosed	O
,	O
in	O
at	O
least	O
one	O
of	O
the	O
three	O
affected	O
females	O
,	O
at	O
age	O
<	O
50	O
years	O
.	O
</ALL>	O

<ALL>	O
A	O
total	O
of	O
26	O
families	O
had	O
both	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancers	I-Disease
,	O
4	O
families	O
had	O
ovarian	B-Disease
cancers	I-Disease
only	O
,	O
and	O
36	O
families	O
had	O
breast	B-Disease
cancers	I-Disease
only	O
.	O
</ALL>	O

<ALL>	O
Genomic	O
DNA	O
was	O
prepared	O
from	O
the	O
peripheral	O
blood	O
leukocytes	O
of	O
at	O
least	O
one	O
affected	O
woman	B-Species
from	O
each	O
family	O
.	O
</ALL>	O

<ALL>	O
The	O
entire	O
coding	O
region	O
of	O
BRCA1	B-Gene
and	O
BRCA2	B-Gene
was	O
screened	O
for	O
the	O
presence	O
of	O
germline	O
mutations	O
,	O
by	O
use	O
of	O
SSCP	O
followed	O
by	O
direct	O
sequencing	O
of	O
observed	O
variants	O
.	O
</ALL>	O

<ALL>	O
Mutations	O
were	O
found	O
in	O
35	O
(	O
53	O
%	O
)	O
of	O
the	O
66	O
families	O
studied	O
.	O
</ALL>	O

<ALL>	O
All	O
but	O
one	O
of	O
the	O
mutations	O
were	O
detected	O
within	O
the	O
BRCA1	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
BRCA1	B-Disease
abnormalities	I-Disease
were	O
identified	O
in	O
all	O
four	O
families	O
with	O
ovarian	B-Disease
cancer	I-Disease
only	O
,	O
in	O
67	O
%	O
of	O
27	O
families	O
with	O
both	O
breast	B-Disease
and	I-Disease
ovarian	I-Disease
cancer	I-Disease
,	O
and	O
in	O
34	O
%	O
of	O
35	O
families	O
with	O
breast	B-Disease
cancer	I-Disease
only	O
.	O
</ALL>	O

<ALL>	O
The	O
single	O
family	O
with	O
a	O
BRCA2	B-Gene
mutation	O
had	O
the	O
breast	B-Disease
-	I-Disease
ovarian	I-Disease
cancer	I-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Seven	O
distinct	O
mutations	O
were	O
identified	O
;	O
five	O
of	O
these	O
occurred	O
in	O
two	O
or	O
more	O
families	O
.	O
</ALL>	O

<ALL>	O
In	O
total	O
,	O
recurrent	O
mutations	O
were	O
found	O
in	O
33	O
(	O
94	O
%	O
)	O
of	O
the	O
35	O
families	O
with	O
detected	O
mutations	O
.	O
</ALL>	O

<ALL>	O
Three	O
BRCA1	B-Disease
abnormalities	I-Disease
-	O
5382insC	B-Variant
,	O
C61	B-Variant
G	I-Variant
,	O
and	O
4153delA	B-Variant
-	O
accounted	O
for	O
51	O
%	O
,	O
20	O
%	O
,	O
and	O
11	O
%	O
of	O
the	O
identified	O
mutations	O
,	O
respectively	O
..	O
</ALL>	O

<ALL>	O
Apomorphine	B-Chemical
:	O
an	O
underutilized	O
therapy	O
for	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
Apomorphine	B-Chemical
was	O
the	O
first	O
dopaminergic	B-Chemical
drug	I-Chemical
ever	O
used	O
to	O
treat	O
symptoms	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
While	O
powerful	O
antiparkinsonian	O
effects	O
had	O
been	O
observed	O
as	O
early	O
as	O
1951	O
,	O
the	O
potential	O
of	O
treating	O
fluctuating	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
by	O
subcutaneous	O
administration	O
of	O
apomorphine	B-Chemical
has	O
only	O
recently	O
become	O
the	O
subject	O
of	O
systematic	O
study	O
.	O
</ALL>	O

<ALL>	O
A	O
number	O
of	O
small	O
scale	O
clinical	O
trials	O
have	O
unequivocally	O
shown	O
that	O
intermittent	O
subcutaneous	O
apomorphine	B-Chemical
injections	O
produce	O
antiparkinsonian	O
benefit	O
close	O
if	O
not	O
identical	O
to	O
that	O
seen	O
with	O
levodopa	B-Chemical
and	O
that	O
apomorphine	B-Chemical
rescue	O
injections	O
can	O
reliably	O
revert	O
off	O
-	O
periods	O
even	O
in	O
patients	B-Species
with	O
complex	O
on	O
-	O
off	O
motor	O
swings	O
.	O
</ALL>	O

<ALL>	O
Continuous	O
subcutaneous	O
apomorphine	B-Chemical
infusions	O
can	O
reduce	O
daily	O
off	O
-	O
time	O
by	O
more	O
than	O
50	O
%	O
in	O
this	O
group	O
of	O
patients	B-Species
,	O
which	O
appears	O
to	O
be	O
a	O
stronger	O
effect	O
than	O
that	O
generally	O
seen	O
with	O
add	O
-	O
on	O
therapy	O
with	O
oral	O
dopamine	B-Chemical
agonists	I-Chemical
or	O
COMT	B-Chemical
inhibitors	I-Chemical
.	O
</ALL>	O

<ALL>	O
Extended	O
follow	O
-	O
up	O
studies	O
of	O
up	O
to	O
8	O
years	O
have	O
demonstrated	O
long	O
-	O
term	O
persistence	O
of	O
apomorphine	B-Chemical
efficacy	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
there	O
is	O
convincing	O
clinical	O
evidence	O
that	O
monotherapy	O
with	O
continuous	O
subcutaneous	O
apomorphine	B-Chemical
infusions	O
is	O
associated	O
with	O
marked	O
reductions	O
of	O
preexisting	O
levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
main	O
side	O
effects	O
of	O
subcutaneous	O
apomorphine	B-Chemical
treatment	O
are	O
related	O
to	O
cutaneous	O
tolerability	O
problems	O
,	O
whereas	O
sedation	O
and	O
psychiatric	B-Disease
complications	I-Disease
play	O
a	O
lesser	O
role	O
.	O
</ALL>	O

<ALL>	O
Given	O
the	O
marked	O
degree	O
of	O
efficacy	O
of	O
subcutaneous	O
apomorphine	B-Chemical
treatment	O
in	O
fluctuating	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
,	O
this	O
approach	O
seems	O
to	O
deserve	O
more	O
widespread	O
clinical	O
use	O
.	O
</ALL>	O

<ALL>	O
Rab6c	B-Gene
,	O
a	O
new	O
member	O
of	O
the	O
rab	B-Gene
gene	O
family	O
,	O
is	O
involved	O
in	O
drug	O
resistance	O
in	O
MCF7	B-CellLine
/	I-CellLine
AdrR	I-CellLine
cells	O
.	O
</ALL>	O

<ALL>	O
A	O
new	O
Rab6	B-Gene
homolog	O
cDNA	O
,	O
Rab6c	B-Gene
,	O
was	O
discovered	O
by	O
a	O
hypermethylated	O
DNA	O
fragment	O
probe	O
that	O
was	O
isolated	O
from	O
a	O
human	B-Species
multidrug	O
resistant	O
(	O
MDR	O
)	O
breast	B-Disease
cancer	I-Disease
cell	O
line	O
,	O
MCF7	B-CellLine
/	I-CellLine
AdrR	I-CellLine
,	O
by	O
the	O
methylation	O
sensitive	O
-	O
representational	O
difference	O
analysis	O
(	O
MS	O
-	O
RDA	O
)	O
technique	O
.	O
</ALL>	O

<ALL>	O
Rab6c	B-Gene
was	O
found	O
to	O
be	O
under	O
-	O
expressed	O
in	O
MCF7	B-CellLine
/	I-CellLine
AdrR	I-CellLine
and	O
MES	B-CellLine
-	I-CellLine
SA	I-CellLine
/	I-CellLine
Dx5	I-CellLine
(	O
a	O
human	B-Species
MDR	O
uterine	B-Disease
sarcoma	I-Disease
cell	O
line	O
)	O
compared	O
with	O
their	O
non	O
-	O
MDR	O
parental	O
cell	O
lines	O
.	O
</ALL>	O

<ALL>	O
MCF7	B-CellLine
/	I-CellLine
AdrR	I-CellLine
cells	O
expressing	O
the	O
exogenous	O
Rab6c	B-Gene
exhibited	O
less	O
resistance	O
to	O
several	O
anti	O
-	O
cancer	O
drugs	O
,	O
such	O
as	O
doxorubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
,	O
taxol	B-Chemical
,	O
vinblastine	B-Chemical
,	O
and	O
vincristine	B-Chemical
,	O
than	O
the	O
control	O
cells	O
containing	O
the	O
empty	O
vector	O
.	O
</ALL>	O

<ALL>	O
Flow	O
cytometry	O
experiments	O
confirmed	O
that	O
the	O
transfectants	O
'	O
diminished	O
resistance	O
to	O
DOX	B-Chemical
was	O
caused	O
by	O
increased	O
drug	O
accumulation	O
induced	O
by	O
the	O
exogenous	O
Rab6c	B-Gene
.	O
</ALL>	O

<ALL>	O
These	O
results	O
indicate	O
that	O
Rab6c	B-Gene
is	O
involved	O
in	O
drug	O
resistance	O
in	O
MCF7	B-CellLine
/	I-CellLine
AdrR	I-CellLine
cells	O
.	O
</ALL>	O

<ALL>	O
End	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	B-Disease
)	O
after	O
orthotopic	O
liver	O
transplantation	O
(	O
OLTX	O
)	O
using	O
calcineurin	B-Gene
-	O
based	O
immunotherapy	O
:	O
risk	O
of	O
development	O
and	O
treatment	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
The	O
calcineurin	B-Gene
inhibitors	O
cyclosporine	B-Chemical
and	O
tacrolimus	B-Chemical
are	O
both	O
known	O
to	O
be	O
nephrotoxic	B-Disease
.	O
</ALL>	O

<ALL>	O
Their	O
use	O
in	O
orthotopic	O
liver	O
transplantation	O
(	O
OLTX	O
)	O
has	O
dramatically	O
improved	O
success	O
rates	O
.	O
</ALL>	O

<ALL>	O
Recently	O
,	O
however	O
,	O
we	O
have	O
had	O
an	O
increase	O
of	O
patients	B-Species
who	O
are	O
presenting	O
after	O
OLTX	O
with	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
This	O
retrospective	O
study	O
examines	O
the	O
incidence	O
and	O
treatment	O
of	O
ESRD	B-Disease
and	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
(	O
CRF	B-Disease
)	O
in	O
OLTX	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Patients	B-Species
receiving	O
an	O
OLTX	O
only	O
from	O
June	O
1985	O
through	O
December	O
of	O
1994	O
who	O
survived	O
6	O
months	O
postoperatively	O
were	O
studied	O
(	O
n	O
=	O
834	O
)	O
.	O
</ALL>	O

<ALL>	O
Our	O
prospectively	O
collected	O
database	O
was	O
the	O
source	O
of	O
information	O
.	O
</ALL>	O

<ALL>	O
Patients	B-Species
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	O
,	O
no	O
CRF	B-Disease
or	O
ESRD	B-Disease
,	O
n	O
=	O
748	O
;	O
CRF	B-Disease
,	O
sustained	O
serum	O
creatinine	B-Chemical
>	O
2.5	O
mg	O
/	O
dl	O
,	O
n	O
=	O
41	O
;	O
and	O
ESRD	B-Disease
,	O
n	O
=	O
45	O
.	O
</ALL>	O

<ALL>	O
Groups	O
were	O
compared	O
for	O
preoperative	O
laboratory	O
variables	O
,	O
diagnosis	O
,	O
postoperative	O
variables	O
,	O
survival	O
,	O
type	O
of	O
ESRD	B-Disease
therapy	O
,	O
and	O
survival	O
from	O
onset	O
of	O
ESRD	B-Disease
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
At	O
13	O
years	O
after	O
OLTX	O
,	O
the	O
incidence	O
of	O
severe	O
renal	B-Disease
dysfunction	I-Disease
was	O
18.1	O
%	O
(	O
CRF	B-Disease
8.6	O
%	O
and	O
ESRD	B-Disease
9.5	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
Compared	O
with	O
control	O
patients	B-Species
,	O
CRF	B-Disease
and	O
ESRD	B-Disease
patients	B-Species
had	O
higher	O
preoperative	O
serum	O
creatinine	B-Chemical
levels	O
,	O
a	O
greater	O
percentage	O
of	O
patients	B-Species
with	O
hepatorenal	B-Disease
syndrome	I-Disease
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
1	O
-	O
year	O
serum	O
creatinine	B-Chemical
.	O
</ALL>	O

<ALL>	O
Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
using	O
preoperative	O
and	O
postoperative	O
variables	O
identified	O
that	O
an	O
increase	O
of	O
serum	O
creatinine	B-Chemical
compared	O
with	O
average	O
at	O
1	O
year	O
,	O
3	O
months	O
,	O
and	O
4	O
weeks	O
postoperatively	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
CRF	B-Disease
or	O
ESRD	B-Disease
with	O
odds	O
ratios	O
of	O
2.6	O
,	O
2.2	O
,	O
and	O
1.6	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
Overall	O
survival	O
from	O
the	O
time	O
of	O
OLTX	O
was	O
not	O
significantly	O
different	O
among	O
groups	O
,	O
but	O
by	O
year	O
13	O
,	O
the	O
survival	O
of	O
the	O
patients	B-Species
who	O
had	O
ESRD	B-Disease
was	O
only	O
28.2	O
%	O
compared	O
with	O
54.6	O
%	O
in	O
the	O
control	O
group	O
.	O
</ALL>	O

<ALL>	O
Patients	B-Species
developing	O
ESRD	B-Disease
had	O
a	O
6	O
-	O
year	O
survival	O
after	O
onset	O
of	O
ESRD	B-Disease
of	O
27	O
%	O
for	O
the	O
patients	B-Species
receiving	O
hemodialysis	O
versus	O
71.4	O
%	O
for	O
the	O
patients	B-Species
developing	O
ESRD	B-Disease
who	O
subsequently	O
received	O
kidney	O
transplants	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Patients	B-Species
who	O
are	O
more	O
than	O
10	O
years	O
post	O
-	O
OLTX	O
have	O
CRF	B-Disease
and	O
ESRD	B-Disease
at	O
a	O
high	O
rate	O
.	O
</ALL>	O

<ALL>	O
The	O
development	O
of	O
ESRD	B-Disease
decreases	O
survival	O
,	O
particularly	O
in	O
those	O
patients	B-Species
treated	O
with	O
dialysis	O
only	O
.	O
</ALL>	O

<ALL>	O
Patients	B-Species
who	O
develop	O
ESRD	B-Disease
have	O
a	O
higher	O
preoperative	O
and	O
1	O
-	O
year	O
serum	O
creatinine	B-Chemical
and	O
are	O
more	O
likely	O
to	O
have	O
hepatorenal	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
an	O
increase	O
of	O
serum	O
creatinine	B-Chemical
at	O
various	O
times	O
postoperatively	O
is	O
more	O
predictive	O
of	O
the	O
development	O
of	O
CRF	B-Disease
or	O
ESRD	B-Disease
.	O
</ALL>	O

<ALL>	O
New	O
strategies	O
for	O
long	O
-	O
term	O
immunosuppression	O
may	O
be	O
needed	O
to	O
decrease	O
this	O
complication	O
.	O
</ALL>	O

<ALL>	O
D90A	B-Variant
-	O
SOD1	B-Gene
mediated	O
amyotrophic	B-Disease
lateral	I-Disease
sclerosis	I-Disease
:	O
a	O
single	O
founder	O
for	O
all	O
cases	O
with	O
evidence	O
for	O
a	O
Cis	O
-	O
acting	O
disease	O
modifier	O
in	O
the	O
recessive	O
haplotype	O
.	O
</ALL>	O

<ALL>	O
More	O
than	O
100	O
different	O
heterozygous	O
mutations	O
in	O
copper	B-Gene
/	I-Gene
zinc	I-Gene
superoxide	I-Gene
dismutase	I-Gene
(	O
SOD1	B-Gene
)	O
have	O
been	O
found	O
in	O
patients	B-Species
with	O
amyotrophic	B-Disease
lateral	I-Disease
sclerosis	I-Disease
(	O
ALS	B-Disease
)	O
,	O
a	O
fatal	O
neurodegenerative	B-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
Uniquely	O
,	O
D90A	B-Variant
-	O
SOD1	B-Gene
has	O
been	O
identified	O
in	O
recessive	O
,	O
dominant	O
and	O
apparently	O
sporadic	O
pedigrees	O
.	O
</ALL>	O

<ALL>	O
The	O
phenotype	O
of	O
homozygotes	O
is	O
stereotyped	O
with	O
an	O
extended	O
survival	O
,	O
whereas	O
that	O
of	O
affected	O
heterozygotes	O
varies	O
.	O
</ALL>	O

<ALL>	O
The	O
frequency	O
of	O
D90A	B-Variant
-	O
SOD1	B-Gene
is	O
50	O
times	O
higher	O
in	O
Scandinavia	O
(	O
2.5	O
%	O
)	O
than	O
elsewhere	O
,	O
though	O
ALS	B-Disease
prevalence	O
is	O
not	O
raised	O
there	O
.	O
</ALL>	O

<ALL>	O
Our	O
earlier	O
study	O
indicated	O
separate	O
founders	O
for	O
recessive	O
and	O
dominant	O
/	O
sporadic	O
ALS	B-Disease
and	O
we	O
proposed	O
a	O
disease	O
-	O
modifying	O
factor	O
linked	O
to	O
the	O
recessive	O
mutation	O
.	O
</ALL>	O

<ALL>	O
Here	O
we	O
have	O
doubled	O
our	O
sample	O
set	O
and	O
employed	O
novel	O
markers	O
to	O
characterise	O
the	O
mutation	O
's	O
origin	O
and	O
localise	O
any	O
modifying	O
factor	O
.	O
</ALL>	O

<ALL>	O
Linkage	O
disequilibrium	O
analysis	O
indicates	O
that	O
D90A	B-Variant
homozygotes	O
and	O
heterozygotes	O
share	O
a	O
rare	O
haplotype	O
and	O
are	O
all	O
descended	O
from	O
a	O
single	O
ancient	O
founder	O
(	O
alpha	O
0.974	O
)	O
c.895	O
generations	O
ago	O
.	O
</ALL>	O

<ALL>	O
Homozygotes	O
arose	O
subsequently	O
only	O
c.63	O
generations	O
ago	O
(	O
alpha	O
0.878	O
)	O
.	O
</ALL>	O

<ALL>	O
Recombination	O
has	O
reduced	O
the	O
region	O
shared	O
by	O
recessive	O
kindreds	O
to	O
97	O
-	O
265	O
kb	O
around	O
SOD1	B-Gene
,	O
excluding	O
all	O
neighbouring	O
genes	O
.	O
</ALL>	O

<ALL>	O
We	O
propose	O
that	O
a	O
cis	O
-	O
acting	O
regulatory	O
polymorphism	O
has	O
arisen	O
close	O
to	O
D90A	B-Variant
-	O
SOD1	B-Gene
in	O
the	O
recessive	O
founder	O
,	O
which	O
decreases	O
ALS	B-Disease
susceptibility	O
in	O
heterozygotes	O
and	O
slows	O
disease	O
progression	O
.	O
</ALL>	O

<ALL>	O
Late	O
-	O
onset	O
metachromatic	B-Disease
leukodystrophy	I-Disease
:	O
molecular	O
pathology	O
in	O
two	O
siblings	O
.	O
</ALL>	O

<ALL>	O
We	O
report	O
on	O
a	O
new	O
allele	O
at	O
the	O
arylsulfatase	B-Gene
A	I-Gene
(	O
ARSA	B-Gene
)	O
locus	O
causing	O
late	O
-	O
onset	O
metachromatic	B-Disease
leukodystrophy	I-Disease
(	O
MLD	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
In	O
that	O
allele	O
arginine84	B-Variant
,	O
a	O
residue	O
that	O
is	O
highly	O
conserved	O
in	O
the	O
arylsulfatase	B-Gene
gene	O
family	O
,	O
is	O
replaced	O
by	O
glutamine	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
to	O
alleles	O
that	O
cause	O
early	O
-	O
onset	O
MLD	B-Disease
,	O
the	O
arginine84	B-Variant
to	I-Variant
glutamine	I-Variant
substitution	O
is	O
associated	O
with	O
some	O
residual	O
ARSA	B-Gene
activity	O
.	O
</ALL>	O

<ALL>	O
A	O
comparison	O
of	O
genotypes	O
,	O
ARSA	B-Gene
activities	O
,	O
and	O
clinical	O
data	O
on	O
4	O
individuals	O
carrying	O
the	O
allele	O
of	O
81	O
patients	B-Species
with	O
MLD	B-Disease
examined	O
,	O
further	O
validates	O
the	O
concept	O
that	O
different	O
degrees	O
of	O
residual	O
ARSA	B-Gene
activity	O
are	O
the	O
basis	O
of	O
phenotypical	O
variation	O
in	O
MLD	B-Disease
..	O
</ALL>	O

<ALL>	O
Low	O
frequency	O
of	O
deafness	B-Disease
-	O
associated	O
GJB2	B-Gene
variants	O
in	O
Kenya	O
and	O
Sudan	O
and	O
novel	O
GJB2	B-Gene
variants	O
.	O
</ALL>	O

<ALL>	O
A	O
large	O
proportion	O
of	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
autosomal	I-Disease
recessive	I-Disease
deafness	I-Disease
(	O
NSARD	B-Disease
)	O
in	O
many	O
populations	O
is	O
caused	O
by	O
variants	O
of	O
the	O
GJB2	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
the	O
frequency	O
of	O
GJB2	B-Gene
variants	O
was	O
studied	O
in	O
406	O
and	O
183	O
apparently	O
unrelated	O
children	O
from	O
Kenya	O
and	O
Sudan	O
,	O
respectively	O
,	O
with	O
mostly	O
severe	O
to	O
profound	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
deafness	I-Disease
.	O
</ALL>	O

<ALL>	O
Nine	O
(	O
2.2	O
%	O
)	O
Kenyan	O
and	O
12	O
(	O
6.6	O
%	O
)	O
of	O
the	O
Sudanese	O
children	O
only	O
were	O
carriers	O
of	O
variants	O
within	O
the	O
coding	O
sequence	O
of	O
the	O
GJB2	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Variants	O
in	O
the	O
5	O
'	O
-	O
adjacent	O
region	O
were	O
detected	O
in	O
further	O
115	O
individuals	O
.	O
</ALL>	O

<ALL>	O
A	O
total	O
of	O
10	O
novel	O
variants	O
was	O
recognized	O
,	O
among	O
them	O
four	O
variants	O
in	O
the	O
adjacent	O
5	O
'	O
-	O
region	O
of	O
the	O
GJB2	B-Gene
coding	O
exon	O
2	O
(	O
g.3318	B-Variant
-	I-Variant
6	I-Variant
T	I-Variant
>	I-Variant
A	I-Variant
,	O
g.3318	B-Variant
-	I-Variant
15C	I-Variant
>	I-Variant
T	I-Variant
,	O
g.3318	B-Variant
-	I-Variant
34C	I-Variant
>	I-Variant
T	I-Variant
,	O
g.3318	B-Variant
-	I-Variant
35	I-Variant
T	I-Variant
>	I-Variant
G	I-Variant
)	O
,	O
a	O
6	O
base	O
-	O
pair	O
deletion	O
(	O
g.3455	B-Variant
_	I-Variant
3460del	I-Variant
[	O
p	B-Variant
.	I-Variant
Asp46	I-Variant
_	I-Variant
Gln48delinsGlu	I-Variant
]	O
)	O
,	O
a	O
variant	O
leading	O
to	O
a	O
stop	O
codon	O
(	O
g.3512C	B-Variant
>	I-Variant
A	I-Variant
[	O
p	B-Variant
.	I-Variant
Tyr65X	I-Variant
]	O
)	O
,	O
synonymous	O
variants	O
(	O
g.3395C	B-Variant
>	I-Variant
T	I-Variant
[	O
p	B-Variant
.	I-Variant
Thr26	I-Variant
]	O
,	O
g.3503C	B-Variant
>	I-Variant
T	I-Variant
[	O
p	B-Variant
.	I-Variant
Asn62	I-Variant
]	O
,	O
g.3627A	B-Variant
>	I-Variant
C	I-Variant
[	O
p	B-Variant
.	I-Variant
Arg104	I-Variant
]	O
)	O
,	O
and	O
one	O
non	O
-	O
synonymous	O
variant	O
(	O
g.3816C	B-Variant
>	I-Variant
A	I-Variant
[	O
p	B-Variant
.	I-Variant
Val167Met	I-Variant
]	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
the	O
previously	O
described	O
variants	O
g.3352delG	B-Variant
(	O
commonly	O
designated	O
30delG	B-Variant
or	O
35	B-Variant
delG	I-Variant
)	O
,	O
g.3426	B-Variant
G	I-Variant
>	I-Variant
A	I-Variant
[	O
p	B-Variant
.	I-Variant
Val37Ile	I-Variant
]	O
,	O
g.3697	B-Variant
G	I-Variant
>	I-Variant
A	I-Variant
[	O
p	B-Variant
.	I-Variant
Arg127His	I-Variant
]	O
,	O
g.3774	B-Variant
G	I-Variant
>	I-Variant
A	I-Variant
[	O
p	B-Variant
.	I-Variant
Val153Ile	I-Variant
]	O
,	O
and	O
g.3795	B-Variant
G	I-Variant
>	I-Variant
A	I-Variant
[	O
p	B-Variant
.	I-Variant
Gly160Ser	I-Variant
]	O
were	O
identified	O
.	O
</ALL>	O

<ALL>	O
With	O
the	O
exception	O
of	O
g.3318	B-Variant
-	I-Variant
34C	I-Variant
>	I-Variant
T	I-Variant
and	O
g.3352delG	B-Variant
,	O
all	O
variants	O
occurred	O
heterozygously	O
.	O
</ALL>	O

<ALL>	O
For	O
most	O
of	O
the	O
variants	O
identified	O
in	O
the	O
Kenyan	O
and	O
Sudanese	O
study	O
population	O
,	O
a	O
causative	O
association	O
with	O
NSARD	B-Disease
appears	O
to	O
be	O
unlikely	O
.	O
</ALL>	O

<ALL>	O
Compared	O
to	O
many	O
other	O
ethnic	O
groups	O
,	O
deafness	B-Disease
-	O
associated	O
variants	O
of	O
the	O
coding	O
region	O
of	O
GJB2	B-Gene
are	O
rare	O
in	O
Sudan	O
and	O
Kenya	O
,	O
suggesting	O
a	O
role	O
of	O
other	O
genetic	O
,	O
or	O
epigenetic	O
factors	O
as	O
a	O
cause	O
for	O
deafness	B-Disease
in	O
these	O
countries	O
.	O
</ALL>	O

<ALL>	O
Mutations	O
in	O
the	O
PCSK9	B-Gene
gene	O
in	O
Norwegian	O
subjects	O
with	O
autosomal	B-Disease
dominant	I-Disease
hypercholesterolemia	I-Disease
.	O
</ALL>	O

<ALL>	O
Proprotein	B-Gene
convertase	I-Gene
subtilisin	I-Gene
/	I-Gene
kexin	I-Gene
type	I-Gene
9	I-Gene
(	O
PCSK9	B-Gene
)	O
is	O
at	O
a	O
locus	O
for	O
autosomal	B-Disease
dominant	I-Disease
hypercholesterolemia	I-Disease
,	O
and	O
recent	O
data	O
indicate	O
that	O
the	O
PCSK9	B-Gene
gene	O
is	O
involved	O
in	O
cholesterol	B-Chemical
biosynthesis	O
.	O
</ALL>	O

<ALL>	O
Mutations	O
within	O
this	O
gene	O
have	O
previously	O
been	O
found	O
to	O
segregate	O
with	O
hypercholesterolemia	B-Disease
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
DNA	O
sequencing	O
of	O
the	O
12	O
exons	O
of	O
the	O
PCSK9	B-Gene
gene	O
has	O
been	O
performed	O
in	O
51	O
Norwegian	O
subjects	O
with	O
a	O
clinical	O
diagnosis	O
of	O
familial	B-Disease
hypercholesterolemia	I-Disease
where	O
mutations	O
in	O
the	O
low	B-Gene
-	I-Gene
density	I-Gene
lipoprotein	I-Gene
receptor	I-Gene
gene	O
and	O
mutation	O
R3500Q	B-Variant
in	O
the	O
apolipoprotein	B-Gene
B	I-Gene
-	I-Gene
100	I-Gene
gene	O
had	O
been	O
excluded	O
.	O
</ALL>	O

<ALL>	O
Two	O
novel	O
missense	O
mutations	O
were	O
detected	O
in	O
the	O
catalytic	O
subdomain	O
of	O
the	O
PCSK9	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Two	O
patients	B-Species
were	O
heterozygotes	O
for	O
D374Y	B-Variant
,	O
and	O
one	O
patient	B-Species
was	O
a	O
double	O
heterozygote	O
for	O
D374Y	B-Variant
and	O
N157	B-Variant
K	I-Variant
.	O
</ALL>	O

<ALL>	O
D374Y	B-Variant
segregated	O
with	O
hypercholesterolemia	B-Disease
in	O
the	O
two	O
former	O
families	O
where	O
family	O
members	O
were	O
available	O
for	O
study	O
.	O
</ALL>	O

<ALL>	O
Our	O
findings	O
support	O
the	O
notion	O
that	O
mutations	O
in	O
the	O
PCSK9	B-Gene
gene	O
cause	O
autosomal	B-Disease
dominant	I-Disease
hypercholesterolemia	I-Disease
.	O
</ALL>	O

<ALL>	O
Desmin	B-Disease
-	I-Disease
related	I-Disease
myopathy	I-Disease
with	O
Mallory	O
body	O
-	O
like	O
inclusions	O
is	O
caused	O
by	O
mutations	O
of	O
the	O
selenoprotein	B-Gene
N	I-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Desmin	B-Disease
-	I-Disease
related	I-Disease
myopathies	I-Disease
(	O
DRMs	B-Disease
)	O
are	O
a	O
heterogeneous	O
group	O
of	O
muscle	B-Disease
disorders	I-Disease
,	O
morphologically	O
defined	O
by	O
intrasarcoplasmic	O
aggregates	O
of	O
desmin	B-Gene
.	O
</ALL>	O

<ALL>	O
Mutations	O
in	O
the	O
desmin	B-Gene
and	O
the	O
alpha	B-Gene
-	I-Gene
B	I-Gene
crystallin	I-Gene
genes	O
account	O
for	O
approximately	O
one	O
third	O
of	O
the	O
DRM	B-Disease
cases	O
.	O
</ALL>	O

<ALL>	O
The	O
genetic	O
basis	O
of	O
the	O
other	O
forms	O
remain	O
unknown	O
,	O
including	O
the	O
early	O
-	O
onset	O
,	O
recessive	O
form	O
with	O
Mallory	O
body	O
-	O
like	O
inclusions	O
(	O
MB	O
-	O
DRMs	B-Disease
)	O
,	O
first	O
described	O
in	O
five	O
related	O
German	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Recently	O
,	O
we	O
identified	O
the	O
selenoprotein	B-Gene
N	I-Gene
gene	O
(	O
SEPN1	B-Gene
)	O
as	O
responsible	O
for	O
SEPN	B-Disease
-	I-Disease
related	I-Disease
myopathy	I-Disease
(	O
SEPN	B-Disease
-	I-Disease
RM	I-Disease
)	O
,	O
a	O
unique	O
early	O
-	O
onset	O
myopathy	B-Disease
formerly	O
divided	O
in	O
two	O
different	O
nosological	O
categories	O
:	O
rigid	B-Disease
spine	I-Disease
muscular	I-Disease
dystrophy	I-Disease
and	O
the	O
severe	O
form	O
of	O
classical	O
multiminicore	B-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
finding	O
of	O
Mallory	O
body	O
-	O
like	O
inclusions	O
in	O
two	O
cases	O
of	O
genetically	O
documented	O
SEPN	B-Disease
-	I-Disease
RM	I-Disease
led	O
us	O
to	O
suspect	O
a	O
relationship	O
between	O
MB	O
-	O
DRM	B-Disease
and	O
SEPN1	B-Gene
.	O
</ALL>	O

<ALL>	O
In	O
the	O
original	O
MB	O
-	O
DRM	B-Disease
German	O
family	O
,	O
we	O
demonstrated	O
a	O
linkage	O
of	O
the	O
disease	O
to	O
the	O
SEPN1	B-Gene
locus	O
(	O
1p36	O
)	O
,	O
and	O
subsequently	O
a	O
homozygous	O
SEPN1	B-Gene
deletion	O
(	O
del	B-Variant
92	I-Variant
nucleotide	I-Variant
-	I-Variant
19	I-Variant
/	I-Variant
+	I-Variant
73	I-Variant
)	O
in	O
the	O
affected	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
A	O
comparative	O
reevaluation	O
showed	O
that	O
MB	O
-	O
DRM	B-Disease
and	O
SEPN	B-Disease
-	I-Disease
RM	I-Disease
share	O
identical	O
clinical	O
features	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
we	O
propose	O
that	O
MB	O
-	O
DRM	B-Disease
should	O
be	O
categorized	O
as	O
SEPN	B-Disease
-	I-Disease
RM	I-Disease
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
substantiate	O
the	O
molecular	O
heterogeneity	O
of	O
DRM	B-Disease
,	O
expand	O
the	O
morphological	O
spectrum	O
of	O
SEPN	B-Disease
-	I-Disease
RM	I-Disease
,	O
and	O
implicate	O
a	O
necessary	O
reassessment	O
of	O
the	O
nosological	O
boundaries	O
in	O
early	O
-	O
onset	O
myopathies	B-Disease
.	O
</ALL>	O

<ALL>	O
Altered	O
replication	O
timing	O
of	O
the	O
HIRA	B-Gene
/	O
Tuple1	B-Gene
locus	O
in	O
the	O
DiGeorge	B-Disease
and	I-Disease
Velocardiofacial	I-Disease
syndromes	I-Disease
.	O
</ALL>	O

<ALL>	O
DiGeorge	B-Disease
and	I-Disease
Velocardiofacial	I-Disease
syndromes	I-Disease
(	O
DGS	B-Disease
/	O
VCFS	B-Disease
)	O
are	O
endowed	O
by	O
a	O
similar	O
complex	O
phenotype	O
including	O
cardiovascular	B-Disease
,	I-Disease
craniofacial	I-Disease
,	I-Disease
and	I-Disease
thymic	I-Disease
malformations	I-Disease
,	O
and	O
are	O
associated	O
with	O
heterozygous	O
deletions	O
of	O
22q11	O
chromosomal	O
band	O
.	O
</ALL>	O

<ALL>	O
The	O
Typically	O
Deleted	O
Region	O
in	O
the	O
22q11.21	O
subband	O
(	O
here	O
called	O
TDR22	O
)	O
is	O
very	O
gene	O
-	O
dense	O
,	O
and	O
the	O
extent	O
of	O
the	O
deletion	O
has	O
been	O
defined	O
precisely	O
in	O
several	O
studies	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
to	O
date	O
there	O
is	O
no	O
evidence	O
for	O
a	O
mechanism	O
of	O
haploinsufficiency	O
that	O
can	O
fully	O
explain	O
the	O
DGS	B-Disease
/	O
VCFS	B-Disease
phenotype	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
show	O
that	O
the	O
candidate	O
gene	O
HIRA	B-Gene
/	O
Tuple1	B-Gene
mapping	O
on	O
the	O
non	O
-	O
deleted	O
TDR22	O
,	O
in	O
DGS	B-Disease
/	O
VCFS	B-Disease
subjects	O
presents	O
a	O
delayed	O
replication	O
timing	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
we	O
observed	O
an	O
increase	O
in	O
the	O
cell	O
ratio	O
showing	O
the	O
HIRA	B-Gene
/	O
Tuple1	B-Gene
locus	O
localised	O
toward	O
the	O
nuclear	O
periphery	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
known	O
that	O
replication	O
timing	O
and	O
nuclear	O
location	O
are	O
generally	O
correlated	O
to	O
the	O
transcription	O
activity	O
of	O
the	O
relative	O
DNA	O
region	O
.	O
</ALL>	O

<ALL>	O
We	O
propose	O
that	O
the	O
alteration	O
in	O
the	O
replication	O
/	O
nuclear	O
location	O
pattern	O
of	O
the	O
non	O
-	O
deleted	O
TDR22	O
indicates	O
an	O
altered	O
gene	O
regulation	O
hence	O
an	O
altered	O
transcritpion	O
in	O
DGS	B-Disease
/	O
VCFS	B-Disease
.	O
</ALL>	O

<ALL>	O
Severe	O
reversible	O
left	B-Disease
ventricular	I-Disease
systolic	I-Disease
and	I-Disease
diastolic	I-Disease
dysfunction	I-Disease
due	O
to	O
accidental	O
iatrogenic	O
epinephrine	B-Chemical
overdose	O
.	O
</ALL>	O

<ALL>	O
Catecholamine	B-Chemical
-	O
induced	O
cardiomyopathy	B-Disease
due	O
to	O
chronic	O
excess	O
of	O
endogenous	O
catecholamines	B-Chemical
has	O
been	O
recognized	O
for	O
decades	O
as	O
a	O
clinical	O
phenomenon	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
reports	O
of	O
myocardial	B-Disease
dysfunction	I-Disease
due	O
to	O
acute	O
iatrogenic	O
overdose	O
are	O
rare	O
.	O
</ALL>	O

<ALL>	O
A	O
35	O
-	O
year	O
-	O
old	O
woman	B-Species
whose	O
cervix	O
uteri	O
was	O
inadvertently	O
injected	O
with	O
8	O
mg	O
of	O
epinephrine	B-Chemical
developed	O
myocardial	B-Disease
stunning	I-Disease
that	O
was	O
characterized	O
by	O
severe	O
hemodynamic	O
compromise	O
,	O
profound	O
,	O
albeit	O
transient	O
,	O
left	B-Disease
ventricular	I-Disease
systolic	I-Disease
and	I-Disease
diastolic	I-Disease
dysfunction	I-Disease
,	O
and	O
only	O
modestly	O
elevated	O
biochemical	O
markers	O
of	O
myocardial	B-Disease
necrosis	I-Disease
.	O
</ALL>	O

<ALL>	O
Our	O
case	O
illustrates	O
the	O
serious	O
consequences	O
of	O
medical	O
errors	O
that	O
can	O
be	O
avoided	O
through	O
improved	O
medication	O
labeling	O
and	O
staff	O
supervision	O
.	O
</ALL>	O

<ALL>	O
Effects	O
of	O
the	O
cyclooxygenase	B-Gene
-	I-Gene
2	I-Gene
specific	O
inhibitor	O
valdecoxib	B-Chemical
versus	O
nonsteroidal	B-Chemical
antiinflammatory	I-Chemical
agents	I-Chemical
and	O
placebo	O
on	O
cardiovascular	O
thrombotic	B-Disease
events	O
in	O
patients	B-Species
with	O
arthritis	B-Disease
.	O
</ALL>	O

<ALL>	O
There	O
have	O
been	O
concerns	O
that	O
the	O
risk	O
of	O
cardiovascular	O
thrombotic	B-Disease
events	O
may	O
be	O
higher	O
with	O
cyclooxygenase	B-Gene
(	I-Gene
COX	I-Gene
)	I-Gene
-	I-Gene
2	I-Gene
-	O
specific	O
inhibitors	O
than	O
nonselective	O
nonsteroidal	B-Chemical
antiinflammatory	I-Chemical
drugs	I-Chemical
(	O
NSAIDs	B-Chemical
)	O
.	O
</ALL>	O

<ALL>	O
We	O
evaluated	O
cardiovascular	O
event	O
data	O
for	O
valdecoxib	B-Chemical
,	O
a	O
new	O
COX	B-Gene
-	I-Gene
2	I-Gene
-	O
specific	O
inhibitor	O
in	O
approximately	O
8000	O
patients	B-Species
with	O
osteoarthritis	B-Disease
and	O
rheumatoid	B-Disease
arthritis	I-Disease
treated	O
with	O
this	O
agent	O
in	O
randomized	O
clinical	O
trials	O
.	O
</ALL>	O

<ALL>	O
The	O
incidence	O
of	O
cardiovascular	O
thrombotic	B-Disease
events	O
(	O
cardiac	O
,	O
cerebrovascular	O
and	O
peripheral	O
vascular	O
,	O
or	O
arterial	O
thrombotic	B-Disease
)	O
was	O
determined	O
by	O
analyzing	O
pooled	O
valdecoxib	B-Chemical
(	O
10	O
-	O
80	O
mg	O
daily	O
)	O
,	O
nonselective	O
NSAID	B-Chemical
(	O
diclofenac	B-Chemical
75	O
mg	O
bid	O
,	O
ibuprofen	B-Chemical
800	O
mg	O
tid	O
,	O
or	O
naproxen	B-Chemical
500	O
mg	O
bid	O
)	O
and	O
placebo	O
data	O
from	O
10	O
randomized	O
osteoarthritis	B-Disease
and	O
rheumatoid	B-Disease
arthritis	I-Disease
trials	O
that	O
were	O
6	O
-	O
52	O
weeks	O
in	O
duration	O
.	O
</ALL>	O

<ALL>	O
The	O
incidence	O
rates	O
of	O
events	O
were	O
determined	O
in	O
all	O
patients	B-Species
(	O
n	O
=	O
7934	O
)	O
and	O
in	O
users	O
of	O
low	O
-	O
dose	O
(	O
<	O
or	O
=	O
325	O
mg	O
daily	O
)	O
aspirin	B-Chemical
(	O
n	O
=	O
1051	O
)	O
and	O
nonusers	O
of	O
aspirin	B-Chemical
(	O
n	O
=	O
6883	O
)	O
.	O
</ALL>	O

<ALL>	O
Crude	O
and	O
exposure	O
-	O
adjusted	O
incidences	O
of	O
thrombotic	B-Disease
events	O
were	O
similar	O
for	O
valdecoxib	B-Chemical
,	O
NSAIDs	B-Chemical
,	O
and	O
placebo	O
.	O
</ALL>	O

<ALL>	O
The	O
risk	O
of	O
serious	O
thrombotic	B-Disease
events	O
was	O
also	O
similar	O
for	O
each	O
valdecoxib	B-Chemical
dose	O
.	O
</ALL>	O

<ALL>	O
Thrombotic	B-Disease
risk	O
was	O
consistently	O
higher	O
for	O
users	O
of	O
aspirin	B-Chemical
users	O
than	O
nonusers	O
of	O
aspirin	B-Chemical
(	O
placebo	O
,	O
1.4	O
%	O
vs.	O
0	O
%	O
;	O
valdecoxib	B-Chemical
,	O
1.7	O
%	O
vs.	O
0.2	O
%	O
;	O
NSAIDs	B-Chemical
,	O
1.9	O
%	O
vs.	O
0.5	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
rates	O
of	O
events	O
in	O
users	O
of	O
aspirin	B-Chemical
were	O
similar	O
for	O
all	O
3	O
treatment	O
groups	O
and	O
across	O
valdecoxib	B-Chemical
doses	O
.	O
</ALL>	O

<ALL>	O
Short	O
-	O
and	O
intermediate	O
-	O
term	O
treatment	O
with	O
therapeutic	O
(	O
10	O
or	O
20	O
mg	O
daily	O
)	O
and	O
supratherapeutic	O
(	O
40	O
or	O
80	O
mg	O
daily	O
)	O
valdecoxib	B-Chemical
doses	O
was	O
not	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
thrombotic	B-Disease
events	O
relative	O
to	O
nonselective	O
NSAIDs	B-Chemical
or	O
placebo	O
in	O
osteoarthritis	B-Disease
and	O
rheumatoid	B-Disease
arthritis	I-Disease
patients	B-Species
in	O
controlled	O
clinical	O
trials	O
.	O
</ALL>	O

<ALL>	O
Identification	O
of	O
a	O
novel	O
WFS1	B-Gene
mutation	O
(	O
AFF344	B-Variant
-	I-Variant
345ins	I-Variant
)	O
in	O
Japanese	O
patients	B-Species
with	O
Wolfram	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Wolfram	B-Disease
syndrome	I-Disease
(	O
WFS	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
characterized	O
by	O
early	O
onset	O
diabetes	B-Disease
mellitus	I-Disease
,	O
progressive	O
optic	B-Disease
atrophy	I-Disease
,	O
sensorineural	B-Disease
deafness	I-Disease
and	O
diabetes	B-Disease
insipidus	I-Disease
.	O
</ALL>	O

<ALL>	O
Affected	O
individuals	O
may	O
also	O
have	O
renal	B-Disease
tract	I-Disease
abnormalities	I-Disease
as	O
well	O
as	O
neurogical	O
and	O
psychiatric	B-Disease
syndromes	I-Disease
.	O
</ALL>	O

<ALL>	O
WFS1	B-Gene
encoding	O
a	O
transmembrane	O
protein	O
was	O
identified	O
as	O
the	O
gene	O
responsible	O
for	O
WFS	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
report	O
herein	O
a	O
Japanese	O
family	O
,	O
of	O
which	O
two	O
members	O
had	O
this	O
syndrome	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
WFS1	B-Gene
gene	O
of	O
these	O
patients	B-Species
,	O
we	O
identified	O
a	O
novel	O
mutation	O
,	O
a	O
nine	B-Variant
nucleotide	I-Variant
insertion	I-Variant
(	O
AFF344	B-Variant
-	I-Variant
345ins	I-Variant
)	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
one	O
of	O
these	O
patients	B-Species
had	O
preclinical	O
hypopituitarism	B-Disease
,	O
which	O
is	O
an	O
unusual	O
feature	O
of	O
WFS	B-Disease
.	O
</ALL>	O

<ALL>	O
As	O
only	O
the	O
two	O
family	O
members	O
homozygous	O
for	O
the	O
mutation	O
showed	O
WFS	B-Disease
,	O
these	O
data	O
support	O
the	O
notion	O
that	O
this	O
mutation	O
is	O
the	O
cause	O
of	O
WFS	B-Disease
.	O
</ALL>	O

<ALL>	O
A	O
genetic	O
analysis	O
of	O
serotonergic	O
biosynthetic	O
and	O
metabolic	O
enzymes	O
in	O
migraine	B-Disease
using	O
a	O
DNA	O
pooling	O
approach	O
.	O
</ALL>	O

<ALL>	O
Migraine	B-Disease
is	O
a	O
common	O
debilitating	O
primary	O
headache	B-Disease
disorder	I-Disease
with	O
significant	O
mental	O
,	O
physical	O
and	O
social	O
health	O
implications	O
.	O
</ALL>	O

<ALL>	O
The	O
brain	O
neurotransmitter	B-Chemical
5	B-Chemical
-	I-Chemical
hydroxytryptamine	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
;	O
serotonin	B-Chemical
)	O
is	O
involved	O
in	O
nociceptive	O
pathways	O
and	O
has	O
been	O
implicated	O
in	O
the	O
pathophysiology	O
of	O
migraine	B-Disease
.	O
</ALL>	O

<ALL>	O
With	O
few	O
genetic	O
studies	O
investigating	O
biosynthetic	O
and	O
metabolic	O
enzymes	O
governing	O
the	O
rate	O
of	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
activity	O
and	O
their	O
relationship	O
to	O
migraine	B-Disease
,	O
it	O
was	O
the	O
objective	O
of	O
this	O
study	O
to	O
assess	O
genetic	O
variants	O
within	O
the	O
human	B-Species
tryptophan	B-Gene
hydroxylase	I-Gene
(	O
TPH	B-Gene
)	O
,	O
amino	B-Gene
acid	I-Gene
decarboxylase	I-Gene
(	O
AADC	B-Gene
)	O
and	O
monoamine	B-Gene
oxidase	I-Gene
A	I-Gene
(	O
MAOA	B-Gene
)	O
genes	O
in	O
migraine	B-Disease
susceptibility	O
.	O
</ALL>	O

<ALL>	O
This	O
objective	O
was	O
undertaken	O
using	O
a	O
high	O
-	O
throughput	O
DNA	O
pooling	O
experimental	O
design	O
,	O
which	O
proved	O
to	O
be	O
a	O
very	O
accurate	O
,	O
sensitive	O
and	O
specific	O
method	O
of	O
estimating	O
allele	O
frequencies	O
for	O
single	O
nucleotide	O
polymorphism	O
,	O
insertion	O
deletion	O
and	O
variable	O
number	O
tandem	O
repeat	O
loci	O
.	O
</ALL>	O

<ALL>	O
Application	O
of	O
DNA	O
pooling	O
to	O
a	O
wide	O
array	O
of	O
genetic	O
loci	O
provides	O
greater	O
scope	O
in	O
the	O
assessment	O
of	O
population	O
-	O
based	O
genetic	O
association	O
study	O
designs	O
.	O
</ALL>	O

<ALL>	O
Despite	O
the	O
application	O
of	O
this	O
high	O
-	O
throughput	O
genotyping	O
method	O
,	O
negative	O
results	O
from	O
the	O
two	O
-	O
stage	O
DNA	O
pooling	O
design	O
used	O
to	O
screen	O
loci	O
within	O
the	O
TPH	B-Gene
,	O
AADC	B-Gene
and	O
MAOA	B-Gene
genes	O
did	O
not	O
support	O
their	O
role	O
in	O
migraine	B-Disease
susceptibility	O
.	O
</ALL>	O

<ALL>	O
5	B-Chemical
-	I-Chemical
Fluorouracil	I-Chemical
cardiotoxicity	B-Disease
induced	O
by	O
alpha	B-Chemical
-	I-Chemical
fluoro	I-Chemical
-	I-Chemical
beta	I-Chemical
-	I-Chemical
alanine	I-Chemical
.	O
</ALL>	O

<ALL>	O
Cardiotoxicity	B-Disease
is	O
a	O
rare	O
complication	O
occurring	O
during	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
treatment	O
for	O
malignancies	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
herein	O
report	O
the	O
case	O
of	O
a	O
70	O
-	O
year	O
-	O
old	O
man	B-Species
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
,	O
in	O
whom	O
a	O
high	O
serum	O
level	O
of	O
alpha	B-Chemical
-	I-Chemical
fluoro	I-Chemical
-	I-Chemical
beta	I-Chemical
-	I-Chemical
alanine	I-Chemical
(	O
FBAL	B-Chemical
)	O
was	O
observed	O
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
,	O
who	O
had	O
unresectable	O
colon	B-Disease
cancer	I-Disease
metastases	B-Disease
to	O
the	O
liver	O
and	O
lung	O
,	O
was	O
referred	O
to	O
us	O
for	O
chemotherapy	O
from	O
an	O
affiliated	O
hospital	O
;	O
he	O
had	O
no	O
cardiac	O
history	O
.	O
</ALL>	O

<ALL>	O
After	O
admission	O
,	O
the	O
patient	B-Species
received	O
a	O
continuous	O
intravenous	O
infusion	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
(	O
1000	O
mg	O
/	O
day	O
)	O
,	O
during	O
which	O
precordial	B-Disease
pain	I-Disease
with	O
right	B-Disease
bundle	I-Disease
branch	I-Disease
block	I-Disease
occurred	O
concomitantly	O
with	O
a	O
high	O
serum	O
FBAL	B-Chemical
concentration	O
of	O
1955	O
ng	O
/	O
ml	O
.	O
</ALL>	O

<ALL>	O
Both	O
the	O
precordial	B-Disease
pain	I-Disease
and	O
the	O
electrocardiographic	O
changes	O
disappeared	O
spontaneously	O
after	O
the	O
discontinuation	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
.	O
</ALL>	O

<ALL>	O
As	O
the	O
precordial	B-Disease
pain	I-Disease
in	O
this	O
patient	B-Species
was	O
considered	O
to	O
have	O
been	O
due	O
to	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
,	O
the	O
administration	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
was	O
abandoned	O
.	O
</ALL>	O

<ALL>	O
Instead	O
,	O
oral	O
administration	O
of	O
S	B-Chemical
-	I-Chemical
1	I-Chemical
(	O
a	O
derivative	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
,	O
at	O
200	O
mg	O
/	O
day	O
twice	O
a	O
week	O
,	O
was	O
instituted	O
,	O
because	O
S	B-Chemical
-	I-Chemical
1	I-Chemical
has	O
a	O
strong	O
inhibitory	O
effect	O
on	O
dihydropyrimidine	B-Chemical
dehydrogenase	O
,	O
which	O
catalyzes	O
the	O
degradative	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
into	O
FBAL	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
serum	O
FBAL	B-Chemical
concentration	O
subsequently	O
decreased	O
to	O
352	O
ng	O
/	O
ml	O
,	O
the	O
same	O
as	O
the	O
value	O
measured	O
on	O
the	O
first	O
day	O
of	O
S	B-Chemical
-	I-Chemical
1	I-Chemical
administration	O
.	O
</ALL>	O

<ALL>	O
Thereafter	O
,	O
no	O
cardiac	B-Disease
symptoms	I-Disease
were	O
observed	O
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
achieved	O
a	O
partial	O
response	O
6	O
months	O
after	O
the	O
initiation	O
of	O
the	O
S	B-Chemical
-	I-Chemical
1	I-Chemical
treatment	O
.	O
</ALL>	O

<ALL>	O
The	O
experience	O
of	O
this	O
case	O
,	O
together	O
with	O
a	O
review	O
of	O
the	O
literature	O
,	O
suggests	O
that	O
FBAL	B-Chemical
is	O
related	O
to	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
S	B-Chemical
-	I-Chemical
1	I-Chemical
may	O
be	O
administered	O
safely	O
to	O
patients	B-Species
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
Pilocarpine	B-Chemical
seizures	B-Disease
cause	O
age	O
-	O
dependent	O
impairment	B-Disease
in	I-Disease
auditory	I-Disease
location	I-Disease
discrimination	I-Disease
.	O
</ALL>	O

<ALL>	O
Children	O
who	O
have	O
status	B-Disease
epilepticus	I-Disease
have	O
continuous	O
or	O
rapidly	O
repeating	O
seizures	B-Disease
that	O
may	O
be	O
life	O
-	O
threatening	O
and	O
may	O
cause	O
life	O
-	O
long	O
changes	O
in	O
brain	O
and	O
behavior	O
.	O
</ALL>	O

<ALL>	O
The	O
extent	O
to	O
which	O
status	B-Disease
epilepticus	I-Disease
causes	O
deficits	B-Disease
in	I-Disease
auditory	I-Disease
discrimination	I-Disease
is	O
unknown	O
.	O
</ALL>	O

<ALL>	O
A	O
naturalistic	O
auditory	O
location	O
discrimination	O
method	O
was	O
used	O
to	O
evaluate	O
this	O
question	O
using	O
an	O
animal	O
model	O
of	O
status	B-Disease
epilepticus	I-Disease
.	O
</ALL>	O

<ALL>	O
Male	O
Sprague	O
-	O
Dawley	O
rats	B-Species
were	O
injected	O
with	O
saline	O
on	O
postnatal	O
day	O
(	O
P	O
)	O
20	O
,	O
or	O
a	O
convulsant	O
dose	O
of	O
pilocarpine	B-Chemical
on	O
P20	O
or	O
P45	O
.	O
</ALL>	O

<ALL>	O
Pilocarpine	B-Chemical
on	O
either	O
day	O
induced	O
status	B-Disease
epilepticus	I-Disease
;	O
status	B-Disease
epilepticus	I-Disease
at	O
P45	O
resulted	O
in	O
CA3	B-CellLine
cell	O
loss	O
and	O
spontaneous	O
seizures	B-Disease
,	O
whereas	O
P20	O
rats	B-Species
had	O
no	O
cell	O
loss	O
or	O
spontaneous	O
seizures	B-Disease
.	O
</ALL>	O

<ALL>	O
Mature	O
rats	B-Species
were	O
trained	O
with	O
sound	O
-	O
source	O
location	O
and	O
sound	O
-	O
silence	O
discriminations	O
.	O
</ALL>	O

<ALL>	O
Control	O
(	O
saline	O
P20	O
)	O
rats	B-Species
acquired	O
both	O
discriminations	O
immediately	O
.	O
</ALL>	O

<ALL>	O
In	O
status	B-Disease
epilepticus	I-Disease
(	O
P20	O
)	O
rats	B-Species
,	O
acquisition	O
of	O
the	O
sound	O
-	O
source	O
location	O
discrimination	O
was	O
moderately	O
impaired	O
.	O
</ALL>	O

<ALL>	O
Status	B-Disease
epilepticus	I-Disease
(	O
P45	O
)	O
rats	B-Species
failed	O
to	O
acquire	O
either	O
sound	O
-	O
source	O
location	O
or	O
sound	O
-	O
silence	O
discriminations	O
.	O
</ALL>	O

<ALL>	O
Status	B-Disease
epilepticus	I-Disease
in	O
rat	B-Species
causes	O
an	O
age	O
-	O
dependent	O
,	O
long	O
-	O
term	O
impairment	B-Disease
in	I-Disease
auditory	I-Disease
discrimination	I-Disease
.	O
</ALL>	O

<ALL>	O
This	O
impairment	O
may	O
explain	O
one	O
cause	O
of	O
impaired	B-Disease
auditory	I-Disease
location	I-Disease
discrimination	I-Disease
in	O
humans	B-Species
.	O
</ALL>	O

<ALL>	O
No	O
independent	O
role	O
of	O
the	O
-	B-Variant
1123	I-Variant
G	I-Variant
>	I-Variant
C	I-Variant
and	O
+	B-Variant
2740	I-Variant
A	I-Variant
>	I-Variant
G	I-Variant
variants	O
in	O
the	O
association	O
of	O
PTPN22	B-Gene
with	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
and	O
juvenile	B-Disease
idiopathic	I-Disease
arthritis	I-Disease
in	O
two	O
Caucasian	O
populations	O
.	O
</ALL>	O

<ALL>	O
INTRODUCTION	O
:	O
The	O
PTPN22	B-Gene
is	O
a	O
negative	O
regulator	O
of	O
the	O
T	O
cell	O
response	O
.	O
</ALL>	O

<ALL>	O
Its	O
+	B-Variant
1858C	I-Variant
>	I-Variant
T	I-Variant
(	O
R620W	B-Variant
)	O
polymorphism	O
has	O
been	O
shown	O
to	O
associate	O
with	O
a	O
risk	O
for	O
multiple	O
autoimmune	B-Disease
diseases	I-Disease
,	O
including	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
(	O
T1D	B-Disease
)	O
and	O
juvenile	B-Disease
idiopathic	I-Disease
arthritis	I-Disease
(	O
JIA	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
The	O
minor	O
(	O
susceptibility	O
)	O
allele	O
is	O
absent	O
in	O
Asian	O
populations	O
,	O
but	O
a	O
recent	O
study	O
suggested	O
an	O
independent	O
involvement	O
of	O
another	O
polymorphism	O
located	O
within	O
the	O
promoter	O
-	O
1123	O
nucleotides	O
relative	O
to	O
the	O
translational	O
start	O
site	O
.	O
</ALL>	O

<ALL>	O
AIMS	O
:	O
We	O
aimed	O
to	O
analyse	O
the	O
association	O
of	O
three	O
PTPN22	B-Gene
polymorphisms	O
in	O
two	O
distinct	O
Caucasian	O
populations	O
,	O
the	O
Czechs	O
(	O
with	O
T1D	B-Disease
and	O
with	O
JIA	B-Disease
)	O
and	O
Azeri	O
(	O
with	O
T1D	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
The	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
at	O
positions	O
-	O
1123	O
(	O
rs2488457	B-Variant
)	O
,	O
+	O
1858	O
(	O
rs2476601	B-Variant
,	O
the	O
R620W	B-Variant
substitution	O
)	O
,	O
and	O
+	O
2740	O
(	O
rs1217412	B-Variant
)	O
were	O
genotyped	O
using	O
TaqMan	O
assays	O
in	O
372	O
subjects	O
with	O
childhood	O
-	O
onset	O
T1D	B-Disease
,	O
130	O
subjects	O
with	O
JIA	B-Disease
,	O
and	O
400	O
control	O
subjects	O
of	O
Czech	O
origin	O
,	O
and	O
in	O
160	O
subjects	O
with	O
T1D	B-Disease
and	O
271	O
healthy	O
controls	O
of	O
Azeri	O
origin	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
In	O
the	O
Czechs	O
,	O
all	O
three	O
SNPs	O
were	O
in	O
a	O
tight	O
linkage	O
disequlibrium	O
,	O
while	O
in	O
the	O
Azeri	O
,	O
the	O
linkage	O
disequlibrium	O
was	O
limited	O
to	O
between	O
the	O
promoter	O
and	O
3	O
'	O
-	O
UTR	O
polymorphism	O
,	O
D	O
'	O
(	O
-	O
1123	O
,	O
+	O
2740	O
)	O
=	O
0.99	O
,	O
r	O
(	O
2	O
)	O
=	O
0.72	O
.	O
</ALL>	O

<ALL>	O
Haplotype	O
reconstruction	O
via	O
the	O
expectation	O
-	O
maximization	O
algorithm	O
showed	O
in	O
both	O
populations	O
that	O
only	O
the	O
haplotype	O
containing	O
the	O
minor	O
(	B-Variant
W	I-Variant
)	I-Variant
allele	I-Variant
at	I-Variant
codon	I-Variant
620	I-Variant
was	O
associated	O
with	O
T1D	B-Disease
(	O
OR	O
=	O
2.26	O
,	O
95	O
%	O
CI	O
1.68	O
-	O
3.02	O
in	O
Czechs	O
,	O
OR	O
=	O
14.8	O
,	O
95	O
%	O
CI	O
2.0	O
-	O
651	O
in	O
Azeri	O
)	O
or	O
JIA	B-Disease
(	O
OR	O
=	O
2.43	O
,	O
95	O
%	O
CI	O
1.66	O
-	O
3.56	O
in	O
Czechs	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
haplotypes	O
having	O
the	O
wild	O
-	O
type	O
(	B-Variant
R	I-Variant
)	I-Variant
allele	I-Variant
at	I-Variant
codon	I-Variant
620	I-Variant
and	O
minor	O
alleles	O
at	O
-	O
1123	O
and	O
/	O
or	O
+	O
2740	O
were	O
neutral	O
as	O
to	O
the	O
risk	O
of	O
autoimmune	B-Disease
conditions	I-Disease
in	O
both	O
populations	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
In	O
two	O
different	O
Caucasian	O
populations	O
,	O
the	O
Czechs	O
and	O
the	O
Azeri	O
,	O
no	O
independent	O
contribution	O
can	O
be	O
detected	O
either	O
of	O
the	O
-	O
1123	O
promoter	O
SNP	O
or	O
the	O
+	O
2740	O
3	O
'	O
-	O
UTR	O
SNP	O
,	O
and	O
only	O
the	O
minor	O
allele	O
at	O
PTPN22	B-Gene
codon	O
620	O
contributes	O
to	O
the	O
risk	O
of	O
autoimmunity	O
.	O
</ALL>	O

<ALL>	O
A	O
polymorphism	O
of	O
C	B-Variant
-	I-Variant
to	I-Variant
-	I-Variant
T	I-Variant
substitution	I-Variant
at	I-Variant
-	I-Variant
31	I-Variant
IL1B	B-Gene
is	O
associated	O
with	O
the	O
risk	O
of	O
advanced	O
gastric	B-Disease
adenocarcinoma	I-Disease
in	O
a	O
Japanese	O
population	O
.	O
</ALL>	O

<ALL>	O
Proinflammatory	B-Gene
cytokine	I-Gene
gene	O
polymorphisms	O
have	O
been	O
demonstrated	O
to	O
associate	O
with	O
gastric	B-Disease
cancer	I-Disease
risk	O
,	O
of	O
which	O
IL1B	O
-	B-Variant
31	I-Variant
T	I-Variant
/	I-Variant
C	I-Variant
and	O
-	B-Variant
511C	I-Variant
/	I-Variant
T	I-Variant
changes	O
have	O
been	O
well	O
investigated	O
due	O
to	O
the	O
possibility	O
that	O
they	O
may	O
alter	O
the	O
IL1B	B-Gene
transcription	O
.	O
</ALL>	O

<ALL>	O
The	O
signal	O
transduction	O
target	O
upon	O
interleukin	B-Gene
1	I-Gene
beta	I-Gene
(	O
IL1beta	B-Gene
)	O
stimulation	O
,	O
the	O
nuclear	B-Gene
factor	I-Gene
of	I-Gene
kappa	I-Gene
B	I-Gene
(	O
NFkappaB	B-Gene
)	O
activation	O
,	O
supports	O
cancer	B-Disease
development	O
,	O
signal	O
transduction	O
in	O
which	O
is	O
mediated	O
by	O
FS	B-Gene
-	I-Gene
7	I-Gene
cell	I-Gene
-	I-Gene
associated	I-Gene
cell	I-Gene
surface	I-Gene
antigen	I-Gene
(	O
FAS	B-Gene
)	O
signaling	O
.	O
</ALL>	O

<ALL>	O
Based	O
on	O
recent	O
papers	O
describing	O
the	O
prognostic	O
roles	O
of	O
the	O
polymorphisms	O
and	O
the	O
NFkappaB	B-Gene
functions	O
on	O
cancer	B-Disease
development	O
,	O
we	O
sought	O
to	O
determine	O
if	O
Japanese	O
gastric	B-Disease
cancer	I-Disease
patients	B-Species
were	O
affected	O
by	O
the	O
IL1B	B-Gene
-	O
31	O
/	O
-	O
511	O
and	O
FAS	B-Gene
-	O
670	O
polymorphisms	O
.	O
</ALL>	O

<ALL>	O
A	O
case	O
-	O
control	O
study	O
was	O
conducted	O
on	O
incident	O
gastric	B-Disease
adenocarcinoma	I-Disease
patients	B-Species
(	O
n	O
=	O
271	O
)	O
and	O
age	O
-	O
gender	O
frequency	O
-	O
matched	O
control	O
subjects	O
(	O
n	O
=	O
271	O
)	O
.	O
</ALL>	O

<ALL>	O
We	O
observed	O
strong	O
linkage	O
disequilibrium	O
between	O
the	O
T	B-Variant
allele	I-Variant
at	I-Variant
-	I-Variant
511	I-Variant
and	O
the	O
C	B-Variant
allele	I-Variant
at	I-Variant
-	I-Variant
31	I-Variant
and	O
between	O
the	O
C	B-Variant
allele	I-Variant
at	I-Variant
-	I-Variant
511	I-Variant
and	O
the	O
T	B-Variant
allele	I-Variant
at	I-Variant
-	I-Variant
31	I-Variant
in	O
IL1B	B-Gene
in	O
both	O
the	O
cases	O
and	O
controls	O
(	O
R	O
(	O
2	O
)	O
=	O
0.94	O
)	O
.	O
</ALL>	O

<ALL>	O
Neither	O
IL1B	B-Gene
-	O
31	O
,	O
-	O
511	O
nor	O
FAS	B-Gene
-	O
670	O
polymorphisms	O
showed	O
significantly	O
different	O
risks	O
of	O
gastric	B-Disease
adenocarcinoma	I-Disease
.	O
</ALL>	O

<ALL>	O
Though	O
FAS	B-Gene
-	O
670	O
polymorphisms	O
did	O
not	O
show	O
any	O
significant	O
difference	O
,	O
the	O
proportion	O
of	O
subjects	O
with	O
IL1B	O
-	B-Variant
31TT	I-Variant
(	O
or	O
IL1B	O
-	B-Variant
511CC	I-Variant
)	O
increased	O
according	O
to	O
stage	O
(	O
trend	O
P	O
=	O
0.019	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
particular	O
,	O
subjects	O
with	O
stage	O
IV	O
had	O
a	O
two	O
times	O
higher	O
probability	O
of	O
having	O
either	O
IL1B	O
-	B-Variant
31TT	I-Variant
(	O
or	O
IL1B	O
-	B-Variant
511CC	I-Variant
)	O
genotype	O
compared	O
with	O
stage	O
I	O
subjects	O
.	O
</ALL>	O

<ALL>	O
These	O
observations	O
suggest	O
that	O
IL1B	O
-	B-Variant
31TT	I-Variant
and	O
IL1B	O
-	B-Variant
511CC	I-Variant
are	O
associated	O
with	O
disease	O
progression	O
.	O
</ALL>	O

<ALL>	O
Chloroacetaldehyde	B-Chemical
as	O
a	O
sulfhydryl	B-Chemical
reagent	I-Chemical
:	O
the	O
role	O
of	O
critical	O
thiol	B-Chemical
groups	O
in	O
ifosfamide	B-Chemical
nephropathy	B-Disease
.	O
</ALL>	O

<ALL>	O
Chloroacetaldehyde	B-Chemical
(	O
CAA	B-Chemical
)	O
is	O
a	O
metabolite	O
of	O
the	O
alkylating	B-Chemical
agent	I-Chemical
ifosfamide	B-Chemical
(	O
IFO	B-Chemical
)	O
and	O
putatively	O
responsible	O
for	O
renal	B-Disease
damage	I-Disease
following	O
anti	O
-	O
tumor	B-Disease
therapy	O
with	O
IFO	B-Chemical
.	O
</ALL>	O

<ALL>	O
Depletion	O
of	O
sulfhydryl	B-Chemical
(	O
SH	B-Chemical
)	O
groups	O
has	O
been	O
reported	O
from	O
cell	O
culture	O
,	O
animal	O
and	O
clinical	O
studies	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
work	O
the	O
effect	O
of	O
CAA	B-Chemical
on	O
human	B-Species
proximal	O
tubule	O
cells	O
in	O
primary	O
culture	O
(	O
hRPTEC	B-CellLine
)	O
was	O
investigated	O
.	O
</ALL>	O

<ALL>	O
Toxicity	B-Disease
of	O
CAA	B-Chemical
was	O
determined	O
by	O
protein	O
content	O
,	O
cell	O
number	O
,	O
LDH	B-Chemical
release	O
,	O
trypan	B-Chemical
blue	I-Chemical
exclusion	O
assay	O
and	O
caspase	B-Gene
-	I-Gene
3	I-Gene
activity	O
.	O
</ALL>	O

<ALL>	O
Free	O
thiols	B-Chemical
were	O
measured	O
by	O
the	O
method	O
of	O
Ellman	O
.	O
</ALL>	O

<ALL>	O
CAA	B-Chemical
reduced	O
hRPTEC	B-CellLine
cell	O
number	O
and	O
protein	O
,	O
induced	O
a	O
loss	O
in	O
free	O
intracellular	O
thiols	B-Chemical
and	O
an	O
increase	O
in	O
necrosis	B-Disease
markers	O
.	O
</ALL>	O

<ALL>	O
CAA	B-Chemical
but	O
not	O
acrolein	B-Chemical
inhibited	O
the	O
cysteine	B-Gene
proteases	I-Gene
caspase	B-Gene
-	I-Gene
3	I-Gene
,	O
caspase	B-Gene
-	I-Gene
8	I-Gene
and	O
cathepsin	B-Gene
B	I-Gene
.	O
</ALL>	O

<ALL>	O
Caspase	B-Gene
activation	O
by	O
cisplatin	B-Chemical
was	O
inhibited	O
by	O
CAA	B-Chemical
.	O
</ALL>	O

<ALL>	O
In	O
cells	O
stained	O
with	O
fluorescent	O
dyes	O
targeting	O
lysosomes	O
,	O
CAA	B-Chemical
induced	O
an	O
increase	O
in	O
lysosomal	O
size	O
and	O
lysosomal	O
leakage	O
.	O
</ALL>	O

<ALL>	O
The	O
effects	O
of	O
CAA	B-Chemical
on	O
cysteine	B-Gene
protease	I-Gene
activities	O
and	O
thiols	B-Chemical
could	O
be	O
reproduced	O
in	O
cell	O
lysate	O
.	O
</ALL>	O

<ALL>	O
Acidification	O
,	O
which	O
slowed	O
the	O
reaction	O
of	O
CAA	B-Chemical
with	O
thiol	B-Chemical
donors	O
,	O
could	O
also	O
attenuate	O
effects	O
of	O
CAA	B-Chemical
on	O
necrosis	B-Disease
markers	O
,	O
thiol	B-Chemical
depletion	O
and	O
cysteine	B-Gene
protease	I-Gene
inhibition	O
in	O
living	O
cells	O
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
CAA	B-Chemical
directly	O
reacts	O
with	O
cellular	O
protein	O
and	O
non	O
-	O
protein	O
thiols	B-Chemical
,	O
mediating	O
its	O
toxicity	B-Disease
on	O
hRPTEC	B-CellLine
.	O
</ALL>	O

<ALL>	O
This	O
effect	O
can	O
be	O
reduced	O
by	O
acidification	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
urinary	O
acidification	O
could	O
be	O
an	O
option	O
to	O
prevent	O
IFO	B-Chemical
nephropathy	B-Disease
in	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Delayed	O
institution	O
of	O
hypertension	B-Disease
during	O
focal	O
cerebral	B-Disease
ischemia	I-Disease
:	O
effect	O
on	O
brain	B-Disease
edema	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
effect	O
of	O
induced	O
hypertension	B-Disease
instituted	O
after	O
a	O
2	O
-	O
h	O
delay	O
following	O
middle	B-Disease
cerebral	I-Disease
artery	I-Disease
occlusion	I-Disease
(	O
MCAO	B-Disease
)	O
on	O
brain	B-Disease
edema	I-Disease
formation	O
and	O
histochemical	O
injury	O
was	O
studied	O
.	O
</ALL>	O

<ALL>	O
Under	O
isoflurane	B-Chemical
anesthesia	O
,	O
the	O
MCA	O
of	O
14	O
spontaneously	O
hypertensive	B-Disease
rats	B-Species
was	O
occluded	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
control	O
group	O
(	O
n	O
=	O
7	O
)	O
,	O
the	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
was	O
not	O
manipulated	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
hypertensive	B-Disease
group	O
(	O
n	O
=	O
7	O
)	O
,	O
the	O
MAP	O
was	O
elevated	O
by	O
25	O
-	O
30	O
mm	O
Hg	O
beginning	O
2	O
h	O
after	O
MCAO	B-Disease
.	O
</ALL>	O

<ALL>	O
Four	O
hours	O
after	O
MCAO	B-Disease
,	O
the	O
rats	B-Species
were	O
killed	O
and	O
the	O
brains	O
harvested	O
.	O
</ALL>	O

<ALL>	O
The	O
brains	O
were	O
sectioned	O
along	O
coronal	O
planes	O
spanning	O
the	O
distribution	O
of	O
ischemia	B-Disease
produced	O
by	O
MCAO	B-Disease
.	O
</ALL>	O

<ALL>	O
Specific	O
gravity	O
(	O
SG	O
)	O
was	O
determined	O
in	O
the	O
subcortex	O
and	O
in	O
two	O
sites	O
in	O
the	O
cortex	O
(	O
core	O
and	O
periphery	O
of	O
the	O
ischemic	B-Disease
territory	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
extent	O
of	O
neuronal	B-Disease
injury	I-Disease
was	O
determined	O
by	O
2,3,5	B-Chemical
-	I-Chemical
triphenyltetrazolium	I-Chemical
staining	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
ischemic	B-Disease
core	O
,	O
there	O
was	O
no	O
difference	O
in	O
SG	O
in	O
the	O
subcortex	O
and	O
cortex	O
in	O
the	O
two	O
groups	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
periphery	O
of	O
the	O
ischemic	B-Disease
territory	O
,	O
SG	O
in	O
the	O
cortex	O
was	O
greater	O
(	O
less	O
edema	B-Disease
accumulation	O
)	O
in	O
the	O
hypertensive	B-Disease
group	O
(	O
1.041	O
+	O
/	O
-	O
0.001	O
vs	O
1.039	O
+	O
/	O
-	O
0.001	O
,	O
P	O
less	O
than	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
area	O
of	O
histochemical	O
injury	O
(	O
as	O
a	O
percent	O
of	O
the	O
cross	O
-	O
sectional	O
area	O
of	O
the	O
hemisphere	O
)	O
was	O
less	O
in	O
the	O
hypertensive	B-Disease
group	O
(	O
33	O
+	O
/	O
-	O
3	O
%	O
vs	O
21	O
+	O
/	O
-	O
2	O
%	O
,	O
P	O
less	O
than	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
data	O
indicate	O
that	O
phenylephrine	B-Chemical
-	O
induced	O
hypertension	B-Disease
instituted	O
2	O
h	O
after	O
MCAO	B-Disease
does	O
not	O
aggravate	O
edema	B-Disease
in	O
the	O
ischemic	B-Disease
core	O
,	O
that	O
it	O
improves	O
edema	B-Disease
in	O
the	O
periphery	O
of	O
the	O
ischemic	B-Disease
territory	O
,	O
and	O
that	O
it	O
reduces	O
the	O
area	O
of	O
histochemical	O
neuronal	B-Disease
dysfunction	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
phosphatidylethanolamine	B-Gene
N	I-Gene
-	I-Gene
methyltransferase	I-Gene
gene	O
V175	B-Variant
M	I-Variant
single	O
nucleotide	O
polymorphism	O
confers	O
the	O
susceptibility	O
to	O
NASH	B-Disease
in	O
Japanese	O
population	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
/	O
AIMS	O
:	O
The	O
genetic	O
predisposition	O
on	O
the	O
development	O
of	O
nonalcoholic	B-Disease
steatohepatitis	I-Disease
(	O
NASH	B-Disease
)	O
has	O
been	O
poorly	O
understood	O
.	O
</ALL>	O

<ALL>	O
A	O
functional	O
polymorphism	O
Val175Met	B-Variant
was	O
reported	O
in	O
phosphatidylethanolamine	B-Gene
N	I-Gene
-	I-Gene
methyltransferase	I-Gene
(	O
PEMT	B-Gene
)	O
that	O
catalyzes	O
the	O
conversion	O
of	O
phosphatidylethanolamine	B-Chemical
to	O
phosphatidylcholine	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
carriers	O
of	O
Val175Met	B-Variant
variant	O
impaired	O
in	O
PEMT	B-Gene
activity	O
are	O
more	O
susceptible	O
to	O
NASH	B-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Blood	O
samples	O
of	O
107	O
patients	B-Species
with	O
biopsy	O
-	O
proven	O
NASH	B-Disease
and	O
of	O
150	O
healthy	O
volunteers	O
were	O
analyzed	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Val175Met	B-Variant
variant	O
allele	O
of	O
the	O
PEMT	B-Gene
gene	O
was	O
significantly	O
more	O
frequent	O
in	O
NASH	B-Disease
patients	B-Species
than	O
in	O
healthy	O
volunteers	O
(	O
p	O
<	O
0.001	O
)	O
,	O
and	O
carriers	O
of	O
Val175Met	B-Variant
variant	O
were	O
significantly	O
more	O
frequent	O
in	O
NASH	B-Disease
patients	B-Species
than	O
in	O
healthy	O
volunteers	O
(	O
p	O
<	O
0.01	O
)	O
.	O
</ALL>	O

<ALL>	O
Among	O
NASH	B-Disease
patients	B-Species
,	O
body	O
mass	O
index	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0.05	O
)	O
,	O
and	O
non	O
-	O
obese	B-Disease
patients	B-Species
were	O
significantly	O
more	O
frequent	O
(	O
p	O
<	O
0.001	O
)	O
in	O
carriers	O
of	O
Val175Met	B-Variant
variant	O
than	O
in	O
homozygotes	O
of	O
wild	O
type	O
PEMT	B-Gene
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Val175Met	B-Variant
variant	O
of	O
PEMT	B-Gene
could	O
be	O
a	O
candidate	O
molecule	O
that	O
determines	O
the	O
susceptibility	O
to	O
NASH	B-Disease
,	O
because	O
it	O
is	O
more	O
frequently	O
observed	O
in	O
NASH	B-Disease
patients	B-Species
and	O
non	O
-	O
obese	B-Disease
persons	O
with	O
Val175Met	B-Variant
variant	O
of	O
PEMT	B-Gene
are	O
facilitated	O
to	O
develop	O
NASH	B-Disease
.	O
</ALL>	O

<ALL>	O
Tenomodulin	B-Gene
is	O
associated	O
with	O
obesity	B-Disease
and	O
diabetes	B-Disease
risk	O
:	O
the	O
Finnish	O
diabetes	B-Disease
prevention	O
study	O
.	O
</ALL>	O

<ALL>	O
We	O
recently	O
showed	O
that	O
long	O
-	O
term	O
weight	O
reduction	O
changes	O
the	O
gene	O
expression	O
profile	O
of	O
adipose	O
tissue	O
in	O
overweight	B-Disease
individuals	O
with	O
impaired	B-Disease
glucose	I-Disease
tolerance	I-Disease
(	O
IGT	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
One	O
of	O
the	O
responding	O
genes	O
was	O
X	O
-	O
chromosomal	O
tenomodulin	B-Gene
(	O
TNMD	B-Gene
)	O
,	O
a	O
putative	O
angiogenesis	O
inhibitor	O
.	O
</ALL>	O

<ALL>	O
Our	O
aim	O
was	O
to	O
study	O
the	O
associations	O
of	O
individual	O
single	O
nucleotide	O
polymorphisms	O
and	O
haplotypes	O
with	O
adiposity	B-Disease
,	O
glucose	B-Chemical
metabolism	O
,	O
and	O
the	O
risk	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
(	O
T2D	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Seven	O
single	O
nucleotide	O
polymorphisms	O
from	O
two	O
different	O
haploblocks	O
were	O
genotyped	O
from	O
507	O
participants	O
of	O
the	O
Finnish	O
Diabetes	B-Disease
Prevention	O
Study	O
(	O
DPS	O
)	O
.	O
</ALL>	O

<ALL>	O
Sex	O
-	O
specific	O
genotype	O
effects	O
were	O
observed	O
.	O
</ALL>	O

<ALL>	O
Three	O
markers	O
of	O
haploblock	O
1	O
were	O
associated	O
with	O
features	O
of	O
adiposity	B-Disease
in	O
women	B-Species
(	O
rs5966709	B-Variant
,	O
rs4828037	B-Variant
)	O
and	O
men	B-Species
(	O
rs11798018	B-Variant
)	O
.	O
</ALL>	O

<ALL>	O
Markers	O
rs2073163	B-Variant
and	O
rs1155794	B-Variant
from	O
haploblock	O
2	O
were	O
associated	O
with	O
2	O
-	O
hour	O
plasma	O
glucose	B-Chemical
levels	O
in	O
men	B-Species
during	O
the	O
3	O
-	O
year	O
follow	O
-	O
up	O
.	O
</ALL>	O

<ALL>	O
The	O
same	O
two	O
markers	O
together	O
with	O
rs2073162	B-Variant
associated	O
with	O
the	O
conversion	O
of	O
IGT	B-Disease
to	O
T2D	B-Disease
in	O
men	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
risk	O
of	O
developing	O
T2D	B-Disease
was	O
approximately	O
2	O
-	O
fold	O
in	O
individuals	O
with	O
genotypes	O
associated	O
with	O
higher	O
2	O
-	O
hour	O
plasma	O
glucose	B-Chemical
levels	O
;	O
the	O
hazard	O
ratios	O
were	O
2.192	O
(	O
p	O
=	O
0.025	O
)	O
for	O
rs2073162	B-Variant
-	O
A	O
,	O
2.191	O
(	O
p	O
=	O
0.027	O
)	O
for	O
rs2073163	B-Variant
-	O
C	O
,	O
and	O
1.998	O
(	O
p	O
=	O
0.054	O
)	O
for	O
rs1155974	B-Variant
-	O
T.	O
These	O
results	O
suggest	O
that	O
TNMD	B-Gene
polymorphisms	O
are	O
associated	O
with	O
adiposity	B-Disease
and	O
also	O
with	O
glucose	B-Chemical
metabolism	O
and	O
conversion	O
from	O
IGT	B-Disease
to	O
T2D	B-Disease
in	O
men	B-Species
.	O
</ALL>	O

<ALL>	O
Mutations	O
in	O
pattern	O
recognition	O
receptor	O
genes	O
modulate	O
seroreactivity	O
to	O
microbial	O
antigens	O
in	O
patients	B-Species
with	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
AND	O
AIMS	O
:	O
A	O
number	O
of	O
antibodies	O
against	O
microbial	O
epitopes	O
or	O
self	O
-	O
antigens	O
have	O
been	O
associated	O
with	O
Crohn	B-Disease
's	I-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
development	O
of	O
antibodies	O
reflects	O
a	O
loss	O
of	O
tolerance	O
to	O
intestinal	O
bacteria	B-Species
that	O
underlies	O
Crohn	B-Disease
's	I-Disease
disease	I-Disease
,	O
resulting	O
in	O
an	O
exaggerated	O
adaptive	O
immune	O
response	O
to	O
these	O
bacteria	B-Species
.	O
</ALL>	O

<ALL>	O
It	O
was	O
hypothesised	O
that	O
the	O
development	O
of	O
antimicrobial	O
antibodies	O
is	O
influenced	O
by	O
the	O
presence	O
of	O
genetic	O
variants	O
in	O
pattern	O
recognition	O
receptor	O
genes	O
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
this	O
study	O
was	O
therefore	O
to	O
investigate	O
the	O
influence	O
of	O
mutations	O
in	O
these	O
innate	B-Gene
immune	I-Gene
receptor	I-Gene
genes	O
(	O
nucleotide	B-Gene
oligomerisation	I-Gene
domain	I-Gene
(	I-Gene
NOD	I-Gene
)	I-Gene
2	I-Gene
/	O
caspase	B-Gene
recruitment	I-Gene
domain	I-Gene
(	I-Gene
CARD	I-Gene
)	I-Gene
15	I-Gene
,	O
NOD1	B-Gene
/	O
CARD4	B-Gene
,	O
TUCAN	B-Gene
/	O
CARDINAL	B-Gene
/	O
CARD8	B-Gene
,	O
Toll	B-Gene
-	I-Gene
like	I-Gene
receptor	I-Gene
(	I-Gene
TLR	I-Gene
)	I-Gene
4	I-Gene
,	O
TLR2	B-Gene
,	O
TLR1	B-Gene
and	O
TLR6	B-Gene
)	O
on	O
the	O
development	O
of	O
antimicrobial	O
and	O
antiglycan	O
antibodies	O
in	O
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
(	O
IBD	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Materials	O
and	O
METHODS	O
:	O
A	O
cohort	O
of	O
1163	O
unrelated	O
patients	B-Species
with	O
IBD	B-Disease
(	O
874	O
Crohn	B-Disease
's	I-Disease
disease	I-Disease
,	O
259	O
ulcerative	B-Disease
colitis	I-Disease
,	O
30	O
indeterminate	O
colitis	B-Disease
)	O
and	O
312	O
controls	O
were	O
analysed	O
for	O
anti	O
-	O
Saccharomyces	B-Species
cerevisiae	I-Species
antibodies	O
(	O
gASCA	O
)	O
IgG	O
,	O
anti	O
-	O
laminaribioside	O
antibodies	O
(	O
ALCA	O
)	O
IgG	O
,	O
anti	O
-	O
chitobioside	O
antibodies	O
(	O
ACCA	O
)	O
IgA	O
,	O
anti	O
-	O
mannobioside	O
antibodies	O
(	O
AMCA	O
)	O
IgG	O
and	O
outer	O
membrane	O
porin	O
(	O
Omp	O
)	O
IgA	O
and	O
were	O
genotyped	O
for	O
variants	O
in	O
NOD2	B-Gene
/	O
CARD15	B-Gene
,	O
TUCAN	B-Gene
/	O
CARDINAL	B-Gene
/	O
CARD8	B-Gene
,	O
NOD1	B-Gene
/	O
CARD4	B-Gene
,	O
TLR4	B-Gene
,	O
TLR1	B-Gene
,	O
TLR2	B-Gene
and	O
TLR6	B-Gene
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
When	O
compared	O
with	O
Crohn	B-Disease
's	I-Disease
disease	I-Disease
patients	B-Species
without	O
CARD15	B-Gene
mutations	O
,	O
the	O
presence	O
of	O
at	O
least	O
one	O
CARD15	B-Gene
variant	O
in	O
Crohn	B-Disease
's	I-Disease
disease	I-Disease
patients	B-Species
more	O
frequently	O
led	O
to	O
gASCA	O
positivity	O
(	O
66.1	O
%	O
versus	O
51.5	O
%	O
,	O
p	O
<	O
0.0001	O
)	O
and	O
ALCA	O
positivity	O
(	O
43.3	O
%	O
versus	O
34.9	O
%	O
,	O
p	O
=	O
0.018	O
)	O
and	O
higher	O
gASCA	O
titers	O
(	O
85.7	O
versus	O
51.8	O
ELISA	O
units	O
,	O
p	O
<	O
0.0001	O
)	O
,	O
independent	O
of	O
ileal	O
involvement	O
.	O
</ALL>	O

<ALL>	O
A	O
gene	O
dosage	O
effect	O
,	O
with	O
increasing	O
gASCA	O
and	O
ALCA	O
positivity	O
for	O
patients	B-Species
carrying	O
none	O
,	O
one	O
and	O
two	O
CARD15	B-Gene
variants	O
,	O
respectively	O
,	O
was	O
seen	O
for	O
both	O
markers	O
.	O
</ALL>	O

<ALL>	O
Similarly	O
,	O
Crohn	B-Disease
's	I-Disease
disease	I-Disease
patients	B-Species
carrying	O
NOD1	B-Gene
/	O
CARD4	B-Gene
indel	O
had	O
a	O
higher	O
prevalence	O
of	O
gASCA	O
antibodies	O
than	O
wild	O
-	O
type	O
patients	B-Species
(	O
63.8	O
%	O
versus	O
55.2	O
%	O
,	O
p	O
=	O
0.014	O
)	O
,	O
also	O
with	O
a	O
gene	O
dosage	O
effect	O
.	O
</ALL>	O

<ALL>	O
An	O
opposite	O
effect	O
was	O
observed	O
for	O
the	O
TLR4	B-Gene
D299	B-Variant
G	I-Variant
and	O
TLR2	B-Gene
P631H	B-Variant
variants	O
,	O
with	O
a	O
lower	O
prevalence	O
of	O
ACCA	O
antibodies	O
(	O
23.4	O
%	O
versus	O
35	O
%	O
,	O
p	O
=	O
0.013	O
)	O
and	O
Omp	O
antibodies	O
(	O
20.5	O
%	O
versus	O
34.6	O
%	O
,	O
p	O
=	O
0.009	O
)	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Variants	O
in	O
innate	B-Gene
immune	I-Gene
receptor	I-Gene
genes	O
were	O
found	O
to	O
influence	O
antibody	O
formation	O
against	O
microbial	O
epitopes	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
respect	O
,	O
it	O
is	O
intriguing	O
that	O
an	O
opposite	O
effect	O
of	O
CARD15	B-Gene
and	O
TLR4	B-Gene
variants	O
was	O
observed	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
may	O
contribute	O
to	O
an	O
understanding	O
of	O
the	O
aetiology	O
of	O
the	O
seroreactivity	O
observed	O
in	O
IBD	B-Disease
.	O
</ALL>	O

<ALL>	O
An	O
improved	O
tetra	O
-	O
primer	O
PCR	O
approach	O
for	O
the	O
detection	O
of	O
the	O
FGFR3	B-Gene
G380R	B-Variant
mutation	O
responsible	O
for	O
achondroplasia	B-Disease
.	O
</ALL>	O

<ALL>	O
Achondroplasia	B-Disease
is	O
the	O
most	O
common	O
form	O
of	O
dwarfism	B-Disease
and	O
has	O
an	O
incidence	O
of	O
approximately	O
1	O
/	O
7500	O
.	O
</ALL>	O

<ALL>	O
In	O
more	O
than	O
98	O
%	O
of	O
cases	O
,	O
the	O
disease	O
is	O
associated	O
with	O
a	O
G	B-Variant
to	I-Variant
A	I-Variant
or	I-Variant
G	I-Variant
to	I-Variant
C	I-Variant
substitution	I-Variant
at	I-Variant
nucleotide	I-Variant
position	I-Variant
1138	I-Variant
(	O
p	B-Variant
.	I-Variant
G380R	I-Variant
)	O
of	O
the	O
fibroblast	B-Gene
growth	I-Gene
factor	I-Gene
receptor	I-Gene
3	I-Gene
(	O
FGFR3	B-Gene
)	O
gene	O
.	O
</ALL>	O

<ALL>	O
We	O
have	O
developed	O
a	O
sensitive	O
single	O
tube	O
tetra	O
-	O
primer	O
PCR	O
assay	O
to	O
detect	O
both	O
the	O
c.1138	B-Variant
G	I-Variant
>	I-Variant
A	I-Variant
and	O
c.1138	B-Variant
G	I-Variant
>	I-Variant
C	I-Variant
mutations	O
and	O
can	O
successfully	O
distinguish	O
DNA	O
samples	O
that	O
are	O
homozygous	O
and	O
heterozygous	O
for	O
the	O
c.1138	B-Variant
G	I-Variant
>	I-Variant
A	I-Variant
mutation	O
.	O
</ALL>	O

<ALL>	O
Titration	O
studies	O
showed	O
that	O
the	O
assay	O
could	O
reliably	O
detect	O
one	O
copy	O
of	O
the	O
mutant	O
allele	O
in	O
a	O
mix	O
of	O
100	O
wild	O
-	O
type	O
alleles	O
.	O
</ALL>	O

<ALL>	O
The	O
assay	O
has	O
been	O
tested	O
in	O
50	O
healthy	O
controls	O
,	O
3	O
known	O
patients	B-Species
with	O
achondroplasia	B-Disease
,	O
and	O
5	O
amniotic	O
fluids	O
suspected	O
of	O
having	O
achondroplasia	B-Disease
and	O
for	O
whom	O
we	O
had	O
previously	O
determined	O
the	O
genotypes	O
for	O
the	O
c.1138	B-Variant
G	I-Variant
>	I-Variant
A	I-Variant
mutation	O
by	O
PCR	O
-	O
RFLP	O
.	O
</ALL>	O

<ALL>	O
We	O
have	O
observed	O
complete	O
concordance	O
between	O
methods	O
.	O
</ALL>	O

<ALL>	O
Our	O
tetra	O
-	O
primer	O
PCR	O
assay	O
is	O
sensitive	O
,	O
low	O
-	O
cost	O
,	O
and	O
easy	O
to	O
use	O
method	O
for	O
FGFR3	B-Gene
p	B-Variant
.	I-Variant
G380R	I-Variant
genotyping	O
,	O
which	O
could	O
be	O
used	O
even	O
in	O
"	O
low	O
-	O
tech	O
"	O
laboratories	O
.	O
</ALL>	O

<ALL>	O
Genetic	O
investigation	O
of	O
four	O
meiotic	O
genes	O
in	O
women	B-Species
with	O
premature	B-Disease
ovarian	I-Disease
failure	I-Disease
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
mutations	O
of	O
meiotic	O
genes	O
,	O
such	O
as	O
disrupted	O
meiotic	O
cDNA	O
(	O
DMC1	B-Gene
)	O
,	O
MutS	B-Gene
homolog	O
(	O
MSH4	B-Gene
)	O
,	O
MSH5	B-Gene
,	O
and	O
S.	B-Species
cerevisiae	I-Species
homolog	O
(	O
SPO11	B-Gene
)	O
,	O
were	O
associated	O
with	O
premature	B-Disease
ovarian	I-Disease
failure	I-Disease
(	O
POF	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
DESIGN	O
:	O
Case	O
-	O
control	O
study	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Blood	O
sampling	O
,	O
karyotype	O
,	O
hormonal	O
dosage	O
,	O
ultrasound	O
,	O
and	O
ovarian	O
biopsy	O
were	O
carried	O
out	O
on	O
most	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
main	O
outcome	O
measure	O
was	O
the	O
sequencing	O
of	O
genomic	O
DNA	O
from	O
peripheral	O
blood	O
samples	O
of	O
41	O
women	B-Species
with	O
POF	B-Disease
and	O
36	O
fertile	O
women	B-Species
(	O
controls	O
)	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
A	O
single	O
heterozygous	O
missense	O
mutation	O
,	O
substitution	O
of	O
a	O
cytosine	B-Variant
residue	I-Variant
with	I-Variant
thymidine	I-Variant
in	O
exon	O
2	O
of	O
MSH5	B-Gene
,	O
was	O
found	O
in	O
two	O
Caucasian	O
women	B-Species
in	O
whom	O
POF	B-Disease
developed	O
at	O
18	O
and	O
36	O
years	O
of	O
age	O
.	O
</ALL>	O

<ALL>	O
This	O
mutation	O
resulted	O
in	O
replacement	O
of	O
a	O
non	O
-	O
polar	O
amino	O
acid	O
(	B-Variant
proline	I-Variant
)	I-Variant
with	I-Variant
a	I-Variant
polar	I-Variant
amino	I-Variant
acid	I-Variant
(	I-Variant
serine	I-Variant
)	I-Variant
at	I-Variant
position	I-Variant
29	I-Variant
(	O
P29S	B-Variant
)	O
.	O
</ALL>	O

<ALL>	O
Neither	O
36	O
control	O
women	B-Species
nor	O
39	O
other	O
patients	B-Species
with	O
POF	B-Disease
possessed	O
this	O
genetic	O
perturbation	O
.	O
</ALL>	O

<ALL>	O
Another	O
POF	B-Disease
patient	B-Species
of	O
African	O
origin	O
showed	O
a	O
homozygous	O
nucleotide	O
change	O
in	O
the	O
tenth	O
of	O
DMC1	B-Gene
gene	O
that	O
led	O
to	O
an	O
alteration	O
of	O
the	O
amino	O
acid	O
composition	O
of	O
the	O
protein	O
(	O
M200V	B-Variant
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
The	O
symptoms	O
of	O
infertility	B-Disease
observed	O
in	O
the	O
DMC1	B-Gene
homozygote	O
mutation	O
carrier	O
and	O
in	O
both	O
patients	B-Species
with	O
a	O
heterozygous	O
substitution	O
in	O
exon	O
2	O
of	O
the	O
MSH5	B-Gene
gene	O
provide	O
indirect	O
evidence	O
of	O
the	O
role	O
of	O
genes	O
involved	O
in	O
meiotic	O
recombination	O
in	O
the	O
regulation	O
of	O
ovarian	O
function	O
.	O
</ALL>	O

<ALL>	O
MSH5	B-Gene
and	O
DMC1	B-Gene
mutations	O
may	O
be	O
one	O
explanation	O
for	O
POF	B-Disease
,	O
albeit	O
uncommon	O
.	O
</ALL>	O

<ALL>	O
A	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
IRF5	B-Gene
promoter	O
region	O
is	O
associated	O
with	O
susceptibility	O
to	O
rheumatoid	B-Disease
arthritis	I-Disease
in	O
the	O
Japanese	O
population	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVES	O
:	O
Interferon	B-Gene
regulatory	I-Gene
factor	I-Gene
5	I-Gene
(	O
IRF5	B-Gene
)	O
is	O
a	O
member	O
of	O
the	O
IRF	B-Gene
family	O
of	O
transcription	O
factors	O
,	O
which	O
regulate	O
the	O
production	O
of	O
proinflammatory	B-Gene
cytokines	I-Gene
.	O
</ALL>	O

<ALL>	O
Polymorphisms	O
in	O
the	O
IRF5	B-Gene
gene	O
have	O
been	O
associated	O
with	O
susceptibility	O
to	O
systemic	B-Disease
lupus	I-Disease
erythaematosus	I-Disease
(	O
SLE	B-Disease
)	O
in	O
Caucasian	O
and	O
Asian	O
populations	O
,	O
but	O
their	O
involvement	O
in	O
other	O
autoimmune	B-Disease
diseases	I-Disease
is	O
still	O
uncertain	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
assessed	O
the	O
genetic	O
role	O
of	O
IRF5	B-Gene
in	O
susceptibility	O
to	O
rheumatoid	B-Disease
arthritis	I-Disease
(	O
RA	B-Disease
)	O
in	O
Japanese	O
subjects	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
We	O
selected	O
13	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
and	O
a	O
CGGGG	O
insertion	O
-	O
deletion	O
polymorphism	O
in	O
the	O
IRF5	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
We	O
performed	O
2	O
sets	O
of	O
case	O
-	O
control	O
comparisons	O
using	O
Japanese	O
subjects	O
(	O
first	O
set	O
:	O
830	O
patients	B-Species
with	O
RA	B-Disease
and	O
658	O
controls	O
;	O
second	O
set	O
:	O
1112	O
patients	B-Species
with	O
RA	B-Disease
and	O
940	O
controls	O
)	O
,	O
and	O
then	O
performed	O
a	O
stratified	O
analysis	O
using	O
human	B-Species
leukocyte	B-Gene
antigen	I-Gene
(	I-Gene
HLA	I-Gene
)	I-Gene
-	I-Gene
DRB1	I-Gene
shared	O
epitope	O
(	O
SE	O
)	O
status	O
.	O
</ALL>	O

<ALL>	O
We	O
genotyped	O
the	O
SNPs	O
using	O
TaqMan	O
assays	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
A	O
significant	O
association	O
of	O
the	O
rs729302	B-Variant
A	O
allele	O
with	O
RA	B-Disease
susceptibility	O
was	O
found	O
in	O
both	O
sets	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
1.22	O
,	O
95	O
%	O
CI	O
1.09	O
to	O
1.35	O
,	O
p	O
<	O
0.001	O
in	O
the	O
combined	O
analysis	O
)	O
.	O
</ALL>	O

<ALL>	O
When	O
the	O
patients	B-Species
were	O
stratified	O
by	O
the	O
SE	O
,	O
the	O
rs729302	B-Variant
A	O
allele	O
was	O
found	O
to	O
confer	O
increased	O
risk	O
to	O
RA	B-Disease
in	O
patients	B-Species
that	O
were	O
SE	O
negative	O
(	O
OR	O
1.50	O
,	O
95	O
%	O
CI	O
1.17	O
to	O
1.92	O
,	O
p	O
=	O
0.001	O
)	O
as	O
compared	O
with	O
patients	B-Species
carrying	O
the	O
SE	O
(	O
OR	O
1.11	O
,	O
95	O
%	O
CI	O
0.93	O
to	O
1.33	O
,	O
p	O
=	O
0.24	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
both	O
sets	O
,	O
no	O
genotyped	O
polymorphisms	O
were	O
significantly	O
associated	O
with	O
RA	B-Disease
susceptibility	O
,	O
but	O
rs729302	B-Variant
was	O
significantly	O
associated	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
These	O
findings	O
indicate	O
that	O
the	O
promoter	O
polymorphism	O
of	O
IRF5	B-Gene
is	O
a	O
genetic	O
factor	O
conferring	O
predisposition	O
to	O
RA	B-Disease
,	O
and	O
that	O
it	O
contributes	O
considerably	O
to	O
disease	O
pathogenesis	O
in	O
patients	B-Species
that	O
were	O
SE	O
negative	O
.	O
</ALL>	O

<ALL>	O
Association	O
between	O
promoter	O
-	O
1607	O
polymorphism	O
of	O
MMP1	B-Gene
and	O
lumbar	B-Disease
disc	I-Disease
disease	I-Disease
in	O
Southern	O
Chinese	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Matrix	B-Gene
metalloproteinases	I-Gene
(	O
MMPs	B-Gene
)	O
are	O
involved	O
in	O
the	O
degradation	O
of	O
the	O
extracellular	O
matrix	O
of	O
the	O
intervertebral	O
disc	O
.	O
</ALL>	O

<ALL>	O
A	O
SNP	O
for	O
guanine	B-Variant
insertion	I-Variant
/	I-Variant
deletion	I-Variant
(	I-Variant
G	I-Variant
/	I-Variant
D	I-Variant
)	I-Variant
,	I-Variant
the	I-Variant
-	I-Variant
1607	I-Variant
promoter	I-Variant
polymorphism	I-Variant
,	O
of	O
the	O
MMP1	B-Gene
gene	O
was	O
found	O
significantly	O
affecting	O
promoter	O
activity	O
and	O
corresponding	O
transcription	O
level	O
.	O
</ALL>	O

<ALL>	O
Hence	O
it	O
is	O
a	O
good	O
candidate	O
for	O
genetic	O
studies	O
in	O
DDD	B-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Southern	O
Chinese	O
volunteers	O
between	O
18	O
and	O
55	O
years	O
were	O
recruited	O
from	O
the	O
population	O
.	O
</ALL>	O

<ALL>	O
DDD	B-Disease
in	O
the	O
lumbar	O
spine	O
was	O
defined	O
by	O
MRI	O
using	O
Schneiderman	O
's	O
classification	O
.	O
</ALL>	O

<ALL>	O
Genomic	O
DNA	O
was	O
isolated	O
from	O
the	O
leukocytes	O
and	O
genotyping	O
was	O
performed	O
using	O
the	O
Sequenom	O
platform	O
.	O
</ALL>	O

<ALL>	O
Association	O
and	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
checking	O
were	O
assessed	O
by	O
Chi	O
-	O
square	O
test	O
and	O
Mann	O
-	O
Whitney	O
U	O
test	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Our	O
results	O
showed	O
substantial	O
evidence	O
of	O
association	O
between	O
-	O
1607	O
promoter	O
polymorphism	O
of	O
MMP1	B-Gene
and	O
DDD	B-Disease
in	O
the	O
Southern	O
Chinese	O
subjects	O
.	O
</ALL>	O

<ALL>	O
D	O
allelic	O
was	O
significantly	O
associated	O
with	O
DDD	B-Disease
(	O
p	O
value	O
=	O
0.027	O
,	O
odds	O
ratio	O
=	O
1.41	O
with	O
95	O
%	O
CI	O
=	O
1.04	O
-	O
1.90	O
)	O
while	O
Genotypic	O
association	O
on	O
the	O
presence	O
of	O
D	O
allele	O
was	O
also	O
significantly	O
associated	O
with	O
DDD	B-Disease
(	O
p	O
value	O
=	O
0.046	O
,	O
odds	O
ratio	O
=	O
1.50	O
with	O
95	O
%	O
CI	O
=	O
1.01	O
-	O
2.24	O
)	O
.	O
</ALL>	O

<ALL>	O
Further	O
age	O
stratification	O
showed	O
significant	O
genotypic	O
as	O
well	O
as	O
allelic	O
association	O
in	O
the	O
group	O
of	O
over	O
40	O
years	O
(	O
genotypic	O
:	O
p	O
value	O
=	O
0.035	O
,	O
odds	O
ratio	O
=	O
1.617	O
with	O
95	O
%	O
CI	O
=	O
1.033	O
-	O
2.529	O
;	O
allelic	O
:	O
p	O
value	O
=	O
0.033	O
,	O
odds	O
ratio	O
=	O
1.445	O
with	O
95	O
%	O
CI	O
=	O
1.029	O
-	O
2.029	O
)	O
.	O
</ALL>	O

<ALL>	O
Disc	O
bulge	O
,	O
annular	O
tears	O
and	O
the	O
Schmorl	O
's	O
nodes	O
were	O
not	O
associated	O
with	O
the	O
D	O
allele	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
We	O
demonstrated	O
that	O
individuals	O
with	O
the	O
presence	O
of	O
D	B-Variant
allele	I-Variant
for	I-Variant
the	I-Variant
-	I-Variant
1607	I-Variant
promoter	O
polymorphism	O
of	O
MMP1	B-Gene
are	O
about	O
1.5	O
times	O
more	O
susceptible	O
to	O
develop	O
DDD	B-Disease
when	O
compared	O
with	O
those	O
having	O
G	O
allele	O
only	O
.	O
</ALL>	O

<ALL>	O
Further	O
association	O
was	O
identified	O
in	O
individuals	O
over	O
40	O
years	O
of	O
age	O
.	O
</ALL>	O

<ALL>	O
Disc	O
bulge	O
,	O
annular	O
tear	O
as	O
well	O
as	O
Schmorl	O
's	O
nodes	O
were	O
not	O
associated	O
with	O
this	O
polymorphism	O
.	O
</ALL>	O

<ALL>	O
Detailed	O
spectral	O
profile	O
analysis	O
of	O
penicillin	B-Chemical
-	O
induced	O
epileptiform	B-Disease
activity	I-Disease
in	O
anesthetized	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Penicillin	B-Chemical
model	O
is	O
a	O
widely	O
used	O
experimental	O
model	O
for	O
epilepsy	B-Disease
research	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
study	O
we	O
aimed	O
to	O
portray	O
a	O
detailed	O
spectral	O
analysis	O
of	O
penicillin	B-Chemical
-	O
induced	O
epileptiform	B-Disease
activity	I-Disease
in	O
comparison	O
with	O
basal	O
brain	O
activity	O
in	O
anesthetized	O
Wistar	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Male	O
Wistar	O
rats	B-Species
were	O
anesthetized	O
with	O
i.p	O
.	O
</ALL>	O

<ALL>	O
urethane	B-Chemical
and	O
connected	O
to	O
an	O
electrocorticogram	O
setup	O
.	O
</ALL>	O

<ALL>	O
After	O
a	O
short	O
period	O
of	O
basal	O
activity	O
recording	O
,	O
epileptic	B-Disease
focus	O
was	O
induced	O
by	O
injecting	O
400IU	O
/	O
2	O
microl	O
penicillin	B-Chemical
-	I-Chemical
G	I-Chemical
potassium	I-Chemical
into	O
the	O
left	O
lateral	O
ventricle	O
while	O
the	O
cortical	O
activity	O
was	O
continuously	O
recorded	O
.	O
</ALL>	O

<ALL>	O
Basal	O
activity	O
,	O
latent	O
period	O
and	O
the	O
penicillin	B-Chemical
-	O
induced	O
epileptiform	B-Disease
activity	I-Disease
periods	O
were	O
then	O
analyzed	O
using	O
both	O
conventional	O
methods	O
and	O
spectral	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Spectral	O
analyses	O
were	O
conducted	O
by	O
dividing	O
the	O
whole	O
spectrum	O
into	O
different	O
frequency	O
bands	O
including	O
delta	O
,	O
theta	O
(	O
slow	O
and	O
fast	O
)	O
,	O
alpha	O
-	O
sigma	O
,	O
beta	O
(	O
1	O
and	O
2	O
)	O
and	O
gamma	O
(	O
1	O
and	O
2	O
)	O
bands	O
.	O
</ALL>	O

<ALL>	O
Our	O
results	O
show	O
that	O
the	O
most	O
affected	O
frequency	O
bands	O
were	O
delta	O
,	O
theta	O
,	O
beta	O
-	O
2	O
and	O
gamma	O
-	O
2	O
bands	O
during	O
the	O
epileptiform	B-Disease
activity	I-Disease
and	O
there	O
were	O
marked	O
differences	O
in	O
terms	O
of	O
spectral	O
densities	O
between	O
three	O
investigated	O
episodes	O
(	O
basal	O
activity	O
,	O
latent	O
period	O
and	O
epileptiform	B-Disease
activity	I-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Our	O
results	O
may	O
help	O
to	O
analyze	O
novel	O
data	O
obtained	O
using	O
similar	O
experimental	O
models	O
and	O
the	O
simple	O
analysis	O
method	O
described	O
here	O
can	O
be	O
used	O
in	O
similar	O
studies	O
to	O
investigate	O
the	O
basic	O
neuronal	O
mechanism	O
of	O
this	O
or	O
other	O
types	O
of	O
experimental	O
epilepsies	B-Disease
.	O
</ALL>	O

<ALL>	O
Expanding	O
clinical	O
spectrum	O
of	O
non	B-Disease
-	I-Disease
autoimmune	I-Disease
hyperthyroidism	I-Disease
due	O
to	O
an	O
activating	O
germline	O
mutation	O
,	O
p	B-Variant
.	I-Variant
M453	I-Variant
T	I-Variant
,	O
in	O
the	O
thyrotropin	B-Gene
receptor	I-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
To	O
describe	O
clinical	O
and	O
genetic	O
features	O
of	O
a	O
Thai	O
family	O
with	O
non	B-Disease
-	I-Disease
autoimmune	I-Disease
hyperthyroidism	I-Disease
(	O
NAH	B-Disease
)	O
caused	O
by	O
an	O
activating	O
germline	O
mutation	O
in	O
the	O
thyrotropin	B-Gene
receptor	I-Gene
(	O
TSHR	B-Gene
)	O
gene	O
.	O
</ALL>	O

<ALL>	O
PATIENTS	B-Species
:	O
Three	O
affected	O
individuals	O
from	O
the	O
same	O
family	O
(	O
a	O
father	O
and	O
his	O
two	O
children	O
)	O
were	O
studied	O
.	O
</ALL>	O

<ALL>	O
Clinical	O
and	O
imaging	O
findings	O
were	O
reviewed	O
and	O
compared	O
.	O
</ALL>	O

<ALL>	O
GENETIC	O
ANALYSIS	O
:	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
leukocytes	O
and	O
mutation	O
analysis	O
of	O
the	O
entire	O
coding	O
sequence	O
of	O
the	O
TSHR	B-Gene
gene	O
was	O
performed	O
in	O
both	O
children	O
and	O
their	O
parents	O
by	O
direct	O
DNA	O
sequencing	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
A	O
heterozygous	O
germline	O
T	B-Variant
to	I-Variant
C	I-Variant
transition	O
in	O
exon	O
10	O
of	O
the	O
TSHR	B-Gene
gene	O
(	O
c.1358	B-Variant
T	I-Variant
-	I-Variant
-	I-Variant
>	I-Variant
C	I-Variant
)	O
resulting	O
in	O
the	O
substitution	O
of	O
methionine	B-Variant
(	I-Variant
ATG	I-Variant
)	I-Variant
by	I-Variant
threonine	I-Variant
(	I-Variant
ACG	I-Variant
)	I-Variant
at	I-Variant
codon	I-Variant
453	I-Variant
(	O
p	B-Variant
.	I-Variant
M453	I-Variant
T	I-Variant
)	O
was	O
identified	O
in	O
the	O
father	O
and	O
his	O
two	O
children	O
.	O
</ALL>	O

<ALL>	O
They	O
presented	O
with	O
different	O
clinical	O
severity	O
and	O
variable	O
age	O
of	O
onset	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
to	O
hyperthyroidism	B-Disease
,	O
ventriculomegaly	B-Disease
and	O
bilateral	O
shortening	O
of	O
the	O
fifth	O
metacarpal	O
bones	O
and	O
the	O
middle	O
phalanges	O
of	O
the	O
fifth	O
fingers	O
were	O
consistently	O
found	O
in	O
all	O
affected	O
individuals	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Ventriculomegaly	B-Disease
and	O
bilateral	O
shortening	O
of	O
the	O
fifth	O
metacarpal	O
bones	O
and	O
the	O
middle	O
phalanges	O
of	O
the	O
fifth	O
fingers	O
might	O
be	O
characteristic	O
features	O
of	O
NAH	B-Disease
because	O
of	O
an	O
activating	O
TSHR	B-Gene
germline	O
mutation	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
the	O
shortening	O
of	O
the	O
middle	O
phalanges	O
of	O
the	O
fifth	O
fingers	O
has	O
never	O
been	O
previously	O
described	O
,	O
expanding	O
the	O
phenotypic	O
spectrum	O
of	O
the	O
disease	O
.	O
</ALL>	O

<ALL>	O
Hemodynamic	O
parameters	O
and	O
heart	O
rate	O
variability	O
during	O
a	O
tilt	O
test	O
in	O
relation	O
to	O
gene	O
polymorphism	O
of	O
renin	B-Gene
-	O
angiotensin	B-Gene
and	O
serotonin	B-Chemical
system	O
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
renin	B-Gene
-	O
angiotensin	B-Gene
system	O
and	O
serotonin	B-Gene
transporter	I-Gene
gene	O
polymorphisms	O
in	O
relation	O
to	O
hemodynamic	O
parameters	O
and	O
heart	O
rate	O
variability	O
during	O
a	O
head	O
-	O
up	O
tilt	O
test	O
(	O
HUT	O
)	O
in	O
patients	B-Species
with	O
vasovagal	B-Disease
syncope	I-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
DNA	O
was	O
collected	O
from	O
191	O
patients	B-Species
(	O
mean	O
age	O
44	O
+	O
/	O
-	O
18	O
years	O
,	O
61	O
men	B-Species
,	O
130	O
women	B-Species
)	O
.	O
</ALL>	O

<ALL>	O
The	O
following	O
gene	O
polymorphisms	O
were	O
determined	O
in	O
genomic	O
DNA	O
:	O
angiotensin	B-Gene
-	I-Gene
converting	I-Gene
enzyme	I-Gene
insertion	O
/	O
deletion	O
polymorphism	O
(	O
I	O
/	O
D	O
ACE	B-Gene
)	O
,	O
angiotensinogen	B-Gene
gene	O
polymorphism	O
(	O
M	B-Variant
235	I-Variant
)	O
,	O
angiotensin	B-Gene
II	I-Gene
receptor	I-Gene
type	I-Gene
1	I-Gene
(	O
ATR1	B-Gene
)	O
polymorphism	O
(	O
A	B-Variant
11666C	I-Variant
)	O
,	O
and	O
polymorphism	O
of	O
serotonin	B-Gene
transporter	I-Gene
gene	O
(	O
5HTTLPR	B-Gene
)	O
.Heart	O
rate	O
variability	O
during	O
HUT	O
was	O
assessed	O
in	O
5	O
-	O
minute	O
intervals	O
by	O
low	O
frequency	O
,	O
high	O
frequency	O
,	O
standard	O
deviation	O
of	O
the	O
normal	O
-	O
to	O
-	O
normal	O
(	O
SDNN	O
)	O
,	O
and	O
root	O
mean	O
square	O
successive	O
difference	O
parameters	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
AA	O
genotype	O
of	O
A	B-Variant
1166C	I-Variant
polymorphism	O
was	O
associated	O
with	O
lower	O
minimal	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
and	O
diastolic	O
blood	O
pressure	O
(	O
DBP	O
)	O
during	O
HUT	O
compared	O
with	O
other	O
genotypes	O
(	O
minimal	O
SBP	O
:	O
AA	O
59.6	O
+	O
/	O
-	O
21,8	O
,	O
AC	O
79.9	O
+	O
/	O
-	O
22.7	O
,	O
CC	O
65.4	O
+	O
/	O
-	O
22.7	O
mmHg	O
,	O
P	O
=	O
0.007	O
)	O
,	O
(	O
minimal	O
DBP	O
:	O
AA	O
36.4	O
+	O
/	O
-	O
22.7	O
,	O
AC	O
52.3	O
+	O
/	O
-	O
22.9	O
,	O
CC	O
45.4	O
+	O
/	O
-	O
19.5	O
mmHg	O
,	O
P	O
=	O
0.007	O
)	O
.AA	O
genotype	O
was	O
also	O
associated	O
with	O
higher	O
SDNN	O
compared	O
to	O
other	O
genotypes	O
in	O
the	O
early	O
phase	O
of	O
HUT	O
(	O
SDNN	O
in	O
5	O
minutes	O
of	O
tilt	O
:	O
AA	O
59.7	O
+	O
/	O
-	O
24.6	O
,	O
AC	O
50.6	O
+	O
/	O
-	O
20.6	O
,	O
CC	O
46.0	O
+	O
/	O
-	O
13.2	O
,	O
P	O
=	O
0.01	O
)	O
and	O
at	O
syncope	B-Disease
occurrence	O
(	O
SDNN	O
:	O
AA	O
71.0	O
+	O
/	O
-	O
20.9	O
,	O
AC	O
58.2	O
+	O
/	O
-	O
17.9	O
,	O
CC	O
58	O
+	O
/	O
-	O
10	O
,	O
P	O
=	O
0.04	O
)	O
CONCLUSION	O
:	O
AA	O
genotype	O
of	O
A	B-Variant
1166C	I-Variant
polymorphism	O
in	O
the	O
ATR1	B-Gene
gene	O
may	O
be	O
associated	O
with	O
hypotension	B-Disease
and	O
decline	O
in	O
sympathetic	O
tone	O
during	O
HUT	O
.	O
</ALL>	O

<ALL>	O
Its	O
role	O
in	O
genetic	O
predisposition	O
to	O
vasovagal	B-Disease
syncope	I-Disease
can	O
not	O
be	O
excluded	O
.	O
</ALL>	O

<ALL>	O
Hypomorphic	O
mutations	O
in	O
meckelin	B-Gene
(	O
MKS3	B-Gene
/	O
TMEM67	B-Gene
)	O
cause	O
nephronophthisis	B-Disease
with	I-Disease
liver	I-Disease
fibrosis	I-Disease
(	O
NPHP11	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Nephronophthisis	B-Disease
(	O
NPHP	B-Disease
)	O
,	O
a	O
rare	O
recessive	O
cystic	B-Disease
kidney	I-Disease
disease	I-Disease
,	O
is	O
the	O
most	O
frequent	O
genetic	O
cause	O
of	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
in	O
children	O
and	O
young	O
adults	O
.	O
</ALL>	O

<ALL>	O
Mutations	O
in	O
nine	O
genes	O
(	O
NPHP1	B-Gene
-	I-Gene
9	I-Gene
)	O
have	O
been	O
identified	O
.	O
</ALL>	O

<ALL>	O
NPHP	B-Disease
can	O
be	O
associated	O
with	O
retinal	B-Disease
degeneration	I-Disease
(	O
Senior	B-Disease
-	I-Disease
Loken	I-Disease
syndrome	I-Disease
)	O
,	O
brainstem	O
and	O
cerebellar	B-Disease
anomalies	I-Disease
(	O
Joubert	B-Disease
syndrome	I-Disease
)	O
,	O
or	O
liver	B-Disease
fibrosis	I-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
To	O
identify	O
a	O
causative	O
gene	O
for	O
the	O
subset	O
of	O
patients	B-Species
with	O
associated	O
liver	B-Disease
fibrosis	I-Disease
,	O
the	O
authors	O
performed	O
a	O
genome	O
wide	O
linkage	O
search	O
in	O
a	O
consanguineous	O
family	O
with	O
three	O
affected	O
patients	B-Species
using	O
50	O
K	O
SNP	O
microarrays	O
and	O
homozygosity	O
mapping	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
authors	O
obtained	O
a	O
significant	O
maximum	O
parametric	O
LOD	O
(	O
logarithm	O
of	O
odds	O
)	O
score	O
of	O
Z	O
(	O
max	O
)	O
=	O
3.72	O
on	O
chromosome	O
8q22	O
and	O
identified	O
a	O
homozygous	O
missense	O
mutation	O
in	O
the	O
gene	O
MKS3	B-Gene
/	O
TMEM67	B-Gene
.	O
</ALL>	O

<ALL>	O
When	O
examining	O
a	O
worldwide	O
cohort	O
of	O
62	O
independent	O
patients	B-Species
with	O
NPHP	B-Disease
and	O
associated	O
liver	B-Disease
fibrosis	I-Disease
we	O
identified	O
altogether	O
four	O
novel	O
mutations	O
(	O
p	B-Variant
.	I-Variant
W290L	I-Variant
,	O
p	B-Variant
.	I-Variant
C615R	I-Variant
,	O
p	B-Variant
.	I-Variant
G821S	I-Variant
,	O
and	O
p	B-Variant
.	I-Variant
G821R	I-Variant
)	O
in	O
five	O
of	O
them	O
.	O
</ALL>	O

<ALL>	O
Mutations	O
of	O
MKS3	B-Gene
/	O
TMEM67	B-Gene
,	O
found	O
recently	O
in	O
Meckel	B-Disease
-	I-Disease
Gruber	I-Disease
syndrome	I-Disease
(	I-Disease
MKS	I-Disease
)	I-Disease
type	I-Disease
3	I-Disease
and	O
Joubert	B-Disease
syndrome	I-Disease
(	I-Disease
JBTS	I-Disease
)	I-Disease
type	I-Disease
6	I-Disease
,	O
are	O
predominantly	O
truncating	O
mutations	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
the	O
mutations	O
detected	O
here	O
in	O
patients	B-Species
with	O
NPHP	B-Disease
and	O
associated	O
liver	B-Disease
fibrosis	I-Disease
are	O
exclusively	O
missense	O
mutations	O
.	O
</ALL>	O

<ALL>	O
This	O
suggests	O
that	O
they	O
may	O
represent	O
hypomorphic	O
alleles	O
,	O
leading	O
to	O
a	O
milder	O
phenotype	O
compared	O
with	O
the	O
more	O
severe	O
MKS	B-Disease
or	O
JBTS	B-Disease
phenotype	O
.	O
</ALL>	O

<ALL>	O
Additionally	O
,	O
mutation	O
analysis	O
for	O
MKS3	B-Gene
/	O
TMEM67	B-Gene
in	O
120	O
patients	B-Species
with	O
JBTS	B-Disease
yielded	O
seven	O
different	O
(	O
four	O
novel	O
)	O
mutations	O
in	O
five	O
patients	B-Species
,	O
four	O
of	O
whom	O
also	O
presented	O
with	O
congenital	O
liver	B-Disease
fibrosis	I-Disease
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Hypomorphic	O
MKS3	B-Gene
/	O
TMEM67	B-Gene
mutations	O
cause	O
NPHP	B-Disease
with	I-Disease
liver	I-Disease
fibrosis	I-Disease
(	O
NPHP11	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
This	O
is	O
the	O
first	O
report	O
of	O
MKS3	B-Gene
mutations	O
in	O
patients	B-Species
with	O
no	O
vermian	O
agenesis	O
and	O
without	O
neurological	O
signs	O
.	O
</ALL>	O

<ALL>	O
Thus	O
NPHP	B-Disease
,	O
JBTS	B-Disease
,	O
and	O
MKS	B-Disease
represent	O
allelic	B-Disease
disorders	I-Disease
.	O
</ALL>	O

<ALL>	O
Serotonin	B-Gene
transporter	I-Gene
gene	O
polymorphic	O
element	O
5	B-Gene
-	I-Gene
HTTLPR	I-Gene
increases	O
the	O
risk	O
of	O
sporadic	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
in	O
Italy	O
.	O
</ALL>	O

<ALL>	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
is	O
a	O
neurodegenerative	B-Disease
disorder	I-Disease
causing	O
muscular	B-Disease
rigidity	I-Disease
,	O
resting	B-Disease
tremor	I-Disease
and	O
bradykinesia	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
conducted	O
an	O
association	O
study	O
assessing	O
how	O
PD	B-Disease
risk	O
in	O
Italy	O
was	O
influenced	O
by	O
the	O
serotonin	B-Gene
transporter	I-Gene
gene	O
(	O
SLC6A4	B-Gene
)	O
polymorphic	O
region	O
5	B-Gene
-	I-Gene
HTTLPR	I-Gene
,	O
consisting	O
of	O
an	O
insertion	B-Variant
/	I-Variant
deletion	I-Variant
(	I-Variant
long	I-Variant
allele	I-Variant
-	I-Variant
L	I-Variant
/	I-Variant
short	I-Variant
allele	I-Variant
-	I-Variant
S	I-Variant
)	I-Variant
of	I-Variant
43	I-Variant
bp	I-Variant
in	O
the	O
SLC6A4	B-Gene
promoter	O
region	O
.	O
</ALL>	O

<ALL>	O
The	O
SLC6A4	B-Gene
promoter	O
single	O
nucleotide	O
polymorphism	O
rs25531	B-Variant
(	O
A	B-Variant
-	I-Variant
-	I-Variant
>	I-Variant
G	I-Variant
)	O
was	O
evaluated	O
too	O
.	O
</ALL>	O

<ALL>	O
We	O
collected	O
837	O
independent	O
subjects	O
(	O
393	O
PD	B-Disease
,	O
444	O
controls	O
)	O
.	O
</ALL>	O

<ALL>	O
An	O
association	O
between	O
the	O
5	B-Gene
-	I-Gene
HTTLPR	I-Gene
polymorphism	O
and	O
risk	O
of	O
PD	B-Disease
(	O
S	O
/	O
S	O
genotype	O
OR	O
[	O
95	O
%	O
CI	O
]	O
:	O
1.7[1.2	O
-	O
2.5	O
]	O
,	O
p	O
=	O
0.002	O
)	O
was	O
found	O
.	O
</ALL>	O

<ALL>	O
The	O
rs25531	B-Variant
and	O
the	O
haplotype	O
5	B-Gene
-	I-Gene
HTTLPR	I-Gene
/	O
rs25531	B-Variant
did	O
not	O
associate	O
with	O
risk	O
of	O
PD	B-Disease
.	O
</ALL>	O

<ALL>	O
Our	O
data	O
indicate	O
that	O
the	O
5	B-Gene
-	I-Gene
HTTLPR	I-Gene
polymorphic	O
element	O
within	O
the	O
SLC6A4	B-Gene
promoter	O
may	O
govern	O
the	O
genetic	O
risk	O
of	O
PD	B-Disease
in	O
Italians	O
.	O
</ALL>	O

<ALL>	O
Prolonged	O
hypothermia	B-Disease
as	O
a	O
bridge	O
to	O
recovery	O
for	O
cerebral	B-Disease
edema	I-Disease
and	O
intracranial	B-Disease
hypertension	I-Disease
associated	O
with	O
fulminant	B-Disease
hepatic	I-Disease
failure	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
To	O
review	O
evidence	O
-	O
based	O
treatment	O
options	O
in	O
patients	B-Species
with	O
cerebral	B-Disease
edema	I-Disease
complicating	O
fulminant	B-Disease
hepatic	I-Disease
failure	I-Disease
(	O
FHF	B-Disease
)	O
and	O
discuss	O
the	O
potential	O
applications	O
of	O
hypothermia	B-Disease
.	O
</ALL>	O

<ALL>	O
METHOD	O
:	O
Case	O
-	O
based	O
observations	O
from	O
a	O
medical	O
intensive	O
care	O
unit	O
(	O
MICU	O
)	O
in	O
a	O
tertiary	O
care	O
facility	O
in	O
a	O
27	O
-	O
year	O
-	O
old	O
female	O
with	O
FHF	B-Disease
from	O
acetaminophen	B-Chemical
and	O
resultant	O
cerebral	B-Disease
edema	I-Disease
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Our	O
patient	B-Species
was	O
admitted	O
to	O
the	O
MICU	O
after	O
being	O
found	O
unresponsive	O
with	O
presumed	O
toxicity	B-Disease
from	O
acetaminophen	B-Chemical
which	O
was	O
ingested	O
over	O
a	O
2	O
-	O
day	O
period	O
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
had	O
depressed	B-Disease
of	O
mental	O
status	O
lasting	O
at	O
least	O
24	O
h	O
prior	O
to	O
admission	O
.	O
</ALL>	O

<ALL>	O
Initial	O
evaluation	O
confirmed	O
FHF	B-Disease
from	O
acetaminophen	B-Chemical
and	O
cerebral	B-Disease
edema	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
was	O
treated	O
with	O
hyperosmolar	O
therapy	O
,	O
hyperventilation	B-Disease
,	O
sedation	O
,	O
and	O
chemical	O
paralysis	B-Disease
.	O
</ALL>	O

<ALL>	O
Her	O
intracranial	O
pressure	O
remained	O
elevated	O
despite	O
maximal	O
medical	O
therapy	O
.	O
</ALL>	O

<ALL>	O
We	O
then	O
initiated	O
therapeutic	O
hypothermia	B-Disease
which	O
was	O
continued	O
for	O
5	O
days	O
.	O
</ALL>	O

<ALL>	O
At	O
re	O
-	O
warming	O
,	O
patient	B-Species
had	O
resolution	O
of	O
her	O
cerebral	B-Disease
edema	I-Disease
and	O
intracranial	B-Disease
hypertension	I-Disease
.	O
</ALL>	O

<ALL>	O
At	O
discharge	O
,	O
she	O
had	O
complete	O
recovery	O
of	O
neurological	O
and	O
hepatic	O
functions	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
In	O
patients	B-Species
with	O
FHF	B-Disease
and	O
cerebral	B-Disease
edema	I-Disease
from	O
acetaminophen	B-Chemical
overdose	O
,	O
prolonged	O
therapeutic	O
hypothermia	B-Disease
could	O
potentially	O
be	O
used	O
as	O
a	O
life	O
saving	O
therapy	O
and	O
a	O
bridge	O
to	O
hepatic	O
and	O
neurological	O
recovery	O
.	O
</ALL>	O

<ALL>	O
A	O
clinical	O
trial	O
of	O
hypothermia	B-Disease
in	O
patients	B-Species
with	O
this	O
condition	O
is	O
warranted	O
.	O
</ALL>	O

<ALL>	O
hOGG1	B-Gene
Ser326Cys	B-Variant
polymorphism	O
and	O
risk	O
of	O
lung	B-Disease
cancer	I-Disease
by	O
histological	O
type	O
.	O
</ALL>	O

<ALL>	O
Human	B-Species
8	B-Gene
-	I-Gene
oxoguanine	I-Gene
DNA	I-Gene
glycosylase	I-Gene
1	I-Gene
(	O
hOGG1	B-Gene
)	O
has	O
a	O
major	O
role	O
in	O
the	O
repair	O
of	O
8	B-Chemical
-	I-Chemical
hydroxyguanine	I-Chemical
,	O
a	O
major	O
promutagenic	O
DNA	O
lesion	O
.	O
</ALL>	O

<ALL>	O
The	O
genetic	O
polymorphism	O
rs1052133	B-Variant
,	O
which	O
leads	O
to	O
substitution	O
of	O
the	O
amino	O
acid	O
at	O
codon	O
326	B-Variant
from	I-Variant
Ser	I-Variant
to	I-Variant
Cys	I-Variant
,	O
shows	O
functional	O
differences	O
,	O
namely	O
a	O
decrease	O
in	O
enzyme	O
activity	O
in	O
hOGG1	B-Gene
-	O
Cys326	B-Variant
.	O
</ALL>	O

<ALL>	O
Although	O
several	O
studies	O
have	O
investigated	O
the	O
association	O
between	O
rs1052133	B-Variant
and	O
lung	B-Disease
cancer	I-Disease
susceptibility	O
,	O
the	O
effect	O
of	O
this	O
locus	O
on	O
lung	B-Disease
cancer	I-Disease
according	O
to	O
histology	O
remains	O
unclear	O
.	O
</ALL>	O

<ALL>	O
We	O
therefore	O
conducted	O
a	O
case	O
-	O
control	O
study	O
with	O
515	O
incident	O
lung	B-Disease
cancer	I-Disease
cases	O
and	O
1030	O
age	O
-	O
and	O
sex	O
-	O
matched	O
controls	O
without	O
cancer	B-Disease
,	O
and	O
further	O
conducted	O
a	O
meta	O
-	O
analysis	O
.	O
</ALL>	O

<ALL>	O
In	O
overall	O
analysis	O
,	O
the	O
homozygous	O
Cys	O
/	O
Cys	O
genotype	O
showed	O
a	O
significant	O
association	O
with	O
lung	B-Disease
cancer	I-Disease
compared	O
to	O
Ser	O
allele	O
carrier	O
status	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1.31	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1.02	O
-	O
1.69	O
)	O
.	O
</ALL>	O

<ALL>	O
By	O
histology	O
-	O
based	O
analysis	O
,	O
the	O
Cys	O
/	O
Cys	O
genotype	O
showed	O
a	O
significantly	O
positive	O
association	O
with	O
small	B-Disease
-	I-Disease
cell	I-Disease
carcinoma	I-Disease
(	O
OR	O
=	O
2.40	O
,	O
95	O
%	O
CI	O
=	O
1.32	O
-	O
4.49	O
)	O
and	O
marginally	O
significant	O
association	O
with	O
adenocarcinoma	B-Disease
(	O
OR	O
=	O
1.32	O
,	O
95	O
%	O
CI	O
=	O
0.98	O
-	O
1.77	O
)	O
.	O
</ALL>	O

<ALL>	O
A	O
meta	O
-	O
analysis	O
of	O
previous	O
and	O
our	O
present	O
study	O
revealed	O
that	O
this	O
polymorphism	O
is	O
positively	O
associated	O
with	O
adenocarcinoma	B-Disease
,	O
although	O
suggestive	O
associations	O
were	O
also	O
found	O
for	O
squamous	B-Disease
-	I-Disease
and	I-Disease
small	I-Disease
-	I-Disease
cell	I-Disease
lung	I-Disease
cancers	I-Disease
.	O
</ALL>	O

<ALL>	O
These	O
results	O
indicate	O
that	O
rs1052133	B-Variant
contributes	O
to	O
the	O
risk	O
of	O
adenocarcinoma	B-Disease
of	I-Disease
lung	I-Disease
.	O
</ALL>	O

<ALL>	O
A	O
potential	O
regulatory	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
promoter	O
of	O
the	O
Klotho	B-Gene
gene	O
may	O
be	O
associated	O
with	O
essential	B-Disease
hypertension	I-Disease
in	O
the	O
Chinese	O
Han	O
population	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Mice	B-Species
with	O
defects	O
in	O
the	O
Klotho	B-Gene
gene	O
exhibit	O
multiple	O
aging	O
phenotypes	O
including	O
arteriosclerosis	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
hypothesised	O
that	O
the	O
G	B-Variant
-	I-Variant
395A	I-Variant
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
human	B-Species
Klotho	B-Gene
gene	O
may	O
contribute	O
to	O
the	O
prevalence	O
of	O
Essential	B-Disease
Hypertension	I-Disease
(	O
EH	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
We	O
investigate	O
whether	O
the	O
G	B-Variant
-	I-Variant
395A	I-Variant
polymorphism	O
of	O
Klotho	B-Gene
is	O
associated	O
with	O
EH	B-Disease
in	O
a	O
population	O
consisting	O
of	O
215	O
patients	B-Species
with	O
EH	B-Disease
and	O
220	O
non	O
-	O
hypertensive	B-Disease
subjects	O
.	O
</ALL>	O

<ALL>	O
We	O
also	O
tested	O
whether	O
a	O
G	B-Variant
/	I-Variant
A	I-Variant
substitution	O
at	O
the	O
G	B-Variant
-	I-Variant
395A	I-Variant
site	O
affected	O
the	O
transcription	O
level	O
in	O
vitro	O
through	O
the	O
dual	O
-	O
luciferase	O
reporter	O
assay	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Differences	O
in	O
the	O
genotype	O
distributions	O
of	O
the	O
G	B-Variant
-	I-Variant
395A	I-Variant
polymorphism	O
between	O
the	O
EH	B-Disease
and	O
non	O
-	O
hypertension	B-Disease
groups	O
are	O
statistically	O
significant	O
(	O
P	O
=	O
0.032	O
)	O
.	O
</ALL>	O

<ALL>	O
There	O
are	O
differential	O
effects	O
of	O
age	O
,	O
gender	O
and	O
smoking	O
status	O
on	O
the	O
association	O
of	O
the	O
G	B-Variant
-	I-Variant
395A	I-Variant
polymorphism	O
with	O
EH	B-Disease
;	O
the	O
G	B-Variant
-	I-Variant
395A	I-Variant
polymorphism	O
is	O
significantly	O
associated	O
with	O
EH	B-Disease
in	O
subjects	O
over	O
60years	O
old	O
,	O
in	O
females	O
and	O
in	O
nonsmokers	O
.	O
</ALL>	O

<ALL>	O
A	O
multiple	O
logistic	O
regression	O
analysis	O
indicated	O
that	O
the	O
odds	O
ratio	O
for	O
EH	B-Disease
in	O
the	O
-	B-Variant
395A	I-Variant
allele	O
carriers	O
as	O
compared	O
with	O
the	O
control	O
group	O
was	O
0.593	O
(	O
P	O
=	O
0.024	O
)	O
after	O
adjusting	O
for	O
current	O
traditional	O
risk	O
factors	O
.	O
</ALL>	O

<ALL>	O
The	O
dual	O
-	O
luciferase	O
reporter	O
assay	O
revealed	O
that	O
the	O
-	B-Variant
395A	I-Variant
carrier	O
of	O
a	O
498	O
-	O
bp	O
DNA	O
fragment	O
(	O
containing	O
the	O
G	B-Variant
-	I-Variant
395A	I-Variant
site	O
)	O
upstream	O
of	O
the	O
Klotho	B-Gene
gene	O
has	O
higher	O
relative	O
luciferase	O
activity	O
than	O
the	O
-	B-Variant
395	I-Variant
G	I-Variant
carrier	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
The	O
G	B-Variant
-	I-Variant
395A	I-Variant
polymorphism	O
of	O
the	O
human	B-Species
Klotho	B-Gene
gene	O
is	O
associated	O
with	O
EH	B-Disease
and	O
may	O
be	O
a	O
potential	O
regulatory	O
site	O
.	O
</ALL>	O

<ALL>	O
Chemokine	O
CCL2	B-Gene
and	O
its	O
receptor	O
CCR2	B-Gene
are	O
increased	O
in	O
the	O
hippocampus	O
following	O
pilocarpine	B-Chemical
-	O
induced	O
status	B-Disease
epilepticus	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Neuroinflammation	B-Disease
occurs	O
after	O
seizures	B-Disease
and	O
is	O
implicated	O
in	O
epileptogenesis	O
.	O
</ALL>	O

<ALL>	O
CCR2	B-Gene
is	O
a	O
chemokine	B-Gene
receptor	I-Gene
for	O
CCL2	B-Gene
and	O
their	O
interaction	O
mediates	O
monocyte	O
infiltration	O
in	O
the	O
neuroinflammatory	B-Disease
cascade	O
triggered	O
in	O
different	O
brain	O
pathologies	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
work	O
CCR2	B-Gene
and	O
CCL2	B-Gene
expression	O
were	O
examined	O
following	O
status	B-Disease
epilepticus	I-Disease
(	O
SE	B-Disease
)	O
induced	O
by	O
pilocarpine	B-Chemical
injection	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
SE	B-Disease
was	O
induced	O
by	O
pilocarpine	B-Chemical
injection	O
.	O
</ALL>	O

<ALL>	O
Control	O
rats	B-Species
were	O
injected	O
with	O
saline	O
instead	O
of	O
pilocarpine	B-Chemical
.	O
</ALL>	O

<ALL>	O
Five	O
days	O
after	O
SE	B-Disease
,	O
CCR2	B-Gene
staining	O
in	O
neurons	O
and	O
glial	O
cells	O
was	O
examined	O
using	O
imunohistochemical	O
analyses	O
.	O
</ALL>	O

<ALL>	O
The	O
number	O
of	O
CCR2	B-Gene
positive	O
cells	O
was	O
determined	O
using	O
stereology	O
probes	O
in	O
the	O
hippocampus	O
.	O
</ALL>	O

<ALL>	O
CCL2	B-Gene
expression	O
in	O
the	O
hippocampus	O
was	O
examined	O
by	O
molecular	O
assay	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Increased	O
CCR2	B-Gene
was	O
observed	O
in	O
the	O
hippocampus	O
after	O
SE	B-Disease
.	O
</ALL>	O

<ALL>	O
Seizures	B-Disease
also	O
resulted	O
in	O
alterations	O
to	O
the	O
cell	O
types	O
expressing	O
CCR2	B-Gene
.	O
</ALL>	O

<ALL>	O
Increased	O
numbers	O
of	O
neurons	O
that	O
expressed	O
CCR2	B-Gene
was	O
observed	O
following	O
SE	B-Disease
.	O
</ALL>	O

<ALL>	O
Microglial	O
cells	O
were	O
more	O
closely	O
apposed	O
to	O
the	O
CCR2	B-Gene
-	O
labeled	O
cells	O
in	O
SE	B-Disease
rats	B-Species
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
rats	B-Species
that	O
experienced	O
SE	B-Disease
exhibited	O
CCR2	B-Gene
-	O
labeling	O
in	O
populations	O
of	O
hypertrophied	O
astrocytes	O
,	O
especially	O
in	O
CA1	O
and	O
dentate	O
gyrus	O
.	O
</ALL>	O

<ALL>	O
These	O
CCR2	B-Gene
+	O
astroctytes	O
were	O
not	O
observed	O
in	O
control	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Examination	O
of	O
CCL2	B-Gene
expression	O
showed	O
that	O
it	O
was	O
elevated	O
in	O
the	O
hippocampus	O
following	O
SE	B-Disease
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
The	O
data	O
show	O
that	O
CCR2	B-Gene
and	O
CCL2	B-Gene
are	O
up	O
-	O
regulated	O
in	O
the	O
hippocampus	O
after	O
pilocarpine	B-Chemical
-	O
induced	O
SE	B-Disease
.	O
</ALL>	O

<ALL>	O
Seizures	B-Disease
also	O
result	O
in	O
changes	O
to	O
CCR2	B-Gene
receptor	O
expression	O
in	O
neurons	O
and	O
astrocytes	O
.	O
</ALL>	O

<ALL>	O
These	O
changes	O
might	O
be	O
involved	O
in	O
detrimental	O
neuroplasticity	O
and	O
neuroinflammatory	B-Disease
changes	O
that	O
occur	O
following	O
seizures	B-Disease
.	O
</ALL>	O

<ALL>	O
Association	O
of	O
adipocyte	O
genes	O
with	O
ASP	B-Gene
expression	O
:	O
a	O
microarray	O
analysis	O
of	O
subcutaneous	O
and	O
omental	O
adipose	O
tissue	O
in	O
morbidly	O
obese	B-Disease
subjects	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Prevalence	O
of	O
obesity	B-Disease
is	O
increasing	O
to	O
pandemic	O
proportions	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
obese	B-Disease
subjects	O
differ	O
in	O
insulin	B-Disease
resistance	I-Disease
,	O
adipokine	B-Gene
production	O
and	O
co	O
-	O
morbidities	O
.	O
</ALL>	O

<ALL>	O
Based	O
on	O
fasting	O
plasma	O
analysis	O
,	O
obese	B-Disease
subjects	O
were	O
grouped	O
as	O
Low	O
Acylation	B-Gene
Stimulating	I-Gene
protein	I-Gene
(	O
ASP	B-Gene
)	O
and	O
Triglyceride	B-Chemical
(	O
TG	B-Chemical
)	O
(	O
LAT	O
)	O
vs	O
High	O
ASP	B-Gene
and	O
TG	B-Chemical
(	O
HAT	O
)	O
.	O
</ALL>	O

<ALL>	O
Subcutaneous	O
(	O
SC	O
)	O
and	O
omental	O
(	O
OM	O
)	O
adipose	O
tissues	O
(	O
n	O
=	O
21	O
)	O
were	O
analysed	O
by	O
microarray	O
,	O
and	O
biologic	O
pathways	O
in	O
lipid	B-Chemical
metabolism	O
and	O
inflammation	B-Disease
were	O
specifically	O
examined	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
LAT	O
and	O
HAT	O
groups	O
were	O
matched	O
in	O
age	O
,	O
obesity	B-Disease
,	O
insulin	B-Gene
,	O
and	O
glucose	B-Chemical
,	O
and	O
had	O
similar	O
expression	O
of	O
insulin	B-Gene
-	O
related	O
genes	O
(	O
InsR	B-Gene
,	O
IRS	B-Gene
-	I-Gene
1	I-Gene
)	O
.	O
</ALL>	O

<ALL>	O
ASP	B-Gene
related	O
genes	O
tended	O
to	O
be	O
increased	O
in	O
the	O
HAT	O
group	O
and	O
were	O
correlated	O
(	O
factor	B-Gene
B	I-Gene
,	O
adipsin	B-Gene
,	O
complement	B-Gene
C3	I-Gene
,	O
p	O
<	O
0.01	O
each	O
)	O
.	O
</ALL>	O

<ALL>	O
Differences	O
between	O
LAT	O
and	O
HAT	O
group	O
were	O
almost	O
exclusively	O
in	O
SC	O
tissue	O
,	O
with	O
little	O
difference	O
in	O
OM	O
tissue	O
.	O
</ALL>	O

<ALL>	O
Increased	O
C5L2	B-Gene
(	O
p	O
<	O
0.01	O
)	O
,	O
an	O
ASP	B-Gene
receptor	I-Gene
,	O
in	O
HAT	O
suggests	O
a	O
compensatory	O
ASP	B-Gene
pathway	O
,	O
associated	O
with	O
increased	O
TG	B-Chemical
storage	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
HAT	O
adipose	O
tissue	O
demonstrated	O
increased	O
lipid	B-Chemical
related	O
genes	O
for	O
storage	O
(	O
CD36	B-Gene
,	O
DGAT1	B-Gene
,	O
DGAT2	B-Gene
,	O
SCD1	B-Gene
,	O
FASN	B-Gene
,	O
and	O
LPL	B-Gene
)	O
,	O
lipolysis	O
(	O
HSL	B-Gene
,	O
CES1	B-Gene
,	O
perilipin	B-Gene
)	O
,	O
fatty	B-Gene
acid	I-Gene
binding	I-Gene
proteins	I-Gene
(	O
FABP1	B-Gene
,	O
FABP3	B-Gene
)	O
and	O
adipocyte	O
differentiation	O
markers	O
(	O
CEBPalpha	B-Gene
,	O
CEBPbeta	B-Gene
,	O
PPARgamma	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
By	O
contrast	O
,	O
oxidation	O
related	O
genes	O
were	O
decreased	O
(	O
AMPK	B-Gene
,	O
UCP1	B-Gene
,	O
CPT1	B-Gene
,	O
FABP7	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
HAT	O
subjects	O
had	O
increased	O
anti	O
-	O
inflammatory	B-Disease
genes	O
TGFB1	B-Gene
,	O
TIMP1	B-Gene
,	O
TIMP3	B-Gene
,	O
and	O
TIMP4	B-Gene
while	O
proinflammatory	B-Disease
PIG7	B-Gene
and	O
MMP2	B-Gene
were	O
also	O
significantly	O
increased	O
;	O
all	O
genes	O
,	O
p	O
<	O
0.025	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Taken	O
together	O
,	O
the	O
profile	O
of	O
C5L2	B-Gene
receptor	O
,	O
ASP	B-Gene
gene	O
expression	O
and	O
metabolic	O
factors	O
in	O
adipose	O
tissue	O
from	O
morbidly	O
obese	B-Disease
HAT	O
subjects	O
suggests	O
a	O
compensatory	O
response	O
associated	O
with	O
the	O
increased	O
plasma	O
ASP	B-Gene
and	O
TG	B-Chemical
.	O
</ALL>	O

<ALL>	O
Atypical	O
GH	B-Disease
insensitivity	I-Disease
syndrome	I-Disease
and	O
severe	O
insulin	B-Disease
-	I-Disease
like	I-Disease
growth	I-Disease
factor	I-Disease
-	I-Disease
I	I-Disease
deficiency	I-Disease
resulting	O
from	O
compound	O
heterozygous	O
mutations	O
of	O
the	O
GH	B-Gene
receptor	I-Gene
,	O
including	O
a	O
novel	O
frameshift	O
mutation	O
affecting	O
the	O
intracellular	O
domain	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
/	O
AIMS	O
:	O
GH	B-Disease
insensitivity	I-Disease
and	O
IGF	B-Disease
deficiency	I-Disease
may	O
result	O
from	O
aberrations	O
of	O
the	O
GH	B-Gene
receptor	I-Gene
(	O
GHR	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
We	O
describe	O
a	O
4	O
-	O
year	O
-	O
old	O
child	O
with	O
modest	O
growth	B-Disease
failure	I-Disease
and	O
normal	O
serum	O
concentrations	O
of	O
GH	B-Gene
-	I-Gene
binding	I-Gene
protein	I-Gene
(	O
GHBP	B-Gene
)	O
,	O
but	O
clinical	O
evidence	O
of	O
GH	B-Disease
insensitivity	I-Disease
.	O
</ALL>	O

<ALL>	O
METHOD	O
:	O
Serum	O
and	O
DNA	O
samples	O
from	O
the	O
proband	O
and	O
his	O
parents	O
were	O
analyzed	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
child	O
had	O
a	O
height	O
of	O
-	O
4	O
SD	O
,	O
elevated	O
serum	O
GH	B-Gene
concentrations	O
,	O
abnormally	O
low	O
serum	O
IGF	B-Gene
-	I-Gene
I	I-Gene
and	O
IGFBP	B-Gene
-	I-Gene
3	I-Gene
concentrations	O
and	O
normal	O
GHBP	B-Gene
concentrations	O
.	O
</ALL>	O

<ALL>	O
DNA	O
analysis	O
revealed	O
compound	O
heterozygosity	O
for	O
mutations	O
of	O
GHR	B-Gene
,	O
including	O
a	O
previously	O
reported	O
R211H	B-Variant
mutation	O
and	O
a	O
novel	O
duplication	O
of	O
a	O
nucleotide	O
in	O
exon	O
9	O
(	O
899dupC	B-Variant
)	O
,	O
the	O
latter	O
resulting	O
in	O
a	O
frameshift	O
and	O
a	O
premature	O
stop	O
codon	O
.	O
</ALL>	O

<ALL>	O
Treatment	O
with	O
recombinant	O
DNA	O
-	O
derived	O
IGF	B-Gene
-	I-Gene
I	I-Gene
resulted	O
in	O
growth	O
acceleration	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Mutations	O
affecting	O
the	O
intracellular	O
domain	O
of	O
the	O
GHR	B-Gene
can	O
result	O
in	O
GH	B-Disease
insensitivity	I-Disease
and	O
IGF	B-Disease
deficiency	I-Disease
,	O
despite	O
normal	O
serum	O
concentrations	O
of	O
GHBP	B-Gene
.	O
</ALL>	O

<ALL>	O
The	O
presence	O
of	O
clinical	O
and	O
biochemical	O
evidence	O
of	O
GH	B-Gene
resistance	O
is	O
sufficient	O
to	O
consider	O
the	O
possibility	O
of	O
aberrations	O
of	O
the	O
GHR	B-Gene
,	O
even	O
in	O
the	O
presence	O
of	O
normal	O
serum	O
GHBP	B-Gene
concentrations	O
.	O
</ALL>	O

<ALL>	O
Association	O
of	O
DNA	O
polymorphisms	O
within	O
the	O
CYP11B2	B-Gene
/	O
CYP11B1	B-Gene
locus	O
and	O
postoperative	O
hypertension	B-Disease
risk	O
in	O
the	O
patients	B-Species
with	O
aldosterone	B-Disease
-	I-Disease
producing	I-Disease
adenomas	I-Disease
.	O
</ALL>	O

<ALL>	O
OBJECTIVES	O
:	O
Hypertension	B-Disease
often	O
persists	O
after	O
adrenalectomy	O
for	O
primary	O
aldosteronism	O
.	O
</ALL>	O

<ALL>	O
Traditional	O
factors	O
associated	O
with	O
postoperative	O
hypertension	B-Disease
were	O
evaluated	O
,	O
but	O
whether	O
genetic	O
determinants	O
were	O
involved	O
remains	O
poorly	O
understood	O
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
association	O
of	O
DNA	O
polymorphisms	O
within	O
steroid	B-Gene
synthesis	I-Gene
genes	I-Gene
(	O
CYP11B2	B-Gene
,	O
CYP11B1	B-Gene
)	O
and	O
the	O
postoperative	O
resolution	O
of	O
hypertension	B-Disease
in	O
Chinese	O
patients	B-Species
undergoing	O
adrenalectomy	O
for	O
aldosterone	B-Disease
-	I-Disease
producing	I-Disease
adenomas	I-Disease
(	O
APA	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Ninety	O
-	O
three	O
patients	B-Species
with	O
APA	B-Disease
were	O
assessed	O
for	O
postoperative	O
resolution	O
of	O
hypertension	B-Disease
.	O
</ALL>	O

<ALL>	O
All	O
patients	B-Species
were	O
genotyped	O
for	O
rs1799998	B-Variant
(	O
C	B-Variant
-	I-Variant
344	I-Variant
T	I-Variant
)	O
,	O
intron	O
2	O
conversion	O
,	O
rs4539	B-Variant
(	O
A2718	B-Variant
G	I-Variant
)	O
within	O
CYP11B2	B-Gene
and	O
rs6410	B-Variant
(	O
G22	B-Variant
5A	I-Variant
)	O
,	O
rs6387	B-Variant
(	O
A2803	B-Variant
G	I-Variant
)	O
within	O
CYP11B1	B-Gene
.	O
</ALL>	O

<ALL>	O
The	O
associations	O
between	O
CYPB11B2	B-Gene
/	O
CYP11B1	B-Gene
polymorphisms	O
and	O
persistent	O
postoperative	O
hypertension	B-Disease
were	O
assessed	O
by	O
multivariate	O
analysis	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
CYP11B2	B-Gene
-	O
CYP11B1	B-Gene
haplotype	O
was	O
associated	O
with	O
persistent	O
postoperative	O
hypertension	B-Disease
in	O
Chinese	O
patients	B-Species
undergoing	O
adrenalectomy	O
with	O
APA	B-Disease
(	O
P	O
=	O
.006	O
)	O
.	O
</ALL>	O

<ALL>	O
Specifically	O
,	O
the	O
rs4539	B-Variant
(	O
AA	O
)	O
polymorphism	O
was	O
associated	O
with	O
persistent	O
postoperative	O
hypertension	B-Disease
(	O
P	O
=	O
.002	O
)	O
.	O
</ALL>	O

<ALL>	O
Multivariate	O
logistic	O
regression	O
revealed	O
the	O
common	O
haplotypes	O
H1	O
(	O
AGACT	O
)	O
,	O
H2	O
(	O
AGAWT	O
)	O
,	O
and	O
H3	O
(	O
AGAWC	O
)	O
were	O
associated	O
with	O
the	O
persistent	O
postoperative	O
hypertension	B-Disease
(	O
P	O
=	O
.01	O
,	O
0.03	O
,	O
0.005	O
after	O
Bonferroni	O
correction	O
)	O
.	O
</ALL>	O

<ALL>	O
Additional	O
predictors	O
of	O
persistent	O
postoperative	O
hypertension	B-Disease
included	O
duration	O
of	O
hypertension	B-Disease
(	O
P	O
<	O
.0005	O
)	O
,	O
family	O
history	O
of	O
hypertension	B-Disease
(	O
P	O
=	O
.001	O
)	O
,	O
and	O
elevated	O
systolic	O
blood	O
pressure	O
(	O
P	O
=	O
.015	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
The	O
rs4539	B-Variant
(	O
AA	O
)	O
,	O
H1	O
,	O
H2	O
,	O
and	O
H3	O
are	O
genetic	O
predictors	O
for	O
postoperative	O
persistence	O
of	O
hypertension	B-Disease
for	O
Chinese	O
patients	B-Species
treated	O
by	O
adrenalectomy	O
with	O
APA	B-Disease
.	O
</ALL>	O

<ALL>	O
DNA	O
polymorphisms	O
at	O
CYP11B2	B-Gene
/	I-Gene
B1	I-Gene
locus	O
may	O
confer	O
susceptibility	O
to	O
postoperative	O
hypertension	B-Disease
of	O
patients	B-Species
with	O
APA	B-Disease
.	O
</ALL>	O

<ALL>	O
A	O
novel	O
mutation	O
in	O
GJA8	B-Gene
causing	O
congenital	O
cataract	B-Disease
-	I-Disease
microcornea	I-Disease
syndrome	I-Disease
in	O
a	O
Chinese	O
pedigree	O
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
To	O
identify	O
the	O
underlying	O
genetic	B-Disease
defect	I-Disease
in	O
a	O
four	O
-	O
generation	O
family	O
of	O
Chinese	O
origin	O
with	O
autosomal	O
dominant	O
congenital	O
cataract	B-Disease
-	I-Disease
microcornea	I-Disease
syndrome	I-Disease
(	O
CCMC	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
All	O
individuals	O
in	O
the	O
study	O
underwent	O
a	O
full	O
clinical	O
examination	O
and	O
the	O
details	O
of	O
history	O
were	O
collected	O
.	O
</ALL>	O

<ALL>	O
Genomic	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
method	O
and	O
the	O
exons	O
of	O
all	O
candidate	O
genes	O
were	O
sequenced	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Direct	O
sequencing	O
of	O
the	O
encoding	O
regions	O
of	O
the	O
candidate	O
genes	O
revealed	O
a	O
heterozygous	O
mutation	O
c.592C	B-Variant
-	I-Variant
-	I-Variant
>	I-Variant
T	I-Variant
in	O
exon	O
2	O
of	O
the	O
gap	B-Gene
junction	I-Gene
protein	I-Gene
,	I-Gene
alpha	I-Gene
8	I-Gene
(	O
GJA8	B-Gene
)	O
gene	O
.	O
</ALL>	O

<ALL>	O
This	O
mutation	O
was	O
responsible	O
for	O
the	O
familial	O
disorder	O
through	O
the	O
substitution	O
of	O
a	O
highly	O
conserved	O
arginine	B-Variant
to	I-Variant
tryptophan	I-Variant
at	I-Variant
codon	I-Variant
198	I-Variant
(	O
p	B-Variant
.	I-Variant
R198W	I-Variant
)	O
.	O
</ALL>	O

<ALL>	O
This	O
change	O
co	O
-	O
segregated	O
with	O
all	O
affected	O
members	O
of	O
the	O
family	O
,	O
but	O
was	O
not	O
detected	O
either	O
in	O
the	O
non	O
-	O
carrier	O
relatives	O
or	O
in	O
the	O
100	O
normal	O
controls	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
This	O
report	O
is	O
the	O
first	O
to	O
relate	O
p	B-Variant
.	I-Variant
R198W	I-Variant
mutation	O
in	O
GJA8	B-Gene
with	O
CCMC	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
result	O
expands	O
the	O
mutation	O
spectrum	O
of	O
GJA8	B-Gene
in	O
associated	O
with	O
congenital	O
cataract	B-Disease
and	O
microcornea	B-Disease
,	O
and	O
implies	O
that	O
this	O
gene	O
has	O
direct	O
involvement	O
with	O
the	O
development	O
of	O
the	O
lens	O
as	O
well	O
as	O
the	O
other	O
anterior	O
segment	O
of	O
the	O
eye	O
.	O
</ALL>	O

<ALL>	O
The	O
M235	B-Variant
T	I-Variant
polymorphism	O
of	O
the	O
angiotensinogen	B-Gene
gene	O
in	O
South	O
Indian	O
patients	B-Species
of	O
hypertrophic	B-Disease
cardiomyopathy	I-Disease
.	O
</ALL>	O

<ALL>	O
INTRODUCTION	O
:	O
Hypertrophic	B-Disease
cardiomyopathy	I-Disease
(	O
HCM	B-Disease
)	O
is	O
a	O
complex	O
disorder	O
and	O
genetically	O
transmitted	O
cardiac	B-Disease
disease	I-Disease
with	O
a	O
diverse	O
clinical	O
course	O
.	O
</ALL>	O

<ALL>	O
The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
association	O
of	O
the	O
T704C	B-Variant
polymorphism	O
of	O
exon	O
2	O
of	O
the	O
angiotensinogen	B-Gene
(	O
AGT	B-Gene
)	O
gene	O
with	O
HCM	B-Disease
in	O
a	O
South	O
Indian	O
population	O
from	O
Andhra	O
Pradesh	O
.	O
</ALL>	O

<ALL>	O
Subjects	O
and	O
methods	O
.	O
</ALL>	O

<ALL>	O
One	O
-	O
hundred	O
and	O
fifty	O
HCM	B-Disease
(	O
90	O
sporadic	B-Disease
hypertrophic	I-Disease
cardiomyopathy	I-Disease
[	O
SHCM	B-Disease
]	O
and	O
60	O
familial	B-Disease
hypertrophic	I-Disease
cardiomyopathy	I-Disease
[	O
FHCM	B-Disease
]	O
)	O
patients	B-Species
and	O
165	O
age	O
-	O
and	O
sex	O
-	O
matched	O
normal	O
healthy	O
controls	O
without	O
known	O
hypertension	B-Disease
and	O
left	B-Disease
ventricular	I-Disease
hypertrophy	I-Disease
were	O
included	O
in	O
the	O
study	O
.	O
</ALL>	O

<ALL>	O
DNA	O
was	O
isolated	O
from	O
peripheral	O
leukocytes	O
and	O
the	O
region	O
of	O
interest	O
in	O
the	O
AGT	B-Gene
gene	O
bearing	O
a	O
missense	O
mutation	O
methionine	B-Variant
to	I-Variant
threonine	I-Variant
substitution	I-Variant
at	I-Variant
codon	I-Variant
235	I-Variant
(	O
M235	B-Variant
T	I-Variant
)	O
of	O
exon	O
2	O
,	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
PCR	O
products	O
were	O
subjected	O
to	O
restriction	O
digestion	O
with	O
the	O
enzyme	O
SfaNI	B-Chemical
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Significant	O
differences	O
were	O
detected	O
in	O
genotypic	O
distribution	O
(	O
p	O
=	O
0.04	O
)	O
as	O
well	O
as	O
the	O
allelic	O
frequency	O
(	O
p	O
=	O
0.003	O
)	O
between	O
the	O
SHCM	B-Disease
patients	B-Species
and	O
controls	O
.	O
</ALL>	O

<ALL>	O
The	O
polymorphism	O
did	O
not	O
show	O
any	O
association	O
with	O
FHCM	B-Disease
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
T	O
allele	O
of	O
the	O
AGT	B-Gene
gene	O
is	O
significantly	O
associated	O
with	O
SHCM	B-Disease
in	O
a	O
South	O
Indian	O
population	O
from	O
Andhra	O
Pradesh	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
we	O
did	O
not	O
find	O
significant	O
association	O
of	O
this	O
polymorphism	O
with	O
FHCM	B-Disease
.	O
</ALL>	O

<ALL>	O
Interleukin	B-Gene
-	I-Gene
17F	I-Gene
gene	O
polymorphism	O
in	O
patients	B-Species
with	O
chronic	B-Disease
immune	I-Disease
thrombocytopenia	I-Disease
.	O
</ALL>	O

<ALL>	O
INTRODUCTION	O
:	O
IL	B-Gene
-	I-Gene
17F	I-Gene
is	O
a	O
novel	O
inflammatory	B-Gene
cytokine	I-Gene
and	O
plays	O
an	O
important	O
role	O
in	O
some	O
autoimmune	B-Disease
diseases	I-Disease
.	O
</ALL>	O

<ALL>	O
We	O
investigated	O
the	O
association	O
between	O
chronic	B-Disease
ITP	I-Disease
and	O
the	O
frequency	O
of	O
the	O
single	O
-	O
nucleotide	O
polymorphism	O
rs763780	B-Variant
(	O
7488	B-Variant
T	I-Variant
/	I-Variant
C	I-Variant
)	O
,	O
which	O
causes	O
a	O
His	B-Variant
-	I-Variant
to	I-Variant
-	I-Variant
Arg	I-Variant
substitution	I-Variant
at	I-Variant
amino	I-Variant
acid	I-Variant
161	I-Variant
.	O
</ALL>	O

<ALL>	O
PATIENTS	B-Species
AND	O
METHODS	O
:	O
We	O
examined	O
102	O
patients	B-Species
(	O
men	B-Species
/	O
women	B-Species
,	O
40	O
/	O
62	O
;	O
median	O
age	O
,	O
42	O
)	O
diagnosed	O
with	O
chronic	B-Disease
ITP	I-Disease
and	O
188	O
healthy	O
controls	O
(	O
men	B-Species
/	O
women	B-Species
,	O
78	O
/	O
110	O
;	O
median	O
age	O
,	O
38	O
)	O
.	O
</ALL>	O

<ALL>	O
Genotyping	O
was	O
determined	O
by	O
the	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
technique	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Compared	O
with	O
the	O
control	O
group	O
,	O
patients	B-Species
with	O
chronic	B-Disease
ITP	I-Disease
had	O
a	O
significantly	O
lower	O
frequency	O
of	O
the	O
IL	B-Gene
-	I-Gene
17F	I-Gene
7488CC	B-Variant
genotype	O
(	O
0	O
%	O
vs.	O
4.8	O
%	O
,	O
P	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
number	O
of	O
IL	B-Gene
-	I-Gene
17F	I-Gene
7488C	B-Variant
alleles	O
among	O
the	O
patients	B-Species
with	O
chronic	B-Disease
ITP	I-Disease
was	O
also	O
significantly	O
lower	O
than	O
in	O
the	O
control	O
group	O
(	O
8.7	O
%	O
vs.	O
15.2	O
%	O
OR	O
=	O
0.48	O
,	O
95%CI	O
=	O
0.27	O
-	O
0.84	O
,	O
P	O
=	O
0.016	O
)	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
patients	B-Species
with	O
the	O
IL	B-Gene
-	I-Gene
17F	I-Gene
7488TT	B-Variant
genotype	O
showed	O
a	O
severe	O
thrombocytopenic	B-Disease
state	O
(	O
platelet	O
count	O
<	O
10	O
10	O
(	O
9	O
)	O
/	O
L	O
)	O
at	O
diagnosis	O
than	O
those	O
with	O
the	O
IL	B-Gene
-	I-Gene
17F	I-Gene
7488TC	B-Variant
genotype	O
(	O
20.9	O
%	O
vs.	O
0	O
%	O
,	O
P	O
=	O
0.04	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
IL	B-Gene
-	I-Gene
17F	I-Gene
7488	B-Variant
T	I-Variant
allele	O
is	O
significantly	O
associated	O
with	O
the	O
development	O
of	O
chronic	B-Disease
ITP	I-Disease
,	O
suggesting	O
a	O
role	O
for	O
IL	B-Gene
-	I-Gene
17F	I-Gene
in	O
the	O
pathogenesis	O
of	O
chronic	B-Disease
ITP	I-Disease
.	O
</ALL>	O

<ALL>	O
XRCC1	B-Gene
Arg399Gln	B-Variant
gene	O
polymorphism	O
and	O
the	O
risk	O
of	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
in	O
the	O
Polish	O
population	O
.	O
</ALL>	O

<ALL>	O
It	O
has	O
been	O
shown	O
that	O
DNA	O
repair	O
is	O
reduced	O
in	O
patients	B-Species
with	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
(	O
SLE	B-Disease
)	O
and	O
that	O
the	O
X	B-Gene
-	I-Gene
ray	I-Gene
repair	I-Gene
cross	I-Gene
-	I-Gene
complementing	I-Gene
(	O
XRCC1	B-Gene
)	O
Arg399Gln	B-Variant
(	O
rs25487	B-Variant
)	O
polymorphism	O
may	O
contribute	O
to	O
DNA	O
repair	O
.	O
</ALL>	O

<ALL>	O
We	O
evaluated	O
the	O
frequency	O
of	O
the	O
XRCC1	B-Gene
Arg399Gln	B-Variant
substitution	O
in	O
patients	B-Species
with	O
SLE	B-Disease
(	O
n	O
=	O
265	O
)	O
and	O
controls	O
(	O
n	O
=	O
360	O
)	O
in	O
a	O
sample	O
of	O
the	O
Polish	O
population	O
.	O
</ALL>	O

<ALL>	O
The	O
odds	O
ratio	O
(	O
OR	O
)	O
for	O
SLE	B-Disease
patients	B-Species
with	O
the	O
Gln	O
/	O
Gln	O
versus	O
Gln	O
/	O
Arg	O
or	O
Arg	O
/	O
Arg	O
genotypes	O
was	O
1.553	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
0.9573	O
-	O
2.520	O
;	O
p	O
=	O
0.0729	O
)	O
.	O
</ALL>	O

<ALL>	O
OR	O
for	O
the	O
Gln	O
/	O
Gln	O
or	O
Gln	O
/	O
Arg	O
versus	O
Arg	O
/	O
Arg	O
genotype	O
was	O
1.551	O
(	O
95	O
%	O
CI	O
=	O
1.122	O
-	O
2.144	O
,	O
p	O
=	O
0.0077	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
OR	O
for	O
the	O
399	B-Variant
Gln	I-Variant
allele	O
in	O
patients	B-Species
with	O
SLE	B-Disease
was	O
1.406	O
(	O
95	O
%	O
CI	O
=	O
1.111	O
-	O
1.779	O
,	O
p	O
=	O
0.0045	O
)	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
also	O
a	O
statistically	O
significant	O
p	O
-	O
value	O
of	O
the	O
(	O
2	O
)	O
test	O
for	O
the	O
trend	O
observed	O
in	O
the	O
XRCC1	B-Gene
Arg399Gln	B-Variant
polymorphism	O
(	O
ptrend	O
=	O
0.0048	O
)	O
.	O
</ALL>	O

<ALL>	O
We	O
also	O
found	O
a	O
significant	O
contribution	O
of	O
the	O
Gln	O
/	O
Gln	O
or	O
Arg	O
/	O
Gln	O
versus	O
Arg	O
/	O
Arg	O
genotype	O
to	O
the	O
presence	O
of	O
either	O
the	O
malar	B-Disease
rash	I-Disease
or	O
photosensitivity	O
manifestations	O
of	O
SLE	B-Disease
OR	O
=	O
2.241	O
(	O
1.328	O
-	O
3.781	O
,	O
p	O
=	O
0.0023	O
,	O
pcorr	O
=	O
0.0414	O
)	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
the	O
meta	O
-	O
analysis	O
of	O
Taiwanese	O
Han	O
Chinese	O
,	O
Brazilian	O
,	O
and	O
Polish	O
populations	O
showed	O
that	O
the	O
Gln	O
/	O
Gln	O
or	O
Gln	O
/	O
Arg	O
genotype	O
and	O
Gln	O
allele	O
were	O
associated	O
with	O
SLE	B-Disease
incidence	O
.	O
</ALL>	O

<ALL>	O
OR	O
for	O
the	O
Gln	O
/	O
Gln	O
or	O
Gln	O
/	O
Arg	O
versus	O
Arg	O
/	O
Arg	O
genotype	O
was	O
1.440	O
(	O
95	O
%	O
CI	O
=	O
1.15	O
-	O
1.80	O
,	O
p	O
=	O
0.0019	O
)	O
and	O
OR	O
for	O
the	O
Gln	O
allele	O
was	O
1.27	O
(	O
95	O
%	O
CI	O
=	O
1.08	O
-	O
1.51	O
,	O
p	O
=	O
0.0051	O
)	O
.	O
</ALL>	O

<ALL>	O
Our	O
studies	O
may	O
confirm	O
that	O
the	O
XRCC1	B-Gene
Arg399Gln	B-Variant
polymorphism	O
may	O
increase	O
the	O
risk	O
of	O
incidence	O
of	O
SLE	B-Disease
and	O
the	O
occurrence	O
of	O
some	O
SLE	B-Disease
manifestations	O
.	O
</ALL>	O

<ALL>	O
Defining	O
an	O
EPOR	B-Gene
-	O
regulated	O
transcriptome	O
for	O
primary	O
progenitors	O
,	O
including	O
Tnfr	B-Gene
-	I-Gene
sf13c	I-Gene
as	O
a	O
novel	O
mediator	O
of	O
EPO	B-Gene
-	O
dependent	O
erythroblast	O
formation	O
.	O
</ALL>	O

<ALL>	O
Certain	O
concepts	O
concerning	O
EPO	B-Gene
/	O
EPOR	B-Gene
action	O
modes	O
have	O
been	O
challenged	O
by	O
in	O
vivo	O
studies	O
:	O
Bcl	B-Gene
-	I-Gene
x	I-Gene
levels	O
are	O
elevated	O
in	O
maturing	O
erythroblasts	O
,	O
but	O
not	O
in	O
their	O
progenitors	O
;	O
truncated	O
EPOR	B-Gene
alleles	O
that	O
lack	O
a	O
major	O
p85	B-Gene
/	I-Gene
PI3	I-Gene
K	I-Gene
recruitment	O
site	O
nonetheless	O
promote	O
polycythemia	B-Disease
;	O
and	O
Erk1	B-Gene
disruption	O
unexpectedly	O
bolsters	O
erythropoiesis	O
.	O
</ALL>	O

<ALL>	O
To	O
discover	O
novel	O
EPO	B-Gene
/	O
EPOR	B-Gene
action	O
routes	O
,	O
global	O
transcriptome	O
analyses	O
presently	O
are	O
applied	O
to	O
interrogate	O
EPO	B-Gene
/	O
EPOR	B-Gene
effects	O
on	O
primary	O
bone	O
marrow	O
-	O
derived	O
CFUe	O
-	O
like	O
progenitors	O
.	O
</ALL>	O

<ALL>	O
Overall	O
,	O
160	O
EPO	B-Gene
/	O
EPOR	B-Gene
target	O
transcripts	O
were	O
significantly	O
modulated	O
2	O
-	O
to	O
21.8	O
-	O
fold	O
.	O
</ALL>	O

<ALL>	O
A	O
unique	O
set	O
of	O
EPO	B-Gene
-	O
regulated	O
survival	O
factors	O
included	O
Lyl1	B-Gene
,	O
Gas5	B-Gene
,	O
Pim3	B-Gene
,	O
Pim1	B-Gene
,	O
Bim	B-Gene
,	O
Trib3	B-Gene
and	O
Serpina	B-Gene
3	I-Gene
g	I-Gene
.	O
</ALL>	O

<ALL>	O
EPO	B-Gene
/	O
EPOR	B-Gene
-	O
modulated	O
cell	O
cycle	O
mediators	O
included	O
Cdc25a	B-Gene
,	O
Btg3	B-Gene
,	O
Cyclin	B-Gene
-	I-Gene
d2	I-Gene
,	O
p27	B-Gene
-	I-Gene
kip1	I-Gene
,	O
Cyclin	B-Gene
-	I-Gene
g2	I-Gene
and	O
CyclinB1	B-Gene
-	I-Gene
IP	I-Gene
-	I-Gene
1	I-Gene
.	O
</ALL>	O

<ALL>	O
EPO	B-Gene
regulation	O
of	O
signal	O
transduction	O
factors	O
was	O
also	O
interestingly	O
complex	O
.	O
</ALL>	O

<ALL>	O
For	O
example	O
,	O
not	O
only	O
Socs3	B-Gene
plus	O
Socs2	B-Gene
but	O
also	O
Spred2	B-Gene
,	O
Spred1	B-Gene
and	O
Eaf1	B-Gene
were	O
EPO	B-Gene
-	O
induced	O
as	O
negative	O
-	O
feedback	O
components	O
.	O
</ALL>	O

<ALL>	O
Socs2	B-Gene
,	O
plus	O
five	O
additional	O
targets	O
,	O
further	O
proved	O
to	O
comprise	O
new	O
EPOR	B-Gene
/	O
Jak2	B-Gene
/	O
Stat5	B-Gene
response	O
genes	O
(	O
which	O
are	O
important	O
for	O
erythropoiesis	O
during	O
anemia	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Among	O
receptors	O
,	O
an	O
atypical	O
TNF	B-Gene
-	I-Gene
receptor	I-Gene
Tnfr	B-Gene
-	I-Gene
sf13c	I-Gene
was	O
up	O
-	O
modulated	O
>	O
5	O
-	O
fold	O
by	O
EPO	B-Gene
.	O
</ALL>	O

<ALL>	O
Functionally	O
,	O
Tnfr	B-Gene
-	I-Gene
sf13c	I-Gene
ligation	O
proved	O
to	O
both	O
promote	O
proerythroblast	O
survival	O
,	O
and	O
substantially	O
enhance	O
erythroblast	O
formation	O
.	O
</ALL>	O

<ALL>	O
The	O
EPOR	B-Gene
therefore	O
engages	O
a	O
sophisticated	O
set	O
of	O
transcriptome	O
response	O
circuits	O
,	O
with	O
Tnfr	B-Gene
-	I-Gene
sf13c	I-Gene
deployed	O
as	O
one	O
novel	O
positive	O
regulator	O
of	O
proerythroblast	O
formation	O
.	O
</ALL>	O

<ALL>	O
Association	O
of	O
common	O
genetic	O
variants	O
of	O
HOMER1	B-Gene
gene	O
with	O
levodopa	B-Chemical
adverse	O
effects	O
in	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Levodopa	B-Chemical
is	O
the	O
most	O
effective	O
symptomatic	O
therapy	O
for	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
,	O
but	O
its	O
chronic	O
use	O
could	O
lead	O
to	O
chronic	O
adverse	O
outcomes	O
,	O
such	O
as	O
motor	O
fluctuations	O
,	O
dyskinesia	B-Disease
and	O
visual	B-Disease
hallucinations	I-Disease
.	O
</ALL>	O

<ALL>	O
HOMER1	B-Gene
is	O
a	O
protein	O
with	O
pivotal	O
function	O
in	O
glutamate	B-Chemical
transmission	O
,	O
which	O
has	O
been	O
related	O
to	O
the	O
pathogenesis	O
of	O
these	O
complications	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
investigates	O
whether	O
polymorphisms	O
in	O
the	O
HOMER1	B-Gene
gene	O
promoter	O
region	O
are	O
associated	O
with	O
the	O
occurrence	O
of	O
the	O
chronic	O
complications	O
of	O
levodopa	B-Chemical
therapy	O
.	O
</ALL>	O

<ALL>	O
A	O
total	O
of	O
205	O
patients	B-Species
with	O
idiopathic	B-Disease
Parkinson	I-Disease
's	I-Disease
disease	I-Disease
were	O
investigated	O
.	O
</ALL>	O

<ALL>	O
Patients	B-Species
were	O
genotyped	O
for	O
rs4704559	B-Variant
,	O
rs10942891	B-Variant
and	O
rs4704560	B-Variant
by	O
allelic	O
discrimination	O
with	O
Taqman	O
assays	O
.	O
</ALL>	O

<ALL>	O
The	O
rs4704559	B-Variant
G	O
allele	O
was	O
associated	O
with	O
a	O
lower	O
prevalence	O
of	O
dyskinesia	B-Disease
(	O
prevalence	O
ratio	O
(	O
PR	O
)	O
=	O
0.615	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.426	O
-	O
0.887	O
,	O
P	O
=	O
0.009	O
)	O
and	O
visual	B-Disease
hallucinations	I-Disease
(	O
PR	O
=	O
0.515	O
,	O
95	O
%	O
CI	O
0.295	O
-	O
0.899	O
,	O
P	O
=	O
0.020	O
)	O
.	O
</ALL>	O

<ALL>	O
Our	O
data	O
suggest	O
that	O
HOMER1	B-Gene
rs4704559	B-Variant
G	O
allele	O
has	O
a	O
protective	O
role	O
for	O
the	O
development	O
of	O
levodopa	B-Chemical
adverse	O
effects	O
.	O
</ALL>	O

<ALL>	O
Midline	O
B3	O
serotonin	B-Chemical
nerves	O
in	O
rat	B-Species
medulla	O
are	O
involved	O
in	O
hypotensive	B-Disease
effect	O
of	O
methyldopa	B-Chemical
.	O
</ALL>	O

<ALL>	O
Previous	O
experiments	O
in	O
this	O
laboratory	O
have	O
shown	O
that	O
microinjection	O
of	O
methyldopa	B-Chemical
onto	O
the	O
ventrolateral	O
cells	O
of	O
the	O
B3	O
serotonin	B-Chemical
neurons	O
in	O
the	O
medulla	O
elicits	O
a	O
hypotensive	B-Disease
response	O
mediated	O
by	O
a	O
projection	O
descending	O
into	O
the	O
spinal	O
cord	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
experiments	O
were	O
designed	O
to	O
investigate	O
the	O
role	O
of	O
the	O
midline	O
cells	O
of	O
the	O
B3	O
serotonin	B-Chemical
neurons	O
in	O
the	O
medulla	O
,	O
coinciding	O
with	O
the	O
raphe	O
magnus	O
.	O
</ALL>	O

<ALL>	O
In	O
spontaneously	O
hypertensive	B-Disease
,	O
stroke	B-Disease
-	O
prone	O
rats	B-Species
,	O
microinjection	O
of	O
methyldopa	B-Chemical
into	O
the	O
area	O
of	O
the	O
midline	O
B3	O
serotonin	B-Chemical
cell	O
group	O
in	O
the	O
ventral	O
medulla	O
caused	O
a	O
potent	O
hypotension	B-Disease
of	O
30	O
-	O
40	O
mm	O
Hg	O
,	O
which	O
was	O
maximal	O
2	O
-	O
3	O
h	O
after	O
administration	O
and	O
was	O
abolished	O
by	O
the	O
serotonin	B-Chemical
neurotoxin	O
5,7	B-Chemical
-	I-Chemical
dihydroxytryptamine	I-Chemical
(	O
5,7	B-Chemical
-	I-Chemical
DHT	I-Chemical
)	O
injected	O
intracerebroventricularly	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
intraspinal	O
injection	O
of	O
5,7	B-Chemical
-	I-Chemical
DHT	I-Chemical
to	O
produce	O
a	O
more	O
selective	O
lesion	O
of	O
only	O
descending	O
serotonin	B-Chemical
projections	O
in	O
the	O
spinal	O
cord	O
did	O
not	O
affect	O
this	O
hypotension	B-Disease
.	O
</ALL>	O

<ALL>	O
Further	O
,	O
5,7	B-Chemical
-	I-Chemical
DHT	I-Chemical
lesion	O
of	O
serotonin	B-Chemical
nerves	O
travelling	O
in	O
the	O
median	O
forebrain	O
bundle	O
,	O
one	O
of	O
the	O
main	O
ascending	O
pathways	O
from	O
the	O
B3	O
serotonin	B-Chemical
cells	O
,	O
did	O
not	O
affect	O
the	O
fall	O
in	O
blood	O
pressure	O
associated	O
with	O
a	O
midline	O
B3	O
serotonin	B-Chemical
methyldopa	B-Chemical
injection	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
concluded	O
therefore	O
that	O
,	O
unlike	O
the	O
ventrolateral	O
B3	O
cells	O
which	O
mediate	O
a	O
methyldopa	B-Chemical
-	O
induced	O
hypotension	B-Disease
via	O
descending	O
projections	O
,	O
the	O
midline	O
serotonin	B-Chemical
B3	O
cells	O
in	O
the	O
medulla	O
contribute	O
to	O
the	O
hypotensive	B-Disease
action	O
of	O
methyldopa	B-Chemical
,	O
either	O
by	O
way	O
of	O
an	O
ascending	O
projection	O
which	O
does	O
not	O
pass	O
through	O
the	O
median	O
forebrain	O
bundle	O
,	O
or	O
through	O
a	O
projection	O
restricted	O
to	O
the	O
caudal	O
brainstem	O
.	O
</ALL>	O

<ALL>	O
Endothelial	O
NADPH	B-Gene
oxidase	I-Gene
4	I-Gene
mediates	O
vascular	B-Gene
endothelial	I-Gene
growth	I-Gene
factor	I-Gene
receptor	I-Gene
2	I-Gene
-	O
induced	O
intravitreal	O
neovascularization	O
in	O
a	O
rat	B-Species
model	O
of	O
retinopathy	B-Disease
of	I-Disease
prematurity	I-Disease
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
NADPH	B-Gene
oxidase	I-Gene
-	O
generated	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
are	O
implicated	O
in	O
angiogenesis	O
.	O
</ALL>	O

<ALL>	O
Isoforms	O
of	O
NADPH	B-Gene
oxidase	I-Gene
NOX1	B-Gene
,	O
NOX2	B-Gene
,	O
and	O
NOX4	B-Gene
are	O
reported	O
to	O
be	O
expressed	O
in	O
endothelial	O
cells	O
(	O
ECs	O
)	O
.	O
</ALL>	O

<ALL>	O
Of	O
these	O
,	O
NOX1	B-Gene
and	O
NOX2	B-Gene
have	O
been	O
reported	O
to	O
contribute	O
to	O
intravitreal	O
neovascularization	O
(	O
IVNV	O
)	O
in	O
oxygen	B-Chemical
-	O
induced	O
retinopathy	B-Disease
(	O
OIR	B-Disease
)	O
models	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
the	O
isoform	O
NOX4	B-Gene
in	O
ECs	O
contributed	O
to	O
vascular	B-Gene
endothelial	I-Gene
growth	I-Gene
factor	I-Gene
(	O
VEGF	B-Gene
)	O
-	O
induced	O
angiogenesis	O
and	O
IVNV	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Isoforms	O
of	O
NADPH	B-Gene
oxidase	I-Gene
MRNA	O
were	O
measured	O
in	O
several	O
types	O
of	O
cultured	O
vascular	O
ecs	O
:	O
human	B-Species
retinal	O
microvascular	O
ECs	O
(	O
hRMVECs	O
)	O
,	O
choroidal	O
ECs	O
(	O
CECs	O
)	O
,	O
and	O
human	B-Species
umbilical	O
vascular	O
ECs	O
(	O
HUVECs	O
)	O
using	O
real	O
-	O
time	O
PCR	O
.	O
</ALL>	O

<ALL>	O
Newborn	O
rat	B-Species
pups	O
and	O
dams	O
were	O
placed	O
into	O
an	O
OIR	B-Disease
model	O
that	O
cycled	O
oxygen	B-Chemical
concentration	O
between	O
50	O
%	O
and	O
10	O
%	O
every	O
24	O
h	O
for	O
14	O
days	O
,	O
and	O
then	O
were	O
placed	O
in	O
room	O
air	O
(	O
RA	O
)	O
for	O
an	O
additional	O
4	O
days	O
(	O
rat	B-Species
OIR	B-Disease
model	O
)	O
.	O
</ALL>	O

<ALL>	O
NOX4	B-Gene
expression	O
in	O
retinal	O
lysates	O
from	O
the	O
RA	O
-	O
raised	O
pups	O
at	O
postnatal	O
day	O
0	O
(	O
P0	O
)	O
,	O
P14	O
,	O
and	O
P18	O
was	O
determined	O
with	O
western	O
blots	O
.	O
</ALL>	O

<ALL>	O
STAT3	B-Gene
activation	O
was	O
determined	O
as	O
the	O
ratio	O
of	O
phosphorylated	O
STAT3	B-Gene
to	O
total	O
STAT3	B-Gene
with	O
western	O
blot	O
analysis	O
of	O
retinal	O
lysates	O
from	O
pups	O
raised	O
in	O
RA	O
or	O
from	O
the	O
rat	B-Species
OIR	B-Disease
model	O
at	O
P18	O
.	O
</ALL>	O

<ALL>	O
Semiquantitative	O
assessment	O
of	O
the	O
density	O
of	O
NOX4	B-Gene
colabeling	O
with	O
lectin	B-Gene
-	O
stained	O
retinal	O
ECs	O
was	O
determined	O
by	O
immunolabeling	O
of	O
retinal	O
cryosections	O
from	O
P18	O
pups	O
in	O
OIR	B-Disease
or	O
in	O
RA	O
.	O
</ALL>	O

<ALL>	O
In	O
hRMVECs	O
transfected	O
with	O
NOX4	B-Gene
siRNA	O
and	O
treated	O
with	O
VEGF	B-Gene
or	O
control	O
,	O
1	O
)	O
ROS	B-Chemical
generation	O
was	O
measured	O
using	O
the	O
5	B-Chemical
-	I-Chemical
(	I-Chemical
and	I-Chemical
-	I-Chemical
6	I-Chemical
)	I-Chemical
-	I-Chemical
chloromethyl	I-Chemical
-	I-Chemical
2',7	I-Chemical
'	I-Chemical
-	I-Chemical
dichlorodihydrofluorescein	I-Chemical
diacetate	I-Chemical
,	I-Chemical
acetyl	I-Chemical
ester	I-Chemical
fluorescence	O
assay	O
and	O
2	O
)	O
phosphorylated	O
VEGF	B-Gene
receptor	I-Gene
2	I-Gene
and	O
STAT3	B-Gene
,	O
and	O
total	O
VEGFR2	B-Gene
and	O
STAT3	B-Gene
were	O
measured	O
in	O
western	O
blot	O
analyses	O
.	O
</ALL>	O

<ALL>	O
VEGF	B-Gene
-	O
stimulated	O
hRMVEC	O
proliferation	O
was	O
measured	O
following	O
transfection	O
with	O
NOX4	B-Gene
siRNA	O
or	O
STAT3	B-Gene
siRNA	O
,	O
or	O
respective	O
controls	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
NOX4	B-Gene
was	O
the	O
most	O
prevalent	O
isoform	O
of	O
NADPH	B-Gene
oxidase	I-Gene
in	O
vascular	O
ECs	O
.	O
</ALL>	O

<ALL>	O
NOX4	B-Gene
expression	O
in	O
retinal	O
lysates	O
was	O
significantly	O
decreased	O
during	O
development	O
in	O
RA	O
.	O
</ALL>	O

<ALL>	O
Compared	O
to	O
RA	O
,	O
the	O
expression	O
of	O
retinal	O
NOX4	B-Gene
increased	O
at	O
P18	O
.	O
</ALL>	O

<ALL>	O
At	O
p18	O
OIR	B-Disease
,	O
semiquantitative	O
assessment	O
of	O
the	O
density	O
of	O
lectin	B-Gene
and	O
NOX4	B-Gene
colabeling	O
in	O
retinal	O
vascular	O
ECs	O
was	O
greater	O
in	O
retinal	O
cryosections	O
and	O
activated	O
STAT3	B-Gene
was	O
greater	O
in	O
retinal	O
lysates	O
when	O
compared	O
to	O
the	O
RA	O
-	O
raised	O
pups	O
.	O
</ALL>	O

<ALL>	O
In	O
cultured	O
hRMVECs	O
,	O
knockdown	O
of	O
NOX4	B-Gene
by	O
siRNA	O
transfection	O
inhibited	O
VEGF	B-Gene
-	O
induced	O
ROS	B-Chemical
generation	O
.	O
</ALL>	O

<ALL>	O
VEGF	B-Gene
induced	O
a	O
physical	O
interaction	O
of	O
phosphorylated	O
-	O
VEGFR2	B-Gene
and	O
NOX4	B-Gene
.	O
</ALL>	O

<ALL>	O
Knockdown	O
of	O
NOX4	B-Gene
:	O
1	O
)	O
reduced	O
VEGFR2	B-Gene
activation	O
but	O
did	O
not	O
abolish	O
it	O
and	O
2	O
)	O
abolished	O
STAT3	B-Gene
activation	O
in	O
response	O
to	O
VEGF	B-Gene
.	O
</ALL>	O

<ALL>	O
Knockdown	O
of	O
either	O
NOX4	B-Gene
or	O
STAT3	B-Gene
inhibited	O
VEGF	B-Gene
-	O
induced	O
EC	O
proliferation	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
in	O
a	O
model	O
representative	O
of	O
human	B-Species
retinopathy	B-Disease
of	I-Disease
prematurity	I-Disease
,	O
NOX4	B-Gene
was	O
increased	O
at	O
a	O
time	O
point	O
when	O
IVNV	O
developed	O
.	O
</ALL>	O

<ALL>	O
VEGF	B-Gene
-	O
activated	O
NOX4	B-Gene
led	O
to	O
an	O
interaction	O
between	O
VEGF	B-Gene
-	O
activated	O
VEGFR2	B-Gene
and	O
NOX4	B-Gene
that	O
mediated	O
EC	O
proliferation	O
via	O
activation	O
of	O
STAT3	B-Gene
.	O
</ALL>	O

<ALL>	O
Altogether	O
,	O
our	O
results	O
suggest	O
that	O
NOX4	B-Gene
may	O
regulate	O
VEGFR2	B-Gene
-	O
mediated	O
IVNV	O
through	O
activated	O
STAT3	B-Gene
.	O
</ALL>	O

<ALL>	O
Disruption	O
of	O
the	O
temporally	O
regulated	O
cloaca	O
endodermal	O
b	B-Gene
-	I-Gene
catenin	I-Gene
signaling	O
causes	O
anorectal	B-Disease
malformations	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
cloaca	O
is	O
temporally	O
formed	O
and	O
eventually	O
divided	O
by	O
the	O
urorectal	O
septum	O
(	O
URS	O
)	O
during	O
urogenital	O
and	O
anorectal	O
organ	O
development	O
.	O
</ALL>	O

<ALL>	O
Although	O
congenital	B-Disease
malformations	I-Disease
,	O
such	O
as	O
anorectal	B-Disease
malformations	I-Disease
(	O
ARMs	B-Disease
)	O
,	O
are	O
frequently	O
observed	O
during	O
this	O
process	O
,	O
the	O
underlying	O
pathogenic	O
mechanisms	O
remain	O
unclear	O
.	O
</ALL>	O

<ALL>	O
b	B-Gene
-	I-Gene
Catenin	I-Gene
is	O
a	O
critical	O
component	O
of	O
canonical	O
Wnt	B-Gene
signaling	O
and	O
is	O
essential	O
for	O
the	O
regulation	O
of	O
cell	O
differentiation	O
and	O
morphogenesis	O
during	O
embryogenesis	O
.	O
</ALL>	O

<ALL>	O
The	O
expression	O
of	O
b	B-Gene
-	I-Gene
catenin	I-Gene
is	O
observed	O
in	O
endodermal	O
epithelia	O
,	O
including	O
URS	O
epithelia	O
.	O
</ALL>	O

<ALL>	O
We	O
modulated	O
the	O
b	B-Gene
-	I-Gene
catenin	I-Gene
gene	O
conditionally	O
in	O
endodermal	O
epithelia	O
by	O
utilizing	O
tamoxifen	B-Chemical
-	O
inducible	O
Cre	O
driver	O
line	O
(	O
Shh	B-Gene
(	O
CreERT2	O
)	O
)	O
.	O
</ALL>	O

<ALL>	O
Both	O
b	B-Gene
-	I-Gene
catenin	I-Gene
loss	O
-	O
and	O
gain	O
-	O
of	O
-	O
function	O
(	O
LOF	O
and	O
GOF	O
)	O
mutants	O
displayed	O
abnormal	O
clefts	O
in	O
the	O
perineal	O
region	O
and	O
hypoplastic	B-Disease
elongation	O
of	O
the	O
URS	O
.	O
</ALL>	O

<ALL>	O
The	O
mutants	O
also	O
displayed	O
reduced	O
cell	O
proliferation	O
in	O
the	O
URS	O
mesenchyme	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
the	O
b	B-Gene
-	I-Gene
catenin	I-Gene
GOF	O
mutants	O
displayed	O
reduced	O
apoptosis	O
and	O
subsequently	O
increased	O
apoptosis	O
in	O
the	O
URS	O
epithelium	O
.	O
</ALL>	O

<ALL>	O
This	O
instability	O
possibly	O
resulted	O
in	O
reduced	O
expression	O
levels	O
of	O
differentiation	O
markers	O
,	O
such	O
as	O
keratin	B-Gene
1	I-Gene
and	O
filaggrin	B-Gene
,	O
in	O
the	O
perineal	O
epithelia	O
.	O
</ALL>	O

<ALL>	O
The	O
expression	O
of	O
bone	B-Gene
morphogenetic	I-Gene
protein	I-Gene
(	O
Bmp	B-Gene
)	O
genes	O
,	O
such	O
as	O
Bmp4	B-Gene
and	O
Bmp7	B-Gene
,	O
was	O
also	O
ectopically	O
induced	O
in	O
the	O
epithelia	O
of	O
the	O
URS	O
in	O
the	O
b	B-Gene
-	I-Gene
catenin	I-Gene
GOF	O
mutants	O
.	O
</ALL>	O

<ALL>	O
The	O
expression	O
of	O
the	O
Msx2	B-Gene
gene	O
and	O
phosphorylated	O
-	O
Smad1	B-Gene
/	I-Gene
5	I-Gene
/	I-Gene
8	I-Gene
,	O
possible	O
readouts	O
of	O
Bmp	B-Gene
signaling	O
,	O
was	O
also	O
increased	O
in	O
the	O
mutants	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
we	O
introduced	O
an	O
additional	O
mutation	O
for	O
a	O
Bmp	B-Gene
receptor	I-Gene
gene	O
:	O
BmprIA	B-Gene
.	O
</ALL>	O

<ALL>	O
The	O
Shh	B-Gene
(	O
CreERT2	O
/	O
+	O
)	O
;	O
b	B-Gene
-	I-Gene
catenin	I-Gene
(	O
flox	O
(	O
ex3	O
)	O
/	O
+	O
)	O
;	O
BmprIA	B-Gene
(	O
flox	O
/	O
-	O
)	O
mutants	O
displayed	O
partial	O
restoration	O
of	O
URS	O
elongation	O
compared	O
with	O
the	O
b	B-Gene
-	I-Gene
catenin	I-Gene
GOF	O
mutants	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
indicate	O
that	O
some	O
ARM	B-Disease
phenotypes	O
in	O
the	O
b	B-Gene
-	I-Gene
catenin	I-Gene
GOF	O
mutants	O
were	O
caused	O
by	O
abnormal	O
Bmp	B-Gene
signaling	O
.	O
</ALL>	O

<ALL>	O
The	O
current	O
analysis	O
revealed	O
the	O
close	O
relation	O
of	O
endodermal	O
b	B-Gene
-	I-Gene
catenin	I-Gene
signaling	O
to	O
the	O
ARM	B-Disease
phenotypes	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
are	O
considered	O
to	O
shed	O
light	O
on	O
the	O
pathogenic	O
mechanisms	O
of	O
human	B-Species
ARMs	B-Disease
.	O
</ALL>	O

<ALL>	O
Behavioral	O
and	O
neurochemical	O
studies	O
in	O
mice	B-Species
pretreated	O
with	O
garcinielliptone	B-Chemical
FC	I-Chemical
in	O
pilocarpine	B-Chemical
-	O
induced	O
seizures	B-Disease
.	O
</ALL>	O

<ALL>	O
Garcinielliptone	B-Chemical
FC	I-Chemical
(	O
GFC	B-Chemical
)	O
isolated	O
from	O
hexanic	O
fraction	O
seed	O
extract	O
of	O
species	O
Platonia	B-Species
insignis	I-Species
Mart	I-Species
.	O
</ALL>	O

<ALL>	O
It	O
is	O
widely	O
used	O
in	O
folk	O
medicine	O
to	O
treat	O
skin	B-Disease
diseases	I-Disease
in	O
both	O
humans	B-Species
and	O
animals	O
as	O
well	O
as	O
the	O
seed	O
decoction	O
has	O
been	O
used	O
to	O
treat	O
diarrheas	B-Disease
and	O
inflammatory	B-Disease
diseases	I-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
there	O
is	O
no	O
research	O
on	O
GFC	B-Chemical
effects	O
in	O
the	O
central	O
nervous	O
system	O
of	O
rodents	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
aimed	O
to	O
evaluate	O
the	O
GFC	B-Chemical
effects	O
at	O
doses	O
of	O
25	O
,	O
50	O
or	O
75	O
mg	O
/	O
kg	O
on	O
seizure	B-Disease
parameters	O
to	O
determine	O
their	O
anticonvulsant	O
activity	O
and	O
its	O
effects	O
on	O
amino	O
acid	O
(	O
r	B-Chemical
-	I-Chemical
aminobutyric	I-Chemical
acid	I-Chemical
(	O
GABA	B-Chemical
)	O
,	O
glutamine	B-Chemical
,	O
aspartate	B-Chemical
and	O
glutathione	B-Chemical
)	O
levels	O
as	O
well	O
as	O
on	O
acetylcholinesterase	B-Gene
(	O
AChE	B-Gene
)	O
activity	O
in	O
mice	B-Species
hippocampus	O
after	O
seizures	B-Disease
.	O
</ALL>	O

<ALL>	O
GFC	B-Chemical
produced	O
an	O
increased	O
latency	O
to	O
first	O
seizure	B-Disease
,	O
at	O
doses	O
25	O
mg	O
/	O
kg	O
(	O
20.12	O
+	O
2.20	O
min	O
)	O
,	O
50	O
mg	O
/	O
kg	O
(	O
20.95	O
+	O
2.21	O
min	O
)	O
or	O
75	O
mg	O
/	O
kg	O
(	O
23.43	O
+	O
1.99	O
min	O
)	O
when	O
compared	O
with	O
seized	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
GABA	B-Chemical
content	O
of	O
mice	B-Species
hippocampus	O
treated	O
with	O
GFC75	B-Chemical
plus	O
P400	B-Chemical
showed	O
an	O
increase	O
of	O
46.90	O
%	O
when	O
compared	O
with	O
seized	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
In	O
aspartate	B-Chemical
,	O
glutamine	B-Chemical
and	O
glutamate	B-Chemical
levels	O
detected	O
a	O
decrease	O
of	O
5.21	O
%	O
,	O
13.55	O
%	O
and	O
21.80	O
%	O
,	O
respectively	O
in	O
mice	B-Species
hippocampus	O
treated	O
with	O
GFC75	B-Chemical
plus	O
P400	B-Chemical
when	O
compared	O
with	O
seized	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Hippocampus	O
mice	B-Species
treated	O
with	O
GFC75	B-Chemical
plus	O
P400	B-Chemical
showed	O
an	O
increase	O
in	O
AChE	B-Gene
activity	O
(	O
63.30	O
%	O
)	O
when	O
compared	O
with	O
seized	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
results	O
indicate	O
that	O
GFC	B-Chemical
can	O
exert	O
anticonvulsant	O
activity	O
and	O
reduce	O
the	O
frequency	O
of	O
installation	O
of	O
pilocarpine	B-Chemical
-	O
induced	O
status	B-Disease
epilepticus	I-Disease
,	O
as	O
demonstrated	O
by	O
increase	O
in	O
latency	O
to	O
first	O
seizure	B-Disease
and	O
decrease	O
in	O
mortality	O
rate	O
of	O
animals	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
GFC	B-Chemical
may	O
influence	O
in	O
epileptogenesis	O
and	O
promote	O
anticonvulsant	O
actions	O
in	O
pilocarpine	B-Chemical
model	O
by	O
modulating	O
the	O
GABA	B-Chemical
and	O
glutamate	B-Chemical
contents	O
and	O
of	O
AChE	B-Gene
activity	O
in	O
seized	O
mice	B-Species
hippocampus	O
.	O
</ALL>	O

<ALL>	O
This	O
compound	O
may	O
be	O
useful	O
to	O
produce	O
neuronal	O
protection	O
and	O
it	O
can	O
be	O
considered	O
as	O
an	O
anticonvulsant	O
agent	O
.	O
</ALL>	O

<ALL>	O
Conversion	O
to	O
sirolimus	B-Chemical
ameliorates	O
cyclosporine	B-Chemical
-	O
induced	O
nephropathy	B-Disease
in	O
the	O
rat	B-Species
:	O
focus	O
on	O
serum	O
,	O
urine	O
,	O
gene	O
,	O
and	O
protein	O
renal	O
expression	O
biomarkers	O
.	O
</ALL>	O

<ALL>	O
Protocols	O
of	O
conversion	O
from	O
cyclosporin	B-Chemical
A	I-Chemical
(	O
CsA	B-Chemical
)	O
to	O
sirolimus	B-Chemical
(	O
SRL	B-Chemical
)	O
have	O
been	O
widely	O
used	O
in	O
immunotherapy	O
after	O
transplantation	O
to	O
prevent	O
CsA	B-Chemical
-	O
induced	O
nephropathy	B-Disease
,	O
but	O
the	O
molecular	O
mechanisms	O
underlying	O
these	O
protocols	O
remain	O
nuclear	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
aimed	O
to	O
identify	O
the	O
molecular	O
pathways	O
and	O
putative	O
biomarkers	O
of	O
CsA	B-Chemical
-	O
to	O
-	O
SRL	B-Chemical
conversion	O
in	O
a	O
rat	B-Species
model	O
.	O
</ALL>	O

<ALL>	O
Four	O
animal	O
groups	O
(	O
n	O
=	O
6	O
)	O
were	O
tested	O
during	O
9	O
weeks	O
:	O
control	O
,	O
CsA	B-Chemical
,	O
SRL	B-Chemical
,	O
and	O
conversion	O
(	O
CsA	B-Chemical
for	O
3	O
weeks	O
followed	O
by	O
SRL	B-Chemical
for	O
6	O
weeks	O
)	O
.	O
</ALL>	O

<ALL>	O
Classical	O
and	O
emergent	O
serum	O
,	O
urinary	O
,	O
and	O
kidney	O
tissue	O
(	O
gene	O
and	O
protein	O
expression	O
)	O
markers	O
were	O
assessed	O
.	O
</ALL>	O

<ALL>	O
Renal	B-Disease
lesions	I-Disease
were	O
analyzed	O
in	O
hematoxylin	O
and	O
eosin	O
,	O
periodic	O
acid	O
-	O
Schiff	O
,	O
and	O
Masson	O
's	O
trichrome	O
stains	O
.	O
</ALL>	O

<ALL>	O
SRL	B-Chemical
-	O
treated	O
rats	B-Species
presented	O
proteinuria	B-Disease
and	O
NGAL	B-Gene
(	O
serum	O
and	O
urinary	O
)	O
as	O
the	O
best	O
markers	O
of	O
renal	B-Disease
impairment	I-Disease
.	O
</ALL>	O

<ALL>	O
Short	O
CsA	B-Chemical
treatment	O
presented	O
slight	O
or	O
even	O
absent	O
kidney	B-Disease
lesions	I-Disease
and	O
TGF	B-Gene
-	I-Gene
b	I-Gene
,	O
NF	B-Gene
-	I-Gene
kb	I-Gene
,	O
mTOR	B-Gene
,	O
PCNA	B-Gene
,	O
TP53	B-Gene
,	O
KIM	B-Gene
-	I-Gene
1	I-Gene
,	O
and	O
CTGF	B-Gene
as	O
relevant	O
gene	O
and	O
protein	O
changes	O
.	O
</ALL>	O

<ALL>	O
Prolonged	O
CsA	B-Chemical
exposure	O
aggravated	O
renal	B-Disease
damage	I-Disease
,	O
without	O
clear	O
changes	O
on	O
the	O
traditional	O
markers	O
,	O
but	O
with	O
changes	O
in	O
serums	O
TGF	B-Gene
-	I-Gene
b	I-Gene
and	O
IL	B-Gene
-	I-Gene
7	I-Gene
,	O
TBARs	B-Chemical
clearance	O
,	O
and	O
kidney	O
TGF	B-Gene
-	I-Gene
b	I-Gene
and	O
mTOR	B-Gene
.	O
</ALL>	O

<ALL>	O
Conversion	O
to	O
SRL	B-Chemical
prevented	O
CsA	B-Chemical
-	O
induced	O
renal	B-Disease
damage	I-Disease
evolution	O
(	O
absent	O
/	O
mild	O
grade	O
lesions	O
)	O
,	O
while	O
NGAL	B-Gene
(	O
serum	O
versus	O
urine	O
)	O
seems	O
to	O
be	O
a	O
feasible	O
biomarker	O
of	O
CsA	B-Chemical
replacement	O
to	O
SRL	B-Chemical
.	O
</ALL>	O

<ALL>	O
Characterization	O
of	O
a	O
novel	O
BCHE	B-Gene
"	O
silent	O
"	O
allele	O
:	O
point	O
mutation	O
(	O
p	B-Variant
.	I-Variant
Val204Asp	I-Variant
)	O
causes	O
loss	O
of	O
activity	O
and	O
prolonged	O
apnea	B-Disease
with	O
suxamethonium	B-Chemical
.	O
</ALL>	O

<ALL>	O
Butyrylcholinesterase	B-Disease
deficiency	I-Disease
is	O
characterized	O
by	O
prolonged	O
apnea	B-Disease
after	O
the	O
use	O
of	O
muscle	B-Chemical
relaxants	I-Chemical
(	O
suxamethonium	B-Chemical
or	O
mivacurium	B-Chemical
)	O
in	O
patients	B-Species
who	O
have	O
mutations	O
in	O
the	O
BCHE	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
report	O
a	O
case	O
of	O
prolonged	O
neuromuscular	B-Disease
block	I-Disease
after	O
administration	O
of	O
suxamethonium	B-Chemical
leading	O
to	O
the	O
discovery	O
of	O
a	O
novel	O
BCHE	B-Gene
variant	O
(	O
c.695	B-Variant
T	I-Variant
>	I-Variant
A	I-Variant
,	O
p	B-Variant
.	I-Variant
Val204Asp	I-Variant
)	O
.	O
</ALL>	O

<ALL>	O
Inhibition	O
studies	O
,	O
kinetic	O
analysis	O
and	O
molecular	O
dynamics	O
were	O
undertaken	O
to	O
understand	O
how	O
this	O
mutation	O
disrupts	O
the	O
catalytic	O
triad	O
and	O
determines	O
a	O
"	O
silent	O
"	O
phenotype	O
.	O
</ALL>	O

<ALL>	O
Low	O
activity	O
of	O
patient	B-Species
plasma	O
butyrylcholinesterase	B-Gene
with	O
butyrylthiocholine	B-Chemical
(	O
BTC	B-Chemical
)	O
and	O
benzoylcholine	B-Chemical
,	O
and	O
values	O
of	O
dibucaine	B-Chemical
and	O
fluoride	B-Chemical
numbers	O
fit	O
with	O
heterozygous	O
atypical	O
silent	O
genotype	O
.	O
</ALL>	O

<ALL>	O
Electrophoretic	O
analysis	O
of	O
plasma	O
BChE	B-Gene
of	O
the	O
proband	O
and	O
his	O
mother	O
showed	O
that	O
patient	B-Species
has	O
a	O
reduced	O
amount	O
of	O
tetrameric	O
enzyme	O
in	O
plasma	O
and	O
that	O
minor	O
fast	O
-	O
moving	O
BChE	B-Gene
components	O
:	O
monomer	O
,	O
dimer	O
,	O
and	O
monomer	O
-	O
albumin	O
conjugate	O
are	O
missing	O
.	O
</ALL>	O

<ALL>	O
Kinetic	O
analysis	O
showed	O
that	O
the	O
p	B-Variant
.	I-Variant
Val204Asp	I-Variant
/	O
p	B-Variant
.	I-Variant
Asp70Gly	I-Variant
-	O
p	B-Variant
.	I-Variant
Ala539Thr	I-Variant
BChE	B-Gene
displays	O
a	O
pure	O
Michaelian	O
behavior	O
with	O
BTC	B-Chemical
as	O
the	O
substrate	O
.	O
</ALL>	O

<ALL>	O
Both	O
catalytic	O
parameters	O
Km	O
=	O
265	O
uM	O
for	O
BTC	B-Chemical
,	O
two	O
times	O
higher	O
than	O
that	O
of	O
the	O
atypical	O
enzyme	O
,	O
and	O
a	O
low	O
Vmax	O
are	O
consistent	O
with	O
the	O
absence	O
of	O
activity	O
against	O
suxamethonium	B-Chemical
.	O
</ALL>	O

<ALL>	O
Molecular	O
dynamic	O
(	O
MD	O
)	O
simulations	O
showed	O
that	O
the	O
overall	O
effect	O
of	O
the	O
mutation	O
p	B-Variant
.	I-Variant
Val204Asp	I-Variant
is	O
disruption	O
of	O
hydrogen	O
bonding	O
between	O
Gln223	O
and	O
Glu441	O
,	O
leading	O
Ser198	O
and	O
His438	O
to	O
move	O
away	O
from	O
each	O
other	O
with	O
subsequent	O
disruption	O
of	O
the	O
catalytic	O
triad	O
functionality	O
regardless	O
of	O
the	O
type	O
of	O
substrate	O
.	O
</ALL>	O

<ALL>	O
MD	O
also	O
showed	O
that	O
the	O
enzyme	O
volume	O
is	O
increased	O
,	O
suggesting	O
a	O
pre	O
-	O
denaturation	O
state	O
.	O
</ALL>	O

<ALL>	O
This	O
fits	O
with	O
the	O
reduced	O
concentration	O
of	O
p	B-Variant
.	I-Variant
Ala204Asp	I-Variant
/	O
p	B-Variant
.	I-Variant
Asp70Gly	I-Variant
-	O
p	B-Variant
.	I-Variant
Ala539Thr	I-Variant
tetrameric	O
enzyme	O
in	O
the	O
plasma	O
and	O
non	O
-	O
detectable	O
fast	O
moving	O
-	O
bands	O
on	O
electrophoresis	O
gels	O
.	O
</ALL>	O

<ALL>	O
Inhibition	O
of	O
LDHA	B-Gene
suppresses	O
tumor	B-Disease
progression	O
in	O
prostate	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
A	O
key	O
hallmark	O
of	O
cancer	B-Disease
cells	O
is	O
their	O
altered	O
metabolism	O
,	O
known	O
as	O
Warburg	O
effect	O
.	O
</ALL>	O

<ALL>	O
Lactate	B-Gene
dehydrogenase	I-Gene
A	I-Gene
(	O
LDHA	B-Gene
)	O
executes	O
the	O
final	O
step	O
of	O
aerobic	O
glycolysis	O
and	O
has	O
been	O
reported	O
to	O
be	O
involved	O
in	O
the	O
tumor	B-Disease
progression	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
function	O
of	O
LDHA	B-Gene
in	O
prostate	B-Disease
cancer	I-Disease
has	O
not	O
been	O
studied	O
.	O
</ALL>	O

<ALL>	O
In	O
current	O
study	O
,	O
we	O
observed	O
overexpression	O
of	O
LDHA	B-Gene
in	O
the	O
clinical	O
prostate	B-Disease
cancer	I-Disease
samples	O
compared	O
with	O
benign	B-Disease
prostate	I-Disease
hyperplasia	I-Disease
tissues	O
as	O
demonstrated	O
by	O
immunohistochemistry	O
and	O
real	O
-	O
time	O
qPCR	O
.	O
</ALL>	O

<ALL>	O
Attenuated	O
expression	O
of	O
LDHA	B-Gene
by	O
siRNA	O
or	O
inhibition	O
of	O
LDHA	B-Gene
activities	O
by	O
FX11	B-Chemical
inhibited	O
cell	O
proliferation	O
,	O
migration	O
,	O
invasion	O
,	O
and	O
promoted	O
cell	O
apoptosis	O
of	O
PC	B-CellLine
-	I-CellLine
3	I-CellLine
and	O
DU145	B-CellLine
cells	O
.	O
</ALL>	O

<ALL>	O
Mechanistically	O
,	O
decreased	O
Warburg	O
effect	O
as	O
demonstrated	O
by	O
reduced	O
glucose	B-Chemical
consumption	O
and	O
lactate	B-Chemical
secretion	O
and	O
reduced	O
expression	O
of	O
MMP	B-Gene
-	I-Gene
9	I-Gene
,	O
PLAU	B-Gene
,	O
and	O
cathepsin	B-Gene
B	I-Gene
were	O
found	O
after	O
LDHA	B-Gene
knockdown	O
or	O
FX11	B-Chemical
treatment	O
in	O
PC	B-CellLine
-	I-CellLine
3	I-CellLine
and	O
DU145	B-CellLine
cells	O
.	O
</ALL>	O

<ALL>	O
Taken	O
together	O
,	O
our	O
study	O
revealed	O
the	O
oncogenic	O
role	O
of	O
LDHA	B-Gene
in	O
prostate	B-Disease
cancer	I-Disease
and	O
suggested	O
that	O
LDHA	B-Gene
might	O
be	O
a	O
potential	O
therapeutic	O
target	O
.	O
</ALL>	O

<ALL>	O
Erythropoietin	B-Gene
does	O
not	O
activate	O
erythropoietin	B-Gene
receptor	I-Gene
signaling	O
or	O
lipolytic	O
pathways	O
in	O
human	B-Species
subcutaneous	O
white	O
adipose	O
tissue	O
in	O
vivo	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Erythropoietin	B-Gene
(	O
Epo	B-Gene
)	O
exerts	O
direct	O
effects	O
on	O
white	O
adipose	O
tissue	O
(	O
WAT	O
)	O
in	O
mice	B-Species
in	O
addition	O
to	O
its	O
erythropoietic	O
effects	O
,	O
and	O
in	O
humans	B-Species
Epo	B-Gene
increases	O
resting	O
energy	O
expenditure	O
and	O
affect	O
serum	O
lipid	B-Chemical
levels	O
,	O
but	O
direct	O
effects	O
of	O
Epo	B-Gene
in	O
human	B-Species
WAT	O
have	O
not	O
been	O
documented	O
.	O
</ALL>	O

<ALL>	O
We	O
therefore	O
investigated	O
the	O
effects	O
of	O
acute	O
and	O
prolonged	O
Epo	B-Gene
exposure	O
on	O
human	B-Species
WAT	O
in	O
vivo	O
.	O
</ALL>	O

<ALL>	O
METHOD	O
:	O
Data	O
were	O
obtained	O
from	O
two	O
clinical	O
trials	O
:	O
1	O
)	O
acute	O
Epo	B-Gene
exposure	O
(	O
rHuEpo	O
,	O
400	O
IU	O
/	O
kg	O
)	O
followed	O
by	O
WAT	O
biopsies	O
after	O
1	O
h	O
and	O
2	O
)	O
10	O
weeks	O
treatment	O
with	O
the	O
erythropoiesis	B-Chemical
-	I-Chemical
stimulating	I-Chemical
agent	I-Chemical
(	O
ESA	B-Chemical
)	O
Darbepoietin	B-Chemical
-	I-Chemical
alpha	I-Chemical
.	O
</ALL>	O

<ALL>	O
Biopsies	O
were	O
analyzed	O
by	O
PCR	O
for	O
Epo	B-Gene
receptor	I-Gene
(	O
Epo	B-Gene
-	I-Gene
R	I-Gene
)	O
mRNA	O
.	O
</ALL>	O

<ALL>	O
A	O
new	O
and	O
highly	O
specific	O
antibody	O
(	O
A82	O
,	O
Amgen	O
)	O
was	O
used	O
to	O
evaluate	O
the	O
presence	O
of	O
Epo	B-Gene
-	I-Gene
R	I-Gene
by	O
western	O
blot	O
analysis	O
in	O
addition	O
to	O
Epo	B-Gene
-	I-Gene
R	I-Gene
signaling	O
proteins	O
(	O
Akt	B-Gene
,	O
STAT5	B-Gene
,	O
p70s6k	B-Gene
,	O
LYN	B-Gene
,	O
and	O
p38MAPK	B-Gene
)	O
,	O
activation	O
of	O
lipolytic	O
pathways	O
(	O
ATGL	B-Gene
,	O
HSL	B-Gene
,	O
CGI	B-Gene
-	I-Gene
58	I-Gene
,	O
G0S2	B-Gene
,	O
Perilipin	B-Gene
,	O
Cidea	B-Gene
,	O
Cidec	B-Gene
,	O
AMPK	B-Gene
,	O
and	O
ACC	B-Gene
)	O
,	O
and	O
mitochondrial	O
biogenesis	O
(	O
VDAC	B-Gene
,	O
HSP90	B-Gene
,	O
PDH	B-Gene
,	O
and	O
SDHA	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
No	O
evidence	O
of	O
in	O
vivo	O
activation	O
of	O
the	O
Epo	B-Gene
-	I-Gene
R	I-Gene
in	O
WAT	O
could	O
be	O
documented	O
despite	O
detectable	O
levels	O
of	O
Epo	B-Gene
-	I-Gene
R	I-Gene
mRNA	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Thus	O
,	O
in	O
contradiction	O
to	O
animal	O
studies	O
,	O
Epo	B-Gene
treatment	O
within	O
a	O
physiological	O
relevant	O
range	O
in	O
humans	B-Species
does	O
not	O
exert	O
direct	O
effects	O
in	O
a	O
subcutaneous	O
WAT	O
.	O
</ALL>	O

<ALL>	O
A	O
Critical	O
Role	O
for	O
the	O
Type	B-Gene
I	I-Gene
Interferon	I-Gene
Receptor	I-Gene
in	O
Virus	O
-	O
Induced	O
Autoimmune	B-Disease
Diabetes	I-Disease
in	O
Rats	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
pathogenesis	O
of	O
human	B-Species
type	B-Disease
1	I-Disease
diabetes	I-Disease
,	O
characterized	O
by	O
immune	O
-	O
mediated	O
damage	O
of	O
insulin	B-Gene
-	O
producing	O
b	O
-	O
cells	O
of	O
pancreatic	O
islets	O
,	O
may	O
involve	O
viral	B-Disease
infection	I-Disease
.	O
</ALL>	O

<ALL>	O
Essential	O
components	O
of	O
the	O
innate	O
immune	O
antiviral	O
response	O
,	O
including	O
type	B-Gene
I	I-Gene
interferon	I-Gene
(	O
IFN	B-Gene
)	O
and	O
IFN	B-Gene
receptor	I-Gene
-	O
mediated	O
signaling	O
pathways	O
,	O
are	O
candidates	O
for	O
determining	O
susceptibility	O
to	O
human	B-Species
type	B-Disease
1	I-Disease
diabetes	I-Disease
.	O
</ALL>	O

<ALL>	O
Numerous	O
aspects	O
of	O
human	B-Species
type	B-Disease
1	I-Disease
diabetes	I-Disease
pathogenesis	O
are	O
recapitulated	O
in	O
the	O
LEW.1WR1	O
rat	B-Species
model	O
.	O
</ALL>	O

<ALL>	O
Diabetes	B-Disease
can	O
be	O
induced	O
in	O
LEW.1WR1	O
weanling	O
rats	B-Species
challenged	O
with	O
virus	O
or	O
with	O
the	O
viral	O
mimetic	O
polyinosinic	B-Chemical
:	I-Chemical
polycytidylic	I-Chemical
acid	I-Chemical
(	O
poly	B-Chemical
I	I-Chemical
:	I-Chemical
C	I-Chemical
)	O
.	O
</ALL>	O

<ALL>	O
We	O
hypothesized	O
that	O
disrupting	O
the	O
cognate	O
type	B-Gene
I	I-Gene
IFN	I-Gene
receptor	I-Gene
(	O
type	B-Gene
I	I-Gene
IFN	I-Gene
a	I-Gene
/	I-Gene
b	I-Gene
receptor	I-Gene
[	O
IFNAR	B-Gene
]	O
)	O
to	O
interrupt	O
IFN	B-Gene
signaling	O
would	O
prevent	O
or	O
delay	O
the	O
development	O
of	O
virus	O
-	O
induced	O
diabetes	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
generated	O
IFNAR1	B-Gene
subunit	O
-	O
deficient	O
LEW.1WR1	O
rats	B-Species
using	O
CRISPR	O
-	O
Cas9	O
(	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeats	O
-	O
associated	O
protein	O
9	O
)	O
genome	O
editing	O
and	O
confirmed	O
functional	O
disruption	O
of	O
the	O
Ifnar1	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
IFNAR1	B-Gene
deficiency	O
significantly	O
delayed	O
the	O
onset	O
and	O
frequency	O
of	O
diabetes	B-Disease
and	O
greatly	O
reduced	O
the	O
intensity	O
of	O
insulitis	B-Disease
after	O
poly	B-Chemical
I	I-Chemical
:	I-Chemical
C	I-Chemical
treatment	O
.	O
</ALL>	O

<ALL>	O
The	O
occurrence	O
of	O
Kilham	B-Species
rat	I-Species
virus	I-Species
-	O
induced	O
diabetes	B-Disease
was	O
also	O
diminished	O
in	O
IFNAR1	B-Gene
-	O
deficient	O
animals	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
firmly	O
establish	O
that	O
alterations	O
in	O
innate	O
immunity	O
influence	O
the	O
course	O
of	O
autoimmune	B-Disease
diabetes	I-Disease
and	O
support	O
the	O
use	O
of	O
targeted	O
strategies	O
to	O
limit	O
or	O
prevent	O
the	O
development	O
of	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
.	O
</ALL>	O

<ALL>	O
Genetic	O
Variation	O
at	O
the	O
Sulfonylurea	B-Gene
Receptor	I-Gene
,	O
Type	B-Disease
2	I-Disease
Diabetes	I-Disease
,	O
and	O
Coronary	B-Disease
Heart	I-Disease
Disease	I-Disease
.	O
</ALL>	O

<ALL>	O
Despite	O
widespread	O
clinical	O
use	O
in	O
the	O
treatment	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
,	O
the	O
impact	O
of	O
sulfonylurea	B-Chemical
therapy	O
on	O
cardiovascular	O
outcomes	O
remains	O
uncertain	O
.	O
</ALL>	O

<ALL>	O
Studies	O
of	O
naturally	O
occurring	O
genetic	O
variation	O
can	O
be	O
used	O
to	O
anticipate	O
the	O
expected	O
clinical	O
consequences	O
of	O
a	O
pharmacological	O
therapy	O
.	O
</ALL>	O

<ALL>	O
A	O
common	O
missense	O
variant	O
in	O
the	O
gene	O
encoding	O
a	O
component	O
of	O
the	O
sulfonylurea	B-Gene
receptor	I-Gene
(	O
ABCC8	B-Gene
p	B-Variant
.	I-Variant
A1369S	I-Variant
)	O
promotes	O
closure	O
of	O
the	O
target	O
channel	O
of	O
sulfonylurea	B-Chemical
therapy	O
and	O
is	O
associated	O
with	O
increased	O
insulin	B-Gene
secretion	O
,	O
thus	O
mimicking	O
the	O
effects	O
of	O
sulfonylurea	B-Chemical
therapy	O
.	O
</ALL>	O

<ALL>	O
Using	O
individual	O
-	O
level	O
data	O
from	O
120,286	O
participants	O
in	O
the	O
UK	O
Biobank	O
and	O
summary	O
association	O
results	O
from	O
four	O
large	O
-	O
scale	O
genome	O
-	O
wide	O
association	O
studies	O
,	O
we	O
examined	O
the	O
impact	O
of	O
this	O
variant	O
on	O
cardiometabolic	O
traits	O
,	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
,	O
and	O
coronary	B-Disease
heart	I-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
p	B-Variant
.	I-Variant
A1369S	I-Variant
variant	O
was	O
associated	O
with	O
a	O
significantly	O
lower	O
risk	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
(	O
odds	O
ratio	O
[	O
OR	O
]	O
0.93	O
;	O
95	O
%	O
CI	O
0.91	O
,	O
0.95	O
;	O
P	O
=	O
1.2	O
x	O
10	O
(	O
-	O
11	O
)	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
variant	O
was	O
associated	O
with	O
increased	O
BMI	O
(	O
+	O
0.062	O
kg	O
/	O
m	O
(	O
2	O
)	O
;	O
95	O
%	O
CI	O
0.037	O
,	O
0.086	O
;	O
P	O
=	O
8.1	O
x	O
10	O
(	O
-	O
7	O
)	O
)	O
but	O
lower	O
waist	O
-	O
to	O
-	O
hip	O
ratio	O
adjusted	O
for	O
BMI	O
,	O
a	O
marker	O
of	O
abdominal	O
fat	O
distribution	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
p	B-Variant
.	I-Variant
A1369S	I-Variant
was	O
associated	O
with	O
a	O
reduced	O
risk	O
of	O
coronary	B-Disease
heart	I-Disease
disease	I-Disease
(	O
OR	O
0.98	O
;	O
95	O
%	O
CI	O
0.96	O
,	O
0.99	O
;	O
P	O
=	O
5.9	O
x	O
10	O
(	O
-	O
4	O
)	O
)	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
suggest	O
that	O
,	O
despite	O
a	O
known	O
association	O
with	O
increased	O
weight	O
,	O
long	O
-	O
term	O
sulfonylurea	B-Chemical
therapy	O
may	O
reduce	O
the	O
risk	O
of	O
coronary	B-Disease
heart	I-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
Regulation	O
of	O
lung	O
endothelial	O
permeability	O
and	O
inflammatory	B-Disease
responses	O
by	O
prostaglandin	B-Chemical
A2	I-Chemical
:	O
role	O
of	O
EP4	B-Gene
receptor	I-Gene
.	O
</ALL>	O

<ALL>	O
The	O
role	O
of	O
prostaglandin	B-Chemical
A2	I-Chemical
(	O
PGA2	B-Chemical
)	O
in	O
modulation	O
of	O
vascular	O
endothelial	O
function	O
is	O
unknown	O
.	O
</ALL>	O

<ALL>	O
We	O
investigated	O
effects	O
of	O
PGA2	B-Chemical
on	O
pulmonary	O
endothelial	O
cell	O
(	O
EC	O
)	O
permeability	O
and	O
inflammatory	B-Disease
activation	O
and	O
identified	O
a	O
receptor	O
mediating	O
these	O
effects	O
.	O
</ALL>	O

<ALL>	O
PGA2	B-Chemical
enhanced	O
the	O
EC	O
barrier	O
and	O
protected	O
against	O
barrier	O
dysfunction	O
caused	O
by	O
vasoactive	O
peptide	O
thrombin	B-Gene
and	O
proinflammatory	B-Disease
bacterial	O
wall	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)	O
.	O
</ALL>	O

<ALL>	O
Receptor	O
screening	O
using	O
pharmacological	O
and	O
molecular	O
inhibitory	O
approaches	O
identified	O
EP4	B-Gene
as	O
a	O
novel	O
PGA2	B-Gene
receptor	I-Gene
.	O
</ALL>	O

<ALL>	O
EP4	B-Gene
mediated	O
barrier	O
-	O
protective	O
effects	O
of	O
PGA2	B-Chemical
by	O
activating	O
Rap1	B-Gene
/	I-Gene
Rac1	I-Gene
GTPase	I-Gene
and	O
protein	B-Gene
kinase	I-Gene
A	I-Gene
targets	O
at	O
cell	O
adhesions	O
and	O
cytoskeleton	O
:	O
VE	B-Gene
-	I-Gene
cadherin	I-Gene
,	O
p120	B-Gene
-	I-Gene
catenin	I-Gene
,	O
ZO	B-Gene
-	I-Gene
1	I-Gene
,	O
cortactin	B-Gene
,	O
and	O
VASP	B-Gene
.	O
</ALL>	O

<ALL>	O
PGA2	B-Chemical
also	O
suppressed	O
LPS	B-Chemical
-	O
induced	O
inflammatory	B-Disease
signaling	O
by	O
inhibiting	O
the	O
NFkB	B-Gene
pathway	O
and	O
expression	O
of	O
EC	B-Gene
adhesion	I-Gene
molecules	I-Gene
ICAM1	B-Gene
and	O
VCAM1	B-Gene
.	O
</ALL>	O

<ALL>	O
These	O
effects	O
were	O
abolished	O
by	O
pharmacological	O
or	O
molecular	O
inhibition	O
of	O
EP4	B-Gene
.	O
</ALL>	O

<ALL>	O
In	O
vivo	O
,	O
PGA2	B-Chemical
was	O
protective	O
in	O
two	O
distinct	O
models	O
of	O
acute	B-Disease
lung	I-Disease
injury	I-Disease
(	O
ALI	B-Disease
)	O
:	O
LPS	B-Chemical
-	O
induced	O
inflammatory	B-Disease
injury	I-Disease
and	O
two	O
-	O
hit	O
ALI	B-Disease
caused	O
by	O
suboptimal	O
mechanical	O
ventilation	O
and	O
injection	O
of	O
thrombin	B-Gene
receptor	I-Gene
-	O
activating	O
peptide	O
.	O
</ALL>	O

<ALL>	O
These	O
protective	O
effects	O
were	O
abolished	O
in	O
mice	B-Species
with	O
endothelial	O
-	O
specific	O
EP4	B-Gene
knockout	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
suggest	O
a	O
novel	O
role	O
for	O
the	O
PGA2	B-Chemical
-	O
EP4	B-Gene
axis	O
in	O
vascular	O
EC	O
protection	O
that	O
is	O
critical	O
for	O
improvement	O
of	O
pathological	O
states	O
associated	O
with	O
increased	O
vascular	O
leakage	O
and	O
inflammation	B-Disease
.	O
</ALL>	O

<ALL>	O
Hypoglycemic	O
Effect	O
of	O
Combined	O
Ghrelin	B-Gene
and	O
Glucagon	B-Gene
Receptor	I-Gene
Blockade	O
.	O
</ALL>	O

<ALL>	O
Glucagon	B-Gene
receptor	I-Gene
(	O
GcgR	B-Gene
)	O
blockade	O
has	O
been	O
proposed	O
as	O
an	O
alternative	O
to	O
insulin	B-Gene
monotherapy	O
for	O
treating	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
since	O
deletion	O
or	O
inhibition	O
of	O
GcgRs	B-Gene
corrects	O
hyperglycemia	B-Disease
in	O
models	O
of	O
diabetes	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
factors	O
regulating	O
glycemia	B-Chemical
in	O
a	O
setting	O
devoid	O
of	O
insulin	B-Gene
and	O
glucagon	B-Gene
function	O
remain	O
unclear	O
but	O
may	O
include	O
the	O
hormone	O
ghrelin	B-Gene
.	O
</ALL>	O

<ALL>	O
Not	O
only	O
is	O
ghrelin	B-Gene
release	O
controlled	O
by	O
glucose	B-Chemical
but	O
also	O
ghrelin	B-Gene
has	O
many	O
actions	O
that	O
can	O
raise	O
or	O
reduce	O
falls	O
in	O
blood	B-Chemical
glucose	I-Chemical
level	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
ghrelin	B-Gene
rises	O
to	O
prevent	O
hypoglycemia	B-Disease
in	O
the	O
absence	O
of	O
glucagon	B-Gene
function	O
.	O
</ALL>	O

<ALL>	O
Both	O
GcgR	B-Gene
knockout	O
(	O
Gcgr	B-Gene
(	O
-	O
/	O
-	O
)	O
)	O
mice	B-Species
and	O
db	O
/	O
db	O
mice	B-Species
that	O
were	O
administered	O
GcgR	B-Gene
monoclonal	O
antibody	O
displayed	O
lower	O
blood	B-Chemical
glucose	I-Chemical
levels	O
accompanied	O
by	O
elevated	O
plasma	O
ghrelin	B-Gene
levels	O
.	O
</ALL>	O

<ALL>	O
Although	O
treatment	O
with	O
the	O
pancreatic	O
b	O
-	O
cell	O
toxin	O
streptozotocin	B-Chemical
induced	O
hyperglycemia	B-Disease
and	O
raised	O
plasma	O
ghrelin	B-Gene
levels	O
in	O
wild	O
-	O
type	O
mice	B-Species
,	O
hyperglycemia	B-Disease
was	O
averted	O
in	O
similarly	O
treated	O
Gcgr	B-Gene
(	O
-	O
/	O
-	O
)	O
mice	B-Species
and	O
the	O
plasma	O
ghrelin	B-Gene
level	O
was	O
further	O
increased	O
.	O
</ALL>	O

<ALL>	O
Notably	O
,	O
administration	O
of	O
a	O
ghrelin	B-Gene
receptor	I-Gene
antagonist	O
further	O
reduced	O
blood	B-Chemical
glucose	I-Chemical
levels	O
into	O
the	O
markedly	O
hypoglycemic	O
range	O
in	O
overnight	O
-	O
fasted	O
,	O
streptozotocin	B-Chemical
-	O
treated	O
Gcgr	B-Gene
(	O
-	O
/	O
-	O
)	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
A	O
lowered	O
blood	B-Chemical
glucose	I-Chemical
level	O
also	O
was	O
observed	O
in	O
overnight	O
-	O
fasted	O
,	O
streptozotocin	B-Chemical
-	O
treated	O
ghrelin	B-Gene
receptor	I-Gene
-	O
null	O
mice	B-Species
that	O
were	O
administered	O
GcgR	B-Gene
monoclonal	O
antibody	O
.	O
</ALL>	O

<ALL>	O
These	O
data	O
suggest	O
that	O
when	O
glucagon	B-Gene
activity	O
is	O
blocked	O
in	O
the	O
setting	O
of	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
,	O
the	O
plasma	O
ghrelin	B-Gene
level	O
rises	O
,	O
preventing	O
hypoglycemia	B-Disease
.	O
</ALL>	O

<ALL>	O
Gankyrin	B-Gene
induces	O
STAT3	B-Gene
activation	O
in	O
tumor	B-Disease
microenvironment	O
and	O
sorafenib	B-Chemical
resistance	O
in	O
hepatocellular	B-Disease
carcinoma	I-Disease
.	O
</ALL>	O

<ALL>	O
Most	O
hepatocellular	B-Disease
carcinomas	I-Disease
(	O
HCC	B-Disease
)	O
develop	O
as	O
a	O
result	O
of	O
chronic	B-Disease
liver	I-Disease
inflammation	I-Disease
.	O
</ALL>	O

<ALL>	O
We	O
have	O
shown	O
that	O
the	O
oncoprotein	B-Gene
gankyrin	B-Gene
is	O
critical	O
for	O
inflammation	B-Disease
-	O
induced	O
tumorigenesis	B-Disease
in	O
the	O
colon	O
.	O
</ALL>	O

<ALL>	O
Although	O
the	O
in	O
vitro	O
function	O
of	O
gankyrin	B-Gene
is	O
well	O
known	O
,	O
its	O
role	O
in	O
vivo	O
remains	O
to	O
be	O
elucidated	O
.	O
</ALL>	O

<ALL>	O
We	O
investigated	O
the	O
effect	O
of	O
gankyrin	B-Gene
in	O
the	O
tumor	B-Disease
microenvironment	O
of	O
mice	B-Species
with	O
liver	O
parenchymal	O
cell	O
-	O
specific	O
gankyrin	B-Gene
ablation	O
(	O
Alb	B-Gene
-	O
Cre	O
;	O
gankyrin	B-Gene
(	O
f	O
/	O
f	O
)	O
)	O
and	O
gankyrin	B-Gene
deletion	O
both	O
in	O
liver	O
parenchymal	O
and	O
non	O
-	O
parenchymal	O
cells	O
(	O
Mx1	B-Gene
-	O
Cre	O
;	O
gankyrin	B-Gene
(	O
f	O
/	O
f	O
)	O
)	O
.	O
</ALL>	O

<ALL>	O
Gankyrin	B-Gene
upregulates	O
vascular	B-Gene
endothelial	I-Gene
growth	I-Gene
factor	I-Gene
expression	O
in	O
tumor	B-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
Gankyrin	B-Gene
binds	O
to	O
Src	B-Gene
homology	I-Gene
2	I-Gene
domain	I-Gene
-	I-Gene
containing	I-Gene
protein	I-Gene
tyrosine	I-Gene
phosphatase	I-Gene
-	I-Gene
1	I-Gene
(	O
SHP	B-Gene
-	I-Gene
1	I-Gene
)	O
,	O
mainly	O
expressed	O
in	O
liver	O
non	O
-	O
parenchymal	O
cells	O
,	O
resulting	O
in	O
phosphorylation	O
and	O
activation	O
of	O
signal	B-Gene
transducer	I-Gene
and	I-Gene
activator	I-Gene
of	I-Gene
transcription	I-Gene
3	I-Gene
(	O
STAT3	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
Gankyrin	B-Gene
deficiency	O
in	O
non	O
-	O
parenchymal	O
cells	O
,	O
but	O
not	O
in	O
parenchymal	O
cells	O
,	O
reduced	O
STAT3	B-Gene
activity	O
,	O
interleukin	B-Gene
(	I-Gene
IL	I-Gene
)	I-Gene
-	I-Gene
6	I-Gene
production	O
,	O
and	O
cancer	B-Disease
stem	O
cell	O
marker	O
(	O
Bmi1	B-Gene
and	O
epithelial	B-Gene
cell	I-Gene
adhesion	I-Gene
molecule	I-Gene
[	O
EpCAM	B-Gene
]	O
)	O
expression	O
,	O
leading	O
to	O
attenuated	O
tumorigenic	B-Disease
potential	O
.	O
</ALL>	O

<ALL>	O
Chronic	B-Disease
inflammation	I-Disease
enhances	O
gankyrin	B-Gene
expression	O
in	O
the	O
human	B-Species
liver	O
.	O
</ALL>	O

<ALL>	O
Gankyrin	B-Gene
expression	O
in	O
the	O
tumor	B-Disease
microenvironment	O
is	O
negatively	O
correlated	O
with	O
progression	O
-	O
free	O
survival	O
in	O
patients	B-Species
undergoing	O
sorafenib	B-Chemical
treatment	O
for	O
HCC	B-Disease
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
gankyrin	B-Gene
appears	O
to	O
play	O
a	O
critical	O
oncogenic	O
function	O
in	O
tumor	B-Disease
microenvironment	O
and	O
may	O
be	O
a	O
potential	O
target	O
for	O
developing	O
therapeutic	O
and	O
preventive	O
strategies	O
against	O
HCC	B-Disease
.	O
</ALL>	O

<ALL>	O
Pituitary	O
response	O
to	O
luteinizing	B-Gene
hormone	I-Gene
-	I-Gene
releasing	I-Gene
hormone	I-Gene
during	O
haloperidol	B-Chemical
-	O
induced	O
hyperprolactinemia	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
effects	O
of	O
a	O
6	O
-	O
hour	O
infusion	O
with	O
haloperidol	B-Chemical
on	O
serum	O
prolactin	B-Gene
and	O
luteinizing	B-Gene
hormone	I-Gene
(	O
LH	B-Gene
)	O
levels	O
was	O
studied	O
in	O
a	O
group	O
of	O
male	O
subjects	O
.	O
</ALL>	O

<ALL>	O
Five	O
hours	O
after	O
starting	O
the	O
infusions	O
,	O
a	O
study	O
of	O
the	O
pituitary	O
responses	O
to	O
LH	B-Gene
-	I-Gene
releasing	I-Gene
hormone	I-Gene
(	O
LH	B-Gene
-	I-Gene
RH	I-Gene
)	O
was	O
carried	O
out	O
.	O
</ALL>	O

<ALL>	O
Control	O
patients	B-Species
received	O
infusions	O
of	O
0.9	O
%	O
NaCl	B-Chemical
solution	O
.	O
</ALL>	O

<ALL>	O
During	O
the	O
course	O
of	O
haloperidol	B-Chemical
infusions	O
,	O
significant	O
hyperprolactinemia	B-Disease
was	O
found	O
,	O
together	O
with	O
an	O
abolished	O
pituitary	O
response	O
to	O
LH	B-Gene
-	I-Gene
RH	I-Gene
,	O
as	O
compared	O
with	O
responses	O
of	O
control	O
subjects	O
.	O
</ALL>	O

<ALL>	O
Cardiovascular	B-Disease
complications	I-Disease
associated	O
with	O
terbutaline	B-Chemical
treatment	O
for	O
preterm	B-Disease
labor	I-Disease
.	O
</ALL>	O

<ALL>	O
Severe	O
cardiovascular	B-Disease
complications	I-Disease
occurred	O
in	O
eight	O
of	O
160	O
patients	B-Species
treated	O
with	O
terbutaline	B-Chemical
for	O
preterm	B-Disease
labor	I-Disease
.	O
</ALL>	O

<ALL>	O
Associated	O
corticosteroid	B-Chemical
therapy	O
and	O
twin	O
gestations	O
appear	O
to	O
be	O
predisposing	O
factors	O
.	O
</ALL>	O

<ALL>	O
Potential	O
mechanisms	O
of	O
the	O
pathophysiology	O
are	O
briefly	O
discussed	O
.	O
</ALL>	O

<ALL>	O
Cloning	O
of	O
human	B-Species
very	B-Gene
-	I-Gene
long	I-Gene
-	I-Gene
chain	I-Gene
acyl	I-Gene
-	I-Gene
coenzyme	I-Gene
A	I-Gene
dehydrogenase	I-Gene
and	O
molecular	O
characterization	O
of	O
its	O
deficiency	O
in	O
two	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Two	O
overlapping	O
cDNA	O
clones	O
(	O
1	O
,	O
991	O
bp	O
and	O
736	O
bp	O
,	O
respectively	O
)	O
encoding	O
the	O
precursor	O
of	O
human	B-Species
mitochondrial	O
very	B-Gene
-	I-Gene
long	I-Gene
-	I-Gene
chain	I-Gene
acyl	I-Gene
-	I-Gene
coenzyme	I-Gene
A	I-Gene
dehydrogenase	I-Gene
(	O
VLCAD	B-Gene
)	O
were	O
cloned	O
and	O
sequenced	O
.	O
</ALL>	O

<ALL>	O
The	O
cDNA	O
inserts	O
of	O
these	O
clones	O
together	O
encompass	O
a	O
region	O
of	O
2	O
,	O
177	O
bases	O
,	O
encoding	O
the	O
entire	O
protein	O
of	O
655	O
amino	O
acids	O
,	O
including	O
a	O
40	O
-	O
amino	O
acid	O
leader	O
peptide	O
and	O
a	O
615	O
-	O
amino	O
acid	O
mature	O
polypeptide	O
.	O
</ALL>	O

<ALL>	O
PCR	O
-	O
amplified	O
VLCAD	B-Gene
cDNAs	O
were	O
sequenced	O
in	O
cultured	O
fibroblasts	O
from	O
two	O
VLCAD	B-Disease
-	I-Disease
deficient	I-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
In	O
both	O
patients	B-Species
,	O
a	O
105	B-Variant
-	I-Variant
bp	I-Variant
deletion	I-Variant
encompassing	I-Variant
bases	I-Variant
1078	I-Variant
-	I-Variant
1182	I-Variant
in	O
VLCAD	B-Gene
cDNA	O
was	O
identified	O
.	O
</ALL>	O

<ALL>	O
The	O
deletion	O
seems	O
to	O
occur	O
due	O
to	O
exon	O
skipping	O
during	O
processing	O
of	O
VLCAD	B-Gene
pre	O
-	O
mRNA	O
.	O
</ALL>	O

<ALL>	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
mutation	O
causing	O
VLCAD	B-Disease
deficiency	I-Disease
.	O
</ALL>	O

<ALL>	O
Quantitative	O
cDNA	O
expression	O
of	O
normal	O
human	B-Species
VLCAD	B-Gene
was	O
performed	O
in	O
the	O
patients	B-Species
fibroblasts	O
,	O
using	O
vaccinia	O
viral	O
system	O
,	O
which	O
demonstrated	O
that	O
the	O
deficiency	B-Disease
of	I-Disease
the	I-Disease
normal	I-Disease
VLCAD	I-Disease
protein	I-Disease
causes	O
impaired	O
long	B-Chemical
-	I-Chemical
chain	I-Chemical
fatty	I-Chemical
acid	I-Chemical
beta	O
-	O
oxidation	O
activity	O
in	O
the	O
patients	B-Species
fibroblasts	O
.	O
</ALL>	O

<ALL>	O
In	O
patient	B-Species
fibroblasts	O
,	O
raising	O
VLCAD	B-Gene
activity	O
to	O
approximately	O
20	O
%	O
of	O
normal	O
control	O
fibroblast	O
activity	O
raised	O
palmitic	B-Chemical
acid	I-Chemical
beta	O
-	O
oxidation	O
flux	O
to	O
the	O
level	O
found	O
in	O
control	O
fibroblasts	O
,	O
which	O
may	O
offer	O
important	O
information	O
for	O
the	O
rational	O
design	O
of	O
future	O
somatic	O
gene	O
therapy	O
for	O
VLCAD	B-Disease
deficiency	I-Disease
..	O
</ALL>	O

<ALL>	O
Human	B-Species
mu	B-Gene
opiate	I-Gene
receptor	I-Gene
.	O
</ALL>	O

<ALL>	O
cDNA	O
and	O
genomic	O
clones	O
,	O
pharmacologic	O
characterization	O
and	O
chromosomal	O
assignment	O
.	O
</ALL>	O

<ALL>	O
A	O
human	B-Species
mu	B-Gene
opiate	I-Gene
receptor	I-Gene
cDNA	O
has	O
been	O
identified	O
from	O
a	O
cerebral	O
cortical	O
cDNA	O
library	O
using	O
sequences	O
from	O
the	O
rat	B-Species
mu	B-Gene
opiate	I-Gene
receptor	I-Gene
cDNA	O
.	O
</ALL>	O

<ALL>	O
The	O
human	B-Species
mu	B-Gene
opiate	I-Gene
receptor	I-Gene
(	O
h	B-Gene
mu	I-Gene
OR1	I-Gene
)	O
shares	O
95	O
%	O
amino	O
acid	O
identity	O
with	O
the	O
rat	B-Species
sequence	O
.	O
</ALL>	O

<ALL>	O
The	O
expressed	O
mu	B-Gene
OR1	I-Gene
recognized	O
tested	O
opiate	B-Chemical
drugs	O
and	O
opioid	B-Chemical
peptides	I-Chemical
in	O
a	O
sodium	B-Chemical
-	O
and	O
GTP	B-Chemical
-	O
sensitive	O
fashion	O
with	O
affinities	O
virtually	O
identical	O
to	O
those	O
displayed	O
by	O
the	O
rat	B-Species
mu	B-Gene
opiate	I-Gene
receptor	I-Gene
.	O
</ALL>	O

<ALL>	O
Effects	O
on	O
cyclic	B-Chemical
AMP	I-Chemical
are	O
similar	O
to	O
those	O
noted	O
for	O
the	O
rat	B-Species
mu	B-Gene
opiate	I-Gene
receptor	I-Gene
.	O
</ALL>	O

<ALL>	O
An	O
18	O
kb	O
genomic	O
clone	O
hybridizing	O
with	O
the	O
h	B-Gene
mu	I-Gene
OR1	I-Gene
cDNA	O
contains	O
63	O
and	O
489	O
bp	O
exonic	O
sequences	O
flanked	O
by	O
splice	O
donor	O
/	O
acceptor	O
sequences	O
.	O
</ALL>	O

<ALL>	O
Analysis	O
of	O
hybridization	O
to	O
DNA	O
prepared	O
from	O
human	B-Species
rodent	O
hybrid	O
cell	O
lines	O
and	O
chromosomal	O
in	O
situ	O
hybridization	O
studies	O
indicate	O
localization	O
to	O
6q24	O
-	O
25	O
.	O
</ALL>	O

<ALL>	O
An	O
MspI	O
polymorphism	O
,	O
producing	O
a	O
3.7	O
kb	O
band	O
,	O
may	O
prove	O
useful	O
in	O
assessing	O
this	O
gene	O
's	O
involvement	O
in	O
neuropsychiatric	B-Disease
disorders	I-Disease
involving	O
opiatergic	O
systems	O
.	O
</ALL>	O

<ALL>	O
Adrenoleukodystrophy	B-Gene
gene	I-Gene
encodes	O
an	O
80	O
kDa	O
membrane	O
protein	O
.	O
</ALL>	O

<ALL>	O
An	O
antibody	O
against	O
the	O
synthetic	O
C	O
-	O
terminal	O
peptides	O
deduced	O
from	O
the	O
cDNA	O
of	O
the	O
gene	O
responsible	O
for	O
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
ALD	B-Disease
)	O
was	O
produced	O
to	O
characterize	O
the	O
product	O
of	O
the	O
ALD	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
The	O
antibody	O
reacted	O
with	O
the	O
80	O
kDa	O
band	O
protein	O
in	O
control	O
fibroblasts	O
,	O
while	O
no	O
bands	O
were	O
detected	O
in	O
the	O
fibroblasts	O
from	O
a	O
patient	B-Species
with	O
ALD	B-Disease
(	O
#	O
163	O
)	O
,	O
in	O
which	O
mRNA	O
of	O
the	O
ALD	B-Gene
gene	O
was	O
undetectable	O
based	O
on	O
Northern	O
blot	O
analysis	O
.	O
</ALL>	O

<ALL>	O
The	O
293	B-CellLine
T	I-CellLine
cells	O
transfected	O
with	O
the	O
full	O
-	O
coding	O
cDNA	O
inserted	O
in	O
the	O
expression	O
vector	O
produced	O
a	O
new	O
80	O
kDa	O
protein	O
,	O
as	O
detected	O
by	O
Western	O
blot	O
.	O
</ALL>	O

<ALL>	O
In	O
an	O
immunocytological	O
study	O
,	O
the	O
staining	O
was	O
in	O
a	O
punctate	O
pattern	O
,	O
in	O
the	O
normal	O
fibroblasts	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
there	O
was	O
no	O
punctate	O
staining	O
in	O
the	O
#	O
163	O
cells	O
.	O
</ALL>	O

<ALL>	O
These	O
data	O
thus	O
indicate	O
that	O
the	O
ALD	B-Gene
gene	O
encodes	O
an	O
80	O
kDa	O
membrane	O
protein	O
..	O
</ALL>	O

<ALL>	O
Mutations	O
associated	O
with	O
variant	O
phenotypes	O
in	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
.	O
</ALL>	O

<ALL>	O
We	O
have	O
identified	O
14	O
families	O
with	O
ataxia	B-Disease
-	I-Disease
telangiectasia	I-Disease
(	O
A	B-Disease
-	I-Disease
T	I-Disease
)	O
in	O
which	O
mutation	O
of	O
the	O
ATM	B-Gene
gene	O
is	O
associated	O
with	O
a	O
less	O
severe	O
clinical	O
and	O
cellular	O
phenotype	O
(	O
approximately	O
10	O
%	O
-	O
15	O
%	O
of	O
A	B-Disease
-	I-Disease
T	I-Disease
families	O
identified	O
in	O
the	O
United	O
Kingdom	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
10	O
of	O
these	O
families	O
,	O
all	O
the	O
homozygotes	O
have	O
a	O
137	B-Variant
-	I-Variant
bp	I-Variant
insertion	I-Variant
in	O
their	O
cDNA	O
caused	O
by	O
a	O
point	O
mutation	O
in	O
a	O
sequence	O
resembling	O
a	O
splice	O
-	O
donor	O
site	O
.	O
</ALL>	O

<ALL>	O
The	O
second	O
A	B-Disease
-	I-Disease
T	I-Disease
allele	O
has	O
a	O
different	O
mutation	O
in	O
each	O
patient	B-Species
.	O
</ALL>	O

<ALL>	O
We	O
show	O
that	O
the	O
less	O
severe	O
phenotype	O
in	O
these	O
patients	B-Species
is	O
caused	O
by	O
some	O
degree	O
of	O
normal	O
splicing	O
,	O
which	O
occurs	O
as	O
an	O
alternative	O
product	O
from	O
the	O
insertion	O
-	O
containing	O
allele	O
.	O
</ALL>	O

<ALL>	O
The	O
level	O
of	O
the	O
137	O
-	O
bp	O
PCR	O
product	O
containing	O
the	O
insertion	O
was	O
lowest	O
in	O
two	O
patients	B-Species
who	O
showed	O
a	O
later	O
onset	O
of	O
cerebellar	B-Disease
ataxia	I-Disease
.	O
</ALL>	O

<ALL>	O
A	O
further	O
four	O
families	O
who	O
do	O
not	O
have	O
this	O
insertion	O
have	O
been	O
identified	O
.	O
</ALL>	O

<ALL>	O
Mutations	O
detected	O
in	O
two	O
of	O
four	O
of	O
these	O
are	O
missense	O
mutations	O
,	O
normally	O
rare	O
in	O
A	B-Disease
-	I-Disease
T	I-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
demonstration	O
of	O
mutations	O
giving	O
rise	O
to	O
a	O
slightly	O
milder	O
phenotype	O
in	O
A	B-Disease
-	I-Disease
T	I-Disease
raises	O
the	O
interesting	O
question	O
of	O
what	O
range	O
of	O
phenotypes	O
might	O
occur	O
in	O
individuals	O
in	O
whom	O
both	O
mutations	O
are	O
milder	O
.	O
</ALL>	O

<ALL>	O
One	O
possibility	O
might	O
be	O
that	O
individuals	O
who	O
are	O
compound	O
heterozygotes	O
for	O
ATM	B-Gene
mutations	O
are	O
more	O
common	O
than	O
we	O
realize	O
..	O
</ALL>	O

<ALL>	O
Myotonic	B-Gene
dystrophy	I-Gene
protein	I-Gene
kinase	I-Gene
is	O
involved	O
in	O
the	O
modulation	O
of	O
the	O
Ca2	B-Chemical
+	I-Chemical
homeostasis	O
in	O
skeletal	O
muscle	O
cells	O
.	O
</ALL>	O

<ALL>	O
Myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	B-Disease
)	O
,	O
the	O
most	O
prevalent	O
muscular	B-Disease
disorder	I-Disease
in	O
adults	O
,	O
is	O
caused	O
by	O
(	O
CTG	O
)	O
n	O
-	O
repeat	O
expansion	O
in	O
a	O
gene	O
encoding	O
a	O
protein	O
kinase	O
(	O
DM	B-Gene
protein	I-Gene
kinase	I-Gene
;	O
DMPK	B-Gene
)	O
and	O
involves	O
changes	O
in	O
cytoarchitecture	O
and	O
ion	O
homeostasis	O
.	O
</ALL>	O

<ALL>	O
To	O
obtain	O
clues	O
to	O
the	O
normal	O
biological	O
role	O
of	O
DMPK	B-Gene
in	O
cellular	O
ion	O
homeostasis	O
,	O
we	O
have	O
compared	O
the	O
resting	O
[	O
Ca2	B-Chemical
+	I-Chemical
]	O
i	O
,	O
the	O
amplitude	O
and	O
shape	O
of	O
depolarization	O
-	O
induced	O
Ca2	B-Chemical
+	I-Chemical
transients	O
,	O
and	O
the	O
content	O
of	O
ATP	B-Chemical
-	O
driven	O
ion	O
pumps	O
in	O
cultured	O
skeletal	O
muscle	O
cells	O
of	O
wild	O
-	O
type	O
and	O
DMPK	B-Gene
[	O
-	O
/	O
-	O
]	O
knockout	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
In	O
vitro	O
-	O
differentiated	O
DMPK	B-Gene
[	O
-	O
/	O
-	O
]	O
myotubes	O
exhibit	O
a	O
higher	O
resting	O
[	O
Ca2	B-Chemical
+	I-Chemical
]	O
i	O
than	O
do	O
wild	O
-	O
type	O
myotubes	O
because	O
of	O
an	O
altered	O
open	O
probability	O
of	O
voltage	O
-	O
dependent	O
l	O
-	O
type	O
Ca2	B-Chemical
+	I-Chemical
and	O
Na	B-Chemical
+	I-Chemical
channels	O
.	O
</ALL>	O

<ALL>	O
The	O
mutant	O
myotubes	O
exhibit	O
smaller	O
and	O
slower	O
Ca2	B-Chemical
+	I-Chemical
responses	O
upon	O
triggering	O
by	O
acetylcholine	B-Chemical
or	O
high	O
external	O
K	B-Chemical
+	I-Chemical
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
we	O
observed	O
that	O
these	O
Ca2	B-Chemical
+	I-Chemical
transients	O
partially	O
result	O
from	O
an	O
influx	O
of	O
extracellular	O
Ca2	B-Chemical
+	I-Chemical
through	O
the	O
l	O
-	O
type	O
Ca2	B-Chemical
+	I-Chemical
channel	O
.	O
</ALL>	O

<ALL>	O
Neither	O
the	O
content	O
nor	O
the	O
activity	O
of	O
Na	B-Chemical
+	I-Chemical
/	I-Chemical
K	I-Chemical
+	I-Chemical
ATPase	I-Chemical
and	O
sarcoplasmic	B-Chemical
reticulum	I-Chemical
Ca2	I-Chemical
+	I-Chemical
-	I-Chemical
ATPase	I-Chemical
are	O
affected	O
by	O
DMPK	B-Gene
absence	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
DMPK	B-Gene
is	O
involved	O
in	O
modulating	O
the	O
initial	O
events	O
of	O
excitation	O
-	O
contraction	O
coupling	O
in	O
skeletal	O
muscle	O
..	O
</ALL>	O

<ALL>	O
cDNA	O
sequence	O
and	O
chromosomal	O
localization	O
of	O
the	O
remaining	O
three	O
human	B-Species
nuclear	B-Gene
encoded	I-Gene
iron	I-Gene
sulphur	I-Gene
protein	I-Gene
(	I-Gene
IP	I-Gene
)	I-Gene
subunits	I-Gene
of	I-Gene
complex	I-Gene
I	I-Gene
:	O
the	O
human	B-Species
IP	B-Gene
fraction	O
is	O
completed	O
.	O
</ALL>	O

<ALL>	O
NADH	B-Gene
:	I-Gene
ubiquinone	I-Gene
oxidoreductase	I-Gene
(	I-Gene
complex	I-Gene
I	I-Gene
)	I-Gene
of	O
the	O
mitochondrial	O
respiratory	O
chain	O
can	O
be	O
fragmented	O
in	O
a	O
flavoprotein	B-Gene
(	O
FP	B-Gene
)	O
,	O
iron	B-Gene
-	I-Gene
sulfur	I-Gene
protein	I-Gene
(	O
IP	B-Gene
)	O
,	O
and	O
hydrophobic	B-Gene
protein	I-Gene
(	O
HP	B-Gene
)	O
subfraction	O
.	O
</ALL>	O

<ALL>	O
The	O
IP	B-Gene
subfraction	O
is	O
hypothesized	O
to	O
be	O
significant	O
,	O
since	O
it	O
contains	O
important	O
prosthetic	O
groups	O
highly	O
conserved	O
among	O
species	O
.	O
</ALL>	O

<ALL>	O
We	O
cloned	O
the	O
cDNA	O
of	O
three	O
remaining	O
human	B-Species
NADH	B-Gene
:	I-Gene
ubiquinone	I-Gene
oxidoreductase	I-Gene
subunits	I-Gene
of	O
this	O
IP	B-Gene
fraction	O
:	O
the	O
NDUFS2	B-Gene
(	O
49	O
kDa	O
)	O
,	O
NDUFS3	B-Gene
(	O
30	O
kDa	O
)	O
,	O
and	O
NDUFS6	B-Gene
(	O
13	O
kDa	O
)	O
subunits	O
.	O
</ALL>	O

<ALL>	O
All	O
presented	O
cDNAs	O
include	O
the	O
complete	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
,	O
which	O
consist	O
of	O
1392	O
,	O
795	O
,	O
and	O
375	O
base	O
pairs	O
,	O
coding	O
for	O
463	O
,	O
264	O
,	O
and	O
124	O
amino	O
acids	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
The	O
latter	O
show	O
96	O
,	O
90	O
,	O
and	O
83	O
%	O
homology	O
with	O
the	O
corresponding	O
bovine	B-Species
translation	O
products	O
.	O
</ALL>	O

<ALL>	O
The	O
3	O
'	O
untranslated	O
regions	O
(	O
UTR	O
)	O
are	O
complete	O
in	O
all	O
three	O
cDNAs	O
.	O
</ALL>	O

<ALL>	O
Polymerase	O
chain	O
reaction	O
performed	O
with	O
DNA	O
isolated	O
from	O
somatic	O
human	B-Species
-	O
rodent	O
cell	O
hybrids	O
containing	O
defined	O
human	B-Species
chromosomes	O
as	O
template	O
gave	O
a	O
human	B-Species
-	O
specific	O
signal	O
which	O
mapped	O
the	O
NDUFS2	B-Gene
and	O
NDUFS3	B-Gene
subunits	O
to	O
chromosomes	O
1	O
and	O
11	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
case	O
of	O
the	O
NDUFS6	B-Gene
subunit	O
a	O
pseudogene	O
may	O
be	O
present	O
since	O
signals	O
were	O
seen	O
in	O
the	O
lanes	O
containing	O
chromosomes	O
5	O
and	O
6	O
.	O
</ALL>	O

<ALL>	O
The	O
NDUFS2	B-Gene
contains	O
a	O
highly	O
conserved	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
phosphorylation	O
site	O
and	O
the	O
NDUFS3	B-Gene
subunit	O
contains	O
a	O
highly	O
conserved	O
casein	B-Gene
kinase	I-Gene
II	I-Gene
phosphorylation	O
site	O
which	O
make	O
them	O
strong	O
candidates	O
for	O
future	O
mutation	O
detection	O
studies	O
in	O
enzymatic	B-Disease
complex	I-Disease
I	I-Disease
-	I-Disease
deficient	I-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Inappropriate	O
use	O
of	O
carbamazepine	B-Chemical
and	O
vigabatrin	B-Chemical
in	O
typical	O
absence	B-Disease
seizures	I-Disease
.	O
</ALL>	O

<ALL>	O
Carbamazepine	B-Chemical
and	O
vigabatrin	B-Chemical
are	O
contraindicated	O
in	O
typical	O
absence	B-Disease
seizures	I-Disease
.	O
</ALL>	O

<ALL>	O
Of	O
18	O
consecutive	O
referrals	O
of	O
children	O
with	O
resistant	O
typical	O
absences	O
only	O
,	O
eight	O
were	O
erroneously	O
treated	O
with	O
carbamazepine	B-Chemical
either	O
as	O
monotherapy	O
or	O
as	O
an	O
add	O
-	O
on	O
.	O
</ALL>	O

<ALL>	O
Vigabatrin	B-Chemical
was	O
also	O
used	O
in	O
the	O
treatment	O
of	O
two	O
children	O
.	O
</ALL>	O

<ALL>	O
Frequency	O
of	O
absences	O
increased	O
in	O
four	O
children	O
treated	O
with	O
carbamazepine	B-Chemical
and	O
two	O
of	O
these	O
developed	O
myoclonic	B-Disease
jerks	I-Disease
,	O
which	O
resolved	O
on	O
withdrawal	O
of	O
carbamazepine	B-Chemical
.	O
</ALL>	O

<ALL>	O
Absences	O
were	O
aggravated	O
in	O
both	O
cases	O
where	O
vigabatrin	B-Chemical
was	O
added	O
on	O
to	O
concurrent	O
treatment	O
.	O
</ALL>	O

<ALL>	O
Optimal	O
control	O
of	O
the	O
absences	O
was	O
achieved	O
with	O
sodium	B-Chemical
valproate	I-Chemical
,	O
lamotrigine	B-Chemical
,	O
or	O
ethosuximide	B-Chemical
alone	O
or	O
in	O
combination	O
.	O
</ALL>	O

<ALL>	O
CD72	B-Gene
polymorphisms	O
associated	O
with	O
alternative	O
splicing	O
modify	O
susceptibility	O
to	O
human	B-Species
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
through	O
epistatic	O
interaction	O
with	O
FCGR2B	B-Gene
.	O
</ALL>	O

<ALL>	O
We	O
previously	O
reported	O
association	O
of	O
FCGR2B	B-Gene
-	O
Ile232Thr	B-Variant
with	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
(	O
SLE	B-Disease
)	O
in	O
three	O
Asian	O
populations	O
.	O
</ALL>	O

<ALL>	O
Because	O
polymorphism	O
of	O
CD72	B-Gene
,	O
another	O
inhibitory	O
receptor	O
of	O
B	O
cells	O
,	O
was	O
associated	O
with	O
murine	B-Species
SLE	B-Disease
,	O
we	O
identified	O
human	B-Species
CD72	B-Gene
polymorphisms	O
,	O
tested	O
their	O
association	O
with	O
SLE	B-Disease
and	O
examined	O
genetic	O
interaction	O
with	O
FCGR2B	B-Gene
in	O
the	O
Japanese	O
(	O
160	O
SLE	B-Disease
,	O
277	O
controls	O
)	O
,	O
Thais	O
(	O
87	O
SLE	B-Disease
,	O
187	O
controls	O
)	O
and	O
Caucasians	O
(	O
94	O
families	O
containing	O
SLE	B-Disease
members	O
)	O
.	O
</ALL>	O

<ALL>	O
Four	O
polymorphisms	O
and	O
six	O
rare	O
variations	O
were	O
detected	O
.	O
</ALL>	O

<ALL>	O
The	O
former	O
constituted	O
two	O
major	O
haplotypes	O
that	O
contained	O
one	O
or	O
two	O
repeats	O
of	O
13	O
nucleotides	O
in	O
intron	O
8	O
(	O
designated	O
as	O
*	O
1	O
and	O
*	O
2	O
,	O
respectively	O
)	O
.	O
</ALL>	O

<ALL>	O
Although	O
association	O
with	O
susceptibility	O
to	O
SLE	B-Disease
was	O
not	O
detected	O
,	O
the	O
*	O
1	O
allele	O
was	O
significantly	O
associated	O
with	O
nephritis	B-Disease
among	O
the	O
Japanese	O
patients	B-Species
(	O
P	O
=	O
0.024	O
)	O
.	O
</ALL>	O

<ALL>	O
RT	O
-	O
PCR	O
identified	O
a	O
novel	O
alternatively	O
spliced	O
(	O
AS	O
)	O
transcript	O
that	O
was	O
expressed	O
at	O
the	O
protein	O
level	O
in	O
COS	B-CellLine
-	I-CellLine
7	I-CellLine
transfectants	O
.	O
</ALL>	O

<ALL>	O
The	O
ratio	O
of	O
AS	O
/	O
common	O
isoforms	O
was	O
strikingly	O
increased	O
in	O
individuals	O
with	O
*	O
2	O
/	O
*	O
2	O
genotype	O
when	O
compared	O
with	O
*	O
1	O
/	O
*	O
1	O
(	O
P	O
=	O
0.000038	O
)	O
or	O
*	O
1	O
/	O
*	O
2	O
(	O
P	O
=	O
0.0085	O
)	O
genotypes	O
.	O
</ALL>	O

<ALL>	O
Using	O
the	O
two	O
Asian	O
cohorts	O
,	O
significant	O
association	O
of	O
FCGR2B	B-Gene
-	O
232Thr	B-Variant
/	O
Thr	O
with	O
SLE	B-Disease
was	O
observed	O
only	O
in	O
the	O
presence	O
of	O
CD72	B-Gene
-	O
*	O
1	O
/	O
*	O
1	O
genotype	O
(	O
OR	O
4.63	O
,	O
95	O
%	O
CI	O
1.47	O
-	O
14.6	O
,	O
P	O
=	O
0.009	O
versus	O
FCGR2B	B-Gene
-	O
232Ile	B-Variant
/	O
Ile	O
plus	O
CD72	B-Gene
-	O
*	O
2	O
/	O
*	O
2	O
)	O
.	O
</ALL>	O

<ALL>	O
Minigene	O
assays	O
demonstrated	O
that	O
the	O
13	O
-	O
nucleotide	O
repeat	O
and	O
4	O
bp	O
deletion	O
within	O
the	O
same	O
haplotype	O
of	O
intron	O
8	O
could	O
regulate	O
alternative	O
splicing	O
.	O
</ALL>	O

<ALL>	O
The	O
AS	O
isoform	O
lacks	O
exon	O
8	O
,	O
and	O
is	O
deduced	O
to	O
contain	O
49	O
amino	O
acid	O
changes	O
in	O
the	O
membrane	O
-	O
distal	O
portion	O
of	O
the	O
extracellular	O
domain	O
,	O
where	O
considerable	O
amino	O
acid	O
changes	O
are	O
known	O
in	O
CD72	B-Gene
(	O
c	O
)	O
allele	O
associated	O
with	O
murine	B-Species
SLE	B-Disease
.	O
</ALL>	O

<ALL>	O
These	O
results	O
indicated	O
that	O
the	O
presence	O
of	O
CD72	B-Gene
-	O
*	O
2	O
allele	O
decreases	O
risk	O
for	O
human	B-Species
SLE	B-Disease
conferred	O
by	O
FCGR2B	B-Gene
-	O
232Thr	B-Variant
,	O
possibly	O
by	O
increasing	O
the	O
AS	O
isoform	O
of	O
CD72	B-Gene
.	O
</ALL>	O

<ALL>	O
Polymorphic	O
forms	O
of	O
prostate	B-Gene
specific	I-Gene
antigen	I-Gene
and	O
their	O
interaction	O
with	O
androgen	B-Gene
receptor	I-Gene
trinucleotide	O
repeats	O
in	O
prostate	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Recent	O
data	O
has	O
suggested	O
that	O
polymorphisms	O
in	O
the	O
prostate	B-Gene
specific	I-Gene
antigen	I-Gene
(	O
PSA	B-Gene
)	O
may	O
increase	O
prostate	B-Disease
cancer	I-Disease
(	O
PC	B-Disease
)	O
risk	O
.	O
</ALL>	O

<ALL>	O
The	O
PSA	B-Gene
gene	O
contains	O
a	O
G	B-Variant
/	I-Variant
A	I-Variant
substitution	O
in	O
the	O
androgen	B-Chemical
response	O
element	O
(	O
ARE	O
)	O
1	O
region	O
.	O
</ALL>	O

<ALL>	O
The	O
androgen	B-Gene
receptor	I-Gene
(	O
AR	B-Gene
)	O
gene	O
has	O
polymorphic	O
regions	O
containing	O
variable	O
length	O
glutamine	O
and	O
glycine	O
repeats	O
and	O
these	O
are	O
believed	O
to	O
be	O
associated	O
with	O
PC	B-Disease
risk	O
.	O
</ALL>	O

<ALL>	O
The	O
effect	O
on	O
PC	B-Disease
risks	O
from	O
PSA	B-Gene
polymorphisms	O
alone	O
and	O
synergistically	O
with	O
the	O
AR	B-Gene
gene	O
was	O
examined	O
in	O
this	O
report	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
One	O
hundred	O
PC	B-Disease
patients	B-Species
and	O
an	O
age	O
matched	O
cohort	O
of	O
79	O
benign	B-Disease
prostate	I-Disease
hyperplasia	I-Disease
and	O
67	O
population	O
controls	O
were	O
entered	O
in	O
this	O
study	O
.	O
</ALL>	O

<ALL>	O
DNA	O
was	O
extracted	O
from	O
blood	O
and	O
PSA	B-Gene
/	O
ARE	O
promoter	O
region	O
amplified	O
by	O
PCR	O
.	O
</ALL>	O

<ALL>	O
PCR	O
products	O
were	O
cut	O
with	O
Nhe	B-Gene
1	I-Gene
restriction	O
enzyme	O
to	O
distinguish	O
G	B-Variant
/	I-Variant
A	I-Variant
alleles	O
.	O
</ALL>	O

<ALL>	O
AR	B-Gene
/	O
CAG	B-Variant
and	I-Variant
GGC	I-Variant
repeat	I-Variant
length	O
was	O
detected	O
by	O
automated	O
fluorescence	O
from	O
PCR	O
products	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
We	O
found	O
a	O
significantly	O
higher	O
PSA	B-Gene
/	O
GG	O
distribution	O
in	O
PC	B-Disease
(	O
30	O
%	O
)	O
than	O
either	O
benign	B-Disease
prostatic	I-Disease
hyperplasia	I-Disease
(	O
BPH	B-Disease
)	O
(	O
18	O
%	O
)	O
or	O
population	O
controls	O
(	O
16	O
%	O
)	O
(	O
P	O
=	O
0.025	O
)	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
the	O
GG	O
distribution	O
within	O
cases	O
was	O
even	O
greater	O
in	O
younger	O
men	B-Species
(	O
<	O
65	O
years	O
;	O
42	O
%	O
;	O
P	O
=	O
0.012	O
)	O
.	O
</ALL>	O

<ALL>	O
Additionally	O
,	O
when	O
PSA	B-Gene
genotype	O
was	O
cross	O
classified	O
with	O
CAG	B-Variant
repeat	I-Variant
,	O
significantly	O
more	O
cases	O
than	O
both	O
BPH	B-Disease
and	O
population	O
controls	O
were	O
observed	O
to	O
have	O
a	O
short	O
(	O
<	O
22	O
)	O
CAG	O
/	O
GG	O
genotype	O
(	O
P	O
=	O
0.006	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
the	O
PSA	B-Gene
/	O
ARE	O
GG	O
genotype	O
confers	O
an	O
increased	O
risk	O
of	O
PC	B-Disease
especially	O
among	O
younger	O
men	B-Species
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
we	O
confirm	O
previous	O
results	O
that	O
a	O
short	O
glutamine	B-Variant
repeat	I-Variant
in	O
conjunction	O
with	O
GG	O
genotype	O
significantly	O
increases	O
the	O
risk	O
of	O
malignant	B-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
Compound	O
heterozygosity	O
for	O
a	O
novel	O
nine	O
-	O
nucleotide	O
deletion	O
and	O
the	O
Asn45Ser	B-Variant
missense	O
mutation	O
in	O
the	O
glycoprotein	B-Gene
IX	I-Gene
gene	O
in	O
a	O
patient	B-Species
with	O
Bernard	B-Disease
-	I-Disease
Soulier	I-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Bernard	B-Disease
-	I-Disease
Soulier	I-Disease
syndrome	I-Disease
(	O
BSS	B-Disease
)	O
is	O
a	O
rare	O
inherited	B-Disease
bleeding	I-Disease
disorder	I-Disease
due	O
to	O
quantitative	O
or	O
qualitative	O
abnormalities	O
in	O
the	O
platelet	O
glycoprotein	B-Gene
(	I-Gene
GP	I-Gene
)	I-Gene
Ib	I-Gene
/	I-Gene
IX	I-Gene
/	I-Gene
V	I-Gene
complex	O
,	O
the	O
major	O
von	B-Gene
Willebrand	I-Gene
factor	I-Gene
receptor	O
.	O
</ALL>	O

<ALL>	O
The	O
complex	O
comprises	O
four	O
subunits	O
,	O
each	O
encoded	O
by	O
a	O
separate	O
gene	O
.	O
</ALL>	O

<ALL>	O
Several	O
mutations	O
have	O
been	O
described	O
for	O
each	O
of	O
the	O
subunits	O
,	O
except	O
for	O
GPV	B-Gene
,	O
as	O
a	O
cause	O
of	O
BSS	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
describe	O
here	O
the	O
genetic	O
basis	O
of	O
the	O
disorder	O
in	O
a	O
child	O
with	O
BSS	B-Disease
.	O
</ALL>	O

<ALL>	O
Flow	O
-	O
cytometric	O
analysis	O
of	O
the	O
patient	B-Species
's	O
platelets	O
showed	O
a	O
markedly	O
reduced	O
surface	O
expression	O
of	O
all	O
three	O
glycoproteins	B-Gene
of	O
the	O
GPIb	B-Gene
/	I-Gene
IX	I-Gene
/	I-Gene
V	I-Gene
complex	O
.	O
</ALL>	O

<ALL>	O
DNA	O
sequencing	O
analysis	O
showed	O
the	O
patient	B-Species
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
mutations	O
in	O
the	O
GPIX	B-Gene
gene	O
,	O
a	O
novel	O
nine	B-Variant
-	I-Variant
nucleotide	I-Variant
deletion	I-Variant
starting	I-Variant
at	I-Variant
position	I-Variant
1952	I-Variant
of	O
the	O
gene	O
that	O
changes	B-Variant
asparagine	I-Variant
86	I-Variant
for	I-Variant
alanine	I-Variant
and	I-Variant
eliminates	I-Variant
amino	I-Variant
acids	I-Variant
87	I-Variant
,	I-Variant
88	I-Variant
,	I-Variant
and	I-Variant
89	I-Variant
(	I-Variant
arginine	I-Variant
,	I-Variant
threonine	I-Variant
,	I-Variant
and	I-Variant
proline	I-Variant
)	I-Variant
and	O
a	O
previously	O
reported	O
point	O
mutation	O
that	O
changes	O
the	O
codon	O
asparagine	B-Variant
(	I-Variant
AAC	I-Variant
)	I-Variant
for	I-Variant
serine	I-Variant
(	I-Variant
AGC	I-Variant
)	I-Variant
at	I-Variant
residue	I-Variant
45	I-Variant
.	O
</ALL>	O

<ALL>	O
Her	O
mother	O
was	O
heterozygous	O
for	O
the	O
Asn45Ser	B-Variant
mutation	O
,	O
and	O
her	O
father	O
,	O
for	O
the	O
nine	O
-	O
nucleotide	O
deletion	O
.	O
</ALL>	O

<ALL>	O
Our	O
findings	O
suggest	O
that	O
the	O
additive	O
effects	O
of	O
both	O
mutations	O
in	O
the	O
GPIX	B-Gene
gene	O
are	O
responsible	O
for	O
the	O
BSS	B-Disease
phenotype	O
of	O
the	O
patient	B-Species
.	O
</ALL>	O

<ALL>	O
Genetic	O
homogeneity	O
for	O
inherited	O
congenital	B-Disease
microcoria	I-Disease
loci	O
in	O
an	O
Asian	O
Indian	O
pedigree	O
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
Congenital	B-Disease
microcoria	I-Disease
is	O
a	O
rare	O
autosomal	B-Disease
dominant	I-Disease
developmental	I-Disease
disorder	I-Disease
of	I-Disease
the	I-Disease
iris	I-Disease
associated	O
with	O
myopia	B-Disease
and	O
juvenile	B-Disease
open	I-Disease
angle	I-Disease
glaucoma	I-Disease
.	O
</ALL>	O

<ALL>	O
Linkage	O
to	O
the	O
chromosomal	O
locus	O
13q31	O
-	O
q32	O
has	O
previously	O
been	O
reported	O
in	O
a	O
large	O
French	O
family	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
current	O
study	O
,	O
a	O
three	O
generation	O
Asian	O
Indian	O
family	O
with	O
15	O
congenital	B-Disease
microcoria	I-Disease
(	O
pupils	O
with	O
a	O
diameter	O
<	O
2	O
mm	O
)	O
affected	O
members	O
was	O
studied	O
for	O
linkage	O
to	O
candidate	O
microsatellite	O
markers	O
at	O
the	O
13q31	O
-	O
q32	O
locus	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Twenty	O
-	O
four	O
members	O
of	O
the	O
family	O
were	O
clinically	O
examined	O
and	O
genomic	O
DNA	O
was	O
extracted	O
.	O
</ALL>	O

<ALL>	O
Microsatellite	O
markers	O
at	O
13q31	O
-	O
q32	O
were	O
PCR	O
amplified	O
and	O
run	O
on	O
an	O
ABI	O
Prism	O
310	O
genetic	O
analyzer	O
and	O
genotyped	O
with	O
the	O
GeneScan	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Two	O
point	O
and	O
multipoint	O
linkage	O
analyses	O
were	O
performed	O
using	O
the	O
MLINK	O
and	O
SUPERLINK	O
programs	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Peak	O
two	O
point	O
LOD	O
scores	O
of	O
3.5	O
,	O
4.7	O
,	O
and	O
5.3	O
were	O
found	O
co	O
-	O
incident	O
with	O
consecutive	O
markers	O
D13S154	O
,	O
DCT	B-Gene
,	O
and	O
D13S1280	O
.	O
</ALL>	O

<ALL>	O
Multipoint	O
analysis	O
revealed	O
a	O
4	O
cM	O
region	O
encompassing	O
D13S1300	O
to	O
D13S1280	O
where	O
the	O
LOD	O
remains	O
just	O
over	O
6.0	O
Thus	O
we	O
confirm	O
localization	O
of	O
the	O
congenital	B-Disease
microcoria	I-Disease
locus	O
to	O
chromosomal	O
locus	O
13q31	O
-	O
q32	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
eight	O
individuals	O
who	O
had	O
both	O
microcoria	B-Disease
and	O
glaucoma	B-Disease
were	O
screened	O
for	O
glaucoma	B-Disease
genes	O
:	O
myocilin	B-Gene
(	O
MYOC	B-Gene
)	O
,	O
optineurin	B-Gene
(	O
OPTN	B-Gene
)	O
and	O
CYP1B1	B-Gene
.	O
</ALL>	O

<ALL>	O
Using	O
direct	O
sequencing	O
a	O
point	O
mutation	O
(	O
144	B-Variant
G	I-Variant
>	I-Variant
A	I-Variant
)	O
resulting	O
in	O
a	O
Q48H	B-Variant
substitution	O
in	O
exon	O
1	O
of	O
the	O
MYOC	B-Gene
gene	O
was	O
observed	O
in	O
five	O
of	O
the	O
eight	O
glaucoma	B-Disease
patients	B-Species
,	O
but	O
not	O
in	O
unaffected	O
family	O
members	O
and	O
100	O
unrelated	O
controls	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
We	O
have	O
confirmed	O
the	O
localization	O
of	O
the	O
congenital	B-Disease
microcoria	I-Disease
locus	O
(	O
MCOR	B-Gene
)	O
to	O
13q31	O
-	O
q32	O
in	O
a	O
large	O
Asian	O
Indian	O
family	O
and	O
conclude	O
that	O
current	O
information	O
suggests	O
this	O
is	O
a	O
single	O
locus	O
disorder	O
and	O
genetically	O
homogeneous	O
.	O
</ALL>	O

<ALL>	O
When	O
combined	O
with	O
the	O
initial	O
linkage	O
paper	O
our	O
haplotype	O
and	O
linkage	O
data	O
map	O
the	O
MCOR	B-Gene
locus	O
to	O
a	O
6	O
-	O
7	O
cM	O
region	O
between	O
D13S265	O
and	O
D13S1280	O
.	O
</ALL>	O

<ALL>	O
The	O
DCT	B-Gene
locus	O
,	O
a	O
member	O
of	O
the	O
tyrosinase	B-Gene
family	O
involved	O
in	O
pigmentation	B-Disease
,	O
maps	O
within	O
this	O
region	O
.	O
</ALL>	O

<ALL>	O
Data	O
presented	O
here	O
supports	O
the	O
hypothesis	O
that	O
congenital	B-Disease
microcoria	I-Disease
is	O
a	O
potential	O
risk	O
factor	O
for	O
glaucoma	B-Disease
,	O
although	O
this	O
observation	O
is	O
complicated	O
by	O
the	O
partial	O
segregation	O
of	O
MYOC	B-Gene
Q48H	B-Variant
(	O
1q24.3	O
-	O
q25.2	O
)	O
,	O
a	O
mutation	O
known	O
to	O
be	O
associated	O
with	O
glaucoma	B-Disease
in	O
India	O
.	O
</ALL>	O

<ALL>	O
Fine	O
mapping	O
and	O
candidate	O
gene	O
analysis	O
continues	O
with	O
the	O
hope	O
that	O
characterizing	O
the	O
micocoria	B-Gene
gene	O
will	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
microcoria	B-Disease
and	O
glaucoma	B-Disease
causation	O
.	O
</ALL>	O

<ALL>	O
The	O
relationship	O
between	O
microcoria	B-Disease
,	O
glaucoma	B-Disease
,	O
and	O
the	O
MYOC	B-Gene
Q48H	B-Variant
mutation	O
in	O
this	O
family	O
is	O
discussed	O
.	O
</ALL>	O

<ALL>	O
A	O
novel	O
mutation	O
(	O
E333D	B-Variant
)	O
in	O
the	O
thyroid	B-Gene
hormone	I-Gene
beta	I-Gene
receptor	I-Gene
causing	O
resistance	B-Disease
to	I-Disease
thyroid	I-Disease
hormone	I-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Resistance	B-Disease
to	I-Disease
thyroid	I-Disease
hormone	I-Disease
(	O
RTH	B-Disease
)	O
is	O
an	O
inherited	O
syndrome	O
characterized	O
by	O
elevated	O
serum	O
thyroid	B-Chemical
hormones	I-Chemical
(	O
TH	B-Chemical
)	O
,	O
failure	O
to	O
suppress	O
pituitary	O
thyroid	B-Gene
stimulating	I-Gene
hormone	I-Gene
(	O
TSH	B-Gene
)	O
secretion	O
,	O
and	O
variable	O
peripheral	O
tissue	O
responsiveness	O
to	O
TH	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
disorder	O
is	O
associated	O
with	O
diverse	O
mutations	O
in	O
the	O
thyroid	B-Gene
hormone	I-Gene
beta	I-Gene
receptor	I-Gene
(	O
TRbeta	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
report	O
a	O
novel	O
natural	O
RTH	B-Disease
mutation	O
(	O
E333D	B-Variant
)	O
located	O
in	O
the	O
large	O
carboxy	O
-	O
terminal	O
ligand	O
binding	O
domain	O
of	O
TRbeta	B-Gene
.	O
</ALL>	O

<ALL>	O
The	O
mutation	O
was	O
identified	O
in	O
a	O
22	O
-	O
year	O
-	O
old	O
French	O
woman	B-Species
coming	O
to	O
medical	O
attention	O
because	O
of	O
an	O
increasing	O
overweight	B-Disease
.	O
</ALL>	O

<ALL>	O
Biochemical	O
tests	O
showed	O
elevated	O
free	O
thyroxine	B-Chemical
(	O
T4	B-Chemical
:	O
20.8	O
pg	O
/	O
ml	O
(	O
normal	O
,	O
8.5	O
-	O
18	O
)	O
)	O
and	O
triiodothyronine	B-Chemical
(	O
T3	B-Chemical
:	O
5.7	O
pg	O
/	O
ml	O
(	O
normal	O
,	O
1.4	O
-	O
4	O
)	O
)	O
in	O
the	O
serum	O
,	O
together	O
with	O
an	O
inappropriately	O
nonsuppressed	O
TSH	B-Gene
level	O
of	O
4.7	O
mU	O
/	O
ml	O
(	O
normal	O
,	O
0.4	O
-	O
4	O
)	O
.	O
</ALL>	O

<ALL>	O
Her	O
father	O
and	O
her	O
brother	O
's	O
serum	O
tests	O
also	O
showed	O
biochemical	O
abnormalities	O
consistent	O
with	O
RTH	B-Disease
.	O
</ALL>	O

<ALL>	O
Direct	O
sequencing	O
of	O
the	O
TRbeta	B-Gene
gene	O
revealed	O
a	O
heterozygous	O
transition	O
1284A	B-Variant
>	I-Variant
C	I-Variant
in	O
exon	O
9	O
resulting	O
in	O
substitution	O
of	O
glutamic	B-Variant
acid	I-Variant
333	I-Variant
by	I-Variant
aspartic	I-Variant
acid	I-Variant
residue	O
(	O
E333D	B-Variant
)	O
.	O
</ALL>	O

<ALL>	O
Further	O
functional	O
analyses	O
of	O
the	O
novel	O
TRbeta	B-Gene
mutant	O
were	O
conducted	O
.	O
</ALL>	O

<ALL>	O
We	O
found	O
that	O
the	O
E333D	B-Variant
mutation	O
neither	O
significantly	O
affected	O
the	O
affinity	O
of	O
the	O
receptor	O
for	O
T3	B-Chemical
nor	O
modified	O
heterodimer	O
formation	O
with	O
retinoid	B-Gene
X	I-Gene
receptor	I-Gene
(	O
RXR	B-Gene
)	O
when	O
bound	O
to	O
DNA	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
in	O
transient	O
transfection	O
assays	O
,	O
the	O
E333D	B-Variant
TRbeta	B-Gene
mutant	O
exhibited	O
impaired	O
transcriptional	O
regulation	O
on	O
two	O
distinct	O
positively	O
regulated	O
thyroid	O
response	O
elements	O
(	O
F2	O
-	O
and	O
DR4	O
-	O
TREs	O
)	O
as	O
well	O
as	O
on	O
the	O
negatively	O
regulated	O
human	B-Species
TSHalpha	B-Gene
promoter	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
a	O
dominant	O
inhibition	O
of	O
the	O
wild	O
-	O
type	O
TRbeta	B-Gene
counterpart	O
transactivation	O
function	O
was	O
observed	O
on	O
both	O
a	O
positive	O
(	O
F2	O
-	O
TRE	O
)	O
and	O
a	O
negative	O
(	O
TSHalpha	B-Gene
)	O
promoter	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
strongly	O
suggest	O
that	O
the	O
E333D	B-Variant
TRbeta	B-Gene
mutation	O
is	O
responsible	O
for	O
the	O
RTH	B-Disease
phenotype	O
in	O
the	O
proposita	O
's	O
family	O
.	O
</ALL>	O

<ALL>	O
Common	O
germline	O
genetic	O
variation	O
in	O
antioxidant	O
defense	O
genes	O
and	O
survival	O
after	O
diagnosis	O
of	O
breast	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
The	O
prognosis	O
of	O
breast	B-Disease
cancer	I-Disease
varies	O
considerably	O
among	O
individuals	O
,	O
and	O
inherited	O
genetic	O
factors	O
may	O
help	O
explain	O
this	O
variability	O
.	O
</ALL>	O

<ALL>	O
Of	O
particular	O
interest	O
are	O
genes	O
involved	O
in	O
defense	O
against	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
because	O
ROS	B-Chemical
are	O
thought	O
to	O
cause	O
DNA	O
damage	O
and	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
cancer	B-Disease
.	O
</ALL>	O

<ALL>	O
PATIENTS	B-Species
AND	O
METHODS	O
:	O
We	O
examined	O
associations	O
between	O
54	O
polymorphisms	O
that	O
tag	O
the	O
known	O
common	O
variants	O
(	O
minor	O
allele	O
frequency	O
>	O
0.05	O
)	O
in	O
10	O
genes	O
involved	O
in	O
oxidative	O
damage	O
repair	O
(	O
CAT	B-Gene
,	O
SOD1	B-Gene
,	O
SOD2	B-Gene
,	O
GPX1	B-Gene
,	O
GPX4	B-Gene
,	O
GSR	B-Gene
,	O
TXN	B-Gene
,	O
TXN2	B-Gene
,	O
TXNRD1	B-Gene
,	O
and	O
TXNRD2	B-Gene
)	O
and	O
survival	O
in	O
4,470	O
women	B-Species
with	O
breast	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Two	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
GPX4	B-Gene
(	O
rs713041	B-Variant
and	O
rs757229	B-Variant
)	O
were	O
associated	O
with	O
all	O
-	O
cause	O
mortality	O
even	O
after	O
adjusting	O
for	O
multiple	O
hypothesis	O
testing	O
(	O
adjusted	O
P	O
=	O
.0041	O
and	O
P	O
=	O
.0035	O
)	O
.	O
</ALL>	O

<ALL>	O
These	O
SNPs	O
are	O
correlated	O
with	O
each	O
other	O
(	O
r2	O
=	O
0.61	O
)	O
.	O
</ALL>	O

<ALL>	O
GPX4	B-Gene
rs713041	B-Variant
is	O
located	O
near	O
the	O
selenocysteine	B-Chemical
insertion	O
sequence	O
element	O
in	O
the	O
GPX4	B-Gene
3	O
'	O
untranslated	O
region	O
,	O
and	O
the	O
rare	O
allele	O
of	O
this	O
SNP	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	B-Disease
,	O
with	O
a	O
hazard	O
ratio	O
of	O
1.27	O
per	O
rare	O
allele	O
carried	O
(	O
95	O
%	O
CI	O
,	O
1.13	O
to	O
11.43	O
)	O
.	O
</ALL>	O

<ALL>	O
This	O
effect	O
was	O
not	O
attenuated	O
after	O
adjusting	O
for	O
tumor	B-Disease
stage	O
,	O
grade	O
,	O
or	O
estrogen	B-Gene
receptor	I-Gene
status	O
.	O
</ALL>	O

<ALL>	O
We	O
found	O
that	O
the	O
common	O
allele	O
is	O
preferentially	O
expressed	O
in	O
normal	O
lymphocytes	O
,	O
normal	O
breast	O
,	O
and	O
breast	B-Disease
tumors	I-Disease
compared	O
with	O
the	O
rare	O
allele	O
,	O
but	O
there	O
were	O
no	O
differences	O
in	O
total	O
levels	O
of	O
GPX4	B-Gene
mRNA	O
across	O
genotypes	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
These	O
data	O
provide	O
strong	O
support	O
for	O
the	O
hypothesis	O
that	O
common	O
variation	O
in	O
GPX4	B-Gene
is	O
associated	O
with	O
prognosis	O
after	O
a	O
diagnosis	O
of	O
breast	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
Integrated	O
genomic	O
and	O
expression	O
profiling	O
in	O
mantle	B-Disease
cell	I-Disease
lymphoma	I-Disease
:	O
identification	O
of	O
gene	O
-	O
dosage	O
regulated	O
candidate	O
genes	O
.	O
</ALL>	O

<ALL>	O
Mantle	B-Disease
cell	I-Disease
lymphoma	I-Disease
(	O
MCL	B-Disease
)	O
is	O
characterized	O
by	O
the	O
t	O
(	O
11;14	O
)	O
(	O
q13;q32	O
)	O
translocation	O
and	O
several	O
other	O
cytogenetic	O
aberrations	O
,	O
including	O
heterozygous	O
loss	O
of	O
chromosomal	O
arms	O
1p	O
,	O
6q	O
,	O
11q	O
and	O
13q	O
and	O
/	O
or	O
gains	O
of	O
3q	O
and	O
8q	O
.	O
</ALL>	O

<ALL>	O
The	O
common	O
intervals	O
of	O
chromosomal	O
imbalance	O
have	O
been	O
narrowed	O
down	O
using	O
array	O
-	O
comparative	O
genomic	O
hybridization	O
(	O
CGH	O
)	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
chromosomal	O
intervals	O
still	O
contain	O
many	O
genes	O
potentially	O
involved	O
in	O
MCL	B-Disease
pathogeny	O
.	O
</ALL>	O

<ALL>	O
Combined	O
analysis	O
of	O
tiling	O
-	O
resolution	O
array	O
-	O
CGH	O
with	O
gene	O
expression	O
profiling	O
on	O
11	O
MCL	B-Disease
tumours	I-Disease
enabled	O
the	O
identification	O
of	O
genomic	O
alterations	O
and	O
their	O
corresponding	O
gene	O
expression	O
profiles	O
.	O
</ALL>	O

<ALL>	O
Only	O
subsets	O
of	O
genes	O
located	O
within	O
given	O
cytogenetic	O
anomaly	O
-	O
intervals	O
showed	O
a	O
concomitant	O
change	O
in	O
mRNA	O
expression	O
level	O
.	O
</ALL>	O

<ALL>	O
The	O
genes	O
that	O
showed	O
consistent	O
correlation	O
between	O
DNA	O
copy	O
number	O
and	O
RNA	O
expression	O
levels	O
are	O
likely	O
to	O
be	O
important	O
in	O
MCL	B-Disease
pathology	O
.	O
</ALL>	O

<ALL>	O
Besides	O
several	O
'	O
anonymous	O
genes	O
'	O
,	O
we	O
also	O
identified	O
various	O
fully	O
annotated	O
genes	O
,	O
whose	O
gene	O
products	O
are	O
involved	O
in	O
cyclic	B-Chemical
adenosine	I-Chemical
monophosphate	I-Chemical
-	O
regulated	O
pathways	O
(	O
PRKACB	B-Gene
)	O
,	O
DNA	O
damage	O
repair	O
,	O
maintenance	O
of	O
chromosome	O
stability	O
and	O
prevention	O
of	O
rereplication	O
(	O
ATM	B-Gene
,	O
ERCC5	B-Gene
,	O
FBXO5	B-Gene
)	O
,	O
energy	O
metabolism	O
(	O
such	O
as	O
genes	O
that	O
are	O
involved	O
in	O
the	O
synthesis	O
of	O
proteins	O
encoded	O
by	O
the	O
mitochondrial	O
genome	O
)	O
and	O
signal	O
transduction	O
(	O
ARHGAP29	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
Deregulation	O
of	O
these	O
gene	O
products	O
may	O
interfere	O
with	O
the	O
signalling	O
pathways	O
that	O
are	O
involved	O
in	O
MCL	B-Disease
tumour	I-Disease
development	O
and	O
maintenance	O
.	O
</ALL>	O

<ALL>	O
The	O
six	O
-	O
nucleotide	O
deletion	O
/	O
insertion	O
variant	O
in	O
the	O
CASP8	B-Gene
promoter	O
region	O
is	O
inversely	O
associated	O
with	O
risk	O
of	O
squamous	B-Disease
cell	I-Disease
carcinoma	I-Disease
of	I-Disease
the	I-Disease
head	I-Disease
and	I-Disease
neck	I-Disease
.	O
</ALL>	O

<ALL>	O
Caspase	B-Gene
8	I-Gene
(	O
CASP8	B-Gene
)	O
is	O
an	O
apoptosis	O
-	O
related	O
cysteine	O
peptidase	O
involved	O
in	O
the	O
death	O
receptor	O
pathway	O
and	O
likely	O
in	O
the	O
mitochondrial	O
pathway	O
.	O
</ALL>	O

<ALL>	O
A	O
CASP8	B-Gene
promoter	O
region	O
six	O
-	O
nucleotide	O
deletion	O
/	O
insertion	O
(	O
-	B-Variant
652	I-Variant
6N	I-Variant
ins	I-Variant
/	I-Variant
del	I-Variant
)	O
variant	O
and	O
a	O
coding	O
region	O
D302H	B-Variant
polymorphism	O
are	O
reportedly	O
important	O
in	O
cancer	B-Disease
development	O
,	O
but	O
no	O
reported	O
study	O
has	O
assessed	O
the	O
associations	O
of	O
these	O
genetic	O
variations	O
with	O
risk	O
of	O
head	B-Disease
and	I-Disease
neck	I-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
In	O
a	O
hospital	O
-	O
based	O
study	O
of	O
non	O
-	O
Hispanic	O
whites	O
,	O
we	O
genotyped	O
CASP8	B-Gene
-	B-Variant
652	I-Variant
6N	I-Variant
del	I-Variant
and	O
302H	B-Variant
variants	O
in	O
1,023	O
patients	B-Species
with	O
squamous	B-Disease
cell	I-Disease
carcinoma	I-Disease
of	I-Disease
the	I-Disease
head	I-Disease
and	I-Disease
neck	I-Disease
(	O
SCCHN	B-Disease
)	O
and	O
1,052	O
cancer	O
-	O
free	O
controls	O
.	O
</ALL>	O

<ALL>	O
Crude	O
and	O
adjusted	O
odds	O
ratios	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
were	O
estimated	O
using	O
unconditional	O
logistic	O
regression	O
models	O
.	O
</ALL>	O

<ALL>	O
The	O
CASP8	B-Gene
-	B-Variant
652	I-Variant
6N	I-Variant
del	I-Variant
variant	O
genotypes	O
or	O
haplotypes	O
were	O
inversely	O
associated	O
with	O
SCCHN	B-Disease
risk	O
(	O
adjusted	O
OR	O
,	O
0.70	O
;	O
95	O
%	O
CI	O
,	O
0.57	O
-	O
0.85	O
for	O
the	O
ins	O
/	O
del	O
+	O
del	O
/	O
del	O
genotypes	O
compared	O
with	O
the	O
ins	O
/	O
ins	O
genotype	O
;	O
adjusted	O
OR	O
,	O
0.73	O
;	O
95	O
%	O
CI	O
,	O
0.55	O
-	O
0.97	O
for	O
the	O
del	O
-	O
D	O
haplotype	O
compared	O
with	O
the	O
ins	O
-	O
D	O
haplotype	O
)	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
the	O
number	O
of	O
the	O
CASP8	B-Gene
-	B-Variant
652	I-Variant
6N	I-Variant
del	I-Variant
(	O
but	O
not	O
302H	B-Variant
)	O
variant	O
allele	O
tended	O
to	O
correlate	O
with	O
increased	O
levels	O
of	O
camptothecin	B-Chemical
-	O
induced	O
p53	B-Gene
-	O
mediated	O
apoptosis	O
in	O
T	O
lymphocytes	O
from	O
170	O
cancer	O
-	O
free	O
controls	O
.	O
</ALL>	O

<ALL>	O
We	O
concluded	O
that	O
the	O
CASP8	B-Gene
-	B-Variant
652	I-Variant
6N	I-Variant
del	I-Variant
variant	O
allele	O
may	O
contribute	O
to	O
the	O
risk	O
of	O
developing	O
SCCHN	B-Disease
in	O
non	O
-	O
Hispanic	O
white	O
populations	O
.	O
</ALL>	O

<ALL>	O
Further	O
validation	O
by	O
population	O
-	O
based	O
case	O
-	O
control	O
studies	O
and	O
rigorous	O
mechanistic	O
studies	O
is	O
warranted	O
.	O
</ALL>	O

<ALL>	O
Thyroid	B-Gene
hormone	I-Gene
receptor	I-Gene
a	I-Gene
mutation	O
causes	O
a	O
severe	O
and	O
thyroxine	B-Chemical
-	O
resistant	O
skeletal	B-Disease
dysplasia	I-Disease
in	O
female	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
A	O
new	O
genetic	O
disorder	O
has	O
been	O
identified	O
that	O
results	O
from	O
mutation	O
of	O
THRA	B-Gene
,	O
encoding	O
thyroid	B-Gene
hormone	I-Gene
receptor	I-Gene
a1	I-Gene
(	O
TRa1	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
Affected	O
children	O
have	O
a	O
high	O
serum	O
T3	B-Chemical
:	O
T4	B-Chemical
ratio	O
and	O
variable	O
degrees	O
of	O
intellectual	B-Disease
deficit	I-Disease
and	O
constipation	B-Disease
but	O
exhibit	O
a	O
consistently	O
severe	O
skeletal	B-Disease
dysplasia	I-Disease
.	O
</ALL>	O

<ALL>	O
In	O
an	O
attempt	O
to	O
improve	O
developmental	B-Disease
delay	I-Disease
and	O
alleviate	O
symptoms	O
of	O
hypothyroidism	B-Disease
,	O
patients	B-Species
are	O
receiving	O
varying	O
doses	O
and	O
durations	O
of	O
T4	B-Chemical
treatment	O
,	O
but	O
responses	O
have	O
been	O
inconsistent	O
so	O
far	O
.	O
</ALL>	O

<ALL>	O
Thra1	B-Gene
(	O
PV	O
/	O
+	O
)	O
mice	B-Species
express	O
a	O
similar	O
potent	O
dominant	O
-	O
negative	O
mutant	O
TRa1	B-Gene
to	O
affected	O
individuals	O
,	O
and	O
thus	O
represent	O
an	O
excellent	O
disease	O
model	O
.	O
</ALL>	O

<ALL>	O
We	O
hypothesized	O
that	O
Thra1	B-Gene
(	O
PV	O
/	O
+	O
)	O
mice	B-Species
could	O
be	O
used	O
to	O
predict	O
the	O
skeletal	O
outcome	O
of	O
human	B-Species
THRA	B-Gene
mutations	O
and	O
determine	O
whether	O
prolonged	O
treatment	O
with	O
a	O
supraphysiological	O
dose	O
of	O
T4	B-Chemical
ameliorates	O
the	O
skeletal	B-Disease
abnormalities	I-Disease
.	O
</ALL>	O

<ALL>	O
Adult	O
female	O
Thra1	B-Gene
(	O
PV	O
/	O
+	O
)	O
mice	B-Species
had	O
short	B-Disease
stature	I-Disease
,	O
grossly	O
abnormal	O
bone	O
morphology	O
but	O
normal	O
bone	O
strength	O
despite	O
high	O
bone	O
mass	O
.	O
</ALL>	O

<ALL>	O
Although	O
T4	B-Chemical
treatment	O
suppressed	O
TSH	B-Gene
secretion	O
,	O
it	O
had	O
no	O
effect	O
on	O
skeletal	O
maturation	O
,	O
linear	O
growth	O
,	O
or	O
bone	O
mineralization	O
,	O
thus	O
demonstrating	O
profound	O
tissue	O
resistance	B-Disease
to	I-Disease
thyroid	I-Disease
hormone	I-Disease
.	O
</ALL>	O

<ALL>	O
Despite	O
this	O
,	O
prolonged	O
T4	B-Chemical
treatment	O
abnormally	O
increased	O
bone	O
stiffness	O
and	O
strength	O
,	O
suggesting	O
the	O
potential	O
for	O
detrimental	O
consequences	O
in	O
the	O
long	O
term	O
.	O
</ALL>	O

<ALL>	O
Our	O
studies	O
establish	O
that	O
TRa1	B-Gene
has	O
an	O
essential	O
role	O
in	O
the	O
developing	O
and	O
adult	O
skeleton	O
and	O
predict	O
that	O
patients	B-Species
with	O
different	O
THRA	B-Gene
mutations	O
will	O
display	O
variable	O
responses	O
to	O
T4	B-Chemical
treatment	O
,	O
which	O
depend	O
on	O
the	O
severity	O
of	O
the	O
causative	O
mutation	O
.	O
</ALL>	O

<ALL>	O
NF	B-Gene
-	I-Gene
kB	I-Gene
functions	O
as	O
a	O
molecular	O
link	O
between	O
tumor	B-Disease
cells	O
and	O
Th1	O
/	O
Tc1	O
T	O
cells	O
in	O
the	O
tumor	B-Disease
microenvironment	O
to	O
exert	O
radiation	O
-	O
mediated	O
tumor	B-Disease
suppression	O
.	O
</ALL>	O

<ALL>	O
Radiation	O
modulates	O
both	O
tumor	B-Disease
cells	O
and	O
immune	O
cells	O
in	O
the	O
tumor	B-Disease
microenvironment	O
to	O
exert	O
its	O
anti	O
-	O
tumor	B-Disease
activity	O
;	O
however	O
,	O
the	O
molecular	O
connection	O
between	O
tumor	B-Disease
cells	O
and	O
immune	O
cells	O
that	O
mediates	O
radiation	O
-	O
exerted	O
tumor	B-Disease
suppression	O
activity	O
in	O
the	O
tumor	B-Disease
microenvironment	O
is	O
largely	O
unknown	O
.	O
</ALL>	O

<ALL>	O
We	O
report	O
here	O
that	O
radiation	O
induces	O
rapid	O
activation	O
of	O
the	O
p65	B-Gene
/	O
p50	B-Gene
and	O
p50	B-Gene
/	O
p50	B-Gene
NF	B-Gene
-	I-Gene
kB	I-Gene
complexes	O
in	O
human	B-Species
soft	B-Disease
tissue	I-Disease
sarcoma	I-Disease
(	O
STS	B-Disease
)	O
cells	O
.	O
</ALL>	O

<ALL>	O
Radiation	O
-	O
activated	O
p65	B-Gene
/	O
p50	B-Gene
and	O
p50	B-Gene
/	O
p50	B-Gene
bind	O
to	O
the	O
TNFa	B-Gene
promoter	O
to	O
activate	O
its	O
transcription	O
in	O
STS	B-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
Radiation	O
-	O
induced	O
TNFa	B-Gene
induces	O
tumor	B-Disease
cell	O
death	O
in	O
an	O
autocrine	O
manner	O
.	O
</ALL>	O

<ALL>	O
A	O
sublethal	O
dose	O
of	O
Smac	B-Gene
mimetic	O
BV6	B-Chemical
induces	O
cIAP1	B-Gene
and	O
cIAP2	B-Gene
degradation	O
to	O
increase	O
tumor	B-Disease
cell	O
sensitivity	O
to	O
radiation	O
-	O
induced	O
cell	O
death	O
in	O
vitro	O
and	O
to	O
enhance	O
radiation	O
-	O
mediated	O
suppression	O
of	O
STS	B-Disease
xenografts	O
in	O
vivo	O
.	O
</ALL>	O

<ALL>	O
Inhibition	O
of	O
caspases	B-Gene
,	O
RIP1	B-Gene
,	O
or	O
RIP3	B-Gene
blocks	O
radiation	O
/	O
TNFa	B-Gene
-	O
induced	O
cell	O
death	O
,	O
whereas	O
inhibition	O
of	O
RIP1	B-Gene
blocks	O
TNFa	B-Gene
-	O
induced	O
caspase	B-Gene
activation	O
,	O
suggesting	O
that	O
caspases	B-Gene
and	O
RIP1	B-Gene
act	O
sequentially	O
to	O
mediate	O
the	O
non	O
-	O
compensatory	O
cell	O
death	O
pathways	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
we	O
determined	O
in	O
a	O
syngeneic	O
sarcoma	B-Disease
mouse	B-Species
model	O
that	O
radiation	O
up	O
-	O
regulates	O
IRF3	B-Gene
,	O
IFNb	B-Gene
,	O
and	O
the	O
T	O
cell	O
chemokines	B-Gene
CCL2	B-Gene
and	O
CCL5	B-Gene
in	O
the	O
tumor	B-Disease
microenvironment	O
,	O
which	O
are	O
associated	O
with	O
activation	O
and	O
increased	O
infiltration	O
of	O
Th1	O
/	O
Tc1	O
T	O
cells	O
in	O
the	O
tumor	B-Disease
microenvironment	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
tumor	B-Disease
-	O
infiltrating	O
T	O
cells	O
are	O
in	O
their	O
active	O
form	O
since	O
both	O
the	O
perforin	B-Gene
and	O
FasL	B-Gene
pathways	O
are	O
activated	O
in	O
irradiated	O
tumor	B-Disease
tissues	O
.	O
</ALL>	O

<ALL>	O
Consequently	O
,	O
combined	O
BV6	B-Chemical
and	O
radiation	O
completely	O
suppressed	O
tumor	B-Disease
growth	O
in	O
vivo	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
radiation	O
-	O
induced	O
NF	B-Gene
-	I-Gene
kB	I-Gene
functions	O
as	O
a	O
molecular	O
link	O
between	O
tumor	B-Disease
cells	O
and	O
immune	O
cells	O
in	O
the	O
tumor	B-Disease
microenvironment	O
for	O
radiation	O
-	O
mediated	O
tumor	B-Disease
suppression	O
.	O
</ALL>	O

<ALL>	O
Bach1	B-Gene
siRNA	O
attenuates	O
bleomycin	B-Chemical
-	O
induced	O
pulmonary	B-Disease
fibrosis	I-Disease
by	O
modulating	O
oxidative	O
stress	O
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Oxidative	O
stress	O
plays	O
an	O
essential	O
role	O
in	O
inflammation	B-Disease
and	O
fibrosis	B-Disease
.	O
</ALL>	O

<ALL>	O
Bach1	B-Gene
is	O
an	O
important	O
transcriptional	O
repressor	O
that	O
acts	O
by	O
modulating	O
oxidative	O
stress	O
and	O
represents	O
a	O
potential	O
target	O
in	O
the	O
treatment	O
of	O
pulmonary	B-Disease
fibrosis	I-Disease
(	O
PF	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
knocked	O
down	O
Bach1	B-Gene
using	O
adenovirus	O
-	O
mediated	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
to	O
determine	O
whether	O
the	O
use	O
of	O
Bach1	B-Gene
siRNA	O
is	O
an	O
effective	O
therapeutic	O
strategy	O
in	O
mice	B-Species
with	O
bleomycin	B-Chemical
(	O
BLM	B-Chemical
)	O
-	O
induced	O
PF	B-Disease
.	O
</ALL>	O

<ALL>	O
Mouse	B-Species
lung	O
fibroblasts	O
(	O
MLFs	O
)	O
were	O
incubated	O
with	O
transforming	B-Gene
growth	I-Gene
factor	I-Gene
(	I-Gene
TGF	I-Gene
)	I-Gene
-	I-Gene
b1	I-Gene
(	O
5	O
ng	O
/	O
ml	O
)	O
and	O
subsequently	O
infected	O
with	O
recombined	O
adenovirus	O
-	O
like	O
Bach1	B-Gene
siRNA1	O
and	O
Bach1	B-Gene
siRNA2	O
,	O
while	O
an	O
empty	O
adenovirus	O
vector	O
was	O
used	O
as	O
the	O
negative	O
control	O
.	O
</ALL>	O

<ALL>	O
The	O
selected	O
Bach1	B-Gene
siRNA	O
with	O
higher	O
interference	O
efficiency	O
was	O
used	O
for	O
the	O
animal	O
experiments	O
.	O
</ALL>	O

<ALL>	O
A	O
mouse	B-Species
model	O
of	O
BLM	B-Chemical
-	O
induced	O
PF	B-Disease
was	O
established	O
,	O
and	O
Bach1	B-Gene
siRNA	O
(	O
1x109	O
pfu	O
)	O
was	O
administered	O
to	O
the	O
mice	B-Species
via	O
the	O
tail	O
vein	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
revealed	O
that	O
the	O
Bach1	B-Gene
mRNA	O
and	O
protein	O
levels	O
were	O
significantly	O
downregulated	O
by	O
Bach1	B-Gene
siRNA	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
the	O
MLFs	O
infected	O
with	O
Bach1	B-Gene
siRNA	O
exhibited	O
increased	O
mRNA	O
and	O
protein	O
expression	O
levels	O
of	O
heme	B-Gene
oxygenase	I-Gene
-	I-Gene
1	I-Gene
and	O
glutathione	B-Gene
peroxidase	I-Gene
1	I-Gene
,	O
but	O
decreased	O
levels	O
of	O
TGF	B-Gene
-	I-Gene
b1	I-Gene
and	O
interleukin	B-Gene
-	I-Gene
6	I-Gene
in	O
the	O
cell	O
supernatants	O
compared	O
with	O
the	O
cells	O
exposed	O
to	O
TGF	B-Gene
-	I-Gene
b1	I-Gene
alone	O
.	O
</ALL>	O

<ALL>	O
Bach1	B-Gene
knockdown	O
by	O
siRNA	O
also	O
enhanced	O
the	O
expression	O
of	O
antioxidant	B-Gene
factors	I-Gene
,	O
but	O
suppressed	O
that	O
of	O
fibrosis	B-Disease
-	O
related	O
cytokines	O
in	O
mice	B-Species
compared	O
with	O
the	O
BLM	B-Chemical
group	O
.	O
</ALL>	O

<ALL>	O
Finally	O
,	O
the	O
inflammatory	B-Disease
infiltration	O
of	O
alveolar	O
and	O
interstitial	O
cells	O
and	O
the	O
destruction	O
of	O
lung	O
structure	O
were	O
significantly	O
attenuated	O
in	O
the	O
mide	O
administered	O
Bach1	B-Gene
siRNA	O
compared	O
with	O
those	O
in	O
the	O
BLM	B-Chemical
group	O
.	O
</ALL>	O

<ALL>	O
On	O
the	O
whole	O
,	O
our	O
findings	O
demonstrate	O
that	O
Bach1	B-Gene
siRNA	O
exerts	O
protective	O
effects	O
against	O
BLM	B-Chemical
-	O
induced	O
PF	B-Disease
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Our	O
data	O
may	O
provide	O
the	O
basis	O
for	O
the	O
development	O
of	O
novel	O
targeted	O
therapeutic	O
strategies	O
for	O
PF	B-Disease
.	O
</ALL>	O

<ALL>	O
Tissue	O
-	O
Specific	O
Ablation	O
of	O
the	O
LIF	B-Gene
Receptor	I-Gene
in	O
the	O
Murine	B-Species
Uterine	O
Epithelium	O
Results	O
in	O
Implantation	O
Failure	O
.	O
</ALL>	O

<ALL>	O
The	O
cytokine	O
leukemia	B-Gene
inhibitory	I-Gene
factor	I-Gene
(	O
LIF	B-Gene
)	O
is	O
essential	O
for	O
rendering	O
the	O
uterus	O
receptive	O
for	O
blastocyst	O
implantation	O
.	O
</ALL>	O

<ALL>	O
In	O
mice	B-Species
,	O
LIF	B-Gene
receptor	I-Gene
expression	O
(	O
LIFR	B-Gene
)	O
is	O
largely	O
restricted	O
to	O
the	O
uterine	O
luminal	O
epithelium	O
(	O
LE	O
)	O
.	O
</ALL>	O

<ALL>	O
LIF	B-Gene
,	O
secreted	O
from	O
the	O
endometrial	O
glands	O
(	O
GEs	O
)	O
,	O
binds	O
to	O
the	O
LIFR	B-Gene
,	O
activating	O
the	O
Janus	B-Gene
kinase	I-Gene
-	O
signal	B-Gene
transducer	I-Gene
and	I-Gene
activation	I-Gene
of	I-Gene
transcription	I-Gene
(	I-Gene
STAT	I-Gene
)	I-Gene
3	I-Gene
(	O
Jak	B-Gene
-	O
Stat3	B-Gene
)	O
signaling	O
pathway	O
in	O
the	O
LE	O
.	O
</ALL>	O

<ALL>	O
JAK	B-Gene
-	O
STAT	B-Gene
activation	O
converts	O
the	O
LE	O
to	O
a	O
receptive	O
state	O
so	O
that	O
juxtaposed	O
blastocysts	O
begin	O
to	O
implant	O
.	O
</ALL>	O

<ALL>	O
To	O
specifically	O
delete	O
the	O
LIFR	B-Gene
in	O
the	O
LE	O
,	O
we	O
derived	O
a	O
line	O
of	O
mice	B-Species
in	O
which	O
Cre	O
recombinase	O
was	O
inserted	O
into	O
the	O
endogenous	O
lactoferrin	B-Gene
gene	O
(	O
Ltf	B-Gene
-	O
Cre	O
)	O
.	O
</ALL>	O

<ALL>	O
Lactoferrin	B-Gene
expression	O
in	O
the	O
LE	O
is	O
induced	O
by	O
E2	O
,	O
and	O
we	O
demonstrate	O
that	O
Cre	O
recombinase	O
activity	O
is	O
restricted	O
to	O
the	O
LE	O
and	O
GE	O
.	O
</ALL>	O

<ALL>	O
To	O
determine	O
the	O
requirement	O
of	O
the	O
LIFR	B-Gene
in	O
implantation	O
,	O
we	O
derived	O
an	O
additional	O
mouse	B-Species
line	O
carrying	O
a	O
conditional	O
(	O
floxed	O
)	O
Lifr	B-Gene
flx	O
/	O
flx	O
gene	O
.	O
</ALL>	O

<ALL>	O
Crossing	O
Ltf	B-Gene
-	O
Cre	O
mice	B-Species
with	O
Lifr	B-Gene
flx	O
/	O
flx	O
mice	B-Species
generated	O
Lifr	B-Gene
flx	O
/	O
D	O
:	O
Ltf	B-Gene
Cre	O
/	O
+	O
females	O
that	O
were	O
overtly	O
normal	O
but	O
infertile	O
.	O
</ALL>	O

<ALL>	O
Many	O
of	O
these	O
females	O
,	O
despite	O
repeated	O
matings	O
,	O
did	O
not	O
become	O
pregnant	O
.	O
</ALL>	O

<ALL>	O
Unimplanted	O
blastocysts	O
were	O
recovered	O
from	O
the	O
Lifr	B-Gene
flx	O
/	O
D	O
:	O
Ltf	B-Gene
Cre	O
/	O
+	O
uteri	O
and	O
,	O
when	O
transferred	O
to	O
wild	O
-	O
type	O
recipients	O
,	O
implanted	O
normally	O
,	O
indicating	O
that	O
uterine	O
receptivity	O
rather	O
than	O
the	O
embryo	O
's	O
competency	O
is	O
compromised	O
.	O
</ALL>	O

<ALL>	O
The	O
loss	O
of	O
Lifr	B-Gene
results	O
in	O
both	O
the	O
failure	O
for	O
STAT3	B-Gene
to	O
translocate	O
to	O
the	O
LE	O
nuclei	O
and	O
a	O
reduction	O
in	O
the	O
expression	O
of	O
the	O
LIF	B-Gene
regulated	O
gene	O
Msx1	B-Gene
that	O
regulates	O
uterine	O
receptivity	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
reveal	O
that	O
uterine	O
expression	O
of	O
the	O
LIFR	B-Gene
is	O
essential	O
for	O
embryo	O
implantation	O
and	O
further	O
define	O
the	O
components	O
of	O
the	O
LIF	B-Gene
signaling	O
pathway	O
necessary	O
for	O
effective	O
implantation	O
.	O
</ALL>	O

<ALL>	O
Genome	O
-	O
wide	O
loss	O
-	O
of	O
-	O
function	O
genetic	O
screening	O
identifies	O
opioid	B-Gene
receptor	I-Gene
u1	I-Gene
as	O
a	O
key	O
regulator	O
of	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
resistance	O
in	O
pediatric	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
.	O
</ALL>	O

<ALL>	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
is	O
a	O
critical	O
chemotherapeutic	O
agent	O
for	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
(	O
ALL	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
It	O
hydrolyzes	O
plasma	O
asparagine	B-Chemical
into	O
aspartate	B-Chemical
and	O
NH3	B-Chemical
,	O
causing	O
asparagine	B-Disease
deficit	I-Disease
and	O
inhibition	O
of	O
protein	O
synthesis	O
and	O
eventually	O
,	O
leukemic	B-Disease
cell	O
death	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
patient	B-Species
relapse	O
often	O
occurs	O
due	O
to	O
development	O
of	O
resistance	O
.	O
</ALL>	O

<ALL>	O
The	O
molecular	O
mechanism	O
by	O
which	O
ALL	B-Disease
cells	O
acquire	O
resistance	O
to	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
is	O
unknown	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
we	O
sought	O
to	O
identify	O
genes	O
that	O
are	O
involved	O
in	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
resistance	O
in	O
primary	O
leukemic	B-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
By	O
unbiased	O
genome	O
-	O
wide	O
RNAi	O
screening	O
,	O
we	O
found	O
that	O
among	O
10	O
resistant	O
ALL	B-Disease
clones	O
,	O
six	O
hits	O
were	O
for	O
opioid	B-Gene
receptor	I-Gene
mu	I-Gene
1	I-Gene
(	O
oprm1	B-Gene
)	O
,	O
two	O
hits	O
were	O
for	O
carbonic	B-Gene
anhydrase	I-Gene
1	I-Gene
(	O
ca1	B-Gene
)	O
and	O
another	O
two	O
hits	O
were	O
for	O
ubiquitin	B-Gene
-	I-Gene
conjugating	I-Gene
enzyme	I-Gene
E2C	I-Gene
(	O
ube2c	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
We	O
also	O
found	O
that	O
OPRM1	B-Gene
is	O
expressed	O
in	O
all	O
leukemic	B-Disease
cells	O
tested	O
.	O
</ALL>	O

<ALL>	O
Specific	O
knockdown	O
of	O
OPRM1	B-Gene
confers	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
resistance	O
,	O
validating	O
our	O
genome	O
-	O
wide	O
retroviral	O
shRNA	O
library	O
screening	O
data	O
.	O
</ALL>	O

<ALL>	O
Methadone	B-Chemical
,	O
an	O
agonist	O
of	O
OPRM1	B-Gene
,	O
enhances	O
the	O
sensitivity	O
of	O
parental	O
leukemic	B-Disease
cells	O
,	O
but	O
not	O
OPRM1	B-Gene
-	O
depleted	O
cells	O
,	O
to	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
treatment	O
,	O
indicating	O
that	O
OPRM1	B-Gene
is	O
required	O
for	O
the	O
synergistic	O
action	O
of	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
and	O
methadone	B-Chemical
,	O
and	O
that	O
OPRM1	B-Gene
loss	O
promotes	O
leukemic	B-Disease
cell	O
survival	O
likely	O
through	O
downregulation	O
of	O
the	O
OPRM1	B-Gene
-	O
mediated	O
apoptotic	O
pathway	O
.	O
</ALL>	O

<ALL>	O
Consistent	O
with	O
this	O
premise	O
,	O
patient	B-Species
leukemic	B-Disease
cells	O
with	O
relatively	O
high	O
levels	O
of	O
OPRM1	B-Gene
are	O
more	O
sensitive	O
to	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
treatment	O
compared	O
to	O
OPRM1	B-Gene
-	O
depleted	O
leukemic	B-Disease
cells	O
,	O
further	O
indicating	O
that	O
OPRM1	B-Gene
loss	O
has	O
a	O
crucial	O
role	O
in	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
resistance	O
in	O
leukemic	B-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
our	O
study	O
demonstrates	O
for	O
the	O
first	O
time	O
,	O
a	O
novel	O
OPRM1	B-Gene
-	O
mediated	O
mechanism	O
for	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
resistance	O
in	O
ALL	B-Disease
,	O
and	O
identifies	O
OPRM1	B-Gene
as	O
a	O
functional	O
biomarker	O
for	O
defining	O
high	O
-	O
risk	O
subpopulations	O
and	O
for	O
the	O
detection	O
of	O
evolving	O
resistant	O
clones	O
.	O
</ALL>	O

<ALL>	O
Oprm1	B-Gene
may	O
also	O
be	O
utilized	O
for	O
effective	O
treatment	O
of	O
L	B-Chemical
-	I-Chemical
asparaginase	I-Chemical
-	O
resistant	O
ALL	B-Disease
.Oncogene	O
advance	O
online	O
publication	O
,	O
26	O
June	O
2017	O
;	O
doi:10.1038	O
/	O
onc.2017.211	O
.	O
</ALL>	O

<ALL>	O
Photochemoprevention	O
of	O
ultraviolet	O
B	O
signaling	O
and	O
photocarcinogenesis	O
.	O
</ALL>	O

<ALL>	O
Exposure	O
to	O
solar	O
radiation	O
,	O
particularly	O
its	O
ultraviolet	O
(	O
UV	O
)	O
B	O
component	O
,	O
has	O
a	O
variety	O
of	O
harmful	O
effects	O
on	O
human	B-Species
health	O
.	O
</ALL>	O

<ALL>	O
Some	O
of	O
these	O
effects	O
include	O
sunburn	O
cell	O
formation	O
,	O
basal	B-Disease
and	I-Disease
squamous	I-Disease
cell	I-Disease
cancers	I-Disease
,	O
melanoma	B-Disease
,	O
cataracts	B-Disease
,	O
photoaging	O
of	O
the	O
skin	O
,	O
and	O
immune	O
suppression	O
.	O
</ALL>	O

<ALL>	O
Amongst	O
these	O
various	O
adverse	O
effects	O
of	O
UV	O
radiation	O
,	O
skin	B-Disease
cancer	I-Disease
is	O
of	O
the	O
greatest	O
concern	O
.	O
</ALL>	O

<ALL>	O
Over	O
the	O
years	O
,	O
changes	O
in	O
lifestyle	O
has	O
led	O
to	O
a	O
significant	O
increase	O
in	O
the	O
amount	O
of	O
UV	O
radiation	O
that	O
people	O
receive	O
,	O
and	O
this	O
consequently	O
has	O
led	O
to	O
a	O
surge	O
in	O
the	O
incidence	O
of	O
skin	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
development	O
of	O
skin	B-Disease
cancer	I-Disease
is	O
a	O
complex	O
multistage	O
phenomenon	O
involving	O
three	O
distinct	O
stages	O
exemplified	O
by	O
initiation	O
,	O
promotion	O
and	O
progression	O
stages	O
.	O
</ALL>	O

<ALL>	O
Each	O
of	O
these	O
stages	O
is	O
mediated	O
via	O
alterations	O
in	O
various	O
cellular	O
,	O
biochemical	O
,	O
and	O
molecular	O
changes	O
.	O
</ALL>	O

<ALL>	O
Initiation	O
,	O
the	O
first	O
step	O
in	O
the	O
carcinogenesis	B-Disease
process	O
is	O
essentially	O
an	O
irreversible	O
step	O
in	O
which	O
genetic	O
alterations	O
occur	O
in	O
genes	O
that	O
ultimately	O
leads	O
to	O
DNA	O
modification	O
and	O
fixation	O
of	O
mutation	O
.	O
</ALL>	O

<ALL>	O
Tumor	B-Disease
promotion	O
is	O
the	O
essential	O
process	O
in	O
cancer	B-Disease
development	O
involving	O
clonal	O
expansion	O
of	O
initiated	O
cells	O
giving	O
rise	O
to	O
pre	O
-	O
malignant	O
and	O
then	O
to	O
malignant	O
lesions	O
,	O
essentially	O
by	O
alterations	O
in	O
signal	O
transduction	O
pathways	O
.	O
</ALL>	O

<ALL>	O
Tumor	B-Disease
progression	O
involves	O
the	O
conversion	O
of	O
pre	O
-	O
malignant	O
and	O
malignant	O
lesions	O
into	O
an	O
invasive	O
and	O
potentially	O
metastatic	O
malignant	O
tumor	B-Disease
.	O
</ALL>	O

<ALL>	O
All	O
these	O
processes	O
for	O
skin	B-Disease
cancer	I-Disease
development	O
involve	O
stimulation	O
of	O
DNA	O
synthesis	O
,	O
DNA	O
damage	O
and	O
proliferation	O
,	O
inflammation	B-Disease
,	O
immunosuppression	O
,	O
epidermal	B-Disease
hyperplasia	I-Disease
,	O
cell	O
cycle	O
dysregulation	O
,	O
depletion	O
of	O
antioxidant	B-Chemical
defenses	O
,	O
impairment	O
of	O
signal	O
transduction	O
pathways	O
,	O
induction	O
of	O
cyclooxygenase	B-Gene
,	O
increase	O
in	O
prostaglandin	B-Chemical
synthesis	O
,	O
and	O
induction	O
of	O
ornithine	B-Gene
decarboxylase	I-Gene
.	O
</ALL>	O

<ALL>	O
Photochemoprevention	O
has	O
been	O
appreciated	O
as	O
a	O
viable	O
approach	O
to	O
reduce	O
the	O
occurrence	O
of	O
skin	B-Disease
cancer	I-Disease
and	O
in	O
recent	O
years	O
,	O
the	O
use	O
of	O
agents	O
,	O
especially	O
botanical	O
antioxidants	B-Chemical
,	O
present	O
in	O
the	O
common	O
diet	O
and	O
beverages	O
consumed	O
by	O
human	B-Species
population	O
have	O
gained	O
considerable	O
attention	O
as	O
photochemopreventive	O
agents	O
for	O
human	B-Species
use	O
.	O
</ALL>	O

<ALL>	O
Many	O
such	O
agents	O
have	O
also	O
found	O
a	O
place	O
in	O
skin	O
care	O
products	O
.	O
</ALL>	O

<ALL>	O
Although	O
this	O
is	O
more	O
common	O
in	O
oriental	O
countries	O
,	O
its	O
popularity	O
is	O
significantly	O
growing	O
in	O
western	O
countries	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
article	O
,	O
we	O
have	O
summarized	O
the	O
available	O
information	O
of	O
laboratory	O
studies	O
on	O
UVB	O
-	O
mediated	O
signaling	O
that	O
can	O
be	O
exploited	O
as	O
targets	O
for	O
photochemoprevention	O
.	O
</ALL>	O

<ALL>	O
We	O
suggest	O
that	O
the	O
use	O
of	O
skin	O
care	O
products	O
supplemented	O
with	O
proven	O
chemopreventive	O
agents	O
in	O
conjunction	O
with	O
the	O
use	O
of	O
sunscreens	O
along	O
with	O
educational	O
efforts	O
may	O
be	O
an	O
effective	O
strategy	O
for	O
reducing	O
UV	O
-	O
induced	O
photodamage	O
and	O
skin	B-Disease
cancer	I-Disease
in	O
humans	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
mechanistic	O
basis	O
for	O
the	O
use	O
of	O
such	O
products	O
is	O
discussed	O
.	O
</ALL>	O

<ALL>	O
A	O
G1103R	B-Variant
mutation	O
in	O
CRB1	B-Gene
is	O
co	O
-	O
inherited	O
with	O
high	O
hyperopia	B-Disease
and	O
Leber	B-Disease
congenital	I-Disease
amaurosis	I-Disease
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
To	O
identify	O
the	O
genetic	O
basis	O
of	O
recessive	O
inheritance	O
of	O
high	B-Disease
hyperopia	I-Disease
and	O
Leber	B-Disease
congenital	I-Disease
amaurosis	I-Disease
(	O
LCA	B-Disease
)	O
in	O
a	O
family	O
of	O
Middle	O
Eastern	O
origin	O
.	O
</ALL>	O

<ALL>	O
MATERIALS	O
AND	O
METHODS	O
:	O
The	O
patients	B-Species
were	O
examined	O
using	O
standard	O
ophthalmic	O
techniques	O
.	O
</ALL>	O

<ALL>	O
DNA	O
samples	O
were	O
obtained	O
and	O
genetic	O
linkage	O
was	O
carried	O
out	O
using	O
polymorphic	O
markers	O
flanking	O
the	O
known	O
genes	O
and	O
loci	O
for	O
LCA	B-Disease
.	O
</ALL>	O

<ALL>	O
Exons	O
were	O
amplified	O
and	O
sequenced	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
All	O
four	O
members	O
of	O
this	O
family	O
affected	O
by	O
LCA	B-Disease
showed	O
high	O
to	O
extreme	O
hyperopia	B-Disease
,	O
with	O
average	O
spherical	O
refractive	O
errors	O
ranging	O
from	O
+	O
5.00	O
to	O
+	O
10.00	O
.	O
</ALL>	O

<ALL>	O
Linkage	O
was	O
obtained	O
to	O
1q31.3	O
with	O
a	O
maximal	O
LOD	O
score	O
of	O
5.20	O
and	O
a	O
mutation	O
found	O
in	O
exon	O
9	O
of	O
the	O
CRB1	B-Gene
gene	O
,	O
causing	O
a	O
G1103R	B-Variant
substitution	O
at	O
a	O
highly	O
conserved	O
site	O
in	O
the	O
protein	O
.	O
</ALL>	O

<ALL>	O
CRB1	B-Gene
is	O
a	O
vertebrate	O
homolog	O
of	O
the	O
Drosophila	B-Species
crumbs	B-Gene
gene	O
,	O
which	O
is	O
required	O
for	O
photoreceptor	O
morphogenesis	O
,	O
and	O
has	O
been	O
associated	O
with	O
either	O
retinitis	B-Disease
pigmentosa	I-Disease
(	O
RP	B-Disease
)	O
or	O
LCA	B-Disease
.	O
</ALL>	O

<ALL>	O
This	O
sequence	O
variant	O
has	O
previously	O
been	O
reported	O
as	O
a	O
compound	O
heterozygote	O
in	O
one	O
sporadic	O
LCA	B-Disease
patient	B-Species
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Although	O
hyperopia	B-Disease
has	O
been	O
associated	O
with	O
LCA	B-Disease
,	O
it	O
is	O
typically	O
moderate	O
and	O
variable	O
between	O
patients	B-Species
with	O
the	O
same	O
mutation	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
some	O
CRB1	B-Gene
mutations	O
can	O
be	O
associated	O
with	O
either	O
RP	B-Disease
or	O
LCA	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
have	O
shown	O
that	O
hyperopia	B-Disease
and	O
LCA	B-Disease
are	O
linked	O
to	O
the	O
mutant	O
CRB1	B-Gene
gene	O
itself	O
and	O
are	O
not	O
dependent	O
on	O
unlinked	O
modifiers	O
.	O
</ALL>	O

<ALL>	O
MDMA	B-Chemical
polydrug	O
users	O
show	O
process	O
-	O
specific	O
central	O
executive	O
impairments	O
coupled	O
with	O
impaired	B-Disease
social	I-Disease
and	I-Disease
emotional	I-Disease
judgement	I-Disease
processes	I-Disease
.	O
</ALL>	O

<ALL>	O
In	O
recent	O
years	O
working	O
memory	B-Disease
deficits	I-Disease
have	O
been	O
reported	O
in	O
users	O
of	O
MDMA	B-Chemical
(	O
3,4	B-Chemical
-	I-Chemical
methylenedioxymethamphetamine	I-Chemical
,	O
ecstasy	B-Chemical
)	O
.	O
</ALL>	O

<ALL>	O
The	O
current	O
study	O
aimed	O
to	O
assess	O
the	O
impact	O
of	O
MDMA	B-Chemical
use	O
on	O
three	O
separate	O
central	O
executive	O
processes	O
(	O
set	O
shifting	O
,	O
inhibition	O
and	O
memory	O
updating	O
)	O
and	O
also	O
on	O
"	O
prefrontal	O
"	O
mediated	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O
</ALL>	O

<ALL>	O
Fifteen	O
polydrug	O
ecstasy	B-Chemical
users	O
and	O
15	O
polydrug	O
non	O
-	O
ecstasy	B-Chemical
user	O
controls	O
completed	O
a	O
general	O
drug	O
use	O
questionnaire	O
,	O
the	O
Brixton	O
Spatial	O
Anticipation	O
task	O
(	O
set	O
shifting	O
)	O
,	O
Backward	O
Digit	O
Span	O
procedure	O
(	O
memory	O
updating	O
)	O
,	O
Inhibition	O
of	O
Return	O
(	O
inhibition	O
)	O
,	O
an	O
emotional	O
intelligence	O
scale	O
,	O
the	O
Tromso	O
Social	O
Intelligence	O
Scale	O
and	O
the	O
Dysexecutive	O
Questionnaire	O
(	O
DEX	O
)	O
.	O
</ALL>	O

<ALL>	O
Compared	O
with	O
MDMA	B-Chemical
-	O
free	O
polydrug	O
controls	O
,	O
MDMA	B-Chemical
polydrug	O
users	O
showed	O
impairments	O
in	O
set	O
shifting	O
and	O
memory	O
updating	O
,	O
and	O
also	O
in	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O
</ALL>	O

<ALL>	O
The	O
latter	O
two	O
deficits	O
remained	O
significant	O
after	O
controlling	O
for	O
other	O
drug	O
use	O
.	O
</ALL>	O

<ALL>	O
These	O
data	O
lend	O
further	O
support	O
to	O
the	O
proposal	O
that	O
cognitive	O
processes	O
mediated	O
by	O
the	O
prefrontal	O
cortex	O
may	O
be	O
impaired	O
by	O
recreational	O
ecstasy	B-Chemical
use	O
.	O
</ALL>	O

<ALL>	O
Tumor	B-Disease
thymidylate	B-Gene
synthase	I-Gene
1494del6	B-Variant
genotype	O
as	O
a	O
prognostic	O
factor	O
in	O
colorectal	B-Disease
cancer	I-Disease
patients	B-Species
receiving	O
fluorouracil	B-Chemical
-	O
based	O
adjuvant	O
treatment	O
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
value	O
of	O
germline	O
and	O
tumor	B-Disease
thymidylate	B-Gene
synthase	I-Gene
(	O
TS	B-Gene
)	O
genotyping	O
as	O
a	O
prognostic	O
marker	O
in	O
a	O
series	O
of	O
colorectal	B-Disease
cancer	I-Disease
patients	B-Species
receiving	O
adjuvant	O
fluorouracil	B-Chemical
(	O
FU	B-Chemical
)	O
-	O
based	O
treatment	O
.	O
</ALL>	O

<ALL>	O
PATIENTS	B-Species
AND	O
METHODS	O
:	O
One	O
hundred	O
twenty	O
-	O
nine	O
colorectal	B-Disease
cancer	I-Disease
patients	B-Species
homogeneously	O
treated	O
with	O
FU	B-Chemical
plus	O
levamisole	B-Chemical
or	O
leucovorin	B-Chemical
in	O
the	O
adjuvant	O
setting	O
were	O
included	O
.	O
</ALL>	O

<ALL>	O
TS	B-Gene
enhancer	O
region	O
,	O
3R	O
G	B-Variant
>	I-Variant
C	I-Variant
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
,	O
and	O
TS	B-Gene
1494del6	B-Variant
polymorphisms	O
were	O
assessed	O
in	O
both	O
fresh	O
-	O
frozen	O
normal	O
mucosa	O
and	O
tumor	B-Disease
.	O
</ALL>	O

<ALL>	O
Mutational	O
analyses	O
of	O
TS	B-Gene
and	O
allelic	O
imbalances	O
were	O
studied	O
in	O
all	O
primary	O
tumors	B-Disease
and	O
in	O
18	O
additional	O
metachronic	O
metastases	B-Disease
.	O
</ALL>	O

<ALL>	O
TS	B-Gene
protein	O
immunostaining	O
was	O
assessed	O
in	O
an	O
expanded	O
series	O
of	O
214	O
tumors	B-Disease
.	O
</ALL>	O

<ALL>	O
Multivariate	O
Cox	O
models	O
were	O
adjusted	O
for	O
stage	O
,	O
differentiation	O
,	O
and	O
location	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Tumor	B-Disease
genotyping	O
(	O
frequency	O
of	O
allelic	O
loss	O
,	O
26	O
%	O
)	O
showed	O
that	O
the	O
3R	O
/	O
3R	O
genotype	O
was	O
associated	O
with	O
a	O
better	O
outcome	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
=	O
0.38	O
;	O
95	O
%	O
CI	O
,	O
0.16	O
to	O
0.93	O
;	O
P	O
=	O
.020	O
for	O
the	O
recessive	O
model	O
)	O
.	O
</ALL>	O

<ALL>	O
3R	O
G	B-Variant
>	I-Variant
C	I-Variant
SNP	O
genotyping	O
did	O
not	O
add	O
prognostic	O
information	O
.	O
</ALL>	O

<ALL>	O
Tumor	B-Disease
TS	B-Gene
1494del6	B-Variant
allele	O
(	O
frequency	O
of	O
allelic	O
loss	O
,	O
36	O
%	O
)	O
was	O
protective	O
(	O
for	O
each	O
allele	O
with	O
the	O
deletion	O
,	O
based	O
on	O
an	O
additive	O
model	O
,	O
HR	O
=	O
0.42	O
;	O
95	O
%	O
CI	O
,	O
0.22	O
to	O
0.82	O
;	O
P	O
=	O
.0034	O
)	O
.	O
</ALL>	O

<ALL>	O
Both	O
polymorphisms	O
were	O
in	O
strong	O
linkage	O
disequilibrium	O
(	O
D	O
'	O
=	O
0.71	O
,	O
P	O
<	O
.001	O
)	O
,	O
and	O
the	O
3R	O
/	O
-	O
6	O
base	O
pair	O
(	O
bp	O
)	O
haplotype	O
showed	O
a	O
significant	O
overall	O
survival	O
benefit	O
compared	O
with	O
the	O
most	O
prevalent	O
haplotype	O
2R	O
/	O
+	O
6bp	O
(	O
HR	O
=	O
0.42	O
;	O
95	O
%	O
CI	O
,	O
0.20	O
to	O
0.85	O
;	O
P	O
=	O
.017	O
)	O
.	O
</ALL>	O

<ALL>	O
No	O
TS	B-Gene
point	O
mutation	O
was	O
detected	O
in	O
primary	O
tumors	B-Disease
or	O
metastases	B-Disease
.	O
</ALL>	O

<ALL>	O
TS	B-Gene
protein	O
immunostaining	O
was	O
not	O
associated	O
with	O
survival	O
or	O
any	O
of	O
the	O
genotypes	O
analyzed	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Tumor	B-Disease
TS	B-Gene
1494del6	B-Variant
genotype	O
may	O
be	O
a	O
prognostic	O
factor	O
in	O
FU	B-Chemical
-	O
based	O
adjuvant	O
treatment	O
of	O
colorectal	B-Disease
cancer	I-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Valproate	B-Chemical
-	O
induced	O
chorea	B-Disease
and	O
encephalopathy	B-Disease
in	O
atypical	O
nonketotic	B-Disease
hyperglycinemia	I-Disease
.	O
</ALL>	O

<ALL>	O
Nonketotic	B-Disease
hyperglycinemia	I-Disease
is	O
a	O
disorder	B-Disease
of	I-Disease
amino	I-Disease
acid	I-Disease
metabolism	I-Disease
in	O
which	O
a	O
defect	O
in	O
the	O
glycine	B-Chemical
cleavage	O
system	O
leads	O
to	O
an	O
accumulation	O
of	O
glycine	B-Chemical
in	O
the	O
brain	O
and	O
other	O
body	O
compartments	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
classical	O
form	O
it	O
presents	O
as	O
neonatal	O
apnea	B-Disease
,	O
intractable	O
seizures	B-Disease
,	O
and	O
hypotonia	B-Disease
,	O
followed	O
by	O
significant	O
psychomotor	B-Disease
retardation	I-Disease
.	O
</ALL>	O

<ALL>	O
An	O
important	O
subset	O
of	O
children	O
with	O
nonketotic	B-Disease
hyperglycinemia	I-Disease
are	O
atypical	O
variants	O
who	O
present	O
in	O
a	O
heterogeneous	O
manner	O
.	O
</ALL>	O

<ALL>	O
This	O
report	O
describes	O
a	O
patient	B-Species
with	O
mild	O
language	B-Disease
delay	I-Disease
and	O
mental	B-Disease
retardation	I-Disease
,	O
who	O
was	O
found	O
to	O
have	O
nonketotic	B-Disease
hyperglycinemia	I-Disease
following	O
her	O
presentation	O
with	O
acute	O
encephalopathy	B-Disease
and	O
chorea	B-Disease
shortly	O
after	O
initiation	O
of	O
valproate	B-Chemical
therapy	O
.	O
</ALL>	O

<ALL>	O
Bone	B-Gene
morphogenetic	I-Gene
protein	I-Gene
-	I-Gene
4	I-Gene
interacts	O
with	O
activin	B-Gene
and	O
GnRH	B-Gene
to	O
modulate	O
gonadotrophin	B-Gene
secretion	O
in	O
LbetaT2	B-CellLine
gonadotrophs	O
.	O
</ALL>	O

<ALL>	O
We	O
have	O
shown	O
previously	O
that	O
,	O
in	O
sheep	B-Species
primary	O
pituitary	O
cells	O
,	O
bone	B-Gene
morphogenetic	I-Gene
proteins	I-Gene
(	I-Gene
BMP	I-Gene
)	I-Gene
-	I-Gene
4	I-Gene
inhibits	O
FSHbeta	B-Gene
mRNA	O
expression	O
and	O
FSH	B-Gene
release	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
in	O
mouse	B-Species
LbetaT2	B-CellLine
gonadotrophs	O
,	O
others	O
have	O
shown	O
a	O
stimulatory	O
effect	O
of	O
BMPs	B-Gene
on	O
basal	O
or	O
activin	B-Gene
-	O
stimulated	O
FSHbeta	B-Gene
promoter	O
-	O
driven	O
transcription	O
.	O
</ALL>	O

<ALL>	O
As	O
a	O
species	O
comparison	O
with	O
our	O
previous	O
results	O
,	O
we	O
used	O
LbetaT2	B-CellLine
cells	O
to	O
investigate	O
the	O
effects	O
of	O
BMP	B-Gene
-	I-Gene
4	I-Gene
on	O
gonadotrophin	B-Gene
mRNA	O
and	O
secretion	O
modulated	O
by	O
activin	B-Gene
and	O
GnRH	B-Gene
.	O
</ALL>	O

<ALL>	O
BMP	B-Gene
-	I-Gene
4	I-Gene
alone	O
had	O
no	O
effect	O
on	O
FSH	B-Gene
production	O
,	O
but	O
enhanced	O
the	O
activin	B-Gene
+	O
GnRH	B-Gene
-	O
induced	O
stimulation	O
of	O
FSHbeta	B-Gene
mRNA	O
and	O
FSH	B-Gene
secretion	O
,	O
without	O
any	O
effect	O
on	O
follistatin	B-Gene
mRNA	O
.	O
</ALL>	O

<ALL>	O
BMP	B-Gene
-	I-Gene
4	I-Gene
reduced	O
LHbeta	B-Gene
mRNA	O
up	O
-	O
regulation	O
in	O
response	O
to	O
GnRH	B-Gene
(	O
+	O
/	O
-	O
activin	B-Gene
)	O
and	O
decreased	O
GnRH	B-Gene
receptor	I-Gene
expression	O
,	O
which	O
would	O
favour	O
FSH	B-Gene
,	O
rather	O
than	O
LH	B-Gene
,	O
synthesis	O
and	O
secretion	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
to	O
sheep	B-Species
pituitary	O
gonadotrophs	O
,	O
which	O
express	O
only	O
BMP	B-Gene
receptor	I-Gene
types	I-Gene
IA	I-Gene
(	I-Gene
BMPRIA	I-Gene
)	I-Gene
and	I-Gene
II	I-Gene
(	I-Gene
BMPRII	I-Gene
)	I-Gene
,	O
LbetaT2	B-CellLine
cells	O
also	O
express	O
BMPRIB	B-Gene
.	O
</ALL>	O

<ALL>	O
Smad1	B-Gene
/	I-Gene
5	I-Gene
phosphorylation	O
induced	O
by	O
BMP	B-Gene
-	I-Gene
4	I-Gene
,	O
indicating	O
activation	O
of	O
BMP	B-Gene
signalling	O
,	O
was	O
the	O
same	O
whether	O
BMP	B-Gene
-	I-Gene
4	I-Gene
was	O
used	O
alone	O
or	O
combined	O
with	O
activin	B-Gene
+	O
/	O
-	O
GnRH	B-Gene
.	O
</ALL>	O

<ALL>	O
We	O
hypothesized	O
that	O
activin	B-Gene
and	O
/	O
or	O
GnRH	B-Gene
pathways	O
may	O
be	O
modulated	O
by	O
BMP	B-Gene
-	I-Gene
4	I-Gene
,	O
but	O
neither	O
the	O
activin	B-Gene
-	O
stimulated	O
phosphorylation	O
of	O
Smad2	B-Gene
/	I-Gene
3	I-Gene
nor	O
the	O
GnRH	B-Gene
-	O
induced	O
ERK1	B-Gene
/	I-Gene
2	I-Gene
or	O
cAMP	B-Gene
response	I-Gene
element	I-Gene
-	I-Gene
binding	I-Gene
phosphorylation	O
were	O
modified	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
GnRH	B-Gene
-	O
induced	O
activation	O
of	O
p38	B-Gene
MAPK	I-Gene
was	O
decreased	O
by	O
BMP	B-Gene
-	I-Gene
4	I-Gene
.	O
</ALL>	O

<ALL>	O
This	O
was	O
associated	O
with	O
increased	O
FSHbeta	B-Gene
mRNA	O
levels	O
and	O
FSH	B-Gene
secretion	O
,	O
but	O
decreased	O
LHbeta	B-Gene
mRNA	O
levels	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
confirm	O
1	O
.	O
</ALL>	O

<ALL>	O
BMPs	B-Gene
as	O
important	O
modulators	O
of	O
activin	B-Gene
and	O
/	O
or	O
GnRH	B-Gene
-	O
stimulated	O
gonadotrophin	B-Gene
synthesis	O
and	O
release	O
and	O
2	O
.	O
</ALL>	O

<ALL>	O
important	O
species	O
differences	O
in	O
these	O
effects	O
,	O
which	O
could	O
relate	O
to	O
differences	O
in	O
BMP	B-Gene
receptor	I-Gene
expression	O
in	O
gonadotrophs	O
.	O
</ALL>	O

<ALL>	O
Combination	O
of	O
polymorphisms	O
within	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
of	O
thymidylate	B-Gene
synthase	I-Gene
gene	O
modulates	O
survival	O
in	O
5	B-Chemical
fluorouracil	I-Chemical
-	O
treated	O
colorectal	B-Disease
cancer	I-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
study	O
we	O
explored	O
the	O
effect	O
of	O
three	O
polymorphisms	O
of	O
the	O
TS	B-Gene
gene	O
on	O
overall	O
and	O
progression	O
-	O
free	O
survival	O
of	O
colorectal	B-Disease
cancer	I-Disease
(	O
CRC	B-Disease
)	O
patients	B-Species
subjected	O
to	O
5FU	B-Chemical
chemotherapy	O
.	O
</ALL>	O

<ALL>	O
A	O
28	B-Variant
bp	I-Variant
variable	I-Variant
number	I-Variant
of	I-Variant
tandem	I-Variant
repeats	I-Variant
(	O
VNTR	O
)	O
,	O
a	O
G	B-Variant
/	I-Variant
C	I-Variant
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
,	O
and	O
a	O
deletion	B-Variant
of	I-Variant
6	I-Variant
bp	I-Variant
at	I-Variant
position	I-Variant
1494	I-Variant
were	O
studied	O
.	O
</ALL>	O

<ALL>	O
The	O
possible	O
combined	O
effect	O
of	O
these	O
DNA	O
polymorphisms	O
on	O
the	O
clinical	O
outcome	O
of	O
patients	B-Species
was	O
also	O
evaluated	O
.	O
</ALL>	O

<ALL>	O
A	O
retrospective	O
study	O
was	O
carried	O
out	O
on	O
paraffin	B-Chemical
-	O
embedded	O
sections	O
from	O
113	O
patients	B-Species
diagnosed	O
of	O
advanced	O
CRC	B-Disease
.	O
</ALL>	O

<ALL>	O
TS	B-Gene
genotyping	O
methods	O
were	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
for	O
VNTR	O
and	O
PCR	O
,	O
followed	O
by	O
restriction	O
length	O
fragment	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
for	O
SNP	O
and	O
ins	B-Variant
/	I-Variant
del	I-Variant
6	I-Variant
bp	I-Variant
.	O
</ALL>	O

<ALL>	O
To	O
study	O
the	O
combined	O
effect	O
of	O
TS	B-Gene
polymorphisms	O
,	O
four	O
categories	O
were	O
defined	O
accordingly	O
to	O
the	O
level	O
of	O
expression	O
attributed	O
to	O
SNP	O
and	O
ins	B-Variant
/	I-Variant
del	I-Variant
6	I-Variant
bp	I-Variant
genotypes	O
:	O
C	O
_	O
allele	O
6	O
-	O
,	O
C	O
_	O
6	O
+	O
/	O
6	O
+	O
,	O
G	O
_	O
allele6	O
-	O
and	O
G	O
_	O
6	O
+	O
/	O
6	O
+	O
.	O
</ALL>	O

<ALL>	O
VNTR	O
and	O
ins	B-Variant
/	I-Variant
del	I-Variant
6	I-Variant
bp	I-Variant
genotypes	O
varied	O
with	O
tumour	B-Disease
anatomical	O
site	O
:	O
2R	O
/	O
2R	O
genotype	O
was	O
rare	O
in	O
left	O
-	O
sided	O
tumours	B-Disease
(	O
7.0	O
%	O
vs.	O
26.3	O
%	O
of	O
right	O
-	O
sided	O
and	O
24.1	O
%	O
of	O
rectal	B-Disease
cancers	I-Disease
;	O
P	O
<	O
0.01	O
)	O
,	O
where	O
the	O
variant	O
allele	O
6	O
-	O
was	O
very	O
frequent	O
(	O
69.0	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
Instead	O
,	O
most	O
patients	B-Species
with	O
right	O
-	O
sided	O
tumours	B-Disease
were	O
wild	O
-	O
type	O
homozygous	O
6	O
+	O
/	O
6	O
+	O
(	O
63.9	O
%	O
)	O
(	O
P	O
<	O
0.01	O
)	O
.	O
</ALL>	O

<ALL>	O
Heterozygous	O
6	O
+	O
/	O
6	O
-	O
genotype	O
was	O
more	O
frequent	O
among	O
tumours	B-Disease
classified	O
as	O
C	O
(	O
50.0	O
%	O
)	O
and	O
D	O
(	O
76.5	O
%	O
)	O
Dukes	O
stages	O
(	O
P	O
=	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
None	O
of	O
the	O
studied	O
polymorphisms	O
alone	O
affected	O
overall	O
or	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
.	O
</ALL>	O

<ALL>	O
C	O
_	O
6	O
+	O
/	O
6	O
+	O
and	O
G	O
_	O
6	O
+	O
/	O
6	O
+	O
combined	O
genotypes	O
were	O
respectively	O
associated	O
to	O
the	O
best	O
and	O
worst	O
PFS	O
(	O
P	O
=	O
0.03	O
when	O
compared	O
with	O
each	O
other	O
)	O
,	O
while	O
combinations	O
carrying	O
the	O
allele	O
6	O
-	O
determined	O
an	O
intermediate	O
evolution	O
that	O
might	O
be	O
indicative	O
of	O
a	O
variable	O
response	O
to	O
chemotherapy	O
.	O
</ALL>	O

<ALL>	O
The	O
rate	O
of	O
Dukes	O
B	O
stage	O
tumours	B-Disease
was	O
unexpectedly	O
high	O
(	O
59.1	O
%	O
)	O
among	O
patients	B-Species
with	O
the	O
unfavourable	O
G	O
_	O
6	O
+	O
/	O
6	O
+	O
combination	O
.	O
</ALL>	O

<ALL>	O
In	O
our	O
study	O
the	O
combination	O
of	O
high	O
TS	B-Gene
expression	O
genotypes	O
G	O
_	O
6	O
+	O
/	O
6	O
+	O
identifies	O
a	O
group	O
of	O
high	O
risk	O
within	O
CRC	B-Disease
patients	B-Species
treated	O
with	O
5FU	B-Chemical
.	O
</ALL>	O

<ALL>	O
Phosphatidylinositol	B-Gene
3	I-Gene
-	I-Gene
kinase	I-Gene
p85alpha	B-Gene
regulatory	O
subunit	O
gene	O
Met326Ile	B-Variant
polymorphism	O
in	O
women	B-Species
with	O
polycystic	B-Disease
ovary	I-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Insulin	B-Disease
resistance	I-Disease
is	O
a	O
core	O
feature	O
of	O
polycystic	B-Disease
ovary	I-Disease
syndrome	I-Disease
(	O
PCOS	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Phosphatidylinositol	B-Gene
(	I-Gene
PI	I-Gene
)	I-Gene
3	I-Gene
-	I-Gene
kinase	I-Gene
is	O
an	O
important	O
enzyme	O
in	O
the	O
early	O
insulin	B-Gene
signaling	O
cascade	O
and	O
plays	O
a	O
key	O
role	O
in	O
insulin	B-Gene
-	O
mediated	O
glucose	B-Chemical
transport	O
.	O
</ALL>	O

<ALL>	O
In	O
its	O
regulatory	O
subunit	O
,	O
p85alpha	B-Gene
,	O
there	O
is	O
a	O
common	O
amino	O
acid	O
substitution	O
(	O
the	O
Met326Ile	B-Variant
polymorphism	O
)	O
,	O
and	O
this	O
amino	O
acid	O
may	O
be	O
crucial	O
for	O
the	O
function	O
of	O
the	O
p85alpha	B-Gene
regulatory	O
subunit	O
and	O
PI3	B-Gene
-	I-Gene
kinase	I-Gene
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Analysis	O
of	O
the	O
Met326Ile	B-Variant
polymorphism	O
was	O
carried	O
out	O
on	O
DNA	O
samples	O
from	O
256	O
PCOS	B-Disease
patients	B-Species
and	O
283	O
controls	O
.	O
</ALL>	O

<ALL>	O
Clinical	O
and	O
biochemical	O
profiles	O
of	O
participants	O
were	O
also	O
compared	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
genotype	O
distribution	O
of	O
the	O
Met326Ile	B-Variant
polymorphism	O
in	O
the	O
PCOS	B-Disease
group	O
was	O
not	O
different	O
from	O
that	O
of	O
the	O
controls	O
(	O
Met326Met	B-Variant
/	O
Met326Ile	B-Variant
/	O
Ile326Ile	B-Variant
rates	O
were	O
73.4	O
%	O
/	O
23.4	O
%	O
/	O
3.2	O
%	O
and	O
70.3	O
%	O
/	O
26.1	O
%	O
/	O
3.6	O
%	O
for	O
the	O
PCOS	B-Disease
and	O
control	O
groups	O
,	O
respectively	O
,	O
P	O
=	O
0.72	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
PCOS	B-Disease
group	O
was	O
divided	O
into	O
two	O
subgroups	O
according	O
to	O
the	O
presence	O
of	O
the	O
variant	O
326Ile	B-Variant
allele	O
.	O
</ALL>	O

<ALL>	O
Compared	O
with	O
those	O
carrying	O
at	O
least	O
one	O
variant	O
326Ile	B-Variant
allele	O
,	O
carriers	O
with	O
the	O
Met326Met	B-Variant
genotype	O
had	O
higher	O
serum	O
17	B-Chemical
-	I-Chemical
hydroxyprogesterone	I-Chemical
(	O
17	B-Chemical
-	I-Chemical
OHP	I-Chemical
)	O
{	O
1.1	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.1	O
-	O
1.3	O
]	O
ng	O
/	O
ml	O
in	O
those	O
with	O
the	O
Met326Met	B-Variant
genotype	O
versus	O
0.8	O
(	O
95	O
%	O
CI	O
0.7	O
-	O
1.0	O
)	O
ng	O
/	O
ml	O
in	O
those	O
with	O
Ile326Ile	B-Variant
and	O
Met326Ile	B-Variant
genotypes	O
,	O
P	O
=	O
0.0073	O
}	O
and	O
free	O
testosterone	B-Chemical
levels	O
[	O
1.2	O
(	O
95	O
%	O
CI	O
1.1	O
-	O
1.4	O
)	O
pg	O
/	O
ml	O
for	O
Met326Met	B-Variant
genotype	O
versus	O
0.9	O
(	O
95	O
%	O
CI	O
0.6	O
-	O
1.3	O
)	O
pg	O
/	O
ml	O
for	O
Ile326Ile	B-Variant
and	O
Met326Ile	B-Variant
genotypes	O
,	O
P	O
=	O
0.038	O
]	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
PI3	B-Gene
-	I-Gene
kinase	I-Gene
gene	O
Met326Ile	B-Variant
polymorphism	O
may	O
not	O
be	O
a	O
major	O
determinant	O
for	O
the	O
development	O
of	O
PCOS	B-Disease
,	O
but	O
it	O
may	O
modulate	O
the	O
concentrations	O
of	O
serum	O
17	B-Chemical
-	I-Chemical
OHP	I-Chemical
or	O
free	O
testosterone	B-Chemical
in	O
PCOS	B-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
High	O
-	O
dose	O
tranexamic	B-Chemical
Acid	I-Chemical
is	O
associated	O
with	O
nonischemic	O
clinical	O
seizures	B-Disease
in	O
cardiac	O
surgical	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
In	O
2	O
separate	O
centers	O
,	O
we	O
observed	O
a	O
notable	O
increase	O
in	O
the	O
incidence	O
of	O
postoperative	O
convulsive	B-Disease
seizures	I-Disease
from	O
1.3	O
%	O
to	O
3.8	O
%	O
in	O
patients	B-Species
having	O
undergone	O
major	O
cardiac	O
surgical	O
procedures	O
.	O
</ALL>	O

<ALL>	O
These	O
events	O
were	O
temporally	O
coincident	O
with	O
the	O
initial	O
use	O
of	O
high	O
-	O
dose	O
tranexamic	B-Chemical
acid	I-Chemical
(	O
TXA	B-Chemical
)	O
therapy	O
after	O
withdrawal	O
of	O
aprotinin	O
from	O
general	O
clinical	O
usage	O
.	O
</ALL>	O

<ALL>	O
The	O
purpose	O
of	O
this	O
review	O
was	O
to	O
perform	O
a	O
retrospective	O
analysis	O
to	O
examine	O
whether	O
there	O
was	O
a	O
relation	O
between	O
TXA	B-Chemical
usage	O
and	O
seizures	B-Disease
after	O
cardiac	O
surgery	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
An	O
in	O
-	O
depth	O
chart	O
review	O
was	O
undertaken	O
in	O
all	O
24	O
patients	B-Species
who	O
developed	O
perioperative	O
seizures	B-Disease
.	O
</ALL>	O

<ALL>	O
Electroencephalographic	O
activity	O
was	O
recorded	O
in	O
11	O
of	O
these	O
patients	B-Species
,	O
and	O
all	O
patients	B-Species
had	O
a	O
formal	O
neurological	O
evaluation	O
and	O
brain	O
imaging	O
studies	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Twenty	O
-	O
one	O
of	O
the	O
24	O
patients	B-Species
did	O
not	O
have	O
evidence	O
of	O
new	O
cerebral	B-Disease
ischemic	I-Disease
injury	I-Disease
,	O
but	O
seizures	B-Disease
were	O
likely	O
due	O
to	O
ischemic	B-Disease
brain	I-Disease
injury	I-Disease
in	O
3	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
All	O
patients	B-Species
with	O
seizures	B-Disease
did	O
not	O
have	O
permanent	O
neurological	B-Disease
abnormalities	I-Disease
.	O
</ALL>	O

<ALL>	O
All	O
24	O
patients	B-Species
with	O
seizures	B-Disease
received	O
high	O
doses	O
of	O
TXA	B-Chemical
intraoperatively	O
ranging	O
from	O
61	O
to	O
259	O
mg	O
/	O
kg	O
,	O
had	O
a	O
mean	O
age	O
of	O
69.9	O
years	O
,	O
and	O
21	O
of	O
24	O
had	O
undergone	O
open	O
chamber	O
rather	O
than	O
coronary	O
bypass	O
procedures	O
.	O
</ALL>	O

<ALL>	O
All	O
but	O
one	O
patient	B-Species
were	O
managed	O
using	O
cardiopulmonary	O
bypass	O
.	O
</ALL>	O

<ALL>	O
No	O
evidence	O
of	O
brain	B-Disease
ischemic	I-Disease
,	O
metabolic	O
,	O
or	O
hyperthermia	B-Disease
-	O
induced	O
causes	O
for	O
their	O
seizures	B-Disease
was	O
apparent	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
use	O
of	O
high	O
-	O
dose	O
TXA	B-Chemical
in	O
older	O
patients	B-Species
in	O
conjunction	O
with	O
cardiopulmonary	O
bypass	O
and	O
open	O
-	O
chamber	O
cardiac	O
surgery	O
is	O
associated	O
with	O
clinical	O
seizures	B-Disease
in	O
susceptible	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Cocaine	B-Chemical
causes	O
memory	B-Disease
and	I-Disease
learning	I-Disease
impairments	I-Disease
in	O
rats	B-Species
:	O
involvement	O
of	O
nuclear	B-Gene
factor	I-Gene
kappa	I-Gene
B	I-Gene
and	O
oxidative	O
stress	O
,	O
and	O
prevention	O
by	O
topiramate	B-Chemical
.	O
</ALL>	O

<ALL>	O
Different	O
mechanisms	O
have	O
been	O
suggested	O
for	O
cocaine	B-Chemical
toxicity	B-Disease
including	O
an	O
increase	O
in	O
oxidative	O
stress	O
but	O
the	O
association	O
between	O
oxidative	O
status	O
in	O
the	O
brain	O
and	O
cocaine	B-Chemical
induced	O
-	O
behaviour	O
is	O
poorly	O
understood	O
.	O
</ALL>	O

<ALL>	O
Nuclear	B-Gene
factor	I-Gene
kappa	I-Gene
B	I-Gene
(	O
NFkappaB	B-Gene
)	O
is	O
a	O
sensor	O
of	O
oxidative	O
stress	O
and	O
participates	O
in	O
memory	O
formation	O
that	O
could	O
be	O
involved	O
in	O
drug	O
toxicity	B-Disease
and	O
addiction	O
mechanisms	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
NFkappaB	B-Gene
activity	O
,	O
oxidative	O
stress	O
,	O
neuronal	B-Gene
nitric	I-Gene
oxide	I-Gene
synthase	I-Gene
(	O
nNOS	B-Gene
)	O
activity	O
,	O
spatial	O
learning	O
and	O
memory	O
as	O
well	O
as	O
the	O
effect	O
of	O
topiramate	B-Chemical
,	O
a	O
previously	O
proposed	O
therapy	O
for	O
cocaine	B-Disease
addiction	I-Disease
,	O
were	O
evaluated	O
in	O
an	O
experimental	O
model	O
of	O
cocaine	B-Chemical
administration	O
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
NFkappaB	B-Gene
activity	O
was	O
decreased	O
in	O
the	O
frontal	O
cortex	O
of	O
cocaine	B-Chemical
treated	O
rats	B-Species
,	O
as	O
well	O
as	O
GSH	B-Chemical
concentration	O
and	O
glutathione	B-Gene
peroxidase	I-Gene
activity	O
in	O
the	O
hippocampus	O
,	O
whereas	O
nNOS	B-Gene
activity	O
in	O
the	O
hippocampus	O
was	O
increased	O
.	O
</ALL>	O

<ALL>	O
Memory	O
retrieval	O
of	O
experiences	O
acquired	O
prior	O
to	O
cocaine	B-Chemical
administration	O
was	O
impaired	O
and	O
negatively	O
correlated	O
with	O
NFkappaB	B-Gene
activity	O
in	O
the	O
frontal	O
cortex	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
learning	O
of	O
new	O
tasks	O
was	O
enhanced	O
and	O
correlated	O
with	O
the	O
increase	O
of	O
nNOS	B-Gene
activity	O
and	O
the	O
decrease	O
of	O
glutathione	B-Gene
peroxidase	I-Gene
.	O
</ALL>	O

<ALL>	O
These	O
results	O
provide	O
evidence	O
for	O
a	O
possible	O
mechanistic	O
role	O
of	O
oxidative	O
and	O
nitrosative	O
stress	O
and	O
NFkappaB	B-Gene
in	O
the	O
alterations	O
induced	O
by	O
cocaine	B-Chemical
.	O
</ALL>	O

<ALL>	O
Topiramate	B-Chemical
prevented	O
all	O
the	O
alterations	O
observed	O
,	O
showing	O
novel	O
neuroprotective	O
properties	O
.	O
</ALL>	O

<ALL>	O
Antioxidant	B-Chemical
effects	O
of	O
bovine	B-Species
lactoferrin	B-Gene
on	O
dexamethasone	B-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
rat	B-Species
.	O
</ALL>	O

<ALL>	O
Dexamethasone	B-Chemical
-	O
(	O
Dex	B-Chemical
-	O
)	O
induced	O
hypertension	B-Disease
is	O
associated	O
with	O
enhanced	O
oxidative	O
stress	O
.	O
</ALL>	O

<ALL>	O
Lactoferrin	B-Gene
(	O
LF	B-Gene
)	O
is	O
an	O
iron	B-Chemical
-	O
binding	O
glycoprotein	B-Gene
with	O
antihypertensive	O
properties	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
chronic	O
administration	O
of	O
LF	B-Gene
on	O
oxidative	O
stress	O
and	O
hypertension	B-Disease
upon	O
Dex	B-Chemical
administration	O
.	O
</ALL>	O

<ALL>	O
Male	O
Wistar	O
rats	B-Species
were	O
treated	O
by	O
Dex	B-Chemical
(	O
30	O
u	O
g	O
/	O
kg	O
/	O
day	O
subcutaneously	O
)	O
or	O
saline	O
for	O
14	O
days	O
.	O
</ALL>	O

<ALL>	O
Oral	O
bovine	B-Species
LF	B-Gene
(	O
30	O
,	O
100	O
,	O
300	O
mg	O
/	O
kg	O
)	O
was	O
given	O
from	O
day	O
8	O
to	O
14	O
in	O
a	O
reversal	O
study	O
.	O
</ALL>	O

<ALL>	O
In	O
a	O
prevention	O
study	O
,	O
rats	B-Species
received	O
4	O
days	O
of	O
LF	B-Gene
treatment	O
followed	O
by	O
Dex	B-Chemical
and	O
continued	O
during	O
the	O
test	O
period	O
.	O
</ALL>	O

<ALL>	O
Systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
was	O
measured	O
using	O
tail	O
-	O
cuff	O
method	O
.	O
</ALL>	O

<ALL>	O
Thymus	O
weight	O
was	O
used	O
as	O
a	O
marker	O
of	O
glucocorticoid	B-Chemical
activity	O
.	O
</ALL>	O

<ALL>	O
Plasma	O
hydrogen	B-Chemical
peroxide	I-Chemical
(	O
H2O2	B-Chemical
)	O
concentration	O
and	O
ferric	B-Chemical
reducing	O
antioxidant	O
power	O
(	O
FRAP	O
)	O
value	O
were	O
determined	O
.	O
</ALL>	O

<ALL>	O
Dexamethasone	B-Chemical
significantly	O
increased	O
SBP	O
and	O
plasma	O
H2O2	B-Chemical
level	O
and	O
decreased	O
thymus	O
and	O
body	O
weights	O
.	O
</ALL>	O

<ALL>	O
LF	B-Gene
lowered	O
(	O
P	O
<	O
0.01	O
)	O
and	O
dose	O
dependently	O
prevented	O
(	O
P	O
<	O
0.001	O
)	O
Dex	B-Chemical
-	O
induced	O
hypertension	B-Disease
.	O
</ALL>	O

<ALL>	O
LF	B-Gene
prevented	O
body	O
weight	B-Disease
loss	I-Disease
and	O
significantly	O
reduced	O
the	O
elevated	O
plasma	O
H2O2	B-Chemical
and	O
increased	O
FRAP	O
values	O
.	O
</ALL>	O

<ALL>	O
Chronic	O
administration	O
of	O
LF	B-Gene
strongly	O
reduced	O
the	O
blood	O
pressure	O
and	O
production	O
of	O
ROS	B-Chemical
and	O
improved	O
antioxidant	O
capacity	O
in	O
Dex	B-Chemical
-	O
induced	O
hypertension	B-Disease
,	O
suggesting	O
the	O
role	O
of	O
inhibition	O
of	O
oxidative	O
stress	O
as	O
another	O
mechanism	O
of	O
antihypertensive	O
action	O
of	O
LF	B-Gene
.	O
</ALL>	O

<ALL>	O
IL	B-Gene
-	I-Gene
3	I-Gene
and	O
CSF	B-Gene
-	I-Gene
1	I-Gene
interact	O
to	O
promote	O
generation	O
of	O
CD11c	B-Gene
+	O
IL	B-Gene
-	I-Gene
10	I-Gene
-	O
producing	O
macrophages	O
.	O
</ALL>	O

<ALL>	O
Unraveling	O
the	O
mechanisms	O
of	O
hematopoiesis	O
regulated	O
by	O
multiple	O
cytokines	O
remains	O
a	O
challenge	O
in	O
hematology	O
.	O
</ALL>	O

<ALL>	O
IL	B-Gene
-	I-Gene
3	I-Gene
is	O
an	O
allergic	O
cytokine	O
with	O
the	O
multilineage	O
potential	O
,	O
while	O
CSF	B-Gene
-	I-Gene
1	I-Gene
is	O
produced	O
in	O
the	O
steady	O
state	O
with	O
restricted	O
lineage	O
coverage	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
uncovered	O
an	O
instructive	O
role	O
of	O
CSF	B-Gene
-	I-Gene
1	I-Gene
in	O
IL	B-Gene
-	I-Gene
3	I-Gene
-	O
mediated	O
hematopoiesis	O
.	O
</ALL>	O

<ALL>	O
CSF	B-Gene
-	I-Gene
1	I-Gene
significantly	O
promoted	O
IL	B-Gene
-	I-Gene
3	I-Gene
-	O
driven	O
CD11c	B-Gene
+	O
cell	O
expansion	O
and	O
dampened	O
basophil	O
and	O
mast	O
cell	O
generation	O
from	O
C57BL	B-CellLine
/	I-CellLine
6	I-CellLine
bone	O
marrow	O
.	O
</ALL>	O

<ALL>	O
Further	O
studies	O
indicated	O
that	O
the	O
CSF	B-Gene
-	I-Gene
1	I-Gene
/	O
CSF	B-Gene
-	I-Gene
1R	I-Gene
axis	O
contributed	O
significantly	O
to	O
IL	B-Gene
-	I-Gene
3	I-Gene
-	O
induced	O
CD11c	B-Gene
+	O
cell	O
generation	O
through	O
enhancing	O
c	B-Gene
-	I-Gene
Fos	I-Gene
-	O
associated	O
monopoiesis	O
.	O
</ALL>	O

<ALL>	O
CD11c	B-Gene
+	O
cells	O
induced	O
by	O
IL	B-Gene
-	I-Gene
3	I-Gene
or	O
IL	B-Gene
-	I-Gene
3	I-Gene
/	O
CSF	B-Gene
-	I-Gene
1	I-Gene
were	O
competent	O
in	O
cellular	O
maturation	O
and	O
endocytosis	O
.	O
</ALL>	O

<ALL>	O
Both	O
IL	B-Gene
-	I-Gene
3	I-Gene
and	O
IL	B-Gene
-	I-Gene
3	I-Gene
/	O
CSF	B-Gene
-	I-Gene
1	I-Gene
cells	O
lacked	O
classical	O
dendritic	O
cell	O
appearance	O
and	O
resembled	O
macrophages	O
in	O
morphology	O
.	O
</ALL>	O

<ALL>	O
Both	O
populations	O
produced	O
a	O
high	O
level	O
of	O
IL	B-Gene
-	I-Gene
10	I-Gene
,	O
in	O
addition	O
to	O
IL	B-Gene
-	I-Gene
1	I-Gene
,	O
IL	B-Gene
-	I-Gene
6	I-Gene
and	O
TNFa	B-Gene
,	O
in	O
response	O
to	O
LPS	B-Chemical
,	O
and	O
were	O
relatively	O
poor	O
T	O
cell	O
stimulators	O
.	O
</ALL>	O

<ALL>	O
Collectively	O
,	O
these	O
findings	O
reveal	O
a	O
role	O
for	O
CSF	B-Gene
-	I-Gene
1	I-Gene
in	O
mediating	O
the	O
IL	B-Gene
-	I-Gene
3	I-Gene
hematopoietic	O
pathway	O
through	O
monopoiesis	O
,	O
which	O
regulates	O
expansion	O
of	O
CD11c	B-Gene
+	O
macrophages	O
.	O
</ALL>	O

<ALL>	O
FGFR2	B-Gene
is	O
required	O
for	O
airway	O
basal	O
cell	O
self	O
-	O
renewal	O
and	O
terminal	O
differentiation	O
.	O
</ALL>	O

<ALL>	O
Airway	O
stem	O
cells	O
slowly	O
self	O
-	O
renew	O
and	O
produce	O
differentiated	O
progeny	O
to	O
maintain	O
homeostasis	O
throughout	O
the	O
lifespan	O
of	O
an	O
individual	O
.	O
</ALL>	O

<ALL>	O
Mutations	O
in	O
the	O
molecular	O
regulators	O
of	O
these	O
processes	O
may	O
drive	O
cancer	B-Disease
or	O
degenerative	B-Disease
disease	I-Disease
,	O
but	O
are	O
also	O
potential	O
therapeutic	O
targets	O
.	O
</ALL>	O

<ALL>	O
Conditionally	O
deleting	O
one	O
copy	O
of	O
FGF	B-Gene
receptor	I-Gene
2	I-Gene
(	O
FGFR2	B-Gene
)	O
in	O
adult	O
mouse	B-Species
airway	O
basal	O
cells	O
results	O
in	O
self	O
-	O
renewal	O
and	O
differentiation	O
phenotypes	O
.	O
</ALL>	O

<ALL>	O
We	O
show	O
that	O
FGFR2	B-Gene
signalling	O
correlates	O
with	O
maintenance	O
of	O
expression	O
of	O
a	O
key	O
transcription	O
factor	O
for	O
basal	O
cell	O
self	O
-	O
renewal	O
and	O
differentiation	O
:	O
SOX2	B-Gene
.	O
</ALL>	O

<ALL>	O
This	O
heterozygous	O
phenotype	O
illustrates	O
that	O
subtle	O
changes	O
in	O
receptor	B-Gene
tyrosine	I-Gene
kinase	I-Gene
signalling	O
can	O
have	O
significant	O
effects	O
,	O
perhaps	O
providing	O
an	O
explanation	O
for	O
the	O
numerous	O
changes	O
seen	O
in	O
cancer	B-Disease
.	O
</ALL>	O

<ALL>	O
Biophysical	O
and	O
functional	O
characterization	O
of	O
hippocalcin	B-Gene
mutants	O
responsible	O
for	O
human	B-Species
dystonia	B-Disease
.	O
</ALL>	O

<ALL>	O
Dystonia	B-Disease
is	O
a	O
neurological	B-Disease
movement	I-Disease
disorder	I-Disease
that	O
forces	O
the	O
body	O
into	O
twisting	O
,	O
repetitive	O
movements	O
or	O
sometimes	O
painful	O
abnormal	O
postures	O
.	O
</ALL>	O

<ALL>	O
With	O
the	O
advent	O
of	O
next	O
-	O
generation	O
sequencing	O
technologies	O
,	O
the	O
homozygous	O
mutations	O
T71N	B-Variant
and	O
A190	B-Variant
T	I-Variant
in	O
the	O
neuronal	B-Gene
calcium	I-Gene
sensor	I-Gene
(	O
NCS	B-Gene
)	O
hippocalcin	B-Gene
were	O
identified	O
as	O
the	O
genetic	O
cause	O
of	O
primary	B-Disease
isolated	I-Disease
dystonia	I-Disease
(	O
DYT2	B-Gene
dystonia	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
effect	O
of	O
these	O
mutations	O
on	O
the	O
physiological	O
role	O
of	O
hippocalcin	B-Gene
has	O
not	O
yet	O
been	O
elucidated	O
.	O
</ALL>	O

<ALL>	O
Using	O
a	O
multidisciplinary	O
approach	O
,	O
we	O
demonstrated	O
that	O
hippocalcin	B-Gene
oligomerises	O
in	O
a	O
calcium	B-Chemical
-	O
dependent	O
manner	O
and	O
binds	O
to	O
voltage	B-Gene
-	I-Gene
gated	I-Gene
calcium	I-Gene
channels	I-Gene
.	O
</ALL>	O

<ALL>	O
Mutations	O
T71N	B-Variant
and	O
A190	B-Variant
T	I-Variant
in	O
hippocalcin	B-Gene
did	O
not	O
affect	O
stability	O
,	O
calcium	B-Chemical
-	O
binding	O
affinity	O
or	O
translocation	O
to	O
cellular	O
membranes	O
(	O
Ca2	B-Chemical
+	I-Chemical
/	O
myristoyl	O
switch	O
)	O
.	O
</ALL>	O

<ALL>	O
We	O
obtained	O
the	O
first	O
crystal	O
structure	O
of	O
hippocalcin	B-Gene
and	O
alignment	O
with	O
other	O
NCS	B-Gene
proteins	O
showed	O
significant	O
variability	O
in	O
the	O
orientation	O
of	O
the	O
C	O
-	O
terminal	O
part	O
of	O
the	O
molecule	O
,	O
the	O
region	O
expected	O
to	O
be	O
important	O
for	O
target	O
binding	O
.	O
</ALL>	O

<ALL>	O
We	O
demonstrated	O
that	O
the	O
disease	O
-	O
causing	O
mutations	O
did	O
not	O
affect	O
the	O
structure	O
of	O
the	O
protein	O
,	O
however	O
both	O
mutants	O
showed	O
a	O
defect	O
in	O
oligomerisation	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
we	O
observed	O
an	O
increased	O
calcium	B-Chemical
influx	O
in	O
KCl	B-Chemical
-	O
depolarised	O
cells	O
expressing	O
mutated	O
hippocalcin	B-Gene
,	O
mostly	O
driven	O
by	O
N	B-Gene
-	I-Gene
type	I-Gene
voltage	I-Gene
-	I-Gene
gated	I-Gene
calcium	I-Gene
channels	I-Gene
.	O
</ALL>	O

<ALL>	O
Our	O
data	O
demonstrate	O
that	O
the	O
dystonia	B-Disease
-	O
causing	O
mutations	O
strongly	O
affect	O
hippocalcin	B-Gene
cellular	O
functions	O
which	O
suggest	O
a	O
central	O
role	O
for	O
perturbed	O
calcium	B-Chemical
signalling	O
in	O
DYT2	B-Gene
dystonia	B-Disease
.	O
</ALL>	O

<ALL>	O
Ca2	B-Chemical
+	I-Chemical
-	O
dependent	O
endoplasmic	O
reticulum	O
stress	O
correlation	O
with	O
astrogliosis	B-Disease
involves	O
upregulation	O
of	O
KCa3.1	B-Gene
and	O
inhibition	O
of	O
AKT	B-Gene
/	O
mTOR	B-Gene
signaling	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
The	O
intermediate	B-Gene
-	I-Gene
conductance	I-Gene
Ca2	I-Gene
+	I-Gene
-	I-Gene
activated	I-Gene
K	I-Gene
+	I-Gene
channel	I-Gene
KCa3.1	B-Gene
was	O
recently	O
shown	O
to	O
control	O
the	O
phenotype	O
switch	O
of	O
reactive	B-Disease
astrogliosis	I-Disease
(	O
RA	B-Disease
)	O
in	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
(	O
AD	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
KCa3.1	B-Gene
channels	O
expression	O
and	O
cell	O
localization	O
in	O
the	O
brains	O
of	O
AD	B-Disease
patients	B-Species
and	O
APP	B-Gene
/	O
PS1	B-Gene
mice	B-Species
model	O
were	O
measured	O
by	O
immunoblotting	O
and	O
immunostaining	O
.	O
</ALL>	O

<ALL>	O
APP	B-Gene
/	O
PS1	B-Gene
mice	B-Species
and	O
KCa3.1	B-Gene
-	O
/	O
-	O
/	O
APP	B-Gene
/	O
PS1	B-Gene
mice	B-Species
were	O
subjected	O
to	O
Morris	O
water	O
maze	O
test	O
to	O
evaluate	O
the	O
spatial	O
memory	B-Disease
deficits	I-Disease
.	O
</ALL>	O

<ALL>	O
Glia	O
activation	O
and	O
neuron	B-Disease
loss	I-Disease
was	O
measured	O
by	O
immunostaining	O
.	O
</ALL>	O

<ALL>	O
Fluo	B-Chemical
-	I-Chemical
4AM	I-Chemical
was	O
used	O
to	O
measure	O
cytosolic	O
Ca2	B-Chemical
+	I-Chemical
level	O
in	O
beta	B-Gene
-	I-Gene
amyloid	I-Gene
(	O
Abeta	B-Gene
)	O
induced	O
reactive	O
astrocytes	O
in	O
vitro	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
KCa3.1	B-Gene
expression	O
was	O
markedly	O
associated	O
with	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
and	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
in	O
both	O
Abeta	B-Gene
-	O
stimulated	O
primary	O
astrocytes	O
and	O
brain	O
lysates	O
of	O
AD	B-Disease
patients	B-Species
and	O
APP	B-Gene
/	O
PS1	B-Gene
AD	B-Disease
mice	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
KCa3.1	B-Gene
channel	O
was	O
shown	O
to	O
regulate	O
store	O
-	O
operated	O
Ca2	B-Chemical
+	I-Chemical
entry	O
(	O
SOCE	O
)	O
through	O
an	O
interaction	O
with	O
the	O
Ca2	B-Chemical
+	I-Chemical
channel	O
Orai1	B-Gene
in	O
primary	O
astrocytes	O
.	O
</ALL>	O

<ALL>	O
Gene	O
deletion	O
or	O
pharmacological	O
blockade	O
of	O
KCa3.1	B-Gene
protected	O
against	O
SOCE	O
-	O
induced	O
Ca2	B-Chemical
+	I-Chemical
overload	O
and	O
ER	O
stress	O
via	O
the	O
protein	B-Gene
kinase	I-Gene
B	I-Gene
(	O
AKT	B-Gene
)	O
signaling	O
pathway	O
in	O
astrocytes	O
.	O
</ALL>	O

<ALL>	O
Importantly	O
,	O
gene	O
deletion	O
or	O
blockade	O
of	O
KCa3.1	B-Gene
restored	O
AKT	B-Gene
/	O
mechanistic	B-Gene
target	I-Gene
of	I-Gene
rapamycin	I-Gene
signaling	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
</ALL>	O

<ALL>	O
Consistent	O
with	O
these	O
in	O
vitro	O
data	O
,	O
expression	O
levels	O
of	O
the	O
ER	O
stress	O
markers	O
78	B-Gene
-	I-Gene
kDa	I-Gene
glucose	I-Gene
-	I-Gene
regulated	I-Gene
protein	I-Gene
and	O
CCAAT	B-Gene
/	I-Gene
enhancer	I-Gene
-	I-Gene
binding	I-Gene
protein	I-Gene
homologous	I-Gene
protein	I-Gene
,	O
as	O
well	O
as	O
that	O
of	O
the	O
RA	B-Disease
marker	O
glial	B-Gene
fibrillary	I-Gene
acidic	I-Gene
protein	I-Gene
were	O
increased	O
in	O
APP	B-Gene
/	O
PS1	B-Gene
AD	B-Disease
mouse	B-Species
model	O
.	O
</ALL>	O

<ALL>	O
Elimination	O
of	O
KCa3.1	B-Gene
in	O
KCa3.1	B-Gene
-	O
/	O
-	O
/	O
APP	B-Gene
/	O
PS1	B-Gene
mice	B-Species
corrected	O
these	O
abnormal	O
responses	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
glial	O
activation	O
and	O
neuroinflammation	B-Disease
were	O
attenuated	O
in	O
the	O
hippocampi	O
of	O
KCa3.1	B-Gene
-	O
/	O
-	O
/	O
APP	B-Gene
/	O
PS1	B-Gene
mice	B-Species
,	O
as	O
compared	O
with	O
APP	B-Gene
/	O
PS1	B-Gene
mice	B-Species
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
memory	B-Disease
deficits	I-Disease
and	O
neuronal	B-Disease
loss	I-Disease
in	O
APP	B-Gene
/	O
PS1	B-Gene
mice	B-Species
were	O
reversed	O
in	O
KCa3.1	B-Gene
-	O
/	O
-	O
/	O
APP	B-Gene
/	O
PS1	B-Gene
mice	B-Species
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Overall	O
,	O
these	O
results	O
suggest	O
that	O
KCa3.1	B-Gene
is	O
involved	O
in	O
the	O
regulation	O
of	O
Ca2	B-Chemical
+	I-Chemical
homeostasis	O
in	O
astrocytes	O
and	O
attenuation	O
of	O
the	O
UPR	O
and	O
ER	O
stress	O
,	O
thus	O
contributing	O
to	O
memory	B-Disease
deficits	I-Disease
and	O
neuronal	B-Disease
loss	I-Disease
.	O
</ALL>	O

<ALL>	O
Vaccine	O
candidates	O
derived	O
from	O
a	O
novel	O
infectious	O
cDNA	O
clone	O
of	O
an	O
American	O
genotype	O
dengue	B-Species
virus	I-Species
type	I-Species
2	I-Species
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
A	O
dengue	B-Species
virus	I-Species
type	I-Species
2	I-Species
(	O
DEN	B-Species
-	I-Species
2	I-Species
Tonga	O
/	O
74	O
)	O
isolated	O
from	O
a	O
1974	O
epidemic	O
was	O
characterized	O
by	O
mild	O
illness	O
and	O
belongs	O
to	O
the	O
American	O
genotype	O
of	O
DEN	B-Species
-	I-Species
2	I-Species
viruses	O
.	O
</ALL>	O

<ALL>	O
To	O
prepare	O
a	O
vaccine	O
candidate	O
,	O
a	O
previously	O
described	O
30	B-Variant
nucleotide	I-Variant
deletion	I-Variant
(	O
Delta30	B-Variant
)	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
DEN	B-Species
-	I-Species
4	I-Species
has	O
been	O
engineered	O
into	O
the	O
DEN	B-Species
-	I-Species
2	I-Species
isolate	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
A	O
full	O
-	O
length	O
cDNA	O
clone	O
was	O
generated	O
from	O
the	O
DEN	B-Species
-	I-Species
2	I-Species
virus	O
and	O
used	O
to	O
produce	O
recombinant	O
DEN	B-Species
-	I-Species
2	I-Species
(	O
rDEN	B-Species
-	I-Species
2	I-Species
)	O
and	O
rDEN2	O
Delta30	B-Variant
.	O
</ALL>	O

<ALL>	O
Viruses	O
were	O
evaluated	O
for	O
replication	O
in	O
SCID	O
mice	B-Species
transplanted	O
with	O
human	B-Species
hepatoma	B-Disease
cells	O
(	O
SCID	B-CellLine
-	I-CellLine
HuH	I-CellLine
-	I-CellLine
7	I-CellLine
mice	B-Species
)	O
,	O
in	O
mosquitoes	O
,	O
and	O
in	O
rhesus	B-Species
monkeys	I-Species
.	O
</ALL>	O

<ALL>	O
Neutralizing	O
antibody	O
induction	O
and	O
protective	O
efficacy	O
were	O
also	O
assessed	O
in	O
rhesus	B-Species
monkeys	I-Species
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
rDEN2	O
Delta30	B-Variant
virus	O
was	O
ten	O
-	O
fold	O
reduced	O
in	O
replication	O
in	O
SCID	B-CellLine
-	I-CellLine
HuH	I-CellLine
-	I-CellLine
7	I-CellLine
mice	B-Species
when	O
compared	O
to	O
the	O
parent	O
virus	O
.	O
</ALL>	O

<ALL>	O
The	O
rDEN	B-Species
-	I-Species
2	I-Species
viruses	O
were	O
not	O
infectious	O
for	O
Aedes	B-Species
mosquitoes	I-Species
,	O
but	O
both	O
readily	O
infected	O
Toxorynchites	B-Species
mosquitoes	I-Species
.	O
</ALL>	O

<ALL>	O
In	O
rhesus	B-Species
monkeys	I-Species
,	O
rDEN2	O
Delta30	B-Variant
appeared	O
to	O
be	O
slightly	O
attenuated	O
when	O
compared	O
to	O
the	O
parent	O
virus	O
as	O
measured	O
by	O
duration	O
and	O
peak	O
of	O
viremia	B-Disease
and	O
neutralizing	O
antibody	O
induction	O
.	O
</ALL>	O

<ALL>	O
A	O
derivative	O
of	O
rDEN2	O
Delta30	B-Variant
,	O
designated	O
rDEN2	O
Delta30	B-Variant
-	I-Variant
4995	I-Variant
,	O
was	O
generated	O
by	O
incorporation	O
of	O
a	O
point	O
mutation	O
previously	O
identified	O
in	O
the	O
NS3	B-Gene
gene	O
of	O
DEN	B-Species
-	I-Species
4	I-Species
and	O
was	O
found	O
to	O
be	O
more	O
attenuated	O
than	O
rDEN2	O
Delta30	B-Variant
in	O
SCID	B-CellLine
-	I-CellLine
HuH	I-CellLine
-	I-CellLine
7	I-CellLine
mice	B-Species
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
The	O
rDEN2	O
Delta30	B-Variant
and	O
rDEN2	O
Delta30	B-Variant
-	I-Variant
4995	I-Variant
viruses	O
can	O
be	O
considered	O
for	O
evaluation	O
in	O
humans	B-Species
and	O
for	O
inclusion	O
in	O
a	O
tetravalent	O
dengue	B-Disease
vaccine	O
.	O
</ALL>	O

<ALL>	O
Genetic	O
investigation	O
of	O
the	O
TSPYL1	B-Gene
gene	O
in	O
sudden	B-Disease
infant	I-Disease
death	I-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Sudden	B-Disease
infant	I-Disease
death	I-Disease
syndrome	I-Disease
(	O
SIDS	B-Disease
)	O
constitutes	O
the	O
most	O
frequent	O
cause	O
of	O
death	B-Disease
in	O
the	O
postperinatal	O
period	O
in	O
Germany	O
.	O
</ALL>	O

<ALL>	O
Recently	O
,	O
a	O
lethal	O
phenotype	O
characterized	O
by	O
sudden	B-Disease
infant	I-Disease
death	I-Disease
with	I-Disease
dysgenesis	I-Disease
of	I-Disease
the	I-Disease
testes	I-Disease
syndrome	I-Disease
(	O
SIDDT	B-Disease
)	O
was	O
identified	O
to	O
be	O
caused	O
by	O
loss	O
of	O
function	O
mutations	O
in	O
the	O
TSPYL1	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
The	O
study	O
's	O
purpose	O
was	O
to	O
reveal	O
a	O
possible	O
role	O
of	O
TSPYL1	B-Gene
in	O
SIDS	B-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
DNA	O
samples	O
of	O
126	O
SIDS	B-Disease
cases	O
and	O
261	O
controls	O
were	O
investigated	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
We	O
found	O
five	O
sequence	O
variations	O
,	O
each	O
of	O
them	O
causing	O
an	O
amino	O
acid	O
substitution	O
.	O
</ALL>	O

<ALL>	O
No	O
Hardy	O
Weinberg	O
disequilibrium	O
and	O
no	O
significant	O
difference	O
in	O
allele	O
frequencies	O
between	O
patients	B-Species
and	O
controls	O
were	O
observed	O
for	O
any	O
variation	O
.	O
</ALL>	O

<ALL>	O
In	O
one	O
female	O
patient	B-Species
a	O
p	B-Variant
.	I-Variant
F366L	I-Variant
amino	O
acid	O
polymorphism	O
was	O
found	O
heterozygous	O
,	O
which	O
could	O
not	O
be	O
displayed	O
in	O
controls	O
.	O
</ALL>	O

<ALL>	O
A	O
pathogenic	O
implication	O
of	O
this	O
substitution	O
,	O
which	O
is	O
conserved	O
in	O
primates	O
and	O
rodents	O
,	O
can	O
not	O
be	O
ruled	O
out	O
completely	O
.	O
</ALL>	O

<ALL>	O
Because	O
SIDDT	B-Disease
is	O
the	O
result	O
of	O
homozygous	O
TSPYL1	B-Gene
mutations	O
,	O
this	O
heterozygous	O
exchange	O
can	O
not	O
solely	O
explain	O
the	O
sudden	B-Disease
death	I-Disease
in	O
this	O
child	O
.	O
</ALL>	O

<ALL>	O
The	O
reported	O
mutation	O
associated	O
with	O
SIDDT	B-Disease
(	O
457	B-Variant
_	I-Variant
458insG	I-Variant
)	O
was	O
not	O
detectable	O
in	O
our	O
cohort	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
No	O
association	O
of	O
sequence	O
variations	O
in	O
the	O
TSPYL1	B-Gene
gene	O
and	O
SIDS	B-Disease
has	O
been	O
found	O
in	O
a	O
German	O
cohort	O
.	O
</ALL>	O

<ALL>	O
Genetic	O
analysis	O
of	O
TSPYL1	B-Gene
seems	O
to	O
be	O
of	O
limited	O
significance	O
in	O
the	O
differential	O
diagnosis	O
of	O
SIDS	B-Disease
without	O
dysgenesis	B-Disease
of	I-Disease
the	I-Disease
testes	I-Disease
.	O
</ALL>	O

<ALL>	O
Possible	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
related	O
to	O
concomitant	O
treatment	O
with	O
paroxetine	B-Chemical
and	O
alprazolam	B-Chemical
.	O
</ALL>	O

<ALL>	O
A	O
74	O
-	O
year	O
-	O
old	O
man	B-Species
with	O
depressive	B-Disease
symptoms	I-Disease
was	O
admitted	O
to	O
a	O
psychiatric	B-Disease
hospital	O
due	O
to	O
insomnia	B-Disease
,	O
loss	B-Disease
of	I-Disease
appetite	I-Disease
,	O
exhaustion	O
,	O
and	O
agitation	B-Disease
.	O
</ALL>	O

<ALL>	O
Medical	O
treatment	O
was	O
initiated	O
at	O
a	O
daily	O
dose	O
of	O
20	O
mg	O
paroxetine	B-Chemical
and	O
1.2	O
mg	O
alprazolam	B-Chemical
.	O
</ALL>	O

<ALL>	O
On	O
the	O
10th	O
day	O
of	O
paroxetine	B-Chemical
and	O
alprazolam	B-Chemical
treatment	O
,	O
the	O
patient	B-Species
exhibited	O
marked	O
psychomotor	B-Disease
retardation	I-Disease
,	O
disorientation	O
,	O
and	O
severe	O
muscle	B-Disease
rigidity	I-Disease
with	O
tremors	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
had	O
a	O
fever	B-Disease
(	O
38.2	O
degrees	O
C	O
)	O
,	O
fluctuating	O
blood	O
pressure	O
(	O
between	O
165	O
/	O
90	O
and	O
130	O
/	O
70	O
mg	O
mm	O
Hg	O
)	O
,	O
and	O
severe	O
extrapyramidal	B-Disease
symptoms	I-Disease
.	O
</ALL>	O

<ALL>	O
Laboratory	O
tests	O
showed	O
an	O
elevation	O
of	O
creatine	B-Chemical
phosphokinase	I-Chemical
(	O
2218	O
IU	O
/	O
L	O
)	O
,	O
aspartate	B-Chemical
aminotransferase	I-Chemical
(	O
134	O
IU	O
/	O
L	O
)	O
,	O
alanine	B-Chemical
aminotransferase	I-Chemical
(	O
78	O
IU	O
/	O
L	O
)	O
,	O
and	O
BUN	O
(	O
27.9	O
mg	O
/	O
ml	O
)	O
levels	O
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
received	O
bromocriptine	B-Chemical
and	O
diazepam	B-Chemical
to	O
treat	O
his	O
symptoms	O
.	O
</ALL>	O

<ALL>	O
7	O
days	O
later	O
,	O
the	O
fever	B-Disease
disappeared	O
and	O
the	O
patient	B-Species
's	O
serum	O
CPK	B-Chemical
levels	O
were	O
normalized	O
(	O
175	O
IU	O
/	O
L	O
)	O
.	O
</ALL>	O

<ALL>	O
This	O
patient	B-Species
presented	O
with	O
symptoms	O
of	O
neuroleptic	B-Disease
malignant	I-Disease
syndrome	I-Disease
(	O
NMS	B-Disease
)	O
,	O
thus	O
demonstrating	O
that	O
NMS	B-Disease
-	O
like	O
symptoms	O
can	O
occur	O
after	O
combined	O
paroxetine	B-Chemical
and	O
alprazolam	B-Chemical
treatment	O
.	O
</ALL>	O

<ALL>	O
The	O
adverse	O
drug	O
reaction	O
score	O
obtained	O
by	O
the	O
Naranjo	O
algorithm	O
was	O
6	O
in	O
our	O
case	O
,	O
indicating	O
a	O
probable	O
relationship	O
between	O
the	O
patient	B-Species
's	O
NMS	B-Disease
-	O
like	O
adverse	O
symptoms	O
and	O
the	O
combined	O
treatment	O
used	O
in	O
this	O
case	O
.	O
</ALL>	O

<ALL>	O
The	O
involvement	O
of	O
physiologic	O
and	O
environmental	O
aspects	O
specific	O
to	O
this	O
patient	B-Species
was	O
suspected	O
.	O
</ALL>	O

<ALL>	O
Several	O
risk	O
factors	O
for	O
NMS	B-Disease
should	O
be	O
noted	O
in	O
elderly	O
depressive	B-Disease
patients	B-Species
whose	O
symptoms	O
often	O
include	O
dehydration	B-Disease
,	O
agitation	B-Disease
,	O
malnutrition	B-Disease
,	O
and	O
exhaustion	O
.	O
</ALL>	O

<ALL>	O
Careful	O
therapeutic	O
intervention	O
is	O
necessary	O
in	O
cases	O
involving	O
elderly	O
patients	B-Species
who	O
suffer	O
from	O
depression	B-Disease
.	O
</ALL>	O

<ALL>	O
Cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
after	O
epidural	O
steroid	B-Chemical
injection	O
:	O
a	O
case	O
report	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
Conventional	O
treatment	O
methods	O
of	O
lumbusacral	O
radiculopathy	B-Disease
are	O
physical	O
therapy	O
,	O
epidural	O
steroid	B-Chemical
injections	O
,	O
oral	O
medications	O
,	O
and	O
spinal	O
manipulative	O
therapy	O
.	O
</ALL>	O

<ALL>	O
Cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
is	O
a	O
rare	O
complication	O
of	O
epidural	O
anesthesia	O
.	O
</ALL>	O

<ALL>	O
The	O
following	O
case	O
is	O
a	O
report	O
of	O
cauda	B-Disease
equina	I-Disease
syndrome	I-Disease
possibly	O
caused	O
by	O
epidural	O
injection	O
of	O
triamcinolone	B-Chemical
and	O
bupivacaine	B-Chemical
.	O
</ALL>	O

<ALL>	O
CLINICAL	O
FEATURES	O
:	O
A	O
50	O
-	O
year	O
-	O
old	O
woman	B-Species
with	O
low	B-Disease
back	I-Disease
and	I-Disease
right	I-Disease
leg	I-Disease
pain	I-Disease
was	O
scheduled	O
for	O
epidural	O
steroid	B-Chemical
injection	O
.	O
</ALL>	O

<ALL>	O
INTERVENTION	O
AND	O
OUTCOME	O
:	O
An	O
18	O
-	O
gauge	O
Touhy	O
needle	O
was	O
inserted	O
until	O
loss	O
of	O
resistance	O
occurred	O
at	O
the	O
L4	O
-	O
5	O
level	O
.	O
</ALL>	O

<ALL>	O
Spread	O
of	O
the	O
contrast	O
medium	O
within	O
the	O
epidural	O
space	O
was	O
determined	O
by	O
radiographic	O
imaging	O
.	O
</ALL>	O

<ALL>	O
After	O
verifying	O
the	O
epidural	O
space	O
,	O
bupivacaine	B-Chemical
and	O
triamcinolone	B-Chemical
diacetate	I-Chemical
were	O
injected	O
.	O
</ALL>	O

<ALL>	O
After	O
the	O
injection	O
,	O
there	O
was	O
a	O
reduction	O
in	O
radicular	O
symptoms	O
.	O
</ALL>	O

<ALL>	O
Three	O
hours	O
later	O
,	O
she	O
complained	O
of	O
perineal	O
numbness	B-Disease
and	O
lower	B-Disease
extremity	I-Disease
weakness	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
neurologic	O
evaluation	O
revealed	O
loss	B-Disease
of	I-Disease
sensation	I-Disease
in	O
the	O
saddle	O
area	O
and	O
medial	O
aspect	O
of	O
her	O
right	O
leg	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
a	O
decrease	O
in	O
the	O
perception	O
of	O
pinprick	O
test	O
.	O
</ALL>	O

<ALL>	O
Deep	O
-	O
tendon	O
reflexes	O
were	O
decreased	O
especially	O
in	O
the	O
right	O
leg	O
.	O
</ALL>	O

<ALL>	O
She	O
was	O
unable	O
to	O
urinate	O
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
's	O
symptoms	O
improved	O
slightly	O
over	O
the	O
next	O
few	O
hours	O
.	O
</ALL>	O

<ALL>	O
She	O
had	O
a	O
gradual	O
return	O
of	O
motor	O
function	O
and	O
ability	O
of	O
feeling	O
Foley	O
catheter	O
.	O
</ALL>	O

<ALL>	O
All	O
of	O
the	O
symptoms	O
were	O
completely	O
resolved	O
over	O
the	O
next	O
8	O
hours	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Complications	O
associated	O
with	O
epidural	O
steroid	B-Chemical
injections	O
are	O
rare	O
.	O
</ALL>	O

<ALL>	O
Clinical	O
examination	O
and	O
continued	O
vigilance	O
for	O
neurologic	B-Disease
deterioration	I-Disease
after	O
epidural	O
steroid	B-Chemical
injections	O
is	O
important	O
.	O
</ALL>	O

<ALL>	O
Genetic	O
polymorphism	O
of	O
the	O
binding	O
domain	O
of	O
surfactant	B-Gene
protein	I-Gene
-	I-Gene
A2	I-Gene
increases	O
susceptibility	O
to	O
meningococcal	B-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Meningococcal	B-Disease
disease	I-Disease
occurs	O
after	O
colonization	O
of	O
the	O
nasopharynx	O
with	O
Neisseria	B-Disease
meningitidis	I-Disease
.	O
</ALL>	O

<ALL>	O
Surfactant	B-Gene
protein	I-Gene
(	I-Gene
SP	I-Gene
)	I-Gene
-	I-Gene
A	I-Gene
and	O
SP	B-Gene
-	I-Gene
D	I-Gene
are	O
pattern	O
-	O
recognition	O
molecules	O
of	O
the	O
respiratory	O
tract	O
that	O
activate	O
inflammatory	B-Disease
and	O
phagocytic	O
defences	O
after	O
binding	O
to	O
microbial	O
sugars	B-Chemical
.	O
</ALL>	O

<ALL>	O
Variation	O
in	O
the	O
genes	O
of	O
the	O
surfactant	O
proteins	O
affects	O
the	O
expression	O
and	O
function	O
of	O
these	O
molecules	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Allele	O
frequencies	O
of	O
SP	B-Gene
-	I-Gene
A1	I-Gene
,	O
SP	B-Gene
-	I-Gene
A2	I-Gene
,	O
and	O
SP	B-Gene
-	I-Gene
D	I-Gene
were	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
in	O
303	O
patients	B-Species
with	O
microbiologically	O
proven	O
meningococcal	B-Disease
disease	I-Disease
,	O
including	O
18	O
patients	B-Species
who	O
died	B-Disease
,	O
and	O
222	O
healthy	O
control	O
subjects	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Homozygosity	O
of	O
allele	O
1A1	O
of	O
SP	B-Gene
-	I-Gene
A2	I-Gene
increased	O
the	O
risk	O
of	O
meningococcal	B-Disease
disease	I-Disease
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
7.4	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.3	O
-	O
42.4	O
)	O
;	O
carriage	O
of	O
1A5	O
reduced	O
the	O
risk	O
(	O
OR	O
,	O
0.3	O
;	O
95	O
%	O
CI	O
,	O
0.1	O
-	O
0.97	O
)	O
.	O
</ALL>	O

<ALL>	O
An	O
analysis	O
of	O
the	O
multiple	O
single	O
-	O
nucleotide	O
polymorphisms	O
in	O
SP	B-Gene
-	I-Gene
A	I-Gene
demonstrated	O
that	O
homozygosity	O
for	O
alleles	O
encoding	O
lysine	B-Variant
(	I-Variant
in	I-Variant
1A1	I-Variant
)	I-Variant
rather	I-Variant
than	I-Variant
glutamine	I-Variant
(	I-Variant
in	I-Variant
1A5	I-Variant
)	I-Variant
at	I-Variant
amino	I-Variant
acid	I-Variant
223	I-Variant
in	O
the	O
carbohydrate	B-Chemical
recognition	O
domain	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
meningococcal	B-Disease
disease	I-Disease
(	O
OR	O
,	O
6.7	O
;	O
95	O
%	O
CI	O
,	O
1.4	O
-	O
31.5	O
)	O
.	O
</ALL>	O

<ALL>	O
Carriage	O
of	O
alleles	O
encoding	O
lysine	B-Variant
at	I-Variant
residue	I-Variant
223	I-Variant
was	O
found	O
in	O
61	O
%	O
of	O
patients	B-Species
who	O
died	B-Disease
,	O
compared	O
with	O
35	O
%	O
of	O
those	O
who	O
survived	O
(	O
OR	O
adjusted	O
for	O
age	O
,	O
2.9	O
;	O
95	O
%	O
CI	O
,	O
1.1	O
-	O
7.7	O
)	O
.	O
</ALL>	O

<ALL>	O
Genetic	O
variation	O
of	O
SP	B-Gene
-	I-Gene
A1	I-Gene
and	O
SP	B-Gene
-	I-Gene
D	I-Gene
was	O
not	O
associated	O
with	O
meningococcal	B-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Gene	O
polymorphism	O
resulting	O
in	O
the	O
substitution	O
of	O
glutamine	B-Variant
with	I-Variant
lysine	I-Variant
at	I-Variant
residue	I-Variant
223	I-Variant
in	O
the	O
carbohydrate	B-Chemical
recognition	O
domain	O
of	O
SP	B-Gene
-	I-Gene
A2	I-Gene
increases	O
susceptibility	O
to	O
meningococcal	B-Disease
disease	I-Disease
,	O
as	O
well	O
as	O
the	O
risk	O
of	O
death	B-Disease
.	O
</ALL>	O

<ALL>	O
A	O
novel	O
missense	O
mutation	O
in	O
the	O
paired	O
domain	O
of	O
human	B-Species
PAX9	B-Gene
causes	O
oligodontia	B-Disease
.	O
</ALL>	O

<ALL>	O
PAX9	B-Gene
and	O
MSX1	B-Gene
are	O
transcription	O
factors	O
that	O
play	O
essential	O
roles	O
in	O
craniofacial	O
and	O
limb	O
development	O
.	O
</ALL>	O

<ALL>	O
In	O
humans	B-Species
,	O
mutations	O
in	O
both	O
genes	O
are	O
associated	O
with	O
nonsyndromic	B-Disease
and	I-Disease
syndromic	I-Disease
oligodontia	I-Disease
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
We	O
screened	O
one	O
family	O
with	O
nonsyndromic	B-Disease
oligodontia	I-Disease
for	O
mutations	O
in	O
PAX9	B-Gene
and	O
MSX1	B-Gene
.	O
</ALL>	O

<ALL>	O
Single	O
stranded	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
and	O
sequencing	O
revealed	O
a	O
novel	O
heterozygous	O
C139	B-Variant
T	I-Variant
transition	O
in	O
PAX9	B-Gene
in	O
the	O
affected	O
members	O
of	O
the	O
family	O
.	O
</ALL>	O

<ALL>	O
There	O
were	O
no	O
mutations	O
detected	O
in	O
the	O
entire	O
coding	O
sequence	O
of	O
MSX1	B-Gene
.	O
</ALL>	O

<ALL>	O
The	O
C139	B-Variant
T	I-Variant
mutation	O
,	O
predicted	O
to	O
result	O
in	O
the	O
substitution	O
of	O
an	O
arginine	B-Variant
by	I-Variant
a	I-Variant
tryptophan	I-Variant
(	O
R47W	B-Variant
)	O
in	O
the	O
N	O
-	O
terminal	O
subdomain	O
,	O
affected	O
conserved	O
residues	O
in	O
the	O
PAX9	B-Gene
paired	O
domain	O
.	O
</ALL>	O

<ALL>	O
To	O
elucidate	O
the	O
pathogenic	O
mechanism	O
producing	O
oligodontia	B-Disease
phenotype	I-Disease
caused	O
by	O
this	O
mutation	O
,	O
we	O
analyzed	O
the	O
binding	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
PAX9	B-Gene
paired	O
domain	O
protein	O
to	O
double	O
-	O
stranded	O
DNA	O
targets	O
.	O
</ALL>	O

<ALL>	O
The	O
R47W	B-Variant
mutation	O
dramatically	O
reduced	O
DNA	O
binding	O
suggesting	O
that	O
the	O
mutant	O
protein	O
with	O
consequent	O
haploinsufficiency	O
results	O
in	O
a	O
clinical	O
phenotype	O
.	O
</ALL>	O

<ALL>	O
The	O
FH	B-Gene
mutation	O
database	O
:	O
an	O
online	O
database	O
of	O
fumarate	B-Gene
hydratase	I-Gene
mutations	O
involved	O
in	O
the	O
MCUL	B-Disease
(	O
HLRCC	B-Disease
)	O
tumor	B-Disease
syndrome	I-Disease
and	O
congenital	O
fumarase	B-Disease
deficiency	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Fumarate	B-Gene
hydratase	I-Gene
(	O
HGNC	O
approved	O
gene	O
symbol	O
-	O
FH	B-Gene
)	O
,	O
also	O
known	O
as	O
fumarase	B-Gene
,	O
is	O
an	O
enzyme	O
of	O
the	O
tricarboxylic	B-Chemical
acid	I-Chemical
(	O
TCA	B-Chemical
)	O
cycle	O
,	O
involved	O
in	O
fundamental	O
cellular	O
energy	O
production	O
.	O
</ALL>	O

<ALL>	O
First	O
described	O
by	O
Zinn	O
et	O
al	O
in	O
1986	O
,	O
deficiency	B-Disease
of	I-Disease
FH	I-Disease
results	O
in	O
early	O
onset	O
,	O
severe	O
encephalopathy	B-Disease
.	O
</ALL>	O

<ALL>	O
In	O
2002	O
,	O
the	O
Multiple	O
Leiomyoma	B-Disease
Consortium	O
identified	O
heterozygous	O
germline	O
mutations	O
of	O
FH	B-Gene
in	O
patients	B-Species
with	O
multiple	B-Disease
cutaneous	I-Disease
and	I-Disease
uterine	I-Disease
leiomyomas	I-Disease
,	O
(	O
MCUL	B-Disease
:	O
OMIM	B-Disease
150800	I-Disease
)	O
.	O
</ALL>	O

<ALL>	O
In	O
some	O
families	O
renal	B-Disease
cell	I-Disease
cancer	I-Disease
also	O
forms	O
a	O
component	O
of	O
the	O
complex	O
and	O
as	O
such	O
has	O
been	O
described	O
as	O
hereditary	B-Disease
leiomyomatosis	I-Disease
and	I-Disease
renal	I-Disease
cell	I-Disease
cancer	I-Disease
(	O
HLRCC	B-Disease
:	O
OMIM	B-Disease
605839	I-Disease
)	O
.	O
</ALL>	O

<ALL>	O
The	O
identification	O
of	O
FH	B-Gene
as	O
a	O
tumor	B-Disease
suppressor	O
was	O
an	O
unexpected	O
finding	O
and	O
following	O
the	O
identification	O
of	O
subunits	O
of	O
succinate	O
dehydrogenase	O
in	O
2000	O
and	O
2001	O
,	O
was	O
only	O
the	O
second	O
description	O
of	O
the	O
involvement	O
of	O
an	O
enzyme	O
of	O
intermediary	O
metabolism	O
in	O
tumorigenesis	B-Disease
.	O
</ALL>	O

<ALL>	O
DESCRIPTION	O
:	O
The	O
FH	B-Gene
mutation	O
database	O
is	O
a	O
part	O
of	O
the	O
TCA	B-Chemical
cycle	O
gene	O
mutation	O
database	O
(	O
formerly	O
the	O
succinate	O
dehydrogenase	O
gene	O
mutation	O
database	O
)	O
and	O
is	O
based	O
on	O
the	O
Leiden	O
Open	O
(	O
source	O
)	O
Variation	O
Database	O
(	O
LOVD	O
)	O
system	O
.	O
</ALL>	O

<ALL>	O
The	O
variants	O
included	O
in	O
the	O
database	O
were	O
derived	O
from	O
the	O
published	O
literature	O
and	O
annotated	O
to	O
conform	O
to	O
current	O
mutation	O
nomenclature	O
.	O
</ALL>	O

<ALL>	O
The	O
FH	B-Gene
database	O
applies	O
HGVS	O
nomenclature	O
guidelines	O
,	O
and	O
will	O
assist	O
researchers	O
in	O
applying	O
these	O
guidelines	O
when	O
directly	O
submitting	O
new	O
sequence	O
variants	O
online	O
.	O
</ALL>	O

<ALL>	O
Since	O
the	O
first	O
molecular	O
characterization	O
of	O
an	O
FH	B-Gene
mutation	O
by	O
Bourgeron	O
et	O
al	O
in	O
1994	O
,	O
a	O
series	O
of	O
reports	O
of	O
both	O
FH	B-Disease
deficiency	I-Disease
patients	B-Species
and	O
patients	B-Species
with	O
MCUL	B-Disease
/	O
HLRRC	B-Disease
have	O
described	O
107	O
variants	O
,	O
of	O
which	O
93	O
are	O
thought	O
to	O
be	O
pathogenic	O
.	O
</ALL>	O

<ALL>	O
The	O
most	O
common	O
type	O
of	O
mutation	O
is	O
missense	O
(	O
57	O
%	O
)	O
,	O
followed	O
by	O
frameshifts	O
&	O
nonsense	O
(	O
27	O
%	O
)	O
,	O
and	O
diverse	O
deletions	O
,	O
insertions	O
and	O
duplications	O
.	O
</ALL>	O

<ALL>	O
Here	O
we	O
introduce	O
an	O
online	O
database	O
detailing	O
all	O
reported	O
FH	B-Gene
sequence	O
variants	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
The	O
FH	B-Gene
mutation	O
database	O
strives	O
to	O
systematically	O
unify	O
all	O
current	O
genetic	O
knowledge	O
of	O
FH	B-Gene
variants	O
.	O
</ALL>	O

<ALL>	O
We	O
believe	O
that	O
this	O
knowledge	O
will	O
assist	O
clinical	O
geneticists	O
and	O
treating	O
physicians	O
when	O
advising	O
patients	B-Species
and	O
their	O
families	O
,	O
will	O
provide	O
a	O
rapid	O
and	O
convenient	O
resource	O
for	O
research	O
scientists	O
,	O
and	O
may	O
eventually	O
assist	O
in	O
gaining	O
novel	O
insights	O
into	O
FH	B-Gene
and	O
its	O
related	O
clinical	O
syndromes	O
.	O
</ALL>	O

<ALL>	O
A	O
novel	O
point	O
mutation	O
in	O
the	O
amino	O
terminal	O
domain	O
of	O
the	O
human	B-Species
glucocorticoid	B-Gene
receptor	I-Gene
(	O
hGR	B-Gene
)	O
gene	O
enhancing	O
hGR	B-Gene
-	O
mediated	O
gene	O
expression	O
.	O
</ALL>	O

<ALL>	O
CONTEXT	O
:	O
Interindividual	O
variations	O
in	O
glucocorticoid	B-Chemical
sensitivity	O
have	O
been	O
associated	O
with	O
manifestations	O
of	O
cortisol	B-Chemical
excess	O
or	O
deficiency	O
and	O
may	O
be	O
partly	O
explained	O
by	O
polymorphisms	O
in	O
the	O
human	B-Species
glucocorticoid	B-Gene
receptor	I-Gene
(	O
hGR	B-Gene
)	O
gene	O
.	O
</ALL>	O

<ALL>	O
We	O
studied	O
a	O
43	O
-	O
yr	O
-	O
old	O
female	O
,	O
who	O
presented	O
with	O
manifestations	O
consistent	O
with	O
tissue	O
-	O
selective	O
glucocorticoid	B-Chemical
hypersensitivity	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
detected	O
a	O
novel	O
,	O
single	O
,	O
heterozygous	O
nucleotide	O
(	B-Variant
G	I-Variant
-	I-Variant
-	I-Variant
>	I-Variant
C	I-Variant
)	I-Variant
substitution	I-Variant
at	I-Variant
position	I-Variant
1201	I-Variant
(	O
exon	O
2	O
)	O
of	O
the	O
hGR	B-Gene
gene	O
,	O
which	O
resulted	O
in	O
aspartic	B-Variant
acid	I-Variant
to	I-Variant
histidine	I-Variant
substitution	I-Variant
at	I-Variant
amino	I-Variant
acid	I-Variant
position	I-Variant
401	I-Variant
in	O
the	O
amino	O
-	O
terminal	O
domain	O
of	O
the	O
hGRalpha	B-Gene
.	O
</ALL>	O

<ALL>	O
We	O
investigated	O
the	O
molecular	O
mechanisms	O
of	O
action	O
of	O
the	O
natural	O
mutant	O
receptor	O
hGRalpha	B-Gene
D401H.	O
METHODS	O
-	O
RESULTS	O
:	O
Compared	O
with	O
the	O
wild	O
-	O
type	O
hGRalpha	B-Gene
,	O
the	O
mutant	O
receptor	O
hGRalpha	B-Gene
D401H	O
demonstrated	O
a	O
2.4	O
-	O
fold	O
increase	O
in	O
its	O
ability	O
to	O
transactivate	O
the	O
glucocorticoid	B-Chemical
-	O
inducible	O
mouse	B-Species
mammary	I-Species
tumor	I-Species
virus	I-Species
promoter	O
in	O
response	O
to	O
dexamethasone	B-Chemical
but	O
had	O
similar	O
affinity	O
for	O
the	O
ligand	O
(	O
dissociation	O
constant	O
=	O
6.2	O
+	O
/	O
-	O
0.6	O
vs.	O
6.1	O
+	O
/	O
-	O
0.6	O
nm	O
)	O
and	O
time	O
to	O
nuclear	O
translocation	O
(	O
14.75	O
+	O
/	O
-	O
0.25	O
vs.	O
14.25	O
+	O
/	O
-	O
1.13	O
min	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
mutant	O
receptor	O
hGRalpha	B-Gene
D401H	O
did	O
not	O
exert	O
a	O
dominant	O
positive	O
or	O
negative	O
effect	O
upon	O
the	O
wild	O
-	O
type	O
receptor	O
,	O
it	O
preserved	O
its	O
ability	O
to	O
bind	O
to	O
glucocorticoid	B-Chemical
response	O
elements	O
,	O
and	O
displayed	O
a	O
normal	O
interaction	O
with	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
-	I-Gene
interacting	I-Gene
protein	I-Gene
1	I-Gene
coactivator	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
The	O
mutant	O
receptor	O
hGRalpha	B-Gene
D401H	O
enhances	O
the	O
transcriptional	O
activity	O
of	O
glucocorticoid	B-Gene
-	I-Gene
responsive	I-Gene
genes	I-Gene
.	O
</ALL>	O

<ALL>	O
The	O
presence	O
of	O
the	O
D401H	B-Variant
mutation	O
may	O
predispose	O
subjects	O
to	O
obesity	B-Disease
,	O
hypertension	B-Disease
,	O
and	O
other	O
manifestations	O
of	O
the	O
metabolic	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Activated	O
Ras	B-Gene
alters	O
lens	O
and	O
corneal	O
development	O
through	O
induction	O
of	O
distinct	O
downstream	O
targets	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Mammalian	O
Ras	B-Gene
genes	O
regulate	O
diverse	O
cellular	O
processes	O
including	O
proliferation	O
and	O
differentiation	O
and	O
are	O
frequently	O
mutated	O
in	O
human	B-Species
cancers	B-Disease
.	O
</ALL>	O

<ALL>	O
Tumor	B-Disease
development	O
in	O
response	O
to	O
Ras	B-Gene
activation	O
varies	O
between	O
different	O
tissues	O
and	O
the	O
molecular	O
basis	O
for	O
these	O
variations	O
are	O
poorly	O
understood	O
.	O
</ALL>	O

<ALL>	O
The	O
murine	B-Species
lens	O
and	O
cornea	O
have	O
a	O
common	O
embryonic	O
origin	O
and	O
arise	O
from	O
adjacent	O
regions	O
of	O
the	O
surface	O
ectoderm	O
.	O
</ALL>	O

<ALL>	O
Activation	O
of	O
the	O
fibroblast	B-Gene
growth	I-Gene
factor	I-Gene
(	O
FGF	B-Gene
)	O
signaling	O
pathway	O
induces	O
the	O
corneal	O
epithelial	O
cells	O
to	O
proliferate	O
and	O
the	O
lens	O
epithelial	O
cells	O
to	O
exit	O
the	O
cell	O
cycle	O
.	O
</ALL>	O

<ALL>	O
The	O
molecular	O
mechanisms	O
that	O
regulate	O
the	O
differential	O
responses	O
of	O
these	O
two	O
related	O
tissues	O
have	O
not	O
been	O
defined	O
.	O
</ALL>	O

<ALL>	O
We	O
have	O
generated	O
transgenic	O
mice	B-Species
that	O
express	O
a	O
constitutively	O
active	O
version	O
of	O
human	B-Species
H	B-Gene
-	I-Gene
Ras	I-Gene
in	O
their	O
lenses	O
and	O
corneas	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Ras	B-Gene
transgenic	O
lenses	O
and	O
corneal	O
epithelial	O
cells	O
showed	O
increased	O
proliferation	O
with	O
concomitant	O
increases	O
in	O
cyclin	B-Gene
D1	I-Gene
and	I-Gene
D2	I-Gene
expression	O
.	O
</ALL>	O

<ALL>	O
This	O
initial	O
increase	O
in	O
proliferation	O
is	O
sustained	O
in	O
the	O
cornea	O
but	O
not	O
in	O
the	O
lens	O
epithelial	O
cells	O
.	O
</ALL>	O

<ALL>	O
Coincidentally	O
,	O
cdk	B-Gene
inhibitors	O
p27Kip1	B-Gene
and	O
p57Kip2	B-Gene
were	O
upregulated	O
in	O
the	O
Ras	B-Gene
transgenic	O
lenses	O
but	O
not	O
in	O
the	O
corneas	O
.	O
</ALL>	O

<ALL>	O
Phospho	O
-	O
Erk1	B-Gene
and	O
Erk2	B-Gene
levels	O
were	O
elevated	O
in	O
the	O
lens	O
but	O
not	O
in	O
the	O
cornea	O
and	O
Spry	B-Gene
1	I-Gene
and	O
Spry	B-Gene
2	I-Gene
,	O
negative	O
regulators	O
of	O
Ras	B-Gene
-	O
Raf	B-Gene
-	O
Erk	B-Gene
signaling	O
,	O
were	O
upregulated	O
more	O
in	O
the	O
corneal	O
than	O
in	O
the	O
lens	O
epithelial	O
cells	O
.	O
</ALL>	O

<ALL>	O
Both	O
lens	O
and	O
corneal	O
differentiation	O
programs	O
were	O
sensitive	O
to	O
Ras	B-Gene
activation	O
.	O
</ALL>	O

<ALL>	O
Ras	B-Gene
transgenic	O
embryos	O
showed	O
a	O
distinctive	O
alteration	O
in	O
the	O
architecture	O
of	O
the	O
lens	O
pit	O
.	O
</ALL>	O

<ALL>	O
Ras	B-Gene
activation	O
,	O
though	O
sufficient	O
for	O
upregulation	O
of	O
Prox1	B-Gene
,	O
a	O
transcription	O
factor	O
critical	O
for	O
cell	O
cycle	O
exit	O
and	O
initiation	O
of	O
fiber	O
differentiation	O
,	O
is	O
not	O
sufficient	O
for	O
induction	O
of	O
terminal	O
fiber	O
differentiation	O
.	O
</ALL>	O

<ALL>	O
Expression	O
of	O
Keratin	B-Gene
12	I-Gene
,	O
a	O
marker	O
of	O
corneal	O
epithelial	O
differentiation	O
,	O
was	O
reduced	O
in	O
the	O
Ras	B-Gene
transgenic	O
corneas	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Collectively	O
,	O
these	O
results	O
suggest	O
that	O
Ras	B-Gene
activation	O
a	O
)	O
induces	O
distinct	O
sets	O
of	O
downstream	O
targets	O
in	O
the	O
lens	O
and	O
cornea	O
resulting	O
in	O
distinct	O
cellular	O
responses	O
and	O
b	O
)	O
is	O
sufficient	O
for	O
initiation	O
but	O
not	O
completion	O
of	O
lens	O
fiber	O
differentiation	O
.	O
</ALL>	O

<ALL>	O
A	O
novel	O
mutation	O
in	O
the	O
connexin	B-Gene
26	I-Gene
gene	O
(	O
GJB2	B-Gene
)	O
in	O
a	O
child	O
with	O
clinical	O
and	O
histological	O
features	O
of	O
keratitis	B-Disease
-	I-Disease
ichthyosis	I-Disease
-	I-Disease
deafness	I-Disease
(	I-Disease
KID	I-Disease
)	I-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Keratitis	B-Disease
-	I-Disease
ichthyosis	I-Disease
-	I-Disease
deafness	I-Disease
(	I-Disease
KID	I-Disease
)	I-Disease
syndrome	I-Disease
is	O
a	O
rare	O
congenital	B-Disease
ectodermal	I-Disease
disorder	I-Disease
,	O
caused	O
by	O
heterozygous	O
missense	O
mutation	O
in	O
GJB2	B-Gene
,	O
encoding	O
the	O
gap	O
junction	O
protein	O
connexin	B-Gene
26	I-Gene
.	O
</ALL>	O

<ALL>	O
The	O
commonest	O
mutation	O
is	O
the	O
p	B-Variant
.	I-Variant
Asp50Asn	I-Variant
mutation	O
,	O
and	O
only	O
a	O
few	O
other	O
mutations	O
have	O
been	O
described	O
to	O
date	O
.	O
</ALL>	O

<ALL>	O
AIM	O
:	O
To	O
report	O
the	O
fatal	O
clinical	O
course	O
and	O
characterize	O
the	O
genetic	O
background	O
of	O
a	O
premature	O
male	O
neonate	O
with	O
the	O
clinical	O
and	O
histological	O
features	O
of	O
KID	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
and	O
used	O
for	O
PCR	O
amplification	O
of	O
the	O
GJB2	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Direct	O
sequencing	O
was	O
used	O
for	O
mutation	O
analysis	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
clinical	O
features	O
included	O
hearing	B-Disease
impairment	I-Disease
,	O
ichthyosiform	B-Disease
erythroderma	I-Disease
with	O
hyperkeratotic	O
plaques	O
,	O
palmoplantar	B-Disease
keratoderma	I-Disease
,	O
alopecia	B-Disease
of	I-Disease
the	I-Disease
scalp	I-Disease
and	I-Disease
eyelashes	I-Disease
,	O
and	O
a	O
thick	O
vernix	O
caseosa	O
-	O
like	O
covering	O
of	O
the	O
scalp	O
.	O
</ALL>	O

<ALL>	O
On	O
histological	O
analysis	O
,	O
features	O
characteristic	O
of	O
KID	B-Disease
syndrome	I-Disease
,	O
such	O
as	O
acanthosis	B-Disease
and	O
papillomatosis	B-Disease
of	O
the	O
epidermis	O
with	O
basket	O
-	O
weave	O
hyperkeratosis	B-Disease
,	O
were	O
seen	O
.	O
</ALL>	O

<ALL>	O
The	O
skin	O
symptoms	O
were	O
treated	O
successfully	O
with	O
acitretin	B-Chemical
0.5	O
mg	O
/	O
kg	O
.	O
</ALL>	O

<ALL>	O
The	O
boy	O
developed	O
intraventricular	B-Disease
and	I-Disease
intracerebral	I-Disease
haemorrhage	I-Disease
,	O
leading	O
to	O
hydrocephalus	B-Disease
.	O
</ALL>	O

<ALL>	O
His	O
condition	O
was	O
further	O
complicated	O
by	O
septicaemia	B-Disease
and	O
meningitis	B-Disease
caused	O
by	O
infection	B-Disease
with	O
extended	O
-	O
spectrum	O
beta	O
-	O
lactamase	O
-	O
producing	O
Klebsiella	B-Disease
pneumoniae	I-Disease
.	O
</ALL>	O

<ALL>	O
Severe	O
respiratory	B-Disease
failure	I-Disease
followed	O
,	O
and	O
the	O
child	O
died	O
at	O
46	O
weeks	O
of	O
gestational	O
age	O
(	O
13	O
weeks	O
postnatally	O
)	O
.	O
</ALL>	O

<ALL>	O
Sequencing	O
of	O
the	O
GJB2	B-Gene
gene	O
showed	O
that	O
the	O
child	O
was	O
heterozygous	O
for	O
a	O
novel	O
nucleotide	O
change	O
,	O
c.263C	B-Variant
>	I-Variant
T	I-Variant
,	O
in	O
exon	O
2	O
,	O
leading	O
to	O
a	O
substitution	O
of	O
alanine	B-Variant
for	I-Variant
valine	I-Variant
at	I-Variant
position	I-Variant
88	I-Variant
(	O
p	B-Variant
.	I-Variant
Ala88Val	I-Variant
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
This	O
study	O
has	O
identified	O
a	O
new	O
heterozygous	O
de	O
novo	O
mutation	O
in	O
the	O
Cx26	B-Gene
gene	O
(	O
c.263C	B-Variant
>	I-Variant
T	I-Variant
;	O
p	B-Variant
.	I-Variant
Ala88Val	I-Variant
)	O
leading	O
to	O
KID	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Inactivation	O
of	O
Sag	B-Gene
/	O
Rbx2	B-Gene
/	O
Roc2	B-Gene
e3	B-Gene
ubiquitin	I-Gene
ligase	I-Gene
triggers	O
senescence	O
and	O
inhibits	O
kras	B-Gene
-	O
induced	O
immortalization	O
.	O
</ALL>	O

<ALL>	O
Our	O
recent	O
study	O
showed	O
that	O
SAG	B-Gene
/	O
RBX2	B-Gene
E3	B-Gene
ubiquitin	I-Gene
ligase	I-Gene
regulates	O
apoptosis	O
and	O
vasculogenesis	O
by	O
promoting	O
degradation	O
of	O
NOXA	B-Gene
and	O
NF1	B-Gene
,	O
and	O
co	O
-	O
operates	O
with	O
Kras	B-Gene
to	O
promote	O
lung	B-Disease
tumorigenesis	I-Disease
by	O
activating	O
NFkappaB	B-Gene
and	O
mTOR	B-Gene
pathways	O
via	O
targeted	O
degradation	O
of	O
tumor	B-Disease
suppressive	O
substrates	O
including	O
IkappaB	B-Gene
,	O
DEPTOR	B-Gene
,	O
p21	B-Gene
and	O
p27	B-Gene
.	O
</ALL>	O

<ALL>	O
Here	O
we	O
investigated	O
the	O
role	O
of	O
Sag	B-Gene
/	O
Rbx2	B-Gene
E3	B-Gene
ligase	I-Gene
in	O
cellular	O
senescence	O
and	O
immortalization	O
of	O
mouse	B-Species
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
and	O
report	O
that	O
Sag	B-Gene
is	O
required	O
for	O
proper	O
cell	O
proliferation	O
and	O
Kras	B-Gene
(	O
G12D	B-Variant
)	O
-	O
induced	O
immortalization	O
.	O
</ALL>	O

<ALL>	O
Sag	B-Gene
inactivation	O
by	O
genetic	O
deletion	O
remarkably	O
suppresses	O
cell	O
proliferation	O
by	O
inducing	O
senescence	O
,	O
which	O
is	O
associated	O
with	O
accumulation	O
of	O
p16	B-Gene
,	O
but	O
not	O
p53	B-Gene
.	O
</ALL>	O

<ALL>	O
Mechanistically	O
,	O
Sag	B-Gene
deletion	O
caused	O
accumulation	O
of	O
Jun	B-Gene
-	I-Gene
B	I-Gene
,	O
a	O
substrate	O
of	O
Sag	B-Gene
-	O
Fbxw7	B-Gene
E3	B-Gene
ligase	I-Gene
and	O
a	O
transcription	O
factor	O
that	O
drives	O
p16	B-Gene
transcription	O
.	O
</ALL>	O

<ALL>	O
Importantly	O
,	O
senescence	O
triggered	O
by	O
Sag	B-Gene
deletion	O
can	O
be	O
largely	O
rescued	O
by	O
simultaneous	O
deletion	O
of	O
Cdkn2a	B-Gene
,	O
the	O
p16	B-Gene
encoding	O
gene	O
,	O
indicating	O
its	O
causal	O
role	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
Kras	B-Gene
(	O
G12D	B-Variant
)	O
-	O
induced	O
immortalization	O
can	O
also	O
be	O
abrogated	O
by	O
Sag	B-Gene
deletion	O
via	O
senescence	O
induction	O
,	O
which	O
is	O
again	O
rescued	O
by	O
simultaneous	O
deletion	O
of	O
Cdkn2a	B-Gene
.	O
</ALL>	O

<ALL>	O
Finally	O
,	O
we	O
found	O
that	O
Sag	B-Gene
deletion	O
inactivates	O
Kras	B-Gene
(	O
G12D	B-Variant
)	O
activity	O
and	O
block	O
the	O
MAPK	B-Gene
signaling	O
pathway	O
,	O
together	O
with	O
accumulated	O
p16	B-Gene
,	O
to	O
induce	O
senescence	O
.	O
</ALL>	O

<ALL>	O
Taken	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
Sag	B-Gene
is	O
a	O
Kras	B-Gene
(	O
G12D	B-Variant
)	O
-	O
cooperating	O
oncogene	O
required	O
for	O
Kras	B-Gene
(	O
G12D	B-Variant
)	O
-	O
induced	O
immortalization	O
and	O
transformation	O
,	O
and	O
targeting	O
SAG	B-Gene
-	O
SCF	B-Gene
E3	B-Gene
ligase	I-Gene
may	O
,	O
therefore	O
,	O
have	O
therapeutic	O
value	O
for	O
senescence	O
-	O
based	O
cancer	B-Disease
treatment	O
.	O
</ALL>	O

<ALL>	O
Mechanisms	O
Underlying	O
Latent	O
Disease	O
Risk	O
Associated	O
with	O
Early	O
-	O
Life	O
Arsenic	B-Chemical
Exposure	O
:	O
Current	O
Research	O
Trends	O
and	O
Scientific	O
Gaps	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Millions	O
of	O
individuals	O
worldwide	O
,	O
particularly	O
those	O
living	O
in	O
rural	O
and	O
developing	O
areas	O
,	O
are	O
exposed	O
to	O
harmful	O
levels	O
of	O
inorganic	B-Chemical
arsenic	I-Chemical
(	O
iAs	B-Chemical
)	O
in	O
their	O
drinking	O
water	O
.	O
</ALL>	O

<ALL>	O
Inorganic	B-Chemical
As	I-Chemical
exposure	O
during	O
key	O
developmental	O
periods	O
is	O
associated	O
with	O
a	O
variety	O
of	O
adverse	O
health	O
effects	O
including	O
those	O
that	O
are	O
evident	O
in	O
adulthood	O
.	O
</ALL>	O

<ALL>	O
There	O
is	O
considerable	O
interest	O
in	O
identifying	O
the	O
molecular	O
mechanisms	O
that	O
relate	O
early	O
-	O
life	O
iAs	B-Chemical
exposure	O
to	O
the	O
development	O
of	O
these	O
latent	O
diseases	O
,	O
particularly	O
in	O
relationship	O
to	O
cancer	B-Disease
.	O
</ALL>	O

<ALL>	O
OBJECTIVES	O
:	O
This	O
work	O
summarizes	O
research	O
on	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
the	O
increased	O
risk	O
of	O
cancer	B-Disease
development	O
in	O
adulthood	O
that	O
is	O
associated	O
with	O
early	O
-	O
life	O
iAs	B-Chemical
exposure	O
.	O
</ALL>	O

<ALL>	O
DISCUSSION	O
:	O
Epigenetic	O
reprogramming	O
that	O
imparts	O
functional	O
changes	O
in	O
gene	O
expression	O
,	O
the	O
development	O
of	O
cancer	B-Disease
stem	O
cells	O
,	O
and	O
immunomodulation	O
are	O
plausible	O
underlying	O
mechanisms	O
by	O
which	O
early	O
-	O
life	O
iAs	B-Chemical
exposure	O
elicits	O
latent	O
carcinogenic	B-Disease
effects	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Evidence	O
is	O
mounting	O
that	O
relates	O
early	O
-	O
life	O
iAs	B-Chemical
exposure	O
and	O
cancer	B-Disease
development	O
later	O
in	O
life	O
.	O
</ALL>	O

<ALL>	O
Future	O
research	O
should	O
include	O
animal	O
studies	O
that	O
address	O
mechanistic	O
hypotheses	O
and	O
studies	O
of	O
human	B-Species
populations	O
that	O
integrate	O
early	O
-	O
life	O
exposure	O
,	O
molecular	O
alterations	O
,	O
and	O
latent	O
disease	O
outcomes	O
.	O
</ALL>	O

<ALL>	O
Brain	B-Gene
-	I-Gene
derived	I-Gene
neurotrophic	I-Gene
factor	I-Gene
attenuates	O
doxorubicin	B-Chemical
-	O
induced	O
cardiac	B-Disease
dysfunction	I-Disease
through	O
activating	O
Akt	B-Gene
signalling	O
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
clinical	O
application	O
of	O
doxorubicin	B-Chemical
(	O
Dox	B-Chemical
)	O
is	O
limited	O
by	O
its	O
adverse	O
effect	O
of	O
cardiotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
Previous	O
studies	O
have	O
suggested	O
the	O
cardioprotective	O
effect	O
of	O
brain	B-Gene
-	I-Gene
derived	I-Gene
neurotrophic	I-Gene
factor	I-Gene
(	O
BDNF	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
We	O
hypothesize	O
that	O
BDNF	B-Gene
could	O
protect	O
against	O
Dox	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
Sprague	O
Dawley	O
rats	B-Species
were	O
injected	O
with	O
Dox	B-Chemical
(	O
2.5	O
mg	O
/	O
kg	O
,	O
3	O
times	O
/	O
week	O
,	O
i.p	O
.	O
)	O
,	O
</ALL>	O

<ALL>	O
in	O
the	O
presence	O
or	O
absence	O
of	O
recombinant	O
BDNF	B-Gene
(	O
0.4	O
ug	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
</ALL>	O

<ALL>	O
for	O
2	O
weeks	O
.	O
</ALL>	O

<ALL>	O
H9c2	B-CellLine
cells	O
were	O
treated	O
with	O
Dox	B-Chemical
(	O
1	O
uM	O
)	O
and	O
/	O
or	O
BDNF	B-Gene
(	O
400	O
ng	O
/	O
ml	O
)	O
for	O
24	O
hrs	O
.	O
</ALL>	O

<ALL>	O
Functional	O
roles	O
of	O
BDNF	B-Gene
against	O
Dox	B-Chemical
-	O
induced	O
cardiac	B-Disease
injury	I-Disease
were	O
examined	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
</ALL>	O

<ALL>	O
Protein	O
level	O
of	O
BDNF	B-Gene
was	O
reduced	O
in	O
Dox	B-Chemical
-	O
treated	O
rat	B-Species
ventricles	O
,	O
whereas	O
BDNF	B-Gene
and	O
its	O
receptor	O
tropomyosin	B-Gene
-	I-Gene
related	I-Gene
kinase	I-Gene
B	I-Gene
(	O
TrkB	B-Gene
)	O
were	O
markedly	O
up	O
-	O
regulated	O
after	O
BDNF	B-Gene
administration	O
.	O
</ALL>	O

<ALL>	O
Brain	B-Gene
-	I-Gene
derived	I-Gene
neurotrophic	I-Gene
factor	I-Gene
significantly	O
inhibited	O
Dox	B-Chemical
-	O
induced	O
cardiomyocyte	O
apoptosis	O
,	O
oxidative	O
stress	O
and	O
cardiac	B-Disease
dysfunction	I-Disease
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Meanwhile	O
,	O
BDNF	B-Gene
increased	O
cell	O
viability	O
,	O
inhibited	O
apoptosis	O
and	O
DNA	O
damage	O
of	O
Dox	B-Chemical
-	O
treated	O
H9c2	B-CellLine
cells	O
.	O
</ALL>	O

<ALL>	O
Investigations	O
of	O
the	O
underlying	O
mechanisms	O
revealed	O
that	O
BDNF	B-Gene
activated	O
Akt	B-Gene
and	O
preserved	O
phosphorylation	O
of	O
mammalian	B-Gene
target	I-Gene
of	I-Gene
rapamycin	I-Gene
and	O
Bad	B-Gene
without	O
affecting	O
p38	B-Gene
mitogen	I-Gene
-	I-Gene
activated	I-Gene
protein	I-Gene
kinase	I-Gene
and	O
extracellular	B-Gene
regulated	I-Gene
protein	I-Gene
kinase	I-Gene
pathways	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
the	O
beneficial	O
effect	O
of	O
BDNF	B-Gene
was	O
abolished	O
by	O
BDNF	B-Gene
scavenger	O
TrkB	B-Gene
-	O
Fc	O
or	O
Akt	B-Gene
inhibitor	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
our	O
findings	O
reveal	O
a	O
potent	O
protective	O
role	O
of	O
BDNF	B-Gene
against	O
Dox	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
by	O
activating	O
Akt	B-Gene
signalling	O
,	O
which	O
may	O
facilitate	O
the	O
safe	O
use	O
of	O
Dox	B-Chemical
in	O
cancer	B-Disease
treatment	O
.	O
</ALL>	O

<ALL>	O
Atrial	B-Disease
fibrillation	I-Disease
following	O
chemotherapy	O
for	O
stage	O
IIIE	O
diffuse	O
large	O
B	O
-	O
cell	O
gastric	B-Disease
lymphoma	I-Disease
in	O
a	O
patient	B-Species
with	O
myotonic	B-Disease
dystrophy	I-Disease
(	O
Steinert	B-Disease
's	I-Disease
disease	I-Disease
)	O
.	O
</ALL>	O

<ALL>	O
The	O
authors	O
describe	O
the	O
unusual	O
association	O
between	O
diffuse	O
B	O
-	O
cell	O
gastric	B-Disease
lymphoma	I-Disease
and	O
myotonic	B-Disease
dystrophy	I-Disease
,	O
the	O
most	O
common	O
form	O
of	O
adult	O
muscular	B-Disease
dystrophy	I-Disease
,	O
and	O
sudden	O
atrial	B-Disease
fibrillation	I-Disease
following	O
one	O
cycle	O
of	O
doxorubicin	B-Chemical
-	O
based	O
chemotherapy	O
in	O
the	O
same	O
patient	B-Species
.	O
</ALL>	O

<ALL>	O
Atrial	B-Disease
fibrillation	I-Disease
or	O
other	O
cardiac	B-Disease
arrhythmias	I-Disease
are	O
unusual	O
complications	O
in	O
patients	B-Species
treated	O
with	O
chemotherapy	O
.	O
</ALL>	O

<ALL>	O
The	O
cardiac	B-Disease
toxicity	I-Disease
intrinsically	O
associated	O
with	O
the	O
aggressive	O
chemotherapy	O
employed	O
could	O
function	O
as	O
a	O
triggering	O
factor	O
for	O
the	O
arrhythmia	B-Disease
in	O
the	O
predisposed	O
myocardium	O
of	O
this	O
patient	B-Species
.	O
</ALL>	O

<ALL>	O
Ca2	B-Chemical
+	I-Chemical
dependence	O
of	O
the	O
Ca2	B-Chemical
+	I-Chemical
-	O
selective	O
TRPV6	B-Gene
channel	O
.	O
</ALL>	O

<ALL>	O
Microfluorimetry	O
and	O
patch	O
-	O
clamp	O
experiments	O
were	O
performed	O
on	O
TRPV6	B-Gene
-	O
expressing	O
HEK	B-CellLine
cells	O
to	O
determine	O
whether	O
this	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+	I-Chemical
)	I-Chemical
-	O
sensing	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+	I-Chemical
)	I-Chemical
channel	O
is	O
constitutively	O
active	O
.	O
</ALL>	O

<ALL>	O
Intact	O
cells	O
loaded	O
with	O
fura	B-Chemical
-	I-Chemical
2	I-Chemical
had	O
an	O
elevated	O
intracellular	O
free	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+	I-Chemical
)	I-Chemical
concentration	O
(	O
(	O
i	O
)	O
)	O
,	O
which	O
decreased	O
to	O
the	O
same	O
level	O
such	O
as	O
in	O
non	O
-	O
transfected	O
cells	O
if	O
external	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+	I-Chemical
)	I-Chemical
was	O
chelated	O
by	O
EGTA	B-Chemical
.	O
</ALL>	O

<ALL>	O
Whole	O
cell	O
recordings	O
from	O
non	O
-	O
transfected	O
HEK	B-CellLine
cells	O
and	O
cells	O
expressing	O
human	B-Species
TRPV6	B-Gene
revealed	O
the	O
presence	O
of	O
a	O
basal	O
inward	O
current	O
in	O
both	O
types	O
of	O
cells	O
when	O
the	O
internal	O
solution	O
contained	O
0.1	O
mm	O
EGTA	B-Chemical
and	O
100	O
nm	O
(	O
i	O
)	O
or	O
if	O
the	O
cytosolic	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+	I-Chemical
)	I-Chemical
buffering	O
remained	O
undisturbed	O
in	O
perforated	O
patch	O
-	O
clamp	O
experiments	O
.	O
</ALL>	O

<ALL>	O
If	O
recombinantly	O
expressed	O
TRPV6	B-Gene
forms	O
open	O
channels	O
,	O
one	O
would	O
expect	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+	I-Chemical
)	I-Chemical
-	O
induced	O
current	O
inhibition	O
,	O
because	O
TRPV6	B-Gene
is	O
negatively	O
regulated	O
by	O
internal	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+	I-Chemical
)	I-Chemical
.	O
</ALL>	O

<ALL>	O
However	O
,	O
dialyzing	O
solutions	O
with	O
high	O
such	O
as	O
1	O
microm	O
into	O
TRPV6	B-Gene
-	O
expressing	O
cells	O
did	O
not	O
block	O
the	O
basal	O
inward	O
current	O
,	O
which	O
was	O
not	O
different	O
from	O
the	O
recordings	O
from	O
non	O
-	O
transfected	O
cells	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
dialyzing	O
0.5	O
mm	O
EGTA	B-Chemical
into	O
TRPV6	B-Gene
-	O
expressing	O
cells	O
readily	O
activated	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+	I-Chemical
)	I-Chemical
inward	O
currents	O
,	O
which	O
were	O
undetectable	O
in	O
non	O
-	O
transfected	O
cells	O
.	O
</ALL>	O

<ALL>	O
Interestingly	O
,	O
monovalent	O
cations	O
permeated	O
the	O
TRPV6	B-Gene
channels	O
under	O
conditions	O
where	O
no	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+	I-Chemical
)	I-Chemical
permeation	O
was	O
detectable	O
,	O
indicating	O
that	O
divalent	O
cations	O
block	O
TRPV6	B-Gene
channels	O
from	O
the	O
extracellular	O
side	O
.	O
</ALL>	O

<ALL>	O
Like	O
human	B-Species
TRPV6	B-Gene
,	O
the	O
truncated	O
human	B-Species
TRPV6	B-Gene
(	O
Delta695	B-Variant
-	I-Variant
725	I-Variant
)	O
,	O
which	O
lacks	O
the	O
C	O
-	O
terminal	O
domain	O
required	O
for	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+	I-Chemical
)	I-Chemical
-	O
calmodulin	O
binding	O
,	O
does	O
not	O
form	O
constitutive	O
active	O
channels	O
,	O
whereas	O
the	O
human	B-Species
TRPV6	B-Gene
(	O
D542A	B-Variant
)	O
,	O
carrying	O
a	O
point	O
mutation	O
in	O
the	O
presumed	O
pore	O
region	O
,	O
does	O
not	O
function	O
as	O
a	O
channel	O
.	O
</ALL>	O

<ALL>	O
In	O
summary	O
,	O
no	O
constitutive	O
open	O
TRPV6	B-Gene
channels	O
were	O
detected	O
in	O
patch	O
-	O
clamp	O
experiments	O
from	O
transfected	O
HEK	B-CellLine
cells	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
channel	O
activity	O
is	O
highly	O
regulated	O
by	O
intracellular	O
and	O
extracellular	O
divalent	O
cations	O
.	O
</ALL>	O

<ALL>	O
Identification	O
of	O
novel	O
type	O
VII	B-Gene
collagen	I-Gene
gene	O
mutations	O
resulting	O
in	O
severe	O
recessive	B-Disease
dystrophic	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
.	O
</ALL>	O

<ALL>	O
In	O
this	O
work	O
,	O
we	O
studied	O
the	O
proband	O
in	O
a	O
small	O
nuclear	O
family	O
of	O
Chinese	O
and	O
Dutch	O
/	O
German	O
descent	O
and	O
identified	O
two	O
novel	O
mutations	O
in	O
the	O
type	O
VII	B-Gene
collagen	I-Gene
gene	O
leading	O
to	O
recessive	B-Disease
dystrophic	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
,	O
Hallopeau	B-Disease
-	I-Disease
Siemens	I-Disease
variant	O
(	O
HS	B-Disease
-	I-Disease
RDEB	I-Disease
)	O
.	O
</ALL>	O

<ALL>	O
The	O
maternal	O
mutation	O
is	O
a	O
single	B-Variant
base	I-Variant
pair	I-Variant
deletion	I-Variant
of	I-Variant
a	I-Variant
cytosine	I-Variant
nucleotide	I-Variant
in	O
exon	O
26	O
,	O
designated	O
3472delC	B-Variant
,	O
resulting	O
in	O
a	O
frameshift	O
and	O
a	O
premature	O
termination	O
codon	O
(	O
PTC	O
)	O
within	O
the	O
same	O
exon	O
,	O
7	O
bp	O
downstream	O
of	O
the	O
site	O
of	O
the	O
mutation	O
.	O
</ALL>	O

<ALL>	O
The	O
paternal	O
mutation	O
is	O
a	O
G	B-Variant
-	I-Variant
-	I-Variant
>	I-Variant
A	I-Variant
transition	O
located	O
at	O
the	O
5	O
'	O
donor	O
splice	O
site	O
within	O
intron	O
51	O
,	O
designated	O
IVS51	B-Variant
+	I-Variant
1	I-Variant
G	I-Variant
-	I-Variant
-	I-Variant
>	I-Variant
A	I-Variant
.	O
</ALL>	O

<ALL>	O
This	O
mutation	O
leads	O
to	O
the	O
activation	O
of	O
a	O
cryptic	O
splice	O
site	O
,	O
32	O
bp	O
downstream	O
of	O
the	O
mutation	O
site	O
and	O
to	O
subsequent	O
aberrant	O
out	O
-	O
of	O
-	O
frame	O
splicing	O
,	O
resulting	O
in	O
two	O
alternative	O
mRNA	O
transcripts	O
and	O
a	O
downstream	O
PTC	O
.	O
</ALL>	O

<ALL>	O
To	O
our	O
knowledge	O
,	O
these	O
two	O
mutations	O
have	O
not	O
been	O
previously	O
reported	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
extend	O
the	O
body	O
of	O
evidence	O
for	O
compound	O
heterozygous	O
mutations	O
leading	O
to	O
HS	B-Disease
-	I-Disease
RDEB	I-Disease
and	O
provide	O
the	O
basis	O
for	O
prenatal	O
diagnosis	O
in	O
this	O
family	O
.	O
</ALL>	O

<ALL>	O
A	O
Cys	B-Variant
23	I-Variant
-	I-Variant
Ser	I-Variant
23	I-Variant
substitution	O
in	O
the	O
5	B-Gene
-	I-Gene
HT	I-Gene
(	I-Gene
2C	I-Gene
)	I-Gene
receptor	I-Gene
gene	O
influences	O
body	O
weight	O
regulation	O
in	O
females	O
with	O
seasonal	B-Disease
affective	I-Disease
disorder	I-Disease
:	O
an	O
Austrian	O
-	O
Canadian	O
collaborative	O
study	O
.	O
</ALL>	O

<ALL>	O
Most	O
females	O
with	O
seasonal	B-Disease
affective	I-Disease
disorder	I-Disease
(	O
SAD	B-Disease
)	O
exhibit	O
atypical	O
vegetative	O
symptoms	O
such	O
as	O
overeating	O
,	O
and	O
weight	B-Disease
gain	I-Disease
when	I-Disease
depressed	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
serotonin	B-Gene
2C	I-Gene
receptor	I-Gene
(	O
5	B-Gene
-	I-Gene
HT	I-Gene
(	I-Gene
2C	I-Gene
)	I-Gene
)	O
plays	O
a	O
key	O
role	O
in	O
control	O
of	O
appetite	O
and	O
satiety	O
.	O
</ALL>	O

<ALL>	O
A	O
5	B-Gene
-	I-Gene
HT	I-Gene
(	I-Gene
2C	I-Gene
)	I-Gene
Cys	B-Variant
23	I-Variant
Ser	I-Variant
substitution	O
,	O
coded	O
for	O
by	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
Cys	B-Variant
23	I-Variant
Ser	I-Variant
)	O
within	O
the	O
5	B-Gene
-	I-Gene
HT	I-Gene
(	I-Gene
2C	I-Gene
)	I-Gene
gene	O
,	O
has	O
been	O
shown	O
to	O
influence	O
5	B-Gene
-	I-Gene
HT	I-Gene
(	I-Gene
2C	I-Gene
)	I-Gene
function	O
.	O
</ALL>	O

<ALL>	O
We	O
hypothesized	O
that	O
Cys	B-Variant
23	I-Variant
Ser	I-Variant
influences	O
weight	O
regulation	O
in	O
females	O
with	O
SAD	B-Disease
.	O
</ALL>	O

<ALL>	O
Two	O
independent	O
samples	O
from	O
Austria	O
(	O
162	O
females	O
with	O
SAD	B-Disease
,	O
119	O
controls	O
)	O
,	O
and	O
Canada	O
(	O
90	O
females	O
with	O
SAD	B-Disease
,	O
42	O
controls	O
)	O
were	O
genotyped	O
for	O
Cys	B-Variant
23	I-Variant
Ser	I-Variant
.	O
</ALL>	O

<ALL>	O
Influence	O
on	O
weight	O
regulation	O
was	O
analyzed	O
within	O
patients	B-Species
with	O
atypical	O
features	O
.	O
</ALL>	O

<ALL>	O
In	O
Austrians	O
,	O
genotype	O
distribution	O
differed	O
between	O
patients	B-Species
and	O
controls	O
(	O
p	O
=	O
0.044	O
)	O
and	O
Cys	B-Variant
23	I-Variant
Ser	I-Variant
was	O
associated	O
with	O
weight	O
(	O
p	O
=	O
0.039	O
)	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
;	O
p	O
=	O
0.038	O
)	O
,	O
and	O
seasonal	O
appetite	O
change	O
(	O
p	O
=	O
0.031	O
)	O
.	O
</ALL>	O

<ALL>	O
All	O
values	O
were	O
highest	O
in	O
Cys	O
/	O
Cys	O
,	O
intermediate	O
in	O
Cys	O
/	O
Ser	O
,	O
and	O
lowest	O
in	O
Ser	O
/	O
Ser	O
carriers	O
.	O
</ALL>	O

<ALL>	O
In	O
Canadian	O
patients	B-Species
,	O
Cys	B-Variant
23	I-Variant
Ser	I-Variant
was	O
associated	O
with	O
minimum	O
lifetime	O
BMI	O
(	O
p	O
=	O
0.046	O
)	O
,	O
with	O
lowest	O
values	O
in	O
Ser	O
/	O
Ser	O
carriers	O
.	O
</ALL>	O

<ALL>	O
Our	O
data	O
provide	O
evidence	O
that	O
Cys	B-Variant
23	I-Variant
Ser	I-Variant
mediates	O
severity	O
of	O
weight	O
regulation	O
disturbances	O
in	O
females	O
with	O
SAD	B-Disease
,	O
and	O
the	O
gene	O
-	O
dose	O
effect	O
-	O
like	O
differences	O
suggest	O
a	O
direct	O
functional	O
role	O
of	O
Cys	B-Variant
23	I-Variant
Ser	I-Variant
in	O
the	O
behavioral	O
regulation	O
of	O
body	O
weight	O
.	O
</ALL>	O

<ALL>	O
Cytochrome	B-Gene
p4501A1	I-Gene
gene	O
variants	O
as	O
susceptibility	O
marker	O
for	O
prostate	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
CYP1A1	B-Gene
activates	O
environmental	O
procarcinogens	O
and	O
catalyzes	O
oxidative	O
metabolism	O
of	O
estrogens	O
and	O
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
etiology	O
of	O
prostate	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
To	O
evaluate	O
this	O
phenomenon	O
,	O
the	O
association	O
between	O
two	O
single	O
nucleotide	O
polymorphisms	O
(	O
A	B-Variant
to	I-Variant
G	I-Variant
transition	O
in	O
exon7	O
leading	O
to	O
amino	O
acid	O
substitution	O
Ile462Val	B-Variant
and	O
T3801C	B-Variant
at	O
3'UTR	O
)	O
of	O
CYP1A1	B-Gene
gene	O
in	O
prostate	B-Disease
cancer	I-Disease
were	O
analyzed	O
in	O
a	O
case	O
-	O
control	O
study	O
of	O
100	O
individuals	O
in	O
South	O
Indian	O
population	O
.	O
</ALL>	O

<ALL>	O
The	O
estimated	O
relative	O
risk	O
was	O
significantly	O
high	O
for	O
individuals	O
with	O
w1	O
/	O
m1	O
genotype	O
at	O
3'UTR	O
of	O
CYP1A1	B-Gene
gene	O
(	O
OR	O
-	O
4.64	O
;	O
95%CI	O
=	O
1.51	O
-	O
14.86	O
;	O
P	O
<	O
0.01	O
)	O
whereas	O
the	O
CYP1A1	B-Gene
Ile	B-Variant
/	I-Variant
Val	I-Variant
genotype	O
(	O
w2	O
/	O
m2	O
)	O
on	O
exon	O
7	O
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
decreased	O
risk	O
for	O
prostate	B-Disease
cancer	I-Disease
(	O
OR	O
-	O
0.17	O
;	O
95%CI	O
=	O
0.02	O
-	O
0.89	O
;	O
P	O
=	O
0.03	O
)	O
.	O
</ALL>	O

<ALL>	O
A	O
Stratified	O
analysis	O
of	O
the	O
genotypes	O
with	O
age	O
of	O
onset	O
and	O
tumor	B-Disease
grade	O
showed	O
the	O
w1	O
/	O
m1	O
genotype	O
to	O
be	O
significantly	O
associated	O
with	O
an	O
early	O
age	O
of	O
onset	O
;	O
however	O
the	O
tumor	B-Disease
grades	O
did	O
not	O
have	O
significant	O
association	O
with	O
the	O
variant	O
genotypes	O
.	O
</ALL>	O

<ALL>	O
Thus	O
the	O
present	O
study	O
indicates	O
that	O
individuals	O
with	O
the	O
variant	O
w1	O
/	O
m1	O
genotype	O
exhibit	O
an	O
increased	O
risk	O
while	O
those	O
with	O
w2	O
/	O
m2	O
genotype	O
exhibit	O
a	O
decreased	O
risk	O
for	O
prostate	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
An	O
evaluation	O
of	O
amikacin	B-Chemical
nephrotoxicity	B-Disease
in	O
the	O
hematology	O
/	O
oncology	O
population	O
.	O
</ALL>	O

<ALL>	O
Amikacin	B-Chemical
is	O
an	O
aminoglycoside	B-Chemical
commonly	O
used	O
to	O
provide	O
empirical	O
double	O
gram	O
-	O
negative	O
treatment	O
for	O
febrile	B-Disease
neutropenia	I-Disease
and	O
other	O
suspected	O
infections	B-Disease
.	O
</ALL>	O

<ALL>	O
Strategies	O
of	O
extended	O
-	O
interval	O
and	O
conventional	O
dosing	O
have	O
been	O
utilized	O
extensively	O
in	O
the	O
general	O
medical	O
population	O
;	O
however	O
,	O
data	O
are	O
lacking	O
to	O
support	O
a	O
dosing	O
strategy	O
in	O
the	O
hematology	O
/	O
oncology	O
population	O
.	O
</ALL>	O

<ALL>	O
To	O
evaluate	O
amikacin	B-Chemical
-	O
associated	O
nephrotoxicity	B-Disease
in	O
an	O
adult	O
hematology	O
/	O
oncology	O
population	O
,	O
a	O
prospective	O
,	O
randomized	O
,	O
open	O
-	O
label	O
trial	O
was	O
conducted	O
at	O
a	O
university	O
-	O
affiliated	O
medical	O
center	O
.	O
</ALL>	O

<ALL>	O
Forty	O
patients	B-Species
with	O
a	O
diagnosis	O
consistent	O
with	O
a	O
hematologic	B-Disease
/	I-Disease
oncologic	I-Disease
disorder	I-Disease
that	O
required	O
treatment	O
with	O
an	O
aminoglycoside	B-Chemical
were	O
randomized	O
to	O
either	O
conventional	O
or	O
extended	O
-	O
interval	O
amikacin	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
occurrence	O
of	O
nephrotoxicity	B-Disease
by	O
means	O
of	O
an	O
increase	O
in	O
serum	O
creatinine	B-Chemical
and	O
evaluation	O
of	O
efficacy	O
via	O
amikacin	B-Chemical
serum	O
concentrations	O
with	O
respective	O
pathogens	O
were	O
assessed	O
.	O
</ALL>	O

<ALL>	O
The	O
occurrence	O
of	O
nephrotoxicity	B-Disease
was	O
similar	O
between	O
the	O
conventional	O
and	O
extended	O
-	O
interval	O
groups	O
,	O
at	O
10	O
%	O
and	O
5	O
%	O
,	O
respectively	O
(	O
P	O
=	O
1.00	O
)	O
.	O
</ALL>	O

<ALL>	O
Six	O
patients	B-Species
in	O
the	O
conventional	O
group	O
had	O
a	O
positive	O
culture	O
,	O
compared	O
with	O
none	O
in	O
the	O
extended	O
-	O
interval	O
group	O
(	O
P	O
=	O
0.002	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
occurrence	O
of	O
nephrotoxicity	B-Disease
was	O
similar	O
between	O
the	O
two	O
dosing	O
regimens	O
,	O
but	O
the	O
distribution	O
of	O
risk	O
factors	O
was	O
variable	O
between	O
the	O
two	O
groups	O
.	O
</ALL>	O

<ALL>	O
Efficacy	O
could	O
not	O
be	O
assessed	O
.	O
</ALL>	O

<ALL>	O
Single	O
nucleotide	O
polymorphism	O
in	O
ABCG2	B-Gene
is	O
associated	O
with	O
irinotecan	B-Chemical
-	O
induced	O
severe	O
myelosuppression	B-Disease
.	O
</ALL>	O

<ALL>	O
Irinotecan	B-Chemical
is	O
an	O
anti	O
-	O
neoplastic	O
agent	O
that	O
is	O
widely	O
used	O
for	O
treating	O
colorectal	B-Disease
and	I-Disease
lung	I-Disease
cancers	I-Disease
,	O
but	O
often	O
causes	O
toxicities	B-Disease
such	O
as	O
severe	O
myelosuppression	B-Disease
and	O
diarrhea	B-Disease
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
performed	O
a	O
two	O
-	O
stage	O
case	O
-	O
control	O
association	O
study	O
for	O
irinotecan	B-Chemical
-	O
induced	O
severe	O
myelosuppression	B-Disease
(	O
grades	O
3	O
and	O
4	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
first	O
stage	O
,	O
23	O
patients	B-Species
who	O
developed	O
severe	O
myelosuppression	B-Disease
and	O
58	O
patients	B-Species
who	O
did	O
not	O
develop	O
any	O
toxicity	B-Disease
were	O
examined	O
for	O
170	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
14	O
genes	O
involved	O
in	O
the	O
metabolism	O
and	O
transport	O
of	O
irinotecan	B-Chemical
.	O
</ALL>	O

<ALL>	O
A	O
total	O
of	O
five	O
SNPs	O
were	O
identified	O
to	O
show	O
the	O
possible	O
association	O
with	O
severe	O
myelosuppression	B-Disease
(	O
P	O
(	O
Fisher	O
)	O
<	O
0.01	O
)	O
and	O
were	O
further	O
examined	O
in	O
7	O
cases	O
and	O
20	O
controls	O
in	O
the	O
second	O
stage	O
of	O
the	O
study	O
.	O
</ALL>	O

<ALL>	O
An	O
intronic	O
SNP	O
,	O
rs2622604	B-Variant
,	O
in	O
ABCG2	B-Gene
showed	O
P	O
(	O
Fisher	O
)	O
=	O
0.0419	O
in	O
the	O
second	O
stage	O
and	O
indicated	O
a	O
significant	O
association	O
with	O
severe	O
myelosuppression	B-Disease
in	O
the	O
combined	O
study	O
(	O
P	O
(	O
Fisher	O
)	O
=	O
0.000237	O
;	O
P	O
(	O
Corrected	O
)	O
=	O
0.036	O
)	O
.	O
</ALL>	O

<ALL>	O
Although	O
only	O
limited	O
subjects	O
were	O
investigated	O
,	O
our	O
results	O
suggested	O
that	O
a	O
genetic	O
polymorphism	O
in	O
ABCG2	B-Gene
might	O
alter	O
the	O
transport	O
activity	O
for	O
the	O
drug	O
and	O
elevate	O
the	O
systemic	O
circulation	O
level	O
of	O
irinotecan	B-Chemical
,	O
leading	O
to	O
severe	O
myelosuppression	B-Disease
.	O
</ALL>	O

<ALL>	O
Zebrafish	B-Species
chordin	B-Gene
-	I-Gene
like	I-Gene
and	O
chordin	B-Gene
are	O
functionally	O
redundant	O
in	O
regulating	O
patterning	O
of	O
the	O
dorsoventral	O
axis	O
.	O
</ALL>	O

<ALL>	O
Chordin	B-Gene
is	O
the	O
prototype	O
of	O
a	O
group	O
of	O
cysteine	B-Gene
-	I-Gene
rich	I-Gene
domain	I-Gene
-	I-Gene
containing	I-Gene
proteins	I-Gene
that	O
bind	O
and	O
modulate	O
signaling	O
of	O
various	O
TGFbeta	B-Gene
-	O
like	O
ligands	O
.	O
</ALL>	O

<ALL>	O
Chordin	B-Gene
-	I-Gene
like	I-Gene
1	I-Gene
and	I-Gene
2	I-Gene
(	O
CHL1	B-Gene
and	I-Gene
2	I-Gene
)	O
are	O
two	O
members	O
of	O
this	O
group	O
that	O
have	O
been	O
described	O
in	O
human	B-Species
,	O
mouse	B-Species
,	O
and	O
chick	B-Species
.	O
</ALL>	O

<ALL>	O
However	O
,	O
in	O
vivo	O
roles	O
for	O
CHL1	B-Gene
and	I-Gene
2	I-Gene
in	O
early	O
development	O
are	O
unknown	O
due	O
to	O
lack	O
of	O
loss	O
-	O
of	O
-	O
function	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Here	O
we	O
identify	O
and	O
characterize	O
zebrafish	B-Species
,	O
Danio	B-Species
rerio	I-Species
,	O
CHL	B-Gene
(	O
Chl	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
The	O
chl	B-Gene
gene	O
is	O
on	O
a	O
region	O
of	O
chromosome	O
21	O
syntenic	O
with	O
the	O
area	O
of	O
murine	B-Species
chromosome	O
7	O
bearing	O
the	O
CHL2	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Inability	O
to	O
identify	O
a	O
separate	O
zebrafish	B-Species
gene	O
corresponding	O
to	O
the	O
mammalian	O
CHL1	B-Gene
gene	O
suggests	O
that	O
Chl	B-Gene
may	O
serve	O
roles	O
in	O
zebrafish	B-Species
distributed	O
between	O
CHL1	B-Gene
and	O
CHL2	B-Gene
in	O
other	O
species	O
.	O
</ALL>	O

<ALL>	O
Chl	B-Gene
is	O
a	O
maternal	O
factor	O
that	O
is	O
also	O
zygotically	O
expressed	O
later	O
in	O
development	O
and	O
has	O
spatiotemporal	O
expression	O
patterns	O
that	O
differ	O
from	O
but	O
overlap	O
those	O
of	O
zebrafish	B-Species
chordin	B-Gene
(	O
Chd	B-Gene
)	O
,	O
suggesting	O
differences	O
but	O
also	O
possible	O
overlap	O
in	O
developmental	O
roles	O
of	O
the	O
two	O
proteins	O
.	O
</ALL>	O

<ALL>	O
Chl	B-Gene
,	O
like	O
Chd	B-Gene
,	O
dorsalizes	O
embryos	O
upon	O
overexpression	O
and	O
is	O
cleaved	O
by	O
BMP1	B-Gene
,	O
which	O
antagonizes	O
this	O
activity	O
.	O
</ALL>	O

<ALL>	O
Loss	O
-	O
of	O
-	O
function	O
experiments	O
demonstrate	O
that	O
Chl	B-Gene
serves	O
as	O
a	O
BMP	B-Gene
antagonist	O
with	O
functions	O
that	O
overlap	O
and	O
are	O
redundant	O
with	O
those	O
of	O
Chd	B-Gene
in	O
forming	O
the	O
dorsoventral	O
axis	O
.	O
</ALL>	O

<ALL>	O
Identification	O
of	O
a	O
frameshift	O
mutation	O
in	O
Osterix	B-Gene
in	O
a	O
patient	B-Species
with	O
recessive	B-Disease
osteogenesis	I-Disease
imperfecta	I-Disease
.	O
</ALL>	O

<ALL>	O
Osteogenesis	B-Disease
imperfecta	I-Disease
,	O
or	O
"	O
brittle	B-Disease
bone	I-Disease
disease	I-Disease
,	O
"	O
is	O
a	O
type	B-Gene
I	I-Gene
collagen	I-Gene
-	O
related	O
condition	O
associated	O
with	O
osteoporosis	B-Disease
and	O
increased	O
risk	O
of	O
bone	B-Disease
fractures	I-Disease
.	O
</ALL>	O

<ALL>	O
Using	O
a	O
combination	O
of	O
homozygosity	O
mapping	O
and	O
candidate	O
gene	O
approach	O
,	O
we	O
have	O
identified	O
a	O
homozygous	O
single	B-Variant
base	I-Variant
pair	I-Variant
deletion	I-Variant
(	O
c.1052delA	B-Variant
)	O
in	O
SP7	B-Gene
/	O
Osterix	B-Gene
(	O
OSX	B-Gene
)	O
in	O
an	O
Egyptian	O
child	O
with	O
recessive	B-Disease
osteogenesis	I-Disease
imperfecta	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
clinical	O
findings	O
from	O
this	O
patient	B-Species
include	O
recurrent	O
fractures	B-Disease
,	O
mild	O
bone	B-Disease
deformities	I-Disease
,	O
delayed	O
tooth	B-Disease
eruption	I-Disease
,	O
normal	O
hearing	O
,	O
and	O
white	O
sclera	O
.	O
</ALL>	O

<ALL>	O
OSX	B-Gene
encodes	O
a	O
transcription	O
factor	O
containing	O
three	O
Cys2	O
-	O
His2	O
zinc	O
-	O
finger	O
DNA	O
-	O
binding	O
domains	O
at	O
its	O
C	O
terminus	O
,	O
which	O
,	O
in	O
mice	B-Species
,	O
has	O
been	O
shown	O
to	O
be	O
essential	O
for	O
bone	O
formation	O
.	O
</ALL>	O

<ALL>	O
The	O
frameshift	O
caused	O
by	O
the	O
c.1052delA	B-Variant
deletion	O
removes	O
the	O
last	O
81	O
amino	O
acids	O
of	O
the	O
protein	O
,	O
including	O
the	O
third	O
zinc	O
-	O
finger	O
motif	O
.	O
</ALL>	O

<ALL>	O
This	O
finding	O
adds	O
another	O
locus	O
to	O
the	O
spectrum	O
of	O
genes	O
associated	O
with	O
osteogenesis	B-Disease
imperfecta	I-Disease
and	O
reveals	O
that	O
SP7	B-Gene
/	O
OSX	B-Gene
also	O
plays	O
a	O
key	O
role	O
in	O
human	B-Species
bone	O
development	O
.	O
</ALL>	O

<ALL>	O
Variation	O
in	O
the	O
CXCR1	B-Gene
gene	O
(	O
IL8RA	B-Gene
)	O
is	O
not	O
associated	O
with	O
susceptibility	O
to	O
chronic	B-Disease
periodontitis	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
The	O
chemokine	B-Gene
receptor	I-Gene
1	I-Gene
CXCR	I-Gene
-	I-Gene
1	I-Gene
(	O
or	O
IL8R	B-Gene
-	I-Gene
alpha	I-Gene
)	O
is	O
a	O
specific	O
receptor	O
for	O
the	O
interleukin	B-Gene
8	I-Gene
(	O
IL	B-Gene
-	I-Gene
8	I-Gene
)	O
,	O
which	O
is	O
chemoattractant	O
for	O
neutrophils	O
and	O
has	O
an	O
important	O
role	O
in	O
the	O
inflammatory	B-Disease
response	O
.	O
</ALL>	O

<ALL>	O
The	O
polymorphism	O
rs2234671	B-Variant
at	O
position	O
Ex2	B-Variant
+	I-Variant
860	I-Variant
G	I-Variant
>	I-Variant
C	I-Variant
of	O
the	O
CXCR1	B-Gene
gene	O
causes	O
a	O
conservative	O
amino	O
acid	O
substitution	O
(	O
S276	B-Variant
T	I-Variant
)	O
.	O
</ALL>	O

<ALL>	O
This	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
seemed	O
to	O
be	O
functional	O
as	O
it	O
was	O
associated	O
with	O
decreased	O
lung	B-Disease
cancer	I-Disease
risk	O
.	O
</ALL>	O

<ALL>	O
Previous	O
studies	O
of	O
our	O
group	O
found	O
association	O
of	O
haplotypes	O
in	O
the	O
IL8	B-Gene
and	O
in	O
the	O
CXCR2	B-Gene
genes	O
with	O
the	O
multifactorial	O
disease	O
chronic	B-Disease
periodontitis	I-Disease
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
we	O
investigated	O
the	O
polymorphism	O
rs2234671	B-Variant
in	O
395	O
Brazilian	O
subjects	O
with	O
and	O
without	O
chronic	B-Disease
periodontitis	I-Disease
.	O
</ALL>	O

<ALL>	O
FINDINGS	O
:	O
Similar	O
distribution	O
of	O
the	O
allelic	O
and	O
genotypic	O
frequencies	O
were	O
observed	O
between	O
the	O
groups	O
(	O
p	O
>	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
The	O
polymorphism	O
rs2234671	B-Variant
in	O
the	O
CXCR1	B-Gene
gene	O
was	O
not	O
associated	O
with	O
the	O
susceptibility	O
to	O
chronic	B-Disease
periodontitis	I-Disease
in	O
the	O
studied	O
Brazilian	O
population	O
.	O
</ALL>	O

<ALL>	O
TBX21	B-Gene
and	O
HLX1	B-Gene
polymorphisms	O
influence	O
cytokine	O
secretion	O
at	O
birth	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
TBX21	B-Gene
(	O
T	B-Gene
cell	I-Gene
specific	I-Gene
T	I-Gene
-	I-Gene
box	I-Gene
transcription	I-Gene
factor	I-Gene
)	O
and	O
HLX1	B-Gene
(	O
H.20	B-Gene
-	I-Gene
like	I-Gene
homeobox	I-Gene
1	I-Gene
)	O
are	O
crucial	O
transcription	O
factors	O
of	O
T	O
(	O
H	O
)	O
1	O
-	O
cells	O
,	O
inducing	O
their	O
differentiation	O
and	O
suppressing	O
T	O
(	O
H	O
)	O
2	O
commitment	O
,	O
particularly	O
important	O
for	O
early	O
life	O
immune	O
development	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
investigated	O
the	O
influence	O
of	O
TBX21	B-Gene
and	O
HLX1	B-Gene
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
,	O
which	O
have	O
previously	O
been	O
shown	O
to	O
be	O
associated	O
with	O
asthma	B-Disease
,	O
on	O
T	O
(	O
H	O
)	O
1	O
/	O
T	O
(	O
H	O
)	O
2	O
lineage	O
cytokines	O
at	O
birth	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
AND	O
FINDINGS	O
:	O
Cord	O
blood	O
mononuclear	O
cells	O
(	O
CBMCs	O
)	O
of	O
200	O
neonates	O
were	O
genotyped	O
for	O
two	O
TBX21	B-Gene
and	O
three	O
HLX1	B-Gene
SNPs	O
.	O
</ALL>	O

<ALL>	O
CBMCs	O
were	O
stimulated	O
with	O
innate	O
(	O
Lipid	B-Chemical
A	I-Chemical
,	O
LpA	B-Chemical
;	O
Peptidoglycan	B-Chemical
,	O
Ppg	B-Chemical
)	O
,	O
adaptive	O
stimuli	O
(	O
house	O
dust	O
mite	O
Dermatophagoides	B-Gene
pteronyssinus	I-Gene
1	I-Gene
,	O
Derp1	B-Gene
)	O
or	O
mitogen	O
(	O
phytohemagglutinin	B-Chemical
,	O
PHA	B-Chemical
)	O
.	O
</ALL>	O

<ALL>	O
Cytokines	O
,	O
T	O
-	O
cells	O
and	O
mRNA	O
expression	O
of	O
T	O
(	O
H	O
)	O
1	O
/	O
T	O
(	O
H	O
)	O
2	O
-	O
related	O
genes	O
were	O
assessed	O
.	O
</ALL>	O

<ALL>	O
Atopic	O
diseases	O
during	O
the	O
first	O
3	O
years	O
of	O
life	O
were	O
assessed	O
by	O
questionnaire	O
answered	O
by	O
the	O
parents	O
.	O
</ALL>	O

<ALL>	O
Carriers	O
of	O
TBX21	B-Gene
promoter	O
SNP	O
rs17250932	B-Variant
and	O
HLX1	B-Gene
promoter	O
SNP	O
rs2738751	B-Variant
showed	O
reduced	O
or	O
trendwise	O
reduced	O
(	O
p	O
<	O
0.07	O
)	O
IL	B-Gene
-	I-Gene
5	I-Gene
,	O
IL	B-Gene
-	I-Gene
13	I-Gene
and	O
TNF	B-Gene
-	I-Gene
a	I-Gene
secretion	O
after	O
LpA	B-Chemical
-	O
stimulation	O
.	O
</ALL>	O

<ALL>	O
Carriers	O
of	O
HLX1	B-Gene
SNP	O
rs2738751	B-Variant
had	O
lower	O
IL	B-Gene
-	I-Gene
13	I-Gene
levels	O
following	O
Ppg	B-Chemical
-	O
stimulation	O
(	O
p	O
=	O
0.08	O
)	O
.	O
</ALL>	O

<ALL>	O
Carriers	O
of	O
HLX1	B-Gene
exon	O
1	O
SNP	O
rs12141189	B-Variant
showed	O
increased	O
IL	B-Gene
-	I-Gene
5	I-Gene
(	O
LpA	B-Chemical
,	O
p	O
=	O
0.007	O
;	O
Ppg	B-Chemical
,	O
p	O
=	O
0.10	O
)	O
,	O
trendwise	O
increased	O
IL	B-Gene
-	I-Gene
13	I-Gene
(	O
LpA	B-Chemical
)	O
,	O
higher	O
GM	B-Gene
-	I-Gene
CSF	I-Gene
(	O
LpA	B-Chemical
/	O
Ppg	B-Chemical
,	O
p	O
<	O
0.05	O
)	O
and	O
trendwise	O
decreased	O
IFN	B-Gene
-	I-Gene
g	I-Gene
secretion	O
(	O
Derp1	B-Gene
+	O
LpA	B-Chemical
-	O
stimulation	O
,	O
p	O
=	O
0.1	O
)	O
.	O
</ALL>	O

<ALL>	O
Homozygous	O
carriers	O
of	O
HLX1	B-Gene
promoter	O
SNP	O
rs3806325	B-Variant
showed	O
increased	O
IL	B-Gene
-	I-Gene
13	I-Gene
and	O
IL	B-Gene
-	I-Gene
6	I-Gene
(	O
unstimulated	O
,	O
p	O
<	O
0.03	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
carriers	O
of	O
TBX21	B-Gene
intron	O
3	O
SNP	O
rs11079788	B-Variant
no	O
differences	O
in	O
cytokine	O
secretion	O
were	O
observed	O
.	O
</ALL>	O

<ALL>	O
mRNA	O
expression	O
of	O
T	O
(	O
H	O
)	O
1	O
/	O
T	O
(	O
H	O
)	O
2	O
-	O
related	O
genes	O
partly	O
correlated	O
with	O
cytokines	O
at	O
protein	O
level	O
.	O
</ALL>	O

<ALL>	O
TBX21	B-Gene
SNP	O
rs11079788	B-Variant
carriers	O
developed	O
less	O
symptoms	O
of	O
atopic	B-Disease
dermatitis	I-Disease
at	O
3	O
years	O
of	O
age	O
(	O
p	O
=	O
0.03	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Polymorphisms	O
in	O
TBX21	B-Gene
and	O
HLX1	B-Gene
influenced	O
primarily	O
IL	B-Gene
-	I-Gene
5	I-Gene
and	O
IL	B-Gene
-	I-Gene
13	I-Gene
secretion	O
after	O
LpA	B-Chemical
-	O
stimulation	O
in	O
cord	O
blood	O
suggesting	O
that	O
genetic	O
variations	O
in	O
the	O
transcription	O
factors	O
essential	O
for	O
the	O
T	O
(	O
H	O
)	O
1	O
-	O
pathway	O
may	O
contribute	O
to	O
modified	O
T	O
(	O
H	O
)	O
2	O
-	O
immune	O
responses	O
already	O
early	O
in	O
life	O
.	O
</ALL>	O

<ALL>	O
Further	O
follow	O
-	O
up	O
of	O
the	O
cohort	O
is	O
required	O
to	O
study	O
the	O
polymorphisms	O
'	O
relevance	O
for	O
immune	B-Disease
-	I-Disease
mediated	I-Disease
diseases	I-Disease
such	O
as	O
childhood	O
asthma	B-Disease
.	O
</ALL>	O

<ALL>	O
Superoxide	B-Gene
dismutase	I-Gene
1	I-Gene
overexpression	O
in	O
mice	B-Species
abolishes	O
maternal	B-Disease
diabetes	I-Disease
-	O
induced	O
endoplasmic	O
reticulum	O
stress	O
in	O
diabetic	B-Disease
embryopathy	B-Disease
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
Both	O
oxidative	O
stress	O
and	O
endoplasmic	O
reticulum	O
stress	O
(	O
ER	O
stress	O
)	O
are	O
causal	O
events	O
in	O
diabetic	B-Disease
embryopathy	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
tested	O
whether	O
oxidative	O
stress	O
causes	O
ER	O
stress	O
.	O
</ALL>	O

<ALL>	O
STUDY	O
DESIGN	O
:	O
Wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
superoxide	B-Gene
dismutase	I-Gene
1	I-Gene
(	O
SOD1	B-Gene
)	O
-	O
overexpressing	O
day	O
8.75	O
embryos	O
from	O
nondiabetic	O
WT	O
control	O
with	O
SOD1	B-Gene
transgenic	O
male	O
and	O
diabetic	B-Disease
WT	O
female	O
with	O
SOD1	B-Gene
transgenic	O
male	O
were	O
analyzed	O
for	O
ER	O
stress	O
markers	O
:	O
C	B-Gene
/	I-Gene
EBP	I-Gene
-	I-Gene
homologous	I-Gene
protein	I-Gene
(	O
CHOP	B-Gene
)	O
,	O
calnexin	B-Gene
,	O
eukaryotic	B-Gene
initiation	I-Gene
factor	I-Gene
2a	I-Gene
(	O
eIF2a	B-Gene
)	O
,	O
protein	B-Gene
kinase	I-Gene
ribonucleic	I-Gene
acid	I-Gene
(	I-Gene
RNA	I-Gene
)	I-Gene
-	I-Gene
like	I-Gene
ER	I-Gene
kinase	I-Gene
(	O
PERK	B-Gene
)	O
,	O
binding	B-Gene
immunoglobulin	I-Gene
protein	I-Gene
,	O
protein	B-Gene
disulfide	I-Gene
isomerase	I-Gene
family	I-Gene
A	I-Gene
member	I-Gene
3	I-Gene
,	O
kinases	B-Gene
inositol	I-Gene
-	I-Gene
requiring	I-Gene
protein	I-Gene
-	I-Gene
1a	I-Gene
(	O
IRE1a	B-Gene
)	O
,	O
and	O
the	O
X	B-Gene
-	I-Gene
box	I-Gene
binding	I-Gene
protein	I-Gene
(	O
XBP1	B-Gene
)	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
splicing	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Maternal	B-Disease
diabetes	I-Disease
significantly	O
increased	O
the	O
levels	O
of	O
CHOP	B-Gene
,	O
calnexin	B-Gene
,	O
phosphorylated	O
(	O
p	O
)	O
-	O
eIF2a	B-Gene
,	O
p	O
-	O
PERK	B-Gene
,	O
and	O
p	O
-	O
IRE1a	B-Gene
;	O
triggered	O
XBP1	B-Gene
mRNA	O
splicing	O
;	O
and	O
enhanced	O
ER	O
chaperone	O
gene	O
expression	O
in	O
WT	O
embryos	O
.	O
</ALL>	O

<ALL>	O
SOD1	B-Gene
overexpression	O
blocked	O
these	O
diabetes	B-Disease
-	O
induced	O
ER	O
stress	O
markers	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Mitigating	O
oxidative	O
stress	O
via	O
SOD1	B-Gene
overexpression	O
blocks	O
maternal	B-Disease
diabetes	I-Disease
-	O
induced	O
ER	O
stress	O
in	O
vivo	O
.	O
</ALL>	O

<ALL>	O
The	O
autotaxin	B-Gene
-	O
LPA2	B-Gene
GPCR	B-Gene
axis	O
is	O
modulated	O
by	O
gamma	O
-	O
irradiation	O
and	O
facilitates	O
DNA	O
damage	O
repair	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
we	O
characterized	O
the	O
effects	O
of	O
radiation	B-Disease
injury	I-Disease
on	O
the	O
expression	O
and	O
function	O
of	O
the	O
autotaxin	B-Gene
(	O
ATX	B-Gene
)	O
-	O
LPA2	B-Gene
GPCR	B-Gene
axis	O
.	O
</ALL>	O

<ALL>	O
In	O
IEC	B-CellLine
-	I-CellLine
6	I-CellLine
crypt	O
cells	O
and	O
jejunum	O
enteroids	O
quantitative	O
RT	O
-	O
PCR	O
showed	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
upregulation	O
of	O
lpa2	B-Gene
in	O
response	O
to	O
gamma	O
-	O
irradiation	O
that	O
was	O
abolished	O
by	O
mutation	O
of	O
the	O
NF	B-Gene
-	I-Gene
kappaB	I-Gene
site	O
in	O
the	O
lpa2	B-Gene
promoter	O
or	O
by	O
inhibition	O
of	O
ATM	B-Gene
/	I-Gene
ATR	I-Gene
kinases	I-Gene
with	O
CGK	B-Chemical
-	I-Chemical
733	I-Chemical
,	O
suggesting	O
that	O
lpa2	B-Gene
is	O
a	O
DNA	O
damage	O
response	O
gene	O
upregulated	O
by	O
ATM	B-Gene
via	O
NF	B-Gene
-	I-Gene
kappaB	I-Gene
.	O
</ALL>	O

<ALL>	O
The	O
resolution	O
kinetics	O
of	O
the	O
DNA	O
damage	O
marker	O
gamma	B-Gene
-	I-Gene
H2AX	I-Gene
in	O
LPA	B-Gene
-	O
treated	O
IEC	B-CellLine
-	I-CellLine
6	I-CellLine
cells	O
exposed	O
to	O
gamma	O
-	O
irradiation	O
was	O
accelerated	O
compared	O
to	O
vehicle	O
,	O
whereas	O
pharmacological	O
inhibition	O
of	O
LPA2	B-Gene
delayed	O
the	O
resolution	O
of	O
gamma	B-Gene
-	I-Gene
H2AX	I-Gene
.	O
</ALL>	O

<ALL>	O
In	O
LPA2	B-Gene
-	O
reconstituted	O
MEF	B-CellLine
cells	O
lacking	O
LPA1	B-Gene
'	I-Gene
3	I-Gene
the	O
levels	O
of	O
gamma	B-Gene
-	I-Gene
H2AX	I-Gene
decreased	O
rapidly	O
,	O
whereas	O
in	O
Vector	O
MEF	B-CellLine
were	O
high	O
and	O
remained	O
sustained	O
.	O
</ALL>	O

<ALL>	O
Inhibition	O
of	O
ERK1	B-Gene
'	I-Gene
2	I-Gene
or	O
PI3	B-Gene
K	I-Gene
/	O
AKT	B-Gene
signaling	O
axis	O
by	O
pertussis	O
toxin	O
or	O
the	O
C311A	B-Variant
/	O
C314A	B-Variant
/	O
L351A	B-Variant
mutation	O
in	O
the	O
C	O
-	O
terminus	O
of	O
LPA2	B-Gene
abrogated	O
the	O
effect	O
of	O
LPA	B-Gene
on	O
DNA	O
repair	O
.	O
</ALL>	O

<ALL>	O
LPA2	B-Gene
transcripts	O
in	O
Lin	B-Gene
(	O
-	O
)	O
Sca	B-Gene
-	I-Gene
1	I-Gene
(	O
+	O
)	O
c	B-Gene
-	I-Gene
Kit	I-Gene
(	O
+	O
)	O
enriched	O
for	O
bone	O
marrow	O
stem	O
cells	O
were	O
27	O
-	O
and	O
5	O
-	O
fold	O
higher	O
than	O
in	O
common	O
myeloid	O
or	O
lymphoid	O
progenitors	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
after	O
irradiation	O
higher	O
residual	O
gamma	B-Gene
-	I-Gene
H2AX	I-Gene
levels	O
were	O
detected	O
in	O
the	O
bone	O
marrow	O
or	O
jejunum	O
of	O
irradiated	O
LPA2	B-Gene
-	O
KO	O
mice	B-Species
compared	O
to	O
WT	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
We	O
found	O
that	O
gamma	O
-	O
irradiation	O
increases	O
plasma	O
ATX	B-Gene
activity	O
and	O
LPA	B-Gene
level	O
that	O
is	O
in	O
part	O
due	O
to	O
the	O
previously	O
established	O
radiation	O
-	O
induced	O
upregulation	O
of	O
TNFalpha	B-Gene
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
identify	O
ATX	B-Gene
and	O
LPA2	B-Gene
as	O
radiation	O
-	O
regulated	O
genes	O
that	O
appear	O
to	O
play	O
a	O
physiological	O
role	O
in	O
DNA	O
repair	O
.	O
</ALL>	O

<ALL>	O
NEK2	B-Gene
serves	O
as	O
a	O
prognostic	O
biomarker	O
for	O
hepatocellular	B-Disease
carcinoma	I-Disease
.	O
</ALL>	O

<ALL>	O
Never	B-Gene
in	I-Gene
mitosis	I-Gene
gene	I-Gene
A	I-Gene
(	I-Gene
NIMA	I-Gene
)	I-Gene
-	I-Gene
related	I-Gene
kinase	I-Gene
2	I-Gene
(	O
NEK2	B-Gene
)	O
is	O
a	O
microtubule	B-Gene
-	I-Gene
associated	I-Gene
protein	I-Gene
that	O
regulates	O
spindle	O
assembly	O
in	O
human	B-Species
cells	O
and	O
is	O
overexpressed	O
in	O
various	O
malignancies	B-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
role	O
of	O
NEK2	B-Gene
in	O
hepatocellular	B-Disease
carcinoma	I-Disease
(	O
HCC	B-Disease
)	O
remains	O
undetermined	O
.	O
</ALL>	O

<ALL>	O
We	O
performed	O
RNA	O
-	O
seq	O
of	O
the	O
HCC	B-Disease
cell	O
line	O
SMMC	B-CellLine
-	I-CellLine
7721	I-CellLine
and	O
the	O
normal	O
liver	O
cell	O
line	O
HL	B-CellLine
-	I-CellLine
7702	I-CellLine
using	O
the	O
Ion	O
Proton	O
System	O
.	O
</ALL>	O

<ALL>	O
NEK2	B-Gene
expression	O
was	O
detected	O
using	O
quantitative	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
in	O
two	O
cell	O
lines	O
and	O
5	O
matched	O
HCC	B-Disease
and	O
adjacent	O
non	O
-	O
tumorous	O
liver	O
tissues	O
.	O
</ALL>	O

<ALL>	O
The	O
correlation	O
between	O
survival	O
and	O
NEK2	B-Gene
expression	O
was	O
analyzed	O
in	O
359	O
patients	B-Species
with	O
HCC	B-Disease
using	O
RNASeqV2	O
data	O
available	O
from	O
The	O
Cancer	B-Disease
Genome	O
Atlas	O
(	O
TCGA	O
)	O
website	O
(	O
https	O
:	O
/	O
/	O
tcga	O
-	O
data.nci.nih.gov	O
/	O
tcga	O
/	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
expression	O
of	O
NEK2	B-Gene
,	O
phospho	O
-	O
AKT	B-Gene
and	O
MMP	B-Gene
-	I-Gene
2	I-Gene
was	O
evaluated	O
by	O
immunohistochemistry	O
in	O
63	O
cases	O
of	O
HCC	B-Disease
and	O
matched	O
adjacent	O
non	O
-	O
tumorous	O
liver	O
tissues	O
.	O
</ALL>	O

<ALL>	O
Relationships	O
between	O
protein	O
expression	O
and	O
clinicopathological	O
parameters	O
were	O
assessed	O
,	O
and	O
the	O
correlations	O
between	O
NEK2	B-Gene
with	O
phospho	O
-	O
AKT	B-Gene
and	O
MMP	B-Gene
-	I-Gene
2	I-Gene
expressions	O
were	O
evaluated	O
.	O
</ALL>	O

<ALL>	O
A	O
total	O
of	O
610	O
differentially	O
expressed	O
genes	O
(	O
DEGs	O
)	O
were	O
revealed	O
in	O
the	O
transcriptome	O
comparison	O
,	O
297	O
of	O
which	O
were	O
upregulated	O
and	O
313	O
were	O
downregulated	O
in	O
HCC	B-Disease
.	O
</ALL>	O

<ALL>	O
NEK2	B-Gene
,	O
as	O
the	O
most	O
obviously	O
different	O
DEG	O
in	O
cells	O
and	O
tissues	O
from	O
the	O
RNA	O
-	O
seq	O
data	O
,	O
was	O
listed	O
as	O
an	O
HCC	B-Disease
candidate	O
biomarker	O
for	O
further	O
verification	O
.	O
</ALL>	O

<ALL>	O
NEK2	B-Gene
was	O
overexpressed	O
in	O
HCC	B-Disease
cells	O
and	O
tissues	O
(	O
P	O
=	O
0.002	O
,	O
P	O
=	O
0.013	O
)	O
and	O
HCC	B-Disease
patients	B-Species
with	O
a	O
high	O
expression	O
of	O
NEK2	B-Gene
had	O
a	O
poor	O
prognosis	O
(	O
P	O
=	O
0.0145	O
)	O
.	O
</ALL>	O

<ALL>	O
Clinical	O
analysis	O
indicated	O
that	O
the	O
overexpression	O
of	O
NEK2	B-Gene
in	O
HCC	B-Disease
was	O
significantly	O
correlated	O
with	O
diolame	O
complete	O
(	O
P	O
<	O
0.001	O
)	O
,	O
tumor	B-Disease
nodule	O
number	O
(	O
P	O
=	O
0.012	O
)	O
and	O
recurrence	O
(	O
P	O
=	O
0.004	O
)	O
.	O
</ALL>	O

<ALL>	O
NEK2	B-Gene
expression	O
was	O
positively	O
correlated	O
with	O
the	O
expression	O
of	O
phospho	O
-	O
AKT	B-Gene
(	O
r	O
=	O
0.883	O
,	O
P	O
<	O
0.01	O
)	O
and	O
MMP	B-Gene
-	I-Gene
2	I-Gene
(	O
r	O
=	O
0.781	O
,	O
P	O
<	O
0.01	O
)	O
.	O
</ALL>	O

<ALL>	O
Overexpression	O
of	O
NEK2	B-Gene
was	O
associated	O
with	O
clinicopathological	O
characteristics	O
and	O
poor	O
patient	B-Species
outcomes	O
,	O
suggesting	O
that	O
NEK2	B-Gene
serves	O
as	O
a	O
prognostic	O
biomarker	O
for	O
HCC	B-Disease
.	O
</ALL>	O

<ALL>	O
Alteration	O
of	O
NEK2	B-Gene
protein	O
levels	O
may	O
contribute	O
to	O
invasion	O
and	O
metastasis	B-Disease
of	I-Disease
HCC	I-Disease
,	O
which	O
may	O
occur	O
through	O
activation	O
of	O
AKT	B-Gene
signaling	O
and	O
promotion	O
of	O
MMP	B-Gene
-	I-Gene
2	I-Gene
expression	O
.	O
</ALL>	O

<ALL>	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
in	O
13	O
%	O
of	O
age	O
-	O
matched	O
Czech	O
children	O
with	O
primary	B-Disease
microcephaly	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
is	O
a	O
rare	O
autosomal	B-Disease
recessive	I-Disease
chromosomal	I-Disease
instability	I-Disease
disorder	I-Disease
characterized	O
by	O
early	O
growth	B-Disease
retardation	I-Disease
,	O
congenital	B-Disease
microcephaly	I-Disease
,	O
immunodeficiency	B-Disease
,	O
borderline	O
mental	O
development	O
,	O
and	O
a	O
high	O
tendency	O
to	O
lymphoreticular	B-Disease
malignancies	I-Disease
.	O
</ALL>	O

<ALL>	O
Most	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
patients	B-Species
are	O
of	O
Slavonic	O
origin	O
,	O
and	O
all	O
of	O
them	O
known	O
so	O
far	O
carry	O
a	O
founder	O
homozygous	O
5	B-Variant
nucleotide	I-Variant
deletion	I-Variant
in	O
the	O
NBS1	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Microcephaly	B-Disease
was	O
present	O
in	O
100	O
%	O
of	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
patients	B-Species
in	O
a	O
recent	O
large	O
international	O
cooperative	O
study	O
.	O
</ALL>	O

<ALL>	O
The	O
frequency	O
of	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
among	O
children	O
with	O
primary	B-Disease
microcephaly	I-Disease
was	O
not	O
known	O
.	O
</ALL>	O

<ALL>	O
Early	O
correct	O
diagnosis	O
of	O
the	O
syndrome	O
is	O
crucial	O
for	O
appropriate	O
preventive	O
care	O
and	O
therapy	O
.	O
</ALL>	O

<ALL>	O
We	O
tested	O
67	O
Czech	O
patients	B-Species
of	O
different	O
ages	O
with	O
simple	O
microcephaly	O
for	O
the	O
presence	O
of	O
the	O
most	O
common	O
mutation	O
in	O
the	O
NBS1	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Three	O
new	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
cases	O
were	O
detected	O
in	O
this	O
cohort	O
,	O
representing	O
4.5	O
%	O
of	O
the	O
cohort	O
.	O
</ALL>	O

<ALL>	O
All	O
these	O
newly	O
diagnosed	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
patients	B-Species
were	O
younger	O
than	O
10	O
months	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O
</ALL>	O

<ALL>	O
They	O
were	O
all	O
born	O
within	O
a	O
2.5	O
-	O
year	O
period	O
.	O
</ALL>	O

<ALL>	O
Twenty	O
-	O
three	O
of	O
the	O
67	O
children	O
in	O
the	O
cohort	O
were	O
born	O
within	O
this	O
2.5	O
-	O
year	O
period	O
,	O
representing	O
a	O
13	O
%	O
incidence	O
of	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Frequency	O
of	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
heterozygotes	O
among	O
infants	O
in	O
the	O
Czech	O
Republic	O
is	O
1	O
:	O
130	O
-	O
158	O
and	O
the	O
birth	O
rate	O
is	O
90,000	O
per	O
year	O
,	O
therefore	O
in	O
the	O
time	O
span	O
of	O
2.5	O
years	O
,	O
three	O
new	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
homozygotes	O
are	O
expected	O
to	O
be	O
born	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
we	O
assume	O
that	O
by	O
DNA	O
testing	O
of	O
Czech	O
primary	O
microcephalic	O
children	O
it	O
is	O
possible	O
to	O
detect	O
all	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
patients	B-Species
to	O
be	O
expected	O
.	O
</ALL>	O

<ALL>	O
The	O
age	O
at	O
correct	O
diagnosis	O
was	O
lowered	O
from	O
7.1	O
years	O
at	O
the	O
time	O
before	O
DNA	O
testing	O
,	O
to	O
well	O
under	O
1	O
year	O
of	O
age	O
.	O
</ALL>	O

<ALL>	O
All	O
new	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
patients	B-Species
could	O
receive	O
appropriate	O
preventive	O
care	O
,	O
which	O
should	O
significantly	O
improve	O
their	O
life	O
expectancy	O
and	O
prognosis	O
.	O
</ALL>	O

<ALL>	O
Evaluation	O
of	O
the	O
Lys198Asn	B-Variant
and	O
-	B-Variant
134delA	I-Variant
genetic	O
polymorphisms	O
of	O
the	O
endothelin	B-Gene
-	I-Gene
1	I-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Endothelin	B-Gene
-	I-Gene
1	I-Gene
(	O
ET	B-Gene
-	I-Gene
1	I-Gene
)	O
is	O
a	O
potent	O
vasoconstrictor	O
and	O
shows	O
various	O
pharmacological	O
responses	O
.	O
</ALL>	O

<ALL>	O
Two	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
ET	B-Gene
-	I-Gene
1	I-Gene
gene	O
(	O
EDN1	B-Gene
)	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
blood	O
pressure	O
(	O
BP	O
)	O
.	O
</ALL>	O

<ALL>	O
One	O
is	O
the	O
Lys198Asn	B-Variant
polymorphism	O
,	O
which	O
showed	O
a	O
positive	O
association	O
with	O
BP	O
in	O
overweight	B-Disease
people	O
.	O
</ALL>	O

<ALL>	O
Another	O
is	O
the	O
3A	O
/	O
4A	O
polymorphism	O
(	O
-	B-Variant
134delA	I-Variant
)	O
located	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
the	O
Lys198Asn	B-Variant
polymorphism	O
in	O
ET	B-Gene
-	I-Gene
1	I-Gene
in	O
vitro	O
,	O
as	O
well	O
as	O
the	O
association	O
between	O
either	O
of	O
the	O
two	O
polymorphisms	O
and	O
the	O
plasma	O
ET	B-Gene
-	I-Gene
1	I-Gene
level	O
.	O
</ALL>	O

<ALL>	O
We	O
expressed	O
both	O
the	O
major	O
(	O
Lys	O
-	O
type	O
)	O
and	O
minor	O
type	O
(	O
Asn	O
-	O
type	O
)	O
prepro	O
ET	B-Gene
-	I-Gene
1	I-Gene
in	O
three	O
different	O
cell	O
lines	O
,	O
and	O
measured	O
the	O
levels	O
of	O
ET	B-Gene
-	I-Gene
1	I-Gene
and	O
big	O
ET	B-Gene
-	I-Gene
1	I-Gene
in	O
the	O
culture	O
supernatant	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
levels	O
of	O
ET	B-Gene
-	I-Gene
1	I-Gene
or	O
big	O
ET	B-Gene
-	I-Gene
1	I-Gene
between	O
the	O
Asn	B-Variant
-	I-Variant
type	I-Variant
and	I-Variant
Lys	I-Variant
-	I-Variant
type	I-Variant
transfectant	I-Variant
.	O
</ALL>	O

<ALL>	O
In	O
the	O
association	O
study	O
,	O
the	O
plasma	O
levels	O
of	O
ET	B-Gene
-	I-Gene
1	I-Gene
in	O
54	O
hypertensive	B-Disease
patients	B-Species
having	O
an	O
amino	O
acid	O
substitution	O
from	O
Lys	B-Variant
to	I-Variant
Asn	I-Variant
at	I-Variant
position	I-Variant
198	I-Variant
were	O
not	O
different	O
from	O
those	O
of	O
hypertensives	B-Disease
without	O
the	O
substitution	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
we	O
found	O
a	O
significant	O
difference	O
in	O
ET	B-Gene
-	I-Gene
1	I-Gene
levels	O
between	O
individuals	O
with	O
the	O
3A	O
/	O
3A	O
and	O
3A	O
/	O
4A	O
genotypes	O
.	O
</ALL>	O

<ALL>	O
Our	O
transient	O
expression	O
study	O
indicates	O
that	O
the	O
Lys198Asn	B-Variant
polymorphism	O
may	O
not	O
directly	O
affect	O
ET	B-Gene
-	I-Gene
1	I-Gene
and	O
big	O
ET	B-Gene
-	I-Gene
1	I-Gene
production	O
.	O
</ALL>	O

<ALL>	O
Another	O
variant	O
in	O
the	O
EDN1	B-Gene
gene	O
in	O
linkage	O
disequilibrium	O
with	O
the	O
Lys198Asn	B-Variant
polymorphism	O
may	O
be	O
responsible	O
for	O
the	O
association	O
with	O
BP	O
,	O
or	O
the	O
interaction	O
between	O
the	O
EDN1	B-Gene
Lys198Asn	B-Variant
polymorphism	O
and	O
other	O
factors	O
such	O
as	O
obesity	B-Disease
may	O
be	O
involved	O
in	O
the	O
mechanisms	O
elevating	O
BP	O
in	O
vivo	O
.	O
</ALL>	O

<ALL>	O
A	O
single	O
-	O
nucleotide	O
polymorphism	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
of	O
the	O
hPER2	B-Gene
gene	O
is	O
associated	O
with	O
diurnal	O
preference	O
.	O
</ALL>	O

<ALL>	O
The	O
PERIOD2	B-Gene
(	O
PER2	B-Gene
)	O
gene	O
is	O
a	O
key	O
component	O
of	O
the	O
molecular	O
mechanism	O
that	O
generates	O
circadian	O
rhythms	O
in	O
mammals	O
.	O
</ALL>	O

<ALL>	O
A	O
missense	O
mutation	O
in	O
the	O
human	B-Species
PER2	B-Gene
gene	O
has	O
previously	O
been	O
linked	O
to	O
advanced	B-Disease
sleep	I-Disease
phase	I-Disease
syndrome	I-Disease
(	O
ASPS	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
We	O
have	O
investigated	O
three	O
other	O
single	O
-	O
nucleotide	O
polymorphisms	O
in	O
the	O
hPER2	B-Gene
gene	O
,	O
one	O
downstream	O
of	O
the	O
transcription	O
start	O
site	O
(	O
C	B-Variant
-	I-Variant
1228	I-Variant
T	I-Variant
)	O
,	O
one	O
in	O
exon	O
2	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
(	O
5	O
'	O
-	O
UTR	O
)	O
(	O
C111	B-Variant
G	I-Variant
)	O
,	O
and	O
one	O
missense	O
mutation	O
(	O
G3853A	B-Variant
)	O
causing	O
a	O
glycine	B-Variant
to	I-Variant
glutamine	I-Variant
substitution	O
in	O
the	O
predicted	O
protein	O
.	O
</ALL>	O

<ALL>	O
Subjects	O
selected	O
from	O
a	O
group	O
of	O
484	O
volunteers	O
for	O
extreme	O
morning	O
or	O
evening	O
preference	O
,	O
or	O
intermediate	O
diurnal	O
preference	O
were	O
genotyped	O
with	O
regard	O
to	O
the	O
three	O
polymorphisms	O
(	O
n	O
=	O
35	O
for	O
each	O
group	O
)	O
.	O
</ALL>	O

<ALL>	O
Whereas	O
allele	O
frequencies	O
for	O
the	O
other	O
two	O
polymorphisms	O
did	O
not	O
differ	O
significantly	O
between	O
any	O
of	O
the	O
groups	O
,	O
the	O
111	B-Variant
G	I-Variant
allele	O
frequency	O
was	O
significantly	O
higher	O
in	O
subjects	O
with	O
extreme	O
morning	O
preference	O
(	O
0.14	O
)	O
than	O
in	O
subjects	O
with	O
extreme	O
evening	O
preference	O
(	O
0.03	O
)	O
(	O
Fisher	O
's	O
exact	O
test	O
,	O
two	O
-	O
sided	O
P	O
value	O
=	O
0.031	O
,	O
odds	O
ratio	O
=	O
5.67	O
)	O
.	O
</ALL>	O

<ALL>	O
No	O
significant	O
difference	O
in	O
111	B-Variant
G	I-Variant
allele	O
frequency	O
was	O
observed	O
between	O
either	O
of	O
these	O
groups	O
and	O
subjects	O
with	O
intermediate	O
diurnal	O
preference	O
.	O
</ALL>	O

<ALL>	O
Computer	O
prediction	O
indicated	O
that	O
the	O
C111	B-Variant
G	I-Variant
polymorphism	O
,	O
which	O
occurs	O
12	O
bases	O
upstream	O
from	O
the	O
translation	O
start	O
codon	O
,	O
might	O
alter	O
the	O
secondary	O
structure	O
of	O
the	O
transcript	O
.	O
</ALL>	O

<ALL>	O
The	O
PER2	B-Gene
111	B-Variant
G	I-Variant
allele	O
associates	O
with	O
morning	O
preference	O
and	O
is	O
a	O
potential	O
candidate	O
allele	O
for	O
ASPS	B-Disease
.	O
</ALL>	O

<ALL>	O
A	O
haplotype	O
-	O
based	O
analysis	O
of	O
the	O
PTPN22	B-Gene
locus	O
in	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
.	O
</ALL>	O

<ALL>	O
A	O
recent	O
addition	O
to	O
the	O
list	O
of	O
widely	O
confirmed	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
risk	O
loci	O
is	O
the	O
PTPN22	B-Gene
gene	O
encoding	O
a	O
lymphoid	B-Gene
-	I-Gene
specific	I-Gene
phosphatase	I-Gene
(	O
Lyp	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
evidence	O
supporting	O
a	O
role	O
for	O
PTPN22	B-Gene
in	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
derives	O
entirely	O
from	O
the	O
study	O
of	O
just	O
one	O
coding	O
single	O
nucleotide	O
polymorphism	O
,	O
1858C	B-Variant
/	I-Variant
T	I-Variant
.	O
</ALL>	O

<ALL>	O
In	O
the	O
current	O
study	O
,	O
the	O
haplotype	O
structure	O
of	O
the	O
PTPN22	B-Gene
region	O
was	O
determined	O
,	O
and	O
individual	O
haplotypes	O
were	O
tested	O
for	O
association	O
with	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
in	O
family	O
-	O
based	O
tests	O
.	O
</ALL>	O

<ALL>	O
The	O
1858	B-Variant
T	I-Variant
risk	O
allele	O
occurred	O
on	O
only	O
a	O
single	O
haplotype	O
that	O
was	O
strongly	O
associated	O
with	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
(	O
P	O
=	O
7.9	O
x	O
10	O
(	O
-	O
5	O
)	O
)	O
.	O
</ALL>	O

<ALL>	O
After	O
controlling	O
for	O
the	O
effects	O
of	O
this	O
allele	O
,	O
two	O
other	O
haplotypes	O
were	O
observed	O
to	O
be	O
weakly	O
associated	O
with	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
(	O
P	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
Sequencing	O
of	O
the	O
coding	O
region	O
of	O
PTPN22	B-Gene
on	O
these	O
haplotypes	O
revealed	O
a	O
novel	O
variant	O
(	O
2250	B-Variant
G	I-Variant
/	I-Variant
C	I-Variant
)	O
predicted	O
to	O
result	O
in	O
a	O
nonsynonymous	O
amino	O
acid	O
substitution	O
.	O
</ALL>	O

<ALL>	O
Analysis	O
of	O
PTPN22	B-Gene
transcripts	O
from	O
a	O
subject	O
heterozygous	O
for	O
this	O
variant	O
indicated	O
that	O
it	O
interfered	O
with	O
normal	O
mRNA	O
splicing	O
,	O
resulting	O
in	O
a	O
premature	O
termination	O
codon	O
after	O
exon	O
17	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
support	O
the	O
conclusion	O
that	O
the	O
1858C	B-Variant
/	I-Variant
T	I-Variant
allele	O
is	O
the	O
major	O
risk	O
variant	O
for	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
in	O
the	O
PTPN22	B-Gene
locus	O
,	O
but	O
they	O
suggest	O
that	O
additional	O
infrequent	O
coding	O
variants	O
at	O
PTPN22	B-Gene
may	O
also	O
contribute	O
to	O
type	B-Disease
1	I-Disease
diabetes	I-Disease
risk	O
.	O
</ALL>	O

<ALL>	O
Polymorphic	O
Alu	O
insertions	O
and	O
the	O
genetic	O
structure	O
of	O
Iberian	O
Basques	O
.	O
</ALL>	O

<ALL>	O
Eight	O
Alu	O
sequences	O
(	O
ACE	B-Gene
,	O
TPA25	B-Gene
,	O
PV92	B-Gene
,	O
APO	B-Gene
,	O
FXIIIB	B-Gene
,	O
D1	B-Gene
,	O
A25	B-Gene
and	O
B65	B-Gene
)	O
were	O
analyzed	O
in	O
two	O
samples	O
from	O
Navarre	O
and	O
Guipuzcoa	O
provinces	O
(	O
Basque	O
Country	O
,	O
Spain	O
)	O
.	O
</ALL>	O

<ALL>	O
Alu	O
data	O
for	O
other	O
European	O
,	O
Caucasus	O
and	O
North	O
African	O
populations	O
were	O
compiled	O
from	O
the	O
literature	O
for	O
comparison	O
purposes	O
to	O
assess	O
the	O
genetic	O
relationships	O
of	O
the	O
Basques	O
in	O
a	O
broader	O
geographic	O
context	O
.	O
</ALL>	O

<ALL>	O
Results	O
of	O
both	O
MDS	O
plot	O
and	O
AMOVA	O
revealed	O
spatial	O
heterogeneity	O
among	O
these	O
three	O
population	O
clusters	O
clearly	O
defined	O
by	O
geography	O
.	O
</ALL>	O

<ALL>	O
On	O
the	O
contrary	O
,	O
no	O
substantial	O
genetic	O
heterogeneity	O
was	O
found	O
between	O
the	O
Basque	O
samples	O
,	O
or	O
between	O
Basques	O
and	O
other	O
Europeans	O
(	O
excluding	O
Caucasus	O
populations	O
)	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
the	O
genetic	O
information	O
obtained	O
from	O
Alu	O
data	O
conflicts	O
with	O
hypotheses	O
linking	O
the	O
origin	O
of	O
Basques	O
with	O
populations	O
from	O
North	O
Africa	O
(	O
Berbers	O
)	O
or	O
from	O
the	O
Caucasus	O
region	O
(	O
Georgia	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
order	O
to	O
explain	O
the	O
reduced	O
genetic	O
heterogeneity	O
detected	O
by	O
Alu	O
insertions	O
among	O
Basque	O
subpopulations	O
,	O
values	O
of	O
the	O
Wright	O
's	O
F	O
(	O
ST	O
)	O
statistic	O
were	O
estimated	O
for	O
both	O
Alu	O
markers	O
and	O
a	O
set	O
of	O
short	O
tandem	O
repeats	O
(	O
STRs	O
)	O
in	O
terms	O
of	O
two	O
geographical	O
scales	O
:	O
(	O
1	O
)	O
the	O
Basque	O
Country	O
,	O
(	O
2	O
)	O
Europe	O
(	O
including	O
Basques	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
Basque	O
area	O
,	O
estimates	O
of	O
Wahlund	O
's	O
effect	O
for	O
both	O
genetic	O
markers	O
showed	O
no	O
statistical	O
difference	O
between	O
Basque	O
subpopulations	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
when	O
this	O
analysis	O
was	O
performed	O
on	O
a	O
European	O
scale	O
,	O
F	O
(	O
ST	O
)	O
values	O
were	O
significantly	O
higher	O
for	O
Alu	O
insertions	O
than	O
for	O
STR	O
alleles	O
.	O
</ALL>	O

<ALL>	O
From	O
these	O
results	O
,	O
we	O
suggest	O
that	O
the	O
spatial	O
heterogeneity	O
of	O
the	O
Basque	O
gene	O
pool	O
identified	O
in	O
previous	O
polymorphism	O
studies	O
is	O
relatively	O
recent	O
and	O
probably	O
caused	O
by	O
a	O
differential	O
process	O
of	O
genetic	O
admixture	O
with	O
non	O
-	O
Basque	O
neighboring	O
populations	O
modulated	O
by	O
the	O
effect	O
of	O
a	O
linguistic	O
barrier	O
to	O
random	O
mating	O
.	O
</ALL>	O

<ALL>	O
Manganese	B-Gene
superoxide	I-Gene
dismutase	I-Gene
(	O
Mn	B-Gene
-	I-Gene
SOD	I-Gene
)	O
gene	O
polymorphisms	O
in	O
urolithiasis	B-Disease
.	O
</ALL>	O

<ALL>	O
Polymorphism	O
in	O
manganese	B-Gene
superoxide	I-Gene
dismutase	I-Gene
gene	O
(	O
Mn	B-Gene
-	I-Gene
SOD	I-Gene
)	O
is	O
a	O
new	O
approach	O
to	O
identify	O
its	O
probable	O
association	O
with	O
urolithiasis	B-Disease
.	O
</ALL>	O

<ALL>	O
Oxidative	O
stress	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
stone	B-Disease
formation	I-Disease
in	O
the	O
renal	O
system	O
.	O
</ALL>	O

<ALL>	O
MnSOD	B-Gene
is	O
one	O
of	O
the	O
primary	O
enzymes	O
that	O
directly	O
scavenges	O
potential	O
harmful	O
oxidizing	O
species	O
.	O
</ALL>	O

<ALL>	O
A	O
valine	B-Variant
(	I-Variant
Val	I-Variant
)	I-Variant
to	I-Variant
alanine	I-Variant
(	I-Variant
Ala	I-Variant
)	I-Variant
substitution	I-Variant
at	I-Variant
amino	I-Variant
acid	I-Variant
16	I-Variant
,	O
occurring	O
in	O
the	O
mitochondrial	O
targeting	O
sequence	O
of	O
the	O
MnSOD	B-Gene
gene	O
,	O
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
urolithiasis	B-Disease
risk	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
association	O
of	O
MnSOD	B-Gene
gene	O
polymorphism	O
with	O
the	O
risk	O
of	O
urolithiasis	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
investigated	O
the	O
MnSOD	B-Gene
in	O
66	O
stone	B-Disease
-	I-Disease
forming	I-Disease
adults	O
and	O
72	O
healthy	O
volunteers	O
.	O
</ALL>	O

<ALL>	O
DNA	O
was	O
isolated	O
from	O
peripheral	O
blood	O
and	O
genotyping	O
was	O
performed	O
with	O
PCR	O
-	O
based	O
methods	O
.	O
</ALL>	O

<ALL>	O
Then	O
PCR	O
products	O
were	O
cut	O
by	O
BsaW1	O
.	O
</ALL>	O

<ALL>	O
Products	O
were	O
run	O
on	O
3	O
%	O
agarose	B-Chemical
gel	O
,	O
246	O
bp	O
regions	O
were	O
1	O
-	O
Ala	O
-	O
9	O
,	O
164	O
and	O
82	O
bp	O
products	O
were	O
determined	O
as	O
2	O
Val	O
-	O
9	O
.	O
</ALL>	O

<ALL>	O
Chi	O
-	O
square	O
test	O
was	O
used	O
for	O
comparison	O
between	O
patients	B-Species
and	O
controls	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
control	O
group	O
the	O
homozygote	O
Ala	O
allele	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
patient	B-Species
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
distribution	O
of	O
Ala	O
/	O
Val	O
and	O
homozygote	O
Val	O
alleles	O
in	O
the	O
patient	B-Species
group	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
MnSOD	B-Gene
genotype	O
determination	O
may	O
provide	O
a	O
tool	O
to	O
identify	O
individuals	O
who	O
are	O
at	O
risk	O
of	O
urolithiasis	B-Disease
.	O
</ALL>	O

<ALL>	O
This	O
experiment	O
also	O
provides	O
data	O
about	O
antioxidant	O
status	O
and	O
stone	B-Disease
formation	I-Disease
.	O
</ALL>	O

<ALL>	O
P2RX7	B-Gene
:	O
A	O
bipolar	B-Disease
and	I-Disease
unipolar	I-Disease
disorder	I-Disease
candidate	O
susceptibility	O
gene	O
?	O
</ALL>	O

<ALL>	O
The	O
chromosomal	O
region	O
12q24	O
has	O
been	O
previously	O
implicated	O
by	O
linkage	O
studies	O
of	O
both	O
bipolar	B-Disease
disorder	I-Disease
and	O
unipolar	B-Disease
mood	I-Disease
disorder	I-Disease
and	O
we	O
have	O
reported	O
two	O
pedigrees	O
segregating	O
both	O
bipolar	B-Disease
disorder	I-Disease
and	O
Darier	B-Disease
's	I-Disease
disease	I-Disease
that	O
show	O
linkage	O
across	O
this	O
region	O
.	O
</ALL>	O

<ALL>	O
The	O
gene	O
P2RX7	B-Gene
is	O
located	O
in	O
this	O
chromosomal	O
region	O
and	O
has	O
been	O
recently	O
reported	O
as	O
a	O
susceptibility	O
gene	O
for	O
bipolar	B-Disease
disorder	I-Disease
and	O
unipolar	B-Disease
depression	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
non	O
-	O
synonymous	O
SNP	O
rs2230912	B-Variant
(	O
resulting	O
in	O
amino	O
-	O
acid	O
polymorphism	O
Q460R	B-Variant
)	O
showed	O
the	O
strongest	O
association	O
and	O
has	O
been	O
postulated	O
to	O
be	O
pathogenically	O
relevant	O
.	O
</ALL>	O

<ALL>	O
We	O
have	O
investigated	O
this	O
gene	O
in	O
a	O
large	O
UK	O
case	O
-	O
control	O
sample	O
(	O
bipolar	B-Disease
I	I-Disease
disorder	I-Disease
N	O
=	O
687	O
,	O
unipolar	B-Disease
recurrent	I-Disease
major	I-Disease
depression	I-Disease
N	O
=	O
1,036	O
,	O
controls	O
N	O
=	O
1,204	O
)	O
.	O
</ALL>	O

<ALL>	O
Neither	O
rs2230912	B-Variant
nor	O
any	O
of	O
8	O
other	O
SNPs	O
genotyped	O
across	O
P2RX7	B-Gene
was	O
found	O
to	O
be	O
associated	O
with	O
mood	B-Disease
disorder	I-Disease
in	O
general	O
,	O
nor	O
specifically	O
with	O
bipolar	B-Disease
or	I-Disease
unipolar	I-Disease
disorder	I-Disease
.	O
</ALL>	O

<ALL>	O
Further	O
,	O
sequencing	O
of	O
our	O
two	O
chromosome	O
12	O
-	O
linked	O
bipolar	O
-	O
Darier	O
families	O
showed	O
no	O
evidence	O
of	O
rare	O
variants	O
at	O
P2RX7	B-Gene
that	O
could	O
explain	O
the	O
linkage	O
.	O
</ALL>	O

<ALL>	O
Our	O
data	O
do	O
not	O
provide	O
support	O
for	O
rs2230912	B-Variant
or	O
the	O
other	O
polymorphisms	O
studied	O
within	O
the	O
P2RX7	B-Gene
locus	O
,	O
being	O
involved	O
in	O
susceptibility	O
to	O
mood	B-Disease
disorders	I-Disease
.	O
</ALL>	O

<ALL>	O
Efficacy	O
of	O
everolimus	B-Chemical
(	O
RAD001	B-Chemical
)	O
in	O
patients	B-Species
with	O
advanced	O
NSCLC	B-Disease
previously	O
treated	O
with	O
chemotherapy	O
alone	O
or	O
with	O
chemotherapy	O
and	O
EGFR	B-Gene
inhibitors	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Treatment	O
options	O
are	O
scarce	O
in	O
pretreated	O
advanced	O
non	B-Disease
-	I-Disease
small	I-Disease
-	I-Disease
cell	I-Disease
lung	I-Disease
cancer	I-Disease
(	O
NSCLC	B-Disease
)	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
RAD001	B-Chemical
,	O
an	O
oral	O
inhibitor	O
of	O
the	O
mammalian	B-Gene
target	I-Gene
of	I-Gene
rapamycin	I-Gene
(	O
mTOR	B-Gene
)	O
,	O
has	O
shown	O
phase	O
I	O
efficacy	O
in	O
NSCLC	B-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Stage	O
IIIb	O
or	O
IV	O
NSCLC	B-Disease
patients	B-Species
,	O
with	O
two	O
or	O
fewer	O
prior	O
chemotherapy	O
regimens	O
,	O
one	O
platinum	B-Chemical
based	O
(	O
stratum	O
1	O
)	O
or	O
both	O
chemotherapy	O
and	O
epidermal	B-Gene
growth	I-Gene
factor	I-Gene
receptor	I-Gene
tyrosine	I-Gene
kinase	I-Gene
inhibitors	O
(	O
stratum	O
2	O
)	O
,	O
received	O
RAD001	B-Chemical
10	O
mg	O
/	O
day	O
until	O
progression	O
or	O
unacceptable	O
toxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
Primary	O
objective	O
was	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
.	O
</ALL>	O

<ALL>	O
Analyses	O
of	O
markers	O
associated	O
with	O
the	O
mTOR	B-Gene
pathway	O
were	O
carried	O
out	O
on	O
archival	O
tumor	B-Disease
from	O
a	O
subgroup	O
using	O
immunohistochemistry	O
(	O
IHC	O
)	O
and	O
direct	O
mutation	O
sequencing	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Eighty	O
-	O
five	O
patients	B-Species
were	O
enrolled	O
,	O
42	O
in	O
stratum	O
1	O
and	O
43	O
in	O
stratum	O
.	O
</ALL>	O

<ALL>	O
ORR	O
was	O
4.7	O
%	O
(	O
7.1	O
%	O
stratum	O
1	O
;	O
2.3	O
%	O
stratum	O
2	O
)	O
.	O
</ALL>	O

<ALL>	O
Overall	O
disease	O
control	O
rate	O
was	O
47.1	O
%	O
.	O
</ALL>	O

<ALL>	O
Median	O
progression	O
-	O
free	O
survivals	O
(	O
PFSs	O
)	O
were	O
2.6	O
(	O
stratum	O
1	O
)	O
and	O
2.7	O
months	O
(	O
stratum	O
2	O
)	O
.	O
</ALL>	O

<ALL>	O
Common	O
>	O
or	O
=	O
grade	O
3	O
events	O
were	O
fatigue	B-Disease
,	O
dyspnea	B-Disease
,	O
stomatitis	B-Disease
,	O
anemia	B-Disease
,	O
and	O
thrombocytopenia	B-Disease
.	O
</ALL>	O

<ALL>	O
Pneumonitis	B-Disease
,	O
probably	O
or	O
possibly	O
related	O
,	O
mainly	O
grade	O
1	O
/	O
2	O
,	O
occurred	O
in	O
25	O
%	O
.	O
</ALL>	O

<ALL>	O
Cox	O
regression	O
analysis	O
of	O
IHC	O
scores	O
found	O
that	O
only	O
phospho	O
AKT	B-Gene
(	O
pAKT	B-Gene
)	O
was	O
a	O
significant	O
independent	O
predictor	O
of	O
worse	O
PFS	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
RAD001	B-Chemical
10	O
mg	O
/	O
day	O
was	O
well	O
tolerated	O
,	O
showing	O
modest	O
clinical	O
activity	O
in	O
pretreated	O
NSCLC	B-Disease
.	O
</ALL>	O

<ALL>	O
Evaluation	O
of	O
RAD001	B-Chemical
plus	O
standard	O
therapy	O
for	O
metastatic	O
NSCLC	B-Disease
continues	O
.	O
</ALL>	O

<ALL>	O
Clopidogrel	B-Chemical
pharmacogenomics	O
and	O
risk	O
of	O
inadequate	O
platelet	O
inhibition	O
:	O
US	O
FDA	O
recommendations	O
.	O
</ALL>	O

<ALL>	O
Antiplatelet	O
therapy	O
with	O
clopidogrel	B-Chemical
is	O
the	O
current	O
standard	O
of	O
care	O
for	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
patients	B-Species
undergoing	O
a	O
percutaneous	O
coronary	O
intervention	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
approximately	O
25	O
%	O
of	O
patients	B-Species
experience	O
a	O
subtherapeutic	O
antiplatelet	O
response	O
.	O
</ALL>	O

<ALL>	O
Clopidogrel	B-Chemical
is	O
a	O
prodrug	O
that	O
undergoes	O
hepatic	O
biotransformation	O
by	O
CYP2C19	B-Gene
into	O
its	O
active	O
metabolite	O
.	O
</ALL>	O

<ALL>	O
Several	O
studies	O
have	O
reported	O
that	O
,	O
compared	O
with	O
wild	O
-	O
type	O
individuals	O
,	O
CYP2C19	B-Gene
variant	O
allele	O
carriers	O
exhibit	O
a	O
significantly	O
lower	O
capacity	O
to	O
metabolize	O
clopidogrel	B-Chemical
into	O
its	O
active	O
metabolite	O
and	O
inhibit	O
platelet	O
activation	O
,	O
and	O
are	O
therefore	O
at	O
significantly	O
higher	O
risk	O
of	O
adverse	O
cardiovascular	O
events	O
.	O
</ALL>	O

<ALL>	O
Consequently	O
,	O
the	O
US	O
FDA	O
has	O
recently	O
changed	O
clopidogrel	B-Chemical
's	O
prescribing	O
information	O
to	O
highlight	O
the	O
impact	O
of	O
CYP2C19	B-Gene
genotype	O
on	O
clopidogrel	B-Chemical
pharmacokinetics	O
,	O
pharmacodynamics	O
and	O
clinical	O
response	O
.	O
</ALL>	O

<ALL>	O
Future	O
studies	O
remain	O
necessary	O
to	O
develop	O
effective	O
personalized	O
therapeutic	O
strategies	O
for	O
CYP2C19	B-Gene
variant	O
allele	O
carriers	O
and	O
other	O
individuals	O
at	O
risk	O
for	O
clopidogrel	B-Chemical
nonresponsiveness	O
.	O
</ALL>	O

<ALL>	O
Mutation	O
analysis	O
in	O
a	O
Chinese	O
family	O
with	O
multiple	B-Disease
endocrine	I-Disease
neoplasia	I-Disease
type	I-Disease
1	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Multiple	B-Disease
endocrine	I-Disease
neoplasia	I-Disease
type	I-Disease
1	I-Disease
(	O
MEN1	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
cancer	I-Disease
syndrome	I-Disease
which	O
is	O
caused	O
by	O
germline	O
mutations	O
of	O
the	O
tumor	B-Disease
suppressor	O
gene	O
MEN1	B-Gene
.	O
</ALL>	O

<ALL>	O
This	O
study	O
aimed	O
to	O
identify	O
mutations	O
in	O
a	O
Chinese	O
pedigree	O
with	O
MEN1	B-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
A	O
large	O
Chinese	O
family	O
with	O
MEN1	B-Disease
was	O
collected	O
.	O
</ALL>	O

<ALL>	O
All	O
of	O
the	O
coded	O
regions	O
and	O
their	O
adjacent	O
sequences	O
of	O
the	O
MEN1	B-Gene
gene	O
were	O
amplified	O
and	O
sequenced	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
In	O
this	O
family	O
,	O
a	O
heterozygous	O
cytosine	B-Variant
insertion	I-Variant
in	O
exon	O
10	O
(	O
c.1546	B-Variant
_	I-Variant
1547insC	I-Variant
)	O
inducing	O
a	O
frame	O
shift	O
mutation	O
of	O
MEN1	B-Gene
was	O
found	O
in	O
the	O
proband	O
and	O
the	O
other	O
two	O
suffering	O
members	O
of	O
his	O
family	O
.	O
</ALL>	O

<ALL>	O
This	O
mutation	O
was	O
linked	O
to	O
a	O
novel	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
intron	O
3	O
(	O
IVS3	B-Variant
+	I-Variant
18C	I-Variant
>	I-Variant
T	I-Variant
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
The	O
mutation	O
in	O
exon	O
10	O
of	O
MEN1	B-Gene
gene	O
might	O
induce	O
development	O
of	O
parathyroid	B-Disease
hyperplasia	I-Disease
and	O
pituitary	B-Disease
adenoma	I-Disease
and	O
cosegregate	O
with	O
MEN1	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
significance	O
of	O
the	O
new	O
found	O
IVS3	B-Variant
+	I-Variant
18C	I-Variant
>	I-Variant
T	I-Variant
of	O
MEN1	B-Gene
needs	O
a	O
further	O
investigation	O
.	O
</ALL>	O

<ALL>	O
Genetic	O
polymorphism	O
of	O
the	O
glutathione	B-Gene
-	I-Gene
S	I-Gene
-	I-Gene
transferase	I-Gene
P1	I-Gene
gene	O
(	O
GSTP1	B-Gene
)	O
and	O
susceptibility	O
to	O
prostate	B-Disease
cancer	I-Disease
in	O
the	O
Kashmiri	O
population	O
.	O
</ALL>	O

<ALL>	O
Glutathione	B-Gene
-	I-Gene
S	I-Gene
-	I-Gene
transferase	I-Gene
P1	I-Gene
(	O
GSTP1	B-Gene
)	O
is	O
a	O
critical	O
enzyme	O
of	O
the	O
phase	O
II	O
detoxification	O
pathway	O
.	O
</ALL>	O

<ALL>	O
One	O
of	O
the	O
common	O
functional	O
polymorphisms	O
of	O
GSTP1	B-Gene
is	O
A	B-Variant
>	I-Variant
G	I-Variant
at	I-Variant
nucleotide	I-Variant
313	I-Variant
,	O
which	O
results	O
in	O
an	O
amino	O
acid	O
substitution	O
(	O
Ile105Val	B-Variant
)	O
at	O
the	O
substrate	O
binding	O
site	O
of	O
GSTP1	B-Gene
and	O
reduces	O
catalytic	O
activity	O
of	O
GSTP1	B-Gene
.	O
</ALL>	O

<ALL>	O
To	O
investigate	O
the	O
GSTP1	B-Gene
Ile105Val	B-Variant
genotype	O
frequency	O
in	O
prostate	B-Disease
cancer	I-Disease
cases	O
in	O
the	O
Kashmiri	O
population	O
,	O
we	O
designed	O
a	O
case	O
-	O
control	O
study	O
,	O
in	O
which	O
50	O
prostate	B-Disease
cancer	I-Disease
cases	O
and	O
45	O
benign	B-Disease
prostate	I-Disease
hyperplasia	I-Disease
cases	O
were	O
studied	O
for	O
GSTP1	B-Gene
Ile105Val	B-Variant
polymorphism	O
,	O
compared	O
to	O
80	O
controls	O
taken	O
from	O
the	O
general	O
population	O
,	O
employing	O
the	O
PCR	O
-	O
RFLP	O
technique	O
.	O
</ALL>	O

<ALL>	O
We	O
found	O
the	O
frequency	O
of	O
the	O
three	O
different	O
genotypes	O
of	O
GSTP1	B-Gene
Ile105Val	B-Variant
in	O
our	O
ethnic	O
Kashmir	O
population	O
,	O
i.e.	O
,	O
Ile	O
/	O
Ile	O
,	O
Ile	O
/	O
Val	O
and	O
Val	O
/	O
Val	O
,	O
to	O
be	O
52.4	O
,	O
33.3	O
and	O
14.3	O
%	O
among	O
prostate	B-Disease
cancer	I-Disease
cases	O
,	O
48.5	O
,	O
37.5	O
and	O
14	O
%	O
among	O
benign	B-Disease
prostate	I-Disease
hyperplasia	I-Disease
cases	O
and	O
73.8	O
,	O
21.3	O
and	O
5	O
%	O
in	O
the	O
control	O
population	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
a	O
significant	O
association	O
between	O
the	O
GSTP1	B-Gene
Ile	B-Variant
/	I-Variant
Val	I-Variant
genotype	O
and	O
the	O
advanced	O
age	O
group	O
among	O
the	O
cases	O
.	O
</ALL>	O

<ALL>	O
We	O
conclude	O
that	O
GSTP1	B-Gene
Ile	B-Variant
/	I-Variant
Val	I-Variant
polymorphism	O
is	O
involved	O
in	O
the	O
risk	O
of	O
prostate	B-Disease
cancer	I-Disease
development	O
in	O
our	O
population	O
.	O
</ALL>	O

<ALL>	O
Availability	O
of	O
human	B-Species
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
cardiomyocytes	O
in	O
assessment	O
of	O
drug	O
potential	O
for	O
QT	B-Disease
prolongation	I-Disease
.	O
</ALL>	O

<ALL>	O
Field	O
potential	O
duration	O
(	O
FPD	O
)	O
in	O
human	B-Species
-	O
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
cardiomyocytes	O
(	O
hiPS	O
-	O
CMs	O
)	O
,	O
which	O
can	O
express	O
QT	O
interval	O
in	O
an	O
electrocardiogram	O
,	O
is	O
reported	O
to	O
be	O
a	O
useful	O
tool	O
to	O
predict	O
K	B-Chemical
(	I-Chemical
+	I-Chemical
)	I-Chemical
channel	I-Chemical
and	I-Chemical
Ca	I-Chemical
(	I-Chemical
2	I-Chemical
+	I-Chemical
)	I-Chemical
channel	I-Chemical
blocker	I-Chemical
effects	O
on	O
QT	O
interval	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
there	O
is	O
no	O
report	O
showing	O
that	O
this	O
technique	O
can	O
be	O
used	O
to	O
predict	O
multichannel	O
blocker	O
potential	O
for	O
QT	B-Disease
prolongation	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
show	O
that	O
FPD	O
from	O
MEA	O
(	O
Multielectrode	O
array	O
)	O
of	O
hiPS	O
-	O
CMs	O
can	O
detect	O
QT	B-Disease
prolongation	I-Disease
induced	O
by	O
multichannel	O
blockers	O
.	O
</ALL>	O

<ALL>	O
hiPS	O
-	O
CMs	O
were	O
seeded	O
onto	O
MEA	O
and	O
FPD	O
was	O
measured	O
for	O
2min	O
every	O
10min	O
for	O
30min	O
after	O
drug	O
exposure	O
for	O
the	O
vehicle	O
and	O
each	O
drug	O
concentration	O
.	O
</ALL>	O

<ALL>	O
IKr	O
and	O
IKs	O
blockers	O
concentration	O
-	O
dependently	O
prolonged	O
corrected	O
FPD	O
(	O
FPDc	O
)	O
,	O
whereas	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+	I-Chemical
)	I-Chemical
channel	I-Chemical
blockers	I-Chemical
concentration	O
-	O
dependently	O
shortened	O
FPDc	O
.	O
</ALL>	O

<ALL>	O
Also	O
,	O
the	O
multichannel	O
blockers	O
Amiodarone	B-Chemical
,	O
Paroxetine	B-Chemical
,	O
Terfenadine	B-Chemical
and	O
Citalopram	B-Chemical
prolonged	O
FPDc	O
in	O
a	O
concentration	O
dependent	O
manner	O
.	O
</ALL>	O

<ALL>	O
Finally	O
,	O
the	O
IKr	O
blockers	O
,	O
Terfenadine	B-Chemical
and	O
Citalopram	B-Chemical
,	O
which	O
are	O
reported	O
to	O
cause	O
Torsade	B-Disease
de	I-Disease
Pointes	I-Disease
(	O
TdP	B-Disease
)	O
in	O
clinical	O
practice	O
,	O
produced	O
early	O
afterdepolarization	O
(	O
EAD	O
)	O
.	O
</ALL>	O

<ALL>	O
hiPS	O
-	O
CMs	O
using	O
MEA	O
system	O
and	O
FPDc	O
can	O
predict	O
the	O
effects	O
of	O
drug	O
candidates	O
on	O
QT	O
interval	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
also	O
shows	O
that	O
this	O
assay	O
can	O
help	O
detect	O
EAD	O
for	O
drugs	O
with	O
TdP	B-Disease
potential	O
.	O
</ALL>	O

<ALL>	O
Serum	O
levels	O
of	O
chemokines	B-Gene
CCL4	B-Gene
and	O
CCL5	B-Gene
in	O
cirrhotic	B-Disease
patients	B-Species
indicate	O
the	O
presence	O
of	O
hepatocellular	B-Disease
carcinoma	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Most	O
hepatocellular	B-Disease
carcinomas	I-Disease
(	O
HCCs	B-Disease
)	O
are	O
diagnosed	O
at	O
an	O
advanced	O
stage	O
.	O
</ALL>	O

<ALL>	O
The	O
prognostic	O
value	O
of	O
serum	O
tumour	B-Disease
markers	O
alpha	B-Gene
-	I-Gene
fetoprotein	I-Gene
(	O
AFP	B-Gene
)	O
and	O
des	B-Gene
-	I-Gene
gamma	I-Gene
-	I-Gene
carboxy	I-Gene
prothrombin	I-Gene
(	O
DCP	B-Gene
)	O
is	O
limited	O
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
our	O
study	O
is	O
to	O
evaluate	O
the	O
diagnostic	O
value	O
of	O
serum	O
growth	O
factors	O
,	O
apoptotic	O
and	O
inflammatory	B-Disease
mediators	O
of	O
cirrhotic	B-Disease
patients	B-Species
with	O
and	O
without	O
HCC	B-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Serum	O
samples	O
were	O
collected	O
from	O
cirrhotic	B-Disease
potential	O
liver	O
transplant	O
patients	B-Species
(	O
LTx	O
)	O
with	O
(	O
n	O
=	O
61	O
)	O
and	O
without	O
HCC	B-Disease
(	O
n	O
=	O
78	O
)	O
as	O
well	O
as	O
from	O
healthy	O
controls	O
(	O
HCs	O
;	O
n	O
=	O
39	O
)	O
.	O
</ALL>	O

<ALL>	O
Serum	O
concentrations	O
of	O
CRP	B-Gene
,	O
neopterin	B-Chemical
and	O
IL	B-Gene
-	I-Gene
6	I-Gene
as	O
markers	O
of	O
inflammation	B-Disease
and	O
thrombopoietin	B-Gene
(	O
TPO	B-Gene
)	O
,	O
GCSF	B-Gene
,	O
FGF	B-Gene
basic	I-Gene
and	O
VEGF	B-Gene
,	O
HMGB1	B-Gene
,	O
CK	B-Gene
-	I-Gene
18	I-Gene
(	O
M65	O
)	O
and	O
CK18	B-Gene
fragment	O
(	O
M30	O
)	O
and	O
a	O
panel	O
of	O
proinflammatory	B-Gene
chemokines	I-Gene
(	O
CCL2	B-Gene
,	O
CCL3	B-Gene
,	O
CCL4	B-Gene
,	O
CCL5	B-Gene
,	O
CXCL5	B-Gene
and	O
IL	B-Gene
-	I-Gene
8	I-Gene
)	O
were	O
measured	O
.	O
</ALL>	O

<ALL>	O
Chi	O
square	O
,	O
Fisher	O
exact	O
,	O
Mann	O
-	O
Whitney	O
U	O
-	O
tests	O
,	O
ROC	O
curve	O
analysis	O
and	O
forward	O
stepwise	O
logistic	O
regression	O
analyses	O
were	O
applied	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Patients	B-Species
with	O
HCC	B-Disease
had	O
higher	O
serum	O
TPO	B-Gene
and	O
chemokines	B-Gene
(	O
P	O
<	O
0.001	O
for	O
TPO	B-Gene
,	O
CCL4	B-Gene
,	O
CCL5	B-Gene
and	O
CXCL5	B-Gene
)	O
and	O
lower	O
CCL2	B-Gene
(	O
P	O
=	O
0.008	O
)	O
levels	O
than	O
cirrhotic	B-Disease
patients	B-Species
without	O
HCC	B-Disease
.	O
</ALL>	O

<ALL>	O
Multivariate	O
forward	O
stepwise	O
regression	O
analysis	O
for	O
significant	O
parameters	O
showed	O
that	O
among	O
the	O
studied	O
parameters	O
CCL4	B-Gene
and	O
CCL5	B-Gene
(	O
P	O
=	O
0.001	O
)	O
are	O
diagnostic	O
markers	O
of	O
HCC	B-Disease
.	O
</ALL>	O

<ALL>	O
Serum	O
levels	O
of	O
TPO	B-Gene
and	O
chemokines	B-Gene
were	O
lower	O
,	O
whereas	O
M30	O
was	O
significantly	O
higher	O
in	O
cirrhotic	B-Disease
patients	B-Species
than	O
in	O
HCs	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
High	O
serum	O
levels	O
of	O
inflammatory	B-Disease
chemokines	B-Gene
such	O
as	O
CCL4	B-Gene
and	O
CCL5	B-Gene
in	O
the	O
serum	O
of	O
cirrhotic	B-Disease
patients	B-Species
indicate	O
the	O
presence	O
of	O
HCC	B-Disease
.	O
</ALL>	O

<ALL>	O
Disease	O
-	O
associated	O
mutations	O
in	O
human	B-Species
BICD2	B-Gene
hyperactivate	O
motility	O
of	O
dynein	B-Gene
-	O
dynactin	B-Gene
.	O
</ALL>	O

<ALL>	O
Bicaudal	B-Gene
D2	I-Gene
(	O
BICD2	B-Gene
)	O
joins	O
dynein	B-Gene
with	O
dynactin	B-Gene
into	O
a	O
ternary	O
complex	O
(	O
termed	O
DDB	B-Gene
)	O
capable	O
of	O
processive	O
movement	O
.	O
</ALL>	O

<ALL>	O
Point	O
mutations	O
in	O
the	O
BICD2	B-Gene
gene	O
have	O
been	O
identified	O
in	O
patients	B-Species
with	O
a	O
dominant	O
form	O
of	O
spinal	B-Disease
muscular	I-Disease
atrophy	I-Disease
,	O
but	O
how	O
these	O
mutations	O
cause	O
disease	O
is	O
unknown	O
.	O
</ALL>	O

<ALL>	O
To	O
investigate	O
this	O
question	O
,	O
we	O
have	O
developed	O
in	O
vitro	O
motility	O
assays	O
with	O
purified	O
DDB	B-Gene
and	O
BICD2	B-Gene
's	O
membrane	O
vesicle	O
partner	O
,	O
the	O
GTPase	B-Gene
Rab6a	I-Gene
.	O
</ALL>	O

<ALL>	O
Rab6a	B-Gene
-	I-Gene
GTP	I-Gene
,	O
either	O
in	O
solution	O
or	O
bound	O
to	O
artificial	O
liposomes	O
,	O
released	O
BICD2	B-Gene
from	O
an	O
autoinhibited	O
state	O
and	O
promoted	O
robust	O
dynein	B-Gene
-	O
dynactin	B-Gene
transport	O
.	O
</ALL>	O

<ALL>	O
In	O
these	O
assays	O
,	O
BICD2	B-Gene
mutants	O
showed	O
an	O
enhanced	O
ability	O
to	O
form	O
motile	O
DDB	B-Gene
complexes	O
.	O
</ALL>	O

<ALL>	O
Increased	O
retrograde	O
transport	O
by	O
BICD2	B-Gene
mutants	O
also	O
was	O
observed	O
in	O
cells	O
using	O
an	O
inducible	O
organelle	O
transport	O
assay	O
.	O
</ALL>	O

<ALL>	O
When	O
overexpressed	O
in	O
rat	B-Species
hippocampal	O
neurons	O
,	O
the	O
hyperactive	O
BICD2	B-Gene
mutants	O
decreased	O
neurite	O
growth	O
.	O
</ALL>	O

<ALL>	O
Our	O
results	O
reveal	O
that	O
dominant	O
mutations	O
in	O
BICD2	B-Gene
hyperactivate	O
DDB	B-Gene
motility	O
and	O
suggest	O
that	O
an	O
imbalance	O
of	O
minus	O
versus	O
plus	O
end	O
-	O
directed	O
microtubule	O
motility	O
in	O
neurons	O
may	O
underlie	O
spinal	B-Disease
muscular	I-Disease
atrophy	I-Disease
.	O
</ALL>	O

<ALL>	O
Thiamine	B-Disease
deficiency	I-Disease
activates	O
hypoxia	B-Gene
inducible	I-Gene
factor	I-Gene
-	I-Gene
1a	I-Gene
to	O
facilitate	O
pro	O
-	O
apoptotic	O
responses	O
in	O
mouse	B-Species
primary	O
astrocytes	O
.	O
</ALL>	O

<ALL>	O
Thiamine	B-Chemical
is	O
an	O
essential	O
enzyme	O
cofactor	O
required	O
for	O
proper	O
metabolic	O
function	O
and	O
maintenance	O
of	O
metabolism	O
and	O
energy	O
production	O
in	O
the	O
brain	O
.	O
</ALL>	O

<ALL>	O
In	O
developed	O
countries	O
,	O
thiamine	B-Disease
deficiency	I-Disease
(	O
TD	B-Disease
)	O
is	O
most	O
often	O
manifested	O
following	O
chronic	O
alcohol	B-Chemical
consumption	O
leading	O
to	O
impaired	B-Disease
mitochondrial	I-Disease
function	I-Disease
,	O
oxidative	O
stress	O
,	O
inflammation	B-Disease
and	O
excitotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
These	O
biochemical	O
lesions	O
result	O
in	O
apoptotic	O
cell	O
death	O
in	O
both	O
neurons	O
and	O
astrocytes	O
.	O
</ALL>	O

<ALL>	O
Comparable	O
histological	O
injuries	O
in	O
patients	B-Species
with	O
hypoxia	B-Disease
/	O
ischemia	B-Disease
and	O
TD	B-Disease
have	O
been	O
described	O
in	O
the	O
thalamus	O
and	O
mammillary	O
bodies	O
,	O
suggesting	O
a	O
congruency	O
between	O
the	O
cellular	O
responses	O
to	O
these	O
stresses	O
.	O
</ALL>	O

<ALL>	O
Consistent	O
with	O
hypoxia	B-Disease
/	O
ischemia	B-Disease
,	O
TD	B-Disease
stabilizes	O
and	O
activates	O
Hypoxia	B-Gene
Inducible	I-Gene
Factor	I-Gene
-	I-Gene
1a	I-Gene
(	O
HIF	B-Gene
-	I-Gene
1a	I-Gene
)	O
under	O
physiological	O
oxygen	B-Chemical
levels	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
role	O
of	O
TD	B-Disease
-	O
induced	O
HIF	B-Gene
-	I-Gene
1a	I-Gene
in	O
neurological	B-Disease
injury	I-Disease
is	O
currently	O
unknown	O
.	O
</ALL>	O

<ALL>	O
Using	O
Western	O
blot	O
analysis	O
and	O
RT	O
-	O
PCR	O
,	O
we	O
have	O
demonstrated	O
that	O
TD	B-Disease
induces	O
HIF	B-Gene
-	I-Gene
1a	I-Gene
expression	O
and	O
activity	O
in	O
primary	O
mouse	B-Species
astrocytes	O
.	O
</ALL>	O

<ALL>	O
We	O
observed	O
a	O
time	O
-	O
dependent	O
increase	O
in	O
mRNA	O
and	O
protein	O
expression	O
of	O
the	O
pro	O
-	O
apoptotic	O
and	O
pro	O
-	O
inflammatory	B-Disease
HIF	B-Gene
-	I-Gene
1a	I-Gene
target	O
genes	O
MCP1	B-Gene
,	O
BNIP3	B-Gene
,	O
Nix	B-Gene
and	O
Noxa	B-Gene
during	O
TD	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
also	O
observed	O
apoptotic	O
cell	O
death	O
in	O
TD	B-Disease
as	O
demonstrated	O
by	O
PI	O
/	O
Annexin	B-Gene
V	I-Gene
staining	O
,	O
TUNEL	O
assay	O
,	O
and	O
Cell	O
Death	O
ELISA	O
.	O
</ALL>	O

<ALL>	O
Pharmacological	O
inhibition	O
of	O
HIF	B-Gene
-	I-Gene
1a	I-Gene
activity	O
using	O
YC1	B-Gene
and	O
thiamine	B-Chemical
repletion	O
both	O
reduced	O
expression	O
of	O
pro	O
-	O
apoptotic	O
HIF	B-Gene
-	I-Gene
1a	I-Gene
target	O
genes	O
and	O
apoptotic	O
cell	O
death	O
in	O
TD	B-Disease
.	O
</ALL>	O

<ALL>	O
These	O
results	O
demonstrate	O
that	O
induction	O
of	O
HIF	B-Gene
-	I-Gene
1a	I-Gene
mediated	O
transcriptional	O
up	O
-	O
regulation	O
of	O
pro	O
-	O
apoptotic	O
/	O
inflammatory	B-Disease
signaling	O
contributes	O
to	O
astrocyte	O
cell	O
death	O
during	O
thiamine	B-Disease
deficiency	I-Disease
.	O
</ALL>	O

<ALL>	O
Recurrent	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
induced	O
by	O
azithromycin	B-Chemical
.	O
</ALL>	O

<ALL>	O
A	O
14	O
-	O
year	O
-	O
old	O
girl	O
is	O
reported	O
with	O
recurrent	O
,	O
azithromycin	B-Chemical
-	O
induced	O
,	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
second	O
episode	O
was	O
more	O
severe	O
than	O
the	O
first	O
;	O
and	O
although	O
both	O
were	O
treated	O
with	O
intensive	O
corticosteroid	B-Chemical
therapy	O
,	O
renal	O
function	O
remained	O
impaired	O
.	O
</ALL>	O

<ALL>	O
Although	O
most	O
cases	O
of	O
antibiotic	B-Chemical
induced	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
are	O
benign	O
and	O
self	O
-	O
limited	O
,	O
some	O
patients	B-Species
are	O
at	O
risk	O
for	O
permanent	O
renal	B-Disease
injury	I-Disease
.	O
</ALL>	O

<ALL>	O
Behavioral	O
effects	O
of	O
urotensin	B-Gene
-	I-Gene
II	I-Gene
centrally	O
administered	O
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Urotensin	B-Gene
-	I-Gene
II	I-Gene
(	O
U	B-Gene
-	I-Gene
II	I-Gene
)	O
receptors	O
are	O
widely	O
distributed	O
in	O
the	O
central	O
nervous	O
system	O
.	O
</ALL>	O

<ALL>	O
Intracerebroventricular	O
(	O
i.c.v	O
.	O
)	O
</ALL>	O

<ALL>	O
injection	O
of	O
U	B-Gene
-	I-Gene
II	I-Gene
causes	O
hypertension	B-Disease
and	O
bradycardia	B-Disease
and	O
stimulates	O
prolactin	B-Gene
and	O
thyrotropin	B-Gene
secretion	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
behavioral	O
effects	O
of	O
centrally	O
administered	O
U	B-Gene
-	I-Gene
II	I-Gene
have	O
received	O
little	O
attention	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
study	O
,	O
we	O
tested	O
the	O
effects	O
of	O
i.c.v	O
.	O
</ALL>	O

<ALL>	O
injections	O
of	O
U	B-Gene
-	I-Gene
II	I-Gene
on	O
behavioral	O
,	O
metabolic	O
,	O
and	O
endocrine	O
responses	O
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Administration	O
of	O
graded	O
doses	O
of	O
U	B-Gene
-	I-Gene
II	I-Gene
(	O
1	O
-	O
10,000	O
ng	O
/	O
mouse	B-Species
)	O
provoked	O
:	O
(	O
1	O
)	O
a	O
dose	O
-	O
dependent	O
reduction	O
in	O
the	O
number	O
of	O
head	O
dips	O
in	O
the	O
hole	O
-	O
board	O
test	O
;	O
(	O
2	O
)	O
a	O
dose	O
-	O
dependent	O
reduction	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
white	O
chamber	O
in	O
the	O
black	O
-	O
and	O
-	O
white	O
compartment	O
test	O
,	O
and	O
in	O
the	O
number	O
of	O
entries	O
in	O
the	O
central	O
platform	O
and	O
open	O
arms	O
in	O
the	O
plus	O
-	O
maze	O
test	O
;	O
and	O
(	O
3	O
)	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
duration	O
of	O
immobility	O
in	O
the	O
forced	O
-	O
swimming	O
test	O
and	O
tail	O
suspension	O
test	O
.	O
</ALL>	O

<ALL>	O
Intracerebroventricular	O
injection	O
of	O
U	B-Gene
-	I-Gene
II	I-Gene
also	O
caused	O
an	O
increase	O
in	O
:	O
food	O
intake	O
at	O
doses	O
of	O
100	O
and	O
1,000	O
ng	O
/	O
mouse	B-Species
,	O
water	O
intake	O
at	O
doses	O
of	O
100	O
-	O
10,000	O
ng	O
/	O
mouse	B-Species
,	O
and	O
horizontal	O
locomotion	O
activity	O
at	O
a	O
dose	O
of	O
10,000	O
ng	O
/	O
mouse	B-Species
.	O
</ALL>	O

<ALL>	O
Whatever	O
was	O
the	O
dose	O
,	O
the	O
central	O
administration	O
of	O
U	B-Gene
-	I-Gene
II	I-Gene
had	O
no	O
effect	O
on	O
body	O
temperature	O
,	O
nociception	O
,	O
apomorphine	B-Chemical
-	O
induced	O
penile	O
erection	O
and	O
climbing	O
behavior	O
,	O
and	O
stress	O
-	O
induced	O
plasma	O
corticosterone	B-Chemical
level	O
.	O
</ALL>	O

<ALL>	O
Taken	O
together	O
,	O
the	O
present	O
study	O
demonstrates	O
that	O
the	O
central	O
injection	O
of	O
U	B-Gene
-	I-Gene
II	I-Gene
at	O
doses	O
of	O
1	O
-	O
10,000	O
ng	O
/	O
mouse	B-Species
induces	O
anxiogenic	B-Disease
-	O
and	O
depressant	B-Disease
-	O
like	O
effects	O
in	O
mouse	B-Species
.	O
</ALL>	O

<ALL>	O
These	O
data	O
suggest	O
that	O
U	B-Gene
-	I-Gene
II	I-Gene
may	O
be	O
involved	O
in	O
some	O
aspects	O
of	O
psychiatric	B-Disease
disorders	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
promoter	O
of	O
inducible	O
nitric	B-Gene
oxide	I-Gene
synthase	I-Gene
implicated	O
in	O
glaucoma	B-Disease
based	O
on	O
genetic	O
analysis	O
and	O
nuclear	O
factor	O
binding	O
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
Nitric	B-Chemical
oxide	I-Chemical
has	O
many	O
beneficial	O
functions	O
in	O
the	O
human	B-Species
body	O
at	O
the	O
right	O
amounts	O
,	O
but	O
it	O
can	O
also	O
be	O
hazardous	O
if	O
it	O
is	O
produced	O
in	O
amounts	O
more	O
than	O
needed	O
and	O
has	O
therefore	O
been	O
studied	O
in	O
relation	O
to	O
several	O
neurological	B-Disease
and	I-Disease
non	I-Disease
-	I-Disease
neurological	I-Disease
disorders	I-Disease
.	O
</ALL>	O

<ALL>	O
In	O
vitro	O
and	O
in	O
vivo	O
studies	O
demonstrate	O
a	O
connection	O
between	O
the	O
inducible	O
form	O
of	O
Nitric	B-Gene
Oxide	I-Gene
Synthase	I-Gene
,	O
iNOS	B-Gene
,	O
and	O
the	O
neuropathological	B-Disease
disorder	I-Disease
glaucoma	I-Disease
,	O
one	O
of	O
the	O
major	O
causes	O
of	O
blindness	B-Disease
in	O
the	O
world	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
sought	O
to	O
establish	O
the	O
genetic	O
association	O
between	O
iNOS	B-Gene
and	O
primary	B-Disease
open	I-Disease
angle	I-Disease
glaucoma	I-Disease
,	O
POAG	B-Disease
,	O
and	O
to	O
find	O
the	O
functional	O
element	O
(	O
s	O
)	O
connected	O
with	O
the	O
pathogenesis	O
of	O
the	O
disease	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Two	O
microsatellites	O
,	O
1	O
insertion	O
/	O
deletion	O
,	O
and	O
8	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
regulatory	O
region	O
of	O
iNOS	B-Gene
were	O
genotyped	O
in	O
200	O
POAG	B-Disease
patients	B-Species
and	O
200	O
age	O
-	O
matched	O
controls	O
.	O
</ALL>	O

<ALL>	O
Also	O
,	O
the	O
CCTTT	O
-	O
microsatellite	O
was	O
examined	O
for	O
its	O
protein	O
-	O
binding	O
capability	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
EMSA	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
There	O
was	O
a	O
significant	O
difference	O
in	O
allele	O
distribution	O
of	O
the	O
CCTTT	O
-	O
microsatellite	O
,	O
between	O
patients	B-Species
and	O
controls	O
.	O
</ALL>	O

<ALL>	O
(	B-Variant
CCTTT	I-Variant
)	I-Variant
14	I-Variant
,	O
which	O
has	O
been	O
reported	O
to	O
have	O
a	O
higher	O
activity	O
in	O
a	O
reporter	O
-	O
construct	O
,	O
was	O
significantly	O
more	O
abundant	O
in	O
POAG	B-Disease
patients	B-Species
,	O
while	O
(	B-Variant
CCTTT	I-Variant
)	I-Variant
10	I-Variant
and	O
(	B-Variant
CCTTT	I-Variant
)	I-Variant
13	I-Variant
were	O
less	O
common	O
.	O
</ALL>	O

<ALL>	O
In	O
EMSA	O
,	O
the	O
(	B-Variant
CCTTT	I-Variant
)	I-Variant
14	I-Variant
allele	O
exhibited	O
specific	O
binding	O
of	O
nuclear	O
proteins	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
These	O
results	O
,	O
together	O
with	O
other	O
studies	O
on	O
this	O
gene	O
and	O
the	O
CCTTT	O
-	O
microsatellite	O
,	O
establish	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
genetic	O
association	O
of	O
iNOS	B-Gene
with	O
POAG	B-Disease
and	O
suggest	O
a	O
regulatory	O
function	O
for	O
the	O
microsatellite	O
.	O
</ALL>	O

<ALL>	O
Homozygous	O
deletion	O
and	O
reduced	O
expression	O
of	O
the	O
DOCK8	B-Gene
gene	O
in	O
human	B-Species
lung	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
A	O
homozygous	O
deletion	O
of	O
the	O
DOCK8	B-Gene
(	O
dedicator	B-Gene
of	I-Gene
cytokinesis	I-Gene
8	I-Gene
)	O
locus	O
at	O
chromosome	O
9p24	O
was	O
found	O
in	O
a	O
lung	B-Disease
cancer	I-Disease
cell	O
line	O
by	O
array	O
-	O
CGH	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Cloning	O
of	O
the	O
full	O
-	O
length	O
DOCK8	B-Gene
cDNA	O
led	O
us	O
to	O
define	O
that	O
the	O
DOCK8	B-Gene
gene	O
encodes	O
a	O
protein	O
consisting	O
of	O
2,099	O
amino	O
acids	O
.	O
</ALL>	O

<ALL>	O
DOCK8	B-Gene
was	O
expressed	O
in	O
a	O
variety	O
of	O
human	B-Species
organs	O
,	O
including	O
the	O
lungs	O
,	O
and	O
was	O
also	O
expressed	O
in	O
type	O
II	O
alveolar	O
,	O
bronchiolar	O
epithelial	O
and	O
bronchial	O
epithelial	O
cells	O
,	O
which	O
are	O
considered	O
as	O
being	O
progenitors	O
for	O
lung	B-Disease
cancer	I-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
DOCK8	B-Gene
expression	O
was	O
reduced	O
in	O
62	O
/	O
71	O
(	O
87	O
%	O
)	O
primary	O
lung	B-Disease
cancers	I-Disease
compared	O
with	O
normal	O
lung	O
tissue	O
,	O
and	O
the	O
reduction	O
occurred	O
irrespective	O
of	O
the	O
histological	O
type	O
of	O
lung	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
5	B-Chemical
-	I-Chemical
Aza	I-Chemical
-	I-Chemical
2	I-Chemical
'	I-Chemical
-	I-Chemical
deoxy	I-Chemical
-	I-Chemical
cytidine	I-Chemical
and	O
/	O
or	O
Trichostatin	B-Chemical
A	I-Chemical
treatments	O
induced	O
DOCK8	B-Gene
expression	O
in	O
lung	B-Disease
cancer	I-Disease
cell	O
lines	O
with	O
reduced	O
DOCK8	B-Gene
expression	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
epigenetic	O
mechanisms	O
,	O
including	O
DNA	O
methylation	O
and	O
histone	O
deacetylation	O
,	O
were	O
indicated	O
to	O
be	O
involved	O
in	O
DOCK8	B-Gene
down	O
-	O
regulation	O
in	O
lung	B-Disease
cancer	I-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
Further	O
screening	O
revealed	O
homozygous	O
deletions	O
of	O
the	O
DOCK8	B-Gene
gene	O
in	O
a	O
gastric	O
and	O
a	O
breast	B-Disease
cancer	I-Disease
cell	O
line	O
.	O
</ALL>	O

<ALL>	O
DOCK	B-Gene
family	O
proteins	O
have	O
been	O
shown	O
to	O
play	O
roles	O
in	O
regulation	O
of	O
migration	O
,	O
morphology	O
,	O
adhesion	O
and	O
growth	O
of	O
cells	O
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
the	O
present	O
results	O
suggest	O
that	O
genetic	O
and	O
epigenetic	O
inactivation	O
of	O
DOCK8	B-Gene
is	O
involved	O
in	O
the	O
development	O
and	O
/	O
or	O
progression	O
of	O
lung	B-Disease
and	I-Disease
other	I-Disease
cancers	I-Disease
by	O
disturbing	O
such	O
regulations	O
.	O
</ALL>	O

<ALL>	O
A	O
novel	O
mutation	O
at	O
the	O
DFNA36	B-Gene
hearing	B-Disease
loss	I-Disease
locus	O
reveals	O
a	O
critical	O
function	O
and	O
potential	O
genotype	O
-	O
phenotype	O
correlation	O
for	O
amino	O
acid	O
-	O
572	O
of	O
TMC1	B-Gene
.	O
</ALL>	O

<ALL>	O
We	O
ascertained	O
a	O
North	O
American	O
Caucasian	O
family	O
(	O
LMG248	O
)	O
segregating	O
autosomal	O
dominant	O
,	O
non	O
-	O
syndromic	O
,	O
post	O
-	O
lingual	O
,	O
progressive	O
sensorineural	B-Disease
hearing	I-Disease
loss	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
hearing	B-Disease
loss	I-Disease
begins	O
in	O
the	O
second	O
decade	O
of	O
life	O
and	O
initially	O
affects	O
high	O
frequencies	O
.	O
</ALL>	O

<ALL>	O
It	O
progresses	O
to	O
profound	O
deafness	B-Disease
at	O
all	O
frequencies	O
by	O
the	O
fourth	O
or	O
fifth	O
decade	O
.	O
</ALL>	O

<ALL>	O
The	O
phenotype	O
co	O
-	O
segregates	O
with	O
short	O
-	O
tandem	O
repeat	O
markers	O
flanking	O
the	O
TMC1	B-Gene
gene	O
at	O
the	O
DFNA36	B-Gene
locus	O
on	O
chromosome	O
9q31	O
-	O
q21	O
.	O
</ALL>	O

<ALL>	O
The	O
affected	O
individuals	O
carry	O
a	O
novel	O
missense	O
substitution	O
,	O
p	B-Variant
.	I-Variant
D572H	I-Variant
(	O
c	B-Variant
.	I-Variant
G1714C	I-Variant
)	O
,	O
of	O
the	O
TMC1	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
This	O
mutation	O
is	O
at	O
the	O
same	O
nucleotide	O
and	O
amino	O
acid	O
position	O
as	O
the	O
only	O
other	O
reported	O
DFNA36	B-Gene
mutation	O
,	O
p	B-Variant
.	I-Variant
D572N	I-Variant
(	O
c	B-Variant
.	I-Variant
G1714A	I-Variant
)	O
.	O
</ALL>	O

<ALL>	O
Our	O
observations	O
implicate	O
a	O
critical	O
function	O
for	O
amino	O
acid	O
-	O
572	O
for	O
wild	O
-	O
type	O
TMC1	B-Gene
function	O
or	O
the	O
pathogenesis	O
of	O
DFNA36	B-Gene
hearing	B-Disease
loss	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
slower	O
progression	O
of	O
hearing	B-Disease
loss	I-Disease
associated	O
with	O
p	B-Variant
.	I-Variant
D572H	I-Variant
,	O
in	O
comparison	O
with	O
that	O
caused	O
by	O
p	B-Variant
.	I-Variant
D572N	I-Variant
,	O
may	O
reflect	O
a	O
correlation	O
of	O
DFNA36	B-Gene
phenotype	O
with	O
TMC1	B-Gene
genotype	O
.	O
</ALL>	O

<ALL>	O
Interferon	B-Gene
regulatory	I-Gene
factor	I-Gene
6	I-Gene
(	O
IRF6	B-Gene
)	O
and	O
fibroblast	B-Gene
growth	I-Gene
factor	I-Gene
receptor	I-Gene
1	I-Gene
(	O
FGFR1	B-Gene
)	O
contribute	O
to	O
human	B-Species
tooth	B-Disease
agenesis	I-Disease
.	O
</ALL>	O

<ALL>	O
Phenotypic	O
characteristics	O
expressed	O
in	O
syndromes	O
give	O
clues	O
to	O
the	O
factors	O
involved	O
in	O
the	O
cause	O
of	O
isolated	O
forms	O
of	O
the	O
same	O
defects	O
.	O
</ALL>	O

<ALL>	O
We	O
investigated	O
two	O
genes	O
responsible	O
for	O
craniofacial	B-Disease
syndromes	I-Disease
,	O
FGFR1	B-Gene
and	O
IRF6	B-Gene
,	O
in	O
a	O
collection	O
of	O
families	O
with	O
isolated	O
tooth	B-Disease
agenesis	I-Disease
.	O
</ALL>	O

<ALL>	O
Cheek	O
swab	O
samples	O
were	O
obtained	O
for	O
DNA	O
analysis	O
from	O
116	O
case	O
/	O
parent	O
trios	O
.	O
</ALL>	O

<ALL>	O
Probands	O
had	O
at	O
least	O
one	O
developmentally	O
missing	O
tooth	O
,	O
excluding	O
third	O
molars	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
we	O
studied	O
89	O
cases	O
and	O
50	O
controls	O
from	O
Ohio	O
to	O
replicate	O
any	O
positive	O
findings	O
.	O
</ALL>	O

<ALL>	O
Genotyping	O
was	O
performed	O
by	O
kinetic	O
polymerase	O
chain	O
-	O
reaction	O
or	O
TaqMan	O
assays	O
.	O
</ALL>	O

<ALL>	O
Linkage	O
disequilibrium	O
analysis	O
and	O
transmission	O
distortion	O
of	O
the	O
marker	O
alleles	O
were	O
performed	O
.	O
</ALL>	O

<ALL>	O
The	O
same	O
variants	O
in	O
the	O
IRF6	B-Gene
gene	O
that	O
are	O
associated	O
with	O
isolated	O
orofacial	B-Disease
clefts	I-Disease
are	O
also	O
associated	O
with	O
human	B-Species
tooth	B-Disease
agenesis	I-Disease
(	O
rs861019	B-Variant
,	O
P	O
=	O
0.058	O
;	O
rs17015215	B-Variant
-	O
V274I	B-Variant
,	O
P	O
=	O
0.0006	O
;	O
rs7802	B-Variant
,	O
P	O
=	O
0.004	O
)	O
.	O
</ALL>	O

<ALL>	O
Mutations	O
in	O
IRF6	B-Gene
cause	O
Van	B-Disease
der	I-Disease
Woude	I-Disease
and	I-Disease
popliteal	I-Disease
pterygium	I-Disease
syndromes	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
craniofacial	O
phenotypic	O
characteristics	O
of	O
these	O
syndromes	O
include	O
oral	B-Disease
clefts	I-Disease
and	O
preferential	O
tooth	B-Disease
agenesis	I-Disease
of	O
incisors	O
and	O
premolars	O
,	O
besides	O
pits	B-Disease
on	I-Disease
the	I-Disease
lower	I-Disease
lips	I-Disease
.	O
</ALL>	O

<ALL>	O
Also	O
it	O
appears	O
that	O
preferential	O
premolar	O
agenesis	O
is	O
associated	O
with	O
FGFR1	B-Gene
(	O
P	O
=	O
0.014	O
)	O
and	O
IRF6	B-Gene
(	O
P	O
=	O
0.002	O
)	O
markers	O
.	O
</ALL>	O

<ALL>	O
There	O
were	O
statistically	O
significant	O
data	O
suggesting	O
that	O
IRF6	B-Gene
interacts	O
not	O
only	O
with	O
MSX1	B-Gene
(	O
P	O
=	O
0.001	O
)	O
,	O
but	O
also	O
with	O
TGFA	B-Gene
(	O
P	O
=	O
0.03	O
)	O
.	O
</ALL>	O

<ALL>	O
Focal	B-Disease
dermal	I-Disease
hypoplasia	I-Disease
resulting	O
from	O
a	O
new	O
nonsense	O
mutation	O
,	O
p	B-Variant
.	I-Variant
E300X	I-Variant
,	O
in	O
the	O
PORCN	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Focal	B-Disease
dermal	I-Disease
hypoplasia	I-Disease
(	O
FDH	B-Disease
)	O
(	O
OMIM	B-Disease
305600	I-Disease
)	O
is	O
an	O
X	B-Disease
-	I-Disease
linked	I-Disease
dominant	I-Disease
disorder	I-Disease
of	O
ecto	O
-	O
mesodermal	O
development	O
.	O
</ALL>	O

<ALL>	O
Also	O
known	O
as	O
Goltz	B-Disease
syndrome	I-Disease
,	O
FDH	B-Disease
presents	O
with	O
characteristic	O
linear	O
streaks	O
of	O
hypoplastic	B-Disease
dermis	I-Disease
and	O
variable	O
abnormalities	O
of	O
bone	O
,	O
nails	O
,	O
hair	O
,	O
limbs	O
,	O
teeth	O
and	O
eyes	O
.	O
</ALL>	O

<ALL>	O
The	O
molecular	O
basis	O
of	O
FDH	B-Disease
involves	O
mutations	O
in	O
the	O
PORCN	B-Gene
gene	O
,	O
which	O
encodes	O
an	O
enzyme	O
that	O
allows	O
membrane	O
targeting	O
and	O
secretion	O
of	O
several	O
Wnt	O
proteins	O
critical	O
for	O
normal	O
tissue	O
development	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVES	O
:	O
To	O
investigate	O
the	O
molecular	O
basis	O
of	O
FDH	B-Disease
in	O
a	O
2	O
-	O
year	O
-	O
old	O
Thai	O
girl	O
who	O
presented	O
at	O
birth	O
with	O
depressed	B-Disease
,	O
pale	O
linear	O
scars	O
on	O
the	O
trunk	O
and	O
limbs	O
,	O
sparse	O
brittle	O
hair	O
,	O
syndactyly	O
of	O
the	O
right	O
middle	O
and	O
ring	O
fingers	O
,	O
dental	B-Disease
caries	I-Disease
and	O
radiological	O
features	O
of	O
osteopathia	O
striata	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Sequencing	O
of	O
genomic	O
DNA	O
from	O
the	O
affected	O
individual	O
and	O
both	O
parents	O
to	O
search	O
for	O
pathogenic	O
mutations	O
in	O
PORCN	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
DNA	O
sequencing	O
disclosed	O
a	O
heterozygous	O
G	B-Variant
>	I-Variant
T	I-Variant
substitution	I-Variant
at	I-Variant
nucleotide	I-Variant
c.898	I-Variant
within	O
exon	O
10	O
(	O
NM	O
_	O
203475.1	O
)	O
,	O
converting	O
a	O
glutamic	B-Variant
acid	I-Variant
residue	I-Variant
(	I-Variant
GAA	I-Variant
)	I-Variant
to	I-Variant
a	I-Variant
premature	I-Variant
termination	I-Variant
codon	I-Variant
(	I-Variant
TAA	I-Variant
)	I-Variant
.	O
</ALL>	O

<ALL>	O
This	O
mutation	O
,	O
designated	O
p	B-Variant
.	I-Variant
E300X	I-Variant
,	O
was	O
not	O
detected	O
in	O
DNA	O
from	O
either	O
parent	O
or	O
in	O
100	O
control	O
chromosomes	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Identification	O
of	O
this	O
new	O
de	O
novo	O
nonsense	O
mutation	O
confirms	O
the	O
diagnosis	O
of	O
FDH	B-Disease
in	O
this	O
child	O
and	O
highlights	O
the	O
clinical	O
importance	O
of	O
PORCN	B-Gene
and	O
Wnt	O
signalling	O
pathways	O
in	O
embryogenesis	O
.	O
</ALL>	O

<ALL>	O
A	O
recessive	B-Disease
skeletal	I-Disease
dysplasia	I-Disease
,	O
SEMD	B-Disease
aggrecan	B-Gene
type	O
,	O
results	O
from	O
a	O
missense	O
mutation	O
affecting	O
the	O
C	O
-	O
type	O
lectin	O
domain	O
of	O
aggrecan	B-Gene
.	O
</ALL>	O

<ALL>	O
Analysis	O
of	O
a	O
nuclear	O
family	O
with	O
three	O
affected	O
offspring	O
identified	O
an	O
autosomal	O
-	O
recessive	O
form	O
of	O
spondyloepimetaphyseal	B-Disease
dysplasia	I-Disease
characterized	O
by	O
severe	O
short	B-Disease
stature	I-Disease
and	O
a	O
unique	O
constellation	O
of	O
radiographic	O
findings	O
.	O
</ALL>	O

<ALL>	O
Homozygosity	O
for	O
a	O
haplotype	O
that	O
was	O
identical	O
by	O
descent	O
between	O
two	O
of	O
the	O
affected	O
individuals	O
identified	O
a	O
locus	O
for	O
the	O
disease	O
gene	O
within	O
a	O
17.4	O
Mb	O
interval	O
on	O
chromosome	O
15	O
,	O
a	O
region	O
containing	O
296	O
genes	O
.	O
</ALL>	O

<ALL>	O
These	O
genes	O
were	O
assessed	O
and	O
ranked	O
by	O
cartilage	O
selectivity	O
with	O
whole	O
-	O
genome	O
microarray	O
data	O
,	O
revealing	O
only	O
two	O
genes	O
,	O
encoding	O
aggrecan	B-Gene
and	O
chondroitin	B-Gene
sulfate	I-Gene
proteoglycan	I-Gene
4	I-Gene
,	O
that	O
were	O
selectively	O
expressed	O
in	O
cartilage	O
.	O
</ALL>	O

<ALL>	O
Sequence	O
analysis	O
of	O
aggrecan	B-Gene
complementary	O
DNA	O
from	O
an	O
affected	O
individual	O
revealed	O
homozygosity	O
for	O
a	O
missense	O
mutation	O
(	O
c.6799	B-Variant
G	I-Variant
-	I-Variant
-	I-Variant
>	I-Variant
A	I-Variant
)	O
that	O
predicts	O
a	O
p	B-Variant
.	I-Variant
D2267N	I-Variant
amino	O
acid	O
substitution	O
in	O
the	O
C	O
-	O
type	O
lectin	O
domain	O
within	O
the	O
G3	O
domain	O
of	O
aggrecan	B-Gene
.	O
</ALL>	O

<ALL>	O
The	O
D2267	B-Variant
residue	O
is	O
predicted	O
to	O
coordinate	O
binding	O
of	O
a	O
calcium	B-Chemical
ion	O
,	O
which	O
influences	O
the	O
conformational	O
binding	O
loops	O
of	O
the	O
C	O
-	O
type	O
lectin	O
domain	O
that	O
mediate	O
interactions	O
with	O
tenascins	O
and	O
other	O
extracellular	O
-	O
matrix	O
proteins	O
.	O
</ALL>	O

<ALL>	O
Expression	O
of	O
the	O
normal	O
and	O
mutant	O
G3	O
domains	O
in	O
mammalian	O
cells	O
showed	O
that	O
the	O
mutation	O
created	O
a	O
functional	O
N	O
-	O
glycosylation	O
site	O
but	O
did	O
not	O
adversely	O
affect	O
protein	O
trafficking	O
and	O
secretion	O
.	O
</ALL>	O

<ALL>	O
Surface	O
-	O
plasmon	O
-	O
resonance	O
studies	O
showed	O
that	O
the	O
mutation	O
influenced	O
the	O
binding	O
and	O
kinetics	O
of	O
the	O
interactions	O
between	O
the	O
aggrecan	B-Gene
G3	O
domain	O
and	O
tenascin	B-Gene
-	I-Gene
C	I-Gene
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
identify	O
an	O
autosomal	B-Disease
-	I-Disease
recessive	I-Disease
skeletal	I-Disease
dysplasia	I-Disease
and	O
a	O
significant	O
role	O
for	O
the	O
aggrecan	B-Gene
C	O
-	O
type	O
lectin	O
domain	O
in	O
regulating	O
endochondral	O
ossification	O
and	O
,	O
thereby	O
,	O
height	O
.	O
</ALL>	O

<ALL>	O
Matriptase	B-Gene
-	I-Gene
2	I-Gene
mutations	O
in	O
iron	B-Chemical
-	O
refractory	O
iron	B-Disease
deficiency	I-Disease
anemia	I-Disease
patients	B-Species
provide	O
new	O
insights	O
into	O
protease	O
activation	O
mechanisms	O
.	O
</ALL>	O

<ALL>	O
Mutations	O
leading	O
to	O
abrogation	O
of	O
matriptase	B-Gene
-	I-Gene
2	I-Gene
proteolytic	O
activity	O
in	O
humans	B-Species
are	O
associated	O
with	O
an	O
iron	B-Disease
-	I-Disease
refractory	I-Disease
iron	I-Disease
deficiency	I-Disease
anemia	I-Disease
(	O
IRIDA	B-Disease
)	O
due	O
to	O
elevated	O
hepcidin	B-Gene
levels	O
.	O
</ALL>	O

<ALL>	O
Here	O
we	O
describe	O
two	O
novel	O
heterozygous	O
mutations	O
within	O
the	O
matriptase	B-Gene
-	I-Gene
2	I-Gene
(	O
TMPRSS6	B-Gene
)	O
gene	O
of	O
monozygotic	O
twin	O
girls	O
exhibiting	O
an	O
IRIDA	B-Disease
phenotype	O
.	O
</ALL>	O

<ALL>	O
The	O
first	O
is	O
the	O
frameshift	O
mutation	O
(	O
P686fs	B-Variant
)	O
caused	O
by	O
the	O
insertion	B-Variant
of	I-Variant
the	I-Variant
four	I-Variant
nucleotides	I-Variant
CCCC	I-Variant
in	O
exon	O
16	O
(	O
2172	B-Variant
_	I-Variant
2173insCCCC	I-Variant
)	O
that	O
is	O
predicted	O
to	O
terminate	O
translation	O
before	O
the	O
catalytic	O
serine	O
.	O
</ALL>	O

<ALL>	O
The	O
second	O
mutation	O
is	O
the	O
di	O
-	O
nucleotide	O
substitution	O
c.467C	B-Variant
>	I-Variant
A	I-Variant
and	O
c.468C	B-Variant
>	I-Variant
T	I-Variant
in	O
exon	O
3	O
that	O
causes	O
the	O
missense	O
mutation	O
A118D	B-Variant
in	O
the	O
SEA	O
domain	O
of	O
the	O
extracellular	O
stem	O
region	O
of	O
matriptase	B-Gene
-	I-Gene
2	I-Gene
.	O
</ALL>	O

<ALL>	O
Functional	O
analysis	O
of	O
both	O
variant	O
matriptase	B-Gene
-	I-Gene
2	I-Gene
proteases	O
has	O
revealed	O
that	O
they	O
lead	O
to	O
ineffective	O
suppression	O
of	O
hepcidin	B-Gene
transcription	O
.	O
</ALL>	O

<ALL>	O
We	O
also	O
demonstrate	O
that	O
the	O
A118D	B-Variant
SEA	O
domain	O
mutation	O
causes	O
an	O
intra	O
-	O
molecular	O
structural	O
imbalance	O
that	O
impairs	O
matriptase	B-Gene
-	I-Gene
2	I-Gene
activation	O
.	O
</ALL>	O

<ALL>	O
Collectively	O
,	O
these	O
results	O
extend	O
the	O
pattern	O
of	O
TMPRSS6	B-Gene
mutations	O
associated	O
with	O
IRIDA	B-Disease
and	O
functionally	O
demonstrate	O
that	O
mutations	O
affecting	O
protease	O
regions	O
other	O
than	O
the	O
catalytic	O
domain	O
may	O
have	O
a	O
profound	O
impact	O
in	O
the	O
regulatory	O
role	O
of	O
matriptase	B-Gene
-	I-Gene
2	I-Gene
during	O
iron	B-Disease
deficiency	I-Disease
.	O
</ALL>	O

<ALL>	O
Smoking	O
of	O
crack	B-Chemical
cocaine	I-Chemical
as	O
a	O
risk	O
factor	O
for	O
HIV	B-Disease
infection	I-Disease
among	O
people	O
who	O
use	O
injection	O
drugs	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Little	O
is	O
known	O
about	O
the	O
possible	O
role	O
that	O
smoking	O
crack	B-Chemical
cocaine	I-Chemical
has	O
on	O
the	O
incidence	O
of	O
HIV	B-Disease
infection	I-Disease
.	O
</ALL>	O

<ALL>	O
Given	O
the	O
increasing	O
use	O
of	O
crack	B-Chemical
cocaine	I-Chemical
,	O
we	O
sought	O
to	O
examine	O
whether	O
use	O
of	O
this	O
illicit	O
drug	O
has	O
become	O
a	O
risk	O
factor	O
for	O
HIV	B-Disease
infection	I-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
We	O
included	O
data	O
from	O
people	O
participating	O
in	O
the	O
Vancouver	O
Injection	O
Drug	O
Users	O
Study	O
who	O
reported	O
injecting	O
illicit	O
drugs	O
at	O
least	O
once	O
in	O
the	O
month	O
before	O
enrolment	O
,	O
lived	O
in	O
the	O
greater	O
Vancouver	O
area	O
,	O
were	O
HIV	B-Disease
-	O
negative	O
at	O
enrolment	O
and	O
completed	O
at	O
least	O
1	O
follow	O
-	O
up	O
study	O
visit	O
.	O
</ALL>	O

<ALL>	O
To	O
determine	O
whether	O
the	O
risk	O
of	O
HIV	B-Disease
seroconversion	I-Disease
among	O
daily	O
smokers	O
of	O
crack	B-Chemical
cocaine	I-Chemical
changed	O
over	O
time	O
,	O
we	O
used	O
Cox	O
proportional	O
hazards	O
regression	O
and	O
divided	O
the	O
study	O
into	O
3	O
periods	O
:	O
May	O
1	O
,	O
1996	O
-	O
Nov.	O
30	O
,	O
1999	O
(	O
period	O
1	O
)	O
,	O
Dec.	O
1	O
,	O
1999	O
-	O
Nov.	O
30	O
,	O
2002	O
(	O
period	O
2	O
)	O
,	O
and	O
Dec.	O
1	O
,	O
2002	O
-	O
Dec.	O
30	O
,	O
2005	O
(	O
period	O
3	O
)	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Overall	O
,	O
1048	O
eligible	O
injection	O
drug	O
users	O
were	O
included	O
in	O
our	O
study	O
.	O
</ALL>	O

<ALL>	O
Of	O
these	O
,	O
137	O
acquired	O
HIV	B-Disease
infection	I-Disease
during	O
follow	O
-	O
up	O
.	O
</ALL>	O

<ALL>	O
The	O
mean	O
proportion	O
of	O
participants	O
who	O
reported	O
daily	O
smoking	O
of	O
crack	B-Chemical
cocaine	I-Chemical
increased	O
from	O
11.6	O
%	O
in	O
period	O
1	O
to	O
39.7	O
%	O
in	O
period	O
3	O
.	O
</ALL>	O

<ALL>	O
After	O
adjusting	O
for	O
potential	O
confounders	O
,	O
we	O
found	O
that	O
the	O
risk	O
of	O
HIV	B-Disease
seroconversion	I-Disease
among	O
participants	O
who	O
were	O
daily	O
smokers	O
of	O
crack	B-Chemical
cocaine	I-Chemical
increased	O
over	O
time	O
(	O
period	O
1	O
:	O
hazard	O
ratio	O
[	O
HR	O
]	O
1.03	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
0.57	O
-	O
1.85	O
;	O
period	O
2	O
:	O
HR	O
1.68	O
,	O
95	O
%	O
CI	O
1.01	O
-	O
2.80	O
;	O
and	O
period	O
3	O
:	O
HR	O
2.74	O
,	O
95	O
%	O
CI	O
1.06	O
-	O
7.11	O
)	O
.	O
</ALL>	O

<ALL>	O
INTERPRETATION	O
:	O
Smoking	O
of	O
crack	B-Chemical
cocaine	I-Chemical
was	O
found	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
HIV	B-Disease
seroconversion	I-Disease
among	O
people	O
who	O
were	O
injection	O
drug	O
users	O
.	O
</ALL>	O

<ALL>	O
This	O
finding	O
points	O
to	O
the	O
urgent	O
need	O
for	O
evidence	O
-	O
based	O
public	O
health	O
initiatives	O
targeted	O
at	O
people	O
who	O
smoke	O
crack	B-Chemical
cocaine	I-Chemical
.	O
</ALL>	O

<ALL>	O
Roles	O
of	O
G1359A	B-Variant
polymorphism	O
of	O
the	O
cannabinoid	B-Gene
receptor	I-Gene
gene	O
(	O
CNR1	B-Gene
)	O
on	O
weight	B-Disease
loss	I-Disease
and	O
adipocytokines	O
after	O
a	O
hypocaloric	O
diet	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
A	O
intragenic	O
biallelic	O
polymorphism	O
(	O
1359	B-Variant
G	I-Variant
/	I-Variant
A	I-Variant
)	O
of	O
the	O
CB1	B-Gene
gene	O
resulting	O
in	O
the	O
substitution	O
of	O
the	O
G	B-Variant
to	I-Variant
A	I-Variant
at	I-Variant
nucleotide	I-Variant
position	I-Variant
1359	I-Variant
in	O
codon	B-Variant
435	I-Variant
(	I-Variant
Thr	I-Variant
)	I-Variant
,	O
was	O
reported	O
as	O
a	O
common	O
polymorphism	O
in	O
Caucasian	O
populations	O
.	O
</ALL>	O

<ALL>	O
Intervention	O
studies	O
with	O
this	O
polymorphism	O
have	O
not	O
been	O
realized	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
We	O
decided	O
to	O
investigate	O
the	O
role	O
of	O
the	O
polymorphism	O
(	O
G1359A	B-Variant
)	O
of	O
CB1	B-Gene
receptor	I-Gene
gene	O
on	O
adipocytokines	O
response	O
and	O
weight	B-Disease
loss	I-Disease
secondary	O
to	O
a	O
lifestyle	O
modification	O
(	O
Mediterranean	O
hypocaloric	O
diet	O
and	O
exercise	O
)	O
in	O
obese	B-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
DESIGN	O
:	O
A	O
population	O
of	O
94	O
patients	B-Species
with	O
obesity	B-Disease
was	O
analyzed	O
.	O
</ALL>	O

<ALL>	O
Before	O
and	O
after	O
3	O
months	O
on	O
a	O
hypocaloric	O
diet	O
,	O
an	O
anthropometric	O
evaluation	O
,	O
an	O
assessment	O
of	O
nutritional	O
intake	O
and	O
a	O
biochemical	O
analysis	O
were	O
performed	O
.	O
</ALL>	O

<ALL>	O
The	O
statistical	O
analysis	O
was	O
performed	O
for	O
the	O
combined	O
G1359A	B-Variant
and	O
A1359A	B-Variant
as	O
a	O
group	O
and	O
wild	O
type	O
G1359	B-Variant
G	I-Variant
as	O
second	O
group	O
,	O
with	O
a	O
dominant	O
model	O
.	O
</ALL>	O

<ALL>	O
Results	O
:	O
Forty	O
seven	O
patients	B-Species
(	O
50	O
%	O
)	O
had	O
the	O
genotype	O
G1359	B-Variant
G	I-Variant
(	O
wild	O
type	O
group	O
)	O
and	O
47	O
(	O
50	O
%	O
)	O
patients	B-Species
G1359A	B-Variant
(	O
41	O
patients	B-Species
,	O
43.6	O
%	O
)	O
or	O
A1359A	B-Variant
(	O
6	O
patients	B-Species
,	O
6.4	O
%	O
)	O
(	O
mutant	O
type	O
group	O
)	O
had	O
the	O
genotype	O
.	O
</ALL>	O

<ALL>	O
In	O
wild	O
and	O
mutant	O
type	O
groups	O
,	O
weight	O
,	O
body	O
mass	O
index	O
,	O
fat	O
mass	O
,	O
waist	O
circumference	O
and	O
systolic	O
blood	O
pressure	O
decreased	O
.	O
</ALL>	O

<ALL>	O
In	O
mutant	O
type	O
group	O
,	O
resistin	B-Gene
(	O
4.15	O
1.7	O
ng	O
/	O
ml	O
vs.	O
3.90	O
2.1	O
ng	O
/	O
ml	O
:	O
P	O
<	O
0.05	O
)	O
,	O
leptin	B-Gene
(	O
78.4	O
69	O
ng	O
/	O
ml	O
vs	O
66.2	O
32	O
ng	O
/	O
ml	O
:	O
P	O
<	O
0.05	O
)	O
and	O
IL	B-Gene
-	I-Gene
6	I-Gene
(	O
1.40	O
1.9	O
pg	O
/	O
ml	O
vs	O
0.81	O
1.5	O
pg	O
/	O
ml	O
:	O
P	O
<	O
0.05	O
)	O
levels	O
decreased	O
after	O
dietary	O
treatment	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
The	O
novel	O
finding	O
of	O
this	O
study	O
is	O
the	O
association	O
of	O
the	O
mutant	O
allele	O
(	O
A1359	B-Variant
)	O
with	O
a	O
decrease	O
of	O
resistin	B-Gene
,	O
leptin	B-Gene
and	O
interleukin	B-Gene
-	I-Gene
6	I-Gene
secondary	O
to	O
weight	B-Disease
loss	I-Disease
.	O
</ALL>	O

<ALL>	O
HIV	B-Species
-	I-Species
1	I-Species
Tat	B-Gene
activates	O
indoleamine	B-Gene
2,3	I-Gene
dioxygenase	I-Gene
in	O
murine	B-Species
organotypic	O
hippocampal	O
slice	O
cultures	O
in	O
a	O
p38	B-Gene
mitogen	I-Gene
-	I-Gene
activated	I-Gene
protein	I-Gene
kinase	I-Gene
-	O
dependent	O
manner	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
We	O
have	O
established	O
that	O
activation	O
of	O
the	O
tryptophan	B-Chemical
degrading	O
enzyme	O
indoleamine	B-Gene
2,3	I-Gene
dioxygenase	I-Gene
(	O
IDO	B-Gene
)	O
mediates	O
the	O
switch	O
from	O
cytokine	O
-	O
induced	O
sickness	O
behavior	O
to	O
depressive	B-Disease
-	O
like	O
behavior	O
.	O
</ALL>	O

<ALL>	O
Because	O
human	B-Species
immunodeficiency	I-Species
virus	I-Species
type	I-Species
1	I-Species
(	O
HIV	B-Species
-	I-Species
1	I-Species
)	O
Tat	B-Gene
protein	O
causes	O
depressive	B-Disease
-	O
like	O
behavior	O
in	O
mice	B-Species
,	O
we	O
investigated	O
its	O
ability	O
to	O
activate	O
IDO	B-Gene
in	O
organotypic	O
hippocampal	O
slice	O
cultures	O
(	O
OHSCs	O
)	O
derived	O
from	O
neonatal	O
C57BL	B-CellLine
/	I-CellLine
6	I-CellLine
mice	B-Species
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Depressive	B-Disease
-	O
like	O
behavior	O
in	O
C57BL	B-CellLine
/	I-CellLine
6J	I-CellLine
mice	B-Species
was	O
assessed	O
by	O
the	O
forced	O
swim	O
test	O
.	O
</ALL>	O

<ALL>	O
Expression	O
of	O
cytokines	O
and	O
IDO	B-Gene
mRNA	O
in	O
OHSCs	O
was	O
measured	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
and	O
cytokine	O
protein	O
was	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
(	O
ELISAs	O
)	O
.	O
</ALL>	O

<ALL>	O
p38	B-Gene
MAPK	I-Gene
phosphorylation	O
was	O
analyzed	O
by	O
western	O
blot	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Intracerebroventricular	O
(	O
i.c.v	O
.	O
)	O
</ALL>	O

<ALL>	O
administration	O
of	O
Tat	B-Gene
(	O
40	O
ng	O
)	O
induced	O
depressive	B-Disease
-	O
like	O
behavior	O
in	O
the	O
absence	O
of	O
sickness	O
.	O
</ALL>	O

<ALL>	O
Addition	O
of	O
Tat	B-Gene
(	O
40	O
ng	O
/	O
slice	O
)	O
to	O
the	O
medium	O
of	O
OHSCs	O
induced	O
IDO	B-Gene
steady	O
-	O
state	O
mRNA	O
that	O
peaked	O
at	O
6	O
h.	O
This	O
effect	O
was	O
potentiated	O
by	O
pretreatment	O
with	O
IFNg	B-Gene
.	O
</ALL>	O

<ALL>	O
Tat	B-Gene
also	O
induced	O
the	O
synthesis	O
and	O
release	O
of	O
TNFa	B-Gene
and	O
IL	B-Gene
-	I-Gene
6	I-Gene
protein	O
in	O
the	O
supernatant	O
of	O
the	O
slices	O
and	O
increased	O
expression	O
of	O
the	O
inducible	B-Gene
isoform	I-Gene
of	I-Gene
nitric	I-Gene
oxide	I-Gene
synthase	I-Gene
(	O
iNOS	B-Gene
)	O
and	O
the	O
serotonin	B-Gene
transporter	I-Gene
(	O
SERT	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
Tat	B-Gene
had	O
no	O
effect	O
on	O
endogenous	O
synthesis	O
of	O
IFNg	B-Gene
.	O
</ALL>	O

<ALL>	O
To	O
explore	O
the	O
mechanisms	O
of	O
Tat	B-Gene
-	O
induced	O
IDO	B-Gene
expression	O
,	O
slices	O
were	O
pretreated	O
with	O
the	O
p38	B-Gene
mitogen	I-Gene
-	I-Gene
activated	I-Gene
protein	I-Gene
kinase	I-Gene
(	O
MAPK	B-Gene
)	O
inhibitor	O
SB	B-Chemical
202190	I-Chemical
for	O
30	O
min	O
before	O
Tat	B-Gene
treatment	O
.	O
</ALL>	O

<ALL>	O
SB	B-Chemical
202190	I-Chemical
significantly	O
decreased	O
IDO	B-Gene
expression	O
induced	O
by	O
Tat	B-Gene
,	O
and	O
this	O
effect	O
was	O
accompanied	O
by	O
a	O
reduction	O
of	O
Tat	B-Gene
-	O
induced	O
expression	O
of	O
TNFa	B-Gene
,	O
IL	B-Gene
-	I-Gene
6	I-Gene
,	O
iNOS	B-Gene
and	O
SERT	B-Gene
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
These	O
data	O
establish	O
that	O
Tat	B-Gene
induces	O
IDO	B-Gene
expression	O
via	O
an	O
IFNg	B-Gene
-	O
independent	O
mechanism	O
that	O
depends	O
upon	O
activation	O
of	O
p38	B-Gene
MAPK	I-Gene
.	O
</ALL>	O

<ALL>	O
Targeting	O
IDO	B-Gene
itself	O
or	O
the	O
p38	B-Gene
MAPK	I-Gene
signaling	O
pathway	O
could	O
provide	O
a	O
novel	O
therapy	O
for	O
comorbid	O
depressive	B-Disease
disorders	I-Disease
in	O
HIV	B-Disease
-	I-Disease
1	I-Disease
-	I-Disease
infected	I-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Gastrointestinal	B-Chemical
hormones	I-Chemical
/	O
neurotransmitters	B-Chemical
and	O
growth	O
factors	O
can	O
activate	O
P21	B-Gene
activated	I-Gene
kinase	I-Gene
2	I-Gene
in	O
pancreatic	O
acinar	O
cells	O
by	O
novel	O
mechanisms	O
.	O
</ALL>	O

<ALL>	O
P	B-Gene
-	I-Gene
21	I-Gene
-	I-Gene
activated	I-Gene
kinases	I-Gene
(	O
PAKs	B-Gene
)	O
are	O
serine	B-Gene
/	I-Gene
threonine	I-Gene
kinases	I-Gene
comprising	O
six	O
isoforms	O
divided	O
in	O
two	O
groups	O
,	O
group	O
-	O
I	O
(	O
PAK1	B-Gene
-	I-Gene
3	I-Gene
)	O
/	O
group	O
-	O
II	O
(	O
PAK4	B-Gene
-	I-Gene
6	I-Gene
)	O
which	O
play	O
important	O
roles	O
in	O
cell	O
cytoskeletal	O
dynamics	O
,	O
survival	O
,	O
secretion	O
and	O
proliferation	O
and	O
are	O
activated	O
by	O
diverse	O
stimuli	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
little	O
is	O
known	O
about	O
PAKs	B-Gene
ability	O
to	O
be	O
activated	O
by	O
gastrointestinal	B-Chemical
(	I-Chemical
GI	I-Chemical
)	I-Chemical
hormones	I-Chemical
/	O
neurotransmitters	B-Chemical
/	O
growth	O
-	O
factors	O
.	O
</ALL>	O

<ALL>	O
We	O
used	O
rat	B-Species
pancreatic	O
acini	O
to	O
explore	O
the	O
ability	O
of	O
GI	B-Chemical
-	I-Chemical
hormones	I-Chemical
/	O
neurotransmitters	B-Chemical
/	O
growth	O
-	O
factors	O
to	O
activate	O
Group	B-Gene
-	I-Gene
I	I-Gene
-	I-Gene
PAKs	I-Gene
and	O
the	O
signaling	O
cascades	O
involved	O
.	O
</ALL>	O

<ALL>	O
Only	O
PAK2	B-Gene
was	O
present	O
in	O
acini	O
.	O
</ALL>	O

<ALL>	O
PAK2	B-Gene
was	O
activated	O
by	O
some	O
pancreatic	B-Gene
growth	I-Gene
-	I-Gene
factors	I-Gene
[	O
EGF	B-Gene
,	O
PDGF	B-Gene
,	O
bFGF	B-Gene
]	O
,	O
by	O
secretagogues	O
activating	O
phospholipase	B-Gene
-	I-Gene
C	I-Gene
(	O
PLC	B-Gene
)	O
[	O
CCK	B-Gene
,	O
carbachol	B-Chemical
,	O
bombesin	B-Chemical
]	O
and	O
by	O
post	O
-	O
receptor	O
stimulants	O
activating	O
PKC	B-Gene
[	O
TPA	B-Chemical
]	O
,	O
but	O
not	O
agents	O
only	O
mobilizing	O
cellular	O
calcium	B-Chemical
or	O
increasing	O
cyclic	B-Chemical
AMP	I-Chemical
.	O
</ALL>	O

<ALL>	O
CCK	B-Gene
-	O
activation	O
of	O
PAK2	B-Gene
required	O
both	O
high	O
-	O
and	O
low	O
-	O
affinity	O
-	O
CCK1	B-Gene
-	I-Gene
receptor	I-Gene
-	O
state	O
activation	O
.	O
</ALL>	O

<ALL>	O
It	O
was	O
partially	O
reduced	O
by	O
PKC	B-Gene
-	O
or	O
Src	B-Gene
-	O
inhibition	O
,	O
but	O
not	O
with	O
PI3	B-Gene
K	I-Gene
-	O
inhibitors	O
(	O
wortmannin	B-Chemical
,	O
LY294002	B-Chemical
)	O
or	O
thapsigargin	B-Chemical
.	O
</ALL>	O

<ALL>	O
IPA	B-Chemical
-	I-Chemical
3	I-Chemical
,	O
which	O
prevents	O
PAK2	B-Gene
binding	O
to	O
small	B-Gene
-	I-Gene
GTPases	I-Gene
partially	O
inhibited	O
PAK2	B-Gene
-	O
activation	O
,	O
as	O
well	O
as	O
reduced	O
CCK	B-Gene
-	O
induced	O
ERK1	B-Gene
/	I-Gene
2	I-Gene
activation	O
and	O
amylase	B-Gene
release	O
induced	O
by	O
CCK	B-Gene
or	O
bombesin	B-Chemical
.	O
</ALL>	O

<ALL>	O
This	O
study	O
demonstrates	O
pancreatic	O
acini	O
,	O
possess	O
only	O
one	O
Group	B-Gene
-	I-Gene
I	I-Gene
-	I-Gene
PAK	I-Gene
,	O
PAK2	B-Gene
.	O
</ALL>	O

<ALL>	O
CCK	B-Gene
and	O
other	O
GI	B-Chemical
-	I-Chemical
hormones	I-Chemical
/	O
neurotransmitters	B-Chemical
/	O
growth	O
-	O
factors	O
activate	O
PAK2	B-Gene
via	O
small	B-Gene
GTPases	I-Gene
(	O
CDC42	B-Gene
/	O
Rac1	B-Gene
)	O
,	O
PKC	B-Gene
and	O
SFK	B-Gene
but	O
not	O
cytosolic	O
calcium	B-Chemical
or	O
PI3	B-Gene
K	I-Gene
.	O
</ALL>	O

<ALL>	O
CCK	B-Gene
-	O
activation	O
of	O
PAK2	B-Gene
showed	O
several	O
novel	O
features	O
being	O
dependent	O
on	O
both	O
receptor	O
-	O
activation	O
states	O
,	O
having	O
PLC	B-Gene
-	O
and	O
PKC	B-Gene
-	O
dependent	O
/	O
independent	O
components	O
and	O
small	B-Gene
-	I-Gene
GTPase	I-Gene
-	O
dependent	O
/	O
independent	O
components	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
show	O
that	O
PAK2	B-Gene
is	O
important	O
in	O
signaling	O
cascades	O
activated	O
by	O
numerous	O
pancreatic	O
stimuli	O
which	O
mediate	O
their	O
various	O
physiological	O
/	O
pathophysiological	O
responses	O
and	O
thus	O
could	O
be	O
a	O
promising	O
target	O
for	O
the	O
development	O
of	O
therapies	O
in	O
some	O
pancreatic	B-Disease
disorders	I-Disease
such	O
as	O
pancreatitis	B-Disease
.	O
</ALL>	O

<ALL>	O
Whole	O
-	O
Organism	O
Developmental	O
Expression	O
Profiling	O
Identifies	O
RAB	B-Gene
-	I-Gene
28	I-Gene
as	O
a	O
Novel	O
Ciliary	O
GTPase	B-Gene
Associated	O
with	O
the	O
BBSome	B-Gene
and	O
Intraflagellar	O
Transport	O
.	O
</ALL>	O

<ALL>	O
Primary	O
cilia	O
are	O
specialised	O
sensory	O
and	O
developmental	O
signalling	O
devices	O
extending	O
from	O
the	O
surface	O
of	O
most	O
eukaryotic	O
cells	O
.	O
</ALL>	O

<ALL>	O
Defects	O
in	O
these	O
organelles	O
cause	O
inherited	B-Disease
human	I-Disease
disorders	I-Disease
(	O
ciliopathies	B-Disease
)	O
such	O
as	O
retinitis	B-Disease
pigmentosa	I-Disease
and	O
Bardet	B-Disease
-	I-Disease
Biedl	I-Disease
syndrome	I-Disease
(	O
BBS	B-Disease
)	O
,	O
frequently	O
affecting	O
many	O
physiological	O
and	O
developmental	O
processes	O
across	O
multiple	O
organs	O
.	O
</ALL>	O

<ALL>	O
Cilium	O
formation	O
,	O
maintenance	O
and	O
function	O
depend	O
on	O
intracellular	O
transport	O
systems	O
such	O
as	O
intraflagellar	O
transport	O
(	O
IFT	O
)	O
,	O
which	O
is	O
driven	O
by	O
kinesin	B-Gene
-	I-Gene
2	I-Gene
and	O
IFT	O
-	O
dynein	B-Gene
motors	O
and	O
regulated	O
by	O
the	O
Bardet	B-Gene
-	I-Gene
Biedl	I-Gene
syndrome	I-Gene
(	I-Gene
BBS	I-Gene
)	I-Gene
cargo	I-Gene
-	I-Gene
adaptor	I-Gene
protein	I-Gene
complex	I-Gene
,	O
or	O
BBSome	B-Gene
.	O
</ALL>	O

<ALL>	O
To	O
identify	O
new	O
cilium	O
-	O
associated	O
genes	O
,	O
we	O
employed	O
the	O
nematode	O
C.	B-Species
elegans	I-Species
,	O
where	O
ciliogenesis	O
occurs	O
within	O
a	O
short	O
timespan	O
during	O
late	O
embryogenesis	O
when	O
most	O
sensory	O
neurons	O
differentiate	O
.	O
</ALL>	O

<ALL>	O
Using	O
whole	O
-	O
organism	O
RNA	O
-	O
Seq	O
libraries	O
,	O
we	O
discovered	O
a	O
signature	O
expression	O
profile	O
highly	O
enriched	O
for	O
transcripts	O
of	O
known	O
ciliary	O
proteins	O
,	O
including	O
FAM	B-Gene
-	I-Gene
161	I-Gene
(	O
FAM161A	B-Gene
orthologue	O
)	O
,	O
CCDC	B-Gene
-	I-Gene
104	I-Gene
(	O
CCDC104	B-Gene
)	O
,	O
and	O
RPI	B-Gene
-	I-Gene
1	I-Gene
(	O
RP1	B-Gene
/	O
RP1L1	B-Gene
)	O
,	O
which	O
we	O
confirm	O
are	O
cilium	O
-	O
localised	O
in	O
worms	O
.	O
</ALL>	O

<ALL>	O
From	O
a	O
list	O
of	O
185	O
candidate	O
ciliary	O
genes	O
,	O
we	O
uncover	O
orthologues	O
of	O
human	B-Species
MAP9	B-Gene
,	O
YAP	B-Gene
,	O
CCDC149	B-Gene
,	O
and	O
RAB28	B-Gene
as	O
conserved	O
cilium	O
-	O
associated	O
components	O
.	O
</ALL>	O

<ALL>	O
Further	O
analyses	O
of	O
C.	B-Species
elegans	I-Species
RAB	B-Gene
-	I-Gene
28	I-Gene
,	O
recently	O
associated	O
with	O
autosomal	O
-	O
recessive	O
cone	B-Disease
-	I-Disease
rod	I-Disease
dystrophy	I-Disease
,	O
reveal	O
that	O
this	O
small	O
GTPase	B-Gene
is	O
exclusively	O
expressed	O
in	O
ciliated	O
neurons	O
where	O
it	O
dynamically	O
associates	O
with	O
IFT	O
trains	O
.	O
</ALL>	O

<ALL>	O
Whereas	O
inactive	O
GDP	B-Chemical
-	O
bound	O
RAB	B-Gene
-	I-Gene
28	I-Gene
displays	O
no	O
IFT	O
movement	O
and	O
diffuse	O
localisation	O
,	O
GTP	B-Chemical
-	O
bound	O
(	O
activated	O
)	O
RAB	B-Gene
-	I-Gene
28	I-Gene
concentrates	O
at	O
the	O
periciliary	O
membrane	O
in	O
a	O
BBSome	B-Gene
-	O
dependent	O
manner	O
and	O
undergoes	O
bidirectional	O
IFT	O
.	O
</ALL>	O

<ALL>	O
Functional	O
analyses	O
reveal	O
that	O
whilst	O
cilium	O
structure	O
,	O
sensory	O
function	O
and	O
IFT	O
are	O
seemingly	O
normal	O
in	O
a	O
rab	B-Gene
-	I-Gene
28	I-Gene
null	O
allele	O
,	O
overexpression	O
of	O
predicted	O
GDP	B-Chemical
or	O
GTP	B-Chemical
locked	O
variants	O
of	O
RAB	B-Gene
-	I-Gene
28	I-Gene
perturbs	O
cilium	O
and	O
sensory	O
pore	O
morphogenesis	O
and	O
function	O
.	O
</ALL>	O

<ALL>	O
Collectively	O
,	O
our	O
findings	O
present	O
a	O
new	O
approach	O
for	O
identifying	O
ciliary	O
proteins	O
,	O
and	O
unveil	O
RAB28	B-Gene
,	O
a	O
GTPase	B-Gene
most	O
closely	O
related	O
to	O
the	O
BBS	B-Disease
protein	O
RABL4	B-Gene
/	O
IFT27	B-Gene
,	O
as	O
an	O
IFT	O
-	O
associated	O
cargo	O
with	O
BBSome	B-Gene
-	O
dependent	O
cell	O
autonomous	O
and	O
non	O
-	O
autonomous	O
functions	O
at	O
the	O
ciliary	O
base	O
.	O
</ALL>	O

<ALL>	O
Dynamic	O
subunit	O
turnover	O
in	O
ESCRT	B-Gene
-	I-Gene
III	I-Gene
assemblies	O
is	O
regulated	O
by	O
Vps4	B-Gene
to	O
mediate	O
membrane	O
remodelling	O
during	O
cytokinesis	O
.	O
</ALL>	O

<ALL>	O
The	O
endosomal	B-Gene
sorting	I-Gene
complex	I-Gene
required	I-Gene
for	I-Gene
transport	I-Gene
(	I-Gene
ESCRT	I-Gene
)	I-Gene
-	I-Gene
III	I-Gene
mediates	O
membrane	O
fission	O
in	O
fundamental	O
cellular	O
processes	O
,	O
including	O
cytokinesis	O
.	O
</ALL>	O

<ALL>	O
ESCRT	B-Gene
-	I-Gene
III	I-Gene
is	O
thought	O
to	O
form	O
persistent	O
filaments	O
that	O
over	O
time	O
increase	O
their	O
curvature	O
to	O
constrict	O
membranes	O
.	O
</ALL>	O

<ALL>	O
Unexpectedly	O
,	O
we	O
found	O
that	O
ESCRT	B-Gene
-	I-Gene
III	I-Gene
at	O
the	O
midbody	O
of	O
human	B-Species
cells	O
rapidly	O
turns	O
over	O
subunits	O
with	O
cytoplasmic	O
pools	O
while	O
gradually	O
forming	O
larger	O
assemblies	O
.	O
</ALL>	O

<ALL>	O
ESCRT	B-Gene
-	I-Gene
III	I-Gene
turnover	O
depended	O
on	O
the	O
ATPase	B-Gene
VPS4	B-Gene
,	O
which	O
accumulated	O
at	O
the	O
midbody	O
simultaneously	O
with	O
ESCRT	B-Gene
-	I-Gene
III	I-Gene
subunits	O
,	O
and	O
was	O
required	O
for	O
assembly	O
of	O
functional	O
ESCRT	B-Gene
-	I-Gene
III	I-Gene
structures	O
.	O
</ALL>	O

<ALL>	O
In	O
vitro	O
,	O
the	O
Vps2	B-Gene
/	O
Vps24	B-Gene
subunits	O
of	O
ESCRT	B-Gene
-	I-Gene
III	I-Gene
formed	O
side	O
-	O
by	O
-	O
side	O
filaments	O
with	O
Snf7	B-Gene
and	O
inhibited	O
further	O
polymerization	O
,	O
but	O
the	O
growth	O
inhibition	O
was	O
alleviated	O
by	O
the	O
addition	O
of	O
Vps4	B-Gene
and	O
ATP	B-Chemical
.	O
</ALL>	O

<ALL>	O
High	O
-	O
speed	O
atomic	O
force	O
microscopy	O
further	O
revealed	O
highly	O
dynamic	O
arrays	O
of	O
growing	O
and	O
shrinking	O
ESCRT	B-Gene
-	I-Gene
III	I-Gene
spirals	O
in	O
the	O
presence	O
of	O
Vps4	B-Gene
.	O
</ALL>	O

<ALL>	O
Continuous	O
ESCRT	B-Gene
-	I-Gene
III	I-Gene
remodelling	O
by	O
subunit	O
turnover	O
might	O
facilitate	O
shape	O
adaptions	O
to	O
variable	O
membrane	O
geometries	O
,	O
with	O
broad	O
implications	O
for	O
diverse	O
cellular	O
processes	O
.	O
</ALL>	O

<ALL>	O
The	O
effects	O
of	O
short	O
-	O
term	O
raloxifene	B-Chemical
therapy	O
on	O
fibrinolysis	O
markers	O
:	O
TAFI	B-Gene
,	O
tPA	B-Gene
,	O
and	O
PAI	B-Gene
-	I-Gene
1	I-Gene
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Markers	O
of	O
fibrinolysis	O
,	O
thrombin	B-Gene
-	I-Gene
activatable	I-Gene
fibrinolysis	I-Gene
inhibitor	I-Gene
(	O
TAFI	B-Gene
)	O
,	O
tissue	B-Gene
-	I-Gene
type	I-Gene
plasminogen	I-Gene
activator	I-Gene
(	O
tPA	B-Gene
)	O
,	O
and	O
plasminogen	B-Gene
activator	I-Gene
inhibitor	I-Gene
-	I-Gene
1	I-Gene
(	O
PAI	B-Gene
-	I-Gene
1	I-Gene
)	O
levels	O
were	O
studied	O
for	O
the	O
evaluation	O
of	O
short	O
-	O
term	O
effects	O
of	O
raloxifene	B-Chemical
administration	O
in	O
postmenopausal	O
women	B-Species
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Thirty	O
-	O
nine	O
postmenopausal	O
women	B-Species
with	O
osteopenia	B-Disease
or	O
osteoporosis	B-Disease
were	O
included	O
in	O
this	O
prospective	O
,	O
controlled	O
clinical	O
study	O
.	O
</ALL>	O

<ALL>	O
Twenty	O
-	O
five	O
women	B-Species
were	O
given	O
raloxifene	B-Chemical
hydrochloride	I-Chemical
(	O
60	O
mg	O
/	O
day	O
)	O
plus	O
calcium	B-Chemical
(	O
500	O
mg	O
/	O
day	O
)	O
.	O
</ALL>	O

<ALL>	O
Age	O
-	O
matched	O
controls	O
(	O
n	O
=	O
14	O
)	O
were	O
given	O
only	O
calcium	B-Chemical
.	O
</ALL>	O

<ALL>	O
Plasma	O
TAFI	B-Gene
,	O
tPA	B-Gene
,	O
and	O
PAI	B-Gene
-	I-Gene
1	I-Gene
antigen	O
levels	O
were	O
measured	O
at	O
baseline	O
and	O
after	O
3	O
months	O
of	O
treatment	O
by	O
commercially	O
available	O
ELISA	O
kits	O
.	O
</ALL>	O

<ALL>	O
Variations	O
of	O
individuals	O
were	O
assessed	O
by	O
Wilcoxon	O
's	O
test	O
.	O
</ALL>	O

<ALL>	O
Relationship	O
between	O
those	O
markers	O
and	O
demographic	O
characteristics	O
were	O
investigated	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Three	O
months	O
of	O
raloxifene	B-Chemical
treatment	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
the	O
plasma	O
TAFI	B-Gene
antigen	O
concentrations	O
(	O
16	O
%	O
change	O
,	O
P	O
<	O
0.01	O
)	O
,	O
and	O
a	O
significant	O
increase	O
in	O
tPA	B-Gene
antigen	O
concentrations	O
(	O
25	O
%	O
change	O
,	O
P	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
A	O
significant	O
correlation	O
was	O
found	O
between	O
baseline	O
TAFI	B-Gene
antigen	O
concentrations	O
and	O
the	O
duration	O
of	O
amenorrhea	O
(	O
P	O
<	O
0.05	O
;	O
r	O
=	O
0.33	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
We	O
suggest	O
that	O
the	O
increased	O
risk	O
of	O
venous	B-Disease
thromboembolism	I-Disease
due	O
to	O
raloxifene	B-Chemical
treatment	O
may	O
be	O
related	O
to	O
increased	O
tPA	B-Gene
levels	O
,	O
but	O
not	O
TAFI	B-Gene
levels	O
.	O
</ALL>	O

<ALL>	O
Ectodermal	B-Disease
dysplasia	I-Disease
-	I-Disease
skin	I-Disease
fragility	I-Disease
syndrome	I-Disease
resulting	O
from	O
a	O
new	O
homozygous	O
mutation	O
,	O
888delC	B-Variant
,	O
in	O
the	O
desmosomal	O
protein	O
plakophilin	B-Gene
1	I-Gene
.	O
</ALL>	O

<ALL>	O
We	O
report	O
an	O
unusual	O
case	O
of	O
an	O
inherited	B-Disease
disorder	I-Disease
of	O
the	O
desmosomal	O
protein	O
plakophilin	B-Gene
1	I-Gene
,	O
resulting	O
in	O
ectodermal	B-Disease
dysplasia	I-Disease
-	I-Disease
skin	I-Disease
fragility	I-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
affected	O
6	O
-	O
year	O
-	O
old	O
boy	O
had	O
red	O
skin	O
at	O
birth	O
and	O
subsequently	O
developed	O
skin	B-Disease
fragility	I-Disease
,	O
progressive	O
plantar	B-Disease
keratoderma	I-Disease
,	O
nail	B-Disease
dystrophy	I-Disease
,	O
and	O
alopecia	B-Disease
.	O
</ALL>	O

<ALL>	O
Skin	O
biopsy	O
revealed	O
widening	O
of	O
intercellular	O
spaces	O
in	O
the	O
epidermis	O
and	O
a	O
reduced	O
number	O
of	O
small	O
,	O
poorly	O
formed	O
desmosomes	O
.	O
</ALL>	O

<ALL>	O
Mutation	O
analysis	O
of	O
the	O
plakophilin	B-Gene
1	I-Gene
gene	O
PKP1	B-Gene
revealed	O
a	O
homozygous	O
deletion	B-Variant
of	I-Variant
C	I-Variant
at	I-Variant
nucleotide	I-Variant
888	I-Variant
within	O
exon	O
5	O
.	O
</ALL>	O

<ALL>	O
This	O
mutation	O
differs	O
from	O
the	O
PKP1	B-Gene
gene	O
pathology	O
reported	O
in	O
8	O
previously	O
published	O
individuals	O
with	O
this	O
rare	O
genodermatosis	B-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
all	O
cases	O
show	O
similar	O
clinical	O
features	O
,	O
highlighting	O
the	O
importance	O
of	O
functional	O
plakophilin	B-Gene
1	I-Gene
in	O
maintaining	O
desmosomal	O
adhesion	O
in	O
skin	O
,	O
as	O
well	O
as	O
the	O
role	O
of	O
this	O
protein	O
in	O
aspects	O
of	O
ectodermal	O
development	O
.	O
</ALL>	O

<ALL>	O
DNA	O
damage	O
and	O
repair	O
in	O
gastric	B-Disease
cancer	I-Disease
-	O
-	O
a	O
correlation	O
with	O
the	O
hOGG1	B-Gene
and	O
RAD51	B-Gene
genes	O
polymorphisms	O
.	O
</ALL>	O

<ALL>	O
The	O
cell	O
's	O
susceptibility	O
to	O
mutagens	O
and	O
its	O
ability	O
to	O
repair	O
DNA	O
lesions	O
are	O
important	O
for	O
cancer	B-Disease
induction	O
,	O
promotion	O
and	O
progression	O
.	O
</ALL>	O

<ALL>	O
Both	O
the	O
mutagens	O
'	O
sensitivity	O
and	O
the	O
efficacy	O
of	O
DNA	O
repair	O
may	O
be	O
affected	O
by	O
variation	O
in	O
several	O
genes	O
,	O
including	O
DNA	O
repair	O
genes	O
.	O
</ALL>	O

<ALL>	O
The	O
hOGG1	B-Gene
gene	O
encodes	O
glycosylase	O
of	O
base	O
excision	O
repair	O
and	O
RAD51	B-Gene
specifies	O
a	O
key	O
protein	O
in	O
homologues	O
recombination	O
repair	O
.	O
</ALL>	O

<ALL>	O
Both	O
can	O
be	O
involved	O
in	O
the	O
repair	O
of	O
oxidative	O
DNA	O
lesions	O
,	O
which	O
can	O
contribute	O
to	O
stomach	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
work	O
we	O
determined	O
the	O
level	O
of	O
basal	O
and	O
oxidative	O
DNA	O
damage	O
and	O
the	O
kinetics	O
of	O
removal	O
of	O
DNA	O
damage	O
induced	O
by	O
hydrogen	B-Chemical
peroxide	I-Chemical
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
30	O
gastric	B-Disease
cancer	I-Disease
patients	B-Species
and	O
30	O
healthy	O
individuals	O
.	O
</ALL>	O

<ALL>	O
The	O
metrics	O
from	O
DNA	O
damage	O
and	O
repair	O
study	O
were	O
correlated	O
with	O
the	O
genotypes	O
of	O
common	O
polymorphisms	O
of	O
the	O
hOGG1	B-Gene
and	O
RAD51	B-Gene
genes	O
:	O
a	O
G	B-Variant
-	I-Variant
-	I-Variant
>	I-Variant
C	I-Variant
transversion	I-Variant
at	I-Variant
1245	I-Variant
position	I-Variant
of	O
the	O
hOGG1	B-Gene
gene	O
producing	O
a	O
Ser	B-Variant
-	I-Variant
-	I-Variant
>	I-Variant
Cys	I-Variant
substitution	I-Variant
at	I-Variant
the	I-Variant
codon	I-Variant
326	I-Variant
(	O
the	O
Ser326Cys	B-Variant
polymorphism	O
)	O
and	O
a	O
G	B-Variant
-	I-Variant
-	I-Variant
>	I-Variant
C	I-Variant
substitution	I-Variant
at	I-Variant
position	I-Variant
135	I-Variant
(	O
5	O
'	O
-	O
untranslated	O
region	O
)	O
of	O
the	O
RAD51	B-Gene
gene	O
(	O
the	O
G135C	B-Variant
polymorphism	O
)	O
.	O
</ALL>	O

<ALL>	O
DNA	O
damage	O
and	O
repair	O
were	O
evaluated	O
by	O
alkaline	O
single	O
cell	O
gel	O
electrophoresis	O
(	O
comet	O
assay	O
)	O
assisted	O
by	O
DNA	O
repair	O
enzymes	O
:	O
endonuclease	B-Gene
III	I-Gene
(	O
Nth	B-Gene
)	O
and	O
formamidopyrimidine	B-Gene
-	I-Gene
DNA	I-Gene
glycosylase	I-Gene
(	O
Fpg	B-Gene
)	O
,	O
preferentially	O
recognizing	O
oxidized	O
DNA	O
bases	O
.	O
</ALL>	O

<ALL>	O
The	O
genotypes	O
of	O
the	O
polymorphism	O
were	O
determined	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
PCR	O
.	O
</ALL>	O

<ALL>	O
We	O
observed	O
a	O
strong	O
association	O
between	O
gastric	B-Disease
cancer	I-Disease
occurrence	O
,	O
impaired	O
DNA	O
repair	O
in	O
human	B-Species
lymphocytes	O
and	O
the	O
G	B-Variant
/	I-Variant
C	I-Variant
genotype	O
of	O
the	O
G135C	B-Variant
polymorphism	O
of	O
the	O
RAD51	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
there	O
was	O
a	O
strong	O
correlation	O
between	O
that	O
genotype	O
and	O
stomach	B-Disease
cancer	I-Disease
occurrence	O
in	O
subjects	O
with	O
high	O
level	O
of	O
oxidatively	O
damaged	O
DNA	O
.	O
</ALL>	O

<ALL>	O
We	O
did	O
not	O
observe	O
any	O
correlation	O
between	O
the	O
Ser1245Cys	B-Variant
polymorphism	O
of	O
the	O
hOGG1	B-Gene
gene	O
and	O
gastric	B-Disease
cancer	I-Disease
,	O
including	O
subjects	O
with	O
impaired	O
DNA	O
repair	O
and	O
/	O
or	O
high	O
levels	O
of	O
endogenous	O
oxidative	O
DNA	O
lesions	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
our	O
result	O
suggest	O
that	O
the	O
G135C	B-Variant
polymorphism	O
of	O
the	O
RAD51	B-Gene
gene	O
may	O
be	O
linked	O
with	O
gastric	B-Disease
cancer	I-Disease
by	O
the	O
modulation	O
of	O
the	O
cellular	O
response	O
to	O
oxidative	O
stress	O
and	O
this	O
polymorphism	O
may	O
be	O
a	O
useful	O
additional	O
marker	O
in	O
this	O
disease	O
along	O
with	O
the	O
genetic	O
or	O
/	O
and	O
environmental	O
indicators	O
of	O
oxidative	O
stress	O
.	O
</ALL>	O

<ALL>	O
The	O
G51S	B-Variant
purine	B-Gene
nucleoside	I-Gene
phosphorylase	I-Gene
polymorphism	O
is	O
associated	O
with	O
cognitive	B-Disease
decline	I-Disease
in	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
(	O
AD	B-Disease
)	O
is	O
a	O
polygenic	O
and	O
multifactorial	O
complex	O
disease	O
,	O
whose	O
etiopathology	O
is	O
still	O
unclear	O
,	O
however	O
several	O
genetic	O
factors	O
have	O
shown	O
to	O
increase	O
the	O
risk	O
of	O
developing	O
the	O
disease	O
.	O
</ALL>	O

<ALL>	O
Purine	O
nucleotides	O
and	O
nucleosides	O
play	O
an	O
important	O
role	O
in	O
the	O
brain	O
.	O
</ALL>	O

<ALL>	O
Besides	O
their	O
role	O
in	O
neurotransmission	O
and	O
neuromodulation	O
,	O
they	O
are	O
involved	O
in	O
trophic	O
factor	O
release	O
,	O
apoptosis	O
,	O
and	O
inflammatory	B-Disease
responses	O
.	O
</ALL>	O

<ALL>	O
These	O
mediators	O
may	O
also	O
have	O
a	O
pivotal	O
role	O
in	O
the	O
control	O
of	O
neurodegenerative	O
processes	O
associated	O
with	O
AD	B-Disease
.	O
</ALL>	O

<ALL>	O
In	O
this	O
report	O
the	O
distribution	O
of	O
the	O
exonic	O
G	B-Variant
/	I-Variant
A	I-Variant
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
purine	B-Gene
nucleoside	I-Gene
phosphorylase	I-Gene
(	O
PNP	B-Gene
)	O
gene	O
,	O
resulting	O
in	O
the	O
amino	O
acid	O
substitution	O
serine	B-Variant
to	I-Variant
glycine	I-Variant
at	I-Variant
position	I-Variant
51	I-Variant
(	O
G51S	B-Variant
)	O
,	O
was	O
investigated	O
in	O
a	O
large	O
population	O
of	O
AD	B-Disease
patients	B-Species
(	O
n	O
=	O
321	O
)	O
and	O
non	O
-	O
demented	O
control	O
(	O
n	O
=	O
208	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
PNP	B-Gene
polymorphism	O
distribution	O
was	O
not	O
different	O
between	O
patients	B-Species
and	O
controls	O
.	O
</ALL>	O

<ALL>	O
The	O
polymorphism	O
distribution	O
was	O
also	O
analyzed	O
in	O
AD	B-Disease
patients	B-Species
stratified	O
according	O
to	O
differential	O
progressive	O
rate	O
of	O
cognitive	B-Disease
decline	I-Disease
during	O
a	O
2	O
-	O
year	O
follow	O
-	O
up	O
.	O
</ALL>	O

<ALL>	O
An	O
increased	O
representation	O
of	O
the	O
PNP	B-Gene
AA	O
genotype	O
was	O
observed	O
in	O
AD	B-Disease
patients	B-Species
with	O
fast	O
cognitive	B-Disease
deterioration	I-Disease
in	O
comparison	O
with	O
that	O
from	O
patients	B-Species
with	O
slow	O
deterioration	O
rate	O
.	O
</ALL>	O

<ALL>	O
Our	O
findings	O
suggest	O
that	O
the	O
G51S	B-Variant
PNP	B-Gene
polymorphism	O
is	O
associated	O
with	O
a	O
faster	O
rate	O
of	O
cognitive	B-Disease
decline	I-Disease
in	O
AD	B-Disease
patients	B-Species
,	O
highlighting	O
the	O
important	O
role	O
of	O
purine	O
metabolism	O
in	O
the	O
progression	O
of	O
this	O
neurodegenerative	B-Disease
disorder	I-Disease
.	O
</ALL>	O

<ALL>	O
Retinoblastoma	B-Disease
in	O
India	O
:	O
microsatellite	O
analysis	O
and	O
its	O
application	O
in	O
genetic	O
counseling	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVES	O
:	O
This	O
study	O
was	O
conducted	O
with	O
two	O
objectives	O
.	O
</ALL>	O

<ALL>	O
The	O
first	O
was	O
to	O
estimate	O
the	O
frequency	O
of	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
of	O
the	O
RB1	B-Gene
gene	O
as	O
a	O
mechanism	O
in	O
disease	O
causation	O
in	O
tumors	B-Disease
of	O
patients	B-Species
from	O
India	O
.	O
</ALL>	O

<ALL>	O
The	O
second	O
objective	O
was	O
to	O
employ	O
RB1	B-Gene
molecular	O
deletion	O
and	O
microsatellite	O
-	O
based	O
linkage	O
analysis	O
as	O
laboratory	O
tools	O
,	O
while	O
counseling	O
families	O
with	O
a	O
history	O
of	O
retinoblastoma	B-Disease
(	O
RB	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
and	O
tumors	B-Disease
of	O
54	O
RB	B-Disease
patients	B-Species
and	O
their	O
relatives	O
.	O
</ALL>	O

<ALL>	O
Eight	O
fluorescent	O
microsatellite	O
markers	O
,	O
both	O
intragenic	O
and	O
flanking	O
the	O
RB1	B-Gene
gene	O
,	O
were	O
used	O
.	O
</ALL>	O

<ALL>	O
After	O
PCR	O
amplification	O
,	O
samples	O
were	O
run	O
on	O
an	O
ABI	O
PRISM	O
310	O
genetic	O
analyzer	O
for	O
LOH	O
,	O
deletion	O
detection	O
,	O
and	O
haplotype	O
generation	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
LOH	O
was	O
found	O
in	O
conjunction	O
with	O
tumor	B-Disease
formation	O
in	O
72.9	O
%	O
of	O
RB	B-Disease
patients	B-Species
(	O
39	O
/	O
54	O
patients	B-Species
;	O
p	O
=	O
0.001	O
;	O
95	O
%	O
CI	O
0.6028	O
,	O
0.8417	O
)	O
;	O
however	O
,	O
we	O
could	O
not	O
associate	O
various	O
other	O
clinical	O
parameters	O
of	O
RB	B-Disease
patients	B-Species
with	O
the	O
presence	O
or	O
absence	O
of	O
RB1	B-Gene
LOH	O
.	O
</ALL>	O

<ALL>	O
Seven	O
germline	O
deletions	O
(	O
13	O
%	O
of	O
RB	B-Disease
patients	B-Species
)	O
were	O
identified	O
,	O
and	O
the	O
maternal	O
allele	O
was	O
more	O
frequently	O
lost	O
(	O
p	O
=	O
0.01	O
)	O
.	O
</ALL>	O

<ALL>	O
A	O
disease	O
co	O
-	O
segregating	O
haplotype	O
was	O
detected	O
in	O
two	O
hereditary	O
autosomal	O
dominant	O
cases	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
LOH	O
of	O
the	O
RB1	B-Gene
gene	O
could	O
play	O
an	O
important	O
role	O
in	O
tumor	B-Disease
formation	O
.	O
</ALL>	O

<ALL>	O
Large	O
deletions	O
involving	O
RB1	B-Gene
were	O
observed	O
,	O
and	O
a	O
disease	O
co	O
-	O
segregating	O
haplotype	O
was	O
used	O
for	O
indirect	O
genetic	O
testing	O
.	O
</ALL>	O

<ALL>	O
This	O
is	O
the	O
first	O
report	O
from	O
India	O
where	O
molecular	O
testing	O
has	O
been	O
applied	O
for	O
RB	B-Disease
families	O
in	O
conjunction	O
with	O
genetic	O
counseling	O
.	O
</ALL>	O

<ALL>	O
In	O
tertiary	O
ophthalmic	O
practice	O
in	O
India	O
,	O
there	O
is	O
an	O
emerging	O
trend	O
towards	O
the	O
application	O
of	O
genetical	O
knowledge	O
in	O
clinical	O
practice	O
.	O
</ALL>	O

<ALL>	O
Molecular	O
analysis	O
of	O
the	O
CYP2F1	B-Gene
gene	O
:	O
identification	O
of	O
a	O
frequent	O
non	O
-	O
functional	O
allelic	O
variant	O
.	O
</ALL>	O

<ALL>	O
The	O
CYP2F1	B-Gene
is	O
a	O
human	B-Species
cytochrome	B-Gene
P450	I-Gene
that	O
is	O
selectively	O
expressed	O
in	O
lung	O
tissue	O
and	O
involved	O
in	O
the	O
metabolism	O
of	O
various	O
pneumotoxicants	O
with	O
potential	O
carcinogenic	B-Disease
effects	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
study	O
,	O
we	O
report	O
the	O
first	O
systematic	O
investigation	O
of	O
the	O
genetic	O
polymorphism	O
of	O
this	O
enzyme	O
.	O
</ALL>	O

<ALL>	O
We	O
analyzed	O
the	O
nucleotidic	O
sequence	O
of	O
the	O
CYP2F1	B-Gene
gene	O
in	O
DNA	O
samples	O
from	O
90	O
French	O
Caucasians	O
consisting	O
in	O
44	O
patients	B-Species
with	O
lung	B-Disease
cancer	I-Disease
and	O
46	O
control	O
individuals	O
,	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
of	O
PCR	O
products	O
(	O
PCR	O
-	O
SSCP	O
)	O
.	O
</ALL>	O

<ALL>	O
We	O
identified	O
24	O
novel	O
mutations	O
distributed	O
in	O
the	O
promoter	O
region	O
of	O
the	O
gene	O
,	O
as	O
well	O
as	O
in	O
the	O
coding	O
regions	O
and	O
their	O
flanking	O
intronic	O
sequences	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
to	O
the	O
wild	O
-	O
type	O
CYP2F1	B-Gene
*	O
1	O
allele	O
,	O
seven	O
allelic	O
variant	O
,	O
CYP2F1	B-Gene
*	O
2A	O
,	O
*	O
2B	O
,	O
*	O
3	O
,	O
*	O
4	O
,	O
*	O
5A	O
,	O
*	O
5B	O
and	O
*	O
6	O
,	O
were	O
characterized	O
.	O
</ALL>	O

<ALL>	O
The	O
most	O
frequent	O
allelic	O
variant	O
,	O
CYP2F1	B-Gene
*	O
2A	O
(	O
25.6	O
%	O
)	O
,	O
harbors	O
a	O
combination	O
of	O
9	O
mutations	O
,	O
including	O
2	O
missense	O
mutations	O
(	O
Asp218Asn	B-Variant
and	O
Gln266His	B-Variant
)	O
and	O
a	O
1	B-Variant
-	I-Variant
bp	I-Variant
insertion	I-Variant
(	O
c.14	B-Variant
_	I-Variant
15insC	I-Variant
)	O
that	O
creates	O
a	O
premature	O
stop	O
codon	O
in	O
exon	O
2	O
,	O
probably	O
leading	O
to	O
the	O
synthesis	O
of	O
a	O
severely	O
truncated	O
protein	O
with	O
no	O
catalytic	O
activity	O
.	O
</ALL>	O

<ALL>	O
The	O
identification	O
of	O
around	O
7	O
%	O
of	O
homozygotes	O
for	O
the	O
frameshift	O
mutation	O
in	O
our	O
Caucasian	O
population	O
suggests	O
the	O
existence	O
of	O
an	O
interindividual	O
variation	O
of	O
the	O
CYP2F1	B-Gene
activity	O
and	O
,	O
consequently	O
,	O
the	O
possibility	O
of	O
interindividual	O
differences	O
in	O
the	O
toxic	O
response	O
to	O
some	O
pneumotoxicants	O
and	O
in	O
the	O
susceptibility	O
to	O
certain	O
chemically	O
induced	O
diseases	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
our	O
preliminary	O
results	O
did	O
not	O
show	O
any	O
evidence	O
that	O
the	O
CYP2F1	B-Gene
genetic	O
polymorphism	O
has	O
implications	O
in	O
the	O
pathogenesis	O
of	O
lung	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
Comparison	O
of	O
unilateral	O
pallidotomy	O
and	O
subthalamotomy	O
findings	O
in	O
advanced	O
idiopathic	B-Disease
Parkinson	I-Disease
's	I-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
A	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
pilot	O
study	O
to	O
compare	O
the	O
results	O
of	O
stereotactic	O
unilateral	O
pallidotomy	O
and	O
subthalamotomy	O
in	O
advanced	O
idiopathic	B-Disease
Parkinson	I-Disease
's	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
refractory	O
to	O
medical	O
treatment	O
was	O
designed	O
.	O
</ALL>	O

<ALL>	O
Ten	O
consecutive	O
patients	B-Species
(	O
mean	O
age	O
,	O
58.4	O
+	O
/	O
-	O
6.8	O
years	O
;	O
7	O
men	B-Species
,	O
3	O
women	B-Species
)	O
with	O
similar	O
characteristics	O
at	O
the	O
duration	O
of	O
disease	O
(	O
mean	O
disease	O
time	O
,	O
8.4	O
+	O
/	O
-	O
3.5	O
years	O
)	O
,	O
disabling	O
motor	O
fluctuations	O
(	O
Hoehn	O
_	O
Yahr	O
stage	O
3	O
-	O
5	O
in	O
off	O
-	O
drug	O
phases	O
)	O
and	O
levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
were	O
selected	O
.	O
</ALL>	O

<ALL>	O
All	O
patients	B-Species
had	O
bilateral	O
symptoms	O
and	O
their	O
levodopa	B-Chemical
equivalent	O
dosing	O
were	O
analysed	O
.	O
</ALL>	O

<ALL>	O
Six	O
patients	B-Species
were	O
operated	O
on	O
in	O
the	O
globus	O
pallidus	O
interna	O
(	O
GPi	O
)	O
and	O
four	O
in	O
the	O
subthalamic	O
nucleus	O
(	O
STN	O
)	O
.	O
</ALL>	O

<ALL>	O
Clinical	O
evaluation	O
included	O
the	O
use	O
of	O
the	O
Unified	O
Parkinson	B-Disease
's	I-Disease
Disease	I-Disease
Rating	O
Scale	O
(	O
UPDRS	O
)	O
,	O
Hoehn	O
_	O
Yahr	O
score	O
and	O
Schwab	O
England	O
activities	O
of	O
daily	O
living	O
(	O
ADL	O
)	O
score	O
in	O
'	O
on	O
'	O
-	O
and	O
'	O
off	O
'	O
-	O
drug	O
conditions	O
before	O
surgery	O
and	O
6	O
months	O
after	O
surgery	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
statistically	O
significant	O
improvement	O
in	O
all	O
contralateral	O
major	O
parkinsonian	B-Disease
motor	O
signs	O
in	O
all	O
patients	B-Species
followed	O
for	O
6	O
months	O
.	O
</ALL>	O

<ALL>	O
Levodopa	B-Chemical
equivalent	O
daily	O
intake	O
was	O
significantly	O
reduced	O
in	O
the	O
STN	O
group	O
.	O
</ALL>	O

<ALL>	O
Changes	O
in	O
UPDRS	O
,	O
Hoehn	O
_	O
Yahr	O
and	O
Schwab	O
England	O
ADL	O
scores	O
were	O
similar	O
in	O
both	O
groups	O
.	O
</ALL>	O

<ALL>	O
Cognitive	O
functions	O
were	O
unchanged	O
in	O
both	O
groups	O
.	O
</ALL>	O

<ALL>	O
Complications	O
were	O
observed	O
in	O
two	O
patients	B-Species
:	O
one	O
had	O
a	O
left	O
homonymous	B-Disease
hemianopsia	I-Disease
after	O
pallidotomy	O
and	O
another	O
one	O
developed	O
left	O
hemiballistic	O
movements	O
3	O
days	O
after	O
subthalamotomy	O
which	O
partly	O
improved	O
within	O
1	O
month	O
with	O
Valproate	B-Chemical
1000	O
mg	O
/	O
day	O
.	O
</ALL>	O

<ALL>	O
The	O
findings	O
of	O
this	O
study	O
suggest	O
that	O
lesions	O
of	O
the	O
unilateral	O
STN	O
and	O
GPi	O
are	O
equally	O
effective	O
treatment	O
for	O
patients	B-Species
with	O
advanced	O
PD	B-Disease
refractory	O
to	O
medical	O
treatment	O
.	O
</ALL>	O

<ALL>	O
Macular	B-Disease
corneal	I-Disease
dystrophy	I-Disease
in	O
a	O
Chinese	O
family	O
related	O
with	O
novel	O
mutations	O
of	O
CHST6	B-Gene
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
To	O
identify	O
mutations	O
in	O
the	O
carbohydrate	B-Gene
sulfotransferase	I-Gene
gene	I-Gene
(	O
CHST6	B-Gene
)	O
for	O
a	O
Chinese	O
family	O
with	O
macular	B-Disease
corneal	I-Disease
dystrophy	I-Disease
(	O
MCD	B-Disease
)	O
and	O
to	O
investigate	O
the	O
histopathological	O
changes	O
in	O
the	O
affected	O
cornea	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
A	O
corneal	O
button	O
of	O
the	O
proband	O
was	O
obtained	O
by	O
penetrating	O
keratoplasty	O
.	O
</ALL>	O

<ALL>	O
The	O
half	O
button	O
and	O
ultrathin	O
sections	O
from	O
the	O
other	O
half	O
button	O
were	O
examined	O
with	O
special	O
stains	O
under	O
a	O
light	O
microscope	O
(	O
LM	O
)	O
and	O
an	O
electron	O
microscope	O
(	O
EM	O
)	O
separately	O
.	O
</ALL>	O

<ALL>	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
of	O
11	O
family	O
members	O
,	O
and	O
the	O
coding	O
region	O
of	O
CHST6	B-Gene
was	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
method	O
.	O
</ALL>	O

<ALL>	O
The	O
PCR	O
products	O
were	O
analyzed	O
by	O
direct	O
sequencing	O
and	O
restriction	O
enzyme	O
digestion	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
positive	O
reaction	O
to	O
colloidal	O
iron	B-Chemical
stain	O
(	O
extracellular	O
blue	O
accumulations	O
in	O
the	O
stroma	O
)	O
was	O
detected	O
under	O
light	O
microscopy	O
.	O
</ALL>	O

<ALL>	O
Transmission	O
electron	O
microscopy	O
revealed	O
the	O
enlargement	O
of	O
smooth	O
endoplasmic	O
reticulum	O
and	O
the	O
presence	O
of	O
intracytoplasmic	O
vacuoles	O
.	O
</ALL>	O

<ALL>	O
The	O
compound	O
heterozygous	O
mutations	O
,	O
c.892C	B-Variant
>	I-Variant
T	I-Variant
and	O
c.1072	B-Variant
T	I-Variant
>	I-Variant
C	I-Variant
,	O
were	O
identified	O
in	O
exon	O
3	O
of	O
CHST6	B-Gene
in	O
three	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
two	O
transversions	O
resulted	O
in	O
the	O
substitution	O
of	O
a	O
stop	B-Variant
codon	I-Variant
for	I-Variant
glutamine	I-Variant
at	I-Variant
codon	I-Variant
298	I-Variant
(	O
p	B-Variant
.	I-Variant
Q298X	I-Variant
)	O
and	O
a	O
missense	O
mutation	O
at	O
codon	B-Variant
358	I-Variant
,	I-Variant
tyrosine	I-Variant
to	I-Variant
histidine	I-Variant
(	O
p	B-Variant
.	I-Variant
Y358H	I-Variant
)	O
.	O
</ALL>	O

<ALL>	O
The	O
six	O
unaffected	O
family	O
individuals	O
carried	O
alternative	O
heterozygous	O
mutations	O
.	O
</ALL>	O

<ALL>	O
These	O
two	O
mutations	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
100	O
control	O
subjects	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Those	O
novel	O
compound	O
heterozygous	O
mutations	O
were	O
thought	O
to	O
contribute	O
to	O
the	O
loss	O
of	O
CHST6	B-Gene
function	O
,	O
which	O
induced	O
the	O
abnormal	O
metabolism	O
of	O
keratan	B-Chemical
sulfate	I-Chemical
(	O
KS	B-Chemical
)	O
that	O
deposited	O
in	O
the	O
corneal	O
stroma	O
.	O
</ALL>	O

<ALL>	O
It	O
could	O
be	O
proved	O
by	O
the	O
observation	O
of	O
a	O
positive	O
stain	O
reaction	O
and	O
the	O
enlarged	O
collagen	B-Gene
fibers	O
as	O
well	O
as	O
hyperplastic	O
fibroblasts	O
under	O
microscopes	O
.	O
</ALL>	O

<ALL>	O
Acute	B-Disease
renal	I-Disease
failure	I-Disease
in	O
patients	B-Species
with	O
AIDS	B-Disease
on	O
tenofovir	B-Chemical
while	O
receiving	O
prolonged	O
vancomycin	B-Chemical
course	O
for	O
osteomyelitis	B-Disease
.	O
</ALL>	O

<ALL>	O
Renal	B-Disease
failure	I-Disease
developed	O
after	O
a	O
prolonged	O
course	O
of	O
vancomycin	B-Chemical
therapy	O
in	O
2	O
patients	B-Species
who	O
were	O
receiving	O
tenofovir	B-Chemical
disoproxil	I-Chemical
fumarate	I-Chemical
as	O
part	O
of	O
an	O
antiretroviral	O
regimen	O
.	O
</ALL>	O

<ALL>	O
Tenofovir	B-Chemical
has	O
been	O
implicated	O
in	O
the	O
development	O
of	O
Fanconi	B-Disease
syndrome	I-Disease
and	O
renal	B-Disease
insufficiency	I-Disease
because	O
of	O
its	O
effects	O
on	O
the	O
proximal	O
renal	O
tubule	O
.	O
</ALL>	O

<ALL>	O
Vancomycin	B-Chemical
nephrotoxicity	B-Disease
is	O
infrequent	O
but	O
may	O
result	O
from	O
coadministration	O
with	O
a	O
nephrotoxic	B-Disease
agent	O
.	O
</ALL>	O

<ALL>	O
Clinicians	O
should	O
be	O
aware	O
that	O
tenofovir	B-Chemical
may	O
raise	O
the	O
risk	O
of	O
renal	B-Disease
failure	I-Disease
during	O
prolonged	O
administration	O
of	O
vancomycin	B-Chemical
.	O
</ALL>	O

<ALL>	O
Protein	B-Gene
kinase	I-Gene
C	I-Gene
alpha	I-Gene
-	O
dependent	O
signaling	O
mediates	O
endometrial	B-Disease
cancer	I-Disease
cell	O
growth	O
and	O
tumorigenesis	B-Disease
.	O
</ALL>	O

<ALL>	O
Endometrial	B-Disease
cancer	I-Disease
is	O
the	O
most	O
common	O
invasive	O
gynecologic	B-Disease
malignancy	I-Disease
,	O
yet	O
molecular	O
mechanisms	O
and	O
signaling	O
pathways	O
underlying	O
its	O
etiology	O
and	O
pathophysiology	O
remain	O
poorly	O
characterized	O
.	O
</ALL>	O

<ALL>	O
We	O
sought	O
to	O
define	O
a	O
functional	O
role	O
for	O
the	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
(	O
PKC	B-Gene
)	O
isoform	O
,	O
PKCalpha	B-Gene
,	O
in	O
an	O
established	O
cell	O
model	O
of	O
endometrial	B-Disease
adenocarcinoma	I-Disease
.	O
</ALL>	O

<ALL>	O
Ishikawa	B-CellLine
cells	O
depleted	O
of	O
PKCalpha	B-Gene
protein	O
grew	O
slower	O
,	O
formed	O
fewer	O
colonies	O
in	O
anchorage	O
-	O
independent	O
growth	O
assays	O
and	O
exhibited	O
impaired	O
xenograft	O
tumor	B-Disease
formation	O
in	O
nude	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Consistent	O
with	O
impaired	O
growth	O
,	O
PKCalpha	B-Gene
knockdown	O
increased	O
levels	O
of	O
the	O
cyclin	B-Gene
-	I-Gene
dependent	I-Gene
kinase	I-Gene
(	O
CDK	B-Gene
)	O
inhibitors	O
p21	B-Gene
(	O
Cip1	B-Gene
/	O
WAF1	B-Gene
)	O
(	O
p21	B-Gene
)	O
and	O
p27	B-Gene
(	O
Kip1	B-Gene
)	O
(	O
p27	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
Despite	O
the	O
absence	O
of	O
functional	O
phosphatase	B-Gene
and	I-Gene
tensin	I-Gene
homolog	I-Gene
(	O
PTEN	B-Gene
)	O
protein	O
in	O
Ishikawa	B-CellLine
cells	O
,	O
PKCalpha	B-Gene
knockdown	O
reduced	O
Akt	B-Gene
phosphorylation	O
at	O
serine	O
473	O
and	O
concomitantly	O
inhibited	O
phosphorylation	O
of	O
the	O
Akt	B-Gene
target	O
,	O
glycogen	B-Gene
synthase	I-Gene
kinase	I-Gene
-	I-Gene
3beta	I-Gene
(	O
GSK	B-Gene
-	I-Gene
3beta	I-Gene
)	O
.	O
</ALL>	O

<ALL>	O
PKCalpha	B-Gene
knockdown	O
also	O
resulted	O
in	O
decreased	O
basal	O
ERK	B-Gene
phosphorylation	O
and	O
attenuated	O
ERK	B-Gene
activation	O
following	O
EGF	B-Gene
stimulation	O
.	O
</ALL>	O

<ALL>	O
p21	B-Gene
and	O
p27	B-Gene
expression	O
was	O
not	O
increased	O
by	O
treatment	O
of	O
Ishikawa	B-CellLine
cells	O
with	O
ERK	B-Gene
and	O
Akt	B-Gene
inhibitors	O
,	O
suggesting	O
that	O
PKCalpha	B-Gene
regulates	O
CDK	B-Gene
expression	O
independently	O
of	O
Akt	B-Gene
and	O
ERK	B-Gene
.	O
</ALL>	O

<ALL>	O
Immunohistochemical	O
analysis	O
of	O
Grade	O
1	O
endometrioid	B-Disease
adenocarcinoma	I-Disease
revealed	O
aberrant	O
PKCalpha	B-Gene
expression	O
,	O
with	O
foci	O
of	O
elevated	O
PKCalpha	B-Gene
staining	O
,	O
not	O
observed	O
in	O
normal	O
endometrium	O
.	O
</ALL>	O

<ALL>	O
These	O
studies	O
demonstrate	O
a	O
critical	O
role	O
for	O
PKCalpha	B-Gene
signaling	O
in	O
endometrial	O
tumorigenesis	B-Disease
by	O
regulating	O
expression	O
of	O
CDK	B-Gene
inhibitors	O
p21	B-Gene
and	O
p27	B-Gene
and	O
activation	O
of	O
Akt	B-Gene
and	O
ERK	B-Gene
-	O
dependent	O
proliferative	O
pathways	O
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
targeting	O
PKCalpha	B-Gene
may	O
provide	O
novel	O
therapeutic	O
options	O
in	O
endometrial	B-Disease
tumors	I-Disease
.	O
</ALL>	O

<ALL>	O
Metallothionein	B-Chemical
induction	O
reduces	O
caspase	B-Gene
-	I-Gene
3	I-Gene
activity	O
and	O
TNFalpha	B-Gene
levels	O
with	O
preservation	O
of	O
cognitive	O
function	O
and	O
intact	O
hippocampal	O
neurons	O
in	O
carmustine	B-Chemical
-	O
treated	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Hippocampal	O
integrity	O
is	O
essential	O
for	O
cognitive	O
functions	O
.	O
</ALL>	O

<ALL>	O
On	O
the	O
other	O
hand	O
,	O
induction	O
of	O
metallothionein	B-Chemical
(	O
MT	B-Chemical
)	O
by	O
ZnSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
and	O
its	O
role	O
in	O
neuroprotection	O
has	O
been	O
documented	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
aimed	O
to	O
explore	O
the	O
effect	O
of	O
MT	B-Chemical
induction	O
on	O
carmustine	B-Chemical
(	O
BCNU	B-Chemical
)	O
-	O
induced	O
hippocampal	O
cognitive	B-Disease
dysfunction	I-Disease
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
A	O
total	O
of	O
60	O
male	O
Wistar	O
albino	O
rats	B-Species
were	O
randomly	O
divided	O
into	O
four	O
groups	O
(	O
15	O
/	O
group	O
)	O
:	O
The	O
control	O
group	O
injected	O
with	O
single	O
doses	O
of	O
normal	O
saline	O
(	O
i.c.v	O
)	O
followed	O
24	O
h	O
later	O
by	O
BCNU	B-Chemical
solvent	O
(	O
i.v	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
second	O
group	O
administered	O
ZnSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
(	O
0.1	O
micromol	O
/	O
10	O
microl	O
normal	O
saline	O
,	O
i.c.v	O
,	O
once	O
)	O
then	O
BCNU	B-Chemical
solvent	O
(	O
i.v	O
)	O
after	O
24	O
h.	O
Third	O
group	O
received	O
BCNU	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
,	O
i.v	O
,	O
once	O
)	O
24	O
h	O
after	O
injection	O
with	O
normal	O
saline	O
(	O
i.c.v	O
)	O
.	O
</ALL>	O

<ALL>	O
Fourth	O
group	O
received	O
a	O
single	O
dose	O
of	O
ZnSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
(	O
0.1	O
micromol	O
/	O
10	O
microl	O
normal	O
saline	O
,	O
i.c.v	O
)	O
then	O
BCNU	B-Chemical
(	O
20	O
mg	O
/	O
kg	O
,	O
i.v	O
,	O
once	O
)	O
after	O
24	O
h.	O
The	O
obtained	O
data	O
revealed	O
that	O
BCNU	B-Chemical
administration	O
resulted	O
in	O
deterioration	B-Disease
of	I-Disease
learning	I-Disease
and	I-Disease
short	I-Disease
-	I-Disease
term	I-Disease
memory	I-Disease
(	O
STM	O
)	O
,	O
as	O
measured	O
by	O
using	O
radial	O
arm	O
water	O
maze	O
,	O
accompanied	O
with	O
decreased	O
hippocampal	O
glutathione	B-Gene
reductase	I-Gene
(	O
GR	B-Gene
)	O
activity	O
and	O
reduced	O
glutathione	B-Chemical
(	O
GSH	B-Chemical
)	O
content	O
.	O
</ALL>	O

<ALL>	O
Also	O
,	O
BCNU	B-Chemical
administration	O
increased	O
serum	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
-	I-Gene
alpha	I-Gene
(	O
TNFalpha	B-Gene
)	O
,	O
hippocampal	O
MT	B-Chemical
and	O
malondialdehyde	B-Chemical
(	O
MDA	B-Chemical
)	O
contents	O
as	O
well	O
as	O
caspase	B-Gene
-	I-Gene
3	I-Gene
activity	O
in	O
addition	O
to	O
histological	O
alterations	O
.	O
</ALL>	O

<ALL>	O
ZnSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
pretreatment	O
counteracted	O
BCNU	B-Chemical
-	O
induced	O
inhibition	O
of	O
GR	B-Gene
and	O
depletion	O
of	O
GSH	B-Chemical
and	O
resulted	O
in	O
significant	O
reduction	O
in	O
the	O
levels	O
of	O
MDA	B-Chemical
and	O
TNFalpha	B-Gene
as	O
well	O
as	O
the	O
activity	O
of	O
caspase	B-Gene
-	I-Gene
3	I-Gene
.	O
</ALL>	O

<ALL>	O
The	O
histological	O
features	O
were	O
improved	O
in	O
hippocampus	O
of	O
rats	B-Species
treated	O
with	O
ZnSO	B-Chemical
(	I-Chemical
4	I-Chemical
)	I-Chemical
+	O
BCNU	B-Chemical
compared	O
to	O
only	O
BCNU	B-Chemical
-	O
treated	O
animals	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
MT	B-Chemical
induction	O
halts	O
BCNU	B-Chemical
-	O
induced	O
hippocampal	O
toxicity	B-Disease
as	O
it	O
prevented	O
GR	B-Gene
inhibition	O
and	O
GSH	B-Chemical
depletion	O
and	O
counteracted	O
the	O
increased	O
levels	O
of	O
TNFalpha	B-Gene
,	O
MDA	B-Chemical
and	O
caspase	B-Gene
-	I-Gene
3	I-Gene
activity	O
with	O
subsequent	O
preservation	O
of	O
cognition	O
.	O
</ALL>	O

<ALL>	O
Association	O
of	O
obesity	B-Disease
risk	O
SNPs	O
in	O
PCSK1	B-Gene
with	O
insulin	B-Gene
sensitivity	O
and	O
proinsulin	B-Chemical
conversion	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Prohormone	B-Gene
convertase	I-Gene
1	I-Gene
is	O
involved	O
in	O
maturation	O
of	O
peptides	O
.	O
</ALL>	O

<ALL>	O
Rare	O
mutations	O
in	O
gene	O
PCSK1	B-Gene
,	O
encoding	O
this	O
enzyme	O
,	O
cause	O
childhood	O
obesity	B-Disease
and	O
abnormal	B-Disease
glucose	I-Disease
homeostasis	I-Disease
with	O
elevated	O
proinsulin	B-Chemical
concentrations	O
.	O
</ALL>	O

<ALL>	O
Common	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
within	O
this	O
gene	O
,	O
rs6232	B-Variant
and	O
rs6235	B-Variant
,	O
are	O
associated	O
with	O
obesity	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
studied	O
whether	O
these	O
SNPs	O
influence	O
the	O
prediabetic	O
traits	O
insulin	B-Disease
resistance	I-Disease
,	O
beta	B-Disease
-	I-Disease
cell	I-Disease
dysfunction	I-Disease
,	O
or	O
glucose	B-Disease
intolerance	I-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
We	O
genotyped	O
1498	O
German	O
subjects	O
for	O
SNPs	O
rs6232	B-Variant
and	O
rs6235	B-Variant
within	O
PCSK1	B-Gene
.	O
</ALL>	O

<ALL>	O
The	O
subjects	O
were	O
metabolically	O
characterized	O
by	O
oral	O
glucose	B-Chemical
tolerance	O
test	O
with	O
glucose	B-Chemical
,	O
insulin	B-Gene
,	O
proinsulin	B-Chemical
,	O
and	O
C	B-Chemical
-	I-Chemical
peptide	I-Chemical
measurements	O
.	O
</ALL>	O

<ALL>	O
A	O
subgroup	O
of	O
512	O
subjects	O
underwent	O
a	O
hyperinsulinemic	B-Disease
-	I-Disease
euglycemic	I-Disease
clamp	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
minor	O
allele	O
frequencies	O
were	O
25.8	O
%	O
for	O
SNP	O
rs6235	B-Variant
and	O
6.0	O
%	O
for	O
rs6232	B-Variant
.	O
</ALL>	O

<ALL>	O
After	O
adjustment	O
for	O
sex	O
and	O
age	O
,	O
we	O
found	O
no	O
association	O
of	O
SNPs	O
rs6235	B-Variant
and	O
rs6232	B-Variant
with	O
BMI	O
or	O
other	O
weight	O
-	O
related	O
traits	O
(	O
all	O
p	O
>	O
or	O
=	O
0.07	O
)	O
.	O
</ALL>	O

<ALL>	O
Both	O
minor	O
alleles	O
,	O
adjusted	O
for	O
sex	O
,	O
age	O
,	O
BMI	O
and	O
insulin	B-Gene
sensitivity	O
were	O
associated	O
with	O
elevated	O
AUC	O
proinsulin	B-Chemical
and	O
AUC	O
proinsulin	B-Chemical
/	O
AUC	O
insulin	B-Gene
(	O
rs6235	B-Variant
:	O
p	O
(	O
additive	O
)	O
model	O
<	O
or	O
=	O
0.009	O
,	O
effect	O
sizes	O
8	O
/	O
8	O
%	O
,	O
rs6232	B-Variant
:	O
pdominant	O
model	O
<	O
or	O
=	O
0.01	O
,	O
effect	O
sizes	O
10	O
/	O
21	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
Insulin	B-Gene
secretion	O
was	O
not	O
affected	O
by	O
the	O
variants	O
(	O
different	O
secretion	O
parameters	O
,	O
all	O
p	O
>	O
or	O
=	O
0.08	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
minor	O
allele	O
of	O
SNP	O
rs6232	B-Variant
was	O
additionally	O
associated	O
with	O
15	O
%	O
higher	O
OGTT	O
-	O
derived	O
and	O
19	O
%	O
higher	O
clamp	O
-	O
derived	O
insulin	B-Gene
sensitivity	O
(	O
pdom	O
<	O
or	O
=	O
0.0047	O
)	O
,	O
4.5	O
%	O
lower	O
HOMAIR	O
(	O
pdom	O
=	O
0.02	O
)	O
and	O
3.5	O
%	O
lower	O
120	O
-	O
min	O
glucose	B-Chemical
(	O
pdom	O
=	O
0.0003	O
)	O
independently	O
of	O
BMI	O
and	O
proinsulin	B-Chemical
conversion	O
.	O
</ALL>	O

<ALL>	O
SNP	O
rs6235	B-Variant
was	O
not	O
associated	O
with	O
parameters	O
of	O
glucose	O
metabolism	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Like	O
rare	O
mutations	O
in	O
PCSK1	B-Gene
,	O
the	O
more	O
common	O
variants	O
tested	O
determine	O
glucose	B-Chemical
-	O
stimulated	O
proinsulin	B-Chemical
conversion	O
,	O
but	O
not	O
insulin	B-Gene
secretion	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
rs6232	B-Variant
,	O
encoding	O
the	O
amino	O
acid	O
exchange	O
N221D	B-Variant
,	O
influences	O
insulin	B-Gene
sensitivity	O
and	O
glucose	B-Chemical
homeostasis	O
.	O
</ALL>	O

<ALL>	O
Inhibitory	O
effect	O
of	O
emodin	B-Chemical
on	O
fatty	B-Gene
acid	I-Gene
synthase	I-Gene
,	O
colon	B-Disease
cancer	I-Disease
proliferation	O
and	O
apoptosis	O
.	O
</ALL>	O

<ALL>	O
Fatty	B-Gene
acid	I-Gene
synthase	I-Gene
(	O
FASN	B-Gene
)	O
is	O
a	O
key	O
anabolic	O
enzyme	O
for	O
de	O
novo	O
fatty	B-Chemical
acid	I-Chemical
synthesis	O
,	O
which	O
is	O
important	O
in	O
the	O
development	O
of	O
colon	B-Disease
carcinoma	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
high	O
expression	O
of	O
FASN	B-Gene
is	O
considered	O
a	O
promising	O
molecular	O
target	O
for	O
colon	B-Disease
cancer	I-Disease
therapy	O
.	O
</ALL>	O

<ALL>	O
Emodin	B-Chemical
,	O
a	O
naturally	O
occurring	O
anthraquinone	B-Chemical
,	O
exhibits	O
an	O
anticancer	O
effect	O
in	O
various	O
types	O
of	O
human	B-Species
cancer	B-Disease
,	O
including	O
colon	B-Disease
cancer	I-Disease
;	O
however	O
,	O
the	O
molecular	O
mechanisms	O
remain	O
to	O
be	O
fully	O
elucidated	O
.	O
</ALL>	O

<ALL>	O
Cell	O
viability	O
was	O
evaluated	O
using	O
a	O
Cell	O
Counting	O
Kit	O
-	O
8	O
assay	O
.	O
</ALL>	O

<ALL>	O
The	O
apoptosis	O
rate	O
of	O
cells	O
was	O
quantified	O
via	O
flow	O
cytometry	O
following	O
Annexin	B-Gene
V	I-Gene
/	O
propidium	B-Chemical
iodide	I-Chemical
staining	O
.	O
</ALL>	O

<ALL>	O
FASN	B-Gene
activity	O
was	O
measured	O
by	O
monitoring	O
oxidation	O
of	O
nicotinamide	B-Chemical
adenine	I-Chemical
dinucleotide	I-Chemical
phosphate	I-Chemical
at	O
a	O
wavelength	O
of	O
340	O
nm	O
,	O
and	O
intracellular	O
free	B-Chemical
fatty	I-Chemical
acid	I-Chemical
levels	O
were	O
detected	O
using	O
a	O
Free	B-Chemical
Fatty	I-Chemical
Acid	I-Chemical
Quantification	O
kit	O
.	O
</ALL>	O

<ALL>	O
Western	O
blot	O
analysis	O
and	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
were	O
used	O
to	O
detect	O
target	O
gene	O
and	O
protein	O
expression	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
was	O
performed	O
to	O
investigate	O
whether	O
the	O
gene	O
expression	O
of	O
FASN	B-Gene
and	O
its	O
enzymatic	O
activity	O
are	O
regulated	O
by	O
emodin	B-Chemical
in	O
a	O
human	B-Species
colon	B-Disease
cancer	I-Disease
cell	O
line	O
.	O
</ALL>	O

<ALL>	O
Emodin	B-Chemical
markedly	O
inhibited	O
the	O
proliferation	O
of	O
HCT116	B-CellLine
cells	O
and	O
a	O
higher	O
protein	O
level	O
of	O
FASN	B-Gene
was	O
expressed	O
,	O
compared	O
with	O
that	O
in	O
SW480	B-CellLine
,	O
SNU	B-CellLine
-	I-CellLine
C2A	I-CellLine
or	O
SNU	B-CellLine
-	I-CellLine
C5	I-CellLine
cells	O
.	O
</ALL>	O

<ALL>	O
Emodin	B-Chemical
significantly	O
downregulated	O
the	O
protein	O
expression	O
of	O
FASN	B-Gene
in	O
HCT116	B-CellLine
cells	O
,	O
which	O
was	O
caused	O
by	O
protein	O
degradation	O
due	O
to	O
elevated	O
protein	O
ubiquitination	O
.	O
</ALL>	O

<ALL>	O
Emodin	B-Chemical
also	O
inhibited	O
intracellular	O
FASN	B-Gene
enzymatic	O
activity	O
and	O
reduced	O
the	O
levels	O
of	O
intracellular	O
free	B-Chemical
fatty	I-Chemical
acids	I-Chemical
.	O
</ALL>	O

<ALL>	O
Emodin	B-Chemical
enhanced	O
antiproliferation	O
and	O
apoptosis	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O
</ALL>	O

<ALL>	O
The	O
combined	O
treatment	O
of	O
emodin	B-Chemical
and	O
cerulenin	B-Chemical
,	O
a	O
commercial	O
FASN	B-Gene
inhibitor	O
,	O
had	O
an	O
additive	O
effect	O
on	O
these	O
activities	O
.	O
</ALL>	O

<ALL>	O
Palmitate	B-Chemical
,	O
the	O
final	O
product	O
of	O
the	O
FASN	B-Gene
reaction	O
,	O
rescued	O
emodin	B-Chemical
-	O
induced	O
viability	O
and	O
apoptosis	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
emodin	B-Chemical
altered	O
FASN	B-Gene
-	O
involved	O
signaling	O
pathways	O
,	O
including	O
phosphatidylinositol	B-Gene
3	I-Gene
-	I-Gene
kinase	I-Gene
/	O
Akt	B-Gene
and	O
mitogen	B-Gene
-	I-Gene
activated	I-Gene
protein	I-Gene
kinases	I-Gene
/	I-Gene
extracellular	I-Gene
signal	I-Gene
-	I-Gene
regulated	I-Gene
kinases	I-Gene
1	I-Gene
/	I-Gene
2	I-Gene
.	O
</ALL>	O

<ALL>	O
These	O
results	O
suggested	O
that	O
emodin	B-Chemical
-	O
regulated	O
cell	O
growth	O
and	O
apoptosis	O
were	O
mediated	O
by	O
inhibiting	O
FASN	B-Gene
and	O
provide	O
a	O
molecular	O
basis	O
for	O
colon	B-Disease
cancer	I-Disease
therapy	O
.	O
</ALL>	O

<ALL>	O
A	O
single	O
amino	O
acid	O
substitution	O
confers	O
B	O
-	O
cell	O
clonogenic	O
activity	O
to	O
the	O
HIV	B-Species
-	I-Species
1	I-Species
matrix	O
protein	O
p17	B-Gene
.	O
</ALL>	O

<ALL>	O
Recent	O
data	O
highlight	O
the	O
presence	O
,	O
in	O
HIV	B-Disease
-	I-Disease
1	I-Disease
-	I-Disease
seropositive	I-Disease
patients	B-Species
with	O
lymphoma	B-Disease
,	O
of	O
p17	B-Gene
variants	O
(	O
vp17s	O
)	O
endowed	O
with	O
B	O
-	O
cell	O
clonogenicity	O
,	O
suggesting	O
a	O
role	O
of	O
vp17s	O
in	O
lymphomagenesis	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
investigated	O
the	O
mechanisms	O
responsible	O
for	O
the	O
functional	O
disparity	O
on	O
B	O
cells	O
between	O
a	O
wild	O
-	O
type	O
p17	B-Gene
(	O
refp17	O
)	O
and	O
a	O
vp17	O
named	O
S75X	B-Variant
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
show	O
that	O
a	O
single	O
Arginine	B-Variant
(	I-Variant
R	I-Variant
)	I-Variant
to	I-Variant
Glycine	I-Variant
(	I-Variant
G	I-Variant
)	I-Variant
mutation	I-Variant
at	I-Variant
position	I-Variant
76	I-Variant
in	O
the	O
refp17	O
backbone	O
(	O
p17	O
R76	B-Variant
G	I-Variant
)	O
,	O
as	O
in	O
the	O
S75X	B-Variant
variant	O
,	O
is	O
per	O
se	O
sufficient	O
to	O
confer	O
a	O
B	O
-	O
cell	O
clonogenic	O
potential	O
to	O
the	O
viral	O
protein	O
and	O
modulate	O
,	O
through	O
activation	O
of	O
the	O
PTEN	B-Gene
/	O
PI3	B-Gene
K	I-Gene
/	O
Akt	B-Gene
signaling	O
pathway	O
,	O
different	O
molecules	O
involved	O
in	O
apoptosis	O
inhibition	O
(	O
CASP	B-Gene
-	I-Gene
9	I-Gene
,	O
CASP	B-Gene
-	I-Gene
7	I-Gene
,	O
DFF	B-Gene
-	I-Gene
45	I-Gene
,	O
NPM	B-Gene
,	O
YWHAZ	B-Gene
,	O
Src	B-Gene
,	O
PAX2	B-Gene
,	O
MAPK8	B-Gene
)	O
,	O
cell	O
cycle	O
promotion	O
and	O
cancer	B-Disease
progression	O
(	O
CDK1	B-Gene
,	O
CDK2	B-Gene
,	O
CDK8	B-Gene
,	O
CHEK1	B-Gene
,	O
CHEK2	B-Gene
,	O
GSK	B-Gene
-	I-Gene
3	I-Gene
beta	I-Gene
,	O
NPM	B-Gene
,	O
PAK1	B-Gene
,	O
PP2C	B-Gene
-	I-Gene
alpha	I-Gene
)	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
the	O
only	O
R	B-Variant
to	I-Variant
G	I-Variant
mutation	I-Variant
at	I-Variant
position	I-Variant
76	I-Variant
was	O
found	O
to	O
strongly	O
impact	O
on	O
protein	O
folding	O
and	O
oligomerization	O
by	O
altering	O
the	O
hydrogen	O
bond	O
network	O
.	O
</ALL>	O

<ALL>	O
This	O
generates	O
a	O
conformational	O
shift	O
in	O
the	O
p17	B-Gene
R76	B-Variant
G	I-Variant
mutant	O
which	O
enables	O
a	O
functional	O
epitope	O
(	O
s	O
)	O
,	O
masked	O
in	O
refp17	O
,	O
to	O
elicit	O
B	O
-	O
cell	O
growth	O
-	O
promoting	O
signals	O
after	O
its	O
interaction	O
with	O
a	O
still	O
unknown	O
receptor	O
(	O
s	O
)	O
.	O
</ALL>	O

<ALL>	O
Our	O
findings	O
offer	O
new	O
opportunities	O
to	O
understand	O
the	O
molecular	O
mechanisms	O
accounting	O
for	O
the	O
B	O
-	O
cell	O
growth	O
-	O
promoting	O
activity	O
of	O
vp17s	O
.	O
</ALL>	O

<ALL>	O
Genetic	O
alterations	O
in	O
primary	O
glioblastomas	B-Disease
in	O
Japan	O
.	O
</ALL>	O

<ALL>	O
Current	O
knowledge	O
of	O
genetic	O
alterations	O
in	O
glioblastomas	B-Disease
is	O
based	O
largely	O
on	O
genetic	O
analyses	O
of	O
tumors	B-Disease
from	O
mainly	O
caucasian	O
patients	B-Species
in	O
the	O
United	O
States	O
and	O
Europe	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
study	O
,	O
screening	O
for	O
several	O
key	O
genetic	O
alterations	O
was	O
performed	O
on	O
77	O
primary	O
(	O
de	O
novo	O
)	O
glioblastomas	B-Disease
in	O
Japanese	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
SSCP	O
followed	O
by	O
DNA	O
sequencing	O
revealed	O
TP53	B-Gene
mutations	O
in	O
16	O
of	O
73	O
(	O
22	O
%	O
)	O
glioblastomas	B-Disease
and	O
PTEN	B-Gene
mutations	O
in	O
13	O
of	O
63	O
(	O
21	O
%	O
)	O
cases	O
analyzed	O
.	O
</ALL>	O

<ALL>	O
Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
showed	O
EGFR	B-Gene
amplification	O
in	O
25	O
of	O
77	O
(	O
32	O
%	O
)	O
cases	O
and	O
p16	B-Gene
homozygous	O
deletion	O
in	O
32	O
of	O
77	O
(	O
42	O
%	O
)	O
cases	O
.	O
</ALL>	O

<ALL>	O
Quantitative	O
microsatellite	O
analysis	O
revealed	O
LOH	O
10q	O
in	O
41	O
of	O
59	O
(	O
69	O
%	O
)	O
glioblastomas	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
frequencies	O
of	O
these	O
genetic	O
alterations	O
were	O
similar	O
to	O
those	O
reported	O
for	O
primary	O
glioblastomas	B-Disease
at	O
the	O
population	O
level	O
in	O
Switzerland	O
.	O
</ALL>	O

<ALL>	O
As	O
previously	O
observed	O
for	O
glioblastomas	B-Disease
in	O
Europe	O
,	O
there	O
was	O
a	O
positive	O
association	O
between	O
EGFR	B-Gene
amplification	O
and	O
p16	B-Gene
deletion	O
(	O
p	O
=	O
0.009	O
)	O
,	O
whereas	O
there	O
was	O
an	O
inverse	O
association	O
between	O
TP53	B-Gene
mutations	O
and	O
p16	B-Gene
deletion	O
(	O
p	O
=	O
0.049	O
)	O
in	O
glioblastomas	B-Disease
in	O
Japan	O
.	O
</ALL>	O

<ALL>	O
Multivariate	O
analyses	O
showed	O
that	O
radiotherapy	O
was	O
significantly	O
predictive	O
for	O
longer	O
survival	O
of	O
glioblastoma	B-Disease
patients	B-Species
(	O
p	O
=	O
0.002	O
)	O
.	O
</ALL>	O

<ALL>	O
SSCP	O
followed	O
by	O
DNA	O
sequencing	O
of	O
the	O
kinase	O
domain	O
(	O
exons	O
18	O
-	O
21	O
)	O
of	O
the	O
EGFR	B-Gene
gene	O
revealed	O
mutations	O
in	O
2	O
ou	O
of	O
69	O
(	O
3	O
%	O
)	O
glioblastomas	B-Disease
in	O
Japan	O
and	O
in	O
4	O
of	O
81	O
(	O
5	O
%	O
)	O
glioblastomas	B-Disease
in	O
Switzerland	O
.	O
</ALL>	O

<ALL>	O
The	O
allele	O
frequencies	O
of	O
polymorphisms	O
at	O
codon	B-Variant
787	I-Variant
CAG	I-Variant
/	I-Variant
CAA	I-Variant
(	O
Gln	B-Variant
/	I-Variant
Gln	I-Variant
)	O
in	O
glioblastomas	B-Disease
in	O
Japan	O
were	O
G	O
/	O
G	O
(	O
82.4	O
%	O
)	O
,	O
G	O
/	O
A	O
(	O
10.8	O
%	O
)	O
,	O
A	O
/	O
A	O
(	O
6.8	O
%	O
)	O
,	O
corresponding	O
to	O
G	O
0.878	O
versus	O
A	O
0.122	O
,	O
significantly	O
different	O
from	O
those	O
in	O
glioblastomas	B-Disease
in	O
Switzerland	O
:	O
G	O
/	O
G	O
(	O
27.2	O
%	O
)	O
,	O
G	O
/	O
A	O
(	O
28.4	O
%	O
)	O
,	O
A	O
/	O
A	O
(	O
44.4	O
%	O
)	O
,	O
corresponding	O
to	O
G	O
0.414	O
versus	O
A	O
0.586	O
(	O
p	O
<	O
0.0001	O
)	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
suggest	O
that	O
primary	O
glioblastomas	B-Disease
in	O
Japan	O
show	O
genetic	O
alterations	O
similar	O
to	O
those	O
in	O
Switzerland	O
,	O
suggesting	O
a	O
similar	O
molecular	O
basis	O
in	O
caucasians	O
and	O
Asians	O
,	O
despite	O
different	O
genetic	O
backgrounds	O
,	O
including	O
different	O
status	O
of	O
a	O
polymorphism	O
in	O
the	O
EGFR	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Evaluation	O
of	O
RGS4	B-Gene
as	O
a	O
candidate	O
gene	O
for	O
schizophrenia	B-Disease
.	O
</ALL>	O

<ALL>	O
Several	O
studies	O
have	O
suggested	O
that	O
the	O
regulator	B-Gene
of	I-Gene
G	I-Gene
-	I-Gene
protein	I-Gene
signaling	I-Gene
4	I-Gene
(	O
RGS4	B-Gene
)	O
may	O
be	O
a	O
positional	O
and	O
functional	O
candidate	O
gene	O
for	O
schizophrenia	B-Disease
.	O
</ALL>	O

<ALL>	O
Three	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
located	O
at	O
the	O
promoter	O
region	O
(	O
SNP4	O
and	O
SNP7	O
)	O
and	O
the	O
intron	O
1	O
(	O
SNP18	O
)	O
of	O
RGS4	B-Gene
have	O
been	O
verified	O
in	O
different	O
ethnic	O
groups	O
.	O
</ALL>	O

<ALL>	O
Positive	O
results	O
have	O
been	O
reported	O
in	O
these	O
SNPs	O
with	O
different	O
numbers	O
of	O
SNP	O
combinatory	O
haplotypes	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
these	O
three	O
SNP	O
markers	O
were	O
genotyped	O
in	O
218	O
schizophrenia	B-Disease
pedigrees	O
of	O
Taiwan	O
(	O
864	O
individuals	O
)	O
for	O
association	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Among	O
these	O
three	O
SNPs	O
,	O
neither	O
SNP4	O
,	O
SNP7	O
,	O
SNP18	O
has	O
shown	O
significant	O
association	O
with	O
schizophrenia	B-Disease
in	O
single	O
locus	O
association	O
analysis	O
,	O
nor	O
any	O
compositions	O
of	O
the	O
three	O
SNP	O
haplotypes	O
has	O
shown	O
significantly	O
associations	O
with	O
the	O
DSM	O
-	O
IV	O
diagnosed	O
schizophrenia	B-Disease
.	O
</ALL>	O

<ALL>	O
Our	O
results	O
fail	O
to	O
support	O
the	O
RGS4	B-Gene
as	O
a	O
candidate	O
gene	O
for	O
schizophrenia	B-Disease
when	O
evaluated	O
from	O
these	O
three	O
SNP	O
markers	O
.	O
</ALL>	O

<ALL>	O
Analysis	O
of	O
skin	B-Disease
cancer	I-Disease
risk	O
factors	O
in	O
immunosuppressed	O
renal	O
transplant	O
patients	B-Species
shows	O
high	O
levels	O
of	O
UV	O
-	O
specific	O
tandem	O
CC	B-Variant
to	I-Variant
TT	I-Variant
mutations	O
of	O
the	O
p53	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Immunosuppressed	O
renal	O
transplant	O
recipients	O
(	O
RTRs	O
)	O
are	O
predisposed	O
to	O
non	B-Disease
-	I-Disease
melanoma	I-Disease
skin	I-Disease
cancers	I-Disease
(	O
NMSCs	B-Disease
)	O
,	O
predominantly	O
squamous	B-Disease
cell	I-Disease
carcinomas	I-Disease
(	O
SCCs	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
We	O
have	O
analyzed	O
skin	B-Disease
lesions	I-Disease
from	O
RTRs	O
with	O
aggressive	O
tumors	B-Disease
for	O
p53	B-Gene
gene	O
modifications	O
,	O
the	O
presence	O
of	O
Human	B-Species
Papillomas	I-Species
Virus	I-Species
(	O
HPV	B-Species
)	O
DNA	O
in	O
relation	O
to	O
the	O
p53	B-Gene
codon	O
72	O
genotype	O
and	O
polymorphisms	O
of	O
the	O
XPD	B-Gene
repair	O
gene	O
.	O
</ALL>	O

<ALL>	O
We	O
detected	O
24	O
p53	B-Gene
mutations	O
in	O
15	O
/	O
25	O
(	O
60	O
%	O
)	O
NMSCs	B-Disease
,	O
1	O
deletion	O
and	O
23	O
base	O
substitutions	O
,	O
the	O
majority	O
(	O
78	O
%	O
)	O
being	O
UV	O
-	O
specific	O
C	B-Variant
to	I-Variant
T	I-Variant
transitions	O
at	O
bipyrimidine	O
sites	O
.	O
</ALL>	O

<ALL>	O
Importantly	O
,	O
35	O
%	O
(	O
6	O
/	O
17	O
)	O
are	O
tandem	O
mutations	O
,	O
including	O
4	O
UV	O
signature	O
CC	B-Variant
to	I-Variant
TT	I-Variant
transitions	O
possibly	O
linked	O
to	O
modulated	O
DNA	O
repair	O
caused	O
by	O
the	O
immunosuppressive	O
drug	O
cyclosporin	B-Chemical
A	I-Chemical
(	O
CsA	B-Chemical
)	O
.	O
</ALL>	O

<ALL>	O
We	O
found	O
8	O
p53	B-Gene
mutations	O
in	O
7	O
/	O
17	O
(	O
41	O
%	O
)	O
precancerous	B-Disease
actinic	B-Disease
keratosis	I-Disease
(	O
AK	B-Disease
)	O
,	O
suggesting	O
that	O
p53	B-Gene
mutations	O
are	O
early	O
events	O
in	O
RTR	O
skin	B-Disease
carcinogenesis	I-Disease
.	O
</ALL>	O

<ALL>	O
Immunohistochemical	O
analysis	O
shows	O
a	O
good	O
correlation	O
between	O
p53	B-Gene
accumulation	O
and	O
mutations	O
.	O
</ALL>	O

<ALL>	O
HPV	B-Species
DNA	O
was	O
detected	O
in	O
78	O
%	O
of	O
skin	B-Disease
lesions	I-Disease
(	O
60	O
%	O
Basal	B-Disease
Cell	I-Disease
Carcinomas	I-Disease
,	O
82	O
%	O
AK	B-Disease
and	O
79	O
%	O
SCCs	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
immunosuppression	O
has	O
increased	O
the	O
risk	O
of	O
infections	B-Disease
by	O
HPVs	B-Species
,	O
predominantly	O
epidermodysplasia	B-Disease
verruciformis	I-Disease
,	O
speculated	O
to	O
play	O
a	O
role	O
in	O
skin	B-Disease
cancer	I-Disease
development	O
.	O
</ALL>	O

<ALL>	O
No	O
association	O
is	O
found	O
between	O
HPV	B-Species
status	O
and	O
p53	B-Gene
mutation	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
p53	B-Gene
codon	O
72	O
or	O
frequencies	O
of	O
three	O
XPD	B-Gene
genotypes	O
of	O
RTRs	O
are	O
comparable	O
with	O
control	O
populations	O
.	O
</ALL>	O

<ALL>	O
The	O
p53	B-Gene
mutation	O
spectrum	O
,	O
presenting	O
a	O
high	O
level	O
of	O
CC	B-Variant
to	I-Variant
TT	I-Variant
mutations	O
,	O
shows	O
that	O
the	O
UV	O
component	O
of	O
sunlight	O
is	O
the	O
major	O
risk	O
factor	O
and	O
modulated	O
DNA	O
repair	O
by	O
immunosuppressive	O
drug	O
treatment	O
may	O
be	O
significant	O
in	O
the	O
skin	B-Disease
carcinogenesis	I-Disease
of	O
RTRs	O
.	O
</ALL>	O

<ALL>	O
Syncope	B-Disease
and	O
QT	B-Disease
prolongation	I-Disease
among	O
patients	B-Species
treated	O
with	O
methadone	B-Chemical
for	O
heroin	B-Disease
dependence	I-Disease
in	O
the	O
city	O
of	O
Copenhagen	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Methadone	B-Chemical
is	O
prescribed	O
to	O
heroin	B-Disease
addicts	I-Disease
to	O
decrease	O
illicit	O
opioid	B-Chemical
use	O
.	O
</ALL>	O

<ALL>	O
Prolongation	B-Disease
of	I-Disease
the	I-Disease
QT	I-Disease
interval	I-Disease
in	O
the	O
ECG	O
of	O
patients	B-Species
with	O
torsade	B-Disease
de	I-Disease
pointes	I-Disease
(	O
TdP	B-Disease
)	O
has	O
been	O
reported	O
in	O
methadone	B-Chemical
users	O
.	O
</ALL>	O

<ALL>	O
As	O
heroin	B-Disease
addicts	I-Disease
sometimes	O
faint	O
while	O
using	O
illicit	O
drugs	O
,	O
doctors	O
might	O
attribute	O
too	O
many	O
episodes	O
of	O
syncope	B-Disease
to	O
illicit	O
drug	O
use	O
and	O
thereby	O
underestimate	O
the	O
incidence	O
of	O
TdP	B-Disease
in	O
this	O
special	O
population	O
,	O
and	O
the	O
high	O
mortality	O
in	O
this	O
population	O
may	O
,	O
in	O
part	O
,	O
be	O
caused	O
by	O
the	O
proarrhythmic	O
effect	O
of	O
methadone	B-Chemical
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
In	O
this	O
cross	O
-	O
sectional	O
study	O
interview	O
,	O
ECGs	O
and	O
blood	O
samples	O
were	O
collected	O
in	O
a	O
population	O
of	O
adult	O
heroin	B-Disease
addicts	I-Disease
treated	O
with	O
methadone	B-Chemical
or	O
buprenorphine	B-Chemical
on	O
a	O
daily	O
basis	O
.	O
</ALL>	O

<ALL>	O
Of	O
the	O
patients	B-Species
at	O
the	O
Drug	O
Addiction	O
Service	O
in	O
the	O
municipal	O
of	O
Copenhagen	O
,	O
450	O
(	O
approximately	O
52	O
%	O
)	O
were	O
included	O
.	O
</ALL>	O

<ALL>	O
The	O
QT	O
interval	O
was	O
estimated	O
from	O
12	O
lead	O
ECGs	O
.	O
</ALL>	O

<ALL>	O
All	O
participants	O
were	O
interviewed	O
about	O
any	O
experience	O
of	O
syncope	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
association	O
between	O
opioid	B-Chemical
dose	O
and	O
QT	O
,	O
and	O
methadone	B-Chemical
dose	O
and	O
reporting	O
of	O
syncope	B-Disease
was	O
assessed	O
using	O
multivariate	O
linear	O
regression	O
and	O
logistic	O
regression	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Methadone	B-Chemical
dose	O
was	O
associated	O
with	O
longer	B-Disease
QT	I-Disease
interval	I-Disease
of	O
0.140	O
ms	O
/	O
mg	O
(	O
p	O
=	O
0.002	O
)	O
.	O
</ALL>	O

<ALL>	O
No	O
association	O
between	O
buprenorphine	B-Chemical
and	O
QTc	O
was	O
found	O
.	O
</ALL>	O

<ALL>	O
Among	O
the	O
subjects	O
treated	O
with	O
methadone	B-Chemical
,	O
28	O
%	O
men	B-Species
and	O
32	O
%	O
women	B-Species
had	O
prolonged	B-Disease
QTc	I-Disease
interval	I-Disease
.	O
</ALL>	O

<ALL>	O
None	O
of	O
the	O
subjects	O
treated	O
with	O
buprenorphine	B-Chemical
had	O
QTc	O
interval	O
>	O
0.440	O
s	O
(	O
(	O
1	O
/	O
2	O
)	O
)	O
.	O
</ALL>	O

<ALL>	O
A	O
50	O
mg	O
higher	O
methadone	B-Chemical
dose	O
was	O
associated	O
with	O
a	O
1.2	O
(	O
95	O
%	O
CI	O
1.1	O
to	O
1.4	O
)	O
times	O
higher	O
odds	O
for	O
syncope	B-Disease
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Methadone	B-Chemical
is	O
associated	O
with	O
QT	B-Disease
prolongation	I-Disease
and	O
higher	O
reporting	O
of	O
syncope	B-Disease
in	O
a	O
population	O
of	O
heroin	B-Disease
addicts	I-Disease
.	O
</ALL>	O

<ALL>	O
R58fs	B-Variant
mutation	O
in	O
the	O
HGD	B-Gene
gene	O
in	O
a	O
family	O
with	O
alkaptonuria	B-Disease
in	O
the	O
UAE	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
prevalence	O
of	O
alkaptonuria	B-Disease
in	O
the	O
UAE	O
population	O
and	O
to	O
identify	O
the	O
genotype	O
of	O
affected	O
individuals	O
.	O
</ALL>	O

<ALL>	O
In	O
a	O
3	O
stage	O
sampling	O
technique	O
2981	O
pupils	O
from	O
Government	O
schools	O
in	O
Al	O
Ain	O
and	O
private	O
schools	O
in	O
Dubai	O
were	O
selected	O
to	O
take	O
part	O
in	O
the	O
study	O
,	O
of	O
whom	O
2857	O
provided	O
urine	O
samples	O
.	O
</ALL>	O

<ALL>	O
Urine	O
collected	O
was	O
analysed	O
for	O
homogentisic	B-Chemical
acid	I-Chemical
by	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
.	O
</ALL>	O

<ALL>	O
Genomic	O
DNA	O
was	O
isolated	O
from	O
the	O
white	O
blood	O
cells	O
of	O
all	O
family	O
members	O
of	O
the	O
affected	O
case	O
following	O
standard	O
established	O
protocols	O
.	O
</ALL>	O

<ALL>	O
Specific	O
PRC	O
primers	O
were	O
designed	O
to	O
amplify	O
all	O
14	O
exons	O
of	O
the	O
HGD	B-Gene
gene	O
with	O
the	O
flanking	O
intronic	O
sequences	O
including	O
the	O
splice	O
site	O
sequences	O
.	O
</ALL>	O

<ALL>	O
2857	O
children	O
returned	O
a	O
viable	O
urine	O
sample	O
,	O
of	O
which	O
one	O
was	O
highly	O
positive	O
for	O
homogentisic	B-Chemical
acid	I-Chemical
.	O
</ALL>	O

<ALL>	O
All	O
12	O
members	O
of	O
this	O
girl	O
's	O
family	O
were	O
studied	O
and	O
one	O
,	O
a	O
22	O
year	O
old	O
brother	O
,	O
was	O
found	O
to	O
excrete	O
HGA	B-Chemical
.	O
</ALL>	O

<ALL>	O
Another	O
,	O
a	O
sister	O
who	O
had	O
not	O
provided	O
a	O
urine	O
sample	O
,	O
was	O
discovered	O
by	O
genetic	O
testing	O
.	O
</ALL>	O

<ALL>	O
There	O
were	O
no	O
complaints	O
of	O
joint	B-Disease
pain	I-Disease
or	O
other	O
symptoms	O
in	O
any	O
member	O
of	O
this	O
family	O
.	O
</ALL>	O

<ALL>	O
Parents	O
were	O
first	O
cousins	O
.	O
</ALL>	O

<ALL>	O
We	O
found	O
a	O
single	O
nucleotide	O
deletion	O
c.342delA	B-Variant
,	O
located	O
in	O
exon	O
3	O
,	O
which	O
resulted	O
in	O
a	O
frameshift	O
at	O
amino	O
acid	O
position	O
58	O
(	O
p	B-Variant
.	I-Variant
Arg58fs	I-Variant
or	O
p	B-Variant
.	I-Variant
R58fs	I-Variant
)	O
.	O
</ALL>	O

<ALL>	O
Alkaptonuria	B-Disease
may	O
be	O
more	O
common	O
than	O
it	O
is	O
thought	O
to	O
be	O
with	O
an	O
allele	O
prevalence	O
estimated	O
at	O
0.0107	O
(	O
95	O
%	O
CI	O
0.000392	O
-	O
0.03473	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
R58fs	B-Variant
mutation	O
is	O
old	O
,	O
perhaps	O
having	O
occurred	O
several	O
thousand	O
years	O
ago	O
,	O
and	O
has	O
spread	O
over	O
a	O
large	O
geographical	O
area	O
.	O
</ALL>	O

<ALL>	O
Neuregulin	B-Gene
-	I-Gene
1	I-Gene
beta	I-Gene
and	O
neuregulin	B-Gene
-	I-Gene
1	I-Gene
alpha	I-Gene
differentially	O
affect	O
the	O
migration	O
and	O
invasion	O
of	O
malignant	B-Disease
peripheral	I-Disease
nerve	I-Disease
sheath	I-Disease
tumor	I-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
Malignant	B-Disease
peripheral	I-Disease
nerve	I-Disease
sheath	I-Disease
tumors	I-Disease
(	O
MPNSTs	B-Disease
)	O
are	O
the	O
most	O
common	O
malignancy	B-Disease
associated	O
with	O
neurofibromatosis	B-Gene
Type	I-Gene
1	I-Gene
(	O
NF1	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
These	O
Schwann	O
cell	O
lineage	O
-	O
derived	O
sarcomas	B-Disease
aggressively	O
invade	O
adjacent	O
nerve	O
and	O
soft	O
tissue	O
,	O
frequently	O
precluding	O
surgical	O
resection	O
.	O
</ALL>	O

<ALL>	O
Little	O
is	O
known	O
regarding	O
the	O
mechanisms	O
underlying	O
this	O
invasive	O
behavior	O
.	O
</ALL>	O

<ALL>	O
We	O
have	O
shown	O
that	O
MPNSTs	B-Disease
express	O
neuregulin	B-Gene
-	I-Gene
1	I-Gene
(	I-Gene
NRG	I-Gene
-	I-Gene
1	I-Gene
)	I-Gene
beta	I-Gene
isoforms	O
,	O
which	O
promote	O
Schwann	O
cell	O
migration	O
during	O
development	O
,	O
and	O
NRG	B-Gene
-	I-Gene
1	I-Gene
alpha	I-Gene
isoforms	O
,	O
whose	O
effects	O
on	O
Schwann	O
cells	O
are	O
poorly	O
understood	O
.	O
</ALL>	O

<ALL>	O
Hypothesizing	O
that	O
NRG	B-Gene
-	I-Gene
1	I-Gene
beta	I-Gene
and	O
/	O
or	O
NRG	B-Gene
-	I-Gene
1	I-Gene
alpha	I-Gene
promote	O
MPNST	B-Disease
invasion	O
,	O
we	O
found	O
that	O
NRG	B-Gene
-	I-Gene
1	I-Gene
beta	I-Gene
promoted	O
MPNST	B-Disease
migration	O
in	O
a	O
substrate	O
-	O
specific	O
manner	O
,	O
markedly	O
enhancing	O
migration	O
on	O
laminin	B-Gene
but	O
not	O
on	O
collagen	B-Gene
type	I-Gene
I	I-Gene
or	O
fibronectin	B-Gene
.	O
</ALL>	O

<ALL>	O
The	O
NRG	B-Gene
-	I-Gene
1	I-Gene
receptors	O
erbB3	B-Gene
and	O
erbB4	B-Gene
were	O
present	O
in	O
MPNST	B-Disease
invadopodia	O
(	O
processes	O
mediating	O
invasion	O
)	O
,	O
partially	O
colocalized	O
with	O
focal	B-Gene
adhesion	I-Gene
kinase	I-Gene
and	O
the	O
laminin	B-Gene
receptor	I-Gene
beta	B-Gene
(	I-Gene
1	I-Gene
)	I-Gene
-	I-Gene
integrin	I-Gene
and	O
coimmunoprecipitated	O
with	O
beta	B-Gene
(	I-Gene
1	I-Gene
)	I-Gene
-	I-Gene
integrin	I-Gene
.	O
</ALL>	O

<ALL>	O
NRG	B-Gene
-	I-Gene
1	I-Gene
beta	I-Gene
stimulated	O
human	B-Species
and	O
murine	B-Species
MPNST	B-Disease
cell	O
migration	O
and	O
invasion	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
in	O
three	O
-	O
dimensional	O
migration	O
assays	O
,	O
acting	O
as	O
a	O
chemotactic	O
factor	O
.	O
</ALL>	O

<ALL>	O
Both	O
baseline	O
and	O
NRG	B-Gene
-	I-Gene
1	I-Gene
beta	I-Gene
-	O
induced	O
migration	O
were	O
erbB	B-Gene
-	O
dependent	O
and	O
required	O
the	O
action	O
of	O
MEK	B-Gene
1	I-Gene
/	I-Gene
2	I-Gene
,	O
SAPK	B-Gene
/	O
JNK	B-Gene
,	O
PI	B-Gene
-	I-Gene
3	I-Gene
kinase	I-Gene
,	O
Src	B-Gene
family	I-Gene
kinases	I-Gene
and	O
ROCK	B-Gene
-	I-Gene
I	I-Gene
/	I-Gene
II	I-Gene
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
NRG	B-Gene
-	I-Gene
1	I-Gene
alpha	I-Gene
had	O
no	O
effect	O
on	O
the	O
migration	O
and	O
invasion	O
of	O
some	O
MPNST	B-Disease
lines	O
and	O
inhibited	O
the	O
migration	O
of	O
others	O
.	O
</ALL>	O

<ALL>	O
While	O
NRG	B-Gene
-	I-Gene
1	I-Gene
beta	I-Gene
potently	O
and	O
persistently	O
activated	O
Erk	B-Gene
1	I-Gene
/	I-Gene
2	I-Gene
,	O
SAPK	B-Gene
/	O
JNK	B-Gene
,	O
Akt	B-Gene
and	O
Src	B-Gene
family	I-Gene
kinases	I-Gene
,	O
NRG	B-Gene
-	I-Gene
1	I-Gene
alpha	I-Gene
did	O
not	O
activate	O
Akt	B-Gene
and	O
activated	O
these	O
other	O
kinases	O
with	O
kinetics	O
distinct	O
from	O
those	O
evident	O
in	O
NRG	B-Gene
-	I-Gene
1	I-Gene
beta	I-Gene
-	O
stimulated	O
cells	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
suggest	O
that	O
NRG	B-Gene
-	I-Gene
1	I-Gene
beta	I-Gene
enhances	O
MPNST	B-Disease
migration	O
and	O
that	O
NRG	B-Gene
-	I-Gene
1	I-Gene
beta	I-Gene
and	O
NRG	B-Gene
-	I-Gene
1	I-Gene
alpha	I-Gene
differentially	O
modulate	O
this	O
process	O
.	O
</ALL>	O

<ALL>	O
Exploratory	O
investigation	O
on	O
functional	O
significance	O
of	O
ETS2	B-Gene
and	O
SIM2	B-Gene
genes	O
in	O
Down	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Trisomy	O
of	O
the	O
21{st	O
}	O
chromosome	O
leads	O
to	O
an	O
over	O
dosage	O
of	O
several	O
regulatory	O
genes	O
in	O
Down	B-Disease
syndrome	I-Disease
(	O
DS	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Though	O
allelic	O
and	O
genotypic	O
combinations	O
formed	O
between	O
genes	O
are	O
interesting	O
,	O
till	O
date	O
,	O
this	O
particular	O
area	O
has	O
never	O
been	O
explored	O
in	O
DS	B-Disease
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
investigation	O
four	O
SNPs	O
in	O
two	O
transcription	O
factors	O
,	O
Single	B-Gene
minded	I-Gene
2	I-Gene
(	O
SIM2	B-Gene
)	O
and	O
V	B-Gene
-	I-Gene
ets	I-Gene
erythroblastosis	I-Gene
virus	I-Gene
E26	I-Gene
oncogene	I-Gene
homolog2	I-Gene
(	O
ETS2	B-Gene
)	O
,	O
located	O
in	O
the	O
21{st	O
}	O
chromosome	O
were	O
genotyped	O
to	O
understand	O
their	O
role	O
in	O
DS	B-Disease
.	O
</ALL>	O

<ALL>	O
Genomic	O
DNA	O
of	O
eastern	O
Indian	O
probands	O
with	O
DS	B-Disease
(	O
N	O
=	O
132	O
)	O
,	O
their	O
parents	O
(	O
N	O
=	O
209	O
)	O
and	O
ethnically	O
matched	O
controls	O
(	O
N	O
=	O
149	O
)	O
was	O
subjected	O
to	O
PCR	O
-	O
based	O
analyses	O
of	O
functionally	O
important	O
SNPs	O
followed	O
by	O
statistical	O
analyses	O
.	O
</ALL>	O

<ALL>	O
ETS2	B-Gene
rs461155	B-Variant
showed	O
high	O
heterozygosity	O
in	O
DS	B-Disease
.	O
</ALL>	O

<ALL>	O
Significantly	O
lower	O
frequency	O
of	O
SIM2	B-Gene
C	O
-	O
G	O
haplotype	O
(	O
rs2073601	B-Variant
-	O
rs2073416	B-Variant
)	O
was	O
noticed	O
in	O
individuals	O
with	O
DS	B-Disease
(	O
P	O
value	O
=	O
0.01669	O
)	O
and	O
their	O
fathers	O
(	O
P	O
value	O
=	O
0.01185	O
)	O
.	O
</ALL>	O

<ALL>	O
Significantly	O
lower	O
frequency	O
of	O
the	O
A	O
-	O
C	O
-	O
C	O
-	O
G	O
with	O
higher	O
frequency	O
of	O
A	O
-	O
C	O
-	O
A	O
-	O
G	O
haplotypes	O
was	O
also	O
noticed	O
in	O
subjects	O
with	O
DS	B-Disease
(	O
P	O
value	O
=	O
0.02089	O
and	O
0.00588	O
respectively	O
)	O
.	O
</ALL>	O

<ALL>	O
Data	O
obtained	O
indicate	O
that	O
the	O
rs2073601	B-Variant
'	O
A	O
'	O
allele	O
,	O
responsible	O
for	O
nonsynonymous	O
substitution	O
of	O
leucine	B-Variant
to	I-Variant
methionine	I-Variant
,	O
may	O
have	O
some	O
role	O
in	O
DS	B-Disease
in	O
this	O
population	O
.	O
</ALL>	O

<ALL>	O
Crucial	O
role	O
of	O
calbindin	B-Gene
-	I-Gene
D28k	I-Gene
in	O
the	O
pathogenesis	O
of	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
mouse	B-Species
model	O
.	O
</ALL>	O

<ALL>	O
Calbindin	B-Gene
-	I-Gene
D28k	I-Gene
(	O
CB	B-Gene
)	O
,	O
one	O
of	O
the	O
major	O
calcium	B-Chemical
-	O
binding	O
and	O
buffering	O
proteins	O
,	O
has	O
a	O
critical	O
role	O
in	O
preventing	O
a	O
neuronal	B-Disease
death	I-Disease
as	O
well	O
as	O
maintaining	O
calcium	B-Chemical
homeostasis	O
.	O
</ALL>	O

<ALL>	O
Although	O
marked	O
reductions	O
of	O
CB	B-Gene
expression	O
have	O
been	O
observed	O
in	O
the	O
brains	O
of	O
mice	B-Species
and	O
humans	B-Species
with	O
Alzheimer	B-Disease
disease	I-Disease
(	O
AD	B-Disease
)	O
,	O
it	O
is	O
unknown	O
whether	O
these	O
changes	O
contribute	O
to	O
AD	B-Disease
-	O
related	O
dysfunction	O
.	O
</ALL>	O

<ALL>	O
To	O
determine	O
the	O
pathogenic	O
importance	O
of	O
CB	B-Gene
depletions	O
in	O
AD	B-Disease
models	O
,	O
we	O
crossed	O
5	O
familial	O
AD	B-Disease
mutations	O
(	O
5XF	O
AD	B-Disease
;	O
Tg	O
)	O
mice	B-Species
with	O
CB	B-Gene
knock	O
-	O
out	O
(	O
CB	B-Gene
KO	O
)	O
mice	B-Species
and	O
generated	O
a	O
novel	O
line	O
CB	B-Gene
KO.5XF	O
AD	B-Disease
(	O
CB	B-Gene
KOTg	O
)	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
We	O
first	O
identified	O
the	O
change	O
of	O
signaling	O
pathways	O
and	O
differentially	O
expressed	O
proteins	O
globally	O
by	O
removing	O
CB	B-Gene
in	O
Tg	O
mice	B-Species
using	O
mass	O
spectrometry	O
and	O
antibody	O
microarray	O
.	O
</ALL>	O

<ALL>	O
Immunohistochemistry	O
showed	O
that	O
CB	B-Gene
KOTg	O
mice	B-Species
had	O
significant	O
neuronal	B-Disease
loss	I-Disease
in	O
the	O
subiculum	O
area	O
without	O
changing	O
the	O
magnitude	O
(	O
number	O
)	O
of	O
amyloid	B-Gene
b	I-Gene
-	I-Gene
peptide	I-Gene
(	O
Ab	B-Gene
)	O
plaques	O
deposition	O
and	O
elicited	O
significant	O
apoptotic	O
features	O
and	O
mitochondrial	B-Disease
dysfunction	I-Disease
compared	O
with	O
Tg	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
CB	B-Gene
KOTg	O
mice	B-Species
reduced	O
levels	O
of	O
phosphorylated	O
mitogen	B-Gene
-	I-Gene
activated	I-Gene
protein	I-Gene
kinase	I-Gene
(	O
extracellular	B-Gene
signal	I-Gene
-	I-Gene
regulated	I-Gene
kinase	I-Gene
)	I-Gene
1	I-Gene
/	I-Gene
2	I-Gene
and	O
cAMP	B-Gene
response	I-Gene
element	I-Gene
-	I-Gene
binding	I-Gene
protein	I-Gene
at	O
Ser	O
-	O
133	O
and	O
synaptic	O
molecules	O
such	O
as	O
N	B-Gene
-	I-Gene
methyl	I-Gene
-	I-Gene
D	I-Gene
-	I-Gene
aspartate	I-Gene
receptor	I-Gene
1	I-Gene
(	O
NMDA	B-Gene
receptor	I-Gene
1	I-Gene
)	O
,	O
NMDA	B-Gene
receptor	I-Gene
2A	I-Gene
,	O
PSD	B-Gene
-	I-Gene
95	I-Gene
and	O
synaptophysin	B-Gene
in	O
the	O
subiculum	O
compared	O
with	O
Tg	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Importantly	O
,	O
this	O
is	O
the	O
first	O
experimental	O
evidence	O
that	O
removal	O
of	O
CB	B-Gene
from	O
amyloid	B-Gene
precursor	I-Gene
protein	I-Gene
/	O
presenilin	B-Gene
transgenic	O
mice	B-Species
aggravates	O
AD	B-Disease
pathogenesis	O
,	O
suggesting	O
that	O
CB	B-Gene
has	O
a	O
critical	O
role	O
in	O
AD	B-Disease
pathogenesis	O
.	O
</ALL>	O

<ALL>	O
Role	O
of	O
stress	O
-	O
activated	O
OCT4A	B-Gene
in	O
the	O
cell	O
fate	O
decisions	O
of	O
embryonal	B-Disease
carcinoma	I-Disease
cells	O
treated	O
with	O
etoposide	B-Chemical
.	O
</ALL>	O

<ALL>	O
Tumor	O
cellular	O
senescence	O
induced	O
by	O
genotoxic	O
treatments	O
has	O
recently	O
been	O
found	O
to	O
be	O
paradoxically	O
linked	O
to	O
the	O
induction	O
of	O
"	O
stemness	O
.	O
"	O
</ALL>	O

<ALL>	O
This	O
observation	O
is	O
critical	O
as	O
it	O
directly	O
impinges	O
upon	O
the	O
response	O
of	O
tumors	B-Disease
to	O
current	O
chemo	O
-	O
radio	O
-	O
therapy	O
treatment	O
regimens	O
.	O
</ALL>	O

<ALL>	O
Previously	O
,	O
we	O
showed	O
that	O
following	O
etoposide	B-Chemical
(	O
ETO	B-Chemical
)	O
treatment	O
embryonal	B-Disease
carcinoma	I-Disease
PA	B-CellLine
-	I-CellLine
1	I-CellLine
cells	O
undergo	O
a	O
p53	B-Gene
-	O
dependent	O
upregulation	O
of	O
OCT4A	B-Gene
and	O
p21Cip1	B-Gene
(	O
governing	O
self	O
-	O
renewal	O
and	O
regulating	O
cell	O
cycle	O
inhibition	O
and	O
senescence	O
,	O
respectively	O
)	O
.	O
</ALL>	O

<ALL>	O
Here	O
we	O
report	O
further	O
detail	O
on	O
the	O
relationship	O
between	O
these	O
and	O
other	O
critical	O
cell	O
-	O
fate	O
regulators	O
.	O
</ALL>	O

<ALL>	O
PA	B-CellLine
-	I-CellLine
1	I-CellLine
cells	O
treated	O
with	O
ETO	B-Chemical
display	O
highly	O
heterogeneous	O
increases	O
in	O
OCT4A	B-Gene
and	O
p21Cip1	B-Gene
indicative	O
of	O
dis	O
-	O
adaptation	O
catastrophe	O
.	O
</ALL>	O

<ALL>	O
Silencing	O
OCT4A	B-Gene
suppresses	O
p21Cip1	B-Gene
,	O
changes	O
cell	O
cycle	O
regulation	O
and	O
subsequently	O
suppresses	O
terminal	O
senescence	O
;	O
p21Cip1	B-Gene
-	O
silencing	O
did	O
not	O
affect	O
OCT4A	B-Gene
expression	O
or	O
cellular	O
phenotype	O
.	O
</ALL>	O

<ALL>	O
SOX2	B-Gene
and	O
NANOG	B-Gene
expression	O
did	O
not	O
change	O
following	O
ETO	B-Chemical
treatment	O
suggesting	O
a	O
dissociation	O
of	O
OCT4A	B-Gene
from	O
its	O
pluripotency	O
function	O
.	O
</ALL>	O

<ALL>	O
Instead	O
,	O
ETO	B-Chemical
-	O
induced	O
OCT4A	B-Gene
was	O
concomitant	O
with	O
activation	O
of	O
AMPK	B-Gene
,	O
a	O
key	O
component	O
of	O
metabolic	O
stress	O
and	O
autophagy	O
regulation	O
.	O
</ALL>	O

<ALL>	O
p16ink4a	B-Gene
,	O
the	O
inducer	O
of	O
terminal	O
senescence	O
,	O
underwent	O
autophagic	O
sequestration	O
in	O
the	O
cytoplasm	O
of	O
ETO	B-Chemical
-	O
treated	O
cells	O
,	O
allowing	O
alternative	O
cell	O
fates	O
.	O
</ALL>	O

<ALL>	O
Accordingly	O
,	O
failure	O
of	O
autophagy	O
was	O
accompanied	O
by	O
an	O
accumulation	O
of	O
p16ink4a	B-Gene
,	O
nuclear	O
disintegration	O
,	O
and	O
loss	O
of	O
cell	O
recovery	O
.	O
</ALL>	O

<ALL>	O
Together	O
,	O
these	O
findings	O
imply	O
that	O
OCT4A	B-Gene
induction	O
following	O
DNA	O
damage	O
in	O
PA	B-CellLine
-	I-CellLine
1	I-CellLine
cells	O
,	O
performs	O
a	O
cell	O
stress	O
,	O
rather	O
than	O
self	O
-	O
renewal	O
,	O
function	O
by	O
moderating	O
the	O
expression	O
of	O
p21Cip1	B-Gene
,	O
which	O
alongside	O
AMPK	B-Gene
helps	O
to	O
then	O
regulate	O
autophagy	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
this	O
data	O
indicates	O
that	O
exhaustion	O
of	O
autophagy	O
,	O
through	O
persistent	O
DNA	O
damage	O
,	O
is	O
the	O
cause	O
of	O
terminal	O
cellular	O
senescence	O
.	O
</ALL>	O

<ALL>	O
Putative	O
Prostate	B-Disease
Cancer	I-Disease
Risk	O
SNP	O
in	O
an	O
Androgen	B-Gene
Receptor	I-Gene
-	O
Binding	O
Site	O
of	O
the	O
Melanophilin	B-Gene
Gene	O
Illustrates	O
Enrichment	O
of	O
Risk	O
SNPs	O
in	O
Androgen	B-Gene
Receptor	I-Gene
Target	O
Sites	O
.	O
</ALL>	O

<ALL>	O
Genome	O
-	O
wide	O
association	O
studies	O
have	O
identified	O
genomic	O
loci	O
,	O
whose	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
predispose	O
to	O
prostate	B-Disease
cancer	I-Disease
(	O
PCa	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
mechanisms	O
of	O
most	O
of	O
these	O
variants	O
are	O
largely	O
unknown	O
.	O
</ALL>	O

<ALL>	O
We	O
integrated	O
chromatin	O
-	O
immunoprecipitation	O
-	O
coupled	O
sequencing	O
and	O
microarray	O
expression	O
profiling	O
in	O
TMPRSS2	B-Gene
-	O
ERG	B-Gene
gene	O
rearrangement	O
positive	O
DUCaP	B-CellLine
cells	O
with	O
the	O
GWAS	O
PCa	B-Disease
risk	O
SNPs	O
catalog	O
to	O
identify	O
disease	O
susceptibility	O
SNPs	O
localized	O
within	O
functional	O
androgen	B-Gene
receptor	I-Gene
-	O
binding	O
sites	O
(	O
AR	B-Gene
BSs	O
)	O
.	O
</ALL>	O

<ALL>	O
Among	O
the	O
48	O
GWAS	O
index	O
risk	O
SNPs	O
and	O
3,917	O
linked	O
SNPs	O
,	O
80	O
were	O
found	O
located	O
in	O
AR	B-Gene
BSs	O
.	O
</ALL>	O

<ALL>	O
Of	O
these	O
,	O
rs11891426	B-Variant
:	O
T	B-Variant
>	I-Variant
G	I-Variant
in	O
an	O
intron	O
of	O
the	O
melanophilin	B-Gene
gene	O
(	O
MLPH	B-Gene
)	O
was	O
within	O
a	O
novel	O
putative	O
auxiliary	O
AR	B-Gene
-	O
binding	O
motif	O
,	O
which	O
is	O
enriched	O
in	O
the	O
neighborhood	O
of	O
canonical	O
androgen	B-Chemical
-	O
responsive	O
elements	O
.	O
</ALL>	O

<ALL>	O
T	B-Variant
>	I-Variant
G	I-Variant
exchange	O
attenuated	O
the	O
transcriptional	O
activity	O
of	O
the	O
AR	B-Gene
BS	O
in	O
an	O
AR	B-Gene
reporter	O
gene	O
assay	O
.	O
</ALL>	O

<ALL>	O
The	O
expression	O
of	O
MLPH	B-Gene
in	O
primary	O
prostate	B-Disease
tumors	I-Disease
was	O
significantly	O
lower	O
in	O
those	O
with	O
the	O
G	O
compared	O
with	O
the	O
T	O
allele	O
and	O
correlated	O
significantly	O
with	O
AR	B-Gene
protein	O
.	O
</ALL>	O

<ALL>	O
Higher	O
melanophilin	B-Gene
level	O
in	O
prostate	O
tissue	O
of	O
patients	B-Species
with	O
a	O
favorable	O
PCa	B-Disease
risk	O
profile	O
points	O
out	O
a	O
tumor	B-Disease
-	O
suppressive	O
effect	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
unravel	O
a	O
hidden	O
link	O
between	O
AR	B-Gene
and	O
a	O
functional	O
putative	O
PCa	B-Disease
risk	O
SNP	O
,	O
whose	O
allele	O
alteration	O
affects	O
androgen	B-Chemical
regulation	O
of	O
its	O
host	O
gene	O
MLPH	B-Gene
.	O
</ALL>	O

<ALL>	O
Voltage	B-Gene
-	I-Gene
Dependent	I-Gene
Anion	I-Gene
Channel	I-Gene
1	I-Gene
(	O
VDAC1	B-Gene
)	O
Participates	O
the	O
Apoptosis	O
of	O
the	O
Mitochondrial	B-Disease
Dysfunction	I-Disease
in	O
Desminopathy	B-Disease
.	O
</ALL>	O

<ALL>	O
Desminopathies	B-Disease
caused	O
by	O
the	O
mutation	O
in	O
the	O
gene	O
coding	O
for	O
desmin	B-Gene
are	O
genetically	O
protein	O
aggregation	O
myopathies	B-Disease
.	O
</ALL>	O

<ALL>	O
Mitochondrial	B-Disease
dysfunction	I-Disease
is	O
one	O
of	O
pathological	O
changes	O
in	O
the	O
desminopathies	B-Disease
at	O
the	O
earliest	O
stage	O
.	O
</ALL>	O

<ALL>	O
The	O
molecular	O
mechanisms	O
of	O
mitochondria	B-Disease
dysfunction	I-Disease
in	O
desminopathies	B-Disease
remain	O
exclusive	O
.	O
</ALL>	O

<ALL>	O
VDAC1	B-Gene
regulates	O
mitochondrial	O
uptake	O
across	O
the	O
outer	O
membrane	O
and	O
mitochondrial	O
outer	O
membrane	O
permeabilization	O
(	O
MOMP	O
)	O
.	O
</ALL>	O

<ALL>	O
Relationships	O
between	O
desminopathies	B-Disease
and	O
Voltage	B-Gene
-	I-Gene
dependent	I-Gene
anion	I-Gene
channel	I-Gene
1	I-Gene
(	O
VDAC1	B-Gene
)	O
remain	O
unclear	O
.	O
</ALL>	O

<ALL>	O
Here	O
we	O
successfully	O
constructed	O
the	O
desminopathy	B-Disease
rat	B-Species
model	O
,	O
evaluated	O
with	O
conventional	O
stains	O
,	O
containing	O
hematoxylin	O
and	O
eosin	O
(	O
HE	O
)	O
,	O
Gomori	O
Trichrome	O
(	O
MGT	O
)	O
,	O
(	O
PAS	O
)	O
,	O
red	O
oil	O
(	O
ORO	O
)	O
,	O
NADH	O
-	O
TR	O
,	O
SDH	O
staining	O
and	O
immunohistochemistry	O
.	O
</ALL>	O

<ALL>	O
Immunofluorescence	O
results	O
showed	O
that	O
VDAC1	B-Gene
was	O
accumulated	O
in	O
the	O
desmin	B-Gene
highly	O
stained	O
area	O
of	O
muscle	O
fibers	O
of	O
desminopathy	B-Disease
patients	B-Species
or	O
desminopathy	B-Disease
rat	B-Species
model	O
compared	O
to	O
the	O
normal	O
ones	O
.	O
</ALL>	O

<ALL>	O
Meanwhile	O
apoptosis	O
related	O
proteins	O
bax	B-Gene
and	O
ATF2	B-Gene
were	O
involved	O
in	O
desminopathy	B-Disease
patients	B-Species
and	O
desminopathy	B-Disease
rat	B-Species
model	O
,	O
but	O
not	O
bcl	B-Gene
-	I-Gene
2	I-Gene
,	O
bcl	B-Gene
-	I-Gene
xl	I-Gene
or	O
HK2	B-Gene
.	O
</ALL>	O

<ALL>	O
VDAC1	B-Gene
and	O
desmin	B-Gene
are	O
closely	O
relevant	O
in	O
the	O
tissue	O
splices	O
of	O
deminopathies	O
patients	B-Species
and	O
rats	B-Species
with	O
desminopathy	B-Disease
at	O
protein	O
lever	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
apoptotic	O
proteins	O
are	O
also	O
involved	O
in	O
the	O
desminopathies	B-Disease
,	O
like	O
bax	B-Gene
,	O
ATF2	B-Gene
,	O
but	O
not	O
bcl	B-Gene
-	I-Gene
2	I-Gene
,	O
bcl	B-Gene
-	I-Gene
xl	I-Gene
or	O
HK2	B-Gene
.	O
</ALL>	O

<ALL>	O
This	O
pathological	O
analysis	O
presents	O
the	O
correlation	O
between	O
VDAC1	B-Gene
and	O
desmin	B-Gene
,	O
and	O
apoptosis	O
related	O
proteins	O
are	O
correlated	O
in	O
the	O
desminopathy	B-Disease
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
we	O
provide	O
a	O
rat	B-Species
model	O
of	O
desminopathy	B-Disease
for	O
the	O
investigation	O
of	O
desmin	B-Gene
related	O
myopathy	B-Disease
.	O
</ALL>	O

<ALL>	O
Salidroside	B-Chemical
Ameliorates	O
Renal	B-Disease
Interstitial	I-Disease
Fibrosis	I-Disease
by	O
Inhibiting	O
the	O
TLR4	B-Gene
/	O
NF	B-Gene
-	I-Gene
kappaB	I-Gene
and	O
MAPK	B-Gene
Signaling	O
Pathways	O
.	O
</ALL>	O

<ALL>	O
Salidroside	B-Chemical
(	O
Sal	B-Chemical
)	O
is	O
an	O
active	O
ingredient	O
that	O
is	O
isolated	O
from	O
Rhodiola	B-Species
rosea	I-Species
,	O
which	O
has	O
been	O
reported	O
to	O
have	O
anti	O
-	O
inflammatory	B-Disease
activities	O
and	O
a	O
renal	O
protective	O
effect	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
role	O
of	O
Sal	B-Chemical
on	O
renal	B-Disease
fibrosis	I-Disease
has	O
not	O
yet	O
been	O
elucidated	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
the	O
purpose	O
of	O
the	O
current	O
study	O
is	O
to	O
test	O
the	O
protective	O
effects	O
of	O
Sal	B-Chemical
against	O
renal	B-Disease
interstitial	I-Disease
fibrosis	I-Disease
(	O
RIF	B-Disease
)	O
,	O
and	O
to	O
explore	O
the	O
underlying	O
mechanisms	O
using	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
models	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
establish	O
the	O
unilateral	B-Disease
ureteric	I-Disease
obstruction	I-Disease
(	O
UUO	B-Disease
)	O
or	O
folic	B-Chemical
acid	I-Chemical
(	O
FA	B-Chemical
)	O
-	O
induced	O
mice	B-Species
renal	B-Disease
interstitial	I-Disease
fibrosis	I-Disease
in	O
vivo	O
and	O
the	O
transforming	B-Gene
growth	I-Gene
factor	I-Gene
(	I-Gene
TGF	I-Gene
)	I-Gene
-	I-Gene
beta1	I-Gene
-	O
stimulated	O
human	B-Species
proximal	O
tubular	O
epithelial	O
cell	O
(	O
HK	B-CellLine
-	I-CellLine
2	I-CellLine
)	O
model	O
in	O
vitro	O
.	O
</ALL>	O

<ALL>	O
The	O
levels	O
of	O
kidney	O
functional	O
parameters	O
and	O
inflammatory	B-Disease
cytokines	O
in	O
serum	O
are	O
examined	O
.	O
</ALL>	O

<ALL>	O
The	O
degree	O
of	O
renal	B-Disease
damage	I-Disease
and	O
fibrosis	B-Disease
is	O
determined	O
by	O
histological	O
assessment	O
.	O
</ALL>	O

<ALL>	O
Immunohistochemistry	O
and	O
western	O
blotting	O
are	O
used	O
to	O
determine	O
the	O
mechanisms	O
of	O
Sal	B-Chemical
against	O
RIF	B-Disease
.	O
</ALL>	O

<ALL>	O
Our	O
results	O
show	O
that	O
treatment	O
with	O
Sal	B-Chemical
can	O
ameliorate	O
tubular	B-Disease
injury	I-Disease
and	O
deposition	O
of	O
the	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
components	O
(	O
including	O
collagen	B-Gene
SH	I-Gene
and	O
collagen	B-Gene
I	I-Gene
)	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
Sal	B-Chemical
administration	O
significantly	O
suppresses	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
,	O
as	O
evidenced	O
by	O
a	O
decreased	O
expression	O
of	O
alpha	B-Gene
-	I-Gene
SMA	I-Gene
,	O
vimentin	B-Gene
,	O
TGF	B-Gene
-	I-Gene
beta1	I-Gene
,	O
snail	B-Gene
,	O
slug	B-Gene
,	O
and	O
a	O
largely	O
restored	O
expression	O
of	O
E	B-Gene
-	I-Gene
cadherin	I-Gene
.	O
</ALL>	O

<ALL>	O
Additionally	O
,	O
Sal	B-Chemical
also	O
reduces	O
the	O
levels	O
of	O
serum	O
biochemical	O
markers	O
(	O
serum	O
creatinine	B-Chemical
,	O
Scr	O
;	O
blood	O
urea	B-Chemical
nitrogen	B-Chemical
,	O
BUN	O
;	O
and	O
uric	B-Chemical
acid	I-Chemical
,	O
UA	B-Chemical
)	O
and	O
decreases	O
the	O
release	O
of	O
inflammatory	B-Disease
cytokines	O
(	O
IL	B-Gene
-	I-Gene
1beta	I-Gene
,	O
IL	B-Gene
-	I-Gene
6	I-Gene
,	O
TNF	B-Gene
-	I-Gene
alpha	I-Gene
)	O
.	O
</ALL>	O

<ALL>	O
Further	O
study	O
revealed	O
that	O
the	O
effect	O
of	O
Sal	B-Chemical
on	O
renal	B-Disease
interstitial	I-Disease
fibrosis	I-Disease
is	O
associated	O
with	O
the	O
lower	O
expression	O
of	O
TLR4	B-Gene
,	O
p	O
-	O
IkappaBalpha	B-Gene
,	O
p	O
-	O
NF	B-Gene
-	I-Gene
kappaB	I-Gene
and	O
mitogen	B-Gene
-	I-Gene
activated	I-Gene
protein	I-Gene
kinases	I-Gene
(	O
MAPK	B-Gene
)	O
,	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
Sal	B-Chemical
treatment	O
improves	O
kidney	O
function	O
,	O
ameliorates	O
the	O
deposition	O
of	O
the	O
ECM	O
components	O
and	O
relieves	O
the	O
protein	O
levels	O
of	O
EMT	O
markers	O
in	O
mouse	B-Species
kidneys	O
and	O
HK	B-CellLine
-	I-CellLine
2	I-CellLine
cells	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
Sal	B-Chemical
treatment	O
significantly	O
decreases	O
the	O
release	O
of	O
inflammatory	B-Disease
cytokines	O
and	O
inhibits	O
the	O
TLR4	B-Gene
/	O
NF	B-Gene
-	I-Gene
kappaB	I-Gene
and	O
MAPK	B-Gene
signaling	O
pathways	O
.	O
</ALL>	O

<ALL>	O
Collectively	O
,	O
these	O
results	O
suggest	O
that	O
the	O
administration	O
of	O
Sal	B-Chemical
could	O
be	O
a	O
novel	O
therapeutic	O
strategy	O
in	O
treating	O
renal	B-Disease
fibrosis	I-Disease
.	O
</ALL>	O

<ALL>	O
Two	O
novel	O
mutations	O
,	O
L490R	B-Variant
and	O
V561X	B-Variant
,	O
of	O
the	O
transferrin	B-Gene
receptor	I-Gene
2	I-Gene
gene	O
in	O
Japanese	O
patients	B-Species
with	O
hemochromatosis	B-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
The	O
low	O
prevalence	O
of	O
the	O
C282Y	B-Variant
mutation	O
of	O
the	O
HFE	B-Gene
gene	O
in	O
Japan	O
means	O
that	O
the	O
genetic	O
background	O
of	O
hemochromatosis	B-Disease
in	O
Japanese	O
patients	B-Species
remains	O
unclear	O
.	O
</ALL>	O

<ALL>	O
In	O
a	O
previous	O
report	O
,	O
we	O
showed	O
that	O
3	O
patients	B-Species
from	O
one	O
family	O
had	O
an	O
AVAQ	B-Variant
594	I-Variant
-	I-Variant
597	I-Variant
deletion	I-Variant
of	O
the	O
transferrin	B-Gene
receptor	I-Gene
(	O
TfR2	B-Gene
)	O
gene	O
.	O
</ALL>	O

<ALL>	O
This	O
suggests	O
that	O
the	O
TfR2	B-Gene
gene	O
is	O
involved	O
in	O
hemochromatosis	B-Disease
in	O
Japanese	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
DESIGN	O
AND	O
METHODS	O
:	O
Nine	O
patients	B-Species
clinically	O
diagnosed	O
with	O
hemochromatosis	B-Disease
were	O
included	O
in	O
the	O
study	O
.	O
</ALL>	O

<ALL>	O
DNA	O
was	O
extracted	O
from	O
whole	O
blood	O
samples	O
collected	O
with	O
informed	O
consent	O
.	O
</ALL>	O

<ALL>	O
The	O
HFE	B-Gene
and	O
TfR2	B-Gene
genes	O
were	O
analyzed	O
by	O
sequencing	O
the	O
coding	O
region	O
and	O
splicing	O
sites	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
There	O
were	O
no	O
mutations	O
in	O
the	O
HFE	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
TfR2	B-Gene
gene	O
,	O
2	O
novel	O
mutations	O
,	O
1469	B-Variant
T	I-Variant
-	I-Variant
>	I-Variant
G	I-Variant
(	O
L490R	B-Variant
)	O
and	O
1665delC	B-Variant
(	O
V561X	B-Variant
)	O
,	O
were	O
found	O
in	O
2	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
A	O
known	O
variation	O
,	O
714C	B-Variant
-	O
>	O
(	O
I238	B-Variant
M	I-Variant
)	O
,	O
was	O
also	O
found	O
in	O
the	O
patient	B-Species
with	O
L490R	B-Variant
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
homozygous	O
for	O
both	O
L490R	B-Variant
and	O
I238	B-Variant
M	I-Variant
presented	O
with	O
a	O
mild	O
manifestation	O
of	O
hemochromatosis	B-Disease
at	O
the	O
age	O
of	O
41	O
years	O
.	O
</ALL>	O

<ALL>	O
His	O
liver	O
was	O
cirrhotic	B-Disease
with	O
parenchymal	O
iron	B-Chemical
deposits	O
and	O
the	O
result	O
of	O
a	O
glucose	B-Chemical
tolerance	O
test	O
was	O
compatible	O
with	O
diabetes	B-Disease
mellitus	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
homozygous	O
for	O
V561X	B-Variant
had	O
severe	O
iron	B-Disease
overload	I-Disease
with	O
the	O
triad	O
of	O
cirrhosis	B-Disease
,	O
diabetes	B-Disease
mellitus	I-Disease
and	O
skin	B-Disease
pigmentation	I-Disease
at	O
the	O
age	O
of	O
58	O
years	O
.	O
</ALL>	O

<ALL>	O
INTERPRETATION	O
AND	O
CONCLUSIONS	O
:	O
Taken	O
together	O
with	O
the	O
previous	O
report	O
,	O
5	O
of	O
our	O
12	O
patients	B-Species
with	O
hemochromatosis	B-Disease
manifesting	O
in	O
middle	O
age	O
had	O
mutations	O
in	O
the	O
TfR2	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
TfR2	B-Gene
plays	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
hemochromatosis	B-Disease
in	O
Japan	O
.	O
</ALL>	O

<ALL>	O
Succinylcholine	B-Chemical
-	O
induced	O
masseter	B-Disease
muscle	I-Disease
rigidity	I-Disease
during	O
bronchoscopic	O
removal	O
of	O
a	O
tracheal	O
foreign	O
body	O
.	O
</ALL>	O

<ALL>	O
Masseter	B-Disease
muscle	I-Disease
rigidity	I-Disease
during	O
general	O
anesthesia	O
is	O
considered	O
an	O
early	O
warning	O
sign	O
of	O
a	O
possible	O
episode	O
of	O
malignant	B-Disease
hyperthermia	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
decision	O
whether	O
to	O
continue	O
or	O
discontinue	O
the	O
procedure	O
depends	O
on	O
the	O
urgency	O
of	O
the	O
surgery	O
and	O
severity	O
of	O
masseter	B-Disease
muscle	I-Disease
rigidity	I-Disease
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
describe	O
a	O
case	O
of	O
severe	O
masseter	B-Disease
muscle	I-Disease
rigidity	I-Disease
(	O
jaw	B-Disease
of	I-Disease
steel	I-Disease
)	O
after	O
succinylcholine	B-Chemical
(	O
Sch	B-Chemical
)	O
administration	O
during	O
general	O
anesthetic	O
management	O
for	O
rigid	O
bronchoscopic	O
removal	O
of	O
a	O
tracheal	O
foreign	O
body	O
.	O
</ALL>	O

<ALL>	O
Anesthesia	O
was	O
continued	O
uneventfully	O
with	O
propofol	B-Chemical
infusion	O
while	O
all	O
facilities	O
were	O
available	O
to	O
detect	O
and	O
treat	O
malignant	B-Disease
hyperthermia	I-Disease
.	O
</ALL>	O

<ALL>	O
Identities	O
,	O
frequencies	O
and	O
origins	O
of	O
TMC1	B-Gene
mutations	O
causing	O
DFNB7	B-Disease
/	I-Disease
B11	I-Disease
deafness	I-Disease
in	O
Pakistan	O
.	O
</ALL>	O

<ALL>	O
Non	B-Disease
-	I-Disease
syndromic	I-Disease
deafness	I-Disease
is	O
genetically	O
heterogeneous	O
.	O
</ALL>	O

<ALL>	O
We	O
previously	O
reported	O
that	O
mutations	O
of	O
transmembrane	B-Gene
channel	I-Gene
-	I-Gene
like	I-Gene
gene	I-Gene
1	I-Gene
(	O
TMC1	B-Gene
)	O
cause	O
non	B-Disease
-	I-Disease
syndromic	I-Disease
recessive	I-Disease
deafness	I-Disease
at	O
the	O
DFNB7	B-Gene
/	I-Gene
B11	I-Gene
locus	O
on	O
chromosome	O
9q13	O
-	O
q21	O
in	O
nine	O
Pakistani	O
families	O
.	O
</ALL>	O

<ALL>	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
define	O
the	O
identities	O
,	O
origins	O
and	O
frequencies	O
of	O
TMC1	B-Gene
mutations	O
in	O
an	O
expanded	O
cohort	O
of	O
557	O
large	O
Pakistani	O
families	O
segregating	O
recessive	B-Disease
deafness	I-Disease
.	O
</ALL>	O

<ALL>	O
We	O
screened	O
affected	O
family	O
members	O
for	O
homozygosity	O
at	O
short	O
-	O
tandem	O
repeats	O
flanking	O
known	O
autosomal	B-Disease
recessive	I-Disease
(	I-Disease
DFNB	I-Disease
)	I-Disease
deafness	I-Disease
loci	O
,	O
followed	O
by	O
TMC1	B-Gene
sequence	O
analysis	O
in	O
families	O
segregating	O
deafness	B-Disease
linked	O
to	O
DFNB7	B-Gene
/	I-Gene
B11	I-Gene
.	O
</ALL>	O

<ALL>	O
We	O
identified	O
10	O
new	O
families	O
segregating	O
DFNB7	B-Disease
/	I-Disease
B11	I-Disease
deafness	I-Disease
and	O
TMC1	B-Gene
mutations	O
,	O
including	O
three	O
novel	O
alleles	O
.	O
</ALL>	O

<ALL>	O
Overall	O
,	O
9	O
different	O
TMC1	B-Gene
mutations	O
account	O
for	O
deafness	B-Disease
in	O
19	O
(	O
3.4	O
%	O
)	O
of	O
the	O
557	O
Pakistani	O
families	O
.	O
</ALL>	O

<ALL>	O
A	O
single	O
mutation	O
,	O
p	B-Variant
.	I-Variant
R34X	I-Variant
,	O
causes	O
deafness	B-Disease
in	O
10	O
(	O
1.8	O
%	O
)	O
of	O
the	O
families	O
.	O
</ALL>	O

<ALL>	O
Genotype	O
analysis	O
of	O
p	B-Variant
.	I-Variant
R34X	I-Variant
-	O
linked	O
markers	O
indicates	O
that	O
it	O
arose	O
from	O
a	O
common	O
founder	O
.	O
</ALL>	O

<ALL>	O
We	O
also	O
detected	O
p	B-Variant
.	I-Variant
R34X	I-Variant
among	O
normal	O
control	O
samples	O
of	O
African	O
-	O
American	O
and	O
northern	O
European	O
origins	O
,	O
raising	O
the	O
possibility	O
that	O
p	B-Variant
.	I-Variant
R34X	I-Variant
and	O
other	O
mutations	O
of	O
TMC1	B-Gene
are	O
prevalent	O
contributors	O
to	O
the	O
genetic	O
load	O
of	O
deafness	B-Disease
across	O
a	O
variety	O
of	O
populations	O
and	O
continents	O
.	O
</ALL>	O

<ALL>	O
Aryl	B-Gene
hydrocarbon	I-Gene
receptor	I-Gene
interacting	I-Gene
protein	I-Gene
(	O
AIP	B-Gene
)	O
gene	O
mutation	O
analysis	O
in	O
children	O
and	O
adolescents	O
with	O
sporadic	O
pituitary	B-Disease
adenomas	I-Disease
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
Pituitary	B-Disease
adenomas	I-Disease
occur	O
rarely	O
in	O
childhood	O
and	O
adolescence	O
.	O
</ALL>	O

<ALL>	O
Pituitary	B-Disease
adenoma	I-Disease
predisposition	O
(	O
PAP	O
)	O
has	O
been	O
recently	O
associated	O
with	O
germline	O
mutations	O
in	O
the	O
aryl	B-Gene
hydrocarbon	I-Gene
receptor	I-Gene
interacting	I-Gene
protein	I-Gene
(	O
AIP	B-Gene
)	O
gene	O
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
examine	O
the	O
proportion	O
of	O
germline	O
AIP	B-Gene
mutations	O
in	O
apparently	O
sporadic	O
paediatric	O
pituitary	B-Disease
adenomas	I-Disease
.	O
</ALL>	O

<ALL>	O
DESIGN	O
:	O
Genomic	O
DNA	O
was	O
analysed	O
for	O
mutations	O
in	O
the	O
AIP	B-Gene
gene	O
,	O
by	O
PCR	O
amplification	O
and	O
direct	O
sequencing	O
.	O
</ALL>	O

<ALL>	O
PATIENTS	B-Species
:	O
A	O
population	O
-	O
based	O
cohort	O
consisting	O
of	O
36	O
apparently	O
sporadic	O
paediatric	O
pituitary	B-Disease
adenoma	I-Disease
patients	B-Species
,	O
referred	O
to	O
two	O
medical	O
centres	O
in	O
Italy	O
,	O
was	O
included	O
in	O
the	O
study	O
.	O
</ALL>	O

<ALL>	O
Patients	B-Species
were	O
either	O
less	O
than	O
18	O
years	O
at	O
diagnosis	O
,	O
or	O
showed	O
clinical	O
evidence	O
of	O
adenoma	B-Disease
development	O
before	O
the	O
age	O
of	O
18	O
years	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
A	O
heterozygous	O
in	O
-	O
frame	O
deletion	O
Y248del	B-Variant
(	O
c.742	B-Variant
_	I-Variant
744delTAC	I-Variant
)	O
was	O
identified	O
in	O
one	O
GH	B-Disease
-	I-Disease
secreting	I-Disease
adenoma	I-Disease
patient	B-Species
.	O
</ALL>	O

<ALL>	O
Loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
analysis	O
of	O
tumour	B-Disease
DNA	O
revealed	O
the	O
loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
.	O
</ALL>	O

<ALL>	O
First	O
degree	O
relatives	O
carrying	O
the	O
mutation	O
were	O
clinically	O
unaffected	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
While	O
mutations	O
were	O
absent	O
in	O
non	O
-	O
GH	B-Disease
-	I-Disease
secreting	I-Disease
adenoma	I-Disease
patients	B-Species
,	O
germline	O
AIP	B-Gene
mutations	O
can	O
be	O
found	O
in	O
children	O
and	O
adolescents	O
with	O
GH	B-Disease
-	I-Disease
secreting	I-Disease
tumours	I-Disease
,	O
even	O
in	O
the	O
absence	O
of	O
family	O
history	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
reports	O
the	O
AIP	B-Gene
mutation	O
analysis	O
results	O
on	O
patients	B-Species
of	O
a	O
single	O
ethnic	O
origin	O
.	O
</ALL>	O

<ALL>	O
Clearly	O
,	O
further	O
studies	O
are	O
needed	O
to	O
improve	O
our	O
knowledge	O
on	O
the	O
role	O
of	O
AIP	B-Gene
in	O
paediatric	O
pituitary	B-Disease
adenomas	I-Disease
.	O
</ALL>	O

<ALL>	O
Curcumin	B-Chemical
decreases	O
specificity	B-Gene
protein	I-Gene
expression	O
in	O
bladder	B-Disease
cancer	I-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
Curcumin	B-Chemical
is	O
the	O
active	O
component	O
of	O
tumeric	O
,	O
and	O
this	O
polyphenolic	O
compound	O
has	O
been	O
extensively	O
investigated	O
as	O
an	O
anticancer	O
drug	O
that	O
modulates	O
multiple	O
pathways	O
and	O
genes	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
10	O
to	O
25	O
micromol	O
/	O
L	O
curcumin	B-Chemical
inhibited	O
253JB	B-CellLine
-	I-CellLine
V	I-CellLine
and	O
KU7	B-CellLine
bladder	B-Disease
cancer	I-Disease
cell	O
growth	O
,	O
and	O
this	O
was	O
accompanied	O
by	O
induction	O
of	O
apoptosis	O
and	O
decreased	O
expression	O
of	O
the	O
proapoptotic	B-Gene
protein	I-Gene
survivin	B-Gene
and	O
the	O
angiogenic	B-Gene
proteins	I-Gene
vascular	B-Gene
endothelial	I-Gene
growth	I-Gene
factor	I-Gene
(	O
VEGF	B-Gene
)	O
and	O
VEGF	B-Gene
receptor	I-Gene
1	I-Gene
(	O
VEGFR1	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
Because	O
expression	O
of	O
survivin	B-Gene
,	O
VEGF	B-Gene
,	O
and	O
VEGFR1	B-Gene
are	O
dependent	O
on	O
specificity	B-Gene
protein	I-Gene
(	I-Gene
Sp	I-Gene
)	I-Gene
transcription	I-Gene
factors	I-Gene
,	O
we	O
also	O
investigated	O
the	O
effects	O
of	O
curcumin	B-Chemical
on	O
Sp	B-Gene
protein	O
expression	O
as	O
an	O
underlying	O
mechanism	O
for	O
the	O
apoptotic	O
and	O
antiangiogenic	O
activity	O
of	O
this	O
compound	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
show	O
that	O
curcumin	B-Chemical
induced	O
proteasome	B-Gene
-	O
dependent	O
down	O
-	O
regulation	O
of	O
Sp1	B-Gene
,	O
Sp3	B-Gene
,	O
and	O
Sp4	B-Gene
in	O
253JB	B-CellLine
-	I-CellLine
V	I-CellLine
and	O
KU7	B-CellLine
cells	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
using	O
RNA	O
interference	O
with	O
small	O
inhibitory	O
RNAs	O
for	O
Sp1	B-Gene
,	O
Sp3	B-Gene
,	O
and	O
Sp4	B-Gene
,	O
we	O
observed	O
that	O
curcumin	B-Chemical
-	O
dependent	O
inhibition	O
of	O
nuclear	B-Gene
factor	I-Gene
kappaB	I-Gene
(	O
NF	B-Gene
-	I-Gene
kappaB	I-Gene
)	O
-	O
dependent	O
genes	O
,	O
such	O
as	O
bcl	B-Gene
-	I-Gene
2	I-Gene
,	O
survivin	B-Gene
,	O
and	O
cyclin	B-Gene
D1	I-Gene
,	O
was	O
also	O
due	O
,	O
in	O
part	O
,	O
to	O
loss	O
of	O
Sp	B-Gene
proteins	O
.	O
</ALL>	O

<ALL>	O
Curcumin	B-Chemical
also	O
decreased	O
bladder	B-Disease
tumor	I-Disease
growth	O
in	O
athymic	O
nude	O
mice	B-Species
bearing	O
KU7	B-CellLine
cells	O
as	O
xenografts	O
and	O
this	O
was	O
accompanied	O
by	O
decreased	O
Sp1	B-Gene
,	O
Sp3	B-Gene
,	O
and	O
Sp4	B-Gene
protein	O
levels	O
in	O
tumors	B-Disease
.	O
</ALL>	O

<ALL>	O
These	O
results	O
show	O
for	O
the	O
first	O
time	O
that	O
one	O
of	O
the	O
underlying	O
mechanisms	O
of	O
action	O
of	O
curcumin	B-Chemical
as	O
a	O
cancer	B-Disease
chemotherapeutic	O
agent	O
is	O
due	O
,	O
in	O
part	O
,	O
to	O
decreased	O
expression	O
of	O
Sp	B-Gene
transcription	I-Gene
factors	I-Gene
in	O
bladder	B-Disease
cancer	I-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
H3	B-Gene
histamine	I-Gene
receptor	I-Gene
-	O
mediated	O
activation	O
of	O
protein	B-Gene
kinase	I-Gene
Calpha	I-Gene
inhibits	O
the	O
growth	O
of	O
cholangiocarcinoma	B-Disease
in	O
vitro	O
and	O
in	O
vivo	O
.	O
</ALL>	O

<ALL>	O
Histamine	B-Chemical
regulates	O
functions	O
via	O
four	O
receptors	O
(	O
HRH1	B-Gene
,	O
HRH2	B-Gene
,	O
HRH3	B-Gene
,	O
and	O
HRH4	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
The	O
d	B-Chemical
-	I-Chemical
myo	I-Chemical
-	I-Chemical
inositol	I-Chemical
1,4,5	I-Chemical
-	I-Chemical
trisphosphate	I-Chemical
(	O
IP	B-Chemical
(	I-Chemical
3	I-Chemical
)	I-Chemical
)	O
/	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+	I-Chemical
)	I-Chemical
/	O
protein	B-Gene
kinase	I-Gene
C	I-Gene
(	O
PKC	B-Gene
)	O
/	O
mitogen	B-Gene
-	I-Gene
activated	I-Gene
protein	I-Gene
kinase	I-Gene
pathway	O
regulates	O
cholangiocarcinoma	B-Disease
growth	O
.	O
</ALL>	O

<ALL>	O
We	O
evaluated	O
the	O
role	O
of	O
HRH3	B-Gene
in	O
the	O
regulation	O
of	O
cholangiocarcinoma	B-Disease
growth	O
.	O
</ALL>	O

<ALL>	O
Expression	O
of	O
HRH3	B-Gene
in	O
intrahepatic	O
and	O
extrahepatic	O
cell	O
lines	O
,	O
normal	O
cholangiocytes	O
,	O
and	O
human	B-Species
tissue	O
arrays	O
was	O
measured	O
.	O
</ALL>	O

<ALL>	O
In	O
Mz	B-CellLine
-	I-CellLine
ChA	I-CellLine
-	I-CellLine
1	I-CellLine
cells	O
stimulated	O
with	O
(	B-Chemical
R	I-Chemical
)	I-Chemical
-	I-Chemical
(	I-Chemical
alpha	I-Chemical
)	I-Chemical
-	I-Chemical
(	I-Chemical
-	I-Chemical
)	I-Chemical
-	I-Chemical
methylhistamine	I-Chemical
dihydrobromide	I-Chemical
(	O
RAMH	B-Chemical
)	O
,	O
we	O
measured	O
(	O
a	O
)	O
cell	O
growth	O
,	O
(	O
b	O
)	O
IP	B-Chemical
(	I-Chemical
3	I-Chemical
)	I-Chemical
and	O
cyclic	B-Chemical
AMP	I-Chemical
levels	O
,	O
and	O
(	O
c	O
)	O
phosphorylation	O
of	O
PKC	B-Gene
and	O
mitogen	B-Gene
-	I-Gene
activated	I-Gene
protein	I-Gene
kinase	I-Gene
isoforms	O
.	O
</ALL>	O

<ALL>	O
Localization	O
of	O
PKCalpha	B-Gene
was	O
visualized	O
by	O
immunofluorescence	O
in	O
cell	O
smears	O
and	O
immunoblotting	O
for	O
PKCalpha	B-Gene
in	O
cytosol	O
and	O
membrane	O
fractions	O
.	O
</ALL>	O

<ALL>	O
Following	O
knockdown	O
of	O
PKCalpha	B-Gene
,	O
Mz	B-CellLine
-	I-CellLine
ChA	I-CellLine
-	I-CellLine
1	I-CellLine
cells	O
were	O
stimulated	O
with	O
RAMH	B-Chemical
before	O
evaluating	O
cell	O
growth	O
and	O
extracellular	B-Gene
signal	I-Gene
-	I-Gene
regulated	I-Gene
kinase	I-Gene
(	I-Gene
ERK	I-Gene
)	I-Gene
-	I-Gene
1	I-Gene
/	I-Gene
2	I-Gene
phosphorylation	O
.	O
</ALL>	O

<ALL>	O
In	O
vivo	O
experiments	O
were	O
done	O
in	O
BALB	B-CellLine
/	I-CellLine
c	I-CellLine
nude	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Mice	B-Species
were	O
treated	O
with	O
saline	O
or	O
RAMH	B-Chemical
for	O
44	O
days	O
and	O
tumor	B-Disease
volume	O
was	O
measured	O
.	O
</ALL>	O

<ALL>	O
Tumors	B-Disease
were	O
excised	O
and	O
evaluated	O
for	O
proliferation	O
,	O
apoptosis	O
,	O
and	O
expression	O
of	O
PKCalpha	B-Gene
,	O
vascular	B-Gene
endothelial	I-Gene
growth	I-Gene
factor	I-Gene
(	I-Gene
VEGF	I-Gene
)	I-Gene
-	I-Gene
A	I-Gene
,	O
VEGF	B-Gene
-	I-Gene
C	I-Gene
,	O
VEGF	B-Gene
receptor	I-Gene
2	I-Gene
,	O
and	O
VEGF	B-Gene
receptor	I-Gene
3	I-Gene
.	O
</ALL>	O

<ALL>	O
HRH3	B-Gene
expression	O
was	O
found	O
in	O
all	O
cells	O
.	O
</ALL>	O

<ALL>	O
RAMH	B-Chemical
inhibited	O
the	O
growth	O
of	O
cholangiocarcinoma	B-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
RAMH	B-Chemical
increased	O
IP	B-Chemical
(	I-Chemical
3	I-Chemical
)	I-Chemical
levels	O
and	O
PKCalpha	B-Gene
phosphorylation	O
and	O
decreased	O
ERK1	B-Gene
/	I-Gene
2	I-Gene
phosphorylation	O
.	O
</ALL>	O

<ALL>	O
RAMH	B-Chemical
induced	O
a	O
shift	O
in	O
the	O
localization	O
of	O
PKCalpha	B-Gene
expression	O
from	O
the	O
cytosolic	O
domain	O
into	O
the	O
membrane	O
region	O
of	O
Mz	B-CellLine
-	I-CellLine
ChA	I-CellLine
-	I-CellLine
1	I-CellLine
cells	O
.	O
</ALL>	O

<ALL>	O
Silencing	O
of	O
PKCalpha	B-Gene
prevented	O
RAMH	B-Chemical
inhibition	O
of	O
Mz	B-CellLine
-	I-CellLine
ChA	I-CellLine
-	I-CellLine
1	I-CellLine
cell	O
growth	O
and	O
ablated	O
RAMH	B-Chemical
effects	O
on	O
ERK1	B-Gene
/	I-Gene
2	I-Gene
phosphorylation	O
.	O
</ALL>	O

<ALL>	O
In	O
vivo	O
,	O
RAMH	B-Chemical
decreased	O
tumor	B-Disease
growth	O
and	O
expression	O
of	O
VEGF	B-Gene
and	O
its	O
receptors	O
;	O
PKCalpha	B-Gene
expression	O
was	O
increased	O
.	O
</ALL>	O

<ALL>	O
RAMH	B-Chemical
inhibits	O
cholangiocarcinoma	B-Disease
growth	O
by	O
PKCalpha	B-Gene
-	O
dependent	O
ERK1	B-Gene
/	I-Gene
2	I-Gene
dephosphorylation	O
.	O
</ALL>	O

<ALL>	O
Modulation	O
of	O
PKCalpha	B-Gene
by	O
histamine	B-Gene
receptors	I-Gene
may	O
be	O
important	O
in	O
regulating	O
cholangiocarcinoma	B-Disease
growth	O
.	O
</ALL>	O

<ALL>	O
Promoter	O
insertion	O
/	O
deletion	O
in	O
the	O
IRF5	B-Gene
gene	O
is	O
highly	O
associated	O
with	O
susceptibility	O
to	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
in	O
distinct	O
populations	O
,	O
but	O
exerts	O
a	O
modest	O
effect	O
on	O
gene	O
expression	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
We	O
examined	O
the	O
genetic	O
association	O
of	O
the	O
promoter	O
insertion	O
/	O
deletion	O
(	O
indel	O
)	O
in	O
IRF5	B-Gene
gene	O
with	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
(	O
SLE	B-Disease
)	O
in	O
distinct	O
populations	O
and	O
assessed	O
its	O
role	O
in	O
gene	O
expression	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Four	O
IRF5	B-Gene
polymorphisms	O
were	O
genotyped	O
in	O
1488	O
SLE	B-Disease
patients	B-Species
and	O
1466	O
controls	O
.	O
</ALL>	O

<ALL>	O
Gene	O
expression	O
was	O
analyzed	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
using	O
RNA	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
promoter	O
indel	O
and	O
rs2070197	B-Variant
had	O
independent	O
genetic	O
effects	O
,	O
which	O
accounted	O
for	O
the	O
association	O
of	O
rs2004640	B-Variant
and	O
rs10954213	B-Variant
.	O
</ALL>	O

<ALL>	O
Gene	O
expression	O
analysis	O
revealed	O
that	O
rs10954213	B-Variant
exerted	O
the	O
greatest	O
influence	O
on	O
IRF5	B-Gene
transcript	O
levels	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
We	O
corroborated	O
the	O
association	O
of	O
the	O
promoter	O
indel	O
with	O
SLE	B-Disease
in	O
5	O
different	O
populations	O
and	O
revealed	O
that	O
rs10954213	B-Variant
is	O
the	O
main	O
single	O
-	O
nucleotide	O
polymorphism	O
responsible	O
for	O
altered	O
IRF5	B-Gene
expression	O
in	O
PBMC	O
.	O
</ALL>	O

<ALL>	O
Screening	O
and	O
cell	O
-	O
based	O
assessment	O
of	O
mutations	O
in	O
the	O
Aristaless	B-Gene
-	I-Gene
related	I-Gene
homeobox	I-Gene
(	O
ARX	B-Gene
)	O
gene	O
.	O
</ALL>	O

<ALL>	O
ARX	B-Gene
mutations	O
cause	O
a	O
diverse	O
spectrum	O
of	O
human	B-Species
disorders	O
,	O
ranging	O
from	O
severe	O
brain	B-Disease
and	I-Disease
genital	I-Disease
malformations	I-Disease
to	O
non	O
-	O
syndromic	O
intellectual	B-Disease
disability	I-Disease
(	O
ID	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
ARX	B-Gene
is	O
a	O
transcription	O
factor	O
with	O
multiple	O
domains	O
that	O
include	O
four	O
polyalanine	B-Chemical
(	O
pA	B-Chemical
)	O
tracts	O
,	O
the	O
first	O
two	O
of	O
which	O
are	O
frequently	O
expanded	O
by	O
mutations	O
.	O
</ALL>	O

<ALL>	O
We	O
progressively	O
screened	O
DNA	O
samples	O
from	O
613	O
individuals	O
with	O
ID	B-Disease
initially	O
for	O
the	O
most	O
frequent	O
ARX	B-Gene
mutations	O
(	O
c.304ins	B-Variant
(	I-Variant
GCG	I-Variant
)	I-Variant
(	I-Variant
7	I-Variant
)	I-Variant
'	O
expansion	O
'	O
of	O
pA1	O
and	O
c.429	B-Variant
_	I-Variant
452dup	I-Variant
'	O
dup24bp	B-Variant
'	O
of	O
pA2	O
)	O
.	O
</ALL>	O

<ALL>	O
Five	O
hundred	O
samples	O
without	O
pA1	O
or	O
pA2	O
mutations	O
had	O
the	O
entire	O
ARX	B-Gene
ORF	O
screened	O
by	O
single	O
stranded	O
polymorphism	O
conformation	O
(	O
SSCP	O
)	O
and	O
/	O
or	O
denaturing	O
high	O
pressure	O
liquid	O
chromatography	O
(	O
dHPLC	O
)	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Overall	O
,	O
eight	O
families	O
with	O
six	O
mutations	O
in	O
ARX	B-Gene
were	O
identified	O
(	O
1.31	O
%	O
)	O
:	O
five	O
duplication	O
mutations	O
in	O
pA2	O
(	O
0.82	O
%	O
)	O
with	O
three	O
new	O
clinical	O
reports	O
of	O
families	O
with	O
the	O
dup24bp	B-Variant
and	O
two	O
duplications	O
larger	O
than	O
the	O
dup24bp	B-Variant
mutation	O
discovered	O
(	O
dup27bp	B-Variant
,	O
dup33bp	B-Variant
)	O
;	O
and	O
three	O
point	O
mutations	O
(	O
0.6	O
%	O
)	O
,	O
including	O
one	O
novel	O
mutation	O
in	O
the	O
homeodomain	O
(	O
c.1074	B-Variant
G	I-Variant
>	I-Variant
T	I-Variant
)	O
.	O
</ALL>	O

<ALL>	O
Four	O
ultraconserved	O
regions	O
distal	O
to	O
ARX	B-Gene
(	O
uc466	O
-	O
469	O
)	O
were	O
also	O
screened	O
in	O
a	O
subset	O
of	O
94	O
patients	B-Species
,	O
with	O
three	O
unique	O
nucleotide	O
changes	O
identified	O
in	O
two	O
(	O
uc466	O
,	O
uc467	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
subcellular	O
localization	O
of	O
full	O
length	O
ARX	B-Gene
proteins	O
was	O
assessed	O
for	O
11	O
variants	O
.	O
</ALL>	O

<ALL>	O
Protein	O
mislocalization	O
increased	O
as	O
a	O
function	O
of	O
pA2	O
tract	O
length	O
and	O
phenotypic	O
severity	O
,	O
as	O
has	O
been	O
previously	O
suggested	O
for	O
pA1	O
.	O
</ALL>	O

<ALL>	O
Similarly	O
,	O
protein	O
mislocalization	O
of	O
the	O
homeodomain	O
mutations	O
also	O
correlated	O
with	O
clinical	O
severity	O
,	O
suggesting	O
an	O
emerging	O
genotype	O
vs	O
cellular	O
phenotype	O
correlation	O
.	O
</ALL>	O

<ALL>	O
Structural	O
mechanisms	O
determining	O
inhibition	O
of	O
the	O
collagen	B-Gene
receptor	I-Gene
DDR1	B-Gene
by	O
selective	O
and	O
multi	O
-	O
targeted	O
type	O
II	O
kinase	O
inhibitors	O
.	O
</ALL>	O

<ALL>	O
The	O
discoidin	B-Gene
domain	I-Gene
receptors	I-Gene
(	O
DDRs	B-Gene
)	O
,	O
DDR1	B-Gene
and	O
DDR2	B-Gene
,	O
form	O
a	O
unique	O
subfamily	O
of	O
receptor	B-Gene
tyrosine	I-Gene
kinases	I-Gene
that	O
are	O
activated	O
by	O
the	O
binding	O
of	O
triple	O
-	O
helical	O
collagen	B-Gene
.	O
</ALL>	O

<ALL>	O
Excessive	O
signaling	O
by	O
DDR1	B-Gene
and	O
DDR2	B-Gene
has	O
been	O
linked	O
to	O
the	O
progression	O
of	O
various	O
human	B-Species
diseases	O
,	O
including	O
fibrosis	B-Disease
,	O
atherosclerosis	B-Disease
and	O
cancer	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
report	O
the	O
inhibition	O
of	O
these	O
unusual	O
receptor	B-Gene
tyrosine	I-Gene
kinases	I-Gene
by	O
the	O
multi	O
-	O
targeted	O
cancer	B-Disease
drugs	O
imatinib	B-Chemical
and	O
ponatinib	B-Chemical
,	O
as	O
well	O
as	O
the	O
selective	O
type	O
II	O
inhibitor	O
DDR1	B-Chemical
-	I-Chemical
IN	I-Chemical
-	I-Chemical
1	I-Chemical
.	O
</ALL>	O

<ALL>	O
Ponatinib	B-Chemical
is	O
identified	O
as	O
the	O
more	O
potent	O
molecule	O
,	O
which	O
inhibits	O
DDR1	B-Gene
and	O
DDR2	B-Gene
with	O
an	O
IC50	O
of	O
9nM.	O
Co	O
-	O
crystal	O
structures	O
of	O
human	B-Species
DDR1	B-Gene
reveal	O
a	O
DFG	B-Chemical
-	O
out	O
conformation	O
(	O
DFG	B-Chemical
,	O
Asp	B-Chemical
-	I-Chemical
Phe	I-Chemical
-	I-Chemical
Gly	I-Chemical
)	O
of	O
the	O
kinase	O
domain	O
that	O
is	O
stabilized	O
by	O
an	O
unusual	O
salt	O
bridge	O
between	O
the	O
activation	O
loop	O
and	O
aD	O
helix	O
.	O
</ALL>	O

<ALL>	O
Differences	O
to	O
Abelson	B-Gene
kinase	I-Gene
(	O
ABL	B-Gene
)	O
are	O
observed	O
in	O
the	O
DDR1	B-Gene
P	O
-	O
loop	O
,	O
where	O
a	O
b	O
-	O
hairpin	O
replaces	O
the	O
cage	O
-	O
like	O
structure	O
of	O
ABL	B-Gene
.	O
</ALL>	O

<ALL>	O
P	O
-	O
loop	O
residues	O
in	O
DDR1	B-Gene
that	O
confer	O
drug	O
resistance	O
in	O
ABL	B-Gene
are	O
therefore	O
accommodated	O
outside	O
the	O
ATP	B-Chemical
pocket	O
.	O
</ALL>	O

<ALL>	O
Whereas	O
imatinib	B-Chemical
and	O
ponatinib	B-Chemical
bind	O
potently	O
to	O
both	O
the	O
DDR	B-Gene
and	O
ABL	B-Gene
kinases	O
,	O
the	O
hydrophobic	O
interactions	O
of	O
the	O
ABL	B-Gene
P	O
-	O
loop	O
appear	O
poorly	O
satisfied	O
by	O
DDR1	B-Chemical
-	I-Chemical
IN	I-Chemical
-	I-Chemical
1	I-Chemical
suggesting	O
a	O
structural	O
basis	O
for	O
its	O
DDR1	B-Gene
selectivity	O
.	O
</ALL>	O

<ALL>	O
Such	O
inhibitors	O
may	O
have	O
applications	O
in	O
clinical	O
indications	O
of	O
DDR1	B-Gene
and	O
DDR2	B-Gene
overexpression	O
or	O
mutation	O
,	O
including	O
lung	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
Low	O
functional	O
programming	O
of	O
renal	O
AT2R	B-Gene
mediates	O
the	O
developmental	O
origin	O
of	O
glomerulosclerosis	B-Disease
in	O
adult	O
offspring	O
induced	O
by	O
prenatal	O
caffeine	B-Chemical
exposure	O
.	O
</ALL>	O

<ALL>	O
UNASSIGNED	O
:	O
Our	O
previous	O
study	O
has	O
indicated	O
that	O
prenatal	O
caffeine	B-Chemical
exposure	O
(	O
PCE	O
)	O
could	O
induce	O
intrauterine	B-Disease
growth	I-Disease
retardation	I-Disease
(	O
IUGR	B-Disease
)	O
of	O
offspring	O
.	O
</ALL>	O

<ALL>	O
Recent	O
research	O
suggested	O
that	O
IUGR	B-Disease
is	O
a	O
risk	O
factor	O
for	O
glomerulosclerosis	B-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
whether	O
PCE	O
could	O
induce	O
glomerulosclerosis	B-Disease
and	O
its	O
underlying	O
mechanisms	O
remain	O
unknown	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
aimed	O
to	O
demonstrate	O
the	O
induction	O
to	O
glomerulosclerosis	B-Disease
in	O
adult	O
offspring	O
by	O
PCE	O
and	O
its	O
intrauterine	O
programming	O
mechanisms	O
.	O
</ALL>	O

<ALL>	O
A	O
rat	B-Species
model	O
of	O
IUGR	B-Disease
was	O
established	O
by	O
PCE	O
,	O
male	O
fetuses	O
and	O
adult	O
offspring	O
at	O
the	O
age	O
of	O
postnatal	O
week	O
24	O
were	O
euthanized	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
revealed	O
that	O
the	O
adult	O
offspring	O
kidneys	O
in	O
the	O
PCE	O
group	O
exhibited	O
glomerulosclerosis	B-Disease
as	O
well	O
as	O
interstitial	B-Disease
fibrosis	I-Disease
,	O
accompanied	O
by	O
elevated	O
levels	O
of	O
serum	O
creatinine	B-Chemical
and	O
urine	O
protein	O
.	O
</ALL>	O

<ALL>	O
Renal	O
angiotensin	B-Gene
II	I-Gene
receptor	I-Gene
type	I-Gene
2	I-Gene
(	O
AT2R	B-Gene
)	O
gene	O
expression	O
in	O
adult	O
offspring	O
was	O
reduced	O
by	O
PCE	O
,	O
whereas	O
the	O
renal	O
angiotensin	B-Gene
II	I-Gene
receptor	I-Gene
type	I-Gene
1a	I-Gene
(	O
AT1aR	B-Gene
)	O
/	O
AT2R	B-Gene
expression	O
ratio	O
was	O
increased	O
.	O
</ALL>	O

<ALL>	O
The	O
fetal	O
kidneys	O
in	O
the	O
PCE	O
group	O
displayed	O
an	O
enlarged	O
Bowman	O
's	O
space	O
and	O
a	O
shrunken	O
glomerular	O
tuft	O
,	O
accompanied	O
by	O
a	O
reduced	O
cortex	O
width	O
and	O
an	O
increase	O
in	O
the	O
nephrogenic	O
zone	O
/	O
cortical	O
zone	O
ratio	O
.	O
</ALL>	O

<ALL>	O
Observation	O
by	O
electronic	O
microscope	O
revealed	O
structural	O
damage	O
of	O
podocytes	O
;	O
the	O
reduced	O
expression	O
level	O
of	O
podocyte	O
marker	O
genes	O
,	O
nephrin	B-Gene
and	O
podocin	B-Gene
,	O
was	O
also	O
detected	O
by	O
q	O
-	O
PCR	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
AT2R	B-Gene
gene	O
and	O
protein	O
expressions	O
in	O
fetal	O
kidneys	O
were	O
inhibited	O
by	O
PCE	O
,	O
associated	O
with	O
the	O
repression	O
of	O
the	O
gene	O
expression	O
of	O
glial	B-Gene
-	I-Gene
cell	I-Gene
-	I-Gene
line	I-Gene
-	I-Gene
derived	I-Gene
neurotrophic	I-Gene
factor	I-Gene
(	O
GDNF	B-Gene
)	O
/	O
tyrosine	B-Gene
kinase	I-Gene
receptor	I-Gene
(	O
c	B-Gene
-	I-Gene
Ret	I-Gene
)	O
signaling	O
pathway	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
demonstrated	O
that	O
PCE	O
could	O
induce	O
dysplasia	B-Disease
of	I-Disease
fetal	I-Disease
kidneys	I-Disease
as	O
well	O
as	O
glomerulosclerosis	B-Disease
of	O
adult	O
offspring	O
,	O
and	O
the	O
low	O
functional	O
programming	O
of	O
renal	O
AT2R	B-Gene
might	O
mediate	O
the	O
developmental	O
origin	O
of	O
adult	O
glomerulosclerosis	B-Disease
.	O
</ALL>	O

<ALL>	O
Myc	B-Gene
enhances	O
B	B-Gene
-	I-Gene
cell	I-Gene
receptor	I-Gene
signaling	O
in	O
precancerous	B-Disease
B	O
cells	O
and	O
confers	O
resistance	O
to	O
Btk	B-Gene
inhibition	O
.	O
</ALL>	O

<ALL>	O
Dysregulation	O
of	O
the	O
oncogenic	O
transcription	O
factor	O
MYC	B-Gene
induces	O
B	O
-	O
cell	O
transformation	O
and	O
is	O
a	O
driver	O
for	O
B	B-Disease
-	I-Disease
cell	I-Disease
non	I-Disease
-	I-Disease
Hodgkin	I-Disease
lymphoma	I-Disease
(	O
B	B-Disease
-	I-Disease
NHL	I-Disease
)	O
.	O
</ALL>	O

<ALL>	O
MYC	B-Gene
overexpression	O
in	O
B	B-Disease
-	I-Disease
NHL	I-Disease
is	O
associated	O
with	O
more	O
aggressive	O
phenotypes	O
and	O
poor	O
prognosis	O
.	O
</ALL>	O

<ALL>	O
Although	O
genomic	O
studies	O
suggest	O
a	O
link	O
between	O
MYC	B-Gene
overexpression	O
and	O
B	B-Gene
-	I-Gene
cell	I-Gene
receptor	I-Gene
(	O
BCR	B-Gene
)	O
signaling	O
molecules	O
in	O
B	B-Disease
-	I-Disease
NHL	I-Disease
,	O
signaling	O
pathways	O
essential	O
to	O
Myc	B-Gene
-	O
mediated	O
B	O
-	O
cell	O
transformation	O
have	O
not	O
been	O
fully	O
elucidated	O
.	O
</ALL>	O

<ALL>	O
We	O
utilized	O
intracellular	O
phospho	O
-	O
flow	O
cytometry	O
to	O
investigate	O
the	O
relationship	O
between	O
Myc	B-Gene
and	O
BCR	B-Gene
signaling	O
in	O
pre	O
-	O
malignant	O
B	O
cells	O
.	O
</ALL>	O

<ALL>	O
Utilizing	O
the	O
Eu	O
-	O
myc	B-Gene
mouse	B-Species
model	O
,	O
where	O
Myc	B-Gene
is	O
overexpressed	O
specifically	O
in	O
B	O
cells	O
,	O
both	O
basal	O
and	O
stimulated	O
BCR	B-Gene
signaling	O
were	O
increased	O
in	O
precancerous	B-Disease
B	O
lymphocytes	O
from	O
Eu	O
-	O
myc	B-Gene
mice	B-Species
compared	O
with	O
wild	O
-	O
type	O
littermates	O
.	O
</ALL>	O

<ALL>	O
B	O
cells	O
overexpressing	O
Myc	B-Gene
displayed	O
constitutively	O
higher	O
levels	O
of	O
activated	O
CD79a	B-Gene
,	O
Btk	B-Gene
,	O
Plcg2	B-Gene
and	O
Erk1	B-Gene
/	I-Gene
2	I-Gene
.	O
</ALL>	O

<ALL>	O
Notably	O
,	O
Myc	B-Gene
-	O
overexpressing	O
B	O
cells	O
maintained	O
elevated	O
BCR	B-Gene
signaling	O
despite	O
treatment	O
with	O
ibrutinib	B-Chemical
,	O
a	O
Bruton	B-Gene
's	I-Gene
tyrosine	I-Gene
kinase	I-Gene
inhibitor	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
PI3	B-Gene
K	I-Gene
/	O
Akt	B-Gene
pathway	O
signaling	O
was	O
also	O
increased	O
in	O
Eu	O
-	O
myc	B-Gene
B	O
cells	O
,	O
and	O
this	O
increase	O
was	O
partially	O
suppressed	O
with	O
ibrutinib	B-Chemical
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
experiments	O
with	O
Btk	B-Gene
-	O
null	O
B	O
cells	O
revealed	O
off	O
-	O
target	O
effects	O
of	O
ibrutinib	B-Chemical
on	O
BCR	B-Gene
signaling	O
.	O
</ALL>	O

<ALL>	O
Our	O
data	O
show	O
that	O
in	O
pre	O
-	O
malignant	O
B	O
cells	O
,	O
Myc	B-Gene
overexpression	O
is	O
sufficient	O
to	O
activate	O
BCR	B-Gene
and	O
PI3	B-Gene
K	I-Gene
/	O
Akt	B-Gene
signaling	O
pathways	O
and	O
further	O
enhances	O
signaling	O
following	O
BCR	B-Gene
ligation	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
our	O
results	O
indicate	O
that	O
precancerous	B-Disease
B	O
cells	O
have	O
already	O
acquired	O
enhanced	O
survival	O
and	O
growth	O
capabilities	O
before	O
transformation	O
,	O
and	O
that	O
elevated	O
MYC	B-Gene
levels	O
confer	O
resistance	O
to	O
pharmacologic	O
inhibitors	O
of	O
BCR	B-Gene
signaling	O
,	O
which	O
has	O
significant	O
implications	O
for	O
B	B-Disease
-	I-Disease
NHL	I-Disease
treatment	O
.	O
</ALL>	O

<ALL>	O
A	O
TSPO	B-Gene
ligand	O
attenuates	O
brain	B-Disease
injury	I-Disease
after	O
intracerebral	B-Disease
hemorrhage	I-Disease
.	O
</ALL>	O

<ALL>	O
Intracerebral	B-Disease
hemorrhage	I-Disease
(	O
ICH	B-Disease
)	O
is	O
a	O
devastating	O
disease	O
without	O
effective	O
treatment	O
.	O
</ALL>	O

<ALL>	O
After	O
ICH	B-Disease
,	O
the	O
immediate	O
infiltration	O
of	O
leukocytes	O
and	O
activation	O
of	O
microglia	O
are	O
accompanied	O
by	O
a	O
rapid	O
up	O
-	O
regulation	O
of	O
the	O
18	O
-	O
kDa	O
translocator	B-Gene
protein	I-Gene
(	O
TSPO	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
TSPO	B-Gene
ligands	O
have	O
shown	O
anti	O
-	O
inflammatory	B-Disease
and	O
neuroprotective	O
properties	O
in	O
models	O
of	O
CNS	B-Disease
injury	I-Disease
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
determined	O
the	O
impact	O
of	O
a	O
TSPO	B-Gene
ligand	O
,	O
etifoxine	B-Chemical
,	O
on	O
brain	B-Disease
injury	I-Disease
and	O
inflammation	B-Disease
in	O
2	O
mouse	B-Species
models	O
of	O
ICH	B-Disease
.	O
</ALL>	O

<ALL>	O
TSPO	B-Gene
was	O
up	O
-	O
regulated	O
in	O
Iba1	B-Gene
(	O
+	O
)	O
cells	O
from	O
brains	O
of	O
patients	B-Species
with	O
ICH	B-Disease
and	O
in	O
CD11b	B-Gene
(	O
+	O
)	O
CD45	B-Gene
(	O
int	O
)	O
cells	O
from	O
mice	B-Species
subjected	O
to	O
collagenase	B-Chemical
-	O
induced	O
ICH	B-Disease
.	O
</ALL>	O

<ALL>	O
Etifoxine	B-Chemical
significantly	O
reduced	O
neurodeficits	B-Disease
and	O
perihematomal	O
brain	B-Disease
edema	I-Disease
after	O
ICH	B-Disease
induction	O
by	O
injection	O
of	O
either	O
autologous	O
blood	O
or	O
collagenase	B-Chemical
.	O
</ALL>	O

<ALL>	O
In	O
collagenase	B-Chemical
-	O
induced	O
ICH	B-Disease
mice	B-Species
,	O
the	O
protection	O
of	O
etifoxine	B-Chemical
was	O
associated	O
with	O
reduced	O
leukocyte	O
infiltration	O
into	O
the	O
brain	O
and	O
microglial	O
production	O
of	O
IL	B-Gene
-	I-Gene
6	I-Gene
and	O
TNF	B-Gene
-	I-Gene
a	I-Gene
.	O
</ALL>	O

<ALL>	O
Etifoxine	B-Chemical
improved	O
blood	O
-	O
brain	O
barrier	O
integrity	O
and	O
diminished	O
cell	O
death	O
.	O
</ALL>	O

<ALL>	O
Notably	O
,	O
the	O
protective	O
effect	O
of	O
etifoxine	B-Chemical
was	O
abolished	O
in	O
mice	B-Species
depleted	O
of	O
microglia	O
by	O
using	O
a	O
colony	B-Gene
-	I-Gene
stimulating	I-Gene
factor	I-Gene
1	I-Gene
receptor	I-Gene
inhibitor	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
indicate	O
that	O
the	O
TSPO	B-Gene
ligand	O
etifoxine	B-Chemical
attenuates	O
brain	B-Disease
injury	I-Disease
and	O
inflammation	B-Disease
after	O
ICH	B-Disease
.	O
</ALL>	O

<ALL>	O
TSPO	B-Gene
may	O
be	O
a	O
viable	O
therapeutic	O
target	O
that	O
requires	O
further	O
investigations	O
in	O
ICH	B-Disease
.	O
-	O
</ALL>	O

<ALL>	O
Li	O
,	O
M.	O
,	O
Ren	O
,	O
H.	O
,	O
Sheth	O
,	O
K.	O
N.	O
,	O
Shi	O
,	O
F.	O
-	O
D.	O
,	O
Liu	O
,	O
Q.	O
A	O
TSPO	B-Gene
ligand	O
attenuates	O
brain	B-Disease
injury	I-Disease
after	O
intracerebral	B-Disease
hemorrhage	I-Disease
.	O
</ALL>	O

<ALL>	O
Mutation	O
of	O
the	O
a	B-Gene
-	I-Gene
tubulin	I-Gene
Tuba1a	B-Gene
leads	O
to	O
straighter	O
microtubules	O
and	O
perturbs	O
neuronal	O
migration	O
.	O
</ALL>	O

<ALL>	O
Brain	O
development	O
involves	O
extensive	O
migration	O
of	O
neurons	O
.	O
</ALL>	O

<ALL>	O
Microtubules	O
(	O
MTs	O
)	O
are	O
key	O
cellular	O
effectors	O
of	O
neuronal	O
displacement	O
that	O
are	O
assembled	O
from	O
a	B-Gene
/	I-Gene
b	I-Gene
-	I-Gene
tubulin	I-Gene
heterodimers	O
.	O
</ALL>	O

<ALL>	O
Mutation	O
of	O
the	O
a	B-Gene
-	I-Gene
tubulin	I-Gene
isotype	O
TUBA1A	B-Gene
is	O
associated	O
with	O
cortical	B-Disease
malformations	I-Disease
in	O
humans	B-Species
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
provide	O
detailed	O
in	O
vivo	O
and	O
in	O
vitro	O
analyses	O
of	O
Tuba1a	B-Gene
mutants	O
.	O
</ALL>	O

<ALL>	O
In	O
mice	B-Species
carrying	O
a	O
Tuba1a	B-Gene
missense	O
mutation	O
(	O
S140	B-Variant
G	I-Variant
)	O
,	O
neurons	O
accumulate	O
,	O
and	O
glial	O
cells	O
are	O
dispersed	O
along	O
the	O
rostral	O
migratory	O
stream	O
in	O
postnatal	O
and	O
adult	O
brains	O
.	O
</ALL>	O

<ALL>	O
Live	O
imaging	O
of	O
Tuba1a	B-Gene
-	O
mutant	O
neurons	O
revealed	O
slowed	O
migration	O
and	O
increased	O
neuronal	O
branching	O
,	O
which	O
correlated	O
with	O
directionality	O
alterations	O
and	O
perturbed	O
nucleus	O
-	O
centrosome	O
(	O
N	O
-	O
C	O
)	O
coupling	O
.	O
</ALL>	O

<ALL>	O
Tuba1a	B-Gene
mutation	O
led	O
to	O
increased	O
straightness	O
of	O
newly	O
polymerized	O
MTs	O
,	O
and	O
structural	O
modeling	O
data	O
suggest	O
a	O
conformational	O
change	O
in	O
the	O
a	B-Gene
/	I-Gene
b	I-Gene
-	I-Gene
tubulin	I-Gene
heterodimer	O
.	O
</ALL>	O

<ALL>	O
We	O
show	O
that	O
Tuba8	B-Gene
,	O
another	O
a	B-Gene
-	I-Gene
tubulin	I-Gene
isotype	O
previously	O
associated	O
with	O
cortical	B-Disease
malformations	I-Disease
,	O
has	O
altered	O
function	O
compared	O
with	O
Tuba1a	B-Gene
.	O
</ALL>	O

<ALL>	O
Our	O
work	O
shows	O
that	O
Tuba1a	B-Gene
plays	O
an	O
essential	O
,	O
noncompensated	O
role	O
in	O
neuronal	O
saltatory	O
migration	O
in	O
vivo	O
and	O
highlights	O
the	O
importance	O
of	O
MT	O
flexibility	O
in	O
N	O
-	O
C	O
coupling	O
and	O
neuronal	O
-	O
branching	O
regulation	O
during	O
neuronal	O
migration	O
.	O
</ALL>	O

<ALL>	O
HEB	B-Gene
is	O
required	O
for	O
the	O
specification	O
of	O
fetal	O
IL	B-Gene
-	I-Gene
17	I-Gene
-	O
producing	O
gd	O
T	O
cells	O
.	O
</ALL>	O

<ALL>	O
IL	B-Gene
-	I-Gene
17	I-Gene
-	O
producing	O
gd	O
T	O
(	O
gdT17	O
)	O
cells	O
are	O
critical	O
components	O
of	O
the	O
innate	O
immune	O
system	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
gene	O
networks	O
that	O
control	O
their	O
development	O
are	O
unclear	O
.	O
</ALL>	O

<ALL>	O
Here	O
we	O
show	O
that	O
HEB	B-Gene
(	O
HeLa	B-Gene
E	I-Gene
-	I-Gene
box	I-Gene
binding	I-Gene
protein	I-Gene
,	O
encoded	O
by	O
Tcf12	B-Gene
)	O
is	O
required	O
for	O
the	O
generation	O
of	O
a	O
newly	O
defined	O
subset	O
of	O
fetal	O
-	O
derived	O
CD73	B-Gene
-	O
gdT17	O
cells	O
.	O
</ALL>	O

<ALL>	O
HEB	B-Gene
is	O
required	O
in	O
immature	O
CD24	B-Gene
+	O
CD73	B-Gene
-	O
gd	O
T	O
cells	O
for	O
the	O
expression	O
of	O
Sox4	B-Gene
,	O
Sox13	B-Gene
,	O
and	O
Rorc	B-Gene
,	O
and	O
these	O
genes	O
are	O
repressed	O
by	O
acute	O
expression	O
of	O
the	O
HEB	B-Gene
antagonist	O
Id3	B-Gene
.	O
</ALL>	O

<ALL>	O
HEB	B-Gene
-	O
deficiency	O
also	O
affects	O
mature	O
CD73	B-Gene
+	O
gd	O
T	O
cells	O
,	O
which	O
are	O
defective	O
in	O
RORgt	B-Gene
expression	O
and	O
IL	B-Gene
-	I-Gene
17	I-Gene
production	O
.	O
</ALL>	O

<ALL>	O
Additionally	O
,	O
the	O
fetal	O
TCRg	B-Gene
chain	O
repertoire	O
is	O
altered	O
,	O
and	O
peripheral	O
Vg4	B-Gene
gd	O
T	O
cells	O
are	O
mostly	O
restricted	O
to	O
the	O
IFNg	B-Gene
-	O
producing	O
phenotype	O
in	O
HEB	B-Gene
-	O
deficient	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
our	O
work	O
identifies	O
HEB	B-Gene
-	O
dependent	O
pathways	O
for	O
the	O
development	O
of	O
CD73	B-Gene
+	O
and	O
CD73	B-Gene
-	O
gdT17	O
cells	O
,	O
and	O
provides	O
mechanistic	O
evidence	O
for	O
control	O
of	O
the	O
gdT17	O
gene	O
network	O
by	O
HEB	B-Gene
.	O
</ALL>	O

<ALL>	O
Primary	B-Disease
malignant	I-Disease
lymphoma	I-Disease
of	I-Disease
the	I-Disease
brain	I-Disease
:	O
frequent	O
abnormalities	O
and	O
inactivation	O
of	O
p14	B-Gene
tumor	B-Disease
suppressor	O
gene	O
.	O
</ALL>	O

<ALL>	O
Ten	O
primary	B-Disease
central	I-Disease
nervous	I-Disease
system	I-Disease
lymphomas	I-Disease
(	O
PCNSL	B-Disease
,	O
brain	B-Disease
lymphomas	I-Disease
)	O
were	O
examined	O
for	O
p14	B-Gene
gene	O
exon	O
1beta	O
deletion	O
,	O
mutation	O
and	O
methylation	O
by	O
Southern	O
blot	O
analysis	O
,	O
nucleotide	O
analysis	O
of	O
polymerase	O
chain	O
reaction	O
clones	O
and	O
Southern	O
blot	O
-	O
based	O
methylation	O
assay	O
.	O
</ALL>	O

<ALL>	O
In	O
Southern	O
blot	O
analysis	O
,	O
from	O
the	O
signal	O
densities	O
of	O
the	O
hybridized	O
bands	O
and	O
their	O
similarities	O
to	O
those	O
of	O
exons	O
2	O
and	O
3	O
in	O
our	O
previous	O
quantitative	O
study	O
,	O
we	O
found	O
that	O
exon	O
1beta	O
was	O
homozygously	O
deleted	O
in	O
four	O
cases	O
,	O
hemizygously	O
deleted	O
in	O
five	O
cases	O
and	O
not	O
deleted	O
in	O
one	O
case	O
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
the	O
same	O
deletion	O
patterns	O
covered	O
the	O
entire	O
p14	B-Gene
gene	O
for	O
all	O
cases	O
except	O
for	O
one	O
case	O
,	O
which	O
suggested	O
the	O
hemizygous	O
deletion	O
of	O
exons	O
1beta	O
and	O
2	O
and	O
homozygous	O
deletion	O
of	O
exon	O
3	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
although	O
exon	O
1beta	O
mutation	O
is	O
rare	O
in	O
various	O
tumors	B-Disease
,	O
we	O
detected	O
a	O
missense	O
mutation	O
(	O
L50R	B-Variant
)	O
in	O
one	O
case	O
with	O
a	O
hemizygous	O
deletion	O
.	O
</ALL>	O

<ALL>	O
Methylation	O
of	O
the	O
5'CpG	O
island	O
of	O
the	O
p14	B-Gene
gene	O
was	O
not	O
suggested	O
for	O
any	O
case	O
without	O
homozygous	O
deletion	O
.	O
</ALL>	O

<ALL>	O
Our	O
observation	O
of	O
frequent	O
p14	B-Gene
gene	O
abnormalities	O
(	O
90	O
%	O
)	O
and	O
inactivation	O
(	O
40	O
-	O
60	O
%	O
)	O
was	O
in	O
striking	O
contrast	O
to	O
the	O
same	O
pathological	O
subtype	O
of	O
systemic	B-Disease
lymphoma	I-Disease
in	O
which	O
p14	B-Gene
gene	O
abnormalities	O
and	O
inactivation	O
were	O
infrequent	O
,	O
suggesting	O
a	O
difference	O
in	O
carcinogenesis	B-Disease
between	O
PCNSL	B-Disease
and	O
systemic	B-Disease
lymphoma	I-Disease
.	O
</ALL>	O

<ALL>	O
Congenital	B-Disease
disorder	I-Disease
of	I-Disease
glycosylation	I-Disease
Ic	I-Disease
due	O
to	O
a	O
de	O
novo	O
deletion	O
and	O
an	O
hALG	B-Gene
-	I-Gene
6	I-Gene
mutation	O
.	O
</ALL>	O

<ALL>	O
We	O
describe	O
a	O
new	O
cause	O
of	O
congenital	B-Disease
disorder	I-Disease
of	I-Disease
glycosylation	I-Disease
-	I-Disease
Ic	I-Disease
(	O
CDG	B-Disease
-	I-Disease
Ic	I-Disease
)	O
in	O
a	O
young	O
girl	O
with	O
a	O
rather	O
mild	O
CDG	B-Disease
phenotype	O
.	O
</ALL>	O

<ALL>	O
Her	O
cells	O
accumulated	O
lipid	B-Chemical
-	I-Chemical
linked	I-Chemical
oligosaccharides	I-Chemical
lacking	O
three	O
glucose	B-Chemical
residues	O
,	O
and	O
sequencing	O
of	O
the	O
ALG6	B-Gene
gene	O
showed	O
what	O
initially	O
appeared	O
to	O
be	O
a	O
homozygous	O
novel	O
point	O
mutation	O
(	O
338	B-Variant
G	I-Variant
>	I-Variant
A	I-Variant
)	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
haplotype	O
analysis	O
showed	O
that	O
the	O
patient	B-Species
does	O
not	O
carry	O
any	O
paternal	O
DNA	O
markers	O
extending	O
33	O
kb	O
in	O
the	O
telomeric	O
direction	O
from	O
the	O
ALG6	B-Gene
region	O
,	O
and	O
microsatellite	O
analysis	O
extended	O
the	O
abnormal	O
region	O
to	O
at	O
least	O
2.5Mb	O
.	O
</ALL>	O

<ALL>	O
We	O
used	O
high	O
-	O
resolution	O
karyotyping	O
to	O
confirm	O
a	O
deletion	B-Variant
(	I-Variant
10	I-Variant
-	I-Variant
12Mb	I-Variant
)	I-Variant
[	O
del	B-Variant
(	I-Variant
1	I-Variant
)	I-Variant
(	I-Variant
p31.2p32.3	I-Variant
)	I-Variant
]	O
and	O
found	O
no	O
structural	O
abnormalities	O
in	O
the	O
father	O
,	O
suggesting	O
a	O
de	O
novo	O
event	O
.	O
</ALL>	O

<ALL>	O
Our	O
findings	O
extend	O
the	O
causes	O
of	O
CDG	B-Disease
to	O
larger	O
DNA	O
deletions	O
and	O
identify	O
the	O
first	O
Japanese	O
CDG	B-Disease
-	I-Disease
Ic	I-Disease
mutation	O
.	O
</ALL>	O

<ALL>	O
Genetic	O
variation	O
in	O
the	O
COX	B-Gene
-	I-Gene
2	I-Gene
gene	O
and	O
the	O
association	O
with	O
prostate	B-Disease
cancer	I-Disease
risk	O
.	O
</ALL>	O

<ALL>	O
COX	B-Gene
-	I-Gene
2	I-Gene
is	O
a	O
key	O
enzyme	O
in	O
the	O
conversion	O
of	O
arachidonic	B-Chemical
acid	I-Chemical
to	O
prostaglandins	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
prostaglandins	B-Chemical
produced	O
by	O
COX	B-Gene
-	I-Gene
2	I-Gene
are	O
involved	O
in	O
inflammation	B-Disease
and	O
pain	B-Disease
response	O
in	O
different	O
tissues	O
in	O
the	O
body	O
.	O
</ALL>	O

<ALL>	O
Accumulating	O
evidence	O
from	O
epidemiologic	O
studies	O
,	O
chemical	O
carcinogen	O
-	O
induced	O
rodent	O
models	O
and	O
clinical	O
trials	O
indicate	O
that	O
COX	B-Gene
-	I-Gene
2	I-Gene
plays	O
a	O
role	O
in	O
human	B-Species
carcinogenesis	B-Disease
and	O
is	O
overexpressed	O
in	O
prostate	B-Disease
cancer	I-Disease
tissue	O
.	O
</ALL>	O

<ALL>	O
We	O
examined	O
whether	O
sequence	O
variants	O
in	O
the	O
COX	B-Gene
-	I-Gene
2	I-Gene
gene	O
are	O
associated	O
with	O
prostate	B-Disease
cancer	I-Disease
risk	O
.	O
</ALL>	O

<ALL>	O
We	O
analyzed	O
a	O
large	O
population	O
-	O
based	O
case	O
-	O
control	O
study	O
,	O
cancer	B-Disease
prostate	I-Disease
in	O
Sweden	O
(	O
CAPS	O
)	O
consisting	O
of	O
1,378	O
cases	O
and	O
782	O
controls	O
.	O
</ALL>	O

<ALL>	O
We	O
evaluated	O
16	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
spanning	O
the	O
entire	O
COX	B-Gene
-	I-Gene
2	I-Gene
gene	O
in	O
94	O
subjects	O
of	O
the	O
control	O
group	O
.	O
</ALL>	O

<ALL>	O
Five	O
SNPs	O
had	O
a	O
minor	O
allele	O
frequency	O
of	O
more	O
than	O
5	O
%	O
in	O
our	O
study	O
population	O
and	O
these	O
were	O
genotyped	O
in	O
all	O
case	O
patients	B-Species
and	O
control	O
subjects	O
and	O
gene	O
-	O
specific	O
haplotypes	O
were	O
constructed	O
.	O
</ALL>	O

<ALL>	O
A	O
statistically	O
significant	O
difference	O
in	O
allele	O
frequency	O
between	O
cases	O
and	O
controls	O
was	O
observed	O
for	O
2	O
of	O
the	O
SNPs	O
(	O
+	B-Variant
3100	I-Variant
T	I-Variant
/	I-Variant
G	I-Variant
and	O
+	B-Variant
8365	I-Variant
C	I-Variant
/	I-Variant
T	I-Variant
)	O
,	O
with	O
an	O
odds	O
ratio	O
of	O
0.78	O
(	O
95	O
%	O
CI	O
=	O
0.64	O
-	O
0.96	O
)	O
and	O
0.65	O
(	O
95	O
%	O
CI	O
=	O
0.45	O
-	O
0.94	O
)	O
respectively	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
haplotype	O
analysis	O
,	O
1	O
haplotype	O
carrying	O
the	O
variant	O
allele	O
from	O
both	O
+	B-Variant
3100	I-Variant
T	I-Variant
/	I-Variant
G	I-Variant
and	O
+	B-Variant
8365	I-Variant
C	I-Variant
/	I-Variant
T	I-Variant
,	O
with	O
a	O
population	O
frequency	O
of	O
3	O
%	O
,	O
was	O
also	O
significantly	O
associated	O
with	O
decreased	O
risk	O
of	O
prostate	B-Disease
cancer	I-Disease
(	O
p	O
=	O
0.036	O
,	O
global	O
simulated	O
p	O
-	O
value	O
=	O
0.046	O
)	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
supports	O
the	O
hypothesis	O
that	O
inflammation	B-Disease
is	O
involved	O
in	O
prostate	B-Disease
carcinogenesis	I-Disease
and	O
that	O
sequence	O
variation	O
within	O
the	O
COX	B-Gene
-	I-Gene
2	I-Gene
gene	O
influence	O
the	O
risk	O
of	O
prostate	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
Drug	O
-	O
induced	O
long	B-Disease
QT	I-Disease
syndrome	I-Disease
in	O
injection	O
drug	O
users	O
receiving	O
methadone	B-Chemical
:	O
high	O
frequency	O
in	O
hospitalized	O
patients	B-Species
and	O
risk	O
factors	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Drug	O
-	O
induced	O
long	B-Disease
QT	I-Disease
syndrome	I-Disease
is	O
a	O
serious	O
adverse	O
drug	O
reaction	O
.	O
</ALL>	O

<ALL>	O
Methadone	B-Chemical
prolongs	O
the	O
QT	O
interval	O
in	O
vitro	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
inpatient	B-Species
setting	O
,	O
the	O
frequency	O
of	O
QT	B-Disease
interval	I-Disease
prolongation	I-Disease
with	O
methadone	B-Chemical
treatment	O
,	O
its	O
dose	O
dependence	O
,	O
and	O
the	O
importance	O
of	O
cofactors	O
such	O
as	O
drug	O
-	O
drug	O
interactions	O
remain	O
unknown	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
We	O
performed	O
a	O
systematic	O
,	O
retrospective	O
study	O
comparing	O
active	O
or	O
former	O
intravenous	O
drug	O
users	O
receiving	O
methadone	B-Chemical
and	O
those	O
not	O
receiving	O
methadone	B-Chemical
among	O
all	O
patients	B-Species
hospitalized	O
over	O
a	O
5	O
-	O
year	O
period	O
in	O
a	O
tertiary	O
care	O
hospital	O
.	O
</ALL>	O

<ALL>	O
A	O
total	O
of	O
167	O
patients	B-Species
receiving	O
methadone	B-Chemical
fulfilled	O
the	O
inclusion	O
criteria	O
and	O
were	O
compared	O
with	O
a	O
control	O
group	O
of	O
80	O
injection	O
drug	O
users	O
not	O
receiving	O
methadone	B-Chemical
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
to	O
methadone	B-Chemical
dose	O
,	O
15	O
demographic	O
,	O
biological	O
,	O
and	O
pharmacological	O
variables	O
were	O
considered	O
as	O
potential	O
risk	O
factors	O
for	O
QT	B-Disease
prolongation	I-Disease
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Among	O
167	O
methadone	B-Chemical
maintenance	O
patients	B-Species
,	O
the	O
prevalence	O
of	O
QTc	B-Disease
prolongation	I-Disease
to	O
0.50	O
second	O
(	O
(	O
1	O
/	O
2	O
)	O
)	O
or	O
longer	O
was	O
16.2	O
%	O
compared	O
with	O
0	O
%	O
in	O
80	O
control	O
subjects	O
.	O
</ALL>	O

<ALL>	O
Six	O
patients	B-Species
(	O
3.6	O
%	O
)	O
in	O
the	O
methadone	B-Chemical
group	O
presented	O
torsades	B-Disease
de	I-Disease
pointes	I-Disease
.	O
</ALL>	O

<ALL>	O
QTc	O
length	O
was	O
weakly	O
but	O
significantly	O
associated	O
with	O
methadone	B-Chemical
daily	O
dose	O
(	O
Spearman	O
rank	O
correlation	O
coefficient	O
,	O
0.20	O
;	O
P	O
<	O
.01	O
)	O
.	O
</ALL>	O

<ALL>	O
Multivariate	O
regression	O
analysis	O
allowed	O
attribution	O
of	O
31.8	O
%	O
of	O
QTc	O
variability	O
to	O
methadone	B-Chemical
dose	O
,	O
cytochrome	B-Gene
P	I-Gene
-	I-Gene
450	I-Gene
3A4	I-Gene
drug	O
-	O
drug	O
interactions	O
,	O
hypokalemia	B-Disease
,	O
and	O
altered	O
liver	O
function	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
QT	B-Disease
interval	I-Disease
prolongation	I-Disease
in	O
methadone	B-Chemical
maintenance	O
patients	B-Species
hospitalized	O
in	O
a	O
tertiary	O
care	O
center	O
is	O
a	O
frequent	O
finding	O
.	O
</ALL>	O

<ALL>	O
Methadone	B-Chemical
dose	O
,	O
presence	O
of	O
cytochrome	B-Chemical
P	I-Chemical
-	I-Chemical
450	I-Chemical
3A4	I-Chemical
inhibitors	I-Chemical
,	O
potassium	B-Chemical
level	O
,	O
and	O
liver	O
function	O
contribute	O
to	O
QT	B-Disease
prolongation	I-Disease
.	O
</ALL>	O

<ALL>	O
Long	B-Disease
QT	I-Disease
syndrome	I-Disease
can	O
occur	O
with	O
low	O
doses	O
of	O
methadone	B-Chemical
.	O
</ALL>	O

<ALL>	O
Alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
prevents	O
mitochondrial	B-Disease
damage	I-Disease
and	O
neurotoxicity	B-Disease
in	O
experimental	O
chemotherapy	O
neuropathy	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
study	O
investigates	O
if	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
is	O
neuroprotective	O
against	O
chemotherapy	O
induced	O
neurotoxicity	B-Disease
,	O
if	O
mitochondrial	B-Disease
damage	I-Disease
plays	O
a	O
critical	O
role	O
in	O
toxic	B-Disease
neurodegenerative	I-Disease
cascade	I-Disease
,	O
and	O
if	O
neuroprotective	O
effects	O
of	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
depend	O
on	O
mitochondria	O
protection	O
.	O
</ALL>	O

<ALL>	O
We	O
used	O
an	O
in	O
vitro	O
model	O
of	O
chemotherapy	O
induced	O
peripheral	B-Disease
neuropathy	I-Disease
that	O
closely	O
mimic	O
the	O
in	O
vivo	O
condition	O
by	O
exposing	O
primary	O
cultures	O
of	O
dorsal	O
root	O
ganglion	O
(	O
DRG	O
)	O
sensory	O
neurons	O
to	O
paclitaxel	B-Chemical
and	O
cisplatin	B-Chemical
,	O
two	O
widely	O
used	O
and	O
highly	O
effective	O
chemotherapeutic	O
drugs	O
.	O
</ALL>	O

<ALL>	O
This	O
approach	O
allowed	O
investigating	O
the	O
efficacy	O
of	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
in	O
preventing	O
axonal	B-Disease
damage	I-Disease
and	O
apoptosis	O
and	O
the	O
function	O
and	O
ultrastructural	O
morphology	O
of	O
mitochondria	O
after	O
exposure	O
to	O
toxic	O
agents	O
and	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
.	O
</ALL>	O

<ALL>	O
Our	O
results	O
demonstrate	O
that	O
both	O
cisplatin	B-Chemical
and	O
paclitaxel	B-Chemical
cause	O
early	O
mitochondrial	B-Disease
impairment	I-Disease
with	O
loss	O
of	O
membrane	O
potential	O
and	O
induction	O
of	O
autophagic	O
vacuoles	O
in	O
neurons	O
.	O
</ALL>	O

<ALL>	O
Alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
exerts	O
neuroprotective	O
effects	O
against	O
chemotherapy	O
induced	O
neurotoxicity	B-Disease
in	O
sensory	O
neurons	O
:	O
it	O
rescues	O
the	O
mitochondrial	B-Disease
toxicity	I-Disease
and	O
induces	O
the	O
expression	O
of	O
frataxin	B-Gene
,	O
an	O
essential	O
mitochondrial	O
protein	O
with	O
anti	O
-	O
oxidant	O
and	O
chaperone	O
properties	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
mitochondrial	B-Disease
toxicity	I-Disease
is	O
an	O
early	O
common	O
event	O
both	O
in	O
paclitaxel	B-Chemical
and	O
cisplatin	B-Chemical
induced	O
neurotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
Alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
protects	O
sensory	O
neurons	O
through	O
its	O
anti	O
-	O
oxidant	O
and	O
mitochondrial	O
regulatory	O
functions	O
,	O
possibly	O
inducing	O
the	O
expression	O
of	O
frataxin	B-Gene
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
suggest	O
that	O
alpha	B-Chemical
-	I-Chemical
lipoic	I-Chemical
acid	I-Chemical
might	O
reduce	O
the	O
risk	O
of	O
developing	O
peripheral	B-Disease
nerve	I-Disease
toxicity	I-Disease
in	O
patients	B-Species
undergoing	O
chemotherapy	O
and	O
encourage	O
further	O
confirmatory	O
clinical	O
trials	O
.	O
</ALL>	O

<ALL>	O
Bortezomib	B-Chemical
and	O
dexamethasone	B-Chemical
as	O
salvage	O
therapy	O
in	O
patients	B-Species
with	O
relapsed	O
/	O
refractory	O
multiple	B-Disease
myeloma	I-Disease
:	O
analysis	O
of	O
long	O
-	O
term	O
clinical	O
outcomes	O
.	O
</ALL>	O

<ALL>	O
Bortezomib	B-Chemical
(	O
bort	B-Chemical
)	O
-	O
dexamethasone	B-Chemical
(	O
dex	B-Chemical
)	O
is	O
an	O
effective	O
therapy	O
for	O
relapsed	O
/	O
refractory	O
(	O
R	O
/	O
R	O
)	O
multiple	B-Disease
myeloma	I-Disease
(	O
MM	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
This	O
retrospective	O
study	O
investigated	O
the	O
combination	O
of	O
bort	B-Chemical
(	O
1.3	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
11	O
every	O
3	O
weeks	O
)	O
and	O
dex	B-Chemical
(	O
20	O
mg	O
on	O
the	O
day	O
of	O
and	O
the	O
day	O
after	O
bort	B-Chemical
)	O
as	O
salvage	O
treatment	O
in	O
85	O
patients	B-Species
with	O
R	O
/	O
R	O
MM	B-Disease
after	O
prior	O
autologous	O
stem	O
cell	O
transplantation	O
or	O
conventional	O
chemotherapy	O
.	O
</ALL>	O

<ALL>	O
The	O
median	O
number	O
of	O
prior	O
lines	O
of	O
therapy	O
was	O
2	O
.	O
</ALL>	O

<ALL>	O
Eighty	O
-	O
seven	O
percent	O
of	O
the	O
patients	B-Species
had	O
received	O
immunomodulatory	O
drugs	O
included	O
in	O
some	O
line	O
of	O
therapy	O
before	O
bort	B-Chemical
-	O
dex	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
median	O
number	O
of	O
bort	B-Chemical
-	O
dex	B-Chemical
cycles	O
was	O
6	O
,	O
up	O
to	O
a	O
maximum	O
of	O
12	O
cycles	O
.	O
</ALL>	O

<ALL>	O
On	O
an	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
,	O
55	O
%	O
of	O
the	O
patients	B-Species
achieved	O
at	O
least	O
partial	O
response	O
,	O
including	O
19	O
%	O
CR	O
and	O
35	O
%	O
achieved	O
at	O
least	O
very	O
good	O
partial	O
response	O
.	O
</ALL>	O

<ALL>	O
Median	O
durations	O
of	O
response	O
,	O
time	O
to	O
next	O
therapy	O
and	O
treatment	O
-	O
free	O
interval	O
were	O
8	O
,	O
11.2	O
,	O
and	O
5.1	O
months	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
The	O
most	O
relevant	O
adverse	O
event	O
was	O
peripheral	B-Disease
neuropathy	I-Disease
,	O
which	O
occurred	O
in	O
78	O
%	O
of	O
the	O
patients	B-Species
(	O
grade	O
II	O
,	O
38	O
%	O
;	O
grade	O
III	O
,	O
21	O
%	O
)	O
and	O
led	O
to	O
treatment	O
discontinuation	O
in	O
6	O
%	O
.	O
</ALL>	O

<ALL>	O
With	O
a	O
median	O
follow	O
up	O
of	O
22	O
months	O
,	O
median	O
time	O
to	O
progression	O
,	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
were	O
8.9	O
,	O
8.7	O
,	O
and	O
22	O
months	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
Prolonged	O
PFS	O
and	O
OS	O
were	O
observed	O
in	O
patients	B-Species
achieving	O
CR	O
and	O
receiving	O
bort	B-Chemical
-	O
dex	B-Chemical
a	O
single	O
line	O
of	O
prior	O
therapy	O
.	O
</ALL>	O

<ALL>	O
Bort	B-Chemical
-	O
dex	B-Chemical
was	O
an	O
effective	O
salvage	O
treatment	O
for	O
MM	B-Disease
patients	B-Species
,	O
particularly	O
for	O
those	O
in	O
first	O
relapse	O
.	O
</ALL>	O

<ALL>	O
Chronic	O
treatment	O
with	O
metformin	B-Chemical
suppresses	O
toll	B-Gene
-	I-Gene
like	I-Gene
receptor	I-Gene
4	I-Gene
signaling	O
and	O
attenuates	O
left	B-Disease
ventricular	I-Disease
dysfunction	I-Disease
following	O
myocardial	B-Disease
infarction	I-Disease
.	O
</ALL>	O

<ALL>	O
Acute	O
treatment	O
with	O
metformin	B-Chemical
has	O
a	O
protective	O
effect	O
in	O
myocardial	B-Disease
infarction	I-Disease
by	O
suppression	O
of	O
inflammatory	B-Disease
responses	O
due	O
to	O
activation	O
of	O
AMP	B-Gene
-	I-Gene
activated	I-Gene
protein	I-Gene
kinase	I-Gene
(	O
AMPK	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
chronic	O
pre	O
-	O
treatment	O
with	O
metformin	B-Chemical
on	O
cardiac	B-Disease
dysfunction	I-Disease
and	O
toll	B-Gene
-	I-Gene
like	I-Gene
receptor	I-Gene
4	I-Gene
(	O
TLR4	B-Gene
)	O
activities	O
following	O
myocardial	B-Disease
infarction	I-Disease
and	O
their	O
relation	O
with	O
AMPK	B-Gene
were	O
assessed	O
.	O
</ALL>	O

<ALL>	O
Male	O
Wistar	O
rats	B-Species
were	O
randomly	O
assigned	O
to	O
one	O
of	O
5	O
groups	O
(	O
n	O
=	O
6	O
)	O
:	O
normal	O
control	O
and	O
groups	O
were	O
injected	O
isoproterenol	B-Chemical
after	O
chronic	O
pre	O
-	O
treatment	O
with	O
0	O
,	O
25	O
,	O
50	O
,	O
or	O
100	O
mg	O
/	O
kg	O
of	O
metformin	B-Chemical
twice	O
daily	O
for	O
14	O
days	O
.	O
</ALL>	O

<ALL>	O
Isoproterenol	B-Chemical
(	O
100	O
mg	O
/	O
kg	O
)	O
was	O
injected	O
subcutaneously	O
on	O
the	O
13th	O
and	O
14th	O
days	O
to	O
induce	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
.	O
</ALL>	O

<ALL>	O
Isoproterenol	B-Chemical
alone	O
decreased	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
myocardial	O
contractility	O
indexed	O
as	O
LVdp	O
/	O
dtmax	O
and	O
LVdp	O
/	O
dtmin	O
.	O
</ALL>	O

<ALL>	O
The	O
left	B-Disease
ventricular	I-Disease
dysfunction	I-Disease
was	O
significantly	O
lower	O
in	O
the	O
groups	O
treated	O
with	O
25	O
and	O
50	O
mg	O
/	O
kg	O
of	O
metformin	B-Chemical
.	O
</ALL>	O

<ALL>	O
Metfromin	B-Chemical
markedly	O
lowered	O
isoproterenol	B-Chemical
-	O
induced	O
elevation	O
in	O
the	O
levels	O
of	O
TLR4	B-Gene
mRNA	O
,	O
myeloid	B-Gene
differentiation	I-Gene
protein	I-Gene
88	I-Gene
(	O
MyD88	B-Gene
)	O
,	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
-	I-Gene
alpha	I-Gene
(	O
TNF	B-Gene
-	I-Gene
a	I-Gene
)	O
,	O
and	O
interleukin	B-Gene
6	I-Gene
(	O
IL	B-Gene
-	I-Gene
6	I-Gene
)	O
in	O
the	O
heart	O
tissues	O
.	O
</ALL>	O

<ALL>	O
Similar	O
changes	O
were	O
also	O
seen	O
in	O
the	O
serum	O
levels	O
of	O
TNF	B-Gene
-	I-Gene
a	I-Gene
and	O
IL	B-Gene
-	I-Gene
6	I-Gene
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
lower	O
doses	O
of	O
25	O
and	O
50	O
mg	O
/	O
kg	O
were	O
more	O
effective	O
than	O
100	O
mg	O
/	O
kg	O
.	O
</ALL>	O

<ALL>	O
Phosphorylated	O
AMPKa	B-Gene
(	O
p	O
-	O
AMPK	B-Gene
)	O
in	O
the	O
myocardium	O
was	O
significantly	O
elevated	O
by	O
25	O
mg	O
/	O
kg	O
of	O
metformin	B-Chemical
,	O
slightly	O
by	O
50	O
mg	O
/	O
kg	O
,	O
but	O
not	O
by	O
100	O
mg	O
/	O
kg	O
.	O
</ALL>	O

<ALL>	O
Chronic	O
pre	O
-	O
treatment	O
with	O
metformin	B-Chemical
reduces	O
post	O
-	O
myocardial	B-Disease
infarction	I-Disease
cardiac	B-Disease
dysfunction	I-Disease
and	O
suppresses	O
inflammatory	B-Disease
responses	O
,	O
possibly	O
through	O
inhibition	O
of	O
TLR4	B-Gene
activities	O
.	O
</ALL>	O

<ALL>	O
This	O
mechanism	O
can	O
be	O
considered	O
as	O
a	O
target	O
to	O
protect	O
infarcted	B-Disease
myocardium	I-Disease
.	O
</ALL>	O

<ALL>	O
High	O
glucose	B-Chemical
repatterns	O
human	B-Species
podocyte	O
energy	O
metabolism	O
during	O
differentiation	O
and	O
diabetic	B-Disease
nephropathy	I-Disease
.	O
</ALL>	O

<ALL>	O
Podocytes	O
play	O
a	O
key	O
role	O
in	O
diabetic	B-Disease
nephropathy	I-Disease
pathogenesis	O
,	O
but	O
alteration	O
of	O
their	O
metabolism	O
remains	O
unknown	O
in	O
human	B-Species
kidney	O
.	O
</ALL>	O

<ALL>	O
By	O
using	O
a	O
conditionally	O
differentiating	O
human	B-Species
podocyte	O
cell	O
line	O
,	O
we	O
addressed	O
the	O
functional	O
and	O
molecular	O
changes	O
in	O
podocyte	O
energetics	O
during	O
in	O
vitro	O
development	O
or	O
under	O
high	O
glucose	B-Chemical
conditions	O
.	O
</ALL>	O

<ALL>	O
In	O
5	O
mM	O
glucose	B-Chemical
medium	O
,	O
we	O
observed	O
a	O
stepwise	O
activation	O
of	O
oxidative	O
metabolism	O
during	O
cell	O
differentiation	O
that	O
was	O
characterized	O
by	O
peroxisome	B-Gene
proliferator	I-Gene
-	I-Gene
activated	I-Gene
receptor	I-Gene
-	I-Gene
g	I-Gene
coactivator	I-Gene
1a	I-Gene
(	O
PGC	B-Gene
-	I-Gene
1a	I-Gene
)	O
-	O
dependent	O
stimulation	O
of	O
mitochondrial	O
biogenesis	O
and	O
function	O
,	O
with	O
concomitant	O
reduction	O
of	O
the	O
glycolytic	O
enzyme	O
content	O
.	O
</ALL>	O

<ALL>	O
Conversely	O
,	O
when	O
podocytes	O
were	O
cultured	O
in	O
high	O
glucose	B-Chemical
(	O
20	O
mM	O
)	O
,	O
stepwise	O
oxidative	O
phosphorylation	O
biogenesis	O
was	O
aborted	O
,	O
and	O
a	O
glycolytic	O
switch	O
occurred	O
,	O
with	O
consecutive	O
lactic	B-Disease
acidosis	I-Disease
.	O
</ALL>	O

<ALL>	O
Expression	O
of	O
the	O
master	B-Gene
regulators	I-Gene
of	I-Gene
oxidative	I-Gene
metabolism	I-Gene
transcription	I-Gene
factor	I-Gene
A	I-Gene
mitochondrial	I-Gene
,	O
PGC	B-Gene
-	I-Gene
1a	I-Gene
,	O
AMPK	B-Gene
,	O
and	O
serine	B-Gene
-	I-Gene
threonine	I-Gene
liver	I-Gene
kinase	I-Gene
B1	I-Gene
was	O
altered	O
by	O
high	O
glucose	B-Chemical
,	O
as	O
well	O
as	O
their	O
downstream	O
signaling	O
networks	O
.	O
</ALL>	O

<ALL>	O
Focused	O
transcriptomics	O
revealed	O
that	O
myocyte	B-Gene
-	I-Gene
specific	I-Gene
enhancer	I-Gene
factor	I-Gene
2C	I-Gene
(	O
MEF2C	B-Gene
)	O
and	O
myogenic	B-Gene
factor	I-Gene
5	I-Gene
(	O
MYF5	B-Gene
)	O
expression	O
was	O
inhibited	O
by	O
high	O
glucose	B-Chemical
levels	O
,	O
and	O
endoribonuclease	O
-	O
prepared	O
small	O
interfering	O
RNA	O
-	O
mediated	O
combined	O
inhibition	O
of	O
those	O
transcription	O
factors	O
phenocopied	O
the	O
glycolytic	O
shift	O
that	O
was	O
observed	O
in	O
high	O
glucose	B-Chemical
conditions	O
.	O
</ALL>	O

<ALL>	O
Accordingly	O
,	O
a	O
reduced	O
expression	O
of	O
MEF2C	B-Gene
,	O
MYF5	B-Gene
,	O
and	O
PGC	B-Gene
-	I-Gene
1a	I-Gene
was	O
found	O
in	O
kidney	O
tissue	O
sections	O
that	O
were	O
obtained	O
from	O
patients	B-Species
with	O
diabetic	B-Disease
nephropathy	I-Disease
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
obtained	O
in	O
human	B-Species
samples	O
demonstrate	O
that	O
MEF2C	B-Gene
-	O
MYF5	B-Gene
-	O
dependent	O
bioenergetic	O
dedifferentiation	O
occurs	O
in	O
podocytes	O
that	O
are	O
confronted	O
with	O
a	O
high	O
-	O
glucose	B-Chemical
milieu	O
.	O
-	O
</ALL>	O

<ALL>	O
Imasawa	O
,	O
T.	O
,	O
Obre	O
,	O
E.	O
,	O
Bellance	O
,	O
N.	O
,	O
Lavie	O
,	O
J.	O
,	O
Imasawa	O
,	O
T.	O
,	O
Rigothier	O
,	O
C.	O
,	O
Delmas	O
,	O
Y.	O
,	O
Combe	O
,	O
C.	O
,	O
Lacombe	O
,	O
D.	O
,	O
Benard	O
,	O
G.	O
,	O
Claverol	O
,	O
S.	O
,	O
Bonneu	O
,	O
M.	O
,	O
Rossignol	O
,	O
R.	O
High	O
glucose	B-Chemical
repatterns	O
human	B-Species
podocyte	O
energy	O
metabolism	O
during	O
differentiation	O
and	O
diabetic	B-Disease
nephropathy	I-Disease
.	O
</ALL>	O

<ALL>	O
Role	O
of	O
protein	B-Gene
arginine	I-Gene
methyltransferase	I-Gene
5	I-Gene
in	O
inflammation	B-Disease
and	O
migration	O
of	O
fibroblast	O
-	O
like	O
synoviocytes	O
in	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O
</ALL>	O

<ALL>	O
To	O
probe	O
the	O
role	O
of	O
protein	B-Gene
arginine	I-Gene
methyltransferase	I-Gene
5	I-Gene
(	O
PRMT5	B-Gene
)	O
in	O
regulating	O
inflammation	B-Disease
,	O
cell	O
proliferation	O
,	O
migration	O
and	O
invasion	O
of	O
fibroblast	O
-	O
like	O
synoviocytes	O
(	O
FLSs	O
)	O
from	O
patients	B-Species
with	O
rheumatoid	B-Disease
arthritis	I-Disease
(	O
RA	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
FLSs	O
were	O
separated	O
from	O
synovial	O
tissues	O
(	O
STs	O
)	O
from	O
patients	B-Species
with	O
RA	B-Disease
and	O
osteoarthritis	B-Disease
(	O
OA	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
An	O
inhibitor	O
of	O
PRMT5	B-Gene
(	O
EPZ015666	B-Chemical
)	O
and	O
short	O
interference	O
RNA	O
(	O
siRNA	O
)	O
against	O
PRMT5	B-Gene
were	O
used	O
to	O
inhibit	O
PRMT5	B-Gene
expression	O
.	O
</ALL>	O

<ALL>	O
The	O
standard	O
of	O
protein	O
was	O
measured	O
by	O
Western	O
blot	O
or	O
immunofluorescence	O
.	O
</ALL>	O

<ALL>	O
The	O
excretion	O
and	O
genetic	O
expression	O
of	O
inflammatory	B-Disease
factors	O
were	O
,	O
respectively	O
,	O
estimated	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O
</ALL>	O

<ALL>	O
Migration	O
and	O
invasion	O
in	O
vitro	O
were	O
detected	O
by	O
Boyden	O
chamber	O
assay	O
.	O
</ALL>	O

<ALL>	O
FLSs	O
proliferation	O
was	O
detected	O
by	O
BrdU	O
incorporation	O
.	O
</ALL>	O

<ALL>	O
Increased	O
PRMT5	B-Gene
was	O
discovered	O
in	O
STs	O
and	O
FLSs	O
from	O
patients	B-Species
with	O
RA	B-Disease
.	O
</ALL>	O

<ALL>	O
In	O
RA	B-Disease
FLSs	O
,	O
the	O
level	O
of	O
PRMT5	B-Gene
was	O
up	O
-	O
regulated	O
by	O
stimulation	O
with	O
IL	B-Gene
-	I-Gene
1b	I-Gene
and	O
TNF	B-Gene
-	I-Gene
a	I-Gene
.	O
</ALL>	O

<ALL>	O
Inhibition	O
of	O
PRMT5	B-Gene
by	O
EPZ015666	B-Chemical
and	O
siRNA	O
-	O
mediated	O
knockdown	O
reduced	O
IL	B-Gene
-	I-Gene
6	I-Gene
and	O
IL	B-Gene
-	I-Gene
8	I-Gene
production	O
,	O
and	O
proliferation	O
of	O
RA	B-Disease
FLSs	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
inhibition	O
of	O
PRMT5	B-Gene
decreased	O
in	O
vitro	O
migration	O
and	O
invasion	O
of	O
RA	B-Disease
FLSs	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
EPZ015666	B-Chemical
restrained	O
the	O
phosphorylation	O
of	O
IkB	B-Gene
kinaseb	I-Gene
and	O
IkBa	B-Gene
,	O
as	O
well	O
as	O
nucleus	O
transsituation	O
of	O
p65	B-Gene
as	O
well	O
as	O
AKT	B-Gene
in	O
FLSs	O
.	O
</ALL>	O

<ALL>	O
PRMT5	B-Gene
regulated	O
the	O
production	O
of	O
inflammatory	B-Disease
factors	O
,	O
cell	O
proliferation	O
,	O
migration	O
and	O
invasion	O
of	O
RA	B-Disease
FLS	O
,	O
which	O
was	O
mediated	O
by	O
the	O
NF	B-Gene
-	I-Gene
kB	I-Gene
and	O
AKT	B-Gene
pathways	O
.	O
</ALL>	O

<ALL>	O
Our	O
data	O
suggested	O
that	O
targeting	O
PRMT5	B-Gene
to	O
prevent	O
synovial	B-Disease
inflammation	I-Disease
and	O
destruction	O
might	O
be	O
a	O
promising	O
therapy	O
for	O
RA	B-Disease
.	O
</ALL>	O

<ALL>	O
Metalloprotease	B-Gene
-	I-Gene
disintegrin	I-Gene
ADAM12	B-Gene
actively	O
promotes	O
the	O
stem	O
cell	O
-	O
like	O
phenotype	O
in	O
claudin	B-Gene
-	O
low	O
breast	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
ADAM12	B-Gene
is	O
upregulated	O
in	O
human	B-Species
breast	B-Disease
cancers	I-Disease
and	O
is	O
a	O
predictor	O
of	O
chemoresistance	O
in	O
estrogen	B-Gene
receptor	I-Gene
-	O
negative	O
tumors	B-Disease
.	O
</ALL>	O

<ALL>	O
ADAM12	B-Gene
is	O
induced	O
during	O
epithelial	O
-	O
to	O
-	O
mesenchymal	O
transition	O
,	O
a	O
feature	O
associated	O
with	O
claudin	B-Gene
-	O
low	O
breast	B-Disease
tumors	I-Disease
,	O
which	O
are	O
enriched	O
in	O
cancer	B-Disease
stem	O
cell	O
(	O
CSC	O
)	O
markers	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
currently	O
unknown	O
whether	O
ADAM12	B-Gene
plays	O
an	O
active	O
role	O
in	O
promoting	O
the	O
CSC	O
phenotype	O
in	O
breast	B-Disease
cancer	I-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
ADAM12	B-Gene
expression	O
was	O
downregulated	O
in	O
representative	O
claudin	B-Gene
-	O
low	O
breast	B-Disease
cancer	I-Disease
cell	O
lines	O
,	O
SUM159PT	B-CellLine
and	O
Hs578	B-CellLine
T	I-CellLine
,	O
using	O
siRNA	O
transfection	O
or	O
inducible	O
shRNA	O
expression	O
.	O
</ALL>	O

<ALL>	O
Cell	O
characteristics	O
commonly	O
associated	O
with	O
the	O
CSC	O
phenotype	O
in	O
vitro	O
(	O
cell	O
migration	O
,	O
invasion	O
,	O
anoikis	O
resistance	O
,	O
mammosphere	O
formation	O
,	O
ALDH	B-Gene
activity	O
,	O
and	O
expression	O
of	O
the	O
CD44	B-Gene
and	O
CD24	B-Gene
cell	O
surface	O
markers	O
)	O
and	O
in	O
vivo	O
(	O
tumor	B-Disease
formation	O
in	O
mice	B-Species
using	O
limiting	O
dilution	O
transplantation	O
assays	O
)	O
were	O
evaluated	O
.	O
</ALL>	O

<ALL>	O
RNA	O
sequencing	O
was	O
performed	O
to	O
identify	O
global	O
gene	O
expression	O
changes	O
after	O
ADAM12	B-Gene
knockdown	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
We	O
found	O
that	O
sorted	O
SUM159PT	B-CellLine
cell	O
populations	O
with	O
high	O
ADAM12	B-Gene
levels	O
had	O
elevated	O
expression	O
of	O
CSC	O
markers	O
and	O
an	O
increased	O
ability	O
to	O
form	O
mammospheres	O
.	O
</ALL>	O

<ALL>	O
ADAM12	B-Gene
knockdown	O
reduced	O
cell	O
migration	O
and	O
invasion	O
,	O
decreased	O
anoikis	O
resistance	O
,	O
and	O
compromised	O
mammosphere	O
formation	O
.	O
</ALL>	O

<ALL>	O
ADAM12	B-Gene
knockdown	O
also	O
diminished	O
ALDEFLUOR	O
(	O
+	O
)	O
and	O
CD44	B-Gene
(	O
hi	O
)	O
/	O
CD24	B-Gene
(	O
-	O
/	O
lo	O
)	O
CSC	O
-	O
enriched	O
populations	O
in	O
vitro	O
and	O
reduced	O
tumorigenesis	B-Disease
in	O
mice	B-Species
in	O
vivo	O
.	O
</ALL>	O

<ALL>	O
RNA	O
sequencing	O
identified	O
a	O
significant	O
overlap	O
between	O
ADAM12	B-Gene
-	O
and	O
Epidermal	B-Gene
Growth	I-Gene
Factor	I-Gene
Receptor	I-Gene
(	O
EGFR	B-Gene
)	O
-	O
regulated	O
genes	O
.	O
</ALL>	O

<ALL>	O
Consequently	O
,	O
ADAM12	B-Gene
knockdown	O
lowered	O
the	O
basal	O
activation	O
level	O
of	O
EGFR	B-Gene
,	O
and	O
this	O
effect	O
was	O
abolished	O
by	O
batimastat	B-Chemical
,	O
a	O
metalloproteinase	B-Gene
inhibitor	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
incubation	O
of	O
cells	O
with	O
exogenously	O
added	O
EGF	B-Gene
prevented	O
the	O
downregulation	O
of	O
CD44	B-Gene
(	O
hi	O
)	O
/	O
CD24	B-Gene
(	O
-	O
/	O
lo	O
)	O
cell	O
population	O
by	O
ADAM12	B-Gene
knockdown	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
ADAM12	B-Gene
actively	O
supports	O
the	O
CSC	O
phenotype	O
in	O
claudin	B-Gene
-	O
low	O
breast	B-Disease
cancer	I-Disease
cells	O
via	O
modulation	O
of	O
the	O
EGFR	B-Gene
pathway	O
.	O
</ALL>	O

<ALL>	O
Compound	O
heterozygous	O
mutations	O
in	O
the	O
SRD5A2	B-Gene
gene	O
exon	O
4	O
in	O
a	O
male	B-Disease
pseudohermaphrodite	I-Disease
patient	B-Species
of	O
Chinese	O
origin	O
.	O
</ALL>	O

<ALL>	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
perform	O
5	B-Gene
-	I-Gene
alpha	I-Gene
-	I-Gene
reductase	I-Gene
type	I-Gene
2	I-Gene
gene	O
(	O
SRD5A2	B-Gene
)	O
analysis	O
in	O
a	O
male	B-Disease
pseudohermaphrodite	I-Disease
(	O
MPH	B-Disease
)	O
patient	B-Species
with	O
normal	O
testosterone	B-Chemical
(	O
T	B-Chemical
)	O
production	O
and	O
normal	O
androgen	B-Gene
receptor	I-Gene
(	O
AR	B-Gene
)	O
gene	O
coding	O
sequences	O
.	O
</ALL>	O

<ALL>	O
A	O
patient	B-Species
of	O
Chinese	O
origin	O
with	O
ambiguous	O
genitalia	O
at	O
14	O
months	O
,	O
a	O
46,XY	O
karyotype	O
,	O
and	O
normal	O
T	B-Chemical
secretion	O
under	O
human	B-Chemical
chorionic	I-Chemical
gonadotropin	I-Chemical
(	O
hCG	B-Chemical
)	O
stimulation	O
underwent	O
a	O
gonadectomy	O
at	O
20	O
months	O
.	O
</ALL>	O

<ALL>	O
Exons	O
1	O
-	O
8	O
of	O
the	O
AR	B-Gene
gene	O
and	O
exons	O
1	O
-	O
5	O
of	O
the	O
SRD5A2	B-Gene
gene	O
were	O
sequenced	O
from	O
peripheral	O
blood	O
DNA	O
.	O
</ALL>	O

<ALL>	O
AR	B-Gene
gene	O
coding	O
sequences	O
were	O
normal	O
.	O
</ALL>	O

<ALL>	O
SRD5A2	B-Gene
gene	O
analysis	O
revealed	O
2	O
consecutive	O
mutations	O
in	O
exon	O
4	O
,	O
each	O
located	O
in	O
a	O
different	O
allele	O
:	O
1	O
)	O
a	O
T	B-Variant
nucleotide	I-Variant
deletion	I-Variant
,	I-Variant
which	I-Variant
predicts	I-Variant
a	I-Variant
frameshift	I-Variant
mutation	I-Variant
from	I-Variant
codon	I-Variant
219	I-Variant
,	O
and	O
2	O
)	O
a	O
missense	O
mutation	O
at	O
codon	O
227	O
,	O
where	O
the	O
substitution	O
of	O
guanine	B-Variant
(	I-Variant
CGA	I-Variant
)	I-Variant
by	I-Variant
adenine	I-Variant
(	I-Variant
CAA	I-Variant
)	I-Variant
predicts	O
a	O
glutamine	B-Variant
replacement	I-Variant
of	I-Variant
arginine	I-Variant
(	O
R227Q	B-Variant
)	O
.	O
</ALL>	O

<ALL>	O
Testes	O
located	O
in	O
the	O
inguinal	O
canal	O
showed	O
a	O
normal	O
morphology	O
for	O
age	O
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
was	O
a	O
compound	O
heterozygote	O
for	O
SRD5A2	B-Gene
mutations	O
,	O
carrying	O
2	O
mutations	O
in	O
exon	O
4	O
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
showed	O
an	O
R227Q	B-Variant
mutation	O
that	O
has	O
been	O
described	O
in	O
an	O
Asian	O
population	O
and	O
MPH	B-Disease
patients	B-Species
,	O
along	O
with	O
a	O
novel	O
frameshift	O
mutation	O
,	O
Tdel219	B-Variant
.	O
</ALL>	O

<ALL>	O
Testis	O
morphology	O
showed	O
that	O
,	O
during	O
early	O
infancy	O
,	O
the	O
5	B-Gene
-	I-Gene
alpha	I-Gene
-	I-Gene
reductase	I-Gene
enzyme	O
deficiency	O
may	O
not	O
have	O
affected	O
interstitial	O
or	O
tubular	O
development	O
.	O
</ALL>	O

<ALL>	O
Tumor	B-Disease
associated	O
antigen	O
recognition	O
by	O
autologous	O
serum	O
in	O
patients	B-Species
with	O
breast	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
Breast	B-Disease
cancer	I-Disease
accounts	O
for	O
30	O
-	O
40	O
%	O
of	O
all	O
deaths	O
from	O
cancers	B-Disease
in	O
females	O
.	O
</ALL>	O

<ALL>	O
In	O
an	O
effort	O
to	O
identify	O
tumor	B-Disease
associated	O
antigens	O
that	O
may	O
be	O
useful	O
for	O
immunotherapy	O
,	O
we	O
utilized	O
serological	O
analysis	O
of	O
recombinant	O
cDNA	O
expression	O
libraries	O
(	O
SEREX	O
)	O
technique	O
to	O
identify	O
breast	B-Disease
cancer	I-Disease
-	O
associated	O
antigens	O
.	O
</ALL>	O

<ALL>	O
SEREX	O
screening	O
of	O
cDNA	O
expression	O
libraries	O
derived	O
from	O
3	O
breast	B-Disease
cancer	I-Disease
patients	B-Species
identified	O
a	O
total	O
of	O
88	O
positive	O
clones	O
(	O
bcg	O
-	O
1	O
to	O
bcg	O
-	O
88	O
)	O
,	O
including	O
27	O
hitherto	O
unknown	O
sequences	O
.	O
</ALL>	O

<ALL>	O
The	O
cDNA	O
sequences	O
and	O
mRNA	O
expression	O
patterns	O
were	O
characterized	O
.	O
</ALL>	O

<ALL>	O
Seroreactivity	O
of	O
the	O
SEREX	O
clones	O
were	O
determined	O
in	O
sera	O
from	O
75	O
breast	B-Disease
cancer	I-Disease
patients	B-Species
,	O
75	O
colon	B-Disease
cancer	I-Disease
patients	B-Species
,	O
and	O
25	O
healthy	O
donors	O
.	O
</ALL>	O

<ALL>	O
Expression	O
analysis	O
on	O
a	O
cDNA	O
panel	O
from	O
17	O
different	O
normal	O
tissues	O
by	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
revealed	O
tissue	O
restricted	O
mRNA	O
expression	O
of	O
2	O
of	O
the	O
27	O
unknown	O
antigens	O
.	O
</ALL>	O

<ALL>	O
Bcg	O
-	O
72	O
is	O
expressed	O
only	O
in	O
breast	O
,	O
prostate	O
and	O
thymus	O
,	O
while	O
bcg	O
-	O
84	O
is	O
expressed	O
at	O
moderate	O
levels	O
in	O
testis	O
,	O
spleen	O
and	O
breast	O
.	O
</ALL>	O

<ALL>	O
The	O
other	O
25	O
unknown	O
antigens	O
were	O
expressed	O
in	O
most	O
other	O
tissues	O
.	O
</ALL>	O

<ALL>	O
Serologic	O
assay	O
revealed	O
that	O
7	O
out	O
of	O
the	O
88	O
clones	O
showed	O
reactivity	O
to	O
at	O
least	O
one	O
serum	O
from	O
either	O
75	O
breast	O
or	O
75	O
colon	B-Disease
cancer	I-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
These	O
clones	O
did	O
not	O
react	O
with	O
sera	O
from	O
a	O
panel	O
of	O
25	O
healthy	O
adult	O
individuals	O
.	O
</ALL>	O

<ALL>	O
Our	O
results	O
demonstrate	O
the	O
utility	O
of	O
the	O
SEREX	O
approach	O
for	O
the	O
identification	O
of	O
potential	O
tumor	B-Disease
associated	O
antigens	O
in	O
human	B-Species
breast	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
TGFBI	B-Gene
gene	O
mutations	O
causing	O
lattice	B-Disease
and	I-Disease
granular	I-Disease
corneal	I-Disease
dystrophies	I-Disease
in	O
Indian	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
To	O
identify	O
mutations	O
in	O
the	O
TGFBI	B-Gene
gene	O
in	O
Indian	O
patients	B-Species
with	O
lattice	B-Disease
corneal	I-Disease
dystrophy	I-Disease
(	O
LCD	B-Disease
)	O
or	O
granular	B-Disease
corneal	I-Disease
dystrophy	I-Disease
(	O
GCD	B-Disease
)	O
and	O
to	O
look	O
for	O
genotype	O
-	O
phenotype	O
correlations	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Thirty	O
-	O
seven	O
unrelated	O
patients	B-Species
were	O
studied	O
,	O
18	O
with	O
LCD	B-Disease
and	O
19	O
with	O
GCD	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
diagnosis	O
of	O
LCD	B-Disease
or	O
GCD	B-Disease
was	O
made	O
on	O
the	O
basis	O
of	O
clinical	O
and	O
/	O
or	O
histopathological	O
evaluation	O
.	O
</ALL>	O

<ALL>	O
Exons	O
and	O
flanking	O
intron	O
sequences	O
of	O
the	O
TGFBI	B-Gene
gene	O
were	O
amplified	O
by	O
PCR	O
with	O
specific	O
primers	O
.	O
</ALL>	O

<ALL>	O
PCR	O
products	O
were	O
screened	O
by	O
the	O
method	O
of	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
followed	O
by	O
sequencing	O
.	O
</ALL>	O

<ALL>	O
Mutations	O
were	O
confirmed	O
by	O
screening	O
at	O
least	O
100	O
unrelated	O
normal	O
control	O
subjects	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Mutations	O
were	O
identified	O
in	O
14	O
of	O
18	O
patients	B-Species
with	O
LCD	B-Disease
and	O
in	O
all	O
19	O
patients	B-Species
with	O
GCD	B-Disease
.	O
</ALL>	O

<ALL>	O
In	O
LCD	B-Disease
,	O
three	O
novel	O
heterozygous	O
mutations	O
found	O
were	O
glycine	B-Variant
-	I-Variant
594	I-Variant
-	I-Variant
valine	I-Variant
(	O
Gly594Val	B-Variant
)	O
in	O
2	O
of	O
18	O
patients	B-Species
,	O
valine	B-Variant
-	I-Variant
539	I-Variant
-	I-Variant
aspartic	I-Variant
acid	I-Variant
(	O
Val539Asp	B-Variant
)	O
in	O
1	O
patient	B-Species
,	O
and	O
deletion	B-Variant
of	I-Variant
valine	I-Variant
624	I-Variant
,	I-Variant
valine	I-Variant
625	I-Variant
(	O
Val624	B-Variant
-	I-Variant
Val625del	I-Variant
)	O
in	O
1	O
patient	B-Species
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
mutation	O
of	O
arginine	B-Variant
124	I-Variant
-	I-Variant
to	I-Variant
-	I-Variant
cysteine	I-Variant
(	O
Arg124Cys	B-Variant
)	O
was	O
found	O
in	O
8	O
of	O
18	O
patients	B-Species
and	O
histidine	B-Variant
626	I-Variant
-	I-Variant
to	I-Variant
-	I-Variant
arginine	I-Variant
(	O
His626Arg	B-Variant
)	O
in	O
2	O
of	O
18	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Atypical	O
clinical	O
features	O
for	O
LCD	B-Disease
were	O
noted	O
in	O
patients	B-Species
with	O
the	O
Gly594Val	B-Variant
and	O
Val624	B-Variant
-	I-Variant
Val625del	I-Variant
mutations	O
.	O
</ALL>	O

<ALL>	O
In	O
GCD	B-Disease
,	O
18	O
patients	B-Species
with	O
GCD	B-Disease
type	I-Disease
I	I-Disease
had	O
a	O
mutation	O
of	O
arginine	B-Variant
555	I-Variant
-	I-Variant
to	I-Variant
-	I-Variant
tryptophan	I-Variant
(	O
Arg555Trp	B-Variant
)	O
and	O
1	O
patient	B-Species
with	O
GCD	B-Disease
type	I-Disease
III	I-Disease
(	O
Reis	B-Disease
-	I-Disease
Bucklers	I-Disease
dystrophy	I-Disease
)	O
,	O
had	O
the	O
Arg124Leu	B-Variant
mutation	O
.	O
</ALL>	O

<ALL>	O
Seven	O
novel	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
were	O
also	O
found	O
,	O
of	O
which	O
a	O
change	O
of	O
leucine	B-Variant
269	I-Variant
to	I-Variant
phenylalanine	I-Variant
(	O
Leu269Phe	B-Variant
)	O
was	O
found	O
in	O
12	O
of	O
18	O
patients	B-Species
with	O
the	O
Arg555Trp	B-Variant
mutation	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Arg124Cys	B-Variant
and	O
Arg555Trp	B-Variant
appear	O
to	O
be	O
the	O
predominant	O
mutations	O
causing	O
LCD	B-Disease
and	O
GCD	B-Disease
,	O
respectively	O
,	O
in	O
the	O
population	O
studied	O
.	O
</ALL>	O

<ALL>	O
The	O
novel	O
mutations	O
identified	O
in	O
this	O
study	O
are	O
associated	O
with	O
distinct	O
phenotypes	O
.	O
</ALL>	O

<ALL>	O
A	O
two	O
base	O
pair	O
deletion	O
in	O
the	O
PQBP1	B-Gene
gene	O
is	O
associated	O
with	O
microphthalmia	B-Disease
,	O
microcephaly	B-Disease
,	O
and	O
mental	B-Disease
retardation	I-Disease
.	O
</ALL>	O

<ALL>	O
X	B-Disease
-	I-Disease
linked	I-Disease
mental	I-Disease
retardation	I-Disease
has	O
been	O
traditionally	O
divided	O
into	O
syndromic	O
(	O
S	O
-	O
XLMR	B-Disease
)	O
and	O
non	O
-	O
syndromic	O
forms	O
(	O
NS	O
-	O
XLMR	B-Disease
)	O
,	O
although	O
the	O
borderlines	O
between	O
these	O
phenotypes	O
begin	O
to	O
vanish	O
and	O
mutations	O
in	O
a	O
single	O
gene	O
,	O
for	O
example	O
PQBP1	B-Gene
,	O
can	O
cause	O
S	O
-	O
XLMR	B-Disease
as	O
well	O
as	O
NS	O
-	O
XLMR	B-Disease
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
report	O
two	O
maternal	O
cousins	O
with	O
an	O
apparently	O
X	B-Disease
-	I-Disease
linked	I-Disease
phenotype	I-Disease
of	I-Disease
mental	I-Disease
retardation	I-Disease
(	O
MR	B-Disease
)	O
,	O
microphthalmia	B-Disease
,	O
choroid	B-Disease
coloboma	I-Disease
,	O
microcephaly	B-Disease
,	O
renal	B-Disease
hypoplasia	I-Disease
,	O
and	O
spastic	B-Disease
paraplegia	I-Disease
.	O
</ALL>	O

<ALL>	O
By	O
multipoint	O
linkage	O
analysis	O
with	O
markers	O
spanning	O
the	O
entire	O
X	O
-	O
chromosome	O
we	O
mapped	O
the	O
disease	O
locus	O
to	O
a	O
28	O
-	O
Mb	O
interval	O
between	O
Xp11.4	O
and	O
Xq12	O
,	O
including	O
the	O
BCOR	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
A	O
missense	O
mutation	O
in	O
BCOR	B-Gene
was	O
described	O
in	O
a	O
family	O
with	O
Lenz	B-Disease
microphthalmia	I-Disease
syndrome	I-Disease
,	O
a	O
phenotype	O
showing	O
substantial	O
overlapping	O
features	O
with	O
that	O
described	O
in	O
the	O
two	O
cousins	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
no	O
mutation	O
in	O
the	O
BCOR	B-Gene
gene	O
was	O
found	O
in	O
both	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Subsequent	O
mutation	O
analysis	O
of	O
PQBP1	B-Gene
,	O
located	O
within	O
the	O
delineated	O
linkage	O
interval	O
in	O
Xp11.23	O
,	O
revealed	O
a	O
2	O
-	O
bp	O
deletion	O
,	O
c.461	B-Variant
_	I-Variant
462delAG	I-Variant
,	O
that	O
cosegregated	O
with	O
the	O
disease	O
.	O
</ALL>	O

<ALL>	O
Notably	O
,	O
the	O
same	O
mutation	O
is	O
associated	O
with	O
the	O
Hamel	B-Disease
cerebropalatocardiac	I-Disease
syndrome	I-Disease
,	O
another	O
form	O
of	O
S	O
-	O
XLMR	B-Disease
.	O
</ALL>	O

<ALL>	O
Haplotype	O
analysis	O
suggests	O
a	O
germline	O
mosaicism	O
of	O
the	O
2	O
-	O
bp	O
deletion	O
in	O
the	O
maternal	O
grandmother	O
of	O
both	O
affected	O
individuals	O
.	O
</ALL>	O

<ALL>	O
In	O
summary	O
,	O
our	O
findings	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
mutations	O
in	O
PQBP1	B-Gene
are	O
associated	O
with	O
an	O
S	O
-	O
XLMR	B-Disease
phenotype	O
including	O
microphthalmia	B-Disease
,	O
thereby	O
further	O
extending	O
the	O
clinical	O
spectrum	O
of	O
phenotypes	O
associated	O
with	O
PQBP1	B-Gene
mutations	O
.	O
</ALL>	O

<ALL>	O
Interaction	O
between	O
warfarin	B-Chemical
and	O
levofloxacin	B-Chemical
:	O
case	O
series	O
.	O
</ALL>	O

<ALL>	O
Warfarin	B-Chemical
is	O
the	O
most	O
widely	O
used	O
oral	O
anticoagulant	O
and	O
is	O
indicated	O
for	O
many	O
clinical	O
conditions	O
.	O
</ALL>	O

<ALL>	O
Levofloxacin	B-Chemical
,	O
a	O
fluoroquinolone	B-Chemical
,	O
is	O
one	O
of	O
the	O
most	O
commonly	O
prescribed	O
antibiotics	O
in	O
clinical	O
practice	O
and	O
is	O
effective	O
against	O
Gram	O
-	O
positive	O
,	O
Gram	O
-	O
negative	O
,	O
and	O
atypical	O
bacteria	B-Species
.	O
</ALL>	O

<ALL>	O
While	O
small	O
prospective	O
studies	O
have	O
not	O
revealed	O
any	O
significant	O
drug	O
-	O
drug	O
interaction	O
between	O
warfarin	B-Chemical
and	O
levofloxacin	B-Chemical
,	O
several	O
case	O
reports	O
have	O
indicated	O
that	O
levofloxacin	B-Chemical
may	O
significantly	O
potentiate	O
the	O
anticoagulation	O
effect	O
of	O
warfarin	B-Chemical
.	O
</ALL>	O

<ALL>	O
We	O
report	O
3	O
cases	O
of	O
serious	O
bleeding	B-Disease
complications	O
that	O
appear	O
to	O
be	O
the	O
result	O
of	O
the	O
interaction	O
between	O
warfarin	B-Chemical
and	O
levofloxacin	B-Chemical
.	O
</ALL>	O

<ALL>	O
Physicians	O
should	O
be	O
aware	O
of	O
this	O
potential	O
interaction	O
and	O
use	O
caution	O
when	O
prescribing	O
levofloxacin	B-Chemical
to	O
patients	B-Species
taking	O
warfarin	B-Chemical
.	O
</ALL>	O

<ALL>	O
Rapid	O
reversal	O
of	O
anticoagulation	O
reduces	O
hemorrhage	B-Disease
volume	O
in	O
a	O
mouse	B-Species
model	O
of	O
warfarin	B-Chemical
-	O
associated	O
intracerebral	B-Disease
hemorrhage	I-Disease
.	O
</ALL>	O

<ALL>	O
Warfarin	B-Chemical
-	O
associated	O
intracerebral	B-Disease
hemorrhage	I-Disease
(	O
W	B-Chemical
-	O
ICH	B-Disease
)	O
is	O
a	O
severe	O
type	O
of	O
stroke	B-Disease
.	O
</ALL>	O

<ALL>	O
There	O
is	O
no	O
consensus	O
on	O
the	O
optimal	O
treatment	O
for	O
W	B-Chemical
-	O
ICH	B-Disease
.	O
</ALL>	O

<ALL>	O
Using	O
a	O
mouse	B-Species
model	O
,	O
we	O
tested	O
whether	O
the	O
rapid	O
reversal	O
of	O
anticoagulation	O
using	O
human	B-Species
prothrombin	B-Chemical
complex	I-Chemical
concentrate	I-Chemical
(	O
PCC	B-Chemical
)	O
can	O
reduce	O
hemorrhagic	O
blood	O
volume	O
.	O
</ALL>	O

<ALL>	O
Male	O
CD	O
-	O
1	O
mice	B-Species
were	O
treated	O
with	O
warfarin	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
over	O
24	O
h	O
)	O
,	O
resulting	O
in	O
a	O
mean	O
(	O
+	O
/	O
-	O
s.d	O
.	O
)	O
</ALL>	O

<ALL>	O
International	O
Normalized	O
Ratio	O
of	O
3.5	O
+	O
/	O
-	O
0.9	O
.	O
</ALL>	O

<ALL>	O
First	O
,	O
we	O
showed	O
that	O
an	O
intravenous	O
administration	O
of	O
human	B-Species
PCC	B-Chemical
rapidly	O
reversed	O
anticoagulation	O
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Second	O
,	O
a	O
stereotactic	O
injection	O
of	O
collagenase	B-Chemical
was	O
administered	O
to	O
induce	O
hemorrhage	B-Disease
in	O
the	O
right	O
striatum	O
.	O
</ALL>	O

<ALL>	O
Forty	O
-	O
five	O
minutes	O
later	O
,	O
the	O
animals	O
were	O
randomly	O
treated	O
with	O
PCC	B-Chemical
(	O
100	O
U	O
/	O
kg	O
)	O
or	O
saline	O
i.v	O
.	O
(	O
</ALL>	O

<ALL>	O
n	O
=	O
12	O
per	O
group	O
)	O
.	O
</ALL>	O

<ALL>	O
Twenty	O
-	O
four	O
hours	O
after	O
hemorrhage	B-Disease
induction	O
,	O
hemorrhagic	O
blood	O
volume	O
was	O
quantified	O
using	O
a	O
photometric	O
hemoglobin	O
assay	O
.	O
</ALL>	O

<ALL>	O
The	O
mean	O
hemorrhagic	O
blood	O
volume	O
was	O
reduced	O
in	O
PCC	B-Chemical
-	O
treated	O
animals	O
(	O
6.5	O
+	O
/	O
-	O
3.1	O
microL	O
)	O
compared	O
with	O
saline	O
controls	O
(	O
15.3	O
+	O
/	O
-	O
11.2	O
microL	O
,	O
P	O
=	O
0.015	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
saline	O
group	O
,	O
45	O
%	O
of	O
the	O
mice	B-Species
developed	O
large	O
hematomas	B-Disease
(	O
i.e.	O
,	O
>	O
15	O
microL	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
such	O
extensive	O
lesions	O
were	O
never	O
found	O
in	O
the	O
PCC	B-Chemical
group	O
.	O
</ALL>	O

<ALL>	O
We	O
provide	O
experimental	O
data	O
suggesting	O
PCC	B-Chemical
to	O
be	O
an	O
effective	O
acute	O
treatment	O
for	O
W	B-Chemical
-	O
ICH	B-Disease
in	O
terms	O
of	O
reducing	O
hemorrhagic	O
blood	O
volume	O
.	O
</ALL>	O

<ALL>	O
Future	O
studies	O
are	O
needed	O
to	O
assess	O
the	O
therapeutic	O
potential	O
emerging	O
from	O
our	O
finding	O
for	O
human	B-Species
W	B-Chemical
-	O
ICH	B-Disease
.	O
</ALL>	O

<ALL>	O
FGFR4	B-Gene
Gly388Arg	B-Variant
polymorphism	O
and	O
prostate	B-Disease
cancer	I-Disease
risk	O
in	O
Scottish	O
men	B-Species
.	O
</ALL>	O

<ALL>	O
Fibroblast	B-Gene
growth	I-Gene
factor	I-Gene
receptor	I-Gene
4	I-Gene
(	O
FGFR4	B-Gene
)	O
,	O
a	O
member	O
of	O
the	O
fibroblast	B-Gene
growth	I-Gene
receptor	I-Gene
family	O
,	O
was	O
recently	O
reported	O
to	O
be	O
more	O
abundantly	O
expressed	O
in	O
malignant	O
than	O
benign	O
prostate	O
cells	O
.	O
</ALL>	O

<ALL>	O
A	O
single	O
nucleotide	O
polymorphism	O
at	O
position	O
388	O
of	O
the	O
FGFR4	B-Gene
amino	O
-	O
acid	O
sequence	O
results	O
in	O
the	O
substitution	O
of	O
glycine	B-Variant
(	I-Variant
Gly	I-Variant
)	I-Variant
with	I-Variant
arginine	I-Variant
(	I-Variant
Arg	I-Variant
)	I-Variant
and	O
higher	O
frequency	O
of	O
the	O
ArgArg	O
genotype	O
was	O
previously	O
found	O
in	O
prostate	B-Disease
cancer	I-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
DNA	O
was	O
extracted	O
from	O
the	O
blood	O
drawn	O
from	O
399	O
prostate	B-Disease
cancer	I-Disease
patients	B-Species
,	O
150	O
BPH	B-Disease
patients	B-Species
and	O
294	O
healthy	O
community	O
controls	O
.	O
</ALL>	O

<ALL>	O
Polymerase	O
chain	O
reaction	O
was	O
carried	O
out	O
and	O
single	O
nucleotide	O
polymorphisms	O
of	O
FGFR4	B-Gene
were	O
identified	O
by	O
restriction	O
enzyme	O
digestion	O
.	O
</ALL>	O

<ALL>	O
No	O
overall	O
association	O
is	O
detectable	O
between	O
the	O
Arg	O
allele	O
and	O
increased	O
prostate	B-Disease
cancer	I-Disease
risk	O
.	O
</ALL>	O

<ALL>	O
Subgroup	O
analysis	O
shows	O
a	O
higher	O
incidence	O
of	O
the	O
heterozygous	O
ArgGly	O
genotype	O
in	O
cancer	B-Disease
cases	O
than	O
in	O
the	O
combined	O
group	O
of	O
BPH	B-Disease
and	O
controls	O
(	O
P	O
<	O
0.05	O
)	O
;	O
this	O
difference	O
is	O
statistically	O
significant	O
between	O
cancer	B-Disease
and	O
BPH	B-Disease
patients	B-Species
but	O
not	O
between	O
cancer	B-Disease
cases	O
and	O
community	O
controls	O
.	O
</ALL>	O

<ALL>	O
The	O
single	O
nucleotide	O
polymorphism	O
Gly	B-Variant
(	I-Variant
388	I-Variant
)	I-Variant
Arg	I-Variant
in	O
FGFR4	B-Gene
is	O
not	O
associated	O
with	O
increased	O
risk	O
of	O
prostate	B-Disease
cancer	I-Disease
in	O
Scottish	O
men	B-Species
.	O
</ALL>	O

<ALL>	O
This	O
observation	O
is	O
in	O
contrast	O
with	O
results	O
from	O
two	O
previous	O
studies	O
conducted	O
in	O
the	O
USA	O
and	O
Japan	O
.	O
</ALL>	O

<ALL>	O
A	O
novel	O
point	O
mutation	O
in	O
helix	O
10	O
of	O
the	O
human	B-Species
glucocorticoid	B-Gene
receptor	I-Gene
causes	O
generalized	O
glucocorticoid	B-Disease
resistance	I-Disease
by	O
disrupting	O
the	O
structure	O
of	O
the	O
ligand	O
-	O
binding	O
domain	O
.	O
</ALL>	O

<ALL>	O
CONTEXT	O
:	O
Generalized	O
glucocorticoid	B-Disease
resistance	I-Disease
syndrome	O
is	O
a	O
rare	O
familial	O
or	O
sporadic	O
condition	O
characterized	O
by	O
partial	O
insensitivity	O
to	O
glucocorticoids	B-Chemical
,	O
caused	O
by	O
mutations	O
in	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
(	O
GR	B-Gene
)	O
gene	O
.	O
</ALL>	O

<ALL>	O
Most	O
of	O
the	O
reported	O
cases	O
are	O
adults	O
,	O
demonstrating	O
symptoms	O
associated	O
with	O
mineralocorticoid	B-Chemical
and	O
/	O
or	O
adrenal	O
androgen	B-Chemical
excess	O
caused	O
by	O
compensatively	O
increased	O
secretion	O
of	O
the	O
adrenocorticotropic	O
hormone	O
.	O
</ALL>	O

<ALL>	O
PATIENT	B-Species
:	O
We	O
identified	O
a	O
new	O
2	O
-	O
yr	O
-	O
old	O
female	O
case	O
of	O
generalized	O
glucocorticoid	B-Disease
resistance	I-Disease
syndrome	O
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
(	O
TJ	O
)	O
presented	O
with	O
a	O
generalized	O
seizure	B-Disease
associated	O
with	O
hypoglycemia	B-Disease
and	O
hypokalemia	B-Disease
.	O
</ALL>	O

<ALL>	O
She	O
also	O
had	O
hypertension	B-Disease
and	O
premature	B-Disease
pubarche	I-Disease
,	O
whereas	O
dexamethasone	B-Chemical
effectively	O
suppressed	O
these	O
clinical	O
manifestations	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
patient	B-Species
's	O
GR	B-Gene
gene	O
had	O
a	O
heterozygotic	O
mutation	O
(	B-Variant
G	I-Variant
-	I-Variant
-	I-Variant
>	I-Variant
A	I-Variant
)	I-Variant
at	I-Variant
nucleotide	I-Variant
position	I-Variant
2141	I-Variant
(	O
exon	O
8	O
)	O
,	O
which	O
resulted	O
in	O
substitution	O
of	O
arginine	B-Variant
by	I-Variant
glutamine	I-Variant
at	I-Variant
amino	I-Variant
acid	I-Variant
position	I-Variant
714	I-Variant
in	O
the	O
ligand	O
-	O
binding	O
domain	O
(	O
LBD	O
)	O
of	O
the	O
GR	B-Gene
alpha	I-Gene
.	O
</ALL>	O

<ALL>	O
Molecular	O
analysis	O
revealed	O
that	O
the	O
mutant	O
receptor	O
had	O
significantly	O
impaired	O
transactivation	O
activity	O
with	O
a	O
2	O
-	O
fold	O
reduction	O
in	O
affinity	O
to	O
ligand	O
.	O
</ALL>	O

<ALL>	O
It	O
showed	O
attenuated	O
transactivation	O
of	O
the	O
activation	O
function	O
(	O
AF	O
)	O
-	O
2	O
and	O
reduced	O
binding	O
to	O
a	O
p160	B-Gene
nuclear	I-Gene
receptor	I-Gene
coactivator	I-Gene
.	O
</ALL>	O

<ALL>	O
Computer	O
-	O
based	O
structural	O
analysis	O
revealed	O
that	O
replacement	O
of	O
arginine	B-Variant
by	I-Variant
glutamine	I-Variant
at	I-Variant
position	I-Variant
714	I-Variant
transmitted	O
a	O
conformational	O
change	O
to	O
the	O
LBD	O
and	O
the	O
AF	O
-	O
2	O
transactivation	O
surface	O
,	O
resulting	O
in	O
a	O
decreased	O
binding	O
affinity	O
to	O
ligand	O
and	O
to	O
the	O
LXXLL	O
coactivator	O
motif	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Dexamethasone	B-Chemical
treatment	O
is	O
effective	O
in	O
controlling	O
the	O
premature	B-Disease
pubarche	I-Disease
,	O
hypoglycemia	B-Disease
,	O
hypertension	B-Disease
,	O
and	O
hypokalemia	B-Disease
in	O
this	O
child	O
case	O
,	O
wherein	O
arginine	B-Variant
714	I-Variant
plays	O
a	O
key	O
role	O
in	O
the	O
proper	O
formation	O
of	O
the	O
ligand	O
-	O
binding	O
pocket	O
and	O
the	O
AF	O
-	O
2	O
surface	O
of	O
the	O
GR	B-Gene
alpha	I-Gene
LBD	O
.	O
</ALL>	O

<ALL>	O
MHC	B-Gene
region	O
and	O
risk	O
of	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
in	O
African	O
American	O
women	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
major	B-Gene
histocompatibility	I-Gene
complex	I-Gene
(	O
MHC	B-Gene
)	O
on	O
chromosome	O
6p21	O
is	O
a	O
key	O
contributor	O
to	O
the	O
genetic	O
basis	O
of	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
(	O
SLE	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Although	O
SLE	B-Disease
affects	O
African	O
Americans	O
disproportionately	O
compared	O
to	O
European	O
Americans	O
,	O
there	O
has	O
been	O
no	O
comprehensive	O
analysis	O
of	O
the	O
MHC	B-Gene
region	O
in	O
relationship	O
to	O
SLE	B-Disease
in	O
African	O
Americans	O
.	O
</ALL>	O

<ALL>	O
We	O
conducted	O
a	O
screening	O
of	O
the	O
MHC	B-Gene
region	O
for	O
1,536	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
and	O
the	O
deletion	O
of	O
the	O
C4A	B-Gene
gene	O
in	O
a	O
SLE	B-Disease
case	O
-	O
control	O
study	O
(	O
380	O
cases	O
,	O
765	O
age	O
-	O
matched	O
controls	O
)	O
nested	O
within	O
the	O
prospective	O
Black	O
Women	B-Species
's	O
Health	O
Study	O
.	O
</ALL>	O

<ALL>	O
We	O
also	O
genotyped	O
1,509	O
ancestral	O
informative	O
markers	O
throughout	O
the	O
genome	O
to	O
estimate	O
European	O
ancestry	O
to	O
control	O
for	O
population	O
stratification	O
due	O
to	O
population	O
admixture	O
.	O
</ALL>	O

<ALL>	O
The	O
most	O
strongly	O
associated	O
SNP	O
with	O
SLE	B-Disease
was	O
the	O
rs9271366	B-Variant
(	O
odds	O
ratio	O
,	O
OR	O
=	O
1.70	O
,	O
p	O
=	O
5.6	O
10	O
(	O
-	O
5	O
)	O
)	O
near	O
the	O
HLA	B-Gene
-	I-Gene
DRB1	I-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Conditional	O
haplotype	O
analysis	O
revealed	O
three	O
other	O
SNPs	O
,	O
rs204890	B-Variant
(	O
OR	O
=	O
1.86	O
,	O
p	O
=	O
1.2	O
10	O
(	O
-	O
4	O
)	O
)	O
,	O
rs2071349	B-Variant
(	O
OR	O
=	O
1.53	O
,	O
p	O
=	O
1.0	O
10	O
(	O
-	O
3	O
)	O
)	O
,	O
and	O
rs2844580	B-Variant
(	O
OR	O
=	O
1.43	O
,	O
p	O
=	O
1.3	O
10	O
(	O
-	O
3	O
)	O
)	O
,	O
to	O
be	O
associated	O
with	O
SLE	B-Disease
independent	O
of	O
the	O
rs9271366	B-Variant
SNP	O
.	O
</ALL>	O

<ALL>	O
In	O
univariate	O
analysis	O
,	O
the	O
OR	O
for	O
the	O
C4A	B-Gene
deletion	O
was	O
1.38	O
,	O
p	O
=	O
0.075	O
,	O
but	O
after	O
simultaneous	O
adjustment	O
for	O
the	O
other	O
four	O
SNPs	O
the	O
odds	O
ratio	O
was	O
1.01	O
,	O
p	O
=	O
0.98	O
.	O
</ALL>	O

<ALL>	O
A	O
genotype	O
score	O
combining	O
the	O
four	O
newly	O
identified	O
SNPs	O
showed	O
an	O
additive	O
risk	O
according	O
to	O
the	O
number	O
of	O
high	O
-	O
risk	O
alleles	O
(	O
OR	O
=	O
1.67	O
per	O
high	O
-	O
risk	O
allele	O
,	O
p	O
<	O
0.0001	O
)	O
.	O
</ALL>	O

<ALL>	O
Our	O
strongest	O
signal	O
,	O
the	O
rs9271366	B-Variant
SNP	O
,	O
was	O
also	O
associated	O
with	O
higher	O
risk	O
of	O
SLE	B-Disease
in	O
a	O
previous	O
Chinese	O
genome	O
-	O
wide	O
association	O
study	O
(	O
GWAS	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
two	O
SNPs	O
found	O
in	O
a	O
GWAS	O
of	O
European	O
ancestry	O
women	B-Species
were	O
confirmed	O
in	O
our	O
study	O
,	O
indicating	O
that	O
African	O
Americans	O
share	O
some	O
genetic	O
risk	O
factors	O
for	O
SLE	B-Disease
with	O
European	O
and	O
Chinese	O
subjects	O
.	O
</ALL>	O

<ALL>	O
In	O
summary	O
,	O
we	O
found	O
four	O
independent	O
signals	O
in	O
the	O
MHC	B-Gene
region	O
associated	O
with	O
risk	O
of	O
SLE	B-Disease
in	O
African	O
American	O
women	B-Species
.	O
</ALL>	O

<ALL>	O
Plasminogen	B-Gene
activator	I-Gene
inhibitor	I-Gene
type	I-Gene
1	I-Gene
serum	O
levels	O
and	O
4	O
G	O
/	O
5	O
G	O
gene	O
polymorphism	O
in	O
morbidly	O
obese	B-Disease
Hispanic	O
patients	B-Species
with	O
non	B-Disease
-	I-Disease
alcoholic	I-Disease
fatty	I-Disease
liver	I-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
The	O
plasminogen	B-Gene
activator	I-Gene
inhibitor	I-Gene
type	I-Gene
-	I-Gene
1	I-Gene
(	O
PAI	B-Gene
-	I-Gene
1	I-Gene
)	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
fibrinolysis	O
and	O
extracellular	O
matrix	O
components	O
.	O
</ALL>	O

<ALL>	O
The	O
single	O
base	O
pair	O
guanine	O
insertion	O
/	O
deletion	O
polymorphism	O
(	O
4	O
G	O
/	O
5	O
G	O
)	O
within	O
the	O
promoter	O
region	O
of	O
the	O
PAI	B-Gene
-	I-Gene
1	I-Gene
gene	O
influences	O
PAI	B-Gene
-	I-Gene
1	I-Gene
synthesis	O
and	O
may	O
modulate	O
hepatic	B-Disease
fibrogenesis	I-Disease
.	O
</ALL>	O

<ALL>	O
AIM	O
:	O
To	O
evaluate	O
the	O
influence	O
of	O
PAI	B-Gene
-	I-Gene
1	I-Gene
serum	O
levels	O
and	O
4	O
G	O
/	O
5	O
G	O
polymorphism	O
on	O
the	O
risk	O
of	O
liver	B-Disease
fibrosis	I-Disease
associated	O
to	O
non	B-Disease
-	I-Disease
alcoholic	I-Disease
fatty	I-Disease
liver	I-Disease
disease	I-Disease
(	O
NAFLD	B-Disease
)	O
in	O
morbidly	O
obese	B-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
MATERIAL	O
AND	O
METHODS	O
:	O
Case	O
-	O
control	O
study	O
of	O
50	O
obese	B-Disease
patients	B-Species
undergoing	O
bariatric	O
surgery	O
and	O
71	O
non	O
-	O
obese	B-Disease
subjects	O
matched	O
by	O
age	O
and	O
sex	O
.	O
</ALL>	O

<ALL>	O
Anthropometric	O
and	O
biochemical	O
measurements	O
were	O
performed	O
,	O
including	O
PAI	B-Gene
-	I-Gene
1	I-Gene
serum	O
levels	O
.	O
</ALL>	O

<ALL>	O
Genomic	O
DNA	O
was	O
obtained	O
to	O
assess	O
the	O
presence	O
of	O
4	O
G	O
/	O
5	O
G	O
polymorphism	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
BMI	O
,	O
insulinemia	O
,	O
triglycerides	B-Chemical
,	O
HOMA	O
-	O
IR	O
,	O
hypertension	B-Disease
and	O
diabetes	B-Disease
were	O
significantly	O
higher	O
in	O
obese	B-Disease
patients	B-Species
compared	O
to	O
control	O
subjects	O
.	O
</ALL>	O

<ALL>	O
PAI	B-Gene
-	I-Gene
1	I-Gene
serum	O
levels	O
observed	O
in	O
obese	B-Disease
patients	B-Species
were	O
significantly	O
lower	O
(	O
10.63	O
4.82	O
)	O
compared	O
to	O
controls	O
(	O
14.26	O
11.4	O
;	O
p	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
No	O
differences	O
were	O
observed	O
in	O
the	O
PAI	B-Gene
-	I-Gene
1	I-Gene
4	O
G	O
/	O
5	O
G	O
promoter	O
genotypes	O
frequencies	O
(	O
p	O
=	O
0.12	O
)	O
.	O
</ALL>	O

<ALL>	O
No	O
differences	O
were	O
observed	O
in	O
PAI	B-Gene
-	I-Gene
1	I-Gene
plasma	O
levels	O
among	O
obese	B-Disease
patients	B-Species
with	O
liver	B-Disease
fibrosis	I-Disease
(	O
10.64	O
4.35	O
)	O
compared	O
to	O
patients	B-Species
without	O
liver	B-Disease
fibrosis	I-Disease
(	O
10.61	O
5.2	O
;	O
p	O
=	O
0.985	O
)	O
.	O
</ALL>	O

<ALL>	O
PAI	B-Gene
-	I-Gene
1	I-Gene
4	O
G	O
/	O
5	O
G	O
promoter	O
genotypes	O
frequencies	O
were	O
similar	O
in	O
patients	B-Species
with	O
or	O
without	O
liver	B-Disease
fibrosis	I-Disease
associated	O
to	O
NASH	B-Disease
(	O
p	O
=	O
0.6	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Morbidly	O
obese	B-Disease
patients	B-Species
had	O
significantly	O
lower	O
PAI	B-Gene
-	I-Gene
1	I-Gene
serum	O
levels	O
with	O
similar	O
PAI	B-Gene
-	I-Gene
1	I-Gene
4	O
G	O
/	O
5	O
G	O
genotypes	O
frequencies	O
compared	O
to	O
non	O
-	O
obese	B-Disease
subjects	O
.	O
</ALL>	O

<ALL>	O
The	O
frequency	O
of	O
4	O
G	O
/	O
5	O
G	O
genotypes	O
in	O
Chilean	O
Hispanic	O
healthy	O
subjects	O
was	O
similar	O
to	O
that	O
described	O
in	O
other	O
populations	O
.	O
</ALL>	O

<ALL>	O
No	O
association	O
was	O
found	O
between	O
PAI	B-Gene
-	I-Gene
1	I-Gene
serum	O
levels	O
or	O
4	O
G	O
/	O
5	O
G	O
genotype	O
with	O
liver	B-Disease
fibrosis	I-Disease
in	O
obese	B-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Aberrant	O
caveolin	B-Gene
-	I-Gene
1	I-Gene
-	O
mediated	O
Smad	B-Gene
signaling	O
and	O
proliferation	O
identified	O
by	O
analysis	O
of	O
adenine	B-Variant
474	I-Variant
deletion	I-Variant
mutation	O
(	O
c.474delA	B-Variant
)	O
in	O
patient	B-Species
fibroblasts	O
:	O
a	O
new	O
perspective	O
on	O
the	O
mechanism	O
of	O
pulmonary	B-Disease
hypertension	I-Disease
.	O
</ALL>	O

<ALL>	O
A	O
heterozygous	O
caveolin	B-Gene
-	I-Gene
1	I-Gene
c.474delA	B-Variant
mutation	O
has	O
been	O
identified	O
in	O
a	O
family	O
with	O
heritable	O
pulmonary	B-Disease
arterial	I-Disease
hypertension	I-Disease
(	O
PAH	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
This	O
frameshift	O
mutation	O
leads	O
to	O
a	O
caveolin	B-Gene
-	I-Gene
1	I-Gene
protein	O
that	O
contains	O
all	O
known	O
functional	O
domains	O
but	O
has	O
a	O
change	O
in	O
only	O
the	O
final	O
20	O
amino	O
acids	O
of	O
the	O
C	O
-	O
terminus	O
.	O
</ALL>	O

<ALL>	O
Here	O
we	O
studied	O
how	O
this	O
mutation	O
alters	O
caveolin	B-Gene
-	I-Gene
1	I-Gene
function	O
,	O
using	O
patient	B-Species
-	O
derived	O
fibroblasts	O
.	O
</ALL>	O

<ALL>	O
Transmission	O
electron	O
microscopy	O
showed	O
that	O
fibroblasts	O
carrying	O
the	O
c.474delA	B-Variant
mutation	O
form	O
typical	O
caveolae	O
.	O
</ALL>	O

<ALL>	O
Expression	O
of	O
mutated	O
caveolin	B-Gene
-	I-Gene
1	I-Gene
in	O
caveolin	B-Gene
-	I-Gene
1	I-Gene
-	O
null	O
mouse	B-Species
fibroblasts	O
failed	O
to	O
induce	O
formation	O
of	O
caveolae	O
due	O
to	O
retention	O
of	O
the	O
mutated	O
protein	O
in	O
the	O
endoplasmic	O
reticulum	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
coexpression	O
of	O
wild	O
-	O
type	O
caveolin	B-Gene
-	I-Gene
1	I-Gene
with	O
mutated	O
caveolin	B-Gene
-	I-Gene
1	I-Gene
restored	O
the	O
ability	O
to	O
form	O
caveolae	O
.	O
</ALL>	O

<ALL>	O
Importantly	O
,	O
fibroblasts	O
carrying	O
the	O
mutation	O
showed	O
twofold	O
increase	O
in	O
proliferation	O
rate	O
associated	O
with	O
hyperphosphorylation	O
of	O
Smad1	B-Gene
/	I-Gene
5	I-Gene
/	I-Gene
8	I-Gene
.	O
</ALL>	O

<ALL>	O
This	O
mutation	O
impaired	O
the	O
antiproliferative	O
function	O
of	O
caveolin	B-Gene
-	I-Gene
1	I-Gene
.	O
</ALL>	O

<ALL>	O
Inhibition	O
of	O
type	B-Gene
I	I-Gene
TGFb	I-Gene
receptors	I-Gene
ALK1	B-Gene
/	I-Gene
2	I-Gene
/	I-Gene
3	I-Gene
/	I-Gene
6	I-Gene
responsible	O
for	O
phosphorylation	O
of	O
Smad1	B-Gene
/	I-Gene
5	I-Gene
/	I-Gene
8	I-Gene
reduced	O
the	O
hyperproliferation	O
seen	O
in	O
c.474delA	B-Variant
fibroblasts	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
demonstrate	O
the	O
critical	O
role	O
of	O
the	O
final	O
20	O
amino	O
acids	O
of	O
caveolin	B-Gene
-	I-Gene
1	I-Gene
in	O
modulating	O
fibroblast	O
proliferation	O
by	O
dampening	O
Smad	B-Gene
signaling	O
and	O
suggest	O
that	O
augmented	O
Smad	B-Gene
signaling	O
and	O
fibroblast	O
hyperproliferation	O
are	O
contributing	O
factors	O
in	O
the	O
pathogenesis	O
of	O
PAH	B-Disease
in	O
patients	B-Species
with	O
caveolin	B-Gene
-	I-Gene
1	I-Gene
c.474delA	B-Variant
mutation	O
.	O
</ALL>	O

<ALL>	O
Severe	O
form	O
of	O
thyroid	B-Disease
hormone	I-Disease
resistance	I-Disease
in	O
a	O
patient	B-Species
with	O
homozygous	O
/	O
hemizygous	O
mutation	O
of	O
T3	B-Gene
receptor	I-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Resistance	B-Disease
to	I-Disease
thyroid	I-Disease
hormone	I-Disease
syndrome	I-Disease
(	O
RTH	B-Disease
)	O
is	O
a	O
rare	O
disorder	O
,	O
usually	O
inherited	O
as	O
an	O
autosomal	O
dominant	O
trait	O
.	O
</ALL>	O

<ALL>	O
Patients	B-Species
with	O
RTH	B-Disease
are	O
usually	O
euthyroid	O
but	O
can	O
occasionally	O
present	O
with	O
signs	O
and	O
symptoms	O
of	O
thyrotoxicosis	B-Disease
or	O
rarely	O
with	O
hypothyroidism	B-Disease
.	O
</ALL>	O

<ALL>	O
Affected	O
individuals	O
are	O
usually	O
heterozygous	O
for	O
mutations	O
in	O
the	O
thyroid	B-Gene
hormone	I-Gene
receptor	I-Gene
beta	I-Gene
gene	O
(	O
TR	B-Gene
-	I-Gene
beta	I-Gene
)	O
.	O
</ALL>	O

<ALL>	O
We	O
present	O
a	O
patient	B-Species
with	O
RTH	B-Disease
found	O
to	O
be	O
homo	O
-	O
/	O
hemizygous	O
for	O
a	O
mutation	O
in	O
the	O
TR	B-Gene
-	I-Gene
beta	I-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
The	O
single	O
nucleotide	O
substitution	O
I280S	B-Variant
(	O
1123	B-Variant
T	I-Variant
-	I-Variant
-	I-Variant
>	I-Variant
G	I-Variant
)	O
was	O
present	O
either	O
on	O
both	O
alleles	O
or	O
in	O
a	O
hemizygous	O
form	O
with	O
complete	O
deletion	O
of	O
the	O
second	O
allele	O
.	O
</ALL>	O

<ALL>	O
The	O
I280S	B-Variant
mutation	O
was	O
recently	O
reported	O
in	O
a	O
heterozygous	O
patient	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
severe	O
phenotype	O
with	O
seriously	O
impaired	B-Disease
intellectual	I-Disease
development	I-Disease
,	O
hyperkinetic	B-Disease
behaviour	O
,	O
tachycardia	B-Disease
,	O
hearing	B-Disease
and	I-Disease
visual	I-Disease
impairment	I-Disease
is	O
probably	O
due	O
to	O
the	O
dominant	O
negative	O
effect	O
of	O
the	O
I280S	B-Variant
mutant	O
protein	O
and	O
the	O
absence	O
of	O
any	O
functional	O
TR	B-Gene
-	I-Gene
beta	I-Gene
.	O
</ALL>	O

<ALL>	O
The	O
number	O
of	O
lymph	B-Disease
node	I-Disease
metastases	I-Disease
in	O
gastric	B-Disease
cancer	I-Disease
correlates	O
with	O
the	O
angiotensin	B-Gene
I	I-Gene
-	I-Gene
converting	I-Gene
enzyme	I-Gene
gene	O
insertion	O
/	O
deletion	O
polymorphism	O
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
to	O
substantiate	O
the	O
putative	O
significance	O
of	O
angiotensin	B-Gene
I	I-Gene
-	I-Gene
converting	I-Gene
enzyme	I-Gene
(	O
ACE	B-Gene
)	O
on	O
gastric	B-Disease
cancer	I-Disease
biology	O
by	O
investigating	O
the	O
influence	O
of	O
its	O
gene	O
polymorphism	O
on	O
gastric	B-Disease
cancer	I-Disease
progression	O
.	O
</ALL>	O

<ALL>	O
EXPERIMENTAL	O
DESIGN	O
:	O
Genomic	O
DNA	O
was	O
purified	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
or	O
tissue	O
specimens	O
.	O
</ALL>	O

<ALL>	O
Amplified	O
ACE	B-Gene
gene	O
fragments	O
were	O
separated	O
on	O
agarose	B-Chemical
gels	O
.	O
</ALL>	O

<ALL>	O
D	O
or	O
I	O
alleles	O
were	O
identified	O
by	O
the	O
presence	O
of	O
190	O
-	O
or	O
490	O
-	O
bp	O
fragments	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
Local	O
expression	O
of	O
ACE	B-Gene
was	O
investigated	O
by	O
immunohistochemistry	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Twenty	O
-	O
four	O
of	O
113	O
(	O
21	O
%	O
)	O
gastric	B-Disease
cancer	I-Disease
patients	B-Species
had	O
the	O
II	O
,	O
57	O
(	O
51	O
%	O
)	O
the	O
ID	O
,	O
and	O
32	O
(	O
28	O
%	O
)	O
the	O
DD	O
genotype	O
.	O
</ALL>	O

<ALL>	O
The	O
distribution	O
of	O
the	O
ACE	B-Gene
genotypes	O
did	O
not	O
differ	O
significantly	O
from	O
the	O
control	O
group	O
of	O
189	O
patients	B-Species
without	O
gastric	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
ACE	B-Gene
genotypes	O
correlated	O
with	O
the	O
number	O
of	O
lymph	B-Disease
node	I-Disease
metastases	I-Disease
and	O
the	O
Unio	O
Internationale	O
Contra	O
Cancrum	O
(	O
UICC	O
)	O
tumor	B-Disease
stage	O
.	O
</ALL>	O

<ALL>	O
Patients	B-Species
with	O
the	O
II	O
genotype	O
had	O
a	O
highly	O
significantly	O
smaller	O
number	O
of	O
lymph	B-Disease
node	I-Disease
metastases	I-Disease
(	O
P	O
<	O
0.001	O
)	O
and	O
a	O
significantly	O
lower	O
UICC	O
tumor	B-Disease
stage	O
(	O
P	O
=	O
0.01	O
)	O
than	O
patients	B-Species
with	O
the	O
DD	O
genotype	O
.	O
</ALL>	O

<ALL>	O
No	O
correlation	O
was	O
found	O
between	O
tumor	B-Disease
type	O
,	O
tumor	B-Disease
location	O
,	O
local	O
tumor	B-Disease
growth	O
,	O
distant	O
metastases	B-Disease
,	O
and	O
the	O
ACE	B-Gene
genotype	O
.	O
</ALL>	O

<ALL>	O
The	O
expression	O
of	O
ACE	B-Gene
in	O
gastric	B-Disease
cancer	I-Disease
was	O
investigated	O
by	O
immunohistochemistry	O
in	O
100	O
of	O
113	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
ACE	B-Gene
was	O
expressed	O
by	O
endothelial	O
cells	O
in	O
all	O
(	O
100	O
%	O
)	O
specimens	O
and	O
by	O
tumor	B-Disease
cells	O
in	O
56	O
(	O
56	O
%	O
)	O
specimens	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Our	O
study	O
shows	O
that	O
ACE	B-Gene
is	O
expressed	O
locally	O
in	O
gastric	B-Disease
cancer	I-Disease
and	O
that	O
the	O
gene	O
polymorphism	O
influences	O
metastatic	O
behavior	O
.	O
</ALL>	O

<ALL>	O
Distinct	O
patterns	O
of	O
germ	O
-	O
line	O
deletions	O
in	O
MLH1	B-Gene
and	O
MSH2	B-Gene
:	O
the	O
implication	O
of	O
Alu	O
repetitive	O
element	O
in	O
the	O
genetic	O
etiology	O
of	O
Lynch	B-Disease
syndrome	I-Disease
(	O
HNPCC	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
A	O
relatively	O
high	O
frequency	O
of	O
germ	O
-	O
line	O
genomic	O
rearrangements	O
in	O
MLH1	B-Gene
and	O
MSH2	B-Gene
has	O
been	O
reported	O
among	O
Lynch	B-Disease
Syndrome	I-Disease
(	O
HNPCC	B-Disease
)	O
patients	B-Species
from	O
different	O
ethnic	O
populations	O
.	O
</ALL>	O

<ALL>	O
To	O
investigate	O
the	O
underlying	O
molecular	O
mechanisms	O
,	O
we	O
characterized	O
the	O
DNA	O
breakpoints	O
of	O
11	O
germ	O
-	O
line	O
deletions	O
,	O
six	O
for	O
MLH1	B-Gene
and	O
five	O
for	O
MSH2	B-Gene
.	O
</ALL>	O

<ALL>	O
Distinct	O
deletion	O
patterns	O
were	O
found	O
for	O
the	O
two	O
genes	O
.	O
</ALL>	O

<ALL>	O
The	O
five	O
cases	O
of	O
MSH2	B-Gene
deletions	O
result	O
exclusively	O
from	O
intragenic	O
unequal	O
recombination	O
mediated	O
by	O
repetitive	O
Alu	O
sequences	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
five	O
out	O
of	O
the	O
six	O
MLH1	B-Gene
deletions	O
are	O
due	O
to	O
recombinations	O
involving	O
sequences	O
of	O
no	O
significant	O
homology	O
(	O
P	O
=	O
0.015	O
)	O
.	O
</ALL>	O

<ALL>	O
A	O
detailed	O
analysis	O
of	O
the	O
DNA	O
breakpoints	O
in	O
the	O
two	O
genes	O
,	O
previously	O
characterized	O
by	O
other	O
groups	O
,	O
validated	O
the	O
observation	O
that	O
Alu	O
-	O
mediated	O
unequal	O
recombination	O
is	O
the	O
main	O
type	O
of	O
deletion	O
in	O
MSH2	B-Gene
(	O
n	O
=	O
34	O
)	O
,	O
but	O
not	O
in	O
MLH1	B-Gene
(	O
n	O
=	O
21	O
)	O
(	O
P	O
<	O
0.0001	O
)	O
.	O
</ALL>	O

<ALL>	O
Plotting	O
the	O
distribution	O
of	O
known	O
DNA	O
breakpoints	O
among	O
the	O
introns	O
of	O
the	O
two	O
genes	O
showed	O
that	O
,	O
the	O
highest	O
breakpoint	O
density	O
is	O
co	O
-	O
localized	O
with	O
the	O
highest	O
Alu	O
density	O
.	O
</ALL>	O

<ALL>	O
Our	O
study	O
suggests	O
that	O
Alu	O
is	O
a	O
promoting	O
factor	O
for	O
the	O
genomic	O
recombinations	O
in	O
both	O
MLH1	B-Gene
and	O
MSH2	B-Gene
,	O
and	O
the	O
local	O
Alu	O
density	O
may	O
be	O
involved	O
in	O
shaping	O
the	O
deletion	O
pattern	O
.	O
</ALL>	O

<ALL>	O
Families	O
with	O
the	O
risk	O
allele	O
of	O
DISC1	B-Gene
reveal	O
a	O
link	O
between	O
schizophrenia	B-Disease
and	O
another	O
component	O
of	O
the	O
same	O
molecular	O
pathway	O
,	O
NDE1	B-Gene
.	O
</ALL>	O

<ALL>	O
We	O
have	O
previously	O
reported	O
a	O
robust	O
association	O
between	O
an	O
allelic	O
haplotype	O
of	O
'	O
Disrupted	B-Gene
in	I-Gene
Schizophrenia	I-Gene
1	I-Gene
'	O
(	O
DISC1	B-Gene
)	O
and	O
schizophrenia	B-Disease
in	O
a	O
nationwide	O
collection	O
of	O
Finnish	O
schizophrenia	B-Disease
families	O
.	O
</ALL>	O

<ALL>	O
This	O
specific	O
DISC1	B-Gene
allele	O
was	O
later	O
identified	O
to	O
associate	O
with	O
visual	O
working	O
memory	O
,	O
selectively	O
in	O
males	O
.	O
</ALL>	O

<ALL>	O
DISC1	B-Gene
association	O
to	O
schizophrenia	B-Disease
has	O
since	O
been	O
replicated	O
in	O
multiple	O
independent	O
study	O
samples	O
from	O
different	O
populations	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
conditioned	O
our	O
sample	O
of	O
Finnish	O
families	O
for	O
the	O
presence	O
of	O
the	O
Finnish	O
tentative	O
risk	O
allele	O
for	O
DISC1	B-Gene
and	O
re	O
-	O
analyzed	O
our	O
genome	O
-	O
wide	O
scan	O
data	O
of	O
443	O
markers	O
on	O
the	O
basis	O
of	O
this	O
stratification	O
.	O
</ALL>	O

<ALL>	O
Two	O
additional	O
loci	O
displayed	O
an	O
evidence	O
of	O
linkage	O
(	O
LOD	O
>	O
3	O
)	O
and	O
included	O
a	O
locus	O
on	O
16p13	O
,	O
proximal	O
to	O
the	O
gene	O
encoding	O
NDE1	B-Gene
,	O
which	O
has	O
been	O
shown	O
to	O
biologically	O
interact	O
with	O
DISC1	B-Gene
.	O
</ALL>	O

<ALL>	O
Although	O
none	O
of	O
the	O
observed	O
linkages	O
remained	O
significant	O
after	O
multiple	O
test	O
correction	O
through	O
simulation	O
,	O
further	O
analysis	O
of	O
NDE1	B-Gene
revealed	O
an	O
association	O
between	O
a	O
tag	O
-	O
haplotype	O
and	O
schizophrenia	B-Disease
(	O
P	O
=	O
0.00046	O
)	O
specific	O
to	O
females	O
,	O
which	O
proved	O
to	O
be	O
significant	O
(	O
P	O
=	O
0.011	O
)	O
after	O
multiple	O
test	O
correction	O
.	O
</ALL>	O

<ALL>	O
Our	O
finding	O
would	O
support	O
the	O
concept	O
that	O
initial	O
gene	O
findings	O
in	O
multifactorial	O
diseases	O
will	O
assist	O
in	O
the	O
identification	O
of	O
other	O
components	O
of	O
complex	O
genetic	O
etiology	O
.	O
</ALL>	O

<ALL>	O
Notably	O
,	O
this	O
and	O
other	O
converging	O
lines	O
of	O
evidence	O
underline	O
the	O
importance	O
of	O
DISC1	B-Gene
-	O
related	O
functional	O
pathways	O
in	O
the	O
etiology	O
of	O
schizophrenia	B-Disease
.	O
</ALL>	O

<ALL>	O
Identification	O
of	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
of	O
the	O
prolactin	B-Gene
receptor	I-Gene
in	O
women	B-Species
with	O
benign	B-Disease
breast	I-Disease
tumors	I-Disease
.	O
</ALL>	O

<ALL>	O
There	O
is	O
currently	O
no	O
known	O
genetic	B-Disease
disease	I-Disease
linked	O
to	O
prolactin	B-Gene
(	O
Prl	B-Gene
)	O
or	O
its	O
receptor	O
(	O
PrlR	B-Gene
)	O
in	O
humans	B-Species
.	O
</ALL>	O

<ALL>	O
Given	O
the	O
essential	O
role	O
of	O
this	O
hormonal	O
system	O
in	O
breast	O
physiology	O
,	O
we	O
reasoned	O
that	O
genetic	O
anomalies	O
of	O
Prl	B-Gene
/	O
PrlR	B-Gene
genes	O
may	O
be	O
related	O
to	O
the	O
occurrence	O
of	O
breast	B-Disease
diseases	I-Disease
with	O
high	O
proliferative	O
potential	O
.	O
</ALL>	O

<ALL>	O
Multiple	B-Disease
fibroadenomas	I-Disease
(	O
MFA	B-Disease
)	O
are	O
benign	B-Disease
breast	I-Disease
tumors	I-Disease
which	O
appear	O
most	O
frequently	O
in	O
young	O
women	B-Species
,	O
including	O
at	O
puberty	O
,	O
when	O
Prl	B-Gene
has	O
well	O
-	O
recognized	O
proliferative	O
actions	O
on	O
the	O
breast	O
.	O
</ALL>	O

<ALL>	O
In	O
a	O
prospective	O
study	O
involving	O
74	O
MFA	B-Disease
patients	B-Species
and	O
170	O
control	O
subjects	O
,	O
we	O
identified	O
four	O
patients	B-Species
harboring	O
a	O
heterozygous	O
single	O
nucleotide	O
polymorphism	O
in	O
exon	O
6	O
of	O
the	O
PrlR	B-Gene
gene	O
,	O
encoding	O
Ile	B-Variant
(	I-Variant
146	I-Variant
)	I-Variant
-	I-Variant
-	I-Variant
>	I-Variant
Leu	I-Variant
substitution	O
in	O
its	O
extracellular	O
domain	O
.	O
</ALL>	O

<ALL>	O
This	O
sole	O
substitution	O
was	O
sufficient	O
to	O
confer	O
constitutive	O
activity	O
to	O
the	O
receptor	O
variant	O
(	O
PrlR	B-Gene
(	O
I146L	B-Variant
)	O
)	O
,	O
as	O
assessed	O
in	O
three	O
reconstituted	O
cell	O
models	O
(	O
Ba	B-CellLine
/	I-CellLine
F3	I-CellLine
,	O
HEK293	B-CellLine
and	O
MCF	B-CellLine
-	I-CellLine
7	I-CellLine
cells	O
)	O
by	O
Prl	B-Gene
-	O
independent	O
(	O
i	O
)	O
PrlR	B-Gene
tyrosine	O
phosphorylation	O
,	O
(	O
ii	O
)	O
activation	O
of	O
signal	B-Gene
transducer	I-Gene
and	I-Gene
activator	I-Gene
of	I-Gene
transcription	I-Gene
5	I-Gene
(	O
STAT5	B-Gene
)	O
signaling	O
,	O
(	O
iii	O
)	O
transcriptional	O
activity	O
toward	O
a	O
Prl	B-Gene
-	O
responsive	O
reporter	O
gene	O
,	O
and	O
(	O
iv	O
)	O
cell	O
proliferation	O
and	O
protection	O
from	O
cell	O
death	O
.	O
</ALL>	O

<ALL>	O
Constitutive	O
activity	O
of	O
PrlR	B-Gene
(	O
I146L	B-Variant
)	O
in	O
the	O
breast	O
sample	O
from	O
a	O
patient	B-Species
was	O
supported	O
by	O
increased	O
STAT5	B-Gene
signaling	O
.	O
</ALL>	O

<ALL>	O
This	O
is	O
a	O
unique	O
description	O
of	O
a	O
functional	O
mutation	O
of	O
the	O
PrlR	B-Gene
associated	O
with	O
a	O
human	B-Species
disease	O
.	O
</ALL>	O

<ALL>	O
Hallmarks	O
of	O
constitutive	O
activity	O
were	O
all	O
reversed	O
by	O
a	O
specific	O
PrlR	B-Chemical
antagonist	I-Chemical
,	O
which	O
opens	O
potential	O
therapeutic	O
approaches	O
for	O
MFA	B-Disease
,	O
or	O
any	O
other	O
disease	O
that	O
could	O
be	O
associated	O
with	O
this	O
mutation	O
in	O
future	O
.	O
</ALL>	O

<ALL>	O
Reversible	O
inferior	B-Disease
colliculus	I-Disease
lesion	I-Disease
in	O
metronidazole	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
:	O
magnetic	O
resonance	O
findings	O
on	O
diffusion	O
-	O
weighted	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
imaging	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
This	O
is	O
to	O
present	O
reversible	O
inferior	B-Disease
colliculus	I-Disease
lesions	I-Disease
in	O
metronidazole	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
,	O
to	O
focus	O
on	O
the	O
diffusion	O
-	O
weighted	O
imaging	O
(	O
DWI	O
)	O
and	O
fluid	O
attenuated	O
inversion	O
recovery	O
(	O
FLAIR	O
)	O
imaging	O
.	O
</ALL>	O

<ALL>	O
MATERIALS	O
AND	O
METHODS	O
:	O
From	O
November	O
2005	O
to	O
September	O
2007	O
,	O
8	O
patients	B-Species
(	O
5	O
men	B-Species
and	O
3	O
women	B-Species
)	O
were	O
diagnosed	O
as	O
having	O
metronidazole	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
(	O
age	O
range	O
;	O
43	O
-	O
78	O
years	O
)	O
.	O
</ALL>	O

<ALL>	O
They	O
had	O
been	O
taking	O
metronidazole	B-Chemical
(	O
total	O
dosage	O
,	O
45	O
-	O
120	O
g	O
;	O
duration	O
,	O
30	O
days	O
to	O
2	O
months	O
)	O
to	O
treat	O
the	O
infection	B-Disease
in	O
various	O
organs	O
.	O
</ALL>	O

<ALL>	O
Initial	O
brain	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
were	O
obtained	O
after	O
the	O
hospitalization	O
,	O
including	O
DWI	O
(	O
8	O
/	O
8	O
)	O
,	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
map	O
(	O
4	O
/	O
8	O
)	O
,	O
FLAIR	O
(	O
7	O
/	O
8	O
)	O
,	O
and	O
T2	O
-	O
weighted	O
image	O
(	O
8	O
/	O
8	O
)	O
.	O
</ALL>	O

<ALL>	O
Follow	O
-	O
up	O
MRIs	O
were	O
performed	O
on	O
5	O
patients	B-Species
from	O
third	O
to	O
14th	O
days	O
after	O
discontinuation	O
of	O
metronidazole	B-Chemical
administration	O
.	O
</ALL>	O

<ALL>	O
Findings	O
of	O
initial	O
and	O
follow	O
-	O
up	O
MRIs	O
were	O
retrospectively	O
evaluated	O
by	O
2	O
neuroradiologists	O
by	O
consensus	O
,	O
to	O
analyze	O
the	O
presence	O
of	O
abnormal	O
signal	O
intensities	O
,	O
their	O
locations	O
,	O
and	O
signal	O
changes	O
on	O
follow	O
-	O
up	O
images	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Initial	O
MRIs	O
showed	O
abnormal	O
high	O
signal	O
intensities	O
on	O
DWI	O
and	O
FLAIR	O
(	O
or	O
T2	O
-	O
weighted	O
image	O
)	O
at	O
the	O
dentate	O
nucleus	O
(	O
8	O
/	O
8	O
)	O
,	O
inferior	O
colliculus	O
(	O
6	O
/	O
8	O
)	O
,	O
corpus	O
callosum	O
(	O
2	O
/	O
8	O
)	O
,	O
pons	O
(	O
2	O
/	O
8	O
)	O
,	O
medulla	O
(	O
1	O
/	O
8	O
)	O
,	O
and	O
bilateral	O
cerebral	O
white	O
matter	O
(	O
1	O
/	O
8	O
)	O
.	O
</ALL>	O

<ALL>	O
High	O
-	O
signal	O
intensity	O
lesions	O
on	O
DWI	O
tended	O
to	O
show	O
low	O
signal	O
intensity	O
on	O
ADC	O
map	O
(	O
3	O
/	O
4	O
)	O
,	O
but	O
in	O
one	O
patient	B-Species
,	O
high	O
signal	O
intensity	O
was	O
shown	O
at	O
bilateral	O
dentate	O
nuclei	O
on	O
not	O
only	O
DWI	O
but	O
also	O
ADC	O
map	O
.	O
</ALL>	O

<ALL>	O
All	O
the	O
lesions	O
in	O
dentate	O
,	O
inferior	O
colliculus	O
,	O
pons	O
,	O
and	O
medullas	O
had	O
been	O
resolved	O
completely	O
on	O
follow	O
-	O
up	O
MRIs	O
in	O
5	O
patients	B-Species
,	O
but	O
in	O
1	O
patient	B-Species
of	O
them	O
,	O
corpus	O
callosal	B-Disease
lesion	I-Disease
persisted	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Reversible	O
inferior	B-Disease
colliculus	I-Disease
lesions	I-Disease
could	O
be	O
considered	O
as	O
the	O
characteristic	O
for	O
metronidazole	B-Chemical
-	O
induced	O
encephalopathy	B-Disease
,	O
next	O
to	O
the	O
dentate	O
nucleus	O
involvement	O
.	O
</ALL>	O

<ALL>	O
Differential	O
impact	O
of	O
immune	O
escape	O
mutations	O
G145R	B-Variant
and	O
P120	B-Variant
T	I-Variant
on	O
the	O
replication	O
of	O
lamivudine	B-Chemical
-	O
resistant	O
hepatitis	B-Chemical
B	I-Chemical
virus	I-Chemical
e	I-Chemical
antigen	I-Chemical
-	O
positive	O
and	O
-	O
negative	O
strains	O
.	O
</ALL>	O

<ALL>	O
Immune	O
escape	O
variants	O
of	O
the	O
hepatitis	B-Species
B	I-Species
virus	I-Species
(	O
HBV	B-Species
)	O
represent	O
an	O
emerging	O
clinical	O
challenge	O
,	O
because	O
they	O
can	O
be	O
associated	O
with	O
vaccine	O
escape	O
,	O
HBV	B-Species
reactivation	O
,	O
and	O
failure	O
of	O
diagnostic	O
tests	O
.	O
</ALL>	O

<ALL>	O
Recent	O
data	O
suggest	O
a	O
preferential	O
selection	O
of	O
immune	O
escape	O
mutants	O
in	O
distinct	O
peripheral	O
blood	O
leukocyte	O
compartments	O
of	O
infected	O
individuals	O
.	O
</ALL>	O

<ALL>	O
We	O
therefore	O
systematically	O
analyzed	O
the	O
functional	O
impact	O
of	O
the	O
most	O
prevalent	O
immune	O
escape	O
variants	O
,	O
the	O
s	O
G145R	B-Variant
and	O
s	O
P120	B-Variant
T	I-Variant
mutants	O
,	O
on	O
the	O
viral	O
replication	O
efficacy	O
and	O
antiviral	O
drug	O
susceptibility	O
of	O
common	O
treatment	O
-	O
associated	O
mutants	O
with	O
resistance	O
to	O
lamivudine	B-Chemical
(	O
LAM	B-Chemical
)	O
and	O
/	O
or	O
HBeAg	B-Chemical
negativity	O
.	O
</ALL>	O

<ALL>	O
Replication	O
-	O
competent	O
HBV	B-Species
strains	O
with	O
s	O
G145R	B-Variant
or	O
s	O
P120	B-Variant
T	I-Variant
and	O
LAM	B-Chemical
resistance	O
(	O
rt	O
M204I	B-Variant
or	O
rt	O
L180	B-Variant
M	I-Variant
/	O
rt	O
M204V	B-Variant
)	O
were	O
generated	O
on	O
an	O
HBeAg	B-Chemical
-	O
positive	O
and	O
an	O
HBeAg	B-Chemical
-	O
negative	O
background	O
with	O
precore	B-Gene
(	O
PC	B-Gene
)	O
and	O
basal	O
core	O
promoter	O
(	O
BCP	O
)	O
mutants	O
.	O
</ALL>	O

<ALL>	O
The	O
s	O
G145R	B-Variant
mutation	O
strongly	O
reduced	O
HBsAg	B-Chemical
levels	O
and	O
was	O
able	O
to	O
fully	O
restore	O
the	O
impaired	O
replication	O
of	O
LAM	B-Chemical
-	O
resistant	O
HBV	B-Species
mutants	O
to	O
the	O
levels	O
of	O
wild	O
-	O
type	O
HBV	B-Species
,	O
and	O
PC	B-Gene
or	O
BCP	O
mutations	O
further	O
enhanced	O
viral	O
replication	O
.	O
</ALL>	O

<ALL>	O
Although	O
the	O
s	O
P120	B-Variant
T	I-Variant
substitution	O
also	O
impaired	O
HBsAg	B-Chemical
secretion	O
,	O
it	O
did	O
not	O
enhance	O
the	O
replication	O
of	O
LAM	B-Chemical
-	O
resistant	O
clones	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
concomitant	O
occurrence	O
of	O
HBeAg	B-Chemical
negativity	O
(	O
PC	B-Gene
/	O
BCP	O
)	O
,	O
s	O
P120	B-Variant
T	I-Variant
,	O
and	O
LAM	B-Chemical
resistance	O
resulted	O
in	O
the	O
restoration	O
of	O
replication	O
to	O
levels	O
of	O
wild	O
-	O
type	O
HBV	B-Species
.	O
</ALL>	O

<ALL>	O
In	O
all	O
clones	O
with	O
combined	O
immune	O
escape	O
and	O
LAM	B-Chemical
resistance	O
mutations	O
,	O
the	O
nucleotide	O
analogues	O
adefovir	B-Chemical
and	O
tenofovir	B-Chemical
remained	O
effective	O
in	O
suppressing	O
viral	O
replication	O
in	O
vitro	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
reveal	O
the	O
differential	O
impact	O
of	O
immune	O
escape	O
variants	O
on	O
the	O
replication	O
and	O
drug	O
susceptibility	O
of	O
complex	O
HBV	B-Species
mutants	O
,	O
supporting	O
the	O
need	O
of	O
close	O
surveillance	O
and	O
treatment	O
adjustment	O
in	O
response	O
to	O
the	O
selection	O
of	O
distinct	O
mutational	O
patterns	O
.	O
</ALL>	O

<ALL>	O
Molecular	O
diagnosis	O
of	O
46,XY	B-Disease
DSD	I-Disease
and	O
identification	O
of	O
a	O
novel	O
8	B-Variant
nucleotide	I-Variant
deletion	I-Variant
in	O
exon	O
1	O
of	O
the	O
SRD5A2	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Phenotypic	O
presentation	O
of	O
46,XY	B-Disease
DSD	I-Disease
depends	O
on	O
the	O
underlying	O
defects	O
.	O
</ALL>	O

<ALL>	O
Defect	O
in	O
androgen	O
action	O
on	O
the	O
target	O
tissues	O
or	O
production	O
of	O
active	O
metabolite	O
share	O
common	O
morphological	O
features	O
.	O
</ALL>	O

<ALL>	O
Molecular	O
study	O
may	O
help	O
differentiating	O
these	O
abnormalities	O
with	O
precision	O
.	O
</ALL>	O

<ALL>	O
Mutational	O
analysis	O
of	O
androgen	B-Gene
receptor	I-Gene
(	O
AR	B-Gene
)	O
and	O
SRD5A2	B-Gene
genes	O
was	O
performed	O
in	O
29	O
patients	B-Species
with	O
46,XY	B-Disease
DSD	I-Disease
,	O
by	O
PCR	O
-	O
SSCP	O
.	O
</ALL>	O

<ALL>	O
The	O
amplicons	O
that	O
showed	O
an	O
aberrant	O
migration	O
in	O
SSCP	O
were	O
subjected	O
to	O
sequencing	O
.	O
</ALL>	O

<ALL>	O
Interestingly	O
,	O
six	O
patients	B-Species
from	O
4	O
unrelated	O
families	O
(	O
a	O
pair	O
of	O
sibs	O
,	O
uncle	O
/	O
nephew	O
and	O
other	O
two	O
isolated	O
)	O
were	O
identified	O
with	O
mutations	O
in	O
SRD5A2	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
In	O
five	O
patients	B-Species
p	B-Variant
.	I-Variant
R246Q	I-Variant
missense	O
mutation	O
was	O
detected	O
,	O
of	O
which	O
four	O
were	O
homozygous	O
and	O
one	O
was	O
compound	O
heterozygous	O
:	O
g.80	B-Variant
_	I-Variant
87delT	I-Variant
CGCGAAG	I-Variant
(	O
p	B-Variant
.	I-Variant
A27fsX132	I-Variant
)	O
and	O
p	B-Variant
.	I-Variant
R246Q	I-Variant
.	O
</ALL>	O

<ALL>	O
Another	O
patient	B-Species
with	O
isolated	B-Disease
micropenis	I-Disease
harbored	O
a	O
heterozygous	O
p	B-Variant
.	I-Variant
G196S	I-Variant
missense	O
mutation	O
.	O
</ALL>	O

<ALL>	O
No	O
AR	B-Gene
gene	O
mutation	O
was	O
detected	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
our	O
study	O
suggests	O
that	O
p	B-Variant
.	I-Variant
R246Q	I-Variant
mutation	O
is	O
common	O
amongst	O
patients	B-Species
with	O
SRD5A2	B-Gene
gene	O
defect	O
from	O
the	O
Northern	O
states	O
of	O
India	O
.	O
</ALL>	O

<ALL>	O
Also	O
,	O
it	O
records	O
a	O
novel	O
deletion	O
in	O
exon	O
1	O
of	O
SRD5A2	B-Gene
gene	O
in	O
a	O
patient	B-Species
with	O
severe	O
hypospadias	B-Disease
.	O
</ALL>	O

<ALL>	O
Safety	O
of	O
capecitabine	B-Chemical
:	O
a	O
review	O
.	O
</ALL>	O

<ALL>	O
IMPORTANCE	O
OF	O
THE	O
FIELD	O
:	O
Fluoropyrimidines	B-Chemical
,	O
in	O
particular	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
,	O
have	O
been	O
the	O
mainstay	O
of	O
treatment	O
for	O
several	O
solid	O
tumors	B-Disease
,	O
including	O
colorectal	B-Disease
,	I-Disease
breast	I-Disease
and	I-Disease
head	I-Disease
and	I-Disease
neck	I-Disease
cancers	I-Disease
,	O
for	O
>	O
40	O
years	O
.	O
</ALL>	O

<ALL>	O
AREAS	O
COVERED	O
IN	O
THIS	O
REVIEW	O
:	O
This	O
article	O
reviews	O
the	O
pharmacology	O
and	O
efficacy	O
of	O
capecitabine	B-Chemical
with	O
a	O
special	O
emphasis	O
on	O
its	O
safety	O
.	O
</ALL>	O

<ALL>	O
WHAT	O
THE	O
READER	O
WILL	O
GAIN	O
:	O
The	O
reader	O
will	O
gain	O
better	O
insight	O
into	O
the	O
safety	O
of	O
capecitabine	B-Chemical
in	O
special	O
populations	O
such	O
as	O
patients	B-Species
with	O
advanced	O
age	O
,	O
renal	B-Disease
and	I-Disease
kidney	I-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
We	O
also	O
explore	O
different	O
dosing	O
and	O
schedules	O
of	O
capecitabine	B-Chemical
administration	O
.	O
</ALL>	O

<ALL>	O
TAKE	O
HOME	O
MESSAGE	O
:	O
Capecitabine	B-Chemical
is	O
an	O
oral	O
prodrug	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
was	O
developed	O
to	O
fulfill	O
the	O
need	O
for	O
a	O
more	O
convenient	O
therapy	O
and	O
provide	O
an	O
improved	O
safety	O
/	O
efficacy	O
profile	O
.	O
</ALL>	O

<ALL>	O
It	O
has	O
shown	O
promising	O
results	O
alone	O
or	O
in	O
combination	O
with	O
other	O
chemotherapeutic	O
agents	O
in	O
colorectal	B-Disease
,	I-Disease
breast	I-Disease
,	I-Disease
pancreaticobiliary	I-Disease
,	I-Disease
gastric	I-Disease
,	I-Disease
renal	I-Disease
cell	I-Disease
and	I-Disease
head	I-Disease
and	I-Disease
neck	I-Disease
cancers	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
most	O
commonly	O
reported	O
toxic	O
effects	O
of	O
capecitabine	B-Chemical
are	O
diarrhea	B-Disease
,	O
nausea	B-Disease
,	O
vomiting	B-Disease
,	O
stomatitis	B-Disease
and	O
hand	B-Disease
-	I-Disease
foot	I-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Capecitabine	B-Chemical
has	O
a	O
well	O
-	O
established	O
safety	O
profile	O
and	O
can	O
be	O
given	O
safely	O
to	O
patients	B-Species
with	O
advanced	O
age	O
,	O
hepatic	B-Disease
and	I-Disease
renal	I-Disease
dysfunctions	I-Disease
.	O
</ALL>	O

<ALL>	O
Cytostatic	O
and	O
anti	O
-	O
angiogenic	O
effects	O
of	O
temsirolimus	B-Chemical
in	O
refractory	O
mantle	B-Disease
cell	I-Disease
lymphoma	I-Disease
.	O
</ALL>	O

<ALL>	O
Mantle	B-Disease
cell	I-Disease
lymphoma	I-Disease
(	O
MCL	B-Disease
)	O
is	O
a	O
rare	O
and	O
aggressive	O
type	O
of	O
B	B-Disease
-	I-Disease
cell	I-Disease
non	I-Disease
-	I-Disease
Hodgkin	I-Disease
's	I-Disease
lymphoma	I-Disease
.	O
</ALL>	O

<ALL>	O
Patients	B-Species
become	O
progressively	O
refractory	O
to	O
conventional	O
chemotherapy	O
,	O
and	O
their	O
prognosis	O
is	O
poor	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
a	O
38	O
%	O
remission	O
rate	O
has	O
been	O
recently	O
reported	O
in	O
refractory	O
MCL	B-Disease
treated	O
with	O
temsirolimus	B-Chemical
,	O
a	O
mTOR	B-Gene
inhibitor	O
.	O
</ALL>	O

<ALL>	O
Here	O
we	O
had	O
the	O
opportunity	O
to	O
study	O
a	O
case	O
of	O
refractory	O
MCL	B-Disease
who	O
had	O
tumor	B-Disease
regression	O
two	O
months	O
after	O
temsirolimus	B-Chemical
treatment	O
,	O
and	O
a	O
progression	O
-	O
free	O
survival	O
of	O
10	O
months	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
case	O
,	O
lymph	O
node	O
biopsies	O
were	O
performed	O
before	O
and	O
six	O
months	O
after	O
temsirolimus	B-Chemical
therapy	O
.	O
</ALL>	O

<ALL>	O
Comparison	O
of	O
the	O
two	O
biopsies	O
showed	O
that	O
temsirolimus	B-Chemical
inhibited	O
tumor	B-Disease
cell	O
proliferation	O
through	O
cell	O
cycle	O
arrest	O
,	O
but	O
did	O
not	O
induce	O
any	O
change	O
in	O
the	O
number	O
of	O
apoptotic	O
tumor	B-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
Apart	O
from	O
this	O
cytostatic	O
effect	O
,	O
temsirolimus	B-Chemical
had	O
an	O
antiangiogenic	O
effect	O
with	O
decrease	O
of	O
tumor	B-Disease
microvessel	O
density	O
and	O
of	O
VEGF	B-Gene
expression	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
numerous	O
patchy	O
,	O
well	O
-	O
limited	O
fibrotic	O
areas	O
,	O
compatible	O
with	O
post	O
-	O
necrotic	B-Disease
tissue	O
repair	O
,	O
were	O
found	O
after	O
6	O
-	O
month	O
temsirolimus	B-Chemical
therapy	O
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
temsirolimus	B-Chemical
reduced	O
tumor	B-Disease
burden	O
through	O
associated	O
cytostatic	O
and	O
anti	O
-	O
angiogenic	O
effects	O
.	O
</ALL>	O

<ALL>	O
This	O
dual	O
effect	O
of	O
temsirolimus	B-Chemical
on	O
tumor	B-Disease
tissue	O
could	O
contribute	O
to	O
its	O
recently	O
reported	O
efficiency	O
in	O
refractory	O
MCL	B-Disease
resistant	O
to	O
conventional	O
chemotherapy	O
.	O
</ALL>	O

<ALL>	O
The	O
-	B-Variant
930A	I-Variant
>	I-Variant
G	I-Variant
polymorphism	O
of	O
the	O
CYBA	B-Gene
gene	O
is	O
associated	O
with	O
premature	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
A	O
case	O
-	O
control	O
study	O
and	O
gene	O
-	O
risk	O
factors	O
interactions	O
.	O
</ALL>	O

<ALL>	O
Reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
atherosclerosis	B-Disease
and	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
(	O
CAD	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
NADPH	B-Gene
oxidases	I-Gene
are	O
the	O
main	O
source	O
of	O
ROS	B-Chemical
in	O
the	O
vasculature	O
.	O
</ALL>	O

<ALL>	O
p22phox	B-Gene
is	O
a	O
critical	O
component	O
of	O
vascular	O
NADPH	B-Gene
oxidases	I-Gene
and	O
is	O
encoded	O
by	O
the	O
CYBA	B-Gene
(	O
cytochrome	B-Gene
b245	I-Gene
alpha	I-Gene
)	O
gene	O
.	O
</ALL>	O

<ALL>	O
The	O
-	B-Variant
930A	I-Variant
>	I-Variant
G	I-Variant
CYBA	B-Gene
polymorphism	O
(	O
rs9932581	B-Variant
:	O
A	B-Variant
>	I-Variant
G	I-Variant
)	O
modulates	O
the	O
activity	O
of	O
the	O
CYBA	B-Gene
promoter	O
,	O
and	O
influences	O
CYBA	B-Gene
transcriptional	O
activity	O
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
analyze	O
a	O
possible	O
association	O
between	O
the	O
-	B-Variant
930A	I-Variant
>	I-Variant
G	I-Variant
polymorphism	O
and	O
CAD	B-Disease
and	O
to	O
search	O
for	O
gene	O
-	O
traditional	O
risk	O
factors	O
interactions	O
.	O
</ALL>	O

<ALL>	O
480	O
subjects	O
were	O
studied	O
:	O
240	O
patients	B-Species
with	O
premature	O
CAD	B-Disease
,	O
240	O
age	O
and	O
sex	O
matched	O
blood	O
donors	O
.	O
</ALL>	O

<ALL>	O
The	O
-	B-Variant
930A	I-Variant
>	I-Variant
G	I-Variant
polymorphism	O
was	O
genotyped	O
using	O
the	O
TaqMan	O
-	O
Pre	O
-	O
designed	O
SNP	O
Genotyping	O
Assay	O
(	O
Applied	O
Biosystems	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
-	B-Variant
930	I-Variant
G	I-Variant
allele	O
carrier	O
state	O
was	O
a	O
risk	O
factor	O
for	O
CAD	B-Disease
(	O
OR	O
2.03	O
,	O
95	O
%	O
CI	O
1.21	O
-	O
3.44	O
,	O
P	O
=	O
0.007	O
)	O
.	O
</ALL>	O

<ALL>	O
A	O
synergistic	O
effect	O
of	O
the	O
-	B-Variant
930	I-Variant
G	I-Variant
allele	O
with	O
overweight	B-Disease
/	O
obesity	B-Disease
(	O
BMI	O
-	O
-	O
25	O
)	O
and	O
cigarette	O
smoking	O
was	O
found	O
.	O
</ALL>	O

<ALL>	O
The	O
estimated	O
CAD	B-Disease
risk	O
for	O
BMI	O
-	O
-	O
25	O
and	O
the	O
-	B-Variant
930	I-Variant
G	I-Variant
allele	O
interaction	O
was	O
about	O
160	O
%	O
greater	O
than	O
that	O
predicted	O
by	O
assuming	O
additivity	O
of	O
the	O
effects	O
,	O
and	O
about	O
40	O
%	O
greater	O
for	O
interaction	O
of	O
cigarette	O
smoking	O
and	O
the	O
-	B-Variant
930	I-Variant
G	I-Variant
allele	O
.	O
</ALL>	O

<ALL>	O
Overweight	B-Disease
/	O
obesity	B-Disease
was	O
a	O
risk	O
factor	O
for	O
CAD	B-Disease
only	O
in	O
the	O
-	B-Variant
930	I-Variant
G	I-Variant
allele	O
carriers	O
(	O
P	O
<	O
10	O
(	O
-	O
10	O
)	O
)	O
but	O
not	O
in	O
the	O
AA	O
homozygotes	O
(	O
P	O
=	O
1.00	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
the	O
-	B-Variant
930A	I-Variant
>	I-Variant
G	I-Variant
CYBA	B-Gene
polymorphism	O
is	O
associated	O
with	O
CAD	B-Disease
in	O
the	O
Polish	O
population	O
.	O
</ALL>	O

<ALL>	O
The	O
-	B-Variant
930	I-Variant
G	I-Variant
allele	O
carriers	O
are	O
particularly	O
at	O
risk	O
of	O
consequences	O
of	O
obesity	B-Disease
and	O
tobacco	B-Species
smoke	O
exposure	O
.	O
</ALL>	O

<ALL>	O
GLUT4	B-Gene
Is	O
Not	O
Necessary	O
for	O
Overload	O
-	O
Induced	O
Glucose	B-Chemical
Uptake	O
or	O
Hypertrophic	O
Growth	O
in	O
Mouse	B-Species
Skeletal	O
Muscle	O
.	O
</ALL>	O

<ALL>	O
GLUT4	B-Gene
is	O
necessary	O
for	O
acute	O
insulin	B-Gene
-	O
and	O
contraction	O
-	O
induced	O
skeletal	O
muscle	O
glucose	B-Chemical
uptake	O
,	O
but	O
its	O
role	O
in	O
chronic	O
muscle	O
loading	O
(	O
overload	O
)	O
-	O
induced	O
glucose	B-Chemical
uptake	O
is	O
unknown	O
.	O
</ALL>	O

<ALL>	O
Our	O
goal	O
was	O
to	O
determine	O
whether	O
GLUT4	B-Gene
is	O
required	O
for	O
overload	O
-	O
induced	O
glucose	B-Chemical
uptake	O
.	O
</ALL>	O

<ALL>	O
Overload	O
was	O
induced	O
in	O
mouse	B-Species
plantaris	O
muscle	O
by	O
unilateral	O
synergist	O
ablation	O
.	O
</ALL>	O

<ALL>	O
After	O
5	O
days	O
,	O
muscle	O
weights	O
and	O
ex	O
vivo	O
[	B-Chemical
(	I-Chemical
3	I-Chemical
)	I-Chemical
H	I-Chemical
]	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
deoxy	I-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
glucose	I-Chemical
uptake	O
were	O
assessed	O
.	O
</ALL>	O

<ALL>	O
Overload	O
-	O
induced	O
muscle	O
glucose	B-Chemical
uptake	O
and	O
hypertrophic	O
growth	O
were	O
not	O
impaired	O
in	O
muscle	O
-	O
specific	O
GLUT4	B-Gene
knockout	O
mice	B-Species
,	O
demonstrating	O
that	O
GLUT4	B-Gene
is	O
not	O
necessary	O
for	O
these	O
processes	O
.	O
</ALL>	O

<ALL>	O
To	O
assess	O
which	O
transporters	O
mediate	O
overload	O
-	O
induced	O
glucose	B-Chemical
uptake	O
,	O
chemical	O
inhibitors	O
were	O
used	O
.	O
</ALL>	O

<ALL>	O
The	O
facilitative	O
GLUT	B-Gene
inhibitor	O
cytochalasin	B-Chemical
B	I-Chemical
,	O
but	O
not	O
the	O
sodium	B-Chemical
-	O
dependent	O
glucose	B-Chemical
cotransport	O
inhibitor	O
phloridzin	B-Chemical
,	O
prevented	O
overload	O
-	O
induced	O
uptake	O
demonstrating	O
that	O
GLUTs	B-Gene
mediate	O
this	O
effect	O
.	O
</ALL>	O

<ALL>	O
To	O
assess	O
which	O
GLUT	B-Gene
,	O
hexose	B-Chemical
competition	O
experiments	O
were	O
performed	O
.	O
</ALL>	O

<ALL>	O
Overload	O
-	O
induced	O
[	B-Chemical
(	I-Chemical
3	I-Chemical
)	I-Chemical
H	I-Chemical
]	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
deoxy	I-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
glucose	I-Chemical
uptake	O
was	O
not	O
inhibited	O
by	O
d	B-Chemical
-	I-Chemical
fructose	I-Chemical
,	O
demonstrating	O
that	O
the	O
fructose	O
-	O
transporting	O
GLUT2	B-Gene
,	O
GLUT5	B-Gene
,	O
GLUT8	B-Gene
,	O
and	O
GLUT12	B-Gene
do	O
not	O
mediate	O
this	O
effect	O
.	O
</ALL>	O

<ALL>	O
To	O
assess	O
additional	O
GLUTs	B-Gene
,	O
immunoblots	O
were	O
performed	O
.	O
</ALL>	O

<ALL>	O
Overload	O
increased	O
GLUT1	B-Gene
,	O
GLUT3	B-Gene
,	O
GLUT6	B-Gene
,	O
and	O
GLUT10	B-Gene
protein	O
levels	O
twofold	O
to	O
fivefold	O
.	O
</ALL>	O

<ALL>	O
Collectively	O
,	O
these	O
results	O
demonstrate	O
that	O
GLUT4	B-Gene
is	O
not	O
necessary	O
for	O
overload	O
-	O
induced	O
muscle	O
glucose	B-Chemical
uptake	O
or	O
hypertrophic	O
growth	O
and	O
suggest	O
that	O
GLUT1	B-Gene
,	O
GLUT3	B-Gene
,	O
GLUT6	B-Gene
,	O
and	O
/	O
or	O
GLUT10	B-Gene
mediate	O
overload	O
-	O
induced	O
glucose	B-Chemical
uptake	O
.	O
</ALL>	O

<ALL>	O
Ubiquitin	B-Gene
carboxyl	I-Gene
-	I-Gene
terminal	I-Gene
esterase	I-Gene
L1	I-Gene
(	O
UCHL1	B-Gene
)	O
is	O
associated	O
with	O
stem	O
-	O
like	O
cancer	B-Disease
cell	O
functions	O
in	O
pediatric	O
high	O
-	O
grade	O
glioma	B-Disease
.	O
</ALL>	O

<ALL>	O
Pediatric	O
high	O
-	O
grade	O
gliomas	B-Disease
represent	O
8	O
-	O
12	O
%	O
of	O
all	O
primary	O
tumors	B-Disease
of	O
the	O
nervous	O
system	O
in	O
children	O
.	O
</ALL>	O

<ALL>	O
Five	O
-	O
year	O
survival	O
for	O
these	O
pediatric	O
aggressive	O
tumors	B-Disease
is	O
poor	O
(	O
15	O
-	O
35	O
%	O
)	O
indicating	O
the	O
need	O
to	O
develop	O
better	O
treatments	O
for	O
pediatric	O
high	O
-	O
grade	O
gliomas	B-Disease
.	O
</ALL>	O

<ALL>	O
In	O
this	O
work	O
we	O
used	O
SF188	B-CellLine
and	O
SJ	B-CellLine
-	I-CellLine
GBM2	I-CellLine
cell	O
lines	O
to	O
study	O
the	O
function	O
of	O
the	O
ubiquitin	B-Gene
carboxyl	I-Gene
-	I-Gene
terminal	I-Gene
esterase	I-Gene
L1	I-Gene
(	O
UCHL1	B-Gene
)	O
,	O
a	O
deubiquitinase	O
de	O
-	O
regulated	O
in	O
several	O
cancers	B-Disease
,	O
in	O
pediatric	O
high	O
-	O
grade	O
gliomas	B-Disease
.	O
</ALL>	O

<ALL>	O
UCHL1	B-Gene
depletion	O
in	O
SF188	B-CellLine
and	O
SJ	B-CellLine
-	I-CellLine
GBM2	I-CellLine
glioma	B-Disease
cells	O
was	O
associated	O
with	O
decreased	O
cell	O
proliferation	O
and	O
invasion	O
,	O
along	O
with	O
a	O
reduced	O
ability	O
to	O
grow	O
in	O
soft	O
agar	B-Chemical
and	O
to	O
form	O
spheres	O
(	O
i.e.	O
self	O
-	O
renewal	O
measure	O
)	O
.	O
</ALL>	O

<ALL>	O
A	O
70	O
%	O
reduction	O
in	O
Wnt	B-Gene
signaling	O
was	O
also	O
observed	O
in	O
the	O
SF188	B-CellLine
and	O
SJ	B-CellLine
-	I-CellLine
GBM2	I-CellLine
UCHL1	B-Gene
knockdowns	O
(	O
KDs	O
)	O
using	O
a	O
TCF	B-Gene
-	O
dependent	O
TOPflash	O
reporter	O
assay	O
.	O
</ALL>	O

<ALL>	O
Transcriptome	O
comparisons	O
of	O
UCHL1	B-Gene
KDs	O
versus	O
vector	O
control	O
identified	O
a	O
list	O
of	O
306	O
differentially	O
expressed	O
genes	O
(	O
at	O
least	O
2	O
-	O
fold	O
change	O
;	O
p	O
<	O
0.05	O
)	O
which	O
included	O
genes	O
known	O
to	O
be	O
involved	O
in	O
cancer	B-Disease
like	O
ACTA2	B-Gene
,	O
POSTN	B-Gene
,	O
LIF	B-Gene
,	O
FBXL7	B-Gene
,	O
FBXW11	B-Gene
,	O
GDF15	B-Gene
,	O
HEY2	B-Gene
,	O
but	O
also	O
potential	O
novel	O
genes	O
such	O
us	O
IGLL5	B-Gene
,	O
ABCA4	B-Gene
,	O
AQP3	B-Gene
,	O
AQP4	B-Gene
,	O
CALB1	B-Gene
,	O
and	O
ALK	B-Gene
.	O
</ALL>	O

<ALL>	O
Bioinformatics	O
gene	O
ontology	O
(	O
GO	O
)	O
analysis	O
of	O
these	O
306	O
genes	O
revealed	O
significant	O
enrichment	O
in	O
"	O
signal	O
peptides	O
"	O
,	O
"	O
extracellular	O
matrix"and	O
"	O
secreted	O
proteins	O
"	O
GO	O
Terms	O
.	O
"	O
</ALL>	O

<ALL>	O
Angiogenesis	O
and	O
blood	O
vessel	O
development	O
"	O
,	O
"	O
neuron	O
differentiation	O
/	O
development	O
"	O
,	O
cell	O
adhesion	O
"	O
,	O
and	O
"	O
cell	O
migration	O
"	O
also	O
showed	O
significant	O
enrichment	O
in	O
our	O
GO	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Top	O
canonical	O
pathways	O
identified	O
by	O
Ingenuity	O
Pathway	O
Analysis	O
(	O
IPA	O
)	O
included	O
"	O
Clathrin	B-Gene
-	O
mediated	O
Endocytosis	O
Signaling	O
"	O
(	O
p	O
=	O
5.14x10	O
-	O
4	O
)	O
,	O
"	O
Virus	O
Entry	O
via	O
Endocytic	O
Pathways	O
"	O
(	O
p	O
=	O
6.15x	O
10	O
-	O
4	O
)	O
,	O
and	O
"	O
High	B-Gene
Mobility	I-Gene
Group	I-Gene
-	I-Gene
Box	I-Gene
1	I-Gene
(	O
HMGB1	B-Gene
)	O
Signaling	O
"	O
(	O
p	O
=	O
6.15x10	O
-	O
4	O
)	O
.	O
</ALL>	O

<ALL>	O
While	O
FGF2	B-Gene
,	O
IL1B	B-Gene
,	O
TNF	B-Gene
and	O
PDGFB	B-Gene
were	O
predicted	O
as	O
top	O
upstream	O
regulators	O
(	O
p	O
<	O
2x10	O
-	O
16	O
)	O
of	O
the	O
UCHL1	B-Gene
KD	O
-	O
associated	O
transcriptome	O
.	O
</ALL>	O

<ALL>	O
Aberrant	O
expression	O
of	O
UCHL1	B-Gene
in	O
pediatric	O
high	O
-	O
grade	O
gliomas	B-Disease
may	O
promote	O
cell	O
invasion	O
,	O
transformation	O
,	O
and	O
self	O
-	O
renewal	O
properties	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
modulating	O
Wnt	B-Gene
/	O
Beta	B-Gene
catenin	I-Gene
activity	O
.	O
</ALL>	O

<ALL>	O
UCHL1	B-Gene
might	O
act	O
as	O
an	O
oncogene	O
in	O
glioma	B-Disease
within	O
the	O
gene	O
network	O
that	O
imparts	O
stem	O
-	O
like	O
characteristics	O
to	O
these	O
cancer	B-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
Mutations	O
in	O
N	B-Gene
-	I-Gene
acetylglucosamine	I-Gene
(	I-Gene
O	I-Gene
-	I-Gene
GlcNAc	I-Gene
)	I-Gene
transferase	I-Gene
in	O
patients	B-Species
with	O
X	B-Disease
-	I-Disease
linked	I-Disease
intellectual	I-Disease
disability	I-Disease
.	O
</ALL>	O

<ALL>	O
N	B-Gene
-	I-Gene
Acetylglucosamine	I-Gene
(	I-Gene
O	I-Gene
-	I-Gene
GlcNAc	I-Gene
)	I-Gene
transferase	I-Gene
(	O
OGT	B-Gene
)	O
regulates	O
protein	O
O	B-Gene
-	I-Gene
GlcNAcylation	I-Gene
,	O
an	O
essential	O
and	O
dynamic	O
post	O
-	O
translational	O
modification	O
.	O
</ALL>	O

<ALL>	O
The	O
O	B-Gene
-	I-Gene
GlcNAc	I-Gene
modification	O
is	O
present	O
on	O
numerous	O
nuclear	O
and	O
cytosolic	O
proteins	O
and	O
has	O
been	O
implicated	O
in	O
essential	O
cellular	O
functions	O
such	O
as	O
signaling	O
and	O
gene	O
expression	O
.	O
</ALL>	O

<ALL>	O
Accordingly	O
,	O
altered	O
levels	O
of	O
protein	O
O	B-Gene
-	I-Gene
GlcNAcylation	I-Gene
have	O
been	O
associated	O
with	O
developmental	B-Disease
defects	I-Disease
and	O
neurodegeneration	B-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
mutations	O
in	O
the	O
OGT	B-Gene
gene	O
have	O
not	O
yet	O
been	O
functionally	O
confirmed	O
in	O
humans	B-Species
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
report	O
on	O
two	O
hemizygous	O
mutations	O
in	O
OGT	B-Gene
in	O
individuals	O
with	O
X	B-Disease
-	I-Disease
linked	I-Disease
intellectual	I-Disease
disability	I-Disease
(	O
XLID	B-Disease
)	O
and	O
dysmorphic	O
features	O
:	O
one	O
missense	O
mutation	O
(	O
p	B-Variant
.	I-Variant
Arg284Pro	I-Variant
)	O
and	O
one	O
mutation	O
leading	O
to	O
a	O
splicing	O
defect	O
(	O
c.463	B-Variant
-	I-Variant
6	I-Variant
T	I-Variant
>	I-Variant
G	I-Variant
)	O
.	O
</ALL>	O

<ALL>	O
Both	O
mutations	O
reside	O
in	O
the	O
tetratricopeptide	O
repeats	O
of	O
OGT	B-Gene
that	O
are	O
essential	O
for	O
substrate	O
recognition	O
.	O
</ALL>	O

<ALL>	O
We	O
observed	O
slightly	O
reduced	O
levels	O
of	O
OGT	B-Gene
protein	O
and	O
reduced	O
levels	O
of	O
its	O
opposing	O
enzyme	O
O	B-Gene
-	I-Gene
GlcNAcase	I-Gene
in	O
both	O
patient	B-Species
-	O
derived	O
fibroblasts	O
,	O
but	O
global	O
O	B-Gene
-	I-Gene
GlcNAc	I-Gene
levels	O
appeared	O
to	O
be	O
unaffected	O
.	O
</ALL>	O

<ALL>	O
Our	O
data	O
suggest	O
that	O
mutant	O
cells	O
attempt	O
to	O
maintain	O
global	O
O	B-Gene
-	I-Gene
GlcNAcylation	I-Gene
by	O
down	O
-	O
regulating	O
O	B-Gene
-	I-Gene
GlcNAcase	I-Gene
expression	O
.	O
</ALL>	O

<ALL>	O
We	O
also	O
found	O
that	O
the	O
c.463	B-Variant
-	I-Variant
6	I-Variant
T	I-Variant
>	I-Variant
G	I-Variant
mutation	O
leads	O
to	O
aberrant	O
mRNA	O
splicing	O
,	O
but	O
no	O
stable	O
truncated	O
protein	O
was	O
detected	O
in	O
the	O
corresponding	O
patient	B-Species
-	O
derived	O
fibroblasts	O
.	O
</ALL>	O

<ALL>	O
Recombinant	O
OGT	B-Gene
bearing	O
the	O
p	B-Variant
.	I-Variant
Arg284Pro	I-Variant
mutation	O
was	O
prone	O
to	O
unfolding	O
and	O
exhibited	O
reduced	O
glycosylation	O
activity	O
against	O
a	O
complex	O
array	O
of	O
glycosylation	O
substrates	O
and	O
proteolytic	O
processing	O
of	O
the	O
transcription	O
factor	O
host	B-Gene
cell	I-Gene
factor	I-Gene
1	I-Gene
,	O
which	O
is	O
also	O
encoded	O
by	O
an	O
XLID	B-Disease
-	O
associated	O
gene	O
.	O
</ALL>	O

<ALL>	O
We	O
conclude	O
that	O
defects	O
in	O
O	B-Gene
-	I-Gene
GlcNAc	I-Gene
homeostasis	O
and	O
host	B-Gene
cell	I-Gene
factor	I-Gene
1	I-Gene
proteolysis	O
may	O
play	O
roles	O
in	O
mediation	O
of	O
XLID	B-Disease
in	O
individuals	O
with	O
OGT	B-Gene
mutations	O
.	O
</ALL>	O

<ALL>	O
Haplotype	O
structure	O
of	O
the	O
beta	B-Gene
adrenergic	I-Gene
receptor	I-Gene
genes	O
in	O
US	O
Caucasians	O
and	O
African	O
Americans	O
.	O
</ALL>	O

<ALL>	O
The	O
beta	B-Gene
-	I-Gene
adrenergic	I-Gene
receptors	I-Gene
(	O
beta	B-Gene
-	I-Gene
AR	I-Gene
)	O
are	O
G	O
protein	O
-	O
coupled	O
receptors	O
activated	O
by	O
epinephrine	B-Chemical
and	O
norepinephrine	B-Chemical
and	O
are	O
involved	O
in	O
a	O
variety	O
of	O
their	O
physiological	O
functions	O
.	O
</ALL>	O

<ALL>	O
Previously	O
,	O
three	O
beta	B-Gene
-	I-Gene
AR	I-Gene
genes	O
(	O
ADRB1	B-Gene
,	O
ADRB2	B-Gene
and	O
ADRB3	B-Gene
)	O
were	O
resequenced	O
,	O
identifying	O
polymorphisms	O
that	O
were	O
used	O
in	O
genetic	O
association	O
studies	O
of	O
cardiovascular	B-Disease
and	I-Disease
metabolic	I-Disease
disorders	I-Disease
.	O
</ALL>	O

<ALL>	O
These	O
studies	O
have	O
produced	O
intriguing	O
but	O
inconsistent	O
results	O
,	O
potentially	O
because	O
the	O
known	O
functional	O
variants	O
:	O
ADRB1	B-Gene
Arg389Gly	B-Variant
and	O
Gly49Ser	B-Variant
,	O
ADRB2	B-Gene
Arg16Gly	B-Variant
and	O
Gln27Glu	B-Variant
,	O
and	O
ADRB3	B-Gene
Arg64Trp	B-Variant
provided	O
an	O
incomplete	O
picture	O
of	O
the	O
total	O
functional	O
diversity	O
at	O
these	O
genes	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
we	O
created	O
marker	O
panels	O
for	O
each	O
beta	B-Gene
-	I-Gene
AR	I-Gene
gene	O
that	O
included	O
the	O
known	O
functional	O
markers	O
and	O
also	O
other	O
markers	O
evenly	O
spaced	O
and	O
with	O
sufficient	O
density	O
to	O
identify	O
haplotype	O
block	O
structure	O
and	O
to	O
maximize	O
haplotype	O
diversity	O
.	O
</ALL>	O

<ALL>	O
A	O
total	O
of	O
27	O
markers	O
were	O
genotyped	O
in	O
96	O
US	O
Caucasians	O
and	O
96	O
African	O
Americans	O
.	O
</ALL>	O

<ALL>	O
In	O
both	O
populations	O
and	O
for	O
each	O
gene	O
,	O
a	O
single	O
block	O
with	O
little	O
evidence	O
of	O
historical	O
recombination	O
was	O
observed	O
.	O
</ALL>	O

<ALL>	O
For	O
each	O
gene	O
,	O
haplotype	O
captured	O
most	O
of	O
the	O
information	O
content	O
of	O
each	O
functional	O
locus	O
,	O
even	O
if	O
that	O
locus	O
was	O
not	O
genotyped	O
,	O
and	O
presumably	O
haplotype	O
would	O
capture	O
the	O
signal	O
from	O
unknown	O
functional	O
loci	O
whose	O
alleles	O
are	O
of	O
moderate	O
abundance	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
demonstrates	O
the	O
utility	O
of	O
using	O
beta	B-Gene
-	I-Gene
AR	I-Gene
gene	O
haplotype	O
maps	O
and	O
marker	O
panels	O
as	O
tools	O
for	O
linkage	O
studies	O
on	O
beta	B-Gene
-	I-Gene
AR	I-Gene
function	O
.	O
</ALL>	O

<ALL>	O
New	O
mutations	O
,	O
hotspots	O
,	O
and	O
founder	O
effects	O
in	O
Brazilian	O
patients	B-Species
with	O
steroid	B-Disease
5alpha	I-Disease
-	I-Disease
reductase	I-Disease
deficiency	I-Disease
type	I-Disease
2	I-Disease
.	O
</ALL>	O

<ALL>	O
Mutations	O
of	O
the	O
steroid	B-Gene
5alpha	I-Gene
-	I-Gene
reductase	I-Gene
type	I-Gene
2	I-Gene
(	O
SRD5A2	B-Gene
)	O
gene	O
in	O
46,XY	O
subjects	O
cause	O
masculinization	O
defects	O
of	O
varying	O
degrees	O
,	O
due	O
to	O
reduced	O
or	O
impaired	O
enzymatic	O
activity	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
sequence	O
abnormalities	O
of	O
the	O
SRD5A2	B-Gene
gene	O
were	O
assessed	O
by	O
polymerase	O
chain	O
reaction	O
with	O
specific	O
primers	O
and	O
automated	O
sequencing	O
analysis	O
in	O
DNA	O
samples	O
from	O
20	O
patients	B-Species
with	O
suspected	O
steroid	B-Disease
5alpha	I-Disease
-	I-Disease
reductase	I-Disease
type	I-Disease
2	I-Disease
deficiency	I-Disease
from	O
18	O
Brazilian	O
families	O
.	O
</ALL>	O

<ALL>	O
Eleven	O
subjects	O
presented	O
SRD5A2	B-Gene
homozygous	O
single	O
-	O
base	O
mutations	O
(	O
two	O
first	O
cousins	O
and	O
four	O
unrelated	O
patients	B-Species
with	O
G183S	B-Variant
,	O
two	O
with	O
R246W	B-Variant
,	O
one	O
with	O
del642	B-Variant
T	I-Variant
,	O
one	O
with	O
G196S	B-Variant
,	O
and	O
one	O
with	O
217	B-Variant
_	I-Variant
218insC	I-Variant
plus	O
the	O
A49	B-Variant
T	I-Variant
variant	O
in	O
heterozygosis	O
)	O
,	O
whereas	O
four	O
were	O
compound	O
heterozygotes	O
(	O
one	O
with	O
Q126R	B-Variant
/	O
IVS3	B-Variant
+	I-Variant
1	I-Variant
G	I-Variant
>	I-Variant
A	I-Variant
,	O
one	O
with	O
Q126R	B-Variant
/	O
del418	B-Variant
T	I-Variant
,	O
and	O
two	O
brothers	O
with	O
Q126R	B-Variant
/	O
G158R	B-Variant
)	O
.	O
</ALL>	O

<ALL>	O
Three	O
patients	B-Species
were	O
heterozygous	O
for	O
A207D	B-Variant
,	O
G196S	B-Variant
,	O
and	O
R266W	B-Variant
substitutions	O
.	O
</ALL>	O

<ALL>	O
The	O
V89L	B-Variant
polymorphism	O
was	O
found	O
in	O
heterozygosis	O
in	O
one	O
of	O
them	O
(	O
with	O
A207D	B-Variant
)	O
and	O
in	O
one	O
case	O
with	O
an	O
otherwise	O
normal	O
gene	O
sequence	O
.	O
</ALL>	O

<ALL>	O
The	O
A49	B-Variant
T	I-Variant
variant	O
was	O
also	O
detected	O
in	O
heterozygosis	O
in	O
the	O
second	O
case	O
without	O
other	O
sequencing	O
abnormalities	O
.	O
</ALL>	O

<ALL>	O
Four	O
patients	B-Species
harbor	O
yet	O
non	O
-	O
described	O
SRD5A2	B-Gene
gene	O
mutations	O
:	O
a	O
single	O
nucleotide	O
deletion	O
(	O
del642	B-Variant
T	I-Variant
)	O
,	O
a	O
G158R	B-Variant
amino	O
acid	O
substitution	O
,	O
a	O
splice	O
junction	O
mutation	O
(	O
IVS3	B-Variant
+	I-Variant
1	I-Variant
G	I-Variant
>	I-Variant
A	I-Variant
)	O
,	O
and	O
the	O
insertion	O
of	O
a	O
cytosine	O
(	O
217	B-Variant
_	I-Variant
218insC	I-Variant
)	O
occurring	O
at	O
a	O
CCCC	O
motif	O
.	O
</ALL>	O

<ALL>	O
This	O
is	O
the	O
first	O
report	O
of	O
a	O
single	O
-	O
nucleotide	O
insertion	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
SRD5A2	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
to	O
these	O
new	O
mutations	O
,	O
this	O
investigation	O
reveals	O
the	O
prevalence	O
of	O
G183S	B-Variant
substitution	O
among	O
a	O
subset	O
of	O
African	O
-	O
Brazilian	O
patients	B-Species
and	O
presents	O
evidences	O
of	O
the	O
recurrence	O
of	O
already	O
known	O
mutations	O
.	O
</ALL>	O

<ALL>	O
Functional	O
characterization	O
of	O
SLCO1B1	B-Gene
(	O
OATP	B-Gene
-	I-Gene
C	I-Gene
)	O
variants	O
,	O
SLCO1B1	B-Gene
*	O
5	O
,	O
SLCO1B1	B-Gene
*	O
15	O
and	O
SLCO1B1	B-Gene
*	O
15	O
+	O
C1007	B-Variant
G	I-Variant
,	O
by	O
using	O
transient	O
expression	O
systems	O
of	O
HeLa	B-CellLine
and	O
HEK293	B-CellLine
cells	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVES	O
:	O
SLCO1B1	B-Gene
*	O
5	O
and	O
SLCO1B1	B-Gene
*	O
15	O
have	O
been	O
reported	O
to	O
reduce	O
the	O
clearance	O
of	O
pravastatin	B-Chemical
in	O
healthy	O
volunteers	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
there	O
remains	O
controversy	O
in	O
the	O
effects	O
of	O
SLCO1B1	B-Gene
*	O
5	O
on	O
the	O
activity	O
of	O
OATP1B1	B-Gene
in	O
vitro	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
the	O
effect	O
of	O
SLCO1B1	B-Gene
*	O
15	O
on	O
the	O
function	O
of	O
OATP1B1	B-Gene
has	O
not	O
been	O
studied	O
using	O
cDNA	O
-	O
expression	O
systems	O
.	O
</ALL>	O

<ALL>	O
Object	O
of	O
the	O
present	O
study	O
was	O
to	O
study	O
the	O
influence	O
of	O
SLCO1B1	B-Gene
*	O
5	O
,	O
*	O
15	O
and	O
*	O
15	O
+	O
C1007	B-Variant
G	I-Variant
,	O
a	O
novel	O
haplotype	O
found	O
in	O
a	O
patient	B-Species
with	O
pravastatin	B-Chemical
-	O
induced	O
myopathy	B-Disease
,	O
on	O
the	O
functional	O
properties	O
of	O
OATP1B1	B-Gene
by	O
transient	O
expression	O
systems	O
of	O
HEK293	B-CellLine
and	O
HeLa	B-CellLine
cells	O
using	O
endogenous	O
conjugates	O
and	O
statins	O
as	O
substrates	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Transporting	O
assays	O
for	O
endogenous	O
substrates	O
were	O
performed	O
using	O
tritium	B-Chemical
labeled	O
estradiol	B-Chemical
-	I-Chemical
17beta	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
glucuronide	I-Chemical
and	O
estrone	B-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
sulfate	I-Chemical
.	O
</ALL>	O

<ALL>	O
Quantitation	O
of	O
pravastatin	B-Chemical
,	O
atorvastatin	B-Chemical
,	O
cerivastatin	B-Chemical
and	O
simvastatin	B-Chemical
were	O
carried	O
out	O
using	O
HPLC	O
tandem	O
mass	O
spectrometry	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
transporting	O
activities	O
of	O
cells	O
expressing	O
SLCO1B1	B-Gene
*	O
5	O
,	O
*	O
15	O
and	O
*	O
15	O
+	O
C1007	B-Variant
G	I-Variant
decreased	O
significantly	O
but	O
those	O
of	O
SLCO1B1	B-Gene
*	O
1b	O
,	O
*	O
1a	O
+	O
C1007	B-Variant
G	I-Variant
and	O
*	O
1b	O
+	O
C1007	B-Variant
G	I-Variant
were	O
not	O
altered	O
for	O
all	O
of	O
the	O
substrates	O
tested	O
except	O
for	O
simvastatin	B-Chemical
.	O
</ALL>	O

<ALL>	O
Kinetic	O
analysis	O
of	O
pravastatin	B-Chemical
and	O
atorvastatin	B-Chemical
showed	O
that	O
Km	O
values	O
were	O
not	O
altered	O
but	O
Vmax	O
values	O
decreased	O
significantly	O
in	O
cells	O
expressing	O
SLCO1B1	B-Gene
*	O
5	O
,	O
*	O
15	O
and	O
*	O
15	O
+	O
C1007	B-Variant
G	I-Variant
.	O
</ALL>	O

<ALL>	O
Immunocytochemical	O
study	O
showed	O
that	O
SLCO1B1	B-Gene
*	O
5	O
,	O
*	O
15	O
and	O
*	O
15	O
+	O
C1007	B-Variant
G	I-Variant
proteins	O
are	O
localized	O
not	O
only	O
at	O
the	O
plasma	O
membrane	O
but	O
also	O
in	O
the	O
intracellular	O
space	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
These	O
findings	O
suggest	O
that	O
521	B-Variant
T	I-Variant
>	I-Variant
C	I-Variant
,	O
existing	O
commonly	O
in	O
SLCO1B1	B-Gene
*	O
5	O
,	O
*	O
15	O
and	O
*	O
15	O
+	O
C1007	B-Variant
G	I-Variant
,	O
is	O
the	O
key	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
that	O
determines	O
the	O
functional	O
properties	O
of	O
SLCO1B1	B-Gene
*	O
5	O
,	O
*	O
15	O
and	O
*	O
15	O
+	O
C1007	B-Variant
G	I-Variant
allelic	O
proteins	O
and	O
that	O
decreased	O
activities	O
of	O
these	O
variant	O
proteins	O
are	O
mainly	O
caused	O
by	O
a	O
sorting	O
error	O
produced	O
by	O
this	O
SNP	O
.	O
</ALL>	O

<ALL>	O
Identification	O
of	O
the	O
nuclear	O
localization	O
motif	O
in	O
the	O
ETV6	B-Gene
(	O
TEL	B-Gene
)	O
protein	O
.	O
</ALL>	O

<ALL>	O
ETV6	B-Gene
,	O
or	O
Translocation	B-Gene
-	I-Gene
Ets	I-Gene
-	I-Gene
Leukemia	I-Gene
(	O
TEL	B-Gene
)	O
,	O
is	O
an	O
ETS	O
family	O
transcriptional	O
repressor	O
that	O
is	O
essential	O
for	O
establishing	O
hematopoiesis	O
in	O
neonatal	O
bone	O
marrow	O
,	O
and	O
is	O
frequently	O
a	O
target	O
of	O
chromosomal	O
translocations	O
in	O
human	B-Species
cancer	B-Disease
.	O
</ALL>	O

<ALL>	O
ETV6	B-Gene
is	O
predominantly	O
a	O
nuclear	O
phosphoprotein	O
that	O
represses	O
transcription	O
by	O
binding	O
directly	O
to	O
the	O
promoters	O
of	O
target	O
genes	O
.	O
</ALL>	O

<ALL>	O
The	O
nuclear	O
localization	O
mechanism	O
of	O
ETV6	B-Gene
,	O
however	O
,	O
is	O
not	O
well	O
understood	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
report	O
,	O
we	O
provide	O
evidence	O
that	O
a	O
nuclear	O
localization	O
signal	O
(	O
NLS	O
)	O
exists	O
in	O
the	O
C	O
-	O
terminal	O
region	O
of	O
ETV6	B-Gene
.	O
</ALL>	O

<ALL>	O
ETV6	B-Gene
proteins	O
with	O
mutations	O
outside	O
of	O
amino	O
acids	O
332	O
-	O
452	O
localize	O
to	O
the	O
nucleus	O
,	O
whereas	O
proteins	O
with	O
mutations	O
within	O
amino	O
acids	O
332	O
-	O
452	O
remain	O
in	O
the	O
cytoplasm	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
when	O
a	O
fragment	O
of	O
ETV6	B-Gene
comprised	O
of	O
amino	O
acids	O
332	O
-	O
452	O
was	O
fused	O
to	O
cytoplasmic	O
beta	B-Gene
-	I-Gene
galactosidase	I-Gene
protein	O
,	O
the	O
fusion	O
protein	O
was	O
able	O
to	O
enter	O
the	O
nucleus	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
strongly	O
indicate	O
that	O
residues	O
332	O
-	O
452	O
mediate	O
nuclear	O
localization	O
of	O
ETV6	B-Gene
.	O
</ALL>	O

<ALL>	O
Genotyping	O
of	O
five	O
chinese	O
patients	B-Species
with	O
17alpha	B-Disease
-	I-Disease
hydroxylase	I-Disease
deficiency	I-Disease
diagnosed	O
through	O
high	O
-	O
performance	O
liquid	O
chromatography	O
serum	O
adrenal	O
profile	O
:	O
identification	O
of	O
two	O
novel	O
CYP17	B-Gene
mutations	O
.	O
</ALL>	O

<ALL>	O
CONTEXT	O
:	O
17alpha	B-Disease
-	I-Disease
Hydroxylase	I-Disease
deficiency	I-Disease
is	O
a	O
rare	O
form	O
of	O
congenital	B-Disease
adrenal	I-Disease
hyperplasia	I-Disease
caused	O
by	O
CYP17	B-Gene
gene	O
mutations	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
Five	O
Chinese	O
patients	B-Species
with	O
17alpha	B-Disease
-	I-Disease
hydroxylase	I-Disease
deficiency	I-Disease
were	O
genotyped	O
.	O
</ALL>	O

<ALL>	O
PATIENTS	B-Species
:	O
The	O
five	O
patients	B-Species
derived	O
from	O
four	O
families	O
living	O
in	O
Shandong	O
Province	O
,	O
China	O
.	O
</ALL>	O

<ALL>	O
The	O
diagnosis	O
of	O
17alpha	B-Disease
-	I-Disease
hydroxylase	I-Disease
deficiency	I-Disease
was	O
initially	O
established	O
through	O
HPLC	O
serum	O
adrenal	O
profiles	O
in	O
Qilu	O
Hospital	O
,	O
China	O
,	O
from	O
1983	O
-	O
1993	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Three	O
CYP17	B-Gene
gene	O
mutations	O
were	O
identified	O
from	O
these	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Among	O
them	O
,	O
V311fs	B-Variant
and	O
Y329fs	B-Variant
are	O
two	O
novel	O
frame	O
-	O
shifting	O
mutations	O
.	O
</ALL>	O

<ALL>	O
V311fs	B-Variant
is	O
an	O
8	B-Variant
-	I-Variant
bp	I-Variant
nucleotide	I-Variant
(	I-Variant
TTAAATGG	I-Variant
)	I-Variant
deletion	I-Variant
in	O
exon	O
5	O
.	O
</ALL>	O

<ALL>	O
Y329fs	B-Variant
is	O
a	O
deletion	O
-	O
insertion	O
combined	O
mutation	O
(	B-Variant
TAC	I-Variant
-	I-Variant
-	I-Variant
>	I-Variant
AA	I-Variant
)	I-Variant
at	I-Variant
codon	I-Variant
329	I-Variant
in	O
exon	O
6	O
.	O
</ALL>	O

<ALL>	O
Two	O
homozygotes	O
for	O
Y329fs	B-Variant
and	O
one	O
compound	O
heterozygote	O
for	O
Y329fs	B-Variant
and	O
V311fs	B-Variant
were	O
identified	O
from	O
three	O
different	O
families	O
.	O
</ALL>	O

<ALL>	O
Two	O
homozygous	O
sisters	O
for	O
the	O
D487	B-Variant
_	I-Variant
S488	I-Variant
_	I-Variant
F489	I-Variant
deletion	I-Variant
were	O
identified	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
The	O
results	O
confirmed	O
the	O
diagnostic	O
value	O
of	O
the	O
HPLC	O
serum	O
adrenal	O
profile	O
for	O
17alpha	B-Disease
-	I-Disease
hydroxylase	I-Disease
deficiency	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
D487	B-Variant
_	I-Variant
S488	I-Variant
_	I-Variant
F489	I-Variant
deletion	I-Variant
had	O
been	O
identified	O
in	O
two	O
previously	O
genotyped	O
Chinese	O
families	O
.	O
</ALL>	O

<ALL>	O
In	O
our	O
present	O
study	O
,	O
a	O
third	O
Chinese	O
family	O
with	O
this	O
mutation	O
was	O
identified	O
,	O
suggesting	O
that	O
this	O
mutation	O
is	O
a	O
prevalent	O
CYP17	B-Gene
mutation	O
in	O
the	O
Chinese	O
population	O
.	O
</ALL>	O

<ALL>	O
The	O
identification	O
of	O
Y329fs	B-Variant
mutation	O
in	O
addition	O
to	O
three	O
previously	O
identified	O
mutations	O
at	O
codon	O
329	O
suggests	O
that	O
codon	O
329	O
is	O
an	O
unstable	O
point	O
of	O
the	O
CYP17	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
The	O
mutations	O
identified	O
from	O
our	O
five	O
patients	B-Species
appear	O
to	O
be	O
random	O
,	O
but	O
the	O
recurrence	O
of	O
the	O
Y329fs	B-Variant
mutation	O
may	O
be	O
attributed	O
to	O
a	O
founder	O
effect	O
.	O
</ALL>	O

<ALL>	O
Our	O
studies	O
suggest	O
that	O
17alpha	B-Disease
-	I-Disease
hydroxylase	I-Disease
deficiency	I-Disease
may	O
not	O
be	O
rare	O
in	O
the	O
Chinese	O
population	O
.	O
</ALL>	O

<ALL>	O
A	O
dramatic	O
drop	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
following	O
prehospital	O
GTN	B-Chemical
administration	O
.	O
</ALL>	O

<ALL>	O
A	O
male	O
in	O
his	O
sixties	O
with	O
no	O
history	O
of	O
cardiac	O
chest	B-Disease
pain	I-Disease
awoke	O
with	O
chest	B-Disease
pain	I-Disease
following	O
an	O
afternoon	O
sleep	O
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
did	O
not	O
self	O
medicate	O
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
's	O
observations	O
were	O
within	O
normal	O
limits	O
,	O
he	O
was	O
administered	O
oxygen	B-Chemical
via	O
a	O
face	O
mask	O
and	O
glyceryl	B-Chemical
trinitrate	I-Chemical
(	O
GTN	B-Chemical
)	O
.	O
</ALL>	O

<ALL>	O
Several	O
minutes	O
after	O
the	O
GTN	B-Chemical
the	O
patient	B-Species
experienced	O
a	O
sudden	O
drop	B-Disease
in	I-Disease
blood	I-Disease
pressure	I-Disease
and	O
heart	O
rate	O
,	O
this	O
was	O
rectified	O
by	O
atropine	B-Chemical
sulphate	I-Chemical
and	O
a	O
fluid	O
challenge	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
no	O
further	O
deterioration	O
in	O
the	O
patient	B-Species
's	O
condition	O
during	O
transport	O
to	O
hospital	O
.	O
</ALL>	O

<ALL>	O
There	O
are	O
very	O
few	O
documented	O
case	O
like	O
this	O
in	O
the	O
prehospital	O
scientific	O
literature	O
.	O
</ALL>	O

<ALL>	O
The	O
cause	O
appears	O
to	O
be	O
the	O
Bezold	O
-	O
Jarish	O
reflex	O
,	O
stimulation	O
of	O
the	O
ventricular	O
walls	O
which	O
in	O
turn	O
decreases	O
sympathetic	O
outflow	O
from	O
the	O
vasomotor	O
centre	O
.	O
</ALL>	O

<ALL>	O
Prehospital	O
care	O
providers	O
who	O
are	O
managing	O
any	O
patient	B-Species
with	O
a	O
syncopal	B-Disease
episode	I-Disease
that	O
fails	O
to	O
recover	O
within	O
a	O
reasonable	O
time	O
frame	O
should	O
consider	O
the	O
Bezold	O
-	O
Jarisch	O
reflex	O
as	O
the	O
cause	O
and	O
manage	O
the	O
patient	B-Species
accordingly	O
.	O
</ALL>	O

<ALL>	O
RNASEL	B-Gene
and	O
RNASEL	B-Gene
-	O
inhibitor	O
variation	O
and	O
prostate	B-Disease
cancer	I-Disease
risk	O
in	O
Afro	O
-	O
Caribbeans	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Afro	O
-	O
Caribbeans	O
from	O
Tobago	O
are	O
at	O
high	O
risk	O
of	O
developing	O
prostate	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
This	O
elevated	O
risk	O
of	O
prostate	B-Disease
cancer	I-Disease
is	O
shared	O
by	O
populations	O
of	O
African	O
ancestry	O
living	O
in	O
diverse	O
environments	O
in	O
the	O
Western	O
hemisphere	O
.	O
</ALL>	O

<ALL>	O
Variation	O
in	O
the	O
ribonuclease	B-Gene
L	I-Gene
(	O
RNASEL	B-Gene
)	O
gene	O
has	O
recently	O
been	O
reported	O
to	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
prostate	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
whether	O
RNASEL	B-Gene
variation	O
contributes	O
to	O
the	O
increased	O
risk	O
of	O
prostate	B-Disease
cancer	I-Disease
observed	O
in	O
populations	O
of	O
African	O
ancestry	O
remains	O
unclear	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
We	O
resequenced	O
the	O
positional	O
candidate	O
gene	O
RNASEL	B-Gene
in	O
48	O
prostate	B-Disease
cancer	I-Disease
cases	O
and	O
genotyped	O
the	O
previously	O
reported	O
R462Q	B-Variant
and	O
D541E	B-Variant
polymorphisms	O
in	O
230	O
prostate	B-Disease
cancer	I-Disease
cases	O
and	O
458	O
controls	O
.	O
</ALL>	O

<ALL>	O
We	O
also	O
examined	O
the	O
inhibitor	O
of	O
RNASEL	B-Gene
(	O
ABCE1	B-Gene
)	O
for	O
variation	O
associated	O
with	O
prostate	B-Disease
cancer	I-Disease
risk	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
We	O
found	O
no	O
evidence	O
of	O
association	O
between	O
R462Q	B-Variant
and	O
D541E	B-Variant
polymorphisms	O
and	O
prostate	B-Disease
cancer	I-Disease
risk	O
in	O
our	O
case	O
/	O
control	O
analysis	O
.	O
</ALL>	O

<ALL>	O
A	O
novel	O
variant	O
(	O
K294E	B-Variant
)	O
was	O
identified	O
in	O
a	O
single	O
heterozygous	O
individual	O
with	O
prostate	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
We	O
also	O
observed	O
a	O
20	B-Variant
bp	I-Variant
insertion	I-Variant
/	I-Variant
deletion	I-Variant
polymorphism	I-Variant
1,109	I-Variant
bp	I-Variant
upstream	I-Variant
of	I-Variant
the	I-Variant
initiation	I-Variant
codon	I-Variant
,	O
but	O
this	O
variant	O
was	O
not	O
associated	O
with	O
prostate	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
We	O
identified	O
16	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
ABCE1	B-Gene
gene	O
,	O
only	O
3	O
of	O
which	O
had	O
a	O
minor	O
allele	O
frequency	O
>	O
5	O
%	O
.	O
</ALL>	O

<ALL>	O
A	O
common	O
A	B-Variant
/	I-Variant
G	I-Variant
transition	I-Variant
-	I-Variant
1,071	I-Variant
bp	I-Variant
from	O
the	O
transcriptional	O
start	O
site	O
was	O
genotyped	O
and	O
showed	O
no	O
evidence	O
of	O
association	O
with	O
prostate	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
common	O
variation	O
in	O
the	O
putative	O
prostate	B-Disease
cancer	I-Disease
susceptibility	O
gene	O
,	O
RNASEL	B-Gene
,	O
or	O
its	O
inhibitor	O
does	O
not	O
contribute	O
significantly	O
to	O
prostate	B-Disease
cancer	I-Disease
risk	O
in	O
this	O
Afro	O
-	O
Caribbean	O
population	O
.	O
</ALL>	O

<ALL>	O
Exaggerated	O
expression	O
of	O
inflammatory	B-Disease
mediators	O
in	O
vasoactive	B-Gene
intestinal	I-Gene
polypeptide	I-Gene
knockout	O
(	O
VIP	B-Gene
-	O
/	O
-	O
)	O
mice	B-Species
with	O
cyclophosphamide	B-Chemical
(	O
CYP	B-Chemical
)	O
-	O
induced	O
cystitis	B-Disease
.	O
</ALL>	O

<ALL>	O
Vasoactive	B-Gene
intestinal	I-Gene
polypeptide	I-Gene
(	O
VIP	B-Gene
)	O
is	O
an	O
immunomodulatory	O
neuropeptide	O
distributed	O
in	O
micturition	O
pathways	O
.	O
</ALL>	O

<ALL>	O
VIP	B-Gene
(	O
-	O
/	O
-	O
)	O
mice	B-Species
exhibit	O
altered	O
bladder	O
function	O
and	O
neurochemical	O
properties	O
in	O
micturition	O
pathways	O
after	O
cyclophosphamide	B-Chemical
(	O
CYP	B-Chemical
)	O
-	O
induced	O
cystitis	B-Disease
.	O
</ALL>	O

<ALL>	O
Given	O
VIP	B-Gene
's	O
role	O
as	O
an	O
anti	O
-	O
inflammatory	B-Disease
mediator	O
,	O
we	O
hypothesized	O
that	O
VIP	B-Gene
(	O
-	O
/	O
-	O
)	O
mice	B-Species
would	O
exhibit	O
enhanced	O
inflammatory	B-Disease
mediator	O
expression	O
after	O
cystitis	B-Disease
.	O
</ALL>	O

<ALL>	O
A	O
mouse	B-Species
inflammatory	B-Disease
cytokine	O
and	O
receptor	O
RT2	O
profiler	O
array	O
was	O
used	O
to	O
determine	O
regulated	O
transcripts	O
in	O
the	O
urinary	O
bladder	O
of	O
wild	O
type	O
(	O
WT	O
)	O
and	O
VIP	B-Gene
(	O
-	O
/	O
-	O
)	O
mice	B-Species
with	O
or	O
without	O
CYP	B-Chemical
-	O
induced	O
cystitis	B-Disease
(	O
150	O
mg	O
/	O
kg	O
;	O
i.p	O
.	O
;	O
</ALL>	O

<ALL>	O
48	O
h	O
)	O
.	O
</ALL>	O

<ALL>	O
Four	O
binary	O
comparisons	O
were	O
made	O
:	O
WT	O
control	O
versus	O
CYP	B-Chemical
treatment	O
(	O
48	O
h	O
)	O
,	O
VIP	B-Gene
(	O
-	O
/	O
-	O
)	O
control	O
versus	O
CYP	B-Chemical
treatment	O
(	O
48	O
h	O
)	O
,	O
WT	O
control	O
versus	O
VIP	B-Gene
(	O
-	O
/	O
-	O
)	O
control	O
,	O
and	O
WT	O
with	O
CYP	B-Chemical
treatment	O
(	O
48	O
h	O
)	O
versus	O
VIP	B-Gene
(	O
-	O
/	O
-	O
)	O
with	O
CYP	B-Chemical
treatment	O
(	O
48	O
h	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
genes	O
presented	O
represent	O
(	O
1	O
)	O
greater	O
than	O
1.5	O
-	O
fold	O
change	O
in	O
either	O
direction	O
and	O
(	O
2	O
)	O
the	O
p	O
value	O
is	O
less	O
than	O
0.05	O
for	O
the	O
comparison	O
being	O
made	O
.	O
</ALL>	O

<ALL>	O
Several	O
regulated	O
genes	O
were	O
validated	O
using	O
enzyme	O
-	O
linked	O
immunoassays	O
including	O
IL	B-Gene
-	I-Gene
1beta	I-Gene
and	O
CXCL1	B-Gene
.	O
</ALL>	O

<ALL>	O
CYP	B-Chemical
treatment	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
increased	O
expression	O
of	O
CXCL1	B-Gene
and	O
IL	B-Gene
-	I-Gene
1beta	I-Gene
in	O
the	O
urinary	O
bladder	O
of	O
WT	O
and	O
VIP	B-Gene
(	O
-	O
/	O
-	O
)	O
mice	B-Species
,	O
but	O
expression	O
in	O
VIP	B-Gene
(	O
-	O
/	O
-	O
)	O
mice	B-Species
with	O
CYP	B-Chemical
treatment	O
was	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
greater	O
(	O
4.2	O
-	O
to	O
13	O
-	O
fold	O
increase	O
)	O
than	O
that	O
observed	O
in	O
WT	O
urinary	O
bladder	O
(	O
3.6	O
-	O
to	O
5	O
-	O
fold	O
increase	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
data	O
suggest	O
that	O
in	O
VIP	B-Gene
(	O
-	O
/	O
-	O
)	O
mice	B-Species
with	O
bladder	B-Disease
inflammation	I-Disease
,	O
inflammatory	B-Disease
mediators	O
are	O
increased	O
above	O
that	O
observed	O
in	O
WT	O
with	O
CYP	B-Chemical
.	O
</ALL>	O

<ALL>	O
This	O
shift	O
in	O
balance	O
may	O
contribute	O
to	O
increased	O
bladder	B-Disease
dysfunction	I-Disease
in	O
VIP	B-Gene
(	O
-	O
/	O
-	O
)	O
mice	B-Species
with	O
bladder	B-Disease
inflammation	I-Disease
and	O
altered	O
neurochemical	O
expression	O
in	O
micturition	O
pathways	O
.	O
</ALL>	O

<ALL>	O
mToR	B-Chemical
inhibitors	I-Chemical
-	O
induced	O
proteinuria	B-Disease
:	O
mechanisms	O
,	O
significance	O
,	O
and	O
management	O
.	O
</ALL>	O

<ALL>	O
Massive	O
urinary	O
protein	O
excretion	O
has	O
been	O
observed	O
after	O
conversion	O
from	O
calcineurin	B-Chemical
inhibitors	I-Chemical
to	O
mammalian	B-Chemical
target	I-Chemical
of	I-Chemical
rapamycin	I-Chemical
(	I-Chemical
mToR	I-Chemical
)	I-Chemical
inhibitors	I-Chemical
,	O
especially	O
sirolimus	B-Chemical
,	O
in	O
renal	O
transplant	O
recipients	O
with	O
chronic	B-Disease
allograft	I-Disease
nephropathy	I-Disease
.	O
</ALL>	O

<ALL>	O
Because	O
proteinuria	B-Disease
is	O
a	O
major	O
predictive	O
factor	O
of	O
poor	O
transplantation	O
outcome	O
,	O
many	O
studies	O
focused	O
on	O
this	O
adverse	O
event	O
during	O
the	O
past	O
years	O
.	O
</ALL>	O

<ALL>	O
Whether	O
proteinuria	B-Disease
was	O
due	O
to	O
sirolimus	B-Chemical
or	O
only	O
a	O
consequence	O
of	O
calcineurin	B-Chemical
inhibitors	I-Chemical
withdrawal	O
remained	O
unsolved	O
until	O
high	O
range	O
proteinuria	B-Disease
has	O
been	O
observed	O
during	O
sirolimus	B-Chemical
therapy	O
in	O
islet	O
transplantation	O
and	O
in	O
patients	B-Species
who	O
received	O
sirolimus	B-Chemical
de	O
novo	O
.	O
</ALL>	O

<ALL>	O
Podocyte	O
injury	O
and	O
focal	O
segmental	O
glomerulosclerosis	B-Disease
have	O
been	O
related	O
to	O
mToR	B-Gene
inhibition	O
in	O
some	O
patients	B-Species
,	O
but	O
the	O
pathways	O
underlying	O
these	O
lesions	O
remain	O
hypothetic	O
.	O
</ALL>	O

<ALL>	O
We	O
discuss	O
herein	O
the	O
possible	O
mechanisms	O
and	O
the	O
significance	O
of	O
mToR	B-Gene
blockade	O
-	O
induced	O
proteinuria	B-Disease
.	O
</ALL>	O

<ALL>	O
A	O
case	O
of	O
Bernard	B-Disease
-	I-Disease
Soulier	I-Disease
Syndrome	I-Disease
due	O
to	O
a	O
homozygous	O
four	O
bases	O
deletion	B-Variant
(	I-Variant
TGAG	I-Variant
)	I-Variant
of	O
GPIbalpha	B-Gene
gene	O
:	O
lack	O
of	O
GPIbalpha	B-Gene
but	O
absence	O
of	O
bleeding	B-Disease
.	O
</ALL>	O

<ALL>	O
More	O
than	O
20	O
DNA	O
mutations	O
with	O
different	O
inheritance	O
pattern	O
have	O
been	O
described	O
in	O
patients	B-Species
with	O
Bernard	B-Disease
-	I-Disease
Soulier	I-Disease
Syndrome	I-Disease
(	O
BSS	B-Disease
)	O
,	O
leading	O
to	O
abnormal	O
or	O
absent	O
synthesis	O
and	O
/	O
or	O
expression	O
of	O
GPIbalpha	B-Gene
.	O
</ALL>	O

<ALL>	O
Clinical	O
phenotype	O
shows	O
considerable	O
variation	O
between	O
individuals	O
,	O
such	O
as	O
bleeding	B-Disease
,	O
platelet	O
count	O
and	O
the	O
percentage	O
of	O
large	O
platelets	O
.	O
</ALL>	O

<ALL>	O
We	O
describe	O
in	O
a	O
BSS	B-Disease
patient	B-Species
the	O
first	O
case	O
of	O
homozygous	O
four	O
bases	O
deletion	B-Variant
(	I-Variant
TGAG	I-Variant
)	I-Variant
in	O
the	O
gpIbalpha	B-Gene
gene	O
coding	O
sequence	O
,	O
leading	O
to	O
a	O
premature	O
stop	O
codon	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
propositus	O
,	O
blood	O
smears	O
revealed	O
giant	O
platelets	O
(	O
30	O
x	O
10	O
(	O
9	O
)	O
platelets	O
/	O
L	O
)	O
,	O
and	O
platelet	O
agglutination	O
to	O
ristocetin	B-Chemical
was	O
absent	O
.	O
</ALL>	O

<ALL>	O
Propositus	O
'	O
parents	O
are	O
consanguineous	O
.	O
</ALL>	O

<ALL>	O
His	O
father	O
and	O
paternal	O
grandmother	O
showed	O
a	O
mild	O
thrombocytopenia	B-Disease
(	O
108	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
and	O
120	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
platelets	O
respectively	O
)	O
while	O
mothers	O
and	O
sister	O
's	O
referred	O
normal	O
platelet	O
counts	O
.	O
</ALL>	O

<ALL>	O
The	O
surface	O
expression	O
of	O
GPIbalpha	B-Gene
was	O
practically	O
undetectable	O
by	O
flow	O
-	O
cytometry	O
and	O
western	O
blot	O
in	O
the	O
patient	B-Species
and	O
was	O
reduced	O
in	O
the	O
father	O
.	O
</ALL>	O

<ALL>	O
Proband	O
's	O
DNA	O
analysis	O
revealed	O
a	O
homozygous	O
four	O
-	O
base	O
-	O
pair	O
deletion	B-Variant
(	I-Variant
TGAG	I-Variant
)	I-Variant
,	O
starting	O
from	O
the	O
last	O
base	O
of	O
the	O
codon	O
for	O
Ser39	O
,	O
leading	O
to	O
a	O
coding	O
frame	O
shift	O
with	O
a	O
new	O
termination	O
codon	O
after	O
11	O
novel	O
amino	O
acids	O
.	O
</ALL>	O

<ALL>	O
The	O
same	O
mutation	O
was	O
seen	O
in	O
heterozygosis	O
in	O
both	O
parents	O
.	O
</ALL>	O

<ALL>	O
This	O
is	O
the	O
first	O
report	O
of	O
GPIbalpha	B-Gene
TGAG	B-Variant
deletion	I-Variant
in	O
homozygous	O
state	O
even	O
if	O
the	O
defect	O
has	O
already	O
been	O
described	O
in	O
a	O
case	O
of	O
compound	O
heterozygosis	O
.	O
</ALL>	O

<ALL>	O
Surprisingly	O
,	O
the	O
propositus	O
does	O
not	O
report	O
any	O
spontaneous	O
bleeding	B-Disease
tendency	I-Disease
.	O
</ALL>	O

<ALL>	O
Identification	O
and	O
molecular	O
characterization	O
of	O
six	O
novel	O
mutations	O
in	O
the	O
UDP	B-Gene
-	I-Gene
N	I-Gene
-	I-Gene
acetylglucosamine	I-Gene
-	I-Gene
1	I-Gene
-	I-Gene
phosphotransferase	I-Gene
gamma	I-Gene
subunit	I-Gene
(	O
GNPTG	B-Gene
)	O
gene	O
in	O
patients	B-Species
with	O
mucolipidosis	B-Disease
III	I-Disease
gamma	I-Disease
.	O
</ALL>	O

<ALL>	O
Mucolipidosis	B-Disease
type	I-Disease
III	I-Disease
(	O
MLIII	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
affecting	O
lysosomal	O
hydrolase	O
trafficking	O
.	O
</ALL>	O

<ALL>	O
In	O
a	O
study	O
of	O
10	O
patients	B-Species
from	O
seven	O
families	O
with	O
a	O
clinical	O
phenotype	O
and	O
enzymatic	O
diagnosis	O
of	O
MLIII	B-Disease
,	O
six	O
novel	O
GNPTG	B-Gene
gene	O
mutations	O
were	O
identified	O
.	O
</ALL>	O

<ALL>	O
These	O
included	O
missense	O
(	O
p	B-Variant
.	I-Variant
T286	I-Variant
M	I-Variant
)	O
and	O
nonsense	O
(	O
p	B-Variant
.	I-Variant
W111X	I-Variant
)	O
mutations	O
and	O
a	O
transition	O
in	O
the	O
obligate	O
AG	B-Variant
-	I-Variant
dinucleotide	I-Variant
of	O
the	O
intron	O
8	O
acceptor	O
splice	O
site	O
(	O
c.610	B-Variant
-	I-Variant
2A	I-Variant
>	I-Variant
G	I-Variant
)	O
.	O
</ALL>	O

<ALL>	O
Three	O
microdeletions	O
were	O
also	O
identified	O
,	O
two	O
of	O
which	O
(	O
c.611delG	B-Variant
and	O
c.640	B-Variant
_	I-Variant
667del28	I-Variant
)	O
were	O
located	O
within	O
the	O
coding	O
region	O
whereas	O
one	O
(	O
c.609	B-Variant
+	I-Variant
28	I-Variant
_	I-Variant
610	I-Variant
-	I-Variant
16del	I-Variant
)	O
was	O
located	O
entirely	O
within	O
intron	O
8	O
.	O
</ALL>	O

<ALL>	O
RT	O
-	O
PCR	O
analysis	O
of	O
the	O
c.610	B-Variant
-	I-Variant
2A	I-Variant
>	I-Variant
G	I-Variant
transition	O
demonstrated	O
that	O
the	O
change	O
altered	O
splicing	O
,	O
leading	O
to	O
the	O
production	O
of	O
two	O
distinct	O
aberrantly	O
spliced	O
forms	O
,	O
viz	O
.	O
</ALL>	O

<ALL>	O
the	O
skipping	O
of	O
exon	O
9	O
(	O
p	B-Variant
.	I-Variant
G204	I-Variant
_	I-Variant
K247del	I-Variant
)	O
or	O
the	O
retention	O
of	O
introns	O
8	O
and	O
9	O
(	O
p	B-Variant
.	I-Variant
G204VfsX28	I-Variant
)	O
.	O
</ALL>	O

<ALL>	O
RT	O
-	O
PCR	O
analysis	O
,	O
performed	O
on	O
a	O
patient	B-Species
homozygous	O
for	O
the	O
intronic	O
deletion	O
(	O
c.609	B-Variant
+	I-Variant
28	I-Variant
_	I-Variant
610	I-Variant
-	I-Variant
16del	I-Variant
)	O
,	O
failed	O
to	O
detect	O
any	O
GNPTG	B-Gene
RNA	O
transcripts	O
.	O
</ALL>	O

<ALL>	O
To	O
determine	O
whether	O
c.609	B-Variant
+	I-Variant
28	I-Variant
_	I-Variant
610	I-Variant
-	I-Variant
16del	I-Variant
allele	O
-	O
derived	O
transcripts	O
were	O
subject	O
to	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
(	O
NMD	O
)	O
,	O
patient	B-Species
fibroblasts	O
were	O
incubated	O
with	O
the	O
protein	O
synthesis	O
inhibitor	O
anisomycin	B-Chemical
.	O
</ALL>	O

<ALL>	O
An	O
RT	O
-	O
PCR	O
fragment	O
retaining	O
43	O
bp	O
of	O
intron	O
8	O
was	O
consistently	O
detected	O
suggesting	O
that	O
the	O
33	B-Variant
-	I-Variant
bp	I-Variant
genomic	I-Variant
deletion	I-Variant
had	O
elicited	O
NMD	O
.	O
</ALL>	O

<ALL>	O
Quantitative	O
real	O
-	O
time	O
PCR	O
and	O
GNPTG	B-Gene
western	O
blot	O
analysis	O
confirmed	O
that	O
the	O
homozygous	O
microdeletion	O
p	B-Variant
.	I-Variant
G204VfsX17	I-Variant
had	O
elicited	O
NMD	O
resulting	O
in	O
failure	O
to	O
synthesize	O
GNPTG	B-Gene
protein	O
.	O
</ALL>	O

<ALL>	O
Analysis	O
of	O
the	O
sequences	O
surrounding	O
the	O
microdeletion	O
breakpoints	O
revealed	O
either	O
intrinsic	O
repetitivity	O
of	O
the	O
deleted	O
region	O
or	O
short	O
direct	O
repeats	O
adjacent	O
to	O
the	O
breakpoint	O
junctions	O
.	O
</ALL>	O

<ALL>	O
This	O
is	O
consistent	O
with	O
these	O
repeats	O
having	O
mediated	O
the	O
microdeletions	O
via	O
replication	O
slippage	O
and	O
supports	O
the	O
view	O
that	O
the	O
mutational	O
spectrum	O
of	O
the	O
GNPTG	B-Gene
gene	O
is	O
strongly	O
influenced	O
by	O
the	O
properties	O
of	O
the	O
local	O
DNA	O
sequence	O
environment	O
.	O
</ALL>	O

<ALL>	O
A	O
cross	O
-	O
sectional	O
evaluation	O
of	O
the	O
effect	O
of	O
risperidone	B-Chemical
and	O
selective	B-Chemical
serotonin	I-Chemical
reuptake	I-Chemical
inhibitors	I-Chemical
on	O
bone	O
mineral	O
density	O
in	O
boys	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
risperidone	B-Chemical
-	O
induced	O
hyperprolactinemia	B-Disease
on	O
trabecular	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
in	O
children	O
and	O
adolescents	O
.	O
</ALL>	O

<ALL>	O
METHOD	O
:	O
Medically	O
healthy	O
7	O
-	O
to	O
17	O
-	O
year	O
-	O
old	O
males	O
chronically	O
treated	O
,	O
in	O
a	O
naturalistic	O
setting	O
,	O
with	O
risperidone	B-Chemical
were	O
recruited	O
for	O
this	O
cross	O
-	O
sectional	O
study	O
through	O
child	O
psychiatry	O
outpatient	B-Species
clinics	O
between	O
November	O
2005	O
and	O
June	O
2007	O
.	O
</ALL>	O

<ALL>	O
Anthropometric	O
measurements	O
and	O
laboratory	O
testing	O
were	O
conducted	O
.	O
</ALL>	O

<ALL>	O
The	O
clinical	O
diagnoses	O
were	O
based	O
on	O
chart	O
review	O
,	O
and	O
developmental	O
and	O
treatment	O
history	O
was	O
obtained	O
from	O
the	O
medical	O
record	O
.	O
</ALL>	O

<ALL>	O
Volumetric	O
BMD	O
of	O
the	O
ultradistal	O
radius	O
was	O
measured	O
using	O
peripheral	O
quantitative	O
computed	O
tomography	O
,	O
and	O
areal	O
BMD	O
of	O
the	O
lumbar	O
spine	O
was	O
estimated	O
using	O
dual	O
-	O
energy	O
x	O
-	O
ray	O
absorptiometry	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Hyperprolactinemia	B-Disease
was	O
present	O
in	O
49	O
%	O
of	O
83	O
boys	O
(	O
n	O
=	O
41	O
)	O
treated	O
with	O
risperidone	B-Chemical
for	O
a	O
mean	O
of	O
2.9	O
years	O
.	O
</ALL>	O

<ALL>	O
Serum	O
testosterone	B-Chemical
concentration	O
increased	O
with	O
pubertal	O
status	O
but	O
was	O
not	O
affected	O
by	O
hyperprolactinemia	B-Disease
.	O
</ALL>	O

<ALL>	O
As	O
expected	O
,	O
bone	O
mineral	O
content	O
and	O
BMD	O
increased	O
with	O
sexual	O
maturity	O
.	O
</ALL>	O

<ALL>	O
After	O
adjusting	O
for	O
the	O
stage	O
of	O
sexual	O
development	O
and	O
height	O
and	O
BMI	O
z	O
scores	O
,	O
serum	O
prolactin	B-Gene
was	O
negatively	O
associated	O
with	O
trabecular	O
volumetric	O
BMD	O
at	O
the	O
ultradistal	O
radius	O
(	O
P	O
<	O
.03	O
)	O
.	O
</ALL>	O

<ALL>	O
Controlling	O
for	O
relevant	O
covariates	O
,	O
we	O
also	O
found	O
treatment	O
with	O
selective	B-Chemical
serotonin	I-Chemical
reuptake	I-Chemical
inhibitors	I-Chemical
(	O
SSRIs	B-Chemical
)	O
to	O
be	O
associated	O
with	O
lower	O
trabecular	O
BMD	O
at	O
the	O
radius	O
(	O
P	O
=	O
.03	O
)	O
and	O
BMD	O
z	O
score	O
at	O
the	O
lumbar	O
spine	O
(	O
P	O
<	O
.05	O
)	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
became	O
more	O
marked	O
when	O
the	O
analysis	O
was	O
restricted	O
to	O
non	O
-	O
Hispanic	O
white	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Of	O
13	O
documented	O
fractures	B-Disease
,	O
3	O
occurred	O
after	O
risperidone	B-Chemical
and	O
SSRIs	B-Chemical
were	O
started	O
,	O
and	O
none	O
occurred	O
in	O
patients	B-Species
with	O
hyperprolactinemia	B-Disease
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
study	O
to	O
link	O
risperidone	B-Chemical
-	O
induced	O
hyperprolactinemia	B-Disease
and	O
SSRI	B-Chemical
treatment	O
to	O
lower	O
BMD	O
in	O
children	O
and	O
adolescents	O
.	O
</ALL>	O

<ALL>	O
Future	O
research	O
should	O
evaluate	O
the	O
longitudinal	O
course	O
of	O
this	O
adverse	O
event	O
to	O
determine	O
its	O
temporal	O
stability	O
and	O
whether	O
a	O
higher	O
fracture	B-Disease
rate	O
ensues	O
.	O
</ALL>	O

<ALL>	O
The	O
GALT	B-Gene
rush	O
:	O
high	O
carrier	O
frequency	O
of	O
an	O
unusual	O
deletion	O
mutation	O
of	O
the	O
GALT	B-Gene
gene	O
in	O
the	O
Ashkenazi	O
population	O
.	O
</ALL>	O

<ALL>	O
Classic	B-Disease
galactosemia	I-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
of	I-Disease
galactose	I-Disease
metabolism	I-Disease
manifesting	O
in	O
the	O
first	O
weeks	O
of	O
life	O
following	O
exposure	O
to	O
a	O
milk	O
-	O
based	O
diet	O
.	O
</ALL>	O

<ALL>	O
Despite	O
the	O
benefit	O
of	O
avoidance	O
of	O
lactose	B-Chemical
,	O
many	O
patients	B-Species
suffer	O
from	O
long	O
-	O
term	O
complications	O
including	O
neurological	B-Disease
deficits	I-Disease
and	O
ovarian	B-Disease
failure	I-Disease
.	O
</ALL>	O

<ALL>	O
To	O
date	O
,	O
over	O
230	O
mutations	O
have	O
been	O
described	O
in	O
the	O
GALT	B-Gene
gene	O
resulting	O
in	O
galactosemia	B-Disease
.	O
</ALL>	O

<ALL>	O
Recently	O
,	O
an	O
unusual	O
mutation	O
was	O
characterized	O
causing	O
a	O
5.5	B-Variant
kb	I-Variant
deletion	I-Variant
,	O
with	O
a	O
relatively	O
high	O
carrier	O
rate	O
in	O
subjects	O
of	O
Ashkenazi	O
Jewish	O
(	O
AJ	O
)	O
descent	O
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
carrier	O
frequency	O
of	O
this	O
mutation	O
in	O
the	O
AJ	O
population	O
in	O
Israel	O
.	O
</ALL>	O

<ALL>	O
For	O
this	O
purpose	O
we	O
developed	O
a	O
high	O
-	O
throughput	O
methodology	O
to	O
genotype	O
both	O
normal	O
and	O
deleted	O
alleles	O
using	O
a	O
chip	O
-	O
based	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
-	O
time	O
-	O
of	O
-	O
flight	O
(	O
MALDI	O
-	O
TOF	O
)	O
mass	O
spectrometer	O
and	O
Multiplex	O
PCR	O
.	O
</ALL>	O

<ALL>	O
DNA	O
samples	O
of	O
760	O
anonymous	O
AJ	O
subjects	O
were	O
submitted	O
for	O
analysis	O
,	O
subsequently	O
detecting	O
six	O
individuals	O
heterozygous	O
for	O
the	O
GALT	B-Gene
deletion	O
mutation	O
,	O
giving	O
a	O
carrier	O
frequency	O
of	O
1	O
in	O
127	O
(	O
0.79	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
Based	O
on	O
these	O
results	O
,	O
we	O
suggest	O
that	O
the	O
method	O
described	O
here	O
provides	O
a	O
basis	O
for	O
genetic	O
screening	O
and	O
prenatal	O
counseling	O
and	O
can	O
potentially	O
reduce	O
the	O
morbidity	O
and	O
mortality	O
associated	O
with	O
delayed	O
diagnosis	O
of	O
galactosemia	B-Disease
in	O
this	O
patient	B-Species
population	O
.	O
</ALL>	O

<ALL>	O
Long	O
-	O
term	O
oral	O
galactose	B-Chemical
treatment	O
prevents	O
cognitive	B-Disease
deficits	I-Disease
in	O
male	O
Wistar	O
rats	B-Species
treated	O
intracerebroventricularly	O
with	O
streptozotocin	B-Chemical
.	O
</ALL>	O

<ALL>	O
Basic	O
and	O
clinical	O
research	O
has	O
demonstrated	O
that	O
dementia	B-Disease
of	O
sporadic	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
(	O
sAD	B-Disease
)	O
type	O
is	O
associated	O
with	O
dysfunction	O
of	O
the	O
insulin	B-Gene
-	I-Gene
receptor	I-Gene
(	O
IR	B-Gene
)	O
system	O
followed	O
by	O
decreased	O
glucose	B-Chemical
transport	O
via	O
glucose	B-Chemical
transporter	O
GLUT4	B-Gene
and	O
decreased	O
glucose	B-Chemical
metabolism	O
in	O
brain	O
cells	O
.	O
</ALL>	O

<ALL>	O
An	O
alternative	O
source	O
of	O
energy	O
is	O
d	B-Chemical
-	I-Chemical
galactose	I-Chemical
(	O
the	O
C	O
-	O
4	O
-	O
epimer	O
of	O
d	B-Chemical
-	I-Chemical
glucose	I-Chemical
)	O
which	O
is	O
transported	O
into	O
the	O
brain	O
by	O
insulin	B-Gene
-	O
independent	O
GLUT3	B-Gene
transporter	O
where	O
it	O
might	O
be	O
metabolized	O
to	O
glucose	B-Chemical
via	O
the	O
Leloir	O
pathway	O
.	O
</ALL>	O

<ALL>	O
Exclusively	O
parenteral	O
daily	O
injections	O
of	O
galactose	B-Chemical
induce	O
memory	B-Disease
deterioration	I-Disease
in	O
rodents	O
and	O
are	O
used	O
to	O
generate	O
animal	O
aging	O
model	O
,	O
but	O
the	O
effects	O
of	O
oral	O
galactose	B-Chemical
treatment	O
on	O
cognitive	O
functions	O
have	O
never	O
been	O
tested	O
.	O
</ALL>	O

<ALL>	O
We	O
have	O
investigated	O
the	O
effects	O
of	O
continuous	O
daily	O
oral	O
galactose	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
/	O
day	O
)	O
treatment	O
on	O
cognitive	B-Disease
deficits	I-Disease
in	O
streptozotocin	B-Chemical
-	O
induced	O
(	O
STZ	B-Chemical
-	O
icv	O
)	O
rat	B-Species
model	O
of	O
sAD	B-Disease
,	O
tested	O
by	O
Morris	O
Water	O
Maze	O
and	O
Passive	O
Avoidance	O
test	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
One	O
month	O
of	O
oral	O
galactose	B-Chemical
treatment	O
initiated	O
immediately	O
after	O
the	O
STZ	B-Chemical
-	O
icv	O
administration	O
,	O
successfully	O
prevented	O
development	O
of	O
the	O
STZ	B-Chemical
-	O
icv	O
-	O
induced	O
cognitive	B-Disease
deficits	I-Disease
.	O
</ALL>	O

<ALL>	O
Beneficial	O
effect	O
of	O
oral	O
galactose	B-Chemical
was	O
independent	O
of	O
the	O
rat	B-Species
age	O
and	O
of	O
the	O
galactose	B-Chemical
dose	O
ranging	O
from	O
100	O
to	O
300	O
mg	O
/	O
kg	O
/	O
day	O
.	O
</ALL>	O

<ALL>	O
Additionally	O
,	O
oral	O
galactose	B-Chemical
administration	O
led	O
to	O
the	O
appearance	O
of	O
galactose	B-Chemical
in	O
the	O
blood	O
.	O
</ALL>	O

<ALL>	O
The	O
increase	O
of	O
galactose	B-Chemical
concentration	O
in	O
the	O
cerebrospinal	O
fluid	O
was	O
several	O
times	O
lower	O
after	O
oral	O
than	O
after	O
parenteral	O
administration	O
of	O
the	O
same	O
galactose	B-Chemical
dose	O
.	O
</ALL>	O

<ALL>	O
Oral	O
galactose	B-Chemical
exposure	O
might	O
have	O
beneficial	O
effects	O
on	O
learning	O
and	O
memory	O
ability	O
and	O
could	O
be	O
worth	O
investigating	O
for	O
improvement	O
of	O
cognitive	B-Disease
deficits	I-Disease
associated	O
with	O
glucose	B-Disease
hypometabolism	I-Disease
in	O
AD	B-Disease
.	O
</ALL>	O

<ALL>	O
NOTCH1	B-Gene
and	O
SOX10	B-Gene
are	O
Essential	O
for	O
Proliferation	O
and	O
Radiation	O
Resistance	O
of	O
Cancer	B-Disease
Stem	O
-	O
Like	O
Cells	O
in	O
Adenoid	B-Disease
Cystic	I-Disease
Carcinoma	I-Disease
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
Although	O
the	O
existence	O
of	O
cancer	B-Disease
stem	O
cells	O
(	O
CSC	O
)	O
in	O
adenoid	B-Disease
cystic	I-Disease
carcinoma	I-Disease
(	O
ACC	B-Disease
)	O
has	O
been	O
proposed	O
,	O
lack	O
of	O
assays	O
for	O
their	O
propagation	O
and	O
uncertainty	O
about	O
molecular	O
markers	O
prevented	O
their	O
characterization	O
.	O
</ALL>	O

<ALL>	O
Our	O
objective	O
was	O
to	O
isolate	O
CSC	O
from	O
ACC	B-Disease
and	O
provide	O
insight	O
into	O
signaling	O
pathways	O
that	O
support	O
their	O
propagation	O
.	O
</ALL>	O

<ALL>	O
EXPERIMENTAL	O
DESIGN	O
:	O
To	O
isolate	O
CSC	O
from	O
ACC	B-Disease
and	O
characterize	O
them	O
,	O
we	O
used	O
ROCK	B-Gene
inhibitor	O
-	O
supplemented	O
cell	O
culture	O
,	O
immunomagnetic	O
cell	O
sorting	O
,	O
andin	O
vitro	O
/	O
in	O
vivoassays	O
for	O
CSC	O
viability	O
and	O
tumorigenicity	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
We	O
identified	O
in	O
ACC	B-Disease
CD133	B-Gene
-	O
positive	O
CSC	O
that	O
expressed	O
NOTCH1	B-Gene
and	O
SOX10	B-Gene
,	O
formed	O
spheroids	O
,	O
and	O
initiated	O
tumors	B-Disease
in	O
nude	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
CD133	B-Gene
(	O
+	O
)	O
ACC	B-Disease
cells	O
produced	O
activated	O
NOTCH1	B-Gene
(	O
N1ICD	B-Gene
)	O
and	O
generated	O
CD133	B-Gene
(	O
-	O
)	O
cells	O
that	O
expressed	O
JAG1	B-Gene
as	O
well	O
as	O
neural	O
differentiation	O
factors	O
NR2F1	B-Gene
,	O
NR2F2	B-Gene
,	O
and	O
p27Kip1	B-Gene
.	O
</ALL>	O

<ALL>	O
Knockdowns	O
of	O
NOTCH1	B-Gene
,	O
SOX10	B-Gene
,	O
and	O
their	O
common	O
effector	O
FABP7	B-Gene
had	O
negative	O
effects	O
on	O
each	O
other	O
,	O
inhibited	O
spheroidogenesis	O
,	O
and	O
induced	O
cell	O
death	O
pointing	O
at	O
their	O
essential	O
roles	O
in	O
CSC	O
maintenance	O
.	O
</ALL>	O

<ALL>	O
Downstream	O
effects	O
of	O
FABP7	B-Gene
knockdown	O
included	O
suppression	O
of	O
a	O
broad	O
spectrum	O
of	O
genes	O
involved	O
in	O
proliferation	O
,	O
ribosome	O
biogenesis	O
,	O
and	O
metabolism	O
.	O
</ALL>	O

<ALL>	O
Among	O
proliferation	O
-	O
linked	O
NOTCH1	B-Gene
/	O
FABP7	B-Gene
targets	O
,	O
we	O
identified	O
SKP2	B-Gene
and	O
its	O
substrate	O
p27Kip1	B-Gene
.	O
</ALL>	O

<ALL>	O
A	O
g	B-Gene
-	I-Gene
secretase	I-Gene
inhibitor	O
,	O
DAPT	B-Chemical
,	O
selectively	O
depleted	O
CD133	B-Gene
(	O
+	O
)	O
cells	O
,	O
suppressed	O
N1ICD	B-Gene
and	O
SKP2	B-Gene
,	O
induced	O
p27Kip1	B-Gene
,	O
inhibited	O
ACC	B-Disease
growthin	O
vivo	O
,	O
and	O
sensitized	O
CD133	B-Gene
(	O
+	O
)	O
cells	O
to	O
radiation	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
These	O
results	O
establish	O
in	O
the	O
majority	O
of	O
ACC	B-Disease
the	O
presence	O
of	O
a	O
previously	O
uncharacterized	O
population	O
of	O
CD133	B-Gene
(	O
+	O
)	O
cells	O
with	O
neural	O
stem	O
properties	O
,	O
which	O
are	O
driven	O
by	O
SOX10	B-Gene
,	O
NOTCH1	B-Gene
,	O
and	O
FABP7	B-Gene
.	O
</ALL>	O

<ALL>	O
Sensitivity	O
of	O
these	O
cells	O
to	O
Notch	B-Gene
inhibition	O
and	O
their	O
dependence	O
on	O
SKP2	B-Gene
offer	O
new	O
opportunities	O
for	O
targeted	O
ACC	B-Disease
therapies	O
.	O
</ALL>	O

<ALL>	O
Cone	B-Disease
dystrophy	I-Disease
with	I-Disease
supernormal	I-Disease
rod	I-Disease
response	I-Disease
is	O
strictly	O
associated	O
with	O
mutations	O
in	O
KCNV2	B-Gene
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
Cone	B-Disease
dystrophy	I-Disease
with	I-Disease
supernormal	I-Disease
rod	I-Disease
response	I-Disease
(	O
CDSRR	B-Disease
)	O
is	O
a	O
retinal	B-Disease
disorder	I-Disease
characterized	O
by	O
reduced	O
visual	O
acuity	O
,	O
color	B-Disease
vision	I-Disease
defects	I-Disease
,	O
and	O
specific	O
alterations	O
of	O
ERG	O
responses	O
that	O
feature	O
elevated	O
scotopic	O
b	O
-	O
wave	O
amplitudes	O
at	O
high	O
luminance	O
intensities	O
.	O
</ALL>	O

<ALL>	O
Mutations	O
in	O
PDE6H	B-Gene
and	O
in	O
KCNV2	B-Gene
have	O
been	O
described	O
in	O
CDSRR	B-Disease
.	O
</ALL>	O

<ALL>	O
A	O
combined	O
clinical	O
and	O
genetic	O
study	O
was	O
conducted	O
in	O
a	O
cohort	O
of	O
patients	B-Species
with	O
CDSRR	B-Disease
,	O
to	O
substantiate	O
these	O
prior	O
RESULTS	O
:	O
Seventeen	O
patients	B-Species
from	O
13	O
families	O
underwent	O
a	O
detailed	O
ophthalmic	O
examination	O
including	O
color	O
vision	O
testing	O
,	O
Goldmann	O
visual	O
fields	O
,	O
fundus	O
photography	O
,	O
Ganzfeld	O
and	O
multifocal	O
ERGs	O
,	O
and	O
optical	O
coherence	O
tomography	O
.	O
</ALL>	O

<ALL>	O
The	O
coding	O
sequences	O
and	O
flanking	O
intron	O
/	O
UTR	O
sequences	O
of	O
PDE6C	B-Gene
and	O
KCNV2	B-Gene
were	O
screened	O
for	O
mutations	O
by	O
means	O
of	O
DHPLC	O
and	O
direct	O
DNA	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
genomic	O
DNA	O
.	O
</ALL>	O

<ALL>	O
results	O
.	O
</ALL>	O

<ALL>	O
Whereas	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
PDE6H	B-Gene
gene	O
,	O
mutations	O
in	O
KCNV2	B-Gene
were	O
identified	O
in	O
all	O
patients	B-Species
,	O
in	O
either	O
the	O
homozygous	O
or	O
compound	O
heterozygous	O
state	O
.	O
</ALL>	O

<ALL>	O
Ten	O
of	O
the	O
11	O
identified	O
mutations	O
were	O
novel	O
,	O
including	O
three	O
missense	O
and	O
six	O
truncating	O
mutations	O
and	O
one	O
gross	O
deletion	O
.	O
</ALL>	O

<ALL>	O
The	O
mutations	O
concordantly	O
segregate	O
in	O
all	O
available	O
families	O
according	O
a	O
recessive	O
mode	O
of	O
inheritance	O
.	O
</ALL>	O

<ALL>	O
The	O
CDSRR	B-Disease
phenotype	O
was	O
associated	O
with	O
reduced	O
visual	O
acuity	O
of	O
variable	O
degree	O
and	O
color	B-Disease
vision	I-Disease
defects	I-Disease
.	O
</ALL>	O

<ALL>	O
Macular	O
defects	O
ranging	O
from	O
mild	O
pigmentary	O
changes	O
to	O
distinct	O
foveal	O
atrophy	B-Disease
were	O
present	O
in	O
nine	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Progression	O
of	O
the	O
disease	O
was	O
observed	O
in	O
only	O
three	O
of	O
seven	O
patients	B-Species
with	O
follow	O
-	O
up	O
data	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
The	O
phenotype	O
of	O
cone	B-Disease
dystrophy	I-Disease
with	I-Disease
supernormal	I-Disease
rod	I-Disease
response	I-Disease
is	O
tightly	O
linked	O
with	O
mutations	O
in	O
KCNV2	B-Gene
.	O
</ALL>	O

<ALL>	O
Novel	O
CACNA1S	B-Gene
mutation	O
causes	O
autosomal	O
dominant	O
hypokalemic	B-Disease
periodic	I-Disease
paralysis	I-Disease
in	O
a	O
South	O
American	O
family	O
.	O
</ALL>	O

<ALL>	O
Hypokalaemic	B-Disease
periodic	I-Disease
paralysis	I-Disease
(	O
HypoPP	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
dominant	I-Disease
disorder	I-Disease
,	O
which	O
is	O
characterized	O
by	O
periodic	O
attacks	O
of	O
muscle	B-Disease
weakness	I-Disease
associated	O
with	O
a	O
decrease	O
in	O
the	O
serum	O
potassium	B-Chemical
level	O
.	O
</ALL>	O

<ALL>	O
A	O
major	O
disease	O
-	O
causing	O
gene	O
for	O
HypoPP	B-Disease
has	O
been	O
identified	O
as	O
CACNA1S	B-Gene
,	O
which	O
encodes	O
the	O
skeletal	B-Gene
muscle	I-Gene
calcium	I-Gene
channel	I-Gene
alpha	I-Gene
-	I-Gene
subunit	I-Gene
with	O
four	O
transmembrane	O
domains	O
(	O
I	O
-	O
IV	O
)	O
,	O
each	O
with	O
six	O
transmembrane	O
segments	O
(	O
S1	O
-	O
S6	O
)	O
.	O
</ALL>	O

<ALL>	O
To	O
date	O
,	O
all	O
CACNA1S	B-Gene
mutations	O
identified	O
in	O
HypoPP	B-Disease
patients	B-Species
are	O
located	O
within	O
the	O
voltage	O
-	O
sensor	O
S4	O
segment	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
we	O
report	O
a	O
novel	O
CACNA1S	B-Gene
mutation	O
in	O
a	O
new	O
region	O
of	O
the	O
protein	O
,	O
the	O
S3	O
segment	O
of	O
domain	O
III	O
.	O
</ALL>	O

<ALL>	O
We	O
characterized	O
a	O
four	O
-	O
generation	O
South	O
American	O
family	O
with	O
HypoPP	B-Disease
.	O
</ALL>	O

<ALL>	O
Genetic	O
analysis	O
identified	O
a	O
novel	O
V876E	B-Variant
mutation	O
in	O
all	O
HypoPP	B-Disease
patients	B-Species
in	O
the	O
family	O
,	O
but	O
not	O
in	O
normal	O
family	O
members	O
or	O
160	O
control	O
people	O
.	O
</ALL>	O

<ALL>	O
Clinical	O
analysis	O
indicates	O
that	O
mutation	O
V876E	B-Variant
is	O
associated	O
with	O
a	O
severe	O
outcome	O
as	O
characterized	O
by	O
a	O
very	O
early	O
age	O
of	O
onset	O
,	O
complete	O
penetrance	O
and	O
a	O
severe	O
prognosis	O
including	O
death	B-Disease
.	O
</ALL>	O

<ALL>	O
These	O
results	O
identify	O
a	O
new	O
mutation	O
in	O
CACNA1S	B-Gene
and	O
expand	O
the	O
spectrum	O
of	O
CACNA1S	B-Gene
mutations	O
associated	O
with	O
HypoPP	B-Disease
.	O
</ALL>	O

<ALL>	O
Independent	O
and	O
cooperative	O
roles	O
of	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
-	I-Gene
alpha	I-Gene
,	O
nuclear	B-Gene
factor	I-Gene
-	I-Gene
kappaB	I-Gene
,	O
and	O
bone	B-Gene
morphogenetic	I-Gene
protein	I-Gene
-	I-Gene
2	I-Gene
in	O
regulation	O
of	O
metastasis	B-Disease
and	O
osteomimicry	O
of	O
prostate	B-Disease
cancer	I-Disease
cells	O
and	O
differentiation	O
and	O
mineralization	O
of	O
MC3T3	B-CellLine
-	I-CellLine
E1	I-CellLine
osteoblast	O
-	O
like	O
cells	O
.	O
</ALL>	O

<ALL>	O
The	O
molecular	O
mechanisms	O
involved	O
in	O
prostate	B-Disease
cancer	I-Disease
(	I-Disease
PC	I-Disease
)	I-Disease
metastasis	I-Disease
and	O
bone	O
remodeling	O
are	O
poorly	O
understood	O
.	O
</ALL>	O

<ALL>	O
We	O
recently	O
reported	O
that	O
phosphoinositide	B-Gene
3	I-Gene
-	I-Gene
kinase	I-Gene
(	I-Gene
PI3	I-Gene
K	I-Gene
)	I-Gene
/	I-Gene
protein	I-Gene
kinase	I-Gene
B	I-Gene
(	O
Akt	B-Gene
)	O
mediates	O
transcriptional	O
regulation	O
and	O
activation	O
of	O
bone	B-Gene
morphogenetic	I-Gene
protein	I-Gene
(	I-Gene
BMP	I-Gene
)	I-Gene
-	I-Gene
2	I-Gene
signaling	O
by	O
nuclear	B-Gene
factor	I-Gene
(	I-Gene
NF	I-Gene
)	I-Gene
-	I-Gene
kappaB	I-Gene
in	O
bone	O
metastatic	O
prostate	B-Disease
cancer	I-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
NF	B-Gene
-	I-Gene
kappaB	I-Gene
,	O
whether	O
activated	O
by	O
recombinant	O
human	B-Species
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
(	I-Gene
TNF	I-Gene
)	I-Gene
-	I-Gene
alpha	I-Gene
or	O
by	O
ectopic	O
expression	O
of	O
the	O
p65	B-Gene
subunit	O
,	O
is	O
involved	O
in	O
extracellular	O
matrix	O
adhesion	O
and	O
invasion	O
of	O
osteotropic	O
PC	B-CellLine
-	I-CellLine
3	I-CellLine
and	O
C4	B-CellLine
-	I-CellLine
2B	I-CellLine
,	O
but	O
not	O
LNCaP	B-CellLine
,	O
cells	O
.	O
</ALL>	O

<ALL>	O
The	O
enhanced	O
metastatic	O
potential	O
was	O
associated	O
with	O
transcriptional	O
upregulation	O
of	O
osteopontin	B-Gene
,	O
osteocalcin	B-Gene
,	O
and	O
collagen	B-Gene
IA1	I-Gene
in	O
osteotropic	O
PC	B-Disease
cells	O
,	O
suggesting	O
their	O
role	O
in	O
osteomimicry	O
of	O
PC	B-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
Unlike	O
BMP	B-Gene
-	I-Gene
4	I-Gene
,	O
BMP	B-Gene
-	I-Gene
2	I-Gene
protein	O
enhanced	O
the	O
invasive	O
properties	O
of	O
C4	B-CellLine
-	I-CellLine
2B	I-CellLine
cells	O
,	O
but	O
not	O
in	O
LNCaP	B-CellLine
cells	O
.	O
</ALL>	O

<ALL>	O
Also	O
,	O
this	O
effect	O
was	O
nullified	O
by	O
Noggin	B-Gene
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
BMP	B-Gene
-	I-Gene
2	I-Gene
mediates	O
TNF	B-Gene
-	I-Gene
alpha	I-Gene
-	O
induced	O
invasion	O
of	O
C4	B-CellLine
-	I-CellLine
2B	I-CellLine
cells	O
in	O
a	O
NF	B-Gene
-	I-Gene
kappaB	I-Gene
-	O
dependent	O
fashion	O
.	O
</ALL>	O

<ALL>	O
TNF	B-Gene
-	I-Gene
alpha	I-Gene
or	O
conditioned	O
media	O
(	O
CM	O
)	O
of	O
TNF	B-Gene
-	I-Gene
alpha	I-Gene
-	O
stimulated	O
C4	B-CellLine
-	I-CellLine
2B	I-CellLine
cells	O
upregulated	O
BMP	B-Gene
-	I-Gene
2	I-Gene
and	O
BMP	B-Gene
-	O
dependent	O
Smad	B-Gene
transcripts	O
and	O
inhibited	O
receptor	B-Gene
activator	I-Gene
of	I-Gene
NF	I-Gene
-	I-Gene
kappaB	I-Gene
ligand	I-Gene
transcripts	O
in	O
RAW	B-CellLine
264.7	I-CellLine
preosteoclast	O
cells	O
,	O
respectively	O
,	O
implying	O
that	O
this	O
factor	O
may	O
contribute	O
to	O
suppression	O
of	O
osteoclastogenesis	O
via	O
direct	O
and	O
paracrine	O
mechanisms	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
CM	O
of	O
TNF	B-Gene
-	I-Gene
alpha	I-Gene
-	O
stimulate	O
or	O
BMP2	B-Gene
-	O
stimulated	O
C4	B-CellLine
-	I-CellLine
2B	I-CellLine
cells	O
induced	O
in	O
vitro	O
mineralization	O
of	O
MC3T3	B-CellLine
-	I-CellLine
E1	I-CellLine
osteoblast	O
cells	O
in	O
a	O
BMP	B-Gene
-	I-Gene
2	I-Gene
-	O
dependent	O
and	O
NF	B-Gene
-	I-Gene
kappaB	I-Gene
-	O
dependent	O
manner	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
Taken	O
together	O
,	O
the	O
results	O
suggest	O
that	O
mutual	O
interactions	O
between	O
these	O
factors	O
may	O
be	O
pivotal	O
not	O
only	O
in	O
enhancing	O
the	O
osteomimicry	O
and	O
metastatic	O
potential	O
of	O
PC	B-Disease
cells	O
,	O
but	O
also	O
in	O
bone	O
remodeling	O
and	O
in	O
shifting	O
the	O
balance	O
from	O
osteoclastogenesis	O
towards	O
osteoblastogenesis	O
.	O
</ALL>	O

<ALL>	O
Association	O
study	O
of	O
polymorphisms	O
in	O
the	O
promoter	O
region	O
of	O
DRD4	B-Gene
with	O
schizophrenia	B-Disease
,	O
depression	B-Disease
,	O
and	O
heroin	B-Disease
addiction	I-Disease
.	O
</ALL>	O

<ALL>	O
This	O
study	O
investigated	O
the	O
possible	O
association	O
between	O
three	O
functional	O
polymorphisms	O
in	O
the	O
promoter	O
region	O
of	O
the	O
dopamine	B-Gene
D4	I-Gene
receptor	I-Gene
(	O
DRD4	B-Gene
)	O
gene	O
and	O
schizophrenia	B-Disease
,	O
depression	B-Disease
,	O
and	O
heroin	B-Disease
addiction	I-Disease
.	O
</ALL>	O

<ALL>	O
Genomic	O
DNA	O
was	O
isolated	O
from	O
the	O
venous	O
blood	O
leukocytes	O
of	O
322	O
unrelated	O
patients	B-Species
with	O
schizophrenia	B-Disease
,	O
156	O
patients	B-Species
with	O
depression	B-Disease
,	O
300	O
patients	B-Species
with	O
heroin	B-Disease
addiction	I-Disease
,	O
and	O
300	O
healthy	O
unrelated	O
individuals	O
.	O
</ALL>	O

<ALL>	O
Polymorphisms	O
in	O
the	O
promoter	O
region	O
of	O
DRD4	B-Gene
(	O
-	B-Variant
120	I-Variant
bp	I-Variant
duplication	I-Variant
,	O
-	B-Variant
616C	I-Variant
/	I-Variant
G	I-Variant
,	O
and	O
-	B-Variant
521C	I-Variant
/	I-Variant
T	I-Variant
)	O
were	O
genotyped	O
using	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Genotype	O
and	O
allele	O
were	O
analyzed	O
using	O
SPSS	O
11.5	O
software	O
.	O
</ALL>	O

<ALL>	O
Results	O
of	O
this	O
analysis	O
indicated	O
that	O
there	O
is	O
a	O
strong	O
finding	O
of	O
-	B-Variant
120	I-Variant
bp	I-Variant
duplication	I-Variant
allele	O
frequencies	O
with	O
schizophrenia	B-Disease
(	O
p	O
=	O
0.008	O
)	O
and	O
weak	O
finding	O
with	O
-	B-Variant
1240	I-Variant
L	I-Variant
/	I-Variant
S	I-Variant
and	O
for	O
paranoid	B-Disease
schizophrenia	I-Disease
(	O
p	O
=	O
0.022	O
)	O
.	O
</ALL>	O

<ALL>	O
Interestingly	O
,	O
there	O
is	O
a	O
stronger	O
finding	O
with	O
-	B-Variant
521	I-Variant
C	I-Variant
/	I-Variant
T	I-Variant
allele	O
frequencies	O
with	O
heroin	B-Disease
dependence	I-Disease
(	O
p	O
=	O
0.0002	O
)	O
.	O
</ALL>	O

<ALL>	O
These	O
observations	O
strongly	O
suggest	O
that	O
the	O
-	B-Variant
120	I-Variant
-	I-Variant
bp	I-Variant
duplication	I-Variant
polymorphism	O
of	O
DRD4	B-Gene
is	O
associated	O
with	O
schizophrenia	B-Disease
and	O
that	O
the	O
-	B-Variant
521	I-Variant
C	I-Variant
/	I-Variant
T	I-Variant
polymorphism	O
is	O
associated	O
with	O
heroin	B-Disease
addiction	I-Disease
.	O
</ALL>	O

<ALL>	O
Novel	O
CRELD1	B-Gene
gene	O
mutations	O
in	O
patients	B-Species
with	O
atrioventricular	B-Disease
septal	I-Disease
defect	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Atrioventricular	B-Disease
septal	I-Disease
defects	I-Disease
(	O
AVSDs	B-Disease
)	O
occur	O
as	O
clinical	O
defects	O
of	O
several	O
different	O
syndromes	O
,	O
as	O
autosomal	B-Disease
dominant	I-Disease
defects	I-Disease
,	O
and	O
as	O
sporadically	O
occurring	O
malformations	B-Disease
.	O
</ALL>	O

<ALL>	O
Consequently	O
,	O
there	O
is	O
genetic	O
heterogeneity	O
,	O
but	O
until	O
recently	O
,	O
little	O
is	O
known	O
about	O
the	O
genes	O
involving	O
in	O
the	O
pathogenesis	O
of	O
AVSD	B-Disease
.	O
</ALL>	O

<ALL>	O
CRELD1	B-Gene
gene	O
,	O
a	O
novel	O
cell	O
adhesion	O
molecule	O
,	O
is	O
a	O
candidate	O
gene	O
for	O
AVSD	B-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
This	O
study	O
included	O
133	O
patients	B-Species
with	O
AVSD	B-Disease
and	O
200	O
healthy	O
controls	O
.	O
</ALL>	O

<ALL>	O
Peripheral	O
blood	O
samples	O
were	O
collected	O
and	O
genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
leukocytes	O
.	O
</ALL>	O

<ALL>	O
CRELD1	B-Gene
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
with	O
specific	O
primers	O
.	O
</ALL>	O

<ALL>	O
The	O
sequences	O
of	O
PCR	O
products	O
were	O
compared	O
between	O
the	O
patients	B-Species
and	O
controls	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
In	O
a	O
patient	B-Species
,	O
a	O
C	B-Variant
-	I-Variant
to	I-Variant
-	I-Variant
G	I-Variant
transition	I-Variant
was	I-Variant
identified	I-Variant
at	I-Variant
nucleotide	I-Variant
857	I-Variant
in	O
exon	O
8	O
that	O
resulted	O
in	O
a	O
substitution	O
of	O
alanine	B-Variant
for	I-Variant
proline	I-Variant
at	I-Variant
amino	I-Variant
acid	I-Variant
286	I-Variant
in	O
the	O
first	O
calcium	B-Chemical
-	O
binding	O
EGF	B-Gene
domain	O
.	O
</ALL>	O

<ALL>	O
This	O
patient	B-Species
had	O
an	O
isolated	O
partial	O
AVSD	B-Disease
and	O
the	O
mutation	O
was	O
inherited	O
from	O
her	O
mother	O
.	O
</ALL>	O

<ALL>	O
Another	O
mutation	O
was	O
detected	O
in	O
a	O
patient	B-Species
with	O
a	O
partial	O
AVSD	B-Disease
and	O
evidence	O
of	O
Down	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
heterozygous	O
c.973	B-Variant
G	I-Variant
>	I-Variant
A	I-Variant
transition	O
in	O
exon	O
9	O
resulted	O
in	O
a	O
substitution	O
of	O
lysine	B-Variant
for	I-Variant
glutamic	I-Variant
acid	I-Variant
at	I-Variant
amino	I-Variant
acid	I-Variant
325	I-Variant
(	O
E325	B-Variant
K	I-Variant
)	O
in	O
the	O
second	O
calcium	B-Chemical
-	O
binding	O
EGF	B-Gene
domain	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Two	O
novel	O
CRELD1	B-Gene
mutations	O
were	O
identified	O
in	O
the	O
calcium	B-Chemical
-	O
binding	O
EGF	B-Gene
domain	O
in	O
patients	B-Species
with	O
AVSD	B-Disease
.	O
</ALL>	O

<ALL>	O
CRELD1	B-Gene
is	O
likely	O
to	O
be	O
an	O
AVSD	B-Disease
-	O
susceptibility	O
gene	O
and	O
CRELD1	B-Gene
mutations	O
may	O
increase	O
the	O
risk	O
of	O
developing	O
a	O
heart	B-Disease
defect	I-Disease
rather	O
than	O
being	O
a	O
direct	O
causative	O
mutation	O
.	O
</ALL>	O

<ALL>	O
Impact	O
of	O
CCR5	O
delta32	B-Variant
host	O
genetic	O
background	O
and	O
disease	O
progression	O
on	O
HIV	B-Species
-	I-Species
1	I-Species
intrahost	O
evolutionary	O
processes	O
:	O
efficient	O
hypothesis	O
testing	O
through	O
hierarchical	O
phylogenetic	O
models	O
.	O
</ALL>	O

<ALL>	O
The	O
interplay	O
between	O
C	B-Gene
-	I-Gene
C	I-Gene
chemokine	I-Gene
receptor	I-Gene
type	I-Gene
5	I-Gene
(	O
CCR5	B-Gene
)	O
host	O
genetic	O
background	O
,	O
disease	O
progression	O
,	O
and	O
intrahost	O
HIV	B-Species
-	I-Species
1	I-Species
evolutionary	O
dynamics	O
remains	O
unclear	O
because	O
differences	O
in	O
viral	O
evolution	O
between	O
hosts	O
limit	O
the	O
ability	O
to	O
draw	O
conclusions	O
across	O
hosts	O
stratified	O
into	O
clinically	O
relevant	O
populations	O
.	O
</ALL>	O

<ALL>	O
Similar	O
inference	O
problems	O
are	O
proliferating	O
across	O
many	O
measurably	O
evolving	O
pathogens	O
for	O
which	O
intrahost	O
sequence	O
samples	O
are	O
readily	O
available	O
.	O
</ALL>	O

<ALL>	O
To	O
this	O
end	O
,	O
we	O
propose	O
novel	O
hierarchical	O
phylogenetic	O
models	O
(	O
HPMs	O
)	O
that	O
incorporate	O
fixed	O
effects	O
to	O
test	O
for	O
differences	O
in	O
dynamics	O
across	O
host	O
populations	O
in	O
a	O
formal	O
statistical	O
framework	O
employing	O
stochastic	O
search	O
variable	O
selection	O
and	O
model	O
averaging	O
.	O
</ALL>	O

<ALL>	O
To	O
clarify	O
the	O
role	O
of	O
CCR5	B-Gene
host	O
genetic	O
background	O
and	O
disease	O
progression	O
on	O
viral	O
evolutionary	O
patterns	O
,	O
we	O
obtain	O
gp120	B-Gene
envelope	O
sequences	O
from	O
clonal	O
HIV	B-Species
-	I-Species
1	I-Species
variants	O
isolated	O
at	O
multiple	O
time	O
points	O
in	O
the	O
course	O
of	O
infection	B-Disease
from	O
populations	O
of	O
HIV	B-Disease
-	I-Disease
1	I-Disease
-	I-Disease
infected	I-Disease
individuals	O
who	O
only	O
harbored	O
CCR5	B-Gene
-	O
using	O
HIV	B-Species
-	I-Species
1	I-Species
variants	O
at	O
all	O
time	O
points	O
.	O
</ALL>	O

<ALL>	O
Presence	O
or	O
absence	O
of	O
a	O
CCR5	B-Gene
wt	O
/	O
DD32	B-Variant
genotype	O
and	O
progressive	O
or	O
long	O
-	O
term	O
nonprogressive	O
course	O
of	O
infection	B-Disease
stratify	O
the	O
clinical	O
populations	O
in	O
a	O
two	O
-	O
way	O
design	O
.	O
</ALL>	O

<ALL>	O
As	O
compared	O
with	O
the	O
standard	O
approach	O
of	O
analyzing	O
sequences	O
from	O
each	O
patient	B-Species
independently	O
,	O
the	O
HPM	O
provides	O
more	O
efficient	O
estimation	O
of	O
evolutionary	O
parameters	O
such	O
as	O
nucleotide	O
substitution	O
rates	O
and	O
d	O
(	O
N	O
)	O
/	O
d	O
(	O
S	O
)	O
rate	O
ratios	O
,	O
as	O
shown	O
by	O
significant	O
shrinkage	O
of	O
the	O
estimator	O
variance	O
.	O
</ALL>	O

<ALL>	O
The	O
fixed	O
effects	O
also	O
correct	O
for	O
nonindependence	O
of	O
data	O
between	O
populations	O
and	O
results	O
in	O
even	O
further	O
shrinkage	O
of	O
individual	O
patient	B-Species
estimates	O
.	O
</ALL>	O

<ALL>	O
Model	O
selection	O
suggests	O
an	O
association	O
between	O
nucleotide	O
substitution	O
rate	O
and	O
disease	O
progression	O
,	O
but	O
a	O
role	O
for	O
CCR5	B-Gene
genotype	O
remains	O
elusive	O
.	O
</ALL>	O

<ALL>	O
Given	O
the	O
absence	O
of	O
clear	O
d	O
(	O
N	O
)	O
/	O
d	O
(	O
S	O
)	O
differences	O
between	O
patient	B-Species
groups	O
,	O
delayed	O
onset	O
of	O
AIDS	B-Disease
symptoms	O
appears	O
to	O
be	O
solely	O
associated	O
with	O
lower	O
viral	O
replication	O
rates	O
rather	O
than	O
with	O
differences	O
in	O
selection	O
on	O
amino	O
acid	O
fixation	O
.	O
</ALL>	O

<ALL>	O
Late	O
-	O
onset	O
scleroderma	B-Disease
renal	I-Disease
crisis	I-Disease
induced	O
by	O
tacrolimus	B-Chemical
and	O
prednisolone	B-Chemical
:	O
a	O
case	O
report	O
.	O
</ALL>	O

<ALL>	O
Scleroderma	B-Disease
renal	I-Disease
crisis	I-Disease
(	O
SRC	B-Disease
)	O
is	O
a	O
rare	O
complication	O
of	O
systemic	B-Disease
sclerosis	I-Disease
(	O
SSc	B-Disease
)	O
but	O
can	O
be	O
severe	O
enough	O
to	O
require	O
temporary	O
or	O
permanent	O
renal	O
replacement	O
therapy	O
.	O
</ALL>	O

<ALL>	O
Moderate	O
to	O
high	O
dose	O
corticosteroid	B-Chemical
use	O
is	O
recognized	O
as	O
a	O
major	O
risk	O
factor	O
for	O
SRC	B-Disease
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
there	O
have	O
been	O
reports	O
of	O
thrombotic	B-Disease
microangiopathy	I-Disease
precipitated	O
by	O
cyclosporine	B-Chemical
in	O
patients	B-Species
with	O
SSc	B-Disease
.	O
</ALL>	O

<ALL>	O
In	O
this	O
article	O
,	O
we	O
report	O
a	O
patient	B-Species
with	O
SRC	B-Disease
induced	O
by	O
tacrolimus	B-Chemical
and	O
corticosteroids	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
this	O
work	O
is	O
to	O
call	O
attention	O
to	O
the	O
risk	O
of	O
tacrolimus	B-Chemical
use	O
in	O
patients	B-Species
with	O
SSc	B-Disease
.	O
</ALL>	O

<ALL>	O
TIPE2	B-Gene
Inhibits	O
Lung	B-Disease
Cancer	I-Disease
Growth	O
Attributing	O
to	O
Promotion	O
of	O
Apoptosis	O
by	O
Regulating	O
Some	O
Apoptotic	O
Molecules	O
Expression	O
.	O
</ALL>	O

<ALL>	O
Recent	O
studies	O
found	O
that	O
TIPE2	B-Gene
was	O
involved	O
in	O
cancer	B-Disease
development	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
little	O
is	O
known	O
about	O
TIPE2	B-Gene
in	O
lung	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
Our	O
study	O
aims	O
to	O
clarify	O
the	O
role	O
of	O
TIPE2	B-Gene
in	O
lung	B-Disease
carcinogenesis	I-Disease
.	O
</ALL>	O

<ALL>	O
We	O
examined	O
the	O
expression	O
of	O
TIPE2	B-Gene
in	O
lung	B-Disease
squamous	I-Disease
cancer	I-Disease
(	O
LSC	B-Disease
)	O
,	O
small	B-Disease
cell	I-Disease
lung	I-Disease
cancer	I-Disease
and	O
lung	B-Disease
adenocarcinoma	I-Disease
(	O
AdC	B-Disease
)	O
tissues	O
and	O
found	O
that	O
TIPE2	B-Gene
expression	O
was	O
lost	O
in	O
small	B-Disease
cell	I-Disease
lung	I-Disease
cancer	I-Disease
,	O
compared	O
with	O
adjacent	O
non	O
-	O
tumor	B-Disease
tissues	O
.	O
</ALL>	O

<ALL>	O
Overexpression	O
of	O
TIPE2	B-Gene
significantly	O
inhibited	O
the	O
growth	O
of	O
lung	B-Disease
cancer	I-Disease
cell	O
H446	B-CellLine
in	O
vitro	O
and	O
even	O
suppressed	O
tumor	B-Disease
formation	O
in	O
vivo	O
.	O
</ALL>	O

<ALL>	O
Flow	O
cytometry	O
analysis	O
found	O
TIPE2	B-Gene
overexpression	O
promoted	O
apoptosis	O
of	O
H446	B-CellLine
.	O
</ALL>	O

<ALL>	O
In	O
TIPE2	B-Gene
over	O
-	O
expression	O
cells	O
,	O
caspase	B-Gene
-	I-Gene
3	I-Gene
,	O
caspase	B-Gene
-	I-Gene
9	I-Gene
,	O
and	O
Bax	B-Gene
were	O
significantly	O
up	O
-	O
regulated	O
while	O
Bcl	B-Gene
-	I-Gene
2	I-Gene
was	O
down	O
-	O
regulated	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
coincident	O
results	O
were	O
shown	O
by	O
immunohistochemistry	O
in	O
tumors	B-Disease
from	O
nude	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
TIPE2	B-Gene
inhibited	O
the	O
phosphorylation	O
of	O
Akt	B-Gene
,	O
while	O
promoting	O
the	O
phosphorylation	O
of	O
P38	B-Gene
,	O
but	O
had	O
no	O
effect	O
on	O
IkBa	B-Gene
and	O
ERK	B-Gene
pathway	O
.	O
</ALL>	O

<ALL>	O
Taken	O
together	O
,	O
TIPE2	B-Gene
promoted	O
lung	B-Disease
cancer	I-Disease
cell	O
apoptosis	O
through	O
affecting	O
apoptosis	O
-	O
related	O
molecules	O
caspase	B-Gene
-	I-Gene
3	I-Gene
,	O
caspase	B-Gene
-	I-Gene
9	I-Gene
,	O
Bcl	B-Gene
-	I-Gene
2	I-Gene
and	O
Bax	B-Gene
,	O
possibly	O
via	O
regulating	O
P38	B-Gene
and	O
Akt	B-Gene
pathways	O
,	O
indicating	O
that	O
TIPE2	B-Gene
might	O
be	O
a	O
novel	O
marker	O
for	O
lung	B-Disease
cancer	I-Disease
diagnosis	O
and	O
therapy	O
.	O
</ALL>	O

<ALL>	O
Metabolic	O
Symbiosis	O
Enables	O
Adaptive	O
Resistance	O
to	O
Anti	O
-	O
angiogenic	O
Therapy	O
that	O
Is	O
Dependent	O
on	O
mTOR	B-Gene
Signaling	O
.	O
</ALL>	O

<ALL>	O
Therapeutic	O
targeting	O
of	O
tumor	B-Disease
angiogenesis	O
with	O
VEGF	B-Gene
inhibitors	O
results	O
in	O
demonstrable	O
,	O
but	O
transitory	O
efficacy	O
in	O
certain	O
human	B-Species
tumors	B-Disease
and	O
mouse	B-Species
models	O
of	O
cancer	B-Disease
,	O
limited	O
by	O
unconventional	O
forms	O
of	O
adaptive	O
/	O
evasive	O
resistance	O
.	O
</ALL>	O

<ALL>	O
In	O
one	O
such	O
mouse	B-Species
model	O
,	O
potent	O
angiogenesis	O
inhibitors	O
elicit	O
compartmental	O
reorganization	O
of	O
cancer	B-Disease
cells	O
around	O
remaining	O
blood	O
vessels	O
.	O
</ALL>	O

<ALL>	O
The	O
glucose	O
and	O
lactate	O
transporters	O
GLUT1	B-Gene
and	O
MCT4	B-Gene
are	O
induced	O
in	O
distal	O
hypoxic	B-Disease
cells	O
in	O
a	O
HIF1a	B-Gene
-	O
dependent	O
fashion	O
,	O
indicative	O
of	O
glycolysis	O
.	O
</ALL>	O

<ALL>	O
Tumor	B-Disease
cells	O
proximal	O
to	O
blood	O
vessels	O
instead	O
express	O
the	O
lactate	O
transporter	O
MCT1	B-Gene
,	O
and	O
p	B-Gene
-	I-Gene
S6	I-Gene
,	O
the	O
latter	O
reflecting	O
mTOR	B-Gene
signaling	O
.	O
</ALL>	O

<ALL>	O
Normoxic	B-Disease
cancer	I-Disease
cells	O
import	O
and	O
metabolize	O
lactate	B-Chemical
,	O
resulting	O
in	O
upregulation	O
of	O
mTOR	B-Gene
signaling	O
via	O
glutamine	B-Chemical
metabolism	O
enhanced	O
by	O
lactate	B-Chemical
catabolism	O
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
metabolic	O
symbiosis	O
is	O
established	O
in	O
the	O
face	O
of	O
angiogenesis	O
inhibition	O
,	O
whereby	O
hypoxic	O
cancer	B-Disease
cells	O
import	O
glucose	B-Chemical
and	O
export	O
lactate	B-Chemical
,	O
while	O
normoxic	O
cells	O
import	O
and	O
catabolize	O
lactate	B-Chemical
.	O
</ALL>	O

<ALL>	O
mTOR	B-Gene
signaling	O
inhibition	O
disrupts	O
this	O
metabolic	O
symbiosis	O
,	O
associated	O
with	O
upregulation	O
of	O
the	O
glucose	O
transporter	O
GLUT2	B-Gene
.	O
</ALL>	O

<ALL>	O
Metallothionein	B-Gene
-	I-Gene
1	I-Gene
as	O
a	O
biomarker	O
of	O
altered	O
redox	O
metabolism	O
in	O
hepatocellular	B-Disease
carcinoma	I-Disease
cells	O
exposed	O
to	O
sorafenib	B-Chemical
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Sorafenib	B-Chemical
,	O
a	O
kinase	O
inhibitor	O
active	O
against	O
various	O
solid	O
tumours	B-Disease
,	O
induces	O
oxidative	O
stress	O
and	O
ferroptosis	O
,	O
a	O
new	O
form	O
of	O
oxidative	O
necrosis	B-Disease
,	O
in	O
some	O
cancer	B-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
Clinically	O
-	O
applicable	O
biomarkers	O
that	O
reflect	O
the	O
impact	O
of	O
sorafenib	B-Chemical
on	O
the	O
redox	O
metabolism	O
of	O
cancer	B-Disease
cells	O
are	O
lacking	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
We	O
used	O
gene	O
expression	O
microarrays	O
,	O
real	O
-	O
time	O
PCR	O
,	O
immunoblot	O
,	O
protein	O
-	O
specific	O
ELISA	O
,	O
and	O
gene	O
reporter	O
constructs	O
encoding	O
the	O
enzyme	O
luciferase	O
to	O
study	O
the	O
response	O
of	O
a	O
panel	O
of	O
cancer	B-Disease
cells	O
to	O
sorafenib	B-Chemical
.	O
</ALL>	O

<ALL>	O
Tumour	B-Disease
explants	O
prepared	O
from	O
surgical	O
hepatocellular	B-Disease
carcinoma	I-Disease
(	O
HCC	B-Disease
)	O
samples	O
and	O
serum	O
samples	O
obtained	O
from	O
HCC	B-Disease
patients	B-Species
receiving	O
sorafenib	B-Chemical
were	O
also	O
used	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
We	O
observed	O
that	O
genes	O
of	O
the	O
metallothionein	B-Gene
-	I-Gene
1	I-Gene
(	O
MT1	B-Gene
)	O
family	O
are	O
induced	O
in	O
the	O
HCC	B-Disease
cell	O
line	O
Huh7	B-CellLine
exposed	O
to	O
sorafenib	B-Chemical
.	O
</ALL>	O

<ALL>	O
Sorafenib	B-Chemical
increased	O
the	O
expression	O
of	O
MT1	B-Gene
G	I-Gene
mRNA	O
in	O
a	O
panel	O
of	O
human	B-Species
cancer	B-Disease
cells	O
,	O
an	O
effect	O
that	O
was	O
not	O
observed	O
with	O
eight	O
other	O
clinically	O
-	O
approved	O
kinase	O
inhibitors	O
.	O
</ALL>	O

<ALL>	O
We	O
identified	O
the	O
minimal	O
region	O
of	O
the	O
MT1	B-Gene
G	I-Gene
promoter	O
that	O
confers	O
inducibility	O
by	O
sorafenib	B-Chemical
to	O
a	O
133	O
base	O
pair	O
region	O
containing	O
an	O
Anti	O
-	O
oxidant	O
Response	O
Element	O
(	O
ARE	O
)	O
and	O
showed	O
the	O
essential	O
role	O
of	O
the	O
transcription	O
factor	O
NRF2	B-Gene
(	O
Nuclear	B-Gene
factor	I-Gene
erythroid	I-Gene
2	I-Gene
-	I-Gene
Related	I-Gene
Factor	I-Gene
2	I-Gene
)	O
.	O
</ALL>	O

<ALL>	O
We	O
examined	O
the	O
clinical	O
relevance	O
of	O
our	O
findings	O
by	O
analysing	O
the	O
regulation	O
of	O
MT1	B-Gene
G	I-Gene
in	O
five	O
tumour	B-Disease
explants	O
prepared	O
from	O
surgical	O
HCC	B-Disease
samples	O
.	O
</ALL>	O

<ALL>	O
Finally	O
,	O
we	O
showed	O
that	O
the	O
protein	O
levels	O
of	O
MT1	B-Gene
increase	O
in	O
the	O
serum	O
of	O
some	O
HCC	B-Disease
patients	B-Species
receiving	O
sorafenib	B-Chemical
,	O
and	O
found	O
an	O
association	O
with	O
reduced	O
overall	O
survival	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
These	O
findings	O
indicate	O
that	O
MT1	B-Gene
constitute	O
a	O
biomarker	O
adapted	O
for	O
exploring	O
the	O
impact	O
of	O
sorafenib	B-Chemical
on	O
the	O
redox	O
metabolism	O
of	O
cancer	B-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
FGFR1	B-Gene
and	O
NTRK3	B-Gene
actionable	O
alterations	O
in	O
"	O
Wild	O
-	O
Type	O
"	O
gastrointestinal	B-Disease
stromal	I-Disease
tumors	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
About	O
10	O
-	O
15	O
%	O
of	O
adult	O
,	O
and	O
most	O
pediatric	O
,	O
gastrointestinal	B-Disease
stromal	I-Disease
tumors	I-Disease
(	O
GIST	B-Disease
)	O
lack	O
mutations	O
in	O
KIT	B-Gene
,	O
PDGFRA	B-Gene
,	O
SDHx	B-Gene
,	O
or	O
RAS	B-Gene
pathway	O
components	O
(	O
KRAS	B-Gene
,	O
BRAF	B-Gene
,	O
NF1	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
The	O
identification	O
of	O
additional	O
mutated	O
genes	O
in	O
this	O
rare	O
subset	O
of	O
tumors	B-Disease
can	O
have	O
important	O
clinical	O
benefit	O
to	O
identify	O
altered	O
biological	O
pathways	O
and	O
select	O
targeted	O
therapies	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
We	O
performed	O
comprehensive	O
genomic	O
profiling	O
(	O
CGP	O
)	O
for	O
coding	O
regions	O
in	O
more	O
than	O
300	O
cancer	B-Disease
-	O
related	O
genes	O
of	O
186	O
GISTs	B-Disease
to	O
assess	O
for	O
their	O
somatic	O
alterations	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
We	O
identified	O
24	O
GIST	B-Disease
lacking	O
alterations	O
in	O
the	O
canonical	O
KIT	B-Gene
/	O
PDGFRA	B-Gene
/	O
RAS	B-Gene
pathways	O
,	O
including	O
12	O
without	O
SDHx	B-Gene
alterations	O
.	O
</ALL>	O

<ALL>	O
These	O
24	O
patients	B-Species
were	O
mostly	O
adults	O
(	O
96	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
tumors	B-Disease
had	O
a	O
46	O
%	O
rate	O
of	O
nodal	B-Disease
metastases	I-Disease
.	O
</ALL>	O

<ALL>	O
These	O
24	O
GIST	B-Disease
were	O
more	O
commonly	O
mutated	O
at	O
7	O
genes	O
:	O
ARID1B	B-Gene
,	O
ATR	B-Gene
,	O
FGFR1	B-Gene
,	O
LTK	B-Gene
,	O
SUFU	B-Gene
,	O
PARK2	B-Gene
and	O
ZNF217	B-Gene
.	O
</ALL>	O

<ALL>	O
Two	O
tumors	B-Disease
harbored	O
FGFR1	B-Gene
gene	O
fusions	O
(	O
FGFR1	B-Gene
-	O
HOOK3	B-Gene
,	O
FGFR1	B-Gene
-	O
TACC1	B-Gene
)	O
and	O
one	O
harbored	O
an	O
ETV6	B-Gene
-	O
NTRK3	B-Gene
fusion	O
that	O
responded	O
to	O
TRK	B-Gene
inhibition	O
.	O
</ALL>	O

<ALL>	O
In	O
an	O
independent	O
sample	O
set	O
,	O
we	O
identified	O
5	O
GIST	B-Disease
cases	O
lacking	O
alterations	O
in	O
the	O
KIT	B-Gene
/	O
PDGFRA	B-Gene
/	O
SDHx	B-Gene
/	O
RAS	B-Gene
pathways	O
,	O
including	O
two	O
additional	O
cases	O
with	O
FGFR1	B-Gene
-	O
TACC1	B-Gene
and	O
ETV6	B-Gene
-	O
NTRK3	B-Gene
fusions	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Using	O
patient	B-Species
demographics	O
,	O
tumor	B-Disease
characteristics	O
,	O
and	O
CGP	O
,	O
we	O
show	O
that	O
GIST	B-Disease
lacking	O
alterations	O
in	O
canonical	O
genes	O
occur	O
in	O
younger	O
patients	B-Species
,	O
frequently	O
metastasize	B-Disease
to	I-Disease
lymph	I-Disease
nodes	I-Disease
,	O
and	O
most	O
contain	O
deleterious	O
genomic	O
alterations	O
,	O
including	O
gene	O
fusions	O
involving	O
FGFR1	B-Gene
and	O
NTRK3	B-Gene
.	O
</ALL>	O

<ALL>	O
If	O
confirmed	O
in	O
larger	O
series	O
,	O
routine	O
testing	O
for	O
these	O
translocations	O
may	O
be	O
indicated	O
for	O
this	O
subset	O
of	O
GIST	B-Disease
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
these	O
findings	O
can	O
be	O
used	O
to	O
guide	O
personalized	O
treatments	O
for	O
patients	B-Species
with	O
GIST	B-Disease
.	O
</ALL>	O

<ALL>	O
Trial	O
registration	O
NCT	O
02576431	O
.	O
</ALL>	O

<ALL>	O
Registered	O
October	O
12	O
,	O
2015	O
.	O
</ALL>	O

<ALL>	O
TIEG1	B-Gene
deficiency	O
confers	O
enhanced	O
myocardial	O
protection	O
in	O
the	O
infarcted	B-Disease
heart	I-Disease
by	O
mediating	O
the	O
Pten	B-Gene
/	O
Akt	B-Gene
signalling	O
pathway	O
.	O
</ALL>	O

<ALL>	O
The	O
transforming	B-Gene
growth	I-Gene
factor	I-Gene
(	I-Gene
TGF	I-Gene
)	I-Gene
-	I-Gene
b	I-Gene
-	I-Gene
inducible	I-Gene
early	I-Gene
gene	I-Gene
-	I-Gene
1	I-Gene
(	O
TIEG1	B-Gene
)	O
plays	O
a	O
crucial	O
role	O
in	O
modulating	O
cell	O
apoptosis	O
and	O
proliferation	O
in	O
a	O
number	O
of	O
diseases	O
,	O
including	O
pancreatic	B-Disease
cancer	I-Disease
,	O
leukaemia	B-Disease
and	O
osteoporosis	B-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
functional	O
role	O
of	O
TIEG1	B-Gene
in	O
the	O
heart	O
has	O
not	O
been	O
fully	O
defined	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
first	O
investigated	O
the	O
role	O
of	O
TIEG1	B-Gene
in	O
ischaemic	B-Disease
heart	I-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
For	O
in	O
vitro	O
experiments	O
,	O
cardiomyocytes	O
were	O
isolated	O
from	O
both	O
TIEG1	B-Gene
knockout	O
(	O
KO	O
)	O
and	O
wile	O
-	O
type	O
(	O
WT	O
)	O
mice	B-Species
,	O
and	O
the	O
apoptotic	O
ratios	O
were	O
evaluated	O
after	O
a	O
48	O
-	O
h	O
ischaemic	O
insult	O
.	O
</ALL>	O

<ALL>	O
A	O
cell	O
proliferation	O
assay	O
was	O
performed	O
after	O
7	O
days	O
of	O
incubation	O
under	O
normoxic	O
conditions	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
the	O
angiogenic	O
capacity	O
of	O
endothelial	O
cells	O
was	O
determined	O
by	O
tube	O
formation	O
assay	O
.	O
</ALL>	O

<ALL>	O
For	O
in	O
vivo	O
experiments	O
,	O
a	O
model	O
of	O
myocardial	B-Disease
infarction	I-Disease
(	O
MI	B-Disease
)	O
was	O
established	O
using	O
both	O
TIEG1	B-Gene
KO	O
and	O
WT	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Echocardiography	O
was	O
performed	O
at	O
3	O
and	O
28	O
days	O
post	O
-	O
MI	B-Disease
,	O
whereas	O
the	O
haemodynamics	O
test	O
was	O
performed	O
28	O
days	O
post	O
-	O
MI	B-Disease
.	O
</ALL>	O

<ALL>	O
Histological	O
analyses	O
of	O
apoptosis	O
,	O
proliferation	O
,	O
angiogenesis	O
and	O
infarct	B-Disease
zone	O
assessments	O
were	O
performed	O
using	O
terminal	B-Gene
deoxynucleotidyltransferase	I-Gene
-	O
mediated	O
dUTP	B-Chemical
nick	O
-	O
end	O
labelling	O
(	O
TUNEL	O
)	O
staining	O
,	O
BrdU	O
immunostaining	O
,	O
a	B-Gene
-	I-Gene
smooth	I-Gene
muscle	I-Gene
actin	I-Gene
(	O
a	B-Gene
-	I-Gene
SMA	I-Gene
)	O
/	O
CD31	B-Gene
immunostaining	O
and	O
Masson	O
's	O
trichrome	O
staining	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
Changes	O
in	O
the	O
expression	O
of	O
related	O
proteins	O
caused	O
by	O
TIEG1	B-Gene
deficiency	O
were	O
confirmed	O
using	O
both	O
reverse	O
transcription	O
-	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
qPCR	O
)	O
and	O
western	O
blot	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Our	O
results	O
demonstrated	O
that	O
the	O
absence	O
of	O
TIEG1	B-Gene
prevented	O
cardiomyocytes	O
from	O
undergoing	O
apoptosis	O
and	O
promoted	O
higher	O
proliferation	O
;	O
it	O
stimulated	O
the	O
proliferation	O
of	O
endothelial	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
</ALL>	O

<ALL>	O
Improved	O
cardiac	O
function	O
and	O
less	O
scar	O
formation	O
were	O
observed	O
in	O
TIEG1	B-Gene
KO	O
mice	B-Species
,	O
and	O
we	O
also	O
observed	O
the	O
altered	O
expression	O
of	O
phosphatase	B-Gene
and	I-Gene
tensin	I-Gene
homolog	I-Gene
(	O
Pten	B-Gene
)	O
,	O
Akt	B-Gene
and	O
Bcl	B-Gene
-	I-Gene
2	I-Gene
/	O
Bax	B-Gene
,	O
as	O
well	O
as	O
vascular	B-Gene
endothelial	I-Gene
growth	I-Gene
factor	I-Gene
(	O
VEGF	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
On	O
the	O
whole	O
,	O
our	O
findings	O
indicate	O
that	O
the	O
absence	O
of	O
TIEG1	B-Gene
plays	O
a	O
cardioprotective	O
role	O
in	O
ischaemic	B-Disease
heart	I-Disease
disease	I-Disease
by	O
promoting	O
changes	O
in	O
Pten	B-Gene
/	O
Akt	B-Gene
signalling	O
.	O
</ALL>	O

<ALL>	O
An	O
autosomal	B-Disease
dominant	I-Disease
cerebellar	I-Disease
ataxia	I-Disease
linked	O
to	O
chromosome	O
16q22.1	O
is	O
associated	O
with	O
a	O
single	O
-	O
nucleotide	O
substitution	O
in	O
the	O
5	O
'	O
untranslated	O
region	O
of	O
the	O
gene	O
encoding	O
a	O
protein	O
with	O
spectrin	O
repeat	O
and	O
Rho	B-Gene
guanine	I-Gene
-	I-Gene
nucleotide	I-Gene
exchange	I-Gene
-	I-Gene
factor	I-Gene
domains	O
.	O
</ALL>	O

<ALL>	O
Autosomal	B-Disease
dominant	I-Disease
cerebellar	I-Disease
ataxia	I-Disease
(	O
ADCA	B-Disease
)	O
is	O
a	O
group	O
of	O
heterogeneous	O
neurodegenerative	B-Disease
disorders	I-Disease
.	O
</ALL>	O

<ALL>	O
By	O
positional	O
cloning	O
,	O
we	O
have	O
identified	O
the	O
gene	O
strongly	O
associated	O
with	O
a	O
form	O
of	O
degenerative	B-Disease
ataxia	I-Disease
(	O
chromosome	O
16q22.1	O
-	O
linked	O
ADCA	B-Disease
)	O
that	O
clinically	O
shows	O
progressive	O
pure	O
cerebellar	B-Disease
ataxia	I-Disease
.	O
</ALL>	O

<ALL>	O
Detailed	O
examination	O
by	O
use	O
of	O
audiogram	O
suggested	O
that	O
sensorineural	B-Disease
hearing	I-Disease
impairment	I-Disease
may	O
be	O
associated	O
with	O
ataxia	B-Disease
in	O
our	O
families	O
.	O
</ALL>	O

<ALL>	O
After	O
restricting	O
the	O
candidate	O
region	O
in	O
chromosome	O
16q22.1	O
by	O
haplotype	O
analysis	O
,	O
we	O
found	O
that	O
all	O
patients	B-Species
from	O
52	O
unrelated	O
Japanese	O
families	O
harbor	O
a	O
heterozygous	O
C	B-Variant
-	I-Variant
-	I-Variant
>	I-Variant
T	I-Variant
single	O
-	O
nucleotide	O
substitution	O
,	O
16	O
nt	O
upstream	O
of	O
the	O
putative	O
translation	O
initiation	O
site	O
of	O
the	O
gene	O
for	O
a	O
hypothetical	O
protein	O
DKFZP434I216	B-Gene
,	O
which	O
we	O
have	O
called	O
"	O
puratrophin	B-Gene
-	I-Gene
1	I-Gene
"	O
(	O
Purkinje	B-Gene
cell	I-Gene
atrophy	I-Gene
associated	I-Gene
protein	I-Gene
-	I-Gene
1	I-Gene
)	O
.	O
</ALL>	O

<ALL>	O
The	O
full	O
-	O
length	O
puratrophin	B-Gene
-	I-Gene
1	I-Gene
mRNA	O
had	O
an	O
open	O
reading	O
frame	O
of	O
3,576	O
nt	O
,	O
predicted	O
to	O
contain	O
important	O
domains	O
,	O
including	O
the	O
spectrin	O
repeat	O
and	O
the	O
guanine	B-Gene
-	I-Gene
nucleotide	I-Gene
exchange	I-Gene
factor	I-Gene
(	O
GEF	B-Gene
)	O
for	O
Rho	B-Gene
GTPases	I-Gene
,	O
followed	O
by	O
the	O
Dbl	O
-	O
homologous	O
domain	O
,	O
which	O
indicates	O
the	O
role	O
of	O
puratrophin	B-Gene
-	I-Gene
1	I-Gene
in	O
intracellular	O
signaling	O
and	O
actin	B-Gene
dynamics	O
at	O
the	O
Golgi	O
apparatus	O
.	O
</ALL>	O

<ALL>	O
Puratrophin	B-Gene
-	I-Gene
1	I-Gene
-	O
-	O
normally	O
expressed	O
in	O
a	O
wide	O
range	O
of	O
cells	O
,	O
including	O
epithelial	O
hair	O
cells	O
in	O
the	O
cochlea	O
-	O
-	O
was	O
aggregated	O
in	O
Purkinje	O
cells	O
of	O
the	O
chromosome	O
16q22.1	O
-	O
linked	O
ADCA	B-Disease
brains	O
.	O
</ALL>	O

<ALL>	O
Consistent	O
with	O
the	O
protein	O
prediction	O
data	O
of	O
puratrophin	B-Gene
-	I-Gene
1	I-Gene
,	O
the	O
Golgi	O
-	O
apparatus	O
membrane	O
protein	O
and	O
spectrin	O
also	O
formed	O
aggregates	O
in	O
Purkinje	O
cells	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
highlights	O
the	O
importance	O
of	O
the	O
5	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
in	O
identification	O
of	O
genes	O
of	O
human	B-Species
disease	O
,	O
suggests	O
that	O
a	O
single	O
-	O
nucleotide	O
substitution	O
in	O
the	O
5	O
'	O
UTR	O
could	O
be	O
associated	O
with	O
protein	O
aggregation	O
,	O
and	O
indicates	O
that	O
the	O
GEF	B-Gene
protein	O
is	O
associated	O
with	O
cerebellar	B-Disease
degeneration	I-Disease
in	O
humans	B-Species
.	O
</ALL>	O

<ALL>	O
Delineation	O
of	O
the	O
clinical	O
phenotype	O
associated	O
with	O
OPHN1	B-Gene
mutations	O
based	O
on	O
the	O
clinical	O
and	O
neuropsychological	O
evaluation	O
of	O
three	O
families	O
.	O
</ALL>	O

<ALL>	O
Recent	O
reports	O
have	O
demonstrated	O
that	O
mutations	O
in	O
the	O
OPHN1	B-Gene
gene	O
were	O
responsible	O
for	O
a	O
syndromic	O
rather	O
than	O
non	O
-	O
specific	O
mental	B-Disease
retardation	I-Disease
.	O
</ALL>	O

<ALL>	O
Abnormalities	O
of	O
the	O
posterior	O
fossa	O
with	O
cerebellar	B-Disease
hypoplasia	I-Disease
have	O
been	O
demonstrated	O
in	O
all	O
male	O
patients	B-Species
reported	O
to	O
date	O
.	O
</ALL>	O

<ALL>	O
We	O
report	O
here	O
a	O
new	O
family	O
with	O
X	B-Disease
-	I-Disease
linked	I-Disease
mental	I-Disease
retardation	I-Disease
due	O
to	O
mutation	O
in	O
OPHN1	B-Gene
and	O
present	O
unpublished	O
data	O
about	O
two	O
families	O
previously	O
reported	O
,	O
concerning	O
the	O
facial	O
and	O
psychological	O
phenotype	O
of	O
affected	O
males	O
and	O
carrier	O
females	O
.	O
</ALL>	O

<ALL>	O
Our	O
study	O
confirms	O
that	O
cerebellar	B-Disease
hypoplasia	I-Disease
is	O
a	O
hallmark	O
of	O
this	O
syndrome	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
affected	O
males	O
display	O
facial	O
similarities	O
that	O
can	O
help	O
the	O
diagnosis	O
.	O
</ALL>	O

<ALL>	O
Most	O
carrier	O
females	O
have	O
mild	O
mental	B-Disease
retardation	I-Disease
and	O
subtle	O
facial	O
changes	O
.	O
</ALL>	O

<ALL>	O
McArdle	B-Disease
disease	I-Disease
:	O
the	O
mutation	O
spectrum	O
of	O
PYGM	B-Gene
in	O
a	O
large	O
Italian	O
cohort	O
.	O
</ALL>	O

<ALL>	O
Deficiency	B-Disease
of	I-Disease
the	I-Disease
muscle	I-Disease
isozyme	I-Disease
of	I-Disease
glycogen	I-Disease
phosphorylase	I-Disease
is	O
causative	O
of	O
McArdle	B-Disease
disease	I-Disease
or	O
Glycogen	B-Disease
storage	I-Disease
disease	I-Disease
type	I-Disease
V	I-Disease
(	O
GSD	B-Disease
-	I-Disease
V	I-Disease
)	O
,	O
the	O
most	O
common	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
of	O
glycogen	B-Chemical
metabolism	O
.	O
</ALL>	O

<ALL>	O
The	O
typical	O
clinical	O
presentation	O
is	O
characterized	O
by	O
exercise	O
intolerance	O
with	O
cramps	B-Disease
,	O
and	O
recurrent	O
myoglobinuria	B-Disease
.	O
</ALL>	O

<ALL>	O
To	O
date	O
,	O
46	O
mutations	O
in	O
the	O
PYGM	B-Gene
gene	O
have	O
been	O
detected	O
in	O
GSD	B-Disease
-	I-Disease
V	I-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
We	O
report	O
the	O
mutational	O
spectrum	O
in	O
68	O
Italian	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
We	O
identified	O
30	O
different	O
mutations	O
in	O
the	O
PYGM	B-Gene
gene	O
,	O
including	O
19	O
mutations	O
that	O
have	O
not	O
been	O
reported	O
previously	O
.	O
</ALL>	O

<ALL>	O
The	O
novel	O
mutations	O
include	O
:	O
eight	O
missense	O
mutations	O
(	O
c.475	B-Variant
G	I-Variant
>	I-Variant
A	I-Variant
,	O
p	B-Variant
.	I-Variant
G159R	I-Variant
;	O
c.689C	B-Variant
>	I-Variant
G	I-Variant
,	O
p	B-Variant
.	I-Variant
P230R	I-Variant
;	O
c.1094C	B-Variant
>	I-Variant
T	I-Variant
,	O
p	B-Variant
.	I-Variant
A365E	I-Variant
;	O
c.1151C	B-Variant
>	I-Variant
A	I-Variant
,	O
p	B-Variant
.	I-Variant
A384D	I-Variant
;	O
c.1182C	B-Variant
>	I-Variant
T	I-Variant
,	I-Variant
p	B-Variant
.	I-Variant
R428C	I-Variant
;	O
c.1471C	B-Variant
>	I-Variant
T	I-Variant
,	O
p	B-Variant
.	I-Variant
R491C	I-Variant
;	O
c.2444A	B-Variant
>	I-Variant
C	I-Variant
,	O
p	B-Variant
.	I-Variant
D815A	I-Variant
;	O
c.2477	B-Variant
G	I-Variant
>	I-Variant
C	I-Variant
,	O
p	B-Variant
.	I-Variant
W826S	I-Variant
)	O
,	O
two	O
nonsense	O
mutations	O
(	O
c.1475	B-Variant
G	I-Variant
>	I-Variant
A	I-Variant
,	O
p	B-Variant
.	I-Variant
W492X	I-Variant
;	O
c.1627A	B-Variant
>	I-Variant
T	I-Variant
,	O
p	B-Variant
.	I-Variant
K543X	I-Variant
)	O
,	O
five	O
splice	O
site	O
mutations	O
(	O
c.855	B-Variant
+	I-Variant
1	I-Variant
G	I-Variant
>	I-Variant
C	I-Variant
;	O
c.1092	B-Variant
+	I-Variant
1	I-Variant
G	I-Variant
>	I-Variant
A	I-Variant
;	O
c.	B-Variant
1093	I-Variant
-	I-Variant
1	I-Variant
G	I-Variant
>	I-Variant
T	I-Variant
;	O
c.1239	B-Variant
+	I-Variant
1	I-Variant
G	I-Variant
>	I-Variant
A	I-Variant
;	O
c.2380	B-Variant
+	I-Variant
1	I-Variant
G	I-Variant
>	I-Variant
A	I-Variant
)	O
,	O
and	O
four	O
deletions	O
(	O
c.715	B-Variant
_	I-Variant
717delGTC	I-Variant
,	O
p	B-Variant
.	I-Variant
V239del	I-Variant
;	O
c.304delA	B-Variant
,	O
p	B-Variant
.	I-Variant
N102DfsX4	I-Variant
;	O
c.1970	B-Variant
_	I-Variant
2177del	I-Variant
,	O
p	B-Variant
.	I-Variant
V657	I-Variant
_	I-Variant
G726	I-Variant
;	O
c.2113	B-Variant
_	I-Variant
2114delGG	I-Variant
,	O
p	B-Variant
.	I-Variant
G705RfsX16	I-Variant
)	O
.	O
</ALL>	O

<ALL>	O
Whereas	O
we	O
confirmed	O
lack	O
of	O
direct	O
correlation	O
between	O
the	O
clinical	O
phenotype	O
and	O
the	O
genotype	O
,	O
we	O
also	O
found	O
that	O
the	O
so	O
-	O
called	O
'	O
common	O
mutation	O
'	O
(	O
p	B-Variant
.	I-Variant
R50X	I-Variant
)	O
accounted	O
for	O
about	O
43	O
%	O
of	O
alleles	O
in	O
our	O
cohort	O
and	O
that	O
no	O
population	O
-	O
related	O
mutations	O
are	O
clearly	O
identified	O
in	O
Italian	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Gastrointestinal	O
tolerability	O
of	O
etoricoxib	B-Chemical
in	O
rheumatoid	B-Disease
arthritis	I-Disease
patients	B-Species
:	O
results	O
of	O
the	O
etoricoxib	B-Chemical
vs	O
diclofenac	B-Chemical
sodium	I-Chemical
gastrointestinal	O
tolerability	O
and	O
effectiveness	O
trial	O
(	O
EDGE	O
-	O
II	O
)	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
A	O
randomised	O
,	O
double	O
-	O
blind	O
study	O
to	O
compare	O
the	O
gastrointestinal	O
(	O
GI	O
)	O
tolerability	O
,	O
safety	O
and	O
efficacy	O
of	O
etoricoxib	B-Chemical
and	O
diclofenac	B-Chemical
in	O
patients	B-Species
with	O
rheumatoid	B-Disease
arthritis	I-Disease
(	O
RA	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
PATIENTS	B-Species
AND	O
METHODS	O
:	O
A	O
total	O
of	O
4086	O
patients	B-Species
(	O
mean	O
age	O
60.8	O
years	O
)	O
diagnosed	O
with	O
RA	B-Disease
were	O
enrolled	O
and	O
received	O
etoricoxib	B-Chemical
90	O
mg	O
daily	O
(	O
n	O
=	O
2032	O
)	O
or	O
diclofenac	B-Chemical
75	O
mg	O
twice	O
daily	O
(	O
n	O
=	O
2054	O
)	O
.	O
</ALL>	O

<ALL>	O
Use	O
of	O
gastroprotective	O
agents	O
and	O
low	O
-	O
dose	O
aspirin	B-Chemical
was	O
allowed	O
.	O
</ALL>	O

<ALL>	O
The	O
prespecified	O
primary	O
end	O
point	O
consisted	O
of	O
the	O
cumulative	O
rate	O
of	O
patient	B-Species
discontinuations	O
due	O
to	O
clinical	O
and	O
laboratory	O
GI	B-Disease
adverse	I-Disease
experiences	I-Disease
(	O
AEs	O
)	O
.	O
</ALL>	O

<ALL>	O
General	O
safety	O
was	O
also	O
assessed	O
,	O
including	O
adjudicated	O
thrombotic	B-Disease
cardiovascular	I-Disease
event	O
data	O
.	O
</ALL>	O

<ALL>	O
Efficacy	O
was	O
evaluated	O
using	O
the	O
Patient	B-Species
Global	O
Assessment	O
of	O
Disease	O
Status	O
(	O
PGADS	O
;	O
0	O
-	O
4	O
point	O
scale	O
)	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Mean	O
(	O
SD	O
;	O
maximum	O
)	O
duration	O
of	O
treatment	O
was	O
19.3	O
(	O
10.3	O
;	O
32.9	O
)	O
and	O
19.1	O
(	O
10.4	O
;	O
33.1	O
)	O
months	O
in	O
the	O
etoricoxib	B-Chemical
and	O
diclofenac	B-Chemical
groups	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
The	O
cumulative	O
discontinuation	O
rate	O
due	O
to	O
GI	B-Disease
AEs	I-Disease
was	O
significantly	O
lower	O
with	O
etoricoxib	B-Chemical
than	O
diclofenac	B-Chemical
(	O
5.2	O
vs	O
8.5	O
events	O
per	O
100	O
patient	B-Species
-	O
years	O
,	O
respectively	O
;	O
hazard	O
ratio	O
0.62	O
(	O
95	O
%	O
CI	O
:	O
0.47	O
,	O
0.81	O
;	O
p	O
<	O
or	O
=	O
0.001	O
)	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
incidence	O
of	O
discontinuations	O
for	O
hypertension	B-Disease
-	O
related	O
and	O
oedema	B-Disease
-	O
related	O
AEs	O
were	O
significantly	O
higher	O
with	O
etoricoxib	B-Chemical
(	O
2.5	O
%	O
and	O
1.1	O
%	O
respectively	O
)	O
compared	O
with	O
diclofenac	B-Chemical
(	O
1.5	O
%	O
and	O
0.4	O
%	O
respectively	O
;	O
p	O
<	O
0.001	O
for	O
hypertension	B-Disease
and	O
p	O
<	O
0.01	O
for	O
oedema	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Etoricoxib	B-Chemical
and	O
diclofenac	B-Chemical
treatment	O
resulted	O
in	O
similar	O
efficacy	O
(	O
PGADS	O
mean	O
changes	O
from	O
baseline	O
-	O
0.62	O
vs	O
-	O
0.58	O
,	O
respectively	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Etoricoxib	B-Chemical
90	O
mg	O
demonstrated	O
a	O
significantly	O
lower	O
risk	O
for	O
discontinuing	O
treatment	O
due	O
to	O
GI	B-Disease
AEs	I-Disease
compared	O
with	O
diclofenac	B-Chemical
150	O
mg	O
.	O
</ALL>	O

<ALL>	O
Discontinuations	O
from	O
renovascular	O
AEs	O
,	O
although	O
less	O
common	O
than	O
discontinuations	O
from	O
GI	B-Disease
AEs	I-Disease
,	O
were	O
significantly	O
higher	O
with	O
etoricoxib	B-Chemical
.	O
</ALL>	O

<ALL>	O
GATA4	B-Gene
mutations	O
in	O
486	O
Chinese	O
patients	B-Species
with	O
congenital	B-Disease
heart	I-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
Recent	O
studies	O
have	O
reported	O
germline	O
mutations	O
in	O
GATA4	B-Gene
gene	O
in	O
some	O
types	O
of	O
congenital	B-Disease
heart	I-Disease
disease	I-Disease
(	O
CHD	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
prevalence	O
of	O
GATA4	B-Gene
mutations	O
in	O
CHD	B-Disease
and	O
the	O
correlation	O
between	O
the	O
GATA4	B-Gene
genotype	O
and	O
CHD	B-Disease
phenotype	O
have	O
not	O
been	O
extensively	O
studied	O
.	O
</ALL>	O

<ALL>	O
We	O
screened	O
germline	O
mutations	O
in	O
the	O
coding	O
exons	O
and	O
the	O
flanking	O
intron	O
sequences	O
of	O
the	O
GATA4	B-Gene
gene	O
in	O
486	O
CHD	B-Disease
patients	B-Species
by	O
denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
DHPLC	O
)	O
,	O
and	O
confirmed	O
the	O
mutations	O
by	O
sequencing	O
.	O
</ALL>	O

<ALL>	O
Nine	O
distinct	O
mutations	O
including	O
one	O
small	O
deletion	O
mutation	O
(	O
46delS	B-Variant
)	O
,	O
two	O
small	O
insertion	O
mutations	O
(	O
118	B-Variant
-	I-Variant
119insA	I-Variant
and	O
125	B-Variant
-	I-Variant
126insAA	I-Variant
)	O
,	O
and	O
six	O
non	O
-	O
synonymous	O
mutations	O
(	O
A6V	B-Variant
,	O
P163S	B-Variant
,	O
E359	B-Variant
K	I-Variant
,	O
P407Q	B-Variant
,	O
S429	B-Variant
T	I-Variant
and	O
A442V	B-Variant
)	O
were	O
identified	O
in	O
12	O
of	O
the	O
486	O
patients	B-Species
(	O
nine	O
with	O
ventricular	B-Disease
septal	I-Disease
defect	I-Disease
,	O
two	O
with	O
Tetralogy	B-Disease
of	I-Disease
Fallot	I-Disease
,	O
and	O
one	O
with	O
endocardial	B-Disease
cushion	I-Disease
defect	I-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Of	O
them	O
,	O
two	O
patients	B-Species
carrying	O
E359	B-Variant
K	I-Variant
mutation	O
were	O
from	O
two	O
generations	O
in	O
one	O
family	O
with	O
ventricular	B-Disease
septal	I-Disease
defect	I-Disease
(	O
VSD	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Interestingly	O
,	O
a	O
nucleotide	O
insertion	O
of	O
c.1146	B-Variant
+	I-Variant
25insA	I-Variant
in	O
exon	O
6	O
was	O
detected	O
in	O
five	O
VSD	B-Disease
patients	B-Species
,	O
but	O
not	O
in	O
486	O
normal	O
healthy	O
controls	O
.	O
</ALL>	O

<ALL>	O
Our	O
findings	O
are	O
useful	O
in	O
understanding	O
the	O
prevalence	O
of	O
GATA4	B-Gene
mutations	O
and	O
the	O
correlation	O
between	O
the	O
GATA4	B-Gene
genotype	O
and	O
the	O
CHD	B-Disease
phenotype	O
in	O
Chinese	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Serum	B-Gene
-	I-Gene
and	I-Gene
glucocorticoid	I-Gene
-	I-Gene
inducible	I-Gene
kinase	I-Gene
1	I-Gene
in	O
doxorubicin	B-Chemical
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Doxorubicin	B-Chemical
-	O
induced	O
nephropathy	B-Disease
leads	O
to	O
epithelial	O
sodium	B-Chemical
channel	O
(	O
ENaC	O
)	O
-	O
dependent	O
volume	B-Disease
retention	I-Disease
and	O
renal	B-Disease
fibrosis	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
aldosterone	B-Chemical
-	O
sensitive	O
serum	B-Gene
-	I-Gene
and	I-Gene
glucocorticoid	I-Gene
-	I-Gene
inducible	I-Gene
kinase	I-Gene
SGK1	B-Gene
has	O
been	O
shown	O
to	O
participate	O
in	O
the	O
stimulation	O
of	O
ENaC	O
and	O
to	O
mediate	O
renal	B-Disease
fibrosis	I-Disease
following	O
mineralocorticoid	B-Chemical
and	O
salt	B-Chemical
excess	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
was	O
performed	O
to	O
elucidate	O
the	O
role	O
of	O
SGK1	B-Gene
in	O
the	O
volume	B-Disease
retention	I-Disease
and	O
fibrosis	B-Disease
during	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
To	O
this	O
end	O
,	O
doxorubicin	B-Chemical
(	O
15	O
mug	O
/	O
g	O
body	O
wt	O
)	O
was	O
injected	O
intravenously	O
into	O
gene	O
-	O
targeted	O
mice	B-Species
lacking	O
SGK1	B-Gene
(	O
sgk1	B-Gene
(	O
-	O
/	O
-	O
)	O
)	O
and	O
their	O
wild	O
-	O
type	O
littermates	O
(	O
sgk1	B-Gene
(	O
+	O
/	O
+	O
)	O
)	O
.	O
</ALL>	O

<ALL>	O
Doxorubicin	B-Chemical
treatment	O
resulted	O
in	O
heavy	O
proteinuria	B-Disease
(	O
>	O
100	O
mg	O
protein	O
/	O
mg	O
crea	B-Chemical
)	O
in	O
15	O
/	O
44	O
of	O
sgk1	B-Gene
(	O
+	O
/	O
+	O
)	O
and	O
15	O
/	O
44	O
of	O
sgk1	B-Gene
(	O
-	O
/	O
-	O
)	O
mice	B-Species
leading	O
to	O
severe	O
nephrotic	B-Disease
syndrome	I-Disease
with	O
ascites	B-Disease
,	O
lipidemia	B-Disease
,	O
and	O
hypoalbuminemia	B-Disease
in	O
both	O
genotypes	O
.	O
</ALL>	O

<ALL>	O
Plasma	O
aldosterone	B-Chemical
levels	O
increased	O
in	O
nephrotic	B-Disease
mice	B-Species
of	O
both	O
genotypes	O
and	O
was	O
followed	O
by	O
increased	O
SGK1	B-Gene
protein	O
expression	O
in	O
sgk1	B-Gene
(	O
+	O
/	O
+	O
)	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Urinary	O
sodium	B-Chemical
excretion	O
reached	O
signficantly	O
lower	O
values	O
in	O
sgk1	B-Gene
(	O
+	O
/	O
+	O
)	O
mice	B-Species
(	O
15	O
+	O
/	O
-	O
5	O
mumol	O
/	O
mg	O
crea	B-Chemical
)	O
than	O
in	O
sgk1	B-Gene
(	O
-	O
/	O
-	O
)	O
mice	B-Species
(	O
35	O
+	O
/	O
-	O
5	O
mumol	O
/	O
mg	O
crea	B-Chemical
)	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
higher	O
body	O
weight	B-Disease
gain	I-Disease
in	O
sgk1	B-Gene
(	O
+	O
/	O
+	O
)	O
compared	O
with	O
sgk1	B-Gene
(	O
-	O
/	O
-	O
)	O
mice	B-Species
(	O
+	O
6.6	O
+	O
/	O
-	O
0.7	O
vs.	O
+	O
4.1	O
+	O
/	O
-	O
0.8	O
g	O
)	O
.	O
</ALL>	O

<ALL>	O
During	O
the	O
course	O
of	O
nephrotic	B-Disease
syndrome	I-Disease
,	O
serum	O
urea	B-Chemical
concentrations	O
increased	O
significantly	O
faster	O
in	O
sgk1	B-Gene
(	O
-	O
/	O
-	O
)	O
mice	B-Species
than	O
in	O
sgk1	B-Gene
(	O
+	O
/	O
+	O
)	O
mice	B-Species
leading	O
to	O
uremia	B-Disease
and	O
a	O
reduced	O
median	O
survival	O
in	O
sgk1	B-Gene
(	O
-	O
/	O
-	O
)	O
mice	B-Species
(	O
29	O
vs.	O
40	O
days	O
in	O
sgk1	B-Gene
(	O
+	O
/	O
+	O
)	O
mice	B-Species
)	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
gene	O
-	O
targeted	O
mice	B-Species
lacking	O
SGK1	B-Gene
showed	O
blunted	O
volume	B-Disease
retention	I-Disease
,	O
yet	O
were	O
not	O
protected	O
against	O
renal	B-Disease
fibrosis	I-Disease
during	O
experimental	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Antithrombotic	B-Chemical
drug	I-Chemical
use	O
,	O
cerebral	B-Disease
microbleeds	I-Disease
,	O
and	O
intracerebral	B-Disease
hemorrhage	I-Disease
:	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
studies	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
AND	O
PURPOSE	O
:	O
Cerebral	B-Disease
microbleeds	I-Disease
(	O
MB	B-Disease
)	O
are	O
potential	O
risk	O
factors	O
for	O
intracerebral	B-Disease
hemorrhage	I-Disease
(	O
ICH	B-Disease
)	O
,	O
but	O
it	O
is	O
unclear	O
if	O
they	O
are	O
a	O
contraindication	O
to	O
using	O
antithrombotic	B-Chemical
drugs	I-Chemical
.	O
</ALL>	O

<ALL>	O
Insights	O
could	O
be	O
gained	O
by	O
pooling	O
data	O
on	O
MB	B-Disease
frequency	O
stratified	O
by	O
antithrombotic	O
use	O
in	O
cohorts	O
with	O
ICH	B-Disease
and	O
ischemic	B-Disease
stroke	I-Disease
(	O
IS	B-Disease
)	O
/	O
transient	B-Disease
ischemic	I-Disease
attack	I-Disease
(	O
TIA	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
We	O
performed	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
data	O
from	O
cohorts	O
with	O
stroke	B-Disease
or	O
TIA	B-Disease
to	O
compare	O
the	O
presence	O
of	O
MB	B-Disease
in	O
:	O
(	O
1	O
)	O
antithrombotic	O
users	O
vs	O
nonantithrombotic	O
users	O
with	O
ICH	B-Disease
;	O
(	O
2	O
)	O
antithrombotic	O
users	O
vs	O
nonusers	O
with	O
IS	B-Disease
/	O
TIA	B-Disease
;	O
and	O
(	O
3	O
)	O
ICH	B-Disease
vs	O
ischemic	B-Disease
events	O
stratified	O
by	O
antithrombotic	O
use	O
.	O
</ALL>	O

<ALL>	O
We	O
also	O
analyzed	O
published	O
and	O
unpublished	O
follow	O
-	O
up	O
data	O
to	O
determine	O
the	O
risk	O
of	O
ICH	B-Disease
in	O
antithrombotic	O
users	O
with	O
MB	B-Disease
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
In	O
a	O
pooled	O
analysis	O
of	O
1460	O
ICH	B-Disease
and	O
3817	O
IS	B-Disease
/	O
TIA	B-Disease
,	O
MB	B-Disease
were	O
more	O
frequent	O
in	O
ICH	B-Disease
vs	O
IS	B-Disease
/	O
TIA	B-Disease
in	O
all	O
treatment	O
groups	O
,	O
but	O
the	O
excess	O
increased	O
from	O
2.8	O
(	O
odds	O
ratio	O
;	O
range	O
,	O
2.3	O
-	O
3.5	O
)	O
in	O
nonantithrombotic	O
users	O
to	O
5.7	O
(	O
range	O
,	O
3.4	O
-	O
9.7	O
)	O
in	O
antiplatelet	O
users	O
and	O
8.0	O
(	O
range	O
,	O
3.5	O
-	O
17.8	O
)	O
in	O
warfarin	B-Chemical
users	O
(	O
P	O
difference	O
=	O
0.01	O
)	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
also	O
an	O
excess	O
of	O
MB	B-Disease
in	O
warfarin	B-Chemical
users	O
vs	O
nonusers	O
with	O
ICH	B-Disease
(	O
OR	O
,	O
2.7	O
;	O
95	O
%	O
CI	O
,	O
1.6	O
-	O
4.4	O
;	O
P	O
<	O
0.001	O
)	O
but	O
none	O
in	O
warfarin	B-Chemical
users	O
with	O
IS	B-Disease
/	O
TIA	B-Disease
(	O
OR	O
,	O
1.3	O
;	O
95	O
%	O
CI	O
,	O
0.9	O
-	O
1.7	O
;	O
P	O
=	O
0.33	O
;	O
P	O
difference	O
=	O
0.01	O
)	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
a	O
smaller	O
excess	O
of	O
MB	B-Disease
in	O
antiplatelet	O
users	O
vs	O
nonusers	O
with	O
ICH	B-Disease
(	O
OR	O
,	O
1.7	O
;	O
95	O
%	O
CI	O
,	O
1.3	O
-	O
2.3	O
;	O
P	O
<	O
0.001	O
)	O
,	O
but	O
findings	O
were	O
similar	O
for	O
antiplatelet	O
users	O
with	O
IS	B-Disease
/	O
TIA	B-Disease
(	O
OR	O
,	O
1.4	O
;	O
95	O
%	O
CI	O
,	O
1.2	O
-	O
1.7	O
;	O
P	O
<	O
0.001	O
;	O
P	O
difference	O
=	O
0.25	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
pooled	O
follow	O
-	O
up	O
data	O
for	O
768	O
antithrombotic	O
users	O
,	O
presence	O
of	O
MB	B-Disease
at	O
baseline	O
was	O
associated	O
with	O
a	O
substantially	O
increased	O
risk	O
of	O
subsequent	O
ICH	B-Disease
(	O
OR	O
,	O
12.1	O
;	O
95	O
%	O
CI	O
,	O
3.4	O
-	O
42.5	O
;	O
P	O
<	O
0.001	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
The	O
excess	O
of	O
MB	B-Disease
in	O
warfarin	B-Chemical
users	O
with	O
ICH	B-Disease
compared	O
to	O
other	O
groups	O
suggests	O
that	O
MB	B-Disease
increase	O
the	O
risk	O
of	O
warfarin	B-Chemical
-	O
associated	O
ICH	B-Disease
.	O
</ALL>	O

<ALL>	O
Limited	O
prospective	O
data	O
corroborate	O
these	O
findings	O
,	O
but	O
larger	O
prospective	O
studies	O
are	O
urgently	O
required	O
.	O
</ALL>	O

<ALL>	O
The	O
dopamine	B-Gene
b	I-Gene
-	I-Gene
hydroxylase	I-Gene
-	B-Variant
1021C	I-Variant
/	I-Variant
T	I-Variant
polymorphism	O
is	O
associated	O
with	O
the	O
risk	O
of	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
in	O
the	O
Epistasis	O
Project	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
The	O
loss	O
of	O
noradrenergic	O
neurones	O
of	O
the	O
locus	O
coeruleus	O
is	O
a	O
major	O
feature	O
of	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
(	O
AD	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Dopamine	B-Gene
b	I-Gene
-	I-Gene
hydroxylase	I-Gene
(	O
DBH	B-Gene
)	O
catalyses	O
the	O
conversion	O
of	O
dopamine	B-Chemical
to	O
noradrenaline	B-Chemical
.	O
</ALL>	O

<ALL>	O
Interactions	O
have	O
been	O
reported	O
between	O
the	O
low	O
-	O
activity	O
-	B-Variant
1021	I-Variant
T	I-Variant
allele	O
(	O
rs1611115	B-Variant
)	O
of	O
DBH	B-Gene
and	O
polymorphisms	O
of	O
the	O
pro	O
-	O
inflammatory	B-Disease
cytokine	O
genes	O
,	O
IL1A	B-Gene
and	O
IL6	B-Gene
,	O
contributing	O
to	O
the	O
risk	O
of	O
AD	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
therefore	O
examined	O
the	O
associations	O
with	O
AD	B-Disease
of	O
the	O
DBH	B-Gene
-	B-Variant
1021	I-Variant
T	I-Variant
allele	O
and	O
of	O
the	O
above	O
interactions	O
in	O
the	O
Epistasis	O
Project	O
,	O
with	O
1757	O
cases	O
of	O
AD	B-Disease
and	O
6294	O
elderly	O
controls	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
We	O
genotyped	O
eight	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
three	O
genes	O
,	O
DBH	B-Gene
,	O
IL1A	B-Gene
and	O
IL6	B-Gene
.	O
</ALL>	O

<ALL>	O
We	O
used	O
logistic	O
regression	O
models	O
and	O
synergy	O
factor	O
analysis	O
to	O
examine	O
potential	O
interactions	O
and	O
associations	O
with	O
AD	B-Disease
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
We	O
found	O
that	O
the	O
presence	O
of	O
the	O
-	B-Variant
1021	I-Variant
T	I-Variant
allele	O
was	O
associated	O
with	O
AD	B-Disease
:	O
odds	O
ratio	O
=	O
1.2	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
1.06	O
-	O
1.4	O
,	O
p	O
=	O
0.005	O
)	O
.	O
</ALL>	O

<ALL>	O
This	O
association	O
was	O
nearly	O
restricted	O
to	O
men	B-Species
<	O
75	O
years	O
old	O
:	O
odds	O
ratio	O
=	O
2.2	O
(	O
1.4	O
-	O
3.3	O
,	O
0.0004	O
)	O
.	O
</ALL>	O

<ALL>	O
We	O
also	O
found	O
an	O
interaction	O
between	O
the	O
presence	O
of	O
DBH	B-Gene
-	B-Variant
1021	I-Variant
T	I-Variant
and	O
the	O
-	B-Variant
889TT	I-Variant
genotype	O
(	O
rs1800587	B-Variant
)	O
of	O
IL1A	B-Gene
:	O
synergy	O
factor	O
=	O
1.9	O
(	O
1.2	O
-	O
3.1	O
,	O
0.005	O
)	O
.	O
</ALL>	O

<ALL>	O
All	O
these	O
results	O
were	O
consistent	O
between	O
North	O
Europe	O
and	O
North	O
Spain	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Extensive	O
,	O
previous	O
evidence	O
(	O
reviewed	O
here	O
)	O
indicates	O
an	O
important	O
role	O
for	O
noradrenaline	B-Chemical
in	O
the	O
control	O
of	O
inflammation	B-Disease
in	O
the	O
brain	O
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
the	O
-	B-Variant
1021	I-Variant
T	I-Variant
allele	O
with	O
presumed	O
low	O
activity	O
may	O
be	O
associated	O
with	O
misregulation	O
of	O
inflammation	B-Disease
,	O
which	O
could	O
contribute	O
to	O
the	O
onset	O
of	O
AD	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
suggest	O
that	O
such	O
misregulation	O
is	O
the	O
predominant	O
mechanism	O
of	O
the	O
association	O
we	O
report	O
here	O
.	O
</ALL>	O

<ALL>	O
Variation	O
in	O
IL10	B-Gene
and	O
other	O
genes	O
involved	O
in	O
the	O
immune	O
response	O
and	O
in	O
oxidation	O
and	O
prostate	B-Disease
cancer	I-Disease
recurrence	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
To	O
evaluate	O
the	O
association	O
of	O
variation	O
in	O
genes	O
involved	O
in	O
immune	O
response	O
,	O
including	O
IL10	B-Gene
,	O
production	O
and	O
detoxification	O
of	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
,	O
and	O
repair	O
of	O
oxidative	O
DNA	O
damage	O
with	O
risk	O
of	O
recurrence	O
after	O
surgery	O
for	O
localized	O
prostate	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
We	O
conducted	O
a	O
nested	O
case	O
-	O
control	O
study	O
of	O
men	B-Species
who	O
had	O
a	O
radical	O
prostatectomy	O
in	O
1993	O
to	O
2001	O
.	O
</ALL>	O

<ALL>	O
A	O
total	O
of	O
484	O
recurrence	O
cases	O
and	O
484	O
controls	O
were	O
matched	O
on	O
age	O
,	O
race	O
,	O
and	O
pathologic	O
stage	O
and	O
grade	O
.	O
</ALL>	O

<ALL>	O
Germline	O
DNA	O
was	O
extracted	O
from	O
paraffin	B-Chemical
-	O
embedded	O
unaffected	O
lymph	O
nodes	O
.	O
</ALL>	O

<ALL>	O
We	O
genotyped	O
candidate	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
in	O
IL10	B-Gene
,	O
CRP	B-Gene
,	O
GPX1	B-Gene
,	O
GSR	B-Gene
,	O
GSTP1	B-Gene
,	O
hOGG1	B-Gene
,	O
IL1B	B-Gene
,	O
IL1RN	B-Gene
,	O
IL6	B-Gene
,	O
IL8	B-Gene
,	O
MPO	B-Gene
,	O
NOS2	B-Gene
,	O
NOS3	B-Gene
,	O
SOD1	B-Gene
,	O
SOD2	B-Gene
,	O
SOD3	B-Gene
,	O
TLR4	B-Gene
,	O
and	O
TNF	B-Gene
and	O
tagging	O
SNPs	O
in	O
IL10	B-Gene
,	O
CRP	B-Gene
,	O
GSR	B-Gene
,	O
IL1RN	B-Gene
,	O
IL6	B-Gene
,	O
NOS2	B-Gene
,	O
and	O
NOS3	B-Gene
.	O
</ALL>	O

<ALL>	O
We	O
used	O
conditional	O
logistic	O
regression	O
to	O
estimate	O
OR	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
minor	O
allele	O
(	O
A	O
)	O
in	O
IL10	B-Gene
rs1800872	B-Variant
,	O
known	O
to	O
produce	O
less	O
interleukin	B-Gene
-	I-Gene
10	I-Gene
(	O
IL	B-Gene
-	I-Gene
10	I-Gene
)	O
,	O
was	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
recurrence	O
(	O
OR	O
=	O
1.76	O
,	O
95	O
%	O
CI	O
:	O
1.00	O
-	O
3.10	O
)	O
,	O
and	O
the	O
minor	O
allele	O
(	O
G	O
)	O
in	O
rs1800896	B-Variant
,	O
known	O
to	O
produce	O
more	O
IL	B-Gene
-	I-Gene
10	I-Gene
,	O
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
recurrence	O
(	O
OR	O
=	O
0.66	O
,	O
95	O
%	O
CI	O
:	O
0.48	O
-	O
0.91	O
)	O
.	O
</ALL>	O

<ALL>	O
We	O
also	O
observed	O
associations	O
for	O
candidate	O
SNPs	O
in	O
CRP	B-Gene
,	O
GSTP1	B-Gene
,	O
and	O
IL1B	B-Gene
.	O
</ALL>	O

<ALL>	O
A	O
common	O
IL10	B-Gene
haplotype	O
and	O
2	O
common	O
NOS2	B-Gene
haplotypes	O
were	O
associated	O
with	O
recurrence	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Variation	O
in	O
IL10	B-Gene
,	O
CRP	B-Gene
,	O
GSTP1	B-Gene
,	O
IL1B	B-Gene
,	O
and	O
NOS2	B-Gene
was	O
associated	O
with	O
prostate	B-Disease
cancer	I-Disease
recurrence	O
independent	O
of	O
pathologic	O
prognostic	O
factors	O
.	O
</ALL>	O

<ALL>	O
IMPACT	O
:	O
This	O
study	O
supports	O
that	O
genetic	O
variation	O
in	O
immune	O
response	O
and	O
oxidation	O
influence	O
prostate	B-Disease
cancer	I-Disease
recurrence	O
risk	O
and	O
suggests	O
genetic	O
variation	O
in	O
these	O
pathways	O
may	O
inform	O
prognosis	O
.	O
</ALL>	O

<ALL>	O
Negative	O
Selection	O
and	O
Chromosome	B-Disease
Instability	I-Disease
Induced	O
by	O
Mad2	B-Gene
Overexpression	O
Delay	O
Breast	B-Disease
Cancer	I-Disease
but	O
Facilitate	O
Oncogene	O
-	O
Independent	O
Outgrowth	O
.	O
</ALL>	O

<ALL>	O
Chromosome	B-Disease
instability	I-Disease
(	O
CIN	B-Disease
)	O
is	O
associated	O
with	O
poor	O
survival	O
and	O
therapeutic	O
outcome	O
in	O
a	O
number	O
of	O
malignancies	B-Disease
.	O
</ALL>	O

<ALL>	O
Despite	O
this	O
correlation	O
,	O
CIN	B-Disease
can	O
also	O
lead	O
to	O
growth	O
disadvantages	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
show	O
that	O
simultaneous	O
overexpression	O
of	O
the	O
mitotic	O
checkpoint	O
protein	O
Mad2	B-Gene
with	O
Kras	B-Gene
(	O
G12D	B-Gene
)	O
or	O
Her2	B-Gene
in	O
mammary	O
glands	O
of	O
adult	O
mice	B-Species
results	O
in	O
mitotic	O
checkpoint	O
overactivation	O
and	O
a	O
delay	O
in	O
tumor	B-Disease
onset	O
.	O
</ALL>	O

<ALL>	O
Time	O
-	O
lapse	O
imaging	O
of	O
organotypic	O
cultures	O
and	O
pathologic	O
analysis	O
prior	O
to	O
tumor	B-Disease
establishment	O
reveals	O
error	O
-	O
prone	O
mitosis	O
,	O
mitotic	O
arrest	O
,	O
and	O
cell	O
death	O
.	O
</ALL>	O

<ALL>	O
Nonetheless	O
,	O
Mad2	B-Gene
expression	O
persists	O
and	O
increases	O
karyotype	O
complexity	O
in	O
Kras	B-Gene
tumors	B-Disease
.	O
</ALL>	O

<ALL>	O
Faced	O
with	O
the	O
selective	O
pressure	O
of	O
oncogene	O
withdrawal	O
,	O
Mad2	B-Gene
-	O
positive	O
tumors	B-Disease
have	O
a	O
higher	O
frequency	O
of	O
developing	O
persistent	O
subclones	O
that	O
avoid	O
remission	O
and	O
continue	O
to	O
grow	O
.	O
</ALL>	O

<ALL>	O
Analysis	O
of	O
Serum	O
Cytokines	O
and	O
Single	O
-	O
Nucleotide	O
Polymorphisms	O
of	O
SOD1	B-Gene
,	O
SOD2	B-Gene
,	O
and	O
CAT	B-Gene
in	O
Erysipelas	B-Disease
Patients	B-Species
.	O
</ALL>	O

<ALL>	O
Increased	O
free	O
radical	O
production	O
had	O
been	O
documented	O
in	O
group	O
A	O
(	O
beta	O
-	O
hemolytic	O
)	O
streptococcus	B-Disease
infection	I-Disease
cases	O
.	O
</ALL>	O

<ALL>	O
Comparing	O
71	O
erysipelas	B-Disease
patients	B-Species
to	O
55	O
age	O
-	O
matched	O
healthy	O
individuals	O
,	O
we	O
sought	O
for	O
CAT	B-Gene
,	O
SOD1	B-Gene
,	O
and	O
SOD2	B-Gene
single	O
polymorphism	O
mutation	O
(	O
SNPs	O
)	O
interactions	O
with	O
erysipelas	B-Disease
'	O
predisposition	O
and	O
serum	O
cytokine	O
levels	O
in	O
the	O
acute	O
and	O
recovery	O
phases	O
of	O
erysipelas	B-Disease
infection	I-Disease
.	O
</ALL>	O

<ALL>	O
Whereas	O
female	O
patients	B-Species
had	O
a	O
higher	O
predisposition	O
to	O
erysipelas	B-Disease
,	O
male	O
patients	B-Species
were	O
prone	O
to	O
having	O
a	O
facial	O
localization	O
of	O
the	O
infection	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
presence	O
of	O
SOD1	B-Gene
G7958	B-Variant
,	O
SOD2	B-Gene
T2734	B-Variant
,	O
and	O
CAT	B-Gene
C262	B-Variant
alleles	O
was	O
linked	O
to	O
erysipelas	B-Disease
'	O
predisposition	O
.	O
</ALL>	O

<ALL>	O
T	O
and	O
C	O
alleles	O
of	O
SOD2	B-Gene
T2734C	B-Variant
individually	O
were	O
linked	O
to	O
patients	B-Species
with	O
bullous	O
and	O
erythematous	B-Disease
erysipelas	I-Disease
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
G	O
and	O
A	O
alleles	O
of	O
SOD1	B-Gene
G7958A	B-Variant
individually	O
were	O
associated	O
with	O
lower	O
limbs	O
and	O
higher	O
body	O
part	O
localizations	O
of	O
the	O
infection	B-Disease
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
Serum	O
levels	O
of	O
IL	B-Gene
-	I-Gene
1beta	I-Gene
,	O
CCL11	B-Gene
,	O
IL	B-Gene
-	I-Gene
2Ralpha	I-Gene
,	O
CXCL9	B-Gene
,	O
TRAIL	B-Gene
,	O
PDGF	B-Gene
-	I-Gene
BB	I-Gene
,	O
and	O
CCL4	B-Gene
were	O
associated	O
with	O
symptoms	O
accompanying	O
the	O
infection	B-Disease
,	O
while	O
IL	B-Gene
-	I-Gene
6	I-Gene
,	O
IL	B-Gene
-	I-Gene
9	I-Gene
,	O
IL	B-Gene
-	I-Gene
10	I-Gene
,	O
IL	B-Gene
-	I-Gene
13	I-Gene
,	O
IL	B-Gene
-	I-Gene
15	I-Gene
,	O
IL	B-Gene
-	I-Gene
17	I-Gene
,	O
G	B-Gene
-	I-Gene
CSF	I-Gene
,	O
and	O
VEGF	B-Gene
were	O
associated	O
with	O
predisposition	O
and	O
recurrence	O
of	O
erysipelas	B-Disease
.	O
</ALL>	O

<ALL>	O
While	O
variations	O
of	O
IL	B-Gene
-	I-Gene
1beta	I-Gene
,	O
IL	B-Gene
-	I-Gene
7	I-Gene
,	O
IL	B-Gene
-	I-Gene
8	I-Gene
,	O
IL	B-Gene
-	I-Gene
17	I-Gene
,	O
CCL5	B-Gene
,	O
and	O
HGF	B-Gene
were	O
associated	O
with	O
the	O
SOD2	B-Gene
T2734C	B-Variant
SNP	O
,	O
variations	O
of	O
PDFG	B-Gene
-	I-Gene
BB	I-Gene
and	O
CCL2	B-Gene
were	O
associated	O
with	O
the	O
CAT	B-Gene
C262	B-Variant
T	I-Variant
SNP	O
.	O
</ALL>	O

<ALL>	O
An	O
Ag	B-Gene
-	I-Gene
globin	I-Gene
G	B-Variant
-	I-Variant
>	I-Variant
A	I-Variant
gene	O
polymorphism	O
associated	O
with	O
b	B-Gene
(	I-Gene
0	I-Gene
)	I-Gene
39	I-Gene
thalassemia	I-Gene
globin	I-Gene
gene	O
and	O
high	O
fetal	B-Gene
hemoglobin	I-Gene
production	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Increase	O
of	O
the	O
expression	O
of	O
g	B-Gene
-	I-Gene
globin	I-Gene
gene	O
and	O
high	O
production	O
of	O
fetal	B-Gene
hemoglobin	I-Gene
(	O
HbF	B-Gene
)	O
in	O
b	B-Disease
-	I-Disease
thalassemia	I-Disease
patients	B-Species
is	O
widely	O
accepted	O
as	O
associated	O
with	O
a	O
milder	O
or	O
even	O
asymptomatic	O
disease	O
.	O
</ALL>	O

<ALL>	O
The	O
search	O
for	O
HbF	B-Gene
-	O
associated	O
polymorphisms	O
(	O
such	O
as	O
the	O
XmnI	O
,	O
BCL11A	B-Gene
and	O
MYB	B-Gene
polymorphisms	O
)	O
has	O
recently	O
gained	O
great	O
attention	O
,	O
in	O
order	O
to	O
stratify	O
b	B-Disease
-	I-Disease
thalassemia	I-Disease
patients	B-Species
with	O
respect	O
to	O
expectancy	O
of	O
the	O
first	O
transfusion	O
,	O
need	O
for	O
annual	O
intake	O
of	O
blood	O
,	O
response	O
to	O
HbF	B-Gene
inducers	O
(	O
the	O
most	O
studied	O
of	O
which	O
is	O
hydroxyurea	O
)	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Ag	B-Gene
-	I-Gene
globin	I-Gene
gene	O
sequencing	O
was	O
performed	O
on	O
genomic	O
DNA	O
isolated	O
from	O
a	O
total	O
of	O
75	O
b	B-Disease
-	I-Disease
thalassemia	I-Disease
patients	B-Species
,	O
including	O
31	O
b	O
(	O
0	O
)	O
39	O
/	O
b	O
(	O
0	O
)	O
39	O
,	O
33	O
b	O
(	O
0	O
)	O
39	O
/	O
b	O
(	O
+	O
)	O
IVSI	O
-	O
110	O
,	O
9	O
b	O
(	O
+	O
)	O
IVSI	O
-	O
110	O
/	O
b	O
(	O
+	O
)	O
IVSI	O
-	O
110	O
,	O
one	O
b	O
(	O
0	O
)	O
IVSI	O
-	O
1	O
/	O
b	O
(	O
+	O
)	O
IVSI	O
-	O
6	O
and	O
one	O
b	O
(	O
0	O
)	O
39	O
/	O
b	O
(	O
+	O
)	O
IVSI	O
-	O
6	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
results	O
show	O
that	O
the	O
rs368698783	B-Variant
polymorphism	O
is	O
present	O
in	O
b	B-Disease
-	I-Disease
thalassemia	I-Disease
patients	B-Species
in	O
the	O
5'UTR	O
sequence	O
(	O
+	O
25	O
)	O
of	O
the	O
Ag	B-Gene
-	I-Gene
globin	I-Gene
gene	O
,	O
known	O
to	O
affect	O
the	O
LYAR	B-Gene
(	O
human	B-Species
homologue	O
of	O
mouse	B-Species
Ly	B-Gene
-	I-Gene
1	I-Gene
antibody	I-Gene
reactive	I-Gene
clone	I-Gene
)	O
binding	O
site	O
5	O
'	O
-	O
GGTTAT	O
-	O
3	O
'	O
.	O
</ALL>	O

<ALL>	O
This	O
Ag	B-Gene
(	O
+	B-Variant
25	I-Variant
G	I-Variant
-	I-Variant
>	I-Variant
A	I-Variant
)	O
polymorphism	O
is	O
associated	O
with	O
the	O
Gg	B-Gene
-	I-Gene
globin	I-Gene
-	O
XmnI	O
polymorphism	O
and	O
both	O
are	O
linked	O
with	O
the	O
b	B-Gene
(	I-Gene
0	I-Gene
)	I-Gene
39	I-Gene
-	I-Gene
globin	I-Gene
gene	O
,	O
but	O
not	O
with	O
the	O
b	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
IVSI	I-Gene
-	I-Gene
110	I-Gene
-	I-Gene
globin	I-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
In	O
agreement	O
with	O
the	O
expectation	O
that	O
this	O
mutation	O
alters	O
the	O
LYAR	B-Gene
binding	O
activity	O
,	O
we	O
found	O
that	O
the	O
Ag	B-Gene
(	O
+	B-Variant
25	I-Variant
G	I-Variant
-	I-Variant
>	I-Variant
A	I-Variant
)	O
and	O
Gg	B-Gene
-	I-Gene
globin	I-Gene
-	O
XmnI	O
polymorphisms	O
are	O
associated	O
with	O
high	O
HbF	B-Gene
in	O
erythroid	O
precursor	O
cells	O
isolated	O
from	O
b	B-Disease
(	I-Disease
0	I-Disease
)	I-Disease
39	I-Disease
/	I-Disease
b	I-Disease
(	I-Disease
0	I-Disease
)	I-Disease
39	I-Disease
thalassemia	I-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
As	O
a	O
potential	O
explanation	O
of	O
our	O
findings	O
,	O
we	O
hypothesize	O
that	O
in	O
b	B-Disease
-	I-Disease
thalassemia	I-Disease
the	O
Gg	B-Gene
-	I-Gene
globin	I-Gene
-	O
XmnI	O
/	O
Ag	B-Gene
-	I-Gene
globin	I-Gene
-	O
(	O
G	B-Variant
-	I-Variant
>	I-Variant
A	I-Variant
)	O
genotype	O
is	O
frequently	O
under	O
genetic	O
linkage	O
with	O
b	B-Disease
(	I-Disease
0	I-Disease
)	I-Disease
-	I-Disease
thalassemia	I-Disease
mutations	O
,	O
but	O
not	O
with	O
the	O
b	B-Disease
(	I-Disease
+	I-Disease
)	I-Disease
-	I-Disease
thalassemia	I-Disease
mutation	O
here	O
studied	O
(	O
i.e.	O
b	O
(	O
+	O
)	O
IVSI	O
-	O
110	O
)	O
and	O
that	O
this	O
genetic	O
combination	O
has	O
been	O
selected	O
within	O
the	O
population	O
of	O
b	B-Disease
(	I-Disease
0	I-Disease
)	I-Disease
-	I-Disease
thalassemia	I-Disease
patients	B-Species
,	O
due	O
to	O
functional	O
association	O
with	O
high	O
HbF	B-Gene
.	O
</ALL>	O

<ALL>	O
Here	O
we	O
describe	O
the	O
characterization	O
of	O
the	O
rs368698783	B-Variant
(	O
+	B-Variant
25	I-Variant
G	I-Variant
-	I-Variant
>	I-Variant
A	I-Variant
)	O
polymorphism	O
of	O
the	O
Ag	B-Gene
-	I-Gene
globin	I-Gene
gene	O
associated	O
in	O
b	B-Disease
(	I-Disease
0	I-Disease
)	I-Disease
39	I-Disease
thalassemia	I-Disease
patients	B-Species
with	O
high	O
HbF	B-Gene
in	O
erythroid	O
precursor	O
cells	O
.	O
</ALL>	O

<ALL>	O
POLG	B-Gene
mutations	O
associated	O
with	O
Alpers	B-Disease
'	I-Disease
syndrome	I-Disease
and	O
mitochondrial	B-Disease
DNA	I-Disease
depletion	I-Disease
.	O
</ALL>	O

<ALL>	O
Alpers	B-Disease
'	I-Disease
syndrome	I-Disease
is	O
a	O
fatal	O
neurogenetic	B-Disease
disorder	I-Disease
first	O
described	O
more	O
than	O
70	O
years	O
ago	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
an	O
autosomal	O
recessive	O
,	O
developmental	O
mitochondrial	B-Disease
DNA	I-Disease
depletion	I-Disease
disorder	O
characterized	O
by	O
deficiency	O
in	O
mitochondrial	O
DNA	B-Gene
polymerase	I-Gene
gamma	I-Gene
(	O
POLG	B-Gene
)	O
catalytic	O
activity	O
,	O
refractory	O
seizures	B-Disease
,	O
neurodegeneration	B-Disease
,	O
and	O
liver	B-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
In	O
two	O
unrelated	O
pedigrees	O
of	O
Alpers	B-Disease
'	I-Disease
syndrome	I-Disease
,	O
each	O
affected	O
child	O
was	O
found	O
to	O
carry	O
a	O
homozygous	O
mutation	O
in	O
exon	O
17	O
of	O
the	O
POLG	B-Gene
locus	O
that	O
led	O
to	O
a	O
Glu873Stop	B-Variant
mutation	O
just	O
upstream	O
of	O
the	O
polymerase	O
domain	O
of	O
the	O
protein	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
each	O
affected	O
child	O
was	O
heterozygous	O
for	O
the	O
G1681A	B-Variant
mutation	O
in	O
exon	O
7	O
that	O
led	O
to	O
an	O
Ala467Thr	B-Variant
substitution	O
in	O
POLG	B-Gene
,	O
within	O
the	O
linker	O
region	O
of	O
the	O
protein	O
.	O
</ALL>	O

<ALL>	O
People	O
aged	O
over	O
75	O
in	O
atrial	B-Disease
fibrillation	I-Disease
on	O
warfarin	B-Chemical
:	O
the	O
rate	O
of	O
major	O
hemorrhage	B-Disease
and	O
stroke	B-Disease
in	O
more	O
than	O
500	O
patient	B-Species
-	O
years	O
of	O
follow	O
-	O
up	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVES	O
:	O
To	O
determine	O
the	O
incidence	O
of	O
major	O
hemorrhage	B-Disease
and	O
stroke	B-Disease
in	O
people	O
aged	O
76	O
and	O
older	O
with	O
atrial	B-Disease
fibrillation	I-Disease
on	O
adjusted	O
-	O
dose	O
warfarin	B-Chemical
who	O
had	O
been	O
recently	O
been	O
admitted	O
to	O
hospital	O
.	O
</ALL>	O

<ALL>	O
DESIGN	O
:	O
A	O
retrospective	O
observational	O
cohort	O
study	O
.	O
</ALL>	O

<ALL>	O
SETTING	O
:	O
A	O
major	O
healthcare	O
network	O
involving	O
four	O
tertiary	O
hospitals	O
.	O
</ALL>	O

<ALL>	O
PARTICIPANTS	O
:	O
Two	O
hundred	O
thirty	O
-	O
five	O
patients	B-Species
aged	O
76	O
and	O
older	O
admitted	O
to	O
a	O
major	O
healthcare	O
network	O
between	O
July	O
1	O
,	O
2001	O
,	O
and	O
June	O
30	O
,	O
2002	O
,	O
with	O
atrial	B-Disease
fibrillation	I-Disease
on	O
warfarin	B-Chemical
were	O
enrolled	O
.	O
</ALL>	O

<ALL>	O
MEASUREMENTS	O
:	O
Information	O
regarding	O
major	O
bleeding	B-Disease
episodes	O
,	O
strokes	B-Disease
,	O
and	O
warfarin	B-Chemical
use	O
was	O
obtained	O
from	O
patients	B-Species
,	O
relatives	O
,	O
primary	O
physicians	O
,	O
and	O
medical	O
records	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Two	O
hundred	O
twenty	O
-	O
eight	O
patients	B-Species
(	O
42	O
%	O
men	B-Species
)	O
with	O
a	O
mean	O
age	O
of	O
81.1	O
(	O
range	O
76	O
-	O
94	O
)	O
were	O
included	O
in	O
the	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Total	O
follow	O
-	O
up	O
on	O
warfarin	B-Chemical
was	O
530	O
years	O
(	O
mean	O
28	O
months	O
)	O
.	O
</ALL>	O

<ALL>	O
There	O
were	O
53	O
major	O
hemorrhages	B-Disease
,	O
for	O
an	O
annual	O
rate	O
of	O
10.0	O
%	O
,	O
including	O
24	O
(	O
45.3	O
%	O
)	O
life	O
-	O
threatening	O
and	O
five	O
(	O
9.4	O
%	O
)	O
fatal	O
bleeds	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
annual	O
stroke	B-Disease
rate	O
after	O
initiation	O
of	O
warfarin	B-Chemical
was	O
2.6	O
%	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
The	O
rate	O
of	O
major	O
hemorrhage	B-Disease
was	O
high	O
in	O
this	O
old	O
,	O
frail	O
group	O
,	O
but	O
excluding	O
fatalities	O
,	O
resulted	O
in	O
no	O
long	O
-	O
term	O
sequelae	O
,	O
and	O
the	O
stroke	B-Disease
rate	O
on	O
warfarin	B-Chemical
was	O
low	O
,	O
demonstrating	O
how	O
effective	O
warfarin	B-Chemical
treatment	O
is	O
.	O
</ALL>	O

<ALL>	O
Disruption	O
of	O
a	O
synaptotagmin	B-Gene
(	O
SYT14	B-Gene
)	O
associated	O
with	O
neurodevelopmental	B-Disease
abnormalities	I-Disease
.	O
</ALL>	O

<ALL>	O
We	O
report	O
cytogenetic	O
and	O
molecular	O
studies	O
of	O
a	O
de	O
novo	O
,	O
apparently	O
balanced	O
t	O
(	O
1;3	O
)	O
(	O
q32.1;q25.1	O
)	O
identified	O
in	O
a	O
12	O
-	O
year	O
-	O
old	O
female	O
(	O
designated	O
DGAP128	O
)	O
with	O
cerebral	B-Disease
atrophy	I-Disease
,	O
macrocephaly	B-Disease
seizures	B-Disease
,	O
and	O
developmental	B-Disease
delay	I-Disease
.	O
</ALL>	O

<ALL>	O
A	O
combination	O
of	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
and	O
Southern	O
blot	O
analysis	O
demonstrated	O
disruption	O
of	O
a	O
synaptotagmin	B-Gene
gene	O
(	O
SYT14	B-Gene
)	O
at	O
the	O
1q32	O
breakpoint	O
.	O
</ALL>	O

<ALL>	O
Expression	O
of	O
SYT14	B-Gene
in	O
human	B-Species
brain	O
was	O
confirmed	O
using	O
Northern	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Because	O
members	O
of	O
the	O
synaptotagmin	B-Gene
family	O
of	O
proteins	O
function	O
as	O
sensors	O
that	O
link	O
changes	O
in	O
calcium	B-Chemical
levels	O
with	O
a	O
variety	O
of	O
biological	O
processes	O
,	O
including	O
neurotransmission	O
and	O
hormone	O
-	O
responsiveness	O
,	O
SYT14	B-Gene
is	O
an	O
intriguing	O
candidate	O
gene	O
for	O
the	O
abnormal	O
development	O
in	O
this	O
child	O
.	O
</ALL>	O

<ALL>	O
This	O
is	O
the	O
first	O
known	O
constitutional	O
rearrangement	O
of	O
SYT14	B-Gene
,	O
and	O
further	O
systematic	O
genetic	O
analysis	O
and	O
clinical	O
studies	O
of	O
DGAP128	O
may	O
offer	O
unique	O
insights	O
into	O
the	O
role	O
of	O
SYT14	B-Gene
in	O
neurodevelopment	O
.	O
</ALL>	O

<ALL>	O
Isoproterenol	B-Chemical
induces	O
primary	O
loss	O
of	O
dystrophin	B-Gene
in	O
rat	B-Species
hearts	O
:	O
correlation	O
with	O
myocardial	B-Disease
injury	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
mechanism	O
of	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
damage	I-Disease
is	O
unknown	O
,	O
but	O
a	O
mismatch	O
of	O
oxygen	B-Chemical
supply	O
vs.	O
demand	O
following	O
coronary	O
hypotension	B-Disease
and	O
myocardial	B-Disease
hyperactivity	I-Disease
is	O
the	O
best	O
explanation	O
for	O
the	O
complex	O
morphological	O
alterations	O
observed	O
.	O
</ALL>	O

<ALL>	O
Severe	O
alterations	O
in	O
the	O
structural	O
integrity	O
of	O
the	O
sarcolemma	O
of	O
cardiomyocytes	O
have	O
been	O
demonstrated	O
to	O
be	O
caused	O
by	O
isoproterenol	B-Chemical
.	O
</ALL>	O

<ALL>	O
Taking	O
into	O
account	O
that	O
the	O
sarcolemmal	O
integrity	O
is	O
stabilized	O
by	O
the	O
dystrophin	B-Gene
-	O
glycoprotein	B-Gene
complex	O
(	O
DGC	O
)	O
that	O
connects	O
actin	B-Gene
and	O
laminin	B-Gene
in	O
contractile	O
machinery	O
and	O
extracellular	O
matrix	O
and	O
by	O
integrins	O
,	O
this	O
study	O
tests	O
the	O
hypothesis	O
that	O
isoproterenol	B-Chemical
affects	O
sarcolemmal	O
stability	O
through	O
changes	O
in	O
the	O
DGC	O
and	O
integrins	O
.	O
</ALL>	O

<ALL>	O
We	O
found	O
different	O
sensitivity	O
of	O
the	O
DGC	O
and	O
integrin	O
to	O
isoproterenol	B-Chemical
subcutaneous	O
administration	O
.	O
</ALL>	O

<ALL>	O
Immunofluorescent	O
staining	O
revealed	O
that	O
dystrophin	B-Gene
is	O
the	O
most	O
sensitive	O
among	O
the	O
structures	O
connecting	O
the	O
actin	B-Gene
in	O
the	O
cardiomyocyte	O
cytoskeleton	O
and	O
the	O
extracellular	O
matrix	O
.	O
</ALL>	O

<ALL>	O
The	O
sarcomeric	O
actin	B-Gene
dissolution	O
occurred	O
after	O
the	O
reduction	O
or	O
loss	O
of	O
dystrophin	B-Gene
.	O
</ALL>	O

<ALL>	O
Subsequently	O
,	O
after	O
lysis	O
of	O
myofilaments	O
,	O
gamma	B-Gene
-	I-Gene
sarcoglycan	I-Gene
,	O
beta	B-Gene
-	I-Gene
dystroglycan	I-Gene
,	O
beta1	B-Gene
-	I-Gene
integrin	I-Gene
,	O
and	O
laminin	B-Gene
alpha	I-Gene
-	I-Gene
2	I-Gene
expressions	O
were	O
reduced	O
followed	O
by	O
their	O
breakdown	O
,	O
as	O
epiphenomena	O
of	O
the	O
myocytolytic	O
process	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
administration	O
of	O
isoproterenol	B-Chemical
to	O
rats	B-Species
results	O
in	O
primary	O
loss	O
of	O
dystrophin	B-Gene
,	O
the	O
most	O
sensitive	O
among	O
the	O
structural	O
proteins	O
that	O
form	O
the	O
DGC	O
that	O
connects	O
the	O
extracellular	O
matrix	O
and	O
the	O
cytoskeleton	O
in	O
cardiomyocyte	O
.	O
</ALL>	O

<ALL>	O
These	O
changes	O
,	O
related	O
to	O
ischaemic	B-Disease
injury	I-Disease
,	O
explain	O
the	O
severe	O
alterations	O
in	O
the	O
structural	O
integrity	O
of	O
the	O
sarcolemma	O
of	O
cardiomyocytes	O
and	O
hence	O
severe	O
and	O
irreversible	O
injury	O
induced	O
by	O
isoproterenol	B-Chemical
.	O
</ALL>	O

<ALL>	O
Vitamin	B-Chemical
E	I-Chemical
reduces	O
cardiovascular	B-Disease
disease	I-Disease
in	O
individuals	O
with	O
diabetes	B-Disease
mellitus	I-Disease
and	O
the	O
haptoglobin	B-Gene
2	O
-	O
2	O
genotype	O
.	O
</ALL>	O

<ALL>	O
AIMS	O
:	O
Individuals	O
with	O
both	O
diabetes	B-Disease
mellitus	I-Disease
(	O
DM	B-Disease
)	O
and	O
the	O
Haptoglobin	B-Gene
(	O
Hp	B-Gene
)	O
2	O
-	O
2	O
genotype	O
are	O
at	O
increased	O
risk	O
of	O
cardiovascular	B-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
As	O
the	O
antioxidant	O
function	O
of	O
the	O
Hp	B-Gene
2	O
-	O
2	O
protein	O
is	O
impaired	O
,	O
we	O
sought	O
to	O
test	O
the	O
pharmacogenomic	O
hypothesis	O
that	O
antioxidant	B-Chemical
vitamin	B-Chemical
E	I-Chemical
supplementation	O
would	O
provide	O
cardiovascular	O
protection	O
to	O
Hp	B-Gene
2	O
-	O
2	O
DM	B-Disease
individuals	O
.	O
</ALL>	O

<ALL>	O
MATERIALS	O
&	O
METHODS	O
:	O
We	O
determined	O
the	O
Hp	B-Gene
genotype	O
on	O
DM	B-Disease
participants	O
from	O
two	O
trials	O
(	O
HOPE	O
and	O
ICARE	O
)	O
and	O
assessed	O
the	O
effect	O
of	O
vitamin	B-Chemical
E	I-Chemical
by	O
Hp	B-Gene
genotype	O
on	O
their	O
common	O
prespecified	O
outcome	O
,	O
the	O
composite	O
of	O
stroke	B-Disease
,	O
myocardial	B-Disease
infarction	I-Disease
and	O
cardiovascular	B-Disease
death	I-Disease
.	O
</ALL>	O

<ALL>	O
Data	O
was	O
analyzed	O
with	O
a	O
fixed	O
-	O
effect	O
model	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
were	O
input	O
into	O
a	O
simulation	O
model	O
,	O
the	O
Evidence	O
Based	O
Medicine	O
Integrator	O
,	O
in	O
order	O
to	O
estimate	O
their	O
long	O
-	O
term	O
implications	O
in	O
a	O
real	O
-	O
world	O
population	O
from	O
Kaiser	O
Permanente	O
(	O
CA	O
,	O
USA	O
)	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Meta	O
-	O
analysis	O
of	O
the	O
two	O
trials	O
demonstrated	O
a	O
significant	O
overall	O
reduction	O
in	O
the	O
composite	O
end	O
point	O
in	O
Hp	B-Gene
2	O
-	O
2	O
DM	B-Disease
individuals	O
with	O
vitamin	B-Chemical
E	I-Chemical
(	O
odds	O
ratio	O
:	O
0.58	O
;	O
95	O
%	O
CI	O
:	O
0.40	O
-	O
0.86	O
;	O
p	O
=	O
0.006	O
)	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
a	O
statistically	O
significant	O
interaction	O
between	O
the	O
Hp	B-Gene
genotype	O
and	O
vitamin	B-Chemical
E	I-Chemical
on	O
the	O
composite	O
end	O
point	O
.	O
</ALL>	O

<ALL>	O
In	O
these	O
trials	O
,	O
Hp	B-Gene
typing	O
of	O
69	O
DM	B-Disease
individuals	O
and	O
treating	O
those	O
with	O
the	O
Hp	B-Gene
2	O
-	O
2	O
with	O
vitamin	B-Chemical
E	I-Chemical
prevented	O
one	O
myocardial	B-Disease
infarct	I-Disease
,	O
stroke	B-Disease
or	O
cardiovascular	B-Disease
death	I-Disease
.	O
</ALL>	O

<ALL>	O
Lifelong	O
administration	O
of	O
vitamin	B-Chemical
E	I-Chemical
to	O
Hp	B-Gene
2	O
-	O
2	O
DM	B-Disease
individuals	O
in	O
the	O
Kaiser	O
population	O
would	O
increase	O
their	O
life	O
expectancy	O
by	O
3	O
years	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
A	O
pharmacogenomic	O
strategy	O
of	O
screening	O
DM	B-Disease
individuals	O
for	O
the	O
Hp	B-Gene
genotype	O
and	O
treating	O
those	O
with	O
Hp	B-Gene
2	O
-	O
2	O
with	O
vitamin	B-Chemical
E	I-Chemical
appears	O
to	O
be	O
highly	O
clinically	O
effective	O
.	O
</ALL>	O

<ALL>	O
Association	O
study	O
of	O
complement	B-Gene
factor	I-Gene
H	I-Gene
,	O
C2	B-Gene
,	O
CFB	B-Gene
,	O
and	O
C3	B-Gene
and	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
in	O
a	O
Han	O
Chinese	O
population	O
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
Genes	O
in	O
the	O
complement	O
pathway	O
,	O
including	O
complement	B-Gene
factor	I-Gene
H	I-Gene
(	O
CFH	B-Gene
)	O
,	O
C2	B-Gene
/	I-Gene
BF	I-Gene
,	O
and	O
C3	B-Gene
,	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
age	B-Disease
-	I-Disease
related	I-Disease
macular	I-Disease
degeneration	I-Disease
(	O
AMD	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Genetic	O
variants	O
,	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
,	O
in	O
these	O
genes	O
were	O
geno	O
-	O
typed	O
for	O
a	O
case	O
-	O
control	O
association	O
study	O
in	O
a	O
mainland	O
Han	O
Chinese	O
population	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
One	O
hundred	O
and	O
fifty	O
-	O
eight	O
patients	B-Species
with	O
wet	O
AMD	B-Disease
,	O
80	O
patients	B-Species
with	O
soft	O
drusen	B-Disease
,	O
and	O
220	O
matched	O
control	O
subjects	O
were	O
recruited	O
among	O
Han	O
Chinese	O
in	O
mainland	O
China	O
.	O
</ALL>	O

<ALL>	O
Seven	O
SNPs	O
in	O
CFH	B-Gene
and	O
two	O
SNPs	O
in	O
C2	B-Gene
,	O
CFB	B-Gene
'	O
,	O
and	O
C3	B-Gene
were	O
genotyped	O
using	O
the	O
ABI	O
SNaPshot	O
method	O
.	O
</ALL>	O

<ALL>	O
A	O
deletion	O
of	O
84,682	O
base	O
pairs	O
covering	O
the	O
CFHR1	B-Gene
and	O
CFHR3	B-Gene
genes	O
was	O
detected	O
by	O
direct	O
polymerase	O
chain	O
reaction	O
and	O
gel	O
electrophoresis	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Four	O
SNPs	O
,	O
including	O
rs3753394	B-Variant
(	O
P	O
=	O
0.0276	O
)	O
,	O
rs800292	B-Variant
(	O
P	O
=	O
0.0266	O
)	O
,	O
rs1061170	B-Variant
(	O
P	O
=	O
0.00514	O
)	O
,	O
and	O
rs1329428	B-Variant
(	O
P	O
=	O
0.0089	O
)	O
,	O
in	O
CFH	B-Gene
showed	O
a	O
significant	O
association	O
with	O
wet	O
AMD	B-Disease
in	O
the	O
cohort	O
of	O
this	O
study	O
.	O
</ALL>	O

<ALL>	O
A	O
haplotype	O
containing	O
these	O
four	O
SNPs	O
(	O
CATA	O
)	O
significantly	O
increased	O
protection	O
of	O
wet	O
AMD	B-Disease
with	O
a	O
P	O
value	O
of	O
0.0005	O
and	O
an	O
odds	O
ratio	O
of	O
0.29	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
0.15	O
-	O
0.60	O
)	O
.	O
</ALL>	O

<ALL>	O
Unlike	O
in	O
other	O
populations	O
,	O
rs2274700	B-Variant
and	O
rs1410996	B-Variant
did	O
not	O
show	O
a	O
significant	O
association	O
with	O
AMD	B-Disease
in	O
the	O
Chinese	O
population	O
of	O
this	O
study	O
.	O
</ALL>	O

<ALL>	O
None	O
of	O
the	O
SNPs	O
in	O
CFH	B-Gene
showed	O
a	O
significant	O
association	O
with	O
drusen	B-Disease
,	O
and	O
none	O
of	O
the	O
SNPs	O
in	O
CFH	B-Gene
,	O
C2	B-Gene
,	O
CFB	B-Gene
,	O
and	O
C3	B-Gene
showed	O
a	O
significant	O
association	O
with	O
either	O
wet	O
AMD	B-Disease
or	O
drusen	B-Disease
in	O
the	O
cohort	O
of	O
this	O
study	O
.	O
</ALL>	O

<ALL>	O
The	O
CFHR1	B-Gene
and	O
CFHR3	B-Gene
deletion	O
was	O
not	O
polymorphic	O
in	O
the	O
Chinese	O
population	O
and	O
was	O
not	O
associated	O
with	O
wet	O
AMD	B-Disease
or	O
drusen	B-Disease
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
This	O
study	O
showed	O
that	O
SNPs	O
rs3753394	B-Variant
(	O
P	O
=	O
0.0276	O
)	O
,	O
rs800292	B-Variant
(	O
P	O
=	O
0.0266	O
)	O
,	O
rs1061170	B-Variant
(	O
P	O
=	O
0.00514	O
)	O
,	O
and	O
rs1329428	B-Variant
(	O
P	O
=	O
0.0089	O
)	O
,	O
but	O
not	O
rs7535263	B-Variant
,	O
rs1410996	B-Variant
,	O
or	O
rs2274700	B-Variant
,	O
in	O
CFH	B-Gene
were	O
significantly	O
associated	O
with	O
wet	O
AMD	B-Disease
in	O
a	O
mainland	O
Han	O
Chinese	O
population	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
showed	O
that	O
CFH	B-Gene
was	O
more	O
likely	O
to	O
be	O
AMD	B-Disease
susceptibility	O
gene	O
at	O
Chr.1q31	O
based	O
on	O
the	O
finding	O
that	O
the	O
CFHR1	B-Gene
and	O
CFHR3	B-Gene
deletion	O
was	O
not	O
polymorphic	O
in	O
the	O
cohort	O
of	O
this	O
study	O
,	O
and	O
none	O
of	O
the	O
SNPs	O
that	O
were	O
significantly	O
associated	O
with	O
AMD	B-Disease
in	O
a	O
white	O
population	O
in	O
C2	B-Gene
,	O
CFB	B-Gene
,	O
and	O
C3	B-Gene
genes	O
showed	O
a	O
significant	O
association	O
with	O
AMD	B-Disease
.	O
</ALL>	O

<ALL>	O
Alternative	O
splicing	O
at	O
a	O
NAGNAG	O
acceptor	O
site	O
as	O
a	O
novel	O
phenotype	O
modifier	O
.	O
</ALL>	O

<ALL>	O
Approximately	O
30	O
%	O
of	O
alleles	O
causing	O
genetic	O
disorders	O
generate	O
premature	O
termination	O
codons	O
(	O
PTCs	O
)	O
,	O
which	O
are	O
usually	O
associated	O
with	O
severe	O
phenotypes	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
bypassing	O
the	O
deleterious	O
stop	O
codon	O
can	O
lead	O
to	O
a	O
mild	O
disease	O
outcome	O
.	O
</ALL>	O

<ALL>	O
Splicing	O
at	O
NAGNAG	O
tandem	O
splice	O
sites	O
has	O
been	O
reported	O
to	O
result	O
in	O
insertion	O
or	O
deletion	O
(	O
indel	O
)	O
of	O
three	O
nucleotides	O
.	O
</ALL>	O

<ALL>	O
We	O
identified	O
such	O
a	O
mechanism	O
as	O
the	O
origin	O
of	O
the	O
mild	O
to	O
asymptomatic	O
phenotype	O
observed	O
in	O
cystic	B-Disease
fibrosis	I-Disease
patients	B-Species
homozygous	O
for	O
the	O
E831X	B-Variant
mutation	O
(	O
2623	B-Variant
G	I-Variant
>	I-Variant
T	I-Variant
)	O
in	O
the	O
CFTR	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Analyses	O
performed	O
on	O
nasal	O
epithelial	O
cell	O
mRNA	O
detected	O
three	O
distinct	O
isoforms	O
,	O
a	O
considerably	O
more	O
complex	O
situation	O
than	O
expected	O
for	O
a	O
single	O
nucleotide	O
substitution	O
.	O
</ALL>	O

<ALL>	O
Structure	O
-	O
function	O
studies	O
and	O
in	O
silico	O
analyses	O
provided	O
the	O
first	O
experimental	O
evidence	O
of	O
an	O
indel	O
of	O
a	O
stop	O
codon	O
by	O
alternative	O
splicing	O
at	O
a	O
NAGNAG	O
acceptor	O
site	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
to	O
contributing	O
to	O
proteome	O
plasticity	O
,	O
alternative	O
splicing	O
at	O
a	O
NAGNAG	O
tandem	O
site	O
can	O
thus	O
remove	O
a	O
disease	O
-	O
causing	O
UAG	O
stop	O
codon	O
.	O
</ALL>	O

<ALL>	O
This	O
molecular	O
study	O
reveals	O
a	O
naturally	O
occurring	O
mechanism	O
where	O
the	O
effect	O
of	O
either	O
modifier	O
genes	O
or	O
epigenetic	O
factors	O
could	O
be	O
suspected	O
.	O
</ALL>	O

<ALL>	O
This	O
finding	O
is	O
of	O
importance	O
for	O
genetic	O
counseling	O
as	O
well	O
as	O
for	O
deciding	O
appropriate	O
therapeutic	O
strategies	O
.	O
</ALL>	O

<ALL>	O
In	O
vivo	O
characterization	O
of	O
a	O
dual	O
adenosine	B-Chemical
A2A	I-Chemical
/	I-Chemical
A1	I-Chemical
receptor	I-Chemical
antagonist	I-Chemical
in	O
animal	O
models	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
in	O
vivo	O
characterization	O
of	O
a	O
dual	O
adenosine	B-Chemical
A	I-Chemical
(	I-Chemical
2A	I-Chemical
)	I-Chemical
/	I-Chemical
A	I-Chemical
(	I-Chemical
1	I-Chemical
)	I-Chemical
receptor	I-Chemical
antagonist	I-Chemical
in	O
several	O
animal	O
models	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
is	O
described	O
.	O
</ALL>	O

<ALL>	O
Discovery	O
and	O
scale	O
-	O
up	O
syntheses	O
of	O
compound	O
1	O
are	O
described	O
in	O
detail	O
,	O
highlighting	O
optimization	O
steps	O
that	O
increased	O
the	O
overall	O
yield	O
of	O
1	O
from	O
10.0	O
%	O
to	O
30.5	O
%	O
.	O
</ALL>	O

<ALL>	O
Compound	O
1	O
is	O
a	O
potent	O
A	B-Chemical
(	I-Chemical
2A	I-Chemical
)	I-Chemical
/	I-Chemical
A	I-Chemical
(	I-Chemical
1	I-Chemical
)	I-Chemical
receptor	I-Chemical
antagonist	I-Chemical
in	O
vitro	O
(	O
A	O
(	O
2A	O
)	O
K	O
(	O
i	O
)	O
=	O
4.1	O
nM	O
;	O
A	O
(	O
1	O
)	O
K	O
(	O
i	O
)	O
=	O
17.0	O
nM	O
)	O
that	O
has	O
excellent	O
activity	O
,	O
after	O
oral	O
administration	O
,	O
across	O
a	O
number	O
of	O
animal	O
models	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
including	O
mouse	B-Species
and	O
rat	B-Species
models	O
of	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
,	O
mouse	B-Species
model	O
of	O
reserpine	B-Chemical
-	O
induced	O
akinesia	B-Disease
,	O
rat	B-Species
6	B-Chemical
-	I-Chemical
hydroxydopamine	I-Chemical
(	O
6	B-Chemical
-	I-Chemical
OHDA	I-Chemical
)	O
lesion	O
model	O
of	O
drug	O
-	O
induced	O
rotation	O
,	O
and	O
MPTP	B-Chemical
-	O
treated	O
non	O
-	O
human	B-Species
primate	O
model	O
.	O
</ALL>	O

<ALL>	O
Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
PTPN11	B-Gene
cause	O
metachondromatosis	B-Disease
,	O
but	O
not	O
Ollier	B-Disease
disease	I-Disease
or	O
Maffucci	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Metachondromatosis	B-Disease
(	O
MC	B-Disease
)	O
is	O
a	O
rare	O
,	O
autosomal	O
dominant	O
,	O
incompletely	O
penetrant	O
combined	O
exostosis	B-Disease
and	O
enchondromatosis	B-Disease
tumor	I-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
MC	B-Disease
is	O
clinically	O
distinct	O
from	O
other	O
multiple	B-Disease
exostosis	I-Disease
or	O
multiple	B-Disease
enchondromatosis	I-Disease
syndromes	I-Disease
and	O
is	O
unlinked	O
to	O
EXT1	B-Gene
and	O
EXT2	B-Gene
,	O
the	O
genes	O
responsible	O
for	O
autosomal	O
dominant	O
multiple	B-Disease
osteochondromas	I-Disease
(	O
MO	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
To	O
identify	O
a	O
gene	O
for	O
MC	B-Disease
,	O
we	O
performed	O
linkage	O
analysis	O
with	O
high	O
-	O
density	O
SNP	O
arrays	O
in	O
a	O
single	O
family	O
,	O
used	O
a	O
targeted	O
array	O
to	O
capture	O
exons	O
and	O
promoter	O
sequences	O
from	O
the	O
linked	O
interval	O
in	O
16	O
participants	O
from	O
11	O
MC	B-Disease
families	O
,	O
and	O
sequenced	O
the	O
captured	O
DNA	O
using	O
high	O
-	O
throughput	O
parallel	O
sequencing	O
technologies	O
.	O
</ALL>	O

<ALL>	O
DNA	O
capture	O
and	O
parallel	O
sequencing	O
identified	O
heterozygous	O
putative	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
PTPN11	B-Gene
in	O
4	O
of	O
the	O
11	O
families	O
.	O
</ALL>	O

<ALL>	O
Sanger	O
sequence	O
analysis	O
of	O
PTPN11	B-Gene
coding	O
regions	O
in	O
a	O
total	O
of	O
17	O
MC	B-Disease
families	O
identified	O
mutations	O
in	O
10	O
of	O
them	O
(	O
5	O
frameshift	O
,	O
2	O
nonsense	O
,	O
and	O
3	O
splice	O
-	O
site	O
mutations	O
)	O
.	O
</ALL>	O

<ALL>	O
Copy	O
number	O
analysis	O
of	O
sequencing	O
reads	O
from	O
a	O
second	O
targeted	O
capture	O
that	O
included	O
the	O
entire	O
PTPN11	B-Gene
gene	O
identified	O
an	O
additional	O
family	O
with	O
a	O
15	B-Variant
kb	I-Variant
deletion	I-Variant
spanning	O
exon	O
7	O
of	O
PTPN11	B-Gene
.	O
</ALL>	O

<ALL>	O
Microdissected	O
MC	B-Disease
lesions	O
from	O
two	O
patients	B-Species
with	O
PTPN11	B-Gene
mutations	O
demonstrated	O
loss	O
-	O
of	O
-	O
heterozygosity	O
for	O
the	O
wild	O
-	O
type	O
allele	O
.	O
</ALL>	O

<ALL>	O
We	O
next	O
sequenced	O
PTPN11	B-Gene
in	O
DNA	O
samples	O
from	O
54	O
patients	B-Species
with	O
the	O
multiple	O
enchondromatosis	B-Disease
disorders	I-Disease
Ollier	I-Disease
disease	I-Disease
or	O
Maffucci	B-Disease
syndrome	I-Disease
,	O
but	O
found	O
no	O
coding	O
sequence	O
PTPN11	B-Gene
mutations	O
.	O
</ALL>	O

<ALL>	O
We	O
conclude	O
that	O
heterozygous	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
PTPN11	B-Gene
are	O
a	O
frequent	O
cause	O
of	O
MC	B-Disease
,	O
that	O
lesions	O
in	O
patients	B-Species
with	O
MC	B-Disease
appear	O
to	O
arise	O
following	O
a	O
"	O
second	O
hit	O
,	O
"	O
that	O
MC	B-Disease
may	O
be	O
locus	O
heterogeneous	O
since	O
1	O
familial	O
and	O
5	O
sporadically	O
occurring	O
cases	O
lacked	O
obvious	O
disease	O
-	O
causing	O
PTPN11	B-Gene
mutations	O
,	O
and	O
that	O
PTPN11	B-Gene
mutations	O
are	O
not	O
a	O
common	O
cause	O
of	O
Ollier	B-Disease
disease	I-Disease
or	O
Maffucci	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Risk	O
factors	O
and	O
predictors	O
of	O
levodopa	B-Chemical
-	O
induced	O
dyskinesia	B-Disease
among	O
multiethnic	O
Malaysians	O
with	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
Chronic	O
pulsatile	O
levodopa	B-Chemical
therapy	O
for	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
leads	O
to	O
the	O
development	O
of	O
motor	O
fluctuations	O
and	O
dyskinesia	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
studied	O
the	O
prevalence	O
and	O
predictors	O
of	O
levodopa	B-Chemical
-	O
induced	O
dyskinesia	B-Disease
among	O
multiethnic	O
Malaysian	O
patients	B-Species
with	O
PD	B-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
This	O
is	O
a	O
cross	O
-	O
sectional	O
study	O
involving	O
95	O
patients	B-Species
with	O
PD	B-Disease
on	O
uninterrupted	O
levodopa	B-Chemical
therapy	O
for	O
at	O
least	O
6	O
months	O
.	O
</ALL>	O

<ALL>	O
The	O
instrument	O
used	O
was	O
the	O
UPDRS	O
questionnaires	O
.	O
</ALL>	O

<ALL>	O
The	O
predictors	O
of	O
dyskinesia	B-Disease
were	O
determined	O
using	O
multivariate	O
logistic	O
regression	O
analysis	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
mean	O
age	O
was	O
65.6	O
+	O
8.5	O
years	O
.	O
</ALL>	O

<ALL>	O
The	O
mean	O
onset	O
age	O
was	O
58.5	O
+	O
9.8	O
years	O
.	O
</ALL>	O

<ALL>	O
The	O
median	O
disease	O
duration	O
was	O
6	O
(	O
7	O
)	O
years	O
.	O
</ALL>	O

<ALL>	O
Dyskinesia	B-Disease
was	O
present	O
in	O
44	O
%	O
(	O
n	O
=	O
42	O
)	O
with	O
median	O
levodopa	B-Chemical
therapy	O
of	O
3	O
years	O
.	O
</ALL>	O

<ALL>	O
There	O
were	O
64.3	O
%	O
Chinese	O
,	O
31	O
%	O
Malays	O
,	O
and	O
3.7	O
%	O
Indians	O
and	O
other	O
ethnic	O
groups	O
.	O
</ALL>	O

<ALL>	O
Eighty	O
-	O
one	O
percent	O
of	O
patients	B-Species
with	O
dyskinesia	B-Disease
had	O
clinical	O
fluctuations	O
.	O
</ALL>	O

<ALL>	O
Patients	B-Species
with	O
dyskinesia	B-Disease
had	O
lower	O
onset	O
age	O
(	O
p	O
<	O
0.001	O
)	O
,	O
longer	O
duration	O
of	O
levodopa	B-Chemical
therapy	O
(	O
p	O
<	O
0.001	O
)	O
,	O
longer	O
disease	O
duration	O
(	O
p	O
<	O
0.001	O
)	O
,	O
higher	O
total	O
daily	O
levodopa	B-Chemical
dose	O
(	O
p	O
<	O
0.001	O
)	O
,	O
and	O
higher	O
total	O
UPDRS	O
scores	O
(	O
p	O
=	O
0.005	O
)	O
than	O
patients	B-Species
without	O
dyskinesia	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
three	O
significant	O
predictors	O
of	O
dyskinesia	B-Disease
were	O
duration	O
of	O
levodopa	B-Chemical
therapy	O
,	O
onset	O
age	O
,	O
and	O
total	O
daily	O
levodopa	B-Chemical
dose	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
The	O
prevalence	O
of	O
levodopa	B-Chemical
-	O
induced	O
dyskinesia	B-Disease
in	O
our	O
patients	B-Species
was	O
44	O
%	O
.	O
</ALL>	O

<ALL>	O
The	O
most	O
significant	O
predictors	O
were	O
duration	O
of	O
levodopa	B-Chemical
therapy	O
,	O
total	O
daily	O
levodopa	B-Chemical
dose	O
,	O
and	O
onset	O
age	O
.	O
</ALL>	O

<ALL>	O
VPAC2	B-Gene
(	O
vasoactive	B-Gene
intestinal	I-Gene
peptide	I-Gene
receptor	I-Gene
type	I-Gene
2	I-Gene
)	O
receptor	O
deficient	O
mice	B-Species
develop	O
exacerbated	O
experimental	B-Disease
autoimmune	I-Disease
encephalomyelitis	I-Disease
with	O
increased	O
Th1	O
/	O
Th17	O
and	O
reduced	O
Th2	O
/	O
Treg	O
responses	O
.	O
</ALL>	O

<ALL>	O
Vasoactive	B-Gene
intestinal	I-Gene
peptide	I-Gene
(	O
VIP	B-Gene
)	O
and	O
pituitary	B-Gene
adenylyl	I-Gene
cyclase	I-Gene
-	I-Gene
activating	I-Gene
polypeptide	I-Gene
(	O
PACAP	B-Gene
)	O
are	O
two	O
structurally	O
-	O
related	O
neuropeptides	O
with	O
widespread	O
expression	O
in	O
the	O
central	O
and	O
peripheral	O
nervous	O
systems	O
.	O
</ALL>	O

<ALL>	O
Although	O
these	O
peptides	O
have	O
been	O
repeatedly	O
shown	O
to	O
exert	O
potent	O
anti	O
-	O
inflammatory	B-Disease
actions	O
when	O
administered	O
in	O
animal	O
models	O
of	O
inflammatory	B-Disease
disease	I-Disease
,	O
mice	B-Species
deficient	O
in	O
VIP	B-Gene
and	O
PACAP	B-Gene
were	O
recently	O
shown	O
to	O
exhibit	O
different	O
phenotypes	O
(	O
ameliorated	O
and	O
exacerbated	O
,	O
respectively	O
)	O
in	O
response	O
to	O
experimental	B-Disease
autoimmune	I-Disease
encephalomyelitis	I-Disease
(	O
EAE	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
elucidating	O
what	O
are	O
the	O
specific	O
immunoregulatory	O
roles	O
played	O
by	O
each	O
of	O
their	O
receptor	O
subtypes	O
(	O
VPAC1	B-Gene
,	O
VPAC2	B-Gene
,	O
and	O
PAC1	B-Gene
)	O
is	O
critical	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
found	O
that	O
mice	B-Species
with	O
a	O
genetic	O
deletion	O
of	O
VIPR2	B-Gene
,	O
encoding	O
the	O
VPAC2	B-Gene
receptor	I-Gene
,	O
exhibited	O
exacerbated	O
(	O
MOG35	B-Gene
-	I-Gene
55	I-Gene
)	O
-	O
induced	O
EAE	B-Disease
compared	O
to	O
wild	O
type	O
mice	B-Species
,	O
characterized	O
by	O
enhanced	O
clinical	O
and	O
histopathological	O
features	O
,	O
increased	O
proinflammatory	B-Gene
cytokines	I-Gene
(	O
TNF	B-Gene
-	I-Gene
alpha	I-Gene
,	O
IL	B-Gene
-	I-Gene
6	I-Gene
,	O
IFN	B-Gene
-	I-Gene
gamma	I-Gene
(	O
Th1	O
)	O
,	O
and	O
IL	B-Gene
-	I-Gene
17	I-Gene
(	O
Th17	O
)	O
)	O
and	O
reduced	O
anti	B-Gene
-	I-Gene
inflammatory	I-Gene
cytokines	I-Gene
(	O
IL	B-Gene
-	I-Gene
10	I-Gene
,	O
TGFbeta	B-Gene
,	O
and	O
IL	B-Gene
-	I-Gene
4	I-Gene
(	O
Th2	O
)	O
)	O
in	O
the	O
CNS	O
and	O
lymph	O
nodes	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
the	O
abundance	O
and	O
proliferative	O
index	O
of	O
lymph	O
node	O
,	O
thymus	O
and	O
CNS	O
CD4	B-Gene
(	O
+	O
)	O
CD25	B-Gene
(	O
+	O
)	O
FoxP3	B-Gene
(	O
+	O
)	O
Tregs	O
were	O
strikingly	O
reduced	O
in	O
VPAC2	B-Gene
-	O
deficient	O
mice	B-Species
with	O
EAE	B-Disease
.	O
</ALL>	O

<ALL>	O
Finally	O
,	O
the	O
in	O
vitro	O
suppressive	O
activity	O
of	O
lymph	O
node	O
and	O
splenic	O
Tregs	O
from	O
VPAC2	B-Gene
-	O
deficient	O
mice	B-Species
was	O
impaired	O
.	O
</ALL>	O

<ALL>	O
Overall	O
,	O
our	O
results	O
demonstrate	O
critical	O
protective	O
roles	O
for	O
PACAP	B-Gene
and	O
the	O
VPAC2	B-Gene
receptor	I-Gene
against	O
autoimmunity	O
,	O
promoting	O
the	O
expansion	O
and	O
maintenance	O
of	O
the	O
Treg	O
pool	O
.	O
</ALL>	O

<ALL>	O
Alcohol	B-Chemical
consumption	O
and	O
prostate	B-Disease
cancer	I-Disease
incidence	O
and	O
progression	O
:	O
A	O
Mendelian	O
randomisation	O
study	O
.	O
</ALL>	O

<ALL>	O
Prostate	B-Disease
cancer	I-Disease
is	O
the	O
most	O
common	O
cancer	B-Disease
in	O
men	B-Species
in	O
developed	O
countries	O
,	O
and	O
is	O
a	O
target	O
for	O
risk	O
reduction	O
strategies	O
.	O
</ALL>	O

<ALL>	O
The	O
effects	O
of	O
alcohol	B-Chemical
consumption	O
on	O
prostate	B-Disease
cancer	I-Disease
incidence	O
and	O
survival	O
remain	O
unclear	O
,	O
potentially	O
due	O
to	O
methodological	O
limitations	O
of	O
observational	O
studies	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
associations	O
of	O
genetic	O
variants	O
in	O
alcohol	B-Chemical
-	O
metabolising	O
genes	O
with	O
prostate	B-Disease
cancer	I-Disease
incidence	O
and	O
survival	O
.	O
</ALL>	O

<ALL>	O
We	O
analysed	O
data	O
from	O
23,868	O
men	B-Species
with	O
prostate	B-Disease
cancer	I-Disease
and	O
23,051	O
controls	O
from	O
25	O
studies	O
within	O
the	O
international	O
PRACTICAL	O
Consortium	O
.	O
</ALL>	O

<ALL>	O
Study	O
-	O
specific	O
associations	O
of	O
68	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
8	O
alcohol	B-Chemical
-	O
metabolising	O
genes	O
(	O
Alcohol	B-Gene
Dehydrogenases	I-Gene
(	O
ADHs	B-Gene
)	O
and	O
Aldehyde	B-Gene
Dehydrogenases	I-Gene
(	O
ALDHs	B-Gene
)	O
)	O
with	O
prostate	B-Disease
cancer	I-Disease
diagnosis	O
and	O
prostate	B-Disease
cancer	I-Disease
-	O
specific	O
mortality	O
,	O
by	O
grade	O
,	O
were	O
assessed	O
using	O
logistic	O
and	O
Cox	O
regression	O
models	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
The	O
data	O
across	O
the	O
25	O
studies	O
were	O
meta	O
-	O
analysed	O
using	O
fixed	O
-	O
effect	O
and	O
random	O
-	O
effects	O
models	O
.	O
</ALL>	O

<ALL>	O
We	O
found	O
little	O
evidence	O
that	O
variants	O
in	O
alcohol	B-Chemical
metabolising	O
genes	O
were	O
associated	O
with	O
prostate	B-Disease
cancer	I-Disease
diagnosis	O
.	O
</ALL>	O

<ALL>	O
Four	O
variants	O
in	O
two	O
genes	O
exceeded	O
the	O
multiple	O
testing	O
threshold	O
for	O
associations	O
with	O
prostate	B-Disease
cancer	I-Disease
mortality	O
in	O
fixed	O
-	O
effect	O
meta	O
-	O
analyses	O
.	O
</ALL>	O

<ALL>	O
SNPs	O
within	O
ALDH1A2	B-Gene
associated	O
with	O
prostate	B-Disease
cancer	I-Disease
mortality	O
were	O
rs1441817	B-Variant
(	O
fixed	O
effects	O
hazard	O
ratio	O
,	O
HRfixed	O
=	O
0.78	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
95%CI	O
)	O
:	O
0.66,0.91	O
;	O
p	O
values	O
=	O
0.002	O
)	O
;	O
rs12910509	B-Variant
,	O
HRfixed	O
=	O
0.76	O
;	O
95%CI:0.64,0.91	O
;	O
p	O
values	O
=	O
0.003	O
)	O
;	O
and	O
rs8041922	B-Variant
(	O
HRfixed	O
=	O
0.76	O
;	O
95%CI:0.64,0.91	O
;	O
p	O
values	O
=	O
0.002	O
)	O
.	O
</ALL>	O

<ALL>	O
These	O
SNPs	O
were	O
in	O
linkage	O
disequilibrium	O
with	O
each	O
other	O
.	O
</ALL>	O

<ALL>	O
In	O
ALDH1B1	B-Gene
,	O
rs10973794	B-Variant
(	O
HRfixed	O
=	O
1.43	O
;	O
95%CI:1.14,1.79	O
;	O
p	O
values	O
=	O
0.002	O
)	O
was	O
associated	O
with	O
prostate	B-Disease
cancer	I-Disease
mortality	O
in	O
men	B-Species
with	O
low	O
-	O
grade	O
prostate	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
These	O
results	O
suggest	O
that	O
alcohol	B-Chemical
consumption	O
is	O
unlikely	O
to	O
affect	O
prostate	B-Disease
cancer	I-Disease
incidence	O
,	O
but	O
it	O
may	O
influence	O
disease	O
progression	O
.	O
</ALL>	O

<ALL>	O
Acute	O
low	B-Disease
back	I-Disease
pain	I-Disease
during	O
intravenous	O
administration	O
of	O
amiodarone	B-Chemical
:	O
a	O
report	O
of	O
two	O
cases	O
.	O
</ALL>	O

<ALL>	O
Amiodarone	B-Chemical
represents	O
an	O
effective	O
antiarrhythmic	B-Chemical
drug	I-Chemical
for	O
cardioversion	O
of	O
recent	O
-	O
onset	O
atrial	B-Disease
fibrillation	I-Disease
(	O
AF	B-Disease
)	O
and	O
maintenance	O
of	O
sinus	O
rhythm	O
.	O
</ALL>	O

<ALL>	O
We	O
briefly	O
describe	O
two	O
patients	B-Species
suffering	O
from	O
recent	O
-	O
onset	O
atrial	B-Disease
fibrillation	I-Disease
,	O
who	O
experienced	O
an	O
acute	O
devastating	O
low	B-Disease
back	I-Disease
pain	I-Disease
a	O
few	O
minutes	O
after	O
initiation	O
of	O
intravenous	O
amiodarone	B-Chemical
loading	O
.	O
</ALL>	O

<ALL>	O
Notably	O
,	O
this	O
side	O
effect	O
has	O
not	O
been	O
ever	O
reported	O
in	O
the	O
medical	O
literature	O
.	O
</ALL>	O

<ALL>	O
Clinicians	O
should	O
be	O
aware	O
of	O
this	O
reaction	O
since	O
prompt	O
termination	O
of	O
parenteral	O
administration	O
leads	O
to	O
complete	O
resolution	O
.	O
</ALL>	O

<ALL>	O
Common	O
dihydrofolate	B-Gene
reductase	I-Gene
19	B-Variant
-	I-Variant
base	I-Variant
pair	I-Variant
deletion	I-Variant
allele	O
:	O
a	O
novel	O
risk	O
factor	O
for	O
preterm	B-Disease
delivery	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Folate	B-Chemical
is	O
critical	O
for	O
cell	O
division	O
,	O
a	O
major	O
feature	O
of	O
in	O
utero	O
development	O
.	O
</ALL>	O

<ALL>	O
Dihydrofolate	B-Gene
reductase	I-Gene
(	O
DHFR	B-Gene
)	O
is	O
required	O
to	O
convert	O
the	O
folic	B-Chemical
acid	I-Chemical
used	O
in	O
supplements	O
and	O
for	O
food	O
fortification	O
and	O
the	O
dihydrofolate	B-Chemical
produced	O
by	O
thymidylate	B-Gene
synthase	I-Gene
during	O
DNA	O
synthesis	O
to	O
the	O
reduced	O
folate	B-Chemical
forms	O
used	O
by	O
the	O
cell	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
We	O
aimed	O
to	O
determine	O
whether	O
a	O
common	O
,	O
recently	O
discovered	O
deletion	O
polymorphism	O
in	O
the	O
DHFR	B-Gene
gene	O
is	O
a	O
risk	O
factor	O
for	O
preterm	B-Disease
delivery	I-Disease
or	O
low	O
birth	O
weight	O
.	O
</ALL>	O

<ALL>	O
DESIGN	O
:	O
We	O
studied	O
324	O
pregnant	O
women	B-Species
from	O
Camden	O
,	O
NJ	O
.	O
</ALL>	O

<ALL>	O
Folate	B-Chemical
intake	O
was	O
computed	O
from	O
folate	B-Chemical
supplement	O
intake	O
plus	O
the	O
mean	O
of	O
two	O
24	O
-	O
h	O
recalls	O
completed	O
during	O
the	O
course	O
of	O
pregnancy	O
.	O
</ALL>	O

<ALL>	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
women	B-Species
's	O
leukocytes	O
and	O
genotyped	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Women	B-Species
with	O
a	O
deletion	O
allele	O
had	O
a	O
significantly	O
greater	O
risk	O
of	O
preterm	B-Disease
delivery	I-Disease
[	O
adjusted	O
odds	O
ratio	O
(	O
AOR	O
)	O
:	O
3.0	O
;	O
95	O
%	O
CI	O
:	O
1.0	O
,	O
8.8	O
;	O
P	O
<	O
0.05	O
]	O
than	O
did	O
those	O
without	O
a	O
deletion	O
allele	O
.	O
</ALL>	O

<ALL>	O
Women	B-Species
with	O
both	O
a	O
DHFR	B-Gene
deletion	O
allele	O
and	O
low	O
folate	B-Chemical
intake	O
(	O
<	O
400	O
microg	O
/	O
d	O
from	O
diet	O
plus	O
supplements	O
)	O
had	O
a	O
significantly	O
greater	O
risk	O
of	O
preterm	B-Disease
delivery	I-Disease
(	O
AOR	O
:	O
5.5	O
;	O
95	O
%	O
CI	O
:	O
1.5	O
,	O
20.4	O
;	O
P	O
=	O
0.01	O
)	O
and	O
a	O
significantly	O
greater	O
risk	O
of	O
having	O
an	O
infant	O
with	O
a	O
low	O
birth	O
weight	O
(	O
AOR	O
:	O
8.3	O
;	O
95	O
%	O
CI	O
:	O
1.8	O
,	O
38.6	O
;	O
P	O
=	O
0.01	O
)	O
than	O
did	O
women	B-Species
without	O
a	O
deletion	O
allele	O
and	O
with	O
a	O
folate	B-Chemical
intake	O
>	O
/	O
=	O
400	O
microg	O
/	O
d.	O
CONCLUSIONS	O
:	O
The	O
DHFR	B-Gene
19	B-Variant
-	I-Variant
base	I-Variant
pair	I-Variant
deletion	I-Variant
allele	O
may	O
be	O
a	O
risk	O
factor	O
for	O
preterm	B-Disease
delivery	I-Disease
.	O
</ALL>	O

<ALL>	O
In	O
the	O
presence	O
of	O
low	O
dietary	O
folate	B-Chemical
,	O
the	O
allele	O
may	O
also	O
be	O
a	O
risk	O
factor	O
for	O
low	O
birth	O
weight	O
.	O
</ALL>	O

<ALL>	O
This	O
may	O
be	O
a	O
gene	O
-	O
environment	O
interaction	O
.	O
</ALL>	O

<ALL>	O
Mild	O
glycine	B-Disease
encephalopathy	I-Disease
(	O
NKH	B-Disease
)	O
in	O
a	O
large	O
kindred	O
due	O
to	O
a	O
silent	O
exonic	O
GLDC	B-Gene
splice	O
mutation	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Classic	O
neonatal	O
-	O
onset	O
glycine	B-Disease
encephalopathy	I-Disease
(	O
GE	B-Disease
)	O
is	O
devastating	O
and	O
life	O
threatening	O
.	O
</ALL>	O

<ALL>	O
Milder	O
,	O
later	O
onset	O
variants	O
have	O
been	O
reported	O
but	O
were	O
usually	O
sporadic	O
and	O
incompletely	O
defined	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
clinical	O
and	O
biochemical	O
phenotype	O
and	O
molecular	O
basis	O
of	O
mild	O
GE	B-Disease
in	O
nine	O
children	O
from	O
a	O
consanguineous	O
Israeli	O
Bedouin	O
kindred	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Genomic	O
DNA	O
was	O
screened	O
for	O
GLDC	B-Gene
,	O
AMT	B-Gene
,	O
and	O
GCSH	B-Gene
gene	O
mutations	O
.	O
</ALL>	O

<ALL>	O
GLDC	B-Gene
expression	O
in	O
lymphoblasts	O
was	O
studied	O
by	O
Northern	O
blot	O
and	O
reverse	O
transcriptase	O
PCR	O
analysis	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Clinical	O
features	O
included	O
hypotonia	B-Disease
,	O
abnormal	B-Disease
movements	I-Disease
,	O
convulsions	B-Disease
,	O
and	O
moderate	O
mental	B-Disease
retardation	I-Disease
with	O
relative	O
sparing	O
of	O
gross	O
motor	O
function	O
,	O
activities	O
of	O
daily	O
living	O
skills	O
,	O
and	O
receptive	O
language	O
.	O
</ALL>	O

<ALL>	O
Aggression	B-Disease
and	O
irritability	B-Disease
were	O
prominent	O
.	O
</ALL>	O

<ALL>	O
CSF	O
-	O
to	O
-	O
plasma	O
glycine	O
ratio	O
was	O
mildly	O
to	O
moderately	O
elevated	O
.	O
</ALL>	O

<ALL>	O
All	O
nine	O
patients	B-Species
were	O
homozygous	O
and	O
their	O
parents	O
heterozygous	O
for	O
a	O
novel	O
,	O
translationally	O
silent	O
GLDC	B-Gene
exon	O
22	O
transversion	O
c.2607C	B-Variant
>	I-Variant
A	I-Variant
.	O
</ALL>	O

<ALL>	O
Lymphoblast	O
GLDC	B-Gene
mRNA	O
levels	O
were	O
considerably	O
reduced	O
.	O
</ALL>	O

<ALL>	O
Three	O
aberrantly	O
spliced	O
cDNA	O
species	O
were	O
identified	O
:	O
exon	O
22	O
and	O
exon	O
22	O
to	O
23	O
skipping	O
,	O
and	O
insertion	O
of	O
an	O
87	O
-	O
base	O
pair	O
cryptic	O
exon	O
.	O
</ALL>	O

<ALL>	O
Homozygosity	O
for	O
c.2607C	B-Variant
>	I-Variant
A	I-Variant
was	O
also	O
identified	O
in	O
an	O
unrelated	O
but	O
haplotypically	O
identical	O
patient	B-Species
with	O
an	O
unusually	O
favorable	O
outcome	O
despite	O
severe	O
neonatal	O
-	O
onset	O
GE	B-Disease
.	O
</ALL>	O

<ALL>	O
Mutation	O
analysis	O
enabled	O
prenatal	O
diagnosis	O
of	O
three	O
unaffected	O
and	O
one	O
affected	O
pregnancies	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
The	O
mutation	O
in	O
this	O
kindred	O
led	O
to	O
missplicing	O
and	O
reduced	O
GLDC	B-Gene
(	O
glycine	B-Gene
decarboxylase	I-Gene
)	O
expression	O
.	O
</ALL>	O

<ALL>	O
The	O
4	O
to	O
6	O
%	O
of	O
normally	O
spliced	O
GLDC	B-Gene
mRNA	O
in	O
the	O
patients	B-Species
may	O
account	O
for	O
their	O
relatively	O
favorable	O
clinical	O
outcome	O
compared	O
with	O
patients	B-Species
with	O
classic	O
glycine	B-Disease
encephalopathy	I-Disease
.	O
</ALL>	O

<ALL>	O
A	O
family	O
with	O
two	O
consecutive	O
nonsense	O
mutations	O
in	O
BMPR1A	B-Gene
causing	O
juvenile	B-Disease
polyposis	I-Disease
.	O
</ALL>	O

<ALL>	O
We	O
describe	O
a	O
novel	O
germline	O
mutation	O
of	O
BMPR1A	B-Gene
in	O
a	O
family	O
with	O
juvenile	B-Disease
polyposis	I-Disease
and	O
colon	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
This	O
mutation	O
consists	O
of	O
two	O
consecutive	O
substitutions	O
(	O
735	B-Variant
-	I-Variant
6	I-Variant
TG	I-Variant
>	I-Variant
AT	I-Variant
)	O
that	O
cause	O
two	O
nonsense	O
mutations	O
(	O
Y245X	B-Variant
,	O
G246X	B-Variant
)	O
,	O
inherited	O
in	O
an	O
autosomal	O
dominant	O
fashion	O
,	O
on	O
one	O
parental	O
chromosome	O
.	O
</ALL>	O

<ALL>	O
This	O
mutation	O
caused	O
protein	O
truncation	O
,	O
and	O
represents	O
a	O
novel	O
case	O
of	O
consecutive	O
nonsense	O
mutations	O
in	O
human	B-Species
disease	O
.	O
</ALL>	O

<ALL>	O
Anticipation	O
in	O
familial	O
lattice	B-Disease
corneal	I-Disease
dystrophy	I-Disease
type	I-Disease
I	I-Disease
with	O
R124C	B-Variant
mutation	O
in	O
the	O
TGFBI	B-Gene
(	O
BIGH3	B-Gene
)	O
gene	O
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
To	O
report	O
the	O
clinical	O
,	O
ophthalmic	O
,	O
and	O
genetic	O
characteristics	O
for	O
lattice	B-Disease
corneal	I-Disease
dystrophy	I-Disease
type	I-Disease
I	I-Disease
(	O
LCDI	B-Disease
)	O
in	O
a	O
Chilean	O
family	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Six	O
affected	O
family	O
members	O
were	O
examined	O
clinically	O
including	O
visual	O
acuity	O
,	O
color	O
cornea	O
photography	O
,	O
applanation	O
tonography	O
,	O
and	O
fundoscopy	O
.	O
</ALL>	O

<ALL>	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
leukocytes	O
from	O
six	O
affected	O
and	O
three	O
unaffected	O
members	O
of	O
a	O
family	O
with	O
lattice	B-Disease
corneal	I-Disease
dystrophy	I-Disease
type	I-Disease
I	I-Disease
.	O
</ALL>	O

<ALL>	O
Exon	O
4	O
of	O
the	O
transforming	B-Gene
growth	I-Gene
factor	I-Gene
-	I-Gene
induced	I-Gene
gene	I-Gene
(	O
TGFBI	B-Gene
)	O
was	O
screened	O
for	O
the	O
most	O
frequent	O
mutation	O
,	O
R124C	B-Variant
,	O
in	O
the	O
proband	O
by	O
sequencing	O
.	O
</ALL>	O

<ALL>	O
We	O
also	O
designed	O
a	O
rapid	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
method	O
to	O
analyze	O
the	O
same	O
mutation	O
,	O
amplifying	O
exon	O
4	O
and	O
digesting	O
with	O
PstI	B-Gene
restriction	O
enzyme	O
.	O
</ALL>	O

<ALL>	O
Using	O
this	O
strategy	O
,	O
we	O
analyzed	O
the	O
mutation	O
in	O
six	O
affected	O
and	O
three	O
healthy	O
family	O
members	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Three	O
generations	O
of	O
family	O
members	O
were	O
positively	O
diagnosed	O
with	O
lattice	B-Disease
corneal	I-Disease
dystrophy	I-Disease
.	O
</ALL>	O

<ALL>	O
Six	O
participants	O
demonstrated	O
LCD1	B-Disease
in	O
both	O
eyes	O
,	O
most	O
of	O
whom	O
were	O
symmetric	O
.	O
</ALL>	O

<ALL>	O
Age	O
at	O
onset	O
of	O
symptoms	O
was	O
variable	O
(	O
3	O
-	O
42	O
years	O
old	O
)	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
in	O
this	O
family	O
,	O
the	O
age	O
of	O
onset	O
of	O
the	O
disease	O
decreased	O
in	O
succeeding	O
generations	O
,	O
which	O
could	O
be	O
interpreted	O
as	O
anticipation	O
.	O
</ALL>	O

<ALL>	O
Visual	O
acuity	O
varied	O
from	O
1.0	O
to	O
0.13	O
.	O
</ALL>	O

<ALL>	O
Two	O
patients	B-Species
,	O
ages	O
69	O
and	O
44	O
years	O
old	O
,	O
demonstrated	O
a	O
degree	O
of	O
severity	O
"	O
Bad	O
"	O
according	O
to	O
best	O
-	O
corrected	O
vision	O
and	O
corneal	O
commitment	O
.	O
</ALL>	O

<ALL>	O
The	O
exon	O
4	O
sequence	O
of	O
TGFBI	B-Gene
of	O
the	O
proband	O
exhibits	O
the	O
heterozygous	O
single	O
-	O
nucleotide	O
mutation	O
,	O
C417	B-Variant
T	I-Variant
,	O
leading	O
to	O
amino	O
acid	O
substitution	O
(	O
R124C	B-Variant
)	O
in	O
the	O
encoded	O
TGF	B-Gene
-	I-Gene
induced	I-Gene
protein	I-Gene
.	O
</ALL>	O

<ALL>	O
Using	O
PCR	O
-	O
RFLP	O
,	O
we	O
confirmed	O
the	O
heterozygous	O
mutation	O
in	O
six	O
affected	O
family	O
members	O
and	O
excluded	O
it	O
in	O
three	O
healthy	O
members	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
The	O
R124C	B-Variant
mutation	O
in	O
TGFBI	B-Gene
cosegregated	O
with	O
LCD	B-Disease
type	I-Disease
I	I-Disease
in	O
the	O
investigated	O
family	O
.	O
</ALL>	O

<ALL>	O
This	O
is	O
the	O
first	O
report	O
of	O
a	O
molecular	O
analysis	O
of	O
LCD	B-Disease
type	I-Disease
I	I-Disease
in	O
Chilean	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
early	O
onset	O
affected	O
persons	O
in	O
the	O
fourth	O
generation	O
raises	O
the	O
possibility	O
of	O
anticipation	O
.	O
</ALL>	O

<ALL>	O
Novel	O
suppressors	O
of	O
alpha	B-Gene
-	I-Gene
synuclein	I-Gene
toxicity	B-Disease
identified	O
using	O
yeast	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
mechanism	O
by	O
which	O
the	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
-	O
related	O
protein	O
alpha	B-Gene
-	I-Gene
synuclein	I-Gene
(	O
alpha	B-Gene
-	I-Gene
syn	I-Gene
)	O
causes	O
neurodegeneration	B-Disease
has	O
not	O
been	O
elucidated	O
.	O
</ALL>	O

<ALL>	O
To	O
determine	O
the	O
genes	O
that	O
protect	O
cells	O
from	O
alpha	B-Gene
-	I-Gene
syn	I-Gene
,	O
we	O
used	O
a	O
genetic	O
screen	O
to	O
identify	O
suppressors	O
of	O
the	O
super	O
sensitivity	O
of	O
the	O
yeast	B-Species
Saccharomyces	B-Species
cerevisiae	I-Species
expressing	O
alpha	B-Gene
-	I-Gene
syn	I-Gene
to	O
killing	O
by	O
hydrogen	B-Chemical
peroxide	I-Chemical
.	O
</ALL>	O

<ALL>	O
Forty	O
genes	O
in	O
ubiquitin	B-Gene
-	O
dependent	O
protein	O
catabolism	O
,	O
protein	O
biosynthesis	O
,	O
vesicle	O
trafficking	O
and	O
the	O
response	O
to	O
stress	O
were	O
identified	O
.	O
</ALL>	O

<ALL>	O
Five	O
of	O
the	O
forty	O
genes	O
-	O
-	O
ENT3	B-Gene
,	O
IDP3	B-Gene
,	O
JEM1	B-Gene
,	O
ARG2	B-Gene
and	O
HSP82	B-Gene
-	O
-	O
ranked	O
highest	O
in	O
their	O
ability	O
to	O
block	O
alpha	B-Gene
-	I-Gene
syn	I-Gene
-	O
induced	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
accumulation	O
,	O
and	O
these	O
five	O
genes	O
were	O
characterized	O
in	O
more	O
detail	O
.	O
</ALL>	O

<ALL>	O
The	O
deletion	O
of	O
any	O
of	O
these	O
five	O
genes	O
enhanced	O
the	O
toxicity	B-Disease
of	O
alpha	B-Gene
-	I-Gene
syn	I-Gene
as	O
judged	O
by	O
growth	O
defects	O
compared	O
with	O
wild	O
-	O
type	O
cells	O
expressing	O
alpha	B-Gene
-	I-Gene
syn	I-Gene
,	O
which	O
indicates	O
that	O
these	O
genes	O
protect	O
cells	O
from	O
alpha	B-Gene
-	I-Gene
syn	I-Gene
.	O
</ALL>	O

<ALL>	O
Strikingly	O
,	O
four	O
of	O
the	O
five	O
genes	O
are	O
specific	O
for	O
alpha	B-Gene
-	I-Gene
syn	I-Gene
in	O
that	O
they	O
fail	O
to	O
protect	O
cells	O
from	O
the	O
toxicity	B-Disease
of	O
the	O
two	O
inherited	O
mutants	O
A30P	B-Variant
or	O
A53	B-Variant
T	I-Variant
.	O
</ALL>	O

<ALL>	O
This	O
finding	O
suggests	O
that	O
alpha	B-Gene
-	I-Gene
syn	I-Gene
causes	O
toxicity	B-Disease
to	O
cells	O
through	O
a	O
different	O
pathway	O
than	O
these	O
two	O
inherited	O
mutants	O
.	O
</ALL>	O

<ALL>	O
Lastly	O
,	O
overexpression	O
of	O
Ent3p	B-Gene
,	O
which	O
is	O
a	O
clathrin	B-Chemical
adapter	O
protein	O
involved	O
in	O
protein	O
transport	O
between	O
the	O
Golgi	O
and	O
the	O
vacuole	O
,	O
causes	O
alpha	B-Gene
-	I-Gene
syn	I-Gene
to	O
redistribute	O
from	O
the	O
plasma	O
membrane	O
into	O
cytoplasmic	O
vesicular	O
structures	O
.	O
</ALL>	O

<ALL>	O
Our	O
interpretation	O
is	O
that	O
Ent3p	B-Gene
mediates	O
the	O
transport	O
of	O
alpha	B-Gene
-	I-Gene
syn	I-Gene
to	O
the	O
vacuole	O
for	O
proteolytic	O
degradation	O
.	O
</ALL>	O

<ALL>	O
A	O
similar	O
clathrin	B-Chemical
adaptor	O
protein	O
,	O
epsinR	B-Gene
,	O
exists	O
in	O
humans	B-Species
.	O
</ALL>	O

<ALL>	O
Study	O
of	O
a	O
Taiwanese	O
family	O
with	O
oculopharyngeal	B-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Oculopharyngeal	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
OPMD	B-Disease
)	O
is	O
a	O
late	O
onset	O
autosomal	B-Disease
dominant	I-Disease
muscle	I-Disease
disorder	I-Disease
.	O
</ALL>	O

<ALL>	O
OPMD	B-Disease
is	O
caused	O
by	O
a	O
short	O
trinucleotide	O
repeat	O
expansion	O
encoding	O
an	O
expanded	O
polyalanine	B-Chemical
tract	O
in	O
the	O
polyadenylate	B-Gene
binding	I-Gene
-	I-Gene
protein	I-Gene
nuclear	I-Gene
1	I-Gene
(	O
PABPN1	B-Gene
)	O
gene	O
.	O
</ALL>	O

<ALL>	O
We	O
identified	O
and	O
characterized	O
a	O
PABPN1	B-Gene
mutation	O
in	O
a	O
Taiwanese	O
family	O
with	O
OPMD	B-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
The	O
phenotypic	O
and	O
genotypic	O
characteristics	O
of	O
all	O
subjects	O
were	O
evaluated	O
in	O
a	O
Taiwanese	O
OPMD	B-Disease
family	O
.	O
</ALL>	O

<ALL>	O
Genetic	O
alterations	O
in	O
the	O
PABPN1	B-Gene
gene	O
were	O
identified	O
using	O
PCR	O
and	O
DNA	O
sequencing	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Ten	O
subjects	O
with	O
OPMD	B-Disease
(	O
6	O
symptomatic	O
and	O
4	O
asymptomatic	O
)	O
within	O
the	O
Taiwanese	O
family	O
carried	O
a	O
novel	O
mutation	O
in	O
the	O
PABPN1	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
The	O
normal	O
(	B-Variant
GCG	I-Variant
)	I-Variant
6	I-Variant
(	I-Variant
GCA	I-Variant
)	I-Variant
3GCG	I-Variant
sequence	I-Variant
was	I-Variant
replaced	I-Variant
by	I-Variant
(	I-Variant
GCG	I-Variant
)	I-Variant
6	I-Variant
(	I-Variant
GCA	I-Variant
)	I-Variant
(	I-Variant
GCG	I-Variant
)	I-Variant
4	I-Variant
(	I-Variant
GCA	I-Variant
)	I-Variant
3GCG	I-Variant
due	O
to	O
an	O
insertion	B-Variant
of	I-Variant
(	I-Variant
GCG	I-Variant
)	I-Variant
4GCA	I-Variant
into	O
the	O
normal	O
allele	O
in	O
the	O
Taiwanese	O
OPMD	B-Disease
subjects	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
In	O
contrast	O
to	O
a	O
single	O
GCG	O
expansion	O
in	O
most	O
of	O
OPMD	B-Disease
patients	B-Species
in	O
the	O
literature	O
,	O
an	O
insertion	B-Variant
of	I-Variant
(	I-Variant
GCG	I-Variant
)	I-Variant
4GCA	I-Variant
in	O
the	O
PABPN1	B-Gene
gene	O
was	O
found	O
in	O
the	O
Taiwanese	O
OPMD	B-Disease
subjects	O
.	O
</ALL>	O

<ALL>	O
The	O
identification	O
of	O
this	O
mutation	O
appears	O
to	O
support	O
the	O
molecular	O
mechanism	O
of	O
unequal	O
cross	O
-	O
over	O
of	O
two	O
PABPN1	B-Gene
alleles	O
.	O
</ALL>	O

<ALL>	O
TAK1	B-Gene
is	O
an	O
essential	O
regulator	O
of	O
BMP	B-Gene
signalling	O
in	O
cartilage	O
.	O
</ALL>	O

<ALL>	O
TGFbeta	B-Gene
activated	I-Gene
kinase	I-Gene
1	I-Gene
(	O
TAK1	B-Gene
)	O
,	O
a	O
member	O
of	O
the	O
MAPKKK	B-Gene
family	O
,	O
controls	O
diverse	O
functions	O
ranging	O
from	O
innate	O
and	O
adaptive	O
immune	O
system	O
activation	O
to	O
vascular	O
development	O
and	O
apoptosis	O
.	O
</ALL>	O

<ALL>	O
To	O
analyse	O
the	O
in	O
vivo	O
function	O
of	O
TAK1	B-Gene
in	O
cartilage	O
,	O
we	O
generated	O
mice	B-Species
with	O
a	O
conditional	O
deletion	O
of	O
Tak1	B-Gene
driven	O
by	O
the	O
collagen	B-Gene
2	I-Gene
promoter	O
.	O
</ALL>	O

<ALL>	O
Tak1	B-Gene
(	O
col2	B-Gene
)	O
mice	B-Species
displayed	O
severe	O
chondrodysplasia	B-Disease
with	O
runting	O
,	O
impaired	O
formation	O
of	O
secondary	O
centres	O
of	O
ossification	O
,	O
and	O
joint	B-Disease
abnormalities	I-Disease
including	O
elbow	B-Disease
dislocation	I-Disease
and	O
tarsal	B-Disease
fusion	I-Disease
.	O
</ALL>	O

<ALL>	O
This	O
phenotype	O
resembled	O
that	O
of	O
bone	B-Gene
morphogenetic	I-Gene
protein	I-Gene
receptor	I-Gene
(	I-Gene
BMPR	I-Gene
)	I-Gene
1	I-Gene
and	O
Gdf5	B-Gene
-	O
deficient	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
BMPR	B-Gene
signalling	O
was	O
markedly	O
impaired	O
in	O
TAK1	B-Gene
-	O
deficient	O
chondrocytes	O
as	O
evidenced	O
by	O
reduced	O
expression	O
of	O
known	O
BMP	B-Gene
target	O
genes	O
as	O
well	O
as	O
reduced	O
phosphorylation	O
of	O
Smad1	B-Gene
/	I-Gene
5	I-Gene
/	I-Gene
8	I-Gene
and	O
p38	B-Gene
/	O
Jnk	B-Gene
/	O
Erk	B-Gene
MAP	B-Gene
kinases	I-Gene
.	O
</ALL>	O

<ALL>	O
TAK1	B-Gene
mediates	O
Smad1	B-Gene
phosphorylation	O
at	O
C	O
-	O
terminal	O
serine	O
residues	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
provide	O
the	O
first	O
in	O
vivo	O
evidence	O
in	O
a	O
mammalian	O
system	O
that	O
TAK1	B-Gene
is	O
required	O
for	O
BMP	B-Gene
signalling	O
and	O
functions	O
as	O
an	O
upstream	O
activating	O
kinase	O
for	O
Smad1	B-Gene
/	I-Gene
5	I-Gene
/	I-Gene
8	I-Gene
in	O
addition	O
to	O
its	O
known	O
role	O
in	O
regulating	O
MAP	B-Gene
kinase	I-Gene
pathways	O
.	O
</ALL>	O

<ALL>	O
Our	O
experiments	O
reveal	O
an	O
essential	O
role	O
for	O
TAK1	B-Gene
in	O
the	O
morphogenesis	O
,	O
growth	O
,	O
and	O
maintenance	O
of	O
cartilage	O
.	O
</ALL>	O

<ALL>	O
Effect	O
of	O
the	O
abrogation	O
of	O
TGF	B-Gene
-	I-Gene
beta1	I-Gene
by	O
antisense	O
oligonucleotides	B-Chemical
on	O
the	O
expression	O
of	O
TGF	B-Gene
-	I-Gene
beta	I-Gene
-	I-Gene
isoforms	I-Gene
and	I-Gene
their	I-Gene
receptors	I-Gene
I	I-Gene
and	I-Gene
II	I-Gene
in	O
isolated	O
fibroblasts	O
from	O
keloid	B-Disease
scars	I-Disease
.	O
</ALL>	O

<ALL>	O
Disequilibrium	O
of	O
dermal	O
wound	O
repair	O
can	O
result	O
in	O
continued	O
accumulation	O
of	O
ECM	O
and	O
excessive	O
scar	O
formation	O
.	O
</ALL>	O

<ALL>	O
In	O
susceptible	O
genetically	O
predisposed	O
individuals	O
,	O
keloid	B-Disease
formation	O
can	O
be	O
observed	O
.	O
</ALL>	O

<ALL>	O
Keloid	B-Disease
disease	I-Disease
represents	O
a	O
benign	O
dermal	O
fibroproliferative	O
tumor	B-Disease
that	O
is	O
unique	O
to	O
humans	B-Species
.	O
</ALL>	O

<ALL>	O
TGF	B-Gene
-	I-Gene
beta	I-Gene
is	O
known	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	O
of	O
this	O
disease	O
which	O
is	O
still	O
not	O
fully	O
understood	O
.	O
</ALL>	O

<ALL>	O
The	O
isoforms	O
TGF	B-Gene
-	I-Gene
beta1	I-Gene
and	O
TGF	B-Gene
-	I-Gene
beta2	I-Gene
have	O
profibrotic	O
properties	O
,	O
whereas	O
TGF	B-Gene
-	I-Gene
beta3	I-Gene
may	O
have	O
antifibrotic	O
functions	O
.	O
</ALL>	O

<ALL>	O
TGF	B-Gene
-	I-Gene
beta	I-Gene
exerts	O
its	O
influence	O
by	O
binding	O
to	O
type	B-Gene
I	I-Gene
and	I-Gene
type	I-Gene
II	I-Gene
TGF	I-Gene
-	I-Gene
beta	I-Gene
receptors	I-Gene
,	O
thereby	O
forming	O
a	O
complex	O
and	O
activating	O
specific	O
downstream	O
effector	O
molecules	O
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
TGF	B-Gene
-	I-Gene
beta1	I-Gene
targeting	O
by	O
antisense	O
oligonucleotides	B-Chemical
on	O
the	O
RNA	O
synthesis	O
and	O
protein	O
expression	O
of	O
TGF	B-Gene
-	I-Gene
beta	I-Gene
isoforms	O
and	O
their	O
receptors	O
in	O
keloid	B-Disease
-	O
derived	O
fibroblasts	O
.	O
</ALL>	O

<ALL>	O
In	O
tissue	O
samples	O
with	O
normal	O
fibroblasts	O
(	O
NFs	O
)	O
serving	O
as	O
control	O
samples	O
,	O
expression	O
of	O
TGF	B-Gene
-	I-Gene
beta1	I-Gene
and	I-Gene
-	I-Gene
beta2	I-Gene
was	O
decreased	O
when	O
compared	O
to	O
keloid	B-Disease
fibroblasts	O
(	O
KFs	O
)	O
,	O
while	O
expression	O
of	O
TGF	B-Gene
-	I-Gene
beta3	I-Gene
and	O
of	O
TGF	B-Gene
-	I-Gene
betaRII	I-Gene
was	O
significantly	O
higher	O
in	O
NFs	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
ELISA	O
assay	O
,	O
abrogation	O
of	O
TGF	B-Gene
-	I-Gene
beta1	I-Gene
led	O
to	O
a	O
significant	O
decrease	O
in	O
TGF	B-Gene
-	I-Gene
beta1	I-Gene
and	I-Gene
-	I-Gene
beta2	I-Gene
(	O
p	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
Expression	O
of	O
TGF	B-Gene
-	I-Gene
beta2	I-Gene
mRNA	O
was	O
reduced	O
.	O
</ALL>	O

<ALL>	O
Expression	O
of	O
TGF	B-Gene
-	I-Gene
beta3	I-Gene
mRNA	O
revealed	O
contrary	O
patterns	O
in	O
KFs	O
from	O
different	O
patients	B-Species
while	O
expression	O
of	O
TGF	B-Gene
-	I-Gene
betaRI	I-Gene
was	O
found	O
to	O
be	O
equal	O
during	O
the	O
measurement	O
period	O
.	O
</ALL>	O

<ALL>	O
TGF	B-Gene
-	I-Gene
betaRII	I-Gene
mRNA	O
expression	O
was	O
increased	O
after	O
48	O
and	O
72	O
h	O
respectively	O
.	O
</ALL>	O

<ALL>	O
There	O
is	O
growing	O
evidence	O
for	O
a	O
regulatory	O
mechanism	O
between	O
TGF	B-Gene
-	I-Gene
beta1	I-Gene
and	O
its	O
receptors	O
.	O
</ALL>	O

<ALL>	O
Our	O
findings	O
support	O
this	O
theory	O
by	O
suggesting	O
interrelations	O
between	O
the	O
different	O
TGF	B-Gene
-	I-Gene
beta	I-Gene
isoforms	O
and	O
their	O
receptors	O
.	O
</ALL>	O

<ALL>	O
Abnormal	O
response	O
of	O
KFs	O
to	O
TGF	O
-	O
betamight	O
reflect	O
a	O
modification	O
in	O
the	O
regulatory	O
pathway	O
that	O
occurs	O
at	O
the	O
receptor	O
level	O
or	O
during	O
intracellular	O
trans	O
-	O
duction	O
.	O
</ALL>	O

<ALL>	O
Improving	O
the	O
understanding	O
of	O
TGF	B-Gene
-	I-Gene
beta	I-Gene
in	O
keloid	B-Disease
disease	I-Disease
could	O
lead	O
to	O
the	O
development	O
of	O
clinically	O
useful	O
therapeutic	O
modalities	O
for	O
treatment	O
of	O
keloid	B-Disease
disease	I-Disease
or	O
even	O
allow	O
identification	O
of	O
preventive	O
strategies	O
.	O
</ALL>	O

<ALL>	O
Brat	B-Gene
promotes	O
stem	O
cell	O
differentiation	O
via	O
control	O
of	O
a	O
bistable	O
switch	O
that	O
restricts	O
BMP	B-Gene
signaling	O
.	O
</ALL>	O

<ALL>	O
Drosophila	B-Species
ovarian	O
germline	O
stem	O
cells	O
(	O
GSCs	O
)	O
are	O
maintained	O
by	O
Dpp	B-Gene
signaling	O
and	O
the	O
Pumilio	B-Gene
(	O
Pum	B-Gene
)	O
and	O
Nanos	B-Gene
(	O
Nos	B-Gene
)	O
translational	O
repressors	O
.	O
</ALL>	O

<ALL>	O
Upon	O
division	O
,	O
Dpp	B-Gene
signaling	O
is	O
extinguished	O
,	O
and	O
Nos	B-Gene
is	O
downregulated	O
in	O
one	O
daughter	O
cell	O
,	O
causing	O
it	O
to	O
switch	O
to	O
a	O
differentiating	O
cystoblast	O
(	O
CB	O
)	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
downstream	O
effectors	O
of	O
Pum	B-Gene
-	O
Nos	B-Gene
remain	O
unknown	O
,	O
and	O
how	O
CBs	O
lose	O
their	O
responsiveness	O
to	O
Dpp	B-Gene
is	O
unclear	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
identify	O
Brain	B-Gene
Tumor	I-Gene
(	O
Brat	B-Gene
)	O
as	O
a	O
potent	O
differentiation	O
factor	O
and	O
target	O
of	O
Pum	B-Gene
-	O
Nos	B-Gene
regulation	O
.	O
</ALL>	O

<ALL>	O
Brat	B-Gene
is	O
excluded	O
from	O
GSCs	O
by	O
Pum	B-Gene
-	O
Nos	B-Gene
but	O
functions	O
with	O
Pum	B-Gene
in	O
CBs	O
to	O
translationally	O
repress	O
distinct	O
targets	O
,	O
including	O
the	O
Mad	B-Gene
and	O
dMyc	B-Gene
mRNAs	O
.	O
</ALL>	O

<ALL>	O
Regulation	O
of	O
both	O
targets	O
simultaneously	O
lowers	O
cellular	O
responsiveness	O
to	O
Dpp	B-Gene
signaling	O
,	O
forcing	O
the	O
cell	O
to	O
become	O
refractory	O
to	O
the	O
self	O
-	O
renewal	O
signal	O
.	O
</ALL>	O

<ALL>	O
Mathematical	O
modeling	O
elucidates	O
bistability	O
of	O
cell	O
fate	O
in	O
the	O
Brat	B-Gene
-	O
mediated	O
system	O
,	O
revealing	O
how	O
autoregulation	O
of	O
GSC	O
number	O
can	O
arise	O
from	O
Brat	B-Gene
coupling	O
extracellular	O
Dpp	B-Gene
regulation	O
to	O
intracellular	O
interpretation	O
.	O
</ALL>	O

<ALL>	O
Two	O
novel	O
mutations	O
of	O
the	O
PAX6	B-Gene
gene	O
causing	O
different	O
phenotype	O
in	O
a	O
cohort	O
of	O
Chinese	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
Aniridia	B-Disease
(	O
AN	B-Disease
)	O
is	O
a	O
rare	O
congenital	B-Disease
panocular	I-Disease
disorder	I-Disease
caused	O
by	O
the	O
mutations	O
of	O
the	O
paired	B-Gene
box	I-Gene
homeotic	I-Gene
gene	I-Gene
6	I-Gene
(	O
PAX6	B-Gene
)	O
gene	O
.	O
</ALL>	O

<ALL>	O
The	O
PAX6	B-Gene
gene	O
is	O
also	O
involved	O
in	O
other	O
anterior	B-Disease
segment	I-Disease
malformations	I-Disease
including	O
Peters	B-Disease
anomaly	I-Disease
.	O
</ALL>	O

<ALL>	O
We	O
studied	O
the	O
PAX6	B-Gene
gene	O
mutations	O
in	O
a	O
cohort	O
of	O
affected	O
individuals	O
with	O
different	O
clinical	O
phenotype	O
including	O
AN	B-Disease
,	O
coloboma	B-Disease
of	I-Disease
iris	I-Disease
and	I-Disease
choroid	I-Disease
,	O
or	O
anterior	B-Disease
segment	I-Disease
malformations	I-Disease
.	O
</ALL>	O

<ALL>	O
PATIENTS	B-Species
AND	O
METHODS	O
:	O
Six	O
unrelated	O
families	O
and	O
10	O
sporadic	O
patients	B-Species
were	O
examined	O
clinically	O
.	O
</ALL>	O

<ALL>	O
After	O
informed	O
consent	O
was	O
obtained	O
,	O
genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
venous	O
blood	O
of	O
all	O
participants	O
.	O
</ALL>	O

<ALL>	O
Mutation	O
screening	O
of	O
all	O
exons	O
of	O
the	O
PAX6	B-Gene
gene	O
was	O
performed	O
by	O
direct	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
DNA	O
fragments	O
.	O
</ALL>	O

<ALL>	O
Multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MLPA	O
)	O
was	O
performed	O
to	O
detect	O
large	O
deletions	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
By	O
clinical	O
examination	O
,	O
the	O
patients	B-Species
and	O
the	O
pedigrees	O
were	O
divided	O
into	O
the	O
following	O
three	O
groups	O
:	O
AN	B-Disease
,	O
coloboma	B-Disease
of	I-Disease
iris	I-Disease
and	I-Disease
choroids	I-Disease
,	O
and	O
the	O
anterior	B-Disease
segment	I-Disease
malformations	I-Disease
including	O
peters	B-Disease
anomaly	I-Disease
.	O
</ALL>	O

<ALL>	O
Sequencing	O
of	O
the	O
PAX6	B-Gene
gene	O
,	O
three	O
intragenic	O
mutations	O
including	O
a	O
novel	O
heterozygous	O
splicing	O
-	O
site	O
mutations	O
c.357	B-Variant
-	I-Variant
3C	I-Variant
>	I-Variant
G	I-Variant
(	O
p	B-Variant
.	I-Variant
Ser119fsX	I-Variant
)	O
were	O
identified	O
in	O
the	O
patients	B-Species
of	O
the	O
AN	B-Disease
group	O
.	O
</ALL>	O

<ALL>	O
A	O
novel	O
missense	O
mutation	O
c.643	B-Variant
T	I-Variant
>	I-Variant
C	I-Variant
(	O
p	B-Variant
.	I-Variant
S216P	I-Variant
)	O
was	O
detected	O
in	O
the	O
anterior	B-Disease
segment	I-Disease
malformation	I-Disease
group	O
.	O
</ALL>	O

<ALL>	O
The	O
mutation	O
p	B-Variant
.	I-Variant
S216P	I-Variant
located	O
in	O
the	O
homeodomain	O
region	O
of	O
the	O
PAX6	B-Gene
caused	O
the	O
phenotype	O
of	O
Peters	B-Disease
anomaly	I-Disease
in	O
family	O
A6	O
with	O
different	O
expressing	O
.	O
</ALL>	O

<ALL>	O
Through	O
MLPA	O
analysis	O
,	O
a	O
large	O
deletion	O
including	O
the	O
whole	O
PAX6	B-Gene
gene	O
and	O
DKFZ	B-Gene
p686k1684	I-Gene
gene	O
was	O
detected	O
in	O
one	O
sporadic	O
patient	B-Species
from	O
the	O
AN	B-Disease
group	O
.	O
</ALL>	O

<ALL>	O
Neither	O
intragenic	O
mutation	O
nor	O
large	O
deletion	O
was	O
identified	O
in	O
the	O
group	O
with	O
coloboma	B-Disease
of	I-Disease
iris	I-Disease
and	I-Disease
choroid	I-Disease
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Our	O
findings	O
further	O
confirmed	O
that	O
different	O
kind	O
of	O
mutations	O
might	O
cause	O
different	O
ocular	O
phenotype	O
,	O
and	O
clearly	O
clinical	O
phenotype	O
classification	O
might	O
increase	O
the	O
mutation	O
detection	O
rate	O
of	O
the	O
PAX6	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Effects	O
of	O
ginsenosides	B-Chemical
on	O
opioid	B-Chemical
-	O
induced	O
hyperalgesia	B-Disease
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Opioid	B-Chemical
-	O
induced	O
hyperalgesia	B-Disease
(	O
OIH	B-Disease
)	O
is	O
characterized	O
by	O
nociceptive	O
sensitization	O
caused	O
by	O
the	O
cessation	O
of	O
chronic	O
opioid	B-Chemical
use	O
.	O
</ALL>	O

<ALL>	O
OIH	B-Disease
can	O
limit	O
the	O
clinical	O
use	O
of	O
opioid	B-Chemical
analgesics	O
and	O
complicate	O
withdrawal	O
from	O
opioid	B-Disease
addiction	I-Disease
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
Re	B-Chemical
,	I-Chemical
Rg1	I-Chemical
,	I-Chemical
and	I-Chemical
Rb1	I-Chemical
ginsenosides	I-Chemical
,	O
the	O
bioactive	O
components	O
of	O
ginseng	B-Species
,	O
on	O
OIH	B-Disease
.	O
</ALL>	O

<ALL>	O
OIH	B-Disease
was	O
achieved	O
in	O
mice	B-Species
after	O
subcutaneous	O
administration	O
of	O
morphine	B-Chemical
for	O
7	O
consecutive	O
days	O
three	O
times	O
per	O
day	O
.	O
</ALL>	O

<ALL>	O
During	O
withdrawal	O
(	O
days	O
8	O
and	O
9	O
)	O
,	O
these	O
mice	B-Species
were	O
administered	O
Re	B-Chemical
,	O
Rg1	B-Chemical
,	O
or	O
Rb1	B-Chemical
intragastrically	O
two	O
times	O
per	O
day	O
.	O
</ALL>	O

<ALL>	O
On	O
the	O
test	O
day	O
(	O
day	O
10	O
)	O
,	O
mice	B-Species
were	O
subjected	O
to	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	B-Chemical
acid	I-Chemical
-	O
induced	O
writhing	O
test	O
.	O
</ALL>	O

<ALL>	O
Re	B-Chemical
(	O
300	O
mg	O
/	O
kg	O
)	O
inhibited	O
OIH	B-Disease
in	O
both	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	B-Chemical
acid	I-Chemical
-	O
induced	O
writhing	O
test	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
Rg1	B-Chemical
and	I-Chemical
Rb1	I-Chemical
ginsenosides	I-Chemical
failed	O
to	O
prevent	O
OIH	B-Disease
in	O
either	O
test	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
Rg1	B-Chemical
showed	O
a	O
tendency	O
to	O
aggravate	O
OIH	B-Disease
in	O
the	O
acetic	B-Chemical
acid	I-Chemical
-	O
induced	O
writhing	O
test	O
.	O
</ALL>	O

<ALL>	O
Our	O
data	O
suggested	O
that	O
the	O
ginsenoside	B-Chemical
Re	I-Chemical
,	O
but	O
not	O
Rg1	B-Chemical
or	O
Rb1	B-Chemical
,	O
may	O
contribute	O
toward	O
reversal	O
of	O
OIH	B-Disease
.	O
</ALL>	O

<ALL>	O
Long	O
-	O
Lived	O
CD4	B-Gene
+	O
IFN	B-Gene
-	I-Gene
g	I-Gene
+	O
T	O
Cells	O
rather	O
than	O
Short	O
-	O
Lived	O
CD4	B-Gene
+	O
IFN	B-Gene
-	I-Gene
g	I-Gene
+	O
IL	B-Gene
-	I-Gene
10	I-Gene
+	O
T	O
Cells	O
Initiate	O
Rapid	O
IL	B-Gene
-	I-Gene
10	I-Gene
Production	O
To	O
Suppress	O
Anamnestic	O
T	O
Cell	O
Responses	O
during	O
Secondary	O
Malaria	B-Disease
Infection	I-Disease
.	O
</ALL>	O

<ALL>	O
CD4	B-Gene
(	O
+	O
)	O
T	O
cells	O
that	O
produce	O
IFN	B-Gene
-	I-Gene
g	I-Gene
are	O
the	O
source	O
of	O
host	O
-	O
protective	O
IL	B-Gene
-	I-Gene
10	I-Gene
during	O
primary	O
infection	B-Disease
with	O
a	O
number	O
of	O
different	O
pathogens	O
,	O
including	O
Plasmodium	O
spp	O
.	O
</ALL>	O

<ALL>	O
The	O
fate	O
of	O
these	O
CD4	B-Gene
(	O
+	O
)	O
IFN	B-Gene
-	I-Gene
g	I-Gene
(	O
+	O
)	O
IL	B-Gene
-	I-Gene
10	I-Gene
(	O
+	O
)	O
T	O
cells	O
following	O
clearance	O
of	O
primary	O
infection	B-Disease
and	O
their	O
subsequent	O
influence	O
on	O
the	O
course	O
of	O
repeated	O
infections	O
is	O
,	O
however	O
,	O
presently	O
unknown	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
utilizing	O
IFN	B-Gene
-	I-Gene
g	I-Gene
-	O
yellow	O
fluorescent	O
protein	O
(	O
YFP	O
)	O
and	O
IL	B-Gene
-	I-Gene
10	I-Gene
-	O
GFP	O
dual	O
reporter	O
mice	B-Species
,	O
we	O
show	O
that	O
primary	O
malaria	B-Disease
infection	I-Disease
-	O
induced	O
CD4	B-Gene
(	O
+	O
)	O
YFP	O
(	O
+	O
)	O
GFP	O
(	O
+	O
)	O
T	O
cells	O
have	O
limited	O
memory	O
potential	O
,	O
do	O
not	O
stably	O
express	O
IL	B-Gene
-	I-Gene
10	I-Gene
,	O
and	O
are	O
disproportionately	O
lost	O
from	O
the	O
Ag	O
-	O
experienced	O
CD4	B-Gene
(	O
+	O
)	O
T	O
cell	O
memory	O
population	O
during	O
the	O
maintenance	O
phase	O
postinfection	O
.	O
</ALL>	O

<ALL>	O
CD4	B-Gene
(	O
+	O
)	O
YFP	O
(	O
+	O
)	O
GFP	O
(	O
+	O
)	O
T	O
cells	O
generally	O
exhibited	O
a	O
short	O
-	O
lived	O
effector	O
rather	O
than	O
effector	O
memory	O
T	O
cell	O
phenotype	O
postinfection	O
and	O
expressed	O
high	O
levels	O
of	O
PD	B-Gene
-	I-Gene
1	I-Gene
,	O
Lag	B-Gene
-	I-Gene
3	I-Gene
,	O
and	O
TIGIT	B-Gene
,	O
indicative	O
of	O
cellular	O
exhaustion	O
.	O
</ALL>	O

<ALL>	O
Consistently	O
,	O
the	O
surviving	O
CD4	B-Gene
(	O
+	O
)	O
YFP	O
(	O
+	O
)	O
GFP	O
(	O
+	O
)	O
T	O
cell	O
-	O
derived	O
cells	O
were	O
unresponsive	O
and	O
failed	O
to	O
proliferate	O
during	O
the	O
early	O
phase	O
of	O
secondary	O
infection	B-Disease
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
CD4	B-Gene
(	O
+	O
)	O
YFP	O
(	O
+	O
)	O
GFP	O
(	O
-	O
)	O
T	O
cell	O
-	O
derived	O
cells	O
expanded	O
rapidly	O
and	O
upregulated	O
IL	B-Gene
-	I-Gene
10	I-Gene
expression	O
during	O
secondary	O
infection	B-Disease
.	O
</ALL>	O

<ALL>	O
Correspondingly	O
,	O
CD4	B-Gene
(	O
+	O
)	O
T	O
cells	O
were	O
the	O
major	O
producers	O
within	O
an	O
accelerated	O
and	O
amplified	O
IL	B-Gene
-	I-Gene
10	I-Gene
response	O
during	O
the	O
early	O
stage	O
of	O
secondary	O
malaria	B-Disease
infection	I-Disease
.	O
</ALL>	O

<ALL>	O
Notably	O
,	O
IL	B-Gene
-	I-Gene
10	I-Gene
exerted	O
quantitatively	O
stronger	O
regulatory	O
effects	O
on	O
innate	O
and	O
CD4	B-Gene
(	O
+	O
)	O
T	O
cell	O
responses	O
during	O
primary	O
and	O
secondary	O
infections	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
in	O
this	O
study	O
significantly	O
improve	O
our	O
understanding	O
of	O
the	O
durability	O
of	O
IL	B-Gene
-	I-Gene
10	I-Gene
-	O
producing	O
CD4	B-Gene
(	O
+	O
)	O
T	O
cells	O
postinfection	O
and	O
provide	O
information	O
on	O
how	O
IL	B-Gene
-	I-Gene
10	I-Gene
may	O
contribute	O
to	O
optimized	O
parasite	O
control	O
and	O
prevention	O
of	O
immune	O
-	O
mediated	O
pathology	O
during	O
repeated	O
malaria	B-Disease
infections	I-Disease
.	O
</ALL>	O

<ALL>	O
Atorvastatin	B-Chemical
protects	O
against	O
contrast	B-Disease
-	I-Disease
induced	I-Disease
nephropathy	I-Disease
via	O
anti	O
-	O
apoptosis	O
by	O
the	O
upregulation	O
of	O
Hsp27	B-Gene
in	O
vivo	O
and	O
in	O
vitro	O
.	O
</ALL>	O

<ALL>	O
Contrast	B-Disease
-	I-Disease
induced	I-Disease
nephropathy	I-Disease
(	O
CIN	B-Disease
)	O
is	O
an	O
iatrogenic	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
occurring	O
following	O
the	O
intravascular	O
injection	O
of	O
iodinated	O
radiographic	O
contrast	O
medium	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
regulatory	O
mechanisms	O
for	O
CIN	B-Disease
remain	O
to	O
be	O
fully	O
elucidated	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
aimed	O
to	O
investigate	O
whether	O
atorvastatin	B-Chemical
protects	O
against	O
CIN	B-Disease
via	O
anti	O
-	O
apoptotic	O
effects	O
by	O
the	O
upregulation	O
of	O
Hsp27	B-Gene
in	O
vivo	O
and	O
in	O
vitro	O
.	O
</ALL>	O

<ALL>	O
To	O
determine	O
whether	O
atorvastatin	B-Chemical
attenuated	O
CIN	B-Disease
,	O
the	O
inflammatory	B-Disease
response	O
and	O
apoptosis	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
a	O
rat	B-Species
model	O
of	O
iopamidol	B-Chemical
-	O
induced	O
CIN	B-Disease
was	O
used	O
,	O
and	O
human	B-Species
embryonic	O
proximal	O
tubule	O
(	O
HK2	B-CellLine
)	O
cell	O
damage	O
was	O
assessed	O
.	O
</ALL>	O

<ALL>	O
The	O
rats	B-Species
were	O
assigned	O
into	O
four	O
groups	O
(	O
n	O
=	O
10	O
per	O
group	O
)	O
,	O
as	O
follows	O
:	O
Control	O
rats	B-Species
;	O
rats	B-Species
+	O
atorvastatin	B-Chemical
;	O
rats	B-Species
+	O
iopamidol	B-Chemical
;	O
rats	B-Species
+	O
iopamidol	B-Chemical
+	O
atorvastatin	B-Chemical
.	O
</ALL>	O

<ALL>	O
In	O
vitro	O
,	O
the	O
HK2	B-CellLine
cells	O
were	O
treated	O
with	O
iopamidol	B-Chemical
in	O
the	O
presence	O
or	O
absence	O
of	O
atorvastatin	B-Chemical
,	O
heat	B-Gene
shock	I-Gene
protein	I-Gene
(	I-Gene
Hsp	I-Gene
)	I-Gene
27	I-Gene
small	O
interfering	O
(	O
si	O
)	O
RNA	O
or	O
pcDNA3.1	O
-	O
Hsp27	B-Gene
.	O
</ALL>	O

<ALL>	O
The	O
renal	O
tissues	O
were	O
examined	O
histopathologically	O
and	O
collected	O
for	O
western	O
blot	O
analysis	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
showed	O
that	O
atorvastatin	B-Chemical
ameliorated	O
the	O
apoptosis	B-Disease
and	I-Disease
deterioration	I-Disease
of	I-Disease
renal	I-Disease
function	I-Disease
(	O
P	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
atorvastatin	B-Chemical
reduced	O
the	O
iopamidol	B-Chemical
-	O
induced	O
activity	O
of	O
B	B-Gene
cell	I-Gene
lymphoma	I-Gene
-	I-Gene
2	I-Gene
(	I-Gene
Bcl	I-Gene
-	I-Gene
2	I-Gene
)	I-Gene
-	I-Gene
associated	I-Gene
X	I-Gene
protein	I-Gene
(	O
Bax	B-Gene
)	O
/	O
caspase	B-Gene
-	I-Gene
3	I-Gene
and	O
increased	O
the	O
expression	O
of	O
Bcl	B-Gene
-	I-Gene
2	I-Gene
in	O
vivo	O
and	O
in	O
vitro	O
.	O
</ALL>	O

<ALL>	O
Notably	O
,	O
following	O
treatment	O
with	O
Hsp27	B-Gene
siRNA	O
or	O
pcDNA3.1	O
-	O
Hsp27	B-Gene
,	O
it	O
was	O
found	O
that	O
iopamidol	B-Chemical
enhanced	O
or	O
weakened	O
the	O
upregulation	O
of	O
Bax	B-Gene
/	O
caspase	B-Gene
-	I-Gene
3	I-Gene
and	O
downregulation	O
of	O
Bcl	B-Gene
-	I-Gene
2	I-Gene
in	O
the	O
HK2	B-CellLine
cells	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
of	O
the	O
present	O
study	O
suggested	O
that	O
atorvastatin	B-Chemical
protected	O
against	O
contrast	B-Disease
-	I-Disease
induced	I-Disease
renal	I-Disease
tubular	I-Disease
cell	I-Disease
apoptosis	I-Disease
through	O
the	O
upregulation	O
of	O
Hsp27	B-Gene
in	O
vivo	O
and	O
in	O
vitro	O
.	O
</ALL>	O

<ALL>	O
Deletion	O
of	O
endothelial	O
cell	O
-	O
specific	O
liver	B-Gene
kinase	I-Gene
B1	I-Gene
increases	O
angiogenesis	O
and	O
tumor	B-Disease
growth	O
via	O
vascular	B-Gene
endothelial	I-Gene
growth	I-Gene
factor	I-Gene
.	O
</ALL>	O

<ALL>	O
Liver	B-Gene
kinase	I-Gene
B1	I-Gene
(	O
LKB1	B-Gene
)	O
is	O
a	O
serine	B-Gene
/	I-Gene
threonine	I-Gene
protein	I-Gene
kinase	I-Gene
ubiquitously	O
expressed	O
in	O
mammalian	O
cells	O
.	O
</ALL>	O

<ALL>	O
It	O
was	O
first	O
identified	O
in	O
Peutz	B-Disease
-	I-Disease
Jeghers	I-Disease
syndrome	I-Disease
as	O
a	O
tumor	B-Disease
suppressor	O
gene	O
.	O
</ALL>	O

<ALL>	O
Whether	O
endothelial	O
LKB1	B-Gene
regulates	O
angiogenesis	O
and	O
tumor	B-Disease
growth	O
is	O
unknown	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
generated	O
endothelial	O
cell	O
-	O
specific	O
LKB1	B-Gene
-	O
knockout	O
(	O
LKB1	B-Gene
(	O
endo	O
-	O
/	O
-	O
)	O
)	O
mice	B-Species
by	O
crossbreeding	O
vascular	B-Gene
endothelial	I-Gene
-	I-Gene
cadherin	I-Gene
-	O
Cre	O
mice	B-Species
with	O
LKB1	B-Gene
(	O
flox	O
/	O
flox	O
)	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Vascular	B-Gene
endothelial	I-Gene
growth	I-Gene
factor	I-Gene
(	O
VEGF	B-Gene
)	O
level	O
was	O
highly	O
co	O
-	O
stained	O
in	O
endothelial	O
cells	O
but	O
not	O
in	O
macrophages	O
in	O
LKB1	B-Gene
(	O
endo	O
-	O
/	O
-	O
)	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Consistently	O
,	O
LKB1	B-Gene
(	O
endo	O
-	O
/	O
-	O
)	O
mouse	B-Species
tissues	O
including	O
the	O
lung	O
,	O
skin	O
,	O
kidney	O
and	O
liver	O
showed	O
increased	O
vascular	O
permeability	O
.	O
</ALL>	O

<ALL>	O
Tumors	B-Disease
implanted	O
in	O
LKB1	B-Gene
(	O
endo	O
-	O
/	O
-	O
)	O
mice	B-Species
but	O
not	O
macrophage	O
-	O
specific	O
LKB1	B-Gene
-	O
knockout	O
mice	B-Species
grew	O
faster	O
and	O
showed	O
enhanced	O
vascular	O
permeability	O
and	O
increased	O
angiogenesis	O
as	O
compared	O
with	O
those	O
implanted	O
in	O
wild	O
-	O
type	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Injection	O
of	O
VEGF	B-Gene
-	O
neutralizing	O
antibody	O
but	O
not	O
the	O
isotype	O
-	O
matched	O
control	O
antibody	O
decreased	O
endothelial	O
-	O
cell	O
angiogenesis	O
and	O
tumor	B-Disease
growth	O
in	O
vivo	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
LKB1	B-Gene
deletion	O
enhanced	O
mouse	B-Species
retinal	O
and	O
cell	O
angiogenesis	O
,	O
and	O
knockdown	O
of	O
VEGF	B-Gene
by	O
small	O
-	O
interfering	O
RNA	O
decreased	O
endothelial	O
cell	O
proliferation	O
and	O
migration	O
.	O
</ALL>	O

<ALL>	O
Re	O
-	O
expression	O
of	O
LKB1	B-Gene
or	O
knockdown	O
of	O
VEGF	B-Gene
receptor	I-Gene
2	I-Gene
decreased	O
the	O
overproliferation	O
and	O
-	O
migration	O
observed	O
in	O
LKB1	B-Gene
(	O
endo	O
-	O
/	O
-	O
)	O
cells	O
.	O
</ALL>	O

<ALL>	O
Mechanistically	O
,	O
LKB1	B-Gene
could	O
bind	O
to	O
the	O
VEGF	B-Gene
transcription	O
factor	O
,	O
specificity	B-Gene
protein	I-Gene
1	I-Gene
(	O
Sp1	B-Gene
)	O
,	O
which	O
then	O
inhibited	O
the	O
binding	O
of	O
Sp1	B-Gene
to	O
the	O
VEGF	B-Gene
promoter	O
to	O
reduce	O
VEGF	B-Gene
expression	O
.	O
</ALL>	O

<ALL>	O
Endothelial	O
LKB1	B-Gene
may	O
regulate	O
endothelial	O
angiogenesis	O
and	O
tumor	B-Disease
growth	O
by	O
modulating	O
Sp1	B-Gene
-	O
mediated	O
VEGF	B-Gene
expression	O
.	O
</ALL>	O

<ALL>	O
Paraoxonase	B-Gene
1	I-Gene
polymorphisms	O
and	O
survival	O
.	O
</ALL>	O

<ALL>	O
The	O
antioxidant	O
enzyme	O
paraoxonase	B-Gene
1	I-Gene
(	O
PON1	B-Gene
)	O
has	O
previously	O
been	O
suggested	O
to	O
confer	O
protection	O
against	O
coronary	B-Disease
heart	I-Disease
disease	I-Disease
(	O
CHD	B-Disease
)	O
,	O
one	O
of	O
the	O
main	O
causes	O
of	O
death	B-Disease
in	O
the	O
Western	O
world	O
.	O
</ALL>	O

<ALL>	O
Two	O
coding	O
polymorphisms	O
,	O
55	B-Variant
M	I-Variant
/	I-Variant
L	I-Variant
and	O
192Q	B-Variant
/	I-Variant
R	I-Variant
,	O
and	O
a	O
promoter	O
variant	O
,	O
-	B-Variant
107C	I-Variant
/	I-Variant
T	I-Variant
,	O
has	O
been	O
extensively	O
studied	O
with	O
respect	O
to	O
susceptibility	O
to	O
CHD	B-Disease
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
impact	O
of	O
these	O
three	O
polymorphisms	O
on	O
mortality	O
using	O
a	O
sample	O
of	O
1932	O
Danish	O
individuals	O
aged	O
47	O
-	O
93	O
years	O
,	O
previously	O
used	O
in	O
gene	O
-	O
longevity	O
studies	O
.	O
</ALL>	O

<ALL>	O
A	O
cross	O
-	O
sectional	O
study	O
comparing	O
the	O
genotype	O
distribution	O
of	O
the	O
three	O
polymorphisms	O
separately	O
as	O
well	O
as	O
the	O
haplotype	O
distribution	O
in	O
different	O
age	O
groups	O
did	O
not	O
reveal	O
any	O
difference	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
a	O
longitudinal	O
follow	O
-	O
up	O
study	O
on	O
survival	O
in	O
the	O
same	O
sample	O
indicated	O
that	O
192RR	B-Variant
homozygotes	O
have	O
a	O
poorer	O
survival	O
compared	O
to	O
QQ	O
homozygotes	O
(	O
hazard	O
rate	O
:	O
1.38	O
,	O
P	O
=	O
0.04	O
)	O
.	O
</ALL>	O

<ALL>	O
We	O
hereafter	O
used	O
an	O
independent	O
sample	O
of	O
541	O
Danish	O
individuals	O
from	O
the	O
oldest	O
cohort	O
and	O
confirmed	O
the	O
initial	O
findings	O
(	O
hazard	O
rate	O
:	O
1.38	O
,	O
P	O
=	O
0.09	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
both	O
samples	O
,	O
the	O
effect	O
was	O
most	O
pronounced	O
in	O
women	B-Species
.	O
</ALL>	O

<ALL>	O
Using	O
self	O
-	O
reported	O
data	O
on	O
ischemic	B-Disease
heart	I-Disease
disease	I-Disease
to	O
evaluate	O
the	O
impact	O
of	O
the	O
PON	B-Gene
192Q	B-Variant
/	I-Variant
R	I-Variant
polymorphism	O
on	O
susceptibility	O
to	O
CHD	B-Disease
,	O
we	O
found	O
only	O
a	O
nonsignificant	O
trend	O
of	O
192RR	B-Variant
homozygosity	O
in	O
women	B-Species
being	O
a	O
risk	O
factor	O
.	O
</ALL>	O

<ALL>	O
Our	O
results	O
thus	O
indicates	O
that	O
PON1	B-Gene
192RR	B-Variant
homozygosity	O
is	O
associated	O
with	O
increased	O
mortality	O
in	O
women	B-Species
in	O
the	O
second	O
half	O
of	O
life	O
and	O
that	O
this	O
increased	O
mortality	O
is	O
possibly	O
related	O
to	O
CHD	B-Disease
severity	O
and	O
survival	O
after	O
CHD	B-Disease
rather	O
than	O
susceptibility	O
to	O
development	O
of	O
CHD	B-Disease
.	O
</ALL>	O

<ALL>	O
Human	B-Species
TBX1	B-Gene
missense	O
mutations	O
cause	O
gain	O
of	O
function	O
resulting	O
in	O
the	O
same	O
phenotype	O
as	O
22q11.2	B-Disease
deletions	I-Disease
.	O
</ALL>	O

<ALL>	O
Deletion	B-Disease
22q11.2	I-Disease
syndrome	I-Disease
is	O
the	O
most	O
frequent	O
known	O
microdeletion	O
syndrome	O
and	O
is	O
associated	O
with	O
a	O
highly	O
variable	O
phenotype	O
,	O
including	O
DiGeorge	B-Disease
and	I-Disease
Shprintzen	I-Disease
(	I-Disease
velocardiofacial	I-Disease
)	I-Disease
syndromes	I-Disease
.	O
</ALL>	O

<ALL>	O
Although	O
haploinsufficiency	O
of	O
the	O
T	B-Gene
-	I-Gene
box	I-Gene
transcription	I-Gene
factor	I-Gene
gene	O
TBX1	B-Gene
is	O
thought	O
to	O
cause	O
the	O
phenotype	O
,	O
to	O
date	O
,	O
only	O
four	O
different	O
point	O
mutations	O
in	O
TBX1	B-Gene
have	O
been	O
reported	O
in	O
association	O
with	O
six	O
of	O
the	O
major	O
features	O
of	O
22q11.2	B-Disease
deletion	I-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Although	O
,	O
for	O
the	O
two	O
truncating	O
mutations	O
,	O
loss	O
of	O
function	O
was	O
previously	O
shown	O
,	O
the	O
pathomechanism	O
of	O
the	O
missense	O
mutations	O
remains	O
unknown	O
.	O
</ALL>	O

<ALL>	O
We	O
report	O
a	O
novel	O
heterozygous	O
missense	O
mutation	O
,	O
H194Q	B-Variant
,	O
in	O
a	O
familial	O
case	O
of	O
Shprintzen	B-Disease
syndrome	I-Disease
and	O
show	O
that	O
this	O
and	O
the	O
two	O
previously	O
reported	O
missense	O
mutations	O
result	O
in	O
gain	O
of	O
function	O
,	O
possibly	O
through	O
stabilization	O
of	O
the	O
protein	O
dimer	O
DNA	O
complex	O
.	O
</ALL>	O

<ALL>	O
We	O
therefore	O
conclude	O
that	O
TBX1	B-Gene
gain	O
-	O
of	O
-	O
function	O
mutations	O
can	O
result	O
in	O
the	O
same	O
phenotypic	O
spectrum	O
as	O
haploinsufficiency	O
caused	O
by	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
or	O
deletions	O
.	O
</ALL>	O

<ALL>	O
Polymorphic	O
MLH1	B-Gene
and	O
risk	O
of	O
cancer	B-Disease
after	O
methylating	O
chemotherapy	O
for	O
Hodgkin	B-Disease
lymphoma	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Methylating	O
agents	O
are	O
effective	O
chemotherapy	O
agents	O
for	O
Hodgkin	B-Disease
lymphoma	I-Disease
,	O
but	O
are	O
associated	O
with	O
the	O
development	O
of	O
second	O
primary	O
cancers	B-Disease
.	O
</ALL>	O

<ALL>	O
Cytotoxicity	B-Disease
of	O
methylating	O
agents	O
is	O
mediated	O
primarily	O
by	O
the	O
DNA	O
mismatch	O
repair	O
(	O
MMR	O
)	O
system	O
.	O
</ALL>	O

<ALL>	O
Loss	O
of	O
MLH1	B-Gene
,	O
a	O
major	O
component	O
of	O
DNA	O
MMR	O
,	O
results	O
in	O
tolerance	O
to	O
the	O
cytotoxic	B-Disease
effects	O
of	O
methylating	O
agents	O
and	O
persistence	O
of	O
mutagenised	O
cells	O
at	O
high	O
risk	O
of	O
malignant	O
transformation	O
.	O
</ALL>	O

<ALL>	O
We	O
hypothesised	O
that	O
a	O
common	O
substitution	O
in	O
the	O
basal	O
promoter	O
of	O
MLH1	B-Gene
(	O
position	O
-	O
93	O
,	O
rs1800734	B-Variant
)	O
modifies	O
the	O
risk	O
of	O
cancer	B-Disease
after	O
methylating	O
chemotherapy	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
133	O
patients	B-Species
who	O
developed	O
cancer	B-Disease
following	O
chemotherapy	O
and	O
/	O
or	O
radiotherapy	O
(	O
n	O
=	O
133	O
)	O
,	O
420	O
patients	B-Species
diagnosed	O
with	O
de	O
novo	O
myeloid	B-Disease
leukaemia	I-Disease
,	O
242	O
patients	B-Species
diagnosed	O
with	O
primary	B-Disease
Hodgkin	I-Disease
lymphoma	I-Disease
,	O
and	O
1177	O
healthy	O
controls	O
were	O
genotyped	O
for	O
the	O
MLH1	B-Gene
-	O
93	O
polymorphism	O
by	O
allelic	O
discrimination	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
assay	O
.	O
</ALL>	O

<ALL>	O
Odds	O
ratios	O
and	O
95	O
%	O
confidence	O
intervals	O
for	O
cancer	B-Disease
risk	O
by	O
MLH1	B-Gene
-	O
93	O
polymorphism	O
status	O
,	O
and	O
stratified	O
by	O
previous	O
exposure	O
to	O
methylating	O
chemotherapy	O
,	O
were	O
calculated	O
using	O
unconditional	O
logistic	O
regression	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Carrier	O
frequency	O
of	O
the	O
MLH1	B-Gene
-	O
93	O
variant	O
was	O
higher	O
in	O
patients	B-Species
who	O
developed	O
therapy	O
related	O
acute	B-Disease
myeloid	I-Disease
leukaemia	I-Disease
(	O
t	O
-	O
AML	B-Disease
)	O
(	O
75.0	O
%	O
,	O
n	O
=	O
12	O
)	O
or	O
breast	B-Disease
cancer	I-Disease
(	O
53.3	O
%	O
.	O
</ALL>	O

<ALL>	O
n	O
=	O
15	O
)	O
after	O
methylating	O
chemotherapy	O
for	O
Hodgkin	B-Disease
lymphoma	I-Disease
compared	O
to	O
patients	B-Species
without	O
previous	O
methylating	O
exposure	O
(	O
t	O
-	O
AML	B-Disease
,	O
30.4	O
%	O
,	O
n	O
=	O
69	O
;	O
breast	B-Disease
cancer	I-Disease
patients	B-Species
,	O
27.2	O
%	O
,	O
n	O
=	O
22	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
MLH1	B-Gene
-	O
93	O
variant	O
allele	O
was	O
also	O
over	O
-	O
represented	O
in	O
t	O
-	O
AML	B-Disease
cases	O
when	O
compared	O
to	O
de	O
novo	O
AML	B-Disease
cases	O
(	O
36.9	O
%	O
,	O
n	O
=	O
420	O
)	O
and	O
healthy	O
controls	O
(	O
36.3	O
%	O
,	O
n	O
=	O
952	O
)	O
,	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
increased	O
risk	O
of	O
developing	O
t	O
-	O
AML	B-Disease
(	O
odds	O
ratio	O
5.31	O
,	O
95	O
%	O
confidence	O
interval	O
1.40	O
to	O
20.15	O
)	O
,	O
but	O
only	O
in	O
patients	B-Species
previously	O
treated	O
with	O
a	O
methylating	O
agent	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
These	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
common	O
polymorphism	O
at	O
position	O
-	O
93	O
in	O
the	O
core	O
promoter	O
of	O
MLH1	B-Gene
defines	O
a	O
risk	O
allele	O
for	O
the	O
development	O
of	O
cancer	B-Disease
after	O
methylating	O
chemotherapy	O
for	O
Hodgkin	B-Disease
lymphoma	I-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
replication	O
of	O
this	O
finding	O
in	O
larger	O
studies	O
is	O
suggested	O
.	O
</ALL>	O

<ALL>	O
Identification	O
of	O
novel	O
susceptibility	O
genes	O
in	O
childhood	O
-	O
onset	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
using	O
a	O
uniquely	O
designed	O
candidate	O
gene	O
pathway	O
platform	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
Childhood	O
-	O
onset	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
(	O
SLE	B-Disease
)	O
presents	O
a	O
unique	O
subgroup	O
of	O
patients	B-Species
for	O
genetic	O
study	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
was	O
undertaken	O
to	O
identify	O
susceptibility	O
genes	O
contributing	O
to	O
SLE	B-Disease
,	O
using	O
a	O
novel	O
candidate	O
gene	O
pathway	O
microarray	O
platform	O
to	O
investigate	O
gene	O
expression	O
in	O
patients	B-Species
with	O
childhood	O
-	O
onset	O
SLE	B-Disease
and	O
both	O
of	O
their	O
parents	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Utilizing	O
bioinformatic	O
tools	O
,	O
a	O
platform	O
of	O
9,412	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
from	O
1,204	O
genes	O
was	O
designed	O
and	O
validated	O
.	O
</ALL>	O

<ALL>	O
Molecular	O
inversion	O
probes	O
and	O
high	O
-	O
throughput	O
SNP	O
technologies	O
were	O
used	O
for	O
assay	O
development	O
.	O
</ALL>	O

<ALL>	O
Seven	O
hundred	O
fifty	O
three	O
subjects	O
,	O
corresponding	O
to	O
251	O
full	O
trios	O
of	O
childhood	O
-	O
onset	O
SLE	B-Disease
families	O
,	O
were	O
genotyped	O
and	O
analyzed	O
using	O
transmission	O
disequilibrium	O
testing	O
(	O
TDT	O
)	O
and	O
multitest	O
corrections	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Family	O
-	O
based	O
TDT	O
showed	O
a	O
significant	O
association	O
of	O
SLE	B-Disease
with	O
a	O
N673S	B-Variant
polymorphism	O
in	O
the	O
P	B-Gene
-	I-Gene
selectin	I-Gene
gene	O
(	O
SELP	B-Gene
)	O
(	O
P	O
=	O
5.74	O
x	O
10	O
(	O
-	O
6	O
)	O
)	O
and	O
a	O
C203S	B-Variant
polymorphism	O
in	O
the	O
interleukin	B-Gene
-	I-Gene
1	I-Gene
receptor	I-Gene
-	I-Gene
associated	I-Gene
kinase	I-Gene
1	I-Gene
gene	O
(	O
IRAK1	B-Gene
)	O
(	O
P	O
=	O
9.58	O
x	O
10	O
(	O
-	O
6	O
)	O
)	O
.	O
</ALL>	O

<ALL>	O
These	O
2	O
SNPs	O
had	O
a	O
false	O
discovery	O
rate	O
for	O
multitest	O
correction	O
of	O
<	O
0.05	O
,	O
and	O
therefore	O
a	O
>	O
95	O
%	O
probability	O
of	O
being	O
considered	O
as	O
proven	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
7	O
additional	O
SNPs	O
showed	O
q	O
values	O
of	O
<	O
0.5	O
,	O
suggesting	O
association	O
with	O
SLE	B-Disease
and	O
providing	O
a	O
direction	O
for	O
followup	O
studies	O
.	O
</ALL>	O

<ALL>	O
These	O
additional	O
genes	O
notably	O
included	O
TNFRSF6	B-Gene
(	O
Fas	B-Gene
)	O
and	O
IRF5	B-Gene
,	O
supporting	O
previous	O
findings	O
of	O
their	O
association	O
with	O
SLE	B-Disease
pathogenesis	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
SELP	B-Gene
and	O
IRAK1	B-Gene
were	O
identified	O
as	O
novel	O
SLE	B-Disease
-	O
associated	O
genes	O
with	O
a	O
high	O
degree	O
of	O
significance	O
,	O
suggesting	O
new	O
directions	O
in	O
understanding	O
the	O
pathogenesis	O
of	O
SLE	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
overall	O
design	O
and	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
the	O
candidate	O
gene	O
pathway	O
microarray	O
platform	O
used	O
provides	O
a	O
novel	O
and	O
powerful	O
approach	O
that	O
is	O
generally	O
applicable	O
in	O
identifying	O
genetic	O
foundations	O
of	O
complex	O
diseases	O
.	O
</ALL>	O

<ALL>	O
Protective	O
effects	O
of	O
antithrombin	B-Chemical
on	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	B-Disease
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
We	O
investigated	O
the	O
effects	O
of	O
antithrombin	B-Chemical
,	O
a	O
plasma	O
inhibitor	O
of	O
coagulation	O
factors	O
,	O
in	O
rats	B-Species
with	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
nephrosis	B-Disease
,	O
which	O
is	O
an	O
experimental	O
model	O
of	O
human	B-Species
nephrotic	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Antithrombin	B-Chemical
(	O
50	O
or	O
500	O
IU	O
/	O
kg	O
/	O
i.v	O
.	O
)	O
</ALL>	O

<ALL>	O
was	O
administered	O
to	O
rats	B-Species
once	O
a	O
day	O
for	O
10	O
days	O
immediately	O
after	O
the	O
injection	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
50	O
mg	O
/	O
kg	O
/	O
i.v	O
.	O
)	O
.	O
</ALL>	O

<ALL>	O
Treatment	O
with	O
antithrombin	B-Chemical
attenuated	O
the	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
hematological	B-Disease
abnormalities	I-Disease
.	O
</ALL>	O

<ALL>	O
Puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
renal	B-Disease
dysfunction	I-Disease
and	O
hyperlipidemia	B-Disease
were	O
also	O
suppressed	O
.	O
</ALL>	O

<ALL>	O
Histopathological	O
examination	O
revealed	O
severe	O
renal	B-Disease
damage	I-Disease
such	O
as	O
proteinaceous	O
casts	O
in	O
tubuli	O
and	O
tubular	O
expansion	O
in	O
the	O
kidney	O
of	O
control	O
rats	B-Species
,	O
while	O
an	O
improvement	O
of	O
the	O
damage	O
was	O
seen	O
in	O
antithrombin	B-Chemical
-	O
treated	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
antithrombin	B-Chemical
treatment	O
markedly	O
suppressed	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
apoptosis	O
of	O
renal	O
tubular	O
epithelial	O
cells	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
increases	O
in	O
renal	O
cytokine	O
content	O
were	O
also	O
decreased	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
suggest	O
that	O
thrombin	B-Gene
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Treatment	O
with	O
antithrombin	B-Chemical
may	O
be	O
clinically	O
effective	O
in	O
patients	B-Species
with	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Neurofibromin	B-Gene
1	I-Gene
(	O
NF1	B-Gene
)	O
defects	O
are	O
common	O
in	O
human	B-Species
ovarian	B-Disease
serous	I-Disease
carcinomas	I-Disease
and	O
co	O
-	O
occur	O
with	O
TP53	B-Gene
mutations	O
.	O
</ALL>	O

<ALL>	O
Ovarian	B-Disease
serous	I-Disease
carcinoma	I-Disease
(	O
OSC	B-Disease
)	O
is	O
the	O
most	O
common	O
and	O
lethal	O
histologic	O
type	O
of	O
ovarian	B-Disease
epithelial	I-Disease
malignancy	I-Disease
.	O
</ALL>	O

<ALL>	O
Mutations	O
of	O
TP53	B-Gene
and	O
dysfunction	O
of	O
the	O
Brca1	B-Gene
and	O
/	O
or	O
Brca2	B-Gene
tumor	B-Disease
-	O
suppressor	O
proteins	O
have	O
been	O
implicated	O
in	O
the	O
molecular	O
pathogenesis	O
of	O
a	O
large	O
fraction	O
of	O
OSCs	B-Disease
,	O
but	O
frequent	O
somatic	O
mutations	O
in	O
other	O
well	O
-	O
established	O
tumor	B-Disease
-	O
suppressor	O
genes	O
have	O
not	O
been	O
identified	O
.	O
</ALL>	O

<ALL>	O
Using	O
a	O
genome	O
-	O
wide	O
screen	O
of	O
DNA	O
copy	O
number	O
alterations	O
in	O
36	O
primary	O
OSCs	B-Disease
,	O
we	O
identified	O
two	O
tumors	B-Disease
with	O
apparent	O
homozygous	O
deletions	O
of	O
the	O
NF1	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Subsequently	O
,	O
18	O
ovarian	B-Disease
carcinoma	I-Disease
-	O
derived	O
cell	O
lines	O
and	O
41	O
primary	O
OSCs	B-Disease
were	O
evaluated	O
for	O
NF1	B-Gene
alterations	O
.	O
</ALL>	O

<ALL>	O
Markedly	O
reduced	O
or	O
absent	O
expression	O
of	O
Nf1	B-Gene
protein	O
was	O
observed	O
in	O
6	O
of	O
the	O
18	O
cell	O
lines	O
,	O
and	O
using	O
the	O
protein	O
truncation	O
test	O
and	O
sequencing	O
of	O
cDNA	O
and	O
genomic	O
DNA	O
,	O
NF1	B-Gene
mutations	O
resulting	O
in	O
deletion	O
of	O
exons	O
and	O
/	O
or	O
aberrant	O
splicing	O
of	O
NF1	B-Gene
transcripts	O
were	O
detected	O
in	O
5	O
of	O
the	O
6	O
cell	O
lines	O
with	O
loss	O
of	O
NF1	B-Gene
expression	O
.	O
</ALL>	O

<ALL>	O
Similarly	O
,	O
NF1	B-Gene
alterations	O
including	O
homozygous	O
deletions	O
and	O
splicing	O
mutations	O
were	O
identified	O
in	O
9	O
(	O
22	O
%	O
)	O
of	O
41	O
primary	O
OSCs	B-Disease
.	O
</ALL>	O

<ALL>	O
As	O
expected	O
,	O
tumors	B-Disease
and	O
cell	O
lines	O
with	O
NF1	B-Gene
defects	O
lacked	O
mutations	O
in	O
KRAS	B-Gene
or	O
BRAF	B-Gene
but	O
showed	O
Ras	B-Gene
pathway	O
activation	O
based	O
on	O
immunohistochemical	O
detection	O
of	O
phosphorylated	O
MAPK	B-Gene
(	O
primary	O
tumors	B-Disease
)	O
or	O
increased	O
levels	O
of	O
GTP	B-Chemical
-	O
bound	O
Ras	B-Gene
(	O
cell	O
lines	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
TP53	B-Gene
tumor	B-Disease
-	O
suppressor	O
gene	O
was	O
mutated	O
in	O
all	O
OSCs	B-Disease
with	O
documented	O
NF1	B-Gene
mutation	O
,	O
suggesting	O
that	O
the	O
pathways	O
regulated	O
by	O
these	O
two	O
tumor	B-Disease
-	O
suppressor	O
proteins	O
often	O
cooperate	O
in	O
the	O
development	O
of	O
ovarian	B-Disease
carcinomas	I-Disease
with	O
serous	O
differentiation	O
.	O
</ALL>	O

<ALL>	O
Melanocortin	B-Gene
-	I-Gene
4	I-Gene
receptor	I-Gene
activation	O
inhibits	O
c	B-Gene
-	I-Gene
Jun	I-Gene
N	I-Gene
-	I-Gene
terminal	I-Gene
kinase	I-Gene
activity	O
and	O
promotes	O
insulin	B-Gene
signaling	O
.	O
</ALL>	O

<ALL>	O
The	O
melanocortin	B-Gene
system	O
is	O
crucial	O
to	O
regulation	O
of	O
energy	O
homeostasis	O
.	O
</ALL>	O

<ALL>	O
The	O
melanocortin	B-Gene
receptor	I-Gene
type	I-Gene
4	I-Gene
(	O
MC4R	B-Gene
)	O
modulates	O
insulin	B-Gene
signaling	O
via	O
effects	O
on	O
c	B-Gene
-	I-Gene
Jun	I-Gene
N	I-Gene
-	I-Gene
terminal	I-Gene
kinase	I-Gene
(	O
JNK	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
The	O
melanocortin	B-Gene
agonist	O
NDP	B-Chemical
-	I-Chemical
MSH	I-Chemical
dose	O
-	O
dependently	O
inhibited	O
JNK	B-Gene
activity	O
in	O
HEK293	B-CellLine
cells	O
stably	O
expressing	O
the	O
human	B-Species
MC4R	B-Gene
;	O
effects	O
were	O
reversed	O
by	O
melanocortin	B-Gene
receptor	I-Gene
antagonist	O
.	O
</ALL>	O

<ALL>	O
NDP	B-Chemical
-	I-Chemical
MSH	I-Chemical
time	O
-	O
and	O
dose	O
-	O
dependently	O
inhibited	O
IRS	B-Gene
-	I-Gene
1	I-Gene
(	O
ser307	O
)	O
phosphorylation	O
,	O
effects	O
also	O
reversed	O
by	O
a	O
specific	O
melanocortin	B-Gene
receptor	I-Gene
antagonist	O
.	O
</ALL>	O

<ALL>	O
NDP	B-Chemical
-	I-Chemical
MSH	I-Chemical
augmented	O
insulin	B-Gene
-	O
stimulated	O
AKT	B-Gene
phosphorylation	O
in	O
vitro	O
.	O
</ALL>	O

<ALL>	O
The	O
melanocortin	B-Gene
agonist	O
melanotan	B-Chemical
II	I-Chemical
increased	O
insulin	B-Gene
-	O
stimulated	O
AKT	B-Gene
phosphorylation	O
in	O
the	O
rat	B-Species
hypothalamus	O
in	O
vivo	O
.	O
</ALL>	O

<ALL>	O
NDP	B-Chemical
-	I-Chemical
MSH	I-Chemical
increased	O
insulin	B-Gene
-	O
stimulated	O
glucose	B-Chemical
uptake	O
in	O
hypothalamic	O
GT1	B-CellLine
-	I-CellLine
1	I-CellLine
cells	O
.	O
</ALL>	O

<ALL>	O
The	O
current	O
study	O
shows	O
that	O
the	O
melanocortinergic	O
system	O
interacts	O
with	O
insulin	B-Gene
signaling	O
via	O
novel	O
effects	O
on	O
JNK	B-Gene
activity	O
.	O
</ALL>	O

<ALL>	O
The	O
association	O
between	O
tranexamic	B-Chemical
acid	I-Chemical
and	O
convulsive	B-Disease
seizures	I-Disease
after	O
cardiac	O
surgery	O
:	O
a	O
multivariate	O
analysis	O
in	O
11	O
529	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Because	O
of	O
a	O
lack	O
of	O
contemporary	O
data	O
regarding	O
seizures	B-Disease
after	O
cardiac	O
surgery	O
,	O
we	O
undertook	O
a	O
retrospective	O
analysis	O
of	O
prospectively	O
collected	O
data	O
from	O
11	O
529	O
patients	B-Species
in	O
whom	O
cardiopulmonary	O
bypass	O
was	O
used	O
from	O
January	O
2004	O
to	O
December	O
2010	O
.	O
</ALL>	O

<ALL>	O
A	O
convulsive	B-Disease
seizure	I-Disease
was	O
defined	O
as	O
a	O
transient	O
episode	O
of	O
disturbed	O
brain	O
function	O
characterised	O
by	O
abnormal	B-Disease
involuntary	I-Disease
motor	I-Disease
movements	I-Disease
.	O
</ALL>	O

<ALL>	O
Multivariate	O
regression	O
analysis	O
was	O
performed	O
to	O
identify	O
independent	O
predictors	O
of	O
postoperative	O
seizures	B-Disease
.	O
</ALL>	O

<ALL>	O
A	O
total	O
of	O
100	O
(	O
0.9	O
%	O
)	O
patients	B-Species
developed	O
postoperative	O
convulsive	B-Disease
seizures	I-Disease
.	O
</ALL>	O

<ALL>	O
Generalised	B-Disease
and	I-Disease
focal	I-Disease
seizures	I-Disease
were	O
identified	O
in	O
68	O
and	O
32	O
patients	B-Species
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
The	O
median	O
(	O
IQR	O
[	O
range	O
]	O
)	O
time	O
after	O
surgery	O
when	O
the	O
seizure	B-Disease
occurred	O
was	O
7	O
(	O
6	O
-	O
12	O
[	O
1	O
-	O
216	O
]	O
)	O
h	O
and	O
8	O
(	O
6	O
-	O
11	O
[	O
4	O
-	O
18	O
]	O
)	O
h	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
Epileptiform	O
findings	O
on	O
electroencephalography	O
were	O
seen	O
in	O
19	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Independent	O
predictors	O
of	O
postoperative	O
seizures	B-Disease
included	O
age	O
,	O
female	O
sex	O
,	O
redo	O
cardiac	O
surgery	O
,	O
calcification	B-Disease
of	I-Disease
ascending	I-Disease
aorta	I-Disease
,	O
congestive	B-Disease
heart	I-Disease
failure	I-Disease
,	O
deep	O
hypothermic	B-Disease
circulatory	O
arrest	O
,	O
duration	O
of	O
aortic	O
cross	O
-	O
clamp	O
and	O
tranexamic	B-Chemical
acid	I-Chemical
.	O
</ALL>	O

<ALL>	O
When	O
tested	O
in	O
a	O
multivariate	O
regression	O
analysis	O
,	O
tranexamic	B-Chemical
acid	I-Chemical
was	O
a	O
strong	O
independent	O
predictor	O
of	O
seizures	B-Disease
(	O
OR	O
14.3	O
,	O
95	O
%	O
CI	O
5.5	O
-	O
36.7	O
;	O
p	O
<	O
0.001	O
)	O
.	O
</ALL>	O

<ALL>	O
Patients	B-Species
with	O
convulsive	B-Disease
seizures	I-Disease
had	O
2.5	O
times	O
higher	O
in	O
-	O
hospital	O
mortality	O
rates	O
and	O
twice	O
the	O
length	O
of	O
hospital	O
stay	O
compared	O
with	O
patients	B-Species
without	O
convulsive	B-Disease
seizures	I-Disease
.	O
</ALL>	O

<ALL>	O
Mean	O
(	O
IQR	O
[	O
range	O
]	O
)	O
length	O
of	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
was	O
115	O
(	O
49	O
-	O
228	O
[	O
32	O
-	O
481	O
]	O
)	O
h	O
in	O
patients	B-Species
with	O
convulsive	B-Disease
seizures	I-Disease
compared	O
with	O
26	O
(	O
22	O
-	O
69	O
[	O
14	O
-	O
1080	O
]	O
)	O
h	O
in	O
patients	B-Species
without	O
seizures	B-Disease
(	O
p	O
<	O
0.001	O
)	O
.	O
</ALL>	O

<ALL>	O
Convulsive	B-Disease
seizures	I-Disease
are	O
a	O
serious	O
postoperative	B-Disease
complication	I-Disease
after	O
cardiac	O
surgery	O
.	O
</ALL>	O

<ALL>	O
As	O
tranexamic	B-Chemical
acid	I-Chemical
is	O
the	O
only	O
modifiable	O
factor	O
,	O
its	O
administration	O
,	O
particularly	O
in	O
doses	O
exceeding	O
80	O
mg.kg	O
(	O
-	O
1	O
)	O
,	O
should	O
be	O
weighed	O
against	O
the	O
risk	O
of	O
postoperative	O
seizures	B-Disease
.	O
</ALL>	O

<ALL>	O
Changes	O
in	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
during	O
pancreatic	B-Disease
cancer	I-Disease
development	O
and	O
progression	O
in	O
a	O
genetically	O
engineered	O
Kras	B-Gene
G12D	O
;	O
Pdx1	B-Gene
-	O
Cre	O
mouse	B-Species
(	O
KC	O
)	O
model	O
.	O
</ALL>	O

<ALL>	O
Differential	O
expression	O
of	O
microRNAs	O
(	O
miRNAs	O
)	O
has	O
been	O
demonstrated	O
in	O
various	O
cancers	B-Disease
,	O
including	O
pancreatic	B-Disease
cancer	I-Disease
(	O
PC	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Due	O
to	O
the	O
lack	O
of	O
tissue	O
samples	O
from	O
early	O
-	O
stages	O
of	O
PC	B-Disease
,	O
the	O
stage	O
-	O
specific	O
alteration	O
of	O
miRNAs	O
during	O
PC	B-Disease
initiation	O
and	O
progression	O
is	O
largely	O
unknown	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
global	O
miRNA	O
expression	O
profile	O
and	O
their	O
processing	O
machinery	O
during	O
PC	B-Disease
progression	O
using	O
the	O
Kras	B-Gene
G12D	O
;	O
Pdx1	B-Gene
-	O
Cre	O
(	O
KC	O
)	O
mouse	B-Species
model	O
.	O
</ALL>	O

<ALL>	O
At	O
25	O
weeks	O
,	O
the	O
miRNA	O
microarray	O
analysis	O
revealed	O
significant	O
downregulation	O
of	O
miR	B-Gene
-	I-Gene
150	I-Gene
,	O
miR	B-Gene
-	I-Gene
494	I-Gene
,	O
miR	B-Gene
-	I-Gene
138	I-Gene
,	O
miR	B-Gene
-	I-Gene
148a	I-Gene
,	O
miR	B-Gene
-	I-Gene
216a	I-Gene
,	O
and	O
miR	B-Gene
-	I-Gene
217	I-Gene
and	O
upregulation	O
of	O
miR	B-Gene
-	I-Gene
146b	I-Gene
,	O
miR	B-Gene
-	I-Gene
205	I-Gene
,	O
miR	B-Gene
-	I-Gene
31	I-Gene
,	O
miR	B-Gene
-	I-Gene
192	I-Gene
,	O
and	O
miR	B-Gene
-	I-Gene
21	I-Gene
in	O
KC	O
mice	B-Species
compared	O
to	O
controls	O
.	O
</ALL>	O

<ALL>	O
Further	O
,	O
expression	O
of	O
miRNA	O
biosynthetic	O
machinery	O
including	O
Dicer	B-Gene
,	O
Exportin	B-Gene
-	I-Gene
5	I-Gene
,	O
TRKRA	B-Gene
,	O
and	O
TARBP2	B-Gene
were	O
downregulated	O
,	O
while	O
DGCR8	B-Gene
and	O
Ago2	B-Gene
were	O
upregulated	O
in	O
KC	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
from	O
10	O
to	O
50	O
weeks	O
of	O
age	O
,	O
stage	O
-	O
specific	O
expression	O
profiling	O
of	O
miRNA	O
in	O
KC	O
mice	B-Species
revealed	O
downregulation	O
of	O
miR	B-Gene
-	I-Gene
216	I-Gene
,	O
miR	B-Gene
-	I-Gene
217	I-Gene
,	O
miR	B-Gene
-	I-Gene
100	I-Gene
,	O
miR	B-Gene
-	I-Gene
345	I-Gene
,	O
miR	B-Gene
-	I-Gene
141	I-Gene
,	O
miR	B-Gene
-	I-Gene
483	I-Gene
-	I-Gene
3p	I-Gene
,	O
miR	B-Gene
-	I-Gene
26b	I-Gene
,	O
miR	B-Gene
-	I-Gene
150	I-Gene
,	O
miR	B-Gene
-	I-Gene
195	I-Gene
,	O
Let	B-Gene
-	I-Gene
7b	I-Gene
and	O
Let	B-Gene
-	I-Gene
96	I-Gene
and	O
upregulation	O
of	O
miR	B-Gene
-	I-Gene
21	I-Gene
,	O
miR	B-Gene
-	I-Gene
205	I-Gene
,	O
miR	B-Gene
-	I-Gene
146b	I-Gene
,	O
miR	B-Gene
-	I-Gene
34c	I-Gene
,	O
miR	B-Gene
-	I-Gene
1273	I-Gene
,	O
miR	B-Gene
-	I-Gene
223	I-Gene
and	O
miR	B-Gene
-	I-Gene
195	I-Gene
compared	O
to	O
control	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Interestingly	O
,	O
the	O
differential	O
expression	O
of	O
miRNA	O
in	O
mice	B-Species
also	O
corroborated	O
with	O
the	O
miRNA	O
expression	O
in	O
human	B-Species
PC	B-Disease
cell	O
lines	O
and	O
tissue	O
samples	O
;	O
ectopic	O
expression	O
of	O
Let	B-Gene
-	I-Gene
7b	I-Gene
in	O
CD18	B-CellLine
/	I-CellLine
HPAF	I-CellLine
and	O
Capan1	B-CellLine
cells	O
resulted	O
in	O
the	O
downregulation	O
of	O
KRAS	B-Gene
and	O
MSST1	B-Gene
expression	O
.	O
</ALL>	O

<ALL>	O
Overall	O
,	O
the	O
present	O
study	O
aids	O
an	O
understanding	O
of	O
miRNA	O
expression	O
patterns	O
during	O
PC	B-Disease
pathogenesis	O
and	O
helps	O
to	O
facilitate	O
the	O
identification	O
of	O
promising	O
and	O
novel	O
early	O
diagnostic	O
/	O
prognostic	O
markers	O
and	O
therapeutic	O
targets	O
.	O
</ALL>	O

<ALL>	O
DNA	O
-	O
damage	O
response	O
gene	O
GADD45A	B-Gene
induces	O
differentiation	O
in	O
hematopoietic	O
stem	O
cells	O
without	O
inhibiting	O
cell	O
cycle	O
or	O
survival	O
.	O
</ALL>	O

<ALL>	O
Hematopoietic	O
stem	O
cells	O
(	O
HSCs	O
)	O
maintain	O
blood	O
cell	O
production	O
life	O
-	O
long	O
by	O
their	O
unique	O
abilities	O
of	O
self	O
-	O
renewal	O
and	O
differentiation	O
into	O
all	O
blood	O
cell	O
lineages	O
.	O
</ALL>	O

<ALL>	O
Growth	B-Gene
arrest	I-Gene
and	I-Gene
DNA	I-Gene
-	I-Gene
damage	I-Gene
-	I-Gene
inducible	I-Gene
45	I-Gene
alpha	I-Gene
(	O
GADD45A	B-Gene
)	O
is	O
induced	O
by	O
genotoxic	O
stress	O
in	O
HSCs	O
.	O
</ALL>	O

<ALL>	O
GADD45A	B-Gene
has	O
been	O
implicated	O
in	O
cell	O
cycle	O
control	O
,	O
cell	O
death	O
and	O
senescence	O
,	O
as	O
well	O
as	O
in	O
DNA	O
-	O
damage	O
repair	O
.	O
</ALL>	O

<ALL>	O
In	O
general	O
,	O
GADD45A	B-Gene
provides	O
cellular	O
stability	O
by	O
either	O
arresting	O
the	O
cell	O
cycle	O
progression	O
until	O
DNA	O
damage	O
is	O
repaired	O
or	O
,	O
in	O
cases	O
of	O
fatal	O
damage	O
,	O
by	O
inducing	O
apoptosis	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
function	O
of	O
GADD45A	B-Gene
in	O
hematopoiesis	O
remains	O
controversial	O
.	O
</ALL>	O

<ALL>	O
We	O
revealed	O
the	O
changes	O
in	O
murine	B-Species
HSC	O
fate	O
control	O
orchestrated	O
by	O
the	O
expression	O
of	O
GADD45A	B-Gene
at	O
single	O
cell	O
resolution	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
to	O
other	O
cellular	O
systems	O
,	O
GADD45A	B-Gene
expression	O
did	O
not	O
cause	O
a	O
cell	O
cycle	O
arrest	O
or	O
an	O
alteration	O
in	O
the	O
decision	O
between	O
cell	O
survival	O
and	O
apoptosis	O
in	O
HSCs	O
.	O
</ALL>	O

<ALL>	O
Strikingly	O
,	O
GADD45A	B-Gene
strongly	O
induced	O
and	O
accelerated	O
the	O
differentiation	O
program	O
in	O
HSCs	O
.	O
</ALL>	O

<ALL>	O
Continuous	O
tracking	O
of	O
individual	O
HSCs	O
and	O
their	O
progeny	O
via	O
time	O
-	O
lapse	O
microscopy	O
elucidated	O
that	O
once	O
GADD45A	B-Gene
was	O
expressed	O
,	O
HSCs	O
differentiate	O
into	O
committed	O
progenitors	O
within	O
29	O
hours	O
.	O
</ALL>	O

<ALL>	O
GADD45A	B-Gene
-	O
expressing	O
HSCs	O
failed	O
to	O
long	O
-	O
term	O
reconstitute	O
the	O
blood	O
of	O
recipients	O
by	O
inducing	O
multilineage	O
differentiation	O
in	O
vivo	O
.	O
</ALL>	O

<ALL>	O
Importantly	O
,	O
g	O
-	O
irradiation	O
of	O
HSCs	O
induced	O
their	O
differentiation	O
by	O
upregulating	O
endogenous	O
GADD45A	B-Gene
.	O
</ALL>	O

<ALL>	O
The	O
differentiation	O
induction	O
by	O
GADD45A	B-Gene
was	O
transmitted	O
by	O
activating	O
p38	B-Gene
Mitogen	I-Gene
-	I-Gene
activated	I-Gene
protein	I-Gene
kinase	I-Gene
(	O
MAPK	B-Gene
)	O
signaling	O
and	O
allowed	O
the	O
generation	O
of	O
megakaryocytic	O
-	O
erythroid	O
,	O
myeloid	O
,	O
and	O
lymphoid	O
lineages	O
.	O
</ALL>	O

<ALL>	O
These	O
data	O
indicate	O
that	O
genotoxic	O
stress	O
-	O
induced	O
GADD45A	B-Gene
expression	O
in	O
HSCs	O
prevents	O
their	O
fatal	O
transformation	O
by	O
directing	O
them	O
into	O
differentiation	O
and	O
thereby	O
clearing	O
them	O
from	O
the	O
system	O
.	O
</ALL>	O

<ALL>	O
Cisplatin	B-Chemical
induces	O
tolerogenic	O
dendritic	O
cells	O
in	O
response	O
to	O
TLR	B-Gene
agonists	O
via	O
the	O
abundant	O
production	O
of	O
IL	B-Gene
-	I-Gene
10	I-Gene
,	O
thereby	O
promoting	O
Th2	O
-	O
and	O
Tr1	O
-	O
biased	O
T	O
-	O
cell	O
immunity	O
.	O
</ALL>	O

<ALL>	O
Although	O
many	O
advantageous	O
roles	O
of	O
cisplatin	B-Chemical
(	O
cis	B-Chemical
-	I-Chemical
diamminedichloroplatinum	I-Chemical
(	O
II	O
)	O
,	O
CDDP	B-Chemical
)	O
have	O
been	O
reported	O
in	O
cancer	B-Disease
therapy	O
,	O
the	O
immunomodulatory	O
roles	O
of	O
cisplatin	B-Chemical
in	O
the	O
phenotypic	O
and	O
functional	O
alterations	O
of	O
dendritic	O
cells	O
(	O
DCs	O
)	O
are	O
poorly	O
understood	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
cisplatin	B-Chemical
on	O
the	O
functionality	O
of	O
DCs	O
and	O
the	O
changes	O
in	O
signaling	O
pathways	O
activated	O
upon	O
toll	B-Gene
-	I-Gene
like	I-Gene
receptor	I-Gene
(	O
TLR	B-Gene
)	O
stimulation	O
.	O
</ALL>	O

<ALL>	O
Cisplatin	B-Chemical
-	O
treated	O
DCs	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
cell	O
surface	O
molecules	O
(	O
CD80	B-Gene
,	O
CD86	B-Gene
,	O
MHC	B-Gene
class	I-Gene
I	I-Gene
and	I-Gene
II	I-Gene
)	O
and	O
up	O
-	O
regulated	O
endocytic	O
capacity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
</ALL>	O

<ALL>	O
Upon	O
stimulation	O
with	O
various	O
TLR	B-Gene
agonists	O
,	O
cisplatin	B-Chemical
-	O
treated	O
DCs	O
showed	O
markedly	O
increased	O
IL	B-Gene
-	I-Gene
10	I-Gene
production	O
through	O
activation	O
of	O
the	O
p38	B-Gene
MAPK	I-Gene
and	O
NF	B-Gene
-	I-Gene
kappaB	I-Gene
signaling	O
pathways	O
without	O
altering	O
the	O
levels	O
of	O
TNF	B-Gene
-	I-Gene
alpha	I-Gene
and	O
IL	B-Gene
-	I-Gene
12p70	I-Gene
,	O
indicating	O
the	O
cisplatin	B-Chemical
-	O
mediated	O
induction	O
of	O
tolerogenic	O
DCs	O
.	O
</ALL>	O

<ALL>	O
This	O
effect	O
was	O
dependent	O
on	O
the	O
production	O
of	O
IL	B-Gene
-	I-Gene
10	I-Gene
from	O
DCs	O
,	O
as	O
neither	O
DCs	O
isolated	O
from	O
IL	B-Gene
-	I-Gene
10	I-Gene
-	O
/	O
-	O
mice	B-Species
nor	O
IL	B-Gene
-	I-Gene
10	I-Gene
-	O
neutralized	O
DCs	O
generated	O
tolerogenic	O
DCs	O
.	O
</ALL>	O

<ALL>	O
Interestingly	O
,	O
DCs	O
that	O
were	O
co	O
-	O
treated	O
with	O
cisplatin	B-Chemical
and	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)	O
exhibited	O
a	O
decreased	O
immunostimulatory	O
capacity	O
for	O
inducing	O
the	O
proliferation	O
of	O
Th1	O
-	O
and	O
Th17	O
-	O
type	O
T	O
cells	O
;	O
instead	O
,	O
these	O
DCs	O
contributed	O
to	O
Th2	O
-	O
type	O
T	O
cell	O
immunity	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
investigations	O
revealed	O
a	O
unique	O
T	O
cell	O
population	O
,	O
IL	B-Gene
-	I-Gene
10	I-Gene
-	O
producing	O
CD3	B-Gene
+	O
CD4	B-Gene
+	O
LAG	B-Gene
-	I-Gene
3	I-Gene
+	O
CD49b	B-Gene
+	O
CD25	B-Gene
-	O
Foxp3	B-Gene
-	O
Tr1	O
cells	O
,	O
that	O
was	O
significantly	O
increased	O
without	O
altering	O
the	O
Foxp3	B-Gene
+	O
regulatory	O
T	O
cell	O
population	O
.	O
</ALL>	O

<ALL>	O
Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
cisplatin	B-Chemical
induces	O
immune	O
-	O
suppressive	O
tolerogenic	O
DCs	O
in	O
TLR	B-Chemical
agonist	I-Chemical
-	O
induced	O
inflammatory	B-Disease
conditions	O
via	O
abundant	O
IL	B-Gene
-	I-Gene
10	I-Gene
production	O
,	O
thereby	O
skewing	O
Th	O
cell	O
differentiation	O
towards	O
Th2	O
and	O
Tr1	O
cells	O
.	O
</ALL>	O

<ALL>	O
This	O
relationship	O
may	O
provide	O
cancer	B-Disease
cells	O
with	O
an	O
opportunity	O
to	O
evade	O
the	O
immune	O
system	O
.	O
</ALL>	O

<ALL>	O
Hsp90beta	B-Gene
is	O
involved	O
in	O
the	O
development	O
of	O
high	O
salt	B-Chemical
-	O
diet	O
-	O
induced	O
nephropathy	B-Disease
via	O
interaction	O
with	O
various	O
signalling	O
proteins	O
.	O
</ALL>	O

<ALL>	O
A	O
high	O
-	O
salt	B-Chemical
diet	O
often	O
leads	O
to	O
a	O
local	O
intrarenal	O
increase	O
in	O
renal	B-Disease
hypoxia	I-Disease
and	O
oxidative	O
stress	O
,	O
which	O
are	O
responsible	O
for	O
an	O
excess	O
production	O
of	O
pathogenic	O
substances	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
Wistar	O
Kyoto	O
/	O
spontaneous	O
hypertensive	B-Disease
(	O
WKY	O
/	O
SHR	O
)	O
rats	B-Species
fed	O
a	O
high	O
-	O
salt	B-Chemical
diet	O
developed	O
severe	O
proteinuria	B-Disease
,	O
resulting	O
from	O
pronounced	O
renal	B-Disease
inflammation	I-Disease
,	O
fibrosis	B-Disease
and	O
tubular	O
epithelial	O
cell	O
apoptosis	O
.	O
</ALL>	O

<ALL>	O
All	O
these	O
were	O
mainly	O
non	O
-	O
pressure	O
-	O
related	O
effects	O
.	O
</ALL>	O

<ALL>	O
Hsp90beta	B-Gene
,	O
TGF	B-Gene
-	I-Gene
beta	I-Gene
,	I-Gene
HIF	B-Gene
-	I-Gene
1alpha	I-Gene
,	O
TNF	B-Gene
-	I-Gene
alpha	I-Gene
,	O
IL	B-Gene
-	I-Gene
6	I-Gene
and	O
MCP	B-Gene
-	I-Gene
1	I-Gene
were	O
shown	O
to	O
be	O
highly	O
expressed	O
in	O
response	O
to	O
salt	B-Chemical
loading	O
.	O
</ALL>	O

<ALL>	O
Next	O
,	O
we	O
found	O
that	O
Hsp90beta	B-Gene
might	O
play	O
the	O
key	O
role	O
in	O
non	O
-	O
pressure	O
-	O
related	O
effects	O
of	O
salt	B-Chemical
loading	O
through	O
a	O
series	O
of	O
cellular	O
signalling	O
events	O
,	O
including	O
the	O
NF	B-Gene
-	I-Gene
kappaB	I-Gene
,	O
p38	B-Gene
activation	O
and	O
Bcl	B-Gene
-	I-Gene
2	I-Gene
inactivation	O
.	O
</ALL>	O

<ALL>	O
Hsp90beta	B-Gene
was	O
previously	O
proven	O
to	O
regulate	O
the	O
upstream	O
mediators	O
in	O
multiple	O
cellular	O
signalling	O
cascades	O
through	O
stabilizing	O
and	O
maintaining	O
their	O
activities	O
.	O
</ALL>	O

<ALL>	O
In	O
our	O
study	O
,	O
17	B-Chemical
-	I-Chemical
dimethylaminoethylamino	I-Chemical
-	I-Chemical
17	I-Chemical
-	I-Chemical
demethoxygeldanamycin	I-Chemical
(	O
17	B-Chemical
-	I-Chemical
DMAG	I-Chemical
)	O
or	O
Hsp90beta	B-Gene
knockdown	O
dramatically	O
alleviated	O
the	O
high	O
-	O
salt	B-Chemical
-	O
diet	O
-	O
induced	O
proteinuria	B-Disease
and	O
renal	B-Disease
damage	I-Disease
without	O
altering	O
blood	O
pressure	O
significantly	O
,	O
when	O
it	O
reversed	O
activations	O
of	O
NF	B-Gene
-	I-Gene
kappaB	I-Gene
,	O
mTOR	B-Gene
and	O
p38	B-Gene
signalling	O
cascades	O
.	O
</ALL>	O

<ALL>	O
Meanwhile	O
,	O
Co	O
-	O
IP	O
results	O
demonstrated	O
that	O
Hsp90beta	B-Gene
could	O
interact	O
with	O
and	O
stabilize	O
TAK1	B-Gene
,	O
AMPKalpha	B-Gene
,	O
IKKalpha	B-Gene
/	I-Gene
beta	I-Gene
,	O
HIF	B-Gene
-	I-Gene
1alpha	I-Gene
and	O
Raptor	B-Gene
,	O
whereas	O
Hsp90beta	B-Gene
inhibition	O
disrupted	O
this	O
process	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
Hsp90beta	B-Gene
inhibition	O
-	O
mediated	O
renal	O
improvements	O
also	O
accompanied	O
the	O
reduction	O
of	O
renal	O
oxidative	O
stress	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
salt	B-Chemical
loading	O
indeed	O
exhibited	O
non	O
-	O
pressure	O
-	O
related	O
impacts	O
on	O
proteinuria	B-Disease
and	O
renal	B-Disease
dysfunction	I-Disease
in	O
WKY	O
/	O
SHR	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Hsp90beta	B-Gene
inhibition	O
caused	O
the	O
destabilization	O
of	O
upstream	O
mediators	O
in	O
various	O
pathogenic	O
signalling	O
events	O
,	O
thereby	O
effectively	O
ameliorating	O
this	O
nephropathy	B-Disease
owing	O
to	O
renal	B-Disease
hypoxia	I-Disease
and	O
oxidative	O
stress	O
.	O
</ALL>	O

<ALL>	O
Angiotensin	B-Gene
II	I-Gene
subtype	I-Gene
1a	I-Gene
receptor	I-Gene
signaling	O
in	O
resident	O
hepatic	O
macrophages	O
induces	O
liver	B-Disease
metastasis	I-Disease
formation	O
.	O
</ALL>	O

<ALL>	O
Liver	B-Disease
metastases	I-Disease
from	O
colorectal	B-Disease
cancer	I-Disease
(	O
CRC	B-Disease
)	O
are	O
a	O
clinically	O
significant	O
problem	O
.	O
</ALL>	O

<ALL>	O
The	O
renin	B-Gene
-	O
angiotensin	B-Gene
system	O
is	O
involved	O
in	O
tumor	B-Disease
growth	O
and	O
metastases	B-Disease
.	O
</ALL>	O

<ALL>	O
This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
role	O
of	O
angiotensin	B-Gene
II	I-Gene
subtype	I-Gene
receptor	I-Gene
1a	I-Gene
(	O
AT1a	B-Gene
)	O
in	O
the	O
formation	O
of	O
liver	B-Disease
metastasis	I-Disease
in	O
CRC	B-Disease
.	O
</ALL>	O

<ALL>	O
A	O
model	O
of	O
liver	B-Disease
metastasis	I-Disease
was	O
developed	O
by	O
intrasplenic	O
injection	O
of	O
mouse	B-Species
colon	B-Disease
cancer	I-Disease
(	O
CMT	B-CellLine
-	I-CellLine
93	I-CellLine
)	O
into	O
AT1a	B-Gene
knockout	O
mice	B-Species
(	O
AT1a	B-Gene
KO	O
)	O
and	O
wild	O
-	O
type	O
(	O
C57BL	B-CellLine
/	I-CellLine
6	I-CellLine
)	O
mice	B-Species
(	O
WT	O
)	O
.	O
</ALL>	O

<ALL>	O
Compared	O
with	O
WT	O
mice	B-Species
,	O
the	O
liver	O
weight	O
and	O
liver	B-Disease
metastatic	I-Disease
rate	O
were	O
significantly	O
lower	O
in	O
AT1a	B-Gene
KO	O
.	O
</ALL>	O

<ALL>	O
The	O
mRNA	O
levels	O
of	O
CD31	B-Gene
,	O
transforming	B-Gene
growth	I-Gene
factor	I-Gene
-	I-Gene
b1	I-Gene
(	O
TGF	B-Gene
-	I-Gene
b1	I-Gene
)	O
,	O
and	O
F4	B-Gene
/	I-Gene
80	I-Gene
were	O
suppressed	O
in	O
AT1a	B-Gene
KO	O
compared	O
with	O
WT	O
.	O
</ALL>	O

<ALL>	O
Double	O
immunofluorescence	O
analysis	O
showed	O
that	O
the	O
number	O
of	O
accumulated	O
F4	B-Gene
/	I-Gene
80	I-Gene
(	O
+	O
)	O
cells	O
expressing	O
TGF	B-Gene
-	I-Gene
b1	I-Gene
in	O
metastatic	O
areas	O
was	O
higher	O
in	O
WT	O
than	O
in	O
AT1a	B-Gene
KO	O
.	O
</ALL>	O

<ALL>	O
The	O
AT1a	B-Gene
KO	O
bone	O
marrow	O
(	O
BM	O
)	O
(	O
AT1a	B-Gene
KO	O
-	O
BM	O
)	O
>	O
WT	O
showed	O
suppressed	O
formation	O
of	O
liver	B-Disease
metastasis	I-Disease
compared	O
with	O
WT	O
-	O
BM	O
>	O
WT	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
formation	O
of	O
metastasis	B-Disease
was	O
further	O
suppressed	O
in	O
WT	O
-	O
BM	O
>	O
AT1a	B-Gene
KO	O
compared	O
with	O
AT1a	B-Gene
KO	O
-	O
BM	O
>	O
WT	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
accumulated	O
F4	B-Gene
/	I-Gene
80	I-Gene
(	O
+	O
)	O
cells	O
in	O
the	O
liver	B-Disease
metastasis	I-Disease
were	O
not	O
BM	O
-	O
derived	O
F4	B-Gene
/	I-Gene
80	I-Gene
(	O
+	O
)	O
cells	O
,	O
but	O
mainly	O
resident	O
hepatic	O
F4	B-Gene
/	I-Gene
80	I-Gene
(	O
+	O
)	O
cells	O
,	O
and	O
these	O
resident	O
hepatic	O
F4	B-Gene
/	I-Gene
80	I-Gene
(	O
+	O
)	O
cells	O
were	O
positive	O
for	O
TGF	B-Gene
-	I-Gene
b1	I-Gene
.	O
</ALL>	O

<ALL>	O
Angiotensin	B-Gene
II	I-Gene
enhanced	O
TGF	B-Gene
-	I-Gene
b1	I-Gene
expression	O
in	O
Kupffer	O
cells	O
.	O
</ALL>	O

<ALL>	O
Treatment	O
of	O
WT	O
with	O
clodronate	B-Chemical
liposomes	O
suppressed	O
liver	B-Disease
metastasis	I-Disease
by	O
diminishing	O
TGF	B-Gene
-	I-Gene
b1	I-Gene
(	O
+	O
)	O
F4	B-Gene
/	I-Gene
80	I-Gene
(	O
+	O
)	O
cells	O
accumulation	O
.	O
</ALL>	O

<ALL>	O
The	O
formation	O
of	O
liver	B-Disease
metastasis	I-Disease
correlated	O
with	O
collagen	B-Gene
deposition	O
in	O
the	O
metastatic	O
area	O
,	O
which	O
was	O
dependent	O
on	O
AT1a	B-Gene
signaling	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
suggested	O
that	O
resident	O
hepatic	O
macrophages	O
induced	O
liver	B-Disease
metastasis	I-Disease
formation	O
by	O
induction	O
of	O
TGF	B-Gene
-	I-Gene
b1	I-Gene
through	O
AT1a	B-Gene
signaling	O
.	O
</ALL>	O

<ALL>	O
Polymorphisms	O
in	O
the	O
SLC2A2	B-Gene
(	O
GLUT2	B-Gene
)	O
gene	O
are	O
associated	O
with	O
the	O
conversion	O
from	O
impaired	B-Disease
glucose	I-Disease
tolerance	I-Disease
to	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
:	O
the	O
Finnish	O
Diabetes	B-Disease
Prevention	O
Study	O
.	O
</ALL>	O

<ALL>	O
Impaired	B-Disease
insulin	I-Disease
secretion	I-Disease
is	O
a	O
fundamental	O
defect	O
in	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
genes	O
regulating	O
insulin	B-Gene
secretion	O
(	O
SLC2A2	B-Gene
[	O
encoding	O
GLUT2	B-Gene
]	O
,	O
GCK	B-Gene
,	O
TCF1	B-Gene
[	O
encoding	O
HNF	B-Gene
-	I-Gene
1alpha	I-Gene
]	O
,	O
HNF4A	B-Gene
,	O
GIP	B-Gene
,	O
and	O
GLP1R	B-Gene
)	O
are	O
associated	O
with	O
the	O
conversion	O
from	O
impaired	B-Disease
glucose	I-Disease
tolerance	I-Disease
(	O
IGT	B-Disease
)	O
to	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
in	O
participants	O
of	O
the	O
Finnish	O
Diabetes	B-Disease
Prevention	O
Study	O
.	O
</ALL>	O

<ALL>	O
With	O
the	O
exception	O
of	O
SLC2A2	B-Gene
,	O
other	O
genes	O
were	O
not	O
associated	O
with	O
the	O
risk	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
.	O
</ALL>	O

<ALL>	O
All	O
four	O
SNPs	O
of	O
SLC2A2	B-Gene
predicted	O
the	O
conversion	O
to	O
diabetes	B-Disease
,	O
and	O
rs5393	B-Variant
(	O
AA	O
genotype	O
)	O
increased	O
the	O
risk	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
in	O
the	O
entire	O
study	O
population	O
by	O
threefold	O
(	O
odds	O
ratio	O
3.04	O
,	O
95	O
%	O
CI	O
1.34	O
-	O
6.88	O
,	O
P	O
=	O
0.008	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
risk	O
for	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
in	O
the	O
AA	O
genotype	O
carriers	O
was	O
increased	O
in	O
the	O
control	O
group	O
(	O
5.56	O
[	O
1.78	O
-	O
17.39	O
]	O
,	O
P	O
=	O
0.003	O
)	O
but	O
not	O
in	O
the	O
intervention	O
group	O
.	O
</ALL>	O

<ALL>	O
We	O
conclude	O
that	O
the	O
SNPs	O
of	O
SLC2A2	B-Gene
predict	O
the	O
conversion	O
to	O
diabetes	B-Disease
in	O
obese	B-Disease
subjects	O
with	O
IGT	B-Disease
.	O
</ALL>	O

<ALL>	O
Peroxisomal	B-Gene
proliferator	I-Gene
activated	I-Gene
receptor	I-Gene
-	I-Gene
gamma	I-Gene
deficiency	O
in	O
a	O
Canadian	O
kindred	O
with	O
familial	B-Disease
partial	I-Disease
lipodystrophy	I-Disease
type	I-Disease
3	I-Disease
(	O
FPLD3	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Familial	B-Disease
partial	I-Disease
lipodystrophy	I-Disease
(	I-Disease
Dunnigan	I-Disease
)	I-Disease
type	I-Disease
3	I-Disease
(	O
FPLD3	B-Disease
,	O
Mendelian	B-Disease
Inheritance	I-Disease
in	I-Disease
Man	I-Disease
[	I-Disease
MIM	I-Disease
]	I-Disease
604367	I-Disease
)	O
results	O
from	O
heterozygous	O
mutations	O
in	O
PPARG	B-Gene
encoding	O
peroxisomal	B-Gene
proliferator	I-Gene
-	I-Gene
activated	I-Gene
receptor	I-Gene
-	I-Gene
gamma	I-Gene
.	O
</ALL>	O

<ALL>	O
Both	O
dominant	O
-	O
negative	O
and	O
haploinsufficiency	O
mechanisms	O
have	O
been	O
suggested	O
for	O
this	O
condition	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
We	O
present	O
a	O
Canadian	O
FPLD3	B-Disease
kindred	O
with	O
an	O
affected	O
mother	O
who	O
had	O
loss	O
of	O
fat	O
on	O
arms	O
and	O
legs	O
,	O
but	O
no	O
increase	O
in	O
facial	O
,	O
neck	O
,	O
suprascapular	O
or	O
abdominal	O
fat	O
.	O
</ALL>	O

<ALL>	O
She	O
had	O
profound	O
insulin	B-Disease
resistance	I-Disease
,	O
diabetes	B-Disease
,	O
severe	O
hypertriglyceridemia	B-Disease
and	O
relapsing	O
pancreatitis	B-Disease
,	O
while	O
her	O
pre	O
-	O
pubescent	O
daughter	O
had	O
normal	O
fat	O
distribution	O
but	O
elevated	O
plasma	O
triglycerides	B-Chemical
and	O
C	B-Chemical
-	I-Chemical
peptide	I-Chemical
and	O
depressed	O
high	B-Chemical
-	I-Chemical
density	I-Chemical
lipoprotein	I-Chemical
cholesterol	I-Chemical
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
mother	O
and	O
daughter	O
were	O
each	O
heterozygous	O
for	O
PPARG	B-Gene
nonsense	O
mutation	O
Y355X	B-Variant
,	O
whose	O
protein	O
product	O
in	O
vitro	O
was	O
transcriptionally	O
inactive	O
with	O
no	O
dominant	O
-	O
negative	O
activity	O
against	O
the	O
wild	O
-	O
type	O
receptor	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
the	O
mutant	O
protein	O
appeared	O
to	O
be	O
markedly	O
unstable	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Taken	O
together	O
with	O
previous	O
studies	O
of	O
human	B-Species
PPARG	B-Gene
mutations	O
,	O
these	O
findings	O
suggest	O
that	O
PPAR	B-Gene
-	I-Gene
gamma	I-Gene
deficiency	O
due	O
either	O
to	O
haploinsufficiency	O
or	O
to	O
substantial	O
activity	O
loss	O
due	O
to	O
dominant	O
negative	O
interference	O
of	O
the	O
normal	O
allele	O
product	O
's	O
function	O
can	O
each	O
contribute	O
to	O
the	O
FPLD3	B-Disease
phenotype	O
.	O
</ALL>	O

<ALL>	O
Catechol	B-Gene
-	I-Gene
O	I-Gene
-	I-Gene
methyltransferase	I-Gene
(	O
COMT	B-Gene
)	O
gene	O
variants	O
:	O
possible	O
association	O
of	O
the	O
Val158Met	B-Variant
variant	O
with	O
opiate	B-Disease
addiction	I-Disease
in	O
Hispanic	O
women	B-Species
.	O
</ALL>	O

<ALL>	O
Catechol	B-Gene
-	I-Gene
O	I-Gene
-	I-Gene
methyltransferase	I-Gene
(	O
COMT	B-Gene
)	O
catalyzes	O
the	O
breakdown	O
of	O
catechol	B-Chemical
neurotransmitters	I-Chemical
,	O
including	O
dopamine	B-Chemical
,	O
which	O
plays	O
a	O
prominent	O
role	O
in	O
drug	O
reward	O
.	O
</ALL>	O

<ALL>	O
A	O
common	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
,	O
G472A	B-Variant
,	O
codes	O
for	O
a	O
Val158Met	B-Variant
substitution	O
and	O
results	O
in	O
a	O
fourfold	O
down	O
regulation	O
of	O
enzyme	O
activity	O
.	O
</ALL>	O

<ALL>	O
We	O
sequenced	O
exon	O
IV	O
of	O
COMT	B-Gene
gene	O
in	O
search	O
for	O
novel	O
polymorphisms	O
and	O
then	O
genotyped	O
four	O
out	O
of	O
five	O
identified	O
by	O
direct	O
sequencing	O
,	O
using	O
TaqMan	O
assay	O
on	O
266	O
opioid	B-Chemical
-	O
dependent	O
and	O
173	O
control	O
subjects	O
.	O
</ALL>	O

<ALL>	O
Genotype	O
frequencies	O
of	O
the	O
G472A	B-Variant
SNP	O
varied	O
significantly	O
(	O
P	O
=	O
0.029	O
)	O
among	O
the	O
three	O
main	O
ethnic	O
/	O
cultural	O
groups	O
(	O
Caucasians	O
,	O
Hispanics	O
,	O
and	O
African	O
Americans	O
)	O
.	O
</ALL>	O

<ALL>	O
Using	O
a	O
genotype	O
test	O
,	O
we	O
found	O
a	O
trend	O
to	O
point	O
-	O
wise	O
association	O
(	O
P	O
=	O
0.053	O
)	O
of	O
the	O
G472A	B-Variant
SNP	O
in	O
Hispanic	O
subjects	O
with	O
opiate	B-Disease
addiction	I-Disease
.	O
</ALL>	O

<ALL>	O
Further	O
analysis	O
of	O
G472A	B-Variant
genotypes	O
in	O
Hispanic	O
subjects	O
with	O
data	O
stratified	O
by	O
gender	O
identified	O
a	O
point	O
-	O
wise	O
significant	O
(	O
P	O
=	O
0.049	O
)	O
association	O
of	O
G	O
/	O
A	O
and	O
A	O
/	O
A	O
genotypes	O
with	O
opiate	B-Disease
addiction	I-Disease
in	O
women	B-Species
,	O
but	O
not	O
men	B-Species
.	O
</ALL>	O

<ALL>	O
These	O
point	O
-	O
wise	O
significant	O
results	O
are	O
not	O
significant	O
experiment	O
-	O
wise	O
(	O
at	O
P	O
<	O
0.05	O
)	O
after	O
correction	O
for	O
multiple	O
testing	O
.	O
</ALL>	O

<ALL>	O
No	O
significant	O
association	O
was	O
found	O
with	O
haplotypes	O
of	O
the	O
three	O
most	O
common	O
SNPs	O
.	O
</ALL>	O

<ALL>	O
Linkage	O
disequilibrium	O
patterns	O
were	O
similar	O
for	O
the	O
three	O
ethnic	O
/	O
cultural	O
groups	O
.	O
</ALL>	O

<ALL>	O
Depletion	O
of	O
mitochondrial	O
DNA	O
in	O
fibroblast	O
cultures	O
from	O
patients	B-Species
with	O
POLG1	B-Gene
mutations	O
is	O
a	O
consequence	O
of	O
catalytic	O
mutations	O
.	O
</ALL>	O

<ALL>	O
We	O
investigated	O
clinical	O
and	O
cellular	O
phenotypes	O
of	O
24	O
children	O
with	O
mutations	O
in	O
the	O
catalytic	O
(	O
alpha	O
)	O
subunit	O
of	O
the	O
mitochondrial	B-Gene
DNA	I-Gene
(	I-Gene
mtDNA	I-Gene
)	I-Gene
gamma	I-Gene
polymerase	I-Gene
(	O
POLG1	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
Twenty	O
-	O
one	O
had	O
Alpers	B-Disease
syndrome	I-Disease
,	O
the	O
commonest	O
severe	O
POLG1	B-Gene
autosomal	O
recessive	O
phenotype	O
,	O
comprising	O
hepatoencephalopathy	B-Disease
and	O
often	O
mtDNA	O
depletion	O
.	O
</ALL>	O

<ALL>	O
The	O
cellular	O
mtDNA	O
content	O
reflected	O
the	O
genotype	O
more	O
closely	O
than	O
did	O
clinical	O
features	O
.	O
</ALL>	O

<ALL>	O
Patients	B-Species
with	O
tissue	O
depletion	O
of	O
mtDNA	O
all	O
had	O
at	O
least	O
one	O
allele	O
with	O
either	O
a	O
missense	O
mutation	O
in	O
a	O
catalytic	O
domain	O
or	O
a	O
nonsense	O
mutation	O
.	O
</ALL>	O

<ALL>	O
Four	O
out	O
of	O
12	O
patients	B-Species
exhibited	O
a	O
progressive	O
,	O
mosaic	O
pattern	O
of	O
mtDNA	O
depletion	O
in	O
cultured	O
fibroblasts	O
.	O
</ALL>	O

<ALL>	O
All	O
these	O
patients	B-Species
had	O
mutations	O
in	O
a	O
catalytic	O
domain	O
in	O
both	O
POLG1	B-Gene
alleles	O
,	O
in	O
either	O
the	O
polymerase	O
or	O
exonuclease	O
domain	O
or	O
both	O
.	O
</ALL>	O

<ALL>	O
The	O
tissue	O
mtDNA	O
content	O
of	O
patients	B-Species
who	O
had	O
two	O
linker	O
mutations	O
was	O
normal	O
,	O
and	O
their	O
phenotypes	O
the	O
mildest	O
.	O
</ALL>	O

<ALL>	O
Epilepsy	B-Disease
and	O
/	O
or	O
movement	B-Disease
disorder	I-Disease
were	O
major	O
features	O
in	O
all	O
21	O
.	O
</ALL>	O

<ALL>	O
Previous	O
studies	O
have	O
implicated	O
replication	O
stalling	O
as	O
a	O
mechanism	O
for	O
mtDNA	O
depletion	O
.	O
</ALL>	O

<ALL>	O
The	O
mosaic	O
cellular	O
depletion	O
that	O
we	O
have	O
demonstrated	O
in	O
cell	O
cultures	O
may	O
be	O
a	O
manifestation	O
of	O
severe	O
replication	O
stalling	O
.	O
</ALL>	O

<ALL>	O
One	O
patient	B-Species
with	O
a	O
severe	O
cellular	O
and	O
clinical	O
phenotype	O
was	O
a	O
compound	O
heterozygote	O
with	O
POLG1	B-Gene
mutations	O
in	O
the	O
polymerase	O
and	O
exonuclease	O
domain	O
intrans	O
.	O
</ALL>	O

<ALL>	O
This	O
suggests	O
that	O
POLG1	B-Gene
requires	O
both	O
polymerase	O
and	O
3	O
'	O
-	O
5	O
'	O
exonuclease	O
activity	O
in	O
the	O
same	O
molecule	O
.	O
</ALL>	O

<ALL>	O
This	O
is	O
consistent	O
with	O
current	O
functional	O
models	O
for	O
eukaryotic	O
DNA	O
polymerases	O
,	O
which	O
alternate	O
between	O
polymerizing	O
and	O
editing	O
modes	O
,	O
as	O
determined	O
by	O
competition	O
between	O
these	O
two	O
active	O
sites	O
for	O
the	O
3	O
'	O
end	O
of	O
the	O
DNA	O
.	O
</ALL>	O

<ALL>	O
Mutations	O
in	O
phospholipase	B-Gene
C	I-Gene
epsilon	I-Gene
1	I-Gene
are	O
not	O
sufficient	O
to	O
cause	O
diffuse	B-Disease
mesangial	I-Disease
sclerosis	I-Disease
.	O
</ALL>	O

<ALL>	O
Diffuse	B-Disease
mesangial	I-Disease
sclerosis	I-Disease
occurs	O
as	O
an	O
isolated	O
abnormality	O
or	O
as	O
a	O
part	O
of	O
a	O
syndrome	O
.	O
</ALL>	O

<ALL>	O
Recently	O
,	O
mutations	O
in	O
phospholipase	B-Gene
C	I-Gene
epsilon	I-Gene
1	I-Gene
(	O
PLCE1	B-Gene
)	O
were	O
found	O
to	O
cause	O
a	O
nonsyndromic	O
,	O
autosomal	O
recessive	O
form	O
of	O
this	O
disease	O
.	O
</ALL>	O

<ALL>	O
Here	O
we	O
describe	O
three	O
children	O
from	O
one	O
consanguineous	O
kindred	O
of	O
Pakistani	O
origin	O
with	O
diffuse	B-Disease
mesangial	I-Disease
sclerosis	I-Disease
who	O
presented	O
with	O
congenital	B-Disease
or	I-Disease
infantile	I-Disease
nephrotic	I-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Homozygous	O
mutations	O
in	O
PLCE1	B-Gene
(	O
also	O
known	O
as	O
KIAA1516	B-Gene
,	O
PLCE	B-Gene
,	O
or	O
NPHS3	B-Gene
)	O
were	O
identified	O
following	O
genome	O
-	O
wide	O
mapping	O
of	O
single	O
-	O
nucleotide	O
polymorphisms	O
.	O
</ALL>	O

<ALL>	O
All	O
affected	O
children	O
were	O
homozygous	O
for	O
a	O
four	B-Variant
-	I-Variant
basepair	I-Variant
deletion	I-Variant
in	O
exon	O
3	O
,	O
which	O
created	O
a	O
premature	O
translational	O
stop	O
codon	O
.	O
</ALL>	O

<ALL>	O
Analysis	O
of	O
the	O
asymptomatic	O
father	O
of	O
two	O
of	O
the	O
children	O
revealed	O
that	O
he	O
was	O
also	O
homozygous	O
for	O
the	O
same	O
mutation	O
.	O
</ALL>	O

<ALL>	O
We	O
conclude	O
this	O
nonpenetrance	O
may	O
be	O
due	O
to	O
compensatory	O
mutations	O
at	O
a	O
second	O
locus	O
and	O
that	O
mutation	O
within	O
PLCE1	B-Gene
is	O
not	O
always	O
sufficient	O
to	O
cause	O
diffuse	B-Disease
mesangial	I-Disease
sclerosis	I-Disease
.	O
</ALL>	O

<ALL>	O
Seizures	B-Disease
associated	O
with	O
levofloxacin	B-Chemical
:	O
case	O
presentation	O
and	O
literature	O
review	O
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
We	O
present	O
a	O
case	O
of	O
a	O
patient	B-Species
who	O
developed	O
seizures	B-Disease
shortly	O
after	O
initiating	O
treatment	O
with	O
levofloxacin	B-Chemical
and	O
to	O
discuss	O
the	O
potential	O
drug	O
-	O
drug	O
interactions	O
related	O
to	O
the	O
inhibition	O
of	O
cytochrome	B-Gene
P450	I-Gene
(	I-Gene
CYP	I-Gene
)	I-Gene
1A2	I-Gene
in	O
this	O
case	O
,	O
as	O
well	O
as	O
in	O
other	O
cases	O
,	O
of	O
levofloxacin	B-Chemical
-	O
induced	O
seizures	B-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Several	O
biomedical	O
databases	O
were	O
searched	O
including	O
MEDLINE	O
,	O
Cochrane	O
and	O
Ovid	O
.	O
</ALL>	O

<ALL>	O
The	O
main	O
search	O
terms	O
utilized	O
were	O
case	O
report	O
and	O
levofloxacin	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
search	O
was	O
limited	O
to	O
studies	O
published	O
in	O
English	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Six	O
cases	O
of	O
levofloxacin	B-Chemical
-	O
induced	O
seizures	B-Disease
have	O
been	O
reported	O
in	O
the	O
literature	O
.	O
</ALL>	O

<ALL>	O
Drug	O
-	O
drug	O
interactions	O
related	O
to	O
the	O
inhibition	O
of	O
CYP1A2	B-Gene
by	O
levofloxacin	B-Chemical
are	O
likely	O
involved	O
in	O
the	O
clinical	O
outcome	O
of	O
these	O
cases	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Clinicians	O
are	O
exhorted	O
to	O
pay	O
close	O
attention	O
when	O
initiating	O
levofloxacin	B-Chemical
therapy	O
in	O
patients	B-Species
taking	O
medications	O
with	O
epileptogenic	O
properties	O
that	O
are	O
CYP1A2	B-Gene
substrates	O
.	O
</ALL>	O

<ALL>	O
Fatal	O
carbamazepine	B-Chemical
induced	O
fulminant	O
eosinophilic	O
(	O
hypersensitivity	B-Disease
)	O
myocarditis	B-Disease
:	O
emphasis	O
on	O
anatomical	O
and	O
histological	O
characteristics	O
,	O
mechanisms	O
and	O
genetics	O
of	O
drug	B-Disease
hypersensitivity	I-Disease
and	O
differential	O
diagnosis	O
.	O
</ALL>	O

<ALL>	O
The	O
most	O
severe	O
adverse	O
reactions	O
to	O
carbamazepine	B-Chemical
have	O
been	O
observed	O
in	O
the	O
haemopoietic	O
system	O
,	O
the	O
liver	O
and	O
the	O
cardiovascular	O
system	O
.	O
</ALL>	O

<ALL>	O
A	O
frequently	O
fatal	O
,	O
although	O
exceptionally	O
rare	O
side	O
effect	O
of	O
carbamazepine	B-Chemical
is	O
necrotizing	O
eosinophilic	O
(	O
hypersensitivity	B-Disease
)	O
myocarditis	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
report	O
a	O
case	O
of	O
hypersensitivity	B-Disease
myocarditis	B-Disease
secondary	O
to	O
administration	O
of	O
carbamazepine	B-Chemical
.	O
</ALL>	O

<ALL>	O
Acute	O
hypersensitivity	B-Disease
myocarditis	B-Disease
was	O
not	O
suspected	O
clinically	O
,	O
and	O
the	O
diagnosis	O
was	O
made	O
post	O
-	O
mortem	O
.	O
</ALL>	O

<ALL>	O
Histology	O
revealed	O
diffuse	O
infiltration	O
of	O
the	O
myocardium	O
by	O
eosinophils	O
and	O
lymphocytes	O
with	O
myocyte	O
damage	O
.	O
</ALL>	O

<ALL>	O
Clinically	O
,	O
death	B-Disease
was	O
due	O
to	O
cardiogenic	B-Disease
shock	I-Disease
.	O
</ALL>	O

<ALL>	O
To	O
best	O
of	O
our	O
knowledge	O
this	O
is	O
the	O
second	O
case	O
of	O
fatal	O
carbamazepine	B-Chemical
induced	O
myocarditis	B-Disease
reported	O
in	O
English	O
literature	O
.	O
</ALL>	O

<ALL>	O
Lack	O
of	O
association	O
between	O
ADRA2B	O
-	B-Variant
4825	I-Variant
gene	I-Variant
insertion	I-Variant
/	I-Variant
deletion	I-Variant
polymorphism	O
and	O
migraine	B-Disease
in	O
Chinese	O
Han	O
population	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
The	O
present	O
study	O
aimed	O
to	O
estimate	O
the	O
association	O
between	O
susceptibility	O
to	O
migraine	B-Disease
and	O
the	O
12	B-Variant
-	I-Variant
nucleotide	I-Variant
insertion	I-Variant
/	I-Variant
deletion	I-Variant
(	I-Variant
indel	I-Variant
)	I-Variant
polymorphism	O
in	O
promoter	O
region	O
of	O
alpha	B-Gene
(	I-Gene
2B	I-Gene
)	I-Gene
-	I-Gene
adrenergic	I-Gene
receptor	I-Gene
gene	O
(	O
ADRA2B	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
A	O
case	O
-	O
control	O
study	O
was	O
carried	O
out	O
in	O
Chinese	O
Han	O
population	O
,	O
including	O
368	O
cases	O
of	O
migraine	B-Disease
and	O
517	O
controls	O
.	O
</ALL>	O

<ALL>	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
blood	O
samples	O
,	O
and	O
DNA	O
fragments	O
containing	O
the	O
site	O
of	O
polymorphism	O
were	O
amplified	O
by	O
PCR	O
.	O
</ALL>	O

<ALL>	O
Data	O
were	O
adjusted	O
for	O
sex	O
,	O
age	O
,	O
migraine	B-Disease
history	O
and	O
family	O
history	O
,	O
and	O
analyzed	O
using	O
a	O
logistic	O
regression	O
model	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
There	O
was	O
no	O
association	O
between	O
indel	O
polymorphism	O
and	O
migraine	B-Disease
,	O
at	O
either	O
the	O
allele	O
or	O
the	O
genotype	O
level	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
These	O
findings	O
do	O
not	O
support	O
a	O
functional	O
significance	O
of	O
ADRA2B	B-Gene
indel	B-Variant
polymorphism	I-Variant
at	I-Variant
position	I-Variant
-	I-Variant
4825	I-Variant
relative	O
to	O
the	O
start	O
codon	O
in	O
the	O
far	O
upstream	O
region	O
of	O
the	O
promoter	O
in	O
the	O
present	O
migraine	B-Disease
subjects	O
.	O
</ALL>	O

<ALL>	O
A	O
novel	O
apolipoprotein	B-Gene
E	I-Gene
mutation	O
,	O
ApoE	B-Gene
Osaka	O
(	O
Arg158	B-Variant
Pro	I-Variant
)	O
,	O
in	O
a	O
dyslipidemic	B-Disease
patient	B-Species
with	O
lipoprotein	B-Disease
glomerulopathy	I-Disease
.	O
</ALL>	O

<ALL>	O
Lipoprotein	B-Disease
glomerulopathy	I-Disease
(	O
LPG	B-Disease
)	O
is	O
a	O
rare	O
disease	O
characterized	O
by	O
the	O
presence	O
of	O
thrombuslike	O
deposition	O
in	O
markedly	O
dilated	O
glomerular	O
capillaries	O
and	O
is	O
often	O
accompanied	O
by	O
an	O
increased	O
serum	O
apolipoprotein	B-Gene
E	I-Gene
(	O
apoE	B-Gene
)	O
level	O
.	O
</ALL>	O

<ALL>	O
Several	O
gene	O
mutations	O
of	O
apoE	B-Gene
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
LPG	B-Disease
.	O
</ALL>	O

<ALL>	O
In	O
the	O
current	O
study	O
,	O
we	O
report	O
an	O
LPG	B-Disease
patient	B-Species
with	O
a	O
novel	O
apoE	B-Gene
mutation	O
,	O
apoE	B-Gene
Osaka	O
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
was	O
a	O
45	O
-	O
year	O
-	O
old	O
man	B-Species
who	O
was	O
hospitalized	O
due	O
to	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Light	O
and	O
electron	O
microscopic	O
observations	O
of	O
renal	O
biopsy	O
clearly	O
showed	O
characteristic	O
findings	O
of	O
LPG	B-Disease
,	O
including	O
lamellate	B-Disease
thrombi	I-Disease
in	O
the	O
lumen	O
of	O
dilated	O
glomerular	O
capillaries	O
.	O
</ALL>	O

<ALL>	O
His	O
apoE	B-Gene
phenotype	O
was	O
apoE3	B-Gene
/	I-Gene
2	I-Gene
and	O
he	O
had	O
mild	O
dyslipidemia	B-Disease
with	O
a	O
mid	O
-	O
band	O
on	O
polyacrylamide	B-Chemical
gel	O
electrophoresis	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
intriguing	O
that	O
the	O
serum	O
apoE	B-Gene
level	O
was	O
within	O
normal	O
limits	O
.	O
</ALL>	O

<ALL>	O
We	O
determined	O
the	O
sequence	O
of	O
the	O
apoE	B-Gene
gene	O
using	O
direct	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
products	O
.	O
</ALL>	O

<ALL>	O
ApoE	B-Gene
gene	O
analysis	O
showed	O
a	O
nucleotide	O
substitution	O
of	O
G	B-Variant
to	I-Variant
C	I-Variant
at	I-Variant
codon	I-Variant
158	I-Variant
of	O
exon	O
4	O
.	O
</ALL>	O

<ALL>	O
This	O
mutation	O
denoted	O
an	O
amino	O
acid	O
substitution	O
of	O
arginine	B-Variant
residue	I-Variant
for	I-Variant
the	I-Variant
proline	I-Variant
residue	I-Variant
at	I-Variant
position	I-Variant
158	I-Variant
of	O
apoE	B-Gene
.	O
</ALL>	O

<ALL>	O
The	O
result	O
of	O
PCR	O
associated	O
with	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
also	O
suggested	O
that	O
this	O
mutation	O
is	O
heterozygous	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
possible	O
that	O
apoE	B-Gene
Osaka	O
mutation	O
causes	O
a	O
conformational	O
change	O
of	O
apoE	B-Gene
protein	O
and	O
affects	O
the	O
interaction	O
between	O
abnormal	O
apoE	B-Gene
-	O
containing	O
lipoproteins	O
and	O
the	O
endothelial	O
cells	O
of	O
glomerular	O
capillaries	O
.	O
</ALL>	O

<ALL>	O
The	O
precise	O
mechanism	O
of	O
LPG	B-Disease
related	O
with	O
apoE	B-Gene
Osaka	O
,	O
however	O
,	O
remains	O
to	O
be	O
elucidated	O
.	O
</ALL>	O

<ALL>	O
PTCH1	B-Gene
gene	O
mutations	O
in	O
exon	O
17	O
and	O
loss	O
of	O
heterozygosity	O
on	O
D9S180	O
microsatellite	O
in	O
sporadic	O
and	O
inherited	O
human	B-Species
basal	B-Disease
cell	I-Disease
carcinomas	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Basal	B-Disease
cell	I-Disease
carcinomas	I-Disease
(	O
BCCs	B-Disease
)	O
are	O
the	O
most	O
frequent	O
human	B-Species
cancer	B-Disease
that	O
results	O
from	O
malignant	O
transformation	O
of	O
basal	O
cells	O
in	O
the	O
epidermis	O
.	O
</ALL>	O

<ALL>	O
Gorlin	B-Disease
syndrome	I-Disease
is	O
a	O
rare	O
inherited	B-Disease
autosomal	I-Disease
dominant	I-Disease
disease	I-Disease
that	O
predisposes	O
with	O
multiple	O
BCCs	B-Disease
and	O
other	O
birth	B-Disease
defects	I-Disease
.	O
</ALL>	O

<ALL>	O
Both	O
sporadic	O
and	O
inherited	O
BCCs	B-Disease
are	O
associated	O
with	O
mutations	O
in	O
the	O
tumor	B-Disease
suppressor	O
gene	O
PTCH1	B-Gene
,	O
but	O
there	O
is	O
still	O
uncertainty	O
on	O
the	O
role	O
of	O
its	O
homolog	O
PTCH2	B-Gene
.	O
</ALL>	O

<ALL>	O
OBJECTIVES	O
:	O
To	O
search	O
for	O
mutations	O
and	O
genomic	O
instability	O
in	O
sporadic	O
and	O
inherited	O
BCCs	B-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
DNA	O
obtained	O
from	O
leukocytes	O
and	O
tumor	B-Disease
cells	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
regarding	O
five	O
exons	O
of	O
PTCH1	B-Gene
and	O
PTCH2	B-Gene
and	O
neighboring	O
microsatellites	O
.	O
</ALL>	O

<ALL>	O
Exons	O
were	O
sequenced	O
and	O
compared	O
with	O
the	O
GenBank	O
database	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Only	O
D9S180	O
,	O
of	O
six	O
microsatellites	O
,	O
showed	O
loss	O
of	O
heterozygosity	O
in	O
three	O
BCCs	B-Disease
(	O
two	O
sporadic	O
and	O
one	O
inherited	O
)	O
.	O
</ALL>	O

<ALL>	O
One	O
sporadic	O
BCC	B-Disease
presented	O
the	O
mutation	O
g.2885	B-Variant
G	I-Variant
>	I-Variant
C	I-Variant
in	O
exon	O
17	O
of	O
PTCH1	B-Gene
,	O
which	O
predicts	O
the	O
substitution	O
p	B-Variant
.	I-Variant
R962	I-Variant
T	I-Variant
in	O
an	O
external	O
domain	O
of	O
the	O
protein	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
the	O
leukocytes	O
and	O
tumor	B-Disease
cells	O
of	O
one	O
patient	B-Species
with	O
Gorlin	B-Disease
syndrome	I-Disease
showed	O
the	O
mutation	O
g.2839	B-Variant
T	I-Variant
>	I-Variant
G	I-Variant
in	O
the	O
same	O
exon	O
and	O
gene	O
,	O
which	O
predicts	O
a	O
p	B-Variant
.	I-Variant
E947stop	I-Variant
and	O
truncated	O
protein	O
.	O
</ALL>	O

<ALL>	O
All	O
control	O
and	O
tumor	B-Disease
samples	O
presented	O
IVS9	B-Variant
+	I-Variant
217	I-Variant
T	I-Variant
in	O
intron	O
9	O
of	O
PTCH1	B-Gene
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Mutations	O
found	O
in	O
the	O
PTCH1	B-Gene
gene	O
and	O
neighboring	O
repetitive	O
sequences	O
may	O
have	O
contributed	O
to	O
the	O
development	O
of	O
the	O
studied	O
BCCs	B-Disease
.	O
</ALL>	O

<ALL>	O
Novel	O
compound	O
heterozygous	O
mutation	O
of	O
MLYCD	B-Gene
in	O
a	O
Chinese	O
patient	B-Species
with	O
malonic	B-Disease
aciduria	I-Disease
.	O
</ALL>	O

<ALL>	O
A	O
3	O
-	O
year	O
-	O
old	O
Chinese	O
boy	O
presented	O
with	O
prominent	O
clinical	O
features	O
of	O
malonic	B-Disease
aciduria	I-Disease
,	O
including	O
developmental	B-Disease
delay	I-Disease
,	O
short	B-Disease
stature	I-Disease
,	O
brain	B-Disease
abnormalities	I-Disease
and	O
massive	O
excretion	O
of	O
malonic	B-Chemical
acid	I-Chemical
and	O
methylmalonic	B-Chemical
acid	I-Chemical
.	O
</ALL>	O

<ALL>	O
Molecular	O
characterization	O
by	O
DNA	O
sequencing	O
analysis	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
of	O
the	O
MLYCD	B-Gene
gene	O
revealed	O
a	O
heterozygous	O
mutation	O
(	O
c.920	B-Variant
T	I-Variant
>	I-Variant
G	I-Variant
,	O
p	B-Variant
.	I-Variant
Leu307Arg	I-Variant
)	O
in	O
the	O
patient	B-Species
and	O
his	O
father	O
and	O
a	O
heterozygous	O
deletion	O
comprising	O
exon	O
1	O
in	O
the	O
patient	B-Species
and	O
his	O
mother	O
.	O
</ALL>	O

<ALL>	O
The	O
missense	O
mutation	O
(	O
c.920	B-Variant
T	I-Variant
>	I-Variant
G	I-Variant
)	O
was	O
not	O
found	O
in	O
100	O
healthy	O
controls	O
and	O
has	O
not	O
been	O
reported	O
previously	O
.	O
</ALL>	O

<ALL>	O
Our	O
findings	O
expand	O
the	O
number	O
of	O
reported	O
cases	O
and	O
add	O
a	O
novel	O
entry	O
to	O
the	O
repertoire	O
of	O
MLYCD	B-Gene
mutations	O
.	O
</ALL>	O

<ALL>	O
Sepsis	B-Disease
-	O
induced	O
changes	O
in	O
amino	B-Gene
acid	I-Gene
transporters	I-Gene
and	O
leucine	B-Chemical
signaling	O
via	O
mTOR	B-Gene
in	O
skeletal	O
muscle	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
tested	O
the	O
hypothesis	O
that	O
sepsis	B-Disease
-	O
induced	O
leucine	B-Chemical
(	O
Leu	B-Chemical
)	O
resistance	O
in	O
skeletal	O
muscle	O
is	O
associated	O
with	O
a	O
down	O
-	O
regulation	O
of	O
amino	B-Gene
acid	I-Gene
transporters	I-Gene
important	O
in	O
regulating	O
Leu	B-Chemical
flux	O
or	O
an	O
impairment	O
in	O
the	O
formation	O
of	O
the	O
Leu	B-Chemical
-	O
sensitive	O
mTOR	B-Gene
-	O
Ragulator	B-Gene
complex	I-Gene
.	O
</ALL>	O

<ALL>	O
Sepsis	B-Disease
in	O
adult	O
male	O
rats	B-Species
decreased	O
basal	O
protein	O
synthesis	O
in	O
gastrocnemius	O
,	O
associated	O
with	O
a	O
reduction	O
in	O
mTOR	B-Gene
activation	O
as	O
indicated	O
by	O
decreased	O
4E	B-Gene
-	I-Gene
BP1	I-Gene
and	O
S6K1	B-Gene
phosphorylation	O
.	O
</ALL>	O

<ALL>	O
The	O
ability	O
of	O
oral	O
Leu	B-Chemical
to	O
increase	O
protein	O
synthesis	O
and	O
mTOR	B-Gene
kinase	O
after	O
1	O
h	O
was	O
largely	O
prevented	O
in	O
sepsis	B-Disease
.	O
</ALL>	O

<ALL>	O
Sepsis	B-Disease
increased	O
CAT1	B-Gene
,	O
LAT2	B-Gene
and	O
SNAT2	B-Gene
mRNA	O
content	O
two	O
-	O
to	O
fourfold	O
,	O
but	O
only	O
the	O
protein	O
content	O
for	O
CAT1	B-Gene
(	O
20	O
%	O
decrease	O
)	O
differed	O
significantly	O
.	O
</ALL>	O

<ALL>	O
Conversely	O
,	O
sepsis	B-Disease
decreased	O
the	O
proton	B-Gene
-	I-Gene
assisted	I-Gene
amino	I-Gene
acid	I-Gene
transporter	I-Gene
(	I-Gene
PAT	I-Gene
)	I-Gene
-	I-Gene
2	I-Gene
mRNA	O
by	O
60	O
%	O
,	O
but	O
without	O
a	O
coordinate	O
change	O
in	O
PAT2	B-Gene
protein	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
no	O
sepsis	B-Disease
or	O
Leu	B-Chemical
effect	O
on	O
the	O
protein	O
content	O
for	O
RagA	B-Gene
-	I-Gene
D	I-Gene
,	O
LAMTOR	B-Gene
-	I-Gene
1	I-Gene
and	I-Gene
-	I-Gene
2	I-Gene
,	O
raptor	B-Gene
,	O
Rheb	B-Gene
or	O
mTOR	B-Gene
in	O
muscle	O
.	O
</ALL>	O

<ALL>	O
The	O
binding	O
of	O
mTOR	B-Gene
,	O
PRAS40	B-Gene
and	O
RagC	B-Gene
to	O
raptor	B-Gene
did	O
not	O
differ	O
for	O
control	O
and	O
septic	O
muscle	O
in	O
the	O
basal	O
condition	O
;	O
however	O
,	O
the	O
Leu	B-Chemical
-	O
induced	O
decrease	O
in	O
PRAS40	B-Gene
raptor	B-Gene
and	O
increase	O
in	O
RagC	B-Gene
raptor	B-Gene
seen	O
in	O
control	O
muscle	O
was	O
absent	O
in	O
sepsis	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
intracellular	O
Leu	B-Chemical
concentration	O
was	O
increased	O
in	O
septic	O
muscle	O
,	O
compared	O
to	O
basal	O
control	O
conditions	O
,	O
and	O
oral	O
Leu	B-Chemical
further	O
increased	O
the	O
intracellular	O
Leu	B-Chemical
concentration	O
similarly	O
in	O
both	O
control	O
and	O
septic	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Hence	O
,	O
while	O
alterations	O
in	O
select	O
amino	B-Gene
acid	I-Gene
transporters	I-Gene
are	O
not	O
associated	O
with	O
development	O
of	O
sepsis	B-Disease
-	O
induced	O
Leu	B-Chemical
resistance	O
,	O
the	O
Leu	B-Chemical
-	O
stimulated	O
binding	O
of	O
raptor	B-Gene
with	O
RagC	B-Gene
and	O
the	O
recruitment	O
of	O
mTOR	B-Gene
/	O
raptor	B-Gene
to	O
the	O
endosome	O
-	O
lysosomal	O
compartment	O
may	O
partially	O
explain	O
the	O
inability	O
of	O
Leu	B-Chemical
to	O
fully	O
activate	O
mTOR	B-Gene
and	O
muscle	O
protein	O
synthesis	O
.	O
</ALL>	O

<ALL>	O
Star	B-Gene
-	I-Gene
PAP	I-Gene
,	O
a	O
poly	B-Gene
(	I-Gene
A	I-Gene
)	I-Gene
polymerase	I-Gene
,	O
functions	O
as	O
a	O
tumor	B-Disease
suppressor	O
in	O
an	O
orthotopic	O
human	B-Species
breast	B-Disease
cancer	I-Disease
model	O
.	O
</ALL>	O

<ALL>	O
Star	B-Gene
-	I-Gene
PAP	I-Gene
is	O
a	O
noncanonical	O
poly	B-Gene
(	I-Gene
A	I-Gene
)	I-Gene
polymerase	I-Gene
and	O
required	O
for	O
the	O
expression	O
of	O
a	O
select	O
set	O
of	O
mRNAs	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
pathological	O
role	O
of	O
Star	B-Gene
-	I-Gene
PAP	I-Gene
in	O
cancer	B-Disease
largely	O
remains	O
unknown	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
observed	O
decreased	O
expression	O
of	O
Star	B-Gene
-	I-Gene
PAP	I-Gene
in	O
breast	B-Disease
cancer	I-Disease
cell	O
lines	O
and	O
tissues	O
.	O
</ALL>	O

<ALL>	O
Ectopic	O
Star	B-Gene
-	I-Gene
PAP	I-Gene
expression	O
inhibited	O
proliferation	O
as	O
well	O
as	O
colony	O
-	O
forming	O
ability	O
of	O
breast	B-Disease
cancer	I-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
In	O
breast	B-Disease
cancer	I-Disease
patients	B-Species
,	O
high	O
levels	O
of	O
Star	B-Gene
-	I-Gene
PAP	I-Gene
correlated	O
with	O
an	O
improved	O
prognosis	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
by	O
regulating	O
the	O
expression	O
of	O
BIK	B-Gene
(	O
BCL2	B-Gene
-	I-Gene
interacting	I-Gene
killer	I-Gene
)	O
,	O
Star	B-Gene
-	I-Gene
PAP	I-Gene
induced	O
apoptosis	O
of	O
breast	B-Disease
cancer	I-Disease
cells	O
through	O
the	O
mitochondrial	O
pathway	O
.	O
</ALL>	O

<ALL>	O
The	O
growth	O
of	O
breast	B-Disease
cancer	I-Disease
xenografts	O
in	O
NOD	O
/	O
SCID	B-Disease
mice	B-Species
was	O
also	O
inhibited	O
by	O
the	O
doxycycline	B-Chemical
-	O
induced	O
Star	B-Gene
-	I-Gene
PAP	I-Gene
overexpression	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
Star	B-Gene
-	I-Gene
PAP	I-Gene
sensitized	O
breast	B-Disease
cancer	I-Disease
cells	O
to	O
chemotherapy	O
drugs	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
</ALL>	O

<ALL>	O
In	O
mammary	O
epithelial	O
cells	O
,	O
Star	B-Gene
-	I-Gene
PAP	I-Gene
knockdown	O
partially	O
transformed	O
these	O
cells	O
and	O
induced	O
them	O
to	O
undergo	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
suggested	O
that	O
Star	B-Gene
-	I-Gene
PAP	I-Gene
possesses	O
tumor	B-Disease
-	O
suppressing	O
activity	O
and	O
can	O
be	O
a	O
valuable	O
target	O
for	O
developing	O
new	O
cancer	B-Disease
therapeutic	O
strategies	O
.	O
</ALL>	O

<ALL>	O
Lack	O
of	O
major	O
involvement	O
of	O
human	B-Species
uroplakin	B-Gene
genes	O
in	O
vesicoureteral	B-Disease
reflux	I-Disease
:	O
implications	O
for	O
disease	O
heterogeneity	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Primary	O
vesicoureteral	B-Disease
reflux	I-Disease
(	O
VUR	B-Disease
)	O
is	O
a	O
hereditary	B-Disease
disorder	I-Disease
characterized	O
by	O
the	O
retrograde	O
flow	O
of	O
urine	O
into	O
the	O
ureters	O
and	O
kidneys	O
.	O
</ALL>	O

<ALL>	O
It	O
affects	O
about	O
1	O
%	O
of	O
the	O
young	O
children	O
and	O
is	O
thus	O
one	O
of	O
the	O
most	O
common	O
hereditary	B-Disease
diseases	I-Disease
.	O
</ALL>	O

<ALL>	O
Its	O
associated	O
nephropathy	B-Disease
is	O
an	O
important	O
cause	O
of	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
failure	I-Disease
in	O
children	O
and	O
adults	O
.	O
</ALL>	O

<ALL>	O
Recent	O
studies	O
indicate	O
that	O
genetic	O
ablation	O
of	O
mouse	B-Species
uroplakin	B-Gene
(	I-Gene
UP	I-Gene
)	I-Gene
III	I-Gene
gene	O
,	O
which	O
encodes	O
a	O
47	O
kD	O
urothelial	O
-	O
specific	O
integral	O
membrane	O
protein	O
forming	O
urothelial	O
plaques	O
,	O
causes	O
VUR	B-Disease
and	O
hydronephrosis	B-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
To	O
begin	O
to	O
determine	O
whether	O
mutations	O
in	O
UP	B-Gene
genes	O
might	O
play	O
a	O
role	O
in	O
human	B-Species
VUR	B-Disease
,	O
we	O
genotyped	O
all	O
four	O
UP	B-Gene
genes	O
in	O
76	O
patients	B-Species
with	O
radiologically	O
proven	O
primary	O
VUR	B-Disease
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
and	O
sequencing	O
of	O
all	O
their	O
exons	O
plus	O
50	O
to	O
150	O
bp	O
of	O
flanking	O
intronic	O
sequences	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Eighteen	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
were	O
identified	O
,	O
seven	O
of	O
which	O
were	O
missense	O
,	O
with	O
no	O
truncation	O
or	O
frame	O
shift	O
mutations	O
.	O
</ALL>	O

<ALL>	O
Since	O
healthy	O
relatives	O
of	O
the	O
VUR	B-Disease
probands	O
are	O
not	O
reliable	O
negative	O
controls	O
for	O
VUR	B-Disease
,	O
we	O
used	O
a	O
population	O
of	O
90	O
race	O
-	O
matched	O
,	O
healthy	O
individuals	O
,	O
unrelated	O
to	O
the	O
VUR	B-Disease
patients	B-Species
,	O
as	O
controls	O
to	O
perform	O
an	O
association	O
study	O
.	O
</ALL>	O

<ALL>	O
Most	O
of	O
the	O
SNPs	O
were	O
not	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
VUR	B-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
SNP1	O
of	O
UP	B-Gene
Ia	I-Gene
gene	O
affecting	O
a	O
C	B-Variant
to	I-Variant
T	I-Variant
conversion	O
and	O
an	O
Ala7Val	B-Variant
change	O
,	O
and	O
SNP7	O
of	O
UP	B-Gene
III	I-Gene
affecting	O
a	O
C	B-Variant
to	I-Variant
G	I-Variant
conversion	O
and	O
a	O
Pro154Ala	B-Variant
change	O
,	O
were	O
marginally	O
associated	O
with	O
VUR	B-Disease
(	O
both	O
P	O
=	O
0.08	O
)	O
.	O
</ALL>	O

<ALL>	O
Studies	O
of	O
additional	O
cases	O
yielded	O
a	O
second	O
set	O
of	O
data	O
that	O
,	O
in	O
combination	O
with	O
the	O
first	O
set	O
,	O
confirmed	O
a	O
weak	O
association	O
of	O
UP	B-Gene
III	I-Gene
SNP7	O
in	O
VUR	B-Disease
(	O
P	O
=	O
0.036	O
adjusted	O
for	O
both	O
subsets	O
of	O
cases	O
vs.	O
controls	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Such	O
a	O
weak	O
association	O
and	O
the	O
lack	O
of	O
families	O
with	O
simple	O
dominant	O
Mendelian	O
inheritance	O
suggest	O
that	O
missense	O
changes	O
of	O
uroplakin	B-Gene
genes	O
can	O
not	O
play	O
a	O
dominant	O
role	O
in	O
causing	O
VUR	B-Disease
in	O
humans	B-Species
,	O
although	O
they	O
may	O
be	O
weak	O
risk	O
factors	O
contributing	O
to	O
a	O
complex	O
polygenic	O
disease	O
.	O
</ALL>	O

<ALL>	O
The	O
fact	O
that	O
no	O
truncation	O
or	O
frame	O
shift	O
mutations	O
have	O
been	O
found	O
in	O
any	O
of	O
the	O
VUR	B-Disease
patients	B-Species
,	O
coupled	O
with	O
our	O
recent	O
finding	O
that	O
some	O
breeding	O
pairs	O
of	O
UP	B-Gene
III	I-Gene
knockout	O
mice	B-Species
yield	O
litters	O
that	O
show	O
not	O
only	O
VUR	B-Disease
,	O
but	O
also	O
severe	O
hydronephrosis	B-Disease
and	O
neonatal	B-Disease
death	I-Disease
,	O
raises	O
the	O
possibility	O
that	O
major	O
uroplakin	B-Gene
mutations	O
could	O
be	O
embryonically	O
or	O
postnatally	O
lethal	O
in	O
humans	B-Species
.	O
</ALL>	O

<ALL>	O
Does	O
domperidone	B-Chemical
potentiate	O
mirtazapine	B-Chemical
-	O
associated	O
restless	B-Disease
legs	I-Disease
syndrome	I-Disease
?	O
</ALL>	O

<ALL>	O
There	O
is	O
now	O
evidence	O
to	O
suggest	O
a	O
central	O
role	O
for	O
the	O
dopaminergic	O
system	O
in	O
restless	B-Disease
legs	I-Disease
syndrome	I-Disease
(	O
RLS	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
For	O
example	O
,	O
the	O
symptoms	O
of	O
RLS	B-Disease
can	O
be	O
dramatically	O
improved	O
by	O
levodopa	B-Chemical
and	O
dopamine	B-Chemical
agonists	O
,	O
whereas	O
central	O
dopamine	B-Chemical
D2	I-Chemical
receptor	I-Chemical
antagonists	I-Chemical
can	O
induce	O
or	O
aggravate	O
RLS	B-Disease
symptoms	O
.	O
</ALL>	O

<ALL>	O
To	O
our	O
knowledge	O
,	O
there	O
is	O
no	O
previous	O
report	O
regarding	O
whether	O
domperidone	B-Chemical
,	O
a	O
peripheral	O
dopamine	B-Gene
D2	I-Gene
receptor	I-Gene
antagonist	O
,	O
can	O
also	O
induce	O
or	O
aggravate	O
symptoms	O
of	O
RLS	B-Disease
.	O
</ALL>	O

<ALL>	O
Mirtazapine	B-Chemical
,	O
the	O
first	O
noradrenergic	B-Chemical
and	I-Chemical
specific	I-Chemical
serotonergic	I-Chemical
antidepressant	I-Chemical
(	O
NaSSA	B-Chemical
)	O
,	O
has	O
been	O
associated	O
with	O
RLS	B-Disease
in	O
several	O
recent	O
publications	O
.	O
</ALL>	O

<ALL>	O
The	O
authors	O
report	O
here	O
a	O
depressed	B-Disease
patient	B-Species
comorbid	O
with	O
postprandial	B-Disease
dyspepsia	I-Disease
who	O
developed	O
RLS	B-Disease
after	O
mirtazapine	B-Chemical
had	O
been	O
added	O
to	O
his	O
domperidone	B-Chemical
therapy	O
.	O
</ALL>	O

<ALL>	O
Our	O
patient	B-Species
started	O
to	O
have	O
symptoms	O
of	O
RLS	B-Disease
only	O
after	O
he	O
had	O
been	O
treated	O
with	O
mirtazapine	B-Chemical
,	O
and	O
his	O
RLS	B-Disease
symptoms	O
resolved	O
completely	O
upon	O
discontinuation	O
of	O
his	O
mirtazapine	B-Chemical
.	O
</ALL>	O

<ALL>	O
Such	O
a	O
temporal	O
relationship	O
between	O
the	O
use	O
of	O
mirtazapine	B-Chemical
and	O
the	O
symptoms	O
of	O
RLS	B-Disease
in	O
our	O
patient	B-Species
did	O
not	O
support	O
a	O
potentiating	O
effect	O
of	O
domperione	B-Chemical
on	O
mirtazapine	B-Chemical
-	O
associated	O
RLS	B-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
physicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
that	O
mirtazapine	B-Chemical
can	O
be	O
associated	O
with	O
RLS	B-Disease
in	O
some	O
individuals	O
,	O
especially	O
those	O
receiving	O
concomitant	O
dopamine	B-Chemical
D2	I-Chemical
receptor	I-Chemical
antagonists	I-Chemical
.	O
</ALL>	O

<ALL>	O
Regional	O
analysis	O
on	O
the	O
occurrence	O
of	O
oral	B-Disease
clefts	I-Disease
in	O
South	O
America	O
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
this	O
work	O
was	O
to	O
search	O
for	O
unequal	O
birth	O
prevalence	O
rates	O
(	O
BPRs	O
)	O
of	O
cleft	B-Disease
lip	I-Disease
+	O
/	O
-	O
cleft	B-Disease
palate	I-Disease
(	O
CL	B-Disease
/	I-Disease
P	I-Disease
)	O
,	O
and	O
cleft	B-Disease
palate	I-Disease
only	O
(	O
CPO	B-Disease
)	O
,	O
among	O
different	O
geographic	O
areas	O
in	O
South	O
America	O
,	O
and	O
to	O
analyze	O
phenotypic	O
characteristics	O
and	O
associated	O
risk	O
factors	O
in	O
each	O
identified	O
cluster	O
.	O
</ALL>	O

<ALL>	O
Included	O
were	O
5,128	O
CL	B-Disease
/	I-Disease
P	I-Disease
cases	O
,	O
1,745	O
CPO	B-Disease
cases	O
,	O
and	O
3,712	O
controls	O
(	O
like	O
-	O
sexed	O
,	O
non	O
-	O
malformed	O
liveborn	O
infant	O
,	O
born	O
immediately	O
after	O
a	O
malformed	O
one	O
,	O
in	O
the	O
same	O
hospital	O
)	O
,	O
over	O
4,199,630	O
consecutive	O
births	O
.	O
</ALL>	O

<ALL>	O
They	O
were	O
ascertained	O
between	O
1967	O
and	O
2004	O
,	O
in	O
190	O
maternity	O
hospitals	O
of	O
the	O
ECLAMC	O
(	O
Estudio	O
Colaborativo	O
Latinoamericano	O
de	O
Malformaciones	O
Congenitas	O
)	O
network	O
,	O
in	O
102	O
cities	O
of	O
all	O
10	O
South	O
American	O
countries	O
.	O
</ALL>	O

<ALL>	O
Non	O
-	O
predefined	O
geographical	O
areas	O
with	O
significantly	O
unusual	O
cleft	O
BPRs	O
were	O
identified	O
with	O
Kulldorf	O
and	O
Nagarwalla	O
's	O
spatial	O
scan	O
statistic	O
,	O
employing	O
number	O
of	O
cases	O
and	O
births	O
,	O
and	O
exact	O
location	O
of	O
each	O
hospital	O
.	O
</ALL>	O

<ALL>	O
Expected	O
values	O
were	O
cleft	O
BPRs	O
registered	O
for	O
the	O
entire	O
ECLAMC	O
hospital	O
network	O
.	O
</ALL>	O

<ALL>	O
Syndromic	O
and	O
non	O
-	O
syndromic	O
clefts	B-Disease
were	O
considered	O
for	O
cluster	O
analysis	O
,	O
and	O
phenotypic	O
characterization	O
,	O
while	O
only	O
non	O
-	O
syndromic	O
for	O
risk	O
factor	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Seven	O
clusters	O
for	O
CL	B-Disease
/	I-Disease
P	I-Disease
,	O
and	O
four	O
for	O
CPO	B-Disease
,	O
with	O
unusual	O
BPRs	O
were	O
identified	O
.	O
</ALL>	O

<ALL>	O
CL	B-Disease
/	I-Disease
P	I-Disease
cases	O
in	O
high	O
BPR	O
areas	O
were	O
more	O
severe	O
than	O
elsewhere	O
in	O
the	O
sample	O
,	O
similar	O
to	O
a	O
previous	O
ECLAMC	O
report	O
on	O
microtia	B-Disease
.	O
</ALL>	O

<ALL>	O
For	O
CL	B-Disease
/	I-Disease
P	I-Disease
,	O
high	O
BPR	O
clusters	O
were	O
associated	O
with	O
high	O
altitude	O
above	O
sea	O
level	O
,	O
Amerindian	O
ancestry	O
,	O
and	O
low	O
socioeconomic	O
strata	O
;	O
low	O
BPR	O
clusters	O
showed	O
association	O
with	O
African	O
Black	O
ancestry	O
.	O
</ALL>	O

<ALL>	O
Advanced	O
maternal	O
age	O
,	O
a	O
recognized	O
risk	O
factor	O
for	O
CPO	B-Disease
,	O
was	O
also	O
associated	O
with	O
the	O
only	O
identified	O
geographic	O
cluster	O
for	O
CPO	B-Disease
.	O
</ALL>	O

<ALL>	O
L1503R	B-Variant
is	O
a	O
member	O
of	O
group	O
I	O
mutation	O
and	O
has	O
dominant	O
-	O
negative	O
effect	O
on	O
secretion	O
of	O
full	O
-	O
length	O
VWF	B-Gene
multimers	O
:	O
an	O
analysis	O
of	O
two	O
patients	B-Species
with	O
type	B-Disease
2A	I-Disease
von	I-Disease
Willebrand	I-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
Type	B-Disease
2A	I-Disease
von	I-Disease
Willebrand	I-Disease
disease	I-Disease
(	O
VWD	B-Disease
)	O
is	O
characterized	O
by	O
decreased	O
platelet	O
-	O
dependent	O
function	O
of	O
von	B-Gene
Willebrand	I-Gene
factor	I-Gene
(	O
VWF	B-Gene
)	O
;	O
this	O
in	O
turn	O
is	O
associated	O
with	O
an	O
absence	O
of	O
high	O
-	O
molecular	O
-	O
weight	O
multimers	O
.	O
</ALL>	O

<ALL>	O
Sequence	O
analysis	O
of	O
the	O
VWF	B-Gene
gene	O
from	O
two	O
unrelated	O
type	B-Disease
2A	I-Disease
VWD	I-Disease
patients	B-Species
showed	O
an	O
identical	O
,	O
novel	O
,	O
heterozygous	O
T	B-Variant
-	I-Variant
-	I-Variant
>	I-Variant
G	I-Variant
transversion	I-Variant
at	I-Variant
nucleotide	I-Variant
4508	I-Variant
,	O
resulting	O
in	O
the	O
substitution	O
of	O
L1503R	B-Variant
in	O
the	O
VWF	B-Gene
A2	O
domain	O
.	O
</ALL>	O

<ALL>	O
This	O
substitution	O
,	O
which	O
was	O
not	O
found	O
in	O
60	O
unrelated	O
normal	O
individuals	O
,	O
was	O
introduced	O
into	O
a	O
full	O
-	O
length	O
VWF	B-Gene
cDNA	O
and	O
subsequently	O
expressed	O
in	O
293	B-CellLine
T	I-CellLine
cells	O
.	O
</ALL>	O

<ALL>	O
Only	O
trace	O
amount	O
of	O
the	O
mutant	O
VWF	B-Gene
protein	O
was	O
secreted	O
but	O
most	O
of	O
the	O
same	O
was	O
retained	O
in	O
293	B-CellLine
T	I-CellLine
cells	O
.	O
</ALL>	O

<ALL>	O
Co	O
-	O
transfection	O
experiment	O
of	O
both	O
wild	O
-	O
type	O
and	O
mutant	O
plasmids	O
indicated	O
the	O
dominant	O
-	O
negative	O
mechanism	O
of	O
disease	O
development	O
;	O
as	O
more	O
of	O
mutant	O
DNA	O
was	O
transfected	O
,	O
VWF	B-Gene
secretion	O
was	O
impaired	O
in	O
the	O
media	O
,	O
whereas	O
more	O
of	O
VWF	B-Gene
was	O
stored	O
in	O
the	O
cell	O
lysates	O
.	O
</ALL>	O

<ALL>	O
Molecular	O
dynamic	O
simulations	O
of	O
structural	O
changes	O
induced	O
by	O
L1503R	B-Variant
indicated	O
that	O
the	O
mean	O
value	O
of	O
all	O
-	O
atom	O
root	O
-	O
mean	O
-	O
squared	O
-	O
deviation	O
was	O
shifted	O
from	O
those	O
with	O
wild	O
type	O
or	O
another	O
mutation	O
L1503Q	B-Variant
that	O
has	O
been	O
reported	O
to	O
be	O
a	O
group	O
II	O
mutation	O
,	O
which	O
is	O
susceptible	O
to	O
ADAMTS13	B-Gene
proteolysis	O
.	O
</ALL>	O

<ALL>	O
Protein	O
instability	O
of	O
L1503R	B-Variant
may	O
be	O
responsible	O
for	O
its	O
intracellular	O
retention	O
and	O
perhaps	O
the	O
larger	O
VWF	B-Gene
multimers	O
,	O
containing	O
more	O
mutant	O
VWF	B-Gene
subunits	O
,	O
are	O
likely	O
to	O
be	O
mal	O
-	O
processed	O
and	O
retained	O
within	O
the	O
cell	O
.	O
</ALL>	O

<ALL>	O
Is	O
the	O
European	O
spatial	O
distribution	O
of	O
the	O
HIV	B-Species
-	I-Species
1	I-Species
-	O
resistant	O
CCR5	B-Gene
-	O
Delta32	B-Variant
allele	O
formed	O
by	O
a	O
breakdown	O
of	O
the	O
pathocenosis	O
due	O
to	O
the	O
historical	O
Roman	O
expansion	O
?	O
</ALL>	O

<ALL>	O
We	O
studied	O
the	O
possible	O
effects	O
of	O
the	O
expansion	O
of	O
ancient	O
Mediterranean	O
civilizations	O
during	O
the	O
five	O
centuries	O
before	O
and	O
after	O
Christ	O
on	O
the	O
European	O
distribution	O
of	O
the	O
mutant	O
allele	O
for	O
the	O
chemokine	B-Gene
receptor	I-Gene
gene	O
CCR5	B-Gene
which	O
has	O
a	O
32	B-Variant
-	I-Variant
bp	I-Variant
deletion	I-Variant
(	O
CCR5	B-Gene
-	O
Delta32	B-Variant
)	O
.	O
</ALL>	O

<ALL>	O
There	O
is	O
a	O
strong	O
evidence	O
for	O
the	O
unitary	O
origin	O
of	O
the	O
CCR5	B-Gene
-	O
Delta32	B-Variant
mutation	O
,	O
this	O
it	O
is	O
found	O
principally	O
in	O
Europe	O
and	O
Western	O
Asia	O
,	O
with	O
generally	O
a	O
north	O
-	O
south	O
downhill	O
cline	O
frequency	O
.	O
</ALL>	O

<ALL>	O
Homozygous	O
carriers	O
of	O
this	O
mutation	O
show	O
a	O
resistance	O
to	O
HIV	B-Disease
-	I-Disease
1	I-Disease
infection	I-Disease
and	O
a	O
slower	O
progression	O
towards	O
AIDS	B-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
HIV	B-Species
has	O
clearly	O
emerged	O
too	O
recently	O
to	O
have	O
been	O
the	O
selective	O
force	O
on	O
CCR5	B-Gene
.	O
</ALL>	O

<ALL>	O
Our	O
analyses	O
showed	O
strong	O
negative	O
correlations	O
in	O
Europe	O
between	O
the	O
allele	O
frequency	O
and	O
two	O
historical	O
parameters	O
,	O
i.e.	O
the	O
first	O
colonization	O
dates	O
by	O
the	O
great	O
ancient	O
Mediterranean	O
civilizations	O
,	O
and	O
the	O
distances	O
from	O
the	O
Northern	O
frontiers	O
of	O
the	O
Roman	O
Empire	O
in	O
its	O
greatest	O
expansion	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
other	O
studies	O
have	O
shown	O
that	O
the	O
deletion	O
frequencies	O
in	O
both	O
German	O
Bronze	O
Age	O
and	O
Swedish	O
Neolithic	O
populations	O
were	O
similar	O
to	O
those	O
found	O
in	O
the	O
corresponding	O
modern	O
populations	O
,	O
and	O
this	O
deletion	O
has	O
been	O
found	O
in	O
ancient	O
DNA	O
of	O
around	O
7000	O
years	O
ago	O
,	O
suggesting	O
that	O
in	O
the	O
past	O
,	O
the	O
deletion	O
frequency	O
could	O
have	O
been	O
relatively	O
high	O
in	O
European	O
populations	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
in	O
West	B-Species
Nile	I-Species
virus	I-Species
pathogenesis	O
,	O
CCR5	B-Gene
plays	O
an	O
antimicrobial	O
role	O
showing	O
that	O
host	O
genetic	O
factors	O
are	O
highly	O
pathogen	O
-	O
specific	O
.	O
</ALL>	O

<ALL>	O
Our	O
results	O
added	O
to	O
all	O
these	O
previous	O
data	O
suggest	O
that	O
the	O
actual	O
European	O
allele	O
frequency	O
distribution	O
might	O
not	O
be	O
due	O
to	O
genes	O
spreading	O
,	O
but	O
to	O
a	O
negative	O
selection	O
resulting	O
in	O
the	O
spread	O
of	O
pathogens	O
principally	O
during	O
Roman	O
expansion	O
.	O
</ALL>	O

<ALL>	O
Indeed	O
,	O
as	O
gene	O
flows	O
from	O
colonizers	O
to	O
European	O
native	O
populations	O
were	O
extremely	O
low	O
,	O
the	O
mutational	O
changes	O
might	O
be	O
associated	O
with	O
vulnerability	O
to	O
imported	O
infections	B-Disease
.	O
</ALL>	O

<ALL>	O
To	O
date	O
,	O
the	O
nature	O
of	O
the	O
parasites	O
remains	O
unknown	O
;	O
however	O
,	O
zoonoses	O
could	O
be	O
incriminated	O
.	O
</ALL>	O

<ALL>	O
The	O
human	B-Species
AHR	B-Gene
:	O
identification	O
of	O
single	O
nucleotide	O
polymorphisms	O
from	O
six	O
ethnic	O
populations	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
The	O
effects	O
of	O
2,3,7,8	B-Chemical
-	I-Chemical
tetrachlorodibenzo	I-Chemical
-	I-Chemical
p	I-Chemical
-	I-Chemical
dioxin	I-Chemical
and	O
related	O
dioxin	B-Chemical
-	O
like	O
chemicals	O
are	O
mediated	O
through	O
binding	O
-	O
dependent	O
activation	O
of	O
the	O
cytosolic	O
aryl	B-Gene
hydrocarbon	I-Gene
receptor	I-Gene
(	O
AHR	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
The	O
human	B-Species
AHR	B-Gene
is	O
a	O
low	O
-	O
affinity	O
receptor	O
relative	O
to	O
most	O
rodents	O
,	O
but	O
some	O
reports	O
suggest	O
that	O
there	O
may	O
be	O
individuals	O
with	O
polymorphic	O
high	O
-	O
affinity	O
receptors	O
,	O
thereby	O
possibly	O
increasing	O
the	O
sensitivity	O
to	O
dioxins	B-Chemical
in	O
such	O
people	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Although	O
no	O
polymorphisms	O
have	O
been	O
reported	O
in	O
the	O
ligand	O
binding	O
region	O
of	O
the	O
AHR	B-Gene
in	O
the	O
over	O
100	O
reported	O
sequences	O
,	O
we	O
sequenced	O
108	O
additional	O
human	B-Species
AHR	B-Gene
genes	O
in	O
an	O
effort	O
to	O
further	O
identify	O
single	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
within	O
the	O
open	O
reading	O
frames	O
of	O
the	O
AHR	B-Gene
locus	O
.	O
</ALL>	O

<ALL>	O
The	O
DNA	O
was	O
sequenced	O
from	O
six	O
ethnic	O
populations	O
that	O
included	O
Japanese	O
,	O
Chinese	O
,	O
European	O
/	O
Caucasian	O
,	O
African	O
-	O
American	O
,	O
South	O
East	O
Asian	O
,	O
and	O
Hispanic	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Six	O
exonic	O
SNPs	O
were	O
identified	O
;	O
four	O
had	O
been	O
described	O
as	O
previously	O
reported	O
and	O
two	O
seem	O
to	O
be	O
novel	O
.	O
</ALL>	O

<ALL>	O
Four	O
of	O
the	O
SNPs	O
identified	O
lead	O
to	O
amino	O
acid	O
changes	O
in	O
the	O
AHR	B-Gene
protein	O
and	O
two	O
of	O
the	O
SNPs	O
lead	O
to	O
synonymous	O
substitutions	O
.	O
</ALL>	O

<ALL>	O
An	O
additional	O
four	O
SNPs	O
have	O
been	O
reported	O
elsewhere	O
that	O
were	O
not	O
identified	O
in	O
the	O
current	O
analysis	O
.	O
</ALL>	O

<ALL>	O
With	O
these	O
new	O
sequences	O
,	O
more	O
than	O
200	O
human	B-Species
AHR	B-Gene
gene	O
sequences	O
have	O
been	O
analyzed	O
for	O
SNPs	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
The	O
results	O
indicate	O
a	O
very	O
limited	O
presence	O
of	O
polymorphisms	O
in	O
the	O
core	O
ligand	O
binding	O
region	O
of	O
the	O
human	B-Species
AHR	B-Gene
.	O
</ALL>	O

<ALL>	O
Other	O
regions	O
,	O
such	O
as	O
the	O
transactivation	O
domain	O
,	O
seem	O
to	O
be	O
slightly	O
more	O
polymorphic	O
in	O
the	O
human	B-Species
population	O
and	O
the	O
impact	O
on	O
functionality	O
should	O
be	O
further	O
examined	O
.	O
</ALL>	O

<ALL>	O
Permeability	O
,	O
ultrastructural	O
changes	O
,	O
and	O
distribution	O
of	O
novel	O
proteins	O
in	O
the	O
glomerular	O
barrier	O
in	O
early	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	B-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
/	O
AIMS	O
:	O
It	O
is	O
still	O
unclear	O
what	O
happens	O
in	O
the	O
glomerulus	O
when	O
proteinuria	B-Disease
starts	O
.	O
</ALL>	O

<ALL>	O
Using	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
nephrosis	B-Disease
(	O
PAN	B-Disease
)	O
rats	B-Species
,	O
we	O
studied	O
early	O
ultrastructural	O
and	O
permeability	O
changes	O
in	O
relation	O
to	O
the	O
expression	O
of	O
the	O
podocyte	O
-	O
associated	O
molecules	O
nephrin	B-Gene
,	O
a	B-Gene
-	I-Gene
actinin	I-Gene
,	O
dendrin	B-Gene
,	O
and	O
plekhh2	B-Gene
,	O
the	O
last	O
two	O
of	O
which	O
were	O
only	O
recently	O
discovered	O
in	O
podocytes	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Using	O
immune	O
stainings	O
,	O
semiquantitative	O
measurement	O
was	O
performed	O
under	O
the	O
electron	O
microscope	O
.	O
</ALL>	O

<ALL>	O
Permeability	O
was	O
assessed	O
using	O
isolated	O
kidney	O
perfusion	O
with	O
tracers	O
.	O
</ALL>	O

<ALL>	O
Possible	O
effects	O
of	O
ACE	B-Gene
inhibition	O
were	O
tested	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
By	O
day	O
2	O
,	O
some	O
patchy	O
foot	O
process	O
effacement	O
,	O
but	O
no	O
proteinuria	B-Disease
,	O
appeared	O
.	O
</ALL>	O

<ALL>	O
The	O
amount	O
of	O
nephrin	B-Gene
was	O
reduced	O
in	O
both	O
diseased	O
and	O
normal	O
areas	O
.	O
</ALL>	O

<ALL>	O
The	O
other	O
proteins	O
showed	O
few	O
changes	O
,	O
which	O
were	O
limited	O
to	O
diseased	O
areas	O
.	O
</ALL>	O

<ALL>	O
By	O
day	O
4	O
,	O
foot	O
process	O
effacement	O
was	O
complete	O
and	O
proteinuria	B-Disease
appeared	O
in	O
parallel	O
with	O
signs	O
of	O
size	O
barrier	O
damage	O
.	O
</ALL>	O

<ALL>	O
Nephrin	B-Gene
decreased	O
further	O
,	O
while	O
dendrin	B-Gene
and	O
plekhh2	B-Gene
also	O
decreased	O
but	O
a	B-Gene
-	I-Gene
actinin	I-Gene
remained	O
unchanged	O
.	O
</ALL>	O

<ALL>	O
ACE	B-Gene
inhibition	O
had	O
no	O
significant	O
protective	O
effect	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
PAN	B-Disease
glomeruli	O
already	O
showed	O
significant	O
pathology	O
by	O
day	O
4	O
,	O
despite	O
relatively	O
mild	O
proteinuria	B-Disease
.	O
</ALL>	O

<ALL>	O
This	O
was	O
preceded	O
by	O
altered	O
nephrin	B-Gene
expression	O
,	O
supporting	O
its	O
pivotal	O
role	O
in	O
podocyte	O
morphology	O
.	O
</ALL>	O

<ALL>	O
The	O
novel	O
proteins	O
dendrin	B-Gene
and	O
plekhh2	B-Gene
were	O
both	O
reduced	O
,	O
suggesting	O
roles	O
in	O
PAN	B-Disease
,	O
whereas	O
a	B-Gene
-	I-Gene
actinin	I-Gene
was	O
unchanged	O
.	O
</ALL>	O

<ALL>	O
SLURP1	B-Gene
mutation	O
-	O
impaired	O
T	O
-	O
cell	O
activation	O
in	O
a	O
family	O
with	O
mal	B-Disease
de	I-Disease
Meleda	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Mal	B-Disease
de	I-Disease
Meleda	I-Disease
(	O
MDM	B-Disease
)	O
is	O
palmoplantar	B-Disease
erythrokeratoderma	I-Disease
with	O
an	O
autosomal	O
recessive	O
inheritance	O
and	O
is	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
gene	O
encoding	O
SLURP	B-Gene
-	I-Gene
1	I-Gene
(	O
lymphocyte	B-Gene
antigen	I-Gene
6	I-Gene
/	O
urokinase	B-Gene
-	I-Gene
type	I-Gene
plasminogen	I-Gene
activator	I-Gene
receptor	I-Gene
related	I-Gene
protein	I-Gene
-	I-Gene
1	I-Gene
)	O
.	O
</ALL>	O

<ALL>	O
SLURP	B-Gene
-	I-Gene
1	I-Gene
is	O
an	O
allosteric	O
agonist	O
to	O
the	O
nicotinic	B-Gene
acetylcholine	I-Gene
receptor	I-Gene
(	O
nAchR	B-Gene
)	O
and	O
it	O
regulates	O
epidermal	O
homeostasis	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
murine	B-Species
studies	O
have	O
shown	O
that	O
nAchR	B-Gene
signalling	O
is	O
important	O
for	O
the	O
regulation	O
of	O
T	O
-	O
cell	O
function	O
.	O
</ALL>	O

<ALL>	O
Among	O
the	O
family	O
members	O
,	O
patients	B-Species
with	O
the	O
homozygous	O
SLURP1	B-Gene
(	O
previously	O
known	O
as	O
ARS	O
component	O
B	O
)	O
mutation	O
are	O
prone	O
to	O
melanoma	B-Disease
and	O
viral	B-Disease
infection	I-Disease
,	O
which	O
might	O
link	O
to	O
defective	O
T	O
-	O
cell	O
function	O
as	O
well	O
as	O
a	O
derangement	O
of	O
epidermal	O
homeostasis	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVES	O
:	O
To	O
investigate	O
the	O
association	O
of	O
the	O
SLURP1	B-Gene
gene	O
mutation	O
with	O
T	O
-	O
cell	O
activation	O
in	O
a	O
Taiwanese	O
family	O
with	O
MDM	B-Disease
.	O
</ALL>	O

<ALL>	O
To	O
test	O
that	O
SLURP	B-Gene
-	I-Gene
1	I-Gene
is	O
essential	O
for	O
T	O
-	O
cell	O
activation	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Human	B-Species
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
were	O
isolated	O
from	O
a	O
Taiwanese	O
MDM	B-Disease
family	O
bearing	O
the	O
G	B-Variant
to	I-Variant
A	I-Variant
substitution	I-Variant
in	I-Variant
nucleotide	I-Variant
256	I-Variant
in	O
the	O
SLURP1	B-Gene
gene	O
,	O
corresponding	O
to	O
a	O
glycine	B-Variant
to	I-Variant
arginine	I-Variant
substitution	I-Variant
at	I-Variant
amino	I-Variant
acid	I-Variant
86	I-Variant
(	O
G86R	B-Variant
)	O
in	O
the	O
SLURP	B-Gene
-	I-Gene
1	I-Gene
protein	O
.	O
</ALL>	O

<ALL>	O
PBMCs	O
from	O
homozygotes	O
and	O
wild	O
-	O
type	O
controls	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3	B-Gene
/	O
anti	O
-	O
CD28	B-Gene
antibodies	O
and	O
the	O
level	O
of	O
T	O
-	O
cell	O
activation	O
was	O
determined	O
by	O
the	O
stimulation	O
index	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
PBMCs	O
with	O
the	O
heterozygous	O
and	O
homozygous	O
SLURP	B-Gene
-	I-Gene
1	I-Gene
G86R	B-Variant
mutation	O
had	O
defective	O
T	O
-	O
cell	O
activation	O
.	O
</ALL>	O

<ALL>	O
This	O
was	O
restored	O
by	O
the	O
addition	O
of	O
0	O
5	O
ug	O
mL	O
(	O
-	O
1	O
)	O
recombinant	O
human	B-Species
SLURP	B-Gene
-	I-Gene
1	I-Gene
protein	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Patients	B-Species
with	O
MDM	B-Disease
with	O
the	O
homozygous	O
SLURP	B-Gene
-	I-Gene
1	I-Gene
G86R	B-Variant
mutation	O
may	O
have	O
an	O
impaired	O
T	O
-	O
cell	O
activation	O
.	O
</ALL>	O

<ALL>	O
The	O
presence	O
of	O
wild	O
-	O
type	O
SLURP	B-Gene
-	I-Gene
1	I-Gene
is	O
essential	O
for	O
normal	O
T	O
-	O
cell	O
activation	O
.	O
</ALL>	O

<ALL>	O
Resequencing	O
of	O
IRS2	B-Gene
reveals	O
rare	O
variants	O
for	O
obesity	B-Disease
but	O
not	O
fasting	O
glucose	B-Chemical
homeostasis	O
in	O
Hispanic	O
children	O
.	O
</ALL>	O

<ALL>	O
Our	O
objective	O
was	O
to	O
resequence	O
insulin	B-Gene
receptor	I-Gene
substrate	I-Gene
2	I-Gene
(	O
IRS2	B-Gene
)	O
to	O
identify	O
variants	O
associated	O
with	O
obesity	B-Disease
-	O
and	O
diabetes	B-Disease
-	O
related	O
traits	O
in	O
Hispanic	O
children	O
.	O
</ALL>	O

<ALL>	O
Exonic	O
and	O
intronic	O
segments	O
,	O
5	O
'	O
and	O
3	O
'	O
flanking	O
regions	O
of	O
IRS2	B-Gene
(	O
14.5	O
kb	O
)	O
,	O
were	O
bidirectionally	O
sequenced	O
for	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
discovery	O
in	O
934	O
Hispanic	O
children	O
using	O
3730XL	O
DNA	O
Sequencers	O
.	O
</ALL>	O

<ALL>	O
Additionally	O
,	O
15	O
SNPs	O
derived	O
from	O
Illumina	O
HumanOmni1	O
-	O
Quad	O
BeadChips	O
were	O
analyzed	O
.	O
</ALL>	O

<ALL>	O
Measured	O
genotype	O
analysis	O
tested	O
associations	O
between	O
SNPs	O
and	O
obesity	B-Disease
and	O
diabetes	B-Disease
-	O
related	O
traits	O
.	O
</ALL>	O

<ALL>	O
Bayesian	O
quantitative	O
trait	O
nucleotide	O
analysis	O
was	O
used	O
to	O
statistically	O
infer	O
the	O
most	O
likely	O
functional	O
polymorphisms	O
.	O
</ALL>	O

<ALL>	O
A	O
total	O
of	O
140	O
SNPs	O
were	O
identified	O
with	O
minor	O
allele	O
frequencies	O
(	O
MAF	O
)	O
ranging	O
from	O
0.001	O
to	O
0.47	O
.	O
</ALL>	O

<ALL>	O
Forty	O
-	O
two	O
of	O
the	O
70	O
coding	O
SNPs	O
result	O
in	O
nonsynonymous	O
amino	O
acid	O
substitutions	O
relative	O
to	O
the	O
consensus	O
sequence	O
;	O
28	O
SNPs	O
were	O
detected	O
in	O
the	O
promoter	O
,	O
12	O
in	O
introns	O
,	O
28	O
in	O
the	O
3	O
'	O
-	O
UTR	O
,	O
and	O
2	O
in	O
the	O
5	O
'	O
-	O
UTR	O
.	O
</ALL>	O

<ALL>	O
Two	O
insertion	O
/	O
deletions	O
(	O
indels	O
)	O
were	O
detected	O
.	O
</ALL>	O

<ALL>	O
Ten	O
independent	O
rare	O
SNPs	O
(	O
MAF	O
=	O
0.001	O
-	O
0.009	O
)	O
were	O
associated	O
with	O
obesity	B-Disease
-	O
related	O
traits	O
(	O
P	O
=	O
0.01	O
-	O
0.00002	O
)	O
.	O
</ALL>	O

<ALL>	O
SNP	B-Variant
10510452	I-Variant
_	I-Variant
139	I-Variant
in	O
the	O
promoter	O
region	O
was	O
shown	O
to	O
have	O
a	O
high	O
posterior	O
probability	O
(	O
P	O
=	O
0.77	O
-	O
0.86	O
)	O
of	O
influencing	O
BMI	O
,	O
fat	O
mass	O
,	O
and	O
waist	O
circumference	O
in	O
Hispanic	O
children	O
.	O
</ALL>	O

<ALL>	O
SNP	B-Variant
10510452	I-Variant
_	I-Variant
139	I-Variant
contributed	O
between	O
2	O
and	O
4	O
%	O
of	O
the	O
population	O
variance	O
in	O
body	O
weight	O
and	O
composition	O
.	O
</ALL>	O

<ALL>	O
None	O
of	O
the	O
SNPs	O
or	O
indels	O
were	O
associated	O
with	O
diabetes	B-Disease
-	O
related	O
traits	O
or	O
accounted	O
for	O
a	O
previously	O
identified	O
quantitative	O
trait	O
locus	O
on	O
chromosome	O
13	O
for	O
fasting	O
serum	O
glucose	B-Chemical
.	O
</ALL>	O

<ALL>	O
Rare	O
but	O
not	O
common	O
IRS2	B-Gene
variants	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
body	O
weight	O
but	O
not	O
an	O
essential	O
role	O
in	O
fasting	O
glucose	B-Chemical
homeostasis	O
in	O
Hispanic	O
children	O
.	O
</ALL>	O

<ALL>	O
Takotsubo	B-Disease
syndrome	I-Disease
(	O
or	O
apical	B-Disease
ballooning	I-Disease
syndrome	I-Disease
)	O
secondary	O
to	O
Zolmitriptan	B-Chemical
.	O
</ALL>	O

<ALL>	O
Takotsubo	B-Disease
syndrome	I-Disease
(	O
TS	B-Disease
)	O
,	O
also	O
known	O
as	O
broken	B-Disease
heart	I-Disease
syndrome	I-Disease
,	O
is	O
characterized	O
by	O
left	O
ventricle	O
apical	O
ballooning	O
with	O
elevated	O
cardiac	O
biomarkers	O
and	O
electrocardiographic	O
changes	O
suggestive	O
of	O
an	O
acute	B-Disease
coronary	I-Disease
syndrome	I-Disease
(	O
ie	O
,	O
ST	O
-	O
segment	O
elevation	O
,	O
T	O
wave	O
inversions	O
,	O
and	O
pathologic	O
Q	O
waves	O
)	O
.	O
</ALL>	O

<ALL>	O
We	O
report	O
a	O
case	O
of	O
54	O
-	O
year	O
-	O
old	O
woman	B-Species
with	O
medical	O
history	O
of	O
mitral	B-Disease
valve	I-Disease
prolapse	I-Disease
and	O
migraines	B-Disease
,	O
who	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
substernal	O
chest	B-Disease
pain	I-Disease
and	O
electrocardiogram	O
demonstrated	O
1	O
/	O
2	O
mm	O
ST	O
-	O
segment	O
elevation	O
in	O
leads	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V5	O
,	O
and	O
V6	O
and	O
positive	O
troponin	O
I.	O
Emergent	O
coronary	O
angiogram	O
revealed	O
normal	O
coronary	O
arteries	O
with	O
moderately	O
reduced	O
left	O
ventricular	O
ejection	O
fraction	O
with	O
wall	O
motion	B-Disease
abnormalities	I-Disease
consistent	O
with	O
TS	B-Disease
.	O
</ALL>	O

<ALL>	O
Detailed	O
history	O
obtained	O
retrospectively	O
revealed	O
that	O
the	O
patient	B-Species
took	O
zolmitriptan	B-Chemical
sparingly	O
only	O
when	O
she	O
had	O
migraines	B-Disease
.	O
</ALL>	O

<ALL>	O
But	O
before	O
this	O
event	O
,	O
she	O
was	O
taking	O
zolmitriptan	B-Chemical
2	O
-	O
3	O
times	O
daily	O
for	O
several	O
days	O
because	O
of	O
a	O
persistent	O
migraine	B-Disease
headache	I-Disease
.	O
</ALL>	O

<ALL>	O
She	O
otherwise	O
reported	O
that	O
she	O
is	O
quite	O
active	O
,	O
rides	O
horses	B-Species
,	O
and	O
does	O
show	O
jumping	O
without	O
any	O
limitations	O
in	O
her	O
physical	O
activity	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
no	O
evidence	O
of	O
any	O
recent	O
stress	O
or	O
status	B-Disease
migrainosus	I-Disease
.	O
</ALL>	O

<ALL>	O
Extensive	O
literature	O
search	O
revealed	O
multiple	O
cases	O
of	O
coronary	B-Disease
artery	I-Disease
vasospasm	I-Disease
secondary	O
to	O
zolmitriptan	B-Chemical
,	O
but	O
none	O
of	O
the	O
cases	O
were	O
associated	O
with	O
TS	B-Disease
.	O
</ALL>	O

<ALL>	O
CD25	B-Gene
(	O
+	O
)	O
Bcl6	B-Gene
(	O
low	O
)	O
T	O
follicular	O
helper	O
cells	O
provide	O
help	O
to	O
maturing	O
B	O
cells	O
in	O
germinal	O
centers	O
of	O
human	B-Species
tonsil	O
.	O
</ALL>	O

<ALL>	O
The	O
majority	O
of	O
CXCR5	B-Gene
(	O
+	O
)	O
PD1	B-Gene
(	O
+	O
)	O
CD4	B-Gene
(	O
+	O
)	O
T	O
follicular	O
helper	O
(	O
Tfh	O
)	O
cells	O
(	O
>	O
90	O
%	O
)	O
are	O
CD25	B-Gene
(	O
-	O
)	O
Bcl6	B-Gene
(	O
hi	O
)	O
,	O
while	O
a	O
small	O
subpopulation	O
(	O
<	O
10	O
%	O
)	O
are	O
CD25	B-Gene
(	O
+	O
)	O
Bcl6	B-Gene
(	O
low	O
)	O
but	O
do	O
not	O
express	O
FoxP3	B-Gene
and	O
are	O
not	O
T	O
regulatory	O
cells	O
.	O
</ALL>	O

<ALL>	O
We	O
purified	O
T	O
:	O
B	O
-	O
cell	O
conjugates	O
from	O
tonsils	O
and	O
found	O
they	O
were	O
enriched	O
for	O
the	O
CD25	B-Gene
(	O
+	O
)	O
Bcl6	B-Gene
(	O
low	O
)	O
Tfh	O
-	O
cell	O
subpopulation	O
.	O
</ALL>	O

<ALL>	O
In	O
response	O
to	O
IL	B-Gene
-	I-Gene
2	I-Gene
,	O
these	O
CD25	B-Gene
(	O
+	O
)	O
Tfh	O
cells	O
increased	O
expression	O
of	O
costimulatory	O
molecules	O
ICOS	B-Gene
or	O
OX40	B-Gene
,	O
upregulated	O
transcription	O
factor	O
cMaf	B-Gene
,	O
produced	O
cytokines	O
IL	B-Gene
-	I-Gene
21	I-Gene
,	O
IL	B-Gene
-	I-Gene
17	I-Gene
,	O
and	O
IL	B-Gene
-	I-Gene
10	I-Gene
,	O
and	O
raised	O
the	O
levels	O
of	O
antiapoptotic	O
protein	O
Bcl2	B-Gene
.	O
</ALL>	O

<ALL>	O
Conjugates	O
formed	O
with	O
CD25	B-Gene
(	O
+	O
)	O
BCl6	B-Gene
(	O
low	O
)	O
Tfh	O
cells	O
included	O
B	O
cells	O
expressing	O
higher	O
levels	O
of	O
activation	B-Gene
-	I-Gene
induced	I-Gene
cytidine	I-Gene
deaminase	I-Gene
(	O
AID	B-Gene
)	O
,	O
memory	O
marker	O
CD45RO	B-Gene
,	O
surface	O
IgG	B-Gene
or	O
IgA	B-Gene
,	O
and	O
MHC	B-Gene
class	I-Gene
II	I-Gene
compared	O
to	O
B	O
-	O
cell	O
conjugates	O
including	O
CD25	B-Gene
(	O
-	O
)	O
Bcl6	B-Gene
(	O
hi	O
)	O
Tfh	O
cells	O
.	O
</ALL>	O

<ALL>	O
While	O
IL	B-Gene
-	I-Gene
2	I-Gene
suppresses	O
early	O
Tfh	O
-	O
cell	O
differentiation	O
,	O
Tfh	O
-	O
cell	O
recognition	O
of	O
antigen	O
-	O
presenting	O
B	O
cells	O
and	O
signaling	O
through	O
the	O
T	B-Gene
-	I-Gene
cell	I-Gene
receptor	I-Gene
likely	O
triggers	O
expression	O
of	O
the	O
high	O
-	O
affinity	O
IL	B-Gene
-	I-Gene
2	I-Gene
receptor	I-Gene
and	O
responses	O
to	O
IL	B-Gene
-	I-Gene
2	I-Gene
including	O
downregulation	O
of	O
Bcl6	B-Gene
.	O
</ALL>	O

<ALL>	O
CD25	B-Gene
expression	O
on	O
Tfh	O
cells	O
and	O
local	O
production	O
of	O
IL	B-Gene
-	I-Gene
2	I-Gene
in	O
tonsil	O
or	O
lymph	O
node	O
may	O
support	O
B	O
helper	O
T	O
-	O
cell	O
function	O
during	O
later	O
stages	O
of	O
B	O
-	O
cell	O
maturation	O
and	O
the	O
development	O
of	O
immune	O
memory	O
.	O
</ALL>	O

<ALL>	O
Differential	O
expression	O
of	O
filamin	B-Gene
B	I-Gene
splice	O
variants	O
in	O
giant	B-Disease
cell	I-Disease
tumor	I-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
Giant	B-Disease
cell	I-Disease
tumor	I-Disease
of	I-Disease
bone	I-Disease
(	O
GCT	B-Disease
)	O
is	O
the	O
most	O
commonly	O
reported	O
non	O
-	O
malignant	O
bone	B-Disease
tumor	I-Disease
in	O
Hong	O
Kong	O
.	O
</ALL>	O

<ALL>	O
This	O
kind	O
of	O
tumor	B-Disease
usually	O
affects	O
people	O
aged	O
20	O
-	O
40	O
years	O
.	O
</ALL>	O

<ALL>	O
Also	O
,	O
it	O
is	O
well	O
known	O
for	O
recurrence	O
locally	O
,	O
especially	O
when	O
the	O
tumor	B-Disease
can	O
not	O
be	O
removed	O
completely	O
.	O
</ALL>	O

<ALL>	O
Filamins	B-Gene
are	O
actin	B-Gene
-	I-Gene
binding	I-Gene
proteins	I-Gene
which	O
contain	O
three	O
family	O
members	O
,	O
filamin	B-Gene
A	I-Gene
,	I-Gene
B	I-Gene
and	I-Gene
C	I-Gene
.	O
</ALL>	O

<ALL>	O
They	O
are	O
the	O
products	O
of	O
three	O
different	O
genes	O
,	O
FLNA	B-Gene
,	O
FLNB	B-Gene
and	O
FLNC	B-Gene
,	O
which	O
can	O
generate	O
various	O
transcript	O
variants	O
in	O
different	O
cell	O
types	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
focused	O
on	O
the	O
effects	O
of	O
FLNBv2	B-Gene
and	O
FLNBv4	B-Gene
toward	O
GCT	B-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
The	O
only	O
difference	O
between	O
FLNBv2	B-Gene
and	O
FLNBv4	B-Gene
is	O
that	O
FLNBv4	B-Gene
does	O
not	O
contain	O
hinge	O
1	O
region	O
.	O
</ALL>	O

<ALL>	O
We	O
found	O
that	O
the	O
relative	O
abundance	O
of	O
FLNBv4	B-Gene
varies	O
among	O
different	O
GCT	B-Disease
cell	O
lines	O
while	O
the	O
expression	O
level	O
of	O
FLNBv4	B-Gene
in	O
normal	O
osteoblasts	O
was	O
only	O
marginally	O
detectable	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
functional	O
aspect	O
,	O
overexpression	O
of	O
FLNBv4	B-Gene
led	O
to	O
upregulation	O
of	O
RANKL	B-Gene
,	O
OCN	B-Gene
,	O
OPG	B-Gene
and	O
RUNX2	B-Gene
,	O
which	O
are	O
closely	O
related	O
to	O
GCT	B-Disease
cell	O
survival	O
and	O
differentiation	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
FLNBv4	B-Gene
can	O
have	O
a	O
negative	O
effect	O
on	O
cell	O
viability	O
of	O
GCT	B-Disease
cells	O
when	O
compare	O
with	O
FLNBv2	B-Gene
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
splicing	O
variants	O
of	O
FLNB	B-Gene
are	O
differentially	O
expressed	O
in	O
GCT	B-Disease
cells	O
and	O
may	O
play	O
a	O
role	O
in	O
the	O
proliferation	O
and	O
differentiation	O
of	O
tumor	B-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
Spirulina	B-Species
lipopolysaccharides	B-Chemical
inhibit	O
tumor	B-Disease
growth	O
in	O
a	O
Toll	B-Gene
-	I-Gene
like	I-Gene
receptor	I-Gene
4	I-Gene
-	O
dependent	O
manner	O
by	O
altering	O
the	O
cytokine	O
milieu	O
from	O
interleukin	B-Gene
-	I-Gene
17	I-Gene
/	O
interleukin	B-Gene
-	I-Gene
23	I-Gene
to	O
interferon	B-Gene
-	I-Gene
g	I-Gene
.	O
</ALL>	O

<ALL>	O
Th17	O
cells	O
and	O
the	O
cytokine	O
they	O
produce	O
,	O
interleukin	B-Gene
(	I-Gene
IL	I-Gene
)	I-Gene
-	I-Gene
17	I-Gene
,	O
play	O
an	O
important	O
role	O
in	O
tumor	B-Disease
progression	O
in	O
humans	B-Species
and	O
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
IL	B-Gene
-	I-Gene
6	I-Gene
and	O
IL	B-Gene
-	I-Gene
23	I-Gene
are	O
critical	O
cytokines	O
for	O
the	O
differentiation	O
and	O
propagation	O
of	O
Th17	O
cells	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
Bacterial	O
lipopolysaccharides	B-Chemical
(	O
LPS	B-Chemical
)	O
are	O
known	O
to	O
stimulate	O
immune	O
cells	O
to	O
produce	O
such	O
inflammatory	B-Gene
cytokines	I-Gene
.	O
</ALL>	O

<ALL>	O
Contrary	O
to	O
Escherichia	B-Species
coli	I-Species
(	O
E.	B-Species
coli	I-Species
)	O
LPS	B-Chemical
,	O
LPS	B-Chemical
from	O
Spirulina	B-Species
has	O
low	O
toxicity	B-Disease
and	O
barely	O
induces	O
in	O
vivo	O
production	O
of	O
IL	B-Gene
-	I-Gene
6	I-Gene
and	O
IL	B-Gene
-	I-Gene
23	I-Gene
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
We	O
examined	O
the	O
antitumor	O
effects	O
of	O
Spirulina	B-Species
LPS	B-Chemical
compared	O
to	O
E.	B-Species
coli	I-Species
LPS	B-Chemical
in	O
an	O
MH134	B-CellLine
hepatoma	B-Disease
model	O
.	O
</ALL>	O

<ALL>	O
Administration	O
of	O
Spirulina	B-Species
LPS	B-Chemical
suppressed	O
tumor	B-Disease
growth	O
in	O
C3H	O
/	O
HeN	O
mice	B-Species
,	O
but	O
not	O
in	O
Toll	B-Gene
-	I-Gene
like	I-Gene
receptor	I-Gene
4	I-Gene
(	O
TLR4	B-Gene
)	O
-	O
mutant	O
C3H	O
/	O
HeJ	O
mice	B-Species
,	O
by	O
reducing	O
serum	O
levels	O
of	O
IL	B-Gene
-	I-Gene
17	I-Gene
and	O
IL	B-Gene
-	I-Gene
23	I-Gene
,	O
while	O
increasing	O
interferon	B-Gene
(	I-Gene
IFN	I-Gene
)	I-Gene
-	I-Gene
g	I-Gene
levels	O
.	O
</ALL>	O

<ALL>	O
The	O
antitumor	O
activity	O
and	O
IFN	B-Gene
-	I-Gene
g	I-Gene
production	O
were	O
mediated	O
by	O
T	O
cells	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
in	O
vitro	O
experiments	O
showed	O
that	O
Spirulina	B-Species
LPS	B-Chemical
impaired	O
the	O
antigen	O
-	O
presenting	O
function	O
that	O
supports	O
the	O
generation	O
of	O
IL	B-Gene
-	I-Gene
17	I-Gene
-	O
producing	O
cells	O
in	O
a	O
toll	B-Gene
-	I-Gene
like	I-Gene
receptor	I-Gene
(	I-Gene
TLR	I-Gene
)	I-Gene
4	I-Gene
-	O
dependent	O
manner	O
.	O
</ALL>	O

<ALL>	O
Of	O
note	O
,	O
injection	O
of	O
anti	O
-	O
IL	B-Gene
-	I-Gene
17	I-Gene
antibody	O
in	O
tumor	B-Disease
-	O
bearing	O
C3H	O
/	O
HeN	O
mice	B-Species
in	O
the	O
absence	O
of	O
Spirulina	B-Species
LPS	B-Chemical
markedly	O
suppressed	O
tumor	B-Disease
growth	O
and	O
augmented	O
IFN	B-Gene
-	I-Gene
g	I-Gene
responses	O
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
our	O
results	O
support	O
the	O
notion	O
that	O
IFN	B-Gene
-	I-Gene
g	I-Gene
and	O
IL	B-Gene
-	I-Gene
17	I-Gene
/	O
IL	B-Gene
-	I-Gene
23	I-Gene
mutually	O
regulate	O
Th17	O
and	O
Th1	O
responses	O
in	O
tumor	B-Disease
-	O
bearing	O
hosts	O
,	O
and	O
Spirulina	B-Species
LPS	B-Chemical
modulates	O
the	O
balance	O
of	O
the	O
IFN	B-Gene
-	I-Gene
g	I-Gene
-	O
IL	B-Gene
-	I-Gene
17	I-Gene
/	O
IL	B-Gene
-	I-Gene
23	I-Gene
axis	O
towards	O
IFN	B-Gene
-	I-Gene
g	I-Gene
production	O
,	O
which	O
leads	O
to	O
tumor	B-Disease
inhibition	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
Spirulina	B-Species
LPS	B-Chemical
effectively	O
inhibited	O
the	O
spontaneous	O
development	O
of	O
mammary	B-Disease
tumors	I-Disease
.	O
</ALL>	O

<ALL>	O
This	O
study	O
has	O
important	O
implications	O
for	O
the	O
exploitation	O
of	O
TLR	B-Gene
-	O
based	O
immunomodulators	O
for	O
cancer	B-Disease
immunotherapy	O
.	O
</ALL>	O

<ALL>	O
Insulin	B-Gene
-	I-Gene
like	I-Gene
growth	I-Gene
factor	I-Gene
1	I-Gene
receptor	I-Gene
-	O
mediated	O
cell	O
survival	O
in	O
hypoxia	B-Disease
depends	O
on	O
the	O
promotion	O
of	O
autophagy	O
via	O
suppression	O
of	O
the	O
PI3	B-Gene
K	I-Gene
/	O
Akt	B-Gene
/	O
mTOR	B-Gene
signaling	O
pathway	O
.	O
</ALL>	O

<ALL>	O
Hypoxia	B-Disease
is	O
widely	O
accepted	O
as	O
a	O
fundamental	O
biological	O
phenomenon	O
,	O
which	O
is	O
strongly	O
associated	O
with	O
tissue	O
damage	O
and	O
cell	O
viability	O
under	O
stress	O
conditions	O
.	O
</ALL>	O

<ALL>	O
Insulin	B-Gene
-	I-Gene
like	I-Gene
growth	I-Gene
factor	I-Gene
-	I-Gene
1	I-Gene
(	O
IGF	B-Gene
-	I-Gene
1	I-Gene
)	O
is	O
known	O
to	O
protect	O
tissues	O
from	O
multiple	O
types	O
of	O
damage	O
,	O
and	O
protect	O
cells	O
from	O
apoptosis	O
.	O
</ALL>	O

<ALL>	O
Hypoxia	B-Disease
is	O
a	O
regulatory	O
factor	O
of	O
the	O
IGF	B-Gene
system	O
,	O
however	O
the	O
role	O
of	O
the	O
IGF	B-Gene
-	I-Gene
1	I-Gene
receptor	I-Gene
(	O
IGF	B-Gene
-	I-Gene
1R	I-Gene
)	O
in	O
hypoxia	B-Disease
-	O
induced	O
apoptosis	O
remains	O
unclear	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
investigated	O
the	O
potential	O
mechanisms	O
associated	O
with	O
IGF	B-Gene
-	I-Gene
1R	I-Gene
-	O
associated	O
apoptosis	O
under	O
hypoxic	B-Disease
conditions	O
.	O
</ALL>	O

<ALL>	O
Mouse	B-Species
embryonic	O
fibroblasts	O
exhibiting	O
disruption	O
or	O
overexpression	O
of	O
IGF	B-Gene
-	I-Gene
1R	I-Gene
(	O
R	O
-	O
cells	O
and	O
R	O
+	O
cells	O
)	O
were	O
used	O
to	O
examine	O
the	O
level	O
of	O
apoptosis	O
,	O
autophagy	O
,	O
and	O
production	O
of	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
.	O
</ALL>	O

<ALL>	O
The	O
autophagy	O
inhibitor	O
3	B-Chemical
-	I-Chemical
methyladenine	I-Chemical
was	O
used	O
to	O
assess	O
the	O
effect	O
of	O
autophagy	O
on	O
ROS	B-Chemical
production	O
and	O
apoptosis	O
under	O
hypoxic	B-Disease
conditions	O
.	O
</ALL>	O

<ALL>	O
A	O
potential	O
downstream	O
signaling	O
pathway	O
involving	O
phosphatidylinositol	B-Gene
3	I-Gene
-	I-Gene
kinase	I-Gene
(	O
PI3	B-Gene
K	I-Gene
)	O
/	O
threonine	B-Gene
protein	I-Gene
kinase	I-Gene
B	I-Gene
(	O
Akt	B-Gene
)	O
/	O
mammalian	B-Gene
target	I-Gene
of	I-Gene
rapamycin	I-Gene
(	O
mTOR	B-Gene
)	O
was	O
identifiedby	O
western	O
blot	O
analysis	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
demonstrated	O
that	O
hypoxia	B-Disease
induced	O
apoptosis	O
,	O
increased	O
ROS	B-Chemical
production	O
,	O
and	O
promoted	O
autophagy	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
relative	O
to	O
that	O
observed	O
under	O
normoxia	O
.	O
</ALL>	O

<ALL>	O
R	O
+	O
cells	O
exhibited	O
a	O
lower	O
percentage	O
of	O
apoptotic	O
cells	O
,	O
lower	O
ROS	B-Chemical
production	O
,	O
and	O
higher	O
levels	O
of	O
autophagy	O
when	O
compared	O
to	O
that	O
of	O
R	O
-	O
cells	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
inhibition	O
of	O
autophagy	O
led	O
to	O
increased	O
ROS	B-Chemical
production	O
and	O
a	O
higher	O
percentage	O
of	O
apoptotic	O
cells	O
in	O
the	O
two	O
cell	O
types	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
IGF	B-Gene
-	I-Gene
1R	I-Gene
is	O
related	O
with	O
PI3	B-Gene
K	I-Gene
/	O
Akt	B-Gene
/	O
mTOR	B-Gene
signaling	O
pathway	O
and	O
enhanced	O
autophagy	O
-	O
associated	O
protein	O
expression	O
,	O
which	O
was	O
verified	O
following	O
treatment	O
with	O
the	O
PI3	B-Gene
K	I-Gene
inhibitor	O
LY294002	B-Chemical
.	O
</ALL>	O

<ALL>	O
These	O
results	O
indicated	O
that	O
IGF	B-Gene
-	I-Gene
1R	I-Gene
may	O
increase	O
cell	O
viability	O
under	O
hypoxic	B-Disease
conditions	O
by	O
promoting	O
autophagy	O
and	O
scavenging	O
ROS	B-Chemical
production	O
,	O
which	O
is	O
closed	O
with	O
PI3	B-Gene
K	I-Gene
/	O
Akt	B-Gene
/	O
mTOR	B-Gene
signaling	O
pathway	O
.	O
</ALL>	O

<ALL>	O
Increased	O
expression	O
and	O
apical	O
targeting	O
of	O
renal	O
ENaC	B-Gene
subunits	I-Gene
in	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Nephrotic	B-Disease
syndrome	I-Disease
is	O
often	O
accompanied	O
by	O
sodium	B-Chemical
retention	O
and	O
generalized	O
edema	B-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
decreased	O
renal	O
sodium	B-Chemical
excretion	O
remains	O
undefined	O
.	O
</ALL>	O

<ALL>	O
We	O
hypothesized	O
that	O
epithelial	B-Gene
Na	I-Gene
channel	I-Gene
(	I-Gene
ENaC	I-Gene
)	I-Gene
subunit	I-Gene
dysregulation	O
may	O
be	O
responsible	O
for	O
the	O
increased	O
sodium	B-Chemical
retention	O
.	O
</ALL>	O

<ALL>	O
An	O
experimental	O
group	O
of	O
rats	B-Species
was	O
treated	O
with	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
(	O
PAN	B-Chemical
;	O
180	O
mg	O
/	O
kg	O
iv	O
)	O
,	O
whereas	O
the	O
control	O
group	O
received	O
only	O
vehicle	O
.	O
</ALL>	O

<ALL>	O
After	O
7	O
days	O
,	O
PAN	B-Chemical
treatment	O
induced	O
significant	O
proteinuria	B-Disease
,	O
hypoalbuminemia	B-Disease
,	O
decreased	O
urinary	O
sodium	B-Chemical
excretion	O
,	O
and	O
extensive	O
ascites	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
protein	O
abundance	O
of	O
alpha	B-Gene
-	I-Gene
ENaC	I-Gene
and	O
beta	B-Gene
-	I-Gene
ENaC	I-Gene
was	O
increased	O
in	O
the	O
inner	O
stripe	O
of	O
the	O
outer	O
medulla	O
(	O
ISOM	O
)	O
and	O
in	O
the	O
inner	O
medulla	O
(	O
IM	O
)	O
but	O
was	O
not	O
altered	O
in	O
the	O
cortex	O
.	O
</ALL>	O

<ALL>	O
gamma	B-Gene
-	I-Gene
ENaC	I-Gene
abundance	O
was	O
increased	O
in	O
the	O
cortex	O
,	O
ISOM	O
,	O
and	O
IM	O
.	O
</ALL>	O

<ALL>	O
Immunoperoxidase	O
brightfield	O
-	O
and	O
laser	O
-	O
scanning	O
confocal	O
fluorescence	O
microscopy	O
demonstrated	O
increased	O
targeting	O
of	O
alpha	B-Gene
-	I-Gene
ENaC	I-Gene
,	O
beta	B-Gene
-	I-Gene
ENaC	I-Gene
,	O
and	O
gamma	B-Gene
-	I-Gene
ENaC	I-Gene
subunits	O
to	O
the	O
apical	O
plasma	O
membrane	O
in	O
the	O
distal	O
convoluted	O
tubule	O
(	O
DCT2	O
)	O
,	O
connecting	O
tubule	O
,	O
and	O
cortical	O
and	O
medullary	O
collecting	O
duct	O
segments	O
.	O
</ALL>	O

<ALL>	O
Immunoelectron	O
microscopy	O
further	O
revealed	O
an	O
increased	O
labeling	O
of	O
alpha	B-Gene
-	I-Gene
ENaC	I-Gene
in	O
the	O
apical	O
plasma	O
membrane	O
of	O
cortical	O
collecting	O
duct	O
principal	O
cells	O
of	O
PAN	B-Chemical
-	O
treated	O
rats	B-Species
,	O
indicating	O
enhanced	O
apical	O
targeting	O
of	O
alpha	B-Gene
-	I-Gene
ENaC	I-Gene
subunits	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
the	O
protein	O
abundances	O
of	O
Na	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
/	I-Gene
H	I-Gene
(	I-Gene
+	I-Gene
)	I-Gene
exchanger	I-Gene
type	I-Gene
3	I-Gene
(	O
NHE3	B-Gene
)	O
,	O
Na	B-Gene
(	I-Gene
+	I-Gene
)	I-Gene
-	I-Gene
K	I-Gene
(	I-Gene
+	I-Gene
)	I-Gene
-	I-Gene
2Cl	I-Gene
(	I-Gene
-	I-Gene
)	I-Gene
cotransporter	I-Gene
(	O
BSC	B-Gene
-	I-Gene
1	I-Gene
)	O
,	O
and	O
thiazide	B-Gene
-	I-Gene
sensitive	I-Gene
Na	I-Gene
(	I-Gene
+	I-Gene
)	I-Gene
-	I-Gene
Cl	I-Gene
(	I-Gene
-	I-Gene
)	I-Gene
cotransporter	I-Gene
(	O
TSC	B-Gene
)	O
were	O
decreased	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
the	O
abundance	O
of	O
the	O
alpha	B-Gene
(	I-Gene
1	I-Gene
)	I-Gene
-	I-Gene
subunit	I-Gene
of	I-Gene
the	I-Gene
Na	I-Gene
-	I-Gene
K	I-Gene
-	I-Gene
ATPase	I-Gene
was	O
decreased	O
in	O
the	O
cortex	O
and	O
ISOM	O
,	O
but	O
it	O
remained	O
unchanged	O
in	O
the	O
IM	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
the	O
increased	O
or	O
sustained	O
expression	O
of	O
ENaC	B-Gene
subunits	I-Gene
combined	O
with	O
increased	O
apical	O
targeting	O
in	O
the	O
DCT2	O
,	O
connecting	O
tubule	O
,	O
and	O
collecting	O
duct	O
are	O
likely	O
to	O
play	O
a	O
role	O
in	O
the	O
sodium	B-Chemical
retention	O
associated	O
with	O
PAN	B-Chemical
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
decreased	O
abundance	O
of	O
NHE3	B-Gene
,	O
BSC	B-Gene
-	I-Gene
1	I-Gene
,	O
TSC	B-Gene
,	O
and	O
Na	B-Gene
-	I-Gene
K	I-Gene
-	I-Gene
ATPase	I-Gene
may	O
play	O
a	O
compensatory	O
role	O
to	O
promote	O
sodium	B-Chemical
excretion	O
.	O
</ALL>	O

<ALL>	O
Differential	O
modulation	O
by	O
estrogen	B-Chemical
of	O
alpha2	B-Gene
-	I-Gene
adrenergic	I-Gene
and	I-Gene
I1	I-Gene
-	I-Gene
imidazoline	I-Gene
receptor	I-Gene
-	O
mediated	O
hypotension	B-Disease
in	O
female	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
We	O
have	O
recently	O
shown	O
that	O
estrogen	B-Chemical
negatively	O
modulates	O
the	O
hypotensive	B-Disease
effect	O
of	O
clonidine	B-Chemical
(	O
mixed	O
alpha2	B-Gene
-	I-Gene
/	I-Gene
I1	I-Gene
-	I-Gene
receptor	I-Gene
agonist	O
)	O
in	O
female	O
rats	B-Species
and	O
implicates	O
the	O
cardiovascular	O
autonomic	O
control	O
in	O
this	O
interaction	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
investigated	O
whether	O
this	O
effect	O
of	O
estrogen	B-Chemical
involves	O
interaction	O
with	O
alpha2	B-Gene
-	I-Gene
and	I-Gene
/	I-Gene
or	I-Gene
I1	I-Gene
-	I-Gene
receptors	I-Gene
.	O
</ALL>	O

<ALL>	O
Changes	O
evoked	O
by	O
a	O
single	O
intraperitoneal	O
injection	O
of	O
rilmenidine	B-Chemical
(	O
600	O
microg	O
/	O
kg	O
)	O
or	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
(	O
100	O
mg	O
/	O
kg	O
)	O
,	O
selective	O
I1	B-Gene
-	I-Gene
and	I-Gene
alpha2	I-Gene
-	I-Gene
receptor	I-Gene
agonists	O
,	O
respectively	O
,	O
in	O
blood	O
pressure	O
,	O
hemodynamic	O
variability	O
,	O
and	O
locomotor	O
activity	O
were	O
assessed	O
in	O
radiotelemetered	O
sham	O
-	O
operated	O
and	O
ovariectomized	O
(	O
Ovx	O
)	O
Sprague	O
-	O
Dawley	O
female	O
rats	B-Species
with	O
or	O
without	O
12	O
-	O
wk	O
estrogen	B-Chemical
replacement	O
.	O
</ALL>	O

<ALL>	O
Three	O
time	O
domain	O
indexes	O
of	O
hemodynamic	O
variability	O
were	O
employed	O
:	O
the	O
standard	O
deviation	O
of	O
mean	O
arterial	O
pressure	O
as	O
a	O
measure	O
of	O
blood	O
pressure	O
variability	O
and	O
the	O
standard	O
deviation	O
of	O
beat	O
-	O
to	O
-	O
beat	O
intervals	O
(	O
SDRR	O
)	O
and	O
the	O
root	O
mean	O
square	O
of	O
successive	O
differences	O
in	O
R	O
-	O
wave	O
-	O
to	O
-	O
R	O
-	O
wave	O
intervals	O
as	O
measures	O
of	O
heart	O
rate	O
variability	O
.	O
</ALL>	O

<ALL>	O
In	O
sham	O
-	O
operated	O
rats	B-Species
,	O
rilmenidine	B-Chemical
or	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
elicited	O
similar	O
hypotension	B-Disease
that	O
lasted	O
at	O
least	O
5	O
h	O
and	O
was	O
associated	O
with	O
reductions	O
in	O
standard	O
deviation	O
of	O
mean	O
arterial	O
pressure	O
.	O
</ALL>	O

<ALL>	O
SDRR	O
was	O
reduced	O
only	O
by	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
.	O
</ALL>	O

<ALL>	O
Ovx	O
significantly	O
enhanced	O
the	O
hypotensive	B-Disease
response	O
to	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
,	O
in	O
contrast	O
to	O
no	O
effect	O
on	O
rilmenidine	B-Chemical
hypotension	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
enhanced	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
hypotension	B-Disease
in	O
Ovx	O
rats	B-Species
was	O
paralleled	O
with	O
further	O
reduction	O
in	O
SDRR	O
and	O
a	B-Disease
reduced	I-Disease
locomotor	I-Disease
activity	I-Disease
.	O
</ALL>	O

<ALL>	O
Estrogen	O
replacement	O
(	O
17beta	B-Chemical
-	I-Chemical
estradiol	I-Chemical
subcutaneous	O
pellet	O
,	O
14.2	O
microg	O
/	O
day	O
,	O
12	O
wk	O
)	O
of	O
Ovx	O
rats	B-Species
restored	O
the	O
hemodynamic	O
and	O
locomotor	O
effects	O
of	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
to	O
sham	O
-	O
operated	O
levels	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
suggest	O
that	O
estrogen	B-Chemical
downregulates	O
alpha2	B-Gene
-	I-Gene
but	I-Gene
not	I-Gene
I1	I-Gene
-	I-Gene
receptor	I-Gene
-	O
mediated	O
hypotension	B-Disease
and	O
highlight	O
a	O
role	O
for	O
the	O
cardiac	O
autonomic	O
control	O
in	O
alpha	B-Chemical
-	I-Chemical
methyldopa	I-Chemical
-	O
estrogen	B-Chemical
interaction	O
.	O
</ALL>	O

<ALL>	O
The	O
effects	O
of	O
sevoflurane	B-Chemical
on	O
lidocaine	B-Chemical
-	O
induced	O
convulsions	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
influence	O
of	O
sevoflurane	B-Chemical
on	O
lidocaine	B-Chemical
-	O
induced	O
convulsions	B-Disease
was	O
studied	O
in	O
cats	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
convulsive	B-Disease
threshold	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
was	O
41.4	O
+	O
/	O
-	O
6.5	O
mg	O
.	O
</ALL>	O

<ALL>	O
l	O
(	O
-	O
1	O
)	O
with	O
lidocaine	B-Chemical
infusion	O
(	O
6	O
mg.kg	O
(	O
-	O
1	O
)	O
.min	O
(	O
-	O
1	O
)	O
)	O
,	O
increasing	O
significantly	O
to	O
66.6	O
+	O
/	O
-	O
10.9	O
mg	O
.	O
</ALL>	O

<ALL>	O
l	O
(	O
-	O
1	O
)	O
when	O
the	O
end	O
-	O
tidal	O
concentration	O
of	O
sevoflurane	B-Chemical
was	O
0.8	O
%	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
threshold	O
(	O
61.6	O
+	O
/	O
-	O
8.7	O
mg	O
.	O
</ALL>	O

<ALL>	O
l	O
(	O
-	O
1	O
)	O
)	O
during	O
1.6	O
%	O
sevoflurane	B-Chemical
was	O
not	O
significant	O
from	O
that	O
during	O
0.8	O
%	O
sevoflurane	B-Chemical
,	O
indicating	O
a	O
celling	O
effect	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
convulsive	B-Disease
threshold	O
between	O
sevoflurane	B-Chemical
and	O
enflurane	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
rise	O
in	O
blood	O
pressure	O
became	O
less	O
marked	O
when	O
higher	O
concentrations	O
of	O
sevoflurane	B-Chemical
or	O
enflurane	B-Chemical
were	O
administered	O
and	O
the	O
blood	O
pressure	O
at	O
convulsions	B-Disease
decreased	O
significantly	O
in	O
1.6	O
%	O
sevoflurane	B-Chemical
,	O
and	O
in	O
0.8	O
%	O
and	O
1.6	O
%	O
enflurane	B-Chemical
.	O
</ALL>	O

<ALL>	O
However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
lidocaine	B-Chemical
concentrations	O
measured	O
when	O
the	O
systolic	O
blood	O
pressure	O
became	O
70	O
mmHg	O
.	O
</ALL>	O

<ALL>	O
Apamin	B-Chemical
,	O
a	O
selective	O
blocker	O
of	O
calcium	B-Chemical
-	O
dependent	O
potassium	B-Chemical
channels	O
,	O
was	O
administered	O
intracerebroventricularly	O
in	O
rats	B-Species
anesthetized	O
with	O
0.8	O
%	O
sevoflurane	B-Chemical
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
anticonvulsive	O
effects	O
.	O
</ALL>	O

<ALL>	O
Apamin	B-Chemical
(	O
10	O
ng	O
)	O
had	O
a	O
tendency	O
to	O
decrease	O
the	O
convulsive	B-Disease
threshold	O
(	O
21.6	O
+	O
/	O
-	O
2.2	O
to	O
19.9	O
+	O
/	O
-	O
2.5	O
mg	O
.	O
</ALL>	O

<ALL>	O
l	O
(	O
-	O
1	O
)	O
)	O
but	O
this	O
was	O
not	O
statistically	O
significant	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
suggested	O
that	O
sevoflurane	B-Chemical
reduces	O
the	O
convulsive	B-Disease
effect	O
of	O
lidocaine	B-Chemical
toxicity	B-Disease
but	O
carries	O
some	O
risk	O
due	O
to	O
circulatory	O
depression	B-Disease
.	O
</ALL>	O

<ALL>	O
Effects	O
of	O
the	O
antidepressant	O
trazodone	B-Chemical
,	O
a	O
5	B-Gene
-	I-Gene
HT	I-Gene
2A	I-Gene
/	I-Gene
2C	I-Gene
receptor	I-Gene
antagonist	O
,	O
on	O
dopamine	B-Chemical
-	O
dependent	O
behaviors	O
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
RATIONALE	O
:	O
5	B-Chemical
-	I-Chemical
Hydroxytryptamine	I-Chemical
,	O
via	O
stimulation	O
of	O
5	B-Gene
-	I-Gene
HT	I-Gene
2C	I-Gene
receptors	I-Gene
,	O
exerts	O
a	O
tonic	O
inhibitory	O
influence	O
on	O
dopaminergic	O
neurotransmission	O
,	O
whereas	O
activation	O
of	O
5	B-Gene
-	I-Gene
HT	I-Gene
2A	I-Gene
receptors	I-Gene
enhances	O
stimulated	O
DAergic	O
neurotransmission	O
.	O
</ALL>	O

<ALL>	O
The	O
antidepressant	O
trazodone	B-Chemical
is	O
a	O
5	B-Gene
-	I-Gene
HT	I-Gene
2A	I-Gene
/	I-Gene
2C	I-Gene
receptor	I-Gene
antagonist	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
trazodone	B-Chemical
treatment	O
on	O
behaviors	O
dependent	O
on	O
the	O
functional	O
status	O
of	O
the	O
nigrostriatal	O
DAergic	O
system	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
The	O
effect	O
of	O
pretreatment	O
with	O
trazodone	B-Chemical
on	O
dexamphetamine	B-Chemical
-	O
and	O
apomorphine	B-Chemical
-	O
induced	O
oral	B-Disease
stereotypies	I-Disease
,	O
on	O
catalepsy	B-Disease
induced	O
by	O
haloperidol	B-Chemical
and	O
apomorphine	B-Chemical
(	O
0.05	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
,	O
</ALL>	O

<ALL>	O
on	O
ergometrine	B-Chemical
-	O
induced	O
wet	O
dog	O
shake	O
(	O
WDS	O
)	O
behavior	O
and	O
fluoxetine	B-Chemical
-	O
induced	O
penile	O
erections	O
was	O
studied	O
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
We	O
also	O
investigated	O
whether	O
trazodone	B-Chemical
induces	O
catalepsy	B-Disease
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Trazodone	B-Chemical
at	O
2.5	O
-	O
20	O
mg	O
/	O
kg	O
i.p	O
.	O
</ALL>	O

<ALL>	O
did	O
not	O
induce	O
catalepsy	B-Disease
,	O
and	O
did	O
not	O
antagonize	O
apomorphine	B-Chemical
(	O
1.5	O
and	O
3	O
mg	O
/	O
kg	O
)	O
stereotypy	O
and	O
apomorphine	B-Chemical
(	O
0.05	O
mg	O
/	O
kg	O
)	O
-	O
induced	O
catalepsy	B-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
pretreatment	O
with	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
i.p	O
.	O
</ALL>	O

<ALL>	O
trazodone	B-Chemical
enhanced	O
dexamphetamine	B-Chemical
stereotypy	O
,	O
and	O
antagonized	O
haloperidol	B-Chemical
catalepsy	B-Disease
,	O
ergometrine	B-Chemical
-	O
induced	O
WDS	O
behavior	O
and	O
fluoxetine	B-Chemical
-	O
induced	O
penile	O
erections	O
.	O
</ALL>	O

<ALL>	O
Trazodone	B-Chemical
at	O
30	O
,	O
40	O
and	O
50	O
mg	O
/	O
kg	O
i.p	O
.	O
</ALL>	O

<ALL>	O
induced	O
catalepsy	B-Disease
and	O
antagonized	O
apomorphine	B-Chemical
and	O
dexamphetamine	B-Chemical
stereotypies	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
trazodone	B-Chemical
at	O
2.5	O
-	O
20	O
mg	O
/	O
kg	O
does	O
not	O
block	O
pre	O
-	O
and	O
postsynaptic	O
striatal	O
D2	B-Gene
DA	I-Gene
receptors	I-Gene
,	O
while	O
at	O
30	O
,	O
40	O
and	O
50	O
mg	O
/	O
kg	O
it	O
blocks	O
postsynaptic	O
striatal	O
D2	B-Gene
DA	I-Gene
receptors	I-Gene
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
at	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
,	O
trazodone	B-Chemical
blocks	O
5	B-Gene
-	I-Gene
HT	I-Gene
2A	I-Gene
and	I-Gene
5	I-Gene
-	I-Gene
HT	I-Gene
2C	I-Gene
receptors	I-Gene
.	O
</ALL>	O

<ALL>	O
We	O
suggest	O
that	O
trazodone	B-Chemical
(	O
5	O
,	O
10	O
and	O
20	O
mg	O
/	O
kg	O
)	O
,	O
by	O
blocking	O
the	O
5	B-Gene
-	I-Gene
HT	I-Gene
2C	I-Gene
receptors	I-Gene
,	O
releases	O
the	O
nigrostriatal	O
DAergic	O
neurons	O
from	O
tonic	O
inhibition	O
caused	O
by	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
,	O
and	O
thereby	O
potentiates	O
dexamphetamine	B-Chemical
stereotypy	O
and	O
antagonizes	O
haloperidol	B-Chemical
catalepsy	B-Disease
.	O
</ALL>	O

<ALL>	O
Glucose	B-Chemical
metabolism	O
in	O
patients	B-Species
with	O
schizophrenia	B-Disease
treated	O
with	O
atypical	O
antipsychotic	B-Chemical
agents	I-Chemical
:	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B-Chemical
tolerance	O
test	O
and	O
minimal	O
model	O
analysis	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
While	O
the	O
incidence	O
of	O
new	O
-	O
onset	O
diabetes	B-Disease
mellitus	I-Disease
may	O
be	O
increasing	O
in	O
patients	B-Species
with	O
schizophrenia	B-Disease
treated	O
with	O
certain	O
atypical	O
antipsychotic	B-Chemical
agents	I-Chemical
,	O
it	O
remains	O
unclear	O
whether	O
atypical	O
agents	O
are	O
directly	O
affecting	O
glucose	B-Chemical
metabolism	O
or	O
simply	O
increasing	O
known	O
risk	O
factors	O
for	O
diabetes	B-Disease
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
To	O
study	O
the	O
2	O
drugs	O
most	O
clearly	O
implicated	O
(	O
clozapine	B-Chemical
and	O
olanzapine	B-Chemical
)	O
and	O
risperidone	B-Chemical
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B-Chemical
tolerance	O
test	O
.	O
</ALL>	O

<ALL>	O
DESIGN	O
:	O
A	O
cross	O
-	O
sectional	O
design	O
in	O
stable	O
,	O
treated	O
patients	B-Species
with	O
schizophrenia	B-Disease
evaluated	O
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B-Chemical
tolerance	O
test	O
and	O
the	O
Bergman	O
minimal	O
model	O
analysis	O
.	O
</ALL>	O

<ALL>	O
SETTING	O
:	O
Subjects	O
were	O
recruited	O
from	O
an	O
urban	O
community	O
mental	O
health	O
clinic	O
and	O
were	O
studied	O
at	O
a	O
general	O
clinical	O
research	O
center	O
.	O
</ALL>	O

<ALL>	O
Patients	B-Species
Fifty	O
subjects	O
signed	O
informed	O
consent	O
and	O
41	O
underwent	O
the	O
frequently	O
sampled	O
intravenous	O
glucose	B-Chemical
tolerance	O
test	O
.	O
</ALL>	O

<ALL>	O
Thirty	O
-	O
six	O
nonobese	O
subjects	O
with	O
schizophrenia	B-Disease
or	O
schizoaffective	B-Disease
disorder	I-Disease
,	O
matched	O
by	O
body	O
mass	O
index	O
and	O
treated	O
with	O
either	O
clozapine	B-Chemical
,	O
olanzapine	B-Chemical
,	O
or	O
risperidone	B-Chemical
,	O
were	O
included	O
in	O
the	O
analysis	O
.	O
</ALL>	O

<ALL>	O
MAIN	O
OUTCOME	O
MEASURES	O
:	O
Fasting	O
plasma	O
glucose	B-Chemical
and	O
fasting	O
serum	O
insulin	B-Chemical
levels	O
,	O
insulin	O
sensitivity	O
index	O
,	O
homeostasis	O
model	O
assessment	O
of	O
insulin	B-Disease
resistance	I-Disease
,	O
and	O
glucose	B-Chemical
effectiveness	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
mean	O
+	O
/	O
-	O
SD	O
duration	O
of	O
treatment	O
with	O
the	O
identified	O
atypical	O
antipsychotic	B-Chemical
agent	I-Chemical
was	O
68.3	O
+	O
/	O
-	O
28.9	O
months	O
(	O
clozapine	B-Chemical
)	O
,	O
29.5	O
+	O
/	O
-	O
17.5	O
months	O
(	O
olanzapine	B-Chemical
)	O
,	O
and	O
40.9	O
+	O
/	O
-	O
33.7	O
(	O
risperidone	B-Chemical
)	O
.	O
</ALL>	O

<ALL>	O
Fasting	O
serum	O
insulin	B-Chemical
concentrations	O
differed	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
3.35	O
;	O
P	O
=	O
.047	O
)	O
(	O
clozapine	B-Chemical
>	O
olanzapine	B-Chemical
>	O
risperidone	B-Chemical
)	O
with	O
significant	O
differences	O
between	O
clozapine	B-Chemical
and	O
risperidone	B-Chemical
(	O
t	O
(	O
33	O
)	O
=	O
2.32	O
;	O
P	O
=	O
.03	O
)	O
and	O
olanzapine	B-Chemical
and	O
risperidone	B-Chemical
(	O
t	O
(	O
33	O
)	O
=	O
2.15	O
;	O
P	O
=	O
.04	O
)	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
a	O
significant	O
difference	O
in	O
insulin	O
sensitivity	O
index	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
10.66	O
;	O
P	O
<	O
.001	O
)	O
(	O
clozapine	B-Chemical
<	O
olanzapine	B-Chemical
<	O
risperidone	B-Chemical
)	O
,	O
with	O
subjects	O
who	O
received	O
clozapine	B-Chemical
and	O
olanzapine	B-Chemical
exhibiting	O
significant	O
insulin	B-Disease
resistance	I-Disease
compared	O
with	O
subjects	O
who	O
were	O
treated	O
with	O
risperidone	B-Chemical
(	O
clozapine	B-Chemical
vs	O
risperidone	B-Chemical
,	O
t	O
(	O
33	O
)	O
=	O
-	O
4.29	O
;	O
P	O
<	O
.001	O
;	O
olanzapine	B-Chemical
vs	O
risperidone	B-Chemical
,	O
t	O
(	O
33	O
)	O
=	O
-	O
3.62	O
;	O
P	O
=	O
.001	O
[	O
P	O
<	O
.001	O
]	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
homeostasis	O
model	O
assessment	O
of	O
insulin	B-Disease
resistance	I-Disease
also	O
differed	O
significantly	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
4.92	O
;	O
P	O
=	O
.01	O
)	O
(	O
clozapine	B-Chemical
>	O
olanzapine	B-Chemical
>	O
risperidone	B-Chemical
)	O
(	O
clozapine	B-Chemical
vs	O
risperidone	B-Chemical
,	O
t	O
(	O
33	O
)	O
=	O
2.94	O
;	O
P	O
=	O
.006	O
;	O
olanzapine	B-Chemical
vs	O
risperidone	B-Chemical
,	O
t	O
(	O
33	O
)	O
=	O
2.42	O
;	O
P	O
=	O
.02	O
)	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
a	O
significant	O
difference	O
among	O
groups	O
in	O
glucose	B-Chemical
effectiveness	O
(	O
F	O
(	O
30	O
)	O
=	O
4.18	O
;	O
P	O
=	O
.02	O
)	O
(	O
clozapine	B-Chemical
<	O
olanzapine	B-Chemical
<	O
risperidone	B-Chemical
)	O
with	O
significant	O
differences	O
between	O
clozapine	B-Chemical
and	O
risperidone	B-Chemical
(	O
t	O
(	O
30	O
)	O
=	O
-	O
2.59	O
;	O
P	O
=	O
.02	O
)	O
and	O
olanzapine	B-Chemical
and	O
risperidone	B-Chemical
(	O
t	O
(	O
30	O
)	O
=	O
-	O
2.34	O
,	O
P	O
=	O
.03	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Both	O
nonobese	O
clozapine	B-Chemical
-	O
and	O
olanzapine	B-Chemical
-	O
treated	O
groups	O
displayed	O
significant	O
insulin	B-Disease
resistance	I-Disease
and	O
impairment	O
of	O
glucose	B-Chemical
effectiveness	O
compared	O
with	O
risperidone	B-Chemical
-	O
treated	O
subjects	O
.	O
</ALL>	O

<ALL>	O
Patients	B-Species
taking	O
clozapine	B-Chemical
and	O
olanzapine	B-Chemical
must	O
be	O
examined	O
for	O
insulin	B-Disease
resistance	I-Disease
and	O
its	O
consequences	O
.	O
</ALL>	O

<ALL>	O
Valproic	B-Chemical
acid	I-Chemical
I	O
:	O
time	O
course	O
of	O
lipid	B-Chemical
peroxidation	O
biomarkers	O
,	O
liver	B-Disease
toxicity	I-Disease
,	O
and	O
valproic	B-Chemical
acid	I-Chemical
metabolite	O
levels	O
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
A	O
single	O
dose	O
of	O
valproic	B-Chemical
acid	I-Chemical
(	O
VPA	B-Chemical
)	O
,	O
which	O
is	O
a	O
widely	O
used	O
antiepileptic	B-Chemical
drug	I-Chemical
,	O
is	O
associated	O
with	O
oxidative	O
stress	O
in	O
rats	B-Species
,	O
as	O
recently	O
demonstrated	O
by	O
elevated	O
levels	O
of	O
15	B-Chemical
-	I-Chemical
F	I-Chemical
(	I-Chemical
2	I-Chemical
t	I-Chemical
)	I-Chemical
-	I-Chemical
isoprostane	I-Chemical
(	O
15	B-Chemical
-	I-Chemical
F	I-Chemical
(	I-Chemical
2	I-Chemical
t	I-Chemical
)	I-Chemical
-	I-Chemical
IsoP	I-Chemical
)	O
.	O
</ALL>	O

<ALL>	O
To	O
determine	O
whether	O
there	O
was	O
a	O
temporal	O
relationship	O
between	O
VPA	B-Chemical
-	O
associated	O
oxidative	O
stress	O
and	O
hepatotoxicity	B-Disease
,	O
adult	O
male	O
Sprague	O
-	O
Dawley	O
rats	B-Species
were	O
treated	O
ip	O
with	O
VPA	B-Chemical
(	O
500	O
mg	O
/	O
kg	O
)	O
or	O
0.9	O
%	O
saline	O
(	O
vehicle	O
)	O
once	O
daily	O
for	O
2	O
,	O
4	O
,	O
7	O
,	O
10	O
,	O
or	O
14	O
days	O
.	O
</ALL>	O

<ALL>	O
Oxidative	O
stress	O
was	O
assessed	O
by	O
determining	O
plasma	O
and	O
liver	O
levels	O
of	O
15	B-Chemical
-	I-Chemical
F	I-Chemical
(	I-Chemical
2	I-Chemical
t	I-Chemical
)	I-Chemical
-	I-Chemical
IsoP	I-Chemical
,	O
lipid	B-Chemical
hydroperoxides	I-Chemical
(	O
LPO	B-Chemical
)	O
,	O
and	O
thiobarbituric	B-Chemical
acid	I-Chemical
reactive	I-Chemical
substances	I-Chemical
(	O
TBARs	B-Chemical
)	O
.	O
</ALL>	O

<ALL>	O
Plasma	O
and	O
liver	O
15	B-Chemical
-	I-Chemical
F	I-Chemical
(	I-Chemical
2	I-Chemical
t	I-Chemical
)	I-Chemical
-	I-Chemical
IsoP	I-Chemical
were	O
elevated	O
and	O
reached	O
a	O
plateau	O
after	O
day	O
2	O
of	O
VPA	B-Chemical
treatment	O
compared	O
to	O
control	O
.	O
</ALL>	O

<ALL>	O
Liver	O
LPO	B-Chemical
levels	O
were	O
not	O
elevated	O
until	O
day	O
7	O
of	O
treatment	O
(	O
1.8	O
-	O
fold	O
versus	O
control	O
,	O
p	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
Liver	O
and	O
plasma	O
TBARs	B-Chemical
were	O
not	O
increased	O
until	O
14	O
days	O
(	O
2	O
-	O
fold	O
vs.	O
control	O
,	O
p	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
Liver	B-Disease
toxicity	I-Disease
was	O
evaluated	O
based	O
on	O
serum	O
levels	O
of	O
alpha	B-Gene
-	I-Gene
glutathione	I-Gene
S	I-Gene
-	I-Gene
transferase	I-Gene
(	O
alpha	B-Gene
-	I-Gene
GST	I-Gene
)	O
and	O
by	O
histology	O
.	O
</ALL>	O

<ALL>	O
Serum	O
alpha	B-Gene
-	I-Gene
GST	I-Gene
levels	O
were	O
significantly	O
elevated	O
by	O
day	O
4	O
,	O
which	O
corresponded	O
to	O
hepatotoxicity	B-Disease
as	O
shown	O
by	O
the	O
increasing	O
incidence	O
of	O
inflammation	B-Disease
of	I-Disease
the	I-Disease
liver	I-Disease
capsule	I-Disease
,	O
necrosis	B-Disease
,	O
and	O
steatosis	B-Disease
throughout	O
the	O
study	O
.	O
</ALL>	O

<ALL>	O
The	O
liver	O
levels	O
of	O
beta	O
-	O
oxidation	O
metabolites	O
of	O
VPA	B-Chemical
were	O
decreased	O
by	O
day	O
14	O
,	O
while	O
the	O
levels	O
of	O
4	B-Chemical
-	I-Chemical
ene	I-Chemical
-	I-Chemical
VPA	I-Chemical
and	O
(	O
E	O
)	O
-	O
2,4	B-Chemical
-	I-Chemical
diene	I-Chemical
-	I-Chemical
VPA	I-Chemical
were	O
not	O
elevated	O
throughout	O
the	O
study	O
.	O
</ALL>	O

<ALL>	O
Overall	O
,	O
these	O
findings	O
indicate	O
that	O
VPA	B-Chemical
treatment	O
results	O
in	O
oxidative	O
stress	O
,	O
as	O
measured	O
by	O
levels	O
of	O
15	B-Chemical
-	I-Chemical
F	I-Chemical
(	I-Chemical
2	I-Chemical
t	I-Chemical
)	I-Chemical
-	I-Chemical
IsoP	I-Chemical
,	O
which	O
precedes	O
the	O
onset	O
of	O
necrosis	B-Disease
,	O
steatosis	B-Disease
,	O
and	O
elevated	O
levels	O
of	O
serum	O
alpha	B-Gene
-	I-Gene
GST	I-Gene
.	O
</ALL>	O

<ALL>	O
Safety	O
of	O
celecoxib	B-Chemical
in	O
patients	B-Species
with	O
adverse	O
skin	B-Disease
reactions	I-Disease
to	O
acetaminophen	B-Chemical
(	O
paracetamol	B-Chemical
)	O
and	O
nimesulide	B-Chemical
associated	O
or	O
not	O
with	O
common	O
non	B-Chemical
-	I-Chemical
steroidal	I-Chemical
anti	I-Chemical
-	I-Chemical
inflammatory	I-Chemical
drugs	I-Chemical
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Acetaminophen	B-Chemical
(	O
paracetamol	B-Chemical
-	O
-	O
P	B-Chemical
)	O
and	O
Nimesulide	B-Chemical
(	O
N	B-Chemical
)	O
are	O
widely	O
used	O
analgesic	O
-	O
antipyretic	B-Chemical
/	O
anti	B-Chemical
-	I-Chemical
inflammatory	I-Chemical
drugs	I-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
rate	O
of	O
adverse	O
hypersensitivity	B-Disease
reactions	O
to	O
these	O
agents	O
is	O
generally	O
low	O
.	O
</ALL>	O

<ALL>	O
On	O
the	O
contrary	O
non	B-Chemical
-	I-Chemical
steroidal	I-Chemical
anti	I-Chemical
-	I-Chemical
inflammatory	I-Chemical
drugs	I-Chemical
(	O
NSAIDs	B-Chemical
)	O
are	O
commonly	O
involved	O
in	O
such	O
reactions	O
.	O
</ALL>	O

<ALL>	O
Celecoxib	B-Chemical
(	O
CE	B-Chemical
)	O
is	O
a	O
novel	O
drug	O
,	O
with	O
high	O
selectivity	O
and	O
affinity	O
for	O
COX	B-Gene
-	I-Gene
2	I-Gene
enzyme	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
We	O
evaluated	O
the	O
tolerability	O
of	O
CE	B-Chemical
in	O
a	O
group	O
of	O
patients	B-Species
with	O
documented	O
history	O
of	O
adverse	O
cutaneous	B-Disease
reactions	I-Disease
to	O
P	B-Chemical
and	O
N	B-Chemical
associated	O
or	O
not	O
to	O
classic	O
NSAIDs	B-Chemical
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
We	O
studied	O
9	O
patients	B-Species
with	O
hypersensitivity	B-Disease
to	O
P	B-Chemical
and	O
N	B-Chemical
with	O
or	O
without	O
associated	O
reactions	O
to	O
classic	O
NSAIDs	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
diagnosis	O
of	O
P	B-Chemical
and	O
N	B-Chemical
-	O
induced	O
skin	B-Disease
reactions	I-Disease
was	O
based	O
in	O
vivo	O
challenge	O
.	O
</ALL>	O

<ALL>	O
The	O
placebo	O
was	O
blindly	O
administered	O
at	O
the	O
beginning	O
of	O
each	O
challenge	O
.	O
</ALL>	O

<ALL>	O
After	O
three	O
days	O
,	O
a	O
cumulative	O
dosage	O
of	O
200	O
mg	O
of	O
CE	B-Chemical
in	O
refracted	O
doses	O
were	O
given	O
.	O
</ALL>	O

<ALL>	O
After	O
2	O
-	O
3	O
days	O
,	O
a	O
single	O
dose	O
of	O
200	O
mg	O
was	O
administered	O
.	O
</ALL>	O

<ALL>	O
All	O
patients	B-Species
were	O
observed	O
for	O
6	O
hours	O
after	O
each	O
challenge	O
,	O
and	O
controlled	O
again	O
after	O
24	O
hours	O
to	O
exclude	O
delayed	O
reactions	O
.	O
</ALL>	O

<ALL>	O
The	O
challenge	O
was	O
considered	O
positive	O
if	O
one	O
or	O
more	O
of	O
the	O
following	O
appeared	O
:	O
erythema	B-Disease
,	O
rush	O
or	O
urticaria	B-Disease
-	O
angioedema	B-Disease
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
No	O
reaction	O
was	O
observed	O
with	O
placebo	O
and	O
eight	O
patients	B-Species
(	O
88.8	O
%	O
)	O
tolerated	O
CE	B-Chemical
.	O
</ALL>	O

<ALL>	O
Only	O
one	O
patient	B-Species
developed	O
a	O
moderate	O
angioedema	B-Disease
of	O
the	O
lips	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Only	O
one	O
hypersensitivity	B-Disease
reaction	O
to	O
CE	B-Chemical
was	O
documented	O
among	O
9	O
P	B-Chemical
and	O
N	B-Chemical
-	O
highly	O
NSAIDs	B-Chemical
intolerant	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
we	O
conclude	O
that	O
CE	B-Chemical
is	O
a	O
reasonably	O
safe	O
alternative	O
to	O
be	O
used	O
in	O
subjects	O
who	O
do	O
not	O
tolerate	O
P	B-Chemical
and	O
N	B-Chemical
.	O
</ALL>	O

<ALL>	O
Dexrazoxane	B-Chemical
protects	O
against	O
myelosuppression	B-Disease
from	O
the	O
DNA	O
cleavage	O
-	O
enhancing	O
drugs	O
etoposide	B-Chemical
and	O
daunorubicin	B-Chemical
but	O
not	O
doxorubicin	B-Chemical
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
The	O
anthracyclines	B-Chemical
daunorubicin	B-Chemical
and	O
doxorubicin	B-Chemical
and	O
the	O
epipodophyllotoxin	B-Chemical
etoposide	B-Chemical
are	O
potent	O
DNA	O
cleavage	O
-	O
enhancing	O
drugs	O
that	O
are	O
widely	O
used	O
in	O
clinical	O
oncology	O
;	O
however	O
,	O
myelosuppression	B-Disease
and	O
cardiac	B-Disease
toxicity	I-Disease
limit	O
their	O
use	O
.	O
</ALL>	O

<ALL>	O
Dexrazoxane	B-Chemical
(	O
ICRF	B-Chemical
-	I-Chemical
187	I-Chemical
)	O
is	O
recommended	O
for	O
protection	O
against	O
anthracycline	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
EXPERIMENTAL	O
DESIGN	O
:	O
Because	O
of	O
their	O
widespread	O
use	O
,	O
the	O
hematologic	B-Disease
toxicity	I-Disease
following	O
coadministration	O
of	O
dexrazoxane	B-Chemical
and	O
these	O
three	O
structurally	O
different	O
DNA	O
cleavage	O
enhancers	O
was	O
investigated	O
:	O
Sensitivity	O
of	O
human	B-Species
and	O
murine	B-Species
blood	O
progenitor	O
cells	O
to	O
etoposide	B-Chemical
,	O
daunorubicin	B-Chemical
,	O
and	O
doxorubicin	B-Chemical
+	O
/	O
-	O
dexrazoxane	B-Chemical
was	O
determined	O
in	O
granulocyte	O
-	O
macrophage	O
colony	O
forming	O
assays	O
.	O
</ALL>	O

<ALL>	O
Likewise	O
,	O
in	O
vivo	O
,	O
B6D2F1	O
mice	B-Species
were	O
treated	O
with	O
etoposide	B-Chemical
,	O
daunorubicin	B-Chemical
,	O
and	O
doxorubicin	B-Chemical
,	O
with	O
or	O
without	O
dexrazoxane	B-Chemical
over	O
a	O
wide	O
range	O
of	O
doses	O
:	O
posttreatment	O
,	O
a	O
full	O
hematologic	O
evaluation	O
was	O
done	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Nontoxic	O
doses	O
of	O
dexrazoxane	B-Chemical
reduced	O
myelosuppression	B-Disease
and	O
weight	B-Disease
loss	I-Disease
from	O
daunorubicin	B-Chemical
and	O
etoposide	B-Chemical
in	O
mice	B-Species
and	O
antagonized	O
their	O
antiproliferative	O
effects	O
in	O
the	O
colony	O
assay	O
;	O
however	O
,	O
dexrazoxane	B-Chemical
neither	O
reduced	O
myelosuppression	B-Disease
,	O
weight	B-Disease
loss	I-Disease
,	O
nor	O
the	O
in	O
vitro	O
cytotoxicity	B-Disease
from	O
doxorubicin	B-Chemical
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Although	O
our	O
findings	O
support	O
the	O
observation	O
that	O
dexrazoxane	B-Chemical
reduces	O
neither	O
hematologic	O
activity	O
nor	O
antitumor	O
activity	O
from	O
doxorubicin	B-Chemical
clinically	O
,	O
the	O
potent	O
antagonism	O
of	O
daunorubicin	B-Chemical
activity	O
raises	O
concern	O
;	O
a	O
possible	O
interference	O
with	O
anticancer	O
efficacy	O
certainly	O
would	O
call	O
for	O
renewed	O
attention	O
.	O
</ALL>	O

<ALL>	O
Our	O
data	O
also	O
suggest	O
that	O
significant	O
etoposide	B-Chemical
dose	O
escalation	O
is	O
perhaps	O
possible	O
by	O
the	O
use	O
of	O
dexrazoxane	B-Chemical
.	O
</ALL>	O

<ALL>	O
Clinical	O
trials	O
in	O
patients	B-Species
with	O
brain	O
metastases	B-Disease
combining	O
dexrazoxane	B-Chemical
and	O
high	O
doses	O
of	O
etoposide	B-Chemical
is	O
ongoing	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
without	O
aggravating	O
hematologic	B-Disease
toxicity	I-Disease
.	O
</ALL>	O

<ALL>	O
If	O
successful	O
,	O
this	O
represents	O
an	O
exciting	O
mechanism	O
for	O
pharmacologic	O
regulation	O
of	O
side	O
effects	O
from	O
cytotoxic	B-Disease
chemotherapy	O
.	O
</ALL>	O

<ALL>	O
The	O
selective	O
5	B-Gene
-	I-Gene
HT6	I-Gene
receptor	I-Gene
antagonist	O
Ro4368554	B-Chemical
restores	O
memory	O
performance	O
in	O
cholinergic	B-Chemical
and	O
serotonergic	B-Chemical
models	O
of	O
memory	B-Disease
deficiency	I-Disease
in	O
the	O
rat	B-Species
.	O
</ALL>	O

<ALL>	O
Antagonists	O
at	O
serotonin	B-Gene
type	I-Gene
6	I-Gene
(	I-Gene
5	I-Gene
-	I-Gene
HT	I-Gene
(	I-Gene
6	I-Gene
)	I-Gene
)	I-Gene
receptors	I-Gene
show	O
activity	O
in	O
models	O
of	O
learning	O
and	O
memory	O
.	O
</ALL>	O

<ALL>	O
Although	O
the	O
underlying	O
mechanism	O
(	O
s	O
)	O
are	O
not	O
well	O
understood	O
,	O
these	O
effects	O
may	O
involve	O
an	O
increase	O
in	O
acetylcholine	B-Chemical
(	O
ACh	B-Chemical
)	O
levels	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
sought	O
to	O
characterize	O
the	O
cognitive	O
-	O
enhancing	O
effects	O
of	O
the	O
5	B-Gene
-	I-Gene
HT	I-Gene
(	I-Gene
6	I-Gene
)	I-Gene
antagonist	O
Ro4368554	B-Chemical
(	O
3	B-Chemical
-	I-Chemical
benzenesulfonyl	I-Chemical
-	I-Chemical
7	I-Chemical
-	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
piperazin	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)	I-Chemical
1H	I-Chemical
-	I-Chemical
indole	I-Chemical
)	O
in	O
a	O
rat	B-Species
object	O
recognition	O
task	O
employing	O
a	O
cholinergic	B-Chemical
(	O
scopolamine	B-Chemical
pretreatment	O
)	O
and	O
a	O
serotonergic	B-Chemical
-	O
(	O
tryptophan	B-Chemical
(	O
TRP	B-Chemical
)	O
depletion	O
)	O
deficient	O
model	O
,	O
and	O
compared	O
its	O
pattern	O
of	O
action	O
with	O
that	O
of	O
the	O
acetylcholinesterase	B-Gene
inhibitor	O
metrifonate	B-Chemical
.	O
</ALL>	O

<ALL>	O
Initial	O
testing	O
in	O
a	O
time	O
-	O
dependent	O
forgetting	O
task	O
employing	O
a	O
24	O
-	O
h	O
delay	O
between	O
training	O
and	O
testing	O
showed	O
that	O
metrifonate	B-Chemical
improved	O
object	O
recognition	O
(	O
at	O
10	O
and	O
30	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
,	O
</ALL>	O

<ALL>	O
whereas	O
Ro4368554	B-Chemical
was	O
inactive	O
.	O
</ALL>	O

<ALL>	O
Both	O
,	O
Ro4368554	B-Chemical
(	O
3	O
and	O
10	O
mg	O
/	O
kg	O
,	O
intraperitoneally	O
(	O
i.p	O
.	O
)	O
)	O
</ALL>	O

<ALL>	O
and	O
metrifonate	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
,	O
</ALL>	O

<ALL>	O
respectively	O
)	O
reversed	O
memory	B-Disease
deficits	I-Disease
induced	O
by	O
scopolamine	B-Chemical
and	O
TRP	B-Chemical
depletion	O
(	O
10	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
,	O
</ALL>	O

<ALL>	O
and	O
3	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
,	O
</ALL>	O

<ALL>	O
respectively	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
although	O
Ro4368554	B-Chemical
did	O
not	O
improve	O
a	O
time	O
-	O
related	O
retention	O
deficit	O
,	O
it	O
reversed	O
a	O
cholinergic	B-Chemical
and	O
a	O
serotonergic	B-Chemical
memory	B-Disease
deficit	I-Disease
,	O
suggesting	O
that	O
both	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
facilitation	O
of	O
object	O
memory	O
by	O
Ro4368554	B-Chemical
and	O
,	O
possibly	O
,	O
other	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
(	I-Chemical
6	I-Chemical
)	I-Chemical
receptor	I-Chemical
antagonists	I-Chemical
.	O
</ALL>	O

<ALL>	O
Microinjection	O
of	O
ritanserin	B-Chemical
into	O
the	O
CA1	O
region	O
of	O
hippocampus	O
improves	O
scopolamine	B-Chemical
-	O
induced	O
amnesia	B-Disease
in	O
adult	O
male	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
effect	O
of	O
ritanserin	B-Chemical
(	O
5	B-Gene
-	I-Gene
HT2	I-Gene
antagonist	O
)	O
on	O
scopolamine	B-Chemical
(	O
muscarinic	B-Gene
cholinergic	I-Gene
antagonist	O
)	O
-	O
induced	O
amnesia	B-Disease
in	O
Morris	O
water	O
maze	O
(	O
MWM	O
)	O
was	O
investigated	O
.	O
</ALL>	O

<ALL>	O
Rats	B-Species
were	O
divided	O
into	O
eight	O
groups	O
and	O
bilaterally	O
cannulated	O
into	O
CA1	O
region	O
of	O
the	O
hippocampus	O
.	O
</ALL>	O

<ALL>	O
One	O
week	O
later	O
,	O
they	O
received	O
repeatedly	O
vehicles	O
(	O
saline	O
,	O
DMSO	B-Chemical
,	O
saline	O
+	O
DMSO	B-Chemical
)	O
,	O
scopolamine	B-Chemical
(	O
2	O
microg	O
/	O
0.5	O
microl	O
saline	O
/	O
side	O
;	O
30	O
min	O
before	O
training	O
)	O
,	O
ritanserin	B-Chemical
(	O
2	O
,	O
4	O
and	O
8	O
microg	O
/	O
0.5	O
microl	O
DMSO	B-Chemical
/	O
side	O
;	O
20	O
min	O
before	O
training	O
)	O
and	O
scopolamine	B-Chemical
(	O
2	O
microg	O
/	O
0.5	O
microl	O
;	O
30	O
min	O
before	O
ritanserin	B-Chemical
injection	O
)	O
+	O
ritanserin	B-Chemical
(	O
4	O
microg	O
/	O
0.5	O
microl	O
DMSO	B-Chemical
)	O
through	O
cannulae	O
each	O
day	O
.	O
</ALL>	O

<ALL>	O
Animals	O
were	O
tested	O
for	O
four	O
consecutive	O
days	O
(	O
4	O
trial	O
/	O
day	O
)	O
in	O
MWM	O
during	O
which	O
the	O
position	O
of	O
hidden	O
platform	O
was	O
unchanged	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
fifth	O
day	O
,	O
the	O
platform	O
was	O
elevated	O
above	O
the	O
water	O
surface	O
in	O
another	O
position	O
to	O
evaluate	O
the	O
function	O
of	O
motor	O
,	O
motivational	O
and	O
visual	O
systems	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
showed	O
a	O
significant	O
increase	O
in	O
escape	O
latencies	O
and	O
traveled	O
distances	O
to	O
find	O
platform	O
in	O
scopolamine	B-Chemical
-	O
treated	O
group	O
as	O
compared	O
to	O
saline	O
group	O
.	O
</ALL>	O

<ALL>	O
Ritanserin	B-Chemical
-	O
treated	O
rats	B-Species
(	O
4	O
microg	O
/	O
0.5	O
microl	O
/	O
side	O
)	O
showed	O
a	O
significant	O
decrease	O
in	O
the	O
mentioned	O
parameters	O
as	O
compared	O
to	O
DMSO	B-Chemical
-	O
treated	O
group	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
scopolamine	B-Chemical
and	O
ritanserin	B-Chemical
co	O
-	O
administration	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
escape	O
latencies	O
and	O
traveled	O
distances	O
as	O
compared	O
to	O
the	O
scopolamine	B-Chemical
-	O
treated	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Our	O
findings	O
show	O
that	O
microinjection	O
of	O
ritanserin	B-Chemical
into	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
improves	O
the	O
scopolamine	B-Chemical
-	O
induced	O
amnesia	B-Disease
.	O
</ALL>	O

<ALL>	O
Memory	O
function	O
and	O
serotonin	B-Gene
transporter	I-Gene
promoter	O
gene	O
polymorphism	O
in	O
ecstasy	B-Chemical
(	O
MDMA	B-Chemical
)	O
users	O
.	O
</ALL>	O

<ALL>	O
Although	O
3,4	B-Chemical
-	I-Chemical
methylenedioxymethamphetamine	I-Chemical
(	O
MDMA	B-Chemical
or	O
ecstasy	B-Chemical
)	O
has	O
been	O
shown	O
to	O
damage	O
brain	O
serotonin	B-Chemical
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
neurons	O
in	O
animals	O
and	O
possibly	O
humans	B-Species
,	O
little	O
is	O
known	O
about	O
the	O
long	O
-	O
term	O
consequences	O
of	O
MDMA	B-Chemical
-	O
induced	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
neurotoxic	B-Disease
lesions	I-Disease
on	O
functions	O
in	O
which	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
is	O
involved	O
,	O
such	O
as	O
cognitive	O
function	O
.	O
</ALL>	O

<ALL>	O
Because	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
transporters	O
play	O
a	O
key	O
element	O
in	O
the	O
regulation	O
of	O
synaptic	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
transmission	O
it	O
may	O
be	O
important	O
to	O
control	O
for	O
the	O
potential	O
covariance	O
effect	O
of	O
a	O
polymorphism	O
in	O
the	O
5	B-Gene
-	I-Gene
HT	I-Gene
transporter	I-Gene
promoter	I-Gene
gene	I-Gene
region	I-Gene
(	O
5	B-Gene
-	I-Gene
HTTLPR	I-Gene
)	O
when	O
studying	O
the	O
effects	O
of	O
MDMA	B-Chemical
as	O
well	O
as	O
cognitive	O
functioning	O
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
moderate	O
and	O
heavy	O
MDMA	B-Chemical
use	O
on	O
cognitive	O
function	O
,	O
as	O
well	O
as	O
the	O
effects	O
of	O
long	O
-	O
term	O
abstention	O
from	O
MDMA	B-Chemical
,	O
in	O
subjects	O
genotyped	O
for	O
5	B-Gene
-	I-Gene
HTTLPR	I-Gene
.	O
</ALL>	O

<ALL>	O
A	O
second	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
whether	O
these	O
effects	O
differ	O
for	O
females	O
and	O
males	O
.	O
</ALL>	O

<ALL>	O
Fifteen	O
moderate	O
MDMA	B-Chemical
users	O
(	O
<	O
55	O
lifetime	O
tablets	O
)	O
,	O
22	O
heavy	O
MDMA	B-Chemical
+	O
users	O
(	O
>	O
55	O
lifetime	O
tablets	O
)	O
,	O
16	O
ex	O
-	O
MDMA	B-Chemical
+	O
users	O
(	O
last	O
tablet	O
>	O
1	O
year	O
ago	O
)	O
and	O
13	O
controls	O
were	O
compared	O
on	O
a	O
battery	O
of	O
neuropsychological	O
tests	O
.	O
</ALL>	O

<ALL>	O
DNA	O
from	O
peripheral	O
nuclear	O
blood	O
cells	O
was	O
genotyped	O
for	O
5	B-Gene
-	I-Gene
HTTLPR	I-Gene
using	O
standard	O
polymerase	O
chain	O
reaction	O
methods	O
.	O
</ALL>	O

<ALL>	O
A	O
significant	O
group	O
effect	O
was	O
observed	O
only	O
on	O
memory	O
function	O
tasks	O
(	O
p	O
=	O
0.04	O
)	O
but	O
not	O
on	O
reaction	O
times	O
(	O
p	O
=	O
0.61	O
)	O
or	O
attention	O
/	O
executive	O
functioning	O
(	O
p	O
=	O
0.59	O
)	O
.	O
</ALL>	O

<ALL>	O
Heavy	O
and	O
ex	O
-	O
MDMA	B-Chemical
+	O
users	O
performed	O
significantly	O
poorer	O
on	O
memory	O
tasks	O
than	O
controls	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
no	O
evidence	O
of	O
memory	B-Disease
impairment	I-Disease
was	O
observed	O
in	O
moderate	O
MDMA	B-Chemical
users	O
.	O
</ALL>	O

<ALL>	O
No	O
significant	O
effect	O
of	O
5	B-Gene
-	I-Gene
HTTLPR	I-Gene
or	O
gender	O
was	O
observed	O
.	O
</ALL>	O

<ALL>	O
While	O
the	O
use	O
of	O
MDMA	B-Chemical
in	O
quantities	O
that	O
may	O
be	O
considered	O
"	O
moderate	O
"	O
is	O
not	O
associated	O
with	O
impaired	B-Disease
memory	I-Disease
functioning	I-Disease
,	O
heavy	O
use	O
of	O
MDMA	B-Chemical
use	O
may	O
lead	O
to	O
long	O
lasting	O
memory	B-Disease
impairments	I-Disease
.	O
</ALL>	O

<ALL>	O
No	O
effect	O
of	O
5	B-Gene
-	I-Gene
HTTLPR	I-Gene
or	O
gender	O
on	O
memory	O
function	O
or	O
MDMA	B-Chemical
use	O
was	O
observed	O
.	O
</ALL>	O

<ALL>	O
Role	O
of	O
mangiferin	B-Chemical
on	O
biochemical	O
alterations	O
and	O
antioxidant	O
status	O
in	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
current	O
study	O
dealt	O
with	O
the	O
protective	O
role	O
of	O
mangiferin	B-Chemical
,	O
a	O
polyphenol	B-Chemical
from	O
Mangifera	B-Species
indica	I-Species
Linn	I-Species
.	O
(	O
</ALL>	O

<ALL>	O
Anacardiaceae	O
)	O
,	O
on	O
isoproterenol	B-Chemical
(	O
ISPH	B-Chemical
)	O
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
(	O
MI	B-Disease
)	O
in	O
rats	B-Species
through	O
its	O
antioxidative	O
mechanism	O
.	O
</ALL>	O

<ALL>	O
Subcutaneous	O
injection	O
of	O
ISPH	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
body	O
weight	O
in	O
1	O
ml	O
saline	O
)	O
to	O
rats	B-Species
for	O
2	O
consecutive	O
days	O
caused	O
myocardial	B-Disease
damage	I-Disease
in	O
rat	B-Species
heart	O
,	O
which	O
was	O
determined	O
by	O
the	O
increased	O
activity	O
of	O
serum	O
lactate	B-Gene
dehydrogenase	I-Gene
(	O
LDH	B-Gene
)	O
and	O
creatine	B-Gene
phosphokinase	I-Gene
isoenzymes	I-Gene
(	O
CK	B-Gene
-	I-Gene
MB	I-Gene
)	O
,	O
increased	O
uric	B-Chemical
acid	I-Chemical
level	O
and	O
reduced	O
plasma	O
iron	B-Chemical
binding	O
capacity	O
.	O
</ALL>	O

<ALL>	O
The	O
protective	O
role	O
of	O
mangiferin	B-Chemical
was	O
analyzed	O
by	O
triphenyl	B-Chemical
tetrazolium	I-Chemical
chloride	I-Chemical
(	O
TTC	B-Chemical
)	O
test	O
used	O
for	O
macroscopic	O
enzyme	O
mapping	O
assay	O
of	O
the	O
ischemic	B-Disease
myocardium	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
heart	O
tissue	O
antioxidant	O
enzymes	O
such	O
as	O
superoxide	B-Gene
dismutase	I-Gene
,	O
catalase	B-Gene
,	O
glutathione	B-Gene
peroxidase	I-Gene
,	O
glutathione	B-Gene
transferase	I-Gene
and	O
glutathione	B-Gene
reductase	I-Gene
activities	O
,	O
non	O
-	O
enzymic	O
antioxidants	O
such	O
as	O
cerruloplasmin	B-Gene
,	O
Vitamin	B-Chemical
C	I-Chemical
,	O
Vitamin	B-Chemical
E	I-Chemical
and	O
glutathione	B-Chemical
levels	O
were	O
altered	O
in	O
MI	B-Disease
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Upon	O
pretreatment	O
with	O
mangiferin	B-Chemical
(	O
100	O
mg	O
/	O
kg	O
body	O
weight	O
suspended	O
in	O
2	O
ml	O
of	O
dimethyl	B-Chemical
sulphoxide	I-Chemical
)	O
given	O
intraperitoneally	O
for	O
28	O
days	O
to	O
MI	B-Disease
rats	B-Species
protected	O
the	O
above	O
-	O
mentioned	O
parameters	O
to	O
fall	O
from	O
the	O
normal	O
levels	O
.	O
</ALL>	O

<ALL>	O
Activities	O
of	O
heart	O
tissue	O
enzymic	O
antioxidants	O
and	O
serum	O
non	O
-	O
enzymic	O
antioxidants	O
levels	O
rose	O
significantly	O
upon	O
mangiferin	B-Chemical
administration	O
as	O
compared	O
to	O
ISPH	B-Chemical
-	O
induced	O
MI	B-Disease
rats	B-Species
.	O
</ALL>	O

<ALL>	O
From	O
the	O
present	O
study	O
it	O
is	O
concluded	O
that	O
mangiferin	B-Chemical
exerts	O
a	O
beneficial	O
effect	O
against	O
ISPH	B-Chemical
-	O
induced	O
MI	B-Disease
due	O
to	O
its	O
antioxidant	O
potential	O
,	O
which	O
regulated	O
the	O
tissues	O
defense	O
system	O
against	O
cardiac	B-Disease
damage	I-Disease
.	O
</ALL>	O

<ALL>	O
Cardiovascular	O
risk	O
with	O
cyclooxygenase	B-Chemical
inhibitors	I-Chemical
:	O
general	O
problem	O
with	O
substance	O
specific	O
differences	O
?	O
</ALL>	O

<ALL>	O
Randomised	O
clinical	O
trials	O
and	O
observational	O
studies	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
myocardial	B-Disease
infarction	I-Disease
,	O
stroke	B-Disease
,	O
hypertension	B-Disease
and	O
heart	B-Disease
failure	I-Disease
during	O
treatment	O
with	O
cyclooxygenase	B-Chemical
inhibitors	I-Chemical
.	O
</ALL>	O

<ALL>	O
Adverse	O
cardiovascular	O
effects	O
occurred	O
mainly	O
,	O
but	O
not	O
exclusively	O
,	O
in	O
patients	B-Species
with	O
concomitant	O
risk	O
factors	O
.	O
</ALL>	O

<ALL>	O
Cyclooxygenase	B-Chemical
inhibitors	I-Chemical
cause	O
complex	O
changes	O
in	O
renal	O
,	O
vascular	O
and	O
cardiac	O
prostanoid	B-Chemical
profiles	O
thereby	O
increasing	O
vascular	O
resistance	O
and	O
fluid	O
retention	O
.	O
</ALL>	O

<ALL>	O
The	O
incidence	O
of	O
cardiovascular	B-Disease
adverse	I-Disease
events	I-Disease
tends	O
to	O
increase	O
with	O
the	O
daily	O
dose	O
and	O
total	O
exposure	O
time	O
.	O
</ALL>	O

<ALL>	O
A	O
comparison	O
of	O
individual	O
selective	O
and	O
unselective	O
cyclooxygenase	B-Chemical
inhibitors	I-Chemical
suggests	O
substance	O
-	O
specific	O
differences	O
,	O
which	O
may	O
depend	O
on	O
differences	O
in	O
pharmacokinetic	O
parameters	O
or	O
inhibitory	O
potency	O
and	O
may	O
be	O
contributed	O
by	O
prostaglandin	B-Chemical
-	O
independent	O
effects	O
.	O
</ALL>	O

<ALL>	O
Diagnostic	O
markers	O
such	O
as	O
N	B-Chemical
-	I-Chemical
terminal	I-Chemical
pro	I-Chemical
brain	I-Chemical
natriuretic	I-Chemical
peptide	I-Chemical
(	O
NT	B-Chemical
-	I-Chemical
proBNP	I-Chemical
)	O
or	O
high	O
-	O
sensitive	O
C	B-Gene
-	I-Gene
reactive	I-Gene
protein	I-Gene
might	O
help	O
in	O
the	O
early	O
identification	O
of	O
patients	B-Species
at	O
risk	O
,	O
thus	O
avoiding	O
the	O
occurrence	O
of	O
serious	O
cardiovascular	B-Disease
toxicity	I-Disease
.	O
</ALL>	O

<ALL>	O
Impact	O
of	O
alcohol	B-Chemical
exposure	O
after	O
pregnancy	O
recognition	O
on	O
ultrasonographic	O
fetal	O
growth	O
measures	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
More	O
than	O
3	O
decades	O
after	O
Jones	O
and	O
Smith	O
(	O
1973	O
)	O
reported	O
on	O
the	O
devastation	O
caused	O
by	O
alcohol	B-Chemical
exposure	O
on	O
fetal	O
development	O
,	O
the	O
rates	O
of	O
heavy	O
drinking	O
during	O
pregnancy	O
remain	O
relatively	O
unchanged	O
.	O
</ALL>	O

<ALL>	O
Early	O
identification	O
of	O
fetal	O
alcohol	B-Chemical
exposure	O
and	O
maternal	O
abstinence	O
led	O
to	O
better	O
infant	O
outcomes	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
examined	O
the	O
utility	O
of	O
biometry	O
for	O
detecting	O
alcohol	B-Chemical
-	O
related	O
fetal	O
growth	B-Disease
impairment	I-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
We	O
obtained	O
fetal	O
ultrasound	O
measures	O
from	O
routine	O
ultrasound	O
examinations	O
for	O
167	O
pregnant	O
hazardous	O
drinkers	O
who	O
were	O
enrolled	O
in	O
a	O
brief	O
alcohol	B-Chemical
intervention	O
study	O
.	O
</ALL>	O

<ALL>	O
The	O
fetal	O
measures	O
for	O
women	B-Species
who	O
quit	O
after	O
learning	O
of	O
their	O
pregnancies	O
were	O
compared	O
with	O
measures	O
for	O
women	B-Species
who	O
continued	O
some	O
drinking	O
throughout	O
the	O
course	O
of	O
their	O
pregnancies	O
.	O
</ALL>	O

<ALL>	O
Because	O
intensity	O
of	O
alcohol	B-Chemical
consumption	O
is	O
associated	O
with	O
poorer	O
fetal	O
outcomes	O
,	O
separate	O
analyses	O
were	O
conducted	O
for	O
the	O
heavy	O
(	O
average	O
of	O
>	O
or	O
=	O
5	O
drinks	O
per	O
drinking	O
day	O
)	O
alcohol	B-Chemical
consumers	O
.	O
</ALL>	O

<ALL>	O
Fetal	O
measures	O
from	O
the	O
heavy	O
-	O
exposed	O
fetuses	O
were	O
also	O
compared	O
with	O
measures	O
from	O
a	O
nondrinking	O
group	O
that	O
was	O
representative	O
of	O
normal	O
,	O
uncomplicated	O
pregnancies	O
from	O
our	O
clinics	O
.	O
</ALL>	O

<ALL>	O
Analyses	O
of	O
covariance	O
were	O
used	O
to	O
determine	O
whether	O
there	O
were	O
differences	O
between	O
groups	O
after	O
controlling	O
for	O
influences	O
of	O
gestational	O
age	O
and	O
drug	B-Disease
abuse	I-Disease
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Nearly	O
half	O
of	O
the	O
pregnant	O
drinkers	O
abstained	O
after	O
learning	O
of	O
their	O
pregnancies	O
.	O
</ALL>	O

<ALL>	O
When	O
women	B-Species
reportedly	O
quit	O
drinking	O
early	O
in	O
their	O
pregnancies	O
,	O
fetal	O
growth	O
measures	O
were	O
not	O
significantly	O
different	O
from	O
a	O
non	O
-	O
alcohol	B-Chemical
-	O
exposed	O
group	O
,	O
regardless	O
of	O
prior	O
drinking	O
patterns	O
.	O
</ALL>	O

<ALL>	O
Any	O
alcohol	B-Chemical
consumption	O
postpregnancy	O
recognition	O
among	O
the	O
heavy	O
drinkers	O
resulted	O
in	O
reduced	B-Disease
cerebellar	I-Disease
growth	I-Disease
as	O
well	O
as	O
decreased	B-Disease
cranial	I-Disease
to	I-Disease
body	I-Disease
growth	I-Disease
in	O
comparison	O
with	O
women	B-Species
who	O
either	O
quit	O
drinking	O
or	O
who	O
were	O
nondrinkers	O
.	O
</ALL>	O

<ALL>	O
Amphetamine	B-Chemical
abuse	O
was	O
predictive	O
of	O
larger	O
cranial	O
to	O
body	O
growth	O
ratios	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Alterations	O
in	O
fetal	O
biometric	O
measurements	O
were	O
observed	O
among	O
the	O
heavy	O
drinkers	O
only	O
when	O
they	O
continued	O
drinking	O
after	O
becoming	O
aware	O
of	O
their	O
pregnancies	O
.	O
</ALL>	O

<ALL>	O
Although	O
the	O
reliance	O
on	O
self	O
-	O
reported	O
drinking	O
is	O
a	O
limitation	O
in	O
this	O
study	O
,	O
these	O
findings	O
support	O
the	O
benefits	O
of	O
early	O
abstinence	O
and	O
the	O
potential	O
for	O
ultrasound	O
examinations	O
in	O
the	O
detection	O
of	O
fetal	O
alcohol	B-Chemical
effects	O
.	O
</ALL>	O

<ALL>	O
Down	O
-	O
regulation	O
of	O
norepinephrine	B-Gene
transporter	I-Gene
function	O
induced	O
by	O
chronic	O
administration	O
of	O
desipramine	B-Chemical
linking	O
to	O
the	O
alteration	O
of	O
sensitivity	O
of	O
local	O
-	O
anesthetics	B-Chemical
-	O
induced	O
convulsions	B-Disease
and	O
the	O
counteraction	O
by	O
co	O
-	O
administration	O
with	O
local	O
anesthetics	B-Chemical
.	O
</ALL>	O

<ALL>	O
Alterations	O
of	O
norepinephrine	B-Gene
transporter	I-Gene
(	O
NET	B-Gene
)	O
function	O
by	O
chronic	O
inhibition	O
of	O
NET	B-Gene
in	O
relation	O
to	O
sensitization	O
to	O
seizures	B-Disease
induce	O
by	O
cocaine	B-Chemical
and	O
local	O
anesthetics	B-Chemical
were	O
studied	O
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Daily	O
administration	O
of	O
desipramine	B-Chemical
,	O
an	O
inhibitor	O
of	O
the	O
NET	B-Gene
,	O
for	O
5	O
days	O
decreased	O
[	B-Chemical
(	I-Chemical
3	I-Chemical
)	I-Chemical
H]norepinephrine	I-Chemical
uptake	O
in	O
the	O
P2	O
fractions	O
of	O
hippocampus	O
but	O
not	O
cortex	O
,	O
striatum	O
or	O
amygdalae	O
.	O
</ALL>	O

<ALL>	O
Co	O
-	O
administration	O
of	O
lidocaine	B-Chemical
,	O
bupivacaine	B-Chemical
or	O
tricaine	B-Chemical
with	O
desipramine	B-Chemical
reversed	O
this	O
effect	O
.	O
</ALL>	O

<ALL>	O
Daily	O
treatment	O
of	O
cocaine	B-Chemical
increased	O
[	B-Chemical
(	I-Chemical
3	I-Chemical
)	I-Chemical
H]norepinephrine	I-Chemical
uptake	O
into	O
the	O
hippocampus	O
.	O
</ALL>	O

<ALL>	O
Daily	O
administration	O
of	O
desipramine	B-Chemical
increased	O
the	O
incidence	O
of	O
appearance	O
of	O
lidocaine	B-Chemical
-	O
induced	O
convulsions	B-Disease
and	O
decreased	O
that	O
of	O
cocaine	B-Chemical
-	O
induced	O
convulsions	B-Disease
.	O
</ALL>	O

<ALL>	O
Co	O
-	O
administration	O
of	O
lidocaine	B-Chemical
with	O
desipramine	B-Chemical
reversed	O
the	O
changes	O
of	O
convulsive	B-Disease
activity	O
of	O
lidocaine	B-Chemical
and	O
cocaine	B-Chemical
induced	O
by	O
repeated	O
administration	O
of	O
desipramine	B-Chemical
.	O
</ALL>	O

<ALL>	O
These	O
results	O
suggest	O
that	O
down	O
-	O
regulation	O
of	O
hippocampal	O
NET	B-Gene
induced	O
by	O
chronic	O
administration	O
of	O
desipramine	B-Chemical
may	O
be	O
relevant	O
to	O
desipramine	B-Chemical
-	O
induced	O
sensitization	O
of	O
lidocaine	B-Chemical
convulsions	B-Disease
.	O
</ALL>	O

<ALL>	O
Inhibition	O
of	O
Na	B-Chemical
(	I-Chemical
+	I-Chemical
)	I-Chemical
channels	O
by	O
local	O
anesthetics	B-Chemical
may	O
regulate	O
desipramine	B-Chemical
-	O
induced	O
down	O
-	O
regulation	O
of	O
NET	B-Gene
function	O
.	O
</ALL>	O

<ALL>	O
Repeated	O
administration	O
of	O
cocaine	B-Chemical
induces	O
up	O
-	O
regulation	O
of	O
hippocampal	O
NET	B-Gene
function	O
.	O
</ALL>	O

<ALL>	O
Desipramine	B-Chemical
-	O
induced	O
sensitization	O
of	O
lidocaine	B-Chemical
seizures	B-Disease
may	O
have	O
a	O
mechanism	O
distinct	O
from	O
kindling	O
resulting	O
from	O
repeated	O
administration	O
of	O
cocaine	B-Chemical
.	O
</ALL>	O

<ALL>	O
Pharmacological	O
evidence	O
for	O
the	O
potential	O
of	O
Daucus	B-Species
carota	I-Species
in	O
the	O
management	O
of	O
cognitive	B-Disease
dysfunctions	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
was	O
aimed	O
at	O
investigating	O
the	O
effects	O
of	O
Daucus	B-Species
carota	I-Species
seeds	O
on	O
cognitive	O
functions	O
,	O
total	O
serum	O
cholesterol	B-Chemical
levels	O
and	O
brain	O
cholinesterase	B-Gene
activity	O
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
ethanolic	O
extract	B-Chemical
of	I-Chemical
Daucus	I-Chemical
carota	I-Chemical
seeds	I-Chemical
(	O
DCE	B-Chemical
)	O
was	O
administered	O
orally	O
in	O
three	O
doses	O
(	O
100	O
,	O
200	O
,	O
400	O
mg	O
/	O
kg	O
)	O
for	O
seven	O
successive	O
days	O
to	O
different	O
groups	O
of	O
young	O
and	O
aged	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Elevated	O
plus	O
maze	O
and	O
passive	O
avoidance	O
apparatus	O
served	O
as	O
the	O
exteroceptive	O
behavioral	O
models	O
for	O
testing	O
memory	O
.	O
</ALL>	O

<ALL>	O
Diazepam	B-Chemical
-	O
,	O
scopolamine	B-Chemical
-	O
and	O
ageing	O
-	O
induced	O
amnesia	B-Disease
served	O
as	O
the	O
interoceptive	O
behavioral	O
models	O
.	O
</ALL>	O

<ALL>	O
DCE	B-Chemical
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
</ALL>	O

<ALL>	O
showed	O
significant	O
improvement	O
in	O
memory	O
scores	O
of	O
young	O
and	O
aged	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
extent	O
of	O
memory	O
improvement	O
evoked	O
by	O
DCE	B-Chemical
was	O
23	O
%	O
at	O
the	O
dose	O
of	O
200	O
mg	O
/	O
kg	O
and	O
35	O
%	O
at	O
the	O
dose	O
of	O
400	O
mg	O
/	O
kg	O
in	O
young	O
mice	B-Species
using	O
elevated	O
plus	O
maze	O
.	O
</ALL>	O

<ALL>	O
Similarly	O
,	O
significant	O
improvements	O
in	O
memory	O
scores	O
were	O
observed	O
using	O
passive	O
avoidance	O
apparatus	O
and	O
aged	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
DCE	B-Chemical
reversed	O
the	O
amnesia	B-Disease
induced	O
by	O
scopolamine	B-Chemical
(	O
0.4	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
</ALL>	O

<ALL>	O
and	O
diazepam	B-Chemical
(	O
1	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
.	O
</ALL>	O

<ALL>	O
Daucus	B-Chemical
carota	I-Chemical
extract	I-Chemical
(	O
200	O
,	O
400	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
</ALL>	O

<ALL>	O
reduced	O
significantly	O
the	O
brain	O
acetylcholinesterase	B-Gene
activity	O
and	O
cholesterol	B-Chemical
levels	O
in	O
young	O
and	O
aged	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
extent	O
of	O
inhibition	O
of	O
brain	O
cholinesterase	B-Gene
activity	O
evoked	O
by	O
DCE	B-Chemical
at	O
the	O
dose	O
of	O
400	O
mg	O
/	O
kg	O
was	O
22	O
%	O
in	O
young	O
and	O
19	O
%	O
in	O
aged	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
There	O
was	O
a	O
remarkable	O
reduction	O
in	O
total	O
cholesterol	B-Chemical
level	O
as	O
well	O
,	O
to	O
the	O
extent	O
of	O
23	O
%	O
in	O
young	O
and	O
21	O
%	O
in	O
aged	O
animals	O
with	O
this	O
dose	O
of	O
DCE	B-Chemical
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
DCE	B-Chemical
may	O
prove	O
to	O
be	O
a	O
useful	O
remedy	O
for	O
the	O
management	O
of	O
cognitive	B-Disease
dysfunctions	I-Disease
on	O
account	O
of	O
its	O
multifarious	O
beneficial	O
effects	O
such	O
as	O
,	O
memory	O
improving	O
property	O
,	O
cholesterol	B-Chemical
lowering	O
property	O
and	O
anticholinesterase	O
activity	O
.	O
</ALL>	O

<ALL>	O
Mechanisms	O
of	O
hypertension	B-Disease
induced	O
by	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
deficiency	O
:	O
focus	O
on	O
venous	O
function	O
.	O
</ALL>	O

<ALL>	O
Loss	O
of	O
endothelial	O
cell	O
-	O
derived	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
in	O
hypertension	B-Disease
is	O
a	O
hallmark	O
of	O
arterial	B-Disease
dysfunction	I-Disease
.	O
</ALL>	O

<ALL>	O
Experimental	O
hypertension	B-Disease
created	O
by	O
the	O
removal	O
of	O
NO	B-Chemical
,	O
however	O
,	O
involves	O
mechanisms	O
in	O
addition	O
to	O
decreased	O
arterial	O
vasodilator	O
activity	O
.	O
</ALL>	O

<ALL>	O
These	O
include	O
augmented	O
endothelin	B-Gene
-	I-Gene
1	I-Gene
(	O
ET	B-Gene
-	I-Gene
1	I-Gene
)	O
release	O
,	O
increased	O
sympathetic	O
nervous	O
system	O
activity	O
,	O
and	O
elevated	O
tissue	O
oxidative	O
stress	O
.	O
</ALL>	O

<ALL>	O
We	O
hypothesized	O
that	O
increased	O
venous	O
smooth	O
muscle	O
(	O
venomotor	O
)	O
tone	O
plays	O
a	O
role	O
in	O
Nomega	B-Chemical
-	I-Chemical
nitro	I-Chemical
-	I-Chemical
L	I-Chemical
-	I-Chemical
arginine	I-Chemical
(	O
LNNA	B-Chemical
)	O
hypertension	B-Disease
through	O
these	O
mechanisms	O
.	O
</ALL>	O

<ALL>	O
Rats	B-Species
were	O
treated	O
with	O
the	O
NO	B-Gene
synthase	I-Gene
inhibitor	O
LNNA	B-Chemical
(	O
0.5	O
g	O
/	O
L	O
in	O
drinking	O
water	O
)	O
for	O
2	O
weeks	O
.	O
</ALL>	O

<ALL>	O
Mean	O
arterial	O
pressure	O
of	O
conscious	O
rats	B-Species
was	O
119	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
in	O
control	O
and	O
194	O
+	O
/	O
-	O
5	O
mm	O
Hg	O
in	O
LNNA	B-Chemical
rats	B-Species
(	O
P	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
Carotid	O
arteries	O
and	O
vena	O
cava	O
were	O
removed	O
for	O
measurement	O
of	O
isometric	O
contraction	O
.	O
</ALL>	O

<ALL>	O
Maximal	O
contraction	O
to	O
norepinephrine	B-Chemical
was	O
modestly	O
reduced	O
in	O
arteries	O
from	O
LNNA	B-Chemical
compared	O
with	O
control	O
rats	B-Species
whereas	O
the	O
maximum	O
contraction	O
to	O
ET	B-Gene
-	I-Gene
1	I-Gene
was	O
significantly	O
reduced	O
(	O
54	O
%	O
control	O
)	O
.	O
</ALL>	O

<ALL>	O
Maximum	O
contraction	O
of	O
vena	O
cava	O
to	O
norepinephrine	B-Chemical
(	O
37	O
%	O
control	O
)	O
also	O
was	O
reduced	O
but	O
no	O
change	O
in	O
response	O
to	O
ET	B-Gene
-	I-Gene
1	I-Gene
was	O
observed	O
.	O
</ALL>	O

<ALL>	O
Mean	O
circulatory	O
filling	O
pressure	O
,	O
an	O
in	O
vivo	O
measure	O
of	O
venomotor	O
tone	O
,	O
was	O
not	O
elevated	O
in	O
LNNA	B-Chemical
hypertension	B-Disease
at	O
1	O
or	O
2	O
weeks	O
after	O
LNNA	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
superoxide	B-Chemical
scavenger	O
tempol	B-Chemical
(	O
30	O
,	O
100	O
,	O
and	O
300	O
micromol	O
kg	O
(	O
-	O
1	O
)	O
,	O
IV	O
)	O
did	O
not	O
change	O
arterial	O
pressure	O
in	O
control	O
rats	B-Species
but	O
caused	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
LNNA	B-Chemical
rats	B-Species
(	O
-	O
18	O
+	O
/	O
-	O
8	O
,	O
-	O
26	O
+	O
/	O
-	O
15	O
,	O
and	O
-	O
54	O
+	O
/	O
-	O
11	O
mm	O
Hg	O
)	O
.	O
</ALL>	O

<ALL>	O
Similarly	O
,	O
ganglionic	O
blockade	O
with	O
hexamethonium	B-Chemical
caused	O
a	O
significantly	O
greater	O
fall	O
in	O
LNNA	B-Chemical
hypertensive	B-Disease
rats	B-Species
(	O
76	O
+	O
/	O
-	O
9	O
mm	O
Hg	O
)	O
compared	O
with	O
control	O
rats	B-Species
(	O
35	O
+	O
/	O
-	O
10	O
mm	O
Hg	O
)	O
.	O
</ALL>	O

<ALL>	O
Carotid	O
arteries	O
,	O
vena	O
cava	O
,	O
and	O
sympathetic	O
ganglia	O
from	O
LNNA	B-Chemical
rats	B-Species
had	O
higher	O
basal	O
levels	O
of	O
superoxide	B-Chemical
compared	O
with	O
those	O
from	O
control	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
These	O
data	O
suggest	O
that	O
while	O
NO	B-Chemical
deficiency	O
increases	O
oxidative	O
stress	O
and	O
sympathetic	O
activity	O
in	O
both	O
arterial	O
and	O
venous	O
vessels	O
,	O
the	O
impact	O
on	O
veins	O
does	O
not	O
make	O
a	O
major	O
contribution	O
to	O
this	O
form	O
of	O
hypertension	B-Disease
.	O
</ALL>	O

<ALL>	O
Anticonvulsant	O
effect	O
of	O
eslicarbazepine	B-Chemical
acetate	I-Chemical
(	O
BIA	B-Chemical
2	I-Chemical
-	I-Chemical
093	I-Chemical
)	O
on	O
seizures	B-Disease
induced	O
by	O
microperfusion	O
of	O
picrotoxin	B-Chemical
in	O
the	O
hippocampus	O
of	O
freely	O
moving	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Eslicarbazepine	B-Chemical
acetate	I-Chemical
(	O
BIA	B-Chemical
2	I-Chemical
-	I-Chemical
093	I-Chemical
,	O
S	B-Chemical
-	I-Chemical
(	I-Chemical
-	I-Chemical
)	I-Chemical
-	I-Chemical
10	I-Chemical
-	I-Chemical
acetoxy	I-Chemical
-	I-Chemical
10,11	I-Chemical
-	I-Chemical
dihydro	I-Chemical
-	I-Chemical
5H	I-Chemical
-	I-Chemical
dibenzo	I-Chemical
/	I-Chemical
b	I-Chemical
,	I-Chemical
f	I-Chemical
/	I-Chemical
azepine	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
carboxamide	I-Chemical
)	O
is	O
a	O
novel	O
antiepileptic	B-Chemical
drug	I-Chemical
,	O
now	O
in	O
Phase	O
III	O
clinical	O
trials	O
,	O
designed	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
and	O
safety	O
in	O
comparison	O
with	O
the	O
structurally	O
related	O
drugs	O
carbamazepine	B-Chemical
(	O
CBZ	B-Chemical
)	O
and	O
oxcarbazepine	B-Chemical
(	O
OXC	B-Chemical
)	O
.	O
</ALL>	O

<ALL>	O
We	O
have	O
studied	O
the	O
effects	O
of	O
oral	O
treatment	O
with	O
eslicarbazepine	B-Chemical
acetate	I-Chemical
on	O
a	O
whole	O
-	O
animal	O
model	O
in	O
which	O
partial	O
seizures	B-Disease
can	O
be	O
elicited	O
repeatedly	O
on	O
different	O
days	O
without	O
changes	O
in	O
threshold	O
or	O
seizure	B-Disease
patterns	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
animals	O
treated	O
with	O
threshold	O
doses	O
of	O
picrotoxin	B-Chemical
,	O
the	O
average	O
number	O
of	O
seizures	B-Disease
was	O
2.3	O
+	O
/	O
-	O
1.2	O
,	O
and	O
average	O
seizure	B-Disease
duration	O
was	O
39.5	O
+	O
/	O
-	O
8.4s	O
.	O
</ALL>	O

<ALL>	O
Pre	O
-	O
treatment	O
with	O
a	O
dose	O
of	O
30	O
mg	O
/	O
kg	O
2h	O
before	O
picrotoxin	B-Chemical
microperfusion	O
prevented	O
seizures	B-Disease
in	O
the	O
75	O
%	O
of	O
the	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Lower	O
doses	O
(	O
3	O
and	O
10	O
mg	O
/	O
kg	O
)	O
did	O
not	O
suppress	O
seizures	B-Disease
,	O
however	O
,	O
after	O
administration	O
of	O
10	O
mg	O
/	O
kg	O
,	O
significant	O
reductions	O
in	O
seizures	B-Disease
duration	O
(	O
24.3	O
+	O
/	O
-	O
6.8s	O
)	O
and	O
seizure	B-Disease
number	O
(	O
1.6	O
+	O
/	O
-	O
0.34	O
)	O
were	O
found	O
.	O
</ALL>	O

<ALL>	O
No	O
adverse	O
effects	O
of	O
eslicarbazepine	B-Chemical
acetate	I-Chemical
were	O
observed	O
in	O
the	O
behavioral	O
/	O
EEG	O
patterns	O
studied	O
,	O
including	O
sleep	O
/	O
wakefulness	O
cycle	O
,	O
at	O
the	O
doses	O
studied	O
.	O
</ALL>	O

<ALL>	O
Anti	O
-	O
oxidant	O
effects	O
of	O
atorvastatin	B-Chemical
in	O
dexamethasone	B-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
the	O
rat	B-Species
.	O
</ALL>	O

<ALL>	O
1	O
.	O
</ALL>	O

<ALL>	O
Dexamethasone	B-Chemical
(	O
Dex	B-Chemical
)	O
-	O
induced	O
hypertension	B-Disease
is	O
characterized	O
by	O
endothelial	O
dysfunction	O
associated	O
with	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
deficiency	O
and	O
increased	O
superoxide	B-Chemical
(	O
O2	B-Chemical
-	I-Chemical
)	O
production	O
.	O
</ALL>	O

<ALL>	O
Atorvastatin	B-Chemical
(	O
Ato	B-Chemical
)	O
possesses	O
pleiotropic	O
properties	O
that	O
have	O
been	O
reported	O
to	O
improve	O
endothelial	O
function	O
through	O
increased	O
availability	O
of	O
NO	B-Chemical
and	O
reduced	O
O2	B-Chemical
-	I-Chemical
production	O
in	O
various	O
forms	O
of	O
hypertension	B-Disease
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
50	O
mg	O
/	O
kg	O
per	O
day	O
,	O
p.o	O
.	O
,	O
</ALL>	O

<ALL>	O
Ato	B-Chemical
could	O
prevent	O
endothelial	B-Gene
NO	I-Gene
synthase	I-Gene
(	O
eNOS	B-Gene
)	O
downregulation	O
and	O
the	O
increase	O
in	O
O2	B-Chemical
-	I-Chemical
in	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	B-Species
,	O
thereby	O
reducing	O
blood	O
pressure	O
.	O
</ALL>	O

<ALL>	O
2	O
.	O
</ALL>	O

<ALL>	O
Male	O
SD	O
rats	B-Species
(	O
n	O
=	O
30	O
)	O
were	O
treated	O
with	O
Ato	B-Chemical
(	O
50	O
mg	O
/	O
kg	O
per	O
day	O
in	O
drinking	O
water	O
)	O
or	O
tap	O
water	O
for	O
15	O
days	O
.	O
</ALL>	O

<ALL>	O
Dexamethasone	B-Chemical
(	O
10	O
microg	O
/	O
kg	O
per	O
day	O
,	O
s.c	O
.	O
)	O
</ALL>	O

<ALL>	O
or	O
saline	O
was	O
started	O
after	O
4	O
days	O
in	O
Ato	B-Chemical
-	O
treated	O
and	O
non	O
-	O
treated	O
rats	B-Species
and	O
continued	O
for	O
11	O
-	O
13	O
days	O
.	O
</ALL>	O

<ALL>	O
Systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
was	O
measured	O
on	O
alternate	O
days	O
using	O
the	O
tail	O
-	O
cuff	O
method	O
.	O
</ALL>	O

<ALL>	O
Endothelial	O
function	O
was	O
assessed	O
by	O
acetylcholine	B-Chemical
-	O
induced	O
vasorelaxation	O
and	O
phenylephrine	B-Chemical
-	O
induced	O
vasoconstriction	O
in	O
aortic	O
segments	O
.	O
</ALL>	O

<ALL>	O
Vascular	O
eNOS	B-Gene
mRNA	O
was	O
assessed	O
by	O
semi	O
-	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O
</ALL>	O

<ALL>	O
3	O
.	O
</ALL>	O

<ALL>	O
In	O
rats	B-Species
treated	O
with	O
Dex	B-Chemical
alone	O
,	O
SBP	O
was	O
increased	O
from	O
109	O
+	O
/	O
-	O
2	O
to	O
133	O
+	O
/	O
-	O
2	O
mmHg	O
on	O
Days	O
4	O
and	O
Day	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
Ato	B-Chemical
+	O
Dex	B-Chemical
group	O
,	O
SBP	O
was	O
increased	O
from	O
113	O
+	O
/	O
-	O
2	O
to	O
119	O
+	O
/	O
-	O
2	O
mmHg	O
on	O
Days	O
4	O
to	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
)	O
,	O
but	O
was	O
significantly	O
lower	O
than	O
SBP	O
in	O
the	O
group	O
treated	O
with	O
Dex	B-Chemical
alone	O
(	O
P	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
Endothelial	O
-	O
dependent	O
relaxation	O
and	O
eNOS	B-Gene
mRNA	O
expression	O
were	O
greater	O
in	O
the	O
Dex	B-Chemical
+	O
Ato	B-Chemical
group	O
than	O
in	O
the	O
Dex	B-Chemical
only	O
group	O
(	O
P	O
<	O
0.05	O
and	O
P	O
<	O
0.0001	O
,	O
respectively	O
)	O
.	O
</ALL>	O

<ALL>	O
Aortic	O
superoxide	B-Chemical
production	O
was	O
lower	O
in	O
the	O
Dex	B-Chemical
+	O
Ato	B-Chemical
group	O
compared	O
with	O
the	O
group	O
treated	O
with	O
Dex	B-Chemical
alone	O
(	O
P	O
<	O
0.0001	O
)	O
.	O
</ALL>	O

<ALL>	O
4	O
.	O
</ALL>	O

<ALL>	O
Treatment	O
with	O
Ato	B-Chemical
improved	O
endothelial	O
function	O
,	O
reduced	O
superoxide	B-Chemical
production	O
and	O
reduced	O
SBP	O
in	O
Dex	B-Chemical
-	O
treated	O
SD	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Behavioral	O
effects	O
of	O
pubertal	O
anabolic	B-Chemical
androgenic	I-Chemical
steroid	I-Chemical
exposure	O
in	O
male	O
rats	B-Species
with	O
low	O
serotonin	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
interactive	O
effects	O
of	O
chronic	O
anabolic	B-Chemical
androgenic	I-Chemical
steroid	I-Chemical
(	O
AAS	B-Chemical
)	O
exposure	O
and	O
brain	O
serotonin	B-Chemical
(	O
5	B-Chemical
-	I-Chemical
hydroxytryptamine	I-Chemical
,	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
depletion	O
on	O
behavior	O
of	O
pubertal	O
male	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Serotonin	B-Chemical
was	O
depleted	O
beginning	O
on	O
postnatal	O
day	O
26	O
with	O
parachlorophenylalanine	B-Chemical
(	O
PCPA	B-Chemical
100	O
mg	O
/	O
kg	O
,	O
every	O
other	O
day	O
)	O
;	O
controls	O
received	O
saline	O
.	O
</ALL>	O

<ALL>	O
At	O
puberty	O
(	O
P40	O
)	O
,	O
half	O
the	O
PCPA	B-Chemical
-	O
treated	O
rats	B-Species
and	O
half	O
the	O
saline	O
-	O
treated	O
rats	B-Species
began	O
treatment	O
with	O
testosterone	B-Chemical
(	O
T	B-Chemical
,	O
5	O
mg	O
/	O
kg	O
,	O
5	O
days	O
/	O
week	O
)	O
.	O
</ALL>	O

<ALL>	O
Behavioral	O
measures	O
included	O
locomotion	O
,	O
irritability	B-Disease
,	O
copulation	O
,	O
partner	O
preference	O
,	O
and	O
aggression	B-Disease
.	O
</ALL>	O

<ALL>	O
Animals	O
were	O
tested	O
for	O
aggression	B-Disease
in	O
their	O
home	O
cage	O
,	O
both	O
with	O
and	O
without	O
physical	O
provocation	O
(	O
mild	O
tail	O
pinch	O
)	O
.	O
</ALL>	O

<ALL>	O
Brain	O
levels	O
of	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
and	O
its	O
metabolite	O
,	O
5	B-Chemical
-	I-Chemical
hydroxyindoleacetic	I-Chemical
acid	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
HIAA	I-Chemical
)	O
,	O
were	O
determined	O
using	O
HPLC	O
.	O
</ALL>	O

<ALL>	O
PCPA	B-Chemical
significantly	O
and	O
substantially	O
depleted	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
and	O
5	B-Chemical
-	I-Chemical
HIAA	I-Chemical
in	O
all	O
brain	O
regions	O
examined	O
.	O
</ALL>	O

<ALL>	O
Chronic	O
T	B-Chemical
treatment	O
significantly	O
decreased	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
and	O
5	B-Chemical
-	I-Chemical
HIAA	I-Chemical
in	O
certain	O
brain	O
areas	O
,	O
but	O
to	O
a	O
much	O
lesser	O
extent	O
than	O
PCPA	B-Chemical
.	O
</ALL>	O

<ALL>	O
Chronic	O
exposure	O
to	O
PCPA	B-Chemical
alone	O
significantly	O
decreased	O
locomotor	O
activity	O
and	O
increased	O
irritability	B-Disease
but	O
had	O
no	O
effect	O
on	O
sexual	O
behavior	O
,	O
partner	O
preference	O
,	O
or	O
aggression	B-Disease
.	O
</ALL>	O

<ALL>	O
T	B-Chemical
alone	O
had	O
no	O
effect	O
on	O
locomotion	O
,	O
irritability	B-Disease
,	O
or	O
sexual	O
behavior	O
but	O
increased	O
partner	O
preference	O
and	O
aggression	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
most	O
striking	O
effect	O
of	O
combining	O
T	B-Chemical
+	O
PCPA	B-Chemical
was	O
a	O
significant	O
increase	O
in	O
attack	O
frequency	O
as	O
well	O
as	O
a	O
significant	O
decrease	O
in	O
the	O
latency	O
to	O
attack	O
,	O
particularly	O
following	O
physical	O
provocation	O
.	O
</ALL>	O

<ALL>	O
Based	O
on	O
these	O
data	O
,	O
it	O
can	O
be	O
speculated	O
that	O
pubertal	O
AAS	B-Chemical
users	O
with	O
low	O
central	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
may	O
be	O
especially	O
prone	O
to	O
exhibit	O
aggressive	B-Disease
behavior	I-Disease
.	O
</ALL>	O

<ALL>	O
In	O
vitro	O
characterization	O
of	O
parasympathetic	O
and	O
sympathetic	O
responses	O
in	O
cyclophosphamide	B-Chemical
-	O
induced	O
cystitis	B-Disease
in	O
the	O
rat	B-Species
.	O
</ALL>	O

<ALL>	O
In	O
cyclophosphamide	B-Chemical
-	O
induced	O
cystitis	B-Disease
in	O
the	O
rat	B-Species
,	O
detrusor	O
function	O
is	O
impaired	O
and	O
the	O
expression	O
and	O
effects	O
of	O
muscarinic	B-Gene
receptors	I-Gene
altered	O
.	O
</ALL>	O

<ALL>	O
Whether	O
or	O
not	O
the	O
neuronal	O
transmission	O
may	O
be	O
affected	O
by	O
cystitis	B-Disease
was	O
presently	O
investigated	O
.	O
</ALL>	O

<ALL>	O
Responses	O
of	O
urinary	O
strip	O
preparations	O
from	O
control	O
and	O
cyclophosphamide	B-Chemical
-	O
pretreated	O
rats	B-Species
to	O
electrical	O
field	O
stimulation	O
and	O
to	O
agonists	O
were	O
assessed	O
in	O
the	O
absence	O
and	O
presence	O
of	O
muscarinic	B-Chemical
,	I-Chemical
adrenergic	I-Chemical
and	I-Chemical
purinergic	I-Chemical
receptor	I-Chemical
antagonists	I-Chemical
.	O
</ALL>	O

<ALL>	O
Generally	O
,	O
atropine	B-Chemical
reduced	O
contractions	O
,	O
but	O
in	O
contrast	O
to	O
controls	O
,	O
it	O
also	O
reduced	O
responses	O
to	O
low	O
electrical	O
field	O
stimulation	O
intensity	O
(	O
1	O
-	O
5	O
Hz	O
)	O
in	O
inflamed	O
preparations	O
.	O
</ALL>	O

<ALL>	O
In	O
both	O
types	O
,	O
purinoceptor	O
desensitization	O
with	O
alpha	B-Chemical
,	I-Chemical
beta	I-Chemical
-	I-Chemical
methylene	I-Chemical
adenosine	I-Chemical
-	I-Chemical
5	I-Chemical
'	I-Chemical
-	I-Chemical
triphosphate	I-Chemical
(	O
alpha	B-Chemical
,	I-Chemical
beta	I-Chemical
-	I-Chemical
meATP	I-Chemical
)	O
caused	O
further	O
reductions	O
at	O
low	O
frequencies	O
(	O
<	O
10	O
Hz	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
muscarinic	B-Gene
receptor	I-Gene
antagonists	O
atropine	B-Chemical
,	O
4	B-Chemical
-	I-Chemical
diphenylacetoxy	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
methylpiperidine	I-Chemical
(	O
4	B-Chemical
-	I-Chemical
DAMP	I-Chemical
)	O
(	O
'	O
M	O
(	O
1	O
)	O
/	O
M	O
(	O
3	O
)	O
/	O
M	O
(	O
5	O
)	O
-	O
selective	O
'	O
)	O
,	O
methoctramine	B-Chemical
(	O
'	O
M	O
(	O
2	O
)	O
-	O
selective	O
'	O
)	O
and	O
pirenzepine	B-Chemical
(	O
'	O
M	O
(	O
1	O
)	O
-	O
selective	O
'	O
)	O
antagonized	O
the	O
tonic	O
component	O
of	O
the	O
electrical	O
field	O
stimulation	O
-	O
evoked	O
contractile	O
response	O
more	O
potently	O
than	O
the	O
phasic	O
component	O
.	O
</ALL>	O

<ALL>	O
4	B-Chemical
-	I-Chemical
DAMP	I-Chemical
inhibited	O
the	O
tonic	O
contractions	O
in	O
controls	O
more	O
potently	O
than	O
methoctramine	B-Chemical
and	O
pirenzepine	B-Chemical
.	O
</ALL>	O

<ALL>	O
In	O
inflamed	O
preparations	O
,	O
the	O
muscarinic	B-Chemical
receptor	I-Chemical
antagonism	I-Chemical
on	O
the	O
phasic	O
component	O
of	O
the	O
electrical	O
field	O
stimulation	O
-	O
evoked	O
contraction	O
was	O
decreased	O
and	O
the	O
pirenzepine	B-Chemical
and	O
4	B-Chemical
-	I-Chemical
DAMP	I-Chemical
antagonism	O
on	O
the	O
tonic	O
component	O
was	O
much	O
less	O
efficient	O
than	O
in	O
controls	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
to	O
controls	O
,	O
methoctramine	B-Chemical
increased	O
-	O
-	O
instead	O
of	O
decreased	O
-	O
-	O
the	O
tonic	O
responses	O
at	O
high	O
frequencies	O
.	O
</ALL>	O

<ALL>	O
While	O
contractions	O
to	O
carbachol	B-Chemical
and	O
ATP	B-Chemical
were	O
the	O
same	O
in	O
inflamed	O
and	O
in	O
control	O
strips	O
when	O
related	O
to	O
a	O
reference	O
potassium	B-Chemical
response	O
,	O
isoprenaline	B-Chemical
-	O
induced	O
relaxations	O
were	O
smaller	O
in	O
inflamed	O
strips	O
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
in	O
cystitis	B-Disease
substantial	O
changes	O
of	O
the	O
efferent	O
functional	O
responses	O
occur	O
.	O
</ALL>	O

<ALL>	O
While	O
postjunctional	O
beta	B-Gene
-	I-Gene
adrenoceptor	I-Gene
-	O
mediated	O
relaxations	O
are	O
reduced	O
,	O
effects	O
by	O
prejunctional	O
inhibitory	O
muscarinic	B-Gene
receptors	I-Gene
may	O
be	O
increased	O
.	O
</ALL>	O

<ALL>	O
Comparison	O
of	O
valsartan	B-Chemical
/	O
hydrochlorothiazide	B-Chemical
combination	O
therapy	O
at	O
doses	O
up	O
to	O
320	O
/	O
25	O
mg	O
versus	O
monotherapy	O
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
followed	O
by	O
long	O
-	O
term	O
combination	O
therapy	O
in	O
hypertensive	B-Disease
adults	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
One	O
third	O
of	O
patients	B-Species
treated	O
for	O
hypertension	B-Disease
attain	O
adequate	O
blood	O
pressure	O
(	O
BP	O
)	O
control	O
,	O
and	O
multidrug	O
regimens	O
are	O
often	O
required	O
.	O
</ALL>	O

<ALL>	O
Given	O
the	O
lifelong	O
nature	O
of	O
hypertension	B-Disease
,	O
there	O
is	O
a	O
need	O
to	O
evaluate	O
the	O
long	O
-	O
term	O
efficacy	O
and	O
tolerability	O
of	O
higher	O
doses	O
of	O
combination	O
anti	O
-	O
hypertensive	B-Disease
therapies	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
This	O
study	O
investigated	O
the	O
efficacy	O
and	O
tolerability	O
of	O
valsartan	B-Chemical
(	O
VAL	B-Chemical
)	O
or	O
hydrochlorothiazide	B-Chemical
(	O
HCTZ	B-Chemical
)	O
-	O
monotherapy	O
and	O
higher	O
-	O
dose	O
combinations	O
in	O
patients	B-Species
with	O
essential	B-Disease
hypertension	I-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
The	O
first	O
part	O
of	O
this	O
study	O
was	O
an	O
8	O
-	O
week	O
,	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
controlled	O
,	O
parallel	O
-	O
group	O
trial	O
.	O
</ALL>	O

<ALL>	O
Patients	B-Species
with	O
essential	B-Disease
hypertension	I-Disease
(	O
mean	O
sitting	O
diastolic	O
BP	O
[	O
MSDBP	O
]	O
,	O
>	O
or	O
=	O
95	O
mm	O
Hg	O
and	O
<	O
110	O
mm	O
Hg	O
)	O
were	O
randomized	O
to	O
1	O
of	O
8	O
treatment	O
groups	O
:	O
VAL	B-Chemical
160	O
or	O
320	O
mg	O
;	O
HCTZ	B-Chemical
12.5	O
or	O
25	O
mg	O
;	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
160	O
/	O
12.5	O
,	O
320	O
/	O
12.5	O
,	O
or	O
320	O
/	O
25	O
mg	O
;	O
or	O
placebo	O
.	O
</ALL>	O

<ALL>	O
Mean	O
changes	O
in	O
MSDBP	O
and	O
mean	O
sitting	O
systolic	O
BP	O
(	O
MSSBP	O
)	O
were	O
analyzed	O
at	O
the	O
8	O
-	O
week	O
core	O
study	O
end	O
point	O
.	O
</ALL>	O

<ALL>	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
320	O
/	O
12.5	O
and	O
320	O
/	O
25	O
mg	O
were	O
further	O
investigated	O
in	O
a	O
54	O
-	O
week	O
,	O
open	O
-	O
label	O
extension	O
.	O
</ALL>	O

<ALL>	O
Response	O
was	O
defined	O
as	O
MSDBP	O
<	O
90	O
mm	O
Hg	O
or	O
a	O
>	O
or	O
=	O
10	O
mm	O
Hg	O
decrease	O
compared	O
to	O
baseline	O
.	O
</ALL>	O

<ALL>	O
Control	O
was	O
defined	O
as	O
MSDBP	O
<	O
90	O
mm	O
Hg	O
compared	O
with	O
baseline	O
.	O
</ALL>	O

<ALL>	O
Tolerability	O
was	O
assessed	O
by	O
monitoring	O
adverse	O
events	O
at	O
randomization	O
and	O
all	O
subsequent	O
study	O
visits	O
and	O
regular	O
evaluation	O
of	O
hematology	O
and	O
blood	O
chemistry	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
A	O
total	O
of	O
1346	O
patients	B-Species
were	O
randomized	O
into	O
the	O
8	O
-	O
week	O
core	O
study	O
(	O
734	O
men	B-Species
,	O
612	O
women	B-Species
;	O
924	O
white	O
,	O
291	O
black	O
,	O
23	O
Asian	O
,	O
108	O
other	O
;	O
mean	O
age	O
,	O
52.7	O
years	O
;	O
mean	O
weight	O
,	O
92.6	O
kg	O
)	O
.	O
</ALL>	O

<ALL>	O
All	O
active	O
treatments	O
were	O
associated	O
with	O
significantly	O
reduced	O
MSSBP	O
and	O
MSDBP	O
during	O
the	O
core	O
8	O
-	O
week	O
study	O
,	O
with	O
each	O
monotherapy	O
significantly	O
contributing	O
to	O
the	O
overall	O
effect	O
of	O
combination	O
therapy	O
(	O
VAL	B-Chemical
and	O
HCTZ	B-Chemical
,	O
P	O
<	O
0.001	O
)	O
.	O
</ALL>	O

<ALL>	O
Each	O
combination	O
was	O
associated	O
with	O
significantly	O
greater	O
reductions	O
in	O
MSSBP	O
and	O
MSDBP	O
compared	O
with	O
the	O
monotherapies	O
and	O
placebo	O
(	O
all	O
,	O
P	O
<	O
0.001	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
mean	O
reduction	O
in	O
MSSBP	O
/	O
MSDBP	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
320	O
/	O
25	O
mg	O
was	O
24.7	O
/	O
16.6	O
mm	O
Hg	O
,	O
compared	O
with	O
5.9	O
/	O
7.0	O
mm	O
Hg	O
with	O
placebo	O
.	O
</ALL>	O

<ALL>	O
The	O
reduction	O
in	O
MSSBP	O
was	O
significantly	O
greater	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
320	O
/	O
25	O
mg	O
compared	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
160	O
/	O
12.5	O
mg	O
(	O
P	O
<	O
0.002	O
)	O
.	O
</ALL>	O

<ALL>	O
Rates	O
of	O
response	O
and	O
BP	O
control	O
were	O
significantly	O
higher	O
in	O
the	O
groups	O
that	O
received	O
combination	O
treatment	O
compared	O
with	O
those	O
that	O
received	O
monotherapy	O
.	O
</ALL>	O

<ALL>	O
The	O
incidence	O
of	O
hypokalemia	B-Disease
was	O
lower	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
combinations	O
(	O
1.8	O
%	O
-	O
6.1	O
%	O
)	O
than	O
with	O
HCTZ	B-Chemical
monotherapies	O
(	O
7.1	O
%	O
-	O
13.3	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
majority	O
of	O
adverse	O
events	O
in	O
the	O
core	O
study	O
were	O
of	O
mild	O
to	O
moderate	O
severity	O
.	O
</ALL>	O

<ALL>	O
The	O
efficacy	O
and	O
tolerability	O
of	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
combinations	O
were	O
maintained	O
during	O
the	O
extension	O
(	O
797	O
patients	B-Species
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
In	O
this	O
study	O
population	O
,	O
combination	O
therapies	O
with	O
VAL	B-Chemical
/	O
HCTZ	B-Chemical
were	O
associated	O
with	O
significantly	O
greater	O
BP	O
reductions	O
compared	O
with	O
either	O
monotherapy	O
,	O
were	O
well	O
tolerated	O
,	O
and	O
were	O
associated	O
with	O
less	O
hypokalemia	B-Disease
than	O
HCTZ	B-Chemical
alone	O
.	O
</ALL>	O

<ALL>	O
Role	O
of	O
xanthine	B-Chemical
oxidase	I-Chemical
in	O
dexamethasone	B-Chemical
-	O
induced	O
hypertension	B-Disease
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
1	O
.	O
</ALL>	O

<ALL>	O
Glucocorticoid	B-Chemical
-	O
induced	O
hypertension	B-Disease
(	O
GC	B-Chemical
-	O
HT	B-Disease
)	O
in	O
the	O
rat	B-Species
is	O
associated	O
with	O
nitric	B-Chemical
oxide	I-Chemical
-	O
redox	O
imbalance	O
.	O
</ALL>	O

<ALL>	O
2	O
.	O
</ALL>	O

<ALL>	O
We	O
studied	O
the	O
role	O
of	O
xanthine	B-Chemical
oxidase	I-Chemical
(	O
XO	B-Chemical
)	O
,	O
which	O
is	O
implicated	O
in	O
the	O
production	O
of	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
,	O
in	O
dexamethasone	B-Chemical
-	O
induced	O
hypertension	B-Disease
(	O
dex	B-Chemical
-	O
HT	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
3	O
.	O
</ALL>	O

<ALL>	O
Thirty	O
male	O
Sprague	O
-	O
Dawley	O
rats	B-Species
were	O
divided	O
randomly	O
into	O
four	O
treatment	O
groups	O
:	O
saline	O
,	O
dexamethasone	B-Chemical
(	O
dex	B-Chemical
)	O
,	O
allopurinol	B-Chemical
plus	O
saline	O
,	O
and	O
allopurinol	B-Chemical
plus	O
dex	B-Chemical
.	O
</ALL>	O

<ALL>	O
4	O
.	O
</ALL>	O

<ALL>	O
Systolic	O
blood	O
pressures	O
(	O
SBP	O
)	O
and	O
bodyweights	O
were	O
recorded	O
each	O
alternate	O
day	O
.	O
</ALL>	O

<ALL>	O
Thymus	O
weight	O
was	O
used	O
as	O
a	O
marker	O
of	O
glucocorticoid	B-Chemical
activity	O
,	O
and	O
serum	O
urate	B-Chemical
to	O
assess	O
XO	B-Chemical
inhibition	O
.	O
</ALL>	O

<ALL>	O
5	O
.	O
</ALL>	O

<ALL>	O
Dex	B-Chemical
increased	O
SBP	O
(	O
110	O
+	O
/	O
-	O
2	O
-	O
126	O
+	O
/	O
-	O
3	O
mmHg	O
;	O
P	O
<	O
0.001	O
)	O
and	O
decreased	O
thymus	O
(	O
P	O
<	O
0.001	O
)	O
and	O
bodyweights	O
(	O
P	O
"	O
<	O
0.01	O
)	O
.	O
</ALL>	O

<ALL>	O
Allopurinol	B-Chemical
decreased	O
serum	O
urate	B-Chemical
from	O
76	O
+	O
/	O
-	O
5	O
to	O
30	O
+	O
/	O
-	O
3	O
micromol	O
/	O
L	O
(	O
P	O
<	O
0.001	O
)	O
in	O
saline	O
and	O
from	O
84	O
+	O
/	O
-	O
13	O
to	O
28	O
+	O
/	O
-	O
2	O
micromol	O
/	O
L	O
in	O
dex	B-Chemical
-	O
treated	O
(	O
P	O
<	O
0.01	O
)	O
groups	O
.	O
</ALL>	O

<ALL>	O
6	O
.	O
</ALL>	O

<ALL>	O
Allopurinol	B-Chemical
did	O
not	O
prevent	O
dex	B-Chemical
-	O
HT	B-Disease
.	O
</ALL>	O

<ALL>	O
This	O
,	O
together	O
with	O
our	O
previous	O
findings	O
that	O
allopurinol	B-Chemical
failed	O
to	O
prevent	O
adrenocorticotrophic	B-Gene
hormone	I-Gene
induced	O
hypertension	B-Disease
,	O
suggests	O
that	O
XO	B-Chemical
activity	O
is	O
not	O
a	O
major	O
determinant	O
of	O
GC	B-Chemical
-	O
HT	B-Disease
in	O
the	O
rat	B-Species
.	O
</ALL>	O

<ALL>	O
Neuroprotective	O
effects	O
of	O
melatonin	B-Chemical
upon	O
the	O
offspring	O
cerebellar	O
cortex	O
in	O
the	O
rat	B-Species
model	O
of	O
BCNU	B-Chemical
-	O
induced	O
cortical	B-Disease
dysplasia	I-Disease
.	O
</ALL>	O

<ALL>	O
Cortical	B-Disease
dysplasia	I-Disease
is	O
a	O
malformation	O
characterized	O
by	O
defects	O
in	O
proliferation	O
,	O
migration	O
and	O
maturation	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
alterations	O
in	O
offspring	O
rat	B-Species
cerebellum	O
induced	O
by	O
maternal	O
exposure	O
to	O
carmustine	B-Chemical
-	O
[	O
1,3	B-Chemical
-	I-Chemical
bis	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
chloroethyl	I-Chemical
)	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
nitrosoure	I-Chemical
]	O
(	O
BCNU	B-Chemical
)	O
and	O
to	O
investigate	O
the	O
effects	O
of	O
exogenous	O
melatonin	B-Chemical
upon	O
cerebellar	O
BCNU	B-Chemical
-	O
induced	O
cortical	B-Disease
dysplasia	I-Disease
,	O
using	O
histological	O
and	O
biochemical	O
analyses	O
.	O
</ALL>	O

<ALL>	O
Pregnant	O
Wistar	O
rats	B-Species
were	O
assigned	O
to	O
five	O
groups	O
:	O
intact	O
-	O
control	O
,	O
saline	O
-	O
control	O
,	O
melatonin	B-Chemical
-	O
treated	O
,	O
BCNU	B-Chemical
-	O
exposed	O
and	O
BCNU	B-Chemical
-	O
exposed	O
plus	O
melatonin	B-Chemical
.	O
</ALL>	O

<ALL>	O
Rats	B-Species
were	O
exposed	O
to	O
BCNU	B-Chemical
on	O
embryonic	O
day	O
15	O
and	O
melatonin	B-Chemical
was	O
given	O
until	O
delivery	O
.	O
</ALL>	O

<ALL>	O
Immuno	O
/	O
histochemistry	O
and	O
electron	O
microscopy	O
were	O
carried	O
out	O
on	O
the	O
offspring	O
cerebellum	O
,	O
and	O
levels	O
of	O
malondialdehyde	B-Chemical
and	O
superoxide	B-Chemical
dismutase	O
were	O
determined	O
.	O
</ALL>	O

<ALL>	O
Histopathologically	O
,	O
typical	O
findings	O
were	O
observed	O
in	O
the	O
cerebella	O
from	O
the	O
control	O
groups	O
,	O
but	O
the	O
findings	O
consistent	O
with	O
early	O
embryonic	O
development	O
were	O
noted	O
in	O
BCNU	B-Chemical
-	O
exposed	O
cortical	B-Disease
dysplasia	I-Disease
group	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
a	O
marked	O
increase	O
in	O
the	O
number	O
of	O
TUNEL	O
positive	O
cells	O
and	O
nestin	O
positive	O
cells	O
in	O
BCNU	B-Chemical
-	O
exposed	O
group	O
,	O
but	O
a	O
decreased	O
immunoreactivity	O
to	O
glial	B-Gene
fibrillary	I-Gene
acidic	I-Gene
protein	I-Gene
,	O
synaptophysin	B-Gene
and	O
transforming	B-Gene
growth	I-Gene
factor	I-Gene
beta1	I-Gene
was	O
observed	O
,	O
indicating	O
a	O
delayed	O
maturation	O
,	O
and	O
melatonin	B-Chemical
significantly	O
reversed	O
these	O
changes	O
.	O
</ALL>	O

<ALL>	O
Malondialdehyde	B-Chemical
level	O
in	O
BCNU	B-Chemical
-	O
exposed	O
group	O
was	O
higher	O
than	O
those	O
in	O
control	O
groups	O
and	O
melatonin	B-Chemical
decreased	O
malondialdehyde	B-Chemical
levels	O
in	O
BCNU	B-Chemical
group	O
(	O
P	O
<	O
0.01	O
)	O
,	O
while	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
superoxide	B-Gene
dismutase	I-Gene
levels	O
between	O
these	O
groups	O
.	O
</ALL>	O

<ALL>	O
These	O
data	O
suggest	O
that	O
exposure	O
of	O
animals	O
to	O
BCNU	B-Chemical
during	O
pregnancy	O
leads	O
to	O
delayed	O
maturation	O
of	O
offspring	O
cerebellum	O
and	O
melatonin	B-Chemical
protects	O
the	O
cerebellum	O
against	O
the	O
effects	O
of	O
BCNU	B-Chemical
.	O
</ALL>	O

<ALL>	O
Severe	O
rhabdomyolysis	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
secondary	O
to	O
concomitant	O
use	O
of	O
simvastatin	B-Chemical
,	O
amiodarone	B-Chemical
,	O
and	O
atazanavir	B-Chemical
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
a	O
severe	O
interaction	O
between	O
simvastatin	B-Chemical
,	O
amiodarone	B-Chemical
,	O
and	O
atazanavir	B-Chemical
resulting	O
in	O
rhabdomyolysis	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
A	O
72	O
-	O
year	O
-	O
old	O
white	O
man	B-Species
with	O
underlying	O
human	B-Species
immunodeficiency	I-Species
virus	I-Species
,	O
atrial	B-Disease
fibrillation	I-Disease
,	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
,	O
and	O
hyperlipidemia	B-Disease
presented	O
with	O
generalized	O
pain	B-Disease
,	O
fatigue	B-Disease
,	O
and	O
dark	O
orange	O
urine	O
for	O
3	O
days	O
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
was	O
taking	O
80	O
mg	O
simvastatin	B-Chemical
at	O
bedtime	O
(	O
initiated	O
27	O
days	O
earlier	O
)	O
;	O
amiodarone	B-Chemical
at	O
a	O
dose	O
of	O
400	O
mg	O
daily	O
for	O
7	O
days	O
,	O
then	O
200	O
mg	O
daily	O
(	O
initiated	O
19	O
days	O
earlier	O
)	O
;	O
and	O
400	O
mg	O
atazanavir	B-Chemical
daily	O
(	O
initiated	O
at	O
least	O
2	O
years	O
previously	O
)	O
.	O
</ALL>	O

<ALL>	O
Laboratory	O
evaluation	O
revealed	O
66,680	O
U	O
/	O
L	O
creatine	B-Chemical
kinase	I-Chemical
,	O
93	O
mg	O
/	O
dL	O
blood	B-Chemical
urea	I-Chemical
nitrogen	I-Chemical
,	O
4.6	O
mg	O
/	O
dL	O
creatinine	B-Chemical
,	O
1579	O
U	O
/	O
L	O
aspartate	B-Chemical
aminotransferase	I-Chemical
,	O
and	O
738	O
U	O
/	O
L	O
alanine	B-Chemical
aminotransferase	I-Chemical
.	O
</ALL>	O

<ALL>	O
Simvastatin	B-Chemical
,	O
amiodarone	B-Chemical
,	O
and	O
the	O
patient	B-Species
's	O
human	B-Species
immunodeficiency	I-Species
virus	I-Species
medications	O
were	O
all	O
temporarily	O
discontinued	O
and	O
the	O
patient	B-Species
was	O
given	O
forced	O
alkaline	O
diuresis	O
and	O
started	O
on	O
dialysis	O
.	O
</ALL>	O

<ALL>	O
Nine	O
days	O
later	O
the	O
patient	B-Species
's	O
creatine	B-Chemical
kinase	I-Chemical
had	O
dropped	O
to	O
1695	O
U	O
/	O
L	O
and	O
creatinine	B-Chemical
was	O
3.3	O
mg	O
/	O
dL.	O
The	O
patient	B-Species
was	O
discharged	O
and	O
continued	O
outpatient	B-Species
dialysis	O
for	O
1	O
month	O
until	O
his	O
renal	O
function	O
recovered	O
.	O
</ALL>	O

<ALL>	O
DISCUSSION	O
:	O
The	O
risk	O
of	O
rhabdomyolysis	B-Disease
is	O
increased	O
in	O
the	O
presence	O
of	O
concomitant	O
drugs	O
that	O
inhibit	O
simvastatin	B-Chemical
metabolism	O
.	O
</ALL>	O

<ALL>	O
Simvastatin	B-Chemical
is	O
metabolized	O
by	O
CYP3A4	B-Gene
.	O
</ALL>	O

<ALL>	O
Amiodarone	B-Chemical
and	O
atazanavir	B-Chemical
are	O
recognized	O
CYP3A4	B-Gene
inhibitors	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Pharmacokinetic	O
differences	O
in	O
statins	B-Chemical
are	O
an	O
important	O
consideration	O
for	O
assessing	O
the	O
risk	O
of	O
potential	O
drug	O
interactions	O
.	O
</ALL>	O

<ALL>	O
In	O
patients	B-Species
requiring	O
the	O
concurrent	O
use	O
of	O
statins	B-Chemical
and	O
CYP3A4	B-Gene
inhibitors	O
,	O
pravastatin	B-Chemical
,	O
fluvastatin	B-Chemical
,	O
and	O
rosuvastatin	B-Chemical
carry	O
the	O
lowest	O
risk	O
of	O
drug	O
interactions	O
;	O
atorvastatin	B-Chemical
carries	O
moderate	O
risk	O
,	O
whereas	O
simvastatin	B-Chemical
and	O
lovastatin	B-Chemical
have	O
the	O
highest	O
risk	O
and	O
should	O
be	O
avoided	O
in	O
patients	B-Species
taking	O
concomitant	O
CYP3A4	B-Chemical
inhibitors	I-Chemical
.	O
</ALL>	O

<ALL>	O
Mutations	O
associated	O
with	O
lamivudine	B-Chemical
-	O
resistance	O
in	O
therapy	O
-	O
na	O
ve	O
hepatitis	B-Disease
B	I-Disease
virus	I-Disease
(	I-Disease
HBV	I-Disease
)	I-Disease
infected	I-Disease
patients	B-Species
with	O
and	O
without	O
HIV	B-Disease
co	I-Disease
-	I-Disease
infection	I-Disease
:	O
implications	O
for	O
antiretroviral	O
therapy	O
in	O
HBV	B-Disease
and	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
South	O
African	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
This	O
was	O
an	O
exploratory	O
study	O
to	O
investigate	O
lamivudine	B-Chemical
-	O
resistant	O
hepatitis	B-Species
B	I-Species
virus	I-Species
(	O
HBV	B-Species
)	O
strains	O
in	O
selected	O
lamivudine	B-Chemical
-	O
na	O
ve	O
HBV	B-Species
carriers	O
with	O
and	O
without	O
human	B-Disease
immunodeficiency	I-Disease
virus	I-Disease
(	I-Disease
HIV	I-Disease
)	I-Disease
co	I-Disease
-	I-Disease
infection	I-Disease
in	O
South	O
African	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Thirty	O
-	O
five	O
lamivudine	B-Chemical
-	O
na	O
ve	O
HBV	B-Disease
infected	I-Disease
patients	B-Species
with	O
or	O
without	O
HIV	B-Disease
co	I-Disease
-	I-Disease
infection	I-Disease
were	O
studied	O
:	O
15	O
chronic	O
HBV	B-Disease
mono	I-Disease
-	I-Disease
infected	I-Disease
patients	B-Species
and	O
20	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
latter	O
group	O
was	O
further	O
sub	O
-	O
divided	O
into	O
13	O
occult	O
HBV	B-Species
(	O
HBsAg	B-Chemical
-	O
negative	O
)	O
and	O
7	O
overt	O
HBV	B-Species
(	O
HBsAg	B-Chemical
-	O
positive	O
)	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
HBsAg	B-Chemical
,	O
anti	O
-	O
HBs	O
,	O
anti	O
-	O
HBc	O
,	O
and	O
anti	O
-	O
HIV	B-Species
1	I-Species
/	I-Species
2	I-Species
were	O
determined	O
as	O
part	O
of	O
routine	O
diagnosis	O
using	O
Axsym	O
assays	O
(	O
Abbott	O
Laboratories	O
,	O
North	O
Chicago	O
,	O
IL	O
)	O
.	O
</ALL>	O

<ALL>	O
Serum	O
samples	O
were	O
PCR	O
amplified	O
with	O
HBV	B-Species
reverse	O
transcriptase	O
(	O
RT	O
)	O
primers	O
,	O
followed	O
by	O
direct	O
sequencing	O
across	O
the	O
tyrosine	O
-	O
methionine	O
-	O
aspartate	O
-	O
aspartate	O
(	O
YMDD	O
)	O
motif	O
of	O
the	O
major	O
catalytic	O
region	O
in	O
the	O
C	O
domain	O
of	O
the	O
HBV	B-Species
RT	O
enzyme	O
.	O
</ALL>	O

<ALL>	O
HBV	B-Species
viral	O
load	O
was	O
performed	O
with	O
Amplicor	O
HBV	B-Species
Monitor	O
test	O
v2.0	O
(	O
Roche	O
Diagnostics	O
,	O
Penzberg	O
,	O
Germany	O
)	O
.	O
</ALL>	O

<ALL>	O
HBV	B-Species
lamivudine	B-Chemical
-	O
resistant	O
strains	O
were	O
detected	O
in	O
3	O
of	O
15	O
mono	O
-	O
infected	O
chronic	O
hepatitis	B-Disease
B	I-Disease
patients	B-Species
and	O
10	O
of	O
20	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
constitutes	O
the	O
first	O
report	O
of	O
HBV	B-Species
lamivudine	B-Chemical
-	O
resistant	O
strains	O
in	O
therapy	O
-	O
na	O
ve	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
HBV	B-Species
viral	O
loads	O
for	O
mono	O
-	O
infected	O
and	O
co	O
-	O
infected	O
patients	B-Species
ranged	O
from	O
3.32	O
x	O
10	O
(	O
2	O
)	O
to	O
3.82	O
x	O
10	O
(	O
7	O
)	O
and	O
<	O
200	O
to	O
4.40	O
x	O
10	O
(	O
3	O
)	O
copies	O
/	O
ml	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
It	O
remains	O
to	O
be	O
seen	O
whether	O
such	O
pre	O
-	O
existing	O
antiviral	O
mutations	O
could	O
result	O
in	O
widespread	O
emergence	O
of	O
HBV	B-Species
resistant	O
strains	O
when	O
lamivudine	B-Chemical
-	O
containing	O
highly	O
active	O
antiretroviral	O
(	O
ARV	O
)	O
treatment	O
(	O
HAART	O
)	O
regimens	O
become	O
widely	O
applied	O
in	O
South	O
Africa	O
,	O
as	O
this	O
is	O
likely	O
to	O
have	O
potential	O
implications	O
in	O
the	O
management	O
of	O
HBV	B-Disease
-	I-Disease
HIV	I-Disease
co	I-Disease
-	I-Disease
infected	I-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Anxiogenic	B-Disease
potential	O
of	O
ciprofloxacin	B-Chemical
and	O
norfloxacin	B-Chemical
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
INTRODUCTION	O
:	O
The	O
possible	O
anxiogenic	B-Disease
effects	O
of	O
fluoroquinolones	B-Chemical
,	O
namely	O
ciprofloxacin	B-Chemical
and	O
norfloxacin	B-Chemical
,	O
were	O
investigated	O
in	O
adult	O
Charles	O
Foster	O
albino	O
rats	B-Species
of	O
either	O
sex	O
,	O
weighing	O
150	O
-	O
200	O
g.	O
METHODS	O
:	O
The	O
drugs	O
were	O
given	O
orally	O
,	O
in	O
doses	O
of	O
50	O
mg	O
/	O
kg	O
for	O
five	O
consecutive	O
days	O
and	O
the	O
experiments	O
were	O
performed	O
on	O
the	O
fifth	O
day	O
.	O
</ALL>	O

<ALL>	O
The	O
tests	O
included	O
open	O
-	O
field	O
exploratory	O
behaviour	O
,	O
elevated	O
plus	O
maze	O
and	O
elevated	O
zero	O
maze	O
,	O
social	O
interaction	O
and	O
novelty	O
-	O
suppressed	O
feeding	O
latency	O
behaviour	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
results	O
indicate	O
that	O
ciprofloxacin	B-Chemical
-	O
and	O
norfloxacin	B-Chemical
-	O
treated	O
rats	B-Species
showed	O
anxious	B-Disease
behaviour	I-Disease
in	O
comparison	O
to	O
control	O
rats	B-Species
in	O
all	O
the	O
parameters	O
studied	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
ciprofloxacin	B-Chemical
-	O
and	O
norfloxacin	B-Chemical
-	O
treated	O
rats	B-Species
did	O
not	O
differ	O
significantly	O
from	O
each	O
other	O
in	O
various	O
behavioural	O
parameters	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
The	O
present	O
experimental	O
findings	O
substantiate	O
the	O
clinically	O
observed	O
anxiogenic	B-Disease
potential	O
of	O
ciprofloxacin	B-Chemical
and	O
norfloxacin	B-Chemical
.	O
</ALL>	O

<ALL>	O
Norepinephrine	B-Chemical
signaling	O
through	O
beta	B-Gene
-	I-Gene
adrenergic	I-Gene
receptors	I-Gene
is	O
critical	O
for	O
expression	O
of	O
cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Cocaine	B-Chemical
is	O
a	O
widely	O
abused	O
psychostimulant	O
that	O
has	O
both	O
rewarding	O
and	O
aversive	O
properties	O
.	O
</ALL>	O

<ALL>	O
While	O
the	O
mechanisms	O
underlying	O
cocaine	B-Chemical
's	O
rewarding	O
effects	O
have	O
been	O
studied	O
extensively	O
,	O
less	O
attention	O
has	O
been	O
paid	O
to	O
the	O
unpleasant	O
behavioral	O
states	O
induced	O
by	O
cocaine	B-Chemical
,	O
such	O
as	O
anxiety	B-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
performance	O
of	O
dopamine	B-Gene
beta	I-Gene
-	I-Gene
hydroxylase	I-Gene
knockout	O
(	O
Dbh	B-Gene
-	O
/	O
-	O
)	O
mice	B-Species
,	O
which	O
lack	O
norepinephrine	B-Chemical
(	O
NE	B-Chemical
)	O
,	O
in	O
the	O
elevated	O
plus	O
maze	O
(	O
EPM	O
)	O
to	O
examine	O
the	O
contribution	O
of	O
noradrenergic	O
signaling	O
to	O
cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
We	O
found	O
that	O
cocaine	B-Chemical
dose	O
-	O
dependently	O
increased	O
anxiety	B-Disease
-	O
like	O
behavior	O
in	O
control	O
(	O
Dbh	B-Gene
+	O
/	O
-	O
)	O
mice	B-Species
,	O
as	O
measured	O
by	O
a	O
decrease	O
in	O
open	O
arm	O
exploration	O
.	O
</ALL>	O

<ALL>	O
The	O
Dbh	B-Gene
-	O
/	O
-	O
mice	B-Species
had	O
normal	O
baseline	O
performance	O
in	O
the	O
EPM	O
but	O
were	O
completely	O
resistant	O
to	O
the	O
anxiogenic	O
effects	O
of	O
cocaine	B-Chemical
.	O
</ALL>	O

<ALL>	O
Cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
was	O
also	O
attenuated	O
in	O
Dbh	B-Gene
+	O
/	O
-	O
mice	B-Species
following	O
administration	O
of	O
disulfiram	B-Chemical
,	O
a	O
dopamine	B-Gene
beta	I-Gene
-	I-Gene
hydroxylase	I-Gene
(	O
DBH	B-Gene
)	O
inhibitor	O
.	O
</ALL>	O

<ALL>	O
In	O
experiments	O
using	O
specific	O
adrenergic	B-Chemical
antagonists	I-Chemical
,	O
we	O
found	O
that	O
pretreatment	O
with	O
the	O
beta	B-Gene
-	I-Gene
adrenergic	I-Gene
receptor	I-Gene
antagonist	O
propranolol	B-Chemical
blocked	O
cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
-	O
like	O
behavior	O
in	O
Dbh	B-Gene
+	O
/	O
-	O
and	O
wild	O
-	O
type	O
C57BL6	O
/	O
J	O
mice	B-Species
,	O
while	O
the	O
alpha	B-Gene
(	I-Gene
1	I-Gene
)	I-Gene
antagonist	O
prazosin	B-Chemical
and	O
the	O
alpha	B-Gene
(	I-Gene
2	I-Gene
)	I-Gene
antagonist	O
yohimbine	B-Chemical
had	O
no	O
effect	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
noradrenergic	O
signaling	O
via	O
beta	B-Gene
-	I-Gene
adrenergic	I-Gene
receptors	I-Gene
is	O
required	O
for	O
cocaine	B-Chemical
-	O
induced	O
anxiety	B-Disease
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
differential	O
effects	O
of	O
bupivacaine	B-Chemical
and	O
lidocaine	B-Chemical
on	O
prostaglandin	B-Gene
E2	I-Gene
release	O
,	O
cyclooxygenase	B-Gene
gene	O
expression	O
and	O
pain	B-Disease
in	O
a	O
clinical	O
pain	B-Disease
model	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
In	O
addition	O
to	O
blocking	O
nociceptive	O
input	O
from	O
surgical	O
sites	O
,	O
long	O
-	O
acting	O
local	O
anesthetics	O
might	O
directly	O
modulate	O
inflammation	B-Disease
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
study	O
,	O
we	O
describe	O
the	O
proinflammatory	O
effects	O
of	O
bupivacaine	B-Chemical
on	O
local	O
prostaglandin	B-Gene
E2	I-Gene
(	O
PGE2	B-Gene
)	O
production	O
and	O
cyclooxygenase	B-Gene
(	O
COX	B-Gene
)	O
gene	O
expression	O
that	O
increases	O
postoperative	B-Disease
pain	I-Disease
in	O
human	B-Species
subjects	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Subjects	O
(	O
n	O
=	O
114	O
)	O
undergoing	O
extraction	O
of	O
impacted	O
third	O
molars	O
received	O
either	O
2	O
%	O
lidocaine	B-Chemical
or	O
0.5	O
%	O
bupivacaine	B-Chemical
before	O
surgery	O
and	O
either	O
rofecoxib	B-Chemical
50	O
mg	O
or	O
placebo	O
orally	O
90	O
min	O
before	O
surgery	O
and	O
for	O
the	O
following	O
48	O
h.	O
Oral	O
mucosal	O
biopsies	O
were	O
taken	O
before	O
surgery	O
and	O
48	O
h	O
after	O
surgery	O
.	O
</ALL>	O

<ALL>	O
After	O
extraction	O
,	O
a	O
microdialysis	O
probe	O
was	O
placed	O
at	O
the	O
surgical	O
site	O
for	O
PGE2	B-Gene
and	O
thromboxane	B-Chemical
B2	I-Chemical
(	O
TXB2	B-Chemical
)	O
measurements	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
bupivacaine	B-Chemical
/	O
rofecoxib	B-Chemical
group	O
reported	O
significantly	O
less	O
pain	B-Disease
,	O
as	O
assessed	O
by	O
a	O
visual	O
analog	O
scale	O
,	O
compared	O
with	O
the	O
other	O
three	O
treatment	O
groups	O
over	O
the	O
first	O
4	O
h.	O
However	O
,	O
the	O
bupivacaine	B-Chemical
/	O
placebo	O
group	O
reported	O
significantly	O
more	O
pain	B-Disease
at	O
24	O
h	O
and	O
PGE2	B-Gene
levels	O
during	O
the	O
first	O
4	O
h	O
were	O
significantly	O
higher	O
than	O
the	O
other	O
three	O
treatment	O
groups	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
bupivacaine	B-Chemical
significantly	O
increased	O
COX	B-Gene
-	I-Gene
2	I-Gene
gene	O
expression	O
at	O
48	O
h	O
as	O
compared	O
with	O
the	O
lidocaine	B-Chemical
/	O
placebo	O
group	O
.	O
</ALL>	O

<ALL>	O
Thromboxane	B-Chemical
levels	O
were	O
not	O
significantly	O
affected	O
by	O
any	O
of	O
the	O
treatments	O
,	O
indicating	O
that	O
the	O
effects	O
seen	O
were	O
attributable	O
to	O
inhibition	O
of	O
COX	B-Gene
-	I-Gene
2	I-Gene
,	O
but	O
not	O
COX	B-Gene
-	I-Gene
1	I-Gene
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
bupivacaine	B-Chemical
stimulates	O
COX	B-Gene
-	I-Gene
2	I-Gene
gene	O
expression	O
after	O
tissue	B-Disease
injury	I-Disease
,	O
which	O
is	O
associated	O
with	O
higher	O
PGE2	B-Gene
production	O
and	O
pain	B-Disease
after	O
the	O
local	O
anesthetic	O
effect	O
dissipates	O
.	O
</ALL>	O

<ALL>	O
Clonidine	B-Chemical
for	O
attention	B-Disease
-	I-Disease
deficit	I-Disease
/	I-Disease
hyperactivity	I-Disease
disorder	I-Disease
:	O
II	O
.	O
</ALL>	O

<ALL>	O
ECG	O
changes	O
and	O
adverse	O
events	O
analysis	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
To	O
examine	O
the	O
safety	O
and	O
tolerability	O
of	O
clonidine	B-Chemical
used	O
alone	O
or	O
with	O
methylphenidate	B-Chemical
in	O
children	O
with	O
attention	B-Disease
-	I-Disease
deficit	I-Disease
/	I-Disease
hyperactivity	I-Disease
disorder	I-Disease
(	O
ADHD	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
METHOD	O
:	O
In	O
a	O
16	O
-	O
week	O
multicenter	O
,	O
double	O
-	O
blind	O
trial	O
,	O
122	O
children	O
with	O
ADHD	B-Disease
were	O
randomly	O
assigned	O
to	O
clonidine	B-Chemical
(	O
n	O
=	O
31	O
)	O
,	O
methylphenidate	B-Chemical
(	O
n	O
=	O
29	O
)	O
,	O
clonidine	B-Chemical
and	O
methylphenidate	B-Chemical
(	O
n	O
=	O
32	O
)	O
,	O
or	O
placebo	O
(	O
n	O
=	O
30	O
)	O
.	O
</ALL>	O

<ALL>	O
Doses	O
were	O
flexibly	O
titrated	O
up	O
to	O
0.6	O
mg	O
/	O
day	O
for	O
clonidine	B-Chemical
and	O
60	O
mg	O
/	O
day	O
for	O
methylphenidate	B-Chemical
(	O
both	O
with	O
divided	O
dosing	O
)	O
.	O
</ALL>	O

<ALL>	O
Groups	O
were	O
compared	O
regarding	O
adverse	O
events	O
and	O
changes	O
from	O
baseline	O
to	O
week	O
16	O
in	O
electrocardiograms	O
and	O
vital	O
signs	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
There	O
were	O
more	O
incidents	O
of	O
bradycardia	B-Disease
in	O
subjects	O
treated	O
with	O
clonidine	B-Chemical
compared	O
with	O
those	O
not	O
treated	O
with	O
clonidine	B-Chemical
(	O
17.5	O
%	O
versus	O
3.4	O
%	O
;	O
p	O
=	O
.02	O
)	O
,	O
but	O
no	O
other	O
significant	O
group	O
differences	O
regarding	O
electrocardiogram	O
and	O
other	O
cardiovascular	O
outcomes	O
.	O
</ALL>	O

<ALL>	O
There	O
were	O
no	O
suggestions	O
of	O
interactions	O
between	O
clonidine	B-Chemical
and	O
methylphenidate	B-Chemical
regarding	O
cardiovascular	O
outcomes	O
.	O
</ALL>	O

<ALL>	O
Moderate	O
or	O
severe	O
adverse	O
events	O
were	O
more	O
common	O
in	O
subjects	O
on	O
clonidine	B-Chemical
(	O
79.4	O
%	O
versus	O
49.2	O
%	O
;	O
p	O
=	O
.0006	O
)	O
but	O
not	O
associated	O
with	O
higher	O
rates	O
of	O
early	O
study	O
withdrawal	O
.	O
</ALL>	O

<ALL>	O
Drowsiness	B-Disease
was	O
common	O
on	O
clonidine	B-Chemical
,	O
but	O
generally	O
resolved	O
by	O
6	O
to	O
8	O
weeks	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Clonidine	B-Chemical
,	O
used	O
alone	O
or	O
with	O
methylphenidate	B-Chemical
,	O
appears	O
safe	O
and	O
well	O
tolerated	O
in	O
childhood	O
ADHD	B-Disease
.	O
</ALL>	O

<ALL>	O
Physicians	O
prescribing	O
clonidine	B-Chemical
should	O
monitor	O
for	O
bradycardia	B-Disease
and	O
advise	O
patients	B-Species
about	O
the	O
high	O
likelihood	O
of	O
initial	O
drowsiness	B-Disease
.	O
</ALL>	O

<ALL>	O
Azathioprine	B-Chemical
-	O
induced	O
suicidal	O
erythrocyte	O
death	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Azathioprine	B-Chemical
is	O
widely	O
used	O
as	O
an	O
immunosuppressive	O
drug	O
.	O
</ALL>	O

<ALL>	O
The	O
side	O
effects	O
of	O
azathioprine	B-Chemical
include	O
anemia	B-Disease
,	O
which	O
has	O
been	O
attributed	O
to	O
bone	B-Disease
marrow	I-Disease
suppression	I-Disease
.	O
</ALL>	O

<ALL>	O
Alternatively	O
,	O
anemia	B-Disease
could	O
result	O
from	O
accelerated	O
suicidal	O
erythrocyte	O
death	O
or	O
eryptosis	O
,	O
which	O
is	O
characterized	O
by	O
exposure	O
of	O
phosphatidylserine	B-Chemical
(	O
PS	B-Chemical
)	O
at	O
the	O
erythrocyte	O
surface	O
and	O
by	O
cell	O
shrinkage	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
The	O
present	O
experiments	O
explored	O
whether	O
azathioprine	B-Chemical
influences	O
eryptosis	O
.	O
</ALL>	O

<ALL>	O
According	O
to	O
annexin	B-Gene
V	I-Gene
binding	O
,	O
erythrocytes	O
from	O
patients	B-Species
indeed	O
showed	O
a	O
significant	O
increase	O
of	O
PS	B-Chemical
exposure	O
within	O
1	O
week	O
of	O
treatment	O
with	O
azathioprine	B-Chemical
.	O
</ALL>	O

<ALL>	O
In	O
a	O
second	O
series	O
,	O
cytosolic	O
Ca2	B-Chemical
+	I-Chemical
activity	O
(	O
Fluo3	B-Chemical
fluorescence	O
)	O
,	O
cell	O
volume	O
(	O
forward	O
scatter	O
)	O
,	O
and	O
PS	B-Chemical
-	O
exposure	O
(	O
annexin	B-Gene
V	I-Gene
binding	O
)	O
were	O
determined	O
by	O
FACS	O
analysis	O
in	O
erythrocytes	O
from	O
healthy	O
volunteers	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Exposure	O
to	O
azathioprine	B-Chemical
(	O
>	O
or	O
=	O
2	O
microg	O
/	O
mL	O
)	O
for	O
48	O
hours	O
increased	O
cytosolic	O
Ca2	B-Chemical
+	I-Chemical
activity	O
and	O
annexin	B-Gene
V	I-Gene
binding	O
and	O
decreased	O
forward	O
scatter	O
.	O
</ALL>	O

<ALL>	O
The	O
effect	O
of	O
azathioprine	B-Chemical
on	O
both	O
annexin	B-Gene
V	I-Gene
binding	O
and	O
forward	O
scatter	O
was	O
significantly	O
blunted	O
in	O
the	O
nominal	O
absence	O
of	O
extracellular	O
Ca2	B-Chemical
+	I-Chemical
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Azathioprine	B-Chemical
triggers	O
suicidal	O
erythrocyte	O
death	O
,	O
an	O
effect	O
presumably	O
contributing	O
to	O
azathioprine	B-Chemical
-	O
induced	O
anemia	B-Disease
.	O
</ALL>	O

<ALL>	O
Methamphetamine	B-Chemical
-	O
induced	O
neurotoxicity	B-Disease
and	O
microglial	O
activation	O
are	O
not	O
mediated	O
by	O
fractalkine	B-Gene
receptor	I-Gene
signaling	O
.	O
</ALL>	O

<ALL>	O
Methamphetamine	B-Chemical
(	O
METH	B-Chemical
)	O
damages	O
dopamine	B-Chemical
(	O
DA	B-Chemical
)	O
nerve	O
endings	O
by	O
a	O
process	O
that	O
has	O
been	O
linked	O
to	O
microglial	O
activation	O
but	O
the	O
signaling	O
pathways	O
that	O
mediate	O
this	O
response	O
have	O
not	O
yet	O
been	O
delineated	O
.	O
</ALL>	O

<ALL>	O
Cardona	O
et	O
al	O
.	O
[	O
</ALL>	O

<ALL>	O
Nat	O
.	O
</ALL>	O

<ALL>	O
Neurosci	O
.	O
</ALL>	O

<ALL>	O
9	O
(	O
2006	O
)	O
,	O
917	O
]	O
recently	O
identified	O
the	O
microglial	O
-	O
specific	O
fractalkine	B-Gene
receptor	I-Gene
(	O
CX3CR1	B-Gene
)	O
as	O
an	O
important	O
mediator	O
of	O
MPTP	B-Chemical
-	O
induced	O
neurodegeneration	B-Disease
of	O
DA	B-Chemical
neurons	O
.	O
</ALL>	O

<ALL>	O
Because	O
the	O
CNS	B-Disease
damage	I-Disease
caused	O
by	O
METH	B-Chemical
and	O
MPTP	B-Chemical
is	O
highly	O
selective	O
for	O
the	O
DA	B-Chemical
neuronal	O
system	O
in	O
mouse	B-Species
models	O
of	O
neurotoxicity	B-Disease
,	O
we	O
hypothesized	O
that	O
the	O
CX3CR1	B-Gene
plays	O
a	O
role	O
in	O
METH	B-Chemical
-	O
induced	O
neurotoxicity	B-Disease
and	O
microglial	O
activation	O
.	O
</ALL>	O

<ALL>	O
Mice	B-Species
in	O
which	O
the	O
CX3CR1	B-Gene
gene	O
has	O
been	O
deleted	O
and	O
replaced	O
with	O
a	O
cDNA	O
encoding	O
enhanced	B-Chemical
green	I-Chemical
fluorescent	I-Chemical
protein	I-Chemical
(	O
eGFP	B-Chemical
)	O
were	O
treated	O
with	O
METH	B-Chemical
and	O
examined	O
for	O
striatal	O
neurotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
METH	B-Chemical
depleted	O
DA	B-Chemical
,	O
caused	O
microglial	O
activation	O
,	O
and	O
increased	O
body	O
temperature	O
in	O
CX3CR1	B-Gene
knockout	O
mice	B-Species
to	O
the	O
same	O
extent	O
and	O
over	O
the	O
same	O
time	O
course	O
seen	O
in	O
wild	O
-	O
type	O
controls	O
.	O
</ALL>	O

<ALL>	O
The	O
effects	O
of	O
METH	B-Chemical
in	O
CX3CR1	B-Gene
knockout	O
mice	B-Species
were	O
not	O
gender	O
-	O
dependent	O
and	O
did	O
not	O
extend	O
beyond	O
the	O
striatum	O
.	O
</ALL>	O

<ALL>	O
Striatal	O
microglia	O
expressing	O
eGFP	B-Chemical
constitutively	O
show	O
morphological	O
changes	O
after	O
METH	B-Chemical
that	O
are	O
characteristic	O
of	O
activation	O
.	O
</ALL>	O

<ALL>	O
This	O
response	O
was	O
restricted	O
to	O
the	O
striatum	O
and	O
contrasted	O
sharply	O
with	O
unresponsive	O
eGFP	B-Chemical
-	O
microglia	O
in	O
surrounding	O
brain	O
areas	O
that	O
are	O
not	O
damaged	O
by	O
METH	B-Chemical
.	O
</ALL>	O

<ALL>	O
We	O
conclude	O
from	O
these	O
studies	O
that	O
CX3CR1	B-Gene
signaling	O
does	O
not	O
modulate	O
METH	B-Chemical
neurotoxicity	B-Disease
or	O
microglial	O
activation	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
it	O
appears	O
that	O
striatal	O
-	O
resident	O
microglia	O
respond	O
to	O
METH	B-Chemical
with	O
an	O
activation	O
cascade	O
and	O
then	O
return	O
to	O
a	O
surveying	O
state	O
without	O
undergoing	O
apoptosis	O
or	O
migration	O
.	O
</ALL>	O

<ALL>	O
Spectrum	O
of	O
adverse	O
events	O
after	O
generic	O
HAART	O
in	O
southern	O
Indian	O
HIV	B-Disease
-	I-Disease
infected	I-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
To	O
determine	O
the	O
incidence	O
of	O
clinically	O
significant	O
adverse	O
events	O
after	O
long	O
-	O
term	O
,	O
fixed	O
-	O
dose	O
,	O
generic	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
use	O
among	O
HIV	B-Disease
-	I-Disease
infected	I-Disease
individuals	O
in	O
South	O
India	O
,	O
we	O
examined	O
the	O
experiences	O
of	O
3154	O
HIV	B-Disease
-	I-Disease
infected	I-Disease
individuals	O
who	O
received	O
a	O
minimum	O
of	O
3	O
months	O
of	O
generic	O
HAART	O
between	O
February	O
1996	O
and	O
December	O
2006	O
at	O
a	O
tertiary	O
HIV	O
care	O
referral	O
center	O
in	O
South	O
India	O
.	O
</ALL>	O

<ALL>	O
The	O
most	O
common	O
regimens	O
were	O
3TC	B-Chemical
+	O
d4	B-Chemical
T	I-Chemical
+	O
nevirapine	B-Chemical
(	O
NVP	B-Chemical
)	O
(	O
54.8	O
%	O
)	O
,	O
zidovudine	B-Chemical
(	O
AZT	B-Chemical
)	O
+	O
3TC	B-Chemical
+	O
NVP	B-Chemical
(	O
14.5	O
%	O
)	O
,	O
3TC	B-Chemical
+	O
d4	B-Chemical
T	I-Chemical
+	O
efavirenz	B-Chemical
(	O
EFV	B-Chemical
)	O
(	O
20.1	O
%	O
)	O
,	O
and	O
AZT	B-Chemical
+	O
3TC	B-Chemical
+	O
EFV	B-Chemical
(	O
5.4	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
most	O
common	O
adverse	O
events	O
and	O
median	O
CD4	B-Gene
at	O
time	O
of	O
event	O
were	O
rash	B-Disease
(	O
15.2	O
%	O
;	O
CD4	B-Gene
,	O
285	O
cells	O
/	O
microL	O
)	O
and	O
peripheral	B-Disease
neuropathy	I-Disease
(	O
9.0	O
%	O
and	O
348	O
cells	O
/	O
microL	O
)	O
.	O
</ALL>	O

<ALL>	O
Clinically	O
significant	O
anemia	B-Disease
(	O
hemoglobin	B-Gene
<	O
7	O
g	O
/	O
dL	O
)	O
was	O
observed	O
in	O
5.4	O
%	O
of	O
patients	B-Species
(	O
CD4	B-Gene
,	O
165	O
cells	O
/	O
microL	O
)	O
and	O
hepatitis	B-Disease
(	O
clinical	O
jaundice	B-Disease
with	O
alanine	B-Chemical
aminotransferase	I-Chemical
>	O
5	O
times	O
upper	O
limits	O
of	O
normal	O
)	O
in	O
3.5	O
%	O
of	O
patients	B-Species
(	O
CD4	B-Gene
,	O
260	O
cells	O
/	O
microL	O
)	O
.	O
</ALL>	O

<ALL>	O
Women	B-Species
were	O
significantly	O
more	O
likely	O
to	O
experience	O
lactic	B-Disease
acidosis	I-Disease
,	O
while	O
men	B-Species
were	O
significantly	O
more	O
likely	O
to	O
experience	O
immune	B-Disease
reconstitution	I-Disease
syndrome	I-Disease
(	O
p	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
Among	O
the	O
patients	B-Species
with	O
1	O
year	O
of	O
follow	O
-	O
up	O
,	O
NVP	B-Chemical
therapy	O
was	O
significantly	O
associated	O
with	O
developing	O
rash	B-Disease
and	O
d4	B-Chemical
T	I-Chemical
therapy	O
with	O
developing	O
peripheral	B-Disease
neuropathy	I-Disease
(	O
p	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
Anemia	B-Disease
and	O
hepatitis	B-Disease
often	O
occur	O
within	O
12	O
weeks	O
of	O
initiating	O
generic	O
HAART	O
.	O
</ALL>	O

<ALL>	O
Frequent	O
and	O
early	O
monitoring	O
for	O
these	O
toxicities	B-Disease
is	O
warranted	O
in	O
developing	O
countries	O
where	O
generic	O
HAART	O
is	O
increasingly	O
available	O
.	O
</ALL>	O

<ALL>	O
Protective	O
effect	O
of	O
verapamil	B-Chemical
on	O
gastric	B-Disease
hemorrhagic	I-Disease
ulcers	I-Disease
in	O
severe	O
atherosclerotic	B-Disease
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Studies	O
concerning	O
with	O
pathogenesis	O
of	O
gastric	B-Disease
hemorrhage	I-Disease
and	O
mucosal	O
ulceration	O
produced	O
in	O
atherosclerotic	B-Disease
rats	B-Species
are	O
lacking	O
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
examine	O
the	O
role	O
of	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
mast	O
cell	O
histamine	B-Chemical
release	O
,	O
lipid	B-Chemical
peroxide	I-Chemical
(	O
LPO	B-Chemical
)	O
generation	O
and	O
mucosal	O
microvascular	O
permeability	O
in	O
modulating	O
gastric	B-Disease
hemorrhage	I-Disease
and	I-Disease
ulcer	I-Disease
in	O
rats	B-Species
with	O
atherosclerosis	B-Disease
induced	O
by	O
coadministration	O
of	O
vitamin	B-Chemical
D2	I-Chemical
and	O
cholesterol	B-Chemical
.	O
</ALL>	O

<ALL>	O
Additionally	O
,	O
the	O
protective	O
effect	O
of	O
verapamil	B-Chemical
on	O
this	O
ulcer	B-Disease
model	O
was	O
evaluated	O
.	O
</ALL>	O

<ALL>	O
Male	O
Wistar	O
rats	B-Species
were	O
challenged	O
intragastrically	O
once	O
daily	O
for	O
9	O
days	O
with	O
1.0	O
ml	O
/	O
kg	O
of	O
corn	B-Chemical
oil	I-Chemical
containing	O
vitamin	B-Chemical
D2	I-Chemical
and	O
cholesterol	B-Chemical
to	O
induce	O
atherosclerosis	B-Disease
.	O
</ALL>	O

<ALL>	O
Control	O
rats	B-Species
received	O
corn	B-Chemical
oil	I-Chemical
only	O
.	O
</ALL>	O

<ALL>	O
After	O
gastric	O
surgery	O
,	O
rat	B-Species
stomachs	O
were	O
irrigated	O
for	O
3	O
h	O
with	O
either	O
simulated	O
gastric	O
juice	O
or	O
normal	O
saline	O
.	O
</ALL>	O

<ALL>	O
Gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
mucosal	O
LPO	B-Chemical
generation	O
,	O
histamine	B-Chemical
concentration	O
,	O
microvascular	O
permeability	O
,	O
luminal	B-Chemical
hemoglobin	B-Gene
content	O
and	O
ulcer	B-Disease
areas	O
were	O
determined	O
.	O
</ALL>	O

<ALL>	O
Elevated	O
atherosclerotic	B-Disease
parameters	O
,	O
such	O
as	O
serum	O
calcium	B-Chemical
,	O
total	O
cholesterol	B-Chemical
and	O
low	B-Chemical
-	I-Chemical
density	I-Chemical
lipoprotein	I-Chemical
concentration	O
were	O
obtained	O
in	O
atherosclerotic	B-Disease
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Severe	O
gastric	B-Disease
ulcers	I-Disease
accompanied	O
with	O
increased	O
ulcerogenic	O
factors	O
,	O
including	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
histamine	B-Chemical
release	O
,	O
LPO	B-Chemical
generation	O
and	O
luminal	B-Chemical
hemoglobin	B-Gene
content	O
were	O
also	O
observed	O
in	O
these	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
a	O
positive	O
correlation	O
of	O
histamine	B-Chemical
to	O
gastric	B-Disease
hemorrhage	I-Disease
and	O
to	O
ulcer	B-Disease
was	O
found	O
in	O
those	O
atherosclerotic	B-Disease
rats	B-Species
.	O
</ALL>	O

<ALL>	O
This	O
hemorrhagic	B-Disease
ulcer	I-Disease
and	O
various	O
ulcerogenic	O
parameters	O
were	O
dose	O
-	O
dependently	O
ameliorated	O
by	O
daily	O
intragastric	O
verapamil	B-Chemical
.	O
</ALL>	O

<ALL>	O
Atherosclerosis	B-Disease
could	O
produce	O
gastric	B-Disease
hemorrhagic	I-Disease
ulcer	I-Disease
via	O
aggravation	O
of	O
gastric	O
acid	O
back	O
-	O
diffusion	O
,	O
LPO	B-Chemical
generation	O
,	O
histamine	B-Chemical
release	O
and	O
microvascular	O
permeability	O
that	O
could	O
be	O
ameliorated	O
by	O
verapamil	B-Chemical
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Omitting	O
fentanyl	B-Chemical
reduces	O
nausea	B-Disease
and	O
vomiting	B-Disease
,	O
without	O
increasing	O
pain	B-Disease
,	O
after	O
sevoflurane	B-Chemical
for	O
day	O
surgery	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Despite	O
advantages	O
of	O
induction	O
and	O
maintenance	O
of	O
anaesthesia	O
with	O
sevoflurane	B-Chemical
,	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
occurs	O
frequently	O
.	O
</ALL>	O

<ALL>	O
Fentanyl	B-Chemical
is	O
a	O
commonly	O
used	O
supplement	O
that	O
may	O
contribute	O
to	O
this	O
,	O
although	O
it	O
may	O
also	O
improve	O
analgesia	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
This	O
double	O
-	O
blind	O
study	O
examined	O
the	O
incidence	O
and	O
severity	O
of	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
and	I-Disease
pain	I-Disease
in	O
the	O
first	O
24	O
h	O
after	O
sevoflurane	B-Chemical
anaesthesia	O
in	O
216	O
adult	O
day	O
surgery	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Patients	B-Species
were	O
randomly	O
allocated	O
to	O
either	O
receive	O
or	O
not	O
receive	O
1	O
1	O
fentanyl	B-Chemical
,	O
while	O
a	O
third	O
group	O
received	O
dexamethasone	B-Chemical
in	O
addition	O
to	O
fentanyl	B-Chemical
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Omission	O
of	O
fentanyl	B-Chemical
did	O
not	O
reduce	O
the	O
overall	O
incidence	O
of	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
,	O
but	O
did	O
reduce	O
the	O
incidence	O
of	O
vomiting	B-Disease
and	O
/	O
or	O
moderate	O
to	O
severe	O
nausea	B-Disease
prior	O
to	O
discharge	O
from	O
20	O
%	O
and	O
17	O
%	O
with	O
fentanyl	B-Chemical
and	O
fentanyl	B-Chemical
-	O
dexamethasone	B-Chemical
,	O
respectively	O
,	O
to	O
5	O
%	O
(	O
P	O
=	O
0.013	O
)	O
.	O
</ALL>	O

<ALL>	O
Antiemetic	O
requirements	O
were	O
reduced	O
from	O
24	O
%	O
and	O
31	O
%	O
to	O
7	O
%	O
(	O
P	O
=	O
0.0012	O
)	O
.	O
</ALL>	O

<ALL>	O
Dexamethasone	B-Chemical
had	O
no	O
significant	O
effect	O
on	O
the	O
incidence	O
or	O
severity	O
of	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
.	O
</ALL>	O

<ALL>	O
Combining	O
the	O
two	O
fentanyl	B-Chemical
groups	O
revealed	O
further	O
significant	O
benefits	O
from	O
the	O
avoidance	O
of	O
opioids	O
,	O
reducing	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
and	O
nausea	B-Disease
prior	O
to	O
discharge	O
from	O
35	O
%	O
and	O
33	O
%	O
to	O
22	O
%	O
and	O
19	O
%	O
(	O
P	O
=	O
0.049	O
and	O
P	O
=	O
0.035	O
)	O
,	O
respectively	O
,	O
while	O
nausea	B-Disease
in	O
the	O
first	O
24	O
h	O
was	O
decreased	O
from	O
42	O
%	O
to	O
27	O
%	O
(	O
P	O
=	O
0.034	O
)	O
.	O
</ALL>	O

<ALL>	O
Pain	B-Disease
severity	O
and	O
analgesic	O
requirements	O
were	O
unaffected	O
by	O
the	O
omission	O
of	O
fentanyl	B-Chemical
.	O
</ALL>	O

<ALL>	O
Fentanyl	B-Chemical
did	O
reduce	O
minor	O
intraoperative	O
movement	O
but	O
had	O
no	O
sevoflurane	B-Chemical
-	O
sparing	O
effect	O
and	O
increased	O
respiratory	B-Disease
depression	I-Disease
,	O
hypotension	B-Disease
and	O
bradycardia	B-Disease
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
As	O
fentanyl	B-Chemical
exacerbated	O
postoperative	B-Disease
nausea	I-Disease
and	I-Disease
vomiting	I-Disease
without	O
an	O
improvement	O
in	O
postoperative	B-Disease
pain	I-Disease
and	O
also	O
had	O
adverse	O
cardiorespiratory	O
effects	O
,	O
it	O
appears	O
to	O
be	O
an	O
unnecessary	O
and	O
possibly	O
detrimental	O
supplement	O
to	O
sevoflurane	B-Chemical
in	O
day	O
surgery	O
.	O
</ALL>	O

<ALL>	O
High	O
fat	B-Chemical
diet	O
-	O
fed	O
obese	B-Disease
rats	B-Species
are	O
highly	O
sensitive	O
to	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
Often	O
,	O
chemotherapy	O
by	O
doxorubicin	B-Chemical
(	O
Adriamycin	B-Chemical
)	O
is	O
limited	O
due	O
to	O
life	O
threatening	O
cardiotoxicity	B-Disease
in	O
patients	B-Species
during	O
and	O
posttherapy	O
.	O
</ALL>	O

<ALL>	O
Recently	O
,	O
we	O
have	O
shown	O
that	O
moderate	O
diet	O
restriction	O
remarkably	O
protects	O
against	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
This	O
cardioprotection	O
is	O
accompanied	O
by	O
decreased	O
cardiac	O
oxidative	O
stress	O
and	O
triglycerides	B-Chemical
and	O
increased	O
cardiac	O
fatty	B-Chemical
-	I-Chemical
acid	I-Chemical
oxidation	O
,	O
ATP	B-Chemical
synthesis	O
,	O
and	O
upregulated	O
JAK	B-Gene
/	O
STAT3	B-Gene
pathway	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
whether	O
a	O
physiological	O
intervention	O
by	O
feeding	O
40	O
%	O
high	O
fat	B-Chemical
diet	O
(	O
HFD	O
)	O
,	O
which	O
induces	O
obesity	B-Disease
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	B-Species
(	O
250	O
-	O
275	O
g	O
)	O
,	O
sensitizes	O
to	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
A	O
LD	O
(	O
10	O
)	O
dose	O
(	O
8	O
mg	O
doxorubicin	B-Chemical
/	O
kg	O
,	O
ip	O
)	O
administered	O
on	O
day	O
43	O
of	O
the	O
HFD	O
feeding	O
regimen	O
led	O
to	O
higher	O
cardiotoxicity	B-Disease
,	O
cardiac	B-Disease
dysfunction	I-Disease
,	O
lipid	B-Chemical
peroxidation	O
,	O
and	O
80	O
%	O
mortality	O
in	O
the	O
obese	B-Disease
(	O
OB	B-Disease
)	O
rats	B-Species
in	O
the	O
absence	O
of	O
any	O
significant	O
renal	B-Disease
or	I-Disease
hepatic	I-Disease
toxicity	I-Disease
.	O
</ALL>	O

<ALL>	O
Doxorubicin	B-Chemical
toxicokinetics	O
studies	O
revealed	O
no	O
change	O
in	O
accumulation	O
of	O
doxorubicin	B-Chemical
and	O
doxorubicinol	B-Chemical
(	O
toxic	O
metabolite	O
)	O
in	O
the	O
normal	O
diet	O
-	O
fed	O
(	O
ND	O
)	O
and	O
OB	B-Disease
hearts	O
.	O
</ALL>	O

<ALL>	O
Mechanistic	O
studies	O
revealed	O
that	O
OB	B-Disease
rats	B-Species
are	O
sensitized	O
due	O
to	O
:	O
(	O
1	O
)	O
higher	O
oxyradical	O
stress	O
leading	O
to	O
upregulation	O
of	O
uncoupling	B-Gene
proteins	I-Gene
2	I-Gene
and	I-Gene
3	I-Gene
,	O
(	O
2	O
)	O
downregulation	O
of	O
cardiac	O
peroxisome	B-Gene
proliferators	I-Gene
activated	I-Gene
receptor	I-Gene
-	I-Gene
alpha	I-Gene
,	O
(	O
3	O
)	O
decreased	O
plasma	O
adiponectin	B-Gene
levels	O
,	O
(	O
4	O
)	O
decreased	O
cardiac	O
fatty	B-Chemical
-	I-Chemical
acid	I-Chemical
oxidation	O
(	O
666.9	O
+	O
/	O
-	O
14.0	O
nmol	O
/	O
min	O
/	O
g	O
heart	O
in	O
ND	O
versus	O
400.2	O
+	O
/	O
-	O
11.8	O
nmol	O
/	O
min	O
/	O
g	O
heart	O
in	O
OB	B-Disease
)	O
,	O
(	O
5	O
)	O
decreased	O
mitochondrial	O
AMP	B-Gene
-	I-Gene
alpha2	I-Gene
protein	I-Gene
kinase	I-Gene
,	O
and	O
(	O
6	O
)	O
86	O
%	O
drop	O
in	O
cardiac	O
ATP	B-Chemical
levels	O
accompanied	O
by	O
decreased	O
ATP	B-Chemical
/	O
ADP	B-Chemical
ratio	O
after	O
doxorubicin	B-Chemical
administration	O
.	O
</ALL>	O

<ALL>	O
Decreased	O
cardiac	O
erythropoietin	B-Gene
and	O
increased	O
SOCS3	B-Gene
further	O
downregulated	O
the	O
cardioprotective	O
JAK	B-Gene
/	O
STAT3	B-Gene
pathway	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
HFD	O
-	O
induced	O
obese	B-Disease
rats	B-Species
are	O
highly	O
sensitized	O
to	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
by	O
substantially	O
downregulating	O
cardiac	O
mitochondrial	O
ATP	B-Chemical
generation	O
,	O
increasing	O
oxidative	O
stress	O
and	O
downregulating	O
the	O
JAK	B-Gene
/	O
STAT3	B-Gene
pathway	O
.	O
</ALL>	O

<ALL>	O
Simvastatin	B-Chemical
-	I-Chemical
ezetimibe	I-Chemical
-	O
induced	O
hepatic	B-Disease
failure	I-Disease
necessitating	O
liver	O
transplantation	O
.	O
</ALL>	O

<ALL>	O
Abstract	O
Serum	B-Chemical
aminotransferase	I-Chemical
elevations	O
are	O
a	O
commonly	O
known	O
adverse	O
effect	O
of	O
3	B-Gene
-	I-Gene
hydroxy	I-Gene
-	I-Gene
3	I-Gene
-	I-Gene
methylglutaryl	I-Gene
coenzyme	I-Gene
A	I-Gene
reductase	I-Gene
inhibitor	O
(	O
statin	B-Chemical
)	O
therapy	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
hepatotoxic	B-Disease
events	O
have	O
not	O
been	O
widely	O
published	O
with	O
ezetimibe	B-Chemical
or	O
the	O
combination	O
agent	O
simvastatin	B-Chemical
-	I-Chemical
ezetimibe	I-Chemical
.	O
</ALL>	O

<ALL>	O
We	O
describe	O
a	O
70	O
-	O
year	O
-	O
old	O
Hispanic	O
woman	B-Species
who	O
developed	O
fulminant	B-Disease
hepatic	I-Disease
failure	I-Disease
necessitating	O
liver	O
transplantation	O
10	O
weeks	O
after	O
conversion	O
from	O
simvastatin	B-Chemical
40	O
mg	O
/	O
day	O
to	O
simvastatin	B-Chemical
10	O
mg	O
-	O
ezetimibe	B-Chemical
40	O
mg	O
/	O
day	O
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
's	O
lipid	B-Chemical
panel	O
had	O
been	O
maintained	O
with	O
simvastatin	B-Chemical
for	O
18	O
months	O
before	O
the	O
conversion	O
without	O
evidence	O
of	O
hepatotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
A	O
routine	O
laboratory	O
work	O
-	O
up	O
10	O
weeks	O
after	O
conversion	O
revealed	O
elevated	O
serum	B-Chemical
aminotransferase	I-Chemical
levels	O
.	O
</ALL>	O

<ALL>	O
Simvastatinezetimibe	B-Chemical
and	O
escitalopram	B-Chemical
(	O
which	O
she	O
was	O
taking	O
for	O
depression	B-Disease
)	O
were	O
discontinued	O
,	O
and	O
other	O
potential	O
causes	O
of	O
hepatotoxicity	B-Disease
were	O
excluded	O
.	O
</ALL>	O

<ALL>	O
A	O
repeat	O
work	O
-	O
up	O
revealed	O
further	O
elevations	O
in	O
aminotransferase	B-Chemical
levels	O
,	O
and	O
liver	O
biopsy	O
revealed	O
evidence	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
drug	B-Disease
toxicity	I-Disease
.	O
</ALL>	O

<ALL>	O
She	O
underwent	O
liver	O
transplantation	O
with	O
an	O
uneventful	O
postoperative	O
course	O
.	O
</ALL>	O

<ALL>	O
Her	O
aminotransferase	B-Chemical
levels	O
returned	O
to	O
normal	O
by	O
postoperative	O
day	O
23	O
,	O
and	O
her	O
2	O
-	O
year	O
follow	O
-	O
up	O
showed	O
no	O
adverse	O
events	O
.	O
</ALL>	O

<ALL>	O
Ezetimibe	B-Chemical
undergoes	O
extensive	O
glucuronidation	O
by	O
uridine	B-Gene
diphosphate	I-Gene
glucoronosyltransferases	I-Gene
(	O
UGT	B-Gene
)	O
in	O
the	O
intestine	O
and	O
liver	O
and	O
may	O
have	O
inhibited	O
the	O
glucuronidation	O
of	O
simvastatin	B-Chemical
hydroxy	I-Chemical
acid	I-Chemical
,	O
resulting	O
in	O
increased	O
simvastatin	B-Chemical
exposure	O
and	O
subsequent	O
hepatotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
report	O
of	O
simvastatin	B-Chemical
-	I-Chemical
ezetimibe	I-Chemical
-	O
induced	O
liver	B-Disease
failure	I-Disease
that	O
resulted	O
in	O
liver	O
transplantation	O
.	O
</ALL>	O

<ALL>	O
We	O
postulate	O
that	O
the	O
mechanism	O
of	O
the	O
simvastatinezetimibe	B-Chemical
-	O
induced	O
hepatotoxicity	B-Disease
is	O
the	O
increased	O
simvastatin	B-Chemical
exposure	O
by	O
ezetimibe	B-Chemical
inhibition	O
of	O
UGT	B-Gene
enzymes	O
.	O
</ALL>	O

<ALL>	O
Clinicians	O
should	O
be	O
aware	O
of	O
potential	O
hepatotoxicity	B-Disease
with	O
simvastatin	B-Chemical
-	I-Chemical
ezetimibe	I-Chemical
especially	O
in	O
elderly	O
patients	B-Species
and	O
should	O
carefully	O
monitor	O
serum	B-Chemical
aminotransferase	I-Chemical
levels	O
when	O
starting	O
therapy	O
and	O
titrating	O
the	O
dosage	O
.	O
</ALL>	O

<ALL>	O
Massive	O
proteinuria	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
after	O
oral	O
bisphosphonate	B-Chemical
(	O
alendronate	B-Chemical
)	O
administration	O
in	O
a	O
patient	B-Species
with	O
focal	B-Disease
segmental	I-Disease
glomerulosclerosis	I-Disease
.	O
</ALL>	O

<ALL>	O
A	O
61	O
-	O
year	O
-	O
old	O
Japanese	O
man	B-Species
with	O
nephrotic	B-Disease
syndrome	I-Disease
due	O
to	O
focal	B-Disease
segmental	I-Disease
glomerulosclerosis	I-Disease
was	O
initially	O
responding	O
well	O
to	O
steroid	B-Chemical
therapy	O
.	O
</ALL>	O

<ALL>	O
The	O
amount	O
of	O
daily	O
urinary	O
protein	O
decreased	O
from	O
15.6	O
to	O
2.8	O
g.	O
Within	O
14	O
days	O
of	O
the	O
oral	O
bisphosphonate	B-Chemical
(	O
alendronate	B-Chemical
sodium	I-Chemical
)	O
administration	O
,	O
the	O
amount	O
of	O
daily	O
urinary	O
protein	O
increased	O
rapidly	O
up	O
to	O
12.8	O
g	O
with	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O
</ALL>	O

<ALL>	O
After	O
discontinuing	O
the	O
oral	O
alendronate	B-Chemical
,	O
the	O
patient	B-Species
underwent	O
six	O
cycles	O
of	O
hemodialysis	O
and	O
four	O
cycles	O
of	O
LDL	O
apheresis	O
.	O
</ALL>	O

<ALL>	O
Urinary	O
volume	O
and	O
serum	O
creatinine	B-Chemical
levels	O
recovered	O
to	O
the	O
normal	O
range	O
,	O
with	O
urinary	O
protein	O
disappearing	O
completely	O
within	O
40	O
days	O
.	O
</ALL>	O

<ALL>	O
This	O
report	O
demonstrates	O
that	O
not	O
only	O
intravenous	O
,	O
but	O
also	O
oral	O
bisphosphonates	B-Chemical
can	O
aggravate	O
proteinuria	B-Disease
and	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
.	O
</ALL>	O

<ALL>	O
Risk	O
of	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
associated	O
with	O
initial	O
sulphonylurea	B-Chemical
treatment	O
of	O
patients	B-Species
with	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
:	O
a	O
matched	O
case	O
-	O
control	O
study	O
.	O
</ALL>	O

<ALL>	O
AIMS	O
:	O
This	O
study	O
sought	O
to	O
assess	O
the	O
risk	O
of	O
developing	O
coronary	B-Disease
artery	I-Disease
disease	I-Disease
(	O
CAD	B-Disease
)	O
associated	O
with	O
initial	O
treatment	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
with	O
different	O
sulphonylureas	B-Chemical
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
In	O
type	B-Disease
2	I-Disease
diabetic	I-Disease
patients	B-Species
,	O
cases	O
who	O
developed	O
CAD	B-Disease
were	O
compared	O
retrospectively	O
with	O
controls	O
that	O
did	O
not	O
.	O
</ALL>	O

<ALL>	O
The	O
20	O
-	O
year	O
risk	O
of	O
CAD	B-Disease
at	O
diagnosis	O
of	O
diabetes	B-Disease
,	O
using	O
the	O
UKPDS	O
risk	O
engine	O
,	O
was	O
used	O
to	O
match	O
cases	O
with	O
controls	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
76	O
cases	O
of	O
CAD	B-Disease
were	O
compared	O
with	O
152	O
controls	O
.	O
</ALL>	O

<ALL>	O
The	O
hazard	O
of	O
developing	O
CAD	B-Disease
(	O
95	O
%	O
CI	O
)	O
associated	O
with	O
initial	O
treatment	O
increased	O
by	O
2.4	O
-	O
fold	O
(	O
1.3	O
-	O
4.3	O
,	O
P	O
=	O
0.004	O
)	O
with	O
glibenclamide	B-Chemical
;	O
2	O
-	O
fold	O
(	O
0.9	O
-	O
4.6	O
,	O
P	O
=	O
0.099	O
)	O
with	O
glipizide	B-Chemical
;	O
2.9	O
-	O
fold	O
(	O
1.6	O
-	O
5.1	O
,	O
P	O
=	O
0.000	O
)	O
with	O
either	O
,	O
and	O
was	O
unchanged	O
with	O
metformin	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
hazard	O
decreased	O
0.3	O
-	O
fold	O
(	O
0.7	O
-	O
1.7	O
,	O
P	O
=	O
0.385	O
)	O
with	O
glimepiride	B-Chemical
,	O
0.4	O
-	O
fold	O
(	O
0.7	O
-	O
1.3	O
,	O
P	O
=	O
0.192	O
)	O
with	O
gliclazide	B-Chemical
,	O
and	O
0.4	O
-	O
fold	O
(	O
0.7	O
-	O
1.1	O
,	O
P	O
=	O
0.09	O
)	O
with	O
either	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Initiating	O
treatment	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
with	O
glibenclamide	B-Chemical
or	O
glipizide	B-Chemical
is	O
associated	O
with	O
increased	O
risk	O
of	O
CAD	B-Disease
in	O
comparison	O
to	O
gliclazide	B-Chemical
or	O
glimepiride	B-Chemical
.	O
</ALL>	O

<ALL>	O
If	O
confirmed	O
,	O
this	O
may	O
be	O
important	O
because	O
most	O
Indian	O
patients	B-Species
receive	O
the	O
cheaper	O
older	O
sulphonylureas	B-Chemical
,	O
and	O
present	O
guidelines	O
do	O
not	O
distinguish	O
between	O
individual	O
agents	O
.	O
</ALL>	O

<ALL>	O
Reduced	O
progression	O
of	O
adriamycin	B-Chemical
nephropathy	B-Disease
in	O
spontaneously	O
hypertensive	B-Disease
rats	B-Species
treated	O
by	O
losartan	B-Chemical
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
antihypertensive	O
effects	O
of	O
angiotensin	B-Gene
II	I-Gene
type	I-Gene
-	I-Gene
1	I-Gene
receptor	I-Gene
blocker	O
,	O
losartan	B-Chemical
,	O
and	O
its	O
potential	O
in	O
slowing	O
down	O
renal	B-Disease
disease	I-Disease
progression	O
in	O
spontaneously	O
hypertensive	B-Disease
rats	B-Species
(	O
SHR	O
)	O
with	O
adriamycin	B-Chemical
(	O
ADR	B-Chemical
)	O
nephropathy	B-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Six	O
-	O
month	O
-	O
old	O
female	O
SHR	O
were	O
randomly	O
selected	O
in	O
six	O
groups	O
.	O
</ALL>	O

<ALL>	O
Two	O
control	O
groups	O
(	O
SH	O
(	O
6	O
)	O
,	O
SH	O
(	O
12	O
)	O
)	O
received	O
vehicle	O
.	O
</ALL>	O

<ALL>	O
Groups	O
ADR	B-Chemical
(	O
6	O
)	O
,	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
6	O
)	O
and	O
ADR	B-Chemical
(	O
12	O
)	O
,	O
and	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
12	O
)	O
received	O
ADR	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
/	O
b.w	O
.	O
</ALL>	O

<ALL>	O
i.v	O
.	O
)	O
</ALL>	O

<ALL>	O
twice	O
in	O
a	O
3	O
-	O
week	O
interval	O
.	O
</ALL>	O

<ALL>	O
Group	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
6	O
)	O
received	O
losartan	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
/	O
b.w	O
.	O
/	O
</ALL>	O

<ALL>	O
day	O
by	O
gavages	O
)	O
for	O
6	O
weeks	O
and	O
group	O
ADR	B-Chemical
+	O
LOS	B-Chemical
(	O
12	O
)	O
for	O
12	O
weeks	O
after	O
second	O
injection	O
of	O
ADR	B-Chemical
.	O
</ALL>	O

<ALL>	O
Animals	O
were	O
killed	O
after	O
6	O
or	O
12	O
weeks	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
Haemodynamic	O
measurements	O
were	O
performed	O
on	O
anaesthetized	O
animals	O
,	O
blood	O
and	O
urine	O
samples	O
were	O
taken	O
for	O
biochemical	O
analysis	O
and	O
the	O
left	O
kidney	O
was	O
processed	O
for	O
morphological	O
studies	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Short	O
-	O
term	O
losartan	B-Chemical
treatment	O
,	O
besides	O
antihypertensive	O
effect	O
,	O
improved	O
glomerular	O
filtration	O
rate	O
and	O
ameliorated	O
glomerulosclerosis	B-Disease
resulting	O
in	O
decreased	O
proteinuria	B-Disease
.	O
</ALL>	O

<ALL>	O
Prolonged	O
treatment	O
with	O
losartan	B-Chemical
showed	O
further	O
reduction	O
of	O
glomerulosclerosis	B-Disease
associated	O
with	O
reduced	O
progression	O
of	O
tubular	O
atrophy	B-Disease
and	O
interstitial	B-Disease
fibrosis	I-Disease
,	O
thus	O
preventing	O
heavy	O
proteinuria	B-Disease
and	O
chronic	B-Disease
renal	I-Disease
failure	I-Disease
.	O
</ALL>	O

<ALL>	O
Losartan	B-Chemical
reduced	O
uraemia	B-Disease
and	O
increased	O
urea	B-Chemical
clearance	O
in	O
advanced	O
ADR	B-Chemical
nephropathy	B-Disease
in	O
SHR	O
.	O
</ALL>	O

<ALL>	O
Histological	O
examination	O
showed	O
that	O
losartan	B-Chemical
could	O
prevent	O
tubular	O
atrophy	B-Disease
,	O
interstitial	O
infiltration	O
and	O
fibrosis	B-Disease
in	O
ADR	B-Chemical
nephropathy	B-Disease
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Losartan	B-Chemical
reduces	O
the	O
rate	O
of	O
progression	O
of	O
ADR	B-Chemical
-	O
induced	O
focal	B-Disease
segmental	I-Disease
glomerulosclerosis	I-Disease
to	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
in	O
SHR	O
.	O
</ALL>	O

<ALL>	O
Effect	O
of	O
green	B-Chemical
tea	I-Chemical
and	O
vitamin	B-Chemical
E	I-Chemical
combination	O
in	O
isoproterenol	B-Chemical
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
was	O
aimed	O
to	O
investigate	O
the	O
combined	O
effects	O
of	O
green	B-Chemical
tea	I-Chemical
and	O
vitamin	B-Chemical
E	I-Chemical
on	O
heart	O
weight	O
,	O
body	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	B-Chemical
peroxidation	O
,	O
endogenous	O
antioxidants	B-Chemical
and	O
membrane	O
bound	O
ATPases	O
in	O
isoproterenol	B-Chemical
(	O
ISO	B-Chemical
)	O
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Adult	O
male	O
albino	O
rats	B-Species
,	O
treated	O
with	O
ISO	B-Chemical
(	O
200	O
mg	O
/	O
kg	O
,	O
s.c	O
.	O
)	O
</ALL>	O

<ALL>	O
for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h	O
caused	O
a	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
elevation	O
of	O
heart	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	B-Chemical
peroxidation	O
and	O
Ca	B-Chemical
+	I-Chemical
2	I-Chemical
ATPase	I-Chemical
level	O
whereas	O
there	O
was	O
a	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
decrease	O
in	O
body	O
weight	O
,	O
endogenous	O
antioxidants	B-Chemical
,	O
Na	B-Chemical
+	I-Chemical
/	I-Chemical
K	I-Chemical
+	I-Chemical
ATPase	I-Chemical
and	O
Mg	B-Chemical
+	I-Chemical
2	I-Chemical
ATPase	I-Chemical
levels	O
.	O
</ALL>	O

<ALL>	O
Administration	O
of	O
green	B-Chemical
tea	I-Chemical
(	O
100	O
mg	O
/	O
kg	O
/	O
day	O
,	O
p.o	O
.	O
)	O
</ALL>	O

<ALL>	O
and	O
vitamin	B-Chemical
E	I-Chemical
(	O
100	O
mg	O
/	O
kg	O
/	O
day	O
,	O
p.o	O
.	O
)	O
</ALL>	O

<ALL>	O
together	O
for	O
30	O
consecutive	O
days	O
and	O
challenged	O
with	O
ISO	B-Chemical
on	O
the	O
day	O
29th	O
and	O
30th	O
,	O
showed	O
a	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
decrease	O
in	O
heart	O
weight	O
,	O
serum	O
marker	O
enzymes	O
,	O
lipid	B-Chemical
peroxidation	O
,	O
Ca	B-Chemical
+	I-Chemical
2	I-Chemical
ATPase	I-Chemical
and	O
a	O
significant	O
increase	O
in	O
the	O
body	O
weight	O
,	O
endogenous	O
antioxidants	B-Chemical
,	O
Na	B-Chemical
+	I-Chemical
/	I-Chemical
K	I-Chemical
+	I-Chemical
ATPase	I-Chemical
and	O
Mg	B-Chemical
+	I-Chemical
2	I-Chemical
ATPase	I-Chemical
when	O
compared	O
with	O
ISO	B-Chemical
treated	O
group	O
and	O
green	B-Chemical
tea	I-Chemical
or	O
vitamin	B-Chemical
E	I-Chemical
alone	O
treated	O
groups	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
indicate	O
the	O
synergistic	O
protective	O
effect	O
of	O
green	B-Chemical
tea	I-Chemical
and	O
vitamin	B-Chemical
E	I-Chemical
during	O
ISO	B-Chemical
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
biological	O
properties	O
of	O
the	O
optical	O
isomers	O
of	O
propranolol	B-Chemical
and	O
their	O
effects	O
on	O
cardiac	B-Disease
arrhythmias	I-Disease
.	O
</ALL>	O

<ALL>	O
1	O
.	O
</ALL>	O

<ALL>	O
The	O
optical	O
isomers	O
of	O
propranolol	B-Chemical
have	O
been	O
compared	O
for	O
their	O
beta	O
-	O
blocking	O
and	O
antiarrhythmic	O
activities.2	O
.	O
</ALL>	O

<ALL>	O
In	O
blocking	O
the	O
positive	O
inotropic	O
and	O
chronotropic	O
responses	O
to	O
isoprenaline	B-Chemical
,	O
(	O
+	O
)	O
-	O
propranolol	B-Chemical
had	O
less	O
than	O
one	O
hundredth	O
the	O
potency	O
of	O
(	O
-	O
)	O
-	O
propranolol	B-Chemical
.	O
</ALL>	O

<ALL>	O
At	O
dose	O
levels	O
of	O
(	O
+	O
)	O
-	O
propranolol	B-Chemical
which	O
attenuated	O
the	O
responses	O
to	O
isoprenaline	B-Chemical
,	O
there	O
was	O
a	O
significant	O
prolongation	O
of	O
the	O
PR	O
interval	O
of	O
the	O
electrocardiogram.3	O
.	O
</ALL>	O

<ALL>	O
The	O
metabolic	O
responses	O
to	O
isoprenaline	B-Chemical
in	O
dogs	B-Species
(	O
an	O
increase	O
in	O
circulating	O
glucose	B-Chemical
,	O
lactate	B-Chemical
and	O
free	O
fatty	B-Chemical
acids	I-Chemical
)	O
were	O
all	O
blocked	O
by	O
(	O
-	O
)	O
-	O
propranolol	B-Chemical
.	O
(	O
</ALL>	O

<ALL>	O
+	O
)	O
-	O
Propranolol	B-Chemical
had	O
no	O
effect	O
on	O
fatty	B-Chemical
acid	I-Chemical
mobilization	O
but	O
significantly	O
reduced	O
the	O
increments	O
in	O
both	O
lactate	B-Chemical
and	O
glucose	B-Chemical
.4	O
.	O
</ALL>	O

<ALL>	O
Both	O
isomers	O
of	O
propranolol	B-Chemical
possessed	O
similar	O
depressant	O
potency	O
on	O
isolated	O
atrial	O
muscle	O
taken	O
from	O
guinea	B-Species
-	I-Species
pigs	I-Species
.5	O
.	O
</ALL>	O

<ALL>	O
The	O
isomers	O
of	O
propranolol	B-Chemical
exhibited	O
similar	O
local	O
anaesthetic	O
potencies	O
on	O
an	O
isolated	O
frog	O
nerve	O
preparation	O
at	O
a	O
level	O
approximately	O
three	O
times	O
that	O
of	O
procaine	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
racemic	O
compound	O
was	O
significantly	O
less	O
potent	O
than	O
either	O
isomer.6	O
.	O
</ALL>	O

<ALL>	O
Both	O
isomers	O
of	O
propranolol	B-Chemical
were	O
capable	O
of	O
preventing	O
adrenaline	B-Chemical
-	O
induced	O
cardiac	B-Disease
arrhythmias	I-Disease
in	O
cats	B-Species
anaesthetized	O
with	O
halothane	B-Chemical
,	O
but	O
the	O
mean	O
dose	O
of	O
(	O
-	O
)	O
-	O
propranolol	B-Chemical
was	O
0.09	O
+	O
/	O
-	O
0.02	O
mg	O
/	O
kg	O
whereas	O
that	O
of	O
(	O
+	O
)	O
-	O
propranolol	B-Chemical
was	O
4.2	O
+	O
/	O
-	O
1.2	O
mg	O
/	O
kg	O
.	O
</ALL>	O

<ALL>	O
At	O
the	O
effective	O
dose	O
level	O
of	O
(	O
+	O
)	O
-	O
propranolol	B-Chemical
there	O
was	O
a	O
significant	O
prolongation	O
of	O
the	O
PR	O
interval	O
of	O
the	O
electrocardiogram	O
.	O
</ALL>	O

<ALL>	O
Blockade	O
of	O
arrhythmias	B-Disease
with	O
both	O
isomers	O
was	O
surmountable	O
by	O
increasing	O
the	O
dose	O
of	O
adrenaline	B-Chemical
.7	O
.	O
</ALL>	O

<ALL>	O
Both	O
isomers	O
of	O
propranolol	B-Chemical
were	O
also	O
capable	O
of	O
reversing	O
ventricular	B-Disease
tachycardia	I-Disease
caused	O
by	O
ouabain	B-Chemical
in	O
anaesthetized	O
cats	B-Species
and	O
dogs	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
dose	O
of	O
(	O
-	O
)	O
-	O
propranolol	B-Chemical
was	O
significantly	O
smaller	O
than	O
that	O
of	O
(	O
+	O
)	O
-	O
propranolol	B-Chemical
in	O
both	O
species	O
but	O
much	O
higher	O
than	O
that	O
required	O
to	O
produce	O
evidence	O
of	O
beta	O
-	O
blockade.8	O
.	O
</ALL>	O

<ALL>	O
The	O
implications	O
of	O
these	O
results	O
are	O
discussed	O
.	O
</ALL>	O

<ALL>	O
Cardioprotective	O
effect	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
on	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
cardioprotective	O
potential	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
on	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Hemodynamic	O
parameters	O
and	O
lead	O
II	O
electrocardiograph	O
were	O
monitored	O
and	O
recorded	O
continuously	O
.	O
</ALL>	O

<ALL>	O
Cardiac	O
marker	O
enzymes	O
and	O
antioxidative	O
parameters	O
in	O
serum	O
and	O
heart	O
tissues	O
were	O
measured	O
.	O
</ALL>	O

<ALL>	O
Assay	O
for	O
mitochondrial	O
respiratory	O
function	O
and	O
histopathological	O
examination	O
of	O
heart	O
tissues	O
were	O
performed	O
.	O
</ALL>	O

<ALL>	O
Isoproterenol	B-Chemical
-	O
treated	O
rats	B-Species
showed	O
significant	O
increases	O
in	O
the	O
levels	O
of	O
lactate	B-Gene
dehydrogenase	I-Gene
,	O
aspartate	B-Gene
transaminase	I-Gene
,	O
creatine	B-Gene
kinase	I-Gene
and	O
malondialdehyde	B-Chemical
and	O
significant	O
decreases	O
in	O
the	O
activities	O
of	O
superoxide	B-Gene
dismutase	I-Gene
,	O
catalase	B-Gene
and	O
glutathione	B-Gene
peroxidase	I-Gene
in	O
serum	O
and	O
heart	O
.	O
</ALL>	O

<ALL>	O
These	O
rats	B-Species
also	O
showed	O
declines	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
,	O
maximum	O
and	O
minimum	O
rate	O
of	O
developed	O
left	O
ventricular	O
pressure	O
,	O
and	O
elevation	O
of	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
and	O
ST	O
-	O
segment	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
mitochondrial	B-Disease
respiratory	I-Disease
dysfunction	I-Disease
characterized	O
by	O
decreased	O
respiratory	O
control	O
ratio	O
and	O
ADP	B-Chemical
/	O
O	O
was	O
observed	O
in	O
isoproterenol	B-Chemical
-	O
treated	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Administration	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
for	O
a	O
period	O
of	O
8	O
days	O
significantly	O
attenuated	O
isoproterenol	B-Chemical
-	O
induced	O
cardiac	B-Disease
dysfunction	I-Disease
and	O
myocardial	B-Disease
injury	I-Disease
and	O
improved	O
mitochondrial	O
respiratory	O
function	O
.	O
</ALL>	O

<ALL>	O
The	O
protective	O
role	O
of	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
against	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
damage	I-Disease
was	O
further	O
confirmed	O
by	O
histopathological	O
examination	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
of	O
our	O
study	O
suggest	O
that	O
salvianolic	B-Chemical
acid	I-Chemical
A	I-Chemical
possessing	O
antioxidant	O
activity	O
has	O
a	O
significant	O
protective	O
effect	O
against	O
isoproterenol	B-Chemical
-	O
induced	O
myocardial	B-Disease
infarction	I-Disease
.	O
</ALL>	O

<ALL>	O
Learning	B-Disease
and	I-Disease
memory	I-Disease
deficits	I-Disease
in	O
ecstasy	B-Chemical
users	O
and	O
their	O
neural	O
correlates	O
during	O
a	O
face	O
-	O
learning	O
task	O
.	O
</ALL>	O

<ALL>	O
It	O
has	O
been	O
consistently	O
shown	O
that	O
ecstasy	B-Chemical
users	O
display	O
impairments	B-Disease
in	I-Disease
learning	I-Disease
and	I-Disease
memory	I-Disease
performance	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
working	O
memory	O
processing	O
in	O
ecstasy	B-Chemical
users	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
neural	O
alterations	O
in	O
hippocampal	O
and	O
/	O
or	O
cortical	O
regions	O
as	O
measured	O
by	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
.	O
</ALL>	O

<ALL>	O
Using	O
functional	O
imaging	O
and	O
a	O
face	O
-	O
learning	O
task	O
,	O
we	O
investigated	O
neural	O
correlates	O
of	O
encoding	O
and	O
recalling	O
face	O
-	O
name	O
associations	O
in	O
20	O
recreational	O
drug	O
users	O
whose	O
predominant	O
drug	O
use	O
was	O
ecstasy	B-Chemical
and	O
20	O
controls	O
.	O
</ALL>	O

<ALL>	O
To	O
address	O
the	O
potential	O
confounding	O
effects	O
of	O
the	O
cannabis	B-Chemical
use	O
of	O
the	O
ecstasy	B-Chemical
using	O
group	O
,	O
a	O
second	O
analysis	O
included	O
14	O
previously	O
tested	O
cannabis	B-Chemical
users	O
(	O
Nestor	O
,	O
L.	O
,	O
Roberts	O
,	O
G.	O
,	O
Garavan	O
,	O
H.	O
,	O
Hester	O
,	O
R.	O
,	O
2008	O
.	O
</ALL>	O

<ALL>	O
Deficits	B-Disease
in	I-Disease
learning	I-Disease
and	I-Disease
memory	I-Disease
:	O
parahippocampal	O
hyperactivity	B-Disease
and	O
frontocortical	O
hypoactivity	O
in	O
cannabis	B-Chemical
users	O
.	O
</ALL>	O

<ALL>	O
Neuroimage	O
40	O
,	O
1328	O
-	O
1339	O
)	O
.	O
</ALL>	O

<ALL>	O
Ecstasy	B-Chemical
users	O
performed	O
significantly	O
worse	O
in	O
learning	O
and	O
memory	O
compared	O
to	O
controls	O
and	O
cannabis	B-Chemical
users	O
.	O
</ALL>	O

<ALL>	O
A	O
conjunction	O
analysis	O
of	O
the	O
encode	O
and	O
recall	O
phases	O
of	O
the	O
task	O
revealed	O
ecstasy	B-Chemical
-	O
specific	O
hyperactivity	B-Disease
in	O
bilateral	O
frontal	O
regions	O
,	O
left	O
temporal	O
,	O
right	O
parietal	O
,	O
bilateral	O
temporal	O
,	O
and	O
bilateral	O
occipital	O
brain	O
regions	O
.	O
</ALL>	O

<ALL>	O
Ecstasy	B-Chemical
-	O
specific	O
hypoactivity	O
was	O
evident	O
in	O
the	O
right	O
dorsal	O
anterior	O
cingulated	O
cortex	O
(	O
ACC	O
)	O
and	O
left	O
posterior	O
cingulated	O
cortex	O
.	O
</ALL>	O

<ALL>	O
In	O
both	O
ecstasy	B-Chemical
and	O
cannabis	B-Chemical
groups	O
brain	O
activation	O
was	O
decreased	O
in	O
the	O
right	O
medial	O
frontal	O
gyrus	O
,	O
left	O
parahippocampal	O
gyrus	O
,	O
left	O
dorsal	O
cingulate	O
gyrus	O
,	O
and	O
left	O
caudate	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
elucidated	O
ecstasy	B-Chemical
-	O
related	O
deficits	O
,	O
only	O
some	O
of	O
which	O
might	O
be	O
attributed	O
to	O
cannabis	B-Chemical
use	O
.	O
</ALL>	O

<ALL>	O
These	O
ecstasy	B-Chemical
-	O
specific	O
effects	O
may	O
be	O
related	O
to	O
the	O
vulnerability	O
of	O
isocortical	O
and	O
allocortical	O
regions	O
to	O
the	O
neurotoxic	B-Disease
effects	O
of	O
ecstasy	B-Chemical
.	O
</ALL>	O

<ALL>	O
Mice	B-Species
lacking	O
mPGES	B-Gene
-	I-Gene
1	I-Gene
are	O
resistant	O
to	O
lithium	B-Chemical
-	O
induced	O
polyuria	B-Disease
.	O
</ALL>	O

<ALL>	O
Cyclooxygenase	B-Gene
-	I-Gene
2	I-Gene
activity	O
is	O
required	O
for	O
the	O
development	O
of	O
lithium	B-Chemical
-	O
induced	O
polyuria	B-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
involvement	O
of	O
a	O
specific	O
,	O
terminal	O
prostaglandin	B-Chemical
(	O
PG	B-Chemical
)	O
isomerase	O
has	O
not	O
been	O
evaluated	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
was	O
undertaken	O
to	O
assess	O
lithium	B-Chemical
-	O
induced	O
polyuria	B-Disease
in	O
mice	B-Species
deficient	O
in	O
microsomal	B-Gene
prostaglandin	I-Gene
E	I-Gene
synthase	I-Gene
-	I-Gene
1	I-Gene
(	O
mPGES	B-Gene
-	I-Gene
1	I-Gene
)	O
.	O
</ALL>	O

<ALL>	O
A	O
2	O
-	O
wk	O
administration	O
of	O
LiCl	B-Chemical
(	O
4	O
mmol.kg	O
(	O
-	O
1	O
)	O
.day	O
(	O
-	O
1	O
)	O
ip	O
)	O
in	O
mPGES	B-Gene
-	I-Gene
1	I-Gene
+	O
/	O
+	O
mice	B-Species
led	O
to	O
a	O
marked	O
polyuria	B-Disease
with	O
hyposmotic	O
urine	O
.	O
</ALL>	O

<ALL>	O
This	O
was	O
associated	O
with	O
elevated	O
renal	O
mPGES	B-Gene
-	I-Gene
1	I-Gene
protein	O
expression	O
and	O
increased	O
urine	O
PGE	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
excretion	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
mPGES	B-Gene
-	I-Gene
1	I-Gene
-	O
/	O
-	O
mice	B-Species
were	O
largely	O
resistant	O
to	O
lithium	B-Chemical
-	O
induced	O
polyuria	B-Disease
and	O
a	O
urine	O
concentrating	O
defect	O
,	O
accompanied	O
by	O
nearly	O
complete	O
blockade	O
of	O
high	O
urine	O
PGE	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
and	O
cAMP	B-Chemical
output	O
.	O
</ALL>	O

<ALL>	O
Immunoblotting	O
,	O
immunohistochemistry	O
,	O
and	O
quantitative	O
(	O
q	O
)	O
RT	O
-	O
PCR	O
consistently	O
detected	O
a	O
significant	O
decrease	O
in	O
aquaporin	B-Gene
-	I-Gene
2	I-Gene
(	O
AQP2	B-Gene
)	O
protein	O
expression	O
in	O
both	O
the	O
renal	O
cortex	O
and	O
medulla	O
of	O
lithium	B-Chemical
-	O
treated	O
+	O
/	O
+	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
This	O
decrease	O
was	O
significantly	O
attenuated	O
in	O
the	O
-	O
/	O
-	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
qRT	O
-	O
PCR	O
detected	O
similar	O
patterns	O
of	O
changes	O
in	O
AQP2	B-Gene
mRNA	O
in	O
the	O
medulla	O
but	O
not	O
in	O
the	O
cortex	O
.	O
</ALL>	O

<ALL>	O
Similarly	O
,	O
the	O
total	O
protein	O
abundance	O
of	O
the	O
Na	B-Gene
-	I-Gene
K	I-Gene
-	I-Gene
2Cl	I-Gene
cotransporter	I-Gene
(	O
NKCC2	B-Gene
)	O
in	O
the	O
medulla	O
but	O
not	O
in	O
the	O
cortex	O
of	O
the	O
+	O
/	O
+	O
mice	B-Species
was	O
significantly	O
reduced	O
by	O
lithium	B-Chemical
treatment	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
the	O
dowregulation	O
of	O
renal	O
medullary	O
NKCC2	B-Gene
expression	O
was	O
significantly	O
attenuated	O
in	O
the	O
-	O
/	O
-	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
We	O
conclude	O
that	O
mPGES	B-Gene
-	I-Gene
1	I-Gene
-	O
derived	O
PGE	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
mediates	O
lithium	B-Chemical
-	O
induced	O
polyuria	B-Disease
likely	O
via	O
inhibition	O
of	O
AQP2	B-Gene
and	O
NKCC2	B-Gene
expression	O
.	O
</ALL>	O

<ALL>	O
Dextran	B-Chemical
-	O
etodolac	B-Chemical
conjugates	O
:	O
synthesis	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
evaluation	O
.	O
</ALL>	O

<ALL>	O
Etodolac	B-Chemical
(	O
E	B-Chemical
)	O
,	O
is	O
a	O
non	O
-	O
narcotic	O
analgesic	O
and	O
antiinflammatory	B-Chemical
drug	I-Chemical
.	O
</ALL>	O

<ALL>	O
A	O
biodegradable	O
polymer	O
dextran	B-Chemical
has	O
been	O
utilized	O
as	O
a	O
carrier	O
for	O
synthesis	O
of	O
etodolac	B-Chemical
-	O
dextran	B-Chemical
conjugates	O
(	O
ED	B-Chemical
)	O
to	O
improve	O
its	O
aqueous	O
solubility	O
and	O
reduce	O
gastrointestinal	O
side	O
effects	O
.	O
</ALL>	O

<ALL>	O
An	O
activated	O
moiety	O
,	O
i.e.	O
N	B-Chemical
-	I-Chemical
acylimidazole	I-Chemical
derivative	O
of	O
etodolac	B-Chemical
(	O
EAI	B-Chemical
)	O
,	O
was	O
condensed	O
with	O
the	O
polysaccharide	O
polymer	O
dextran	B-Chemical
of	O
different	O
molecular	O
weights	O
(	O
40000	O
,	O
60000	O
,	O
110000	O
and	O
200000	O
)	O
.	O
</ALL>	O

<ALL>	O
IR	O
spectral	O
data	O
confirmed	O
formation	O
of	O
ester	B-Chemical
bonding	O
in	O
the	O
conjugates	O
.	O
</ALL>	O

<ALL>	O
Etodolac	B-Chemical
contents	O
were	O
evaluated	O
by	O
UV	O
-	O
spectrophotometric	O
analysis	O
.	O
</ALL>	O

<ALL>	O
The	O
molecular	O
weights	O
were	O
determined	O
by	O
measuring	O
viscosity	O
using	O
the	O
Mark	O
-	O
Howink	O
-	O
Sakurada	O
equation	O
.	O
</ALL>	O

<ALL>	O
In	O
vitro	O
hydrolysis	O
of	O
ED	B-Chemical
was	O
done	O
in	O
aqueous	O
buffers	O
(	O
pH	O
1.2	O
,	O
7.4	O
,	O
9	O
)	O
and	O
in	O
80	O
%	O
(	O
v	O
/	O
v	O
)	O
human	B-Species
plasma	O
(	O
pH	O
7.4	O
)	O
.	O
</ALL>	O

<ALL>	O
At	O
pH	O
9	O
,	O
a	O
higher	O
rate	O
of	O
etodolac	B-Chemical
release	O
from	O
ED	B-Chemical
was	O
observed	O
as	O
compared	O
to	O
aqueous	O
buffer	O
of	O
pH	O
7.4	O
and	O
80	O
%	O
human	B-Species
plasma	O
(	O
pH	O
7.4	O
)	O
,	O
following	O
first	O
-	O
order	O
kinetics	O
.	O
</ALL>	O

<ALL>	O
In	O
vivo	O
investigations	O
were	O
performed	O
in	O
animals	O
.	O
</ALL>	O

<ALL>	O
Acute	O
analgesic	O
and	O
antiinflammatory	O
activities	O
were	O
ascertained	O
using	O
acetic	B-Chemical
acid	I-Chemical
induced	O
writhing	O
model	O
(	O
mice	B-Species
)	O
and	O
carrageenan	B-Chemical
-	O
induced	O
rat	B-Species
paw	O
edema	B-Disease
model	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
In	O
comparison	O
to	O
control	O
,	O
E	B-Chemical
and	O
ED1	O
-	O
ED4	O
showed	O
highly	O
significant	O
analgesic	O
and	O
antiinflammatory	O
activities	O
(	O
p	O
<	O
0.001	O
)	O
.	O
</ALL>	O

<ALL>	O
Biological	O
evaluation	O
suggested	O
that	O
conjugates	O
(	O
ED1	O
-	O
ED4	O
)	O
retained	O
comparable	O
analgesic	O
and	O
antiinflammatory	O
activities	O
with	O
remarkably	O
reduced	O
ulcerogenicity	O
as	O
compared	O
to	O
their	O
parent	O
drug	O
-	O
-	O
etodolac	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
antiarrhythmic	O
effect	O
and	O
possible	O
ionic	O
mechanisms	O
of	O
pilocarpine	B-Chemical
on	O
animal	O
models	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
effects	O
of	O
pilocarpine	B-Chemical
and	O
explore	O
the	O
underlying	O
ionic	O
mechanism	O
,	O
using	O
both	O
aconitine	B-Chemical
-	O
induced	O
rat	B-Species
and	O
ouabain	B-Chemical
-	O
induced	O
guinea	B-Species
pig	I-Species
arrhythmia	B-Disease
models	O
.	O
</ALL>	O

<ALL>	O
Confocal	O
microscopy	O
was	O
used	O
to	O
measure	O
intracellular	O
free	O
-	O
calcium	B-Chemical
concentrations	O
(	O
[	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+	I-Chemical
)	I-Chemical
]	O
(	O
i	O
)	O
)	O
in	O
isolated	O
myocytes	O
.	O
</ALL>	O

<ALL>	O
The	O
current	O
data	O
showed	O
that	O
pilocarpine	B-Chemical
significantly	O
delayed	O
onset	O
of	O
arrhythmias	B-Disease
,	O
decreased	O
the	O
time	O
course	O
of	O
ventricular	B-Disease
tachycardia	I-Disease
and	I-Disease
fibrillation	I-Disease
,	O
reduced	O
arrhythmia	B-Disease
score	O
,	O
and	O
increased	O
the	O
survival	O
time	O
of	O
arrhythmic	B-Disease
rats	B-Species
and	O
guinea	B-Species
pigs	I-Species
.	O
[	O
</ALL>	O

<ALL>	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+	I-Chemical
)	I-Chemical
]	O
(	O
i	O
)	O
overload	O
induced	O
by	O
aconitine	B-Chemical
or	O
ouabain	B-Chemical
was	O
reduced	O
in	O
isolated	O
myocytes	O
pretreated	O
with	O
pilocarpine	B-Chemical
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
M	B-Gene
(	I-Gene
3	I-Gene
)	I-Gene
-	I-Gene
muscarinic	I-Gene
acetylcholine	I-Gene
receptor	I-Gene
(	O
mAChR	B-Gene
)	O
antagonist	O
4	B-Chemical
-	I-Chemical
DAMP	I-Chemical
(	O
4	B-Chemical
-	I-Chemical
diphenylacetoxy	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
methylpiperidine	I-Chemical
-	I-Chemical
methiodide	I-Chemical
)	O
partially	O
abolished	O
the	O
beneficial	O
effects	O
of	O
pilocarpine	B-Chemical
.	O
</ALL>	O

<ALL>	O
These	O
data	O
suggest	O
that	O
pilocarpine	B-Chemical
produced	O
antiarrhythmic	O
actions	O
on	O
arrhythmic	B-Disease
rat	B-Species
and	O
guinea	B-Species
pig	I-Species
models	O
induced	O
by	O
aconitine	B-Chemical
or	O
ouabain	B-Chemical
via	O
stimulating	O
the	O
cardiac	O
M	B-Gene
(	I-Gene
3	I-Gene
)	I-Gene
-	I-Gene
mAChR	I-Gene
.	O
</ALL>	O

<ALL>	O
The	O
mechanism	O
may	O
be	O
related	O
to	O
the	O
improvement	O
of	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+	I-Chemical
)	I-Chemical
handling	O
.	O
</ALL>	O

<ALL>	O
Nimodipine	B-Chemical
prevents	O
memory	B-Disease
impairment	I-Disease
caused	O
by	O
nitroglycerin	B-Chemical
-	O
induced	O
hypotension	B-Disease
in	O
adult	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Hypotension	B-Disease
and	O
a	O
resultant	O
decrease	O
in	O
cerebral	O
blood	O
flow	O
have	O
been	O
implicated	O
in	O
the	O
development	O
of	O
cognitive	B-Disease
dysfunction	I-Disease
.	O
</ALL>	O

<ALL>	O
We	O
tested	O
the	O
hypothesis	O
that	O
nimodipine	B-Chemical
(	O
NIMO	B-Chemical
)	O
administered	O
at	O
the	O
onset	O
of	O
nitroglycerin	B-Chemical
(	O
NTG	B-Chemical
)	O
-	O
induced	O
hypotension	B-Disease
would	O
preserve	O
long	O
-	O
term	O
associative	O
memory	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
The	O
passive	O
avoidance	O
(	O
PA	O
)	O
paradigm	O
was	O
used	O
to	O
assess	O
memory	O
retention	O
.	O
</ALL>	O

<ALL>	O
For	O
PA	O
training	O
,	O
latencies	O
(	O
seconds	O
)	O
were	O
recorded	O
for	O
entry	O
from	O
a	O
suspended	O
platform	O
into	O
a	O
Plexiglas	O
tube	O
where	O
a	O
shock	O
was	O
automatically	O
delivered	O
.	O
</ALL>	O

<ALL>	O
Latencies	O
were	O
recorded	O
48	O
h	O
later	O
for	O
a	O
testing	O
trial	O
.	O
</ALL>	O

<ALL>	O
Ninety	O
-	O
six	O
Swiss	O
-	O
Webster	O
mice	B-Species
(	O
30	O
-	O
35	O
g	O
,	O
6	O
-	O
8	O
wk	O
)	O
,	O
were	O
randomized	O
into	O
6	O
groups	O
1	O
)	O
saline	O
(	O
control	O
)	O
,	O
2	O
)	O
NTG	B-Chemical
immediately	O
after	O
learning	O
,	O
3	O
)	O
NTG	B-Chemical
3	O
h	O
after	O
learning	O
,	O
4	O
)	O
NTG	B-Chemical
and	O
NIMO	B-Chemical
,	O
5	O
)	O
vehicle	O
,	O
and	O
6	O
)	O
NIMO	B-Chemical
alone	O
.	O
</ALL>	O

<ALL>	O
The	O
extent	O
of	O
hypotension	B-Disease
and	O
changes	O
in	O
brain	O
tissue	O
oxygenation	O
(	O
PbtO	O
(	O
2	O
)	O
)	O
and	O
in	O
cerebral	O
blood	O
flow	O
were	O
studied	O
in	O
a	O
separate	O
group	O
of	O
animals	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
All	O
groups	O
exhibited	O
similar	O
training	O
latencies	O
(	O
17.0	O
+	O
/	O
-	O
4.6	O
s	O
)	O
.	O
</ALL>	O

<ALL>	O
Mice	B-Species
subjected	O
to	O
hypotensive	B-Disease
episodes	O
showed	O
a	O
significant	O
decrease	O
in	O
latency	O
time	O
(	O
178	O
+	O
/	O
-	O
156	O
s	O
)	O
compared	O
with	O
those	O
injected	O
with	O
saline	O
,	O
NTG	B-Chemical
+	O
NIMO	B-Chemical
,	O
or	O
delayed	O
NTG	B-Chemical
(	O
580	O
+	O
/	O
-	O
81	O
s	O
,	O
557	O
+	O
/	O
-	O
67	O
s	O
,	O
and	O
493	O
+	O
/	O
-	O
146	O
s	O
,	O
respectively	O
)	O
.	O
</ALL>	O

<ALL>	O
A	O
Kruskal	O
-	O
Wallis	O
1	O
-	O
way	O
analysis	O
of	O
variance	O
indicated	O
a	O
significant	O
difference	O
among	O
the	O
4	O
treatment	O
groups	O
(	O
H	O
=	O
15.34	O
;	O
P	O
<	O
0.001	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
a	O
separate	O
group	O
of	O
mice	B-Species
not	O
subjected	O
to	O
behavioral	O
studies	O
,	O
the	O
same	O
dose	O
of	O
NTG	B-Chemical
(	O
n	O
=	O
3	O
)	O
and	O
NTG	B-Chemical
+	O
NIMO	B-Chemical
(	O
n	O
=	O
3	O
)	O
caused	O
mean	O
arterial	O
blood	O
pressure	O
to	O
decrease	O
from	O
85.9	O
+	O
/	O
-	O
3.8	O
mm	O
Hg	O
sem	O
to	O
31.6	O
+	O
/	O
-	O
0.8	O
mm	O
Hg	O
sem	O
and	O
from	O
86.2	O
+	O
/	O
-	O
3.7	O
mm	O
Hg	O
sem	O
to	O
32.6	O
+	O
/	O
-	O
0.2	O
mm	O
Hg	O
sem	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
Mean	O
arterial	O
blood	O
pressure	O
in	O
mice	B-Species
treated	O
with	O
NIMO	B-Chemical
alone	O
decreased	O
from	O
88.1	O
+	O
/	O
-	O
3.8	O
mm	O
Hg	O
to	O
80.0	O
+	O
/	O
-	O
2.9	O
mm	O
Hg	O
.	O
</ALL>	O

<ALL>	O
The	O
intergroup	O
difference	O
was	O
statistically	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
PbtO	O
(	O
2	O
)	O
decreased	O
from	O
51.7	O
+	O
/	O
-	O
4.5	O
mm	O
Hg	O
sem	O
to	O
33.8	O
+	O
/	O
-	O
5.2	O
mm	O
Hg	O
sem	O
in	O
the	O
NTG	B-Chemical
group	O
and	O
from	O
38.6	O
+	O
/	O
-	O
6.1	O
mm	O
Hg	O
sem	O
to	O
25.4	O
+	O
/	O
-	O
2.0	O
mm	O
Hg	O
sem	O
in	O
the	O
NTG	B-Chemical
+	O
NIMO	B-Chemical
groups	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
There	O
were	O
no	O
significant	O
differences	O
among	O
groups	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
In	O
a	O
PA	O
retention	O
paradigm	O
,	O
the	O
injection	O
of	O
NTG	B-Chemical
immediately	O
after	O
learning	O
produced	O
a	O
significant	O
impairment	O
of	O
long	O
-	O
term	O
associative	O
memory	O
in	O
mice	B-Species
,	O
whereas	O
delayed	O
induced	O
hypotension	B-Disease
had	O
no	O
effect	O
.	O
</ALL>	O

<ALL>	O
NIMO	B-Chemical
attenuated	O
the	O
disruption	O
in	O
consolidation	O
of	O
long	O
-	O
term	O
memory	O
caused	O
by	O
NTG	B-Chemical
but	O
did	O
not	O
improve	O
latency	O
in	O
the	O
absence	O
of	O
hypotension	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
observed	O
effect	O
of	O
NIMO	B-Chemical
may	O
have	O
been	O
attributable	O
to	O
the	O
preservation	O
of	O
calcium	B-Chemical
homeostasis	O
during	O
hypotension	B-Disease
,	O
because	O
there	O
were	O
no	O
differences	O
in	O
the	O
PbtO	O
(	O
2	O
)	O
indices	O
among	O
groups	O
.	O
</ALL>	O

<ALL>	O
Normalizing	O
effects	O
of	O
modafinil	B-Chemical
on	O
sleep	O
in	O
chronic	O
cocaine	B-Chemical
users	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
morning	O
-	O
dosed	O
modafinil	B-Chemical
on	O
sleep	O
and	O
daytime	B-Disease
sleepiness	I-Disease
in	O
chronic	O
cocaine	B-Chemical
users	O
.	O
</ALL>	O

<ALL>	O
METHOD	O
:	O
Twenty	O
cocaine	B-Chemical
-	O
dependent	O
participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
modafinil	B-Chemical
,	O
400	O
mg	O
(	O
N	O
=	O
10	O
)	O
,	O
or	O
placebo	O
(	O
N	O
=	O
10	O
)	O
every	O
morning	O
at	O
7:30	O
a.m.	O
for	O
16	O
days	O
in	O
an	O
inpatient	B-Species
,	O
double	O
-	O
blind	O
randomized	O
trial	O
.	O
</ALL>	O

<ALL>	O
Participants	O
underwent	O
polysomnographic	O
sleep	O
recordings	O
on	O
days	O
1	O
to	O
3	O
,	O
7	O
to	O
9	O
,	O
and	O
14	O
to	O
16	O
(	O
first	O
,	O
second	O
,	O
and	O
third	O
weeks	O
of	O
abstinence	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
Multiple	O
Sleep	O
Latency	O
Test	O
was	O
performed	O
at	O
11:30	O
a.m.	O
,	O
2:00	O
p.m.	O
,	O
and	O
4:30	O
p.m.	O
on	O
days	O
2	O
,	O
8	O
,	O
and	O
15	O
.	O
</ALL>	O

<ALL>	O
For	O
comparison	O
of	O
sleep	O
architecture	O
variables	O
,	O
12	O
healthy	O
comparison	O
participants	O
underwent	O
a	O
single	O
night	O
of	O
experimental	O
polysomnography	O
that	O
followed	O
1	O
night	O
of	O
accommodation	O
polysomnography	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Progressive	O
abstinence	O
from	O
cocaine	B-Chemical
was	O
associated	O
with	O
worsening	O
of	O
all	O
measured	O
polysomnographic	O
sleep	O
outcomes	O
.	O
</ALL>	O

<ALL>	O
Compared	O
with	O
placebo	O
,	O
modafinil	B-Chemical
decreased	O
nighttime	O
sleep	O
latency	O
and	O
increased	O
slow	O
-	O
wave	O
sleep	O
time	O
in	O
cocaine	B-Chemical
-	O
dependent	O
participants	O
.	O
</ALL>	O

<ALL>	O
The	O
effect	O
of	O
modafinil	B-Chemical
interacted	O
with	O
the	O
abstinence	O
week	O
and	O
was	O
associated	O
with	O
longer	O
total	O
sleep	O
time	O
and	O
shorter	O
REM	O
sleep	O
latency	O
in	O
the	O
third	O
week	O
of	O
abstinence	O
.	O
</ALL>	O

<ALL>	O
Comparison	O
of	O
slow	O
-	O
wave	O
sleep	O
time	O
,	O
total	O
sleep	O
time	O
,	O
and	O
sleep	O
latency	O
in	O
cocaine	B-Chemical
-	O
dependent	O
and	O
healthy	O
participants	O
revealed	O
a	O
normalizing	O
effect	O
of	O
modafinil	B-Chemical
in	O
cocaine	B-Chemical
-	O
dependent	O
participants	O
.	O
</ALL>	O

<ALL>	O
Modafinil	B-Chemical
was	O
associated	O
with	O
increased	O
daytime	O
sleep	O
latency	O
,	O
as	O
measured	O
by	O
the	O
Multiple	O
Sleep	O
Latency	O
Test	O
,	O
and	O
a	O
nearly	O
significant	O
decrease	O
in	O
subjective	O
daytime	B-Disease
sleepiness	I-Disease
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Morning	O
-	O
dosed	O
modafinil	B-Chemical
promotes	O
nocturnal	O
sleep	O
,	O
normalizes	O
sleep	O
architecture	O
,	O
and	O
decreases	O
daytime	B-Disease
sleepiness	I-Disease
in	O
abstinent	O
cocaine	B-Chemical
users	O
.	O
</ALL>	O

<ALL>	O
These	O
effects	O
may	O
be	O
relevant	O
in	O
the	O
treatment	O
of	O
cocaine	B-Chemical
dependence	O
.	O
</ALL>	O

<ALL>	O
Studies	O
of	O
synergy	O
between	O
morphine	B-Chemical
and	O
a	O
novel	O
sodium	B-Chemical
channel	I-Chemical
blocker	I-Chemical
,	O
CNSB002	B-Chemical
,	O
in	O
rat	B-Species
models	O
of	O
inflammatory	B-Disease
and	O
neuropathic	B-Disease
pain	I-Disease
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
This	O
study	O
determined	O
the	O
antihyperalgesic	O
effect	O
of	O
CNSB002	B-Chemical
,	O
a	O
sodium	B-Chemical
channel	I-Chemical
blocker	I-Chemical
with	O
antioxidant	O
properties	O
given	O
alone	O
and	O
in	O
combinations	O
with	O
morphine	B-Chemical
in	O
rat	B-Species
models	O
of	O
inflammatory	B-Disease
and	O
neuropathic	B-Disease
pain	I-Disease
.	O
</ALL>	O

<ALL>	O
DESIGN	O
:	O
Dose	O
response	O
curves	O
for	O
nonsedating	O
doses	O
of	O
morphine	B-Chemical
and	O
CNSB002	B-Chemical
given	O
intraperitoneally	O
alone	O
and	O
together	O
in	O
combinations	O
were	O
constructed	O
for	O
antihyperalgesic	O
effect	O
using	O
paw	O
withdrawal	O
from	O
noxious	O
heat	O
in	O
two	O
rat	B-Species
pain	B-Disease
models	O
:	O
carrageenan	B-Chemical
-	O
induced	O
paw	O
inflammation	B-Disease
and	O
streptozotocin	B-Chemical
(	O
STZ	B-Chemical
)	O
-	O
induced	O
diabetic	B-Disease
neuropathy	I-Disease
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
maximum	O
nonsedating	O
doses	O
were	O
:	O
morphine	B-Chemical
,	O
3.2	O
mg	O
/	O
kg	O
;	O
CNSB002	B-Chemical
10.0	O
mg	O
/	O
kg	O
;	O
5.0	O
mg	O
/	O
kg	O
CNSB002	B-Chemical
with	O
morphine	B-Chemical
3.2	O
mg	O
/	O
kg	O
in	O
combination	O
.	O
</ALL>	O

<ALL>	O
The	O
doses	O
calculated	O
to	O
cause	O
50	O
%	O
reversal	O
of	O
hyperalgesia	B-Disease
(	O
ED50	O
)	O
were	O
7.54	O
(	O
1.81	O
)	O
and	O
4.83	O
(	O
1.54	O
)	O
in	O
the	O
carrageenan	B-Chemical
model	O
and	O
44.18	O
(	O
1.37	O
)	O
and	O
9.14	O
(	O
1.24	O
)	O
in	O
the	O
STZ	B-Chemical
-	O
induced	O
neuropathy	B-Disease
model	O
for	O
CNSB002	B-Chemical
and	O
morphine	B-Chemical
,	O
respectively	O
(	O
mg	O
/	O
kg	O
;	O
mean	O
,	O
SEM	O
)	O
.	O
</ALL>	O

<ALL>	O
These	O
values	O
were	O
greater	O
than	O
the	O
maximum	O
nonsedating	O
doses	O
.	O
</ALL>	O

<ALL>	O
The	O
ED50	O
values	O
for	O
morphine	B-Chemical
when	O
given	O
in	O
combination	O
with	O
CNSB002	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
)	O
were	O
less	O
than	O
the	O
maximum	O
nonsedating	O
dose	O
:	O
0.56	O
(	O
1.55	O
)	O
in	O
the	O
carrageenan	B-Chemical
model	O
and	O
1.37	O
(	O
1.23	O
)	O
in	O
the	O
neuropathy	B-Disease
model	O
(	O
mg	O
/	O
kg	O
;	O
mean	O
,	O
SEM	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
antinociception	O
after	O
morphine	B-Chemical
(	O
3.2	O
mg	O
/	O
kg	O
)	O
was	O
increased	O
by	O
co	O
-	O
administration	O
with	O
CNSB002	B-Chemical
from	O
28.0	O
and	O
31.7	O
%	O
to	O
114.6	O
and	O
56.9	O
%	O
reversal	O
of	O
hyperalgesia	B-Disease
in	O
the	O
inflammatory	B-Disease
and	O
neuropathic	B-Disease
models	O
,	O
respectively	O
(	O
P	O
<	O
0.01	O
;	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
-	O
significantly	O
greater	O
than	O
either	O
drug	O
given	O
alone	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
The	O
maximum	O
antihyperalgesic	O
effect	O
achievable	O
with	O
nonsedating	O
doses	O
of	O
morphine	B-Chemical
may	O
be	O
increased	O
significantly	O
when	O
the	O
drug	O
is	O
used	O
in	O
combination	O
with	O
CNSB002	B-Chemical
.	O
</ALL>	O

<ALL>	O
Coenzyme	B-Chemical
Q10	I-Chemical
treatment	O
ameliorates	O
acute	O
cisplatin	B-Chemical
nephrotoxicity	B-Disease
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
nephroprotective	O
effect	O
of	O
coenzyme	B-Chemical
Q10	I-Chemical
was	O
investigated	O
in	O
mice	B-Species
with	O
acute	B-Disease
renal	I-Disease
injury	I-Disease
induced	O
by	O
a	O
single	O
i.p	O
.	O
</ALL>	O

<ALL>	O
injection	O
of	O
cisplatin	B-Chemical
(	O
5	O
mg	O
/	O
kg	O
)	O
.	O
</ALL>	O

<ALL>	O
Coenzyme	B-Chemical
Q10	I-Chemical
treatment	O
(	O
10	O
mg	O
/	O
kg	O
/	O
day	O
,	O
i.p	O
.	O
)	O
</ALL>	O

<ALL>	O
was	O
applied	O
for	O
6	O
consecutive	O
days	O
,	O
starting	O
1	O
day	O
before	O
cisplatin	B-Chemical
administration	O
.	O
</ALL>	O

<ALL>	O
Coenzyme	B-Chemical
Q10	I-Chemical
significantly	O
reduced	O
blood	B-Chemical
urea	I-Chemical
nitrogen	I-Chemical
and	O
serum	O
creatinine	B-Chemical
levels	O
which	O
were	O
increased	O
by	O
cisplatin	B-Chemical
.	O
</ALL>	O

<ALL>	O
Coenzyme	B-Chemical
Q10	I-Chemical
significantly	O
compensated	O
deficits	O
in	O
the	O
antioxidant	O
defense	O
mechanisms	O
(	O
reduced	O
glutathione	B-Chemical
level	O
and	O
superoxide	B-Gene
dismutase	I-Gene
activity	O
)	O
,	O
suppressed	O
lipid	B-Chemical
peroxidation	O
,	O
decreased	O
the	O
elevations	O
of	O
tumor	B-Gene
necrosis	I-Gene
factor	I-Gene
-	I-Gene
alpha	I-Gene
,	O
nitric	B-Chemical
oxide	I-Chemical
and	O
platinum	B-Chemical
ion	O
concentration	O
,	O
and	O
attenuated	O
the	O
reductions	O
of	O
selenium	B-Chemical
and	O
zinc	B-Chemical
ions	O
in	O
renal	O
tissue	O
resulted	O
from	O
cisplatin	B-Chemical
administration	O
.	O
</ALL>	O

<ALL>	O
Also	O
,	O
histopathological	O
renal	B-Disease
tissue	I-Disease
damage	I-Disease
mediated	O
by	O
cisplatin	B-Chemical
was	O
ameliorated	O
by	O
coenzyme	B-Chemical
Q10	I-Chemical
treatment	O
.	O
</ALL>	O

<ALL>	O
Immunohistochemical	O
analysis	O
revealed	O
that	O
coenzyme	B-Chemical
Q10	I-Chemical
significantly	O
decreased	O
the	O
cisplatin	B-Chemical
-	O
induced	O
overexpression	O
of	O
inducible	O
nitric	B-Gene
oxide	I-Gene
synthase	I-Gene
,	O
nuclear	B-Gene
factor	I-Gene
-	I-Gene
kappaB	I-Gene
,	O
caspase	B-Gene
-	I-Gene
3	I-Gene
and	O
p53	B-Gene
in	O
renal	O
tissue	O
.	O
</ALL>	O

<ALL>	O
It	O
was	O
concluded	O
that	O
coenzyme	B-Chemical
Q10	I-Chemical
represents	O
a	O
potential	O
therapeutic	O
option	O
to	O
protect	O
against	O
acute	O
cisplatin	B-Chemical
nephrotoxicity	B-Disease
commonly	O
encountered	O
in	O
clinical	O
practice	O
.	O
</ALL>	O

<ALL>	O
Efficacy	O
and	O
safety	O
of	O
asenapine	B-Chemical
in	O
a	O
placebo	O
-	O
and	O
haloperidol	B-Chemical
-	O
controlled	O
trial	O
in	O
patients	B-Species
with	O
acute	O
exacerbation	O
of	O
schizophrenia	B-Disease
.	O
</ALL>	O

<ALL>	O
Asenapine	B-Chemical
is	O
approved	O
by	O
the	O
Food	O
and	O
Drugs	O
Administration	O
in	O
adults	O
for	O
acute	O
treatment	O
of	O
schizophrenia	B-Disease
or	O
of	O
manic	B-Disease
or	O
mixed	O
episodes	O
associated	O
with	O
bipolar	B-Disease
I	I-Disease
disorder	I-Disease
with	O
or	O
without	O
psychotic	B-Disease
features	O
.	O
</ALL>	O

<ALL>	O
In	O
a	O
double	O
-	O
blind	O
6	O
-	O
week	O
trial	O
,	O
458	O
patients	B-Species
with	O
acute	O
schizophrenia	B-Disease
were	O
randomly	O
assigned	O
to	O
fixed	O
-	O
dose	O
treatment	O
with	O
asenapine	B-Chemical
at	O
5	O
mg	O
twice	O
daily	O
(	O
BID	O
)	O
,	O
asenapine	B-Chemical
at	O
10	O
mg	O
BID	O
,	O
placebo	O
,	O
or	O
haloperidol	B-Chemical
at	O
4	O
mg	O
BID	O
(	O
to	O
verify	O
assay	O
sensitivity	O
)	O
.	O
</ALL>	O

<ALL>	O
With	O
last	O
observations	O
carried	O
forward	O
(	O
LOCF	O
)	O
,	O
mean	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
total	O
score	O
reductions	O
from	O
baseline	O
to	O
endpoint	O
were	O
significantly	O
greater	O
with	O
asenapine	B-Chemical
at	O
5	O
mg	O
BID	O
(	O
-	O
16.2	O
)	O
and	O
haloperidol	B-Chemical
(	O
-	O
15.4	O
)	O
than	O
placebo	O
(	O
-	O
10.7	O
;	O
both	O
P	O
<	O
0.05	O
)	O
;	O
using	O
mixed	O
model	O
for	O
repeated	O
measures	O
(	O
MMRM	O
)	O
,	O
changes	O
at	O
day	O
42	O
were	O
significantly	O
greater	O
with	O
asenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
(	O
-	O
21.3	O
and	O
-	O
19.4	O
,	O
respectively	O
)	O
and	O
haloperidol	B-Chemical
(	O
-	O
20.0	O
)	O
than	O
placebo	O
(	O
-	O
14.6	O
;	O
all	O
P	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
On	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
positive	O
subscale	O
,	O
all	O
treatments	O
were	O
superior	O
to	O
placebo	O
with	O
LOCF	O
and	O
MMRM	O
;	O
asenapine	B-Chemical
at	O
5	O
mg	O
BID	O
was	O
superior	O
to	O
placebo	O
on	O
the	O
negative	O
subscale	O
with	O
MMRM	O
and	O
on	O
the	O
general	O
psychopathology	O
subscale	O
with	O
LOCF	O
and	O
MMRM	O
.	O
</ALL>	O

<ALL>	O
Treatment	O
-	O
related	O
adverse	O
events	O
(	O
AEs	O
)	O
occurred	O
in	O
44	O
%	O
and	O
52	O
%	O
,	O
57	O
%	O
,	O
and	O
41	O
%	O
of	O
the	O
asenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperidol	B-Chemical
,	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
Extrapyramidal	B-Disease
symptoms	I-Disease
reported	O
as	O
AEs	O
occurred	O
in	O
15	O
%	O
and	O
18	O
%	O
,	O
34	O
%	O
,	O
and	O
10	O
%	O
of	O
the	O
asenapine	B-Chemical
at	O
5	O
and	O
10	O
mg	O
BID	O
,	O
haloperidol	B-Chemical
,	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
Across	O
all	O
groups	O
,	O
no	O
more	O
than	O
5	O
%	O
of	O
patients	B-Species
had	O
clinically	O
significant	O
weight	O
change	O
.	O
</ALL>	O

<ALL>	O
Post	O
hoc	O
analyses	O
indicated	O
that	O
efficacy	O
was	O
similar	O
with	O
asenapine	B-Chemical
and	O
haloperidol	B-Chemical
;	O
greater	O
contrasts	O
were	O
seen	O
in	O
AEs	O
,	O
especially	O
extrapyramidal	B-Disease
symptoms	I-Disease
.	O
</ALL>	O

<ALL>	O
Salvage	O
therapy	O
with	O
nelarabine	B-Chemical
,	O
etoposide	B-Chemical
,	O
and	O
cyclophosphamide	B-Chemical
in	O
relapsed	O
/	O
refractory	O
paediatric	O
T	B-Disease
-	I-Disease
cell	I-Disease
lymphoblastic	I-Disease
leukaemia	I-Disease
and	I-Disease
lymphoma	I-Disease
.	O
</ALL>	O

<ALL>	O
A	O
combination	O
of	O
5	O
d	O
of	O
nelarabine	B-Chemical
(	O
AraG	B-Chemical
)	O
with	O
5	O
d	O
of	O
etoposide	B-Chemical
(	O
VP	B-Chemical
)	O
and	O
cyclophosphamide	B-Chemical
(	O
CPM	B-Chemical
)	O
and	O
prophylactic	O
intrathecal	O
chemotherapy	O
was	O
used	O
as	O
salvage	O
therapy	O
in	O
seven	O
children	O
with	O
refractory	O
or	O
relapsed	O
T	B-Disease
-	I-Disease
cell	I-Disease
leukaemia	I-Disease
or	I-Disease
lymphoma	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
most	O
common	O
side	O
effects	O
attributable	O
to	O
the	O
AraG	B-Chemical
included	O
Grade	O
2	O
and	O
3	O
sensory	O
and	O
motor	O
neuropathy	B-Disease
and	O
musculoskeletal	B-Disease
pain	I-Disease
.	O
</ALL>	O

<ALL>	O
Haematological	B-Disease
toxicity	I-Disease
was	O
greater	O
for	O
the	O
combination	O
than	O
AraG	B-Chemical
alone	O
,	O
although	O
median	O
time	O
to	O
neutrophil	O
and	O
platelet	O
recovery	O
was	O
consistent	O
with	O
other	O
salvage	O
therapies	O
.	O
</ALL>	O

<ALL>	O
All	O
patients	B-Species
had	O
some	O
response	O
to	O
the	O
combined	O
therapy	O
and	O
five	O
of	O
the	O
seven	O
went	O
into	O
complete	O
remission	O
after	O
one	O
or	O
two	O
courses	O
of	O
AraG	B-Chemical
/	O
VP	B-Chemical
/	O
CPM	B-Chemical
.	O
</ALL>	O

<ALL>	O
Our	O
experience	O
supports	O
the	O
safety	O
of	O
giving	O
AraG	B-Chemical
as	O
salvage	O
therapy	O
in	O
synchrony	O
with	O
etoposide	B-Chemical
and	O
cyclophosphamide	B-Chemical
,	O
although	O
neurological	B-Disease
toxicity	I-Disease
must	O
be	O
closely	O
monitored	O
.	O
</ALL>	O

<ALL>	O
Dopamine	B-Chemical
is	O
not	O
essential	O
for	O
the	O
development	O
of	O
methamphetamine	B-Chemical
-	O
induced	O
neurotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
It	O
is	O
widely	O
believed	O
that	O
dopamine	B-Chemical
(	O
DA	B-Chemical
)	O
mediates	O
methamphetamine	B-Chemical
(	O
METH	B-Chemical
)	O
-	O
induced	O
toxicity	B-Disease
to	O
brain	O
dopaminergic	O
neurons	O
,	O
because	O
drugs	O
that	O
interfere	O
with	O
DA	B-Chemical
neurotransmission	O
decrease	O
toxicity	B-Disease
,	O
whereas	O
drugs	O
that	O
increase	O
DA	B-Chemical
neurotransmission	O
enhance	O
toxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
temperature	O
effects	O
of	O
drugs	O
that	O
have	O
been	O
used	O
to	O
manipulate	O
brain	O
DA	B-Chemical
neurotransmission	O
confound	O
interpretation	O
of	O
the	O
data	O
.	O
</ALL>	O

<ALL>	O
Here	O
we	O
show	O
that	O
the	O
recently	O
reported	O
ability	O
of	O
L	B-Chemical
-	I-Chemical
dihydroxyphenylalanine	I-Chemical
to	O
reverse	O
the	O
protective	O
effect	O
of	O
alpha	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
para	I-Chemical
-	I-Chemical
tyrosine	I-Chemical
on	O
METH	B-Chemical
-	O
induced	O
DA	B-Chemical
neurotoxicity	B-Disease
is	O
also	O
confounded	O
by	O
drug	O
effects	O
on	O
body	O
temperature	O
.	O
</ALL>	O

<ALL>	O
Further	O
,	O
we	O
show	O
that	O
mice	B-Species
genetically	O
engineered	O
to	O
be	O
deficient	O
in	O
brain	O
DA	B-Chemical
develop	O
METH	B-Chemical
neurotoxicity	B-Disease
,	O
as	O
long	O
as	O
the	O
thermic	O
effects	O
of	O
METH	B-Chemical
are	O
preserved	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
we	O
demonstrate	O
that	O
mice	B-Species
genetically	O
engineered	O
to	O
have	O
unilateral	O
brain	O
DA	B-Chemical
deficits	O
develop	O
METH	B-Chemical
-	O
induced	O
dopaminergic	B-Disease
deficits	I-Disease
that	O
are	O
of	O
comparable	O
magnitude	O
on	O
both	O
sides	O
of	O
the	O
brain	O
.	O
</ALL>	O

<ALL>	O
Taken	O
together	O
,	O
these	O
findings	O
demonstrate	O
that	O
DA	B-Chemical
is	O
not	O
essential	O
for	O
the	O
development	O
of	O
METH	B-Chemical
-	O
induced	O
dopaminergic	O
neurotoxicity	B-Disease
and	O
suggest	O
that	O
mechanisms	O
independent	O
of	O
DA	B-Chemical
warrant	O
more	O
intense	O
investigation	O
.	O
</ALL>	O

<ALL>	O
Glutamatergic	O
neurotransmission	O
mediated	O
by	O
NMDA	B-Gene
receptors	I-Gene
in	O
the	O
inferior	O
colliculus	O
can	O
modulate	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
inferior	O
colliculus	O
(	O
IC	O
)	O
is	O
primarily	O
involved	O
in	O
the	O
processing	O
of	O
auditory	O
information	O
,	O
but	O
it	O
is	O
distinguished	O
from	O
other	O
auditory	O
nuclei	O
in	O
the	O
brainstem	O
by	O
its	O
connections	O
with	O
structures	O
of	O
the	O
motor	O
system	O
.	O
</ALL>	O

<ALL>	O
Functional	O
evidence	O
relating	O
the	O
IC	O
to	O
motor	O
behavior	O
derives	O
from	O
experiments	O
showing	O
that	O
activation	O
of	O
the	O
IC	O
by	O
electrical	O
stimulation	O
or	O
excitatory	O
amino	O
acid	O
microinjection	O
causes	O
freezing	O
,	O
escape	O
-	O
like	O
behavior	O
,	O
and	O
immobility	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
nature	O
of	O
this	O
immobility	O
is	O
still	O
unclear	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
examined	O
the	O
influence	O
of	O
excitatory	O
amino	O
acid	O
-	O
mediated	O
mechanisms	O
in	O
the	O
IC	O
on	O
the	O
catalepsy	B-Disease
induced	O
by	O
the	O
dopamine	B-Gene
receptor	I-Gene
blocker	O
haloperidol	B-Chemical
administered	O
systemically	O
(	O
1	O
or	O
0.5	O
mg	O
/	O
kg	O
)	O
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
was	O
challenged	O
with	O
prior	O
intracollicular	O
microinjections	O
of	O
glutamate	B-Gene
NMDA	I-Gene
receptor	I-Gene
antagonists	O
,	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
(	O
15	O
or	O
30	O
mmol	O
/	O
0.5	O
microl	O
)	O
and	O
AP7	B-Chemical
(	O
10	O
or	O
20	O
nmol	O
/	O
0.5	O
microl	O
)	O
,	O
or	O
of	O
the	O
NMDA	B-Gene
receptor	I-Gene
agonist	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
aspartate	I-Chemical
(	O
NMDA	B-Chemical
,	O
20	O
or	O
30	O
nmol	O
/	O
0.5	O
microl	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
showed	O
that	O
intracollicular	O
microinjection	O
of	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
and	O
AP7	B-Chemical
previous	O
to	O
systemic	O
injections	O
of	O
haloperidol	B-Chemical
significantly	O
attenuated	O
the	O
catalepsy	B-Disease
,	O
as	O
indicated	O
by	O
a	O
reduced	O
latency	O
to	O
step	O
down	O
from	O
a	O
horizontal	O
bar	O
.	O
</ALL>	O

<ALL>	O
Accordingly	O
,	O
intracollicular	O
microinjection	O
of	O
NMDA	B-Chemical
increased	O
the	O
latency	O
to	O
step	O
down	O
the	O
bar	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
suggest	O
that	O
glutamate	B-Chemical
-	O
mediated	O
mechanisms	O
in	O
the	O
neural	O
circuits	O
at	O
the	O
IC	O
level	O
influence	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
and	O
participate	O
in	O
the	O
regulation	O
of	O
motor	O
activity	O
.	O
</ALL>	O

<ALL>	O
Curcumin	B-Chemical
ameliorates	O
cognitive	B-Disease
dysfunction	I-Disease
and	O
oxidative	O
damage	O
in	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
administered	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
antiepileptic	B-Chemical
drugs	I-Chemical
,	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
are	O
well	O
known	O
to	O
cause	O
cognitive	B-Disease
impairment	I-Disease
on	O
chronic	O
use	O
.	O
</ALL>	O

<ALL>	O
The	O
increase	O
in	O
free	O
radical	O
generation	O
has	O
been	O
implicated	O
as	O
one	O
of	O
the	O
important	O
mechanisms	O
of	O
cognitive	B-Disease
impairment	I-Disease
by	O
antiepileptic	B-Chemical
drugs	I-Chemical
.	O
</ALL>	O

<ALL>	O
Curcumin	B-Chemical
has	O
shown	O
antioxidant	B-Chemical
,	O
anti	O
-	O
inflammatory	B-Disease
and	O
neuro	O
-	O
protective	O
properties	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
the	O
present	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
effect	O
of	O
chronic	O
curcumin	B-Chemical
administration	O
on	O
phenobarbitone	B-Chemical
-	O
and	O
carbamazepine	B-Chemical
-	O
induced	O
cognitive	B-Disease
impairment	I-Disease
and	O
oxidative	O
stress	O
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Pharmacokinetic	O
interactions	O
of	O
curcumin	B-Chemical
with	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
were	O
also	O
studied	O
.	O
</ALL>	O

<ALL>	O
Vehicle	O
/	O
drugs	O
were	O
administered	O
daily	O
for	O
21days	O
to	O
male	O
Wistar	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Passive	O
avoidance	O
paradigm	O
and	O
elevated	O
plus	O
maze	O
test	O
were	O
used	O
to	O
assess	O
cognitive	O
function	O
.	O
</ALL>	O

<ALL>	O
At	O
the	O
end	O
of	O
study	O
period	O
,	O
serum	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
,	O
whole	O
brain	O
malondialdehyde	B-Chemical
and	O
reduced	O
glutathione	B-Chemical
levels	O
were	O
estimated	O
.	O
</ALL>	O

<ALL>	O
The	O
administration	O
of	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
for	O
21days	O
caused	O
a	O
significant	O
impairment	B-Disease
of	I-Disease
learning	I-Disease
and	I-Disease
memory	I-Disease
as	O
well	O
as	O
an	O
increased	O
oxidative	O
stress	O
.	O
</ALL>	O

<ALL>	O
Concomitant	O
curcumin	B-Chemical
administration	O
prevented	O
the	O
cognitive	B-Disease
impairment	I-Disease
and	O
decreased	O
the	O
increased	O
oxidative	O
stress	O
induced	O
by	O
these	O
antiepileptic	B-Chemical
drugs	I-Chemical
.	O
</ALL>	O

<ALL>	O
Curcumin	B-Chemical
co	O
-	O
administration	O
did	O
not	O
cause	O
any	O
significant	O
alteration	O
in	O
the	O
serum	O
concentrations	O
of	O
both	O
phenobarbitone	B-Chemical
as	O
well	O
as	O
carbamazepine	B-Chemical
.	O
</ALL>	O

<ALL>	O
These	O
results	O
show	O
that	O
curcumin	B-Chemical
has	O
beneficial	O
effect	O
in	O
mitigating	O
the	O
deterioration	B-Disease
of	I-Disease
cognitive	I-Disease
functions	I-Disease
and	O
oxidative	O
damage	O
in	O
rats	B-Species
treated	O
with	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
without	O
significantly	O
altering	O
their	O
serum	O
concentrations	O
.	O
</ALL>	O

<ALL>	O
The	O
findings	O
suggest	O
that	O
curcumin	B-Chemical
can	O
be	O
considered	O
as	O
a	O
potential	O
safe	O
and	O
effective	O
adjuvant	O
to	O
phenobarbitone	B-Chemical
and	O
carbamazepine	B-Chemical
therapy	O
in	O
preventing	O
cognitive	B-Disease
impairment	I-Disease
associated	O
with	O
these	O
drugs	O
.	O
</ALL>	O

<ALL>	O
Effects	O
of	O
active	O
constituents	B-Chemical
of	I-Chemical
Crocus	I-Chemical
sativus	I-Chemical
L.	I-Chemical
,	O
crocin	B-Chemical
on	O
streptozocin	B-Chemical
-	O
induced	O
model	O
of	O
sporadic	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
in	O
male	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
The	O
involvement	O
of	O
water	O
-	O
soluble	O
carotenoids	B-Chemical
,	O
crocins	B-Chemical
,	O
as	O
the	O
main	O
and	O
active	O
components	O
of	O
Crocus	B-Chemical
sativus	I-Chemical
L.	I-Chemical
extract	I-Chemical
in	O
learning	O
and	O
memory	O
processes	O
has	O
been	O
proposed	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
crocins	B-Chemical
on	O
sporadic	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
induced	O
by	O
intracerebroventricular	O
(	O
icv	O
)	O
streptozocin	B-Chemical
(	O
STZ	B-Chemical
)	O
in	O
male	O
rats	B-Species
was	O
investigated	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Male	O
adult	O
Wistar	O
rats	B-Species
(	O
n	O
=	O
90	O
and	O
260	O
-	O
290	O
g	O
)	O
were	O
divided	O
into	O
1	O
,	O
control	O
;	O
2	O
and	O
3	O
,	O
crocins	B-Chemical
(	O
15	O
and	O
30	O
mg	O
/	O
kg	O
)	O
;	O
4	O
,	O
STZ	B-Chemical
;	O
5	O
and	O
6	O
,	O
STZ	B-Chemical
+	O
crocins	B-Chemical
(	O
15	O
and	O
30	O
mg	O
/	O
kg	O
)	O
groups	O
.	O
</ALL>	O

<ALL>	O
In	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
groups	O
,	O
rats	B-Species
were	O
injected	O
with	O
STZ	B-Chemical
-	O
icv	O
bilaterally	O
(	O
3	O
mg	O
/	O
kg	O
)	O
in	O
first	O
day	O
and	O
3	O
days	O
later	O
,	O
a	O
similar	O
STZ	B-Chemical
-	O
icv	O
application	O
was	O
repeated	O
.	O
</ALL>	O

<ALL>	O
In	O
STZ	B-Chemical
+	O
crocin	B-Chemical
animal	O
groups	O
,	O
crocin	B-Chemical
was	O
applied	O
in	O
doses	O
of	O
15	O
and	O
30	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
,	O
</ALL>	O

<ALL>	O
one	O
day	O
pre	O
-	O
surgery	O
and	O
continued	O
for	O
three	O
weeks	O
.	O
</ALL>	O

<ALL>	O
Prescription	O
of	O
crocin	B-Chemical
in	O
each	O
dose	O
was	O
repeated	O
once	O
for	O
two	O
days	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
learning	O
and	O
memory	O
performance	O
was	O
assessed	O
using	O
passive	O
avoidance	O
paradigm	O
,	O
and	O
for	O
spatial	O
cognition	O
evaluation	O
,	O
Y	O
-	O
maze	O
task	O
was	O
used	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
It	O
was	O
found	O
out	O
that	O
crocin	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
)	O
-	O
treated	O
STZ	B-Chemical
-	O
injected	O
rats	B-Species
show	O
higher	O
correct	O
choices	O
and	O
lower	O
errors	O
in	O
Y	O
-	O
maze	O
than	O
vehicle	O
-	O
treated	O
STZ	B-Chemical
-	O
injected	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
crocin	B-Chemical
in	O
the	O
mentioned	O
dose	O
could	O
significantly	O
attenuated	O
learning	B-Disease
and	I-Disease
memory	I-Disease
impairment	I-Disease
in	O
treated	O
STZ	B-Chemical
-	O
injected	O
group	O
in	O
passive	O
avoidance	O
test	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Therefore	O
,	O
these	O
results	O
demonstrate	O
the	O
effectiveness	O
of	O
crocin	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
)	O
in	O
antagonizing	O
the	O
cognitive	B-Disease
deficits	I-Disease
caused	O
by	O
STZ	B-Chemical
-	O
icv	O
in	O
rats	B-Species
and	O
its	O
potential	O
in	O
the	O
treatment	O
of	O
neurodegenerative	B-Disease
diseases	I-Disease
such	O
as	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
role	O
of	O
nitric	B-Chemical
oxide	I-Chemical
in	O
convulsions	B-Disease
induced	O
by	O
lindane	B-Chemical
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Lindane	B-Chemical
is	O
an	O
organochloride	B-Chemical
pesticide	B-Chemical
and	O
scabicide	B-Chemical
.	O
</ALL>	O

<ALL>	O
It	O
evokes	O
convulsions	B-Disease
mainly	O
trough	O
the	O
blockage	O
of	O
GABA	B-Gene
(	I-Gene
A	I-Gene
)	I-Gene
receptors	I-Gene
.	O
</ALL>	O

<ALL>	O
Nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)	O
,	O
gaseous	O
neurotransmitter	O
,	O
has	O
contradictor	O
role	O
in	O
epileptogenesis	O
due	O
to	O
opposite	O
effects	O
of	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
,	O
precursor	O
of	O
NO	B-Gene
syntheses	I-Gene
(	O
NOS	B-Gene
)	O
,	O
and	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
(	O
NOS	B-Gene
inhibitor	O
)	O
observed	O
in	O
different	O
epilepsy	B-Disease
models	O
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
NO	B-Chemical
on	O
the	O
behavioral	O
and	O
EEG	O
characteristics	O
of	O
lindane	B-Chemical
-	O
induced	O
epilepsy	B-Disease
in	O
male	O
Wistar	O
albino	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
administration	O
of	O
L	B-Chemical
-	I-Chemical
arginine	I-Chemical
(	O
600	O
,	O
800	O
and	O
1000	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
</ALL>	O

<ALL>	O
in	O
dose	O
-	O
dependent	O
manner	O
significantly	O
increased	O
convulsion	B-Disease
incidence	O
and	O
severity	O
and	O
shortened	O
latency	O
time	O
to	O
first	O
convulsion	B-Disease
elicited	O
by	O
lower	O
lindane	B-Chemical
dose	O
(	O
4	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
.	O
</ALL>	O

<ALL>	O
On	O
the	O
contrary	O
,	O
pretreatment	O
with	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
(	O
500	O
,	O
700	O
and	O
900	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
</ALL>	O

<ALL>	O
decreased	O
convulsion	B-Disease
incidence	O
and	O
severity	O
and	O
prolonged	O
latency	O
time	O
to	O
convulsion	B-Disease
following	O
injection	O
with	O
a	O
convulsive	B-Disease
dose	O
of	O
lindane	B-Chemical
(	O
8	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
.	O
</ALL>	O

<ALL>	O
EEG	O
analyses	O
showed	O
increase	O
of	O
number	O
and	O
duration	O
of	O
ictal	O
periods	O
in	O
EEG	O
of	O
rats	B-Species
receiving	O
l	B-Chemical
-	I-Chemical
arginine	I-Chemical
prior	O
to	O
lindane	B-Chemical
and	O
decrease	O
of	O
this	O
number	O
in	O
rats	B-Species
pretreated	O
with	O
L	B-Chemical
-	I-Chemical
NAME	I-Chemical
.	O
</ALL>	O

<ALL>	O
These	O
results	O
support	O
the	O
conclusion	O
that	O
NO	B-Chemical
plays	O
a	O
role	O
of	O
endogenous	O
convulsant	B-Disease
in	O
rat	B-Species
model	O
of	O
lindane	B-Chemical
seizures	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
cytogenetic	O
action	O
of	O
ifosfamide	B-Chemical
,	O
mesna	B-Chemical
,	O
and	O
their	O
combination	O
on	O
peripheral	O
rabbit	B-Species
lymphocytes	O
:	O
an	O
in	O
vivo	O
/	O
in	O
vitro	O
cytogenetic	O
study	O
.	O
</ALL>	O

<ALL>	O
Ifosfamide	B-Chemical
(	O
IFO	B-Chemical
)	O
is	O
an	O
alkylating	B-Chemical
nitrogen	I-Chemical
mustard	I-Chemical
,	O
administrated	O
as	O
an	O
antineoplasmic	O
agent	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
characterized	O
by	O
its	O
intense	O
urotoxic	O
action	O
,	O
leading	O
to	O
hemorrhagic	B-Disease
cystitis	B-Disease
.	O
</ALL>	O

<ALL>	O
This	O
side	O
effect	O
of	O
IFO	B-Chemical
raises	O
the	O
requirement	O
for	O
the	O
co	O
-	O
administration	O
with	O
sodium	B-Chemical
2	I-Chemical
-	I-Chemical
sulfanylethanesulfonate	I-Chemical
(	O
Mesna	B-Chemical
)	O
aiming	O
to	O
avoid	O
or	O
minimize	O
this	O
effect	O
.	O
</ALL>	O

<ALL>	O
IFO	B-Chemical
and	O
Mesna	B-Chemical
were	O
administrated	O
separately	O
on	O
rabbit	B-Species
's	O
lymphocytes	O
in	O
vivo	O
,	O
which	O
were	O
later	O
developed	O
in	O
vitro	O
.	O
</ALL>	O

<ALL>	O
Cytogenetic	O
markers	O
for	O
sister	O
chromatid	O
exchanges	O
(	O
SCEs	O
)	O
,	O
proliferation	O
rate	O
index	O
(	O
PRI	O
)	O
and	O
Mitotic	O
Index	O
were	O
recorded	O
.	O
</ALL>	O

<ALL>	O
Mesna	B-Chemical
's	O
action	O
,	O
in	O
conjunction	O
with	O
IFO	B-Chemical
reduces	O
the	O
frequency	O
of	O
SCEs	O
,	O
in	O
comparison	O
with	O
the	O
SCEs	O
recordings	O
obtained	O
when	O
IFO	B-Chemical
is	O
administered	O
alone	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
to	O
this	O
,	O
when	O
high	O
concentrations	O
of	O
Mesna	B-Chemical
were	O
administered	O
alone	O
significant	O
reductions	O
of	O
the	O
PRI	O
were	O
noted	O
,	O
than	O
with	O
IFO	B-Chemical
acting	O
at	O
the	O
same	O
concentration	O
on	O
the	O
lymphocytes	O
.	O
</ALL>	O

<ALL>	O
Mesna	B-Chemical
significantly	O
reduces	O
IFO	B-Chemical
's	O
genotoxicity	B-Disease
,	O
while	O
when	O
administered	O
in	O
high	O
concentrations	O
it	O
acts	O
in	O
an	O
inhibitory	O
fashion	O
on	O
the	O
cytostatic	O
action	O
of	O
the	O
drug	O
.	O
</ALL>	O

<ALL>	O
Crocin	B-Chemical
improves	O
lipid	B-Chemical
dysregulation	O
in	O
subacute	O
diazinon	B-Chemical
exposure	O
through	O
ERK1	B-Gene
/	I-Gene
2	I-Gene
pathway	O
in	O
rat	B-Species
liver	O
.	O
</ALL>	O

<ALL>	O
INTRODUCTION	O
:	O
Diazinon	B-Chemical
Yis	O
one	O
of	O
the	O
most	O
broadly	O
used	O
organophosphorus	B-Chemical
insecticides	O
in	O
agriculture	O
.	O
</ALL>	O

<ALL>	O
It	O
has	O
been	O
shown	O
that	O
exposure	O
to	O
diazinon	B-Chemical
may	O
interfere	O
with	O
lipid	B-Chemical
metabolism	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
the	O
hypolipidemic	O
effect	O
of	O
crocin	B-Chemical
has	O
been	O
established	O
.	O
</ALL>	O

<ALL>	O
Earlier	O
studies	O
revealed	O
the	O
major	O
role	O
of	O
Extracellular	B-Gene
signal	I-Gene
-	I-Gene
regulated	I-Gene
kinase	I-Gene
(	O
ERK	B-Gene
)	O
pathways	O
in	O
low	B-Gene
-	I-Gene
density	I-Gene
lipoprotein	I-Gene
receptor	I-Gene
(	O
LDLr	B-Gene
)	O
expression	O
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
changes	O
in	O
the	O
regulation	O
of	O
lipid	B-Chemical
metabolism	O
,	O
ERK	B-Gene
and	O
LDLr	B-Gene
expression	O
in	O
the	O
liver	O
of	O
rats	B-Species
exposed	O
to	O
subacute	O
diazinon	B-Chemical
.	O
</ALL>	O

<ALL>	O
Furthermore	O
ameliorating	O
effect	O
of	O
crocin	B-Chemical
on	O
diazinon	B-Chemical
induced	O
disturbed	O
cholesterol	B-Chemical
homeostasis	O
was	O
studied	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
24	O
Rats	B-Species
were	O
divided	O
into	O
4	O
groups	O
and	O
received	O
following	O
treatments	O
for	O
4	O
weeks	O
;	O
Corn	B-Chemical
oil	I-Chemical
(	O
control	O
)	O
,	O
diazinon	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
per	O
day	O
,	O
orally	O
)	O
and	O
crocin	B-Chemical
(	O
12.5	O
and	O
25	O
mg	O
/	O
kg	O
per	O
day	O
,	O
intraperitoneally	O
)	O
in	O
combination	O
with	O
diazinon	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
levels	O
of	O
cholesterol	B-Chemical
,	O
triglyceride	B-Chemical
and	O
LDL	B-Chemical
in	O
blood	O
of	O
rats	B-Species
were	O
analyzed	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
mRNA	O
levels	O
of	O
LDLr	B-Gene
and	O
ERK1	B-Gene
/	I-Gene
2	I-Gene
as	O
well	O
as	O
protein	O
levels	O
of	O
total	O
and	O
activated	O
forms	O
of	O
ERK1	B-Gene
/	I-Gene
2	I-Gene
in	O
rat	B-Species
liver	O
were	O
evaluated	O
by	O
Western	O
blotting	O
and	O
quantitative	O
real	O
time	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Our	O
data	O
showed	O
that	O
subacute	O
exposure	O
to	O
diazinon	B-Chemical
significantly	O
increased	O
concentrations	O
of	O
cholesterol	B-Chemical
,	O
triglyceride	B-Chemical
and	O
LDL	B-Chemical
.	O
</ALL>	O

<ALL>	O
Moreover	O
diazinon	B-Chemical
decreased	O
ERK1	B-Gene
/	I-Gene
2	I-Gene
protein	O
phosphorylation	O
and	O
LDLr	B-Gene
transcript	O
.	O
</ALL>	O

<ALL>	O
Crocin	B-Chemical
reduced	O
inhibition	O
of	O
ERK	B-Gene
activation	O
and	O
diazinon	B-Chemical
-	O
induced	O
hyperlipemia	B-Disease
and	O
increased	O
levels	O
of	O
LDLr	B-Gene
transcript	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Crocin	B-Chemical
may	O
be	O
considered	O
as	O
a	O
novel	O
protective	O
agent	O
in	O
diazinon	B-Chemical
-	O
induced	O
hyperlipemia	B-Disease
through	O
modulating	O
of	O
ERK	B-Gene
pathway	O
and	O
increase	O
of	O
LDLr	B-Gene
expression	O
.	O
</ALL>	O

<ALL>	O
Cholecystokinin	B-Chemical
-	I-Chemical
octapeptide	I-Chemical
restored	O
morphine	B-Chemical
-	O
induced	O
hippocampal	O
long	O
-	O
term	O
potentiation	O
impairment	O
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Cholecystokinin	B-Chemical
-	I-Chemical
octapeptide	I-Chemical
(	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
)	O
,	O
which	O
is	O
a	O
typical	O
brain	O
-	O
gut	O
peptide	O
,	O
exerts	O
a	O
wide	O
range	O
of	O
biological	O
activities	O
on	O
the	O
central	O
nervous	O
system	O
.	O
</ALL>	O

<ALL>	O
We	O
have	O
previously	O
reported	O
that	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
significantly	O
alleviated	O
morphine	B-Chemical
-	O
induced	O
amnesia	B-Disease
and	O
reversed	O
spine	O
density	O
decreases	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
in	O
morphine	B-Chemical
-	O
treated	O
animals	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
on	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
in	O
the	O
lateral	O
perforant	O
path	O
(	O
LPP	O
)	O
-	O
granule	O
cell	O
synapse	O
of	O
rat	B-Species
dentate	O
gyrus	O
(	O
DG	O
)	O
in	O
acute	O
saline	O
or	O
morphine	B-Chemical
-	O
treated	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Population	O
spikes	O
(	O
PS	O
)	O
,	O
which	O
were	O
evoked	O
by	O
stimulation	O
of	O
the	O
LPP	O
,	O
were	O
recorded	O
in	O
the	O
DG	O
region	O
.	O
</ALL>	O

<ALL>	O
Acute	O
morphine	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
,	O
s.c	O
.	O
)	O
</ALL>	O

<ALL>	O
treatment	O
significantly	O
attenuated	O
hippocampal	O
LTP	O
and	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
(	O
1ug	O
,	O
i.c.v	O
.	O
)	O
</ALL>	O

<ALL>	O
restored	O
the	O
amplitude	O
of	O
PS	O
that	O
was	O
attenuated	O
by	O
morphine	B-Chemical
injection	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
microinjection	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
(	O
0.1	O
and	O
1ug	O
,	O
i.c.v	O
.	O
)	O
</ALL>	O

<ALL>	O
also	O
significantly	O
augmented	O
hippocampal	O
LTP	O
in	O
saline	O
-	O
treated	O
(	O
1ml	O
/	O
kg	O
,	O
s.c	O
.	O
)	O
</ALL>	O

<ALL>	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Pre	O
-	O
treatment	O
of	O
the	O
CCK2	B-Gene
receptor	I-Gene
antagonist	O
L	B-Chemical
-	I-Chemical
365,260	I-Chemical
(	O
10ug	O
,	O
i.c.v	O
)	O
reversed	O
the	O
effects	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
,	O
but	O
the	O
CCK1	B-Gene
receptor	I-Gene
antagonist	O
L	B-Chemical
-	I-Chemical
364,718	I-Chemical
(	O
10ug	O
,	O
i.c.v	O
)	O
did	O
not	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
results	O
demonstrate	O
that	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
attenuates	O
the	O
effect	O
of	O
morphine	B-Chemical
on	O
hippocampal	O
LTP	O
through	O
CCK2	B-Gene
receptors	I-Gene
and	O
suggest	O
an	O
ameliorative	O
function	O
of	O
CCK	B-Chemical
-	I-Chemical
8	I-Chemical
on	O
morphine	B-Chemical
-	O
induced	O
memory	B-Disease
impairment	I-Disease
.	O
</ALL>	O

<ALL>	O
Comparison	O
of	O
effects	O
of	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
with	O
diltiazem	B-Chemical
in	O
prevention	O
of	O
contrast	B-Chemical
-	O
induced	O
nephropathy	B-Disease
.	O
</ALL>	O

<ALL>	O
INTRODUCTION	O
AND	O
OBJECTIVE	O
:	O
Contrast	B-Chemical
-	O
induced	O
nephropathy	B-Disease
(	O
CIN	B-Disease
)	O
significantly	O
increases	O
the	O
morbidity	O
and	O
mortality	O
of	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
and	O
compare	O
the	O
protective	O
effects	O
of	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
with	O
sodium	B-Chemical
bicarbonate	I-Chemical
infusion	O
and	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
infusion	O
with	O
diltiazem	B-Chemical
,	O
a	O
calcium	B-Chemical
channel	O
blocker	O
,	O
in	O
preventing	O
CIN	B-Disease
.	O
</ALL>	O

<ALL>	O
MATERIALS	O
AND	O
METHODS	O
:	O
Our	O
study	O
included	O
patients	B-Species
who	O
were	O
administered	O
30	O
-	O
60	O
mL	O
of	O
iodinated	O
contrast	B-Chemical
agent	O
for	O
percutaneous	O
coronary	O
angiography	O
(	O
PCAG	O
)	O
,	O
all	O
with	O
creatinine	B-Chemical
values	O
between	O
1.1	O
and	O
3.1	O
mg	O
/	O
dL.	O
Patients	B-Species
were	O
divided	O
into	O
three	O
groups	O
and	O
each	O
group	O
had	O
20	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
first	O
group	O
of	O
patients	B-Species
was	O
administered	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
;	O
the	O
second	O
group	O
was	O
administered	O
a	O
solution	O
that	O
of	O
5	O
%	O
dextrose	B-Chemical
and	O
sodium	B-Chemical
bicarbonate	I-Chemical
,	O
while	O
the	O
third	O
group	O
was	O
administered	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
before	O
and	O
after	O
the	O
contrast	B-Chemical
injection	O
.	O
</ALL>	O

<ALL>	O
The	O
third	O
group	O
received	O
an	O
additional	O
injection	O
of	O
diltiazem	B-Chemical
the	O
day	O
before	O
and	O
first	O
2	O
days	O
after	O
the	O
contrast	B-Chemical
injection	O
.	O
</ALL>	O

<ALL>	O
All	O
of	O
the	O
patients	B-Species
'	O
plasma	O
blood	B-Chemical
urea	I-Chemical
nitrogen	I-Chemical
(	O
BUN	B-Chemical
)	O
and	O
creatinine	B-Chemical
levels	O
were	O
measured	O
on	O
the	O
second	O
and	O
seventh	O
day	O
after	O
the	O
administration	O
of	O
intravenous	O
contrast	B-Chemical
material	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
basal	O
creatinine	B-Chemical
levels	O
were	O
similar	O
for	O
all	O
three	O
groups	O
(	O
p	O
>	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
Among	O
a	O
total	O
of	O
60	O
patients	B-Species
included	O
in	O
the	O
study	O
,	O
16	O
patients	B-Species
developed	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
(	O
ARF	B-Disease
)	O
on	O
the	O
second	O
day	O
after	O
contrast	B-Chemical
material	O
was	O
injected	O
(	O
26.6	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
number	O
of	O
patients	B-Species
who	O
developed	O
ARF	B-Disease
on	O
the	O
second	O
day	O
after	O
the	O
injection	O
in	O
the	O
first	O
group	O
was	O
five	O
(	O
25	O
%	O
)	O
,	O
in	O
the	O
second	O
group	O
was	O
six	O
(	O
30	O
%	O
)	O
and	O
the	O
third	O
group	O
was	O
five	O
(	O
25	O
%	O
)	O
(	O
p	O
>	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
,	O
sodium	B-Chemical
bicarbonate	I-Chemical
and	O
isotonic	O
sodium	B-Chemical
chloride	I-Chemical
with	O
diltiazem	B-Chemical
application	O
in	O
prevention	O
of	O
CIN	B-Disease
.	O
</ALL>	O

<ALL>	O
Prevention	O
of	O
etomidate	B-Chemical
-	O
induced	O
myoclonus	B-Disease
:	O
which	O
is	O
superior	O
:	O
Fentanyl	B-Chemical
,	O
midazolam	B-Chemical
,	O
or	O
a	O
combination	O
?	O
</ALL>	O

<ALL>	O
A	O
Retrospective	O
comparative	O
study	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
In	O
this	O
retrospective	O
comparative	O
study	O
,	O
we	O
aimed	O
to	O
compare	O
the	O
effectiveness	O
of	O
fentanyl	B-Chemical
,	O
midazolam	B-Chemical
,	O
and	O
a	O
combination	O
of	O
fentanyl	B-Chemical
and	O
midazolam	B-Chemical
to	O
prevent	O
etomidate	B-Chemical
-	O
induced	O
myoclonus	B-Disease
.	O
</ALL>	O

<ALL>	O
MATERIAL	O
AND	O
METHODS	O
:	O
This	O
study	O
was	O
performed	O
based	O
on	O
anesthesia	O
records	O
.	O
</ALL>	O

<ALL>	O
Depending	O
on	O
the	O
drugs	O
that	O
would	O
be	O
given	O
before	O
the	O
induction	O
of	O
anesthesia	O
with	O
etomidate	B-Chemical
,	O
the	O
patients	B-Species
were	O
separated	O
into	O
4	O
groups	O
:	O
no	O
pretreatment	O
(	O
Group	O
NP	O
)	O
,	O
fentanyl	B-Chemical
1	O
ug.kg	O
-	O
1	O
(	O
Group	O
F	O
)	O
,	O
midazolam	B-Chemical
0.03	O
mg.kg	O
-	O
1	O
(	O
Group	O
M	O
)	O
,	O
and	O
midazolam	B-Chemical
0.015	O
mg.kg	O
-	O
1	O
+	O
fentanyl	B-Chemical
0.5	O
ug.kg	O
-	O
1	O
(	O
Group	O
FM	O
)	O
.	O
</ALL>	O

<ALL>	O
Patients	B-Species
who	O
received	O
the	O
same	O
anesthetic	O
procedure	O
were	O
selected	O
:	O
2	O
minutes	O
after	O
intravenous	O
injections	O
of	O
the	O
pretreatment	O
drugs	O
,	O
anesthesia	O
is	O
induced	O
with	O
0.3	O
mg.kg	O
-	O
1	O
etomidate	B-Chemical
injected	O
intravenously	O
over	O
a	O
period	O
of	O
20	O
-	O
30	O
seconds	O
.	O
</ALL>	O

<ALL>	O
Myoclonic	B-Disease
movements	I-Disease
are	O
evaluated	O
,	O
which	O
were	O
observed	O
and	O
graded	O
according	O
to	O
clinical	O
severity	O
during	O
the	O
2	O
minutes	O
after	O
etomidate	B-Chemical
injection	O
.	O
</ALL>	O

<ALL>	O
The	O
severity	O
of	O
pain	B-Disease
due	O
to	O
etomidate	B-Chemical
injection	O
,	O
mean	O
arterial	O
pressure	O
,	O
heart	O
rate	O
,	O
and	O
adverse	O
effects	O
were	O
also	O
evaluated	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Study	O
results	O
showed	O
that	O
myoclonus	B-Disease
incidence	O
was	O
85	O
%	O
,	O
40	O
%	O
,	O
70	O
%	O
,	O
and	O
25	O
%	O
in	O
Group	O
NP	O
,	O
Group	O
F	O
,	O
Group	O
M	O
,	O
and	O
Group	O
FM	O
,	O
respectively	O
,	O
and	O
were	O
significantly	O
lower	O
in	O
Group	O
F	O
and	O
Group	O
FM	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
pretreatment	O
with	O
fentanyl	B-Chemical
or	O
combination	O
of	O
fentanyl	B-Chemical
and	O
midazolam	B-Chemical
was	O
effective	O
in	O
preventing	O
etomidate	B-Chemical
-	O
induced	O
myoclonus	B-Disease
.	O
</ALL>	O

<ALL>	O
Testosterone	B-Chemical
ameliorates	O
streptozotocin	B-Chemical
-	O
induced	O
memory	B-Disease
impairment	I-Disease
in	O
male	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
AIM	O
:	O
To	O
study	O
the	O
effects	O
of	O
testosterone	B-Chemical
on	O
streptozotocin	B-Chemical
(	O
STZ	B-Chemical
)	O
-	O
induced	O
memory	B-Disease
impairment	I-Disease
in	O
male	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Adult	O
male	O
Wistar	O
rats	B-Species
were	O
intracerebroventricularly	O
(	O
icv	O
)	O
infused	O
with	O
STZ	B-Chemical
(	O
750	O
ug	O
)	O
on	O
d	O
1	O
and	O
d	O
3	O
,	O
and	O
a	O
passive	O
avoidance	O
task	O
was	O
assessed	O
2	O
weeks	O
after	O
the	O
first	O
injection	O
of	O
STZ	B-Chemical
.	O
</ALL>	O

<ALL>	O
Castration	O
surgery	O
was	O
performed	O
in	O
another	O
group	O
of	O
rats	B-Species
,	O
and	O
the	O
passive	O
avoidance	O
task	O
was	O
assessed	O
4	O
weeks	O
after	O
the	O
operation	O
.	O
</ALL>	O

<ALL>	O
Testosterone	B-Chemical
(	O
1	O
mg.kg	O
(	O
-	O
1	O
)	O
.d	O
(	O
-	O
1	O
)	O
,	O
sc	O
)	O
,	O
the	O
androgen	B-Gene
receptor	I-Gene
antagonist	O
flutamide	B-Chemical
(	O
10	O
mg.kg	O
(	O
-	O
1	O
)	O
.d	O
(	O
-	O
1	O
)	O
,	O
ip	O
)	O
,	O
the	O
estrogen	B-Gene
receptor	I-Gene
antagonist	O
tamoxifen	B-Chemical
(	O
1	O
mg.kg	O
(	O
-	O
1	O
)	O
.d	O
(	O
-	O
1	O
)	O
,	O
ip	O
)	O
or	O
the	O
aromatase	B-Gene
inhibitor	O
letrozole	B-Chemical
(	O
4	O
mg.kg	O
(	O
-	O
1	O
)	O
.d	O
(	O
-	O
1	O
)	O
,	O
ip	O
)	O
were	O
administered	O
for	O
6	O
d	O
after	O
the	O
first	O
injection	O
of	O
STZ	B-Chemical
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
STZ	B-Chemical
administration	O
and	O
castration	O
markedly	O
decreased	O
both	O
STL1	B-Gene
(	O
the	O
short	O
memory	O
)	O
and	O
STL2	B-Gene
(	O
the	O
long	O
memory	O
)	O
in	O
passive	O
avoidance	O
tests	O
.	O
</ALL>	O

<ALL>	O
Testosterone	B-Chemical
replacement	O
almost	O
restored	O
the	O
STL1	B-Gene
and	O
STL2	B-Gene
in	O
castrated	O
rats	B-Species
,	O
and	O
significantly	O
prolonged	O
the	O
STL1	B-Gene
and	O
STL2	B-Gene
in	O
STZ	B-Chemical
-	O
treated	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Administration	O
of	O
flutamide	B-Chemical
,	O
letrozole	B-Chemical
or	O
tamoxifen	B-Chemical
significantly	O
impaired	O
the	O
memory	O
in	O
intact	O
rats	B-Species
,	O
and	O
significantly	O
attenuated	O
the	O
testosterone	B-Chemical
replacement	O
in	O
improving	O
STZ	B-Chemical
-	O
and	O
castration	O
-	O
induced	O
memory	B-Disease
impairment	I-Disease
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Testosterone	B-Chemical
administration	O
ameliorates	O
STZ	B-Chemical
-	O
and	O
castration	O
-	O
induced	O
memory	B-Disease
impairment	I-Disease
in	O
male	O
Wistar	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Rhabdomyolysis	B-Disease
in	O
a	O
hepatitis	B-Disease
C	I-Disease
virus	I-Disease
infected	I-Disease
patient	B-Species
treated	O
with	O
telaprevir	B-Chemical
and	O
simvastatin	B-Chemical
.	O
</ALL>	O

<ALL>	O
A	O
46	O
-	O
year	O
old	O
man	B-Species
with	O
a	O
chronic	O
hepatitis	B-Disease
C	I-Disease
virus	I-Disease
infection	I-Disease
received	O
triple	O
therapy	O
with	O
ribavirin	B-Chemical
,	O
pegylated	B-Chemical
interferon	I-Chemical
and	O
telaprevir	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
also	O
received	O
simvastatin	B-Chemical
.	O
</ALL>	O

<ALL>	O
One	O
month	O
after	O
starting	O
the	O
antiviral	O
therapy	O
,	O
the	O
patient	B-Species
was	O
admitted	O
to	O
the	O
hospital	O
because	O
he	O
developed	O
rhabdomyolysis	B-Disease
.	O
</ALL>	O

<ALL>	O
At	O
admission	O
simvastatin	B-Chemical
and	O
all	O
antiviral	B-Chemical
drugs	I-Chemical
were	O
discontinued	O
because	O
toxicity	B-Disease
due	O
to	O
a	O
drug	O
-	O
drug	O
interaction	O
was	O
suspected	O
.	O
</ALL>	O

<ALL>	O
The	O
creatine	B-Chemical
kinase	I-Chemical
peaked	O
at	O
62,246	O
IU	O
/	O
L	O
and	O
the	O
patient	B-Species
was	O
treated	O
with	O
intravenous	O
normal	O
saline	O
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
's	O
renal	O
function	O
remained	O
unaffected	O
.	O
</ALL>	O

<ALL>	O
Fourteen	O
days	O
after	O
hospitalization	O
,	O
creatine	B-Chemical
kinase	I-Chemical
level	O
had	O
returned	O
to	O
230	O
IU	O
/	O
L	O
and	O
the	O
patient	B-Species
was	O
discharged	O
.	O
</ALL>	O

<ALL>	O
Telaprevir	B-Chemical
was	O
considered	O
the	O
probable	O
causative	O
agent	O
of	O
an	O
interaction	O
with	O
simvastatin	B-Chemical
according	O
to	O
the	O
Drug	O
Interaction	O
Probability	O
Scale	O
.	O
</ALL>	O

<ALL>	O
The	O
interaction	O
is	O
due	O
to	O
inhibition	O
of	O
CYP3A4	B-Gene
-	O
mediated	O
simvastatin	B-Chemical
clearance	O
.	O
</ALL>	O

<ALL>	O
Simvastatin	B-Chemical
plasma	O
concentration	O
increased	O
30	O
times	O
in	O
this	O
patient	B-Species
and	O
statin	B-Chemical
induced	O
muscle	B-Disease
toxicity	I-Disease
is	O
related	O
to	O
the	O
concentration	O
of	O
the	O
statin	B-Chemical
in	O
blood	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
with	O
this	O
case	O
we	O
illustrate	O
that	O
telaprevir	B-Chemical
as	O
well	O
as	O
statins	B-Chemical
are	O
susceptible	O
to	O
clinical	O
relevant	O
drug	O
-	O
drug	O
interactions	O
.	O
</ALL>	O

<ALL>	O
Congenital	B-Disease
hypothyroidism	I-Disease
due	O
to	O
a	O
new	O
deletion	O
in	O
the	O
sodium	B-Gene
/	I-Gene
iodide	I-Gene
symporter	I-Gene
protein	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
Iodide	B-Disease
transport	I-Disease
defect	I-Disease
(	O
ITD	B-Disease
)	O
is	O
a	O
rare	O
disorder	O
characterised	O
by	O
an	O
inability	B-Disease
of	I-Disease
the	I-Disease
thyroid	I-Disease
to	O
maintain	O
an	O
iodide	B-Chemical
gradient	O
across	O
the	O
basolateral	O
membrane	O
of	O
thyroid	O
follicular	O
cells	O
,	O
that	O
often	O
results	O
in	O
congenital	B-Disease
hypothyroidism	I-Disease
.	O
</ALL>	O

<ALL>	O
When	O
present	O
the	O
defect	O
is	O
also	O
found	O
in	O
the	O
salivary	O
glands	O
and	O
gastric	O
mucosa	O
and	O
it	O
has	O
been	O
shown	O
to	O
arise	O
from	O
abnormalities	O
of	O
the	O
sodium	B-Gene
/	I-Gene
iodide	I-Gene
symporter	I-Gene
(	O
NIS	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
PATIENT	B-Species
:	O
We	O
describe	O
a	O
woman	B-Species
with	O
hypothyroidism	B-Disease
identified	O
at	O
the	O
3rd	O
month	O
of	O
life	O
.	O
</ALL>	O

<ALL>	O
The	O
diagnosis	O
of	O
ITD	B-Disease
was	O
suspected	O
because	O
of	O
nodular	B-Disease
goitre	I-Disease
,	O
and	O
little	O
if	O
any	O
iodide	B-Chemical
uptake	O
by	O
the	O
thyroid	O
and	O
salivary	O
glands	O
.	O
</ALL>	O

<ALL>	O
Treatment	O
with	O
iodide	B-Chemical
partially	O
corrected	O
the	O
hypothyroidism	B-Disease
;	O
however	O
,	O
long	O
-	O
term	O
substitution	O
therapy	O
with	O
L	B-Chemical
-	I-Chemical
thyroxine	I-Chemical
was	O
started	O
.	O
</ALL>	O

<ALL>	O
MEASUREMENTS	O
:	O
Thyroid	O
radioiodide	B-Chemical
uptake	O
was	O
only	O
1.4	O
%	O
and	O
0.3	O
%	O
at	O
1	O
and	O
24	O
h	O
after	O
the	O
administration	O
of	O
recombinant	O
human	B-Species
TSH	B-Gene
.	O
</ALL>	O

<ALL>	O
The	O
saliva	O
to	O
plasma	O
I	B-Chemical
-	I-Chemical
ratio	O
was	O
1.1	O
indicating	O
that	O
the	O
inability	O
of	O
the	O
thyroid	O
gland	O
to	O
concentrate	O
I	B-Chemical
-	I-Chemical
was	O
also	O
present	O
in	O
the	O
salivary	O
glands	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Analysis	O
of	O
the	O
patient	B-Species
's	O
NIS	B-Gene
gene	O
revealed	O
a	O
15	O
nucleotide	O
(	O
nt	O
)	O
deletion	B-Variant
of	I-Variant
the	I-Variant
coding	I-Variant
sequence	I-Variant
(	I-Variant
nt	I-Variant
1314	I-Variant
through	I-Variant
nt	I-Variant
1328	I-Variant
)	I-Variant
and	O
the	O
insertion	B-Variant
of	I-Variant
15	I-Variant
nt	I-Variant
duplicating	I-Variant
the	I-Variant
first	I-Variant
15	I-Variant
nt	O
of	O
the	O
adjacent	O
intron	O
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
was	O
homozygous	O
for	O
this	O
insertion	O
/	O
deletion	O
,	O
while	O
both	O
consanguineous	O
parents	O
were	O
heterozygous	O
.	O
</ALL>	O

<ALL>	O
This	O
deletion	O
predicts	O
the	O
production	O
of	O
a	O
protein	O
lacking	B-Variant
the	I-Variant
five	I-Variant
terminal	I-Variant
amino	I-Variant
acids	I-Variant
of	I-Variant
exon	I-Variant
XI	I-Variant
(	I-Variant
439	I-Variant
-	I-Variant
443	I-Variant
)	I-Variant
which	O
are	O
located	O
in	O
the	O
6th	O
intracellular	O
loop	O
.	O
</ALL>	O

<ALL>	O
COS	B-CellLine
-	I-CellLine
7	I-CellLine
cells	O
transfected	O
with	O
a	O
vector	O
expressing	O
the	O
mutant	O
del	B-Variant
-	I-Variant
(	I-Variant
439	I-Variant
-	I-Variant
443	I-Variant
)	I-Variant
NIS	B-Gene
failed	O
to	O
concentrate	O
iodide	B-Chemical
,	O
suggesting	O
that	O
the	O
mutation	O
was	O
the	O
direct	O
cause	O
of	O
the	O
ITD	B-Disease
in	O
this	O
patient	B-Species
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
In	O
conclusion	O
we	O
describe	O
the	O
first	O
Italian	O
case	O
of	O
congenital	B-Disease
hypothyroidism	I-Disease
due	O
to	O
a	O
new	O
deletion	O
in	O
the	O
NIS	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Pallidal	O
stimulation	O
:	O
an	O
alternative	O
to	O
pallidotomy	O
?	O
</ALL>	O

<ALL>	O
A	O
resurgence	O
of	O
interest	O
in	O
the	O
surgical	O
treatment	O
of	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
came	O
with	O
the	O
rediscovery	O
of	O
posteroventral	O
pallidotomy	O
by	O
Laitinen	O
in	O
1985	O
.	O
</ALL>	O

<ALL>	O
Laitinen	O
's	O
procedure	O
improved	O
most	O
symptoms	O
in	O
drug	O
-	O
resistant	O
PD	B-Disease
,	O
which	O
engendered	O
wide	O
interest	O
in	O
the	O
neurosurgical	O
community	O
.	O
</ALL>	O

<ALL>	O
Another	O
lesioning	O
procedure	O
,	O
ventrolateral	O
thalamotomy	O
,	O
has	O
become	O
a	O
powerful	O
alternative	O
to	O
stimulate	O
the	O
nucleus	O
ventralis	O
intermedius	O
,	O
producing	O
high	O
long	O
-	O
term	O
success	O
rates	O
and	O
low	O
morbidity	O
rates	O
.	O
</ALL>	O

<ALL>	O
Pallidal	O
stimulation	O
has	O
not	O
met	O
with	O
the	O
same	O
success	O
.	O
</ALL>	O

<ALL>	O
According	O
to	O
the	O
literature	O
pallidotomy	O
improves	O
the	O
"	O
on	O
"	O
symptoms	O
of	O
PD	B-Disease
,	O
such	O
as	O
dyskinesias	B-Disease
,	O
as	O
well	O
as	O
the	O
"	O
off	O
"	O
symptoms	O
,	O
such	O
as	O
rigidity	B-Disease
,	O
bradykinesia	B-Disease
,	O
and	O
on	O
-	O
off	O
fluctuations	O
.	O
</ALL>	O

<ALL>	O
Pallidal	O
stimulation	O
improves	O
bradykinesia	B-Disease
and	O
rigidity	B-Disease
to	O
a	O
minor	O
extent	O
;	O
however	O
,	O
its	O
strength	O
seems	O
to	O
be	O
in	O
improving	O
levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
.	O
</ALL>	O

<ALL>	O
Stimulation	O
often	O
produces	O
an	O
improvement	O
in	O
the	O
hyper	B-Disease
-	I-Disease
or	I-Disease
dyskinetic	I-Disease
upper	O
limbs	O
,	O
but	O
increases	O
the	O
"	O
freezing	O
"	O
phenomenon	O
in	O
the	O
lower	O
limbs	O
at	O
the	O
same	O
time	O
.	O
</ALL>	O

<ALL>	O
Considering	O
the	O
small	O
increase	O
in	O
the	O
patient	B-Species
's	O
independence	O
,	O
the	O
high	O
costs	O
of	O
bilateral	O
implants	O
,	O
and	O
the	O
difficulty	O
most	O
patients	B-Species
experience	O
in	O
handling	O
the	O
devices	O
,	O
the	O
question	O
arises	O
as	O
to	O
whether	O
bilateral	O
pallidal	O
stimulation	O
is	O
a	O
real	O
alternative	O
to	O
pallidotomy	O
.	O
</ALL>	O

<ALL>	O
Carrier	O
frequency	O
of	O
mutation	O
657del5	B-Variant
in	O
the	O
NBS1	B-Gene
gene	O
in	O
a	O
population	O
of	O
Polish	O
pediatric	O
patients	B-Species
with	O
sporadic	B-Disease
lymphoid	I-Disease
malignancies	I-Disease
.	O
</ALL>	O

<ALL>	O
Nijmegen	B-Disease
breakage	I-Disease
syndrome	I-Disease
(	O
NBS	B-Disease
)	O
is	O
a	O
human	B-Species
autosomal	B-Disease
recessive	I-Disease
disease	I-Disease
characterized	O
by	O
genomic	O
instability	O
and	O
enhanced	O
cancer	B-Disease
predisposition	O
,	O
in	O
particular	O
to	O
lymphoma	B-Disease
and	O
leukemia	B-Disease
.	O
</ALL>	O

<ALL>	O
Recently	O
,	O
significantly	O
higher	O
frequencies	O
of	O
heterozygous	O
carriers	O
of	O
the	O
Slavic	O
founder	O
NBS1	B-Gene
mutation	O
,	O
657del5	B-Variant
,	O
were	O
found	O
in	O
Russian	O
children	O
with	O
sporadic	B-Disease
lymphoid	I-Disease
malignancies	I-Disease
,	O
and	O
in	O
Polish	O
adults	O
with	O
non	B-Disease
-	I-Disease
Hodgkin	I-Disease
lymphoma	I-Disease
(	O
NHL	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
the	O
substitution	O
643C	B-Variant
>	I-Variant
T	I-Variant
(	O
R215W	B-Variant
)	O
has	O
also	O
been	O
found	O
in	O
excess	O
among	O
children	O
with	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
(	O
ALL	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
In	O
an	O
attempt	O
to	O
asses	O
the	O
contribution	O
of	O
both	O
mutations	O
to	O
the	O
development	O
of	O
sporadic	B-Disease
lymphoid	I-Disease
malignancies	I-Disease
,	O
we	O
analyzed	O
DNA	O
samples	O
from	O
a	O
large	O
group	O
of	O
Polish	O
pediatric	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
NBS1	B-Gene
mutation	O
657del5	B-Variant
on	O
one	O
allele	O
was	O
found	O
in	O
3	O
of	O
270	O
patients	B-Species
with	O
ALL	B-Disease
and	O
2	O
of	O
212	O
children	O
and	O
adolescents	O
with	O
NHL	B-Disease
;	O
no	O
carrier	O
was	O
found	O
among	O
63	O
patients	B-Species
with	O
Hodgkin	B-Disease
lymphoma	I-Disease
(	O
HL	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
No	O
carriers	O
of	O
the	O
variant	O
R215W	B-Variant
were	O
detected	O
in	O
any	O
studied	O
group	O
.	O
</ALL>	O

<ALL>	O
The	O
relative	O
frequency	O
of	O
the	O
657del5	B-Variant
mutation	O
was	O
calculated	O
from	O
a	O
total	O
of	O
6,984	O
controls	O
matched	O
by	O
place	O
of	O
patient	B-Species
residence	O
,	O
of	O
whom	O
42	O
were	O
found	O
to	O
be	O
carriers	O
(	O
frequency	O
=	O
0.006	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
analyzed	O
population	O
with	O
malignancies	B-Disease
,	O
an	O
increased	O
odds	O
ratio	O
for	O
the	O
occurrence	O
of	O
mutation	O
657del5	B-Variant
was	O
found	O
in	O
comparison	O
with	O
the	O
control	O
Polish	O
population	O
(	O
OR	O
range	O
1.48	O
-	O
1.85	O
,	O
95	O
%	O
confidence	O
interval	O
1.18	O
-	O
2.65	O
)	O
.	O
</ALL>	O

<ALL>	O
This	O
finding	O
indicates	O
that	O
the	O
frequency	O
of	O
the	O
mutation	O
carriers	O
was	O
indeed	O
increased	O
in	O
patients	B-Species
with	O
ALL	B-Disease
and	O
NHL	B-Disease
(	O
p	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
Nonetheless	O
,	O
NBS1	B-Gene
gene	O
heterozygosity	O
is	O
not	O
a	O
major	O
risk	O
factor	O
for	O
lymphoid	B-Disease
malignancies	I-Disease
in	O
childhood	O
and	O
adolescence	O
.	O
</ALL>	O

<ALL>	O
Segregation	O
of	O
a	O
M404V	B-Variant
mutation	O
of	O
the	O
p62	B-Gene
/	O
sequestosome	B-Gene
1	I-Gene
(	O
p62	B-Gene
/	O
SQSTM1	B-Gene
)	O
gene	O
with	O
polyostotic	O
Paget	B-Disease
's	I-Disease
disease	I-Disease
of	I-Disease
bone	I-Disease
in	O
an	O
Italian	O
family	O
.	O
</ALL>	O

<ALL>	O
Mutations	O
of	O
the	O
p62	B-Gene
/	O
Sequestosome	B-Gene
1	I-Gene
gene	O
(	O
p62	B-Gene
/	O
SQSTM1	B-Gene
)	O
account	O
for	O
both	O
sporadic	O
and	O
familial	O
forms	O
of	O
Paget	B-Disease
's	I-Disease
disease	I-Disease
of	I-Disease
bone	I-Disease
(	O
PDB	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
We	O
originally	O
described	O
a	O
methionine	B-Variant
-	I-Variant
-	I-Variant
>	I-Variant
valine	I-Variant
substitution	I-Variant
at	I-Variant
codon	I-Variant
404	I-Variant
(	O
M404V	B-Variant
)	O
of	O
exon	O
8	O
,	O
in	O
the	O
ubiquitin	O
protein	O
-	O
binding	O
domain	O
of	O
p62	B-Gene
/	O
SQSTM1	B-Gene
gene	O
in	O
an	O
Italian	O
PDB	B-Disease
patient	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
collection	O
of	O
data	O
from	O
the	O
patient	B-Species
's	O
pedigree	O
provided	O
evidence	O
for	O
a	O
familial	O
form	O
of	O
PDB	B-Disease
.	O
</ALL>	O

<ALL>	O
Extension	O
of	O
the	O
genetic	O
analysis	O
to	O
other	O
relatives	O
in	O
this	O
family	O
demonstrated	O
segregation	O
of	O
the	O
M404V	B-Variant
mutation	O
with	O
the	O
polyostotic	O
PDB	B-Disease
phenotype	O
and	O
provided	O
the	O
identification	O
of	O
six	O
asymptomatic	O
gene	O
carriers	O
.	O
</ALL>	O

<ALL>	O
DNA	O
for	O
mutational	O
analysis	O
of	O
the	O
exon	O
8	O
coding	O
sequence	O
was	O
obtained	O
from	O
22	O
subjects	O
,	O
4	O
PDB	B-Disease
patients	B-Species
and	O
18	O
clinically	O
unaffected	O
members	O
.	O
</ALL>	O

<ALL>	O
Of	O
the	O
five	O
clinically	O
ascertained	O
affected	O
members	O
of	O
the	O
family	O
,	O
four	O
possessed	O
the	O
M404V	B-Variant
mutation	O
and	O
exhibited	O
the	O
polyostotic	O
form	O
of	O
PDB	B-Disease
,	O
except	O
one	O
patient	B-Species
with	O
a	O
single	O
X	O
-	O
ray	O
-	O
assessed	O
skeletal	O
localization	O
and	O
one	O
with	O
a	O
polyostotic	B-Disease
disease	I-Disease
who	O
had	O
died	O
several	O
years	O
before	O
the	O
DNA	O
analysis	O
.	O
</ALL>	O

<ALL>	O
By	O
both	O
reconstitution	O
and	O
mutational	O
analysis	O
of	O
the	O
pedigree	O
,	O
six	O
unaffected	O
subjects	O
were	O
shown	O
to	O
bear	O
the	O
M404V	B-Variant
mutation	O
,	O
representing	O
potential	O
asymptomatic	O
gene	O
carriers	O
whose	O
circulating	O
levels	O
of	O
alkaline	B-Chemical
phosphatase	I-Chemical
were	O
recently	O
assessed	O
as	O
still	O
within	O
the	O
normal	O
range	O
.	O
</ALL>	O

<ALL>	O
Taken	O
together	O
,	O
these	O
results	O
support	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
between	O
the	O
M404V	B-Variant
mutation	O
in	O
the	O
p62	B-Gene
/	O
SQSTM1	B-Gene
gene	O
and	O
a	O
polyostotic	O
form	O
of	O
PDB	B-Disease
in	O
this	O
family	O
.	O
</ALL>	O

<ALL>	O
The	O
high	O
penetrance	O
of	O
the	O
PDB	B-Disease
trait	O
in	O
this	O
family	O
together	O
with	O
the	O
study	O
of	O
the	O
asymptomatic	O
gene	O
carriers	O
will	O
allow	O
us	O
to	O
confirm	O
the	O
proposed	O
genotype	O
-	O
phenotype	O
correlation	O
and	O
to	O
evaluate	O
the	O
potential	O
use	O
of	O
mutational	O
analysis	O
of	O
the	O
p62	B-Gene
/	O
SQSTM1	B-Gene
gene	O
in	O
the	O
early	O
detection	O
of	O
relatives	O
at	O
risk	O
for	O
PDB	B-Disease
.	O
</ALL>	O

<ALL>	O
Two	O
distinct	O
mutations	O
at	O
a	O
single	O
BamHI	O
site	O
in	O
phenylketonuria	B-Disease
.	O
</ALL>	O

<ALL>	O
Classical	B-Disease
phenylketonuria	I-Disease
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disease	I-Disease
caused	O
by	O
a	O
deficiency	B-Disease
of	I-Disease
hepatic	I-Disease
phenylalanine	I-Disease
hydroxylase	I-Disease
(	O
PAH	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
The	O
abolition	O
of	O
an	O
invariant	O
BamHI	O
site	O
located	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
PAH	B-Gene
gene	O
(	O
exon	O
7	O
)	O
led	O
to	O
the	O
recognition	O
of	O
two	O
new	O
point	O
mutations	O
at	O
codon	O
272	O
and	O
273	O
(	O
272gly	B-Variant
-	I-Variant
-	I-Variant
-	I-Variant
-	I-Variant
stop	I-Variant
and	O
273ser	B-Variant
-	I-Variant
-	I-Variant
-	I-Variant
-	I-Variant
phe	I-Variant
,	O
respectively	O
)	O
.	O
</ALL>	O

<ALL>	O
Both	O
mutations	O
were	O
detected	O
in	O
north	O
eastern	O
France	O
or	O
Belgium	O
and	O
occurred	O
on	O
the	O
background	O
of	O
RFLP	O
haplotype	O
7	O
alleles	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
supports	O
the	O
view	O
that	O
the	O
clinical	O
heterogeneity	O
in	O
PKU	B-Disease
is	O
accounted	O
for	O
by	O
the	O
large	O
variety	O
of	O
mutant	O
genotypes	O
associated	O
with	O
PAH	B-Disease
deficiencies	I-Disease
..	O
</ALL>	O

<ALL>	O
Association	O
of	O
DRD2	B-Gene
polymorphisms	O
and	O
chlorpromazine	B-Chemical
-	O
induced	O
extrapyramidal	B-Disease
syndrome	I-Disease
in	O
Chinese	O
schizophrenic	B-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
AIM	O
:	O
Extrapyramidal	B-Disease
syndrome	I-Disease
(	O
EPS	B-Disease
)	O
is	O
most	O
commonly	O
affected	O
by	O
typical	O
antipsychotic	B-Chemical
drugs	I-Chemical
that	O
have	O
a	O
high	O
affinity	O
with	O
the	O
D2	B-Gene
receptor	I-Gene
.	O
</ALL>	O

<ALL>	O
Recently	O
,	O
many	O
research	O
groups	O
have	O
reported	O
on	O
the	O
positive	O
relationship	O
between	O
the	O
genetic	O
variations	O
in	O
the	O
DRD2	B-Gene
gene	O
and	O
the	O
therapeutic	O
response	O
in	O
schizophrenia	B-Disease
patients	B-Species
as	O
a	O
result	O
of	O
the	O
role	O
of	O
variations	O
in	O
the	O
receptor	O
in	O
modulating	O
receptor	O
expression	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
evaluate	O
the	O
role	O
DRD2	B-Gene
plays	O
in	O
chlorpromazine	B-Chemical
-	O
induced	O
EPS	B-Disease
in	O
schizophrenic	B-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
We	O
identified	O
seven	O
SNP	O
(	O
single	O
nucleotide	O
polymorphism	O
)	O
(	O
-	B-Variant
141Cins	I-Variant
>	I-Variant
del	I-Variant
,	O
TaqIB	O
,	O
TaqID	O
,	O
Ser311Cys	B-Variant
,	O
rs6275	B-Variant
,	O
rs6277	B-Variant
and	O
TaqIA	O
)	O
in	O
the	O
DRD2	B-Gene
gene	O
in	O
146	O
schizophrenic	B-Disease
inpatients	B-Species
(	O
59	O
with	O
EPS	B-Disease
and	O
87	O
without	O
EPS	B-Disease
according	O
to	O
the	O
Simpson	O
-	O
Angus	O
Scale	O
)	O
treated	O
with	O
chlorpromazine	B-Chemical
after	O
8	O
weeks	O
.	O
</ALL>	O

<ALL>	O
The	O
alleles	O
of	O
all	O
loci	O
were	O
determined	O
by	O
PCR	O
(	O
polymerase	O
chain	O
reaction	O
)	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Polymorphisms	O
TaqID	O
,	O
Ser311Cys	B-Variant
and	O
rs6277	B-Variant
were	O
not	O
polymorphic	O
in	O
the	O
population	O
recruited	O
in	O
the	O
present	O
study	O
.	O
</ALL>	O

<ALL>	O
No	O
statistical	O
significance	O
was	O
found	O
in	O
the	O
allele	O
distribution	O
of	O
-	B-Variant
141Cins	I-Variant
>	I-Variant
del	I-Variant
,	O
TaqIB	O
,	O
rs6275	B-Variant
and	O
TaqIA	O
or	O
in	O
the	O
estimated	O
haplotypes	O
(	O
constituted	O
by	O
TaqIB	O
,	O
rs6275	B-Variant
and	O
TaqIA	O
)	O
in	O
linkage	O
disequilibrium	O
between	O
the	O
two	O
groups	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Our	O
results	O
did	O
not	O
lend	O
strong	O
support	O
to	O
the	O
view	O
that	O
the	O
genetic	O
variation	O
of	O
the	O
DRD2	B-Gene
gene	O
plays	O
a	O
major	O
role	O
in	O
the	O
individually	O
variable	O
adverse	O
effect	O
induced	O
by	O
chlorpromazine	B-Chemical
,	O
at	O
least	O
in	O
Chinese	O
patients	B-Species
with	O
schizophrenia	B-Disease
.	O
</ALL>	O

<ALL>	O
Our	O
results	O
confirmed	O
a	O
previous	O
study	O
on	O
the	O
relationship	O
between	O
DRD2	B-Gene
and	O
EPS	B-Disease
in	O
Caucasians	O
.	O
</ALL>	O

<ALL>	O
A	O
novel	O
IRF6	B-Gene
nonsense	O
mutation	O
(	O
Y67X	B-Variant
)	O
in	O
a	O
German	O
family	O
with	O
Van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Van	B-Disease
der	I-Disease
Woude	I-Disease
syndrome	I-Disease
(	O
VWS	B-Disease
)	O
is	O
the	O
most	O
common	O
type	O
of	O
syndromic	B-Disease
orofacial	I-Disease
cleft	I-Disease
,	O
which	O
accounts	O
for	O
approximately	O
2	O
%	O
of	O
all	O
cleft	B-Disease
lip	I-Disease
and	I-Disease
palate	I-Disease
cases	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
characterised	O
by	O
variable	O
association	O
of	O
lower	O
lip	B-Disease
pits	I-Disease
,	O
cleft	B-Disease
lip	I-Disease
and	O
cleft	B-Disease
palate	I-Disease
,	O
and	O
hypodontia	B-Disease
.	O
</ALL>	O

<ALL>	O
VWS	B-Disease
arises	O
as	O
the	O
result	O
of	O
mutations	O
in	O
the	O
gene	O
encoding	O
interferon	B-Gene
regulatory	I-Gene
factor	I-Gene
6	I-Gene
(	O
IRF6	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
The	O
disorder	O
is	O
transmitted	O
in	O
an	O
autosomal	O
dominant	O
manner	O
,	O
with	O
high	O
penetrance	O
and	O
variable	O
expressivity	O
.	O
</ALL>	O

<ALL>	O
Very	O
recently	O
,	O
mutations	O
of	O
the	O
IRF6	B-Gene
gene	O
in	O
exons	O
2	O
-	O
9	O
have	O
been	O
found	O
in	O
VWS	B-Disease
patients	B-Species
,	O
suggesting	O
that	O
this	O
gene	O
plays	O
an	O
important	O
role	O
in	O
orofacial	O
development	O
.	O
</ALL>	O

<ALL>	O
We	O
report	O
a	O
novel	O
mutation	O
of	O
the	O
IRF6	B-Gene
gene	O
in	O
a	O
German	O
family	O
.	O
</ALL>	O

<ALL>	O
Five	O
out	O
of	O
the	O
12	O
persons	O
affected	O
were	O
able	O
to	O
be	O
investigated	O
.	O
</ALL>	O

<ALL>	O
The	O
mutation	O
produced	O
a	O
stop	O
codon	O
within	O
exon	O
4	O
of	O
the	O
IRF6	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
All	O
5	O
patients	B-Species
were	O
heterozygous	O
for	O
a	O
base	O
substitution	O
c.201C	B-Variant
>	I-Variant
A	I-Variant
changing	O
the	O
tyrosine	B-Variant
codon	I-Variant
at	I-Variant
amino	I-Variant
acid	I-Variant
position	I-Variant
67	I-Variant
into	I-Variant
a	I-Variant
stop	I-Variant
codon	O
(	O
p	B-Variant
.	I-Variant
Y67X	I-Variant
)	O
in	O
exon	O
4	O
.	O
</ALL>	O

<ALL>	O
The	O
premature	O
stop	O
codon	O
was	O
responsible	O
for	O
a	O
truncated	O
protein	O
lacking	O
parts	O
of	O
the	O
DNA	O
-	O
binding	O
domain	O
and	O
the	O
complete	O
Smad	B-Gene
-	O
interferon	B-Gene
regulatory	I-Gene
factor	I-Gene
-	O
binding	O
domain	O
probably	O
essential	O
for	O
interactions	O
with	O
the	O
Smad	B-Gene
transcription	O
factors	O
.	O
</ALL>	O

<ALL>	O
Skewed	O
X	O
inactivation	O
in	O
an	O
X	B-Disease
linked	I-Disease
nystagmus	I-Disease
family	O
resulted	O
from	O
a	O
novel	O
,	O
p	B-Variant
.	I-Variant
R229	I-Variant
G	I-Variant
,	O
missense	O
mutation	O
in	O
the	O
FRMD7	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
AIMS	O
:	O
This	O
study	O
aimed	O
to	O
identify	O
the	O
underlying	O
genetic	B-Disease
defect	I-Disease
of	O
a	O
large	O
Turkish	O
X	B-Disease
linked	I-Disease
nystagmus	I-Disease
(	O
NYS	B-Disease
)	O
family	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Both	O
Xp11	O
and	O
Xq26	O
loci	O
were	O
tested	O
by	O
linkage	O
analysis	O
.	O
</ALL>	O

<ALL>	O
The	O
12	O
exons	O
and	O
intron	O
-	O
exon	O
junctions	O
of	O
the	O
FRMD7	B-Gene
gene	O
were	O
screened	O
by	O
direct	O
sequencing	O
.	O
</ALL>	O

<ALL>	O
X	O
chromosome	O
inactivation	O
analysis	O
was	O
performed	O
by	O
enzymatic	O
predigestion	O
of	O
DNA	O
with	O
a	O
methylation	O
-	O
sensitive	O
enzyme	O
,	O
followed	O
by	O
PCR	O
of	O
the	O
polymorphic	O
CAG	B-Variant
repeat	I-Variant
of	O
the	O
androgen	B-Gene
receptor	I-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
family	O
contained	O
162	O
individuals	O
,	O
among	O
whom	O
28	O
had	O
NYS	B-Disease
.	O
</ALL>	O

<ALL>	O
Linkage	O
analysis	O
confirmed	O
the	O
Xq26	O
locus	O
.	O
</ALL>	O

<ALL>	O
A	O
novel	O
missense	O
c.686C	B-Variant
>	I-Variant
G	I-Variant
mutation	O
,	O
which	O
causes	O
the	O
substitution	O
of	O
a	O
conserved	O
arginine	B-Variant
at	I-Variant
amino	I-Variant
acid	I-Variant
position	I-Variant
229	I-Variant
by	I-Variant
glycine	I-Variant
(	O
p	B-Variant
.	I-Variant
R229	I-Variant
G	I-Variant
)	O
in	O
exon	O
8	O
of	O
the	O
FRMD7	B-Gene
gene	O
,	O
was	O
observed	O
.	O
</ALL>	O

<ALL>	O
This	O
change	O
was	O
not	O
documented	O
in	O
120	O
control	O
individuals	O
.	O
</ALL>	O

<ALL>	O
The	O
clinical	O
findings	O
in	O
a	O
female	O
who	O
was	O
homozygous	O
for	O
the	O
mutation	O
were	O
not	O
different	O
from	O
those	O
of	O
affected	O
heterozygous	O
females	O
.	O
</ALL>	O

<ALL>	O
Skewed	O
X	O
inactivation	O
was	O
remarkable	O
in	O
the	O
affected	O
females	O
of	O
the	O
family	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
A	O
novel	O
p	B-Variant
.	I-Variant
R229	I-Variant
G	I-Variant
mutation	O
in	O
the	O
FRMD7	B-Gene
gene	O
causes	O
the	O
NYS	B-Disease
phenotype	O
,	O
and	O
skewed	O
X	O
inactivation	O
influences	O
the	O
manifestation	O
of	O
the	O
disease	O
in	O
X	B-Disease
linked	I-Disease
NYS	I-Disease
females	O
.	O
</ALL>	O

<ALL>	O
Identification	O
of	O
apolipoprotein	B-Gene
E	I-Gene
Guangzhou	O
(	O
arginine	B-Variant
150	I-Variant
proline	I-Variant
)	O
,	O
a	O
new	O
variant	O
associated	O
with	O
lipoprotein	B-Disease
glomerulopathy	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
/	O
AIMS	O
:	O
Lipoprotein	B-Disease
glomerulopathy	I-Disease
(	O
LPG	B-Disease
)	O
is	O
a	O
rare	O
disease	O
characterized	O
by	O
thrombus	B-Disease
-	O
like	O
substances	O
in	O
markedly	O
dilated	B-Disease
glomerular	I-Disease
capillaries	I-Disease
and	O
elevated	O
plasma	O
levels	O
of	O
apolipoprotein	B-Gene
E	I-Gene
(	O
apoE	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
Previous	O
studies	O
have	O
shown	O
that	O
genetic	O
disorders	O
of	O
apoE	B-Gene
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
LPG	B-Disease
,	O
but	O
LPG	B-Disease
may	O
not	O
be	O
caused	O
by	O
apoE	B-Gene
gene	O
mutations	O
in	O
Chinese	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
This	O
study	O
investigated	O
the	O
association	O
of	O
a	O
new	O
variant	O
of	O
apoE	B-Gene
with	O
LPG	B-Disease
in	O
a	O
Chinese	O
family	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
The	O
apoE	B-Gene
gene	O
in	O
a	O
family	O
with	O
4	O
LPG	B-Disease
patients	B-Species
was	O
sequenced	O
.	O
</ALL>	O

<ALL>	O
The	O
polymerase	O
chain	O
reaction	O
product	O
of	O
coding	O
region	O
of	O
apoE	B-Gene
exon	O
4	O
was	O
cloned	O
into	O
pMD	O
18	O
-	O
T	O
vector	O
and	O
then	O
sequenced	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
A	O
novel	O
point	O
mutation	O
in	O
exon	O
4	O
of	O
the	O
apoE	B-Gene
gene	O
was	O
identified	O
in	O
all	O
4	O
LPG	B-Disease
patients	B-Species
and	O
1	O
asymptomatic	O
family	O
member	O
.	O
</ALL>	O

<ALL>	O
Sequence	O
analysis	O
confirmed	O
a	O
nucleotide	O
G	B-Variant
to	I-Variant
C	I-Variant
point	I-Variant
mutation	I-Variant
in	I-Variant
exon	I-Variant
4	I-Variant
(	I-Variant
base	I-Variant
308	I-Variant
)	I-Variant
of	O
the	O
apoE	B-Gene
gene	O
in	O
all	O
patients	B-Species
and	O
the	O
asymptomatic	O
family	O
member	O
.	O
</ALL>	O

<ALL>	O
This	O
missense	O
mutation	O
denotes	O
amino	O
acid	O
substitution	O
of	O
the	O
proline	B-Variant
residue	I-Variant
for	I-Variant
arginine	I-Variant
residue	I-Variant
at	I-Variant
position	I-Variant
150	I-Variant
of	O
apoE	B-Gene
.	O
</ALL>	O

<ALL>	O
Those	O
patients	B-Species
were	O
all	O
heterozygotes	O
with	O
apoE	B-Gene
Guangzhou	O
.	O
</ALL>	O

<ALL>	O
One	O
of	O
2	O
grandsons	O
was	O
a	O
heterozygous	O
carrier	O
of	O
apoE	B-Gene
Guangzhou	O
,	O
although	O
he	O
did	O
not	O
have	O
proteinuria	B-Disease
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
apoE	B-Gene
(	O
arginine	B-Variant
150	I-Variant
proline	I-Variant
)	O
is	O
a	O
novel	O
apoE	B-Gene
variant	O
that	O
etiologically	O
related	O
to	O
LPG	B-Disease
.	O
</ALL>	O

<ALL>	O
This	O
variant	O
(	O
apoE	B-Gene
Guangzhou	O
)	O
may	O
cause	O
a	O
marked	O
molecular	O
conformational	O
change	O
of	O
the	O
apoE	B-Gene
and	O
thus	O
impair	O
its	O
binding	O
ability	O
to	O
lipids	B-Chemical
.	O
</ALL>	O

<ALL>	O
Mutational	O
analysis	O
of	O
CYP2C8	B-Gene
in	O
hypertensive	B-Disease
patients	B-Species
using	O
denaturing	O
high	O
performance	O
liquid	O
chromatography	O
.	O
</ALL>	O

<ALL>	O
WHAT	O
IS	O
KNOWN	O
AND	O
OBJECTIVE	O
:	O
CYP2C8	B-Gene
is	O
involved	O
in	O
the	O
cytochrome	B-Gene
P450	I-Gene
(	I-Gene
CYP	I-Gene
)	I-Gene
epoxygenase	I-Gene
pathway	O
.	O
</ALL>	O

<ALL>	O
Arachidonic	B-Chemical
acid	I-Chemical
metabolites	O
such	O
as	O
epoxyeicosatrienenoic	B-Chemical
acids	I-Chemical
and	O
hydroxyeicosatetrenoic	B-Chemical
acids	I-Chemical
,	O
produced	O
may	O
have	O
a	O
role	O
in	O
hypertension	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
aimed	O
to	O
develop	O
a	O
medium	O
through	O
-	O
put	O
method	O
for	O
screening	O
samples	O
of	O
known	O
and	O
new	O
mutations	O
of	O
CYP2C8	B-Gene
using	O
denaturing	O
high	O
performance	O
liquid	O
chromatography	O
(	O
DHPLC	O
)	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
DNA	O
samples	O
from	O
200	O
subjects	O
(	O
hypertensive	B-Disease
patients	B-Species
and	O
healthy	O
controls	O
)	O
were	O
screened	O
for	O
SNPs	O
in	O
CYP2C8	B-Gene
using	O
DHPLC	O
.	O
</ALL>	O

<ALL>	O
Genotypes	O
and	O
allelic	O
frequencies	O
of	O
CYP2C8	B-Gene
between	O
the	O
healthy	O
controls	O
and	O
patients	B-Species
with	O
hypertension	B-Disease
were	O
compared	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
AND	O
DISCUSSIONS	O
:	O
Six	O
variants	O
were	O
detected	O
and	O
two	O
were	O
new	O
;	O
T	B-Variant
deletion	I-Variant
at	I-Variant
5063	I-Variant
and	O
substitution	O
of	O
C	B-Variant
to	I-Variant
T	I-Variant
at	I-Variant
33468	I-Variant
in	O
exon	O
8	O
.	O
</ALL>	O

<ALL>	O
Differences	O
in	O
variant	O
frequencies	O
were	O
detected	O
between	O
the	O
controls	O
and	O
hypertensive	B-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
controls	O
have	O
significantly	O
higher	O
prevalence	O
of	O
C35322C	B-Variant
compared	O
to	O
the	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
functional	O
significance	O
of	O
the	O
SNP	O
at	O
35322	O
requires	O
further	O
study	O
.	O
</ALL>	O

<ALL>	O
Having	O
homozygous	O
C35322C	B-Variant
could	O
be	O
a	O
protective	O
factor	O
for	O
hypertension	B-Disease
.	O
</ALL>	O

<ALL>	O
WHAT	O
IS	O
NEW	O
AND	O
CONCLUSION	O
:	O
Denaturing	O
high	O
performance	O
liquid	O
chromatography	O
is	O
useful	O
for	O
population	O
screening	O
to	O
identify	O
new	O
and	O
existing	O
SNPs	O
.	O
</ALL>	O

<ALL>	O
A	O
higher	O
frequency	O
of	O
the	O
C35322	B-Variant
T	I-Variant
SNP	O
was	O
observed	O
among	O
hypertensive	B-Disease
patients	B-Species
than	O
control	O
subjects	O
.	O
</ALL>	O

<ALL>	O
This	O
potentially	O
important	O
observation	O
requires	O
confirmation	O
and	O
the	O
clinical	O
significance	O
assessed	O
.	O
</ALL>	O

<ALL>	O
TNFR	B-Gene
-	I-Gene
associated	I-Gene
factor	I-Gene
2	I-Gene
deficiency	O
in	O
B	O
lymphocytes	O
predisposes	O
to	O
chronic	B-Disease
lymphocytic	I-Disease
leukemia	I-Disease
/	O
small	B-Disease
lymphocytic	I-Disease
lymphoma	I-Disease
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
We	O
have	O
previously	O
shown	O
that	O
transgenic	O
(	O
tg	O
)	O
mice	B-Species
expressing	O
in	O
B	O
lymphocytes	O
both	O
BCL	B-Gene
-	I-Gene
2	I-Gene
and	O
a	O
TNFR	B-Gene
-	I-Gene
associated	I-Gene
factor	I-Gene
2	I-Gene
(	O
TRAF2	B-Gene
)	O
mutant	O
lacking	O
the	O
really	O
interesting	O
new	O
gene	O
and	O
zinc	O
finger	O
domains	O
(	O
TRAF2DN	O
)	O
develop	O
small	B-Disease
lymphocytic	I-Disease
lymphoma	I-Disease
and	O
chronic	B-Disease
lymphocytic	I-Disease
leukemia	I-Disease
with	O
high	O
incidence	O
(	O
Zapata	O
et	O
al	O
.	O
</ALL>	O

<ALL>	O
2004	O
.	O
</ALL>	O

<ALL>	O
Proc	O
.	O
</ALL>	O

<ALL>	O
Nat	O
.	O
</ALL>	O

<ALL>	O
Acad	O
.	O
</ALL>	O

<ALL>	O
Sci	O
.	O
</ALL>	O

<ALL>	O
USA	O
101	O
:	O
16600	O
-	O
16605	O
)	O
.	O
</ALL>	O

<ALL>	O
Further	O
analysis	O
of	O
the	O
expression	O
of	O
TRAF2	B-Gene
and	O
TRAF2DN	O
in	O
purified	O
B	O
cells	O
demonstrated	O
that	O
expression	O
of	O
both	O
endogenous	O
TRAF2	B-Gene
and	O
tg	O
TRAF2DN	O
was	O
negligible	O
in	O
Traf2DN	B-CellLine
-	I-CellLine
tg	I-CellLine
B	I-CellLine
cells	O
compared	O
with	O
wild	O
-	O
type	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
This	O
was	O
the	O
result	O
of	O
proteasome	B-Gene
-	O
dependent	O
degradation	O
,	O
and	O
rendered	O
TRAF2DN	O
B	O
cells	O
as	O
bona	O
fide	O
TRAF2	B-Gene
-	O
deficient	O
B	O
cells	O
.	O
</ALL>	O

<ALL>	O
Similar	O
to	O
B	O
cells	O
with	O
targeted	O
Traf2	B-Gene
deletion	O
,	O
Traf2DN	B-CellLine
-	I-CellLine
tg	I-CellLine
mice	B-Species
show	O
expanded	O
marginal	O
zone	O
B	O
cell	O
population	O
and	O
have	O
constitutive	O
p100	B-Gene
NF	I-Gene
-	I-Gene
kappaB2	I-Gene
processing	O
.	O
</ALL>	O

<ALL>	O
Also	O
,	O
TRAF3	B-Gene
,	O
X	B-Gene
-	I-Gene
linked	I-Gene
inhibitor	I-Gene
of	I-Gene
apoptosis	I-Gene
,	O
and	O
Bcl	B-Gene
-	I-Gene
X	I-Gene
(	I-Gene
L	I-Gene
)	I-Gene
expression	O
levels	O
were	O
increased	O
,	O
whereas	O
cellular	B-Gene
inhibitors	I-Gene
of	I-Gene
apoptosis	I-Gene
1	I-Gene
and	I-Gene
2	I-Gene
levels	O
were	O
drastically	O
reduced	O
compared	O
with	O
those	O
found	O
in	O
wild	O
-	O
type	O
B	O
cells	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
consistent	O
with	O
previous	O
results	O
,	O
we	O
also	O
show	O
that	O
TRAF2	B-Gene
was	O
required	O
for	O
efficient	O
JNK	B-Gene
and	O
ERK	B-Gene
activation	O
in	O
response	O
to	O
CD40	B-Gene
engagement	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
TRAF2	B-Gene
was	O
deleterious	O
for	O
BCR	B-Gene
-	O
mediated	O
activation	O
of	O
these	O
kinases	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
TRAF2	B-Gene
deficiency	O
had	O
no	O
effect	O
on	O
CD40	B-Gene
-	O
mediated	O
p38	B-Gene
MAPK	I-Gene
activation	O
but	O
significantly	O
reduced	O
BCR	B-Gene
-	O
mediated	O
p38	B-Gene
activation	O
.	O
</ALL>	O

<ALL>	O
Finally	O
,	O
we	O
further	O
confirm	O
that	O
TRAF2	B-Gene
was	O
required	O
for	O
CD40	B-Gene
-	O
mediated	O
proliferation	O
,	O
but	O
its	O
absence	O
relieved	O
B	O
cells	O
of	O
the	O
need	O
for	O
B	B-Gene
cell	I-Gene
activating	I-Gene
factor	I-Gene
for	O
survival	O
.	O
</ALL>	O

<ALL>	O
Altogether	O
,	O
our	O
results	O
suggest	O
that	O
TRAF2	B-Gene
deficiency	O
cooperates	O
with	O
BCL	B-Gene
-	I-Gene
2	I-Gene
in	O
promoting	O
chronic	B-Disease
lymphocytic	I-Disease
leukemia	I-Disease
/	O
small	B-Disease
lymphocytic	I-Disease
lymphoma	I-Disease
in	O
mice	B-Species
,	O
possibly	O
by	O
specifically	O
enforcing	O
marginal	O
zone	O
B	O
cell	O
accumulation	O
,	O
increasing	O
X	B-Gene
-	I-Gene
linked	I-Gene
inhibitor	I-Gene
of	I-Gene
apoptosis	I-Gene
expression	O
,	O
and	O
rendering	O
B	O
cells	O
independent	O
of	O
B	B-Gene
cell	I-Gene
activating	I-Gene
factor	I-Gene
for	O
survival	O
.	O
</ALL>	O

<ALL>	O
CTR9	B-Gene
/	O
PAF1c	B-Gene
regulates	O
molecular	O
lineage	O
identity	O
,	O
histone	B-Gene
H3	I-Gene
K36	O
trimethylation	O
and	O
genomic	O
imprinting	O
during	O
preimplantation	O
development	O
.	O
</ALL>	O

<ALL>	O
Genome	O
-	O
wide	O
epigenetic	O
reprogramming	O
is	O
required	O
for	O
successful	O
preimplantation	O
development	O
.	O
</ALL>	O

<ALL>	O
Inappropriate	O
or	O
deficient	O
chromatin	O
regulation	O
can	O
result	O
in	O
defective	O
lineage	O
specification	O
and	O
loss	O
of	O
genomic	O
imprinting	O
,	O
compromising	O
normal	O
development	O
.	O
</ALL>	O

<ALL>	O
Here	O
we	O
report	O
that	O
two	O
members	O
of	O
the	O
RNA	B-Gene
polymerase	I-Gene
II	I-Gene
associated	I-Gene
factor	I-Gene
,	I-Gene
homolog	I-Gene
(	I-Gene
Saccharomyces	I-Gene
cerevisiae	I-Gene
)	I-Gene
complex	I-Gene
(	O
PAF1	B-Gene
complex	I-Gene
)	O
components	O
,	O
Ctr9	B-Gene
and	O
Rtf1	B-Gene
,	O
are	O
required	O
during	O
mammalian	O
preimplantation	O
development	O
.	O
</ALL>	O

<ALL>	O
We	O
demonstrate	O
that	O
Ctr9	B-Gene
-	O
deficient	O
embryos	O
fail	O
to	O
correctly	O
specify	O
lineages	O
at	O
the	O
blastocyst	O
stage	O
.	O
</ALL>	O

<ALL>	O
Expression	O
of	O
some	O
lineage	O
specific	O
factors	O
is	O
markedly	O
reduced	O
in	O
Ctr9	B-Gene
knockdown	O
embryos	O
,	O
including	O
Eomes	B-Gene
,	O
Elf5	B-Gene
and	O
Sox2	B-Gene
,	O
while	O
others	O
are	O
inappropriately	O
expressed	O
(	O
Oct4	B-Gene
,	O
Nanog	B-Gene
,	O
Gata6	B-Gene
,	O
Fgf4	B-Gene
and	O
Sox17	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
We	O
also	O
show	O
that	O
several	O
imprinted	O
genes	O
(	O
Mest	B-Gene
,	O
Peg3	B-Gene
,	O
Snrpn	B-Gene
and	O
Meg3	B-Gene
)	O
are	O
aberrantly	O
expressed	O
although	O
allele	O
specific	O
DNA	O
methylation	O
is	O
not	O
altered	O
.	O
</ALL>	O

<ALL>	O
We	O
document	O
a	O
loss	O
of	O
histone	B-Gene
H3	I-Gene
lysine	O
36	O
trimethylation	O
(	O
H3	B-Gene
K36me3	O
)	O
in	O
Ctr9	B-Gene
-	O
deficient	O
embryos	O
and	O
confirm	O
that	O
knockdown	O
of	O
either	O
Setd2	B-Gene
or	O
Rtf1	B-Gene
results	O
in	O
similar	O
phenotypes	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
show	O
that	O
the	O
PAF1	B-Gene
complex	I-Gene
is	O
required	O
for	O
mammalian	O
development	O
,	O
likely	O
through	O
regulation	O
of	O
H3	B-Gene
K36me3	O
,	O
and	O
indicate	O
functional	O
conservation	O
of	O
the	O
PAF1	B-Gene
complex	I-Gene
from	O
yeast	B-Species
to	O
mammals	O
in	O
vivo	O
.	O
</ALL>	O

<ALL>	O
Regulation	O
of	O
signal	B-Gene
transducer	I-Gene
and	I-Gene
activator	I-Gene
of	I-Gene
transcription	I-Gene
3	I-Gene
and	O
apoptotic	O
pathways	O
by	O
betaine	B-Chemical
attenuates	O
isoproterenol	B-Chemical
-	O
induced	O
acute	O
myocardial	B-Disease
injury	I-Disease
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
cardioprotective	O
effects	O
of	O
betaine	B-Chemical
on	O
acute	O
myocardial	B-Disease
ischemia	I-Disease
induced	O
experimentally	O
in	O
rats	B-Species
focusing	O
on	O
regulation	O
of	O
signal	B-Gene
transducer	I-Gene
and	I-Gene
activator	I-Gene
of	I-Gene
transcription	I-Gene
3	I-Gene
(	O
STAT3	B-Gene
)	O
and	O
apoptotic	O
pathways	O
as	O
the	O
potential	O
mechanism	O
underlying	O
the	O
drug	O
effect	O
.	O
</ALL>	O

<ALL>	O
Male	O
Sprague	O
Dawley	O
rats	B-Species
were	O
treated	O
with	O
betaine	B-Chemical
(	O
100	O
,	O
200	O
,	O
and	O
400	O
mg	O
/	O
kg	O
)	O
orally	O
for	O
40	O
days	O
.	O
</ALL>	O

<ALL>	O
Acute	O
myocardial	B-Disease
ischemic	I-Disease
injury	I-Disease
was	O
induced	O
in	O
rats	B-Species
by	O
subcutaneous	O
injection	O
of	O
isoproterenol	B-Chemical
(	O
85	O
mg	O
/	O
kg	O
)	O
,	O
for	O
two	O
consecutive	O
days	O
.	O
</ALL>	O

<ALL>	O
Serum	O
cardiac	O
marker	O
enzyme	O
,	O
histopathological	O
variables	O
and	O
expression	O
of	O
protein	O
levels	O
were	O
analyzed	O
.	O
</ALL>	O

<ALL>	O
Oral	O
administration	O
of	O
betaine	B-Chemical
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
significantly	O
reduced	O
the	O
level	O
of	O
cardiac	O
marker	O
enzyme	O
in	O
the	O
serum	O
and	O
prevented	O
left	O
ventricular	B-Disease
remodeling	I-Disease
.	O
</ALL>	O

<ALL>	O
Western	O
blot	O
analysis	O
showed	O
that	O
isoproterenol	B-Chemical
-	O
induced	O
phosphorylation	O
of	O
STAT3	B-Gene
was	O
maintained	O
or	O
further	O
enhanced	O
by	O
betaine	B-Chemical
treatment	O
in	O
myocardium	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
betaine	B-Chemical
(	O
200	O
and	O
400	O
mg	O
/	O
kg	O
)	O
treatment	O
increased	O
the	O
ventricular	O
expression	O
of	O
Bcl	B-Gene
-	I-Gene
2	I-Gene
and	O
reduced	O
the	O
level	O
of	O
Bax	B-Gene
,	O
therefore	O
causing	O
a	O
significant	O
increase	O
in	O
the	O
ratio	O
of	O
Bcl	B-Gene
-	I-Gene
2	I-Gene
/	O
Bax	B-Gene
.	O
</ALL>	O

<ALL>	O
The	O
protective	O
role	O
of	O
betaine	B-Chemical
on	O
myocardial	B-Disease
damage	I-Disease
was	O
further	O
confirmed	O
by	O
histopathological	O
examination	O
.	O
</ALL>	O

<ALL>	O
In	O
summary	O
,	O
our	O
results	O
showed	O
that	O
betaine	B-Chemical
pretreatment	O
attenuated	O
isoproterenol	B-Chemical
-	O
induced	O
acute	O
myocardial	B-Disease
ischemia	I-Disease
via	O
the	O
regulation	O
of	O
STAT3	B-Gene
and	O
apoptotic	O
pathways	O
.	O
</ALL>	O

<ALL>	O
Combination	O
of	O
the	O
histone	B-Gene
deacetylase	I-Gene
inhibitor	O
depsipeptide	B-Chemical
and	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
upregulates	O
major	B-Gene
histocompatibility	I-Gene
complex	I-Gene
class	I-Gene
II	I-Gene
and	O
p21	B-Gene
genes	O
and	O
activates	O
caspase	B-Gene
-	I-Gene
3	I-Gene
/	I-Gene
7	I-Gene
in	O
human	B-Species
colon	B-Disease
cancer	I-Disease
HCT	B-CellLine
-	I-CellLine
116	I-CellLine
cells	O
.	O
</ALL>	O

<ALL>	O
Epigenetic	O
anticancer	O
drugs	O
such	O
as	O
histone	B-Gene
deacetylase	I-Gene
(	O
HDAC	B-Gene
)	O
inhibitors	O
have	O
been	O
combined	O
with	O
existing	O
anticancer	O
drugs	O
for	O
synergistic	O
or	O
additive	O
effects	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
a	O
very	O
low	O
concentration	O
of	O
depsipeptide	B-Chemical
,	O
an	O
HDAC	B-Gene
inhibitor	O
,	O
potentiated	O
the	O
antitumor	O
activity	O
of	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
in	O
a	O
human	B-Species
colon	B-Disease
cancer	I-Disease
cell	O
model	O
using	O
HCT	B-CellLine
-	I-CellLine
116	I-CellLine
,	O
HT29	B-CellLine
,	O
and	O
SW48	B-CellLine
cells	O
via	O
the	O
inhibition	O
of	O
colony	O
formation	O
ability	O
or	O
cellular	O
viability	O
.	O
</ALL>	O

<ALL>	O
Exposure	O
to	O
a	O
combination	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
(	O
1.75	O
uM	O
)	O
and	O
1	O
nM	O
depsipeptide	B-Chemical
for	O
24	O
and	O
48	O
h	O
resulted	O
in	O
a	O
3	O
-	O
to	O
4	O
-	O
fold	O
increase	O
in	O
activated	O
caspase	B-Gene
-	I-Gene
3	I-Gene
/	I-Gene
7	I-Gene
,	O
while	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
alone	O
failed	O
to	O
activate	O
caspase	B-Gene
-	I-Gene
3	I-Gene
/	I-Gene
7	I-Gene
.	O
</ALL>	O

<ALL>	O
Microarray	O
and	O
subsequent	O
gene	O
ontology	O
analyses	O
revealed	O
that	O
compared	O
to	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
or	O
depsipeptide	B-Chemical
alone	O
,	O
the	O
combination	O
treatment	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
depsipeptide	B-Chemical
upregulated	O
genes	O
related	O
to	O
cell	O
death	O
and	O
the	O
apoptotic	O
process	O
consistent	O
with	O
the	O
inhibition	O
of	O
colony	O
formation	O
and	O
caspase	B-Gene
-	I-Gene
3	I-Gene
/	I-Gene
7	I-Gene
activation	O
.	O
</ALL>	O

<ALL>	O
These	O
analyses	O
indicated	O
marked	O
upregulation	O
of	O
antigen	O
processing	O
and	O
presentation	O
of	O
peptide	O
or	O
polysaccharide	B-Chemical
antigen	O
via	O
major	B-Gene
histocompatibility	I-Gene
complex	I-Gene
(	I-Gene
MHC	I-Gene
)	I-Gene
class	I-Gene
(	O
GO:0002504	O
)	O
and	O
MHC	B-Gene
protein	I-Gene
complex	I-Gene
(	O
GO:0042611	O
)	O
.	O
</ALL>	O

<ALL>	O
Compared	O
with	O
vehicle	O
controls	O
,	O
the	O
cells	O
treated	O
with	O
the	O
combination	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
depsipeptide	B-Chemical
showed	O
marked	O
induction	O
(	O
3	O
-	O
to	O
8.5	O
-	O
fold	O
)	O
of	O
expression	O
of	O
MHC	B-Gene
class	I-Gene
II	I-Gene
genes	I-Gene
,	O
but	O
not	O
of	O
MHC	B-Gene
class	I-Gene
I	I-Gene
genes	I-Gene
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
our	O
global	O
analysis	O
of	O
gene	O
expression	O
,	O
which	O
was	O
focused	O
on	O
genes	O
involved	O
in	O
the	O
molecular	O
regulation	O
of	O
MHC	B-Gene
class	I-Gene
II	I-Gene
genes	I-Gene
,	O
showed	O
enhancement	O
of	O
pro	O
-	O
apoptotic	O
PCAF	B-Gene
and	O
CIITA	B-Gene
after	O
the	O
combination	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
depsipeptide	B-Chemical
.	O
</ALL>	O

<ALL>	O
These	O
results	O
may	O
indicate	O
a	O
closer	O
relationship	O
between	O
elevation	O
of	O
MHC	B-Gene
class	I-Gene
II	I-Gene
expression	O
and	O
cellular	O
apoptosis	O
induced	O
by	O
the	O
combination	O
of	O
depsipeptide	B-Chemical
and	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
.	O
</ALL>	O

<ALL>	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
to	O
report	O
that	O
the	O
combination	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
depsipeptide	B-Chemical
induces	O
human	B-Species
colon	B-Disease
cancer	I-Disease
cell	O
apoptosis	O
in	O
a	O
concerted	O
manner	O
with	O
the	O
induction	O
of	O
MHC	B-Gene
class	I-Gene
II	I-Gene
gene	O
expression	O
.	O
</ALL>	O

<ALL>	O
Seven	O
novel	O
and	O
six	O
de	O
novo	O
PHEX	B-Gene
gene	O
mutations	O
in	O
patients	B-Species
with	O
hypophosphatemic	B-Disease
rickets	I-Disease
.	O
</ALL>	O

<ALL>	O
Inactivating	O
mutations	O
in	O
phosphate	B-Gene
-	I-Gene
regulating	I-Gene
gene	I-Gene
with	I-Gene
homologies	I-Gene
to	I-Gene
endopeptidase	I-Gene
on	I-Gene
the	I-Gene
X	I-Gene
chromosome	I-Gene
(	O
PHEX	B-Gene
)	O
have	O
been	O
identified	O
as	O
a	O
cause	O
of	O
X	B-Disease
-	I-Disease
linked	I-Disease
hypophosphatemic	I-Disease
rickets	I-Disease
(	O
XLH	B-Disease
;	O
OMIM	B-Disease
307800	I-Disease
)	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
study	O
,	O
we	O
enrolled	O
43	O
patients	B-Species
from	O
18	O
unrelated	O
families	O
clinically	O
diagnosed	O
with	O
hypophosphatemic	B-Disease
rickets	I-Disease
and	O
250	O
healthy	O
controls	O
.	O
</ALL>	O

<ALL>	O
For	O
each	O
available	O
individual	O
,	O
all	O
22	O
exons	O
with	O
their	O
exon	O
-	O
intron	O
boundaries	O
of	O
the	O
PHEX	B-Gene
gene	O
were	O
directly	O
sequenced	O
.	O
</ALL>	O

<ALL>	O
The	O
levels	O
of	O
serum	O
fibroblast	B-Gene
growth	I-Gene
factor	I-Gene
23	I-Gene
(	O
FGF23	B-Gene
)	O
were	O
measured	O
as	O
well	O
.	O
</ALL>	O

<ALL>	O
Sequencing	O
analysis	O
detected	O
17	O
different	O
PHEX	B-Gene
gene	O
mutations	O
,	O
and	O
7	O
of	O
these	O
were	O
identified	O
as	O
novel	O
:	O
3	O
missense	O
mutations	O
,	O
including	O
c.304	B-Variant
G	I-Variant
>	I-Variant
A	I-Variant
(	O
p	B-Variant
.	I-Variant
Gly102Arg	I-Variant
)	O
in	O
exon	O
3	O
,	O
c.229	B-Variant
T	I-Variant
>	I-Variant
C	I-Variant
(	O
p	B-Variant
.	I-Variant
Cys77Arg	I-Variant
)	O
in	O
exon	O
3	O
and	O
c.824	B-Variant
T	I-Variant
>	I-Variant
C	I-Variant
(	O
p	B-Variant
.	I-Variant
Leu275Pro	I-Variant
)	O
in	O
exon	O
7	O
;	O
2	O
deletion	O
mutations	O
,	O
including	O
c.528delT	B-Variant
(	O
p	B-Variant
.	I-Variant
Glu177LysfsX44	I-Variant
)	O
in	O
exon	O
5	O
and	O
c.1234delA	B-Variant
(	O
p	B-Variant
.	I-Variant
Ser412ValfsX12	I-Variant
)	O
in	O
exon	O
11	O
;	O
and	O
2	O
alternative	O
splicing	O
mutations	O
,	O
including	O
c.436	B-Variant
_	I-Variant
436	I-Variant
+	I-Variant
1delAG	I-Variant
in	O
intron	O
4	O
at	O
splicing	O
donor	O
sites	O
and	O
c.1483	B-Variant
-	I-Variant
1	I-Variant
G	I-Variant
>	I-Variant
C	I-Variant
in	O
intron	O
13	O
at	O
splicing	O
acceptor	O
sites	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
6	O
mutations	O
were	O
proven	O
to	O
be	O
de	O
novo	O
in	O
6	O
sporadic	O
cases	O
and	O
the	O
probands	O
were	O
all	O
females	O
.	O
</ALL>	O

<ALL>	O
No	O
mutations	O
were	O
found	O
in	O
the	O
250	O
healthy	O
controls	O
.	O
</ALL>	O

<ALL>	O
The	O
serum	O
levels	O
of	O
FGF23	B-Gene
varied	O
widely	O
among	O
the	O
patients	B-Species
with	O
XLH	B-Disease
,	O
and	O
no	O
significant	O
difference	O
was	O
found	O
when	O
compared	O
with	O
those	O
of	O
the	O
healthy	O
controls	O
.	O
</ALL>	O

<ALL>	O
On	O
the	O
whole	O
,	O
the	O
findings	O
of	O
this	O
study	O
provide	O
new	O
insight	O
into	O
the	O
spectrum	O
of	O
PHEX	B-Gene
mutations	O
and	O
provide	O
potential	O
evidence	O
of	O
a	O
critical	O
domain	O
in	O
PHEX	B-Gene
protein	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
the	O
finding	O
of	O
an	O
overlap	O
of	O
the	O
serum	O
FGF23	B-Gene
levels	O
between	O
the	O
patients	B-Species
with	O
XLH	B-Disease
and	O
the	O
healthy	O
controls	O
indicates	O
its	O
limited	O
diagnostic	O
value	O
in	O
XLH	B-Disease
.	O
</ALL>	O

<ALL>	O
Localisation	O
of	O
the	O
Becker	B-Gene
muscular	I-Gene
dystrophy	I-Gene
gene	I-Gene
on	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
by	O
linkage	O
to	O
cloned	O
DNA	O
sequences	O
.	O
</ALL>	O

<ALL>	O
A	O
linkage	O
study	O
in	O
30	O
Becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
BMD	B-Disease
)	O
kindreds	O
using	O
three	O
cloned	O
DNA	O
sequences	O
from	O
the	O
X	O
chromosome	O
which	O
demonstrate	O
restriction	O
fragment	O
length	O
polymorphisms	O
(	O
RFLPs	O
)	O
,	O
suggests	O
that	O
the	O
BMD	B-Gene
gene	O
is	O
located	O
on	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
,	O
in	O
the	O
p21	O
region	O
.	O
</ALL>	O

<ALL>	O
The	O
genes	O
for	O
Becker	B-Disease
and	I-Disease
Duchenne	I-Disease
dystrophies	I-Disease
must	O
therefore	O
be	O
closely	O
linked	O
,	O
if	O
not	O
allelic	O
,	O
and	O
any	O
future	O
DNA	O
probes	O
found	O
to	O
be	O
of	O
practical	O
use	O
in	O
one	O
disorder	O
should	O
be	O
equally	O
applicable	O
to	O
the	O
other	O
.	O
</ALL>	O

<ALL>	O
The	O
linkage	O
analysis	O
also	O
provides	O
data	O
on	O
the	O
frequency	O
of	O
recombination	O
along	O
the	O
short	O
arm	O
of	O
the	O
X	O
chromosome	O
,	O
and	O
across	O
the	O
centromeric	O
region	O
..	O
</ALL>	O

<ALL>	O
X	B-Disease
-	I-Disease
linked	I-Disease
adrenoleukodystrophy	I-Disease
(	O
ALD	B-Disease
)	O
:	O
a	O
novel	O
mutation	O
of	O
the	O
ALD	B-Gene
gene	O
in	O
6	O
members	O
of	O
a	O
family	O
presenting	O
with	O
5	O
different	O
phenotypes	O
.	O
</ALL>	O

<ALL>	O
Fragments	O
of	O
the	O
adrenoleukodystrophy	B-Disease
(	O
ALD	B-Disease
)	O
cDNA	O
from	O
a	O
patient	B-Species
with	O
adolescent	O
ALD	B-Disease
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
subcloned	O
.	O
</ALL>	O

<ALL>	O
Bidirectional	O
sequencing	O
of	O
the	O
entire	O
coding	O
ALD	B-Gene
gene	O
disclosed	O
a	O
cytosine	B-Variant
to	I-Variant
guanine	I-Variant
transversion	I-Variant
at	I-Variant
nucleotide	I-Variant
1451	I-Variant
in	O
exon	O
five	O
,	O
resulting	O
in	O
substitution	O
of	O
proline	B-Variant
484	I-Variant
by	I-Variant
arginine	I-Variant
.	O
</ALL>	O

<ALL>	O
Five	O
of	O
nine	O
siblings	O
of	O
the	O
patient	B-Species
,	O
comprising	O
two	O
cerebral	O
ALD	B-Disease
,	O
one	O
adrenomyeloneuropathy	B-Disease
,	O
one	O
Addison	B-Disease
only	O
as	O
well	O
as	O
the	O
symptomatic	O
mother	O
(	O
all	O
accumulating	O
very	O
long	B-Chemical
chain	I-Chemical
fatty	I-Chemical
acids	I-Chemical
)	O
carried	O
this	O
mutation	O
,	O
which	O
was	O
not	O
found	O
in	O
the	O
unaffected	O
persons	O
,	O
in	O
five	O
unrelated	O
ALD	B-Disease
patients	B-Species
,	O
and	O
in	O
twenty	O
controls	O
.	O
</ALL>	O

<ALL>	O
We	O
propose	O
that	O
this	O
missense	O
mutation	O
generated	O
the	O
disease	O
per	O
se	O
as	O
well	O
as	O
the	O
metabolic	O
defect	O
;	O
the	O
different	O
phenotypes	O
,	O
however	O
,	O
must	O
have	O
originated	O
by	O
means	O
of	O
additional	O
pathogenetic	O
factors	O
..	O
</ALL>	O

<ALL>	O
Detection	O
of	O
heterozygous	O
mutations	O
in	O
BRCA1	B-Gene
using	O
high	O
density	O
oligonucleotide	O
arrays	O
and	O
two	O
-	O
colour	O
fluorescence	O
analysis	O
.	O
</ALL>	O

<ALL>	O
The	O
ability	O
to	O
scan	O
a	O
large	O
gene	O
rapidly	O
and	O
accurately	O
for	O
all	O
possible	O
heterozygous	O
mutations	O
in	O
large	O
numbers	O
of	O
patient	B-Species
samples	O
will	O
be	O
critical	O
for	O
the	O
future	O
of	O
medicine	O
.	O
</ALL>	O

<ALL>	O
We	O
have	O
designed	O
high	O
-	O
density	O
arrays	O
consisting	O
of	O
over	O
96	O
,	O
600	O
oligonucleotides	O
20	O
-	O
nucleotides	O
(	O
nt	O
)	O
in	O
length	O
to	O
screen	O
for	O
a	O
wide	O
range	O
of	O
heterozygous	O
mutations	O
in	O
the	O
3	O
.	O
</ALL>	O

<ALL>	O
45	O
-	O
kilobases	O
(	O
kb	O
)	O
exon	O
11	O
of	O
the	O
hereditary	O
breast	B-Gene
and	I-Gene
ovarian	I-Gene
cancer	I-Gene
gene	I-Gene
BRCA1	B-Gene
.	O
</ALL>	O

<ALL>	O
Reference	O
and	O
test	O
samples	O
were	O
co	O
-	O
hybridized	O
to	O
these	O
arrays	O
and	O
differences	O
in	O
hybridization	O
patterns	O
quantitated	O
by	O
two	O
-	O
colour	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Fourteen	O
of	O
fifteen	O
patient	B-Species
samples	O
with	O
known	O
mutations	O
were	O
accurately	O
diagnosed	O
,	O
and	O
no	O
false	O
positive	O
mutations	O
were	O
identified	O
in	O
20	O
control	O
samples	O
.	O
</ALL>	O

<ALL>	O
Eight	O
single	O
nucleotide	O
polymorphisms	O
were	O
also	O
readily	O
detected	O
.	O
</ALL>	O

<ALL>	O
DNA	O
chip	O
-	O
based	O
assays	O
may	O
provide	O
a	O
valuable	O
new	O
technology	O
for	O
high	O
-	O
throughput	O
cost	O
-	O
efficient	O
detection	O
of	O
genetic	O
alterations	O
.	O
</ALL>	O

<ALL>	O
Single	O
nucleotide	O
polymorphisms	O
of	O
the	O
HNF4alpha	B-Gene
gene	O
are	O
associated	O
with	O
the	O
conversion	O
to	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
mellitus	I-Disease
:	O
the	O
STOP	O
-	O
NIDDM	O
trial	O
.	O
</ALL>	O

<ALL>	O
Hepatocyte	B-Gene
nuclear	I-Gene
factor	I-Gene
4alpha	I-Gene
(	O
HNF4alpha	B-Gene
)	O
is	O
a	O
transcription	O
factor	O
,	O
which	O
is	O
necessary	O
for	O
normal	O
function	O
of	O
human	B-Species
liver	O
and	O
pancreatic	O
islets	O
.	O
</ALL>	O

<ALL>	O
We	O
investigated	O
whether	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
of	O
HNF4A	B-Gene
,	O
encoding	O
HNF4alpha	B-Gene
,	O
influenced	O
the	O
conversion	O
from	O
impaired	B-Disease
glucose	I-Disease
tolerance	I-Disease
(	O
IGT	B-Disease
)	O
to	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
mellitus	I-Disease
in	O
subjects	O
of	O
the	O
STOP	O
-	O
NIDDM	O
trial	O
.	O
</ALL>	O

<ALL>	O
This	O
trial	O
aimed	O
at	O
evaluating	O
the	O
effect	O
of	O
acarbose	B-Chemical
compared	O
to	O
placebo	O
in	O
the	O
prevention	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
mellitus	I-Disease
.	O
</ALL>	O

<ALL>	O
Eight	O
SNPs	O
covering	O
the	O
intragenic	O
and	O
alternate	O
P2	O
promoter	O
regions	O
of	O
HNF4A	B-Gene
were	O
genotyped	O
in	O
study	O
samples	O
using	O
the	O
TaqMan	O
Allelic	O
Discrimination	O
Assays	O
.	O
</ALL>	O

<ALL>	O
Three	O
SNPs	O
in	O
the	O
P2	O
promoter	O
region	O
(	O
rs4810424	B-Variant
,	O
rs1884614	B-Variant
,	O
and	O
rs2144908	B-Variant
)	O
were	O
in	O
almost	O
complete	O
association	O
(	O
D	O
'	O
>	O
0.97	O
,	O
r	O
(	O
2	O
)	O
>	O
0.95	O
)	O
and	O
,	O
therefore	O
,	O
only	O
rs4810424	B-Variant
was	O
included	O
in	O
further	O
analyses	O
.	O
</ALL>	O

<ALL>	O
Female	O
carriers	O
of	O
the	O
less	O
frequent	O
C	O
allele	O
of	O
rs4810424	B-Variant
had	O
a	O
1.7	O
-	O
fold	O
elevated	O
risk	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.09	O
-	O
2.66	O
;	O
P	O
=	O
0.020	O
]	O
for	O
the	O
conversion	O
to	O
diabetes	B-Disease
compared	O
to	O
women	B-Species
with	O
the	O
common	O
genotype	O
after	O
the	O
adjustment	O
for	O
age	O
,	O
treatment	O
group	O
(	O
placebo	O
or	O
acarbose	B-Chemical
)	O
,	O
smoking	O
,	O
weight	O
at	O
baseline	O
,	O
and	O
weight	O
change	O
.	O
</ALL>	O

<ALL>	O
No	O
association	O
was	O
found	O
in	O
men	B-Species
.	O
</ALL>	O

<ALL>	O
Haplotype	O
analysis	O
based	O
on	O
three	O
SNPs	O
(	O
rs4810424	B-Variant
,	O
rs2071197	B-Variant
,	O
and	O
rs3818247	B-Variant
)	O
representing	O
the	O
linkage	O
disequilibrium	O
blocks	O
in	O
our	O
study	O
population	O
indicated	O
that	O
the	O
conversion	O
to	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
mellitus	I-Disease
was	O
dependent	O
on	O
the	O
number	O
of	O
risk	O
alleles	O
in	O
different	O
haplotypes	O
in	O
women	B-Species
.	O
</ALL>	O

<ALL>	O
Our	O
results	O
suggest	O
that	O
SNPs	O
of	O
HNF4A	B-Gene
and	O
their	O
haplotypes	O
predispose	O
to	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
mellitus	I-Disease
in	O
female	O
subjects	O
of	O
the	O
STOP	O
-	O
NIDDM	O
study	O
population	O
.	O
</ALL>	O

<ALL>	O
Hepatic	O
but	O
not	O
brain	O
iron	B-Chemical
is	O
rapidly	O
chelated	O
by	O
deferasirox	B-Chemical
in	O
aceruloplasminemia	B-Disease
due	O
to	O
a	O
novel	O
gene	O
mutation	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
_	O
#	O
38	O
;	O
AIMS	O
:	O
Aceruloplasminemia	B-Disease
is	O
a	O
rare	O
autosomal	B-Disease
recessive	I-Disease
neurodegenerative	I-Disease
disease	I-Disease
associated	O
with	O
brain	O
and	O
liver	O
iron	B-Chemical
accumulation	O
which	O
typically	O
presents	O
with	O
movement	B-Disease
disorders	I-Disease
,	O
retinal	B-Disease
degeneration	I-Disease
,	O
and	O
diabetes	B-Disease
mellitus	I-Disease
.	O
</ALL>	O

<ALL>	O
Ceruloplasmin	B-Gene
is	O
a	O
multi	O
-	O
copper	O
ferroxidase	B-Chemical
that	O
is	O
secreted	O
into	O
plasma	O
and	O
facilitates	O
cellular	O
iron	B-Chemical
export	O
and	O
iron	B-Chemical
binding	O
to	O
transferrin	B-Gene
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
A	O
novel	O
homozygous	O
ceruloplasmin	B-Gene
gene	O
mutation	O
,	O
c.2554	B-Variant
+	I-Variant
1	I-Variant
G	I-Variant
>	I-Variant
T	I-Variant
,	O
was	O
identified	O
as	O
the	O
cause	O
of	O
aceruloplasminemia	B-Disease
in	O
three	O
affected	O
siblings	O
.	O
</ALL>	O

<ALL>	O
Two	O
siblings	O
presented	O
with	O
movement	B-Disease
disorders	I-Disease
and	O
diabetes	B-Disease
.	O
</ALL>	O

<ALL>	O
Complementary	O
DNA	O
sequencing	O
showed	O
that	O
this	O
mutation	O
causes	O
skipping	O
of	O
exon	O
14	O
and	O
deletion	B-Variant
of	I-Variant
amino	I-Variant
acids	I-Variant
809	I-Variant
-	I-Variant
852	I-Variant
while	O
preserving	O
the	O
open	O
reading	O
frame	O
.	O
</ALL>	O

<ALL>	O
Western	O
blotting	O
of	O
liver	O
extracts	O
and	O
sera	O
of	O
affected	O
patients	B-Species
showed	O
retention	O
of	O
the	O
abnormal	O
protein	O
in	O
the	O
liver	O
.	O
</ALL>	O

<ALL>	O
Aceruloplasminemia	B-Disease
was	O
associated	O
with	O
severe	O
brain	O
and	O
liver	O
iron	B-Disease
overload	I-Disease
,	O
where	O
hepatic	O
mRNA	O
expression	O
of	O
the	O
iron	B-Chemical
hormone	O
hepcidin	B-Gene
was	O
increased	O
,	O
corresponding	O
to	O
the	O
degree	O
of	O
iron	B-Disease
overload	I-Disease
.	O
</ALL>	O

<ALL>	O
Hepatic	O
iron	B-Chemical
concentration	O
normalized	O
after	O
3	O
and	O
5months	O
of	O
iron	B-Chemical
chelation	O
therapy	O
with	O
deferasirox	B-Chemical
,	O
which	O
was	O
also	O
associated	O
with	O
reduced	O
insulin	B-Gene
demands	O
.	O
</ALL>	O

<ALL>	O
During	O
short	O
term	O
treatment	O
there	O
was	O
no	O
clinical	O
or	O
imaging	O
evidence	O
for	O
significant	O
effects	O
on	O
brain	O
iron	B-Disease
overload	I-Disease
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Aceruloplasminemia	B-Disease
can	O
show	O
an	O
incomplete	O
clinical	O
penetrance	O
but	O
is	O
invariably	O
associated	O
with	O
iron	B-Chemical
accumulation	O
in	O
the	O
liver	O
and	O
in	O
the	O
brain	O
.	O
</ALL>	O

<ALL>	O
Iron	B-Chemical
accumulation	O
in	O
aceruloplasminemia	B-Disease
is	O
a	O
result	O
of	O
defective	O
cellular	O
iron	B-Chemical
export	O
,	O
where	O
hepcidin	B-Gene
regulation	O
is	O
appropriate	O
for	O
the	O
degree	O
of	O
iron	B-Disease
overload	I-Disease
.	O
</ALL>	O

<ALL>	O
Iron	B-Chemical
chelation	O
with	O
deferasirox	B-Chemical
was	O
effective	O
in	O
mobilizing	O
hepatic	O
iron	B-Chemical
but	O
has	O
no	O
effect	O
on	O
brain	O
iron	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
androgen	B-Gene
receptor	I-Gene
confers	O
protection	O
against	O
diet	O
-	O
induced	O
atherosclerosis	B-Disease
,	O
obesity	B-Disease
,	O
and	O
dyslipidemia	B-Disease
in	O
female	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Androgens	B-Chemical
have	O
important	O
cardiometabolic	O
actions	O
in	O
males	O
,	O
but	O
their	O
metabolic	O
role	O
in	O
females	O
is	O
unclear	O
.	O
</ALL>	O

<ALL>	O
To	O
determine	O
the	O
physiologic	O
androgen	B-Gene
receptor	I-Gene
(	O
AR	B-Gene
)	O
-	O
dependent	O
actions	O
of	O
androgens	B-Chemical
on	O
atherogenesis	B-Disease
in	O
female	O
mice	B-Species
,	O
we	O
generated	O
female	O
AR	B-Gene
-	O
knockout	O
(	O
AR	B-Gene
KO	O
)	O
mice	B-Species
on	O
an	O
atherosclerosis	B-Disease
-	O
prone	O
apolipoprotein	B-Gene
E	I-Gene
(	O
apoE	B-Gene
)	O
-	O
deficient	O
background	O
.	O
</ALL>	O

<ALL>	O
After	O
8	O
weeks	O
on	O
a	O
high	O
-	O
fat	O
diet	O
,	O
but	O
not	O
on	O
a	O
normal	O
chow	O
diet	O
,	O
atherosclerosis	B-Disease
in	O
aorta	O
was	O
increased	O
in	O
AR	B-Gene
KO	O
females	O
(	O
+	O
59	O
%	O
vs.	O
control	O
apoE	B-Gene
-	O
deficient	O
mice	B-Species
with	O
intact	O
AR	B-Gene
gene	O
)	O
.	O
</ALL>	O

<ALL>	O
They	O
also	O
displayed	O
increased	O
body	O
weight	O
(	O
+	O
18	O
%	O
)	O
,	O
body	O
fat	O
percentage	O
(	O
+	O
62	O
%	O
)	O
,	O
and	O
hepatic	O
triglyceride	B-Gene
levels	O
,	O
reduced	O
insulin	B-Gene
sensitivity	O
,	O
and	O
a	O
marked	O
atherogenic	B-Disease
dyslipidemia	B-Disease
(	O
serum	O
cholesterol	B-Chemical
,	O
+	O
52	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
Differences	O
in	O
atherosclerosis	B-Disease
,	O
body	O
weight	O
,	O
and	O
lipid	B-Chemical
levels	O
between	O
AR	B-Gene
KO	O
and	O
control	O
mice	B-Species
were	O
abolished	O
in	O
mice	B-Species
that	O
were	O
ovariectomized	O
before	O
puberty	O
,	O
consistent	O
with	O
a	O
protective	O
action	O
of	O
ovarian	O
androgens	B-Chemical
mediated	O
via	O
the	O
AR	B-Gene
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
the	O
AR	B-Gene
agonist	O
dihydrotestosterone	B-Chemical
reduced	O
atherosclerosis	B-Disease
(	O
-	O
41	O
%	O
;	O
thoracic	O
aorta	O
)	O
,	O
subcutaneous	O
fat	O
mass	O
(	O
-	O
44	O
%	O
)	O
,	O
and	O
cholesterol	B-Chemical
levels	O
(	O
-	O
35	O
%	O
)	O
in	O
ovariectomized	O
mice	B-Species
,	O
reduced	O
hepatocyte	O
lipid	B-Chemical
accumulation	O
in	O
hepatoma	B-Disease
cells	O
in	O
vitro	O
,	O
and	O
regulated	O
mRNA	O
expression	O
of	O
hepatic	O
genes	O
pivotal	O
for	O
lipid	B-Chemical
homeostasis	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
we	O
demonstrate	O
that	O
the	O
AR	B-Gene
protects	O
against	O
diet	O
-	O
induced	O
atherosclerosis	B-Disease
in	O
female	O
mice	B-Species
and	O
propose	O
that	O
this	O
is	O
mediated	O
by	O
modulation	O
of	O
body	O
composition	O
and	O
lipid	B-Chemical
metabolism	O
.	O
</ALL>	O

<ALL>	O
Circulating	O
Fatty	B-Gene
Acid	I-Gene
Synthase	I-Gene
in	O
pregnant	O
women	B-Species
:	O
Relationship	O
to	O
blood	O
pressure	O
,	O
maternal	O
metabolism	O
and	O
newborn	O
parameters	O
.	O
</ALL>	O

<ALL>	O
The	O
enzyme	O
FASN	B-Gene
(	O
fatty	B-Gene
acid	I-Gene
synthase	I-Gene
)	O
is	O
potentially	O
related	O
with	O
hypertension	B-Disease
and	O
metabolic	B-Disease
dysfunction	I-Disease
.	O
</ALL>	O

<ALL>	O
FASN	B-Gene
is	O
highly	O
expressed	O
in	O
the	O
human	B-Species
placenta	O
.	O
</ALL>	O

<ALL>	O
We	O
aimed	O
to	O
investigate	O
the	O
relationship	O
circulating	O
FASN	B-Gene
has	O
with	O
blood	O
pressure	O
,	O
maternal	O
metabolism	O
and	O
newborn	O
parameters	O
in	O
healthy	O
pregnant	O
women	B-Species
.	O
</ALL>	O

<ALL>	O
Circulating	O
FASN	B-Gene
was	O
assessed	O
in	O
115	O
asymptomatic	O
pregnant	O
women	B-Species
in	O
the	O
second	O
trimester	O
of	O
gestation	O
along	O
with	O
C	B-Chemical
-	I-Chemical
peptide	I-Chemical
,	O
fasting	O
glucose	B-Chemical
and	O
insulin	B-Gene
,	O
post	O
-	O
load	O
glucose	B-Chemical
lipids	B-Chemical
,	O
HMW	B-Gene
-	O
adiponectin	B-Gene
and	O
blood	O
pressure	O
(	O
the	O
latter	O
was	O
assessed	O
in	O
each	O
trimester	O
of	O
gestation	O
)	O
.	O
</ALL>	O

<ALL>	O
At	O
birth	O
,	O
newborns	O
and	O
placentas	O
were	O
weighed	O
.	O
</ALL>	O

<ALL>	O
FASN	B-Gene
expression	O
was	O
also	O
able	O
to	O
be	O
assessed	O
in	O
80	O
placentas	O
.	O
</ALL>	O

<ALL>	O
Higher	O
circulating	O
FASN	B-Gene
was	O
associated	O
with	O
lower	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
,	O
with	O
a	O
more	O
favourable	O
metabolic	O
phenotype	O
(	O
lower	O
fasting	O
glucose	B-Chemical
and	O
insulin	B-Gene
,	O
post	O
load	O
glucose	B-Chemical
,	O
HbAc1	B-Gene
,	O
HOMA	O
-	O
IR	O
and	O
C	B-Chemical
-	I-Chemical
peptide	I-Chemical
)	O
,	O
and	O
with	O
lower	O
placental	O
and	O
birth	O
weight	O
(	O
all	O
p	O
<	O
0.05	O
to	O
p	O
<	O
0.001	O
)	O
.	O
</ALL>	O

<ALL>	O
Placental	O
FASN	B-Gene
expression	O
related	O
positively	O
to	O
circulating	O
FASN	B-Gene
(	O
p	O
<	O
0.005	O
)	O
and	O
negatively	O
to	O
placental	O
weight	O
(	O
p	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
Our	O
observations	O
suggest	O
a	O
physiological	O
role	O
of	O
placental	O
FASN	B-Gene
in	O
human	B-Species
pregnancy	O
.	O
</ALL>	O

<ALL>	O
Future	O
studies	O
will	O
clarify	O
whether	O
circulating	O
FASN	B-Gene
of	O
placental	O
origin	O
does	O
actually	O
regulate	O
placental	O
and	O
fetal	O
growth	O
,	O
and	O
(	O
thereby	O
)	O
has	O
a	O
favourable	O
influence	O
on	O
the	O
pregnant	O
mother	O
's	O
insulin	B-Gene
sensitivity	O
and	O
blood	O
pressure	O
.	O
</ALL>	O

<ALL>	O
Sildenafil	B-Chemical
attenuates	O
hypoxic	B-Disease
pulmonary	I-Disease
remodelling	I-Disease
by	O
inhibiting	O
bone	O
marrow	O
progenitor	O
cells	O
.	O
</ALL>	O

<ALL>	O
The	O
recruitment	O
of	O
bone	O
marrow	O
(	O
BM	O
)	O
-	O
derived	O
progenitor	O
cells	O
to	O
the	O
lung	O
is	O
related	O
to	O
pulmonary	B-Disease
remodelling	I-Disease
and	O
the	O
pathogenesis	O
of	O
pulmonary	B-Disease
hypertension	I-Disease
(	O
PH	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Although	O
sildenafil	B-Chemical
is	O
a	O
known	O
target	O
in	O
PH	B-Disease
treatment	O
,	O
the	O
underlying	O
molecular	O
mechanism	O
is	O
still	O
elusive	O
.	O
</ALL>	O

<ALL>	O
To	O
test	O
the	O
hypothesis	O
that	O
the	O
therapeutic	O
effect	O
of	O
sildenafil	B-Chemical
is	O
linked	O
to	O
the	O
reduced	O
recruitment	O
of	O
BM	O
-	O
derived	O
progenitor	O
cells	O
,	O
we	O
induced	O
pulmonary	B-Disease
remodelling	I-Disease
in	O
rats	B-Species
by	O
two	O
-	O
week	O
exposure	O
to	O
chronic	O
hypoxia	B-Disease
(	O
CH	B-Disease
,	O
10	O
%	O
oxygen	B-Chemical
)	O
,	O
a	O
trigger	O
of	O
BM	O
-	O
derived	O
progenitor	O
cells	O
.	O
</ALL>	O

<ALL>	O
Rats	B-Species
were	O
treated	O
with	O
either	O
placebo	O
(	O
saline	O
)	O
or	O
sildenafil	B-Chemical
(	O
1.4	O
mg	O
/	O
kg	O
/	O
day	O
ip	O
)	O
during	O
CH	B-Disease
.	O
</ALL>	O

<ALL>	O
Control	O
rats	B-Species
were	O
kept	O
in	O
room	O
air	O
(	O
21	O
%	O
oxygen	B-Chemical
)	O
with	O
no	O
treatment	O
.	O
</ALL>	O

<ALL>	O
As	O
expected	O
,	O
sildenafil	B-Chemical
attenuated	O
the	O
CH	B-Disease
-	O
induced	O
increase	O
in	O
right	O
ventricular	O
systolic	O
pressure	O
and	O
right	B-Disease
ventricular	I-Disease
hypertrophy	I-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
sildenafil	B-Chemical
suppressed	O
the	O
CH	B-Disease
-	O
induced	O
increase	O
in	O
c	B-Gene
-	I-Gene
kit	I-Gene
(	O
+	O
)	O
cells	O
in	O
the	O
adventitia	O
of	O
pulmonary	O
arteries	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
sildenafil	B-Chemical
reduced	O
the	O
number	O
of	O
c	B-Gene
-	I-Gene
kit	I-Gene
(	O
+	O
)	O
cells	O
that	O
colocalize	O
with	O
tyrosine	B-Gene
kinase	I-Gene
receptor	I-Gene
2	I-Gene
(	O
VEGF	B-Gene
-	I-Gene
R2	I-Gene
)	O
and	O
CD68	B-Gene
(	O
a	O
marker	O
for	O
macrophages	O
)	O
,	O
indicating	O
a	O
positive	O
effect	O
on	O
moderating	O
hypoxia	B-Disease
-	O
induced	O
smooth	O
muscle	O
cell	O
proliferation	O
and	O
inflammation	B-Disease
without	O
affecting	O
the	O
pulmonary	O
levels	O
of	O
hypoxia	B-Gene
-	I-Gene
inducible	I-Gene
factor	I-Gene
(	I-Gene
HIF	I-Gene
)	I-Gene
-	I-Gene
1a	I-Gene
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
sildenafil	B-Chemical
depressed	O
the	O
number	O
of	O
CXCR4	B-Gene
(	O
+	O
)	O
cells	O
.	O
</ALL>	O

<ALL>	O
Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
improvement	O
in	O
pulmonary	O
haemodynamic	O
by	O
sildenafil	B-Chemical
is	O
linked	O
to	O
decreased	O
recruitment	O
of	O
BM	O
-	O
derived	O
c	B-Gene
-	I-Gene
kit	I-Gene
(	O
+	O
)	O
cells	O
in	O
the	O
pulmonary	O
tissue	O
.	O
</ALL>	O

<ALL>	O
The	O
attenuation	O
of	O
the	O
recruitment	O
of	O
BM	O
-	O
derived	O
c	B-Gene
-	I-Gene
kit	I-Gene
(	O
+	O
)	O
cells	O
by	O
sildenafil	B-Chemical
may	O
provide	O
novel	O
therapeutic	O
insights	O
into	O
the	O
control	O
of	O
pulmonary	B-Disease
remodelling	I-Disease
.	O
</ALL>	O

<ALL>	O
Genetic	O
variants	O
of	O
the	O
T	B-Gene
-	I-Gene
cell	I-Gene
immunoglobulin	I-Gene
mucin	I-Gene
1	I-Gene
but	O
not	O
the	O
T	B-Gene
-	I-Gene
cell	I-Gene
immunoglobulin	I-Gene
mucin	I-Gene
3	I-Gene
gene	O
are	O
associated	O
with	O
asthma	B-Disease
in	O
an	O
African	O
American	O
population	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
The	O
T	B-Gene
-	I-Gene
cell	I-Gene
immunoglobulin	I-Gene
mucin	I-Gene
(	O
TIM	B-Gene
)	O
proteins	O
and	O
their	O
genetic	O
variants	O
have	O
been	O
suggested	O
to	O
play	O
a	O
role	O
in	O
regulating	O
allergic	B-Disease
diseases	I-Disease
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
Genetic	O
association	O
of	O
the	O
sequence	O
variants	O
for	O
TIM	B-Gene
-	I-Gene
1	I-Gene
and	O
TIM	B-Gene
-	I-Gene
3	I-Gene
genes	O
with	O
asthma	B-Disease
in	O
an	O
African	O
American	O
population	O
was	O
investigated	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Both	O
case	O
-	O
control	O
and	O
family	O
-	O
based	O
association	O
analyses	O
were	O
performed	O
for	O
a	O
total	O
of	O
7	O
polymorphisms	O
,	O
including	O
3	O
single	O
nucleotide	O
polymorphism	O
(	O
SNPs	O
)	O
and	O
1	O
insertion	O
/	O
deletion	O
polymorphism	O
in	O
the	O
TIM	B-Gene
-	I-Gene
1	I-Gene
and	I-Gene
3	I-Gene
SNPs	O
in	O
the	O
TIM	B-Gene
-	I-Gene
3	I-Gene
genes	O
.	O
</ALL>	O

<ALL>	O
The	O
exposure	O
to	O
hepatitis	B-Species
A	I-Species
virus	I-Species
as	O
judged	O
by	O
seropositivity	O
was	O
also	O
examined	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
In	O
the	O
case	O
-	O
control	O
design	O
,	O
the	O
frequencies	O
of	O
the	O
TT	O
genotype	O
for	O
SNP	O
rs2277025	B-Variant
and	O
the	O
homozygous	O
deletion	O
variant	O
(	O
157delMTTTVP	B-Variant
)	O
in	O
the	O
fourth	O
exon	O
of	O
the	O
TIM	B-Gene
-	I-Gene
1	I-Gene
gene	O
were	O
higher	O
among	O
patients	B-Species
with	O
patients	B-Species
with	O
asthma	B-Disease
compared	O
with	O
the	O
controls	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
2.779	O
,	O
P	O
=	O
.016	O
;	O
and	O
OR	O
,	O
3.09	O
,	O
P	O
=	O
.022	O
,	O
respectively	O
)	O
.	O
</ALL>	O

<ALL>	O
This	O
association	O
was	O
substantiated	O
by	O
haplotype	O
analysis	O
of	O
these	O
and	O
2	O
additional	O
SNPs	O
(	O
OR	O
,	O
2.48	O
;	O
P	O
=	O
.004	O
)	O
,	O
and	O
also	O
by	O
family	O
-	O
based	O
tests	O
for	O
the	O
allele	O
and	O
haplotype	O
carrying	O
157delMTTTVP	B-Variant
(	O
P	O
=	O
.009	O
and	O
P	O
=	O
.048	O
,	O
respectively	O
)	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
this	O
association	O
seems	O
to	O
exist	O
even	O
in	O
the	O
hepatitis	B-Species
A	I-Species
virus	I-Species
-	O
seronegative	O
subjects	O
in	O
our	O
data	O
.	O
</ALL>	O

<ALL>	O
None	O
of	O
the	O
3	O
variants	O
in	O
TIM	B-Gene
-	I-Gene
3	I-Gene
genes	O
yielded	O
significant	O
association	O
with	O
either	O
asthma	B-Disease
or	O
asthma	B-Disease
-	O
related	O
phenotypes	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
the	O
genetic	O
variants	O
of	O
the	O
TIM	B-Gene
-	I-Gene
1	I-Gene
but	O
not	O
the	O
TIM	B-Gene
-	I-Gene
3	I-Gene
gene	O
contribute	O
to	O
asthma	B-Disease
susceptibility	O
in	O
this	O
African	O
-	O
American	O
population	O
.	O
</ALL>	O

<ALL>	O
Identification	O
of	O
the	O
BRAF	B-Gene
V600E	B-Variant
mutation	O
in	O
gastroenteropancreatic	B-Disease
neuroendocrine	I-Disease
tumors	I-Disease
.	O
</ALL>	O

<ALL>	O
Genomic	O
profiles	O
of	O
gastroenteropancreatic	B-Disease
neuroendocrine	I-Disease
tumors	I-Disease
(	O
GEP	B-Disease
-	I-Disease
NETs	I-Disease
)	O
are	O
still	O
insufficiently	O
understood	O
,	O
and	O
the	O
genetic	O
alterations	O
associated	O
with	O
drug	O
responses	O
have	O
not	O
been	O
studied	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
performed	O
whole	O
exome	O
sequencing	O
of	O
12	O
GEP	B-Disease
-	I-Disease
NETs	I-Disease
from	O
patients	B-Species
enrolled	O
in	O
a	O
nonrandomized	O
,	O
open	O
-	O
labeled	O
,	O
single	O
-	O
center	O
phase	O
II	O
study	O
for	O
pazopanib	B-Chemical
,	O
and	O
integrated	O
our	O
results	O
with	O
previously	O
published	O
results	O
on	O
pancreas	O
(	O
n	O
=	O
12	O
)	O
and	O
small	O
intestine	B-Disease
NETs	I-Disease
(	O
n	O
=	O
50	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
mean	O
numbers	O
of	O
somatic	O
mutations	O
in	O
each	O
case	O
varied	O
widely	O
from	O
20	O
to	O
4682	O
.	O
</ALL>	O

<ALL>	O
Among	O
12	O
GEP	B-Disease
-	I-Disease
NETs	I-Disease
,	O
eight	O
showed	O
mutations	O
of	O
more	O
than	O
one	O
cancer	B-Disease
-	O
related	O
gene	O
,	O
including	O
TP53	B-Gene
,	O
CNBD1	B-Gene
,	O
RB1	B-Gene
,	O
APC	B-Gene
,	O
BCOR	B-Gene
,	O
BRAF	B-Gene
,	O
CTNNB1	B-Gene
,	O
EGFR	B-Gene
,	O
EP300	B-Gene
,	O
ERBB3	B-Gene
,	O
KDM6A	B-Gene
,	O
KRAS	B-Gene
,	O
MGA	B-Gene
,	O
MLL3	B-Gene
,	O
PTEN	B-Gene
,	O
RASA1	B-Gene
,	O
SMARCB1	B-Gene
,	O
SPEN	B-Gene
,	O
TBC1D12	B-Gene
,	O
and	O
VHL	B-Gene
.	O
</ALL>	O

<ALL>	O
TP53	B-Gene
was	O
recurrently	O
mutated	O
in	O
three	O
cases	O
,	O
whereas	O
CNBD1	B-Gene
and	O
RB1	B-Gene
mutations	O
were	O
identified	O
in	O
two	O
cases	O
.	O
</ALL>	O

<ALL>	O
Three	O
GEP	B-Disease
-	I-Disease
NET	I-Disease
patients	B-Species
with	O
TP53	B-Gene
mutations	O
demonstrated	O
a	O
durable	O
response	O
and	O
one	O
small	O
intestinal	B-Disease
grade	I-Disease
(	I-Disease
G	I-Disease
)	I-Disease
1	I-Disease
NET	I-Disease
patient	B-Species
with	O
BRAF	B-Gene
V600E	B-Variant
mutation	O
showed	O
progression	O
after	O
pazopanib	B-Chemical
treatment	O
.	O
</ALL>	O

<ALL>	O
We	O
found	O
BRAF	B-Gene
V600E	B-Variant
(	O
G1	O
NET	B-Disease
from	O
rectum	O
and	O
two	O
G3	O
NETs	B-Disease
from	O
colon	O
)	O
and	O
BRAF	B-Gene
G593S	B-Variant
(	O
G2	O
NET	B-Disease
from	O
pancreas	O
)	O
missense	O
mutations	O
(	O
9.1	O
%	O
)	O
in	O
an	O
independent	O
cohort	O
of	O
44	O
GEP	B-Disease
-	I-Disease
NETs	I-Disease
from	O
the	O
rectum	O
(	O
n	O
=	O
26	O
)	O
,	O
colon	O
(	O
n	O
=	O
7	O
)	O
,	O
pancreas	O
(	O
n	O
=	O
4	O
)	O
,	O
small	O
intestine	O
(	O
n	O
=	O
3	O
)	O
,	O
stomach	O
(	O
n	O
=	O
3	O
)	O
and	O
appendix	O
(	O
n	O
=	O
1	O
)	O
by	O
Sanger	O
sequencing	O
.	O
</ALL>	O

<ALL>	O
All	O
tumor	B-Disease
specimens	O
were	O
obtained	O
before	O
chemotherapy	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
BRAF	B-Gene
V600E	B-Variant
mutation	O
is	O
likely	O
to	O
result	O
in	O
resistance	O
to	O
pazopanib	B-Chemical
but	O
may	O
be	O
a	O
potentianally	O
actionable	O
mutation	O
in	O
metastatic	O
GEP	B-Disease
-	I-Disease
NETs	I-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
MicroRNA	O
deep	O
sequencing	O
in	O
two	O
adult	O
stem	O
cell	O
populations	O
identifies	O
miR	B-Gene
-	I-Gene
501	I-Gene
as	O
a	O
novel	O
regulator	O
of	O
myosin	B-Gene
heavy	I-Gene
chain	I-Gene
during	O
muscle	O
regeneration	O
.	O
</ALL>	O

<ALL>	O
MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
important	O
regulators	O
of	O
skeletal	O
muscle	O
regeneration	O
,	O
but	O
the	O
underlying	O
mechanisms	O
are	O
still	O
incompletely	O
understood	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
comparative	O
miRNA	O
sequencing	O
analysis	O
of	O
myogenic	O
progenitor	O
cells	O
(	O
MPs	O
)	O
and	O
non	O
-	O
myogenic	O
fibroblast	O
-	O
adipocyte	O
progenitors	O
(	O
FAPs	O
)	O
during	O
cardiotoxin	B-Chemical
(	O
CTX	B-Chemical
)	O
-	O
induced	O
muscle	B-Disease
injury	I-Disease
uncovered	O
miR	B-Gene
-	I-Gene
501	I-Gene
as	O
a	O
novel	O
muscle	O
-	O
specific	O
miRNA	O
.	O
</ALL>	O

<ALL>	O
miR	B-Gene
-	I-Gene
501	I-Gene
is	O
an	O
intronic	O
miRNA	O
and	O
its	O
expression	O
levels	O
in	O
MPs	O
correlated	O
with	O
its	O
host	O
gene	O
,	O
chloride	B-Gene
channel	I-Gene
,	I-Gene
voltage	I-Gene
-	I-Gene
sensitive	I-Gene
5	I-Gene
(	O
Clcn5	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
Pharmacological	O
inhibition	O
of	O
miR	B-Gene
-	I-Gene
501	I-Gene
dramatically	O
blunted	O
the	O
induction	O
of	O
embryonic	O
myosin	B-Gene
heavy	I-Gene
chain	I-Gene
(	O
MYH3	B-Gene
)	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
adult	B-Gene
myosin	I-Gene
isoforms	I-Gene
during	O
muscle	O
regeneration	O
,	O
and	O
promoted	O
small	O
-	O
diameter	O
neofibers	O
.	O
</ALL>	O

<ALL>	O
An	O
unbiased	O
target	O
identification	O
approach	O
in	O
primary	O
myoblasts	O
validated	O
gigaxonin	B-Gene
as	O
a	O
target	O
of	O
miR	B-Gene
-	I-Gene
501	I-Gene
that	O
mimicked	O
the	O
effect	O
of	O
miR	B-Gene
-	I-Gene
501	I-Gene
inhibition	O
on	O
MYH3	B-Gene
expression	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
mdx	O
mouse	B-Species
model	O
,	O
which	O
models	O
a	O
pathological	O
disease	O
state	O
,	O
not	O
only	O
was	O
miR	B-Gene
-	I-Gene
501	I-Gene
induced	O
in	O
regenerating	O
skeletal	O
muscle	O
,	O
but	O
also	O
its	O
serum	O
levels	O
were	O
increased	O
,	O
which	O
correlated	O
with	O
the	O
disease	O
state	O
of	O
the	O
animals	O
.	O
</ALL>	O

<ALL>	O
Our	O
results	O
suggest	O
that	O
miR	B-Gene
-	I-Gene
501	I-Gene
plays	O
a	O
key	O
role	O
in	O
adult	O
muscle	O
regeneration	O
and	O
might	O
serve	O
as	O
a	O
novel	O
serum	O
biomarker	O
for	O
the	O
activation	O
of	O
adult	O
muscle	O
stem	O
cells	O
.	O
</ALL>	O

<ALL>	O
Strong	O
association	O
of	O
677	B-Variant
C	I-Variant
>	I-Variant
T	I-Variant
substitution	O
in	O
the	O
MTHFR	B-Gene
gene	O
with	O
male	B-Disease
infertility	I-Disease
-	O
-	O
a	O
study	O
on	O
an	O
indian	O
population	O
and	O
a	O
meta	O
-	O
analysis	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Methylenetetrahydrofolate	B-Gene
reductase	I-Gene
(	O
MTHFR	B-Gene
)	O
is	O
an	O
important	O
enzyme	O
of	O
folate	B-Chemical
and	O
methionine	B-Chemical
metabolism	O
,	O
making	O
it	O
crucial	O
for	O
DNA	O
synthesis	O
and	O
methylation	O
.	O
</ALL>	O

<ALL>	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
analyze	O
MTHFR	B-Gene
gene	O
677C	B-Variant
>	I-Variant
T	I-Variant
polymorphism	O
in	O
infertile	O
male	O
individuals	O
from	O
North	O
India	O
,	O
followed	O
by	O
a	O
meta	O
-	O
analysis	O
on	O
our	O
data	O
and	O
published	O
studies	O
.	O
</ALL>	O

<ALL>	O
METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
We	O
undertook	O
genotyping	O
on	O
a	O
total	O
of	O
837	O
individuals	O
including	O
well	O
characterized	O
infertile	O
(	O
N	O
=	O
522	O
)	O
and	O
confirmed	O
fertile	O
(	O
N	O
=	O
315	O
)	O
individuals	O
.	O
</ALL>	O

<ALL>	O
The	O
SNP	O
was	O
typed	O
by	O
direct	O
DNA	O
sequencing	O
.	O
</ALL>	O

<ALL>	O
Chi	O
square	O
test	O
was	O
done	O
for	O
statistical	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Published	O
studies	O
were	O
searched	O
using	O
appropriate	O
keywords	O
.	O
</ALL>	O

<ALL>	O
Source	O
of	O
data	O
collection	O
for	O
meta	O
-	O
analysis	O
included	O
'	O
Pubmed	O
'	O
,	O
'	O
Ovid	O
'	O
and	O
'	O
Google	O
Scholar	O
'	O
.	O
</ALL>	O

<ALL>	O
Those	O
studies	O
analyzing	O
677C	B-Variant
>	I-Variant
T	I-Variant
polymorphism	O
in	O
male	B-Disease
infertility	I-Disease
and	O
presenting	O
all	O
relevant	O
data	O
were	O
included	O
in	O
meta	O
-	O
analysis	O
.	O
</ALL>	O

<ALL>	O
The	O
genotype	O
data	O
for	O
infertile	O
subjects	O
and	O
fertile	O
controls	O
was	O
extracted	O
from	O
each	O
study	O
.	O
</ALL>	O

<ALL>	O
Chi	O
square	O
test	O
was	O
done	O
to	O
obtain	O
odds	O
ratio	O
(	O
OR	O
)	O
and	O
p	O
-	O
value	O
.	O
</ALL>	O

<ALL>	O
Meta	O
-	O
analysis	O
was	O
performed	O
using	O
Comprehensive	O
Meta	O
-	O
analysis	O
software	O
(	O
Version	O
2	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
frequency	O
of	O
mutant	O
(	O
T	O
)	O
allele	O
(	O
p	O
=	O
0.0025	O
)	O
and	O
genotypes	O
(	O
CT	O
+	O
TT	O
)	O
(	O
p	O
=	O
0.0187	O
)	O
was	O
significantly	O
higher	O
in	O
infertile	O
individuals	O
in	O
comparison	O
to	O
fertile	O
controls	O
in	O
our	O
case	O
-	O
control	O
study	O
.	O
</ALL>	O

<ALL>	O
The	O
overall	O
summary	O
estimate	O
(	O
OR	O
)	O
for	O
allele	O
and	O
genotype	O
meta	O
-	O
analysis	O
were	O
1.304	O
(	O
p	O
=	O
0.000	O
)	O
,	O
1.310	O
(	O
p	O
=	O
0.000	O
)	O
,	O
respectively	O
,	O
establishing	O
significant	O
association	O
of	O
677C	B-Variant
>	I-Variant
T	I-Variant
polymorphism	O
with	O
male	B-Disease
infertility	I-Disease
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
677C	B-Variant
>	I-Variant
T	I-Variant
substitution	O
associated	O
strongly	O
with	O
male	B-Disease
infertility	I-Disease
in	O
Indian	O
population	O
.	O
</ALL>	O

<ALL>	O
Allele	O
and	O
genotype	O
meta	O
-	O
analysis	O
also	O
supported	O
its	O
strong	O
correlation	O
with	O
male	B-Disease
infertility	I-Disease
,	O
thus	O
establishing	O
it	O
as	O
a	O
risk	O
factor	O
.	O
</ALL>	O

<ALL>	O
Screening	O
for	O
exonic	O
copy	O
number	O
mutations	O
at	O
MSH2	B-Gene
and	O
MLH1	B-Gene
by	O
MAPH	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Exonic	O
deletions	O
in	O
MSH2	B-Gene
and	O
MLH1	B-Gene
are	O
significant	O
contributors	O
to	O
the	O
mutation	O
spectrum	O
in	O
HNPCC	B-Disease
,	O
and	O
heterozygous	O
changes	O
in	O
exon	O
copy	O
number	O
are	O
not	O
detected	O
by	O
conventional	O
mutation	O
screening	O
methods	O
.	O
</ALL>	O

<ALL>	O
AIMS	O
:	O
We	O
aimed	O
to	O
develop	O
methods	O
for	O
screening	O
copy	O
number	O
changes	O
in	O
all	O
the	O
exons	O
of	O
the	O
MLH1	B-Gene
and	O
MSH2	B-Gene
genes	O
using	O
a	O
single	O
multiplex	O
amplifiable	O
probe	O
hybridisation	O
(	O
MAPH	O
)	O
assay	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
We	O
developed	O
a	O
probe	O
set	O
consisting	O
of	O
probes	O
from	O
the	O
19	O
exons	O
of	O
MLH1	B-Gene
and	O
16	O
exons	O
of	O
MSH2	B-Gene
,	O
and	O
3	O
control	O
probes	O
,	O
and	O
applied	O
it	O
to	O
screening	O
for	O
deletions	O
and	O
duplications	O
using	O
fluorescent	O
detection	O
of	O
amplified	O
fragments	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
We	O
tested	O
73	O
DNA	O
samples	O
from	O
controls	O
and	O
50	O
from	O
HNPCC	B-Disease
patients	B-Species
in	O
whom	O
no	O
point	O
mutations	O
had	O
been	O
found	O
,	O
and	O
detected	O
10	O
copy	O
number	O
changes	O
among	O
the	O
patient	B-Species
samples	O
.	O
</ALL>	O

<ALL>	O
A	O
deletion	O
of	O
about	O
1.4	O
kb	O
including	O
exon	O
3	O
of	O
MSH2	B-Gene
was	O
confirmed	O
by	O
amplification	O
of	O
a	O
junction	O
fragment	O
,	O
and	O
was	O
shown	O
to	O
be	O
the	O
result	O
of	O
an	O
unequal	O
recombination	O
between	O
intronic	O
Alu	O
elements	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
MAPH	O
can	O
detect	O
exonic	O
copy	O
number	O
changes	O
in	O
MLH1	B-Gene
and	O
MSH2	B-Gene
in	O
DNA	O
from	O
HNPCC	B-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Since	O
finding	O
an	O
exonic	O
deletion	O
or	O
duplication	O
makes	O
full	O
sequence	O
analysis	O
unnecessary	O
,	O
it	O
may	O
be	O
most	O
cost	O
-	O
effective	O
to	O
pre	O
-	O
screen	O
samples	O
by	O
MAPH	O
or	O
MLPA	O
before	O
screening	O
for	O
point	O
mutations	O
.	O
</ALL>	O

<ALL>	O
Analysis	O
of	O
-	O
1082	O
IL	B-Gene
-	I-Gene
10	I-Gene
gene	O
polymorphism	O
in	O
Iranian	O
patients	B-Species
with	O
generalized	O
aggressive	B-Disease
periodontitis	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Periodontitis	B-Disease
is	O
a	O
multifactorial	O
disease	O
and	O
its	O
severe	O
forms	O
,	O
such	O
as	O
aggressive	B-Disease
periodontitis	I-Disease
,	O
are	O
suggested	O
to	O
have	O
a	O
genetic	O
basis	O
.	O
</ALL>	O

<ALL>	O
Among	O
the	O
genetic	O
factors	O
,	O
polymorphisms	O
in	O
cytokine	O
genes	O
have	O
recently	O
been	O
described	O
in	O
susceptibility	O
to	O
periodontitis	B-Disease
.	O
</ALL>	O

<ALL>	O
IL	B-Gene
-	I-Gene
10	I-Gene
is	O
a	O
multi	O
-	O
functional	O
cytokine	O
thought	O
to	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
periodontitis	B-Disease
.	O
</ALL>	O

<ALL>	O
A	O
substitution	O
G	B-Variant
/	I-Variant
A	I-Variant
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
IL	B-Gene
-	I-Gene
10	I-Gene
gene	O
at	O
position	O
-	O
1082	O
has	O
been	O
associated	O
with	O
different	O
amounts	O
of	O
IL	B-Gene
-	I-Gene
10	I-Gene
production	O
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
possible	O
links	O
between	O
-	B-Variant
1082	I-Variant
(	I-Variant
G	I-Variant
/	I-Variant
A	I-Variant
)	I-Variant
polymorphism	O
of	O
the	O
IL	B-Gene
-	I-Gene
10	I-Gene
gene	O
and	O
the	O
generalized	O
form	O
of	O
aggressive	B-Disease
periodontitis	I-Disease
.	O
</ALL>	O

<ALL>	O
MATERIAL	O
/	O
METHODS	O
:	O
This	O
study	O
included	O
52	O
Iranian	O
Khorasanian	O
(	O
north	O
-	O
east	O
province	O
of	O
Iran	O
)	O
subjects	O
suffering	O
from	O
generalized	O
aggressive	B-Disease
periodontitis	I-Disease
referred	O
to	O
the	O
Periodontology	O
Department	O
of	O
Mashhad	O
Dental	O
School	O
.	O
</ALL>	O

<ALL>	O
They	O
were	O
compared	O
to	O
61	O
age	O
and	O
sex	O
-	O
matched	O
healthy	O
controls	O
of	O
the	O
same	O
race	O
.	O
</ALL>	O

<ALL>	O
DNA	O
was	O
isolated	O
from	O
peripheral	O
blood	O
cells	O
and	O
genotyping	O
was	O
performed	O
by	O
means	O
of	O
the	O
amplification	O
refractory	O
mutation	O
system	O
polymerase	O
chain	O
reaction	O
(	O
ARMS	O
-	O
PCR	O
)	O
method	O
.	O
</ALL>	O

<ALL>	O
Data	O
were	O
analyzed	O
using	O
the	O
chi	O
-	O
squared	O
test	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
There	O
was	O
no	O
marked	O
difference	O
in	O
genotype	O
frequencies	O
between	O
the	O
controls	O
and	O
generalized	O
aggressive	B-Disease
periodontitis	I-Disease
patients	B-Species
(	O
p	O
=	O
0.585	O
)	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
no	O
association	O
between	O
patients	B-Species
and	O
normal	O
subjects	O
was	O
found	O
in	O
their	O
allele	O
frequency	O
(	O
p	O
=	O
0.329	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
the	O
polymorphic	O
nucleotide	O
A	B-Variant
at	I-Variant
position	I-Variant
-	I-Variant
1082	I-Variant
of	O
the	O
IL	B-Gene
-	I-Gene
10	I-Gene
gene	O
is	O
not	O
associated	O
with	O
generalized	O
aggressive	B-Disease
periodontitis	I-Disease
in	O
the	O
Iranian	O
population	O
.	O
</ALL>	O

<ALL>	O
U87MG	B-CellLine
decoded	O
:	O
the	O
genomic	O
sequence	O
of	O
a	O
cytogenetically	O
aberrant	O
human	B-Species
cancer	B-Disease
cell	O
line	O
.	O
</ALL>	O

<ALL>	O
U87MG	B-CellLine
is	O
a	O
commonly	O
studied	O
grade	B-Disease
IV	I-Disease
glioma	I-Disease
cell	O
line	O
that	O
has	O
been	O
analyzed	O
in	O
at	O
least	O
1,700	O
publications	O
over	O
four	O
decades	O
.	O
</ALL>	O

<ALL>	O
In	O
order	O
to	O
comprehensively	O
characterize	O
the	O
genome	O
of	O
this	O
cell	O
line	O
and	O
to	O
serve	O
as	O
a	O
model	O
of	O
broad	O
cancer	B-Disease
genome	O
sequencing	O
,	O
we	O
have	O
generated	O
greater	O
than	O
30x	O
genomic	O
sequence	O
coverage	O
using	O
a	O
novel	O
50	O
-	O
base	O
mate	O
paired	O
strategy	O
with	O
a	O
1.4	O
kb	O
mean	O
insert	O
library	O
.	O
</ALL>	O

<ALL>	O
A	O
total	O
of	O
1,014,984,286	O
mate	O
-	O
end	O
and	O
120,691,623	O
single	O
-	O
end	O
two	O
-	O
base	O
encoded	O
reads	O
were	O
generated	O
from	O
five	O
slides	O
.	O
</ALL>	O

<ALL>	O
All	O
data	O
were	O
aligned	O
using	O
a	O
custom	O
designed	O
tool	O
called	O
BFAST	O
,	O
allowing	O
optimal	O
color	O
space	O
read	O
alignment	O
and	O
accurate	O
identification	O
of	O
DNA	O
variants	O
.	O
</ALL>	O

<ALL>	O
The	O
aligned	O
sequence	O
reads	O
and	O
mate	O
-	O
pair	O
information	O
identified	O
35	O
interchromosomal	O
translocation	O
events	O
,	O
1,315	O
structural	O
variations	O
(	O
>	O
100	O
bp	O
)	O
,	O
191,743	O
small	O
(	O
<	O
21	O
bp	O
)	O
insertions	O
and	O
deletions	O
(	O
indels	O
)	O
,	O
and	O
2,384,470	O
single	O
nucleotide	O
variations	O
(	O
SNVs	O
)	O
.	O
</ALL>	O

<ALL>	O
Among	O
these	O
observations	O
,	O
the	O
known	O
homozygous	O
mutation	O
in	O
PTEN	B-Gene
was	O
robustly	O
identified	O
,	O
and	O
genes	O
involved	O
in	O
cell	O
adhesion	O
were	O
overrepresented	O
in	O
the	O
mutated	O
gene	O
list	O
.	O
</ALL>	O

<ALL>	O
Data	O
were	O
compared	O
to	O
219,187	O
heterozygous	O
single	O
nucleotide	O
polymorphisms	O
assayed	O
by	O
Illumina	O
1	O
M	O
Duo	O
genotyping	O
array	O
to	O
assess	O
accuracy	O
:	O
93.83	O
%	O
of	O
all	O
SNPs	O
were	O
reliably	O
detected	O
at	O
filtering	O
thresholds	O
that	O
yield	O
greater	O
than	O
99.99	O
%	O
sequence	O
accuracy	O
.	O
</ALL>	O

<ALL>	O
Protein	O
coding	O
sequences	O
were	O
disrupted	O
predominantly	O
in	O
this	O
cancer	B-Disease
cell	O
line	O
due	O
to	O
small	O
indels	O
,	O
large	O
deletions	O
,	O
and	O
translocations	O
.	O
</ALL>	O

<ALL>	O
In	O
total	O
,	O
512	O
genes	O
were	O
homozygously	O
mutated	O
,	O
including	O
154	O
by	O
SNVs	O
,	O
178	O
by	O
small	O
indels	O
,	O
145	O
by	O
large	O
microdeletions	O
,	O
and	O
35	O
by	O
interchromosomal	O
translocations	O
to	O
reveal	O
a	O
highly	O
mutated	O
cell	O
line	O
genome	O
.	O
</ALL>	O

<ALL>	O
Of	O
the	O
small	O
homozygously	O
mutated	O
variants	O
,	O
8	O
SNVs	O
and	O
99	O
indels	O
were	O
novel	O
events	O
not	O
present	O
in	O
dbSNP	O
.	O
</ALL>	O

<ALL>	O
These	O
data	O
demonstrate	O
that	O
routine	O
generation	O
of	O
broad	O
cancer	B-Disease
genome	O
sequence	O
is	O
possible	O
outside	O
of	O
genome	O
centers	O
.	O
</ALL>	O

<ALL>	O
The	O
sequence	O
analysis	O
of	O
U87MG	B-CellLine
provides	O
an	O
unparalleled	O
level	O
of	O
mutational	O
resolution	O
compared	O
to	O
any	O
cell	O
line	O
to	O
date	O
.	O
</ALL>	O

<ALL>	O
Repeated	O
otilonium	B-Chemical
bromide	I-Chemical
administration	O
prevents	O
neurotransmitter	B-Chemical
changes	O
in	O
colon	O
of	O
rats	B-Species
underwent	O
to	O
wrap	O
restraint	O
stress	O
.	O
</ALL>	O

<ALL>	O
Otilonium	B-Chemical
bromide	I-Chemical
(	O
OB	B-Chemical
)	O
is	O
a	O
spasmolytic	O
drug	O
successfully	O
used	O
for	O
the	O
treatment	O
of	O
irritable	B-Disease
bowel	I-Disease
syndrome	I-Disease
(	O
IBS	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Its	O
efficacy	O
has	O
been	O
attributed	O
to	O
the	O
block	O
of	O
L	B-Gene
-	I-Gene
and	I-Gene
T	I-Gene
-	I-Gene
type	I-Gene
Ca	I-Gene
(	I-Gene
2	I-Gene
+	I-Gene
)	I-Gene
channels	I-Gene
and	O
muscarinic	B-Gene
and	I-Gene
tachykinin	I-Gene
receptors	I-Gene
in	O
the	O
smooth	O
muscle	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
in	O
healthy	O
rats	B-Species
,	O
repeated	O
OB	B-Chemical
administration	O
modified	O
neurotransmitter	B-Chemical
expression	O
and	O
function	O
suggesting	O
other	O
mechanisms	O
of	O
action	O
.	O
</ALL>	O

<ALL>	O
On	O
this	O
basis	O
,	O
we	O
investigated	O
whether	O
repeated	O
OB	B-Chemical
treatment	O
prevented	O
the	O
functional	O
and	O
neurochemical	O
changes	O
observed	O
in	O
the	O
colon	O
of	O
rats	B-Species
underwent	O
to	O
wrap	O
restrain	O
stress	O
(	O
WRS	O
)	O
a	O
psychosocial	O
stressor	O
considered	O
suitable	O
to	O
reproduce	O
the	O
main	O
IBS	B-Disease
signs	O
and	O
symptoms	O
.	O
</ALL>	O

<ALL>	O
In	O
control	O
,	O
WRS	O
and	O
OB	B-Chemical
/	O
WRS	O
rats	B-Species
functional	O
parameters	O
were	O
measured	O
in	O
vivo	O
and	O
morphological	O
investigations	O
were	O
done	O
ex	O
vivo	O
in	O
the	O
colon	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
showed	O
that	O
OB	B-Chemical
counteracts	O
most	O
of	O
the	O
neurotransmitters	B-Chemical
changes	O
caused	O
by	O
WRS	O
.	O
</ALL>	O

<ALL>	O
In	O
particular	O
,	O
the	O
drug	O
prevents	O
the	O
decrease	O
in	O
SP	B-Gene
-	O
,	O
NK1r	B-Gene
-	O
,	O
nNOS	B-Gene
-	O
,	O
VIP	B-Gene
-	O
,	O
and	O
S100b	B-Gene
-	O
immunoreactivity	O
(	O
IR	O
)	O
and	O
the	O
increase	O
in	O
CGRP	B-Gene
-	O
,	O
and	O
CRF1r	B-Gene
-	O
IR	O
.	O
</ALL>	O

<ALL>	O
On	O
the	O
contrary	O
,	O
OB	B-Chemical
does	O
not	O
affect	O
the	O
increase	O
in	O
CRF2r	B-Gene
-	O
IR	O
neurons	O
observed	O
in	O
WRS	O
rats	B-Species
and	O
does	O
not	O
interfere	O
with	O
the	O
mild	O
mucosal	B-Disease
inflammation	I-Disease
due	O
to	O
WRS	O
.	O
</ALL>	O

<ALL>	O
Finally	O
,	O
OB	B-Chemical
per	O
se	O
increases	O
the	O
Mr2	B-Gene
expression	O
in	O
the	O
muscle	O
wall	O
and	O
decreases	O
the	O
number	O
of	O
the	O
myenteric	O
ChAT	B-Gene
-	O
IR	O
neurons	O
.	O
</ALL>	O

<ALL>	O
Functional	O
findings	O
show	O
a	O
significantly	O
reduction	O
in	O
the	O
number	O
of	O
spontaneous	O
abdominal	O
contraction	O
in	O
OB	B-Chemical
treated	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
ability	O
of	O
OB	B-Chemical
to	O
block	O
L	B-Gene
-	I-Gene
type	I-Gene
Ca	I-Gene
(	I-Gene
2	I-Gene
+	I-Gene
)	I-Gene
channels	I-Gene
,	O
also	O
expressed	O
by	O
enteric	O
neurons	O
,	O
might	O
represent	O
a	O
possible	O
mechanism	O
through	O
which	O
OB	B-Chemical
exerts	O
its	O
actions	O
.	O
</ALL>	O

<ALL>	O
Clusters	O
of	O
multidrug	O
-	O
resistant	O
Mycobacterium	B-Species
tuberculosis	I-Species
cases	O
,	O
Europe	O
.	O
</ALL>	O

<ALL>	O
Molecular	O
surveillance	O
of	O
multidrug	B-Disease
-	I-Disease
resistant	I-Disease
tuberculosis	I-Disease
(	O
MDR	B-Disease
TB	I-Disease
)	O
was	O
implemented	O
in	O
Europe	O
as	O
case	O
reporting	O
in	O
2005	O
.	O
</ALL>	O

<ALL>	O
For	O
all	O
new	O
MDR	B-Disease
TB	I-Disease
cases	O
detected	O
from	O
January	O
2003	O
through	O
June	O
2007	O
,	O
countries	O
reported	O
case	O
-	O
based	O
epidemiologic	O
data	O
and	O
DNA	O
fingerprint	O
patterns	O
of	O
MDR	B-Disease
TB	I-Disease
strains	O
when	O
available	O
.	O
</ALL>	O

<ALL>	O
International	O
clusters	O
were	O
detected	O
and	O
analyzed	O
.	O
</ALL>	O

<ALL>	O
From	O
2003	O
through	O
mid	O
-	O
2007	O
in	O
Europe	O
,	O
2,494	O
cases	O
of	O
MDR	B-Disease
TB	I-Disease
were	O
reported	O
from	O
24	O
European	O
countries	O
.	O
</ALL>	O

<ALL>	O
Epidemiologic	O
and	O
molecular	O
data	O
were	O
linked	O
for	O
593	O
(	O
39	O
%	O
)	O
cases	O
,	O
and	O
672	O
insertion	O
sequence	O
6110	O
DNA	O
fingerprint	O
patterns	O
were	O
reported	O
from	O
19	O
countries	O
.	O
</ALL>	O

<ALL>	O
Of	O
these	O
patterns	O
,	O
288	O
(	O
43	O
%	O
)	O
belonged	O
to	O
18	O
European	O
clusters	O
;	O
7	O
clusters	O
(	O
242	O
/	O
288	O
cases	O
,	O
84	O
%	O
)	O
were	O
characterized	O
by	O
strains	O
of	O
the	O
Beijing	O
genotype	O
family	O
,	O
including	O
the	O
largest	O
cluster	O
(	O
175	O
/	O
288	O
cases	O
,	O
61	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
Both	O
clustering	O
and	O
the	O
Beijing	O
genotype	O
were	O
associated	O
with	O
strains	O
originating	O
in	O
eastern	O
European	O
countries	O
.	O
</ALL>	O

<ALL>	O
Molecular	O
cluster	O
detection	O
contributes	O
to	O
identification	O
of	O
transmission	O
profile	O
,	O
risk	O
factors	O
,	O
and	O
control	O
measures	O
.	O
</ALL>	O

<ALL>	O
An	O
inducible	O
mouse	B-Species
model	O
of	O
podocin	B-Gene
-	O
mutation	O
-	O
related	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Mutations	O
in	O
the	O
NPHS2	B-Gene
gene	O
,	O
encoding	O
podocin	B-Gene
,	O
cause	O
hereditary	O
nephrotic	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
most	O
common	O
podocin	B-Gene
mutation	O
,	O
R138Q	B-Variant
,	O
is	O
associated	O
with	O
early	O
disease	O
onset	O
and	O
rapid	O
progression	O
to	O
end	O
-	O
stage	O
renal	B-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
Knock	O
-	O
in	O
mice	B-Species
carrying	O
a	O
R140Q	B-Variant
mutation	O
,	O
the	O
mouse	B-Species
analogue	O
of	O
human	B-Species
R138Q	B-Variant
,	O
show	O
developmental	O
arrest	O
of	O
podocytes	O
and	O
lethal	O
renal	B-Disease
failure	I-Disease
at	O
neonatal	O
age	O
.	O
</ALL>	O

<ALL>	O
Here	O
we	O
created	O
a	O
conditional	O
podocin	B-Gene
knock	O
-	O
in	O
model	O
named	O
NPHS2	B-Gene
R140Q	B-Variant
/	O
-	O
,	O
using	O
a	O
tamoxifen	B-Chemical
-	O
inducible	O
Cre	O
recombinase	O
,	O
which	O
permits	O
to	O
study	O
the	O
effects	O
of	O
the	O
mutation	O
in	O
postnatal	O
life	O
.	O
</ALL>	O

<ALL>	O
Within	O
the	O
first	O
week	O
of	O
R140Q	B-Variant
hemizygosity	O
induction	O
the	O
animals	O
developed	O
proteinuria	B-Disease
,	O
which	O
peaked	O
after	O
4	O
-	O
5	O
weeks	O
.	O
</ALL>	O

<ALL>	O
Subsequently	O
the	O
animals	O
developed	O
progressive	O
renal	B-Disease
failure	I-Disease
,	O
with	O
a	O
median	O
survival	O
time	O
of	O
12	O
(	O
95	O
%	O
CI	O
:	O
11	O
-	O
13	O
)	O
weeks	O
.	O
</ALL>	O

<ALL>	O
Foot	O
process	O
fusion	O
was	O
observed	O
within	O
one	O
week	O
,	O
progressing	O
to	O
severe	O
and	O
global	O
effacement	O
in	O
the	O
course	O
of	O
the	O
disease	O
.	O
</ALL>	O

<ALL>	O
The	O
number	O
of	O
podocytes	O
per	O
glomerulus	O
gradually	O
diminished	O
to	O
18	O
%	O
compared	O
to	O
healthy	O
controls	O
12	O
-	O
16	O
weeks	O
after	O
induction	O
.	O
</ALL>	O

<ALL>	O
The	O
fraction	O
of	O
segmentally	O
sclerosed	O
glomeruli	O
was	O
25	O
%	O
,	O
85	O
%	O
and	O
97	O
%	O
at	O
2	O
,	O
4	O
and	O
8	O
weeks	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
Severe	O
tubulointerstitial	B-Disease
fibrosis	I-Disease
was	O
present	O
at	O
later	O
disease	O
stage	O
and	O
was	O
correlated	O
quantitatively	O
with	O
the	O
level	O
of	O
proteinuria	B-Disease
at	O
early	O
disease	O
stages	O
.	O
</ALL>	O

<ALL>	O
While	O
R140Q	B-Variant
podocin	B-Gene
mRNA	O
expression	O
was	O
elevated	O
,	O
protein	O
abundance	O
was	O
reduced	O
by	O
more	O
than	O
50	O
%	O
within	O
one	O
week	O
following	O
induction	O
.	O
</ALL>	O

<ALL>	O
Whereas	O
miRNA21	B-Gene
expression	O
persistently	O
increased	O
during	O
the	O
first	O
4	O
weeks	O
,	O
miRNA	B-Gene
-	I-Gene
193a	I-Gene
expression	O
peaked	O
2	O
weeks	O
after	O
induction	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
the	O
inducible	O
R140Q	B-Variant
-	O
podocin	B-Gene
mouse	B-Species
model	O
is	O
an	O
auspicious	O
model	O
of	O
the	O
most	O
common	O
genetic	O
cause	O
of	O
human	B-Species
nephrotic	B-Disease
syndrome	I-Disease
,	O
with	O
a	O
spontaneous	O
disease	O
course	O
strongly	O
reminiscent	O
of	O
the	O
human	B-Species
disorder	O
.	O
</ALL>	O

<ALL>	O
This	O
model	O
constitutes	O
a	O
valuable	O
tool	O
to	O
test	O
the	O
efficacy	O
of	O
novel	O
pharmacological	O
interventions	O
aimed	O
to	O
improve	O
podocyte	O
function	O
and	O
viability	O
and	O
attenuate	O
proteinuria	B-Disease
,	O
glomerulosclerosis	B-Disease
and	O
progressive	O
renal	B-Disease
failure	I-Disease
.	O
</ALL>	O

<ALL>	O
Over	O
-	O
expression	O
of	O
BMP4	B-Gene
and	O
BMP5	B-Gene
in	O
a	O
child	O
with	O
axial	B-Disease
skeletal	I-Disease
malformations	I-Disease
and	O
heterotopic	B-Disease
ossification	I-Disease
:	O
a	O
new	O
syndrome	O
.	O
</ALL>	O

<ALL>	O
Bone	B-Gene
morphogenetic	I-Gene
proteins	I-Gene
(	O
BMPs	B-Gene
)	O
are	O
a	O
highly	O
conserved	O
class	O
of	O
signaling	O
molecules	O
that	O
induce	O
ectopic	B-Disease
cartilage	I-Disease
and	I-Disease
bone	I-Disease
formation	I-Disease
in	O
vivo	O
.	O
</ALL>	O

<ALL>	O
Dysregulated	O
expression	O
of	O
bone	B-Gene
morphogenetic	I-Gene
protein	I-Gene
4	I-Gene
(	O
BMP4	B-Gene
)	O
is	O
found	O
in	O
the	O
cells	O
of	O
patients	B-Species
who	O
have	O
fibrodysplasia	B-Disease
ossificans	I-Disease
progressiva	I-Disease
(	O
FOP	B-Disease
)	O
,	O
a	O
genetic	O
disorder	O
of	O
axial	B-Disease
and	I-Disease
appendicular	I-Disease
skeletal	I-Disease
malformation	I-Disease
and	O
progressive	O
heterotopic	B-Disease
ossification	I-Disease
.	O
</ALL>	O

<ALL>	O
Loss	O
of	O
function	O
mutations	O
in	O
the	O
bone	B-Gene
morphogenetic	I-Gene
protein	I-Gene
5	I-Gene
(	O
bmp5	B-Gene
)	O
gene	O
leading	O
to	O
under	O
-	O
expression	O
of	O
BMP5	B-Gene
cause	O
the	O
murine	B-Species
short	B-Disease
ear	I-Disease
syndrome	I-Disease
,	O
characterized	O
by	O
small	O
malformed	O
ears	O
and	O
a	O
broad	O
range	O
of	O
axial	B-Disease
skeletal	I-Disease
malformations	I-Disease
.	O
</ALL>	O

<ALL>	O
We	O
found	O
features	O
reminiscent	O
of	O
both	O
the	O
short	O
ear	O
mouse	B-Species
and	O
FOP	B-Disease
in	O
a	O
child	O
with	O
malformed	B-Disease
external	I-Disease
ears	I-Disease
,	O
multiple	B-Disease
malformations	I-Disease
of	I-Disease
the	I-Disease
axial	I-Disease
skeleton	I-Disease
,	O
and	O
progressive	O
heterotopic	B-Disease
ossification	I-Disease
in	O
the	O
neck	O
and	O
back	O
.	O
</ALL>	O

<ALL>	O
We	O
examined	O
BMP	B-Gene
mRNA	O
expression	O
in	O
transformed	O
lymphocytes	O
by	O
semi	O
-	O
quantitative	O
RT	O
-	O
PCR	O
and	O
protein	O
expression	O
by	O
ELISA	O
assays	O
and	O
immunohistochemistry	O
.	O
</ALL>	O

<ALL>	O
Elevated	O
levels	O
of	O
BMP4	B-Gene
and	O
BMP5	B-Gene
mRNA	O
and	O
protein	O
were	O
detected	O
in	O
the	O
patient	B-Species
's	O
cells	O
while	O
levels	O
of	O
BMP2	B-Gene
mRNA	O
were	O
unchanged	O
.	O
</ALL>	O

<ALL>	O
Our	O
data	O
suggest	O
that	O
dysregulated	O
expression	O
of	O
BMP4	B-Gene
and	O
BMP5	B-Gene
genes	O
is	O
associated	O
with	O
an	O
array	O
of	O
human	B-Species
axial	B-Disease
skeletal	I-Disease
abnormalities	I-Disease
similar	O
to	O
the	O
short	O
ear	O
mouse	B-Species
and	O
FOP	B-Disease
.	O
</ALL>	O

<ALL>	O
Sex	O
-	O
differential	O
genetic	O
effect	O
of	O
phosphodiesterase	B-Gene
4D	I-Gene
(	O
PDE4D	B-Gene
)	O
on	O
carotid	B-Disease
atherosclerosis	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
The	O
phosphodiesterase	B-Gene
4D	I-Gene
(	O
PDE4D	B-Gene
)	O
gene	O
was	O
reported	O
as	O
a	O
susceptibility	O
gene	O
to	O
stroke	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
genetic	O
effect	O
might	O
be	O
attributed	O
to	O
its	O
role	O
in	O
modulating	O
the	O
atherogenic	B-Disease
process	O
in	O
the	O
carotid	O
arteries	O
.	O
</ALL>	O

<ALL>	O
Using	O
carotid	O
intima	O
-	O
media	O
thickness	O
(	O
IMT	O
)	O
and	O
plaque	O
index	O
as	O
phenotypes	O
,	O
the	O
present	O
study	O
sought	O
to	O
determine	O
the	O
influence	O
of	O
this	O
gene	O
on	O
subclinical	O
atherosclerosis	B-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Carotid	O
ultrasonography	O
was	O
performed	O
on	O
1013	O
stroke	B-Disease
-	O
free	O
subjects	O
who	O
participated	O
in	O
the	O
health	O
screening	O
programs	O
(	O
age	O
52.6	O
+	O
/	O
-	O
12.2	O
;	O
47.6	O
%	O
men	B-Species
)	O
.	O
</ALL>	O

<ALL>	O
Genotype	O
distribution	O
was	O
compared	O
among	O
the	O
high	O
-	O
risk	O
(	O
plaque	O
index	O
>	O
or	O
=	O
4	O
)	O
,	O
low	O
-	O
risk	O
(	O
index	O
=	O
1	O
-	O
3	O
)	O
,	O
and	O
reference	O
(	O
index	O
=	O
0	O
)	O
groups	O
.	O
</ALL>	O

<ALL>	O
We	O
analyzed	O
continuous	O
IMT	O
data	O
and	O
further	O
dichotomized	O
IMT	O
data	O
using	O
mean	O
plus	O
one	O
standard	O
deviation	O
as	O
the	O
cutoff	O
level	O
.	O
</ALL>	O

<ALL>	O
Because	O
the	O
plaque	O
prevalence	O
and	O
IMT	O
values	O
displayed	O
a	O
notable	O
difference	O
between	O
men	B-Species
and	O
women	B-Species
,	O
we	O
carried	O
out	O
sex	O
-	O
specific	O
analyses	O
in	O
addition	O
to	O
analyzing	O
the	O
overall	O
data	O
.	O
</ALL>	O

<ALL>	O
Rs702553	B-Variant
at	O
the	O
PDE4D	B-Gene
gene	O
was	O
selected	O
because	O
it	O
conferred	O
a	O
risk	O
for	O
young	O
stroke	B-Disease
in	O
our	O
previous	O
report	O
.	O
</ALL>	O

<ALL>	O
Previous	O
young	O
stroke	B-Disease
data	O
(	O
190	O
cases	O
and	O
211	O
controls	O
)	O
with	O
an	O
additional	O
532	O
control	O
subjects	O
without	O
ultrasonic	O
data	O
were	O
shown	O
as	O
a	O
cross	O
-	O
validation	O
for	O
the	O
genetic	O
effect	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
In	O
the	O
overall	O
analyses	O
,	O
the	O
rare	O
homozygote	O
of	O
rs702553	B-Variant
led	O
to	O
an	O
OR	O
of	O
3.1	O
(	O
p	O
=	O
0.034	O
)	O
for	O
a	O
plaque	O
index	O
>	O
or	O
=	O
4	O
.	O
</ALL>	O

<ALL>	O
When	O
subjects	O
were	O
stratified	O
by	O
sex	O
,	O
the	O
genetic	O
effect	O
was	O
only	O
evident	O
in	O
men	B-Species
but	O
not	O
in	O
women	B-Species
.	O
</ALL>	O

<ALL>	O
Comparing	O
male	O
subjects	O
with	O
plaque	O
index	O
>	O
or	O
=	O
4	O
and	O
those	O
with	O
plaque	O
index	O
=	O
0	O
,	O
the	O
TT	O
genotype	O
was	O
over	O
-	O
represented	O
(	O
27.6	O
%	O
vs.	O
13.4	O
%	O
,	O
p	O
=	O
0.008	O
)	O
.	O
</ALL>	O

<ALL>	O
For	O
dichotomized	O
IMT	O
data	O
in	O
men	B-Species
,	O
the	O
TT	O
genotype	O
had	O
an	O
OR	O
of	O
2.1	O
(	O
p	O
=	O
0.032	O
)	O
for	O
a	O
thicker	O
IMT	O
at	O
the	O
common	O
carotid	O
artery	O
compared	O
with	O
the	O
(	O
AA	O
+	O
AT	O
)	O
genotypes	O
.	O
</ALL>	O

<ALL>	O
In	O
women	B-Species
,	O
neither	O
IMT	O
nor	O
plaque	O
index	O
was	O
associated	O
with	O
rs702553	B-Variant
.	O
</ALL>	O

<ALL>	O
Similarly	O
,	O
SNP	O
rs702553	B-Variant
was	O
only	O
significant	O
in	O
young	O
stroke	B-Disease
men	B-Species
(	O
OR	O
=	O
1.8	O
,	O
p	O
=	O
0.025	O
)	O
but	O
not	O
in	O
women	B-Species
(	O
p	O
=	O
0.27	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
The	O
present	O
study	O
demonstrates	O
a	O
sex	O
-	O
differential	O
effect	O
of	O
PDE4D	B-Gene
on	O
IMT	O
,	O
plaque	O
index	O
and	O
stroke	B-Disease
,	O
which	O
highlights	O
its	O
influence	O
on	O
various	O
aspects	O
of	O
atherogenesis	B-Disease
.	O
</ALL>	O

<ALL>	O
Detection	O
of	O
EGFR	B-Gene
mutations	O
in	O
plasma	O
DNA	O
from	O
lung	B-Disease
cancer	I-Disease
patients	B-Species
by	O
mass	O
spectrometry	O
genotyping	O
is	O
predictive	O
of	O
tumor	B-Disease
EGFR	B-Gene
status	O
and	O
response	O
to	O
EGFR	B-Gene
inhibitors	O
.	O
</ALL>	O

<ALL>	O
AIMS	O
:	O
EGFR	B-Gene
mutations	O
now	O
guide	O
the	O
clinical	O
use	O
of	O
EGFR	B-Gene
-	O
targeted	O
therapy	O
in	O
lung	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
standard	O
EGFR	B-Gene
mutation	O
analysis	O
requires	O
a	O
minimum	O
amount	O
of	O
tumor	B-Disease
tissue	O
,	O
which	O
may	O
not	O
be	O
available	O
in	O
certain	O
situations	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
combined	O
a	O
mass	O
spectrometry	O
genotyping	O
assay	O
(	O
Sequenom	O
)	O
with	O
a	O
mutant	O
-	O
enriched	O
PCR	O
(	O
ME	O
-	O
PCR	O
)	O
to	O
detect	O
EGFR	B-Gene
mutations	O
in	O
free	O
plasma	O
DNA	O
from	O
patients	B-Species
with	O
lung	B-Disease
cancer	I-Disease
.	O
</ALL>	O

<ALL>	O
METHOD	O
:	O
DNAs	O
were	O
extracted	O
from	O
31	O
plasma	O
samples	O
from	O
31	O
patients	B-Species
and	O
analyzed	O
by	O
both	O
methods	O
for	O
EGFR	B-Gene
Exon	O
19	O
deletion	O
and	O
EGFR	B-Gene
L858R	B-Variant
mutation	O
.	O
</ALL>	O

<ALL>	O
Results	O
in	O
plasma	O
DNA	O
samples	O
were	O
compared	O
with	O
EGFR	B-Gene
mutation	O
status	O
obtained	O
in	O
tumor	B-Disease
DNA	O
(	O
18	O
/	O
31	O
EGFR	B-Gene
mutant	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
relationship	O
of	O
EGFR	B-Gene
mutation	O
status	O
in	O
tumor	B-Disease
and	O
/	O
or	O
plasma	O
samples	O
to	O
overall	O
survival	O
was	O
assessed	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
EGFR	B-Gene
mutation	O
status	O
in	O
plasma	O
DNA	O
was	O
identical	O
to	O
the	O
primary	O
tumor	B-Disease
in	O
61	O
%	O
of	O
patients	B-Species
(	O
19	O
/	O
31	O
)	O
.	O
</ALL>	O

<ALL>	O
By	O
mass	O
spectrometry	O
genotyping	O
,	O
the	O
plasma	O
samples	O
contained	O
mutant	O
DNA	O
corresponding	O
to	O
5	O
/	O
14	O
EGFR	B-Gene
Exon	O
19	O
deletions	O
and	O
3	O
/	O
4	O
EGFR	B-Gene
L858R	B-Variant
mutations	O
previously	O
diagnosed	O
in	O
the	O
matched	O
tumors	B-Disease
.	O
</ALL>	O

<ALL>	O
Two	O
samples	O
were	O
positive	O
in	O
plasma	O
DNA	O
but	O
negative	O
in	O
primary	O
tumor	B-Disease
tissue	O
.	O
</ALL>	O

<ALL>	O
Results	O
were	O
similar	O
for	O
samples	O
studied	O
by	O
ME	O
-	O
PCR	O
.	O
</ALL>	O

<ALL>	O
For	O
patients	B-Species
treated	O
with	O
erlotinib	B-Chemical
,	O
overall	O
survival	O
was	O
correlated	O
with	O
the	O
presence	O
of	O
EGFR	B-Gene
mutation	O
in	O
plasma	O
and	O
/	O
or	O
tumor	B-Disease
tissue	O
(	O
p	O
=	O
0.002	O
)	O
,	O
with	O
the	O
two	O
patients	B-Species
positive	O
only	O
in	O
plasma	O
DNA	O
showing	O
responses	O
and	O
favorable	O
outcomes	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
The	O
detection	O
of	O
EGFR	B-Gene
mutations	O
in	O
plasma	O
DNA	O
samples	O
by	O
mass	O
spectrometry	O
genotyping	O
and	O
ME	O
-	O
PCR	O
is	O
feasible	O
.	O
</ALL>	O

<ALL>	O
A	O
positive	O
EGFR	B-Gene
result	O
in	O
plasma	O
DNA	O
has	O
a	O
high	O
predictive	O
value	O
for	O
tumor	B-Disease
EGFR	B-Gene
status	O
and	O
for	O
favorable	O
clinical	O
course	O
on	O
EGFR	B-Gene
-	O
targeted	O
therapy	O
and	O
could	O
therefore	O
be	O
useful	O
in	O
guiding	O
clinical	O
decisions	O
in	O
patients	B-Species
with	O
insufficient	O
or	O
unavailable	O
tumor	B-Disease
specimens	O
.	O
</ALL>	O

<ALL>	O
Psoriasin	B-Gene
promotes	O
invasion	O
,	O
aggregation	O
and	O
survival	O
of	O
pancreatic	B-Disease
cancer	I-Disease
cells	O
;	O
association	O
with	O
disease	O
progression	O
.	O
</ALL>	O

<ALL>	O
Psoriasin	B-Gene
(	O
S100A7	B-Gene
)	O
is	O
an	O
11	O
-	O
kDa	O
small	O
calcium	B-Gene
binding	I-Gene
protein	I-Gene
initially	O
isolated	O
from	O
psoriatic	B-Disease
skin	I-Disease
lesions	I-Disease
.	O
</ALL>	O

<ALL>	O
It	O
belongs	O
to	O
the	O
S100	B-Gene
family	O
of	O
proteins	O
which	O
play	O
an	O
important	O
role	O
in	O
a	O
range	O
of	O
cell	O
functions	O
including	O
proliferation	O
,	O
differentiation	O
,	O
migration	O
and	O
apoptosis	O
.	O
</ALL>	O

<ALL>	O
Aberrant	O
Psoriasin	B-Gene
expression	O
has	O
been	O
implicated	O
in	O
a	O
range	O
of	O
cancers	B-Disease
and	O
is	O
often	O
associated	O
with	O
poor	O
prognosis	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
examined	O
the	O
role	O
of	O
Psoriasin	B-Gene
on	O
pancreatic	B-Disease
cancer	I-Disease
cell	O
functions	O
and	O
the	O
implication	O
in	O
progression	O
of	O
the	O
disease	O
.	O
</ALL>	O

<ALL>	O
Expression	O
of	O
Psoriasin	B-Gene
was	O
determined	O
in	O
a	O
cohort	O
of	O
pancreatic	O
tissues	O
comprised	O
of	O
126	O
pancreatic	B-Disease
tumours	I-Disease
and	O
114	O
adjacent	O
non	O
-	O
tumour	O
pancreatic	O
tissues	O
.	O
</ALL>	O

<ALL>	O
Knockdown	O
and	O
overexpression	O
of	O
Psoriasin	B-Gene
in	O
pancreatic	B-Disease
cancer	I-Disease
cells	O
was	O
performed	O
using	O
specifically	O
constructed	O
plasmids	O
,	O
which	O
either	O
had	O
anti	O
-	O
Psoriasin	B-Gene
ribozyme	O
transgene	O
or	O
the	O
full	O
length	O
human	B-Species
Psoriasin	B-Gene
coding	O
sequence	O
.	O
</ALL>	O

<ALL>	O
Psoriasin	B-Gene
knockdown	O
and	O
overexpression	O
was	O
verified	O
using	O
conventional	O
RT	O
-	O
PCR	O
and	O
qPCR	O
.	O
</ALL>	O

<ALL>	O
The	O
effect	O
of	O
manipulating	O
Psoriasin	B-Gene
expression	O
on	O
pancreatic	B-Disease
cancer	I-Disease
cell	O
functions	O
was	O
assessed	O
using	O
several	O
in	O
vitro	O
cell	O
function	O
assays	O
.	O
</ALL>	O

<ALL>	O
Local	O
invasive	O
pancreatic	B-Disease
cancers	I-Disease
extended	O
beyond	O
the	O
pancreas	O
expressed	O
higher	O
levels	O
of	O
Psoriasin	B-Gene
transcripts	O
compared	O
with	O
the	O
cancers	B-Disease
confined	O
to	O
the	O
pancreas	O
.	O
</ALL>	O

<ALL>	O
Primary	B-Disease
tumours	I-Disease
with	O
distant	O
metastases	B-Disease
exhibited	O
a	O
reduced	O
expression	O
of	O
Psoriasin	B-Gene
.	O
</ALL>	O

<ALL>	O
Psoriasin	B-Gene
overexpression	O
cell	O
lines	O
exhibited	O
significantly	O
increased	O
growth	O
and	O
migration	O
compared	O
to	O
control	O
cells	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
Psoriasin	B-Gene
overexpression	O
resulted	O
in	O
increased	O
pancreatic	B-Disease
cancer	I-Disease
cell	O
invasion	O
which	O
was	O
associated	O
with	O
upregulation	O
of	O
matrix	B-Gene
metalloproteinase	I-Gene
-	I-Gene
2	I-Gene
(	O
MMP	B-Gene
-	I-Gene
2	I-Gene
)	O
and	O
MMP	B-Gene
-	I-Gene
9	I-Gene
.	O
</ALL>	O

<ALL>	O
Overexpression	O
of	O
Psoriasin	B-Gene
also	O
promoted	O
aggregation	O
and	O
survival	O
of	O
pancreatic	B-Disease
cancer	I-Disease
cells	O
when	O
they	O
lost	O
anchorage	O
.	O
</ALL>	O

<ALL>	O
Taken	O
together	O
,	O
higher	O
expression	O
of	O
Psoriasin	B-Gene
was	O
associated	O
with	O
local	O
invasion	O
in	O
pancreatic	B-Disease
cancers	I-Disease
.	O
</ALL>	O

<ALL>	O
Psoriasin	B-Gene
expression	O
is	O
associated	O
with	O
pancreatic	B-Disease
cancer	I-Disease
cell	O
growth	O
,	O
migration	O
,	O
cell	O
-	O
matrix	O
adhesion	O
,	O
and	O
invasion	O
via	O
regulation	O
of	O
MMPs	B-Gene
.	O
</ALL>	O

<ALL>	O
As	O
such	O
,	O
the	O
proposed	O
implications	O
of	O
Psoriasin	B-Gene
in	O
invasion	O
,	O
disease	O
progression	O
and	O
as	O
a	O
potential	O
therapeutic	O
target	O
warrant	O
further	O
investigation	O
.	O
</ALL>	O

<ALL>	O
Two	O
novel	O
mutations	O
in	O
SRY	B-Gene
gene	O
form	O
Chinese	O
sex	B-Disease
reversal	I-Disease
XY	I-Disease
females	O
.	O
</ALL>	O

<ALL>	O
The	O
SRY	B-Gene
gene	O
(	O
sex	O
determining	O
region	O
on	O
Y	O
chromosome	O
)	O
acts	O
as	O
TDF	O
and	O
is	O
required	O
for	O
regulating	O
male	O
sex	O
determination	O
.	O
</ALL>	O

<ALL>	O
SRY	B-Gene
represents	O
a	O
transcription	O
factor	O
belonging	O
to	O
the	O
superfamily	O
of	O
genes	O
sharing	O
the	O
HMG	O
-	O
box	O
motif	O
(	O
high	O
-	O
mobility	O
group	O
-	O
box	O
)	O
,	O
which	O
acts	O
as	O
DNA	O
binding	O
region	O
.	O
</ALL>	O

<ALL>	O
Deletion	O
and	O
inactivating	O
mutations	O
of	O
SRY	B-Gene
are	O
among	O
the	O
known	O
causes	O
of	O
XY	B-Disease
sex	I-Disease
reversal	I-Disease
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
described	O
the	O
screening	O
of	O
10	O
patients	B-Species
who	O
presented	O
with	O
46,XY	B-Disease
sex	I-Disease
reversal	I-Disease
for	O
mutations	O
in	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
of	O
SRY	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
DNA	O
was	O
isolated	O
from	O
blood	O
samples	O
using	O
standard	O
techniques	O
.	O
</ALL>	O

<ALL>	O
A	O
609	O
bp	O
fragment	O
from	O
the	O
central	O
portion	O
of	O
the	O
SRY	B-Gene
gene	O
was	O
amplified	O
,	O
using	O
primers	O
XES	O
-	O
2	O
and	O
XES	O
-	O
7	O
.	O
</ALL>	O

<ALL>	O
The	O
amplified	O
PCR	O
fragments	O
were	O
cloned	O
into	O
the	O
pUCm	O
-	O
T	O
vectors	O
,	O
and	O
direct	O
sequencing	O
were	O
carried	O
out	O
on	O
an	O
ABI	O
377	O
-	O
3	O
automated	O
DNA	O
sequencer	O
to	O
detect	O
the	O
mutation	O
.	O
</ALL>	O

<ALL>	O
PCR	O
-	O
restriction	O
enzyme	O
digestion	O
was	O
applied	O
to	O
detect	O
the	O
results	O
of	O
DNA	O
sequencing	O
.	O
</ALL>	O

<ALL>	O
In	O
two	O
patients	B-Species
,	O
de	O
novo	O
mutations	O
led	O
to	O
an	O
amino	O
acid	O
substitution	O
.	O
</ALL>	O

<ALL>	O
An	O
A	B-Variant
was	I-Variant
replaced	I-Variant
by	I-Variant
a	I-Variant
G	I-Variant
in	I-Variant
codon	I-Variant
38	I-Variant
upstream	O
of	O
the	O
5	O
'	O
border	O
outside	O
the	O
HMG	O
box	O
of	O
the	O
SRY	B-Gene
gene	O
,	O
resulting	O
in	O
the	O
replacement	O
of	O
the	O
amino	O
acid	O
glutamate	B-Variant
by	I-Variant
glycine	I-Variant
.	O
</ALL>	O

<ALL>	O
Another	O
heterozygous	O
T	B-Variant
to	I-Variant
A	I-Variant
transition	I-Variant
at	I-Variant
the	I-Variant
nucleotide	I-Variant
position	I-Variant
+	I-Variant
387	I-Variant
which	O
encodes	O
for	O
a	O
Tyrosine	B-Variant
(	I-Variant
Tyr	I-Variant
)	I-Variant
instead	I-Variant
of	I-Variant
a	I-Variant
Term	I-Variant
,	O
whereas	O
her	O
father	O
was	O
proven	O
to	O
have	O
the	O
wild	O
-	O
type	O
sequence	O
.	O
</ALL>	O

<ALL>	O
These	O
point	O
mutations	O
have	O
been	O
confirmed	O
with	O
PCR	O
-	O
restrict	O
enzyme	O
method	O
.	O
</ALL>	O

<ALL>	O
As	O
demonstrated	O
by	O
the	O
Human	B-Species
Gene	O
Mutation	O
Database	O
analysis	O
,	O
homology	O
search	O
,	O
and	O
review	O
of	O
the	O
literature	O
,	O
these	O
two	O
mutations	O
were	O
not	O
described	O
previously	O
and	O
brought	O
the	O
total	O
number	O
of	O
SRY	B-Gene
gene	O
nucleotide	O
substitutions	O
(	O
missense	O
/	O
nonsense	O
)	O
to	O
45	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
indicated	O
that	O
these	O
amino	O
acid	O
substitutions	O
may	O
be	O
responsible	O
for	O
the	O
sex	B-Disease
reversal	I-Disease
,	O
not	O
only	O
inside	O
the	O
HMG	O
-	O
box	O
but	O
also	O
outside	O
the	O
HMG	O
-	O
box	O
.	O
</ALL>	O

<ALL>	O
The	O
two	O
novel	O
mutations	O
in	O
SRY	B-Gene
gene	O
provided	O
valuable	O
information	O
for	O
understanding	O
the	O
molecular	O
mechanism	O
of	O
the	O
patient	B-Species
with	O
46,XY	B-Disease
female	I-Disease
sex	I-Disease
reversal	I-Disease
.	O
</ALL>	O

<ALL>	O
A	O
novel	O
missense	O
mutation	O
,	O
F826Y	B-Variant
,	O
in	O
the	O
mineralocorticoid	B-Gene
receptor	I-Gene
gene	O
in	O
Japanese	O
hypertensives	B-Disease
:	O
its	O
implications	O
for	O
clinical	O
phenotypes	O
.	O
</ALL>	O

<ALL>	O
A	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
resulting	O
in	O
the	O
S810L	B-Variant
amino	O
acid	O
substitution	O
in	O
the	O
hormone	O
-	O
binding	O
domain	O
of	O
the	O
mineralocorticoid	B-Gene
receptor	I-Gene
(	O
MR	B-Gene
,	O
locus	O
symbol	O
NR3C2	B-Gene
)	O
is	O
responsible	O
for	O
early	O
-	O
onset	O
hypertension	B-Disease
that	O
is	O
exacerbated	O
in	O
pregnancy	O
.	O
</ALL>	O

<ALL>	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
test	O
whether	O
other	O
types	O
of	O
missense	O
mutations	O
in	O
the	O
hormone	O
-	O
binding	O
domain	O
could	O
be	O
implicated	O
in	O
hypertension	B-Disease
in	O
Japanese	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
screened	O
942	O
Japanese	O
patients	B-Species
with	O
hypertension	B-Disease
for	O
the	O
S810L	B-Variant
mutation	O
in	O
exon	O
6	O
in	O
the	O
MR	B-Gene
.	O
</ALL>	O

<ALL>	O
We	O
did	O
not	O
identify	O
the	O
S810L	B-Variant
mutation	O
in	O
our	O
hypertensive	B-Disease
population	O
,	O
indicating	O
that	O
S810L	B-Variant
does	O
not	O
play	O
a	O
major	O
role	O
in	O
the	O
etiology	O
of	O
essential	B-Disease
hypertension	I-Disease
in	O
Japanese	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
we	O
identified	O
a	O
novel	O
missense	O
mutation	O
,	O
F826Y	B-Variant
,	O
in	O
three	O
patients	B-Species
in	O
a	O
heterozygous	O
state	O
,	O
in	O
addition	O
to	O
four	O
single	O
nucleotide	O
polymorphisms	O
,	O
including	O
one	O
synonymous	O
mutation	O
(	O
L809L	B-Variant
)	O
.	O
</ALL>	O

<ALL>	O
The	O
F826Y	B-Variant
mutation	O
is	O
present	O
in	O
the	O
MR	B-Gene
hormone	O
-	O
binding	O
domain	O
and	O
might	O
affect	O
the	O
ligand	O
affinity	O
.	O
</ALL>	O

<ALL>	O
The	O
F826Y	B-Variant
mutation	O
was	O
also	O
identified	O
in	O
13	O
individuals	O
(	O
5	O
hypertensives	B-Disease
and	O
8	O
normotensives	O
)	O
in	O
a	O
Japanese	O
general	O
population	O
(	O
n	O
=	O
3,655	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
allele	O
frequency	O
was	O
0.00178	O
.	O
</ALL>	O

<ALL>	O
The	O
frequencies	O
of	O
the	O
F826Y	B-Variant
mutation	O
in	O
the	O
hypertensive	B-Disease
population	O
(	O
3	O
/	O
942	O
)	O
and	O
in	O
the	O
hypertensive	B-Disease
group	O
(	O
5	O
/	O
1,480	O
)	O
and	O
the	O
normotensive	O
group	O
(	O
8	O
/	O
2,175	O
)	O
in	O
the	O
general	O
population	O
were	O
not	O
significantly	O
different	O
,	O
suggesting	O
that	O
this	O
mutation	O
does	O
not	O
greatly	O
affect	O
hypertension	B-Disease
.	O
</ALL>	O

<ALL>	O
Although	O
it	O
is	O
unclear	O
at	O
present	O
whether	O
or	O
not	O
the	O
F826Y	B-Variant
mutation	O
makes	O
a	O
substantial	O
contribution	O
to	O
the	O
mineralocorticoid	B-Gene
receptor	I-Gene
activity	O
,	O
this	O
missense	O
mutation	O
may	O
contribute	O
,	O
to	O
some	O
extent	O
,	O
to	O
clinical	O
phenotypes	O
through	O
its	O
effects	O
on	O
MR	B-Gene
.	O
</ALL>	O

<ALL>	O
Myocardial	O
Fas	B-Gene
ligand	I-Gene
expression	O
increases	O
susceptibility	O
to	O
AZT	B-Chemical
-	O
induced	O
cardiomyopathy	B-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Dilated	B-Disease
cardiomyopathy	I-Disease
(	O
DCM	B-Disease
)	O
and	O
myocarditis	B-Disease
occur	O
in	O
many	O
HIV	B-Disease
-	I-Disease
infected	I-Disease
individuals	O
,	O
resulting	O
in	O
symptomatic	O
heart	B-Disease
failure	I-Disease
in	O
up	O
to	O
5	O
%	O
of	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
has	O
significantly	O
reduced	O
morbidity	O
and	O
mortality	O
of	O
acquired	B-Disease
immunodeficiency	I-Disease
syndrome	I-Disease
(	O
AIDS	B-Disease
)	O
,	O
but	O
has	O
resulted	O
in	O
an	O
increase	O
in	O
cardiac	B-Disease
and	I-Disease
skeletal	I-Disease
myopathies	I-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
AND	O
RESULTS	O
:	O
In	O
order	O
to	O
investigate	O
whether	O
the	O
HAART	O
component	O
zidovudine	B-Chemical
(	O
3	B-Chemical
'	I-Chemical
-	I-Chemical
azido	I-Chemical
-	I-Chemical
2',3	I-Chemical
'	I-Chemical
-	I-Chemical
deoxythymidine	I-Chemical
;	O
AZT	B-Chemical
)	O
triggers	O
the	O
Fas	B-Gene
-	O
dependent	O
cell	O
-	O
death	O
pathway	O
and	O
cause	O
cytoskeletal	O
disruption	O
in	O
a	O
murine	B-Species
model	O
of	O
DCM	B-Disease
,	O
8	O
-	O
week	O
-	O
old	O
transgenic	O
(	O
expressing	O
Fas	B-Gene
ligand	I-Gene
in	O
the	O
myocardium	O
:	O
FasL	B-Gene
Tg	O
)	O
and	O
non	O
-	O
transgenic	O
(	O
NTg	O
)	O
mice	B-Species
received	O
water	O
ad	O
libitum	O
containing	O
different	O
concentrations	O
of	O
AZT	B-Chemical
(	O
0	O
,	O
0.07	O
,	O
0.2	O
,	O
and	O
0.7	O
mg	O
/	O
ml	O
)	O
.	O
</ALL>	O

<ALL>	O
After	O
6	O
weeks	O
,	O
cardiac	O
function	O
was	O
assessed	O
by	O
echocardiography	O
and	O
morphology	O
was	O
assessed	O
by	O
histopathologic	O
and	O
immunohistochemical	O
methods	O
.	O
</ALL>	O

<ALL>	O
NTg	O
and	O
untreated	O
FasL	B-Gene
Tg	O
mice	B-Species
showed	O
little	O
or	O
no	O
change	O
in	O
cardiac	O
structure	O
or	O
function	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
AZT	B-Chemical
-	O
treated	O
FasL	B-Gene
Tg	O
mice	B-Species
developed	O
cardiac	B-Disease
dilation	I-Disease
and	O
depressed	B-Disease
cardiac	I-Disease
function	I-Disease
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
with	O
concomitant	O
inflammatory	B-Disease
infiltration	O
of	O
both	O
ventricles	O
.	O
</ALL>	O

<ALL>	O
These	O
changes	O
were	O
associated	O
with	O
an	O
increased	O
sarcolemmal	O
expression	O
of	O
Fas	B-Gene
and	O
FasL	B-Gene
,	O
as	O
well	O
as	O
increased	O
activation	O
of	O
caspase	B-Gene
3	I-Gene
,	O
translocation	O
of	O
calpain	B-Gene
1	I-Gene
to	O
the	O
sarcolemma	O
and	O
sarcomere	O
,	O
and	O
increased	O
numbers	O
of	O
cells	O
undergoing	O
apoptosis	O
.	O
</ALL>	O

<ALL>	O
These	O
were	O
associated	O
with	O
changes	O
in	O
dystrophin	B-Gene
and	O
cardiac	B-Gene
troponin	I-Gene
I	I-Gene
localization	O
,	O
as	O
well	O
as	O
loss	O
of	O
sarcolemmal	O
integrity	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
The	O
expression	O
of	O
Fas	B-Gene
ligand	I-Gene
in	O
the	O
myocardium	O
,	O
as	O
identified	O
in	O
HIV	B-Species
-	O
positive	O
patients	B-Species
,	O
might	O
increase	O
the	O
susceptibility	O
to	O
HAART	O
-	O
induced	O
cardiomyopathy	B-Disease
due	O
to	O
activation	O
of	O
apoptotic	O
pathways	O
,	O
resulting	O
in	O
cardiac	B-Disease
dilation	I-Disease
and	I-Disease
dysfunction	I-Disease
.	O
</ALL>	O

<ALL>	O
Familial	O
glucocorticoid	B-Gene
receptor	I-Gene
haploinsufficiency	O
by	O
non	O
-	O
sense	O
mediated	O
mRNA	O
decay	O
,	O
adrenal	B-Disease
hyperplasia	I-Disease
and	O
apparent	B-Disease
mineralocorticoid	I-Disease
excess	I-Disease
.	O
</ALL>	O

<ALL>	O
Primary	O
glucocorticoid	B-Disease
resistance	I-Disease
(	O
OMIM	B-Disease
138040	I-Disease
)	O
is	O
a	O
rare	O
hereditary	B-Disease
disease	I-Disease
that	O
causes	O
a	O
generalized	O
partial	O
insensitivity	O
to	O
glucocorticoid	B-Chemical
action	O
,	O
due	O
to	O
genetic	O
alterations	O
of	O
the	O
glucocorticoid	B-Gene
receptor	I-Gene
(	O
GR	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
Investigation	O
of	O
adrenal	B-Disease
incidentalomas	I-Disease
led	O
to	O
the	O
discovery	O
of	O
a	O
family	O
(	O
eight	O
affected	O
individuals	O
spanning	O
three	O
generations	O
)	O
,	O
prone	O
to	O
cortisol	B-Disease
resistance	I-Disease
,	O
bilateral	B-Disease
adrenal	I-Disease
hyperplasia	I-Disease
,	O
arterial	O
hypertension	B-Disease
and	O
hypokalemia	B-Disease
.	O
</ALL>	O

<ALL>	O
This	O
phenotype	O
exacerbated	O
over	O
time	O
,	O
cosegregates	O
with	O
the	O
first	O
heterozygous	O
nonsense	O
mutation	O
p	B-Variant
.	I-Variant
R469[R	I-Variant
,	I-Variant
X	I-Variant
]	I-Variant
reported	O
to	O
date	O
for	O
the	O
GR	B-Gene
,	O
replacing	O
an	O
arginine	B-Variant
(	I-Variant
CGA	I-Variant
)	I-Variant
by	I-Variant
a	I-Variant
stop	I-Variant
(	I-Variant
TGA	I-Variant
)	I-Variant
at	I-Variant
amino	I-Variant
-	I-Variant
acid	I-Variant
469	I-Variant
in	O
the	O
second	O
zinc	O
finger	O
of	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
receptor	O
.	O
</ALL>	O

<ALL>	O
In	O
vitro	O
,	O
this	O
mutation	O
leads	O
to	O
a	O
truncated	O
50	O
-	O
kDa	O
GR	B-Gene
lacking	O
hormone	O
and	O
DNA	O
binding	O
capacity	O
,	O
devoid	O
of	O
hormone	O
-	O
dependent	O
nuclear	O
translocation	O
and	O
transactivation	O
properties	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
proband	O
's	O
fibroblasts	O
,	O
we	O
provided	O
evidence	O
for	O
the	O
lack	O
of	O
expression	O
of	O
the	O
defective	O
allele	O
in	O
vivo	O
.	O
</ALL>	O

<ALL>	O
The	O
absence	O
of	O
detectable	O
mutated	O
GR	B-Gene
mRNA	O
was	O
accompanied	O
by	O
a	O
50	O
%	O
reduction	O
in	O
wild	O
type	O
GR	B-Gene
transcript	O
and	O
protein	O
.	O
</ALL>	O

<ALL>	O
This	O
reduced	O
GR	B-Gene
expression	O
leads	O
to	O
a	O
significantly	O
below	O
-	O
normal	O
induction	O
of	O
glucocorticoid	B-Chemical
-	O
induced	O
target	O
genes	O
,	O
FKBP5	B-Gene
in	O
fibroblasts	O
.	O
</ALL>	O

<ALL>	O
We	O
demonstrated	O
that	O
the	O
molecular	O
mechanisms	O
of	O
glucocorticoid	B-Chemical
signaling	O
dysfunction	O
involved	O
GR	B-Gene
haploinsufficiency	O
due	O
to	O
the	O
selective	O
degradation	O
of	O
the	O
mutated	O
GR	B-Gene
transcript	O
through	O
a	O
nonsense	O
-	O
mediated	O
mRNA	O
Decay	O
that	O
was	O
experimentally	O
validated	O
on	O
emetine	B-Chemical
-	O
treated	O
propositus	O
'	O
fibroblasts	O
.	O
</ALL>	O

<ALL>	O
GR	B-Gene
haploinsufficiency	O
leads	O
to	O
hypertension	B-Disease
due	O
to	O
illicit	O
occupation	O
of	O
renal	O
mineralocorticoid	B-Gene
receptor	I-Gene
by	O
elevated	O
cortisol	B-Chemical
rather	O
than	O
to	O
increased	O
mineralocorticoid	B-Chemical
production	O
reported	O
in	O
primary	O
glucocorticoid	B-Disease
resistance	I-Disease
.	O
</ALL>	O

<ALL>	O
Indeed	O
,	O
apparent	B-Disease
mineralocorticoid	I-Disease
excess	I-Disease
was	O
demonstrated	O
by	O
a	O
decrease	O
in	O
urinary	O
tetrahydrocortisone	B-Chemical
-	O
tetrahydrocortisol	B-Chemical
ratio	O
in	O
affected	O
patients	B-Species
,	O
revealing	O
reduced	O
glucocorticoid	B-Chemical
degradation	O
by	O
renal	O
activity	O
of	O
the	O
11b	B-Gene
-	I-Gene
hydroxysteroid	I-Gene
dehydrogenase	I-Gene
type	I-Gene
2	I-Gene
,	O
a	O
GR	B-Gene
regulated	O
gene	O
.	O
</ALL>	O

<ALL>	O
We	O
propose	O
thus	O
that	O
GR	B-Gene
haploinsufficiency	O
compromises	O
glucocorticoid	B-Chemical
sensitivity	O
and	O
may	O
represent	O
a	O
novel	O
genetic	O
cause	O
of	O
subclinical	O
hypercortisolism	B-Disease
,	O
incidentally	O
revealed	O
bilateral	B-Disease
adrenal	I-Disease
hyperplasia	I-Disease
and	O
mineralocorticoid	B-Chemical
-	O
independent	O
hypertension	B-Disease
.	O
</ALL>	O

<ALL>	O
Polymorphism	O
of	O
the	O
PEMT	B-Gene
gene	O
and	O
susceptibility	O
to	O
nonalcoholic	B-Disease
fatty	I-Disease
liver	I-Disease
disease	I-Disease
(	O
NAFLD	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Phosphatidylethanolamine	B-Gene
N	I-Gene
-	I-Gene
methyltransferase	I-Gene
(	O
PEMT	B-Gene
)	O
catalyzes	O
phosphatidylcholine	B-Chemical
synthesis	O
.	O
</ALL>	O

<ALL>	O
PEMT	B-Gene
knockout	O
mice	B-Species
have	O
fatty	B-Disease
livers	I-Disease
,	O
and	O
it	O
is	O
possible	O
that	O
,	O
in	O
humans	B-Species
,	O
nonalcoholic	B-Disease
fatty	I-Disease
liver	I-Disease
disease	I-Disease
(	O
NAFLD	B-Disease
)	O
might	O
be	O
associated	O
with	O
PEMT	B-Gene
gene	O
polymorphisms	O
.	O
</ALL>	O

<ALL>	O
DNA	O
samples	O
from	O
59	O
humans	B-Species
without	O
fatty	B-Disease
liver	I-Disease
and	O
from	O
28	O
humans	B-Species
with	O
NAFLD	B-Disease
were	O
genotyped	O
for	O
a	O
single	O
nucleotide	O
polymorphism	O
in	O
exon	O
8	O
of	O
PEMT	B-Gene
,	O
which	O
leads	O
to	O
a	O
V175	B-Variant
M	I-Variant
substitution	O
.	O
</ALL>	O

<ALL>	O
V175	B-Variant
M	I-Variant
is	O
a	O
loss	O
of	O
function	O
mutation	O
,	O
as	O
determined	O
by	O
transiently	O
transfecting	O
McArdle	B-CellLine
-	I-CellLine
RH7777	I-CellLine
cells	O
with	O
constructs	O
of	O
wild	O
-	O
type	O
PEMT	B-Gene
open	O
reading	O
frame	O
or	O
the	O
V175	B-Variant
M	I-Variant
mutant	O
.	O
</ALL>	O

<ALL>	O
Met	B-Variant
/	I-Variant
Met	I-Variant
at	I-Variant
residue	I-Variant
175	I-Variant
(	O
loss	O
of	O
function	O
SNP	O
)	O
occurred	O
in	O
67.9	O
%	O
of	O
the	O
NAFLD	B-Disease
subjects	O
and	O
in	O
only	O
40.7	O
%	O
of	O
control	O
subjects	O
(	O
P	O
<	O
0.03	O
)	O
.	O
</ALL>	O

<ALL>	O
For	O
the	O
first	O
time	O
we	O
report	O
that	O
a	O
polymorphism	O
of	O
the	O
human	B-Species
PEMT	B-Gene
gene	O
(	O
V175	B-Variant
M	I-Variant
)	O
is	O
associated	O
with	O
diminished	O
activity	O
and	O
may	O
confer	O
susceptibility	O
to	O
NAFLD	B-Disease
.	O
</ALL>	O

<ALL>	O
Polymorphisms	O
in	O
the	O
FOXP3	B-Gene
gene	O
in	O
Han	O
Chinese	O
psoriasis	B-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Psoriasis	B-Disease
is	O
a	O
common	O
dermatological	B-Disease
disorder	I-Disease
,	O
in	O
which	O
autoimmunity	O
plays	O
an	O
important	O
role	O
.	O
</ALL>	O

<ALL>	O
CD4	B-Gene
(	O
+	O
)	O
CD25	B-Gene
(	O
+	O
)	O
regulatory	O
T	O
cells	O
(	O
T	O
-	O
regs	O
)	O
have	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
some	O
autoimmune	B-Disease
diseases	I-Disease
.	O
</ALL>	O

<ALL>	O
T	O
-	O
regs	O
express	O
the	O
fork	O
head	O
/	O
winged	O
helix	O
transcription	O
factor	O
,	O
FOXP3	B-Gene
,	O
which	O
appears	O
to	O
be	O
of	O
key	O
importance	O
in	O
the	O
development	O
and	O
function	O
of	O
T	O
-	O
regs	O
.	O
</ALL>	O

<ALL>	O
Studies	O
have	O
found	O
that	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
FOXP3	B-Gene
gene	O
contribute	O
to	O
susceptibility	O
to	O
some	O
autoimmune	B-Disease
disorders	I-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
information	O
about	O
FOXP3	B-Gene
gene	O
in	O
psoriasis	B-Disease
is	O
limited	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
This	O
study	O
evaluated	O
the	O
association	O
between	O
FOXP3	B-Gene
gene	O
SNPs	O
and	O
susceptibility	O
to	O
psoriasis	B-Disease
in	O
a	O
Han	O
Chinese	O
population	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
In	O
a	O
hospital	O
-	O
based	O
case	O
-	O
control	O
study	O
,	O
524	O
patients	B-Species
with	O
psoriasis	B-Disease
and	O
549	O
psoriasis	B-Disease
-	O
free	O
controls	O
were	O
recruited	O
according	O
to	O
age	O
and	O
gender	O
.	O
</ALL>	O

<ALL>	O
We	O
investigated	O
four	O
SNPs	O
in	O
the	O
FOXP3	B-Gene
gene	O
(	O
-	B-Variant
6054	I-Variant
,	I-Variant
deletion	I-Variant
/	I-Variant
ATT	I-Variant
;	O
-	B-Variant
3279	I-Variant
,	I-Variant
A	I-Variant
/	I-Variant
C	I-Variant
;	O
-	B-Variant
924	I-Variant
,	I-Variant
A	I-Variant
/	I-Variant
G	I-Variant
;	O
IVS9	B-Variant
+	I-Variant
459	I-Variant
,	I-Variant
A	I-Variant
/	I-Variant
G	I-Variant
)	O
in	O
psoriatic	B-Disease
patients	B-Species
,	O
and	O
assessed	O
allele	O
and	O
genotype	O
frequencies	O
in	O
psoriatic	B-Disease
patients	B-Species
(	O
237	O
females	O
,	O
287	O
males	O
)	O
and	O
normal	O
controls	O
(	O
272	O
females	O
,	O
277	O
males	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
polymorphisms	O
were	O
genotyped	O
using	O
the	O
PCR	O
sequence	O
-	O
specific	O
primer	O
(	O
PCR	O
-	O
SSP	O
)	O
technique	O
and	O
PCR	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
We	O
found	O
that	O
increased	O
risk	O
of	O
psoriasis	B-Disease
was	O
associated	O
with	O
the	O
FOXP3	B-Gene
-	B-Variant
3279	I-Variant
AC	I-Variant
genotype	O
(	O
adjusted	O
OR	O
,	O
1.32	O
;	O
95	O
%	O
CI	O
,	O
1.01	O
-	O
1.74	O
)	O
and	O
the	O
combined	O
AC	O
+	O
AA	O
genotype	O
(	O
adjusted	O
OR	O
,	O
1.38	O
;	O
95	O
%	O
CI	O
,	O
1.07	O
-	O
1.78	O
)	O
,	O
compared	O
with	O
the	O
-	B-Variant
3279	I-Variant
CC	I-Variant
genotype	O
.	O
</ALL>	O

<ALL>	O
We	O
also	O
found	O
that	O
an	O
increased	O
risk	O
of	O
psoriasis	B-Disease
was	O
associated	O
with	O
the	O
FOXP3	B-Gene
IVS9	B-Variant
+	I-Variant
459	I-Variant
GG	I-Variant
genotype	O
(	O
adjusted	O
OR	O
,	O
2.24	O
;	O
95	O
%	O
CI	O
,	O
1.41	O
-	O
3.58	O
)	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
combined	O
GA	O
+	O
GG	O
genotype	O
showed	O
no	O
such	O
tendency	O
(	O
adjusted	O
OR	O
=	O
1.28	O
;	O
95	O
%	O
CI	O
,	O
1.00	O
-	O
1.64	O
)	O
,	O
compared	O
with	O
the	O
IVS9	B-Variant
+	I-Variant
459	I-Variant
AA	I-Variant
genotype	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
no	O
evidence	O
of	O
an	O
increased	O
risk	O
associated	O
with	O
the	O
FOXP3	O
-	B-Variant
6054	I-Variant
deletion	I-Variant
/	I-Variant
ATT	I-Variant
or	O
FOXP3	O
-	B-Variant
924	I-Variant
A	I-Variant
/	I-Variant
G	I-Variant
genotype	O
.	O
</ALL>	O

<ALL>	O
In	O
combined	O
genotype	O
analyses	O
,	O
the	O
FOXP3	O
-	B-Variant
3279	I-Variant
AC	I-Variant
+	I-Variant
AA	I-Variant
genotype	O
was	O
more	O
obviously	O
associated	O
in	O
males	O
(	O
adjusted	O
OR	O
=	O
1.60	O
,	O
95	O
%	O
CI	O
=	O
1.11	O
-	O
2.31	O
)	O
and	O
severe	O
psoriasis	B-Disease
patients	B-Species
(	O
PASI	O
score	O
>	O
20	O
;	O
adjusted	O
OR	O
=	O
1.97	O
,	O
95	O
%	O
CI	O
=	O
1.41	O
-	O
2.75	O
)	O
.	O
</ALL>	O

<ALL>	O
Meanwhile	O
,	O
the	O
FOXP3	B-Gene
IVS9	B-Variant
+	I-Variant
459	I-Variant
GA	I-Variant
+	I-Variant
GG	I-Variant
genotype	O
was	O
also	O
associated	O
with	O
severe	O
psoriasis	B-Disease
patients	B-Species
(	O
adjusted	O
OR	O
=	O
1.69	O
,	O
95	O
%	O
CI	O
=	O
1.21	O
-	O
2.36	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
FOXP3	B-Gene
polymorphisms	O
appear	O
to	O
contribute	O
to	O
the	O
risk	O
of	O
psoriasis	B-Disease
in	O
a	O
Han	O
Chinese	O
population	O
.	O
</ALL>	O

<ALL>	O
Larger	O
studies	O
are	O
needed	O
to	O
confirm	O
these	O
findings	O
.	O
</ALL>	O

<ALL>	O
Autosomal	O
dominant	O
mutation	O
in	O
the	O
signal	O
peptide	O
of	O
renin	B-Gene
in	O
a	O
kindred	O
with	O
anemia	B-Disease
,	O
hyperuricemia	B-Disease
,	O
and	O
CKD	B-Disease
.	O
</ALL>	O

<ALL>	O
Homozygous	O
or	O
compound	O
heterozygous	O
mutations	O
in	O
renin	B-Gene
(	O
REN	B-Gene
)	O
cause	O
renal	B-Disease
tubular	I-Disease
dysgenesis	I-Disease
,	O
which	O
is	O
characterized	O
by	O
death	B-Disease
in	O
utero	O
due	O
to	O
kidney	B-Disease
failure	I-Disease
and	O
pulmonary	B-Disease
hypoplasia	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
phenotype	O
resembles	O
the	O
fetopathy	B-Disease
caused	O
by	O
angiotensin	B-Chemical
-	I-Chemical
converting	I-Chemical
enzyme	I-Chemical
inhibitor	I-Chemical
or	O
angiotensin	B-Chemical
receptor	I-Chemical
blocker	I-Chemical
intake	O
during	O
pregnancy	O
.	O
</ALL>	O

<ALL>	O
Recently	O
,	O
heterozygous	O
REN	B-Gene
mutations	O
were	O
shown	O
to	O
result	O
in	O
early	O
-	O
onset	O
hyperuricemia	B-Disease
,	O
anemia	B-Disease
,	O
and	O
chronic	B-Disease
kidney	I-Disease
disease	I-Disease
(	O
CKD	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
To	O
date	O
,	O
only	O
3	O
different	O
heterozygous	O
REN	B-Gene
mutations	O
have	O
been	O
published	O
.	O
</ALL>	O

<ALL>	O
We	O
report	O
mutation	O
analysis	O
of	O
the	O
REN	B-Gene
gene	O
in	O
39	O
kindreds	O
with	O
hyperuricemia	B-Disease
and	O
CKD	B-Disease
who	O
previously	O
tested	O
negative	O
for	O
mutations	O
in	O
the	O
UMOD	B-Gene
(	O
uromodulin	B-Gene
)	O
and	O
HNF1B	B-Gene
(	O
hepatocyte	B-Gene
nuclear	I-Gene
factor	I-Gene
1b	I-Gene
)	O
genes	O
.	O
</ALL>	O

<ALL>	O
We	O
identified	O
one	O
kindred	O
with	O
a	O
novel	O
thymidine	B-Variant
to	I-Variant
cytosine	I-Variant
mutation	I-Variant
at	I-Variant
position	I-Variant
28	I-Variant
in	O
the	O
REN	B-Gene
complementary	O
DNA	O
,	O
corresponding	O
to	O
a	O
tryptophan	B-Variant
to	I-Variant
arginine	I-Variant
substitution	I-Variant
at	I-Variant
amino	I-Variant
acid	I-Variant
10	I-Variant
,	O
which	O
is	O
found	O
within	O
the	O
signal	O
sequence	O
(	O
c.28	B-Variant
T	I-Variant
>	I-Variant
C	I-Variant
;	O
p	B-Variant
.	I-Variant
W10R	I-Variant
)	O
.	O
</ALL>	O

<ALL>	O
On	O
this	O
basis	O
,	O
we	O
conclude	O
that	O
REN	B-Gene
mutations	O
are	O
rare	O
events	O
in	O
patients	B-Species
with	O
CKD	B-Disease
.	O
</ALL>	O

<ALL>	O
Within	O
the	O
kindred	O
,	O
we	O
found	O
affected	O
individuals	O
over	O
4	O
generations	O
who	O
carried	O
the	O
novel	O
REN	B-Gene
mutation	O
and	O
were	O
characterized	O
by	O
significant	O
anemia	B-Disease
,	O
hyperuricemia	B-Disease
,	O
and	O
CKD	B-Disease
.	O
</ALL>	O

<ALL>	O
Anemia	B-Disease
was	O
severe	O
and	O
disproportional	O
to	O
the	O
degree	O
of	O
decreased	O
kidney	O
function	O
.	O
</ALL>	O

<ALL>	O
Because	O
all	O
heterozygous	O
REN	B-Gene
mutations	O
that	O
have	O
been	O
described	O
are	O
localized	O
in	O
the	O
signal	O
sequence	O
,	O
screening	O
of	O
the	O
REN	B-Gene
gene	O
for	O
patients	B-Species
with	O
CKD	B-Disease
with	O
hyperuricemia	B-Disease
and	O
anemia	B-Disease
may	O
best	O
be	O
focused	O
on	O
sequencing	O
of	O
exon	O
1	O
,	O
which	O
encodes	O
the	O
signal	O
peptide	O
.	O
</ALL>	O

<ALL>	O
On	O
the	O
pivotal	O
role	O
of	O
PPARa	B-Gene
in	O
adaptation	O
of	O
the	O
heart	O
to	O
hypoxia	B-Disease
and	O
why	O
fat	O
in	O
the	O
diet	O
increases	O
hypoxic	B-Disease
injury	O
.	O
</ALL>	O

<ALL>	O
The	O
role	O
of	O
peroxisome	B-Gene
proliferator	I-Gene
-	I-Gene
activated	I-Gene
receptor	I-Gene
a	I-Gene
(	O
PPARa	B-Gene
)	O
-	O
mediated	O
metabolic	O
remodeling	O
in	O
cardiac	O
adaptation	O
to	O
hypoxia	B-Disease
has	O
yet	O
to	O
be	O
defined	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
mice	B-Species
were	O
housed	O
in	O
hypoxia	B-Disease
for	O
3	O
wk	O
before	O
in	O
vivo	O
contractile	O
function	O
was	O
measured	O
using	O
cine	O
MRI	O
.	O
</ALL>	O

<ALL>	O
In	O
isolated	O
,	O
perfused	O
hearts	O
,	O
energetics	O
were	O
measured	O
using	O
(	O
31	O
)	O
P	O
magnetic	O
resonance	O
spectroscopy	O
(	O
MRS	O
)	O
,	O
and	O
glycolysis	O
and	O
fatty	B-Chemical
acid	I-Chemical
oxidation	O
were	O
measured	O
using	O
[	O
(	B-Chemical
3	I-Chemical
)	I-Chemical
H	I-Chemical
]	O
labeling	O
.	O
</ALL>	O

<ALL>	O
Compared	O
with	O
a	O
normoxic	O
,	O
chow	O
-	O
fed	O
control	O
mouse	B-Species
heart	O
,	O
hypoxia	B-Disease
decreased	O
PPARa	B-Gene
expression	O
,	O
fatty	B-Chemical
acid	I-Chemical
oxidation	O
,	O
and	O
mitochondrial	B-Gene
uncoupling	I-Gene
protein	I-Gene
3	I-Gene
(	O
UCP3	B-Gene
)	O
levels	O
,	O
while	O
increasing	O
glycolysis	O
,	O
all	O
of	O
which	O
served	O
to	O
maintain	O
normal	O
ATP	B-Chemical
concentrations	O
(	O
[	O
ATP	B-Chemical
]	O
)	O
and	O
thereby	O
,	O
ejection	O
fractions	O
.	O
</ALL>	O

<ALL>	O
A	O
high	O
-	O
fat	O
diet	O
increased	O
cardiac	O
PPARa	B-Gene
expression	O
,	O
fatty	B-Chemical
acid	I-Chemical
oxidation	O
,	O
and	O
UCP3	B-Gene
levels	O
with	O
decreased	O
glycolysis	O
.	O
</ALL>	O

<ALL>	O
Hypoxia	B-Disease
was	O
unable	O
to	O
alter	O
the	O
high	O
PPARa	B-Gene
expression	O
or	O
reverse	O
the	O
metabolic	O
changes	O
caused	O
by	O
the	O
high	O
-	O
fat	O
diet	O
,	O
with	O
the	O
result	O
that	O
[	O
ATP	B-Chemical
]	O
and	O
contractile	O
function	O
decreased	O
significantly	O
.	O
</ALL>	O

<ALL>	O
The	O
adaptive	O
metabolic	O
changes	O
caused	O
by	O
hypoxia	B-Disease
in	O
control	O
mouse	B-Species
hearts	O
were	O
found	O
to	O
have	O
occurred	O
already	O
in	O
PPARa	B-Gene
-	O
deficient	O
(	O
PPARa	B-Gene
(	O
-	O
/	O
-	O
)	O
)	O
mouse	B-Species
hearts	O
and	O
sustained	O
function	O
in	O
hypoxia	B-Disease
despite	O
an	O
inability	O
for	O
further	O
metabolic	O
remodeling	O
.	O
</ALL>	O

<ALL>	O
We	O
conclude	O
that	O
decreased	O
cardiac	O
PPARa	B-Gene
expression	O
is	O
essential	O
for	O
adaptive	O
metabolic	O
remodeling	O
in	O
hypoxia	B-Disease
,	O
but	O
is	O
prevented	O
by	O
dietary	O
fat	O
.	O
-	O
</ALL>	O

<ALL>	O
Cole	O
,	O
M.	O
A.	O
,	O
Abd	O
Jamil	O
,	O
A.	O
H.	O
,	O
Heather	O
,	O
L.	O
C.	O
,	O
Murray	O
,	O
A.	O
J.	O
,	O
Sutton	O
,	O
E.	O
R.	O
,	O
Slingo	O
,	O
M.	O
,	O
Sebag	O
-	O
Montefiore	O
,	O
L.	O
,	O
Tan	O
,	O
S.	O
C.	O
,	O
Aksentijevic	O
,	O
D.	O
,	O
Gildea	O
,	O
O.	O
S.	O
,	O
Stuckey	O
,	O
D.	O
J.	O
,	O
Yeoh	O
,	O
K.	O
K.	O
,	O
Carr	O
,	O
C.	O
A.	O
,	O
Evans	O
,	O
R.	O
D.	O
,	O
Aasum	O
,	O
E.	O
,	O
Schofield	O
,	O
C.	O
J.	O
,	O
Ratcliffe	O
,	O
P.	O
J.	O
,	O
Neubauer	O
,	O
S.	O
,	O
Robbins	O
,	O
P.	O
A.	O
,	O
Clarke	O
,	O
K.	O
On	O
the	O
pivotal	O
role	O
of	O
PPARa	B-Gene
in	O
adaptation	O
of	O
the	O
heart	O
to	O
hypoxia	B-Disease
and	O
why	O
fat	O
in	O
the	O
diet	O
increases	O
hypoxic	B-Disease
injury	O
.	O
</ALL>	O

<ALL>	O
Gartanin	B-Chemical
induces	O
cell	O
cycle	O
arrest	O
and	O
autophagy	O
and	O
suppresses	O
migration	O
involving	O
PI3	B-Gene
K	I-Gene
/	O
Akt	B-Gene
/	O
mTOR	B-Gene
and	O
MAPK	B-Gene
signalling	O
pathway	O
in	O
human	B-Species
glioma	B-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
In	O
central	O
nervous	O
system	O
,	O
glioma	B-Disease
is	O
the	O
most	O
common	O
primary	B-Disease
brain	I-Disease
tumour	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
diffuse	O
migration	O
and	O
rapid	O
proliferation	O
are	O
main	O
obstacles	O
for	O
successful	O
treatment	O
.	O
</ALL>	O

<ALL>	O
Gartanin	B-Chemical
,	O
a	O
natural	O
xanthone	B-Chemical
of	O
mangosteen	B-Species
,	O
suppressed	O
proliferation	O
,	O
migration	O
and	O
colony	O
formation	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
in	O
T98	B-CellLine
G	I-CellLine
glioma	B-Disease
cells	O
but	O
not	O
in	O
mouse	B-Species
normal	O
neuronal	O
HT22	B-CellLine
cells	O
.	O
</ALL>	O

<ALL>	O
Gartanin	B-Chemical
,	O
at	O
low	O
micromole	O
,	O
led	O
to	O
cell	O
cycle	O
arrest	O
in	O
G1	O
phase	O
accompanied	O
by	O
inhibited	O
expression	O
level	O
of	O
G1	O
cell	O
cycle	O
regulatory	O
proteins	O
cyclin	B-Gene
D1	I-Gene
,	O
while	O
increased	O
expression	O
level	O
of	O
cyclin	B-Gene
-	I-Gene
dependent	I-Gene
kinase	I-Gene
inhibitor	O
p27Kip1	B-Gene
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
the	O
secretion	O
and	O
activity	O
of	O
matrix	B-Gene
metalloproteinases	I-Gene
2	I-Gene
/	I-Gene
9	I-Gene
(	O
MMP	B-Gene
-	I-Gene
2	I-Gene
/	I-Gene
-	I-Gene
9	I-Gene
)	O
were	O
significantly	O
suppressed	O
in	O
T98	B-CellLine
G	I-CellLine
cells	O
treated	O
with	O
gartanin	B-Chemical
,	O
and	O
it	O
might	O
result	O
from	O
modulating	O
mitogen	B-Gene
-	I-Gene
activated	I-Gene
protein	I-Gene
kinases	I-Gene
(	O
MAPK	B-Gene
)	O
signalling	O
pathway	O
in	O
T98	B-CellLine
G	I-CellLine
glioma	B-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
gartanin	B-Chemical
significantly	O
induced	O
autophagy	O
in	O
T98	B-CellLine
G	I-CellLine
cells	O
and	O
increased	O
GFP	O
-	O
LC3	B-Gene
punctate	O
fluorescence	O
accompanied	O
by	O
the	O
increased	O
expression	O
level	O
of	O
Beclin	B-Gene
1	I-Gene
and	O
LC3	B-Gene
-	O
II	O
,	O
while	O
suppressed	O
expression	O
level	O
of	O
p62	B-Gene
.	O
</ALL>	O

<ALL>	O
Gartanin	B-Chemical
treatment	O
resulted	O
in	O
obvious	O
inhibition	O
of	O
PI3	B-Gene
K	I-Gene
/	O
Akt	B-Gene
/	O
mTOR	B-Gene
signalling	O
pathway	O
,	O
which	O
is	O
important	O
in	O
modulating	O
autophagy	O
.	O
</ALL>	O

<ALL>	O
Notably	O
,	O
gartanin	B-Chemical
-	O
mediated	O
anti	O
-	O
viability	O
was	O
significantly	O
abrogated	O
by	O
autophagy	O
inhibitors	O
including	O
3	B-Chemical
-	I-Chemical
methyladenine	I-Chemical
(	O
3	B-Chemical
-	I-Chemical
MA	I-Chemical
)	O
and	O
chloroquine	B-Chemical
(	O
CQ	B-Chemical
)	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
indicate	O
that	O
anti	O
-	O
proliferation	O
effect	O
of	O
gartanin	B-Chemical
in	O
T98	B-CellLine
G	I-CellLine
cells	O
is	O
most	O
likely	O
via	O
cell	O
cycle	O
arrest	O
modulated	O
by	O
autophagy	O
,	O
which	O
is	O
regulated	O
by	O
PI3	B-Gene
K	I-Gene
/	O
Akt	B-Gene
/	O
mTOR	B-Gene
signalling	O
pathway	O
,	O
while	O
anti	O
-	O
migration	O
effect	O
is	O
most	O
likely	O
via	O
suppression	O
of	O
MMP	B-Gene
-	I-Gene
2	I-Gene
/	I-Gene
-	I-Gene
9	I-Gene
activity	O
which	O
is	O
involved	O
in	O
MAPK	B-Gene
signalling	O
pathway	O
.	O
</ALL>	O

<ALL>	O
Gene	O
therapy	O
for	O
cystic	B-Disease
fibrosis	I-Disease
airway	O
disease	O
-	O
is	O
clinical	O
success	O
imminent	O
?	O
</ALL>	O

<ALL>	O
Cystic	B-Disease
fibrosis	I-Disease
(	O
CF	B-Disease
)	O
was	O
one	O
of	O
the	O
first	O
inherited	B-Disease
disorders	I-Disease
for	O
which	O
gene	O
therapy	O
was	O
seriously	O
considered	O
as	O
a	O
realistic	O
option	O
for	O
treatment	O
,	O
and	O
as	O
such	O
,	O
it	O
has	O
long	O
provided	O
a	O
paradigm	O
for	O
gene	O
therapy	O
of	O
inherited	B-Disease
diseases	I-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
despite	O
the	O
cloning	O
of	O
the	O
cystic	B-Gene
fibrosis	I-Gene
transmembrane	I-Gene
conductance	I-Gene
regulator	I-Gene
gene	O
in	O
1989	O
,	O
over	O
15	O
years	O
later	O
a	O
practical	O
gene	O
therapy	O
for	O
CF	B-Disease
has	O
not	O
eventuated	O
.	O
</ALL>	O

<ALL>	O
There	O
are	O
a	O
number	O
of	O
reasons	O
for	O
this	O
,	O
and	O
analysis	O
of	O
the	O
specific	O
issues	O
that	O
have	O
delayed	O
the	O
successful	O
development	O
of	O
gene	O
therapy	O
for	O
CF	B-Disease
also	O
provides	O
general	O
insights	O
into	O
the	O
practical	O
complexities	O
involved	O
in	O
the	O
development	O
of	O
gene	O
therapy	O
for	O
inherited	B-Disease
disorders	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
issues	O
which	O
have	O
prevented	O
the	O
application	O
of	O
gene	O
therapy	O
for	O
CF	B-Disease
to	O
date	O
include	O
the	O
lack	O
of	O
suitable	O
gene	O
delivery	O
technologies	O
,	O
the	O
complexities	O
of	O
the	O
interactions	O
between	O
the	O
host	O
and	O
vector	O
,	O
the	O
biology	O
of	O
the	O
lung	O
airways	O
,	O
and	O
the	O
nature	O
of	O
the	O
pathology	O
found	O
in	O
individuals	O
with	O
CF	B-Disease
.	O
</ALL>	O

<ALL>	O
We	O
will	O
discuss	O
the	O
history	O
of	O
CF	B-Disease
gene	O
therapy	O
with	O
specific	O
reference	O
to	O
these	O
and	O
other	O
issues	O
that	O
pre	O
-	O
occupy	O
the	O
field	O
at	O
present	O
:	O
namely	O
,	O
the	O
question	O
of	O
what	O
vectors	O
appear	O
to	O
be	O
suitable	O
for	O
airway	O
gene	O
delivery	O
in	O
CF	B-Disease
,	O
what	O
cells	O
must	O
be	O
targeted	O
,	O
how	O
airway	O
epithelium	O
defences	O
can	O
be	O
overcome	O
or	O
eluded	O
to	O
allow	O
efficient	O
gene	O
delivery	O
,	O
how	O
to	O
ensure	O
safe	O
and	O
long	O
-	O
term	O
transgene	O
expression	O
and	O
the	O
need	O
to	O
identify	O
relevant	O
surrogate	O
success	O
measures	O
that	O
can	O
be	O
used	O
to	O
assess	O
the	O
outcome	O
of	O
gene	O
therapy	O
in	O
CF	B-Disease
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Mutation	O
in	O
the	O
auxiliary	O
calcium	B-Chemical
-	O
channel	O
subunit	O
CACNA2D4	B-Gene
causes	O
autosomal	O
recessive	O
cone	B-Disease
dystrophy	I-Disease
.	O
</ALL>	O

<ALL>	O
Retinal	O
signal	O
transmission	O
depends	O
on	O
the	O
activity	O
of	O
high	O
voltage	O
-	O
gated	O
l	O
-	O
type	O
calcium	B-Chemical
channels	O
in	O
photoreceptor	O
ribbon	O
synapses	O
.	O
</ALL>	O

<ALL>	O
We	O
recently	O
identified	O
a	O
truncating	O
frameshift	O
mutation	O
in	O
the	O
Cacna2d4	B-Gene
gene	O
in	O
a	O
spontaneous	O
mouse	B-Species
mutant	O
with	O
profound	O
loss	O
of	O
retinal	O
signaling	O
and	O
an	O
abnormal	O
morphology	O
of	O
ribbon	O
synapses	O
in	O
rods	O
and	O
cones	O
.	O
</ALL>	O

<ALL>	O
The	O
Cacna2d4	B-Gene
gene	O
encodes	O
an	O
l	B-Gene
-	I-Gene
type	I-Gene
calcium	I-Gene
-	I-Gene
channel	I-Gene
auxiliary	I-Gene
subunit	I-Gene
of	I-Gene
the	I-Gene
alpha	I-Gene
(	I-Gene
2	I-Gene
)	I-Gene
delta	I-Gene
type	I-Gene
.	O
</ALL>	O

<ALL>	O
Mutations	O
in	O
its	O
human	B-Species
orthologue	O
,	O
CACNA2D4	B-Gene
,	O
were	O
not	O
yet	O
known	O
to	O
be	O
associated	O
with	O
a	O
disease	O
.	O
</ALL>	O

<ALL>	O
We	O
performed	O
mutation	O
analyses	O
of	O
34	O
patients	B-Species
who	O
received	O
an	O
initial	O
diagnosis	O
of	O
night	B-Disease
blindness	I-Disease
,	O
and	O
,	O
in	O
two	O
affected	O
siblings	O
,	O
we	O
detected	O
a	O
homozygous	O
nucleotide	O
substitution	O
(	O
c.2406C	B-Variant
-	I-Variant
-	I-Variant
>	I-Variant
A	I-Variant
)	O
in	O
CACNA2D4	B-Gene
.	O
</ALL>	O

<ALL>	O
The	O
mutation	O
introduces	O
a	O
premature	O
stop	O
codon	O
that	O
truncates	O
one	O
-	O
third	O
of	O
the	O
corresponding	O
open	O
reading	O
frame	O
.	O
</ALL>	O

<ALL>	O
Both	O
patients	B-Species
share	O
symptoms	O
of	O
slowly	O
progressing	O
cone	B-Disease
dystrophy	I-Disease
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
represent	O
the	O
first	O
report	O
of	O
a	O
mutation	O
in	O
the	O
human	B-Species
CACNA2D4	B-Gene
gene	O
and	O
define	O
a	O
novel	O
gene	O
defect	O
that	O
causes	O
autosomal	O
recessive	O
cone	B-Disease
dystrophy	I-Disease
.	O
</ALL>	O

<ALL>	O
A	O
homozygous	O
mutation	O
in	O
LYRM7	B-Gene
/	O
MZM1L	B-Gene
associated	O
with	O
early	O
onset	O
encephalopathy	B-Disease
,	O
lactic	B-Disease
acidosis	I-Disease
,	O
and	O
severe	O
reduction	B-Disease
of	I-Disease
mitochondrial	I-Disease
complex	I-Disease
III	I-Disease
activity	O
.	O
</ALL>	O

<ALL>	O
Mutations	O
in	O
nuclear	O
genes	O
associated	O
with	O
defective	B-Disease
complex	I-Disease
III	I-Disease
(	I-Disease
cIII	I-Disease
)	I-Disease
of	I-Disease
the	I-Disease
mitochondrial	I-Disease
respiratory	O
chain	O
are	O
rare	O
,	O
having	O
been	O
found	O
in	O
only	O
two	O
cIII	B-Gene
assembly	O
factors	O
and	O
,	O
as	O
private	O
changes	O
in	O
single	O
families	O
,	O
three	O
cIII	B-Gene
structural	O
subunits	O
.	O
</ALL>	O

<ALL>	O
Recently	O
,	O
human	B-Species
LYRM7	B-Gene
/	O
MZM1L	B-Gene
,	O
the	O
ortholog	O
of	O
yeast	B-Species
MZM1	B-Gene
,	O
has	O
been	O
identified	O
as	O
a	O
new	O
assembly	O
factor	O
for	O
cIII	B-Gene
.	O
</ALL>	O

<ALL>	O
In	O
a	O
baby	O
patient	B-Species
with	O
early	O
onset	O
,	O
severe	O
encephalopathy	B-Disease
,	O
lactic	B-Disease
acidosis	I-Disease
and	O
profound	O
,	O
isolated	O
cIII	B-Disease
deficiency	I-Disease
in	O
skeletal	O
muscle	O
,	O
we	O
identified	O
a	O
disease	O
-	O
segregating	O
homozygous	O
mutation	O
(	O
c.73	B-Variant
G	I-Variant
>	I-Variant
A	I-Variant
)	O
in	O
LYRM7	B-Gene
/	O
MZM1L	B-Gene
,	O
predicting	O
a	O
drastic	O
change	O
in	O
a	O
highly	O
conserved	O
amino	O
-	O
acid	O
residue	O
(	O
p	B-Variant
.	I-Variant
Asp25Asn	I-Variant
)	O
.	O
</ALL>	O

<ALL>	O
In	O
a	O
mzm1D	B-Gene
yeast	B-Species
strain	O
,	O
the	O
expression	O
of	O
a	O
mzm1	B-Gene
(	O
D25N	B-Variant
)	O
mutant	O
allele	O
caused	O
temperature	O
-	O
sensitive	O
respiratory	B-Disease
growth	I-Disease
defect	I-Disease
,	O
decreased	O
oxygen	B-Chemical
consumption	O
,	O
impaired	O
maturation	O
/	O
stabilization	O
of	O
the	O
Rieske	B-Gene
Fe	I-Gene
-	I-Gene
S	I-Gene
protein	I-Gene
,	O
and	O
reduced	O
complex	B-Gene
III	I-Gene
activity	O
and	O
amount	O
.	O
</ALL>	O

<ALL>	O
LYRM7	B-Gene
/	O
MZM1L	B-Gene
is	O
a	O
novel	O
disease	O
gene	O
,	O
causing	O
cIII	B-Disease
-	I-Disease
defective	I-Disease
,	O
early	O
onset	O
,	O
severe	O
mitochondrial	B-Disease
encephalopathy	I-Disease
.	O
</ALL>	O

<ALL>	O
Comparison	O
of	O
sequential	O
cytomegalovirus	B-Species
isolates	O
in	O
a	O
patient	B-Species
with	O
lymphoma	B-Disease
and	O
failing	O
antiviral	O
therapy	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Long	B-Disease
-	I-Disease
term	I-Disease
anti	I-Disease
-	I-Disease
cytomegalovirus	I-Disease
(	O
CMV	B-Disease
)	O
treatments	O
in	O
immunocompromised	O
patients	B-Species
are	O
hampered	O
by	O
resistance	O
to	O
antiviral	O
drugs	O
.	O
</ALL>	O

<ALL>	O
Longitudinal	O
changes	O
in	O
the	O
resistance	O
genotype	O
may	O
depend	O
on	O
changes	O
in	O
selective	O
pressure	O
and	O
the	O
complexity	O
of	O
CMV	B-Disease
isolates	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
To	O
evaluate	O
longitudinal	O
changes	O
in	O
the	O
CMV	B-Disease
resistance	O
genotype	O
and	O
phenotype	O
along	O
with	O
strain	O
-	O
specific	O
variability	O
in	O
a	O
patient	B-Species
with	O
non	B-Disease
-	I-Disease
Hodgkin	I-Disease
's	I-Disease
lymphoma	I-Disease
in	O
whom	O
successive	O
anti	O
-	O
CMV	B-Disease
treatments	O
failed	O
.	O
</ALL>	O

<ALL>	O
STUDY	O
DESIGN	O
:	O
The	O
resistance	O
phenotype	O
and	O
genotype	O
of	O
seven	O
CMV	B-Disease
isolates	O
collected	O
from	O
one	O
patient	B-Species
during	O
a	O
2	O
-	O
year	O
follow	O
-	O
up	O
period	O
were	O
retrospectively	O
analysed	O
.	O
</ALL>	O

<ALL>	O
In	O
parallel	O
,	O
we	O
used	O
glycoprotein	B-Gene
B	I-Gene
(	O
gB	B-Gene
)	O
genotyping	O
,	O
and	O
a	O
-	O
and	O
UL10	O
-	O
13	O
-	O
sequence	O
analysis	O
to	O
study	O
CMV	B-Disease
interstrain	O
variability	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
patient	B-Species
was	O
infected	O
by	O
at	O
least	O
three	O
CMV	B-Disease
strains	O
plus	O
variants	O
of	O
the	O
parental	O
strains	O
.	O
</ALL>	O

<ALL>	O
Resistance	O
to	O
ganciclovir	B-Chemical
,	O
cidofovir	B-Chemical
and	O
foscarnet	B-Chemical
was	O
successively	O
detected	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O
</ALL>	O

<ALL>	O
UL97	B-Gene
protein	I-Gene
kinase	I-Gene
changes	O
responsible	O
for	O
resistance	O
to	O
ganciclovir	B-Chemical
were	O
initially	O
detected	O
at	O
residues	O
591	O
and	O
592	O
,	O
and	O
then	O
at	O
position	O
594	O
.	O
</ALL>	O

<ALL>	O
Decreased	O
sensitivity	O
to	O
foscarnet	B-Chemical
coincided	O
with	O
the	O
appearance	O
of	O
amino	O
acid	O
substitution	O
N495	B-Variant
K	I-Variant
in	O
DNA	O
polymerase	O
,	O
whereas	O
cross	O
-	O
resistance	O
to	O
ganciclovir	B-Chemical
and	O
cidofovir	B-Chemical
was	O
due	O
to	O
the	O
L501I	B-Variant
substitution	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
The	O
CMV	B-Disease
isolates	O
obtained	O
from	O
our	O
patient	B-Species
were	O
complex	O
mixtures	O
of	O
strains	O
.	O
</ALL>	O

<ALL>	O
Changes	O
in	O
resistance	O
genotypes	O
depended	O
on	O
resistance	O
selective	O
pressure	O
and	O
were	O
not	O
linked	O
to	O
interstrain	O
variation	O
.	O
</ALL>	O

<ALL>	O
Coincidence	O
of	O
mutations	O
in	O
different	O
connexin	O
genes	O
in	O
Hungarian	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Mutations	O
in	O
the	O
GJB2	B-Gene
gene	O
are	O
the	O
most	O
common	O
cause	O
of	O
hereditary	O
prelingual	O
sensorineural	B-Disease
hearing	I-Disease
impairment	I-Disease
in	O
Europe	O
.	O
</ALL>	O

<ALL>	O
Several	O
studies	O
indicate	O
that	O
different	O
members	O
of	O
the	O
connexin	O
protein	O
family	O
interact	O
to	O
form	O
gap	O
junctions	O
in	O
the	O
inner	O
ear	O
.	O
</ALL>	O

<ALL>	O
Mutations	O
in	O
different	O
connexin	O
genes	O
may	O
accumulate	O
and	O
,	O
consequently	O
lead	O
to	O
hearing	B-Disease
impairment	I-Disease
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
we	O
screened	O
47	O
Hungarian	O
GJB2	B-Gene
-	O
heterozygous	O
(	O
one	O
mutation	O
in	O
coding	O
exon	O
of	O
the	O
GJB2	B-Gene
gene	O
)	O
patients	B-Species
with	O
hearing	B-Disease
impairment	I-Disease
for	O
DNA	O
changes	O
in	O
two	O
further	O
connexin	O
genes	O
(	O
GJB6	B-Gene
and	O
GJB3	B-Gene
)	O
and	O
in	O
the	O
5	O
'	O
non	O
-	O
coding	O
region	O
of	O
GJB2	B-Gene
including	O
the	O
splice	O
sites	O
.	O
</ALL>	O

<ALL>	O
Eleven	O
out	O
of	O
47	O
GJB2	B-Gene
-	O
heterozygous	O
patients	B-Species
analyzed	O
carried	O
the	O
splice	O
site	O
mutation	O
-	B-Variant
3170	I-Variant
G	I-Variant
>	I-Variant
A	I-Variant
in	O
the	O
5'UTR	O
region	O
of	O
GJB2	B-Gene
.	O
</ALL>	O

<ALL>	O
One	O
out	O
of	O
these	O
11	O
patients	B-Species
showed	O
homozygous	O
-	B-Variant
3170	I-Variant
G	I-Variant
>	I-Variant
A	I-Variant
genotype	O
in	O
combination	O
with	O
p	B-Variant
.	I-Variant
R127H	I-Variant
.	O
</ALL>	O

<ALL>	O
Next	O
to	O
the	O
GJB2	B-Gene
mutations	O
we	O
noted	O
2	O
cases	O
of	O
deletion	O
in	O
GJB6	B-Gene
[	O
Delta	O
(	O
GJB6	B-Gene
-	O
D13S1830	O
)	O
]	O
and	O
3	O
(	O
2	O
new	O
and	O
1	O
described	O
)	O
base	O
substitutions	O
in	O
GJB3	B-Gene
[	O
c.357C	B-Variant
>	I-Variant
T	I-Variant
,	O
c.798C	B-Variant
>	I-Variant
T	I-Variant
and	O
c.94C	B-Variant
>	I-Variant
T	I-Variant
(	O
p	B-Variant
.	I-Variant
R32W	I-Variant
)	O
]	O
which	O
are	O
unlikely	O
disease	O
-	O
causing	O
.	O
</ALL>	O

<ALL>	O
Our	O
results	O
suggest	O
the	O
importance	O
of	O
routine	O
screening	O
for	O
the	O
rather	O
frequent	O
-	B-Variant
3170	I-Variant
G	I-Variant
>	I-Variant
A	I-Variant
mutation	O
(	O
in	O
addition	O
to	O
c.35delG	B-Variant
)	O
in	O
patients	B-Species
with	O
hearing	B-Disease
impairment	I-Disease
.	O
</ALL>	O

<ALL>	O
Calcium	B-Gene
sensing	I-Gene
receptor	I-Gene
protects	O
high	O
glucose	B-Chemical
-	O
induced	O
energy	O
metabolism	B-Disease
disorder	I-Disease
via	O
blocking	O
gp78	B-Gene
-	O
ubiquitin	O
proteasome	O
pathway	O
.	O
</ALL>	O

<ALL>	O
Diabetic	B-Disease
cardiomyopathy	I-Disease
(	O
DCM	B-Disease
)	O
is	O
a	O
major	O
complication	O
and	O
fatal	O
cause	O
of	O
the	O
patients	B-Species
with	O
diabetes	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
calcium	B-Gene
sensing	I-Gene
receptor	I-Gene
(	O
CaSR	B-Gene
)	O
is	O
a	O
G	B-Gene
protein	I-Gene
-	I-Gene
coupled	I-Gene
receptor	I-Gene
,	O
which	O
is	O
involved	O
in	O
maintaining	O
calcium	B-Chemical
homeostasis	O
,	O
regulating	O
cell	O
proliferation	O
and	O
apoptosis	O
,	O
and	O
so	O
on	O
.	O
</ALL>	O

<ALL>	O
In	O
our	O
previous	O
study	O
,	O
we	O
found	O
that	O
CaSR	B-Gene
expression	O
,	O
intracellular	O
calcium	B-Chemical
levels	O
and	O
cardiac	O
function	O
were	O
all	O
significantly	O
decreased	O
in	O
DCM	B-Disease
rats	B-Species
;	O
however	O
,	O
the	O
exact	O
mechanism	O
are	O
not	O
clear	O
yet	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
revealed	O
the	O
protective	O
role	O
of	O
CaSR	B-Gene
in	O
myocardial	B-Disease
energy	I-Disease
metabolism	I-Disease
disorder	I-Disease
induced	O
by	O
high	O
glucose	B-Chemical
(	O
HG	O
)	O
as	O
well	O
as	O
the	O
underlying	O
mechanism	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
demonstrated	O
that	O
HG	O
decreased	O
the	O
expression	O
of	O
CaSR	B-Gene
,	O
mitochondrial	O
fusion	O
proteins	O
(	O
Mfn1	B-Gene
,	O
Mfn2	B-Gene
)	O
,	O
cell	O
gap	O
junction	O
related	O
proteins	O
(	O
Cx43	B-Gene
,	O
beta	B-Gene
-	I-Gene
catenin	I-Gene
,	O
N	B-Gene
-	I-Gene
cadherin	I-Gene
)	O
,	O
and	O
intracellular	O
ATP	B-Chemical
concentration	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
HG	O
increased	O
extracellular	O
ATP	B-Chemical
concentration	O
,	O
the	O
expression	O
of	O
gp78	B-Gene
,	O
mitochondrial	O
fission	O
proteins	O
(	O
Fis1	B-Gene
,	O
Drp1	B-Gene
)	O
,	O
and	O
the	O
ubiquitination	O
levels	O
of	O
Mfn1	B-Gene
,	O
Mfn2	B-Gene
and	O
Cx43	B-Gene
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
CaSR	B-Gene
agonist	O
and	O
gp78	B-Gene
-	O
siRNA	O
significantly	O
reduced	O
the	O
above	O
changes	O
.	O
</ALL>	O

<ALL>	O
Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
HG	O
induces	O
myocardial	B-Disease
energy	I-Disease
metabolism	I-Disease
disorder	I-Disease
via	O
decrease	O
of	O
CaSR	B-Gene
expression	O
,	O
and	O
activation	O
of	O
gp78	B-Gene
-	O
ubiquitin	O
proteasome	O
system	O
.	O
</ALL>	O

<ALL>	O
In	O
turn	O
,	O
these	O
effects	O
disrupt	O
the	O
structure	O
and	O
function	O
of	O
the	O
mitochondria	O
and	O
the	O
cell	O
gap	O
junction	O
,	O
result	O
in	O
the	O
reduced	O
ATP	B-Chemical
synthesis	O
and	O
the	O
increased	O
ATP	B-Chemical
leakage	O
.	O
</ALL>	O

<ALL>	O
Stimulation	O
of	O
CaSR	B-Gene
significantly	O
attenuates	O
HG	O
-	O
induced	O
abnormal	B-Disease
myocardial	I-Disease
energy	I-Disease
metabolism	I-Disease
,	O
suggesting	O
CaSR	B-Gene
would	O
be	O
a	O
promising	O
potential	O
therapeutic	O
target	O
for	O
DCM	B-Disease
.	O
</ALL>	O

<ALL>	O
A	O
novel	O
compound	O
,	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
,	O
attenuates	O
cognitive	B-Disease
deficits	I-Disease
and	O
shows	O
neuroprotective	O
effects	O
in	O
vitro	O
and	O
in	O
vivo	O
dementia	B-Disease
models	O
.	O
</ALL>	O

<ALL>	O
To	O
develop	O
a	O
novel	O
and	O
effective	O
drug	O
that	O
could	O
enhance	O
cognitive	O
function	O
and	O
neuroprotection	O
,	O
we	O
newly	O
synthesized	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
by	O
the	O
esterification	O
of	O
maltol	B-Chemical
and	O
p	B-Chemical
-	I-Chemical
coumaric	I-Chemical
acid	I-Chemical
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
could	O
improve	O
cognitive	B-Disease
decline	I-Disease
in	O
scopolamine	B-Chemical
-	O
injected	O
rats	B-Species
and	O
in	O
amyloid	B-Chemical
beta	I-Chemical
peptide	I-Chemical
(	I-Chemical
1	I-Chemical
-	I-Chemical
42	I-Chemical
)	I-Chemical
-	O
infused	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
was	O
found	O
to	O
attenuate	O
cognitive	B-Disease
deficits	I-Disease
in	O
both	O
rat	B-Species
models	O
using	O
passive	O
avoidance	O
test	O
and	O
to	O
reduce	O
apoptotic	O
cell	O
death	O
observed	O
in	O
the	O
hippocampus	O
of	O
the	O
amyloid	B-Chemical
beta	I-Chemical
peptide	I-Chemical
(	I-Chemical
1	I-Chemical
-	I-Chemical
42	I-Chemical
)	I-Chemical
-	O
infused	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
We	O
also	O
examined	O
the	O
neuroprotective	O
effects	O
of	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
in	O
vitro	O
using	O
SH	B-CellLine
-	I-CellLine
SY5Y	I-CellLine
cells	O
.	O
</ALL>	O

<ALL>	O
Cells	O
were	O
pretreated	O
with	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
,	O
before	O
exposed	O
to	O
amyloid	B-Chemical
beta	I-Chemical
peptide	I-Chemical
(	I-Chemical
1	I-Chemical
-	I-Chemical
42	I-Chemical
)	I-Chemical
,	O
glutamate	B-Chemical
or	O
H2O2	B-Chemical
.	O
</ALL>	O

<ALL>	O
We	O
found	O
that	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
significantly	O
decreased	O
apoptotic	O
cell	O
death	O
and	O
reduced	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
,	O
cytochrome	B-Chemical
c	I-Chemical
release	O
,	O
and	O
caspase	B-Gene
3	I-Gene
activation	O
.	O
</ALL>	O

<ALL>	O
Taking	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
results	O
together	O
,	O
our	O
study	O
suggests	O
that	O
maltolyl	B-Chemical
p	I-Chemical
-	I-Chemical
coumarate	I-Chemical
is	O
a	O
potentially	O
effective	O
candidate	O
against	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
that	O
is	O
characterized	O
by	O
wide	O
spread	O
neuronal	B-Disease
death	I-Disease
and	O
progressive	O
decline	B-Disease
of	I-Disease
cognitive	I-Disease
function	I-Disease
.	O
</ALL>	O

<ALL>	O
Mono	O
-	O
allelic	O
POLG	B-Gene
expression	O
resulting	O
from	O
nonsense	O
-	O
mediated	O
decay	O
and	O
alternative	O
splicing	O
in	O
a	O
patient	B-Species
with	O
Alpers	B-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
Alpers	B-Disease
syndrome	I-Disease
is	O
an	O
autosomal	O
recessive	O
mitochondrial	B-Disease
DNA	I-Disease
depletion	I-Disease
disorder	O
that	O
affects	O
children	O
and	O
young	O
adults	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
characterized	O
by	O
a	O
progressive	O
,	O
fatal	O
brain	O
and	O
liver	B-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
This	O
syndrome	O
has	O
been	O
associated	O
with	O
mutations	O
in	O
POLG	B-Gene
,	O
the	O
gene	O
encoding	O
the	O
mitochondrial	O
DNA	O
polymerase	O
(	O
pol	B-Gene
gamma	I-Gene
)	O
.	O
</ALL>	O

<ALL>	O
Most	O
patients	B-Species
with	O
Alpers	B-Disease
syndrome	I-Disease
have	O
been	O
found	O
to	O
be	O
compound	O
heterozygotes	O
,	O
carrying	O
two	O
pathogenic	O
mutations	O
in	O
trans	O
at	O
the	O
POLG	B-Gene
locus	O
.	O
</ALL>	O

<ALL>	O
POLG	B-Gene
is	O
a	O
nuclear	O
-	O
encoded	O
gene	O
whose	O
protein	O
product	O
is	O
imported	O
into	O
mitochondria	O
,	O
where	O
it	O
is	O
essential	O
for	O
mtDNA	O
replication	O
and	O
repair	O
.	O
</ALL>	O

<ALL>	O
We	O
studied	O
the	O
skin	O
fibroblasts	O
of	O
a	O
patient	B-Species
with	O
Alpers	B-Disease
syndrome	I-Disease
having	O
the	O
genotype	O
E873stop	B-Variant
/	O
A467	B-Variant
T	I-Variant
.	O
</ALL>	O

<ALL>	O
The	O
E873stop	B-Variant
mutation	O
produces	O
a	O
premature	O
termination	O
codon	O
(	O
TAG	O
)	O
in	O
exon	O
17	O
.	O
</ALL>	O

<ALL>	O
The	O
A467	B-Variant
T	I-Variant
mutation	O
produces	O
a	O
threonine	B-Variant
to	I-Variant
alanine	I-Variant
substitution	O
at	O
a	O
highly	O
conserved	O
site	O
in	O
exon	O
7	O
.	O
</ALL>	O

<ALL>	O
The	O
allele	O
bearing	O
the	O
stop	O
codon	O
(	O
E873	B-Variant
-	I-Variant
TAG	I-Variant
)	O
is	O
predicted	O
to	O
produce	O
a	O
truncated	O
,	O
catalytically	O
inactive	O
polymerase	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
only	O
full	O
-	O
length	O
pol	B-Gene
gamma	I-Gene
protein	O
was	O
detected	O
by	O
Western	O
blot	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
show	O
that	O
transcripts	O
containing	O
this	O
stop	O
codon	O
undergo	O
nonsense	O
-	O
associated	O
alternative	O
splicing	O
and	O
nonsense	O
-	O
mediated	O
decay	O
.	O
</ALL>	O

<ALL>	O
More	O
than	O
95	O
%	O
of	O
the	O
functional	O
POLG	B-Gene
mRNA	O
was	O
derived	O
from	O
the	O
allele	O
bearing	O
the	O
A467	B-Variant
T	I-Variant
mutation	O
and	O
less	O
than	O
5	O
%	O
contained	O
the	O
E873stop	B-Variant
mutation	O
.	O
</ALL>	O

<ALL>	O
These	O
events	O
ensured	O
that	O
virtually	O
all	O
POLG	B-Gene
protein	O
in	O
the	O
cell	O
was	O
expressed	O
from	O
the	O
A467	B-Variant
T	I-Variant
allele	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
the	O
Alpers	O
phenotype	O
in	O
this	O
patient	B-Species
was	O
a	O
consequence	O
of	O
a	O
single	O
-	O
copy	O
gene	O
dose	O
of	O
the	O
A467	B-Variant
T	I-Variant
allele	O
,	O
and	O
selective	O
elimination	O
of	O
transcripts	O
bearing	O
the	O
E873stop	B-Variant
mutation	O
.	O
</ALL>	O

<ALL>	O
Large	O
deletion	O
involving	O
exon	O
5	O
of	O
the	O
arylsulfatase	B-Gene
B	I-Gene
gene	O
caused	O
apparent	O
homozygosity	O
in	O
a	O
mucopolysaccharidosis	B-Disease
type	I-Disease
VI	I-Disease
patient	B-Species
.	O
</ALL>	O

<ALL>	O
Apparent	O
homozygosity	O
for	O
the	O
mutation	O
p	B-Variant
.	I-Variant
R315X	I-Variant
present	O
on	O
exon	O
5	O
of	O
the	O
arylsulfatase	B-Gene
B	I-Gene
(	O
ARSB	B-Gene
)	O
gene	O
in	O
a	O
mucopolysaccharidosis	B-Disease
type	I-Disease
VI	I-Disease
patient	B-Species
was	O
solved	O
in	O
this	O
study	O
by	O
further	O
testing	O
for	O
a	O
second	O
mutation	O
.	O
</ALL>	O

<ALL>	O
Patient	B-Species
cDNA	O
analysis	O
revealed	O
that	O
the	O
entire	O
exon	O
5	O
of	O
the	O
ARSB	B-Gene
gene	O
was	O
lacking	O
;	O
this	O
new	O
mutation	O
was	O
identified	O
as	O
c.899	B-Variant
-	I-Variant
1142del	I-Variant
.	O
</ALL>	O

<ALL>	O
As	O
the	O
genomic	O
DNA	O
sequencing	O
excluded	O
the	O
presence	O
of	O
splicing	O
mutations	O
,	O
polymerase	O
chain	O
reaction	O
analysis	O
was	O
performed	O
for	O
polymorphisms	O
listed	O
in	O
the	O
NCBI	O
SNP	O
database	O
for	O
the	O
ARSB	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
This	O
allowed	O
the	O
mutation	O
at	O
the	O
genomic	O
DNA	O
level	O
to	O
be	O
identified	O
as	O
g.99367	B-Variant
-	I-Variant
102002del	I-Variant
;	O
this	O
gross	O
deletion	O
,	O
involving	O
the	O
entire	O
exon	O
5	O
of	O
the	O
gene	O
and	O
parts	O
of	O
introns	O
4	O
and	O
5	O
led	O
to	O
a	O
frameshift	O
starting	O
at	O
amino	O
acid	O
300	O
and	O
resulting	O
in	O
a	O
protein	O
with	O
39	O
%	O
amino	O
acids	O
different	O
from	O
the	O
normal	O
enzyme	O
.	O
</ALL>	O

<ALL>	O
We	O
stress	O
that	O
extensive	O
DNA	O
analysis	O
needs	O
to	O
be	O
performed	O
in	O
case	O
of	O
apparent	O
homozygosity	O
to	O
avoid	O
potential	O
errors	O
in	O
genetic	O
counseling	O
.	O
</ALL>	O

<ALL>	O
Hypoxia	B-Disease
in	O
renal	B-Disease
disease	I-Disease
with	O
proteinuria	B-Disease
and	O
/	O
or	O
glomerular	O
hypertension	B-Disease
.	O
</ALL>	O

<ALL>	O
Despite	O
the	O
increasing	O
need	O
to	O
identify	O
and	O
quantify	O
tissue	O
oxygenation	O
at	O
the	O
cellular	O
level	O
,	O
relatively	O
few	O
methods	O
have	O
been	O
available	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
developed	O
a	O
new	O
hypoxia	B-Disease
-	O
responsive	O
reporter	O
vector	O
using	O
a	O
hypoxia	B-Disease
-	O
responsive	O
element	O
of	O
the	O
5	O
'	O
vascular	B-Gene
endothelial	I-Gene
growth	I-Gene
factor	I-Gene
untranslated	O
region	O
and	O
generated	O
a	O
novel	O
hypoxia	B-Disease
-	O
sensing	O
transgenic	O
rat	B-Species
.	O
</ALL>	O

<ALL>	O
We	O
then	O
applied	O
this	O
animal	O
model	O
to	O
the	O
detection	O
of	O
tubulointerstitial	O
hypoxia	B-Disease
in	O
the	O
diseased	B-Disease
kidney	I-Disease
.	O
</ALL>	O

<ALL>	O
With	O
this	O
model	O
,	O
we	O
were	O
able	O
to	O
identify	O
diffuse	O
cortical	O
hypoxia	B-Disease
in	O
the	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
-	O
induced	O
nephrotic	B-Disease
syndrome	I-Disease
and	O
focal	O
and	O
segmental	O
hypoxia	B-Disease
in	O
the	O
remnant	O
kidney	O
model	O
.	O
</ALL>	O

<ALL>	O
Expression	O
of	O
the	O
hypoxia	B-Disease
-	O
responsive	O
transgene	O
increased	O
throughout	O
the	O
observation	O
period	O
,	O
reaching	O
2.2	O
-	O
fold	O
at	O
2	O
weeks	O
in	O
the	O
puromycin	B-Chemical
aminonucleoside	I-Chemical
model	O
and	O
2.6	O
-	O
fold	O
at	O
4	O
weeks	O
in	O
the	O
remnant	O
kidney	O
model	O
,	O
whereas	O
that	O
of	O
vascular	B-Gene
endothelial	I-Gene
growth	I-Gene
factor	I-Gene
showed	O
a	O
mild	O
decrease	O
,	O
reflecting	O
distinct	O
behaviors	O
of	O
the	O
two	O
genes	O
.	O
</ALL>	O

<ALL>	O
The	O
degree	O
of	O
hypoxia	B-Disease
showed	O
a	O
positive	O
correlation	O
with	O
microscopic	O
tubulointerstitial	B-Disease
injury	I-Disease
in	O
both	O
models	O
.	O
</ALL>	O

<ALL>	O
Finally	O
,	O
we	O
identified	O
the	O
localization	O
of	O
proliferating	O
cell	O
nuclear	O
antigen	O
-	O
positive	O
,	O
ED	B-Gene
-	I-Gene
1	I-Gene
-	O
positive	O
,	O
and	O
terminal	O
dUTP	B-Chemical
nick	O
-	O
end	O
labeled	O
-	O
positive	O
cells	O
in	O
the	O
hypoxic	B-Disease
cortical	O
area	O
in	O
the	O
remnant	O
kidney	O
model	O
.	O
</ALL>	O

<ALL>	O
We	O
propose	O
here	O
a	O
possible	O
pathological	O
tie	O
between	O
chronic	O
tubulointerstitial	O
hypoxia	B-Disease
and	O
progressive	O
glomerular	B-Disease
diseases	I-Disease
.	O
</ALL>	O

<ALL>	O
Novel	O
somatic	O
MEN1	B-Gene
gene	O
alterations	O
in	O
sporadic	O
primary	B-Disease
hyperparathyroidism	I-Disease
and	O
correlation	O
with	O
clinical	O
characteristics	O
.	O
</ALL>	O

<ALL>	O
Primary	B-Disease
hyperparathyroidism	I-Disease
(	O
pHPT	B-Disease
)	O
is	O
a	O
common	O
endocrine	B-Disease
disease	I-Disease
that	O
in	O
more	O
than	O
95	O
%	O
of	O
cases	O
is	O
sporadic	O
and	O
only	O
in	O
some	O
cases	O
is	O
caused	O
by	O
inherited	B-Disease
disorders	I-Disease
,	O
isolated	O
or	O
as	O
part	O
of	O
multiple	B-Disease
endocrine	I-Disease
neoplasia	I-Disease
(	O
MEN1	B-Disease
and	I-Disease
2	I-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Somatic	O
mutations	O
of	O
MEN1	B-Gene
gene	O
have	O
also	O
been	O
described	O
in	O
sporadic	O
parathyroid	B-Disease
tumors	I-Disease
.	O
</ALL>	O

<ALL>	O
In	O
our	O
study	O
,	O
we	O
examined	O
the	O
presence	O
of	O
alterations	O
in	O
MEN1	B-Gene
gene	O
in	O
a	O
series	O
of	O
39	O
patients	B-Species
who	O
had	O
undergone	O
surgery	O
for	O
sporadic	O
pHPT	B-Disease
(	O
35	O
with	O
parathyroid	B-Disease
adenoma	I-Disease
or	I-Disease
hyperplasia	I-Disease
,	O
4	O
with	O
a	O
carcinoma	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
A	O
genotype	O
-	O
phenotype	O
correlation	O
was	O
also	O
analysed	O
.	O
</ALL>	O

<ALL>	O
After	O
DNA	O
extraction	O
from	O
paraffin	B-Chemical
-	O
embedded	O
tissues	O
,	O
we	O
amplified	O
by	O
PCR	O
and	O
sequenced	O
the	O
exons	O
2	O
-	O
10	O
of	O
the	O
MEN1	B-Gene
gene	O
.	O
</ALL>	O

<ALL>	O
Somatic	O
MEN1	B-Gene
mutations	O
were	O
detected	O
in	O
6	O
of	O
the	O
35	O
patients	B-Species
with	O
a	O
benign	B-Disease
parathyroid	I-Disease
lesion	I-Disease
examined	O
(	O
17.1	O
%	O
)	O
,	O
whereas	O
no	O
alterations	O
were	O
found	O
in	O
the	O
carcinomas	B-Disease
.	O
</ALL>	O

<ALL>	O
Four	O
novel	O
MEN1	B-Gene
gene	O
mutations	O
were	O
identified	O
as	O
follows	O
:	O
one	O
frameshift	O
mutation	O
(	O
222insT	B-Variant
,	O
exon	O
2	O
)	O
,	O
one	O
frameshift	O
deletion	O
(	O
912delTA	B-Variant
,	O
exon	O
5	O
)	O
,	O
one	O
in	O
-	O
frame	O
deletion	O
(	O
835del18	B-Variant
,	O
exon	O
4	O
)	O
and	O
one	O
missense	O
mutation	O
(	O
P291A	B-Variant
,	O
exon	O
6	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
one	O
missense	O
mutation	O
(	O
L89R	B-Variant
,	O
exon	O
2	O
)	O
and	O
one	O
nonsense	O
mutation	O
(	O
Q536X	B-Variant
,	O
exon	O
10	O
)	O
were	O
previously	O
reported	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
two	O
polymorphisms	O
were	O
also	O
found	O
:	O
one	O
allele	O
carried	O
a	O
R171Q	B-Variant
polymorphism	O
(	O
1	O
/	O
39	O
tumors	B-Disease
)	O
,	O
while	O
a	O
D418D	B-Variant
polymorphism	O
(	O
GAC	B-Variant
/	I-Variant
GAT	I-Variant
)	O
was	O
found	O
in	O
15	O
and	O
8	O
tumors	B-Disease
in	O
hetero	O
(	O
CT	O
)	O
and	O
homozygosity	O
(	O
TT	O
)	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
In	O
no	O
case	O
(	O
mutations	O
and	O
/	O
or	O
polymorphisms	O
)	O
did	O
we	O
find	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
our	O
data	O
demonstrate	O
the	O
presence	O
of	O
somatic	O
alterations	O
of	O
the	O
MEN1	B-Gene
tumor	B-Disease
suppressor	O
gene	O
in	O
about	O
one	O
fifth	O
of	O
benign	O
sporadic	O
parathyroid	B-Disease
tumors	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
absence	O
of	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
,	O
however	O
,	O
suggests	O
the	O
involvement	O
of	O
other	O
genetic	O
/	O
epigenetic	O
factors	O
for	O
the	O
full	O
expression	O
of	O
the	O
disease	O
.	O
</ALL>	O

<ALL>	O
Identification	O
of	O
novel	O
mutations	O
and	O
sequence	O
variants	O
in	O
the	O
SOX2	B-Gene
and	O
CHX10	B-Gene
genes	O
in	O
patients	B-Species
with	O
anophthalmia	B-Disease
/	O
microphthalmia	B-Disease
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
Mutations	O
in	O
the	O
SOX2	B-Gene
and	O
CHX10	B-Gene
genes	O
have	O
been	O
reported	O
in	O
patients	B-Species
with	O
anophthalmia	B-Disease
and	O
/	O
or	O
microphthalmia	B-Disease
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
34	O
anophthalmic	B-Disease
/	O
microphthalmic	B-Disease
patient	B-Species
DNA	O
samples	O
(	O
two	O
sets	O
of	O
siblings	O
included	O
)	O
for	O
mutations	O
and	O
sequence	O
variants	O
in	O
SOX2	B-Gene
and	O
CHX10	B-Gene
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Conformational	O
sensitive	O
gel	O
electrophoresis	O
(	O
CSGE	O
)	O
was	O
used	O
for	O
the	O
initial	O
SOX2	B-Gene
and	O
CHX10	B-Gene
screening	O
of	O
34	O
affected	O
individuals	O
(	O
two	O
sets	O
of	O
siblings	O
)	O
,	O
five	O
unaffected	O
family	O
members	O
,	O
and	O
80	O
healthy	O
controls	O
.	O
</ALL>	O

<ALL>	O
Patient	B-Species
samples	O
containing	O
heteroduplexes	O
were	O
selected	O
for	O
sequence	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Base	O
pair	O
changes	O
in	O
SOX2	B-Gene
and	O
CHX10	B-Gene
were	O
confirmed	O
by	O
sequencing	O
bidirectionally	O
in	O
patient	B-Species
samples	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Two	O
novel	O
heterozygous	O
mutations	O
and	O
two	O
sequence	O
variants	O
(	O
one	O
known	O
)	O
in	O
SOX2	B-Gene
were	O
identified	O
in	O
this	O
cohort	O
.	O
</ALL>	O

<ALL>	O
Mutation	O
c.310	B-Variant
G	I-Variant
>	I-Variant
T	I-Variant
(	O
p.	B-Variant
Glu104X	I-Variant
)	O
,	O
found	O
in	O
one	O
patient	B-Species
,	O
was	O
in	O
the	O
region	O
encoding	O
the	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
DNA	O
-	O
binding	O
domain	O
and	O
resulted	O
in	O
a	O
change	O
from	O
glutamic	B-Variant
acid	I-Variant
to	I-Variant
a	I-Variant
stop	I-Variant
codon	I-Variant
.	O
</ALL>	O

<ALL>	O
The	O
second	O
mutation	O
,	O
noted	O
in	O
two	O
affected	O
siblings	O
,	O
was	O
a	O
single	O
nucleotide	O
deletion	O
c.549delC	B-Variant
(	O
p.	B-Variant
Pro184ArgfsX19	I-Variant
)	O
in	O
the	O
region	O
encoding	O
the	O
activation	O
domain	O
,	O
resulting	O
in	O
a	O
frameshift	O
and	O
premature	O
termination	O
of	O
the	O
coding	O
sequence	O
.	O
</ALL>	O

<ALL>	O
The	O
shortened	O
protein	O
products	O
may	O
result	O
in	O
the	O
loss	O
of	O
function	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
a	O
novel	O
nucleotide	O
substitution	O
c.*557	B-Variant
G	I-Variant
>	I-Variant
A	I-Variant
was	O
identified	O
in	O
the	O
3	O
'	O
-	O
untranslated	O
region	O
in	O
one	O
patient	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
relationship	O
between	O
the	O
nucleotide	O
change	O
and	O
the	O
protein	O
function	O
is	O
indeterminate	O
.	O
</ALL>	O

<ALL>	O
A	O
known	O
single	O
nucleotide	O
polymorphism	O
(	O
c.	B-Variant
*	I-Variant
469	I-Variant
C	I-Variant
>	I-Variant
A	I-Variant
,	O
SNP	O
rs11915160	B-Variant
)	O
was	O
also	O
detected	O
in	O
2	O
of	O
the	O
34	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
Screening	O
of	O
CHX10	B-Gene
identified	O
two	O
synonymous	O
sequence	O
variants	O
,	O
c.471	B-Variant
C	I-Variant
>	I-Variant
T	I-Variant
(	O
p	B-Variant
.	I-Variant
Ser157Ser	I-Variant
,	O
rs35435463	B-Variant
)	O
and	O
c.579	B-Variant
G	I-Variant
>	I-Variant
A	I-Variant
(	O
p.	B-Variant
Gln193Gln	I-Variant
,	O
novel	O
SNP	O
)	O
,	O
and	O
one	O
non	O
-	O
synonymous	O
sequence	O
variant	O
,	O
c.871	B-Variant
G	I-Variant
>	I-Variant
A	I-Variant
(	O
p.	B-Variant
Asp291Asn	I-Variant
,	O
novel	O
SNP	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
non	O
-	O
synonymous	O
polymorphism	O
was	O
also	O
present	O
in	O
healthy	O
controls	O
,	O
suggesting	O
non	O
-	O
causality	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
These	O
results	O
support	O
the	O
role	O
of	O
SOX2	B-Gene
in	O
ocular	O
development	O
.	O
</ALL>	O

<ALL>	O
Loss	O
of	O
SOX2	B-Gene
function	O
results	O
in	O
severe	O
eye	B-Disease
malformation	I-Disease
.	O
</ALL>	O

<ALL>	O
CHX10	B-Gene
was	O
not	O
implicated	O
with	O
microphthalmia	B-Disease
/	O
anophthalmia	B-Disease
in	O
our	O
patient	B-Species
cohort	O
.	O
</ALL>	O

<ALL>	O
Pharmacogenetic	O
Analysis	O
of	O
INT	O
0144	O
Trial	O
:	O
Association	O
of	O
Polymorphisms	O
with	O
Survival	O
and	O
Toxicity	B-Disease
in	O
Rectal	B-Disease
Cancer	I-Disease
Patients	B-Species
Treated	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
Radiation	O
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
We	O
tested	O
whether	O
18	O
polymorphisms	O
in	O
16	O
genes	O
(	O
GSTP1	B-Gene
,	O
COX2	B-Gene
,	O
IL10	B-Gene
,	O
EGFR	B-Gene
,	O
EGF	B-Gene
,	O
FGFR4	B-Gene
,	O
CCDN1	B-Gene
,	O
VEGFR2	B-Gene
,	O
VEGF	B-Gene
,	O
CXCR2	B-Gene
,	O
IL8	B-Gene
,	O
MMP3	B-Gene
,	O
ICAM1	B-Gene
,	O
ERCC1	B-Gene
,	O
RAD51	B-Gene
,	O
and	O
XRCC3	B-Gene
)	O
would	O
predict	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
,	O
overall	O
survival	O
(	O
OS	O
)	O
,	O
and	O
toxicity	B-Disease
in	O
the	O
INT0144	O
trial	O
,	O
which	O
was	O
designed	O
to	O
investigate	O
different	O
postoperative	O
regimens	O
of	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
-	O
based	O
chemoradiation	O
(	O
CRT	O
)	O
in	O
locally	O
advanced	O
rectal	B-Disease
cancers	I-Disease
:	O
Arm	O
1	O
consisted	O
of	O
bolus	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
followed	O
by	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
protracted	O
venous	O
infusion	O
(	O
PVI	O
)	O
with	O
radiotherapy	O
;	O
arm	O
2	O
was	O
induction	O
and	O
concomitant	O
PVI	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
with	O
radiotherapy	O
and	O
arm	O
3	O
was	O
induction	O
and	O
concomitant	O
bolus	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
with	O
radiotherapy	O
.	O
</ALL>	O

<ALL>	O
EXPERIMENTAL	O
DESIGN	O
:	O
DNA	O
from	O
746	O
stage	O
II	O
/	O
III	O
rectal	O
patients	B-Species
enrolled	O
in	O
the	O
Southwest	O
Oncology	O
Group	O
(	O
SWOG	O
)	O
S9304	O
phase	O
III	O
trial	O
was	O
analyzed	O
.	O
</ALL>	O

<ALL>	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
formalin	B-Chemical
-	O
fixed	O
,	O
paraffin	B-Chemical
-	O
embedded	O
(	O
FFPE	O
)	O
tumor	B-Disease
tissue	O
.	O
</ALL>	O

<ALL>	O
The	O
polymorphisms	O
were	O
analyzed	O
using	O
direct	O
DNA	O
-	O
sequencing	O
or	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
GSTP1	B-Gene
-	O
Ile105Val	B-Variant
(	O
rs1695	B-Variant
)	O
was	O
significantly	O
associated	O
with	O
DFS	O
and	O
OS	O
and	O
its	O
effect	O
did	O
not	O
vary	O
by	O
treatment	O
arm	O
.	O
</ALL>	O

<ALL>	O
The	O
five	O
-	O
year	O
DFS	O
and	O
OS	O
were	O
53	O
%	O
and	O
58	O
%	O
,	O
respectively	O
,	O
for	O
G	O
/	O
G	O
,	O
66	O
%	O
and	O
72	O
%	O
for	O
G	O
/	O
A	O
,	O
and	O
57	O
%	O
and	O
66	O
%	O
for	O
A	O
/	O
A	O
patients	B-Species
.	O
</ALL>	O

<ALL>	O
In	O
arm	O
2	O
,	O
IL8	O
-	B-Variant
251A	I-Variant
/	I-Variant
A	I-Variant
genotype	O
(	O
rs4073	B-Variant
)	O
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
toxicities	B-Disease
(	O
P	O
=	O
0.04	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
VEGFR2	B-Gene
H472Q	B-Variant
Q	O
/	O
Q	O
genotype	O
(	O
rs1870377	B-Variant
)	O
was	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
grade	O
3	O
-	O
5	O
proximal	O
upper	O
gastrointestinal	O
tract	O
(	O
PUGIT	O
)	O
mucositis	B-Disease
(	O
P	O
=	O
0.04	O
)	O
in	O
arm	O
2	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
in	O
arm	O
1	O
,	O
this	O
genotype	O
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
PUGIT	O
mucositis	B-Disease
(	O
P	O
=	O
0.004	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
rs1695	B-Variant
may	O
be	O
prognostic	O
in	O
patients	B-Species
with	O
rectal	B-Disease
cancer	I-Disease
treated	O
with	O
adjuvant	O
CRT	O
.	O
</ALL>	O

<ALL>	O
rs4073	B-Variant
and	O
rs1870377	B-Variant
may	O
exhibit	O
different	O
associations	O
with	O
toxicity	B-Disease
,	O
according	O
to	O
the	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
schedule	O
.	O
</ALL>	O

<ALL>	O
Identification	O
of	O
three	O
F5	B-Gene
gene	O
mutations	O
associated	O
with	O
inherited	B-Disease
coagulation	I-Disease
factor	I-Disease
V	I-Disease
deficiency	I-Disease
in	O
two	O
Chinese	O
pedigrees	O
.	O
</ALL>	O

<ALL>	O
To	O
investigate	O
the	O
molecular	O
defects	O
in	O
two	O
Chinese	O
pedigrees	O
with	O
inherited	B-Disease
factor	I-Disease
V	I-Disease
(	I-Disease
FV	I-Disease
)	I-Disease
deficiency	I-Disease
.	O
</ALL>	O

<ALL>	O
A	O
37	O
-	O
year	O
-	O
old	O
male	O
(	O
proband	O
1	O
)	O
and	O
an	O
18	O
-	O
month	O
-	O
old	O
boy	O
(	O
proband	O
2	O
)	O
were	O
diagnosed	O
as	O
inherited	B-Disease
coagulation	I-Disease
FV	I-Disease
deficiency	I-Disease
by	O
severely	O
reduced	O
plasma	O
levels	O
of	O
FV	B-Gene
activity	O
and	O
antigen	O
.	O
</ALL>	O

<ALL>	O
All	O
25	O
exons	O
and	O
their	O
flanking	O
sequence	O
of	O
F5	B-Gene
gene	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
for	O
both	O
probands	O
and	O
the	O
PCR	O
products	O
were	O
directly	O
sequenced	O
.	O
</ALL>	O

<ALL>	O
Total	O
RNA	O
was	O
extracted	O
from	O
the	O
peripheral	O
lymphocytes	O
of	O
proband	O
1	O
for	O
detecting	O
the	O
changes	O
at	O
mRNA	O
level	O
.	O
</ALL>	O

<ALL>	O
The	O
homozygous	O
deletion	O
IVS8	B-Variant
-	I-Variant
2A	I-Variant
>	I-Variant
G	I-Variant
was	O
identified	O
in	O
the	O
F5	B-Gene
gene	O
of	O
proband	O
1	O
and	O
complementary	O
DNA	O
(	O
cDNA	O
)	O
analysis	O
revealed	O
the	O
abolishment	O
of	O
the	O
canonical	O
splicing	O
site	O
by	O
the	O
mutation	O
and	O
the	O
activation	O
of	O
the	O
cryptic	O
acceptor	O
site	O
24	O
bp	O
upstream	O
instead	O
.	O
</ALL>	O

<ALL>	O
The	O
insertion	B-Variant
introduced	I-Variant
eight	I-Variant
additional	I-Variant
amino	I-Variant
acids	I-Variant
(	O
AA	O
)	O
into	O
the	O
FV	B-Gene
protein	O
.	O
</ALL>	O

<ALL>	O
Two	O
heterozygous	O
mutations	O
of	O
F5	B-Gene
gene	O
were	O
discovered	O
in	O
proband	O
2	O
.	O
</ALL>	O

<ALL>	O
The	O
2238	B-Variant
-	I-Variant
9del	I-Variant
AG	I-Variant
in	O
exon	O
13	O
introduced	O
a	O
premature	O
termination	O
code	O
at	O
689	B-Variant
AA	I-Variant
and	O
the	O
substitution	O
of	O
G6410	B-Variant
by	I-Variant
T	I-Variant
in	O
exon	O
23	O
lead	O
to	O
the	O
missense	O
mutation	O
Gly2079Val	B-Variant
.	O
</ALL>	O

<ALL>	O
Three	O
F5	B-Gene
gene	O
mutations	O
,	O
IVS8	B-Variant
-	I-Variant
2A	I-Variant
>	I-Variant
G	I-Variant
,	O
2238	B-Variant
-	I-Variant
9del	I-Variant
AG	I-Variant
and	O
G6410	B-Variant
T	I-Variant
,	O
have	O
been	O
identified	O
in	O
two	O
Chinese	O
pedigree	O
with	O
congenital	B-Disease
FV	I-Disease
deficiency	I-Disease
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
Bradykinin	B-Chemical
receptors	I-Chemical
antagonists	I-Chemical
and	O
nitric	B-Chemical
oxide	I-Chemical
synthase	I-Chemical
inhibitors	I-Chemical
in	O
vincristine	B-Chemical
and	O
streptozotocin	B-Chemical
induced	O
hyperalgesia	B-Disease
in	O
chemotherapy	O
and	O
diabetic	B-Disease
neuropathy	I-Disease
rat	B-Species
model	O
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
The	O
influence	O
of	O
an	O
irreversible	O
inhibitor	O
of	O
constitutive	B-Gene
NO	I-Gene
synthase	I-Gene
(	O
L	B-Chemical
-	I-Chemical
NOArg	I-Chemical
;	O
1.0	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
a	O
relatively	O
selective	O
inhibitor	O
of	O
inducible	B-Gene
NO	I-Gene
synthase	I-Gene
(	O
L	B-Chemical
-	I-Chemical
NIL	I-Chemical
;	O
1.0	O
mg	O
/	O
kg	O
ip	O
)	O
and	O
a	O
relatively	O
specific	O
inhibitor	O
of	O
neuronal	B-Gene
NO	I-Gene
synthase	I-Gene
(	O
7	B-Chemical
-	I-Chemical
NI	I-Chemical
;	O
0.1	O
mg	O
/	O
kg	O
ip	O
)	O
,	O
on	O
antihyperalgesic	O
action	O
of	O
selective	O
antagonists	O
of	O
B2	B-Gene
and	I-Gene
B1	I-Gene
receptors	I-Gene
:	O
D	B-Chemical
-	I-Chemical
Arg	I-Chemical
-	I-Chemical
[	I-Chemical
Hyp3,Thi5,D	I-Chemical
-	I-Chemical
Tic7,Oic8	I-Chemical
]	I-Chemical
bradykinin	I-Chemical
(	O
HOE	B-Chemical
140	I-Chemical
;	O
70	O
nmol	O
/	O
kg	O
ip	O
)	O
or	O
des	B-Chemical
Arg10	I-Chemical
HOE	I-Chemical
140	I-Chemical
(	O
70	O
nmol	O
/	O
kg	O
ip	O
)	O
respectively	O
,	O
in	O
model	O
of	O
diabetic	B-Disease
(	I-Disease
streptozotocin	I-Disease
-	I-Disease
induced	I-Disease
)	I-Disease
and	I-Disease
toxic	I-Disease
(	I-Disease
vincristine	I-Disease
-	I-Disease
induced	I-Disease
)	I-Disease
neuropathy	I-Disease
was	O
investigated	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
The	O
changes	O
in	O
pain	B-Disease
thresholds	O
were	O
determined	O
using	O
mechanical	O
stimuli	O
-	O
-	O
the	O
modification	O
of	O
the	O
classic	O
paw	O
withdrawal	O
test	O
described	O
by	O
Randall	O
-	O
Selitto	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
results	O
of	O
this	O
paper	O
confirm	O
that	O
inhibition	O
of	O
bradykinin	B-Gene
receptors	I-Gene
and	O
inducible	B-Gene
NO	I-Gene
synthase	I-Gene
but	O
not	O
neuronal	B-Gene
NO	I-Gene
synthase	I-Gene
activity	O
reduces	O
diabetic	B-Disease
hyperalgesia	I-Disease
.	O
</ALL>	O

<ALL>	O
Pretreatment	O
with	O
L	B-Chemical
-	I-Chemical
NOArg	I-Chemical
and	O
L	B-Chemical
-	I-Chemical
NIL	I-Chemical
but	O
not	O
7	B-Chemical
-	I-Chemical
NI	I-Chemical
,	O
significantly	O
increases	O
antihyperalgesic	O
activity	O
both	O
HOE	B-Chemical
140	I-Chemical
and	O
des	B-Chemical
Arg10	I-Chemical
HOE	I-Chemical
140	I-Chemical
.	O
</ALL>	O

<ALL>	O
It	O
was	O
also	O
shown	O
that	O
both	O
products	O
of	O
inducible	B-Gene
NO	I-Gene
synthase	I-Gene
and	O
neuronal	B-Gene
NO	I-Gene
synthase	I-Gene
activation	O
as	O
well	O
as	O
bradykinin	B-Gene
are	O
involved	O
in	O
hyperalgesia	B-Disease
produced	O
by	O
vincristine	B-Chemical
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
L	B-Chemical
-	I-Chemical
NOArg	I-Chemical
and	O
7	B-Chemical
-	I-Chemical
NI	I-Chemical
but	O
not	O
L	B-Chemical
-	I-Chemical
NIL	I-Chemical
intensify	O
antihyperalgesic	O
activity	O
of	O
HOE	B-Chemical
140	I-Chemical
or	O
des	B-Chemical
-	I-Chemical
Arg10HOE	I-Chemical
140	I-Chemical
in	O
toxic	B-Disease
neuropathy	I-Disease
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Results	O
of	O
these	O
studies	O
suggest	O
that	O
B1	B-Gene
and	I-Gene
B2	I-Gene
receptors	I-Gene
are	O
engaged	O
in	O
transmission	O
of	O
nociceptive	O
stimuli	O
in	O
both	O
diabetic	B-Disease
and	I-Disease
toxic	I-Disease
neuropathy	I-Disease
.	O
</ALL>	O

<ALL>	O
In	O
streptozotocin	B-Chemical
-	O
induced	O
hyperalgesia	B-Disease
,	O
inducible	B-Gene
NO	I-Gene
synthase	I-Gene
participates	O
in	O
pronociceptive	O
activity	O
of	O
bradykinin	B-Gene
,	O
whereas	O
in	O
vincristine	B-Chemical
-	O
induced	O
hyperalgesia	B-Disease
bradykinin	B-Gene
seemed	O
to	O
activate	O
neuronal	B-Gene
NO	I-Gene
synthase	I-Gene
pathway	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
concomitant	O
administration	O
of	O
small	O
doses	O
of	O
bradykinin	B-Chemical
receptor	I-Chemical
antagonists	I-Chemical
and	O
NO	B-Chemical
synthase	I-Chemical
inhibitors	I-Chemical
can	O
be	O
effective	O
in	O
alleviation	O
of	O
neuropathic	B-Disease
pain	I-Disease
,	O
even	O
in	O
hospital	O
care	O
.	O
</ALL>	O

<ALL>	O
Association	O
of	O
a	O
FGFR	B-Gene
-	I-Gene
4	I-Gene
gene	O
polymorphism	O
with	O
bronchopulmonary	B-Disease
dysplasia	I-Disease
and	O
neonatal	B-Disease
respiratory	I-Disease
distress	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Bronchopulmonary	B-Disease
dysplasia	I-Disease
(	O
BPD	B-Disease
)	O
is	O
the	O
most	O
common	O
chronic	O
lung	B-Disease
disease	I-Disease
of	O
premature	B-Disease
birth	I-Disease
,	O
characterized	O
by	O
impaired	B-Disease
alveolar	I-Disease
development	I-Disease
and	O
inflammation	B-Disease
.	O
</ALL>	O

<ALL>	O
Pathomechanisms	O
contributing	O
to	O
BPD	B-Disease
are	O
poorly	O
understood	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
it	O
is	O
assumed	O
that	O
genetic	O
factors	O
predispose	O
to	O
BPD	B-Disease
and	O
other	O
pulmonary	B-Disease
diseases	I-Disease
of	O
preterm	O
neonates	O
,	O
such	O
as	O
neonatal	B-Disease
respiratory	I-Disease
distress	I-Disease
syndrome	I-Disease
(	O
RDS	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
For	O
association	O
studies	O
,	O
genes	O
upregulated	O
during	O
alveolarization	O
are	O
major	O
candidates	O
for	O
genetic	O
analysis	O
,	O
for	O
example	O
,	O
matrix	B-Gene
metalloproteinases	I-Gene
(	O
MMPs	B-Gene
)	O
and	O
fibroblast	B-Gene
growth	I-Gene
factors	I-Gene
(	O
FGFs	B-Gene
)	O
and	O
their	O
receptors	O
(	O
FGFR	B-Gene
)	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
Determining	O
genetic	O
risk	O
variants	O
in	O
a	O
Caucasian	O
population	O
of	O
premature	O
neonates	O
with	O
BPD	B-Disease
and	O
RDS	B-Disease
.	O
</ALL>	O

<ALL>	O
Methods	O
.	O
</ALL>	O

<ALL>	O
We	O
genotyped	O
27	O
polymorphisms	O
within	O
14	O
candidate	O
genes	O
via	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
:	O
MMP	B-Gene
-	I-Gene
1	I-Gene
,	I-Gene
-	I-Gene
2	I-Gene
,	I-Gene
-	I-Gene
9	I-Gene
,	I-Gene
and	I-Gene
-	I-Gene
12	I-Gene
,	I-Gene
-	I-Gene
16	I-Gene
,	O
FGF	B-Gene
receptors	I-Gene
2	I-Gene
and	I-Gene
4	I-Gene
,	O
FGF	B-Gene
-	I-Gene
2	I-Gene
,	I-Gene
-	I-Gene
3	I-Gene
,	I-Gene
-	I-Gene
4	I-Gene
,	I-Gene
-	I-Gene
7	I-Gene
,	I-Gene
and	I-Gene
-	I-Gene
18	I-Gene
,	O
Signal	B-Gene
-	I-Gene
Regulatory	I-Gene
Protein	I-Gene
a	I-Gene
(	O
SIRPA	B-Gene
)	O
and	O
Thyroid	B-Gene
Transcription	I-Gene
Factor	I-Gene
-	I-Gene
1	I-Gene
(	O
TTF	B-Gene
-	I-Gene
1	I-Gene
)	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Five	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
MMP	B-Gene
-	I-Gene
9	I-Gene
,	O
MMP	B-Gene
-	I-Gene
12	I-Gene
,	O
FGFR	B-Gene
-	I-Gene
4	I-Gene
,	O
FGF	B-Gene
-	I-Gene
3	I-Gene
,	O
and	O
FGF	B-Gene
-	I-Gene
7	I-Gene
are	O
associated	O
(	O
P	O
<	O
0.05	O
)	O
with	O
RDS	B-Disease
,	O
defined	O
as	O
surfactant	O
application	O
within	O
the	O
first	O
24	O
hours	O
after	O
birth	O
.	O
</ALL>	O

<ALL>	O
One	O
of	O
them	O
,	O
in	O
FGFR	B-Gene
-	I-Gene
4	I-Gene
(	O
rs1966265	B-Variant
)	O
,	O
is	O
associated	O
with	O
both	O
RDS	B-Disease
(	O
P	O
=	O
0.003	O
)	O
and	O
BPD	B-Disease
(	O
P	O
=	O
0.023	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
rs1966265	B-Variant
in	O
FGF	B-Gene
receptor	I-Gene
4	I-Gene
is	O
a	O
possible	O
genetic	O
key	O
variant	O
in	O
alveolar	B-Disease
diseases	I-Disease
of	O
preterm	O
newborns	O
.	O
</ALL>	O

<ALL>	O
Pleomorphic	B-Gene
adenoma	I-Gene
gene	I-Gene
like	I-Gene
-	I-Gene
2	I-Gene
induces	O
epithelial	O
-	O
mesenchymal	O
transition	O
via	O
Wnt	B-Gene
/	O
b	B-Gene
-	I-Gene
catenin	I-Gene
signaling	O
pathway	O
in	O
human	B-Species
colorectal	B-Disease
adenocarcinoma	I-Disease
.	O
</ALL>	O

<ALL>	O
Epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
is	O
a	O
critical	O
step	O
in	O
the	O
acquisition	O
of	O
metastatic	O
and	O
invasive	O
power	O
for	O
tumor	B-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
Colorectal	B-Disease
adenocarcinoma	I-Disease
(	O
CRC	B-Disease
)	O
is	O
a	O
common	O
cancer	B-Disease
where	O
metastasis	B-Disease
is	O
directly	O
linked	O
to	O
patient	B-Species
survival	O
.	O
</ALL>	O

<ALL>	O
Recent	O
studies	O
show	O
that	O
pleomorphic	B-Gene
adenoma	I-Gene
gene	I-Gene
like	I-Gene
-	I-Gene
2	I-Gene
(	O
PLAGL2	B-Gene
)	O
could	O
induce	O
tumor	B-Disease
EMT	O
and	O
is	O
an	O
independent	O
predictive	O
factor	O
associated	O
with	O
poor	O
prognosis	O
in	O
cancer	B-Disease
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
study	O
,	O
we	O
confirmed	O
the	O
role	O
of	O
PLAGL2	B-Gene
in	O
the	O
prognosis	O
of	O
CRC	B-Disease
patients	B-Species
and	O
provide	O
molecular	O
evidence	O
of	O
PLAGL2	B-Gene
promoted	O
EMT	O
in	O
CRC	B-Disease
cell	O
line	O
SW480	B-CellLine
.	O
</ALL>	O

<ALL>	O
We	O
found	O
that	O
PLAGL2	B-Gene
expression	O
was	O
upregulated	O
in	O
the	O
paraffin	B-Chemical
-	O
embedded	O
CRC	B-Disease
tissues	O
compared	O
to	O
borderline	O
or	O
benign	O
tissues	O
.	O
</ALL>	O

<ALL>	O
Experimental	O
EMT	O
induced	O
by	O
PLAGL2	B-Gene
plasmid	O
transfection	O
proved	O
PLAGL2	B-Gene
protein	O
overexpression	O
could	O
enhance	O
the	O
cell	O
scratch	O
wound	O
-	O
healing	O
and	O
transwell	O
ability	O
and	O
significantly	O
upregulated	O
mesenchymal	O
marker	O
proteins	O
,	O
N	B-Gene
-	I-Gene
cadherin	I-Gene
and	O
vimentin	B-Gene
and	O
concurrently	O
downregulated	O
epithelial	O
marker	O
of	O
E	B-Gene
-	I-Gene
cadherin	I-Gene
.	O
</ALL>	O

<ALL>	O
Subsequently	O
,	O
through	O
western	O
blot	O
assay	O
,	O
we	O
found	O
that	O
PLAGL2	B-Gene
could	O
activate	O
the	O
wnt	B-Gene
-	O
signaling	O
component	O
b	B-Gene
-	I-Gene
catenin	I-Gene
in	O
the	O
nuclei	O
.	O
</ALL>	O

<ALL>	O
More	O
CRC	B-Disease
cell	O
metastasis	B-Disease
to	O
the	O
lungs	O
was	O
observed	O
when	O
the	O
PLAGL2	B-Gene
overexpressing	O
SW480	B-CellLine
cells	O
were	O
injected	O
into	O
the	O
tail	O
vein	O
of	O
rats	B-Species
,	O
compared	O
with	O
the	O
cell	O
control	O
and	O
PLAGL2	B-Gene
silence	O
group	O
.	O
</ALL>	O

<ALL>	O
Our	O
findings	O
indicated	O
that	O
PLAGL2	B-Gene
might	O
be	O
a	O
very	O
upstream	O
key	O
molecule	O
regulating	O
EMT	O
involved	O
in	O
Wnt	B-Gene
/	O
b	B-Gene
-	I-Gene
catenin	I-Gene
signaling	O
pathway	O
.	O
</ALL>	O

<ALL>	O
Successful	O
therapy	O
with	O
argatroban	B-Chemical
for	O
superior	O
mesenteric	O
vein	B-Disease
thrombosis	I-Disease
in	O
a	O
patient	B-Species
with	O
congenital	B-Disease
antithrombin	I-Disease
deficiency	I-Disease
.	O
</ALL>	O

<ALL>	O
A	O
38	O
-	O
year	O
-	O
old	O
woman	B-Species
was	O
admitted	O
with	O
superior	B-Disease
mesenteric	I-Disease
vein	I-Disease
(	I-Disease
SMV	I-Disease
)	I-Disease
thrombosis	I-Disease
,	O
which	O
was	O
refractory	O
to	O
anticoagulation	O
therapy	O
.	O
</ALL>	O

<ALL>	O
The	O
plasma	O
antithrombin	B-Gene
activity	O
was	O
decreased	O
and	O
hardly	O
compensated	O
by	O
concentrated	O
antithrombin	B-Gene
preparation	O
due	O
to	O
high	O
consumption	O
rate	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
successful	O
anticoagulation	O
was	O
achieved	O
by	O
administration	O
of	O
direct	O
thrombin	B-Gene
inhibitor	O
,	O
argatroban	B-Chemical
.	O
</ALL>	O

<ALL>	O
Family	O
studies	O
of	O
antithrombin	B-Gene
activity	O
revealed	O
that	O
she	O
had	O
type	B-Disease
I	I-Disease
congenital	I-Disease
antithrombin	I-Disease
deficiency	I-Disease
.	O
</ALL>	O

<ALL>	O
A	O
novel	O
heterozygous	O
mutation	O
in	O
the	O
gene	O
for	O
antithrombin	B-Gene
(	O
single	O
nucleotide	B-Variant
T	I-Variant
insertion	I-Variant
at	I-Variant
7916	I-Variant
and	I-Variant
7917	I-Variant
,	O
Glu	B-Variant
272	I-Variant
to	I-Variant
stop	I-Variant
in	O
exon	O
4	O
)	O
was	O
identified	O
.	O
</ALL>	O

<ALL>	O
Argatroban	B-Chemical
administration	O
would	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
congenital	B-Disease
antithrombin	I-Disease
deficiency	I-Disease
with	O
SMV	B-Disease
thrombosis	I-Disease
.	O
</ALL>	O

<ALL>	O
Amisulpride	B-Chemical
related	O
tic	B-Disease
-	I-Disease
like	I-Disease
symptoms	I-Disease
in	O
an	O
adolescent	O
schizophrenic	B-Disease
.	O
</ALL>	O

<ALL>	O
Tic	B-Disease
disorders	I-Disease
can	O
be	O
effectively	O
treated	O
by	O
atypical	O
antipsychotics	B-Chemical
such	O
as	O
risperidone	B-Chemical
,	O
olanzapine	B-Chemical
and	O
ziprasidone	B-Chemical
.	O
</ALL>	O

<ALL>	O
However	O
,	O
there	O
are	O
two	O
case	O
reports	O
that	O
show	O
tic	B-Disease
-	I-Disease
like	I-Disease
symptoms	I-Disease
,	O
including	O
motor	O
and	O
phonic	O
variants	O
,	O
occurring	O
during	O
treatment	O
with	O
quetiapine	B-Chemical
or	O
clozapine	B-Chemical
.	O
</ALL>	O

<ALL>	O
We	O
present	O
a	O
15	O
-	O
year	O
-	O
old	O
girl	O
schizophrenic	B-Disease
who	O
developed	O
frequent	O
involuntary	B-Disease
eye	I-Disease
-	I-Disease
blinking	I-Disease
movements	I-Disease
after	O
5	O
months	O
of	O
amisulpride	B-Chemical
treatment	O
(	O
1000	O
mg	O
per	O
day	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
tic	B-Disease
-	I-Disease
like	I-Disease
symptoms	I-Disease
resolved	O
completely	O
after	O
we	O
reduced	O
the	O
dose	O
of	O
amisulpride	B-Chemical
down	O
to	O
800	O
mg	O
per	O
day	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
her	O
psychosis	B-Disease
recurred	O
after	O
the	O
dose	O
reduction	O
.	O
</ALL>	O

<ALL>	O
We	O
then	O
placed	O
her	O
on	O
an	O
additional	O
100	O
mg	O
per	O
day	O
of	O
quetiapine	B-Chemical
.	O
</ALL>	O

<ALL>	O
She	O
has	O
been	O
in	O
complete	O
remission	O
under	O
the	O
combined	O
medications	O
for	O
more	O
than	O
one	O
year	O
and	O
maintains	O
a	O
fair	O
role	O
function	O
.	O
</ALL>	O

<ALL>	O
No	O
more	O
tic	B-Disease
-	I-Disease
like	I-Disease
symptoms	I-Disease
or	O
other	O
side	O
effects	O
have	O
been	O
reported	O
.	O
</ALL>	O

<ALL>	O
Together	O
with	O
previously	O
reported	O
cases	O
,	O
our	O
patient	B-Species
suggests	O
that	O
tic	B-Disease
-	I-Disease
like	I-Disease
symptoms	I-Disease
might	O
occur	O
in	O
certain	O
vulnerable	O
individuals	O
during	O
treatment	O
with	O
atypical	O
antipsychotics	B-Chemical
such	O
as	O
quetiapine	B-Chemical
,	O
clozapine	B-Chemical
,	O
or	O
amisulpride	B-Chemical
.	O
</ALL>	O

<ALL>	O
Syncope	B-Disease
caused	O
by	O
hyperkalemia	B-Disease
during	O
use	O
of	O
a	O
combined	O
therapy	O
with	O
the	O
angiotensin	B-Chemical
-	I-Chemical
converting	I-Chemical
enzyme	I-Chemical
inhibitor	I-Chemical
and	O
spironolactone	B-Chemical
.	O
</ALL>	O

<ALL>	O
A	O
76	O
year	O
-	O
old	O
woman	B-Species
with	O
a	O
history	O
of	O
coronary	O
artery	O
bypass	O
grafting	O
and	O
prior	O
myocardial	B-Disease
infarction	I-Disease
was	O
transferred	O
to	O
the	O
emergency	O
room	O
with	O
loss	B-Disease
of	I-Disease
consciousness	I-Disease
due	O
to	O
marked	O
bradycardia	B-Disease
caused	O
by	O
hyperkalemia	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
concentration	O
of	O
serum	O
potassium	B-Chemical
was	O
high	O
,	O
and	O
normal	O
sinus	O
rhythm	O
was	O
restored	O
after	O
correction	O
of	O
the	O
serum	O
potassium	B-Chemical
level	O
.	O
</ALL>	O

<ALL>	O
The	O
cause	O
of	O
hyperkalemia	B-Disease
was	O
considered	O
to	O
be	O
several	O
doses	O
of	O
spiranolactone	B-Chemical
,	O
an	O
aldosterone	B-Chemical
antagonist	O
,	O
in	O
addition	O
to	O
the	O
long	O
-	O
term	O
intake	O
of	O
ramipril	B-Chemical
,	O
an	O
ACE	B-Gene
inhibitor	O
.	O
</ALL>	O

<ALL>	O
This	O
case	O
is	O
a	O
good	O
example	O
of	O
electrolyte	O
imbalance	O
causing	O
acute	O
life	O
-	O
threatening	O
cardiac	O
events	O
.	O
</ALL>	O

<ALL>	O
Clinicians	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
hyperkalemia	B-Disease
,	O
especially	O
in	O
elderly	O
patients	B-Species
using	O
ACE	B-Gene
/	O
ARB	B-Chemical
in	O
combination	O
with	O
potassium	B-Chemical
sparing	O
agents	O
and	O
who	O
have	O
mild	O
renal	B-Disease
disturbance	I-Disease
.	O
</ALL>	O

<ALL>	O
A	O
first	O
Taiwanese	O
Chinese	O
family	O
of	O
type	B-Disease
2B	I-Disease
von	I-Disease
Willebrand	I-Disease
disease	I-Disease
with	O
R1306W	B-Variant
mutation	O
.	O
</ALL>	O

<ALL>	O
Clinical	O
,	O
laboratory	O
and	O
genetic	B-Disease
defect	I-Disease
of	O
a	O
Taiwanese	O
family	O
with	O
type	B-Disease
2B	I-Disease
von	I-Disease
Willebrand	I-Disease
disease	I-Disease
(	O
VWD	B-Disease
)	O
were	O
studied	O
.	O
</ALL>	O

<ALL>	O
The	O
proband	O
was	O
a	O
55	O
-	O
year	O
-	O
old	O
woman	B-Species
who	O
gave	O
birth	O
to	O
two	O
daughters	O
and	O
one	O
son	O
aged	O
30	O
,	O
29	O
and	O
27	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
All	O
had	O
abnormal	O
mucocutaneous	O
bleedings	B-Disease
since	O
their	O
childhood	O
.	O
</ALL>	O

<ALL>	O
In	O
proband	O
,	O
PT	O
,	O
PTT	O
and	O
platelet	O
count	O
were	O
normal	O
;	O
template	O
bleeding	B-Disease
time	O
was	O
14	O
min	O
;	O
VIII	B-Gene
:	O
C	O
was	O
51	O
%	O
,	O
von	B-Gene
Willebrand	I-Gene
factor	I-Gene
antigen	O
(	O
VWF	B-Gene
:	O
Ag	O
)	O
,	O
42	O
%	O
and	O
von	B-Gene
Willerand	I-Gene
factor	I-Gene
ristocetin	B-Chemical
-	O
cofactor	O
(	O
VWF	B-Gene
:	O
RCo	O
,	O
15	O
%	O
)	O
;	O
ristocetin	B-Disease
-	I-Disease
induced	I-Disease
platelet	I-Disease
aggregation	I-Disease
(	O
RIPA	B-Disease
)	O
at	O
0.3	O
and	O
0.6	O
mg	O
/	O
ml	O
of	O
ristocetin	B-Chemical
was	O
16	O
%	O
and	O
68	O
%	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
The	O
enhanced	O
response	O
to	O
ristocetin	B-Chemical
was	O
identified	O
to	O
be	O
in	O
plasma	O
,	O
not	O
in	O
platelet	O
itself	O
,	O
by	O
mixing	O
studies	O
.	O
</ALL>	O

<ALL>	O
Analysis	O
of	O
von	B-Gene
Willebrand	I-Gene
factor	I-Gene
(	O
VWF	B-Gene
)	O
multimer	O
of	O
plasma	O
but	O
not	O
of	O
platelets	O
showed	O
absence	O
of	O
high	O
-	O
molecular	O
weight	O
(	O
HMW	O
)	O
multimer	O
.	O
</ALL>	O

<ALL>	O
All	O
three	O
children	O
had	O
similar	O
laboratory	O
findings	O
.	O
</ALL>	O

<ALL>	O
Exon	O
28	O
of	O
VWF	B-Gene
gene	O
was	O
amplified	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
sequenced	O
.	O
</ALL>	O

<ALL>	O
The	O
proband	O
and	O
three	O
children	O
were	O
all	O
found	O
to	O
be	O
heterozygous	O
for	O
C	B-Variant
to	I-Variant
T	I-Variant
transition	I-Variant
at	I-Variant
nucleotide	I-Variant
3916	I-Variant
resulting	O
in	O
Arg	B-Variant
1306	I-Variant
Trp	I-Variant
(	O
R1306W	B-Variant
)	O
substitution	O
.	O
</ALL>	O

<ALL>	O
This	O
mutation	O
in	O
the	O
glycoprotein	B-Gene
Ib	I-Gene
(	O
GPIb	B-Gene
)	O
-	O
binding	O
site	O
has	O
been	O
found	O
to	O
increase	O
the	O
affinity	O
of	O
plasma	O
VWF	B-Gene
for	O
platelets	O
,	O
and	O
thus	O
cause	O
loss	O
of	O
HMW	O
multimers	O
and	O
often	O
thrombocytopenia	B-Disease
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
a	O
first	O
report	O
of	O
type	B-Disease
2B	I-Disease
VWD	I-Disease
in	O
a	O
Taiwanese	O
Chinese	O
family	O
who	O
show	O
R1306W	B-Variant
mutation	O
in	O
VWF	B-Gene
gene	O
was	O
described	O
.	O
</ALL>	O

<ALL>	O
Identification	O
of	O
PVT1	B-Gene
as	O
a	O
candidate	O
gene	O
for	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
in	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
using	O
a	O
pooling	O
-	O
based	O
genome	O
-	O
wide	O
single	O
nucleotide	O
polymorphism	O
association	O
study	O
.	O
</ALL>	O

<ALL>	O
To	O
identify	O
genetic	O
variants	O
contributing	O
to	O
end	B-Disease
-	I-Disease
stage	I-Disease
renal	I-Disease
disease	I-Disease
(	O
ESRD	B-Disease
)	O
in	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
,	O
we	O
performed	O
a	O
genome	O
-	O
wide	O
analysis	O
of	O
115,352	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
pools	O
of	O
105	O
unrelated	O
case	O
subjects	O
with	O
ESRD	B-Disease
and	O
102	O
unrelated	O
control	O
subjects	O
who	O
have	O
had	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
for	O
>	O
or	O
=	O
10	O
years	O
without	O
macroalbuminuria	O
.	O
</ALL>	O

<ALL>	O
Using	O
a	O
sliding	O
window	O
statistic	O
of	O
ranked	O
SNPs	O
,	O
we	O
identified	O
a	O
200	O
-	O
kb	O
region	O
on	O
8q24	O
harboring	O
three	O
SNPs	O
showing	O
substantial	O
differences	O
in	O
allelic	O
frequency	O
between	O
case	O
and	O
control	O
pools	O
.	O
</ALL>	O

<ALL>	O
These	O
SNPs	O
were	O
genotyped	O
in	O
individuals	O
comprising	O
each	O
pool	O
,	O
and	O
strong	O
evidence	O
for	O
association	O
was	O
found	O
with	O
rs2720709	B-Variant
(	O
P	O
=	O
0.000021	O
;	O
odds	O
ratio	O
2.57	O
[	O
95	O
%	O
CI	O
1.66	O
-	O
3.96	O
]	O
)	O
,	O
which	O
is	O
located	O
in	O
the	O
plasmacytoma	O
variant	O
translocation	O
gene	O
PVT1	B-Gene
.	O
</ALL>	O

<ALL>	O
We	O
sequenced	O
all	O
exons	O
,	O
exon	O
-	O
intron	O
boundaries	O
,	O
and	O
the	O
promoter	O
of	O
PVT1	B-Gene
and	O
identified	O
47	O
variants	O
,	O
11	O
of	O
which	O
represented	O
nonredundant	O
markers	O
with	O
minor	O
allele	O
frequency	O
>	O
or	O
=	O
0.05	O
.	O
</ALL>	O

<ALL>	O
We	O
subsequently	O
genotyped	O
these	O
11	O
variants	O
and	O
an	O
additional	O
87	O
SNPs	O
identified	O
through	O
public	O
databases	O
in	O
319	O
-	O
kb	O
flanking	O
rs2720709	B-Variant
(	O
approximately	O
1	O
SNP	O
/	O
3.5	O
kb	O
)	O
;	O
23	O
markers	O
were	O
associated	O
with	O
ESRD	B-Disease
at	O
P	O
<	O
0.01	O
.	O
</ALL>	O

<ALL>	O
The	O
strongest	O
evidence	O
for	O
association	O
was	O
found	O
for	O
rs2648875	B-Variant
(	O
P	O
=	O
0.0000018	O
;	O
2.97	O
[	O
1.90	O
-	O
4.65	O
]	O
)	O
,	O
which	O
maps	O
to	O
intron	O
8	O
of	O
PVT1	B-Gene
.	O
</ALL>	O

<ALL>	O
Together	O
,	O
these	O
results	O
suggest	O
that	O
PVT1	B-Gene
may	O
contribute	O
to	O
ESRD	B-Disease
susceptibility	O
in	O
diabetes	B-Disease
.	O
</ALL>	O

<ALL>	O
Reduced	O
adiponectin	B-Gene
expression	O
after	O
high	O
-	O
fat	O
diet	O
is	O
associated	O
with	O
selective	O
up	O
-	O
regulation	O
of	O
ALDH1A1	B-Gene
and	O
further	O
retinoic	B-Gene
acid	I-Gene
receptor	I-Gene
signaling	O
in	O
adipose	O
tissue	O
.	O
</ALL>	O

<ALL>	O
Adiponectin	B-Gene
is	O
an	O
adipocyte	O
-	O
derived	O
adipokine	B-Gene
with	O
potent	O
antidiabetic	O
,	O
anti	O
-	O
inflammatory	B-Disease
,	O
and	O
antiatherogenic	O
activity	O
.	O
</ALL>	O

<ALL>	O
Long	O
-	O
term	O
,	O
high	O
-	O
fat	O
diet	O
results	O
in	O
gain	O
of	O
body	O
weight	O
,	O
adiposity	B-Disease
,	O
further	O
inflammatory	B-Disease
-	O
based	O
cardiovascular	B-Disease
diseases	I-Disease
,	O
and	O
reduced	O
adiponectin	B-Gene
secretion	O
.	O
</ALL>	O

<ALL>	O
Vitamin	B-Chemical
A	I-Chemical
derivatives	O
/	O
retinoids	B-Chemical
are	O
involved	O
in	O
several	O
of	O
these	O
processes	O
,	O
which	O
mainly	O
take	O
place	O
in	O
white	O
adipose	O
tissue	O
(	O
WAT	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
examined	O
adiponectin	B-Gene
expression	O
as	O
a	O
function	O
of	O
dietary	O
high	O
-	O
fat	O
and	O
high	O
-	O
vitamin	B-Chemical
A	I-Chemical
conditions	O
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
A	O
decrease	O
of	O
adiponectin	B-Gene
expression	O
in	O
addition	O
to	O
an	O
up	O
-	O
regulation	O
of	O
aldehyde	B-Gene
dehydrogenase	I-Gene
A1	I-Gene
(	O
ALDH1A1	B-Gene
)	O
,	O
retinoid	O
signaling	O
,	O
and	O
retinoic	B-Chemical
acid	I-Chemical
response	O
element	O
signaling	O
was	O
selectively	O
observed	O
in	O
WAT	O
of	O
mice	B-Species
fed	O
a	O
normal	O
-	O
vitamin	B-Chemical
A	I-Chemical
,	O
high	O
-	O
fat	O
diet	O
.	O
</ALL>	O

<ALL>	O
Reduced	O
adiponectin	B-Gene
expression	O
in	O
WAT	O
was	O
also	O
observed	O
in	O
mice	B-Species
fed	O
a	O
high	O
-	O
vitamin	B-Chemical
A	I-Chemical
diet	O
.	O
</ALL>	O

<ALL>	O
Adipocyte	O
cell	O
culture	O
revealed	O
that	O
endogenous	O
and	O
synthetic	O
retinoic	B-Gene
acid	I-Gene
receptor	I-Gene
(	I-Gene
RAR	I-Gene
)	I-Gene
a	I-Gene
-	O
and	O
RARg	B-Gene
-	O
selective	O
agonists	O
,	O
as	O
well	O
as	O
a	O
synthetic	O
retinoid	B-Gene
X	I-Gene
receptor	I-Gene
agonist	O
,	O
efficiently	O
reduced	O
adiponectin	B-Gene
expression	O
,	O
whereas	O
ALDH1A1	B-Gene
expression	O
only	O
increased	O
with	O
RAR	B-Gene
agonists	O
.	O
</ALL>	O

<ALL>	O
We	O
conclude	O
that	O
reduced	O
adiponectin	B-Gene
expression	O
under	O
high	O
-	O
fat	O
dietary	O
conditions	O
is	O
dependent	O
on	O
1	O
)	O
increased	O
ALDH1A1	B-Gene
expression	O
in	O
adipocytes	O
,	O
which	O
does	O
not	O
increase	O
all	O
-	O
trans	O
-	O
retinoic	B-Chemical
acid	I-Chemical
levels	O
;	O
2	O
)	O
further	O
RAR	B-Gene
ligand	O
-	O
induced	O
,	O
WAT	O
-	O
selective	O
,	O
increased	O
retinoic	B-Chemical
acid	I-Chemical
response	O
element	O
-	O
mediated	O
signaling	O
;	O
and	O
3	O
)	O
RAR	B-Gene
ligand	O
-	O
dependent	O
reduction	O
of	O
adiponectin	B-Gene
expression	O
.	O
-	O
</ALL>	O

<ALL>	O
Landrier	O
,	O
J.	O
-	O
F.	O
,	O
Kasiri	O
,	O
E.	O
,	O
Karkeni	O
,	O
E.	O
,	O
Mihaly	O
,	O
J.	O
,	O
Beke	O
,	O
G.	O
,	O
Weiss	O
,	O
K.	O
,	O
Lucas	O
,	O
R.	O
,	O
Aydemir	O
,	O
G.	O
,	O
Salles	O
,	O
J.	O
,	O
Walrand	O
,	O
S.	O
,	O
de	O
Lera	O
,	O
A.	O
R.	O
,	O
Ruhl	O
,	O
R.	O
Reduced	O
adiponectin	B-Gene
expression	O
after	O
high	O
-	O
fat	O
diet	O
is	O
associated	O
with	O
selective	O
up	O
-	O
regulation	O
of	O
ALDH1A1	B-Gene
and	O
further	O
retinoic	B-Gene
acid	I-Gene
receptor	I-Gene
signaling	O
in	O
adipose	O
tissue	O
.	O
</ALL>	O

<ALL>	O
Arginase	B-Gene
1	I-Gene
deletion	O
in	O
myeloid	O
cells	O
affects	O
the	O
inflammatory	B-Disease
response	O
in	O
allergic	O
asthma	B-Disease
,	O
but	O
not	O
lung	O
mechanics	O
,	O
in	O
female	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
(	O
Over	O
-	O
)	O
expression	O
of	O
arginase	B-Gene
may	O
limit	O
local	O
availability	O
of	O
arginine	O
for	O
nitric	B-Chemical
oxide	I-Chemical
synthesis	O
.	O
</ALL>	O

<ALL>	O
We	O
investigated	O
the	O
significance	O
of	O
arginase1	B-Gene
(	O
ARG1	B-Gene
)	O
for	O
the	O
development	O
of	O
airway	O
hyperresponsiveness	O
(	O
AHR	O
)	O
and	O
lung	B-Disease
inflammation	I-Disease
in	O
female	O
mice	B-Species
with	O
ovalbumin	B-Gene
(	O
OVA	B-Gene
)	O
-	O
induced	O
allergic	O
asthma	B-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Arg1	B-Gene
was	O
ablated	O
in	O
the	O
lung	O
by	O
crossing	O
Arg1	B-Gene
fl	O
/	O
fl	O
and	O
Tie2Cre	O
tg	O
/	O
-	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
OVA	B-Gene
sensitization	O
and	O
challenge	O
were	O
conducted	O
,	O
and	O
AHR	O
to	O
methacholine	B-Chemical
was	O
determined	O
using	O
the	O
Flexivent	O
system	O
.	O
</ALL>	O

<ALL>	O
Changes	O
in	O
gene	O
expression	O
,	O
chemokine	O
and	O
cytokine	O
secretion	O
,	O
plasma	O
IgE	B-Gene
,	O
and	O
lung	O
histology	O
were	O
quantified	O
using	O
RT	O
-	O
qPCR	O
,	O
ELISA	O
,	O
and	O
immunohistochemistry	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Arg1	B-Gene
ablation	O
had	O
no	O
influence	O
on	O
the	O
development	O
of	O
OVA	B-Gene
-	O
induced	O
AHR	O
,	O
but	O
attenuated	O
OVA	B-Gene
-	O
induced	O
increases	O
in	O
expression	O
of	O
Arg2	B-Gene
and	O
Nos2	B-Gene
,	O
Slc7a1	B-Gene
,	O
Slc7a2	B-Gene
,	O
and	O
Slc7a7	B-Gene
(	O
arginine	B-Gene
transporters	I-Gene
)	O
,	O
Il4	B-Gene
,	O
Il5	B-Gene
and	O
Il13	B-Gene
(	O
TH2	B-Gene
-	I-Gene
type	I-Gene
cytokines	I-Gene
)	O
,	O
Ccl2	B-Gene
and	O
Ccl11	B-Gene
(	O
chemokines	B-Gene
)	O
,	O
Ifng	B-Gene
(	O
TH1	B-Gene
-	I-Gene
type	I-Gene
cytokine	I-Gene
)	O
,	O
Clca3	B-Gene
and	O
Muc5ac	B-Gene
(	O
goblet	O
cell	O
markers	O
)	O
,	O
and	O
OVA	B-Gene
-	O
specific	O
IgE	B-Gene
.	O
</ALL>	O

<ALL>	O
Pulmonary	O
IL	B-Gene
-	I-Gene
10	I-Gene
protein	O
content	O
increased	O
,	O
but	O
IL	B-Gene
-	I-Gene
4	I-Gene
,	O
IL	B-Gene
-	I-Gene
5	I-Gene
,	O
IL	B-Gene
-	I-Gene
13	I-Gene
,	O
TNFalpha	B-Gene
and	O
IFNgamma	B-Gene
content	O
,	O
and	O
lung	O
histopathology	O
,	O
were	O
not	O
affected	O
.	O
</ALL>	O

<ALL>	O
Arg1	B-Gene
elimination	O
also	O
decreased	O
number	O
and	O
tightness	O
of	O
correlations	O
between	O
adaptive	O
changes	O
in	O
lung	O
function	O
and	O
inflammatory	B-Disease
parameters	O
in	O
OVA	B-Gene
/	O
OVA	B-Gene
-	O
treated	O
female	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
OVA	B-Gene
/	O
OVA	B-Gene
-	O
treated	O
female	O
mice	B-Species
mounted	O
a	O
higher	O
OVA	B-Gene
-	O
IgE	B-Gene
response	O
than	O
males	O
,	O
but	O
the	O
correlation	O
between	O
lung	O
function	O
and	O
inflammation	B-Disease
was	O
lower	O
.	O
</ALL>	O

<ALL>	O
Arg1	B-Gene
-	O
deficient	O
OVA	B-Gene
/	O
OVA	B-Gene
-	O
treated	O
females	O
differed	O
from	O
males	O
in	O
a	O
more	O
pronounced	O
decline	O
of	O
arginine	O
-	O
metabolizing	O
and	O
-	O
transporting	O
genes	O
,	O
higher	O
plasma	O
arginine	O
levels	O
,	O
a	O
smaller	O
OVA	B-Gene
-	O
specific	O
IgE	B-Gene
response	O
,	O
and	O
no	O
improvement	O
of	O
peripheral	O
lung	O
function	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Complete	O
ablation	O
of	O
Arg1	B-Gene
in	O
the	O
lung	O
affects	O
mRNA	O
abundance	O
of	O
arginine	O
-	O
transporting	O
and	O
-	O
metabolizing	O
genes	O
,	O
and	O
pro	O
-	O
inflammatory	B-Disease
genes	O
,	O
but	O
not	O
methacholine	B-Chemical
responsiveness	O
or	O
accumulation	O
of	O
inflammatory	B-Disease
cells	O
.	O
</ALL>	O

<ALL>	O
Cerebrospinal	O
fluid	O
penetration	O
of	O
high	O
-	O
dose	O
daptomycin	B-Chemical
in	O
suspected	O
Staphylococcus	B-Species
aureus	I-Species
meningitis	B-Disease
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
methicillin	B-Chemical
-	O
sensitive	O
Staphylococcus	B-Species
aureus	I-Species
(	O
MSSA	O
)	O
bacteremia	B-Disease
with	O
suspected	O
MSSA	O
meningitis	B-Disease
treated	O
with	O
high	O
-	O
dose	O
daptomycin	B-Chemical
assessed	O
with	O
concurrent	O
serum	O
and	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
concentrations	O
.	O
</ALL>	O

<ALL>	O
CASE	O
SUMMARY	O
:	O
A	O
54	O
-	O
year	O
-	O
old	O
male	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
generalized	O
weakness	B-Disease
and	O
presumed	O
health	O
-	O
care	O
-	O
associated	O
pneumonia	B-Disease
shown	O
on	O
chest	O
radiograph	O
.	O
</ALL>	O

<ALL>	O
Treatment	O
was	O
empirically	O
initiated	O
with	O
vancomycin	B-Chemical
,	O
levofloxacin	B-Chemical
,	O
and	O
piperacillin	B-Chemical
/	I-Chemical
tazobactam	I-Chemical
.	O
</ALL>	O

<ALL>	O
Blood	O
cultures	O
revealed	O
S.	B-Species
aureus	I-Species
susceptible	O
to	O
oxacillin	B-Chemical
.	O
</ALL>	O

<ALL>	O
Empiric	O
antibiotic	B-Chemical
treatment	O
was	O
narrowed	O
to	O
nafcillin	B-Chemical
on	O
day	O
4	O
.	O
</ALL>	O

<ALL>	O
On	O
day	O
8	O
,	O
the	O
patient	B-Species
developed	O
acute	B-Disease
renal	I-Disease
failure	I-Disease
(	O
serum	O
creatinine	B-Chemical
1.9	O
mg	O
/	O
dL	O
,	O
increased	O
from	O
1.2	O
mg	O
/	O
dL	O
the	O
previous	O
day	O
and	O
0.8	O
mg	O
/	O
dL	O
on	O
admission	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
's	O
Glasgow	O
Coma	B-Disease
Score	O
was	O
3	O
,	O
with	O
normal	O
findings	O
shown	O
on	O
computed	O
tomography	O
scan	O
of	O
the	O
head	O
72	O
hours	O
following	O
an	O
episode	O
of	O
cardiac	B-Disease
arrest	I-Disease
on	O
day	O
10	O
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
experienced	O
relapsing	O
MSSA	O
bacteremia	B-Disease
on	O
day	O
9	O
,	O
increasing	O
the	O
suspicion	O
for	O
a	O
central	B-Disease
nervous	I-Disease
system	I-Disease
(	I-Disease
CNS	I-Disease
)	I-Disease
infection	I-Disease
.	O
</ALL>	O

<ALL>	O
Nafcillin	B-Chemical
was	O
discontinued	O
and	O
daptomycin	B-Chemical
9	O
mg	O
/	O
kg	O
daily	O
was	O
initiated	O
for	O
suspected	O
meningitis	B-Disease
and	O
was	O
continued	O
until	O
the	O
patient	B-Species
's	O
death	B-Disease
on	O
day	O
16	O
.	O
</ALL>	O

<ALL>	O
Daptomycin	B-Chemical
serum	O
and	O
CSF	O
trough	O
concentrations	O
were	O
11.21	O
ug	O
/	O
mL	O
and	O
0.52	O
ug	O
/	O
mL	O
,	O
respectively	O
,	O
prior	O
to	O
the	O
third	O
dose	O
.	O
</ALL>	O

<ALL>	O
Lumbar	O
puncture	O
results	O
were	O
inconclusive	O
and	O
no	O
further	O
blood	O
cultures	O
were	O
positive	O
for	O
MSSA	O
.	O
</ALL>	O

<ALL>	O
Creatine	B-Gene
kinase	I-Gene
levels	O
were	O
normal	O
prior	O
to	O
daptomycin	B-Chemical
therapy	O
and	O
were	O
not	O
reassessed	O
.	O
</ALL>	O

<ALL>	O
DISCUSSION	O
:	O
Daptomycin	B-Chemical
was	O
initiated	O
in	O
our	O
patient	B-Species
secondary	O
to	O
possible	O
nafcillin	B-Chemical
-	O
induced	O
acute	O
interstitial	B-Disease
nephritis	I-Disease
and	O
relapsing	O
bacteremia	B-Disease
.	O
</ALL>	O

<ALL>	O
At	O
a	O
dose	O
of	O
9	O
mg	O
/	O
kg	O
,	O
resultant	O
penetration	O
of	O
5	O
%	O
was	O
higher	O
than	O
in	O
previous	O
reports	O
,	O
more	O
consistent	O
with	O
inflamed	O
meninges	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
High	O
-	O
dose	O
daptomycin	B-Chemical
may	O
be	O
an	O
alternative	O
option	O
for	O
MSSA	O
bacteremia	B-Disease
with	O
or	O
without	O
a	O
CNS	O
source	O
in	O
patients	B-Species
who	O
have	O
failed	O
or	O
can	O
not	O
tolerate	O
standard	O
therapy	O
.	O
</ALL>	O

<ALL>	O
Further	O
clinical	O
evaluation	O
in	O
patients	B-Species
with	O
confirmed	O
meningitis	B-Disease
is	O
warranted	O
.	O
</ALL>	O

<ALL>	O
Lack	O
of	O
association	O
of	O
C	B-Gene
-	I-Gene
C	I-Gene
chemokine	I-Gene
receptor	I-Gene
5	I-Gene
DD32	B-Variant
deletion	I-Variant
status	O
with	O
rheumatoid	B-Disease
arthritis	I-Disease
,	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
,	O
lupus	B-Disease
nephritis	I-Disease
,	O
and	O
disease	O
severity	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
C	B-Gene
-	I-Gene
C	I-Gene
chemokine	I-Gene
receptor	I-Gene
5	I-Gene
(	O
CCR5	B-Gene
)	O
plays	O
an	O
important	O
role	O
in	O
inflammation	B-Disease
.	O
</ALL>	O

<ALL>	O
A	O
32	B-Variant
base	I-Variant
-	I-Variant
pair	I-Variant
(	I-Variant
DD32	I-Variant
)	I-Variant
deletion	I-Variant
in	O
the	O
CCR5	B-Gene
gene	O
leads	O
to	O
a	O
nonfunctional	O
receptor	O
.	O
</ALL>	O

<ALL>	O
This	O
deletion	O
has	O
been	O
reported	O
to	O
have	O
a	O
protective	O
effect	O
on	O
the	O
development	O
and	O
progression	O
of	O
several	O
autoimmune	B-Disease
diseases	I-Disease
.	O
</ALL>	O

<ALL>	O
We	O
investigated	O
whether	O
the	O
DD32	B-Variant
deletion	I-Variant
is	O
associated	O
with	O
disease	O
susceptibility	O
in	O
a	O
population	O
of	O
patients	B-Species
with	O
rheumatoid	B-Disease
arthritis	I-Disease
(	O
RA	B-Disease
)	O
,	O
systemic	B-Disease
lupus	I-Disease
erythematosus	I-Disease
(	O
SLE	B-Disease
)	O
,	O
and	O
lupus	B-Disease
nephritis	I-Disease
(	O
LN	B-Disease
)	O
;	O
and	O
whether	O
it	O
is	O
associated	O
with	O
disease	O
severity	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
DNA	O
samples	O
from	O
405	O
RA	B-Disease
patients	B-Species
,	O
97	O
SLE	B-Disease
patients	B-Species
,	O
113	O
LN	B-Disease
patients	B-Species
,	O
and	O
431	O
healthy	O
controls	O
were	O
genotyped	O
for	O
the	O
CCR5	B-Gene
DD32	B-Variant
deletion	I-Variant
.	O
</ALL>	O

<ALL>	O
Differences	O
in	O
genotype	O
frequencies	O
were	O
tested	O
between	O
patients	B-Species
and	O
controls	O
.	O
</ALL>	O

<ALL>	O
Association	O
of	O
genotypes	O
with	O
disease	O
severity	O
was	O
analyzed	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Genotype	O
frequencies	O
of	O
each	O
group	O
were	O
in	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
.	O
</ALL>	O

<ALL>	O
The	O
genotype	O
frequencies	O
of	O
patients	B-Species
did	O
not	O
differ	O
significantly	O
from	O
controls	O
(	O
CCR5	B-Gene
/	O
DD32	B-Variant
,	O
DD32	B-Variant
/	O
DD32	B-Variant
:	O
RA	B-Disease
18.3	O
%	O
and	O
1.2	O
%	O
,	O
respectively	O
;	O
SLE	B-Disease
17.5	O
%	O
and	O
2.1	O
%	O
;	O
LN	B-Disease
13.3	O
%	O
and	O
1.8	O
%	O
;	O
controls	O
20.0	O
%	O
and	O
2.8	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
there	O
was	O
a	O
trend	O
for	O
lower	O
DD32	B-Variant
deletion	I-Variant
allele	O
frequency	O
in	O
LN	B-Disease
patients	B-Species
compared	O
to	O
controls	O
(	O
p	O
=	O
0.08	O
)	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
no	O
significant	O
association	O
between	O
the	O
CCR5	B-Gene
status	O
and	O
disease	O
severity	O
in	O
RA	B-Disease
,	O
SLE	B-Disease
,	O
or	O
LN	B-Disease
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Although	O
an	O
association	O
with	O
LN	B-Disease
can	O
not	O
be	O
excluded	O
,	O
the	O
CCR5	B-Gene
DD32	B-Variant
deletion	I-Variant
does	O
not	O
seem	O
to	O
be	O
a	O
disease	O
susceptibility	O
genotype	O
for	O
RA	B-Disease
,	O
SLE	B-Disease
,	O
or	O
LN	B-Disease
.	O
</ALL>	O

<ALL>	O
No	O
significant	O
effect	O
of	O
the	O
DD32	B-Variant
deletion	I-Variant
on	O
disease	O
severity	O
was	O
demonstrated	O
.	O
</ALL>	O

<ALL>	O
Context	O
-	O
and	O
cell	O
-	O
dependent	O
effects	O
of	O
Delta	B-Gene
-	I-Gene
like	I-Gene
4	I-Gene
targeting	O
in	O
the	O
bone	O
marrow	O
microenvironment	O
.	O
</ALL>	O

<ALL>	O
Delta	B-Gene
-	I-Gene
like	I-Gene
4	I-Gene
(	O
Dll4	B-Gene
)	O
is	O
a	O
ligand	O
of	O
the	O
Notch	B-Gene
pathway	O
family	O
which	O
has	O
been	O
widely	O
studied	O
in	O
the	O
context	O
of	O
tumor	B-Disease
angiogenesis	O
,	O
its	O
blockade	O
shown	O
to	O
result	O
in	O
non	O
-	O
productive	O
angiogenesis	O
and	O
halted	O
tumor	B-Disease
growth	O
.	O
</ALL>	O

<ALL>	O
As	O
Dll4	B-Gene
inhibitors	O
enter	O
the	O
clinic	O
,	O
there	O
is	O
an	O
emerging	O
need	O
to	O
understand	O
their	O
side	O
effects	O
,	O
namely	O
the	O
systemic	O
consequences	O
of	O
Dll4	B-Gene
:	O
Notch	B-Gene
blockade	O
in	O
tissues	O
other	O
than	O
tumors	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
focused	O
on	O
the	O
effects	O
of	O
systemic	O
anti	O
-	O
Dll4	B-Gene
targeting	O
in	O
the	O
bone	O
marrow	O
(	O
BM	O
)	O
microenvironment	O
.	O
</ALL>	O

<ALL>	O
Here	O
we	O
show	O
that	O
Dll4	B-Gene
blockade	O
with	O
monoclonal	O
antibodies	O
perturbs	O
the	O
BM	O
vascular	O
niche	O
of	O
sub	O
-	O
lethally	O
irradiated	O
mice	B-Species
,	O
resulting	O
in	O
increased	O
CD31	B-Gene
(	O
+	O
)	O
,	O
VE	B-Gene
-	I-Gene
Cadherin	I-Gene
(	O
+	O
)	O
and	O
c	B-Gene
-	I-Gene
kit	I-Gene
(	O
+	O
)	O
vessel	O
density	O
,	O
and	O
also	O
increased	O
megakaryocytes	O
,	O
whereas	O
CD105	B-Gene
(	O
+	O
)	O
,	O
VEGFR3	B-Gene
(	O
+	O
)	O
,	O
SMA	B-Gene
(	O
+	O
)	O
and	O
lectin	B-Gene
(	O
+	O
)	O
vessel	O
density	O
remained	O
unaltered	O
.	O
</ALL>	O

<ALL>	O
We	O
investigated	O
also	O
the	O
expression	O
of	O
angiocrine	O
genes	O
upon	O
Dll4	B-Gene
treatment	O
in	O
vivo	O
,	O
and	O
demonstrate	O
that	O
IGFbp2	B-Gene
,	O
IGFbp3	B-Gene
,	O
Angpt2	B-Gene
,	O
Dll4	B-Gene
,	O
DHH	B-Gene
and	O
VEGF	B-Gene
-	I-Gene
A	I-Gene
are	O
upregulated	O
,	O
while	O
FGF1	B-Gene
and	O
CSF2	B-Gene
are	O
reduced	O
.	O
</ALL>	O

<ALL>	O
In	O
vitro	O
treatment	O
of	O
endothelial	O
cells	O
with	O
anti	O
-	O
Dll4	B-Gene
reduced	O
Akt	B-Gene
phosphorylation	O
while	O
maintaining	O
similar	O
levels	O
of	O
Erk	B-Gene
1	I-Gene
/	I-Gene
2	I-Gene
phosphorylation	O
.	O
</ALL>	O

<ALL>	O
Besides	O
its	O
effects	O
in	O
the	O
BM	O
vascular	O
niche	O
,	O
anti	O
-	O
Dll4	B-Gene
treatment	O
perturbed	O
hematopoiesis	O
,	O
as	O
evidenced	O
by	O
increased	O
myeloid	O
(	O
CD11b	B-Gene
(	O
+	O
)	O
)	O
,	O
decreased	O
B	O
(	O
B220	B-Gene
(	O
+	O
)	O
)	O
and	O
T	O
(	O
CD3	B-Gene
(	O
+	O
)	O
)	O
lymphoid	O
BM	O
content	O
of	O
treated	O
mice	B-Species
,	O
with	O
a	O
corresponding	O
increase	O
in	O
myeloid	O
circulating	O
cells	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
anti	O
-	O
Dll4	B-Gene
treatment	O
also	O
increased	O
the	O
number	O
of	O
CFU	O
-	O
M	O
and	O
-	O
G	O
colonies	O
in	O
methylcellulose	O
assays	O
,	O
independently	O
of	O
Notch1	B-Gene
.	O
</ALL>	O

<ALL>	O
Finally	O
,	O
anti	O
-	O
Dll4	B-Gene
treatment	O
of	O
donor	O
BM	O
improved	O
the	O
hematopoietic	O
recovery	O
of	O
lethally	O
irradiated	O
recipients	O
in	O
a	O
transplant	O
setting	O
.	O
</ALL>	O

<ALL>	O
Together	O
,	O
our	O
data	O
reveals	O
the	O
hematopoietic	O
(	O
BM	O
)	O
effects	O
of	O
systemic	O
anti	O
-	O
Dll4	B-Gene
treatment	O
result	O
from	O
qualitative	O
vascular	O
changes	O
and	O
also	O
direct	O
hematopoietic	O
cell	O
modulation	O
,	O
which	O
may	O
be	O
favorable	O
in	O
a	O
transplant	O
setting	O
.	O
</ALL>	O

<ALL>	O
Role	O
of	O
angiotensin	B-Gene
II	I-Gene
type	I-Gene
1a	I-Gene
receptor	I-Gene
in	O
renal	B-Disease
injury	I-Disease
induced	O
by	O
deoxycorticosterone	B-Chemical
acetate	I-Chemical
-	O
salt	O
hypertension	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
in	O
vivo	O
role	O
of	O
angiotensin	B-Gene
II	I-Gene
type	I-Gene
1a	I-Gene
(	I-Gene
AT1a	I-Gene
)	I-Gene
receptor	I-Gene
in	O
renal	B-Disease
damage	I-Disease
as	O
a	O
result	O
of	O
hypertension	B-Disease
by	O
using	O
transgenic	O
mice	B-Species
with	O
AT1a	B-Gene
receptor	I-Gene
gene	O
disruption	O
.	O
</ALL>	O

<ALL>	O
Transgenic	O
mice	B-Species
that	O
express	O
human	B-Species
liver	B-Gene
-	I-Gene
type	I-Gene
fatty	I-Gene
acid	I-Gene
binding	I-Gene
protein	I-Gene
(	O
L	B-Gene
-	I-Gene
FABP	I-Gene
)	O
with	O
or	O
without	O
disruption	O
of	O
the	O
AT1a	B-Gene
receptor	I-Gene
gene	O
(	O
L	B-Gene
-	I-Gene
FABP	I-Gene
(	O
+	O
/	O
-	O
)	O
AT1a	B-Gene
(	O
-	O
/	O
-	O
)	O
,	O
and	O
L	B-Gene
-	I-Gene
FABP	I-Gene
(	O
+	O
/	O
-	O
)	O
AT1a	B-Gene
(	O
+	O
/	O
+	O
)	O
,	O
respectively	O
)	O
were	O
used	O
with	O
urinary	O
L	B-Gene
-	I-Gene
FABP	I-Gene
as	O
an	O
indicator	O
of	O
tubulointerstitial	B-Disease
damage	I-Disease
.	O
</ALL>	O

<ALL>	O
Those	O
female	O
mice	B-Species
were	O
administered	O
subcutaneously	O
deoxycorticosterone	B-Chemical
acetate	I-Chemical
(	O
DOCA	B-Chemical
)	O
-	O
salt	O
tablets	O
plus	O
drinking	O
water	O
that	O
contained	O
1	O
%	O
saline	O
for	O
28	O
d	O
after	O
uninephrectomy	O
.	O
</ALL>	O

<ALL>	O
In	O
L	B-Gene
-	I-Gene
FABP	I-Gene
(	O
+	O
/	O
-	O
)	O
AT1a	B-Gene
(	O
+	O
/	O
+	O
)	O
mice	B-Species
that	O
received	O
DOCA	B-Chemical
-	O
salt	O
treatment	O
,	O
hypertension	B-Disease
was	O
induced	O
and	O
slight	O
expansion	O
of	O
glomerular	O
area	O
,	O
glomerular	B-Disease
sclerosis	I-Disease
,	O
and	O
tubulointerstitial	B-Disease
damage	I-Disease
were	O
observed	O
.	O
</ALL>	O

<ALL>	O
In	O
L	B-Gene
-	I-Gene
FABP	I-Gene
(	O
+	O
/	O
-	O
)	O
AT1a	B-Gene
(	O
-	O
/	O
-	O
)	O
mice	B-Species
that	O
received	O
DOCA	B-Chemical
-	O
salt	O
treatment	O
,	O
hypertension	B-Disease
was	O
similarly	O
induced	O
and	O
the	O
degree	O
of	O
glomerular	B-Disease
damage	I-Disease
was	O
significantly	O
more	O
severe	O
than	O
in	O
L	B-Gene
-	I-Gene
FABP	I-Gene
(	O
+	O
/	O
-	O
)	O
AT1a	B-Gene
(	O
+	O
/	O
+	O
)	O
-	O
DOCA	B-Chemical
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Urinary	O
L	B-Gene
-	I-Gene
FABP	I-Gene
levels	O
were	O
significantly	O
higher	O
in	O
L	B-Gene
-	I-Gene
FABP	I-Gene
(	O
+	O
/	O
-	O
)	O
AT1a	B-Gene
(	O
-	O
/	O
-	O
)	O
-	O
DOCA	B-Chemical
mice	B-Species
compared	O
with	O
those	O
in	O
L	B-Gene
-	I-Gene
FABP	I-Gene
(	O
+	O
/	O
-	O
)	O
AT1a	B-Gene
(	O
+	O
/	O
+	O
)	O
-	O
DOCA	B-Chemical
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Hydralazine	B-Chemical
treatment	O
significantly	O
attenuated	O
renal	B-Disease
damage	I-Disease
that	O
was	O
found	O
in	O
L	B-Gene
-	I-Gene
FABP	I-Gene
(	O
+	O
/	O
-	O
)	O
AT1a	B-Gene
(	O
-	O
/	O
-	O
)	O
-	O
DOCA	B-Chemical
mice	B-Species
along	O
with	O
a	O
reduction	O
in	O
blood	O
pressure	O
.	O
</ALL>	O

<ALL>	O
In	O
summary	O
,	O
activation	O
of	O
the	O
AT1a	B-Gene
receptor	I-Gene
may	O
contribute	O
to	O
maintenance	O
of	O
the	O
glomerular	O
structure	O
against	O
hypertensive	B-Disease
renal	I-Disease
damage	I-Disease
.	O
-	O
</ALL>	O

<ALL>	O
Hisamichi	O
,	O
M.	O
,	O
Kamijo	O
-	O
Ikemori	O
,	O
A.	O
,	O
Sugaya	O
,	O
T.	O
,	O
Ichikawa	O
,	O
D.	O
,	O
Natsuki	O
,	O
T.	O
,	O
Hoshino	O
,	O
S.	O
,	O
Kimura	O
,	O
K.	O
,	O
Shibagaki	O
,	O
Y.	O
Role	O
of	O
angiotensin	B-Gene
II	I-Gene
type	I-Gene
1a	I-Gene
receptor	I-Gene
in	O
renal	B-Disease
injury	I-Disease
induced	O
by	O
deoxycorticosterone	B-Chemical
acetate	I-Chemical
-	O
salt	O
hypertension	B-Disease
.	O
</ALL>	O

<ALL>	O
PTPN22	B-Gene
Is	O
a	O
Critical	O
Regulator	O
of	O
Fcg	B-Gene
Receptor	I-Gene
-	O
Mediated	O
Neutrophil	O
Activation	O
.	O
</ALL>	O

<ALL>	O
Neutrophils	O
act	O
as	O
a	O
first	O
line	O
of	O
defense	O
against	O
bacterial	O
and	O
fungal	B-Disease
infections	I-Disease
,	O
but	O
they	O
are	O
also	O
important	O
effectors	O
of	O
acute	B-Disease
and	I-Disease
chronic	I-Disease
inflammation	I-Disease
.	O
</ALL>	O

<ALL>	O
Genome	O
-	O
wide	O
association	O
studies	O
have	O
established	O
that	O
the	O
gene	O
encoding	O
the	O
protein	B-Gene
tyrosine	I-Gene
phosphatase	I-Gene
nonreceptor	I-Gene
22	I-Gene
(	O
PTPN22	B-Gene
)	O
makes	O
an	O
important	O
contribution	O
to	O
susceptibility	O
to	O
autoimmune	B-Disease
disease	I-Disease
,	O
notably	O
rheumatoid	B-Disease
arthritis	I-Disease
.	O
</ALL>	O

<ALL>	O
Although	O
PTPN22	B-Gene
is	O
most	O
highly	O
expressed	O
in	O
neutrophils	O
,	O
its	O
function	O
in	O
these	O
cells	O
remains	O
poorly	O
characterized	O
.	O
</ALL>	O

<ALL>	O
We	O
show	O
in	O
this	O
article	O
that	O
neutrophil	O
effector	O
functions	O
,	O
including	O
adhesion	O
,	O
production	O
of	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
,	O
and	O
degranulation	O
induced	O
by	O
immobilized	O
immune	O
complexes	O
,	O
were	O
reduced	O
in	O
Ptpn22	B-Gene
(	O
-	O
/	O
-	O
)	O
neutrophils	O
.	O
</ALL>	O

<ALL>	O
Tyrosine	O
phosphorylation	O
of	O
Lyn	B-Gene
and	O
Syk	B-Gene
was	O
altered	O
in	O
Ptpn22	B-Gene
(	O
-	O
/	O
-	O
)	O
neutrophils	O
.	O
</ALL>	O

<ALL>	O
On	O
stimulation	O
with	O
immobilized	O
immune	O
complexes	O
,	O
Ptpn22	B-Gene
(	O
-	O
/	O
-	O
)	O
neutrophils	O
manifested	O
reduced	O
activation	O
of	O
key	O
signaling	O
intermediates	O
.	O
</ALL>	O

<ALL>	O
Ptpn22	B-Gene
(	O
-	O
/	O
-	O
)	O
mice	B-Species
were	O
protected	O
from	O
immune	O
complex	O
-	O
mediated	O
arthritis	B-Disease
,	O
induced	O
by	O
the	O
transfer	O
of	O
arthritogenic	O
serum	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
in	O
vivo	O
neutrophil	O
recruitment	O
following	O
thioglycollate	B-Chemical
-	O
induced	O
peritonitis	B-Disease
and	O
in	O
vitro	O
chemotaxis	O
were	O
not	O
affected	O
by	O
lack	O
of	O
PTPN22	B-Gene
.	O
</ALL>	O

<ALL>	O
Our	O
data	O
suggest	O
an	O
important	O
role	O
for	O
PTPN22	B-Gene
-	O
dependent	O
dephosphorylation	O
events	O
,	O
which	O
are	O
required	O
to	O
enable	O
full	O
FcgR	B-Gene
-	O
induced	O
activation	O
,	O
pointing	O
to	O
an	O
important	O
role	O
for	O
this	O
molecule	O
in	O
neutrophil	O
function	O
.	O
</ALL>	O

<ALL>	O
Four	O
novel	O
mutations	O
in	O
the	O
thiazide	B-Chemical
-	O
sensitive	O
Na	B-Gene
-	I-Gene
Cl	I-Gene
co	I-Gene
-	I-Gene
transporter	I-Gene
gene	O
in	O
Japanese	O
patients	B-Species
with	O
Gitelman	B-Disease
's	I-Disease
syndrome	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Gitelman	B-Disease
's	I-Disease
syndrome	I-Disease
(	O
GS	B-Disease
)	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
disorder	I-Disease
resulting	O
from	O
inactivating	O
mutations	O
in	O
the	O
thiazide	B-Chemical
-	O
sensitive	O
Na	B-Gene
-	I-Gene
Cl	I-Gene
co	I-Gene
-	I-Gene
transporter	I-Gene
(	O
NCCT	B-Gene
)	O
gene	O
.	O
</ALL>	O

<ALL>	O
To	O
date	O
,	O
almost	O
90	O
mutations	O
have	O
been	O
identified	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
possible	O
that	O
there	O
is	O
a	O
population	O
-	O
specific	O
distribution	O
of	O
mutations	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
analysed	O
mutations	O
in	O
the	O
NCCT	B-Gene
gene	O
of	O
seven	O
Japanese	O
patients	B-Species
with	O
GS	B-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Peripheral	O
blood	O
mononuclear	O
cells	O
were	O
isolated	O
from	O
patients	B-Species
with	O
GS	B-Disease
,	O
their	O
family	O
members	O
and	O
healthy	O
control	O
subjects	O
.	O
</ALL>	O

<ALL>	O
A	O
mutation	O
analysis	O
of	O
the	O
NCCT	B-Gene
gene	O
was	O
performed	O
completely	O
by	O
direct	O
automated	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
-	O
amplified	O
DNA	O
products	O
.	O
</ALL>	O

<ALL>	O
In	O
patients	B-Species
with	O
a	O
deletion	O
or	O
splice	O
site	O
mutation	O
,	O
we	O
undertook	O
cDNA	O
sequence	O
analysis	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
We	O
identified	O
nine	O
mutations	O
.	O
</ALL>	O

<ALL>	O
Five	O
of	O
them	O
[	O
c.185C	B-Variant
>	I-Variant
T	I-Variant
(	O
Thr60Met	B-Variant
)	O
,	O
c.1712C	B-Variant
>	I-Variant
T	I-Variant
(	O
Ala569Val	B-Variant
)	O
,	O
c.1930C	B-Variant
>	I-Variant
T	I-Variant
(	O
Arg642Cys	B-Variant
)	O
,	O
c.2552	B-Variant
T	I-Variant
>	I-Variant
A	I-Variant
(	O
Leu849His	B-Variant
)	O
and	O
c.1932delC	B-Variant
]	O
have	O
been	O
reported	O
in	O
Japanese	O
patients	B-Species
,	O
but	O
not	O
in	O
GS	B-Disease
patients	B-Species
from	O
other	O
ethnic	O
groups	O
.	O
</ALL>	O

<ALL>	O
The	O
remaining	O
four	O
mutations	O
[	O
c.7A	B-Variant
>	I-Variant
T	I-Variant
(	O
Met1Leu	B-Variant
)	O
,	O
c.1181	B-Variant
_	I-Variant
1186	I-Variant
+	I-Variant
20del26	I-Variant
,	O
c.1811	B-Variant
_	I-Variant
1812delAT	I-Variant
and	O
IVS16	B-Variant
+	I-Variant
1	I-Variant
G	I-Variant
>	I-Variant
A	I-Variant
]	O
were	O
novel	O
.	O
</ALL>	O

<ALL>	O
In	O
cDNA	O
derived	O
from	O
a	O
patient	B-Species
with	O
c.1181	B-Variant
_	I-Variant
1186	I-Variant
+	I-Variant
20del26	I-Variant
,	O
a	O
deletion	O
of	O
exon	O
9	O
and	O
a	O
frameshift	O
at	O
the	O
start	O
of	O
exon	O
10	O
were	O
observed	O
.	O
</ALL>	O

<ALL>	O
In	O
cDNA	O
derived	O
from	O
patients	B-Species
with	O
IVS16	B-Variant
+	I-Variant
1	I-Variant
G	I-Variant
>	I-Variant
A	I-Variant
,	O
an	O
additional	O
96	B-Variant
bp	I-Variant
insertion	I-Variant
between	O
exons	O
16	O
and	O
17	O
was	O
observed	O
.	O
</ALL>	O

<ALL>	O
Six	O
out	O
of	O
seven	O
patients	B-Species
were	O
compound	O
heterozygotes	O
,	O
and	O
the	O
remaining	O
one	O
carried	O
a	O
single	O
heterozygous	O
mutation	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
We	O
found	O
four	O
novel	O
mutations	O
in	O
the	O
NCCT	B-Gene
gene	O
in	O
seven	O
Japanese	O
patients	B-Species
with	O
GS	B-Disease
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
our	O
study	O
suggests	O
that	O
the	O
distribution	O
of	O
mutations	O
in	O
the	O
NCCT	B-Gene
gene	O
in	O
Japanese	O
GS	B-Disease
patients	B-Species
potentially	O
differs	O
from	O
that	O
in	O
other	O
populations	O
.	O
</ALL>	O

<ALL>	O
Regulatory	O
network	O
of	O
inflammation	B-Disease
downstream	O
of	O
proteinase	B-Gene
-	I-Gene
activated	I-Gene
receptors	I-Gene
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Protease	B-Gene
-	I-Gene
activated	I-Gene
receptors	I-Gene
(	O
PAR	B-Gene
)	O
are	O
present	O
in	O
the	O
urinary	O
bladder	O
,	O
and	O
their	O
expression	O
is	O
altered	O
in	O
response	O
to	O
inflammation	B-Disease
.	O
</ALL>	O

<ALL>	O
PARs	B-Gene
are	O
a	O
unique	O
class	O
of	O
G	O
protein	O
-	O
coupled	O
that	O
carry	O
their	O
own	O
ligands	O
,	O
which	O
remain	O
cryptic	O
until	O
unmasked	O
by	O
proteolytic	O
cleavage	O
.	O
</ALL>	O

<ALL>	O
Although	O
the	O
canonical	O
signal	O
transduction	O
pathway	O
downstream	O
of	O
PAR	B-Gene
activation	O
and	O
coupling	O
with	O
various	O
G	O
proteins	O
is	O
known	O
and	O
leads	O
to	O
the	O
rapid	O
transcription	O
of	O
genes	O
involved	O
in	O
inflammation	B-Disease
,	O
the	O
effect	O
of	O
PAR	B-Gene
activation	O
on	O
the	O
downstream	O
transcriptome	O
is	O
unknown	O
.	O
</ALL>	O

<ALL>	O
We	O
have	O
shown	O
that	O
intravesical	O
administration	O
of	O
PAR	B-Gene
-	O
activating	O
peptides	O
leads	O
to	O
an	O
inflammatory	B-Disease
reaction	O
characterized	O
by	O
edema	B-Disease
and	O
granulocyte	O
infiltration	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
the	O
inflammatory	B-Disease
response	O
to	O
intravesical	O
instillation	O
of	O
known	O
pro	O
-	O
inflammatory	B-Disease
stimuli	O
such	O
as	O
E.	B-Species
coli	I-Species
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)	O
,	O
substance	B-Chemical
P	I-Chemical
(	O
SP	B-Chemical
)	O
,	O
and	O
antigen	O
was	O
strongly	O
attenuated	O
by	O
PAR1	B-Gene
-	O
and	O
to	O
a	O
lesser	O
extent	O
by	O
PAR2	B-Gene
-	O
deficiency	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Here	O
,	O
cDNA	O
array	O
experiments	O
determined	O
inflammatory	B-Disease
genes	O
whose	O
expression	O
is	O
dependent	O
on	O
PAR1	B-Gene
activation	O
.	O
</ALL>	O

<ALL>	O
For	O
this	O
purpose	O
,	O
we	O
compared	O
the	O
alteration	O
in	O
gene	O
expression	O
in	O
wild	O
type	O
and	O
PAR1	B-Gene
-	O
/	O
-	O
mice	B-Species
induced	O
by	O
classical	O
pro	O
-	O
inflammatory	B-Disease
stimuli	O
(	O
LPS	B-Chemical
,	O
SP	B-Chemical
,	O
and	O
antigen	O
)	O
.	O
</ALL>	O

<ALL>	O
75	O
transcripts	O
were	O
considered	O
to	O
be	O
dependent	O
on	O
PAR	B-Gene
-	I-Gene
1	I-Gene
activation	O
and	O
further	O
annotated	O
in	O
silico	O
by	O
Ingenuity	O
Pathways	O
Analysis	O
(	O
IPA	O
)	O
and	O
gene	O
ontology	O
(	O
GO	O
)	O
.	O
</ALL>	O

<ALL>	O
Selected	O
transcripts	O
were	O
target	O
validated	O
by	O
quantitative	O
PCR	O
(	O
Q	O
-	O
PCR	O
)	O
.	O
</ALL>	O

<ALL>	O
Among	O
PAR1	B-Gene
-	O
dependent	O
transcripts	O
,	O
the	O
following	O
have	O
been	O
implicated	O
in	O
the	O
inflammatory	B-Disease
process	O
:	O
b2	B-Gene
m	I-Gene
,	O
ccl7	B-Gene
,	O
cd200	B-Gene
,	O
cd63	B-Gene
,	O
cdbpd	B-Gene
,	O
cfl1	B-Gene
,	O
dusp1	B-Gene
,	O
fkbp1a	B-Gene
,	O
fth1	B-Gene
,	O
hspb1	B-Gene
,	O
marcksl1	B-Gene
,	O
mmp2	B-Gene
,	O
myo5a	B-Gene
,	O
nfkbia	B-Gene
,	O
pax1	B-Gene
,	O
plaur	B-Gene
,	O
ppia	B-Gene
,	O
ptpn1	B-Gene
,	O
ptprcap	B-Gene
,	O
s100a10	B-Gene
,	O
sim2	B-Gene
,	O
and	O
tnfaip2	B-Gene
.	O
</ALL>	O

<ALL>	O
However	O
,	O
a	O
balanced	O
response	O
to	O
signals	O
of	O
injury	O
requires	O
a	O
transient	O
cellular	O
activation	O
of	O
a	O
panel	O
of	O
genes	O
together	O
with	O
inhibitory	O
systems	O
that	O
temper	O
the	O
overwhelming	O
inflammation	B-Disease
.	O
</ALL>	O

<ALL>	O
In	O
this	O
context	O
,	O
the	O
activation	O
of	O
genes	O
such	O
as	O
dusp1	B-Gene
and	O
nfkbia	B-Gene
seems	O
to	O
counter	O
-	O
balance	O
the	O
inflammatory	B-Disease
response	O
to	O
PAR	B-Gene
activation	O
by	O
limiting	O
prolonged	O
activation	O
of	O
p38	B-Gene
MAPK	I-Gene
and	O
increased	O
cytokine	O
production	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
transcripts	O
such	O
as	O
arf6	B-Gene
and	O
dcnt1	B-Gene
that	O
are	O
involved	O
in	O
the	O
mechanism	O
of	O
PAR	B-Gene
re	O
-	O
sensitization	O
would	O
tend	O
to	O
perpetuate	O
the	O
inflammatory	B-Disease
reaction	O
in	O
response	O
to	O
common	O
pro	O
-	O
inflammatory	B-Disease
stimuli	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
The	O
combination	O
of	O
cDNA	O
array	O
results	O
and	O
genomic	O
networks	O
reveals	O
an	O
overriding	O
participation	O
of	O
PAR1	B-Gene
in	O
bladder	B-Disease
inflammation	I-Disease
,	O
provides	O
a	O
working	O
model	O
for	O
the	O
involvement	O
of	O
downstream	O
signaling	O
,	O
and	O
evokes	O
testable	O
hypotheses	O
regarding	O
the	O
transcriptome	O
downstream	O
of	O
PAR1	B-Gene
activation	O
.	O
</ALL>	O

<ALL>	O
It	O
remains	O
to	O
be	O
determined	O
whether	O
or	O
not	O
mechanisms	O
targeting	O
PAR1	B-Gene
gene	O
silencing	O
or	O
PAR1	B-Gene
blockade	O
will	O
ameliorate	O
the	O
clinical	O
manifestation	O
of	O
cystitis	B-Disease
.	O
</ALL>	O

<ALL>	O
Caffeine	B-Chemical
challenge	O
test	O
in	O
panic	B-Disease
disorder	I-Disease
and	O
depression	B-Disease
with	O
panic	B-Disease
attacks	I-Disease
.	O
</ALL>	O

<ALL>	O
Our	O
aim	O
was	O
to	O
observe	O
if	O
patients	B-Species
with	O
panic	B-Disease
disorder	I-Disease
(	O
PD	B-Disease
)	O
and	O
patients	B-Species
with	O
major	B-Disease
depression	I-Disease
with	O
panic	B-Disease
attacks	I-Disease
(	O
MDP	B-Disease
)	O
(	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	B-Disease
Disorders	I-Disease
,	O
Fourth	O
Edition	O
criteria	O
)	O
respond	O
in	O
a	O
similar	O
way	O
to	O
the	O
induction	O
of	O
panic	B-Disease
attacks	I-Disease
by	O
an	O
oral	O
caffeine	B-Chemical
challenge	O
test	O
.	O
</ALL>	O

<ALL>	O
We	O
randomly	O
selected	O
29	O
patients	B-Species
with	O
PD	B-Disease
,	O
27	O
with	O
MDP	B-Disease
,	O
25	O
with	O
major	B-Disease
depression	I-Disease
without	O
panic	B-Disease
attacks	I-Disease
(	O
MD	B-Disease
)	O
,	O
and	O
28	O
healthy	O
volunteers	O
.	O
</ALL>	O

<ALL>	O
The	O
patients	B-Species
had	O
no	O
psychotropic	O
drug	O
for	O
at	O
least	O
a	O
4	O
-	O
week	O
period	O
.	O
</ALL>	O

<ALL>	O
In	O
a	O
randomized	O
double	O
-	O
blind	O
experiment	O
performed	O
in	O
2	O
occasions	O
7	O
days	O
apart	O
,	O
480	O
mg	O
caffeine	B-Chemical
and	O
a	O
caffeine	B-Chemical
-	O
free	O
(	O
placebo	O
)	O
solution	O
were	O
administered	O
in	O
a	O
coffee	O
form	O
and	O
anxiety	B-Disease
scales	O
were	O
applied	O
before	O
and	O
after	O
each	O
test	O
.	O
</ALL>	O

<ALL>	O
A	O
total	O
of	O
58.6	O
%	O
(	O
n	O
=	O
17	O
)	O
of	O
patients	B-Species
with	O
PD	B-Disease
,	O
44.4	O
%	O
(	O
n	O
=	O
12	O
)	O
of	O
patients	B-Species
with	O
MDP	B-Disease
,	O
12.0	O
%	O
(	O
n	O
=	O
3	O
)	O
of	O
patients	B-Species
with	O
MD	B-Disease
,	O
and	O
7.1	O
%	O
(	O
n	O
=	O
2	O
)	O
of	O
control	O
subjects	O
had	O
a	O
panic	B-Disease
attack	I-Disease
after	O
the	O
480	O
-	O
mg	O
caffeine	B-Chemical
challenge	O
test	O
(	O
chi	O
(	O
2	O
)	O
(	O
3	O
)	O
=	O
16.22	O
,	O
P	O
=	O
.001	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
patients	B-Species
with	O
PD	B-Disease
and	O
MDP	B-Disease
were	O
more	O
sensitive	O
to	O
caffeine	B-Chemical
than	O
were	O
patients	B-Species
with	O
MD	B-Disease
and	O
healthy	O
volunteers	O
.	O
</ALL>	O

<ALL>	O
No	O
panic	B-Disease
attack	I-Disease
was	O
observed	O
after	O
the	O
caffeine	B-Chemical
-	O
free	O
solution	O
intake	O
.	O
</ALL>	O

<ALL>	O
The	O
patients	B-Species
with	O
MD	B-Disease
had	O
a	O
lower	O
heart	O
rate	O
response	O
to	O
the	O
test	O
than	O
all	O
the	O
other	O
groups	O
(	O
2	O
-	O
way	O
analysis	O
of	O
variance	O
,	O
group	O
by	O
time	O
interaction	O
with	O
Greenhouse	O
-	O
Geisser	O
correction	O
:	O
F	O
(	O
3,762	O
)	O
=	O
2.85	O
,	O
P	O
=	O
.026	O
)	O
.	O
</ALL>	O

<ALL>	O
Our	O
data	O
suggest	O
that	O
there	O
is	O
an	O
association	O
between	O
panic	B-Disease
attacks	I-Disease
,	O
no	O
matter	O
if	O
associated	O
with	O
PD	B-Disease
or	O
MDP	B-Disease
,	O
and	O
hyperreactivity	O
to	O
an	O
oral	O
caffeine	B-Chemical
challenge	O
test	O
.	O
</ALL>	O

<ALL>	O
Upregulation	O
of	O
T	B-Gene
-	I-Gene
cell	I-Gene
factor	I-Gene
-	I-Gene
4	I-Gene
isoform	O
-	O
responsive	O
target	O
genes	O
in	O
hepatocellular	B-Disease
carcinoma	I-Disease
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
The	O
Wnt	B-Gene
/	O
beta	B-Gene
-	I-Gene
catenin	I-Gene
signalling	O
pathway	O
regulates	O
genes	O
involved	O
in	O
cell	O
proliferation	O
,	O
survival	O
,	O
migration	O
and	O
invasion	O
through	O
regulation	O
by	O
T	B-Gene
-	I-Gene
cell	I-Gene
factor	I-Gene
(	I-Gene
TCF	I-Gene
)	I-Gene
-	I-Gene
4	I-Gene
transcription	I-Gene
factor	I-Gene
proteins	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
role	O
of	O
TCF	B-Gene
-	I-Gene
4	I-Gene
isoforms	O
generated	O
by	O
alternative	O
splicing	O
events	O
in	O
hepatocellular	B-Disease
carcinoma	I-Disease
(	O
HCC	B-Disease
)	O
is	O
unknown	O
.	O
</ALL>	O

<ALL>	O
AIM	O
:	O
Here	O
,	O
we	O
investigated	O
TCF	B-Gene
-	I-Gene
4	I-Gene
isoforms	O
(	O
TCF	B-Gene
-	I-Gene
4J	I-Gene
and	I-Gene
K	I-Gene
)	O
-	O
responsive	O
target	O
genes	O
that	O
are	O
important	O
in	O
hepatic	B-Disease
oncogenesis	I-Disease
and	O
tumour	B-Disease
development	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Gene	O
expression	O
microarray	O
was	O
performed	O
on	O
HCC	B-Disease
cells	O
overexpressing	O
TCF	B-Gene
-	I-Gene
4J	I-Gene
and	I-Gene
K	I-Gene
isoforms	O
.	O
</ALL>	O

<ALL>	O
Expression	O
level	O
of	O
selected	O
target	O
genes	O
was	O
evaluated	O
and	O
correlations	O
were	O
made	O
between	O
their	O
expression	O
level	O
and	O
that	O
of	O
TCF	B-Gene
-	I-Gene
4	I-Gene
isoform	O
in	O
47	O
pairs	O
of	O
human	B-Species
HCC	B-Disease
tumours	I-Disease
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Comparison	O
by	O
gene	O
expression	O
microarray	O
revealed	O
that	O
447	O
genes	O
were	O
upregulated	O
and	O
343	O
downregulated	O
more	O
than	O
2.0	O
-	O
fold	O
in	O
TCF	B-Gene
-	I-Gene
4J	I-Gene
compared	O
with	O
TCF	B-Gene
-	I-Gene
4	I-Gene
K	I-Gene
expressing	O
cells	O
.	O
</ALL>	O

<ALL>	O
We	O
validated	O
expression	O
of	O
18	O
selected	O
target	O
genes	O
involved	O
in	O
Wnt	B-Gene
/	O
beta	B-Gene
-	I-Gene
catenin	I-Gene
,	O
insulin	B-Gene
/	O
IGF	B-Gene
-	I-Gene
1	I-Gene
/	O
IRS1	B-Gene
and	O
Notch	B-Gene
signalling	O
pathways	O
in	O
47	O
pairs	O
of	O
human	B-Species
HCCs	B-Disease
and	O
adjacent	O
uninvolved	O
liver	O
tissues	O
.	O
</ALL>	O

<ALL>	O
It	O
was	O
observed	O
that	O
13	O
genes	O
(	O
CLDN2	B-Gene
,	O
STK17B	B-Gene
,	O
SPP1	B-Gene
,	O
AXIN2	B-Gene
,	O
WISP2	B-Gene
,	O
MMP7	B-Gene
,	O
IRS1	B-Gene
,	O
ANXA1	B-Gene
,	O
CAMK2N1	B-Gene
,	O
ASPH	B-Gene
,	O
GPR56	B-Gene
,	O
CD24	B-Gene
and	O
JAG1	B-Gene
)	O
activated	O
by	O
TCF	B-Gene
-	I-Gene
4J	I-Gene
isoform	O
in	O
HCC	B-Disease
cells	O
,	O
were	O
also	O
upregulated	O
in	O
HCC	B-Disease
tumours	I-Disease
compared	O
with	O
adjacent	O
peritumour	O
tissue	O
;	O
more	O
importantly	O
,	O
10	O
genes	O
exhibited	O
a	O
significant	O
correlation	O
with	O
the	O
TCF	B-Gene
-	I-Gene
4J	I-Gene
expression	O
level	O
in	O
tumour	B-Disease
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
TCF	B-Gene
-	I-Gene
4	I-Gene
isoforms	O
(	O
TCF	B-Gene
-	I-Gene
4J	I-Gene
and	I-Gene
K	I-Gene
)	O
activated	O
different	O
downstream	O
target	O
genes	O
in	O
HCC	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
biological	O
consequence	O
of	O
TCF	B-Gene
-	I-Gene
4J	I-Gene
isoform	O
expression	O
was	O
upregulation	O
of	O
genes	O
associated	O
with	O
tripartite	O
Wnt	B-Gene
/	O
beta	B-Gene
-	I-Gene
catenin	I-Gene
,	O
insulin	B-Gene
/	O
IGF	B-Gene
-	I-Gene
1	I-Gene
/	O
IRS1	B-Gene
and	O
Notch	B-Gene
signal	O
transduction	O
pathway	O
activation	O
,	O
which	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
HCC	B-Disease
.	O
</ALL>	O

<ALL>	O
Nicotine	B-Chemical
antagonizes	O
caffeine	B-Chemical
-	O
but	O
not	O
pentylenetetrazole	B-Chemical
-	O
induced	O
anxiogenic	B-Disease
effect	I-Disease
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
RATIONALE	O
:	O
Nicotine	B-Chemical
and	O
caffeine	B-Chemical
are	O
widely	O
consumed	O
licit	O
psychoactive	B-Chemical
drugs	I-Chemical
worldwide	O
.	O
</ALL>	O

<ALL>	O
Epidemiological	O
studies	O
showed	O
that	O
they	O
were	O
generally	O
used	O
concurrently	O
.	O
</ALL>	O

<ALL>	O
Although	O
some	O
studies	O
in	O
experimental	O
animals	O
indicate	O
clear	O
pharmacological	O
interactions	O
between	O
them	O
,	O
no	O
studies	O
have	O
shown	O
a	O
specific	O
interaction	O
on	O
anxiety	B-Disease
responses	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVES	O
:	O
The	O
present	O
study	O
investigates	O
the	O
effects	O
of	O
nicotine	B-Chemical
on	O
anxiety	B-Disease
induced	O
by	O
caffeine	B-Chemical
and	O
another	O
anxiogenic	B-Chemical
drug	I-Chemical
,	O
pentylenetetrazole	B-Chemical
,	O
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
elevated	O
plus	O
-	O
maze	O
(	O
EPM	O
)	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
effects	O
of	O
drugs	O
on	O
anxiety	B-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Adult	O
male	O
Swiss	O
Webster	O
mice	B-Species
(	O
25	O
-	O
32	O
g	O
)	O
were	O
given	O
nicotine	B-Chemical
(	O
0.05	O
-	O
0.25	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
</ALL>	O

<ALL>	O
or	O
saline	O
10	O
min	O
before	O
caffeine	B-Chemical
(	O
70	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
</ALL>	O

<ALL>	O
or	O
pentylenetetrazole	B-Chemical
(	O
15	O
and	O
30	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
</ALL>	O

<ALL>	O
injections	O
.	O
</ALL>	O

<ALL>	O
After	O
15	O
min	O
,	O
mice	B-Species
were	O
evaluated	O
for	O
their	O
open	O
-	O
and	O
closed	O
-	O
arm	O
time	O
and	O
entries	O
on	O
the	O
EPM	O
for	O
a	O
10	O
-	O
min	O
session	O
.	O
</ALL>	O

<ALL>	O
Locomotor	O
activity	O
was	O
recorded	O
for	O
individual	O
groups	O
by	O
using	O
the	O
same	O
treatment	O
protocol	O
with	O
the	O
EPM	O
test	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Nicotine	B-Chemical
(	O
0.05	O
-	O
0.25	O
mg	O
/	O
kg	O
)	O
itself	O
did	O
not	O
produce	O
any	O
significant	O
effect	O
in	O
the	O
EPM	O
test	O
,	O
whereas	O
caffeine	B-Chemical
(	O
70	O
mg	O
/	O
kg	O
)	O
and	O
pentylenetetrazole	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
)	O
produced	O
an	O
anxiogenic	B-Disease
effect	I-Disease
,	O
apparent	O
with	O
decreases	O
in	O
open	O
-	O
arm	O
time	O
and	O
entry	O
.	O
</ALL>	O

<ALL>	O
Nicotine	B-Chemical
(	O
0.25	O
mg	O
/	O
kg	O
)	O
pretreatment	O
blocked	O
the	O
caffeine	B-Chemical
-	O
but	O
not	O
pentylenetetrazole	B-Chemical
-	O
induced	O
anxiety	B-Disease
.	O
</ALL>	O

<ALL>	O
Administration	O
of	O
each	O
drug	O
and	O
their	O
combinations	O
did	O
not	O
produce	O
any	O
effect	O
on	O
locomotor	O
activity	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
antagonistic	O
effect	O
of	O
nicotine	B-Chemical
on	O
caffeine	B-Chemical
-	O
induced	O
anxiety	B-Disease
is	O
specific	O
to	O
caffeine	B-Chemical
,	O
instead	O
of	O
a	O
non	O
-	O
specific	O
anxiolytic	O
effect	O
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
it	O
may	O
extend	O
the	O
current	O
findings	O
on	O
the	O
interaction	O
between	O
nicotine	B-Chemical
and	O
caffeine	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
influence	O
of	O
the	O
time	O
interval	O
between	O
monoHER	B-Chemical
and	O
doxorubicin	B-Chemical
administration	O
on	O
the	O
protection	O
against	O
doxorubicin	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
Despite	O
its	O
well	O
-	O
known	O
cardiotoxicity	B-Disease
,	O
the	O
anthracyclin	B-Chemical
doxorubicin	B-Chemical
(	O
DOX	B-Chemical
)	O
continues	O
to	O
be	O
an	O
effective	O
and	O
widely	O
used	O
chemotherapeutic	O
agent	O
.	O
</ALL>	O

<ALL>	O
DOX	B-Chemical
-	O
induced	O
cardiac	B-Disease
damage	I-Disease
presumably	O
results	O
from	O
the	O
formation	O
of	O
free	O
radicals	O
by	O
DOX	B-Chemical
.	O
</ALL>	O

<ALL>	O
Reactive	O
oxygen	B-Chemical
species	O
particularly	O
affect	O
the	O
cardiac	O
myocytes	O
because	O
these	O
cells	O
seem	O
to	O
have	O
a	O
relatively	O
poor	O
antioxidant	O
defense	O
system	O
.	O
</ALL>	O

<ALL>	O
The	O
semisynthetic	O
flavonoid	B-Chemical
monohydroxyethylrutoside	B-Chemical
(	O
monoHER	B-Chemical
)	O
showed	O
cardioprotection	O
against	O
DOX	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
through	O
its	O
radical	O
scavenging	O
and	O
iron	B-Chemical
chelating	O
properties	O
.	O
</ALL>	O

<ALL>	O
Because	O
of	O
the	O
relatively	O
short	O
final	O
half	O
-	O
life	O
of	O
monoHER	B-Chemical
(	O
about	O
30	O
min	O
)	O
,	O
it	O
is	O
expected	O
that	O
the	O
time	O
interval	O
between	O
monoHER	B-Chemical
and	O
DOX	B-Chemical
might	O
be	O
of	O
influence	O
on	O
the	O
cardioprotective	O
effect	O
of	O
monoHER	B-Chemical
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
this	O
possible	O
effect	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Six	O
groups	O
of	O
6	O
BALB	O
/	O
c	O
mice	B-Species
were	O
treated	O
with	O
saline	O
,	O
DOX	B-Chemical
alone	O
or	O
DOX	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
</ALL>	O

<ALL>	O
preceded	O
by	O
monoHER	B-Chemical
(	O
500	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
</ALL>	O

<ALL>	O
with	O
an	O
interval	O
of	O
10	O
,	O
30	O
,	O
60	O
or	O
120	O
min	O
.	O
</ALL>	O

<ALL>	O
After	O
a	O
6	O
-	O
week	O
treatment	O
period	O
and	O
additional	O
observation	O
for	O
2	O
weeks	O
,	O
the	O
mice	B-Species
were	O
sacrificed	O
.	O
</ALL>	O

<ALL>	O
Their	O
cardiac	O
tissues	O
were	O
processed	O
for	O
light	O
microscopy	O
,	O
after	O
which	O
cardiomyocyte	B-Disease
damage	I-Disease
was	O
evaluated	O
according	O
to	O
Billingham	O
(	O
in	O
Cancer	O
Treat	O
Rep	O
62	O
(	O
6	O
)	O
:	O
865	O
-	O
872	O
,	O
1978	O
)	O
.	O
</ALL>	O

<ALL>	O
Microscopic	O
evaluation	O
revealed	O
that	O
treatment	O
with	O
DOX	B-Chemical
alone	O
induced	O
significant	O
cardiac	B-Disease
damage	I-Disease
in	O
comparison	O
to	O
the	O
saline	O
control	O
group	O
(	O
P	O
<	O
0.001	O
)	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
number	O
of	O
damaged	O
cardiomyocytes	O
was	O
9.6	O
-	O
fold	O
(	O
95	O
%	O
CI	O
4.4	O
-	O
21.0	O
)	O
higher	O
in	O
mice	B-Species
treated	O
with	O
DOX	B-Chemical
alone	O
than	O
that	O
in	O
animals	O
of	O
the	O
control	O
group	O
.	O
</ALL>	O

<ALL>	O
The	O
ratio	O
of	O
aberrant	O
cardiomyocytes	O
in	O
mice	B-Species
treated	O
with	O
DOX	B-Chemical
preceded	O
by	O
monoHER	B-Chemical
and	O
those	O
in	O
mice	B-Species
treated	O
with	O
saline	O
ranged	O
from	O
1.6	O
to	O
2.8	O
(	O
mean	O
2.2	O
,	O
95	O
%	O
CI	O
1.2	O
-	O
4.1	O
,	O
P	O
=	O
0.019	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
mean	O
protective	O
effect	O
by	O
adding	O
monoHER	B-Chemical
before	O
DOX	B-Chemical
led	O
to	O
a	O
significant	O
4.4	O
-	O
fold	O
reduction	O
(	O
P	O
<	O
0.001	O
,	O
95	O
%	O
CI	O
2.3	O
-	O
8.2	O
)	O
of	O
abnormal	O
cardiomyocytes	O
.	O
</ALL>	O

<ALL>	O
This	O
protective	O
effect	O
did	O
not	O
depend	O
on	O
the	O
time	O
interval	O
between	O
monoHER	B-Chemical
and	O
DOX	B-Chemical
administration	O
(	O
P	O
=	O
0.345	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
The	O
results	O
indicate	O
that	O
in	O
an	O
outpatient	B-Species
clinical	O
setting	O
monoHER	B-Chemical
may	O
be	O
administered	O
shortly	O
before	O
DOX	B-Chemical
.	O
</ALL>	O

<ALL>	O
Pharmacokinetics	O
of	O
desipramine	B-Chemical
HCl	I-Chemical
when	O
administered	O
with	O
cinacalcet	B-Chemical
HCl	I-Chemical
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
In	O
vitro	O
work	O
has	O
demonstrated	O
that	O
cinacalcet	B-Chemical
is	O
a	O
strong	O
inhibitor	O
of	O
cytochrome	B-Gene
P450	I-Gene
isoenzyme	I-Gene
(	I-Gene
CYP	I-Gene
)	I-Gene
2D6	I-Gene
.	O
</ALL>	O

<ALL>	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
cinacalcet	B-Chemical
on	O
CYP2D6	B-Gene
activity	O
,	O
using	O
desipramine	B-Chemical
as	O
a	O
probe	O
substrate	O
,	O
in	O
healthy	O
subjects	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Seventeen	O
subjects	O
who	O
were	O
genotyped	O
as	O
CYP2D6	B-Gene
extensive	O
metabolizers	O
were	O
enrolled	O
in	O
this	O
randomized	O
,	O
open	O
-	O
label	O
,	O
crossover	O
study	O
to	O
receive	O
a	O
single	O
oral	O
dose	O
of	O
desipramine	B-Chemical
(	O
50	O
mg	O
)	O
on	O
two	O
separate	O
occasions	O
,	O
once	O
alone	O
and	O
once	O
after	O
multiple	O
doses	O
of	O
cinacalcet	B-Chemical
(	O
90	O
mg	O
for	O
7	O
days	O
)	O
.	O
</ALL>	O

<ALL>	O
Blood	O
samples	O
were	O
obtained	O
predose	O
and	O
up	O
to	O
72	O
h	O
postdose	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Fourteen	O
subjects	O
completed	O
both	O
treatment	O
arms	O
.	O
</ALL>	O

<ALL>	O
Relative	O
to	O
desipramine	B-Chemical
alone	O
,	O
mean	O
AUC	O
and	O
C	O
(	O
max	O
)	O
of	O
desipramine	B-Chemical
increased	O
3.6	O
-	O
and	O
1.8	O
-	O
fold	O
when	O
coadministered	O
with	O
cinacalcet	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
t	O
(	O
1	O
/	O
2,z	O
)	O
of	O
desipramine	B-Chemical
was	O
longer	O
when	O
desipramine	B-Chemical
was	O
coadministered	O
with	O
cinacalcet	B-Chemical
(	O
21.0	O
versus	O
43.3	O
hs	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
t	O
(	O
max	O
)	O
was	O
similar	O
between	O
the	O
regimens	O
.	O
</ALL>	O

<ALL>	O
Fewer	O
subjects	O
reported	O
adverse	O
events	O
following	O
treatment	O
with	O
desipramine	B-Chemical
alone	O
than	O
when	O
receiving	O
desipramine	B-Chemical
with	O
cinacalcet	B-Chemical
(	O
33	O
versus	O
86	O
%	O
)	O
,	O
the	O
most	O
frequent	O
of	O
which	O
(	O
nausea	B-Disease
and	O
headache	B-Disease
)	O
have	O
been	O
reported	O
for	O
patients	B-Species
treated	O
with	O
either	O
desipramine	B-Chemical
or	O
cinacalcet	B-Chemical
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
This	O
study	O
demonstrates	O
that	O
cinacalcet	B-Chemical
is	O
a	O
strong	O
inhibitor	O
of	O
CYP2D6	B-Gene
.	O
</ALL>	O

<ALL>	O
These	O
data	O
suggest	O
that	O
during	O
concomitant	O
treatment	O
with	O
cinacalcet	B-Chemical
,	O
dose	O
adjustment	O
may	O
be	O
necessary	O
for	O
drugs	O
that	O
demonstrate	O
a	O
narrow	O
therapeutic	O
index	O
and	O
are	O
metabolized	O
by	O
CYP2D6	B-Gene
.	O
</ALL>	O

<ALL>	O
Antipsychotic	B-Chemical
-	O
like	O
profile	O
of	O
thioperamide	B-Chemical
,	O
a	O
selective	O
H3	B-Gene
-	I-Gene
receptor	I-Gene
antagonist	O
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Experimental	O
and	O
clinical	O
evidence	O
points	O
to	O
a	O
role	O
of	O
central	O
histaminergic	O
system	O
in	O
the	O
pathogenesis	O
of	O
schizophrenia	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
present	O
study	O
was	O
designed	O
to	O
study	O
the	O
effect	O
of	O
histamine	B-Gene
H	I-Gene
(	I-Gene
3	I-Gene
)	I-Gene
-	I-Gene
receptor	I-Gene
ligands	O
on	O
neuroleptic	B-Chemical
-	O
induced	O
catalepsy	B-Disease
,	O
apomorphine	B-Chemical
-	O
induced	O
climbing	O
behavior	O
and	O
amphetamine	B-Chemical
-	O
induced	O
locomotor	O
activities	O
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Catalepsy	B-Disease
was	O
induced	O
by	O
haloperidol	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
p.o	O
.	O
)	O
,	O
</ALL>	O

<ALL>	O
while	O
apomorphine	B-Chemical
(	O
1.5	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
</ALL>	O

<ALL>	O
and	O
amphetamine	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
</ALL>	O

<ALL>	O
were	O
used	O
for	O
studying	O
climbing	O
behavior	O
and	O
locomotor	O
activities	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
(	B-Chemical
R	I-Chemical
)	I-Chemical
-	I-Chemical
alpha	I-Chemical
-	I-Chemical
methylhistamine	I-Chemical
(	O
RAMH	B-Chemical
)	O
(	O
5	O
microg	O
i.c.v	O
.	O
)	O
</ALL>	O

<ALL>	O
and	O
thioperamide	B-Chemical
(	O
THP	B-Chemical
)	O
(	O
15	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
,	O
</ALL>	O

<ALL>	O
per	O
se	O
did	O
not	O
cause	O
catalepsy	B-Disease
.	O
</ALL>	O

<ALL>	O
Administration	O
of	O
THP	B-Chemical
(	O
3.75	O
,	O
7.5	O
and	O
15	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
</ALL>	O

<ALL>	O
1	O
h	O
prior	O
to	O
haloperidol	B-Chemical
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
the	O
catalepsy	B-Disease
times	O
(	O
P	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
pretreatment	O
with	O
RAMH	B-Chemical
significantly	O
reversed	O
such	O
an	O
effect	O
of	O
THP	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
.	O
</ALL>	O

<ALL>	O
RAMH	B-Chemical
per	O
se	O
showed	O
significant	O
reduction	O
in	O
locomotor	O
time	O
,	O
distance	O
traveled	O
and	O
average	O
speed	O
but	O
THP	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
</ALL>	O

<ALL>	O
per	O
se	O
had	O
no	O
effect	O
on	O
these	O
parameters	O
.	O
</ALL>	O

<ALL>	O
On	O
amphetamine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
,	O
THP	B-Chemical
(	O
3.75	O
and	O
7.5	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
</ALL>	O

<ALL>	O
reduced	O
locomotor	O
time	O
,	O
distance	O
traveled	O
and	O
average	O
speed	O
(	O
P	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
Pretreatment	O
with	O
RAMH	B-Chemical
(	O
5	O
microg	O
i.c.v	O
.	O
)	O
</ALL>	O

<ALL>	O
could	O
partially	O
reverse	O
such	O
effects	O
of	O
THP	B-Chemical
(	O
3.75	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
.	O
</ALL>	O

<ALL>	O
Climbing	O
behavior	O
induced	O
by	O
apomorphine	B-Chemical
was	O
reduced	O
in	O
animals	O
treated	O
with	O
THP	B-Chemical
.	O
</ALL>	O

<ALL>	O
Such	O
an	O
effect	O
was	O
,	O
however	O
,	O
reversed	O
in	O
presence	O
of	O
RAMH	B-Chemical
.	O
</ALL>	O

<ALL>	O
THP	B-Chemical
exhibited	O
an	O
antipsychotic	B-Chemical
-	O
like	O
profile	O
by	O
potentiating	O
haloperidol	B-Chemical
-	O
induced	O
catalepsy	B-Disease
,	O
reducing	O
amphetamine	B-Chemical
-	O
induced	O
hyperactivity	B-Disease
and	O
reducing	O
apomorphine	B-Chemical
-	O
induced	O
climbing	O
in	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Such	O
effects	O
of	O
THP	B-Chemical
were	O
reversed	O
by	O
RAMH	B-Chemical
indicating	O
the	O
involvement	O
of	O
histamine	B-Gene
H	I-Gene
(	I-Gene
3	I-Gene
)	I-Gene
-	I-Gene
receptors	I-Gene
.	O
</ALL>	O

<ALL>	O
Findings	O
suggest	O
a	O
potential	O
for	O
H	B-Chemical
(	I-Chemical
3	I-Chemical
)	I-Chemical
-	I-Chemical
receptor	I-Chemical
antagonists	I-Chemical
in	O
improving	O
the	O
refractory	O
cases	O
of	O
schizophrenia	B-Disease
.	O
</ALL>	O

<ALL>	O
Placebo	O
-	O
level	O
incidence	O
of	O
extrapyramidal	B-Disease
symptoms	I-Disease
(	O
EPS	B-Disease
)	O
with	O
quetiapine	B-Chemical
in	O
controlled	O
studies	O
of	O
patients	B-Species
with	O
bipolar	B-Disease
mania	I-Disease
.	O
</ALL>	O

<ALL>	O
OBJECTIVES	O
:	O
To	O
evaluate	O
extrapyramidal	B-Disease
symptoms	I-Disease
(	O
EPS	B-Disease
)	O
,	O
including	O
akathisia	B-Disease
,	O
with	O
quetiapine	B-Chemical
in	O
patients	B-Species
with	O
bipolar	B-Disease
mania	I-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Data	O
were	O
analyzed	O
from	O
four	O
similarly	O
designed	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
3	O
-	O
to	O
12	O
-	O
week	O
studies	O
.	O
</ALL>	O

<ALL>	O
Two	O
studies	O
evaluated	O
quetiapine	B-Chemical
monotherapy	O
(	O
up	O
to	O
800	O
mg	O
/	O
day	O
)	O
(	O
n	O
=	O
209	O
)	O
versus	O
placebo	O
(	O
n	O
=	O
198	O
)	O
,	O
with	O
lithium	B-Chemical
or	O
haloperidol	B-Chemical
monotherapy	O
as	O
respective	O
active	O
controls	O
.	O
</ALL>	O

<ALL>	O
Two	O
studies	O
evaluated	O
quetiapine	B-Chemical
(	O
up	O
to	O
800	O
mg	O
/	O
day	O
)	O
in	O
combination	O
with	O
a	O
mood	O
stabilizer	O
(	O
lithium	B-Chemical
or	O
divalproex	B-Chemical
,	O
QTP	B-Chemical
+	O
Li	B-Chemical
/	O
DVP	B-Chemical
)	O
(	O
n	O
=	O
196	O
)	O
compared	O
to	O
placebo	O
and	O
mood	O
stabilizer	O
(	O
PBO	O
+	O
Li	B-Chemical
/	O
DVP	B-Chemical
)	O
(	O
n	O
=	O
203	O
)	O
.	O
</ALL>	O

<ALL>	O
Extrapyramidal	B-Disease
symptoms	I-Disease
were	O
evaluated	O
using	O
the	O
Simpson	O
-	O
Angus	O
Scale	O
(	O
SAS	O
)	O
,	O
the	O
Barnes	O
Akathisia	O
Rating	O
Scale	O
(	O
BARS	O
)	O
,	O
adverse	O
event	O
reports	O
and	O
anticholinergic	B-Chemical
drug	I-Chemical
usage	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
incidence	O
of	O
EPS	B-Disease
-	O
related	O
adverse	O
events	O
,	O
including	O
akathisia	B-Disease
,	O
was	O
no	O
different	O
with	O
quetiapine	B-Chemical
monotherapy	O
(	O
12.9	O
%	O
)	O
than	O
with	O
placebo	O
(	O
13.1	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
Similarly	O
,	O
EPS	B-Disease
-	O
related	O
adverse	O
events	O
with	O
QTP	B-Chemical
+	O
Li	B-Chemical
/	O
DVP	B-Chemical
(	O
21.4	O
%	O
)	O
were	O
no	O
different	O
than	O
with	O
PBO	O
+	O
Li	B-Chemical
/	O
DVP	B-Chemical
(	O
19.2	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
Adverse	O
events	O
related	O
to	O
EPS	B-Disease
occurred	O
in	O
59.6	O
%	O
of	O
patients	B-Species
treated	O
with	O
haloperidol	B-Chemical
(	O
n	O
=	O
99	O
)	O
monotherapy	O
,	O
whereas	O
26.5	O
%	O
of	O
patients	B-Species
treated	O
with	O
lithium	B-Chemical
(	O
n	O
=	O
98	O
)	O
monotherapy	O
experienced	O
adverse	O
events	O
related	O
to	O
EPS	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
incidence	O
of	O
akathisia	B-Disease
was	O
low	O
and	O
similar	O
with	O
quetiapine	B-Chemical
monotherapy	O
(	O
3.3	O
%	O
)	O
and	O
placebo	O
(	O
6.1	O
%	O
)	O
,	O
and	O
with	O
QTP	B-Chemical
+	O
Li	B-Chemical
/	O
DVP	B-Chemical
(	O
3.6	O
%	O
)	O
and	O
PBO	O
+	O
Li	B-Chemical
/	O
DVP	B-Chemical
(	O
4.9	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
Lithium	B-Chemical
was	O
associated	O
with	O
a	O
significantly	O
higher	O
incidence	O
(	O
p	O
<	O
0.05	O
)	O
of	O
tremor	B-Disease
(	O
18.4	O
%	O
)	O
than	O
quetiapine	B-Chemical
(	O
5.6	O
%	O
)	O
;	O
cerebellar	O
tremor	B-Disease
,	O
which	O
is	O
a	O
known	O
adverse	O
effect	O
of	O
lithium	B-Chemical
,	O
may	O
have	O
contributed	O
to	O
the	O
elevated	O
rate	O
of	O
tremor	B-Disease
in	O
patients	B-Species
receiving	O
lithium	B-Chemical
therapy	O
.	O
</ALL>	O

<ALL>	O
Haloperidol	B-Chemical
induced	O
a	O
significantly	O
higher	O
incidence	O
(	O
p	O
<	O
0.001	O
)	O
of	O
akathisia	B-Disease
(	O
33.3	O
%	O
versus	O
5.9	O
%	O
)	O
,	O
tremor	B-Disease
(	O
30.3	O
%	O
versus	O
7.8	O
%	O
)	O
,	O
and	O
extrapyramidal	B-Disease
syndrome	I-Disease
(	O
35.4	O
%	O
versus	O
5.9	O
%	O
)	O
than	O
quetiapine	B-Chemical
.	O
</ALL>	O

<ALL>	O
No	O
significant	O
differences	O
were	O
observed	O
between	O
quetiapine	B-Chemical
and	O
placebo	O
on	O
SAS	O
and	O
BARS	O
scores	O
.	O
</ALL>	O

<ALL>	O
Anticholinergic	B-Chemical
use	O
was	O
low	O
and	O
similar	O
with	O
quetiapine	B-Chemical
or	O
placebo	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
In	O
bipolar	B-Disease
mania	I-Disease
,	O
the	O
incidence	O
of	O
EPS	B-Disease
,	O
including	O
akathisia	B-Disease
,	O
with	O
quetiapine	B-Chemical
therapy	O
is	O
similar	O
to	O
that	O
with	O
placebo	O
.	O
</ALL>	O

<ALL>	O
Randomized	O
comparison	O
of	O
olanzapine	B-Chemical
versus	O
risperidone	B-Chemical
for	O
the	O
treatment	O
of	O
first	O
-	O
episode	O
schizophrenia	B-Disease
:	O
4	O
-	O
month	O
outcomes	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
The	O
authors	O
compared	O
4	O
-	O
month	O
treatment	O
outcomes	O
for	O
olanzapine	B-Chemical
versus	O
risperidone	B-Chemical
in	O
patients	B-Species
with	O
first	O
-	O
episode	O
schizophrenia	B-Disease
spectrum	O
disorders	O
.	O
</ALL>	O

<ALL>	O
METHOD	O
:	O
One	O
hundred	O
twelve	O
subjects	O
(	O
70	O
%	O
male	O
;	O
mean	O
age	O
=	O
23.3	O
years	O
[	O
SD	O
=	O
5.1	O
]	O
)	O
with	O
first	O
-	O
episode	O
schizophrenia	B-Disease
(	O
75	O
%	O
)	O
,	O
schizophreniform	B-Disease
disorder	I-Disease
(	O
17	O
%	O
)	O
,	O
or	O
schizoaffective	B-Disease
disorder	I-Disease
(	O
8	O
%	O
)	O
were	O
randomly	O
assigned	O
to	O
treatment	O
with	O
olanzapine	B-Chemical
(	O
2.5	O
-	O
20	O
mg	O
/	O
day	O
)	O
or	O
risperidone	B-Chemical
(	O
1	O
-	O
6	O
mg	O
/	O
day	O
)	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Response	O
rates	O
did	O
not	O
significantly	O
differ	O
between	O
olanzapine	B-Chemical
(	O
43.7	O
%	O
,	O
95	O
%	O
CI	O
=	O
28.8	O
%	O
-	O
58.6	O
%	O
)	O
and	O
risperidone	B-Chemical
(	O
54.3	O
%	O
,	O
95	O
%	O
CI	O
=	O
39.9	O
%	O
-	O
68.7	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
Among	O
those	O
responding	O
to	O
treatment	O
,	O
more	O
subjects	O
in	O
the	O
olanzapine	B-Chemical
group	O
(	O
40.9	O
%	O
,	O
95	O
%	O
CI	O
=	O
16.8	O
%	O
-	O
65.0	O
%	O
)	O
than	O
in	O
the	O
risperidone	B-Chemical
group	O
(	O
18.9	O
%	O
,	O
95	O
%	O
CI	O
=	O
0	O
%	O
-	O
39.2	O
%	O
)	O
had	O
subsequent	O
ratings	O
not	O
meeting	O
response	O
criteria	O
.	O
</ALL>	O

<ALL>	O
Negative	O
symptom	O
outcomes	O
and	O
measures	O
of	O
parkinsonism	B-Disease
and	O
akathisia	B-Disease
did	O
not	O
differ	O
between	O
medications	O
.	O
</ALL>	O

<ALL>	O
Extrapyramidal	B-Disease
symptom	I-Disease
severity	O
scores	O
were	O
1.4	O
(	O
95	O
%	O
CI	O
=	O
1.2	O
-	O
1.6	O
)	O
with	O
risperidone	B-Chemical
and	O
1.2	O
(	O
95	O
%	O
CI	O
=	O
1.0	O
-	O
1.4	O
)	O
with	O
olanzapine	B-Chemical
.	O
</ALL>	O

<ALL>	O
Significantly	O
more	O
weight	B-Disease
gain	I-Disease
occurred	O
with	O
olanzapine	B-Chemical
than	O
with	O
risperidone	B-Chemical
:	O
the	O
increase	O
in	O
weight	O
at	O
4	O
months	O
relative	O
to	O
baseline	O
weight	O
was	O
17.3	O
%	O
(	O
95	O
%	O
CI	O
=	O
14.2	O
%	O
-	O
20.5	O
%	O
)	O
with	O
olanzapine	B-Chemical
and	O
11.3	O
%	O
(	O
95	O
%	O
CI	O
=	O
8.4	O
%	O
-	O
14.3	O
%	O
)	O
with	O
risperidone	B-Chemical
.	O
</ALL>	O

<ALL>	O
Body	O
mass	O
index	O
at	O
baseline	O
and	O
at	O
4	O
months	O
was	O
24.3	O
(	O
95	O
%	O
CI	O
=	O
22.8	O
-	O
25.7	O
)	O
versus	O
28.2	O
(	O
95	O
%	O
CI	O
=	O
26.7	O
-	O
29.7	O
)	O
with	O
olanzapine	B-Chemical
and	O
23.9	O
(	O
95	O
%	O
CI	O
=	O
22.5	O
-	O
25.3	O
)	O
versus	O
26.7	O
(	O
95	O
%	O
CI	O
=	O
25.2	O
-	O
28.2	O
)	O
with	O
risperidone	B-Chemical
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
Clinical	O
outcomes	O
with	O
risperidone	B-Chemical
were	O
equal	O
to	O
those	O
with	O
olanzapine	B-Chemical
,	O
and	O
response	O
may	O
be	O
more	O
stable	O
.	O
</ALL>	O

<ALL>	O
Olanzapine	B-Chemical
may	O
have	O
an	O
advantage	O
for	O
motor	O
side	O
effects	O
.	O
</ALL>	O

<ALL>	O
Both	O
medications	O
caused	O
substantial	O
rapid	O
weight	B-Disease
gain	I-Disease
,	O
but	O
weight	B-Disease
gain	I-Disease
was	O
greater	O
with	O
olanzapine	B-Chemical
.	O
</ALL>	O

<ALL>	O
Risks	O
and	O
benefits	O
of	O
COX	B-Chemical
-	I-Chemical
2	I-Chemical
inhibitors	I-Chemical
vs	O
non	O
-	O
selective	O
NSAIDs	B-Chemical
:	O
does	O
their	O
cardiovascular	O
risk	O
exceed	O
their	O
gastrointestinal	O
benefit	O
?	O
</ALL>	O

<ALL>	O
A	O
retrospective	O
cohort	O
study	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVES	O
:	O
The	O
risk	O
of	O
acute	B-Disease
myocardial	I-Disease
infarction	I-Disease
(	O
AMI	B-Disease
)	O
with	O
COX	B-Chemical
-	I-Chemical
2	I-Chemical
inhibitors	I-Chemical
may	O
offset	O
their	O
gastrointestinal	O
(	O
GI	O
)	O
benefit	O
compared	O
with	O
non	O
-	O
selective	O
(	O
NS	O
)	O
non	B-Chemical
-	I-Chemical
steroidal	I-Chemical
anti	I-Chemical
-	I-Chemical
inflammatory	I-Chemical
drugs	I-Chemical
(	O
NSAIDs	B-Chemical
)	O
.	O
</ALL>	O

<ALL>	O
We	O
aimed	O
to	O
compare	O
the	O
risks	O
of	O
hospitalization	O
for	O
AMI	B-Disease
and	O
GI	B-Disease
bleeding	I-Disease
among	O
elderly	O
patients	B-Species
using	O
COX	B-Chemical
-	I-Chemical
2	I-Chemical
inhibitors	I-Chemical
,	O
NS	O
-	O
NSAIDs	B-Chemical
and	O
acetaminophen	B-Chemical
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
cohort	O
study	O
using	O
administrative	O
data	O
of	O
patients	B-Species
>	O
or	O
=	O
65	O
years	O
of	O
age	O
who	O
filled	O
a	O
prescription	O
for	O
NSAID	B-Chemical
or	O
acetaminophen	B-Chemical
during	O
1999	O
-	O
2002	O
.	O
</ALL>	O

<ALL>	O
Outcomes	O
were	O
compared	O
using	O
Cox	O
regression	O
models	O
with	O
time	O
-	O
dependent	O
exposures	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Person	O
-	O
years	O
of	O
exposure	O
among	O
non	O
-	O
users	O
of	O
aspirin	B-Chemical
were	O
:	O
75,761	O
to	O
acetaminophen	B-Chemical
,	O
42,671	O
to	O
rofecoxib	B-Chemical
65,860	O
to	O
celecoxib	B-Chemical
,	O
and	O
37,495	O
to	O
NS	O
-	O
NSAIDs	B-Chemical
.	O
</ALL>	O

<ALL>	O
Among	O
users	O
of	O
aspirin	B-Chemical
,	O
they	O
were	O
:	O
14,671	O
to	O
rofecoxib	B-Chemical
,	O
22,875	O
to	O
celecoxib	B-Chemical
,	O
9,832	O
to	O
NS	O
-	O
NSAIDs	B-Chemical
and	O
38,048	O
to	O
acetaminophen	B-Chemical
.	O
</ALL>	O

<ALL>	O
Among	O
non	O
-	O
users	O
of	O
aspirin	B-Chemical
,	O
the	O
adjusted	O
hazard	O
ratios	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
of	O
hospitalization	O
for	O
AMI	B-Disease
/	O
GI	O
vs	O
the	O
acetaminophen	B-Chemical
(	O
with	O
no	O
aspirin	B-Chemical
)	O
group	O
were	O
:	O
rofecoxib	B-Chemical
1.27	O
(	O
1.13	O
,	O
1.42	O
)	O
,	O
celecoxib	B-Chemical
0.93	O
(	O
0.83	O
,	O
1.03	O
)	O
,	O
naproxen	B-Chemical
1.59	O
(	O
1.31	O
,	O
1.93	O
)	O
,	O
diclofenac	B-Chemical
1.17	O
(	O
0.99	O
,	O
1.38	O
)	O
and	O
ibuprofen	B-Chemical
1.05	O
(	O
0.74	O
,	O
1.51	O
)	O
.	O
</ALL>	O

<ALL>	O
Among	O
users	O
of	O
aspirin	B-Chemical
,	O
they	O
were	O
:	O
rofecoxib	B-Chemical
1.73	O
(	O
1.52	O
,	O
1.98	O
)	O
,	O
celecoxib	B-Chemical
1.34	O
(	O
1.19	O
,	O
1.52	O
)	O
,	O
ibuprofen	B-Chemical
1.51	O
(	O
0.95	O
,	O
2.41	O
)	O
,	O
diclofenac	B-Chemical
1.69	O
(	O
1.35	O
,	O
2.10	O
)	O
,	O
naproxen	B-Chemical
1.35	O
(	O
0.97	O
,	O
1.88	O
)	O
and	O
acetaminophen	B-Chemical
1.29	O
(	O
1.17	O
,	O
1.42	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
Among	O
non	O
-	O
users	O
of	O
aspirin	B-Chemical
,	O
naproxen	B-Chemical
seemed	O
to	O
carry	O
the	O
highest	O
risk	O
for	O
AMI	B-Disease
/	O
GI	B-Disease
bleeding	I-Disease
.	O
</ALL>	O

<ALL>	O
The	O
AMI	B-Disease
/	O
GI	B-Disease
toxicity	I-Disease
of	O
celecoxib	B-Chemical
was	O
similar	O
to	O
that	O
of	O
acetaminophen	B-Chemical
and	O
seemed	O
to	O
be	O
better	O
than	O
those	O
of	O
rofecoxib	B-Chemical
and	O
NS	O
-	O
NSAIDs	B-Chemical
.	O
</ALL>	O

<ALL>	O
Among	O
users	O
of	O
aspirin	B-Chemical
,	O
both	O
celecoxib	B-Chemical
and	O
naproxen	B-Chemical
seemed	O
to	O
be	O
the	O
least	O
toxic	O
.	O
</ALL>	O

<ALL>	O
Quinine	B-Chemical
-	O
induced	O
arrhythmia	B-Disease
in	O
a	O
patient	B-Species
with	O
severe	B-Disease
malaria	I-Disease
.	O
</ALL>	O

<ALL>	O
It	O
was	O
reported	O
that	O
there	O
was	O
a	O
case	O
of	O
severe	B-Disease
malaria	I-Disease
patient	B-Species
with	O
jaundice	B-Disease
who	O
presented	O
with	O
arrhythmia	B-Disease
(	O
premature	B-Disease
ventricular	I-Disease
contraction	I-Disease
)	O
while	O
getting	O
quinine	B-Chemical
infusion	O
was	O
reported	O
.	O
</ALL>	O

<ALL>	O
A	O
man	B-Species
,	O
25	O
years	O
old	O
,	O
was	O
admitted	O
to	O
hospital	O
with	O
high	O
fever	B-Disease
,	O
chill	B-Disease
,	O
vomiting	B-Disease
,	O
jaundice	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
patient	B-Species
was	O
fully	O
conscious	O
,	O
blood	O
pressure	O
120	O
/	O
80	O
mmHg	O
,	O
pulse	O
rate	O
100	O
x	O
/	O
minute	O
,	O
regular	O
.	O
</ALL>	O

<ALL>	O
On	O
admission	O
,	O
laboratory	O
examination	O
showed	O
Plasmodium	B-Species
falciparum	I-Species
(	O
+	O
+	O
+	O
+	O
)	O
,	O
total	O
bilirubin	B-Chemical
8.25	O
mg	O
/	O
dL	O
,	O
conjugated	O
bilirubin	B-Chemical
4.36	O
mg	O
/	O
dL	O
,	O
unconjugated	O
bilirubin	B-Chemical
3.89	O
mg	O
/	O
dL	O
,	O
potassium	B-Chemical
3.52	O
meq	O
/	O
L	O
Patient	B-Species
was	O
diagnosed	O
as	O
severe	B-Disease
malaria	I-Disease
with	O
jaundice	B-Disease
and	O
got	O
quinine	B-Chemical
infusion	O
in	O
dextrose	B-Chemical
5	O
%	O
500	O
mg	O
/	O
8	O
hour	O
.	O
</ALL>	O

<ALL>	O
On	O
the	O
second	O
day	O
the	O
patient	B-Species
had	O
vomitus	B-Disease
,	O
diarrhea	B-Disease
,	O
tinnitus	B-Disease
,	O
loss	B-Disease
of	I-Disease
hearing	I-Disease
.	O
</ALL>	O

<ALL>	O
After	O
30	O
hours	O
of	O
quinine	B-Chemical
infusion	O
the	O
patient	B-Species
felt	O
palpitation	B-Disease
and	O
electrocardiography	O
(	O
ECG	O
)	O
recording	O
showed	O
premature	B-Disease
ventricular	I-Disease
contraction	I-Disease
(	O
PVC	B-Disease
)	O
>	O
5	O
x	O
/	O
minute	O
,	O
trigemini	O
,	O
constant	O
type	O
-	O
-	O
sinoatrial	B-Disease
block	I-Disease
,	O
positive	O
U	O
wave	O
.	O
</ALL>	O

<ALL>	O
He	O
was	O
treated	O
with	O
lidocaine	B-Chemical
50	O
mg	O
intravenously	O
followed	O
by	O
infusion	O
1500	O
mg	O
in	O
dextrose	B-Chemical
5	O
%	O
/	O
24	O
hour	O
and	O
potassium	B-Chemical
aspartate	I-Chemical
tablet	O
.	O
</ALL>	O

<ALL>	O
Quinine	B-Chemical
infusion	O
was	O
discontinued	O
and	O
changed	O
with	O
sulfate	O
quinine	B-Chemical
tablets	O
.	O
</ALL>	O

<ALL>	O
Three	O
hours	O
later	O
the	O
patient	B-Species
felt	O
better	O
,	O
the	O
frequency	O
of	O
PVC	B-Disease
reduced	O
to	O
4	O
-	O
5	O
x	O
/	O
minute	O
and	O
on	O
the	O
third	O
day	O
ECG	O
was	O
normal	O
,	O
potassium	B-Chemical
level	O
was	O
3.34	O
meq	O
/	O
L.	O
He	O
was	O
discharged	O
on	O
7th	O
day	O
in	O
good	O
condition	O
.	O
</ALL>	O

<ALL>	O
Quinine	B-Chemical
,	O
like	O
quinidine	B-Chemical
,	O
is	O
a	O
chincona	B-Chemical
alkaloid	I-Chemical
that	O
has	O
anti	O
-	O
arrhythmic	B-Disease
property	O
,	O
although	O
it	O
also	O
pro	O
-	O
arrhythmic	B-Disease
that	O
can	O
cause	O
various	O
arrhythmias	B-Disease
,	O
including	O
severe	O
arrhythmia	B-Disease
such	O
as	O
multiple	O
PVC	B-Disease
.	O
</ALL>	O

<ALL>	O
Administration	O
of	O
parenteral	O
quinine	B-Chemical
must	O
be	O
done	O
carefully	O
and	O
with	O
good	O
observation	O
because	O
of	O
its	O
pro	O
-	O
arrhythmic	B-Disease
effect	O
,	O
especially	O
in	O
older	O
patients	B-Species
who	O
have	O
heart	B-Disease
diseases	I-Disease
or	O
patients	B-Species
with	O
electrolyte	B-Disease
disorder	I-Disease
(	O
hypokalemia	B-Disease
)	O
which	O
frequently	O
occurs	O
due	O
to	O
vomiting	B-Disease
and	O
or	O
diarrhea	B-Disease
in	O
malaria	B-Disease
cases	O
.	O
</ALL>	O

<ALL>	O
Succimer	B-Chemical
chelation	O
improves	O
learning	O
,	O
attention	O
,	O
and	O
arousal	O
regulation	O
in	O
lead	B-Chemical
-	O
exposed	O
rats	B-Species
but	O
produces	O
lasting	O
cognitive	B-Disease
impairment	I-Disease
in	O
the	O
absence	O
of	O
lead	B-Chemical
exposure	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
There	O
is	O
growing	O
pressure	O
for	O
clinicians	O
to	O
prescribe	O
chelation	O
therapy	O
at	O
only	O
slightly	O
elevated	O
blood	O
lead	B-Chemical
levels	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
very	O
few	O
studies	O
have	O
evaluated	O
whether	O
chelation	O
improves	O
cognitive	O
outcomes	O
in	O
Pb	B-Chemical
-	O
exposed	O
children	O
,	O
or	O
whether	O
these	O
agents	O
have	O
adverse	O
effects	O
that	O
may	O
affect	O
brain	O
development	O
in	O
the	O
absence	O
of	O
Pb	B-Chemical
exposure	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVES	O
:	O
The	O
present	O
study	O
was	O
designed	O
to	O
answer	O
these	O
questions	O
,	O
using	O
a	O
rodent	O
model	O
of	O
early	O
childhood	O
Pb	B-Chemical
exposure	O
and	O
treatment	O
with	O
succimer	B-Chemical
,	O
a	O
widely	O
used	O
chelating	O
agent	O
for	O
the	O
treatment	O
of	O
Pb	B-Disease
poisoning	I-Disease
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Pb	B-Chemical
exposure	O
produced	O
lasting	O
impairments	B-Disease
in	I-Disease
learning	I-Disease
,	I-Disease
attention	I-Disease
,	I-Disease
inhibitory	I-Disease
control	I-Disease
,	I-Disease
and	I-Disease
arousal	I-Disease
regulation	I-Disease
,	O
paralleling	O
the	O
areas	O
of	O
dysfunction	O
seen	O
in	O
Pb	B-Chemical
-	O
exposed	O
children	O
.	O
</ALL>	O

<ALL>	O
Succimer	B-Chemical
treatment	O
of	O
the	O
Pb	B-Chemical
-	O
exposed	O
rats	B-Species
significantly	O
improved	O
learning	O
,	O
attention	O
,	O
and	O
arousal	O
regulation	O
,	O
although	O
the	O
efficacy	O
of	O
the	O
treatment	O
varied	O
as	O
a	O
function	O
of	O
the	O
Pb	B-Chemical
exposure	O
level	O
and	O
the	O
specific	O
functional	O
deficit	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
succimer	B-Chemical
treatment	O
of	O
rats	B-Species
not	O
previously	O
exposed	O
to	O
Pb	B-Chemical
produced	O
lasting	O
and	O
pervasive	O
cognitive	B-Disease
and	I-Disease
affective	I-Disease
dysfunction	I-Disease
comparable	O
in	O
magnitude	O
to	O
that	O
produced	O
by	O
the	O
higher	O
Pb	B-Chemical
exposure	O
regimen	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
These	O
are	O
the	O
first	O
data	O
,	O
to	O
our	O
knowledge	O
,	O
to	O
show	O
that	O
treatment	O
with	O
any	O
chelating	O
agent	O
can	O
alleviate	O
cognitive	B-Disease
deficits	I-Disease
due	O
to	O
Pb	B-Chemical
exposure	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
suggest	O
that	O
it	O
may	O
be	O
possible	O
to	O
identify	O
a	O
succimer	B-Chemical
treatment	O
protocol	O
that	O
improves	O
cognitive	O
outcomes	O
in	O
Pb	B-Chemical
-	O
exposed	O
children	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
they	O
also	O
suggest	O
that	O
succimer	B-Chemical
treatment	O
should	O
be	O
strongly	O
discouraged	O
for	O
children	O
who	O
do	O
not	O
have	O
elevated	O
tissue	O
levels	O
of	O
Pb	B-Chemical
or	O
other	O
heavy	O
metals	O
.	O
</ALL>	O

<ALL>	O
Attenuation	O
of	O
methamphetamine	B-Chemical
-	O
induced	O
nigrostriatal	O
dopaminergic	B-Chemical
neurotoxicity	B-Disease
in	O
mice	B-Species
by	O
lipopolysaccharide	B-Chemical
pretreatment	O
.	O
</ALL>	O

<ALL>	O
Immunological	O
activation	O
has	O
been	O
proposed	O
to	O
play	O
a	O
role	O
in	O
methamphetamine	B-Chemical
-	O
induced	O
dopaminergic	B-Disease
terminal	I-Disease
damage	I-Disease
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
roles	O
of	O
lipopolysaccharide	B-Chemical
,	O
a	O
pro	O
-	O
inflammatory	B-Disease
and	O
inflammatory	B-Disease
factor	O
,	O
treatment	O
in	O
modulating	O
the	O
methamphetamine	B-Chemical
-	O
induced	O
nigrostriatal	O
dopamine	B-Chemical
neurotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
Lipopolysaccharide	B-Chemical
pretreatment	O
did	O
not	O
affect	O
the	O
basal	O
body	O
temperature	O
or	O
methamphetamine	B-Chemical
-	O
elicited	O
hyperthermia	B-Disease
three	O
days	O
later	O
.	O
</ALL>	O

<ALL>	O
Such	O
systemic	O
lipopolysaccharide	B-Chemical
treatment	O
mitigated	O
methamphetamine	B-Chemical
-	O
induced	O
striatal	O
dopamine	B-Chemical
and	O
3,4	B-Chemical
-	I-Chemical
dihydroxyphenylacetic	I-Chemical
acid	I-Chemical
depletions	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
</ALL>	O

<ALL>	O
As	O
the	O
most	O
potent	O
dose	O
(	O
1	O
mg	O
/	O
kg	O
)	O
of	O
lipopolysaccharide	B-Chemical
was	O
administered	O
two	O
weeks	O
,	O
one	O
day	O
before	O
or	O
after	O
the	O
methamphetamine	B-Chemical
dosing	O
regimen	O
,	O
methamphetamine	B-Chemical
-	O
induced	O
striatal	O
dopamine	B-Chemical
and	O
3,4	B-Chemical
-	I-Chemical
dihydroxyphenylacetic	I-Chemical
acid	I-Chemical
depletions	O
remained	O
unaltered	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
systemic	O
lipopolysaccharide	B-Chemical
pretreatment	O
(	O
1	O
mg	O
/	O
kg	O
)	O
attenuated	O
local	O
methamphetamine	B-Chemical
infusion	O
-	O
produced	O
dopamine	B-Chemical
and	O
3,4	B-Chemical
-	I-Chemical
dihydroxyphenylacetic	I-Chemical
acid	I-Chemical
depletions	O
in	O
the	O
striatum	O
,	O
indicating	O
that	O
the	O
protective	O
effect	O
of	O
lipopolysaccharide	B-Chemical
is	O
less	O
likely	O
due	O
to	O
interrupted	O
peripheral	O
distribution	O
or	O
metabolism	O
of	O
methamphetamine	B-Chemical
.	O
</ALL>	O

<ALL>	O
We	O
concluded	O
a	O
critical	O
time	O
window	O
for	O
systemic	O
lipopolysaccharide	B-Chemical
pretreatment	O
in	O
exerting	O
effective	O
protection	O
against	O
methamphetamine	B-Chemical
-	O
induced	O
nigrostriatal	O
dopamine	B-Chemical
neurotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
Hypothalamic	O
prolactin	B-Gene
receptor	I-Gene
messenger	O
ribonucleic	B-Chemical
acid	I-Chemical
levels	O
,	O
prolactin	B-Gene
signaling	O
,	O
and	O
hyperprolactinemic	B-Disease
inhibition	O
of	O
pulsatile	O
luteinizing	B-Chemical
hormone	I-Chemical
secretion	O
are	O
dependent	O
on	O
estradiol	B-Chemical
.	O
</ALL>	O

<ALL>	O
Hyperprolactinemia	B-Disease
can	O
reduce	O
fertility	O
and	O
libido	O
.	O
</ALL>	O

<ALL>	O
Although	O
central	O
prolactin	B-Gene
actions	O
are	O
thought	O
to	O
contribute	O
to	O
this	O
,	O
the	O
mechanisms	O
are	O
poorly	O
understood	O
.	O
</ALL>	O

<ALL>	O
We	O
first	O
tested	O
whether	O
chronic	O
hyperprolactinemia	B-Disease
inhibited	O
two	O
neuroendocrine	O
parameters	O
necessary	O
for	O
female	O
fertility	O
:	O
pulsatile	O
LH	B-Chemical
secretion	O
and	O
the	O
estrogen	B-Chemical
-	O
induced	O
LH	B-Chemical
surge	O
.	O
</ALL>	O

<ALL>	O
Chronic	O
hyperprolactinemia	B-Disease
induced	O
by	O
the	O
dopamine	B-Chemical
antagonist	O
sulpiride	B-Chemical
caused	O
a	O
40	O
%	O
reduction	O
LH	B-Chemical
pulse	O
frequency	O
in	O
ovariectomized	O
rats	B-Species
,	O
but	O
only	O
in	O
the	O
presence	O
of	O
chronic	O
low	O
levels	O
of	O
estradiol	B-Chemical
.	O
</ALL>	O

<ALL>	O
Sulpiride	B-Chemical
did	O
not	O
affect	O
the	O
magnitude	O
of	O
a	O
steroid	B-Chemical
-	O
induced	O
LH	B-Chemical
surge	O
or	O
the	O
percentage	O
of	O
GnRH	O
neurons	O
activated	O
during	O
the	O
surge	O
.	O
</ALL>	O

<ALL>	O
Estradiol	B-Chemical
is	O
known	O
to	O
influence	O
expression	O
of	O
the	O
long	O
form	O
of	O
prolactin	B-Gene
receptors	I-Gene
(	O
PRL	B-Gene
-	I-Gene
R	I-Gene
)	O
and	O
components	O
of	O
prolactin	B-Gene
's	O
signaling	O
pathway	O
.	O
</ALL>	O

<ALL>	O
To	O
test	O
the	O
hypothesis	O
that	O
estrogen	B-Chemical
increases	O
PRL	B-Gene
-	I-Gene
R	I-Gene
expression	O
and	O
sensitivity	O
to	O
prolactin	B-Gene
,	O
we	O
next	O
demonstrated	O
that	O
estradiol	B-Chemical
greatly	O
augments	O
prolactin	B-Gene
-	O
induced	O
STAT5	B-Gene
activation	O
.	O
</ALL>	O

<ALL>	O
Lastly	O
,	O
we	O
measured	O
PRL	B-Gene
-	I-Gene
R	I-Gene
and	O
suppressor	B-Gene
of	I-Gene
cytokine	I-Gene
signaling	I-Gene
(	O
SOCS	B-Gene
-	I-Gene
1	I-Gene
and	I-Gene
-	I-Gene
3	I-Gene
and	O
CIS	B-Gene
,	O
which	O
reflect	O
the	O
level	O
of	O
prolactin	B-Gene
signaling	O
)	O
mRNAs	O
in	O
response	O
to	O
sulpiride	B-Chemical
and	O
estradiol	B-Chemical
.	O
</ALL>	O

<ALL>	O
Sulpiride	B-Chemical
induced	O
only	O
SOCS	B-Gene
-	I-Gene
1	I-Gene
in	O
the	O
medial	O
preoptic	O
area	O
,	O
where	O
GnRH	O
neurons	O
are	O
regulated	O
,	O
but	O
in	O
the	O
arcuate	O
nucleus	O
and	O
choroid	O
plexus	O
,	O
PRL	B-Gene
-	I-Gene
R	I-Gene
,	O
SOCS	B-Gene
-	I-Gene
3	I-Gene
,	O
and	O
CIS	B-Gene
mRNA	O
levels	O
were	O
also	O
induced	O
.	O
</ALL>	O

<ALL>	O
Estradiol	B-Chemical
enhanced	O
these	O
effects	O
on	O
SOCS	B-Gene
-	I-Gene
3	I-Gene
and	O
CIS	B-Gene
.	O
</ALL>	O

<ALL>	O
Interestingly	O
,	O
estradiol	B-Chemical
also	O
induced	O
PRL	B-Gene
-	I-Gene
R	I-Gene
,	O
SOCS	B-Gene
-	I-Gene
3	I-Gene
,	O
and	O
CIS	B-Gene
mRNA	O
levels	O
independently	O
.	O
</ALL>	O

<ALL>	O
These	O
data	O
show	O
that	O
GnRH	O
pulse	O
frequency	O
is	O
inhibited	O
by	O
chronic	O
hyperprolactinemia	B-Disease
in	O
a	O
steroid	B-Chemical
-	O
dependent	O
manner	O
.	O
</ALL>	O

<ALL>	O
They	O
also	O
provide	O
evidence	O
for	O
estradiol	B-Chemical
-	O
dependent	O
and	O
brain	O
region	O
-	O
specific	O
regulation	O
of	O
PRL	B-Gene
-	I-Gene
R	I-Gene
expression	O
and	O
signaling	O
responses	O
by	O
prolactin	B-Gene
.	O
</ALL>	O

<ALL>	O
Ginsenoside	B-Chemical
Rg1	I-Chemical
restores	O
the	O
impairment	B-Disease
of	I-Disease
learning	I-Disease
induced	O
by	O
chronic	O
morphine	B-Chemical
administration	O
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Rg1	B-Chemical
,	O
as	O
a	O
ginsenoside	B-Chemical
extracted	O
from	O
Panax	B-Species
ginseng	I-Species
,	O
could	O
ameliorate	O
spatial	O
learning	B-Disease
impairment	I-Disease
.	O
</ALL>	O

<ALL>	O
Previous	O
studies	O
have	O
demonstrated	O
that	O
Rg1	B-Chemical
might	O
be	O
a	O
useful	O
agent	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
the	O
adverse	O
effects	O
of	O
morphine	B-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
Rg1	B-Chemical
on	O
learning	B-Disease
impairment	I-Disease
by	O
chronic	O
morphine	B-Chemical
administration	O
and	O
the	O
mechanism	O
responsible	O
for	O
this	O
effect	O
.	O
</ALL>	O

<ALL>	O
Male	O
rats	B-Species
were	O
subcutaneously	O
injected	O
with	O
morphine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
twice	O
a	O
day	O
at	O
12	O
hour	O
intervals	O
for	O
10	O
days	O
,	O
and	O
Rg1	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
)	O
was	O
intraperitoneally	O
injected	O
2	O
hours	O
after	O
the	O
second	O
injection	O
of	O
morphine	B-Chemical
once	O
a	O
day	O
for	O
10	O
days	O
.	O
</ALL>	O

<ALL>	O
Spatial	O
learning	O
capacity	O
was	O
assessed	O
in	O
the	O
Morris	O
water	O
maze	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
showed	O
that	O
rats	B-Species
treated	O
with	O
Morphine	B-Chemical
/	O
Rg1	B-Chemical
decreased	O
escape	O
latency	O
and	O
increased	O
the	O
time	O
spent	O
in	O
platform	O
quadrant	O
and	O
entering	O
frequency	O
.	O
</ALL>	O

<ALL>	O
By	O
implantation	O
of	O
electrodes	O
and	O
electrophysiological	O
recording	O
in	O
vivo	O
,	O
the	O
results	O
showed	O
that	O
Rg1	B-Chemical
restored	O
the	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
impaired	O
by	O
morphine	B-Chemical
in	O
both	O
freely	O
moving	O
and	O
anaesthetised	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
electrophysiological	O
recording	O
in	O
vitro	O
showed	O
that	O
Rg1	B-Chemical
restored	O
the	O
LTP	O
in	O
slices	O
from	O
the	O
rats	B-Species
treated	O
with	O
morphine	B-Chemical
,	O
but	O
not	O
changed	O
LTP	O
in	O
the	O
slices	O
from	O
normal	O
saline	O
-	O
or	O
morphine	B-Chemical
/	O
Rg1	B-Chemical
-	O
treated	O
rats	B-Species
;	O
this	O
restoration	O
could	O
be	O
inhibited	O
by	O
N	B-Gene
-	I-Gene
methyl	I-Gene
-	I-Gene
D	I-Gene
-	I-Gene
aspartate	I-Gene
(	I-Gene
NMDA	I-Gene
)	I-Gene
receptor	I-Gene
antagonist	O
MK801	B-Chemical
.	O
</ALL>	O

<ALL>	O
We	O
conclude	O
that	O
Rg1	B-Chemical
may	O
significantly	O
improve	O
the	O
spatial	O
learning	O
capacity	O
impaired	O
by	O
chonic	O
morphine	B-Chemical
administration	O
and	O
restore	O
the	O
morphine	B-Chemical
-	O
inhibited	O
LTP	O
.	O
</ALL>	O

<ALL>	O
This	O
effect	O
is	O
NMDA	B-Gene
receptor	I-Gene
dependent	O
.	O
</ALL>	O

<ALL>	O
Repetitive	O
transcranial	O
magnetic	O
stimulation	O
for	O
levodopa	B-Chemical
-	O
induced	O
dyskinesias	B-Disease
in	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
.	O
</ALL>	O

<ALL>	O
In	O
a	O
placebo	O
-	O
controlled	O
,	O
single	O
-	O
blinded	O
,	O
crossover	O
study	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
"	O
real	O
"	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
versus	O
"	O
sham	O
"	O
rTMS	O
(	O
placebo	O
)	O
on	O
peak	O
dose	O
dyskinesias	B-Disease
in	O
patients	B-Species
with	O
Parkinson	B-Disease
's	I-Disease
disease	I-Disease
(	O
PD	B-Disease
)	O
.	O
</ALL>	O

<ALL>	O
Ten	O
patients	B-Species
with	O
PD	B-Disease
and	O
prominent	O
dyskinesias	B-Disease
had	O
rTMS	O
(	O
1,800	O
pulses	O
;	O
1	O
Hz	O
rate	O
)	O
delivered	O
over	O
the	O
motor	O
cortex	O
for	O
4	O
consecutive	O
days	O
twice	O
,	O
once	O
real	O
stimuli	O
and	O
once	O
sham	O
stimulation	O
were	O
used	O
;	O
evaluations	O
were	O
done	O
at	O
the	O
baseline	O
and	O
1	O
day	O
after	O
the	O
end	O
of	O
each	O
of	O
the	O
treatment	O
series	O
.	O
</ALL>	O

<ALL>	O
Direct	O
comparison	O
between	O
sham	O
and	O
real	O
rTMS	O
effects	O
showed	O
no	O
significant	O
difference	O
in	O
clinician	O
-	O
assessed	O
dyskinesia	B-Disease
severity	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
comparison	O
with	O
the	O
baseline	O
showed	O
small	O
but	O
significant	O
reduction	O
in	O
dyskinesia	B-Disease
severity	O
following	O
real	O
rTMS	O
but	O
not	O
placebo	O
.	O
</ALL>	O

<ALL>	O
The	O
major	O
effect	O
was	O
on	O
dystonia	B-Disease
subscore	O
.	O
</ALL>	O

<ALL>	O
Similarly	O
,	O
in	O
patient	B-Species
diaries	O
,	O
although	O
both	O
treatments	O
caused	O
reduction	O
in	O
subjective	O
dyskinesia	B-Disease
scores	O
during	O
the	O
days	O
of	O
intervention	O
,	O
the	O
effect	O
was	O
sustained	O
for	O
3	O
days	O
after	O
the	O
intervention	O
for	O
the	O
real	O
rTMS	O
only	O
.	O
</ALL>	O

<ALL>	O
Following	O
rTMS	O
,	O
no	O
side	O
effects	O
and	O
no	O
adverse	O
effects	O
on	O
motor	O
function	O
and	O
PD	B-Disease
symptoms	O
were	O
noted	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
suggest	O
the	O
existence	O
of	O
residual	O
beneficial	O
clinical	O
aftereffects	O
of	O
consecutive	O
daily	O
applications	O
of	O
low	O
-	O
frequency	O
rTMS	O
on	O
dyskinesias	B-Disease
in	O
PD	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
effects	O
may	O
be	O
further	O
exploited	O
for	O
potential	O
therapeutic	O
uses	O
.	O
</ALL>	O

<ALL>	O
The	O
glycine	B-Gene
transporter	I-Gene
-	I-Gene
1	I-Gene
inhibitor	O
SSR103800	B-Chemical
displays	O
a	O
selective	O
and	O
specific	O
antipsychotic	O
-	O
like	O
profile	O
in	O
normal	O
and	O
transgenic	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
Schizophrenia	B-Disease
has	O
been	O
initially	O
associated	O
with	O
dysfunction	O
in	O
dopamine	B-Chemical
neurotransmission	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
observation	O
that	O
antagonists	O
of	O
the	O
glutamate	B-Gene
N	I-Gene
-	I-Gene
methyl	I-Gene
-	I-Gene
D	I-Gene
-	I-Gene
aspartate	I-Gene
(	I-Gene
NMDA	I-Gene
)	I-Gene
receptor	I-Gene
produce	O
schizophrenic	B-Disease
-	O
like	O
symptoms	O
in	O
humans	B-Species
has	O
led	O
to	O
the	O
idea	O
of	O
a	O
dysfunctioning	O
of	O
the	O
glutamatergic	O
system	O
via	O
its	O
NMDA	B-Gene
receptor	I-Gene
.	O
</ALL>	O

<ALL>	O
As	O
a	O
result	O
,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
the	O
development	O
of	O
pharmacological	O
agents	O
with	O
potential	O
antipsychotic	O
properties	O
that	O
enhance	O
the	O
activity	O
of	O
the	O
glutamatergic	O
system	O
via	O
a	O
modulation	O
of	O
the	O
NMDA	B-Gene
receptor	I-Gene
.	O
</ALL>	O

<ALL>	O
Among	O
them	O
are	O
glycine	B-Gene
transporter	I-Gene
-	I-Gene
1	I-Gene
(	O
GlyT1	B-Gene
)	O
inhibitors	O
such	O
as	O
SSR103800	B-Chemical
,	O
which	O
indirectly	O
enhance	O
NMDA	B-Gene
receptor	I-Gene
function	O
by	O
increasing	O
the	O
glycine	B-Chemical
(	O
a	O
co	O
-	O
agonist	O
for	O
the	O
NMDA	B-Gene
receptor	I-Gene
)	O
levels	O
in	O
the	O
synapse	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
aimed	O
at	O
investigating	O
the	O
potential	O
antipsychotic	O
-	O
like	O
properties	O
of	O
SSR103800	B-Chemical
,	O
with	O
a	O
particular	O
focus	O
on	O
models	O
of	O
hyperactivity	B-Disease
,	O
involving	O
either	O
drug	O
challenge	O
(	O
ie	O
,	O
amphetamine	B-Chemical
and	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
)	O
or	O
transgenic	O
mice	B-Species
(	O
ie	O
,	O
NMDA	B-Gene
Nr1	I-Gene
(	O
neo	O
-	O
/	O
-	O
)	O
and	O
DAT	B-Gene
(	O
-	O
/	O
-	O
)	O
)	O
.	O
</ALL>	O

<ALL>	O
Results	O
showed	O
that	O
SSR103800	B-Chemical
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p.o	O
.	O
)	O
</ALL>	O

<ALL>	O
blocked	O
hyperactivity	B-Disease
induced	O
by	O
the	O
non	O
-	O
competitive	O
NMDA	B-Gene
receptor	I-Gene
antagonist	O
,	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
and	O
partially	O
reversed	O
spontaneous	O
hyperactivity	B-Disease
of	O
NMDA	B-Gene
Nr1	I-Gene
(	O
neo	O
-	O
/	O
-	O
)	O
mice	B-Species
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
SSR103800	B-Chemical
failed	O
to	O
affect	O
hyperactivity	B-Disease
induced	O
by	O
amphetamine	B-Chemical
or	O
naturally	O
observed	O
in	O
dopamine	B-Gene
transporter	I-Gene
(	O
DAT	B-Gene
(	O
-	O
/	O
-	O
)	O
)	O
knockout	O
mice	B-Species
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p.o	O
.	O
)	O
.	O
</ALL>	O

<ALL>	O
Importantly	O
,	O
both	O
classical	O
(	O
haloperidol	B-Chemical
)	O
and	O
atypical	O
(	O
olanzapine	B-Chemical
,	O
clozapine	B-Chemical
and	O
aripiprazole	B-Chemical
)	O
antipsychotics	O
were	O
effective	O
in	O
all	O
these	O
models	O
of	O
hyperactivity	B-Disease
.	O
</ALL>	O

<ALL>	O
However	O
,	O
unlike	O
these	O
latter	O
,	O
SSR103800	B-Chemical
did	O
not	O
produce	O
catalepsy	B-Disease
(	O
retention	O
on	O
the	O
bar	O
test	O
)	O
up	O
to	O
30	O
mg	O
/	O
kg	O
p.o	O
.	O
</ALL>	O

<ALL>	O
Together	O
these	O
findings	O
show	O
that	O
the	O
GlyT1	B-Gene
inhibitor	O
,	O
SSR103800	B-Chemical
,	O
produces	O
antipsychotic	O
-	O
like	O
effects	O
,	O
which	O
differ	O
from	O
those	O
observed	O
with	O
compounds	O
primarily	O
targeting	O
the	O
dopaminergic	B-Chemical
system	O
,	O
and	O
has	O
a	O
reduced	O
side	O
-	O
effect	O
potential	O
as	O
compared	O
with	O
these	O
latter	O
drugs	O
.	O
</ALL>	O

<ALL>	O
Fluoxetine	B-Chemical
improves	O
the	O
memory	B-Disease
deficits	I-Disease
caused	O
by	O
the	O
chemotherapy	O
agent	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
.	O
</ALL>	O

<ALL>	O
Cancer	B-Disease
patients	B-Species
who	O
have	O
been	O
treated	O
with	O
systemic	O
adjuvant	O
chemotherapy	O
have	O
described	O
experiencing	O
deteriorations	O
in	O
cognition	O
.	O
</ALL>	O

<ALL>	O
A	O
widely	O
used	O
chemotherapeutic	O
agent	O
,	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
,	O
readily	O
crosses	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
so	O
could	O
have	O
a	O
direct	O
effect	O
on	O
brain	O
function	O
.	O
</ALL>	O

<ALL>	O
In	O
particular	O
this	O
anti	O
mitotic	O
drug	O
could	O
reduce	O
cell	O
proliferation	O
in	O
the	O
neurogenic	O
regions	O
of	O
the	O
adult	O
brain	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
reports	O
indicate	O
that	O
hippocampal	O
dependent	O
neurogenesis	O
and	O
cognition	O
are	O
enhanced	O
by	O
the	O
SSRI	B-Chemical
antidepressant	O
Fluoxetine	B-Chemical
.	O
</ALL>	O

<ALL>	O
In	O
this	O
investigation	O
the	O
behavioural	O
effects	O
of	O
chronic	O
(	O
two	O
week	O
)	O
treatment	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
(	O
three	O
weeks	O
)	O
with	O
Fluoxetine	B-Chemical
either	O
separately	O
or	O
in	O
combination	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
were	O
tested	O
on	O
adult	O
Lister	O
hooded	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Behavioural	O
effects	O
were	O
tested	O
using	O
a	O
context	O
dependent	O
conditioned	O
emotional	O
response	O
test	O
(	O
CER	O
)	O
which	O
showed	O
that	O
animals	O
treated	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
had	O
a	O
significant	O
reduction	O
in	O
freezing	O
time	O
compared	O
to	O
controls	O
.	O
</ALL>	O

<ALL>	O
A	O
separate	O
group	O
of	O
animals	O
was	O
tested	O
using	O
a	O
hippocampal	O
dependent	O
spatial	O
working	O
memory	O
test	O
,	O
the	O
object	O
location	O
recognition	O
test	O
(	O
OLR	O
)	O
.	O
</ALL>	O

<ALL>	O
Animals	O
treated	O
only	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
showed	O
significant	O
deficits	O
in	O
their	O
ability	O
to	O
carry	O
out	O
the	O
OLR	O
task	O
but	O
co	O
administration	O
of	O
Fluoxetine	B-Chemical
improved	O
their	O
performance	O
.	O
</ALL>	O

<ALL>	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
chemotherapy	O
caused	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
proliferating	O
cells	O
in	O
the	O
sub	O
granular	O
zone	O
of	O
the	O
dentate	O
gyrus	O
compared	O
to	O
controls	O
.	O
</ALL>	O

<ALL>	O
This	O
reduction	O
was	O
eliminated	O
when	O
Fluoxetine	B-Chemical
was	O
co	O
administered	O
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
.	O
</ALL>	O

<ALL>	O
Fluoxetine	B-Chemical
on	O
its	O
own	O
had	O
no	O
effect	O
on	O
proliferating	O
cell	O
number	O
or	O
behaviour	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
suggest	O
that	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
can	O
negatively	O
affect	O
both	O
cell	O
proliferation	O
and	O
hippocampal	O
dependent	O
working	O
memory	O
and	O
that	O
these	O
deficits	O
can	O
be	O
reversed	O
by	O
the	O
simultaneous	O
administration	O
of	O
the	O
antidepressant	O
Fluoxetine	B-Chemical
.	O
</ALL>	O

<ALL>	O
Risk	O
of	O
nephropathy	B-Disease
after	O
consumption	O
of	O
nonionic	O
contrast	B-Chemical
media	I-Chemical
by	O
children	O
undergoing	O
cardiac	O
angiography	O
:	O
a	O
prospective	O
study	O
.	O
</ALL>	O

<ALL>	O
Despite	O
increasing	O
reports	O
on	O
nonionic	O
contrast	B-Chemical
media	I-Chemical
-	O
induced	O
nephropathy	B-Disease
(	O
CIN	B-Disease
)	O
in	O
hospitalized	O
adult	O
patients	B-Species
during	O
cardiac	O
procedures	O
,	O
the	O
studies	O
in	O
pediatrics	O
are	O
limited	O
,	O
with	O
even	O
less	O
focus	O
on	O
possible	O
predisposing	O
factors	O
and	O
preventive	O
measures	O
for	O
patients	B-Species
undergoing	O
cardiac	O
angiography	O
.	O
</ALL>	O

<ALL>	O
This	O
prospective	O
study	O
determined	O
the	O
incidence	O
of	O
CIN	B-Disease
for	O
two	O
nonionic	O
contrast	B-Chemical
media	I-Chemical
(	O
CM	B-Chemical
)	O
,	O
iopromide	B-Chemical
and	O
iohexol	B-Chemical
,	O
among	O
80	O
patients	B-Species
younger	O
than	O
18	O
years	O
and	O
compared	O
the	O
rates	O
for	O
this	O
complication	O
in	O
relation	O
to	O
the	O
type	O
and	O
dosage	O
of	O
CM	B-Chemical
and	O
the	O
presence	O
of	O
cyanosis	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
80	O
patients	B-Species
in	O
the	O
study	O
consecutively	O
received	O
either	O
iopromide	B-Chemical
(	O
group	O
A	O
,	O
n	O
=	O
40	O
)	O
or	O
iohexol	B-Chemical
(	O
group	O
B	O
,	O
n	O
=	O
40	O
)	O
.	O
</ALL>	O

<ALL>	O
Serum	O
sodium	B-Chemical
(	O
Na	B-Chemical
)	O
,	O
potassium	B-Chemical
(	O
K	B-Chemical
)	O
,	O
and	O
creatinine	B-Chemical
(	O
Cr	B-Chemical
)	O
were	O
measured	O
24	O
h	O
before	O
angiography	O
as	O
baseline	O
values	O
,	O
then	O
measured	O
again	O
at	O
12	O
-	O
,	O
24	O
-	O
,	O
and	O
48	O
-	O
h	O
intervals	O
after	O
CM	B-Chemical
use	O
.	O
</ALL>	O

<ALL>	O
Urine	O
samples	O
for	O
Na	B-Chemical
and	O
Cr	B-Chemical
also	O
were	O
checked	O
at	O
the	O
same	O
intervals	O
.	O
</ALL>	O

<ALL>	O
Risk	O
of	O
renal	B-Disease
failure	I-Disease
,	O
Injury	B-Disease
to	I-Disease
the	I-Disease
kidney	I-Disease
,	O
Failure	B-Disease
of	I-Disease
kidney	I-Disease
function	I-Disease
,	O
Loss	B-Disease
of	I-Disease
kidney	I-Disease
function	I-Disease
,	O
and	O
End	O
-	O
stage	O
renal	B-Disease
damage	I-Disease
(	O
RIFLE	O
criteria	O
)	O
were	O
used	O
to	O
define	O
CIN	B-Disease
and	O
its	O
incidence	O
in	O
the	O
study	O
population	O
.	O
</ALL>	O

<ALL>	O
Accordingly	O
,	O
among	O
the	O
15	O
CIN	B-Disease
patients	B-Species
(	O
18.75	O
%	O
)	O
,	O
7.5	O
%	O
of	O
the	O
patients	B-Species
in	O
group	O
A	O
had	O
increased	O
risk	O
and	O
3.75	O
%	O
had	O
renal	B-Disease
injury	I-Disease
,	O
whereas	O
5	O
%	O
of	O
group	O
B	O
had	O
increased	O
risk	O
and	O
2.5	O
%	O
had	O
renal	B-Disease
injury	I-Disease
.	O
</ALL>	O

<ALL>	O
Whereas	O
33.3	O
%	O
of	O
the	O
patients	B-Species
with	O
CIN	B-Disease
were	O
among	O
those	O
who	O
received	O
the	O
proper	O
dosage	O
of	O
CM	B-Chemical
,	O
the	O
percentage	O
increased	O
to	O
66.6	O
%	O
among	O
those	O
who	O
received	O
larger	O
doses	O
,	O
with	O
a	O
significant	O
difference	O
in	O
the	O
incidence	O
of	O
CIN	B-Disease
related	O
to	O
the	O
different	O
dosages	O
of	O
CM	B-Chemical
(	O
p	O
=	O
0.014	O
)	O
.	O
</ALL>	O

<ALL>	O
Among	O
the	O
15	O
patients	B-Species
with	O
CIN	B-Disease
,	O
6	O
had	O
cyanotic	O
congenital	B-Disease
heart	I-Disease
diseases	I-Disease
,	O
but	O
the	O
incidence	O
did	O
not	O
differ	O
significantly	O
from	O
that	O
for	O
the	O
noncyanotic	O
patients	B-Species
(	O
p	O
=	O
0.243	O
)	O
.	O
</ALL>	O

<ALL>	O
Although	O
clinically	O
silent	O
,	O
CIN	B-Disease
is	O
not	O
rare	O
in	O
pediatrics	O
.	O
</ALL>	O

<ALL>	O
The	O
incidence	O
depends	O
on	O
dosage	O
but	O
not	O
on	O
the	O
type	O
of	O
consumed	O
nonionic	O
CM	B-Chemical
,	O
nor	O
on	O
the	O
presence	O
of	O
cyanosis	B-Disease
,	O
and	O
although	O
CIN	B-Disease
usually	O
is	O
reversible	O
,	O
more	O
concern	O
is	O
needed	O
for	O
the	O
prevention	O
of	O
such	O
a	O
complication	O
in	O
children	O
.	O
</ALL>	O

<ALL>	O
Elevation	O
of	O
ADAM10	B-Gene
,	O
ADAM17	B-Gene
,	O
MMP	B-Gene
-	I-Gene
2	I-Gene
and	O
MMP	B-Gene
-	I-Gene
9	I-Gene
expression	O
with	O
media	O
degeneration	O
features	O
CaCl2	B-Chemical
-	O
induced	O
thoracic	B-Disease
aortic	I-Disease
aneurysm	I-Disease
in	O
a	O
rat	B-Species
model	O
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
This	O
study	O
was	O
designed	O
to	O
establish	O
a	O
rat	B-Species
model	O
of	O
thoracic	B-Disease
aortic	I-Disease
aneurysm	I-Disease
(	O
TAA	B-Disease
)	O
by	O
calcium	B-Chemical
chloride	I-Chemical
(	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
)	O
-	O
induced	O
arterial	B-Disease
injury	I-Disease
and	O
to	O
explore	O
the	O
potential	O
role	O
of	O
a	B-Gene
disintegrin	I-Gene
and	I-Gene
metalloproteinase	I-Gene
(	O
ADAM	B-Gene
)	O
,	O
matrix	B-Gene
metalloproteinases	I-Gene
(	O
MMPs	B-Gene
)	O
and	O
their	O
endogenous	O
inhibitors	O
(	O
TIMPs	O
)	O
in	O
TAA	B-Disease
formation	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Thoracic	O
aorta	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	B-Species
was	O
exposed	O
to	O
0.5	O
M	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
or	O
normal	O
saline	O
(	O
NaCl	B-Chemical
)	O
.	O
</ALL>	O

<ALL>	O
After	O
12weeks	O
,	O
animals	O
were	O
euthanized	O
,	O
and	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treated	O
,	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
untreated	O
(	O
n	O
=	O
12	O
)	O
and	O
NaCl	B-Chemical
-	O
treated	O
aortic	O
segments	O
(	O
n	O
=	O
12	O
)	O
were	O
collected	O
for	O
histological	O
and	O
molecular	O
assessments	O
.	O
</ALL>	O

<ALL>	O
MMP	B-Gene
-	O
TIMP	B-Gene
and	O
ADAM	B-Gene
mRNAs	O
were	O
semi	O
-	O
quantitatively	O
analyzed	O
and	O
protein	O
expressions	O
were	O
determined	O
by	O
immunohistochemistry	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
Despite	O
similar	O
external	O
diameters	O
among	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treated	O
,	O
non	O
-	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treated	O
and	O
NaCl	B-Chemical
-	O
treated	O
segments	O
,	O
aneurymal	O
alteration	O
(	O
n	O
=	O
6	O
,	O
50	O
%	O
)	O
,	O
media	O
degeneration	O
with	O
regional	O
disruption	O
,	O
fragmentation	O
of	O
elastic	O
fiber	O
,	O
and	O
increased	O
collagen	O
deposition	O
(	O
n	O
=	O
12	O
,	O
100	O
%	O
)	O
were	O
demonstrated	O
in	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treated	O
segments	O
.	O
</ALL>	O

<ALL>	O
MMP	B-Gene
-	I-Gene
2	I-Gene
,	O
MMP	B-Gene
-	I-Gene
9	I-Gene
,	O
ADAM	B-Gene
-	I-Gene
10	I-Gene
and	O
ADAM	B-Gene
-	I-Gene
17	I-Gene
mRNA	O
levels	O
were	O
increased	O
in	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treated	O
segments	O
(	O
all	O
p	O
<	O
0.01	O
)	O
,	O
with	O
trends	O
of	O
elevation	O
in	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
untreated	O
segments	O
,	O
as	O
compared	O
with	O
NaCl	B-Chemical
-	O
treated	O
segments	O
.	O
</ALL>	O

<ALL>	O
Immunohistochemistry	O
displayed	O
significantly	O
increased	O
expressions	O
of	O
MMP	B-Gene
-	I-Gene
2	I-Gene
,	O
MMP	B-Gene
-	I-Gene
9	I-Gene
,	O
ADAM	B-Gene
-	I-Gene
10	I-Gene
and	O
ADAM	B-Gene
-	I-Gene
17	I-Gene
(	O
all	O
p	O
<	O
0.01	O
)	O
in	O
intima	O
and	O
media	O
for	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
-	O
treated	O
segments	O
.	O
</ALL>	O

<ALL>	O
TIMP	B-Gene
mRNA	O
and	O
tissue	O
levels	O
did	O
not	O
differ	O
obviously	O
among	O
the	O
three	O
aortic	O
segments	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
This	O
study	O
establishes	O
a	O
TAA	B-Disease
model	O
by	O
periarterial	O
CaCl	B-Chemical
(	I-Chemical
2	I-Chemical
)	I-Chemical
exposure	O
in	O
rats	B-Species
,	O
and	O
demonstrates	O
a	O
significant	O
elevation	O
of	O
expression	O
of	O
MMP	B-Gene
-	I-Gene
2	I-Gene
,	O
MMP	B-Gene
-	I-Gene
9	I-Gene
,	O
ADAM10	B-Gene
and	O
ADAM17	B-Gene
in	O
the	O
pathogenesis	O
of	O
vascular	O
remodeling	O
.	O
</ALL>	O

<ALL>	O
Biochemical	O
effects	O
of	O
Solidago	B-Chemical
virgaurea	I-Chemical
extract	I-Chemical
on	O
experimental	O
cardiotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
Cardiovascular	B-Disease
diseases	I-Disease
(	O
CVDs	B-Disease
)	O
are	O
the	O
major	O
health	O
problem	O
of	O
advanced	O
as	O
well	O
as	O
developing	O
countries	O
of	O
the	O
world	O
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
the	O
Solidago	B-Chemical
virgaurea	I-Chemical
extract	I-Chemical
on	O
isoproterenol	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
subcutaneous	O
injection	O
of	O
isoproterenol	B-Chemical
(	O
30	O
mg	O
/	O
kg	O
)	O
into	O
rats	B-Species
twice	O
at	O
an	O
interval	O
of	O
24	O
h	O
,	O
for	O
two	O
consecutive	O
days	O
,	O
led	O
to	O
a	O
significant	O
increase	O
in	O
serum	O
lactate	B-Gene
dehydrogenase	I-Gene
,	O
creatine	B-Gene
phosphokinase	I-Gene
,	O
alanine	B-Gene
transaminase	I-Gene
,	O
aspartate	B-Gene
transaminase	I-Gene
,	O
and	O
angiotensin	B-Gene
-	I-Gene
converting	I-Gene
enzyme	I-Gene
activities	O
,	O
total	O
cholesterol	B-Chemical
,	O
triglycerides	B-Chemical
,	O
free	O
serum	O
fatty	B-Chemical
acid	I-Chemical
,	O
cardiac	O
tissue	O
malondialdehyde	B-Chemical
(	O
MDA	B-Chemical
)	O
,	O
and	O
nitric	B-Chemical
oxide	I-Chemical
levels	O
and	O
a	O
significant	O
decrease	O
in	O
levels	O
of	O
glutathione	B-Chemical
and	O
superoxide	B-Gene
dismutase	I-Gene
in	O
cardiac	O
tissue	O
as	O
compared	O
to	O
the	O
normal	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O
</ALL>	O

<ALL>	O
Pretreatment	O
with	O
S.	B-Chemical
virgaurea	I-Chemical
extract	I-Chemical
for	O
5	O
weeks	O
at	O
a	O
dose	O
of	O
250	O
mg	O
/	O
kg	O
followed	O
by	O
isoproterenol	B-Chemical
injection	O
significantly	O
prevented	O
the	O
observed	O
alterations	O
.	O
</ALL>	O

<ALL>	O
Captopril	B-Chemical
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
,	O
given	O
orally	O
)	O
,	O
an	O
inhibitor	O
of	O
angiotensin	B-Gene
-	I-Gene
converting	I-Gene
enzyme	I-Gene
used	O
as	O
a	O
standard	O
cardioprotective	B-Chemical
drug	I-Chemical
,	O
was	O
used	O
as	O
a	O
positive	O
control	O
in	O
this	O
study	O
.	O
</ALL>	O

<ALL>	O
The	O
data	O
of	O
the	O
present	O
study	O
suggest	O
that	O
S.	B-Chemical
virgaurea	I-Chemical
extract	I-Chemical
exerts	O
its	O
protective	O
effect	O
by	O
decreasing	O
MDA	B-Chemical
level	O
and	O
increasing	O
the	O
antioxidant	O
status	O
in	O
isoproterenol	B-Chemical
-	O
treated	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
The	O
study	O
emphasizes	O
the	O
beneficial	O
action	O
of	O
S.	B-Chemical
virgaurea	I-Chemical
extract	I-Chemical
as	O
a	O
cardioprotective	B-Chemical
agent	I-Chemical
.	O
</ALL>	O

<ALL>	O
Glial	O
activation	O
and	O
post	O
-	O
synaptic	O
neurotoxicity	B-Disease
:	O
the	O
key	O
events	O
in	O
Streptozotocin	B-Chemical
(	O
ICV	O
)	O
induced	O
memory	B-Disease
impairment	I-Disease
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
study	O
the	O
role	O
of	O
glial	O
activation	O
and	O
post	O
synaptic	O
toxicity	B-Disease
in	O
ICV	O
Streptozotocin	B-Chemical
(	O
STZ	B-Chemical
)	O
induced	O
memory	B-Disease
impaired	I-Disease
rats	B-Species
was	O
explored	O
.	O
</ALL>	O

<ALL>	O
In	O
experiment	O
set	O
up	O
1	O
:	O
Memory	B-Disease
deficit	I-Disease
was	O
found	O
in	O
Morris	O
water	O
maze	O
test	O
on	O
14	O
-	O
16	O
days	O
after	O
STZ	B-Chemical
(	O
ICV	O
;	O
3	O
mg	O
/	O
Kg	O
)	O
administration	O
.	O
</ALL>	O

<ALL>	O
STZ	B-Chemical
causes	O
increased	O
expression	O
of	O
GFAP	B-Gene
,	O
CD11b	B-Gene
and	O
TNF	B-Gene
-	I-Gene
a	I-Gene
indicating	O
glial	O
activation	O
and	O
neuroinflammation	B-Disease
.	O
</ALL>	O

<ALL>	O
STZ	B-Chemical
also	O
significantly	O
increased	O
the	O
level	O
of	O
ROS	B-Chemical
,	O
nitrite	B-Chemical
,	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+	I-Chemical
)	I-Chemical
and	O
reduced	O
the	O
mitochondrial	O
activity	O
in	O
synaptosomal	O
preparation	O
illustrating	O
free	O
radical	O
generation	O
and	O
excitotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
Increased	O
expression	O
and	O
activity	O
of	O
Caspase	B-Gene
-	I-Gene
3	I-Gene
was	O
also	O
observed	O
in	O
STZ	B-Chemical
treated	O
rat	B-Species
which	O
specify	O
apoptotic	O
cell	O
death	O
in	O
hippocampus	O
and	O
cortex	O
.	O
</ALL>	O

<ALL>	O
STZ	B-Chemical
treatment	O
showed	O
decrease	O
expression	O
of	O
post	O
synaptic	O
markers	O
CaMKIIa	B-Gene
and	O
PSD	B-Gene
-	I-Gene
95	I-Gene
,	O
while	O
,	O
expression	O
of	O
pre	O
synaptic	O
markers	O
(	O
synaptophysin	B-Gene
and	O
SNAP	B-Gene
-	I-Gene
25	I-Gene
)	O
remains	O
unaltered	O
indicating	O
selective	O
post	O
synaptic	O
neurotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
Oral	O
treatment	O
with	O
Memantine	B-Chemical
(	O
10	O
mg	O
/	O
kg	O
)	O
and	O
Ibuprofen	B-Chemical
(	O
50	O
mg	O
/	O
kg	O
)	O
daily	O
for	O
13	O
days	O
attenuated	O
STZ	B-Chemical
induced	O
glial	O
activation	O
,	O
apoptotic	O
cell	O
death	O
and	O
post	O
synaptic	O
neurotoxicity	B-Disease
in	O
rat	B-Species
brain	O
.	O
</ALL>	O

<ALL>	O
Further	O
,	O
in	O
experiment	O
set	O
up	O
2	O
:	O
where	O
memory	O
function	O
was	O
not	O
affected	O
i.e.	O
7	O
-	O
9	O
days	O
after	O
STZ	B-Chemical
treatment	O
.	O
</ALL>	O

<ALL>	O
The	O
level	O
of	O
GFAP	B-Gene
,	O
CD11b	B-Gene
,	O
TNF	B-Gene
-	I-Gene
a	I-Gene
,	O
ROS	B-Chemical
and	O
nitrite	B-Chemical
levels	O
were	O
increased	O
.	O
</ALL>	O

<ALL>	O
On	O
the	O
other	O
hand	O
,	O
apoptotic	O
marker	O
,	O
synaptic	O
markers	O
,	O
mitochondrial	O
activity	O
and	O
Ca	B-Chemical
(	I-Chemical
2	I-Chemical
+	I-Chemical
)	I-Chemical
levels	O
remained	O
unaffected	O
.	O
</ALL>	O

<ALL>	O
Collective	O
data	O
indicates	O
that	O
neuroinflammatory	B-Disease
process	O
and	O
oxidative	O
stress	O
occurs	O
earlier	O
to	O
apoptosis	O
and	O
does	O
not	O
affect	O
memory	O
function	O
.	O
</ALL>	O

<ALL>	O
Present	O
study	O
clearly	O
suggests	O
that	O
glial	O
activation	O
and	O
post	O
synaptic	O
neurotoxicity	B-Disease
are	O
the	O
key	O
factors	O
in	O
STZ	B-Chemical
induced	O
memory	B-Disease
impairment	I-Disease
and	O
neuronal	O
cell	O
death	O
.	O
</ALL>	O

<ALL>	O
Pre	O
-	O
treatment	O
of	O
bupivacaine	B-Chemical
-	O
induced	O
cardiovascular	B-Disease
depression	I-Disease
using	O
different	O
lipid	B-Chemical
formulations	O
of	O
propofol	B-Chemical
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
Pre	O
-	O
treatment	O
with	O
lipid	B-Chemical
emulsions	I-Chemical
has	O
been	O
shown	O
to	O
increase	O
lethal	O
doses	O
of	O
bupivacaine	B-Chemical
,	O
and	O
the	O
lipid	B-Chemical
content	O
of	O
propofol	B-Chemical
may	O
alleviate	O
bupivacaine	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
effects	O
of	O
propofol	B-Chemical
in	O
intralipid	B-Chemical
or	O
medialipid	B-Chemical
emulsions	O
on	O
bupivacaine	B-Chemical
-	O
induced	O
cardiotoxicity	B-Disease
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
Rats	B-Species
were	O
anaesthetised	O
with	O
ketamine	B-Chemical
and	O
were	O
given	O
0.5	O
mg	O
/	O
kg	O
/	O
min	O
propofol	B-Chemical
in	O
intralipid	B-Chemical
(	O
Group	O
P	O
)	O
,	O
propofol	B-Chemical
in	O
medialipid	B-Chemical
(	O
Group	O
L	O
)	O
,	O
or	O
saline	O
(	O
Group	O
C	O
)	O
over	O
20	O
min	O
.	O
</ALL>	O

<ALL>	O
Thereafter	O
,	O
2	O
mg	O
/	O
kg	O
/	O
min	O
bupivacaine	B-Chemical
0.5	O
%	O
was	O
infused	O
.	O
</ALL>	O

<ALL>	O
We	O
recorded	O
time	O
to	O
first	O
dysrhythmia	B-Disease
occurrence	O
,	O
respective	O
times	O
to	O
25	O
%	O
and	O
50	O
%	O
reduction	O
of	O
the	O
heart	O
rate	O
(	O
HR	O
)	O
and	O
mean	O
arterial	O
pressure	O
,	O
and	O
time	O
to	O
asystole	B-Disease
and	O
total	O
amount	O
of	O
bupivacaine	B-Chemical
consumption	O
.	O
</ALL>	O

<ALL>	O
Blood	O
and	O
tissue	O
samples	O
were	O
collected	O
following	O
asystole	B-Disease
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
The	O
time	O
to	O
first	O
dysrhythmia	B-Disease
occurrence	O
,	O
time	O
to	O
25	O
%	O
and	O
50	O
%	O
reductions	O
in	O
HR	O
,	O
and	O
time	O
to	O
asystole	B-Disease
were	O
longer	O
in	O
Group	O
P	O
than	O
the	O
other	O
groups	O
.	O
</ALL>	O

<ALL>	O
The	O
cumulative	O
bupivacaine	B-Chemical
dose	O
given	O
at	O
those	O
time	O
points	O
was	O
higher	O
in	O
Group	O
P.	O
Plasma	O
bupivacaine	B-Chemical
levels	O
were	O
significantly	O
lower	O
in	O
Group	O
P	O
than	O
in	O
Group	O
C.	O
Bupivacaine	B-Chemical
levels	O
in	O
the	O
brain	O
and	O
heart	O
were	O
significantly	O
lower	O
in	O
Group	O
P	O
and	O
Group	O
L	O
than	O
in	O
Group	O
C.	O
CONCLUSION	O
:	O
We	O
conclude	O
that	O
pre	O
-	O
treatment	O
with	O
propofol	B-Chemical
in	O
intralipid	B-Chemical
,	O
compared	O
with	O
propofol	B-Chemical
in	O
medialipid	B-Chemical
or	O
saline	O
,	O
delayed	O
the	O
onset	O
of	O
bupivacaine	B-Chemical
-	O
induced	O
cardiotoxic	B-Disease
effects	O
as	O
well	O
as	O
reduced	O
plasma	O
bupivacaine	B-Chemical
levels	O
.	O
</ALL>	O

<ALL>	O
Further	O
studies	O
are	O
needed	O
to	O
explore	O
tissue	O
bupivacaine	B-Chemical
levels	O
of	O
propofol	B-Chemical
in	O
medialipid	B-Chemical
and	O
adapt	O
these	O
results	O
to	O
clinical	O
practice	O
.	O
</ALL>	O

<ALL>	O
Curcumin	B-Chemical
prevents	O
maleate	B-Chemical
-	O
induced	O
nephrotoxicity	B-Disease
:	O
relation	O
to	O
hemodynamic	O
alterations	O
,	O
oxidative	O
stress	O
,	O
mitochondrial	O
oxygen	B-Chemical
consumption	O
and	O
activity	O
of	O
respiratory	B-Chemical
complex	I-Chemical
I	I-Chemical
.	O
</ALL>	O

<ALL>	O
The	O
potential	O
protective	O
effect	O
of	O
the	O
dietary	O
antioxidant	O
curcumin	B-Chemical
(	O
120	O
mg	O
/	O
Kg	O
/	O
day	O
for	O
6	O
days	O
)	O
against	O
the	O
renal	B-Disease
injury	I-Disease
induced	O
by	O
maleate	B-Chemical
was	O
evaluated	O
.	O
</ALL>	O

<ALL>	O
Tubular	O
proteinuria	B-Disease
and	O
oxidative	O
stress	O
were	O
induced	O
by	O
a	O
single	O
injection	O
of	O
maleate	B-Chemical
(	O
400	O
mg	O
/	O
kg	O
)	O
in	O
rats	B-Species
.	O
</ALL>	O

<ALL>	O
Maleate	B-Chemical
-	O
induced	O
renal	B-Disease
injury	I-Disease
included	O
increase	O
in	O
renal	O
vascular	O
resistance	O
and	O
in	O
the	O
urinary	O
excretion	O
of	O
total	O
protein	O
,	O
glucose	B-Chemical
,	O
sodium	B-Chemical
,	O
neutrophil	B-Gene
gelatinase	I-Gene
-	I-Gene
associated	I-Gene
lipocalin	I-Gene
(	O
NGAL	B-Gene
)	O
and	O
N	B-Gene
-	I-Gene
acetyl	I-Gene
b	I-Gene
-	I-Gene
D	I-Gene
-	I-Gene
glucosaminidase	I-Gene
(	O
NAG	B-Gene
)	O
,	O
upregulation	O
of	O
kidney	B-Gene
injury	I-Gene
molecule	I-Gene
(	I-Gene
KIM	I-Gene
)	I-Gene
-	I-Gene
1	I-Gene
,	O
decrease	O
in	O
renal	O
blood	O
flow	O
and	O
claudin	B-Gene
-	I-Gene
2	I-Gene
expression	O
besides	O
of	O
necrosis	B-Disease
and	I-Disease
apoptosis	I-Disease
of	I-Disease
tubular	I-Disease
cells	I-Disease
on	O
24	O
h.	O
Oxidative	O
stress	O
was	O
determined	O
by	O
measuring	O
the	O
oxidation	O
of	O
lipids	B-Chemical
and	O
proteins	O
and	O
diminution	O
in	O
renal	O
Nrf2	B-Gene
levels	O
.	O
</ALL>	O

<ALL>	O
Studies	O
were	O
also	O
conducted	O
in	O
renal	O
epithelial	O
LLC	B-CellLine
-	I-CellLine
PK1	I-CellLine
cells	O
and	O
in	O
mitochondria	O
isolated	O
from	O
kidneys	O
of	O
all	O
the	O
experimental	O
groups	O
.	O
</ALL>	O

<ALL>	O
Maleate	B-Chemical
induced	O
cell	O
damage	O
and	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
production	O
in	O
LLC	B-CellLine
-	I-CellLine
PK1	I-CellLine
cells	O
in	O
culture	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
maleate	B-Chemical
treatment	O
reduced	O
oxygen	B-Chemical
consumption	O
in	O
ADP	B-Chemical
-	O
stimulated	O
mitochondria	O
and	O
diminished	O
respiratory	O
control	O
index	O
when	O
using	O
malate	B-Chemical
/	O
glutamate	B-Chemical
as	O
substrate	O
.	O
</ALL>	O

<ALL>	O
The	O
activities	O
of	O
both	O
complex	O
I	O
and	O
aconitase	B-Gene
were	O
also	O
diminished	O
.	O
</ALL>	O

<ALL>	O
All	O
the	O
above	O
-	O
described	O
alterations	O
were	O
prevented	O
by	O
curcumin	B-Chemical
.	O
</ALL>	O

<ALL>	O
It	O
is	O
concluded	O
that	O
curcumin	B-Chemical
is	O
able	O
to	O
attenuate	O
in	O
vivo	O
maleate	B-Chemical
-	O
induced	O
nephropathy	B-Disease
and	O
in	O
vitro	O
cell	O
damage	O
.	O
</ALL>	O

<ALL>	O
The	O
in	O
vivo	O
protection	O
was	O
associated	O
to	O
the	O
prevention	O
of	O
oxidative	O
stress	O
and	O
preservation	O
of	O
mitochondrial	O
oxygen	B-Chemical
consumption	O
and	O
activity	O
of	O
respiratory	B-Chemical
complex	I-Chemical
I	I-Chemical
,	O
and	O
the	O
in	O
vitro	O
protection	O
was	O
associated	O
to	O
the	O
prevention	O
of	O
ROS	B-Chemical
production	O
.	O
</ALL>	O

